<SEC-DOCUMENT>0000950170-23-007022.txt : 20230309
<SEC-HEADER>0000950170-23-007022.hdr.sgml : 20230309
<ACCEPTANCE-DATETIME>20230309161144
ACCESSION NUMBER:		0000950170-23-007022
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230309
DATE AS OF CHANGE:		20230309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gritstone bio, Inc.
		CENTRAL INDEX KEY:			0001656634
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38663
		FILM NUMBER:		23719866

	BUSINESS ADDRESS:	
		STREET 1:		5959 HORTON STREET, SUITE 300
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 871-6100

	MAIL ADDRESS:	
		STREET 1:		5959 HORTON STREET, SUITE 300
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gritstone Oncology, Inc.
		DATE OF NAME CHANGE:	20151023
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>grts-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-09T14:12:16.2683+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:grts="http://gritstonebio.com/20221231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_9f56e434-2071-40f2-81bc-0ed22f38f4e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_ce7937c5-6a07-4c19-a8ee-29f6ffedab38" format="ixt-sec:durwordsen">1 year</ix:nonNumeric><ix:nonNumeric id="F_571251c0-d226-4450-88eb-7ee8d4a698b0" name="dei:DocumentFiscalPeriodFocus" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00">FY</ix:nonNumeric><ix:nonFraction id="F_e7f9cea4-e613-411c-867e-84c9f2b00028" name="us-gaap:CommitmentsAndContingencies" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9765a238-b117-4b57-9e57-dd79a484561f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_20846724-0d37-49d2-b716-e12511647821" name="us-gaap:OperationsCommencedDate1" contextRef="C_a00793ff-fd1e-4407-a28f-21d728a53d83">2021-04-01</ix:nonNumeric><ix:nonNumeric id="F_faa22fcc-8797-4009-a6ec-9ffd1ef5498e" name="dei:EntityCentralIndexKey" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00">0001656634</ix:nonNumeric><ix:nonNumeric id="F_9eba06f0-bedf-4ded-9f71-17671e82aef7" name="grts:RevenueRecognitionContractEndPeriod" contextRef="C_489a2772-a9a5-4e8f-845d-dfb4142824b9" format="ixt-sec:durwordsen">two years</ix:nonNumeric><ix:nonNumeric id="F_a0ff64f8-6e81-4e07-8318-11c2e3fcc076" name="dei:CurrentFiscalYearEndDate" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00">--12-31</ix:nonNumeric><ix:nonNumeric id="F_c3b0f8bb-78d1-40b5-a178-d0f8420ed0af" name="dei:AmendmentFlag" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="grts-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_c0c7b78e-f4bd-4f7d-a7d7-c851651f4d4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_217b0356-637c-4019-9519-2b40884dd4ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6f99192-3731-4c3e-b249-3bcfe2f628f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91453aed-a1da-44b5-bdcd-23b2fbed997d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f1c0918-b40b-45ce-a32a-5ff2e0cdb811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12768f52-aae1-4e43-bb4c-1b4a1aca508a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_daff6bb1-ec2f-40fb-b9ff-6c866bc3bfce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_654ac5ed-1cde-4438-bd70-e413cdecd6a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5df76468-2d33-4c29-bdf7-4567b8bbe0be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a51fab37-6bd0-4cae-b9b3-b2a75e0d44b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PreJanuary12018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_278c4452-2cac-4960-b90f-088134dd9e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bf29e99-103a-4385-809e-4cd89e8893aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ee0de6e-7969-4192-9194-1f65fcc5fe25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34bb80f1-a84f-4c93-9bd0-b459e3058b14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa58fee8-bbe5-446e-8e6a-a951cc8fb7a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d75caf7-1680-40a2-922d-317eeb129d2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd5de76e-097b-41d2-b92d-4e0353e1ee49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_879914fe-a7ae-42c4-9c44-8a86ed39c875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbe3a914-b528-49c7-8179-6932dd627a2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a579eb0-d553-498a-9517-437c3bb7acbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fb30a1b-bb4d-41a9-b08c-0a5c0e1c4848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d2325a8-cbfa-43c0-bd17-5934a79b43c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_201d8d2c-c046-4388-b915-a88be0e7cc5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd45c0a3-040d-42de-93c8-a06fd1b04f7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a26fbccd-5d77-411c-acc6-ba0395a747d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_525c622a-5ea4-473e-9b25-9d823536fda9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2a83568-2a86-4097-8ffb-41bc0c489eae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcee5e27-efd7-4563-b1c8-df33f67e907f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ac0503d-d066-402e-877d-8f2b3b924843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73ad74f1-0195-424d-8504-c0dca88a9b7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b01748c1-8a6a-4edc-afb0-0081bb1bd20a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:WarehouseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9585647-0f77-46d7-bf67-20e6113a6250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87523886-5199-4d42-8415-694b2b443fbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b0ba039-9d60-4e77-8a56-2a70e004643a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc893192-2b4b-49b4-9a11-52f5e2e37960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4eaebbf5-c3fc-4967-9782-b63169338718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9a3cb9b-7c28-49b3-ba96-6f4a5a29c371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97f8a7f4-7c61-4b23-aa03-20ff4c118788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8437c548-599f-4c6f-9584-e7e7d46f0379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59a0f9dc-319b-473d-b36c-f9544e589028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockWarrantsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7252815e-38c6-46dc-8937-24c805d8b308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a246cd21-ac7d-4072-88f9-4cb7c5a9e332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockWarrantsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6ab88c2-0338-4075-8ed9-d7c8fee513c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_087f69e2-ad7d-4b73-9c6f-f855a261808a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c0e8577-018d-4fd4-82ea-b6e2d68a5f23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11b7e846-cd77-420b-8752-6e1a1f336a59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0619058-b76c-4371-b472-a3486c28b486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_351091de-7324-4fdd-81d4-70155fd963f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a00793ff-fd1e-4407-a28f-21d728a53d83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d761c15a-dc3b-4830-bc90-d5f6864753cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1d550f9-c0a6-4ff2-941b-a0771a52258d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80849ef4-0531-4940-958b-b3800e6ec694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6411ac81-f0a4-466a-b658-bc20a1796628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_816d085d-25a0-4fe5-a1f4-76e96db59467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a755d83-b2d7-4f74-863c-9977b0a91bdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_431f0e99-dc7d-46f0-aaf5-b5f357500cef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_927c9adc-769a-4197-8a7b-ca4f1f62c776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff2af9fa-a502-476a-95ef-6236ae054f89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_077f94f8-990f-491f-98d1-d6eb5debde18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9adf420e-a107-42cb-a6a6-902bddde7540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a63c1a07-67c9-44ee-9005-5e3efd76ad19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f4a9e62-6ab4-4592-9bff-72669d585e09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eea11142-e7ca-4a35-9c72-576024096190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33a09371-b9ca-4410-82c3-2bb6c53a0442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce7937c5-6a07-4c19-a8ee-29f6ffedab38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41e65ead-4e0c-4591-b0c4-a8797159156c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_127f64ce-6b17-4ad1-9892-5332bca5d957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c20b544-b6be-4cb6-a697-7fed0ddcd9cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13677a63-5c18-4b4a-8b7c-a6e88324254f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce01baa0-2b6b-406d-8ec3-3218ac59d5b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0066c1b6-3f4e-430f-9440-978f78dfa308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6370a8f-2667-466f-98d3-1e9d3a327fa7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44dd4f53-eec3-40d8-8778-035eeb8ebe64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c944192d-7243-4e20-9dee-9ed4870b3302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ea98966-ee3e-4c56-b696-2ba4dc84bd5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d48b34dc-8de5-4f5a-8b9a-cf67c0c1b3bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7855eba8-76bc-4a8c-9ce4-0799ef712f67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09a42735-0d75-4484-89b9-5f969e41a1fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_450aa048-1aac-4500-be64-715518ae710b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e95014f8-6dc9-41f7-ad01-70179a6bc0a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92745d9d-b5a1-43ae-ae6e-0738b7391092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6bd0364-0189-46f1-9a87-5b5ae7b4a68b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78424e0d-5b03-41a3-be95-f77504eeecf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e40ec53-a7a5-40bf-91a9-94f9b7f15952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_760e896a-f89d-4fe2-ac56-70d954e97475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">grts:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fed14fa7-fd7b-44c6-a3d0-52c8e4029d8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e244d887-8d8a-4495-81bd-72528b63162d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3030c951-2716-4654-8056-6101e373ddea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9220959-3f8c-49ee-b09b-88b706eaf9b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_822e2920-cab6-4373-82cb-898c8cc385e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b84dd47-84c3-4d2b-8c0c-c84ff401d5a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e515ffd5-9be4-4d3e-800d-0e4d6f432f77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1213544-8876-4d28-b445-ffd3948fc5c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95be0954-d2b5-4a76-b208-0a3189bace59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_489a2772-a9a5-4e8f-845d-dfb4142824b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f8f5e42-0701-4a64-ab34-634cae0498b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b32eb355-55f1-4a0d-a16e-f7a33883834a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfc996c2-5a4e-4564-8277-b7d2ffbeec1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_207cd814-4d37-40e6-b825-ea029fb0acad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64576a2c-bdc6-440d-a223-f398708694c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a08ccbdf-1ba2-463d-8a51-346c12817d18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2152b17d-baee-4d49-a165-456d92d2f320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55acf221-1e8f-4997-82b2-c1790c656f7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-14</xbrli:startDate><xbrli:endDate>2021-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7666188-96ff-45eb-8de2-48af6a561ae7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81ba52a0-a708-443b-b8aa-b7e87669392e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31827499-df5a-4144-a589-97ec604bab7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51209003-b3a4-472c-aa6b-ed22f18ab53e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e8470b2-dcb6-48e3-b5e1-9aa9a258b518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fdb3010-aa4d-4332-a56d-c9ff8991e214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ecd9d54-ec05-4e5b-96c6-c81c04c9fc84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8683aae2-0a3c-46c3-989d-7ac0248bffb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5151ebd-45f6-4030-99a1-58711cd6e0af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_beafcda9-72de-465a-8212-61152dcebbdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8816b30-096f-44ce-9bfe-af5d8d5e416d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad6f9581-caa1-40a5-b25e-f79138f7937a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">grts:FourtyErieLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-01</xbrli:startDate><xbrli:endDate>2016-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b36e023-4632-4679-a7c3-29a735d1414a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_466e6120-0e46-457a-95cb-1badad395cad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e100875-202a-43a8-8544-eea71c373493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d942367c-37c2-422b-a6e8-33a8383c90bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62816055-7eef-44a2-9784-8d2135365bf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae943dac-f283-4812-963a-4a9313be83f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-21</xbrli:startDate><xbrli:endDate>2022-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e931d49-353d-46c5-813c-21ac6372c768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4d4328f-52cc-4211-9428-c5e7e73152dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c93b994-375e-41fb-a65c-a6d06c8a74af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a25d6e22-b4d5-4e42-baee-545cb40fb3b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87c8c355-193a-4647-ba52-79383b1ab058"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5eeb50c4-7bbf-4897-a80f-34577a6faa71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_672dd93b-be85-49d8-84d9-56d83b649236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_323e95b8-22cf-4c13-a39e-cc623d224a74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee3362ce-e6b6-4c81-9ddd-3a4c990659b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_208e185e-fe87-4dc4-85f0-dbddc9b221e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89e4b4f1-1e78-4fc1-8102-81aecb3af80a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f02ae7b-672e-42dd-aa91-702e3930b636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_724282bf-8130-4b80-8ac7-1b0e9d423b87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72241514-75f9-4b94-8b9f-d70213f11d47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74ebd140-1cd3-4d3c-b9b1-9fb227e15317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_881d2648-16d5-4b0f-8455-333f723dd233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc627979-580d-42ff-87f9-72f185ff83f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c1cf7ad-dccd-4502-b51b-e6878b32a7e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e3cea99-52ab-4572-a2f7-6ce19c94f86b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc8a647e-410d-4008-9a55-68854219c87e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a72d7d1-fd42-40dc-a974-f728dcafb2db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ef1f41f-a1a4-42d6-8454-db92942dad65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ed7ca7f-61f0-4950-bc7b-887b37ebb035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96bf1cf8-19d9-4d23-983b-756892fd1ff2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bebca71-1135-472b-9d92-4845eaa4225b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbc0b09b-357b-4c3b-8a22-3402ebee19be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_230e86a9-5523-4a06-934f-3dc71e6f9d7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_380477b0-d459-4fc3-9c66-ba4500d99c6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_990fb369-8f8b-4b5a-aae9-a7fc6e20db39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_609b6c54-99ce-41d7-80bc-f34b80b29690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55f74884-e084-4ff0-ad23-d54d1b1004e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e24acd0-67f6-4df3-a3dd-efc69b71ea26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtmEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1c1fbc0-d63c-43b7-9ffc-6ad92761fe9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c8523e8-eb7f-4abd-894a-724f7b5cac4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97b3c3ab-b721-45c5-a7f8-8b63dd151af6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bca994d1-b72b-4700-b935-07f4a67abfbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e2d29f3-6231-4c61-9133-137f73dc9a4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7091304-4211-4a5d-9df5-4653969e7eae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcd7275c-0ad0-4b30-ad3b-b1c3164715c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockWarrantsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ca307da-79aa-45f0-952e-4bd76b2798b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b56ae1b-3299-420b-a990-12c09f3a38a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2b95b5c-aee8-40eb-8cee-80a189dab5a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fb39eda-b901-4cdd-9a32-7c015ae8998c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PreJanuary12018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56c649f8-782f-49f7-806b-b288e3c37bfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">grts:TwentyOneErieLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd3679ef-3afd-4878-b600-1c49abe1ccaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">grts:PaymentInKindRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_323b919c-2755-47b8-9d63-cde4b993e0b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockWarrantsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17166196-5fed-4356-b3f5-8cfb8175ba74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d996bec-14d2-4de2-a3e4-8cb7d6f0f835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">grts:PrimeRatePlusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f02fe40-880c-4f03-95a7-5100852f2662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fc7bad5-4623-4bd4-9074-af6d60072963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72010145-f061-45d3-99d8-7968eba114aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c139338b-65f8-4c46-9f25-0a151c3415a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grts:TrancheOneAdditionalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af34b684-6740-4987-8a92-febe2af8bcc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39844211-5dca-42b7-88f9-d6efbab7fcb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b402c931-cfd8-4ccd-855e-c61c5c4d4509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34e3705c-6db6-4be4-b4fa-7c9bc996cf50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3371e94-abb3-4b37-894a-d4cc941cf1f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:CommonStockAndOrPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_153cf958-71d1-4706-b096-247c7c793c25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0eca9dc8-8c2d-4467-b653-fbcf9a107933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f06b8a24-0a03-4e60-8fd7-ff440ef473d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ec3fe0f-f635-447a-a11c-3c7d34b2f6e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c884b3b8-4d8e-4b0b-b827-70428cfbef2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e56f5102-fdf2-4a2e-919e-b83d8075a4bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6674d76c-7bfb-45ae-99e4-e6beb133f3b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71524de7-0086-49d7-9417-13f7efabd4d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a86422f-3ae7-47a7-bad8-cd08d7056b6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78bc7e34-ffb9-4a67-a8d3-9000a9429eaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b523bac1-1813-4b7d-a176-50e0e4c5ce15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2634c472-49d7-44a4-939b-8fbd8efaf28d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11b39c77-1e84-4dab-b60a-449a3f0ec0fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a8b90fa-09bc-4b1c-8721-e05897f1cb0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_832bf8ab-67e6-443d-94f3-635dca9a9752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f98f071e-224d-4373-a5ef-1f968dd60d8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80415412-bf63-429e-9fb1-589b8f52c64b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">grts:AdditionalSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80335036-a649-47ad-8c0a-e757af17ab30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c62e59ac-4c24-44ca-b119-f4e4f1990e9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36837d8e-e9eb-4701-ab19-b3e92b394404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94f64277-8372-4366-a998-7f9abe66b1a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6647160-7b5e-4902-9018-3678bdb60427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d082462-60fe-4bab-a12e-cc1b69abbcff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99d8a4f5-b851-48db-a6e7-61d21c828ead"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae54a29d-2a04-4259-9f48-ef7214c95a0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0c4fb4f-d485-41f4-b896-f24d5158e36f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62ff936f-e544-4a9d-b314-581290027ea3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d8263f0-f625-4009-a8d1-d1d4686fc533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">grts:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec0b67b2-f764-458f-92ed-317ed126cda4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c9e7f0e-5e08-4bcf-99d9-2caf8d424011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_687162ff-aef8-4232-aaec-424cb6facc45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd15f766-7703-4fda-b493-3f50dfa95055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d220ecd-5fb6-43bf-b89a-7760384559a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49045c9c-a554-4324-9d92-9288a8abef99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b607420-6945-419e-9f68-f1999ec6386b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddb48a50-1ece-46f1-83ca-c31f25910907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1aaf215-5549-4cb2-84d0-1af1b91cf770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7720965d-c288-42f6-a5f1-b3a368a46f6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cc492f6-e0e9-4dad-b467-56ec30f2625c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e41fdba9-8344-40fa-b5b4-2fdf9fb77166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0d9da16-7637-4109-87b5-f82244fb1e67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8acc4e2f-1b3b-4b68-8d11-a8d5e82e8ae1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87f6c28b-d174-40ca-a77f-7d9cc17bd37c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56b7d049-aed0-43f4-a9e5-39af8293efe5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11b309d8-462b-4ef1-aa32-6924156d9e05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d7f03df-630d-4cad-87f7-614b2528d487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2705b27-ed81-4a40-b53a-b869c0db0739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_489b2495-a848-4ec1-ae47-5647173197f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba0f5eb4-07a4-4e13-a684-5ff64c100781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb0cc90f-3d79-4014-a59c-5f9cf3d2f660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f4d3587-5707-477a-b168-bf3fd63a1a9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c56c0fa-8f94-4d89-a702-a2744c500dc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95d7df61-6b4c-4669-b173-7200708d3836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94a66d4a-e27f-41e7-af27-bdb2e8470a43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79e7ae2f-f2dc-435d-9836-71d230ab5b96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90864408-3972-4c1c-b3b8-325c747633b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e79a84f8-b402-4c06-a64d-be36155f0669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff4ba982-5223-4146-948e-578e4a49e800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68ae43bc-d4ba-46ef-b787-9a1a51cd49b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3daa3e39-3faa-4c82-a714-e0e8c91e437f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c569a47-3f51-4dbb-bef0-103343842833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e91e3869-cc3b-4f71-bed9-29131644937a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc2d3480-29e6-4302-a16c-d5582586d81d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a176657-560e-4e80-8117-9b6ae2388147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4aff01cb-2e26-424b-83a9-fc5583bbca7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75882f1e-2c2b-4a1f-86db-757c8eb713b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4883c551-3073-415a-98c5-41e1b4eb5fea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2f985e7-3856-436a-b098-7d96d2ec9b97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_809dbee3-02e2-412e-b2d8-47155edc68df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02a77114-3193-40d3-9dbf-c33becbaa06d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81630994-2393-4f11-bebf-28fe95a0862c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">grts:FourtyErieLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56766ff0-b624-4f79-bafa-518ca3d728d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8db1bd52-7abc-4eeb-9079-f65d7f8c2c1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grts:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_652f489f-b7e8-4293-9bdf-ece64443c159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10d2b101-f4a6-4310-ae5d-b86276995667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d375ebef-273f-4149-8fb5-f4dc8b70ab63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc0d2494-fb2c-4556-8cfb-8f4cbf34588f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59f476dd-dd0f-4391-85f3-c22402209e5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_858abaa7-2ee9-4eed-9059-5c0651392b80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f752682-fc55-4997-9e66-a13d860093aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afcbe2f3-7dd3-4f15-8cd0-c1d773ae4308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PostDecember312017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c28c4bd4-e62b-479b-85c0-f06e18613cb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_324745d5-c5ad-4d27-9aeb-d15b72a94aaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a69806e-b629-40b1-a18d-6ca603eb73b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ea4d358-ae99-4f6d-8fc9-63316759fe1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_210e3734-9390-4047-8e9e-6e3dac75eb53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84b52d54-d609-4bec-bfa0-0f69992f3096"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a01aa4d-8457-4bc2-9506-f28d7946c515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6117e7e-2c0b-40b3-93ef-a45d9e067e05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cfdaae9-b4b4-47da-bcee-8fd709202da6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">grts:AdditionalSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f5dbf8f-812f-4ffe-9bac-799e8547d2d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65adaa59-8507-450d-85bf-fc379014d32a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_594d238f-4b26-4a67-892c-13ccd5be28e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92f316c5-6c3b-4b21-9a34-423815542a35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">grts:TwentyOneErieLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_969fab0c-3062-4255-b015-879022cee5f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CepInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b83ef403-2580-41b1-b8e4-7f8b49fbd122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f6cd5c7-d0e1-4f81-b026-8285e0af17ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1929cfb6-f656-448a-9d1f-c017d3968257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7439677-3eea-449d-ba9d-9af37deb00df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dded028-e6f7-4811-bc50-0118b2cfd30f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49047d4a-8f63-439f-b6a6-6eae31a95a12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6cfa898-87ba-405c-ab6e-c9fdcb066f80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ceb9099d-6f61-44fa-836a-3e42ead5e190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd4c978d-db21-4656-99dc-dd258c79185d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aadfb6b4-e055-4e7e-82da-133de3937dc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40424169-d409-40ab-8018-026dc29baf15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dbebb0a-177e-4cad-98af-5c26d1198e0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_accde2f9-2b45-4db3-a169-1f19cc7d3a10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9cf46df-3e9b-42ee-b59e-eb74338bcf32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f197d40-b7be-4d35-9b61-95f8f0d5b16c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bc7731c-c74f-40d3-a426-a27f2ea43498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_892682c3-ba06-4a39-8d64-2a527d6f399c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef1d018e-1582-4a48-8fb5-58317716f6c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73444588-46b3-4e78-bfe2-a5e3294d5d4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7de13c8f-bc45-44f8-a635-d16cfe8fed70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aadd6041-4d4d-471c-8758-30fc80ec55da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bec73ca-4c8e-4211-838e-e975e53259b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e7ededb-1c6b-46eb-a02d-62b731c0fb78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f01c328-d8a6-4cb7-a4fa-466c77f2d695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dab2c7d-c16a-4d70-98ba-da1026b8f662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe489596-7a91-4f59-b920-c21979d2bb8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45aa777d-f982-4434-82ec-6619331cbe4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4a6100a-40e8-402e-9f0e-748c76179dad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c50db2bb-cff4-44de-98cc-cf159a62c91f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8900ff95-7d4c-4827-aab8-7f758672ca22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec5c558f-6f66-4786-9d64-c061d097aa83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">grts:AdditionalOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6c766b4-e117-4244-b35d-682f04d91b80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fef5557b-9238-461f-9d8d-6c180e1ea4c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a3ecee8-3b5e-4aae-bb83-c0cec0cf42ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ebc7f82-ba9a-4b25-83ff-fc9b906d1b18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c86bb390-8ee5-48f9-aaf2-89a427c83966"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9faed10b-deab-4fc4-8710-bcca92fcb310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9313b710-4b60-4e1f-b855-6c529b013687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fc9c11d-6f3f-4fe0-a8a9-6900a0dbaae3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bece036d-3f60-44c3-9f38-745d2aac748e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3715424f-76fd-4a70-bcb7-f905fcadf133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4989ea59-69ce-4c78-bdac-1907a737f297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">grts:TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c5761b7-e32b-45b4-becf-3a3c1d25c6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd661f8c-80f3-437b-94c6-39b2d87a6b09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0147e0c5-b128-4b28-ab85-a4f52bbc6baa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d5436e0-6fd6-4397-a2ff-a7a44bc2b153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">grts:TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27904f74-af74-4e0d-afa5-d30b372b7427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_604e35dd-089f-428e-8455-fd00d7905514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grts:RemainingTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a899ce5d-e51a-4a72-98ff-ca5442a68952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f75e133a-4af4-4545-85f4-a47ee76a38e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_024d46a7-8550-44bd-aba2-8e45d258d9a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d50b36e8-0a1e-4794-a381-440b70d6bf56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_292c55aa-2381-4617-8d13-a126676fe9c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6565d2ae-b389-4300-902c-39d3e6e112f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eca7c1be-2d00-460c-b13a-ef933d52f723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8e7ad16-a257-4feb-83b3-d36674cafe9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3295931d-4cf6-4ed7-9b11-e42a2fb87408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17553f60-9678-4458-869e-6553a03fa156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_136628c1-6491-4245-8d0f-4e52ec0eb329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b75ce6de-1369-4078-83cb-4b85b869b56b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e50f083-971a-4ba3-921b-feac5bdbdbc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de1f942a-daf6-4e81-ae8e-4d009e1427bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1b699c9-114f-4029-b6c6-56ba4c312c56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_802790aa-7b46-443c-b5ab-a61e4c953239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23c937ef-9873-4e7b-8401-361c0141be20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cef2dcb9-4d72-401b-9b51-ca2ec7658d4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76e247f4-22b6-4c8d-8bcc-5e1bb0cc9367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1802000b-946a-45cf-9eb1-ab878fd907d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_963260b7-59bc-48cf-9042-018d5b6ef6c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27862347-30f4-4a51-8e69-155b8a286acb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b45ae22-69b8-4005-8ab9-321b6b14f107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d3577c4-db17-46ad-8f60-2c0eb8ff2efa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f58b9b7-d6f4-4132-960e-1c1e70027d7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40e18178-0370-4155-b61f-eb36fe61fe35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f8d1e5e-8021-40a9-af4e-637188703294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6e2641f-a8ab-46ff-80f9-1485fe4c2082"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ec37033-06d8-4931-9ffc-894e1d473c78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd77beb2-c5d1-4f28-877c-995caa385c8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_937c1ade-1906-4692-bcc1-f9d4da800f1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21692f50-7040-4780-a0c1-87357f75dc1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04956885-3d5b-41a6-b35d-28c61c1b73fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcae57c0-074c-498e-8541-1149ef409ac8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6aa0ddf0-5c08-4e9d-a445-164033395389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40a76726-c327-40be-89dd-1c7d982d5836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cc6d2ec-75f6-431d-8f3c-3a9350689079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f1453e1-ff34-4769-91d5-33383d153a3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PostDecember312017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b708b32-49af-4567-b476-e287d5f1de04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b942a7f0-83f7-4782-aba4-13c3f1ec3206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a50f3891-bc8d-430f-8444-964f174a3e3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d80b699-28c2-4bce-ae73-843d1606fcd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd9632a7-d460-4003-8a48-c36e620a0c77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9a61784-ec1b-4689-88b4-604b0656e5e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6215bc4-d5d7-4c03-9ddb-fab6020892dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cba7109a-fc2f-4241-85c7-7086ee1b9b30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce9087bc-c51a-4a95-a2a5-acee855847b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_138bc03a-533d-4ac5-8b52-13e19b3633e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40264f68-b348-4688-915a-7b32fbef6c41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15303075-6c82-43e3-95ac-810ce94f5ad4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39d2c6fe-95e1-4040-9805-ff9f54fdd2c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c95d954-77a7-4eb1-ad4e-f5368fb88348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_082d0a7a-97c2-4602-9ad8-c0587fc21667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25953651-9e56-416b-b771-e53f99a9c2b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9559e13-2a2f-4a2d-bb75-e9c9777abe4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78bd9843-080b-4da9-aa64-2a6e6bff9c0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AmendedAndRestatedCertificateOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58b1c9d9-769e-46b9-8c0b-1522ce09ece0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22a30aad-6a5c-431e-97aa-6d0174548088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70694a1e-9f63-4f26-821a-bb4205582c79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_739f34c4-9e15-4e81-85c9-c9c472575986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8766ca2a-9ff6-4066-8356-6a67a4e463d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_RenewalTerm"><xbrli:measure>grts:RenewalTerm</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>grts:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>grts:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_97423d5b-365f-4428-b992-44f03779e075" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.444%;"></td>
    <td style="width:95.556%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c63d63e-250e-4d37-9d4a-9aba7442fdf5" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fcb2ca52-e6b1-4c27-a09e-4c9e7d2dd0ff" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b5a40593-c0f2-4af2-8a8f-f60f06a57e04" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.444%;"></td>
    <td style="width:95.556%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_10c74e4b-4424-4a0b-9e61-007ca1c5c1c2" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                      </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_411e2d1d-9f2d-48ba-b7d7-712438d51076" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38663</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cd38d5c3-87a6-4fdb-b3d7-e7510b0dc845" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.5%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:49.5%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_043fe9ad-d3cf-4bd2-8da3-84c1b1408c16" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2ed7b25-dc92-4e6c-8a63-73be381b92db" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47-4859534</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b76654ae-3f96-43fe-becc-e59fe8f055bc" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5959 Horton Street</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08d1b9e7-a387-4cc8-b95d-9a3c568953f9" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a9d071a1-117a-483f-b920-975619185f09" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emeryville</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6daf24ac-78d0-434e-9a0c-0da781898051" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d30c30b-9daa-48ec-8eac-2ef206ce0565" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94608</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cc922427-ad9c-4166-bae1-a81b8024dc6b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">510</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c580ea45-83e7-4a7e-8e54-003a5a75949e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">871-6100</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.861%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:41.139%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_57b88ea6-6214-4c75-bfbc-45bc689d4060" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3d9fa77d-86a7-4b0b-b979-f476233b31fb" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GRTS</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3ec26380-eb8f-4840-8538-fffa91baf707" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Registered Pursuant to Section 12(g) of the Act: None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d716ecc-2c8b-47c5-ab8d-81fc22798054" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b28591f5-673c-4c1c-877f-2c40243aadfa" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d68f66ce-2852-46d9-b433-caca7aff35d7" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c44bcb08-0be9-4122-a8ba-ab3ec6b0cd3e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.898%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_904660a9-34a3-403c-8d6e-fc7c0da3d174" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9701aae4-6858-4e21-b170-a91f66db1e3c" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08d296ba-8a0e-4d88-94c8-83222276d777" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2094eee5-625e-4d6a-9549-31fe975fdf48" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3bee35ff-5c24-4e2c-bda7-7ae6439177c0" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d6e0b732-35d0-4cca-944a-5400d102cb13" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2022 (the last business day of the registrant&#x2019;s most recently completed second fiscal quarter) was approximately $</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cb1826d-d1d0-48b5-b867-9237eb862a3d" contextRef="C_c0c7b78e-f4bd-4f7d-a7d7-c851651f4d4e" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">171.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing price of the registrant&#x2019;s common stock, as reported by the Nasdaq Global Select Market on June 30, 2022 of $2.42 per share. Shares of the registrant&#x2019;s common stock held by each executive officer, director, and holder of 5% or more of the outstanding common stock have been excluded in that such persons may deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 7, 2023 was </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30c71761-87d4-44ab-abec-c5b1d3db776f" contextRef="C_dd15f766-7703-4fda-b493-3f50dfa95055" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,661,978</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8642d2ec-fbfd-47ea-accd-25f92e7283ba" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, scheduled to be held on June 16, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the fiscal year to which this report relates.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.0%;"></td>
    <td style="width:86.0%;"></td>
    <td style="width:5.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_related_to_foreign_ju"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K, including &#x201c;Business&#x201d; in Part I Item I and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; in Part II Item 7, contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical fact are statements that could be deemed forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;positioned,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sufficiency of our capital resources and timing of our cash runway, as well as our actual needs for additional financing and our ability to obtain additional capital;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our clinical and regulatory development plans for our product candidates;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding the potential market size and size of the potential patient populations for our product candidates, in particular those within the GRANITE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, SLATE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and CORAL programs, and any future product candidates with limited patient populations, if approved for commercial use;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding the data to be derived in our ongoing and planned clinical trials including, in particular, our expectations for the size and design of our planned clinical trials, timing of commencement and initiation of our trials and the timing of the availability of data from such trials;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding our Gritstone EDGE&#153; artificial intelligence and vaccine platforms, including our ability to utilize (i) our Gritstone EDGE&#153; platform to predict the tumor-specific neoantigens that will be presented on a patient&#x2019;s tumor cells and identify highly conserved T cell epitopes for durable protection for infectious diseases and (ii) our vaccine platform to deliver selected antigens to the patient&#x2019;s immune system to drive the destruction of tumors or virally-infected cells;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of commencement of our future nonclinical studies, clinical trials and research and development programs;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to discover, develop and advance product candidates into, and successfully complete, clinical trials;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans and strategy regarding maintaining existing and entering into new collaborations and/or partnerships;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our product candidates;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations with respect to the commercialization, marketing and manufacturing of our product candidates;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the implementation of our business model and strategic plans for our business, product candidates and technology platforms, including additional indications for which we may pursue;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding the impact of the COVID-19 pandemic or the end of the COVID-19 pandemic on our operations;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the accuracy of our estimates of our expenses, future revenue and capital requirements;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our future financial performance; and</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments and projections relating to our competitors and our industry, including competing therapies. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 1A. Risk Factors</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and elsewhere in this Annual Report on Form 10-K. Any forward-looking statement in this Annual Report on Form 10-K reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates, including data regarding the estimated patient population and market size for our product candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data are derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph are derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note Regarding Company References</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless the context otherwise requires, the terms &#x201c;Gritstone,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; in this Annual Report on Form 10-K refer to Gritstone bio, Inc. and its subsidiary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">siness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview and Strategy</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology company focused on combining immunological insights with proprietary technologies and capabilities to develop next-generation vaccines. Specifically, we discover, develop, manufacture and deliver vaccine-based immunotherapy candidates against cancer and infectious disease. Our goal is to unlock more potent and durable immunity by harnessing vaccine innovation. We aim to achieve that goal by leveraging our in-house capabilities and technologies to address the shortcomings of currently available vaccines and immunotherapies.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The immune system sits at the nexus of many diseases and we believe that immune response modulation is core to several transformational product classes. Recent advances have pointed to T cells as being central to the success of cancer immunotherapy and critical in the elimination of virally infected cells. We believe that our scientific approach of focusing on generating antigen-specific T cells, particularly the challenging but critical cytotoxic CD8+ T cell subclass has the potential to drive transformational therapeutic and prophylactic benefits.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In oncology, we develop personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA. We have two clinical-stage oncology programs, both for common solid cancers. The first, GRANITE, focuses on development of individualized vaccines based on each patient&#x2019;s tumor DNA/RNA sequence (i.e., each vaccine is developed for each individual patient). The second, SLATE, focuses on development of &#x201c;off-the-shelf&#x201d; vaccines for sets of patients that share common  tumor antigens including neoantigens. The scientific approaches to GRANITE and SLATE are similar, and we believe the technologies we developed to execute against them, i.e., to identify neoantigens accurately and deploy powerful killer T cell-stimulating vectors to deliver them, are capable of driving more potent and durable immune responses. In infectious disease, we develop both therapeutic and prophylactic vaccines targeting both T cells and B cells. We believe we are leading the field of  development and application of self-amplifying mRNA (samRNA), a rapidly-emerging platform technology. Our unique approach to immunogen design, whereby our vaccines deliver, as appropriate, whole proteins to drive neutralizing antibodies (nAbs) and/or protein fragments to drive T cell responses, has the potential to both neutralize incoming pathogens (through nAbs) and kill infected cells through CD8+ T cell recognition of foreign, pathogen-derived peptides displayed on the surface of infected cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Key Technologies and Capabilities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Epitope Discovery: Gritstone EDGE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">E</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pitope </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">D</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iscovery for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nomes) Antigen Discovery and T cell Target Identification Platform</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Antigen presentation to T cells is hard to predict since multiple biological steps must be comprehended within any prediction system, and antigenic peptide fragments are displayed on the cell surface by highly variable human leukocyte antigen (HLA) molecules that vary subject-to-subject. Our proprietary epitope discovery platform, EDGE&#153;, has demonstrated the ability to offer accurate identification of T cell antigens that can be recognized by the immune system on tumor or virally-infected cells.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the case of tumor cells, mutations in tumor DNA provide a large set of altered candidate protein fragments that the immune system can recognize. In cancer, we use EDGE&#153; to identify and select those mutations that are most likely to serve as tumor-specific neoantigens (TSNA), i.e., those neoantigens on the tumor that will best serve as targets for killer T cells.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing cancer immunotherapies that include tumor-specific neoantigens is challenging because tumors typically have hundreds of mutations, but only a small percentage of such mutations result in tumor-specific neoantigens (TSNA). Using EDGE&#153;, we are able to sequence data from a patient&#x2019;s routine core needle tumor biopsy in an effort to predict which mutations will generate TSNAs most likely to be presented on the tumor cell surface by the patient&#x2019;s particular human leukocyte antigens (HLA).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that EDGE&#153; leads the field in TSNA identification and previously available technologies are not able to predict the presence of TSNA with sufficient accuracy to design an effective therapy. We have observed a 9-to10-fold improvement in prediction performance with our EDGE&#153; platform compared to traditional approaches and published these data in Nature Biotechnology in December 2018. We continue to improve on EDGE and intend to continue optimizing its use for our cancer and infectious disease applications.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In infectious disease, we use EDGE&#153; to analyze the DNA/RNA sequence of a pathogen with the goal of predicting which gene fragments will likely function as T cell antigens on the surface of virally-infected cells. EDGE&#153; allows us to design the components of our vaccine candidates to include the specific target antigens for administration to humans (immunogens), with the aim of generating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strong immune responses to those antigens to achieve a desired biological effect. Such immune responses can be prophylactic (e.g., protecting against viral infections) or therapeutic (e.g., treating virally infected individuals with the aim to eradicate the virus).</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first US patent covering the EDGE&#153; technology was issued to us in 2018. We are working to identify novel classes of tumor antigens and continually improve the performance of EDGE&#153;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Next-generation Proprietary Vectors (ChAd and samRNA)</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following the identification of suitable targets with the help of EDGE&#153;, we encode such targets within our vaccine vectors to deliver the payload and stimulate the immune system. We have developed two proprietary vectors that we deploy with the aim of eliciting the desired immune response; chimpanzee adenovirus (ChAd) and self-amplifying mRNA (samRNA). ChAd is well-recognized as a leading vector for induction of CD8+ (killer) T cells. samRNA is a next-generation RNA platform technology that has the potential to offer benefits over mRNA relevant to oncology and infectious disease. We selected ChAd and samRNA because we believe they are the best vectors for inducing and boosting CD8+ T cells in our personalized cancer vaccine programs. We believe our proprietary ChAd and samRNA vectors lead the field.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In oncology, we deploy both vectors via a heterologous prime-boost (vaccination with one vector followed by the other, in this case ChAd then samRNA). In infectious disease, we deploy one or both vectors based on the desired therapeutic or prophylactic immune response. The independent and &#x201c;mix and match&#x201d; application of our vectors is one of Gritstone&#x2019;s core competencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chimpanzee Adenovirus 68 (ChAd)</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ChAd vectors have been utilized in clinical studies in infectious disease and oncology over the past 20 years. They have been demonstrated to be well tolerated and effective at generating rapid and substantial CD8+ and CD4+ T cell responses. Additionally, ChAd vectors can induce B cell immune responses, i.e., elicit nAbs. We have developed a proprietary ChAd vector employing an E4 deletion to improve viral production efficiency in manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">self-amplifying mRNA (samRNA)</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone was the first to introduce samRNA encapsulated in lipid nanoparticles (LNP) into clinical trials in 2018. We believe  that samRNA has the ability to boost pre-existing T cell responses and the potential to drive differentiated immune responses (potent and durable) in infectious disease.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our samRNA vector is based on a synthetic RNA molecule derived from a wild-type Venezuelan Equine Encephalitis Virus (VEEV) replicon with the goal of extending the duration and magnitude of immunogen expression to drive potent and durable immune responses. Our samRNA is delivered in a LNP formulation. We are deploying this vector across our clinical stage programs. Like traditional mRNA vaccines, samRNA vaccines use the host cell&#x2019;s transcription system to produce target antigens to stimulate adaptive immunity. Unlike traditional mRNA, the RNA replicates once inside the cell, theoretically leading to high and durable antigen expression.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential benefits of samRNA may include extended duration and magnitude of antigen expression, strong and durable induction or boosting of neutralizing antibody and T cell immunity (CD8+ and CD4+), dose sparing, and a refrigerator-stable product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Self-amplifying mRNA (samRNA) replicates within transduced cells, potentially driving stronger and more durable immune responses compared to traditional mRNA vaccines</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img97084416_0.jpg" alt="img97084416_0.jpg" style="width:720px;height:332px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In-house GMP Manufacturing</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We manufacture our products at our own fully-integrated good manufacturing practice (GMP) biomanufacturing facilities. Our ability to control the manufacturing of high-quality vaccine products, and scale production, if early data are positive, is critical for efficient clinical development and commercialization. We have invested significant resources in our Cambridge, Massachusetts sequencing lab and our Pleasanton, California biomanufacturing facility to address these needs and position ourselves to control the critical steps in the production of our immunotherapy candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immunogen Design</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immunogen design is a key element in vaccine development, and a foundational aspect of design is understanding how vaccines might work for each individual application. Understanding how to elicit specific beneficial T cell responses is crucial to the development of effective therapeutic cancer vaccines. Successful vaccine strategies for infectious disease pathogens require wholly different approaches for the elicitation of antibodies to the pathogen surface antigen.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our unique approach to immunogen design, whereby our vaccines can deliver both surface antigens to drive neutralizing antibodies (nAbs) and protein fragments to drive T cell responses, enables us to optimize our vaccine candidates to engage both arms of the immune system for both antibody and T cell production. Due in part to our chimeric design capabilities, our vaccines have the potential to both neutralize incoming pathogens (through nAbs) and kill infected cells through CD8+ T cell recognition of foreign, pathogen-derived peptides displayed on the surface of infected cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Translational Immunology</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Through our work, we gain invaluable insights that go from &#x201c;bench-to-manufacturing-to-bedside&#x201d; and back at Gritstone. We have processes in place to translate these insights across our internal functions and systems to optimize our vaccine innovation efforts, incorporate them into our research and development work, advance our programs and optimize our product candidates throughout the development cycle.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A notable example of our translational work is within SLATE, our program focused on developing an &#x201c;off the shelf&#x201d; neoantigen immunotherapy for oncology, where we utilized outcomes from our first candidate (SLATE v1) to develop an optimized, second</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">candidate (SLATE-KRAS), which has since exhibited immunogenic superiority over SLATE v1 in both model systems and in humans. Our continuous learnings regarding fundamental mechanisms of innate and adaptive immunity, including the interplay between CD4+ and CD8+ T cell development, and the evolution of antibody responses following vaccination, are a key element in our effort to develop potent and durable vaccines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our team of industry leaders, each possessing specific expertise across our core disciplines of cancer genomics, immunology and vaccinology, clinical development, regulatory, and biomanufacturing, can successfully deliver groundbreaking vaccine-based immunotherapies for cancer and infectious disease by executing on the following strategic priorities:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continue leveraging our proprietary Gritstone EDGE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> platform and maximize its utility across modalities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use EDGE&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to predict, with high accuracy, tumor targets for our oncology programs. This is critical for our GRANITE program, where each patient&#x2019;s targets are individualized. We continue to improve EDGE by expanding its ability to identify novel classes of tumor antigens (such as gene fusions and alternative splicing) across our programs. We also use EDGE to predict viral epitopes for inclusion in our vaccine candidates against viral targets.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continue deploying and optimizing our next-generation vectors to drive potent and durable immune responses suited to the clinical context. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chimpanzee Adenovirus 68 (ChAd) and self-amplifying mRNA (samRNA) are our two vectors of choice based on their unique and synergistic properties. In multiple studies across our oncology and infectious disease platforms, we have exhibited the ability to deploy them individually and in combination to drive potent and durable immune responses based on the clinical context. We continue to improve and optimize these proprietary vectors for their use across our programs.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continue building, automating, and optimizing our in-house biomanufacturing capabilities to increase scalability and capacity.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the speed, quality, reliability, and scalability of our manufacturing capabilities is a core competitive advantage to our clinical development and potential commercial success. We have successfully internalized all biomanufacturing steps to drive down both cost and production time, as well as establish full control over intellectual property and product quality. We have internalized the majority of our quality control testing elements as well, though we outsource where prudent and feasible. We believe that operating our own manufacturing facility provides us with enhanced control of material supply for both clinical trials and the commercial market, will enable the more rapid implementation of process changes, and will allow for better long-term manufacturing cost control. We have the capability to manufacture every element involved in clinical development of our oncology vaccine-based immunotherapies.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continue advancing the GRANITE program through randomized, controlled trials with the goal of evaluating earlier lines of treatment and additional tumor types. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1/2 clinical data to date have demonstrated initial positive safety results, induction of substantial neoantigen-specific CD8+ T cell responses and molecular responses for our individualized vaccine program. We are pleased with results observed with GRANITE to date in hard-to-treat, late-line CRC patients, and are optimistic we could see similar or better results from neoantigen immunotherapy in earlier lines of treatment where immune responses have the potential to be stronger and tumor genomic complexity is lower. GRANITE is now in a randomized Phase 2/3 clinical trial (GRANITE-CRC-1L) as a first-line maintenance treatment for microsatellite stable colorectal cancer (MSS-CRC). Within this study, we are also evaluating the potential of ctDNA as a new biomarker by which cancer progression could be measured. We believe the potential regulatory approval of our individualized vaccine candidate represents a potentially transformative development within cancer care.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continue advancing and optimizing our SLATE program to include other antigen classes to both broaden applicable patient population and drive multiple antigens per patient</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. SLATE is our &#x201c;off-the-shelf&#x201d; TSNA-directed immunotherapy program for solid tumor cancers. SLATE vaccines are produced and delivered to clinical sites proactively, and can be administered rapidly upon patient selection (achieved by standard commercial screening for driver mutations). Phase 1/2 studies within SLATE have provided proof-of-concept for the approach and enabled optimization of the cassette based on results to date. We now believe the SLATE is now ready for &#x201c;plug and play&#x201d; application across solid tumor indications and shared tumor neoantigen classes. Our long-term vision is to continue optimizing this immunotherapy candidate to include other antigen classes to both broaden addressable patient population and also drive multiple antigens per patient.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conduct research and development on additional pathogens/infectious diseases. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research pipeline focuses on the development of novel therapeutic and prophylactic vaccines across oncology and infectious diseases. Preclinical projects include a therapeutic HPV vaccine with support from the Bill and Melinda Gates Foundation, an influenza (flu) vaccine utilizing the samRNA vaccine platform and our capability of generating chimeric vaccine cassettes to drive broad and potent neutralizing antibodies and CD8+ T cells against these viruses, and a new combination respiratory vaccine candidate against multiple respiratory viruses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pipeline</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our unique capabilities have enabled us to advance potentially differentiated clinical assets across multiple therapeutic areas. The table below summarizes key information about our pipeline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img97084416_1.jpg" alt="img97084416_1.jpg" style="width:720px;height:338px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* </span><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Randomized trial in newly-diagnosed metastatic patients</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Oncology Programs</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immuno-oncology (I-O) represents one of the most significant advances in the history of cancer treatment and has saved and extended the lives of an incalculable number of people since the discovery of the T cell receptor in 1982. However, despite the fields&#x2019; advances, the benefits of today&#x2019;s immunotherapies, namely checkpoint inhibitors (CPIs), are limited only to those patients whose immune systems have recognized their tumor. Within CPI therapy, solid tumor patients, whose tumors have been infiltrated by CD8+ T cells (commonly referred to as &#x201c;hot&#x201d; tumors), typically respond to therapy, while the majority of patients, whose tumors lack immune infiltration (commonly referred to as &#x201c;cold&#x201d; tumors), typically develop disease progression and death. The primary challenge to the field today, and our approach to oncology, is to extend the positive outcomes seen in &#x201c;hot&#x201d; tumors to &#x201c;cold&#x201d; tumors by activating (aka &#x201c;priming&#x201d;) de-novo aka na&#xef;ve T cells, thus enabling the immune system to recognize the tumor and form an army of neoantigen-specific CD8+ T cells to enable tumor destruction.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immunologically &#x201c;cold&#x201d; tumors represent many of the deadliest and &#x2018;hardest-to-treat&#x2019; cancers we know today, and unleashing the immune system (notably CD8+ T cells) against them could represent the next transformational advance in I-O.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone&#x2019;s Approach: Induce CD8+ T cells Against &#x201c;Cold&#x201d; Solid Tumors Using Antigen Selection + Prime-boost Approach</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img97084416_2.jpg" alt="img97084416_2.jpg" style="width:720px;height:352px;" />&#160;</p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neoantigens are a novel class of targets for cancer immunotherapy and have been validated in cancer patients as potentially the most critical T cell targets. Neoantigens comprise short, tumor-specific, mutated peptide sequences presented on cancer cells, referred to as tumor-specific neoantigens (TSNA).</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When a solid tumor patient responds to CPI therapy, there is abundant evidence they do so because T cells that recognize tumor-specific neoantigen (TSNA) are activated, enabling them to traffic to and engage the tumor. In GRANITE, we sequence the patients&#x2019; tumor in-house and then use EDGE&#153; to identify those mutations most likely to serve as TSNA. In SLATE, identifying patients&#x2019; driver mutations (and thus whether they are eligible for the &#x201c;off the shelf&#x201d; vaccine) can be done locally using commercially available sequencing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Prime-Boost Approach: Our Construct and Antigen Delivery System for GRANITE and SLATE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Having identified the proper neoantigens to incorporate the vaccine, the next step is to deliver the payload such that it primes na&#xef;ve CD8+ T cells (activating and expanding them) and sustains their activity over time. To achieve this, we deploy a &#x201c;heterologous prime-boost&#x201d; immunization whereby we use ChAd to prime na&#xef;ve T cells and samRNA to augment/sustain or &#x201c;boost&#x201d; the immune response (Figure 3 above). There is abundant literature demonstrating that the heterologous prime boost approach (whereby you &#x201c;prime&#x201d; with one vector and then &#x201c;boost&#x201d; with a different vector, both delivering the same antigens) can elicit greater and longer-lasting levels of immunity compared to the immune response obtained by single vaccination or by inoculations with the same vector.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human infectious disease vaccine experience has taught us that the adenoviral vector is the vector of choice for priming a substantial T cell response consisting of cytotoxic CD8+ T cells (and, to a lesser degree, CD4+ T-helper cells). samRNA was selected as a likely vector of choice for boosting pre-existing T cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that continued strong immune pressure upon the tumor is likely necessary to prevent immune escape by the tumor and drive a durable clinical response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our personalized vaccine candidates consist of (1) a prime vector and (2) a boost vector, both of which contain (3) a neoantigen cassette:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prime Vector (ChAd). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our prime vector is a chimpanzee adenovirus (ChAd). We believe an adenoviral vector is one of the most potent antigen-delivery platforms to prime na&#xef;ve T cells. There is extensive clinical experience demonstrating that </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ChAd vectors are generally well tolerated and consistently generate rapid and substantial CD4+ and CD8+ T cell responses. Findings from our studies are consistent with these general observations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Boost Vector (samRNA).</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our boost vector is a self-amplifying mRNA (samRNA). Once in the cell, the injected source RNA replicates, amplifying the number of copies within the cells and leading to production of large amounts of the delivered target antigens. The presence of large quantities of antigen in an immune-stimulating environment drive profound antigen-specific T cell responses (adaptive immune responses). Additionally, samRNA has demonstrated the ability to be administered multiple times as a boost (aka safe and efficacious when &#x2018;repeat boosting&#x2019;). Additional potential benefits of samRNA include extended antigen expression, nAb and T cell induction, and dose sparing potential.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Neoantigen Cassette</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Within each of the two vectors used for the prime and boost immunizations, we include a cassette that contains neoantigens. For GRANITE, we have designed the cassette to contain 20 TSNA, based on several considerations, including TSNA prediction performance, breadth of the tumor-specific immune response and potential immune competition and manufacturing factors. The cassette is designed and made uniquely for each patient based upon their tumor sequence data and EDGE&#153;-based TSNA predictions.  For SLATE, the cassette is fixed for all patients, and contains common driver mutations (e.g. KRAS), which are known to be processed and presented by certain HLA molecules such as neoantigens that are shared between some patients. Most SLATE patients&#x2019; tumors will only present a single neoantigen contained within the shared cassette. In contrast, although all of the mutations in a GRANITE cassette are contained within the patient&#x2019;s own tumor and can activate T cell responses post immunizations, it is expected that some of the delivered mutations, while present in the tumor genome, will not be processed and presented as a tumor cell surface neoantigenic HLA-peptide complex. We expect this to be acceptable, since these sequences are not wild-type (found in normal cells) and, therefore, only an irrelevant mutated peptide-specific immune response is expected to be elicited.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comparison of Heterologous Prime-Boost with Homologous Prime-Boost and Prime Alone</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img97084416_3.jpg" alt="img97084416_3.jpg" style="width:676px;height:267px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Methods for evaluating efficacy, including circulating tumor DNA (ctDNA)</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The standard method of evaluating early efficacy outcomes in advanced cancer therapy (radiology) is increasingly imprecise in immuno-oncology since it relies upon radiologic assessment of tumor size, with the assumption that tumor shrinkage is necessary for clinical benefit to ensue (RECIST criteria). We aim to drive T cells into lesions, wherein they proliferate and could temporarily increase tumor lesion size (radiologic pseudoprogression), rendering traditional radiologic tools uninformative and, possibly, misleading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that circulating tumor DNA (ctDNA) response data, together with overall survival figures, are the most appropriate and accurate methods to predict and measure outcomes from novel therapeutics such as ours, in patients with advanced, metastatic cancer. Data from Phase 1/2 studies of both GRANITE and SLATE have demonstrated an association between molecular response and overall survival, together with evidence of radiologic pseudoprogression at early timepoints.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRANITE individualized neoantigen-based vaccine program</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GRANITE is our individualized neoantigen-based vaccine program for solid cancers. Development of our GRANITE vaccines begins with receipt of a routine tumor biopsy from the patient. Next, we sequence the tumor sample in-house to identify tumor mutations and apply our proprietary EDGE&#153; platform to identify which mutations form TSNA most likely to be presented on the patient&#x2019;s tumor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Using these TSNA, we design and manufacture a vaccine that contains the relevant neoantigens for that specific patient, which is administered by simple intramuscular injection alongside a patients&#x2019; normal course of treatment. Our individualized immunotherapy candidates are designed to fit easily into a community oncology setting, where most oncology patients are treated. GRANITE was granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of microsatellite stable colorectal cancer (MSS-CRC).</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results from our ongoing Phase 1/2 study evaluating GRANITE combination with checkpoint inhibitors in 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rd</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> line microsatellite-stable colorectal cancer (MSS-CRC) and other advanced solid tumors have demonstrated positive results. Among all cohorts, the vaccine regimen was shown to be generally well-tolerated with no dose limiting toxicities and demonstrated consistent and potent CD8+ neoantigen-specific T cell induction. Additionally, an association between molecular responses (as measured by reduction in circulating tumor DNA, ctDNA) and improved clinical outcomes (including overall survival) was observed in MSS-CRC subjects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of August 31, 2022, the median overall survival (mOS) among molecular responders in this cohort was 22 months (median not yet reached) and demonstrated a molecular response rate of 55% molecular (6/11 evaluable patients; molecular response defined as &#x2265;30% reduction in ctDNA from baseline). This compares to mOS of 7.8 months in evaluable MSS-CRC patients who did not exhibit a molecular response in the study, and a general 6-7 months against standard of care (Trifluridine/tipiracil combo and Regorafenib monotherapy). Interim results from the Phase 1/2 study of GRANITE were published in Nature Medicine in August 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon assessing initial results of the GRANITE Phase 1/2 study, we discussed potential registrational paths with the FDA and subsequently initiated a randomized, controlled Phase 2/3 trial in newly diagnosed metastatic CRC patients that has registrational intent (NCT05141721). The study, which is evaluating GRANITE as a maintenance treatment in patients with first-line MSS-CRC who have completed FOLFOX (or FOLFOXFIRI)-bevacizumab induction therapy, was announced in late 2021 and the first patient was enrolled in January 2022. Preliminary results from the study are expected in 4Q2023.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Activity in Previously Treated MSS-CRC Based on Partial and Complete Molecular Responses and Associated Prolonged Progression-Free Survival</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img97084416_4.jpg" alt="img97084416_4.jpg" style="width:689px;height:419px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SD=stable disease; PD=progressive disease</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">** ctDNA samples not available; Molecular response is defined as &gt;= 30% decrease in ctDNA from baseline at any post-baseline; ctDNA assessment based on Gritstone-developed, tumor-informed assay.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:2.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ctDNA Reduction was Associated with Prolonged Overall Survival in Phase 1/2 trial assessing GRANITE; Median Overall Survival in Molecular Responders Exceeds 22 Months</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img97084416_5.jpg" alt="img97084416_5.jpg" style="width:720px;height:247px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  13 MSS-CRC patients treated; 2 did not have samples for analysis of ctDNA changes relative to baseline and included in without MR group; 6 of 11 were molecular responders; Molecular responders defined as patients with &#x2265;30% reduction in ctDNA</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Mayer et al., The New England Journal of Medicine 372, 1909-1919 (2015)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Grothey et al., The Lancet 381, 303-312 (2013)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes: </span><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GRTS vaccine candidates have not been studied head-to-head with those listed. Data cut-off: Aug 31, 2022; Molecular response is defined as &gt;= 30% decrease in ctDNA from baseline at any post-baseline; ctDNA assessment based on Gritstone-developed, tumor-informed assay.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SLATE &#x201c;off-the-shelf&#x201d; neoantigen-based immunotherapy vaccine</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our &#x201c;off-the-shelf&#x201d; TSNA-directed immunotherapy program, SLATE, utilizes the same heterologous prime-boost approach as GRANITE but contains TSNA that are shared across a subset of cancer patients (rather than TSNA customized for that patient). The key differentiator and advantage of SLATE as compared to GRANITE is speed. SLATE vaccines are produced and delivered to clinical sites proactively and can be administered rapidly upon patient selection (achieved by standard commercial screening for driver mutations). We believe vaccines capable of targeting neoantigens from common tumor driver mutations, such as SLATE, have a clear potential clinical utility and commercialization advantages that are complementary to individualized vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An initial version of SLATE (SLATE v1) was studied in a Phase 1/2 study in patients with metastatic solid tumors (n = 26). SLATE v1 demonstrated induction of CD8+ T cells against multiple KRAS driver mutations and greatest activity was observed in a subset of NSCLC patients with KRASmut G12C mutations. With these initial data, we developed a second SLATE candidate that exclusively includes epitopes from mutated KRAS (SLATE-KRAS) and evaluated it under the same study protocol. In results shared during ESMO 2022, SLATE-KRAS exhibited immunogenic superiority over v1 in human HLA-transgenic mice and cancer patients, and demonstrated similar molecular response and overall survival trends as those seen in Phase 1/2 study of GRANITE. In 38 patients with advanced solid tumors evaluating both SLATE v1 (n =26) and SLATE-KRAS (n=12), the candidates demonstrated a 39% molecular response rate (MRR) in evaluable patients with MSS-CRC and NSCL and among the 18 patients with NSCLC, a molecular response was correlated with extended median OS (mOS of 9.6 months in molecular responders vs. 4.5 months in non-responders).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the results to date demonstrate our ability to both accurately define shared neoantigen targets and engineer the SLATE cassette and vaccine to optimize immune response based on those specific mutations. Having optimized and validated the SLATE cassette, we now believe the SLATE platform is ready for &#x201c;plug and play&#x201d; application across solid tumor indications and shared tumor neoantigen classes. In advancing SLATE, we aim to combine the potential benefits of the full spectrum of tumor antigens with the practicality of the &#x201c;off-the-shelf&#x201d; approach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Off-The-Shelf Immunotherapy Platform, SLATE Ready for Application Across Solid Tumor Indications and Shared Tumor Neoantigen Classes</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img97084416_6.jpg" alt="img97084416_6.jpg" style="width:591px;height:261px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* CTAs &#x2013; cancer testis antigens; HERVs &#x2013; human endogenous retroviruses; neoORFs &#x2013; noncanonical open reading frames</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Infectious Disease Programs</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have two clinical-stage infectious disease programs, a collaboration with Gilead Sciences, Inc. (Gilead) to develop a therapeutic vaccine for human immunodeficiency virus (HIV) and CORAL, a second-generation SARS-CoV-2 program. The HIV program represents the first therapeutic application of our platform against an infectious disease. CORAL serves as proof-of-concept for our ability to develop potent, durable self-amplifying mRNA (samRNA) vaccines for prophylactic application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HIV Vaccine in Collaboration with Gilead Sciences, Inc.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, we entered into a collaboration, option and license agreement with Gilead to research and develop a vaccine-based immunotherapy for HIV. Together, we aim to develop an HIV-specific therapeutic vaccine using our proprietary prime-boost vaccine platform, comprised of samRNA and adenoviral vectors, with antigens developed by Gilead. Under the terms of the agreement, Gilead invested $60.0 million, consisting of a $30.0 million upfront cash payment and a $30.0 million equity investment at the closing. Gilead is responsible for conducting a Phase 1 study for the HIV-specific therapeutic vaccine and holds an exclusive option under the collaboration to obtain an exclusive license to develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. We are also eligible to receive up to an additional $725.0 million if the option is exercised and if certain clinical, regulatory and commercial milestones are achieved, as well as mid-single-digit to low double-digit tiered royalties on net sales upon commercialization. The HIV program is currently in Phase 1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CORAL &#x2013; Second Generation COVID-19 Vaccine Program</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CORAL program was initiated in 2021 in response to emerging limitations of first-generation COVID-19 vaccines, and today, serves as proof-of-concept for our ability to drive more potent and durable responses than those of current vaccines in prophylactic applications. As seen in COVID-19 and other infectious diseases, immune responses can vary, viruses mutate, and neutralizing antibodies wane, necessitating re-dosing (boosters). An approach capable of inducing a potent, broad immune response could have utility across a variety of viral and infectious diseases,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In multiple ongoing Phase 1 trials, we have generated early data demonstrating the potential ability of our vaccines to elicit potent and durable neutralizing antibody responses, and potent cytotoxic cellular responses against Spike and other conserved targets regions of the virus. These results have also provided early signals of the potential advantages of self-amplifying mRNA over first-generation mRNA.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Across the three active Phase 1 trials (CORAL-BOOST, CORAL-CEPI and CORAL-NIH), there are multiple constructs being evaluated with various antigenic cassettes designed to target Wild Type, Beta and Omicron variants. The trials are evaluating our approach in different populations including elderly adults, immunocompromised individuals, those na&#xef;ve to the virus, and previously</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vaccinated individuals using different vaccine regimens. In all, these trials are designed to answer core questions regarding self-amplifying mRNA dose regimen, and the patient populations that could be applicable to other infectious diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our CORAL vaccine candidates have the potential to improve both B cell and T cell responses to Spike and other viral proteins. By creating a cassette that targets several viral antigens including Spike protein and additional TCE from the SARS-CoV-2 virus, some of which are highly conserved between viral strains (such as SARS and SARS-CoV-2), we believe our vaccine candidates may have pan-coronavirus potential to protect against future coronavirus pandemics. While mutations in the Spike protein may reduce protection by antibodies (since the antibody target changes its shape), broad T cell immunity and long-term memory to different viral proteins may provide a second layer of clinical protection. The CORAL program is supported by the Bill &amp; Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovation (CEPI) and the National Institute of Allergy and Infectious Diseases (NIAID).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical Research</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beyond GRANITE, SLATE, CORAL and the HIV collaboration with Gilead, we continue to apply our broad set of capabilities in oncology and infectious diseases through promising preclinical work and partnerships. These projects include development of an optimal immunogen in the context of human papillomavirus (HPV) that is supported by the Gates Foundation. We are also researching the development of an influenza (flu) vaccine and a new combination respiratory vaccine candidate against multiple respiratory viruses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New Developments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Randomized, Phase 2 Trial in SLATE</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, we announced plans to initiate a randomized, Phase 2 study evaluating KRAS-directed SLATE in patients with newly diagnosed metastatic cancer. We expect to initiate this randomized study, which is separate from the ongoing Phase 1/2 study in SLATE, in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NCI Clinical Trial Collaboration</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, we entered into a clinical trial agreement with the National Cancer Institute (NCI) to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone&#x2019;s KRAS-directed vaccine candidate, SLATE-KRAS in a Phase 1 study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and Collaborations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HIV Vaccine in Collaboration with Gilead Sciences, Inc.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, we entered into a collaboration, option and license agreement with Gilead to research and develop a vaccine-based immunotherapy for HIV. Together, we aim to develop an HIV-specific therapeutic vaccine using our proprietary prime-boost vaccine platform, comprised of samRNA and adenoviral vectors, with antigens developed by Gilead. Under the terms of the agreement, Gilead invested $60.0 million, consisting of a $30.0 million upfront cash payment and a $30.0 million equity investment at the closing. Gilead will be responsible for conducting a Phase 1 study for the HIV-specific therapeutic vaccine and holds an exclusive option under the collaboration to obtain an exclusive license to develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. We are also eligible to receive up to an additional $725.0 million if the option is exercised and if certain clinical, regulatory and commercial milestones are achieved, as well as mid-single-digit to low double-digit tiered royalties on net sales upon commercialization. Gritstone and Gilead received IND clearance for this program in December 2021, and the program is currently in Phase 1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Strategic Collaboration with 2seventy bio</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2018, we entered into a research collaboration and license agreement with bluebird bio, Inc. (bluebird), to utilize our EDGE&#153; platform to identify and validate tumor-specific targets and provide TCRs directed to 10 selected targets for use in bluebird&#x2019;s cell therapy platform. In November 2021, bluebird assigned the research collaboration and license agreement to its affiliate, 2seventy bio, Inc. (2seventy), in connection with an internal restructuring and subsequent spin-out of 2seventy (such research collaboration and license agreement, as assigned, 2seventy Agreement). In connection with the 2seventy Agreement, we received a non-refundable up-front cash payment of $20.0 million and an additional $10.0 million in equity investment in our Series C convertible preferred stock. We are also eligible to receive up to an aggregate of $1.2 billion in development, regulatory and commercial milestones associated with 2seventy&#x2019;s resulting cell therapy products, as well as tiered, single-digit royalties on sales of the TCR immunotherapy products that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">utilize the TCRs discovered by us. The royalty term for each TCR immunotherapy product shall be determined on a product-by-product and country-by-country basis and will commence on the first commercial sale of each product in a country and end on the latest of: (i) expiration or termination of the last to expire valid claim of the last licensed patent that covers the product pursuant to the  2seventy Agreement; (ii) expiration of all periods of regulatory exclusivity for the product in such country (in respect of sales in that country); and (iii) 10 years after the first commercial sale of such product in such country (in respect of sales in that country). 2seventy will be solely responsible for all costs and expenses of its development, manufacturing, and commercial activities for resulting therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The identification, validation, selection and development of the TCRs will be conducted during an estimated 5-year research term and may be extended by an additional year under certain conditions. The collaboration will be governed by a joint steering committee with representatives from Gritstone and 2seventy. We and 2seventy have exchanged non-exclusive licenses to carry out the research program, and, on a selected target-by-selected target basis, we have granted 2seventy an exclusive worldwide license to research, develop, and commercialize resulting cell therapy products directed to such targets, including rights to utilize TCRs discovered by us. The collaboration term ends on a country-by-country and product candidate-by-product candidate basis based on completion of all payments owed to us by 2seventy thereon. Either party may terminate the 2seventy Agreement upon written notice to the other party in the event of the other party&#x2019;s uncured material breach, subject to a dispute resolution process. In addition, 2seventy may terminate the 2seventy Agreement for convenience upon prior written notice to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Arbutus Biopharma Corporation and Protiva Biotherapeutics</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 16, 2017, we executed a license agreement with Arbutus Biopharma Corporation (Arbutus) and Protiva Biotherapeutics and subsequently amended certain terms in July 2018 (such amended license agreement, Arbutus License Agreement). Arbutus is a leader in LNP technology with a broad intellectual property estate and a large library of LNPs, including multiple LNPs being used in clinical development by its partners, as well as the chemistry expertise to synthesize novel LNPs with properties optimal for samRNA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Arbutus License Agreement, Arbutus granted us a worldwide, exclusive (even as to Arbutus, subject to certain limited exceptions), sublicensable, transferable license, to research, develop, manufacture, and commercialize our novel RNA-based platform for intracellular delivery of samRNA encoding TSNA in combination with one or more of Arbutus&#x2019; proprietary LNPs. The licensed technology includes Arbutus&#x2019; portfolio of proprietary and clinically validated LNP products and associated intellectual property and includes technology transfer of Arbutus&#x2019; manufacturing know-how. Following the execution of the Arbutus License Agreement, we have identified an LNP formulation that we believe will be optimal for use in our GRANITE and SLATE clinical trials. Our goal is to deliver a second-generation samRNA immunotherapy that has the potential to serve as a homologous prime-boost immunotherapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Arbutus License Agreement, we paid Arbutus an upfront payment of $5.0 million. We also agreed to make (i) aggregate payments of up to $73.5 million upon the achievement of specified development milestones for up to three products, (ii) an aggregate $50.0 million in commercial milestone payments and (iii) royalty payments in the low single-digits on net sales of licensed products for a royalty term lasting until the expiration of the last patent covered under the Arbutus License Agreement. Following acceptance of our first IND in September 2018, we made the first milestone payment of $2.5 million to Arbutus. In August 2019, a milestone was met following the initial patient treatment of SLATE in our GO-005 clinical trial. In connection with such milestone, we recorded $3.0 million as research and development expenses in 2019 and made the milestone payment in October 2019. Further milestone payments are not expected to occur before 2023.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Arbutus License Agreement continues in effect until the last to expire royalty payment or early termination. The Arbutus License Agreement is terminable by us for convenience with 60 days prior written notice, upon payment of a no-cause termination sum. We may also terminate it in the event of material adverse safety data for a product, failure to achieve a primary or secondary efficacy endpoint, or if a regulatory authority takes action that prevents us from commercializing any product. Either party may terminate the Arbutus License Agreement for material breach, and Arbutus may terminate it for abandonment or if we challenge Arbutus patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Genevant Sciences GmbH</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 20, 2020, we entered into an Option and License and Development Agreement with Genevant Sciences GmbH (Genevant, and such agreement, 2020 Genevant Agreement). Pursuant to the 2020 Genevant Agreement, Genevant granted us exclusive license rights under certain intellectual property related to Genevant&#x2019;s lipid nanoparticle technology (LNP Technology) for a single indication (HIV), and we agreed to pay Genevant an initial payment of $2.0 million, up to an aggregate of $71.0 million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The 2020 Genevant Agreement expands our intellectual property rights to the LNP technology originally obtained pursuant to our Arbutus License Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the 2020 Genevant Agreement, Genevant also granted us certain options to expand the licensed field beyond the single indication. If we exercise any options under the 2020 Genevant Agreement to expand the licensed field, we would be required to pay to Genevant additional option exercise fees, certain development, regulatory and commercial milestones and royalties on net sales of licensed products in respect of the expanded licensed field. We also granted Genevant a nonexclusive license to certain intellectual property developed under the Arbutus License Agreement.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Genevant Agreement continues in effect until the last to expire royalty term or early termination. The 2020 Genevant Agreement is terminable by us for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either us or Genevant may terminate the 2020 Genevant Agreement for material breach, subject to a cure period, and Genevant may terminate it if we challenge a licensed patent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Genevant Sciences GmbH</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 15, 2021, we entered into a Non-Exclusive License and Development Agreement with Genevant (2021 Genevant Agreement). Pursuant to the 2021 Genevant Agreement, we obtained a nonexclusive license to Genevant&#x2019;s LNP Technology to develop and commercialize self-amplifying RNA vaccines against SARS-CoV-2. Further, we (i) agreed to pay Genevant an upfront payment of $1.5 million and (ii) are subject to (x) additional payments up to an aggregate of $141.0 million per product, upon achievement of certain development and commercial milestones and (y) tiered royalties ranging from the mid-single digits to mid-teens on net sales of licensed products for a royalty term lasting until the later of expiration of the last covered patent under the  2021 Genevant Agreement. In certain scenarios, in lieu of milestones and royalties, Genevant will be entitled to a percentage of any amounts that we receive from sublicenses to the COVID-19 program subject to certain conditions. The 2021 Genevant Agreement further expands our intellectual property rights to the LNP technology originally obtained pursuant to the Arbutus License Agreement.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The 2021 Genevant Agreement continues in effect until the last to expire royalty term or early termination. The 2021 Genevant Agreement is terminable by us for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either us or Genevant may terminate the 2021 Genevant Agreement for material breach, subject to a cure period, and Genevant may terminate it if we challenge a licensed patent.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Genevant Agreement contains, among other provisions, representation and warranties, indemnification obligations, confidentiality, audit and inspection, and intellectual property sharing provisions in favor of each party that are customary for an agreement of this nature.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CEPI Funding for CORAL Program</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2021, CEPI agreed to provide funding of up to $20.6 million to us to advance our CORAL program, with an initial clinical trial of our second-generation COVID-19 vaccine in South Africa. Under the terms of that agreement (CEPI Funding Agreement), CEPI will fund a multi-arm Phase 1 study evaluating the CORAL program&#x2019;s samRNA vaccine in na&#xef;ve, convalescent, and HIV+ patients. The study initially planned to evaluate two different samRNA vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CEPI Funding Agreement also provides for an agreement on the importance of global equitable access to the vaccine produced pursuant to the CEPI Funding Agreement. The vaccine, if approved, is expected to be made available for procurement and allocation to the COVAX Facility, which aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope and continuation of the CEPI Funding Agreement may be amended depending on ongoing developments of the COVID-19 outbreak and the success of our COVID-19 vaccine candidate developed under the CEPI Funding Agreement relative to other third-party COVID-19 vaccine candidates or treatments. In December 2021, we and CEPI amended the CEPI Funding Agreement to provide for up to $5 million in additional funding to conduct a Phase 1 clinical trial of the CORAL program&#x2019;s Omicron vaccine candidate in South Africa.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the World Health Organization (WHO), CEPI or a regulatory authority having jurisdiction over a clinical trial performed under the CEPI Funding Agreement determines that a third-party product candidate has substantially greater potential than the our COVID-19 vaccine candidate developed under the CEPI Funding Agreement and should be prioritized instead for a particular trial, we must consider in good faith any written request of CEPI not to proceed with a clinical trial of such COVID-19 vaccine candidate (the determination of whether to proceed or not with such trial shall be made by us in our sole discretion). In addition, CEPI has the right to unilaterally terminate the CEPI Funding Agreement upon prior written notice if CEPI determines that (i) there are material safety, regulatory, scientific misconduct or ethical issues with the project undertaken by us under the CEPI Funding Agreement, (ii) the project</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undertaken by us under the CEPI Funding Agreement must be terminated, (iii) we become unable to discharge its obligations under the CEPI Funding Agreement, (iv) we fail to meet certain criteria set forth in the CEPI Funding Agreement, or (v) we commit fraud or a financial irregularity, as such terms are defined in the CEPI Funding Agreement. Certain termination rights for CEPI are subject to cure periods.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For additional information on all our license and collaboration arrangements, see &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; in Note 7 to our consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing is a vital component of our individualized immunotherapy platform, and we are devoting significant resources to manufacturing and process development in an effort to maintain the potential safety and efficacy of our product candidates, as well as to reduce our per-unit manufacturing costs and time to market. The production of our individualized immunotherapy candidates requires two distinct elements for each patient: tumor biopsy analysis to determine candidate neoantigens, followed by manufacture of vectors containing an individualized cassette encoding the selected neoantigens. SLATE and CORAL contains a fixed cassette with TSNA or SARS-CoV-2 vaccine constructs that is shared across cancer patients/subjects rather than a cassette unique to an individual patient, which is designed to provide an off-the-shelf alternative to our individualized manufactured product candidate, GRANITE. The manufacture of these vectors involves complex processes, including per-patient plasmid production, mammalian cell production of virus and RNA synthesis and lipid encapsulation. SLATE and CORAL manufacturing, as a fixed, &#x201c;off-the-shelf&#x201d; product candidate, are not time-sensitive and while manufacturing scale differs, both are relatively straightforward operationally. GRANITE, on the other hand, is an &#x201c;N of 1&#x201d; product candidate and is manufactured in real-time for each patient, which involves a greater logistical burden.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to carefully manage our fixed-cost structure, maximize optionality, and drive long-term cost of goods as low as possible. We have used a hybrid approach to manufacturing and release of our individualized immunotherapy candidates whereby certain elements of our product candidates are manufactured and tested on an outsourced basis at CMOs, and other elements of our product candidates are manufactured and released internally at the 42,600 square foot manufacturing facility we established in 2017 in Pleasanton, California, all designed in compliance with cGMP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our manufacturing process begins with receipt of a patient&#x2019;s routine biopsy and blood sample at our Cambridge, Massachusetts facility, where TSNA identification is performed using the EDGE&#153; platform. The TSNA sequences generated by our platform are sent electronically to our Pleasanton, California manufacturing facility to generate the patient-specific TSNA cassette, which is then cloned into each of the ChAd and samRNA vectors and amplified. Following amplification, the ChAd vector containing the cassette is further manufactured into the final drug product and vialed onsite. In parallel at the Pleasanton facility, the samRNA vector is manufactured into RNA, formulated into LNP, and vialed onsite. Currently, the entire manufacturing process, from biopsy receipt at our facilities to the release and shipment of the individualized immunotherapy candidate to the clinical site for patient administration, often takes approximately 16-20 weeks in principle. Our goal is for this production and release timeline (and associated cost) to diminish over time due to process scaling, potential improvements in production and testing technologies, internal process expertise, internalization of potential reductions in regulatory testing requirements based on clinical experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To achieve this, our process development group is focused on several key initiatives. The first is investigating novel approaches to manufacturing our products, including process optimization and quality by design of each intermediate, drug substance and drug product. Additionally, we are systematically characterizing our manufacturing processes, including product intermediates and manufacturing unit operations. This characterization effort is designed to enable us to implement process changes over the entire product lifecycle and to quickly react to evolving process technologies that can lead to reductions in per-unit manufacturing costs and shorter process cycle times. In addition, we plan to establish automated, closed-platform manufacturing processes. Our goal is for these processes to enable us to conduct manufacturing in a lower-classified, lower cost manufacturing environment for multiple steps of our drug product manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our CORAL program, manufacturing of early-stage clinical lots was initiated on our Pleasanton, California manufacturing facility towards the end of 2020 and we have continued to produce next generation, variant-specific clinical lots through 2021 within this facility. Product candidates include both samRNA and adenoviral vectors to deliver SARS-CoV-2 viral antigens. Additional scale-up activities involving CMOs will be needed as the CORAL program progresses leading to large demand for the product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our manufacturing strategy is currently structured to support our U.S., E.U., South African, and Australian development plans. We believe this manufacturing strategy developed for global distribution will enable use in other geographies. Specific supply strategies for other geographies will be developed as part of our clinical and commercial plans for such other geographies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercialization Plan</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently have any approved therapies, and we do not anticipate receiving marketing authorization for our early development candidates in either the United States or other worldwide regions in the near future. An internal expansion of sales, marketing, and commercial distribution capabilities would be developed once we have obtained clinical data that can support licensure following discussions with the FDA or other worldwide health authorities. If and when any of our development candidates are approved for commercialization, we intend to create an infrastructure to support ongoing sales in the United States and, possibly in other regions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and pharmaceutical industries put significant emphasis and resources into the development of novel and proprietary therapies for treatment of cancer and infectious disease. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. We anticipate that we will continue to face increasing competition in our field as new therapies, technologies, and data emerge.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the current standard of care for patients, a number of parties in the field of immunotherapy are pursuing commercial and academic clinical trials. Results from these trials have fueled continued interest in immunotherapy, and our competitors include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the neoantigen space, BioNTech AG (which acquired Neon Therapeutics in May 2020) in collaboration with Genentech Inc., Moderna Therapeutics, Inc. in collaboration with Merck &amp; Co. Inc., Advaxis Immunotherapies, Achilles Therapeutics, Neogene Therapeutics (acquired by Astrazeneca), NousCom AG, Nykode Therapeutics AS in collaboration with Genentech Inc., PACT Pharma, Inc., Transgene SA, and Geneos Therapeutics, Inc. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the infectious disease space, Moderna, Pfizer Inc. in collaboration with BioNTech AG, AstraZeneca plc, Johnson &amp; Johnson, Merck, Novavax, Inc., Sanofi, GlaxoSmithKline plc, Arcturus Therapeutics in collaboration with CSL, and CureVac AG.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the samRNA space, GlaxoSmithKline plc, Arcturus Therapeutics, Inc., HDT Bio, Corp. and Imperial College London in collaboration with AstraZeneca plc.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of our programs are likely to be their efficacy, safety, cost and convenience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our products and services, to operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. We rely on a combination of patents and trade secrets, as well as contractual protections, to establish and protect our intellectual property rights. We seek to protect our proprietary position by, among other things, filing patent applications in the United States and internationally. Our patent estate includes patents and patent applications with claims relating to our products, methods, and manufacturing processes, and broader claims for potential future products and developments. As of December 31, 2022, our solely-owned patent portfolio includes, on a worldwide basis, pending patent applications and issued patents relating to our products, methods, and manufacturing processes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our solely-owned patent estate includes a portfolio of pending patent applications and issued patents, including those related to our epitope discovery platform, next-generation vectors, and immunogen designs. Details regarding these portfolios are provided below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our solely-owned patent portfolio related to our epitope discovery platform , includes domestic and international patent rights with claims related to antigen identification and related compositions, uses and manufacture. Any patents that have or may issue from these patent rights are expected to expire between 2036 and 2043, absent any patent term adjustments or extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our solely-owned patent portfolio related to our next-generation vectors included domestic and international patent rights with claims related to ChAd- and samRNA-based compositions and their related uses and manufacture. Any patents that have or may issue from these patent rights are expected to expire between 2037 and 2043, absent any patent term adjustments or extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our solely-owned patent portfolio related to our immunogen designs included domestic and international patent rights with claims related to oncology and infectious disease immunogen and their related uses and manufacture. Any patents that have or may issue from these patent rights are expected to expire between 2039 and 2043, absent any patent term adjustments or extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to patents, we have filed for trademark registration with the United States Patent and Trademark Office (USPTO) as well as certain other international trademark agencies, for &#x201c;GRITSTONE,&#x201d; &#x201c;GRANITE,&#x201d; &#x201c;SLATE&#x201d; and our logo. Furthermore, we rely upon trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some instances, we submit patent applications directly with the USPTO as provisional patent applications. Provisional applications for patents were designed to provide a lower-cost first patent filing in the United States. Corresponding non-provisional patent applications must be filed not later than twelve (12) months after the provisional application filing date. The corresponding non-provisional application benefits in that the priority date(s) of the patent application is/are the earlier provisional application filing date(s), and the patent term of the finally issued patent is calculated from the later non-provisional application filing date. This system allows us to obtain an early priority date, add material to the patent application(s) during the priority year, obtain a later start to the patent term and to delay prosecution costs, which may be useful in the event that we decide not to pursue examination in an application. We file U.S. non-provisional applications and Patent Cooperation Treaty (PCT) applications that claim the benefit of the priority date of earlier filed provisional applications, when applicable. The PCT system allows a single application to be filed within twelve (12) months of the original priority date of the patent application, and to designate PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the end of the period of two and a half years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Organization. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first two and a half years of filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For all patent applications, we determine claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses we discover for existing technologies and products, assuming these are strategically valuable. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to ensure that maximum coverage and value are obtained for our processes, and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement of the patent laws. The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success will also depend in part on not infringing the proprietary rights of third parties. In addition, we have licensed rights under proprietary technologies of third parties to develop, manufacture and commercialize specific aspects of our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">products. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, alter our processes, obtain licenses or cease certain activities. The expiration of patents or patent applications licensed from third parties or our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future technology may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We further own trade secrets relating to our technology, and we maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our trade secrets and know-how by entering into confidentiality agreements with third parties, consultants and employees who have access to such trade secrets and know-how. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#x2019;s relationship with us are to be kept confidential and not disclosed to third parties except in specific circumstances. In addition, we enter into employment agreements that require employees to assign to us any inventions, trade secrets or know-how that they develop while employed by us. Although we take steps to protect our proprietary information and trade secrets, including through agreements with our employees and consultants, these agreements may be breached, or third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. To the extent that our employees, consultants, scientific advisors or other contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a more comprehensive discussion of the risks related to our intellectual property, please see the section titled &#x201c;Risk Factors&#x2014;Risks Related to Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates biologic products under both the Federal Food, Drug and Cosmetic Act (FDCA) and the Public Health Service Act and their respective implementing regulations. Our product candidates are subject to regulation by the FDA as biological products. Biological products require the submission of a biologics license application (BLA) and licensure, which constitutes approval, by the FDA before being marketed in the United States. None of our product candidates has been approved by the FDA for marketing in the United States, and we currently have no BLAs pending. Failure to comply with applicable FDA or other requirements at any time during product development, clinical testing, the approval process or after approval may result in administrative or judicial sanctions. These sanctions could include the FDA&#x2019;s refusal to approve pending applications, suspension or revocation of approved applications, warning letters, product recalls, product seizures, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#x2019;s good laboratory practice, or GLP, regulations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an IND which must become effective before clinical trials may begin; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an independent Institutional Review Board (IRB) or ethics committee at each clinical site before the trial is commenced;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with the IND, protocol, and FDA&#x2019;s good clinical practice (GCP) regulations to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#x2019;s continued safety, purity and potency, and of selected clinical investigation sites, </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical and Clinical Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, under the National institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (IBC) a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Generally, a separate submission to the IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of BLA approval, human clinical trials are typically conducted in three (3) sequential phases that may overlap or be combined.</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1&#x2014;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2&#x2014;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3&#x2014;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and they must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">BLA Submission and Review</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA unless a waiver or exemption applies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a BLA has been submitted, within sixty (60) days, the FDA first reviews the BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once filed, the FDA&#x2019;s goal is to review standard applications within ten (10) months after the filing date or, if the application qualifies for priority review, six (6) months after the filing date. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#x2019;s continued safety, purity and potency. The FDA may convene an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites, as well as the sponsor, to assure compliance with GCP.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the product will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use. A REMS program may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug&#x2019;s risks, or other elements to assure safe use, such as limitations on who may prescribe or dispense the drug, dispensing only under certain circumstances, special monitoring and the use of patient registries. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new product candidates that meet certain criteria. Product candidates are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for frequent interactions with the review team during product development. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any marketing application for a biologic submitted to the FDA for approval, including a product candidate with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. Sponsors may also obtain a priority review voucher upon approval of a BLA for certain qualifying diseases and conditions that can be applied to a subsequent BLA submission. Generally, priority review designation means the FDA&#x2019;s goal is to take action on the marketing application within six (6) months of the sixty (60) day filing date, compared with ten (10) months under standard review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. FDA may now exercise authority that would require that this study commence during the accelerated approval application process. Products receiving accelerated approval will also be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2017, the FDA established the new regenerative medicine advanced therapy (RMAT) designation as part of its implementation of the 21st Century Cures Act, which was signed into law in December 2016. To qualify for RMAT designation, the product candidate must meet the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like fast track and breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process. In addition, even if a product candidate qualifies for one or more of these programs, the FDA may later decide that it no longer meets the conditions for designation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, meaning there is no previously approved &#x201c;same drug&#x201d; for the same orphan condition, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same drug or biologic for the same orphan disease or indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An Eleventh Circuit decision in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst Pharmaceuticals, Inc. vs. FDA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> regarding interpretation of the Orphan Drug Act exclusivity provisions as applied to drugs approved for orphan indications narrower than the drug&#x2019;s orphan designation has the potential to adversely impact whether certain products will be able to obtain approval for the remaining, unapproved designated condition without demonstrating clinical superiority, although FDA has indicated that it does not intend to apply </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in other scenarios. A designated orphan drug may not receive orphan drug exclusivity that covers the full approved indication if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Emergency Use Authorization</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Commissioner of the FDA, under delegated authority from the Secretary of Health and Human Services (HHS), may, under certain circumstances in connection with a declared public health emergency, allow for the marketing of a product that does not otherwise comply with FDA regulations by issuing an Emergency Use Authorization (EUA) for such product. Before an EUA may be issued by HHS, the Secretary must declare an emergency based on a determination that public health emergency exists that affects or has the significant potential to affect, national security, and that involves a specified biological, chemical, radiological, or nuclear agent or agents (CBRN), or a specified disease or condition that may be attributable to such CBRN. On February 4, 2020, the HHS Secretary determined that there is such a public health emergency that involves the virus now known as SARS-CoV-2, the virus that causes the COVID-19 infection. Once the determination of the threat or emergency has been made, the Secretary of HHS must then declare that an emergency exists justifying the issuance of EUAs for certain types of products (referred to as EUA declarations). On March 27, 2020, the Secretary of HHS declared, on the basis of his determination of a public health emergency that has the potential to affect national security or the health and security of U.S. citizens living abroad that involves SARS-CoV-2, that circumstances exist justifying authorization of drugs and biologics during the COVID-19 pandemic, subject to the terms of any EUA that is issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an EUA declaration has been issued, the FDA can issue EUAs for products that fall within the scope of that declaration. To issue an EUA, the FDA Commissioner must conclude that (1) the CBRN that is referred to in the EUA declaration can cause serious or life-threatening diseases or conditions; (2) based on the totality of scientific evidence available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing the disease or condition attributable to the CBRN and that the product&#x2019;s known and potential benefits outweigh its known and potential risks; and (3) there is no adequate, approved, and available alternative to the product. Products subject to an EUA must still comply with the conditions of the EUA, including labeling and marketing requirements. Moreover, the authorization to market products under an EUA is limited to the period of time the EUA declaration is in effect, and the FDA can revoke an EUA in certain circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences and significant interruptions in manufacturing, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon BLA sponsors and any third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on post-approval clinical studies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are for uses of the product approved by the FDA, that are considered consistent with the approved label, and for which the company has appropriate substantiation, as applicable. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses or promotion that is otherwise false or misleading. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biosimilars and Reference Product Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively ACA) signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA) which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered to a patient more than once, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four (4) years following the date that the reference product was first licensed by the FDA. In addition, the FDA may not approve a biosimilar product until twelve (12) years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves an original BLA containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the competing product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#x201c;interchangeable&#x201d; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA Regulation of Companion Diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may require use of an in vitro diagnostic to identify appropriate patient populations. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, companion diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (PMA).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If use of companion diagnostic is essential to safe and effective use of a biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August 6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#x201c;In Vitro Companion Diagnostic Devices.&#x201d; According to the guidance, for novel candidates such as our product candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#x2019;s Investigational Device Exemption (IDE) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of in vitro companion diagnostic devices on issues related to co-development of these products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA generally requires companion diagnostics intended to select the patients who will respond to treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these in vitro companion diagnostics in conjunction with the review of biologics involves coordination of review by the FDA&#x2019;s Center for Drug Evaluation and Research and by the FDA&#x2019;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are also subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive pre-clinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#x2019;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#x2019;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Regulation Outside of the United States</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we may be subject to a variety of regulations in other jurisdictions, including the European Union, governing, among other things, clinical trials, marketing authorizations, post-marketing authorization requirements and any advertising, promotion, commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ethical, social and legal concerns about gene-editing technology, gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-clinical studies and clinical trials</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, to the United States, the various phases of non-clinical and clinical research in the European Union are subject to significant regulatory controls.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice, as set forth in European Union Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials of medicinal products in the European Union must be conducted in accordance with EU and national regulations and the International Conference on Harmonization (ICH) guidelines on GCPs, as set out in EU Commission Implementing Regulation (EU) 2017/556, EU Regulation (EU) 2016/679, or GDPR, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products (ATMPs). If the sponsor of the clinical trial is not established within the European Union, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#x2018;no fault&#x2019; compensation to any study subject injured in the clinical trial.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (CTR), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the European Union via a Clinical Trials Information System, which contains a centralized EU portal and database.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">member state&#x2019;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors were still able to choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those are governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medicines used in clinical trials must be manufactured in accordance with GMP, as set out in EU Commission Delegated Regulation (EU) 2017/1569. Other national and EU-wide regulatory requirements may also apply.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketing Authorization</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market our future product candidates in the European Union, and in many other foreign jurisdictions, we must obtain separate regulatory approvals. In the European Union, medicinal product candidates can only be commercialized after obtaining a marketing authorization (MA). To obtain regulatory approval of a product candidate (including an investigational biological product) under EU regulatory systems, we must submit a marketing authorization application (MAA). The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAAs:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Centralized MAAs&#x201d; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and is valid throughout the European Union. It is compulsory for certain types of product candidates, such as (i) medicinal products derived from biotechnological processes, (ii) designated orphan medicinal products, (iii) ATMPs such as gene therapy, somatic cell-therapy or tissue-engineered medicines and (iv) medicinal products containing a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for any other products containing new active substances not authorized in the European Union or for product candidates which constitute a significant therapeutic, scientific, or technical innovation or for which the granting of authorization would be in the interests of public health in the European Union.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Committee for Advanced Therapies (CAT), is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which an MAA is submitted. The CAT&#x2019;s opinion is then taken into account by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#x2019;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion, if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs; the manufacturing and control information that should be submitted in a marketing authorization application; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;National MAs&#x201d; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the Mutual Recognition Procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the Reference member state.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the centralized procedure, the maximum timeframe for the evaluation of an MAA by the EMA is 210 days. In exceptional cases, the CHMP might perform an accelerated review of an MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines (PRIME), which provides incentives similar to the breakthrough therapy designation in the United States. In March 2016, the EMA launched a PRIME scheme as a voluntary scheme aimed at enhancing the EMA&#x2019;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for accelerated assessment, but this is not guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#x2019;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, in the European Union, a &#x201c;conditional&#x201d; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and has to be renewed annually until fulfillment of all the conditions (&#x201c;specific obligations&#x201d;). Once the pending specific obligations are fulfilled, it can become a &#x201c;standard&#x201d; MA. However, if the specific obligations are not fulfilled within the timeframe set by the EMA, the European Commission may, based on a scientific recommendation by the EMA, refuse to renew the MA. Furthermore, MA may also be granted &#x201c;under exceptional circumstances&#x201d; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of an MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#x201c;under exceptional circumstances&#x201d; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the European Commission may, based on a scientific recommendation by the EMA, revoke the MA in case the risk-benefit ratio is no longer favorable.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The European Commission is expected to publish new proposed legislation in March 2023 which, if adopted by the European Parliament and the Council of Ministers, will introduce significant number of changes to the regulatory procedures described above. This may potentially affect the MA renewal procedure and the internal organization of the EMA (disbanding of CAT).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data and marketing exclusivity</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The European Union also provides opportunities for market exclusivity. Upon receiving MA, reference products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the European Union until 10 years have elapsed from the initial MA of the reference product in the European Union. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the European Union&#x2019;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex biological products, such as gene or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently be approved in the European Union. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2023, the European Commission is expected to publish new proposed legislation. If adopted by the European Parliament and the Council of Ministers, this legislation will introduce new data and market exclusivity periods which are likely to include additional requirements and modulation mechanisms. Moreover, it is possible that the proposed legislation also foresees a potential reduction in regulatory requirements for the grant of MA for generics and biosimilars.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Medicinal Products</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The criteria for designating an &#x201c;orphan medicinal product&#x201d; in the European Union are similar in principle to those in the United States. A medicinal product can be designated as an orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life threatening or chronically debilitating condition; (2) either (a) such condition affects not more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from the orphan status, would not generate sufficient return in the European Union to justify the necessary investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized for marketing in the European Union or, if such method exists, the product will be of significant benefit to those affected by that condition.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, an application for designation as an orphan product can be made any time prior to the filing of the application for MA. Orphan drug designation entitles a party to incentives such fee reductions or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of an MA, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the regulatory authorities cannot accept another MAA, grant an MA, or accept an application to extend an MA for a similar product for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan (PIP). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The orphan exclusivity period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan drug destination, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the threshold. Granting of an authorization for another similar orphan medicinal product where another product has market exclusivity can happen at any time if: (i) the second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior, (ii) inability of the applicant to supply sufficient quantities of the orphan medicinal product or (iii) where the applicant consents to a second orphan medicinal product application. A company may voluntarily remove a product from the orphan register.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The European Commission is expected to publish new proposed legislation in March 2023 which, if adopted by the European Parliament and the Council of Ministers, will introduce significant number of changes to the market exclusivities granted to orphan medicinal products and the related procedures and requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric Development</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a PIP agreed with the EMA&#x2019;s Pediatric Committee (PDCO). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which an MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all member states and study results are included in the product information, even when negative, the product is eligible for a six-months supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two-year extension of the orphan market exclusivity is granted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the member states. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (PSURs).</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All new MAAs must include a risk management plan (RMP) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another. A new legislative proposal by the European Commission expected to be published in March 2023 is likely to contain new proposed rules restricting comparative advertising of medicinal products in the EU.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aforementioned EU rules are generally applicable in the European Economic Area (EEA), which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, suspension of the conduct of clinical trials, rejection of clinical trial data, or refusal to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal, revocation or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United Kingdom left the European Union on January 31, 2020, following which existing EU medicinal product legislation continued to apply in the United Kingdom during the transition period under the terms of the EU-UK Withdrawal Agreement. The transition period, which ended on December 31, 2020, maintained access to the EU single market and to the global trade deals negotiated by the European Union on behalf of its members. The transition period provided time for the United Kingdom and European Union to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement (TCA) and became effective on the January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#x201c;retained EU law&#x201d;. However, new legislation such as the EU CTR will not be applicable. The UK government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#x2018;appropriate authority&#x2019; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) is the UK&#x2019;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland (Great Britain); broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a guidance on how various aspects of the UK regulatory regime for medicines will operate in Great Britain and in Northern Ireland following the expiry of the Brexit transition period on December 31, 2020. The guidance includes clinical trials, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the United Kingdom. The new guidance was given effect via the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019 (Exit Regulations).</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in Great Britain (only), free of charge on January 1, 2021, unless the MA holder chooses to opt-out. In order to use the centralized procedure to obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, after Brexit, companies established in the United Kingdom can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the United Kingdom and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the United Kingdom. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a Great Britain authorization or use the MHRA&#x2019;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in Great Britain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There will be no pre-MA orphan designation. Instead, the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the market (i.e., the prevalence of the condition in Great Britain, rather than the European Union, must not be more than five in 10,000). Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in Great Britain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulation of Companion Diagnostics</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, in vitro diagnostic medical devices (IVDs) were regulated by Directive 98/79/EC (the Directive) which regulates the placing on the market, the CE marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufactures and devices as well as the vigilance procedure. In vitro diagnostic medical devices were required to comply with the requirements provided for in the Directive, and with further requirements implemented at national level (as the case may be). For certain IVDs, compliance with the essential requirements was subject to assessment by a notified body. Notified bodies are entities designated by the relevant NCAs and are responsible for assessing the conformity of IVDs before they are placed on the EU market. Under the Directive, the majority of IVDs could be placed on the market as a result of the manufacturer self-certifying the IVD as being in conformity with the essential requirements, without the involvement of a Notified Body.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Directive was replaced by the Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices (EU IVDR) that entered into force in May 2017, and which initially included a 5-year transition period until its original effective date of May 26, 2022. Unlike the Directive, that specifies certain requirements that must be achieved by each Member State and permits each Member State to decide how to transpose the Directive into national law to meet those requirements, the IVDR has direct binding legal force throughout every Member State without the need for national implementation. However, due to multiple challenges to the EU IVDR being ready for full application by the May 2022 implementation date, Regulation (EU) 2022/112 of the Parliament and of the Council was published on 25 January 2022 allowing for a delay to the application of the IVDR by amending the transition provision for certain in vitro diagnostic medical devices. For products classified as Class C under the IVDR, the transition period allows for legacy devices with a valid declaration of conformity drawn up prior to May 26, 2022 to continue to be placed on the market until May 26, 2026. However, certain IVDR requirements, including post-market surveillance, market surveillance, vigilance, and registration of economic operators and devices remained effective on the May 26, 2022 implementation date.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EU IVDR introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue a CE certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or an MAA for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authority or the EMA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business, which may constrain the financial arrangements and relationships through which we and our partners research, sell, market and distribute any products for which we obtain marketing approval. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws regarding drug pricing and payments and other transfer of value to physicians and other healthcare providers. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data Privacy and Security Laws</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data in certain circumstances, many of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. No regulatory authority has granted approval for a individualized cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#x2019; share of sales to federal health care programs. Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.   Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace from February 15, 2021 through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted, including aggregate reductions of Medicare payments which went into effect April 1, 2013 and will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 unless additional Congressional action is taken.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as Executive Orders, designed to, among other things, reduce or limit the prices of drugs and make them more affordable for patients, such as by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries, reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs, bring more transparency to drug pricing rationale and methodologies, enable the government to negotiate prices for drugs covered under Medicare, revise rules associated with the calculation of Medicaid Average Manufacturer Price and Best Price, including removing the current statutory 100% of Average Manufacturer Price per-unit cap on Medicaid rebate liability effective January 1, 2024, which may significantly affect the amount of rebates paid on prescription drugs under Medicaid, and facilitate the importation of certain lower-cost drugs from other countries. More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, went into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023) and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Interactions with the Regulatory Health Authorities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EDGE Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In two separate FDA interactions, the FDA advised us that our machine-learning software will not be subject to medical device diagnostic regulations. In August 2016, the FDA&#x2019;s Center for Devices and Radiological Health, determined that the TSNA prediction software is a Non-Significant Risk (NSR), device, and that an IDE submission was not required to conduct clinical studies with our product candidate. In April 2017, the FDA&#x2019;s Center for Biologics Evaluation and Research (CBER) confirmed that medical device diagnostic regulations did not apply to our testing and processing of the patient-specific TSNA, and that quality requirements could be met through compliance with biologic cGMPs. Based on these interactions, we believe no additional device-related regulatory submissions (such as an investigational device exemption or pre-market approval application) or device development activities are required, and our TSNA prediction software procedure will be regulated as part of our cGMP manufacturing process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRANITE Development Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Safety</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a Pre-IND interaction with the FDA&#x2019;s CBER Office of Tissues and Advanced Therapies (OTAT) the FDA advised us that a single toxicological animal study with a representative vector could be able to support preclinical safety for purposes of IND submission. Subsequent to this discussion, we submitted proposed protocols for GLP toxicology and biodistribution studies for OTAT&#x2019;s review in connection with a Pre-IND meeting, and OTAT confirmed that a single GLP toxicology study could support IND submission. In this GLP toxicology study, we administered our ChAd and the samRNA vectors to Indian Rhesus macaques. The heterologous prime-boost immunotherapy approach when administered intramuscularly was well tolerated at the clinical maximal dose of each platform, with some animals presenting flu-like symptoms. Preclinical chemistry findings included a transient increase in select cytokines, which resolved rapidly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our GRANITE Pre-IND meeting with OTAT the FDA previewed Clinical Protocol GO-004 and confirmed that the overall design appeared reasonable, while providing comments on the study populations and dose determination which we incorporated into the Phase1/2 protocol. OTAT also concurred with our dose limiting toxicity assessment criteria, but reserved comment on the starting dose and dose escalation pending the completion of planned preclinical studies. We intend to include these elements in the protocol, which we believe may permit a faster progression and fewer patients to reach the clinical protocol&#x2019;s combination cohort (Phase 1, Part C).</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our Type-C meeting with OTAT, the FDA reviewed the Phase 2/3 clinical study design for the planned study evaluating first-line maintenance in patients with MSS CRC and discussed approaches for a registrational path. We believe we have aligned with the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA to conduct a combined, yet regulatorily and statistically distinct Phase 2/3 clinical study. Molecular response is the primary endpoint for the phase 2 component of the trial, an exploratory efficacy endpoint in the FDA&#x2019;s view. We expect that preliminary Phase 2 data, including molecular response, RECIST radiologic response and Progression-Free Survival (utilizing iRECIST/iPFS as well as RECIST/PFS), together with available ctDNA data will be previewed with the FDA in a subsequent meeting. We expect that the MSS-CRC patient population will be defined with local testing to exclude MSI-Hi patients, with reference data characterizing the expected negligible contributory effect of PD-(L)1/ipilimumab in combination with GRANITE.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulatory Chemistry, Manufacturing &amp; Controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a Type-C Facilities meeting with the FDA&#x2019;s CBER Division of Manufacturing and Product Quality (DMPQ) we obtained FDA feedback on our then-proposed design for the multi-use clinical manufacturing facility in Pleasanton, California. Importantly, the FDA concurred with our plan to build a facility designed to accommodate manufacture of multiple patient-specific lots in parallel within the same manufacturing suite, which we expect will provide a substantial increase in scalability within a smaller allocation of cleanrooms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At our subsequent GRANITE Pre-IND meeting with OTAT, the FDA concurred with our proposed use of select rapid release testing methods in which we proposed replacing standard cell-culture based tests with faster polymerase chain reaction methods. As discussed with the FDA, we submitted qualification of these methods in our IND submission for GRANITE. The FDA also found our proposed stability program to be generally acceptable to support the then-proposed Phase 1 clinical study of GRANITE, where only one representative patient lot per year was placed on product stability during conduct of the clinical program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In support of transitioning the GRANITE manufacturing process from external contract manufacturing organizations to Our Pleasanton manufacturing facility, an IND amendment was submitted to the FDA outlining the Chemistry, Manufacturing, and Controls documentation changes for the ChAd and samRNA product candidates. These revisions included a plasmid backbone change for the samRNA vector and a process improvement for the samRNA drug substance. These updates have been implemented and are currently being utilized in our Pleasanton manufacturing facility.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our Type-C meeting with OTAT, the FDA clarified phase appropriate CMC requirements to support advancement into late clinical development. The FDA detailed qualification efforts for bioinformatics, manufacturing, and testing to be submitted prior to initiation of the Phase 2 and Phase 3 portions of the Phase 2/3 clinical study. These include providing bioinformatics documentation, qualification of critical analytical assays which include a robust potency assay, as well as materials to support manufacturing process improvements being implemented for GRT-C901 and GRT-R902. We expect that a comprehensive review of CMC will occur in a subsequent pre-Phase 3 meeting with the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRANITE Regulatory Milestones</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA allowed IND for GRANITE to proceed in September 2018. In December 2018, the FDA granted fast track designation to GRANITE for the treatment of colorectal cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SLATE Development Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Safety</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In pre-IND communications with the FDA, following a justification of comparability of ChAd and samRNA products, we received feedback from the FDA noting that pre-clinical pharmacology, pharmacokinetic, and toxicology studies conducted in support of the GRANITE IND, could be used to support the initiation of the clinical study proposed under the SLATE IND. In follow-up correspondence, the FDA requested additional safety pharmacology information on the general anticipated immunogenicity and auto-reactivity elicited with each of the 20 neoantigens expressed in the SLATE cassette, as well as the impact of order and orientation of the neoantigens within the expression cassette.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our SLATE Pre-IND communication with OTAT the FDA previewed Clinical Protocol NCT03953235, GO-005 and confirmed that the overall design appeared reasonable, but requested we add language to clarify our proposed dose escalation and stopping rules. The FDA had additional questions on our proposed Next Generation Sequencing method to screen patients for their HLA type and communicated that this novel method may be viewed as a companion diagnostic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulatory Chemistry, Manufacturing &amp; Controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Much of the manufacturing process contained in SLATE was similar to that used in the GRANITE IND, therefore, the FDA&#x2019;s pre-IND feedback focused primarily on the quality of the reagents, drug product characterization and release, and ongoing stability requests. The FDA inquired on the status of certain research-grade reagents and reminded us of the need to progress to GMP grade materials in the manufacture drug product by the time of BLA approval and commercial licensure. In order to retain consistency in the manufactured drug product across SLATE batches, we were asked to amend the specification of certain release assays&#x2019; criteria and continue the development of quantitative potency assays for the ChAd and samRNA products prior to approval, and we were asked to summarize our QC plan to prevent, detect, and correct deficiencies that may compromise product integrity or function, or that may lead to the possible transmission of adventitious infectious agents. Additionally, the FDA provided feedback on the proposed method for qualifying Gritstone&#x2019;s proposed accelerated adventitious agent release assay.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SLATE Regulatory Milestones</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA allowed our IND for SLATE to proceed in June 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CORAL Development Program</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A pre-IND interaction with the FDA was conducted to review the proposed clinical investigation of ChAd vectors encoding the SARS-CoV-2 and CD8+ T-cell epitope spike antigen sequences in normal healthy subjects. The FDA concluded that the overall manufacturing and release testing for the CORAL vaccines candidates, which is similar to the GRANITE/SLATE process, appeared acceptable and requested detail on the transfection process, grade of materials, and release tests be submitted in the IND. We also received feedback that pre-clinical pharmacokinetic, and toxicology studies conducted in support of the GRANITE IND could be used to support the safety information needed to initiate the SARS-CoV-2 clinical study, and that additional animal immune response pharmacodynamic data would be submitted within the IND. The FDA previewed the proposed clinical protocol, confirmed that the overall design appeared reasonable and requested we include language to clarify dose escalation, stopping rules and a sentinel arm. The FDA requested that we exclude those subjects who are being treated with COVID-19 investigational agents or who have a high risk of potential exposure to SARS-CoV-2.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CORAL Regulatory Milestones</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the FDA acknowledged our biologics master file which provides CMC and non-clinical sections support of NIH&#x2019;s IND to study CORAL program candidates in previously vaccinated healthy volunteers.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2021, the MHRA provided a notice of acceptance for our CTA to initiate a clinical study of certain CORAL program candidates to boost vaccinate healthy volunteers &gt;60 years in the UK.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the MHRA provided a notice of acceptance for our CTA to initiate a clinical study of certain CORAL program candidates in previously vaccinated B-cell deficient subjects in the UK.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">South Africa&#x2019;s SAHPRA provided a notice of acceptance for our CTA to initiate a clinical study to test certain CORAL program candidates in COVID-19 na&#xef;ve, convalescent, and HIV subjects in South Africa.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, Gritstone held a Scientific Advice meeting with the MHRA to discuss the importance of cellular immunity for the development of a COVID vaccine. The MHRA agreed that in principle, T cells could be important for protection against viral infection. The MHRA also acknowledged that T cell responses to non-spike epitopes may create an advantage for protection against new variants and potentially increase durability. The MHRA also agreed that T cell data may be included in the summary of product characteristics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Information About Segments</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We manage our operations as a single reportable segment for the purposes of assessing performance and making operating decisions. See &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; in the notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a mission-driven organization, we value and foster a culture of collaboration, discovery and passion, which is reflected in our hiring and retention strategies. We employ talented individuals who have the skills and expertise to meet the challenges of our mission, and we recognize that our employees are key to our success. Our human capital objectives include hiring goals set to provide us with necessary expertise, integrating new employees, and retaining, incentivizing and developing our existing employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 233 full-time employees, including a total of 54 employees with M.D. or Ph.D. degrees. Within our workforce, 100 employees are engaged in research and development, 85 in manufacturing and quality, and 48 are engaged in business development, finance, legal, human resources, facilities, information technology and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were founded in August 2015 as a Delaware corporation. In May 2021, we changed our name from Gritstone Oncology, Inc. to Gritstone bio, Inc. Our principal executive offices are located at 5959 Horton Street, Suite 300, Emeryville, California 94608, and our telephone number is (510) 871-6100. Our website address is www.gritstonebio.com. The information on, or that can be accessed through, our website is not part of this report and is not incorporated by reference herein. We have included our website address as an inactive textual reference only. We also use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available on our website at www.gritstonebio.com, free of charge, copies of these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The public may read or copy any materials we file with the SEC at the SEC&#x2019;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov. The information in or accessible through the SEC and our website or social media sites does not constitute part of this Annual Report on Form 10-K or any other report or document we file with the SEC, and any references to our website and social media sites are intended to be inactive textual references only.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use Gritstone bio, Inc.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Gritstone bio logo, and other marks as trademarks in the United States and other countries. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or &#153; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#x2019; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by any other entity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and the related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:20.0%;text-indent:8.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Principal Risks Associated with Our Business</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a biotechnology company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control, including external factors that may affect our clinical trial enrollment;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and a failure to obtain such necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our immunotherapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business remains highly dependent on the successful development, regulatory approval and commercialization of our individualized immunotherapy product candidate and GRANITE, our &#x201c;off-the-shelf&#x201d; immunotherapy product candidate, SLATE, which are in clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely, and intend to rely, on third parties in the conduct of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements, or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our immunotherapy product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently perform the majority of the manufacturing of our product candidates internally and rely on qualified third parties to supply some components of our product candidates. Our inability to manufacture sufficient quantities of GRANITE, SLATE or any other current or future product candidates, or the loss of our third-party suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially adversely affect our business;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies and to avoid infringing the rights of others; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price is volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a biotechnology company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product development in the biotechnology industry is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biotechnology company with a limited operating history upon which you can evaluate our business and prospects. We have no products approved for commercial sale, have not yet generated any revenue from product sales and have incurred losses in each year since our inception in August 2015. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, ,complications, delays and other known and unknown factors and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have had significant operating losses since our inception (for additional information, see &#x201c;Liquidity&#x201d; in Note 1 to our consolidated financial statements). Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Our programs will require substantial additional development time and resources before we (or our collaboration partners) would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. In addition, we incur substantial costs associated with operating as a public company. We also do not yet have a sales organization or commercial infrastructure and, accordingly, if our product candidates are approved, we will incur significant expenses to develop a sales organization or commercial infrastructure in advance of generating any commercial product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">will increase as we continue to develop our current and any future immunotherapy product candidates, conduct clinical trials and pursue research and development activities. Even if we achieve profitability at some point in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and a failure to obtain such necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for tumor-specific cancer immunotherapies and infectious disease programs in addition to establishing our in-house manufacturing capabilities. Our preclinical studies, clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current and any other future immunotherapy product candidates we may choose to pursue, as well as the continued development of our manufacturing capabilities and other corporate uses. Specifically, in the near term, we expect to incur substantial expenses as we advance GRANITE and SLATE through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest in our manufacturing facility. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any of our preclinical studies or clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of GRANITE, SLATE or any other current or future immunotherapy product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations for at least twelve (12) months. However, our operating plans and other demands on our capital resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future capital requirements depend on many factors, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of developing each of our product candidates, including conducting preclinical studies and clinical trials, either on our own or in collaboration with others;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential delays in our ongoing clinical trials, including for reasons beyond our control;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and characteristics of any additional product candidates we develop or acquire;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of manufacturing any of our products we successfully commercialize, including the cost of scaling up our internal manufacturing operations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of building a sales force in anticipation of product commercialization;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of commercialization activities, including legal, compliance, marketing, sales and distribution costs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such arrangement, including the timing and amount of any future milestone, royalty or other payments due under any such arrangement;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any product liability or other lawsuits related to our products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expenses needed to attract, hire and retain skilled personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs associated with being a public company;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, receipt and amount of sales of our future approved products, if any.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities or eliminate one or more of our development programs altogether; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize our immunotherapy product candidates, or reduce our flexibility in developing or maintaining our sales and marketing strategy.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights or jointly own some aspects of our technologies or product candidates that we would otherwise pursue on our own. We may not realize revenue from sales of products or royalties from licensed products in the foreseeable future, and no such revenue will be realized unless and until a product candidate is clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities. We will be required to seek additional funding in the future and currently intend to do so through collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants, repayment obligations, or other similar restrictions that may affect our business and limit our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are beyond our control and may be difficult to predict, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and cost of, and level of investment in, research, development and commercialization activities, which may change from time to time;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of receipt of approvals from regulatory authorities in the United States and internationally;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and status of enrollment for our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of manufacturing, as well as building out our supply chain, which may vary depending on the quantity of production, the cost of continuing to establish and scale up our internal manufacturing capabilities, and the terms of any agreements we enter into with third-party suppliers;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">coverage and reimbursement policies with respect to our immunotherapy product candidates, if approved, and potential future drugs that compete with our products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenditures that we may incur to acquire, develop or commercialize additional products and technologies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of demand for our immunotherapy products, if approved, which may vary significantly over time;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any  revenue or earnings guidance we previously provided.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is highly dependent on the successful development, regulatory approval and commercialization of our product candidates, primarily our individualized immunotherapy product candidate, GRANITE, and our &#x201c;off-the-shelf&#x201d; immunotherapy product candidate, SLATE, which are in clinical trials.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no products approved for sale and may never be able to develop marketable products. All three of our clinical programs are in either Phase 1 or Phase 2 clinical trials. As such, we face significant clinical risk with our programs and our tumor and viral-specific immunotherapy approach generally. The success of our business, including our ability to finance our operations and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of GRANITE and SLATE, as well as other product candidates derived from our immunotherapy approach, which may never occur. To date, our product candidates have only been tested in a small number of humans, and, given our early stage of development, it may be many years, if at all, before we have demonstrated the safety and efficacy, especially of an individualized immunotherapy treatment, sufficient to warrant approval for commercialization. In the future, we may also become dependent on other product candidates that we may develop or acquire.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not previously submitted a BLA to the FDA or made a similar filing seeking regulatory approval to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. Further, any product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market a product candidate, our revenue will be dependent, in part, upon a number of factors outside of our control, including, in particular, the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. While the scope of regulatory approval generally is similar in other countries, to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding quality, safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical and commercial success of our current and any future product candidates will depend on several factors, including the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to raise any additional required capital on acceptable terms, or at all;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">timely completion of our preclinical studies and clinical trials, which may be significantly slower, or cost more, than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to timely execute our ongoing clinical trials and enroll a sufficient number of patients on a timely basis to evaluate the potential of our product candidates in clinical development;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support approval of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to complete an IND, or similar foreign applications, enabling studies, and successfully submit an IND or similar foreign applications for future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to consistently manufacture our product candidates on a timely basis;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMPs or similar foreign requirements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the quality, safety, efficacy and acceptable risk-benefit profile of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our current or any future product candidates or approved products, if any;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our individualized cancer immunotherapy approach;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully develop a commercial strategy and thereafter commercialize GRANITE, SLATE, CORAL or any future product candidates (including our partnered HIV therapeutic vaccine) in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our product candidates that may be approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience of our treatment or dosing regimen;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patient demand for our current or future product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and enforce intellectual property rights in and to our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be able to successfully commercialize any product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. We may experience delays in enrolling or completing our clinical trials. Additionally, we cannot be certain that studies or trials for our product candidates will begin on time, not require redesign, enroll an adequate number of subjects on time or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to generate sufficient preclinical, toxicology, or other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> data to support the initiation or continuation of clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining regulatory authorization to commence a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining IRB, ethics committee and, where required, IBC approval at each trial site;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recruiting an adequate number of suitable patients to participate in a trial, which can be impacted by external factors beyond our control, including, due to the COVID-19 or other pandemics;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">having subjects complete a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing subject safety concerns that arise during the course of a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adding a sufficient number of clinical trial sites;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">supplying sufficient quantities of product candidates or other materials for use in preclinical studies or clinical trials; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accessing checkpoint inhibitors for use in combination with our product candidates in preclinical studies or clinical trials, including checkpoint inhibitors that have not been approved by the FDA for such use.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As demonstrated during the COVID-19 pandemic, a public health crisis (or other situation having lasting and widespread societal impact) can result in challenges and delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials, as well as delays in the commencement of our preclinical studies.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent us from receiving marketing approval or commercializing our product candidates, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be affected by safety concerns that have a class effect; for example, if a competitor reports negative results with respect to a product candidate similar to those we are developing, such setbacks could negatively impact our own product development;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon our development programs, including our individualized cancer immunotherapy program;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, or be unable to produce sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive, or if there are safety concerns, we may:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incur unplanned costs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval in some countries and not in others;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to additional post-marketing testing requirements, which could be expensive and time consuming; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have the treatment removed from the market after obtaining marketing approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ethics committees of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board (DSMB), or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we have done in our collaborations related to CORAL and may do for certain of our other product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, we fail to ensure such relationships and compensation are accurately disclosed, or a regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our preclinical studies or clinical trials of our product candidates are delayed or terminated, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates could be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. If our product candidates or our immunotherapy prediction platform generally prove to be ineffective, unsafe or commercially unviable, our entire platform and approach would have little, if any, value, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the FDA&#x2019;s and other regulatory authorities&#x2019; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union recently evolved. The CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate CTA to be submitted in each member state to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#x2019;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors were still able to choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is currently unclear to what extent the United Kingdom, as a free-standing regulatory regime outside of the European Union, will seek to amend its regulations so that they diverge from the regulatory regime in the European Union. The UK regulatory framework in relation to clinical trials is derived from the EU Clinical Trials Directive (as implemented into UK law, through secondary legislation) in place prior to the date of application of the CTR. On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials. The consultation closed on March 14, 2022 (although a response has not yet been published) and aims to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The outcome of the consultation will be closely watched and will determine whether the United Kingdom chooses to align with the new EU CTR or diverge from it to maintain regulatory flexibility. A decision by the United Kingdom not to closely align its regulations with the CTR may have an effect on the cost of conducting clinical trials in the United Kingdom as opposed to other countries and/or make it harder to seek a marketing authorization in the European Union for our product candidates on the basis of clinical trials conducted in the United Kingdom.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may also be impacted.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our tumor-specific cancer immunotherapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regarding our tumor-specific cancer immunotherapies, our foundational science and product development approach are based on our ability to predict the presence of a patient&#x2019;s TSNA and develop a TSNA-directed therapy that will elicit a meaningful T cell response. We believe that this approach may offer an improved therapeutic effect by driving an intense, focused T cell attack selectively upon a patient&#x2019;s tumor. However, this approach to treating cancer is novel and the scientific research that forms the basis of our efforts to predict the presence of TSNA and to develop TSNA-directed cancer immunotherapy candidates is both preliminary and limited. The results of our preclinical animal studies may not translate into humans. For example, our prediction model may fail to accurately predict the presence of TSNA, resulting in little or no tumor-targeted T cell response, or our therapy may fail to elicit a significant or durable enough T cell response to effectively destroy a tumor. As such, we cannot assure you, even if we are able to develop individualized</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cancer immunotherapy candidates capable of recognizing TSNA and eliciting a T cell response, that such therapy would safely and effectively treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No regulatory authority has granted approval for a cancer immunotherapy based on a heterologous prime-boost approach, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We may never receive approval to market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications, lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our personalized immunotherapy candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform and pipeline would have little, if any, value, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulatory approval process and clinical trial requirements for novel product candidates can be more expensive and take longer than for other, better known or more extensively studied product candidates, and we cannot predict how long it will take or how much it will cost to complete clinical developments and obtain regulatory approvals for a cell therapy product candidate in the United States or how long it will take to commercialize a product candidate, if and when approved. Regulatory requirements governing cell therapy products have changed frequently and may continue to change in the future. For example, the FDA established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of cell therapies and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. These and other regulatory review agencies, committees and advisory groups and the requirements and guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval limitations or restrictions. Additionally, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. Additionally, adverse developments in clinical trials conducted by others of cell therapy products or products created using similar technology, or adverse public perception of the field of cell therapies editing, may cause the FDA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing technologies such as ours, either of which could materially harm our business. As we advance our product candidates, we will be required to consult with various regulatory authorities, and we must comply with applicable laws, rules and regulations, which may change from time to time, including during the course of development of our product candidates. If we fail to do so, we may be required to delay or discontinue the clinical development of certain of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Even if we comply with applicable laws, rules, and regulations, and even if we maintain close coordination with the applicable regulatory authorities with oversight over our product candidates, our development programs may fail to succeed. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market would materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure or delay can occur at any time during the clinical trial process. Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any promising results we may have observed in earlier studies and trials, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, the results of our preclinical animal studies, including our non-human primate studies, may not be predictive of the results of outcomes in human clinical trials. For example, our tumor-specific cancer immunotherapy candidates and any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or harmful ways. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates are biologics with complex and time-consuming manufacturing processes, and we may encounter difficulties in production, particularly with respect to process development or scaling-out of our manufacturing capabilities. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our immunotherapy product candidates, GRANITE, SLATE and CORAL, are considered to be biologics, and the manufacturing processes are complex, time-consuming, highly-regulated and subject to multiple risks. Our product candidates for SLATE and CORAL are designed using known genetic sequences available from public databases, while the manufacture of our product candidate GRANITE involves extraction of genetic material from patient tumor samples. GRANITE, SLATE and CORAL require genetic manipulations at the gene sequence level, live cell culture operations, specialized formulations and aseptic fill finish operations. As a result of these complexities, the cost to manufacture biologics in general, and our individualized immunotherapy GRANITE in particular, is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and more difficult and time-consuming to reproduce. In addition, our manufacturing processes for GRANITE and SLATE are in their early stages of development and will be susceptible to product loss or failure, or product variation that may adversely impact patient outcomes. Our supply chain may not function efficiently due to logistical issues associated with but not limited to the collection of a tumor biopsy from the patient, shipping such material to the manufacturing site, sequencing the biopsy specimen, manufacturing the immunotherapy components, shipping the final immunotherapy back to the patient, and injecting the patient with the immunotherapy. Manufacturing issues or different product characteristics resulting from process development activities or even minor deviations during normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If for any reason we lose a patient&#x2019;s biopsy or an in-process product at any point in the process, the manufacturing process for that patient would need to be restarted, and the resulting delay could adversely affect that patient&#x2019;s outcome. Because GRANITE is manufactured specifically for an individual patient, we will be required to maintain a chain of identity and chain of custody with respect to materials as they move from the patient to the manufacturing facility, through the manufacturing process, and back to the patient. Maintaining such a chain of identity and chain of custody is difficult and complex, and the failure to do so could result in adverse patient outcomes, loss of product or regulatory action, including withdrawal of our products from the market, if licensed.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our process development efforts for GRANITE and SLATE, we also may make changes to our manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate, or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, if microbial, viral or other contaminations are discovered in our manufacturing facilities, or those of our CMOs, or in our product candidates manufactured there, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any such contaminations or stability failures or other issues relating to the manufacture of our product candidates will not occur in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay or prevent commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To gain approval to market our product candidates, we must provide the FDA and foreign regulatory authorities with clinical data that adequately demonstrate the safety, purity, potency and efficacy of the product candidate for the intended indication applied for in the applicable regulatory filing. Product development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical development programs. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after promising results in earlier preclinical or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical studies were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not previously submitted a BLA or any other marketing application to the FDA or similar filings to comparable foreign regulatory authorities. A BLA or other similar regulatory filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, effective, pure and potent for each desired indication. The BLA or other similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product. FDA and foreign regulatory authorities may also conduct pre-license inspections of us and/or our CMOs to ensure the manufacture of a product candidate complies with applicable regulatory requirements, including cGMP or similar foreign requirements. Adverse inspection findings could result in the delay or non-approval of a BLA or other similar regulatory filing and require the implementation of costly corrective actions before potential approval can be granted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market our product candidates in the United States or in any foreign countries until they receive the requisite approval from the applicable regulatory authorities of such jurisdictions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates for many reasons, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that any of our product candidates are safe, pure, potent and effective for the requested indication;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s disagreement with our trial protocols or the interpretation or reliability of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to demonstrate that the clinical and other benefits of any of our product candidates outweigh any safety or other perceived risks;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s requirement for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s non-approval of the formulation, labeling or specifications of GRANITE, SLATE, or any of our other current or future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s failure to approve our manufacturing processes and facilities or the facilities of third-party manufacturers upon which we rely; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. For example, the FDA launched Project Optimus as an initiative to reform the dose optimization and dose selection paradigm in oncology product development as the FDA&#x2019;s view is that the current paradigm for dose selection results in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating registration/pivotal trials. Through collaboration with industry, academia, and other stakeholders, the FDA&#x2019;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval. The FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, in part due to questions raised by the process underlying the approval of the Alzheimer&#x2019;s disease drug Aduhelm&#174;, government authorities and other stakeholders have been recently scrutinizing the accelerated approval pathway, with some stakeholders advocating for reforms. Even prior to the Aduhelm approval, FDA has held Oncologic Drugs Advisory Committee meetings to discuss accelerated approvals for which confirmatory trials have not verified clinical benefit. Such scrutiny, among other factors, has resulted in voluntary withdrawals of certain products and indications approved on an accelerated basis. FDA also launched an initiative, known as Project Confirm, to promote the transparency of outcomes related to accelerated approvals for oncology indications. Moreover, spurred by the Aduhelm controversy, the U.S. Department of Health and Human Services Office of Inspector General has initiated, and partially completed, an assessment of how the FDA implements the accelerated approval pathway. In addition, Section 3210 of the Consolidated Appropriations Act, 2023, revised the accelerated approval pathway. Although this legislation did not change the standard for accelerated approval, it, among other things, requires FDA to specify the conditions for required post-marketing trials, permits FDA to require such trials to be underway prior to, or within a specific period after, approval, requires sponsors to provide reports on post-marketing trial progress no later than 180 days after approval and every 180 days thereafter until such trials are completed, makes the failure to conduct required post-marketing trials with due diligence and the failure to submit the required reports prohibited acts, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">details procedures FDA must follow to withdraw an accelerated approval on an expedited basis. At this time, it is not clear what, if any, impact these developments may have on the statutory accelerated approval pathway or our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the large number of biopharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory bodies&#x2019; approval processes and are commercialized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval from the FDA or applicable foreign agencies for any of our product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. Failure to complete such post-marketing requirements in accordance with the timelines and conditions set forth by the FDA or the applicable foreign regulatory agency could significantly increase costs or delay, limit or ultimately restrict the commercialization of the product candidate. The FDA or the applicable foreign regulatory agency also may approve one or more of our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory agency, may not approve our product candidates with the labeling that we believe is necessary or desirable for the successful commercialization of such product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially adversely impact our business and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have chosen to prioritize development of our individualized immunotherapy candidate, GRANITE, and our off-the-shelf immunotherapy candidate, SLATE. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on other product candidates or indications for which there may be a greater likelihood of success or that may be more profitable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our cancer programs, we strategically determined initially to focus solely on the development of individualized cancer immunotherapy candidates (including our &#x201c;off-the-shelf&#x201d; immunotherapy candidate) rather than pursue other types of immunotherapies based, in part, on the significant resources required to develop and manufacture immunotherapies. As a result, we may initially have foregone, and we may continue to forego, other potentially more profitable therapy indications or those with a greater likelihood of success.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the oncology or biopharmaceutical industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain regulatory approval for use of our tumor-specific immunotherapy candidates, GRANITE and SLATE, as a first- and second-line therapy, our commercial opportunity and profitability may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancer therapies for advanced/metastatic cancers are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new systemic therapies initially only for third-line use. When cancer is detected early enough, surgery plus first-line systemic therapy is sometimes adequate to cure the cancer. Whenever first-line therapy (usually chemotherapy, hormone therapy, radiotherapy, surgery or a combination of these) proves unsuccessful, second-line therapy may be administered. Second-line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules or a combination of these. Third-line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies and new technologies such as adoptive cell therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Traditionally, novel oncology therapeutics are developed and approved in late (third) line therapy of cancer patients. Such clinical programs carry risk of failure because patients are often quite frail, with effects of multiple rounds of prior therapy weakening bone marrow, immune systems and general fitness. Immunotherapy, such as checkpoint inhibitors, has generally been shown to be more effective when used in earlier lines of therapy, with the prospect of very durable responses in some patients; and there is a trend towards earlier use of these agents, avoiding in particular cytotoxic chemotherapy agents, which carry substantial toxicity and very little prospect of long-term responses. Our tumor-specific immunotherapy clinical development program also aims to study our products in early stages</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of cancer treatment (referred to as adjuvant therapy), which carry a higher safety bar, and often a greater expectation of efficacy over control arms. Such studies may thus be relatively large and slow to achieve maturity. There are new tools available to stratify cancer patients for risk of recurrence or progression, such as liquid biopsies that measure the amount of circulating tumor-derived DNA. We will utilize these tools to attempt to expedite clinical trials in early-stage cancer patients by focusing upon patients at above-average risk of disease recurrence or progression, which events are typical endpoints in clinical trials. The development of liquid biopsies is at an early stage, however, and these tools may prove to carry low utility and thus render early-stage cancer trials slow, necessarily large and expensive. The safety of our tumor-specific immunotherapy product candidates in combination with checkpoint inhibitors in early lines of therapy may also prove to be unacceptable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to seek approval of our tumor-specific immunotherapy product candidates as a first-line therapy wherever possible, but also as a late-line therapy where appropriate, and potentially as adjuvant therapy. There is no guarantee that our product candidates, even if approved in late-line therapy, would be approved for second-line or first-line or adjuvant therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval for first-line or adjuvant therapy.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our SLATE product is designed to be readily available (off-the-shelf), GRANITE may initially take approximately 14 to 18 weeks post-sequencing to be manufactured and released for human use, and this long timeline demands that either patients are consented and entered into our trials when they start a prior line of therapy, and start our therapy upon disease progression, or we initiate treatment in patients who have entered the maintenance phase of their original line of treatment. For example, we might enroll newly diagnosed patients who are due to receive front-line chemotherapy and then start their therapy with our immunotherapy product candidate as second-line treatment when they progress upon front-line chemotherapy or fail to tolerate it. This carries the risk of time delays or drop-out, i.e., patients may not progress after first-line chemotherapy for a long time, or they may decide not to receive an immunotherapy product candidate we have manufactured for them, at our expense. Alternatively, we may treat first-line patients once they have completed their initial treatment and have not progressed (called maintenance therapy)&#x2014;this renders efficacy harder to interpret versus simple treatment studies (any objective response cannot clearly be attributed to our products) and may be complicated by standard of care treatments, which may necessarily be continued alongside our immunotherapy candidates, further confounding interpretation of efficacy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive first-, second- or third-line therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, and may prove to be incorrect. Regulatory authorities also may establish narrower definitions around when a patient is ineligible for other treatments than we have used in our projections, and that would reduce the size of the patient population eligible for our product candidates. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we anticipate that only a fraction of colorectal cancer patients will be predicted to have a high enough probability of TSNA presence to merit their inclusion into our program. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as a first-line or second-line therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The timely completion of our clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient eligibility criteria defined in the protocol;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of patients to trial sites;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design of the trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trial investigators&#x2019; willingness to enroll patients during a public health crisis, such as the COVID-19 pandemic;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new therapies that may be approved for the indications we are investigating; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patient consents.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and such competition may reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. In addition, as we have faced challenges with patient enrollment and monitoring once on study due to the COVID-19 pandemic, similar challenges are likely in case of a resurgence of the COVID-19 pandemic or if another such public health crisis were to occur.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the targeting of TSNA may result in unforeseen events, including harming healthy tissues in humans. As a result, it is possible that safety concerns could negatively affect patient enrollment among the patient populations that we intend to treat. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As with most biological products, use of our product candidates could be associated with side effects or adverse events, which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. While we have now completed the Phase 1 portions, and we are in the Phase 2 portions, of our clinical trials of GRANITE and SLATE, we do not yet have a comprehensive understanding of their risks, and it is likely that there will be side effects associated with their use in increasing numbers of patients in Phase 2 and beyond. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. Our other product candidates present similar risks, the severity of which is difficult to predict.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, or comparable foreign regulatory authorities, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, even if we successfully advance one of our product candidates through clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been several reported cases of severe thrombosis with thrombocytopenia occurring post-vaccination in individuals who received adenovirus-based vaccines for SARS-CoV-2, including those administered under EUA. This syndrome has been termed &#x201c;vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)&#x201d; or &#x201c;vaccine-induced immune thrombotic thrombocytopenia (VITT)&#x201d; but is now termed &#x201c;thrombosis with thrombocytopenia syndrome (TTS)&#x201d; by the Centers for Disease Control and Prevention (CDC) and the FDA. The syndrome appears to be autoimmune in nature and is associated with autoantibodies to a specific platelet-associated antigen. To date, no patients receiving our adenoviral vaccine candidate against SARS-CoV-2, CORAL, have been known to develop TTS, nor have we observed it in our cancer programs where our adenoviral vaccines are used in conjunction with checkpoint inhibitors (e.g., anti-PD1 antibody), which themselves can be associated with autoimmune toxicities; but we cannot be certain that this or similar complications will not arise.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may vary, suspend or revoke their approval of the product;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to implement a Risk Evaluation and Mitigation Strategy (REMS), or similar risk management measures, or create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product may become less competitive; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially adversely affect our results of operations and business. In addition, if one or more of our product candidates or our TSNA-directed immunotherapy approach generally prove to be unsafe, our entire technology platform and pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if one of our product candidates obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if one of our product candidates receives FDA or other regulatory approvals, the commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree and rate of physician and patient adoption of our current or future product candidates, if approved, will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the safety and efficacy of our product as compared to other available therapies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the time required for manufacture and release of our individualized immunotherapy products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our product candidates that may be approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by physicians, operators of hospitals and clinics and patients of the product as a safe and effective treatment;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">physician and patient willingness to adopt a new therapy for appropriate patients versus other available therapies for a particular indication;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">proper training and administration of our product candidates by physicians and medical staff;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payers, physicians and patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of side effects;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the FDA or foreign regulatory authorities - approved labeling for our products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our products as a solution;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any FDA or foreign regulatory authorities&#x2019; requirement for a REMS or similar risk management measures;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of our sales, marketing and distribution efforts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse publicity about our products or favorable publicity about competitive products; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product liability claims.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians and patients. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently perform most of the manufacturing of our product candidates internally and rely on qualified third parties to supply some components of our product candidates. Our inability to manufacture sufficient quantities of any of our current or future product candidates, or the loss of our third-party suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing is a vital component of our immunotherapy approach, and we have invested significantly in our manufacturing facility. To ensure timely and consistent product supply assurance to our patients, we previously used a hybrid product supply approach whereby certain elements of our product candidates were manufactured internally at our manufacturing facilities in Pleasanton, California, and other elements were manufactured at qualified third-party contract manufacturing organizations (CMOs). All internal and third-party contract manufacturing is performed under cGMP or similar guidelines. We have since internalized most of the manufacturing steps to optimize cost and production time and establish full control over intellectual property and product quality. We will need to continue to scale up our manufacturing operations, as we continue to build the infrastructure and improve the capability internally to manufacture all supplies needed for our product candidates or the materials necessary to produce them for use in the conduct of our preclinical studies or clinical trials. We currently lack the internal resources and the capability to manufacture certain elements of our product candidates on a late-clinical or commercial scale. Accordingly, we have made, and will be required to continue to make, significant investments in our manufacturing facility and processing in the future, and our efforts to scale our manufacturing operations may not succeed.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our facilities and the facilities used by our CMOs to manufacture our product candidates are subject to various regulatory requirements and may be subject to inspection by the FDA or other regulatory authorities. We do not control the manufacturing process at our CMOs and are completely dependent on them for compliance with current regulatory requirements. If we or our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on our or their manufacturing facilities for the manufacture of elements of our product candidates. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds our facilities or those of our CMOs inadequate for the manufacture of our product candidates, or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, even if one of our product candidates receives regulatory approval, successful commercialization depends on our ability to effectively scale up our in-house manufacturing capabilities and those of our manufacturing partners and contractors. Although we have a dedicated manufacturing facility in Pleasanton, we do not have sufficient manufacturing infrastructure to support a global roll-out of our product candidates on our own. We may not be able to timely and effectively produce our product candidates, if approved, in adequate quantities to address global demand. We have not previously had a commercial launch of any product, and  we cannot guarantee that we will be able to meet any of the related challenges and requirements in a timely manner or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finally, we and our CMOs may experience manufacturing and raw material sourcing difficulties due to resource constraints, as a result of labor disputes or unstable political environments, or due to the impact of a public health crisis such as the COVID-19 pandemic. If we or our CMOs were to encounter any of these difficulties, our ability to provide our product candidates to patients in clinical trials, or to provide product for the treatment of patients once approved, would be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend on third-party suppliers for key materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party suppliers for certain materials required for the production of our individualized immunotherapy candidate. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our larger competitors. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely, and intend to continue to rely, on third parties in the conduct of all of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently do not have the ability to independently conduct preclinical studies that comply with good laboratory practice (GLP) regulatory requirements. We also do not currently have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as good clinical practice (GCP) requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Further, under certain circumstances, these third parties may terminate their agreements with us upon as little as 10 days&#x2019; prior written notice. Some of these agreements may also be terminated with immediate effect by such third parties under certain other circumstances, including our insolvency. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLPs/GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial results and the commercial prospects for our product candidates could be harmed, our costs could increase, and our ability to generate revenues could be delayed.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA or foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#x2019;s or foreign regulatory authorities&#x2019; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#x2019;s or foreign regulatory authorities&#x2019; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plan to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic and has also indicated that it intends to utilize remote regulatory assessments and other alternative tools beyond the COVID-19 pandemic. Regulatory authorities outside the United States have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on developing proprietary therapeutics. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes that may compete with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of product candidates are currently under development, and may become commercially available in the future, for the treatment of diseases and other conditions for which we may try to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and antibody and immunoregulatory therapeutics fields. We believe that, while our discovery platform, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded biopharmaceutical, biotechnological and therapeutics companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective, or less expensive than the therapeutics we develop.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, if either of our GRANITE or SLATE vaccine candidates is approved, it will compete with a range of therapeutic treatments that are either in development or currently marketed, of which there are many. Such marketed therapies range from immune checkpoint inhibitors such as Bristol-Myers Squibb Company&#x2019;s OPDIVO and YERVOY, Merck &amp; Co., Inc.&#x2019;s KEYTRUDA, AstraZeneca&#x2019;s IMFINZI, and Genentech, Inc.&#x2019;s TECENTRIQ, T cell engager immunotherapies such as Amgen, Inc.&#x2019;s BLINCYTO, and multi-kinase inhibitors such as Bayer&#x2019;s STIVARGA. The most common therapeutic treatments for common solid tumors are chemotherapeutic compounds, radiation therapy, targeted therapies and now immunotherapies. In addition, numerous compounds are in clinical development for cancer treatment. The clinical development pipeline for cancer treatments includes small molecules, antibodies and immunotherapies from a variety of groups, including in the neoantigen space, the bispecific antibody space and engineered cell therapy and T cell receptor (TCR) space. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite funding provided to us to date, many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. If any competitors are successful in producing more efficacious products or if any competitors are able to manufacture and distribute competitive products with greater efficiency there may be a diversion of potential governmental and other funding away from us and toward such other parties. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers, and other third-party payors provide coverage, adequate reimbursement levels and implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The availability of coverage and adequacy of reimbursement by managed care plans, governmental healthcare programs, such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates that receive FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by third-party payors will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult due to general price sensitivity associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products, or procedures using our products, could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates, or procedures using our product candidates, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union Member States or elsewhere will be available for our product candidates or procedures using our product candidates, or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may not necessarily inform the price for our product candidates. These third-party payors may deny or revoke the reimbursement status of our product candidates, if approved. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products, especially novel products like our immunotherapy product candidates. No regulatory authority has granted approval for a tumor-specific cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that future changes in these rules and regulations are likely. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. For example, the recently-enacted Inflation Reduction Act directs the Secretary to negotiate maximum fair prices for certain Medicare drugs. The law also requires manufacturers to pay a rebate if the price of a Medicare Part B or Part D drug increases at a rate that exceeds inflation and redesigns the Medicare Part D benefit in a way that potentially obligates manufacturers to increased discounts on Part D utilization. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to support demand for our existing or future services, including ensuring that we have adequate capacity to meet increased demand, or we are unable to successfully manage the evolution of our EDGE&#153; platform, our business could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the demand for our individualized and off-the-shelf vaccine-based immunotherapy candidates increases with our clinical trial needs, we will need to continue to increase our workflow capacity for sample intake and general process improvements, expand our internal quality assurance program, and apply our EDGE&#153; platform at a larger scale within expected turnaround times. We will need additional certified laboratory scientists and technicians and other scientific and technical personnel to process higher volumes of tumor biopsies. Portions of our process are not automated and will require additional personnel to scale. We will also need to purchase additional equipment, some of which can take several months or more to procure, set up, and validate, and increase our software and computing capacity to meet increased volume. There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities, or process enhancements will be successfully implemented, or that we will have adequate space in our laboratory facilities to accommodate such required expansion.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we progress into clinical development and expand our manufacturing capabilities, we will need to incorporate new equipment, implement new technology systems and laboratory processes, and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher service costs, declining service quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our services and could damage our reputation and the prospects for our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and foreign jurisdictions, if approved, or generate product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently do not have a marketing or sales organization. In order to commercialize our product candidates, if approved, in the United States and foreign jurisdictions, we will need to build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of them. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our current or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 233 full-time employees. As our clinical trials progress and we get closer to any potential regulatory approvals, we will need to expand our managerial, regulatory, clinical science, development operations, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize our product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">candidates or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support our future needs. Our need to effectively execute on our growth strategy requires that we:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manage our preclinical studies and clinical trials effectively;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identify, recruit, retain, incentivize and integrate additional employees, including sales personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to improve our operational, financial and management controls, reports systems and procedures.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially adversely affected.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly-qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly our President and Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our products, initiation or completion of our planned clinical trials or the commercialization of our current or any future product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition for qualified personnel in the biotechnology and biopharmaceutical fields is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability as a result of the planned clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for our current or future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize our current or any future product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of our current or any future product candidates we develop. We currently carry product liability insurance covering our clinical trials in the amount of $10.0 million in the aggregate. Nonetheless, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our strategic collaborations, including those with Gilead and with 2seventy as well as any future arrangements that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of such collaborations and adversely affect our ability to develop and commercialize our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2021, we announced that we had entered into a collaboration, option and license agreement with Gilead to research and develop a vaccine for HIV. Under the terms of the agreement, Gilead is responsible for conducting the Phase 1 study and, if it exercises its exclusive option, will develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. In such case, subject to certain clinical, regulatory and commercial milestones being achieved, we would be eligible to receive up to an additional $725.0 million, as well as certain royalties on net sales upon commercialization. Separately, in August 2018, we entered into a strategic collaboration with 2seventy to utilize our EDGE&#153; platform to identify and validate tumor-specific targets and provide TCRs directed to 10 selected targets for use in 2seventy&#x2019;s cell therapy products. Under that collaboration, we are entitled to receive up to an aggregate of $1.2 billion in development, regulatory and commercial milestones and tiered single digit royalties on sales of 2seventy&#x2019;s cell therapy products utilizing the TCRs we develop directed at the targets we discovered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Apart from these strategic collaborations, in the future, we may seek to enter into additional collaboration arrangements for the development or commercialization of certain of our product candidates, depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration arrangements. To the extent that we decide to enter into collaboration agreements in the future, we may face significant competition in seeking appropriate collaborators. Moreover, all such collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain, as well as challenging to manage. We may not be successful in our efforts with Gilead or 2seventy, and we may never receive any of the payments contemplated in those collaboration arrangements. Further, we may be unable to prudently manage these collaborations or enter into new ones. The terms of any new collaborations or other arrangements that we may establish may not be favorable to us.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include risks that:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise perform satisfactorily in carrying out these activities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may be terminated, and, if terminated, this may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may own or co-own intellectual property covering products that result from our collaboration with them, and, in such cases, we would not have the exclusive right to develop or commercialize such intellectual property;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaborator&#x2019;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the issuance of our equity securities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the diversion of our management&#x2019;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We, or the third parties upon whom we depend, may be adversely affected by risks beyond our control, such as natural disasters, political crises, acts of terrorism, war or other catastrophic events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, our suppliers and third-party service providers are vulnerable to damage from natural disasters, including but not limited to earthquakes, fires or floods, power loss, communications failures, public health crises, such as pandemics and epidemics, political</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">crises, such as terrorism, war, political instability or other conflict and similar events. If any disaster were to occur, our ability to operate our business at any of our facilities could be seriously, or potentially completely, impaired.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters and certain of our other facilities, including our manufacturing facility, are located in the San Francisco Bay Area, which in the past has experienced both severe earthquakes and wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. For example, if a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters or other facilities, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in late February 2022, Russian military forces launched significant military action against Ukraine. In response, many countries and organizations implemented new, stricter sanctions against officials, individuals, regions, and industries in Russia and Belarus. These and other actions related to Russia&#x2019;s invasion of Ukraine have also been a major contributing factor to high inflation as well as putting significant downward pressure on economic growth. Apart from the tragic loss of life and human suffering, the war in Ukraine has had, and likely will continue to have, an adverse effect on the global economy and political situation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters or other facilities, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend on our information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business, including our laboratory information management system and our EDGE&#153; platform. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to attack and damage from computer viruses, and malware (e.g., ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk of a security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber-terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, either full-time or on a hybrid basis, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. We have experienced phishing attacks in the past resulting in a security breach of our information technology systems, and we may be a target of phishing attacks or other cyber-attacks in the future. Any significant system failure, accident or security breach could have a material adverse effect on our business, financial condition and results of operations. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. Further, our insurance coverage may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is subject to complex and evolving laws and regulations regarding privacy, data protection and other matters relating to information collection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are numerous state, federal and non-U.S. laws, regulations, decisions, and directives regarding privacy and the collection, storage, transmission, use, processing, disclosure and protection of different types of personal data and personal information and other personal, customer, or other data, the scope of which is continually evolving and subject to differing interpretations. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, although we currently are not subject to the privacy or security regulations implementing HIPAA, many of the persons and organizations with which we interact are subject to those regulations and we have to expend resources to understand their obligations, adjust contractual relationships in light of those obligations, or otherwise modify our business practices. Congress has considered expanding the scope of the HIPAA privacy and security regulations and we may in the future ourselves become subject to them or similar regulations, which would require us to make additional expenditures and create additional liability risks.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, many U.S. states in which we operate have laws that protect the privacy and security of personal information, and other states have proposed privacy legislation that may more stringent or broader in scope, or offer greater individual rights, than the laws to which we currently are subject. This patchwork of evolving privacy law complicates our compliance efforts, at considerable cost. Even a single state&#x2019;s privacy regime can be very complicated. For example, the California Confidentiality of Medical Information Act (the &#x201c;CMIA&#x201d;) imposes on pharmaceutical companies strict data privacy and security requirements and obligations with respect to the personal health information of California residents and authorizes administrative fines and civil penalties of up to $25,000 for willful violations and up to $250,000 if the violation is for purposes of financial gain, as well as criminal fines. In parallel, the California Consumer Privacy Act of 2018 (the &#x201c;CCPA&#x201d;), which was substantially amended in 2020 pursuant to the California Privacy Rights Act (the &#x201c;CPRA&#x201d;), which generally went into effect on January 1, 2023, generally requires us to provide notice to California residents regarding the personal information we collect, use and share and to honor such residents&#x2019; privacy rights, including the right to opt out of the sale of their personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data security breaches that result in the compromise of sensitive personal information. California&#x2019;s aggressive steps to protect consumer privacy have been followed by similar actions in other states, including Virginia, Colorado, Utah and Connecticut, all of which have enacted CCPA/CPRA-like laws to provide their respective residents with similar rights, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The effects on our business of this rapidly growing body of privacy and data protection laws are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, the General Data Protection Regulation (GDPR) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. The GDPR has increased our obligations, for example, by</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposing higher standards when obtaining consent from individuals to process their personal data, requiring more robust disclosures to individuals, strengthening individual data rights, shortening timelines for data breach notifications, limiting retention periods and secondary use of information, increasing requirements pertaining to health data as well as pseudonymized (i.e., key-coded) data, and imposing additional obligations when we contract third-party processors in connection with the processing of personal data. The GDPR also regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data; in July 2020, the Court of Justice of the European Union (&#x201c;CJEU&#x201d;) limited how organizations could lawfully transfer personal data from the EU/EEA to the U.S. by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses (SCCs). In March 2022, the U.S. and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-U.S. Data Privacy Framework has not been implemented beyond an executive order signed by President Biden on October 7, 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. European court and regulatory decisions subsequent to the CJEU decision of July 2020 have taken a restrictive approach to international data transfers. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. From January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR (UK GDPR), which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR (i.e., fines up to the greater of &#x20ac;20 million (&#163;17.5 million) or 4% of global turnover). As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure, or perceived failure, by us to comply with or make effective modifications to our policies, or to comply with any federal, state or international privacy, data-retention or data-protection-related laws, regulations, orders or industry self-regulatory principles could result in proceedings or actions against us by governmental entities or others, a loss of customer confidence, damage to our brand and reputation and a loss of customers, any of which could have an adverse effect on our business. In addition, various federal, state and foreign legislative or regulatory bodies may enact new or additional laws and regulations concerning privacy, data-retention and data-protection issues, including laws or regulations mandating disclosure to domestic or international law enforcement bodies, which could adversely impact our business or our reputation with customers. For example, some countries have adopted laws mandating that some personal information regarding customers in their country be maintained solely in their country. Having to maintain local data centers and redesign product, service and business operations to limit personal information processing to within individual countries could increase our operating costs significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees and independent contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development activities and our third-party manufacturers&#x2019; and suppliers&#x2019; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including the components of our product and product candidates and other hazardous compounds. We and any third-party manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our third-party manufacturers&#x2019; facilities pending their use and disposal. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. In such an event, we may be held liable for any resulting damages; such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses that we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, results of operations and financial condition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">may be materially adversely affected by a public health crisis such as the ongoing COVID-19 pandemic, including a resurgence of the COVID-19 pandemic or localized outbreaks in certain parts of the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the COVID-19 pandemic did not materially adversely affect our business operations during the year ended December 31, 2022, economic and health conditions in the United States and across most of the globe have changed considerably since the pandemic began. In particular, supply chain disruptions have become a concern for many businesses, particularly if critical supplies are sourced from China or other regions where extended lock-downs remain a real possibility. The COVID-19 pandemic also caused significant volatility in the U.S. and international markets and was a contributing factor to high inflation and extended economic downturn. We are subject to inflationary pressures on employee wages, salaries, and the cost of various goods and services that can negatively impact our financial results. We have experienced minor delays in delivery of various products related to our manufacturing processes and in some cases have had to identify new suppliers, which at times resulted in increased costs. While none of the disruptions of our supply chain to date have been material, we cannot exclude the possibility that further supply chain disruptions due to a resurgence of the COVID-19 pandemic, even if limited to localized outbreaks in certain parts of the world, could have a material adverse effect on our business, and the extent to which these issues will impact our results remains uncertain. Moreover, the emergence of any new pandemic or similar public health crisis would subject our business to risks similar to those of the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the risk of such supply chain disruptions, as a result of the COVID-19 pandemic, including a resurgence or localized outbreaks in certain parts of the world, we may also experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are conducting a number of clinical trials for product candidates in geographies that have been heavily affected by the COVID-19 pandemic. While the availability of first-generation vaccines in the United States (and other countries) have greatly improved the outlook for the pandemic, we believe that the emergence of variants of concern and/or the potential waning of the immune protection offered by existing vaccines has the potential to lead to prolonging the effects of the </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pandemic, which could in turn have an impact on various aspects of our clinical trials. For example, with respect to clinical trials for our tumor-specific immunotherapy product candidates, investigators may not want to screen or treat cancer patients with our experimental vaccine and potentially expose them to the novel coronavirus during additional clinic visits. Other potential impacts of the COVID-19 pandemic on our various clinical trials include delays or difficulties in any planned clinical site initiation, including difficulties in obtaining IRB or ethics committee approvals, recruiting clinical site investigators and clinical site staff, delays or difficulties in enrolling patients, interruption of planned key clinical trial activities, such as clinical trial site data monitoring due to diversion of resources at clinical sites or limitation on travel imposed by federal or state governments. This may impact the integrity of subject data.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While chimpanzee-based adenoviral (ChAd) vaccines have not yet been approved in the US, there is a risk that patient candidates to our GRANITE or SLATE vaccine candidates may become ineligible due to pre-existing neutralizing antibodies to ChAd vaccines, for example following participation in SARS-CoV-2 clinical trials using such vaccines. This in turn could slow down recruitment to our clinical trials, especially if we were to consider expanding our trials in the EU, and, ultimately, if these ChAd vaccines against SARS-CoV-2 are proven effective and become widely available in the general population, may render our vaccination approach unsuitable for many cancer patients. Similarly, patients who have been previously vaccinated with a mRNA-based vaccine may be reluctant to receive our samRNA vaccines or may have contraindications, such as allergic reaction to their SARS-CoV-2, mRNA-based vaccines.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our increased reliance on personnel working from home, a shift that began with the COVID-19 pandemic but has become the established norm, may negatively impact productivity or disrupt, delay or otherwise adversely impact our business. In addition, this could increase our cyber-security risk, create data accessibility concerns and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and important agencies and contractors.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and comparable foreign regulatory agencies may experience operational interruptions or delays, which may impact timelines for regulatory submission, trial initiation and regulatory approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 outbreak has become less of a direct threat to public health in countries that have achieved relatively high vaccination rates, such as the United States; but, it remains unclear when the pandemic will cease to pose a threat to the global economy, particularly if full global vaccination is not achieved or existing vaccines prove less effective against new variants of the virus. The extent to which the outbreak may impact our business, manufacturing, preclinical development activities, preclinical studies and planned clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the potential for localized outbreaks of COVID-19 in countries or regions with relatively low vaccination rates, travel restrictions, lock-downs and other actions to contain the outbreak or treat its impact, business closures or business disruptions, and the effectiveness of actions taken to contain and treat the disease.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have applied, and we intend to continue applying, for patents covering aspects of our product candidates, proprietary technologies and their uses that we deem appropriate. However, we may not be able to apply for patents on certain aspects of our current or future product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all, and any potential patent coverage we obtain may not be sufficient to prevent substantial competition. As of December 31, 2022, our solely owned patent portfolio includes pending patent applications and issued patents. We cannot be certain that the claims in any of our patent applications will be considered patentable by the United States Patent and Trademark Office (USPTO) courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators will be successful in protecting our product candidates, proprietary technologies and their uses by obtaining and defending patents. These risks and uncertainties include the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patent applications may not result in any patents being issued;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March 16, 2013;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. Moreover, the patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents, if issued, or the patent rights that we license from others, may be challenged in the courts or patent offices in the United States and abroad. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third parties can raise objections against such initial grant. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our products and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#x2019;s or potential competitor&#x2019;s product or service. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering our products are invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our products, our competitive position could be harmed, or we could be required to incur significant expenses to enforce or defend our rights. If we initiate lawsuits to protect or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any of our pending patent applications or those of our licensors may issue as patents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others will not or may not be able to make, use, offer to sell, or sell products that are the same as or similar to our own but that are not covered by the claims of the patents that we own or license;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we will be able to successfully commercialize our products, if approved, on a substantial scale before the relevant patents that we own or license expire;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we were the first to make the inventions covered by each of the patents and pending patent applications that we own or license;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors were the first to file patent applications for these inventions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others will not develop similar or alternative technologies that do not infringe the patents we own or license;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any of the patents we own or license will be found to ultimately be valid and enforceable;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable products or will provide us with any competitive advantages;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a third party may not challenge the patents we own or license and, if challenged, a court would hold that such patents are valid, enforceable and infringed;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may develop or in-license additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others will not have an adverse effect on our business;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we will develop additional proprietary technologies or products that are separately patentable; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our commercial activities or products will not infringe upon the patents of others.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where we obtain licenses from or collaborate with third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could have a material adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The lives of our patents may not be sufficient to effectively protect our products and business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent life has expired, we may be open to competition. In addition, although upon issuance in the United States a patent&#x2019;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we do not have sufficient patent life to protect our product candidates, proprietary technologies and their uses, our business and results of operations will be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information. We have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such a competitor from using that technology or information to compete with us, which could harm our competitive position. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our products and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs, or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies. The patent protection, prosecution and enforcement for some of our product candidates may be dependent on third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently are reliant upon licenses of certain patent rights and proprietary technology from third parties that is important or necessary to the development of our technology and products, including technology related to our product candidates. For example, we rely on our license agreements with Arbutus and Genevant for certain lipid nanoparticle-based delivery technologies. These and other licenses we may enter into in the future may not provide adequate rights to use such intellectual property and technology in all relevant fields of use or in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to develop and commercialize our technology and products in fields of use and territories for which we are not granted rights pursuant to such licenses.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some circumstances, we may not have the right to control the preparation, filing, prosecution and enforcement of patent applications, or to maintain the patents, covering technology that we license from third parties. In addition, some of our agreements with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that our licensors or collaborators will prosecute, maintain, enforce and defend such intellectual property rights in a manner consistent with the best interests of our business, including by taking reasonable measures to protect the confidentiality of know-how and trade secrets, or by paying all applicable prosecution and maintenance fees related to intellectual property registrations for any of our product candidates. We also cannot be certain that our licensors have drafted or prosecuted the patents and patent applications licensed to us in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our licensed European patents and patent applications could be challenged in the recently created Unified Patent Court (UPC) for the European Union, that is expected to be fully ratified in 2023. Under our current license agreements, we may not have the final or sole decision on whether we are able to opt out certain of our in-licensed European patents and patent applications from the recently created Unified Patent Court (UPC) for the European Union, that is expected to be fully ratified in 2023. Our licensors may decide to not opt out of the UPC, which would subject our in-licensed European patents and patent applications to the jurisdiction of the UPC. Furthermore, even if our licensors decide to opt out of the UPC, we cannot guarantee that our licensors will comply with the legal formalities and requirements for properly opting out of the UPC. Thus, we cannot be certain that our in-licensed European patents and patent applications will not fall under the jurisdiction of the UPC. Under the UPC, a single European patent would be valid and enforceable in numerous European countries. A challenge to the validity of a European patent under the UPC, if successful, could result in a loss of patent protection in numerous European countries which could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current licenses impose, and our future licenses likely will impose, various royalty payments, milestones, and other obligations on us. If we fail to comply with any of these obligations, we may be required to pay damages and the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights and could prevent us from developing and commercializing our product candidates and proprietary technologies. Our business would suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any current or future licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. We cannot assure you that our operations do not, or will not in the future, infringe existing or future patents.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations, inter partes review proceedings and post-grant review proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of and have timely opposed EP Patent 2569633, expiring in May 2031 (absent any patent term adjustments or extensions), directed to certain methods of identifying and using neoantigens. EP Patent 2569633 is currently validated in Great Britain, France, Germany, Netherlands, Italy, Ireland, Spain and Switzerland. Our opposition was filed in our name on November 7, 2016 by Vossius &amp; Partner. Four other parties also filed oppositions to the patent within the required timeframe. The Opposition Division of the European Patent Office (EPO), held opposition hearings on October 15 and 16, 2018, and determined that EP Patent 2569633 does not meet the requirements of the European Patent Convention (EPC) and consequently, revoked the patent. We received notice in April 2019 that EP Patent 2569633 patentees and licensors filed their appeal to the Opposition Division&#x2019;s decision, and we, along with other opposers, filed responses in August 2019. Opponent Christian M&#xfc;ller withdrew his opposition in May 2020, but the appeal proceedings were to be continued between the remaining parties. The EPO scheduled the oral proceedings for the appeal for September 27 and 28,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022. However, on August 22, 2022, Appellant filed for withdrawal of their appeal and the oral proceedings were subsequently cancelled. The Opposition Division&#x2019;s decision revoking EP Patent 2569633 is thus final.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. We do not always conduct independent reviews of pending patent applications of, and patents issued to, third parties.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent applications in the United States and elsewhere are typically published approximately eighteen (18) months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">result in costly litigation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">divert the time and attention of our technical personnel and management;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cause development delays;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to pay the attorney&#x2019;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although no third party has asserted a claim of patent infringement against us as of the date of this report, others may hold proprietary rights that could prevent any of our immunotherapy candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market the affected immunotherapy candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Even if such licenses are available, we could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins, and the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our immunotherapy candidates, which could harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. Also, we may be obligated under our agreements with our collaborators, licensors, suppliers and others to indemnify and hold them harmless for damages arising from intellectual property infringement by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims before the USPTO, even outside the context of litigation. For example, third parties may petition the USPTO for post-grant review within nine (9) months of our patent&#x2019;s issuance date. Further, after the USPTO period for filing post-grant review has expired, third parties may file a petition for inter partes review on certain grounds. Similar mechanisms for challenging the validity and enforceability of a patent exist in ex-U.S. patent offices and may result in the revocation, cancellation, or amendment of any ex-U.S. patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have collaborated with U.S. academic institutions and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are party to various agreements that we depend on to operate our business, including intellectual property rights relating to GRANITE, SLATE and CORAL, in particular, our agreements with Arbutus and Genevant. Our rights to use currently licensed intellectual property or intellectual property to be licensed in the future are subject to the continuation of and our compliance with the terms of these agreements. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sublicensing of patent and other rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope and duration of our payment obligations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our rights upon termination of such agreement; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope and duration of exclusivity obligations of each party to the agreement.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future license agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is common in the biotechnology and biopharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or biopharmaceutical companies including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. In addition, we may face claims by third parties that our agreements with employees, contractors or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension for our product candidates, our business may be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA marketing approval of GRANITE, SLATE, CORAL or any future immunotherapy candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in patent law in the U.S. or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patent rights may be affected by developments or uncertainty in U.S. or ex-U.S. patent statutes, patent case laws in USPTO rules and regulations or in the rules and regulations of ex-U.S. patent offices. There are a number of changes to the U.S. patent laws that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, on September 16, 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#x201c;first to file&#x201d; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. This could have a negative impact on some of our intellectual property and could increase uncertainties surrounding obtaining and enforcement or defense of our issued patents. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, statutory or judicial changes to the patent laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Our European patents and patent applications could be challenged in the recently created Unified Patent Court (UPC) for the European Union, that is expected to be fully ratified in 2023. We may decide to opt out our European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. Under the UPC, a granted European patent would be valid and enforceable in numerous European countries. Although such patent rights would apply to numerous European countries, a successful challenge to a European patent under the UPC could result in loss of patent protection in numerous European countries. Accordingly, a single proceeding under the UPC addressing the validity and infringement of the European patent could result in loss of patent protection in numerous European countries rather than in each validated country separately as such patents always have been adjudicated. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending all current and future patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own, and if we license intellectual property we may have to rely upon our licensors to comply with these requirements and effect payment of these fees with respect to any patents and patent applications that we license. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make next generation cancer and infectious disease immunotherapies that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Government Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If one or more of our product candidates is approved, each will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP or similar regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP or similar regulations and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#x2019;s approved label and truthful and non-misleading.  As such, we may not promote our products &#x201c;off-label&#x201d; for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issue warning letters;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impose civil or criminal penalties;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend, vary or revoke regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend any of our clinical studies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications submitted by us;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impose restrictions on our operations, including closing our contract manufacturers&#x2019; facilities; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seize or detain products, or require or request a product recall.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, the CARES Act made a number of changes to the Federal Food, Drug and Cosmetic Act aimed at preventing drug shortages. Similarly, the FDA has issued a number of guidance documents describing the agency&#x2019;s expectations for how drug manufacturers should comply with various FDA requirements during the pandemic, including with respect to conducting clinical trials, distributing drug samples, and reporting post-marketing adverse events. Moreover, as a result of the COVID-19 pandemic, there has been increasing political and regulatory scrutiny of foreign-sourced drugs and foreign drug supply chains, resulting in proposed and enacted legislative and executive actions, including Executive Orders, to incentivize or compel drug manufacturing operations to relocate to the United States. It is not clear how these changes and proposals could impact our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek orphan drug designation for certain future product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may pursue orphan drug designation for certain of our future product candidates. Under the Orphan Drug Act, the FDA may designate a drug or biologic product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the European Commission, on the basis of a scientific opinion by the EMA&#x2019;s Committee for Orphan Medicinal Products (COMP), grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product. In any event, orphan designation is granted only if there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. It is no longer necessary to obtain orphan designation in Great Britain before an application for marketing authorization is made, and the criteria will be assessed by the MHRA, at the time of assessment of the application for marketing authorization. The criteria in Great Britain are similar to those in the EU but have been tailored for the Great Britain market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax credits for certain clinical trial costs, and application fee waivers. In addition, if an orphan-designated product receives the first FDA approval for the indication for which it has orphan designation (meaning that FDA has not previously approved a drug considered the same drug for same orphan condition), the product is entitled to orphan drug exclusivity. If there is a previously approved same drug for the same orphan condition, to obtain orphan exclusivity, the sponsor of the subsequent drug must demonstrate clinical superiority over the previously approved same drug. If granted, orphan exclusivity means the FDA may not approve any other application to market the same drug for the same disease or condition for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity to meet the needs of the orphan patient population. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval, subject to the positive outcome of the reassessment of the continued compliance with the orphan designation criteria at the time of approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met at the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">end of the fifth year since grant of the approval, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Moreover, upcoming legislative reforms in the European Union may result in a reduction of market exclusivity periods for orphan medicinal products and/or imposition of additional requirements for grant of such exclusivity. In Great Britain, if the criteria for orphan designation are met at the time of assessment of the marketing authorization, the applicant is entitled to a fee reduction and ten years of market exclusivity. The terms of market exclusivity, and possibility for the period to be reduced, are similar to those in the EU. The European Commission is expected to publish new proposed legislation in March 2023 which, if adopted by the European Parliament and the Council of Ministers, will introduce significant number of changes to the market exclusivities granted to orphan medicinal products and the related procedures and requirements in the EU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain orphan drug designation for a product candidate, we may not be the first to obtain marketing approval for the product candidate for any particular orphan indication due to the uncertainties associated with developing novel biologic products. Further, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or foreign regulatory authorities can subsequently approve the same drug with the same active moiety for the same condition if the FDA or foreign regulatory authorities concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, a September 2021 Eleventh Circuit decision in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst Pharmaceuticals, Inc. vs. Becerra</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> regarding interpretation of the Orphan Drug Act exclusivity provisions as applied to drugs approved for orphan indications narrower than the drug&#x2019;s orphan designation could significantly broaden the scope of orphan drug exclusivity for such products. In January 2023, FDA, however, issued a Federal Register notice clarifying its approach to orphan drug exclusivity following the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decision that suggests this may not be the agency&#x2019;s intended direction going forward.  Consistent with the court&#x2019;s decision, FDA set aside its approval of the drug at issue in the case. But otherwise, the notification announced that at this time, while complying with the court&#x2019;s order in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, FDA intends to continue to apply its regulations tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved to matters beyond the scope of that order.  Specifically, FDA intends to continue to apply its longstanding regulations tying the scope of orphan drug exclusivity to the uses or indications for which the orphan drug was approved. Legislation also has been introduced that may reverse the Catalyst decision.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have received fast track designation for GRANITE for the treatment of colorectal cancer, and we may seek such designation for some or all of our other product candidates. If a drug or biologic, in our case, is intended for the treatment of a serious or life-threatening disease or condition and the biologic demonstrates the potential to address unmet medical needs for this disease or condition, the biologic sponsor may apply for FDA fast track designation. The sponsor of a fast-track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development; and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot guarantee that the FDA would grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Some of our product candidates may require pediatric development, which may delay our regulatory approvals and ultimately our commercial licensure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The RACE for Children Act enacted in the U.S. in August 2017 and the European Pediatric Regulation implemented in 2007 as well as similar legislation in the UK may require us to develop our products in pediatric cancer patients. Pediatric cancers are rare, mutational burden is usually low in pediatric tumors and our approach may not be suited for children with cancer, or it may be difficult and slow to accrue children with cancers in our clinical trials. We may incur delays in meeting potential regulatory obligations or require additional investments to fulfill our regulatory commitments, and ultimately may be found incompliant if we cannot deliver pediatric data within the agreed timelines. This could lead to delays in regulatory approval and ultimately commercial licensure of our GRANITE or SLATE products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a licensure framework for follow on biologic products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the expansion of the 340B Drug Discount Program through the ACA has increased the number of purchasers who are eligible for significant discounts on branded drugs. Several drug manufacturers have commenced litigation, which remains ongoing, challenging the legality of contract pharmacy arrangements under the 340B Drug Discount Program, which may affect the way in which manufacturers are required to extend the 340B Drug Discount Program prices to covered entities, including through contract pharmacies. There are also ongoing challenges regarding the implementation of the 340B Drug Discount Program Administrative Dispute Resolution Process, which is in part intended to resolve claims by covered entities that they have been overcharged for covered outpatient drugs by manufacturers. In November 2022, the Health Resources and Services Administration issued a proposed rule to establish and implement an administrative dispute resolution process for certain disputes arising hunder the 340B drug pricing program. The public comment period closed on January 30, 2023. The nature of the Administrative Dispute Resolution Process, once finalized, may have a material adverse impact on our revenue should we participate in the 340B Drug Discount Program after receiving approval for our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace during the COVID-19 pandemic. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted, including aggregate reductions of Medicare payments to providers, which went into effect April 1, 2013 and due to subsequent legislative amendments, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, absent further congressional action. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.  Additionally, Congress has considered a number of bills relating to drug pricing and recently enacted the Inflation Reduction Act of 2022 (IRA), which was signed into law by President Biden and contains a number of provisions regarding drug pricing. The IRA adopted drug pricing reforms that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">will allow the federal government to negotiate prices for some high-cost drugs covered under Medicare Parts B and D, introduce inflationary rebates on certain Medicare Part B and Medicare Part D drugs and redesign the structure of the Part D benefit. It remains unclear how numerous aspects of this law will be implemented and how it will affect our business, and it is possible that Congress will consider other legislation that would affect drug pricing issues going forward. Although the Build Back Better Act stalled in Congress, there are other drug pricing reforms still under consideration in Congress, including elements of the Build Back Better Act aimed at allowing Medicare to negotiate the price of prescription drugs in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as Executive Orders, designed to, among other things, reduce or limit the prices of drugs and make them more affordable for patients, such as by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries, bring more transparency to drug pricing rationale and methodologies (including, for example, by requiring drug manufacturers to disclose planned drug price increases and the rationales for such increases), implement data collection and reporting under Section 204 of Title II of Division BB of the Consolidated Appropriations Act, 2021, which requires, among other things, health plans and issuers to disclose rebates, fees, and other remuneration provided by drug manufacturers related to certain pharmaceutical products, revise rules associated with the calculation of Medicaid Average Manufacturer Price and Best Price, including the removal of the current statutory 100% of Average Manufacturer Price per-unit cap on Medicaid rebate liability for single source and innovator multiple source drugs effective as of January 1, 2024 under the American Rescue Plan Act of 2021, which may significantly affect the amount of rebates paid on prescription drugs under Medicaid and the prices that are required to be charged to covered entities under the 340B Drug Discount Program, and facilitate the importation of certain lower-cost drugs from other countries. In July 2021, President Biden issued an Executive Order directing various executive branch agencies to take actions to lower drug prices and promote generic competition, including directing FDA to support and work with states and Indian Tribes to develop importation plans to import prescription drugs from Canada. The Executive Order required the Secretary of Health and Human Services to develop a comprehensive plan for addressing drug prices. The plan was released on September 9, 2021, and it includes support for legislative and administrative actions that would improve affordability, access and competition, and foster scientific innovation. Following passage of the IRA, in October 2022, President Biden issued an Executive Order directing the Center for Medicare and Medicaid Innovation to consider new models to lower drug costs and promote access to Medicare and Medicaid beneficiaries. The Executive Order directs HHS to issue a report on potential models to the White House within 90 days, and HHS delivered a report to President Biden on February 14, 2023 that outlines three models, including one that would develop payment methods for drugs approved under accelerated approval, in consultation with the Food and Drug Administration, to encourage timely confirmatory trial completion and improve access to post market safety and efficacy data. It is possible that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union and UK, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Moreover, upcoming legislative and policy changes in the European Union may further impact the price and reimbursement status of our products in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act, which prohibit, among other things, including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (as defined by statute), certain non-physician practitioners such as physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our stock price is volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this &#x201c;Risk Factors&#x201d; section of this report and others such as:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results from, and any delays in, our clinical trials, in particular for GRANITE and SLATE or any other current or future clinical development programs, including public misperception of the results of our trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements by academic or other third parties challenging the fundamental premises underlying our approach to treating cancer and infectious disease and/or biopharmaceutical product development;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements of regulatory approval or disapproval of our current or any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure or discontinuation of any of our research and development programs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing setbacks or delays of or issues with the supply of the materials for our personalized immunotherapy candidate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements relating to future licensing, collaboration or development agreements, including the early termination or failure of an existing strategic collaboration;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in the commercialization of our current or any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">public misperception regarding the use of our therapies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquisitions and sales of new products, technologies or businesses;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">quarterly variations in our results of operations or those of our current or future competitors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in earnings estimates or recommendations by securities analysts;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements by us or our competitors of new products, significant contracts, commercial relationships, acquisitions or capital commitments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments with respect to intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our commencement of, or involvement in, litigation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any major changes in our board of directors or management;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">new legislation, particularly in the United States, relating to the sale or pricing of pharmaceuticals;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA or other U.S. or foreign regulatory actions affecting us or our industry;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product liability claims or other litigation or public concern about the safety of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market conditions in the biopharmaceutical and biotechnology sectors, particularly as a result of the volatility in the market caused by the COVID-19 pandemic; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic conditions in the United States and abroad.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock markets in general, and the markets for biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of any particular issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit, and the attention of our management would be diverted from the operation of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements. For example, we have issued and may continue to issue shares in our &#x201c;at the market offering&#x201d; program or other registered offerings under our 2022 Shelf Registration Statement, and we have issued shares in three private placement of public issuer&#x2019;s equity transactions. To the extent that additional capital is raised through the issuance of shares of common stock or other securities convertible into shares of common stock, our stockholders will be diluted. In addition, future issuances of our common stock or other equity securities (or securities convertible into our common stock or other equity securities), or the perception that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or other securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of December 31, 2022, we have a total of 86,894,901 shares of common stock outstanding, as well as approximately 26.8 million shares underlying pre-funded warrants and approximately 7.7 million shares of common stock that are subject to outstanding options, restricted stock units or other equity awards. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset a portion of future taxable income, if any, until such unused losses expire, if ever. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (IRC), if a corporation undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. Any equity financing transactions, private placements and other transactions that occur within</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a three-year testing period may trigger additional ownership changes, which could further limit our use of such tax attributes. Any such limitations, whether as a result of prior or future offerings of our common stock or sales of common stock by existing stockholders, could have an adverse effect on our results of operations in our future years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a prohibition on stockholder action by written consent, which force stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by our chief executive officer or president or by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#x2019;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide for an exclusive forum in the Court of Chancery of the State of Delaware and in the U.S. federal district courts for certain disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. The exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have exclusive jurisdiction. In addition, our amended and restated certificate of incorporation provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees and result in increased costs for investors to bring a claim.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks related to our Loan Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our failure to comply with the covenants or payment obligations under our existing term loan facility could result in an event of default, which may result in increased interest charges, acceleration of our repayment obligations or other actions by the lenders, any of which could negatively impact our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(209,52,56,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 19, 2022, we entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc., Silicon Valley Bank, and certain financial institutions or other entities from time-to-time party thereto (the &#x201c;Lenders&#x201d;) pursuant to which the Lenders made available to us a secured term loan facility in an aggregate principal amount of up to $80 million (the &#x201c;Term Loan&#x201d;). We immediately drew $20.0 million under this facility upon entry into the Loan Agreement. In connection with the Loan Agreement, we granted the Lenders a security interest in substantially all of our personal property and other assets, other than our intellectual property. The Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties, including a covenant against the occurrence of a change in control (as defined by the Loan Agreement), financial reporting obligations, and certain limitations on indebtedness, liens (including a negative pledge on intellectual property and other assets), investments, distributions (including dividends), collateral, investments, transfers, mergers or acquisitions, taxes, corporate changes, and deposit accounts. The Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants following any applicable cure period, the occurrence of certain events that could reasonably be expected to have a material adverse effect (as set forth in the Loan Agreement), cross default to certain third-party indebtedness and certain events relating to bankruptcy or insolvency. Upon the occurrence of an event of default, a default interest rate of an additional 4.0% may be applied to the outstanding principal and interest payments due, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement, including proceeding against the collateral securing such indebtedness. Such increased interest charges, accelerated repayment, proceedings against the collateral or other actions may have a negative impact on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our existing and any future indebtedness may limit our cash flow available to invest in the ongoing needs of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding debt combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requiring us to dedicate cash flow from operations or cash on hand to the payment of interest on, and principal of, our debt, which will reduce the amounts available to fund working capital, capital expenditures, product development efforts and other general corporate purposes;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increasing our vulnerability to adverse changes in general economic, industry and market conditions;   </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limiting our flexibility in planning for, or reacting to, changes in our business and our industry; and   </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to satisfy our current and future debt service obligations with our existing cash and funds from external sources. Nonetheless, we may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our existing or any future debt facility. Funds from external sources may not be available on acceptable terms, if at all. In addition, a failure to comply with the covenants under the Loan Agreement or any future loan agreements we may enter into could result in an event of default and acceleration of amounts due. If an event of default occurs and the lenders accelerate the amounts due under such loan agreements, we may not be able to make accelerated payments, and such lenders could seek to enforce security interests in the collateral securing such indebtedness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We incur substantial costs as a result of operating as a public company, and our management devotes substantial time to governance and compliance matters. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Select Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct, among other requirements. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#x2019; and officers&#x2019; insurance, on acceptable terms or at all.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we are subject to Section 404 of the Sarbanes-Oxley Act of 2002 (Section 404) and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal controls over financial reporting. We will remain an emerging growth company until December 31, 2023.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to provide the reports required by these rules we must conduct reviews and testing of our internal controls. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend on third party vendors to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences that would materially harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#x2019;s conduct was unlawful.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters are currently located at 5959 Horton Street, Emeryville, California, comprising approximately 34,600 square feet of office and laboratory space. The lease term for the 5959 Horton lease expires on November 30, 2029 and we have an option to extend the lease term for two consecutive additional terms of 5 years. We also currently lease an aggregate of 20,700 square feet of space in two Cambridge, Massachusetts facilities, including (i) the lease of approximately 13,900 square feet of office and laboratory space, the term of which expires in April 2025 and (ii) the lease of approximately 6,800 square feet of office and laboratory space, the term of which expires in June 2023.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We lease a manufacturing facility in Pleasanton, California, where we occupy approximately 42,600 square feet of space. The current term of our lease expires in November 2024, with an option to extend the term through November 2029. We also lease an additional space in Pleasanton, California, where we occupy approximately 7,100 square feet of general office space. The current term of the lease expires in November 2024.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we lease part of a newly-built facility in Boston, Massachusetts, comprising approximately 73,495 square feet of office and laboratory space. We expect to take occupancy of this facility in 2023.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For additional information on all our properties, see &#x201c;Leases&#x201d; in Note 6 to our consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our existing facilities are sufficient for our needs for the immediate future and that, with our new facility in Boston, our facilities will meet the anticipated needs of our business in the medium term. As we continue to grow the business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#x201c;GRTS&#x201d; since September 28, 2018. Prior to that date, there was no public trading market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Common Stock</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 7, 2023, there were 18 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial owners of our common stock represented by these record holders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. In addition, future debt instruments may materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of the board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of current or then-existing debt instruments and other factors the board of directors deems relevant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance Graph</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a &#x201c;smaller reporting company&#x201d; as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. [Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. This discussion and analysis, and other parts of this report, contain forward-looking statements, including, but not limited to, statements related to the potential of our therapeutic programs. Such forward-looking statements involve substantial risks and uncertainties that could cause our research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including interim results obtained may differ from those at completion of the studies and clinical trials. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including  our programs&#x2019; early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products,  our ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Our actual results could differ materially from those discussed in these forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see the section titled &#x201c;Risk Factors&#x201d; included elsewhere in this Annual Report on Form 10-K. These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology company focused on combining immunological insights with proprietary technologies and capabilities to develop next-generation vaccines. Specifically, we discover, develop, manufacture, and deliver vaccine-based immunotherapy candidates against cancer and infectious disease. Our goal is to unlock more potent and durable immunity by harnessing vaccine innovation. We aim to achieve that goal by leveraging our in-house capabilities and technologies to address the shortcomings of currently available vaccines and immunotherapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The immune system sits at the nexus of many diseases, and we believe that immune response modulation is core to several transformational product classes. Recent advances have pointed to T cells as being central to the success of cancer immunotherapy and critical in the elimination of virally infected cells. We believe that our scientific approach of focusing on generating antigen-specific T cells, particularly the challenging but critical cytotoxic CD8+ T cell subclass has the potential to drive transformational therapeutic and prophylactic benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In oncology, we develop personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA. In infectious disease, we develop both therapeutic and prophylactic vaccines targeting both T cells and B cells. We believe we are leading the field of development and application of self-amplifying mRNA (samRNA), a rapidly-emerging platform technology. Our unique approach to immunogen design, whereby our vaccines deliver, as appropriate, whole proteins to drive neutralizing antibodies (nAbs) and/or protein fragments to drive T cell responses, has the potential to both neutralize incoming pathogens (through nAbs) and kill infected cells through CD8+ T cell recognition of foreign, pathogen-derived peptides displayed on the surface of infected cells.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical programs include GRANITE, an individualized neoantigen-based vaccine program; SLATE, an &#x201c;off-the-shelf&#x201d; neoantigen-based vaccine program; CORAL, a second-generation SARS-CoV-2 vaccine program; and HIV, HIV vaccine program in collaboration with Gilead Sciences, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below summarizes key information about our clinical-stage programs.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.565%;"></td>
    <td style="width:1.009%;"></td>
    <td style="width:6.167%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:26.361%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:26.361%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.296%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.241%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Program</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Status</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indication(s)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaborator</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial Rights</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GRANITE</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/3</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment Ongoing; Treatment Ongoing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSS-CRC* first line maintenance</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GRANITE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment Complete; Treatment Ongoing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Early stage &amp; advanced solid tumors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SLATE</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment Ongoing; Treatment Ongoing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.9245pt;white-space:pre-wrap;font-weight:normal;font-size:7.035pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">mut</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-driven tumor types</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SLATE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Complete</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KRAS Advanced Solid Tumors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIV</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4Q2021 IND Cleared</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIV treatment/cure</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gilead Sciences</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gilead**</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CORAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment Complete; Treatment Ongoing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SARS-CoV-2 in South Africa</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CEPI</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CORAL</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment Complete; Treatment Ongoing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SARS-CoV-2 booster</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CORAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment Complete; Treatment Ongoing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SARS-CoV-2 na&#xef;ve &amp; booster</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NIAID, IDCRC</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* MSS-CRC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> = </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">microsatellite stable colorectal cancer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">** Gilead is responsible for conducting a Phase 1 study</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beyond GRANITE, SLATE, CORAL and the HIV collaboration with Gilead, we continue to apply our broad set of capabilities in oncology and infectious diseases through promising preclinical work and partnerships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 Update</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since the COVID-19 pandemic began, providers of healthcare services have had to deal with significant strains on their operations. These strains have affected all healthcare institutions, including those where we conduct our clinical trials, with some institutions prohibiting or postponing the initiation of new clinical trials, slowing or halting enrollment in existing trials and restricting the on-site monitoring of clinical trials. Although our operations have not been materially impacted by the COVID-19 pandemic, we have experienced slowing of patient recruitment and sample collection in our ongoing clinical trials. Additionally, as a result of the COVID-19 pandemic, competition for potential patients in our trials may be further exaggerated as a result of multiple clinical site closures. To date, the COVID-19 pandemic has not materially affected our supply chain or production schedule, but further escalation of the health crisis has the potential to cause delays in our supply chain and manufacturing operations, which could materially adversely impact our business.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the COVID-19 pandemic, we have implemented heightened health and safety measures designed to comply with applicable federal, state and local guidelines, and transitioned to a flexible work environment, where employees who can work from home effectively are allowed to do so. We have implemented virtual meeting and messaging technology and encourage employees to follow local health authority guidance. As the pandemic and its impacts continue to evolve, we may need to undertake additional actions that could impact our operations if required by applicable laws or regulations or if we determine such actions to be in the best interests of our employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Funding Sources</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have funded our operations to date primarily through sales of our convertible preferred stock, sales of our common stock in public offerings and under our &#x201c;at-the-market&#x201d; offering program, private placements of our common stock and pre-funded warrants, proceeds from the Loan Agreement (as defined below) and with proceeds received from our collaboration arrangements. We also have received targeted funding from charitable foundations. We do not expect to generate revenue from any product candidates that we develop until we obtain regulatory approval for one or more of such product candidates and commercialize our products or enter into additional collaboration agreements with third parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Our programs will require substantial additional development time and resources before we (or our collaboration partners) would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. In addition, we incur substantial costs associated with operating as a public company. We also do not yet have a sales organization or commercial infrastructure and, accordingly, we will incur significant expenses to develop a sales organization or commercial infrastructure in advance of generating any commercial product sales. As a result, we will need substantial additional capital to support our operating activities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently anticipate that we will seek to fund our operations through equity or debt financings or other sources, such as additional collaboration agreements we may enter into with third parties. Adequate funding may not be available to us on acceptable terms, or at all, particularly in light of the current COVID-19 pandemic and associated economic uncertainty and potential local and/or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">global economic recession. If sufficient funds on acceptable terms are not available when needed, we will be required to significantly reduce our operating expenses and delay, reduce the scope of, or eliminate one or more of our development programs. See &#x201c;Liquidity and Capital Resources&#x201d; below and Note 2 to the consolidated financial statements and related notes included elsewhere for additional information.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing is a vital component of our platform approach to immunotherapy, and we have invested significantly in our manufacturing facility, which opened in November 2017. Until December 2019, we used a hybrid approach to manufacture our individualized immunotherapy, wherein certain elements of our product candidates were manufactured on an outsourced basis at qualified third-party contract manufacturing organizations (CMOs) and other elements of our product candidates were manufactured internally. Beginning in March 2020, we internalized the majority of the outsourced elements of the manufacturing process for our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since we commenced operations in August 2015, we have invested a significant portion of our efforts and financial resources in research and development activities and establishing our manufacturing facility. We have had significant operating losses since our inception, and we do not expect positive cash flows from operations in the foreseeable future (for additional information, see &#x201c;Liquidity&#x201d; in Note 1 to our consolidated financial statements). We do not have any products approved for sale. We expect to continue to incur net operating losses for at least the next several years as we advance our product candidates through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest in our manufacturing facility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following our IPO, in April 2019, we completed an underwritten public offering and sold and issued an aggregate of 6,500,000 shares of common stock at a price to the public of $11.50 per share. We received aggregate net proceeds from the offering of approximately $69.7 million, after deducting underwriting discounts and commissions and offering costs.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, we (i) filed a shelf registration statement on Form S-3 (the &#x201c;2019 Shelf Registration Statement&#x201d;), with the SEC covering up to $250.0 million of common stock, preferred stock, debt securities, warrants and units, and (ii) entered into a Sales Agreement with Cowen and Company, LLC (Cowen), for an &#x201c;at-the market&#x201d; $75.0 million in shares of our common stock (ATM Offering Program). Through December 31, 2022, we had received aggregate proceeds from our ATM Offering Program of $50.0 million, net of commissions and offering costs, pursuant to the issuance of 5,642,712 shares. During the year ended December 31, 2021, we issued and sold 3,990,869 shares of our common stock through our ATM Offering Program and received net proceeds of approximately $36.6 million. As of December 31, 2022, there are no further amounts available for issuance under the 2019 ATM Offering Program.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we entered into private placement transactions, pursuant to which we sold (i) an aggregate of 5,543,351 shares of common stock at a per share purchase price of $3.34, (ii) pre-funded warrants to purchase an aggregate of 27,480,719 shares of common stock, each with an exercise price of $3.34 per share of common stock (of which $3.33 per share was pre-paid by each purchaser), and (iii) an aggregate of 4,043,127 shares of common stock at a per share purchase price of $3.71. The aggregate gross cash proceeds to us for the securities sold in these private placements was $125.0 million, and related costs were $5.7 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 16, 2021, we entered into a Securities Purchase Agreement, pursuant to which we issued and sold, in an unregistered offering in reliance on an exemption from registration, an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share, at a per share purchase price of $11.00 per share. We received aggregate gross proceeds of $55.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we filed the 2022 Shelf Registration Statement, covering the offering of up to $250.0 million of various equity and debt securities, including the sale and issuance of up to $100.0 million worth of shares of our common stock under the 2022 ATM Offering Program. As of December 31, 2022, we have received $20.1 million in gross proceeds from our 2022 ATM Offering Program and have $79.9 million available thereunder.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, we entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;) and Silicon Valley Bank (&#x201c;SVB&#x201d;), which provides us with a 60-month term loan facility for the Company up to $80.0 million in borrowing capacity across five potential tranches. At the closing of the Loan Agreement, we drew $20.0 million from the first tranche, and we can draw up to an additional $10.0 million through March 2023. The remaining tranches provide up to $50.0 million borrowing capacity and become available if and when we meet certain milestones set forth in the Loan Agreement. The term loan is secured by substantially all of our assets, other than intellectual property. There are no warrants associated with the Loan Agreement. Beginning on April 1, 2023, so long as the Company&#x2019;s market capitalization is equal to or less than $400.0 million, the Company is subject to a minimum liquidity requirement equal to the then outstanding balance under the Loan Agreement multiplied by 0.55 or 0.45, which multiplier depends on whether the Company achieves certain performance milestones.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we completed a third private placement of securities (the &#x201c;Third PIPE Financing&#x201d;), pursuant to which we sold an aggregate of 6,637,165 shares of common stock at a per share purchase price of $2.26 and pre-funded warrants to purchase 13,274,923</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares of common stock at a price of $2.26 per share (of which $2.2599 per share was prepaid by each purchaser). The aggregate gross cash proceeds to us for the securities sold in the Third PIPE Financing was $45.0 million, and related costs were $2.6 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Our Operating Results</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License and Grant Revenue</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. For the years ended December 31, 2022, 2021, and 2020, we recognized $19.9 million, $48.2 million, $4.0 million, respectively, of revenue from the 2seventy Agreement, the Gilead Collaboration Agreement, the grant agreements with CEPI and Gates Foundation, and another small collaboration agreement. See Note 7 to our consolidated financial statements for additional information.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the future, we expect to continue to recognize revenue from the 2seventy Agreement and the Gilead Collaboration Agreement and may generate revenue from product sales or other collaboration agreements, strategic alliances and licensing arrangements. We expect our revenue to fluctuate on a quarterly and annual basis due to the timing and amount of license fees, reimbursement of costs incurred, milestone and other payments, as well as product sales, to the extent that any are successfully commercialized. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have committed significant resources to our research and development activities, including conducting preclinical studies, manufacturing development efforts and related development activities for our product candidates.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development activities account for a significant portion of our operating expenses. Research and development costs are expensed as incurred. These costs include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">External research and development expenses, including:</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred under arrangements with third parties, including clinical research organizations, or CROs, preclinical testing organizations, CMOs, academic and non-profit institutions and consultants;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fees related to our license agreements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal research and development expenses, including (i) headcount-related expenses, such as  salaries, payroll taxes, benefits, non-cash stock-based compensation and travel, for employees contributing to research and (ii) development activities, including the costs associated with the development of our EDGE&#153; platform; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expenses, which include direct and allocated expenses for laboratories, facilities and other costs. </span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to our Arbutus License Agreement, Arbutus granted us a worldwide, exclusive license to certain technology of Arbutus, including Arbutus&#x2019; portfolio of proprietary and clinically-validated LNP products and associated intellectual property, as well as technology transfer of Arbutus&#x2019; manufacturing know-how.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to our 2020 Genevant License Agreement, Genevant granted us exclusive license rights under certain intellectual property related to Genevant&#x2019;s LNP technology for a single indication, and we agreed to pay Genevant an initial payment of $2.0 million, and up to an aggregate of $71.0 million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The upfront payment of $2.0 million was included in research and development expenses during 2020. In March 2022, a milestone in the amount of $1.0 million was met, which was included in research and development expense for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to our 2021 Genevant License Agreement, we obtained a nonexclusive license to Genevant&#x2019;s LNP technology to develop and commercialize self-amplifying RNA, or samRNA, vaccines against SARS-CoV-2, the virus that causes COVID-19. Under the 2021 Genevant License Agreement, we made a $1.5 million upfront payment to Genevant, and Genevant is eligible to receive from us up to $141.0 million in contingent milestone payments per product, plus certain royalties on future product sales or licensing (or, in certain scenarios and subject to certain conditions, in lieu of these milestones and royalties Genevant would receive a percentage of amounts we receive from sublicenses). In March 2021, a milestone was met following the initial patient treatment in the Phase 1 clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trial conducted through the NIAID-supported IDCRC. Both the $1.5 million upfront and $1.0 million milestone payments were recorded as research and development expense for the year ended December 31, 2021. No research and development expense was recorded for the year ended December 31, 2022.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our research and development expenses to increase substantially in the future as we continue to advance our product candidates into and through clinical studies and pursue regulatory approval. Such activities are costly and time-consuming and we expect our clinical studies to generally become larger and more costly to conduct as they advance into later stages. The successful development of our product candidates is highly uncertain. The actual probability of success for our product candidates may be affected by a variety of risks and uncertainties associated with drug development, including those described in the section entitled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; included in Part II, Section 1A and elsewhere in this report.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses by program and category (in thousands):</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.578%;"></td>
    <td style="width:1.363%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.649%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.363%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.046999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GRANITE program external expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,832</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,962</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SLATE program external expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,691</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,706</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CORAL program external expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,082</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,879</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other program external research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,403</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,362</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel-related expenses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,030</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,138</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other unallocated research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,365</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,443</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,403</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,490</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.03pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Personnel-related expenses include stock-based compensation expense of $6.7 million and $6.6 million for the years ended December 31, 2022 and 2021, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not track internal related expenses on a program-by-program basis, because our research and development employees and infrastructure resources are utilized across our development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our general and administrative expenses consist primarily of salaries and related costs, including, but not limited to, payroll taxes, benefits, non-cash stock-based compensation and travel. Other general and administrative expenses include legal costs of pursuing patent protection of our intellectual property and professional service fees for auditing, tax and general legal services. We expect our general and administrative expenses to continue to increase in the future as we expand our operating activities and prepare for potential commercialization of our current and future product candidates, increase our headcount and support our operations as a public company, including increased expenses related to legal, accounting, regulatory and tax-related services associated with maintaining compliance with requirements of the Nasdaq Global Select Market and the SEC, directors and officers liability insurance premiums and investor relations activities. Allocated expenses consist of rent expenses related to our office and research and development facilities, depreciation and other allocated costs not otherwise included in research and development expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income consists primarily of interest income and investment income earned on our cash, cash equivalents and marketable securities.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense consists primarily of interest expense related to our debt facility. A portion of the interest expense is non-cash expense relating to the accretion of the final payment fees and amortization of debt discount and debt issuance costs associated with the Loan Agreement (as defined below).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the significant components of our results of operations (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.925%;"></td>
    <td style="width:1.182%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.72%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.173%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.914%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.173%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.914%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and license revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,269</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,717</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(37,448</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,676</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,497</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,179</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,945</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,214</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(28,269</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,403</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,490</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,913</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,970</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,933</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,037</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140,373</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,423</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,950</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(120,428</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(75,209</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(45,219</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,976</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,812</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,235</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(37</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,198</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(119,687</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(75,082</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(44,605</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License, and Grant Revenues</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and licenses revenues were $9.3 million and $46.7 million for the years ended December 31, 2022 and 2021, respectively. During the year ended December 31, 2022, we recorded $1.6 million in collaboration revenue related to the Gilead Collaboration Agreement, and $7.7 million in collaboration revenue related to the 2seventy Agreement. The amount of collaboration revenue recognized related to the 2seventy Agreement during the year ended December 31, 2022 included cumulative catch-up adjustments increasing collaboration revenue by $6.4 million due to revisions to estimated costs to complete the remaining performance obligation. During the year ended December 31, 2021, we recorded $38.6 million in license revenue and $5.1 million in collaboration revenue related to the Gilead Collaboration Agreement, and $3.0 million in collaboration revenue related to the 2seventy Agreement. Grant revenue was $10.7 million and $1.5 million for the years ended December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021, we recognized $9.5 million and $1.5 million, respectively, of grant revenue from the CEPI Funding Agreement. During the year ended December 31, 2022 we recognized $1.2 million of grant revenue from the Gates Agreement. See Note 7 to our consolidated financial statements for additional information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were $111.4 million for the year ended December 31, 2022 compared to $97.5 million for the year ended December 31, 2021. The increase of $13.9 million for the year ended December 31, 2022 was primarily due to increases in personnel-related costs and clinical trial expenses. Personnel-related costs increased by $8.0 million, as a direct result of our increased research and development headcount. Outside services and consultants increased by $7.9 million, as a result of clinical trials and preclinical testing, including additional temporary personnel to carry out the research and development activities. Facility related costs increased by $2.7 million to accommodate our increased research and general personnel. These increases were partially offset by a decrease of $2.9 million in laboratory supplies and consumables and milestone and license payments decreased by $1.8 million primarily reflecting payments to Genevant Sciences GmbH.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses were $29.0 million for the year ended December 31, 2022 compared to $25.9 million for the year ended December 31, 2021. The increase of $3.0 million was primarily attributable to a $4.1 million increase in personnel-related costs as we expanded our headcount and $0.3 million in outside services for legal, finance, recruiting and other professional services to support our ongoing operations, offset by a decrease of $0.4 million of facility related costs and $1.0 million in professional services expense due to costs incurred in the Gilead Collaboration Agreement in 2021 that did not occur again in 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income was $2.0 million for the year ended December 31, 2022. Interest income was $0.2 million for the year ended December 31, 2021. The income for both years represents interest and investment income from cash, cash equivalents and marketable securities. The increase of $1.8 million was primarily due to higher interest rates in 2022 as compared to 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense was $1.2 million for the year ended December 31, 2022. Interest expense was negligible for the year ended December 31, 2021. The interest expense is primarily comprised of the contractual coupon interest expense, the amortization of the debt discount and issuance costs and the accretion of the final payment fee associated with the Loan Agreement (as defined below). The increase of $1.2 million from 2021 to 2022 was due to the Loan Agreement entered into in July 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the significant components of our results of operations (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.734%;"></td>
    <td style="width:1.266%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.687000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.275%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.881%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.275%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.881%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and license revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,717</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,462</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,255</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,497</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">575</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">922</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,214</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,037</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,177</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,490</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,643</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,847</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,933</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,411</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,522</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,423</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,054</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,369</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(75,209</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(106,017</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,808</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">715</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(551</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(37</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(12</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(25</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(75,082</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(105,314</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,232</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discussions of year-to-year comparisons between 2021 and 2020 that are not included in this report on Form 10-K can be found in &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; in Part II, Item 7 of the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have funded our operations primarily through sales of our convertible preferred stock, sales of our common stock in public offerings and under our &#x201c;at-the-market&#x201d; offering programs, private placements of our common stock and pre-funded warrants, proceeds from the Loan Agreement (as defined below), and our collaborations, including with the receipt of proceeds under the 2seventy Agreement and the Gilead Collaboration Agreement, and non-dilutive grants from various nonprofit organizations. As of December 31, 2022, we had cash, cash equivalents, and marketable securities of $175.9 million and an accumulated deficit of $521.1 million, as compared to cash, cash equivalents, and marketable securities of $206.3 million and an accumulated deficit of $401.4 million as of December 31, 2021. We expect that our cash, cash equivalents, and marketable securities as of December 31, 2022 will enable us to fund our current and planned operating expenses and capital expenditures for at least the next 12 months from the date of the filing of this report.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, we filed the 2019 Shelf Registration Statement, covering the offering of up to $250.0 million of various equity and debt securities, including the sale and issuance of up to $75.0 million worth of shares of our common stock under the 2019 ATM Offering Program. Through December 31, 2022, we have received aggregate proceeds from our 2019 ATM Offering Program of $50.0 million, net of commissions and offering costs, pursuant to the issuance of 5,642,712 shares. As of December 31, 2022, there are no further amounts available for issuance under the 2019 ATM Offering Program.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we filed the 2022 Shelf Registration Statement, covering the offering of up to $250.0 million of various equity and debt securities, including the sale and issuance of up to $100.0 million worth of shares of our common stock under the 2022 ATM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offering Program. As of December 31, 2022, we have received $20.1 million in gross proceeds from our 2022 ATM Offering Program and have $79.9 million available thereunder.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we received the second tranche payment of $2.7 million under the CEPI Funding Agreement.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, we entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;) and Silicon Valley Bank (&#x201c;SVB&#x201d;), which provides us with a 60-month term loan facility for the Company up to $80.0 million in borrowing capacity across five potential tranches. At the closing of the Loan Agreement, we drew $20.0 million from the first tranche, and we can draw up to an additional $10.0 million through March 2023. The remaining tranches provide up to $50.0 million borrowing capacity and become available if and when we meet certain milestones set forth in the Loan Agreement. As of December 31, 2022, one milestone had been achieved, which provides the Company to draw up to $10 million through December 15, 2023. The term loan is secured by substantially all of our assets, other than intellectual property. There are no warrants associated with the Loan Agreement.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings under the Loan Agreement bear interest (i) at an annual cash rate equal to the greater of (x) the lesser of (1) the prime rate (as customarily defined) and (2) 5.50%, in either case, plus 3.15%, and (y) 7.15% and (ii) at an annual payment-in-kind rate, which may equal 2.00%. We are required to make monthly interest-only payments prior to the amortization date of January 1, 2025, subject to a potential six-month and one-year extension upon satisfaction of certain conditions. We will also be required to pay a facility charge equal to 0.50% of the principal amount of any borrowings made pursuant to the last four tranches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All unpaid principal and accrued and unpaid interest with respect to each term loan is due and payable in full on July 19, 2027. At our option, we may prepay all or any portion of the outstanding borrowings, plus accrued and unpaid interest thereon and fees and expenses, subject to a prepayment premium ranging from zero to 2.5%, during the first three years after closing, depending on the year of such prepayment. Upon repayment of the term loan, we will be required to make a final payment fee to the lenders equal to 5.75% of the aggregate original principal amount of the loan</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning on April 1, 2023, so long as our market capitalization is equal to or less than $400.0 million, we are subject to a minimum liquidity requirement equal to the then outstanding balance under the Loan Agreement multiplied by 0.55 or 0.45, which multiplier depends on whether we achieve certain performance milestones. Our obligations under the Loan Agreement are subject to acceleration upon the occurrence of customary events of default, including payment default, insolvency and the occurrence of certain events having a material adverse effect, including (but not limited to) material adverse effects upon the business, operations, properties, assets or financial condition of us and our subsidiaries, taken as a whole.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we completed a third private placement of securities (the &#x201c;Third PIPE Financing&#x201d;), pursuant to which we sold an aggregate of 6,637,165 shares of common stock at a per share purchase price of $2.26 and pre-funded warrants to purchase 13,274,923 shares of common stock at a price of $2.26 per share (of which $2.2599 per share was prepaid by each purchaser). The aggregate gross cash proceeds to us for the securities sold in the Third PIPE Financing was $45.0 million, and related costs were $2.6 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future Funding Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not expect positive cash flows from operations in the foreseeable future. Historically, we have incurred operating losses as a result of ongoing efforts to develop our cancer immunotherapy candidates, including conducting ongoing research and development, clinical and preclinical studies and providing general and administrative support for these operations. We do not have any products approved for sale, and we do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our current and future product candidates and/or enter into additional significant collaboration or grant agreements with third parties, and we do not know when, or if, either will occur. We expect to continue to incur net operating losses for at least the next several years and we expect the losses to increase as we advance our CORAL, GRANITE, and SLATE programs, as well as any future product candidates, through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest in our manufacturing facility. We are subject to all the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover, we incur substantial costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until we can generate a sufficient amount of revenue from the commercialization sources of liquidity of immunotherapy product candidates or from additional significant collaboration or license agreements with third parties, if ever, we expect to finance our future cash needs through private and public equity offerings, including our &#x201c;at-the-market&#x201d; offering programs, debt financings, and potential future collaboration, license and development agreements. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our current or future product candidates. If we raise additional</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">funds by issuing equity or convertible debt securities, it could result in dilution to our existing stockholders and increased fixed payment obligations. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term, but we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have incurred significant losses and negative cash flows from operations. We have an accumulated deficit of $521.1 million through December 31, 2022. We expect to incur substantial additional losses in the future as we conduct and expand our research and development activities. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to enable us to fund our projected operations through at least the next twelve (12) months from the date of this Annual Report on Form 10-K. We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our operating capital requirements. Our future capital requirements depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of developing our product candidates, and of conducting preclinical studies and clinical trials, including our clinical trials for GRANITE, SLATE and CORAL;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals for our oncology and infectious disease immunotherapy product candidates; in particular, any costs incurred in connection with any future regulatory requirements that may be imposed by the FDA or foreign regulatory bodies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential delays in our ongoing clinical trials as a result of the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of manufacturing our product candidates we successfully commercialize, including the cost of scaling up our internal manufacturing operations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of building a sales force in anticipation of product commercialization; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of commercialization activities, including building a commercial infrastructure, marketing, sales and distribution costs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any product liability or other lawsuits related to our products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs associated with being a public company;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, receipt and amount of sales of any future approved products, if any.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will need additional funds to meet operational needs and capital requirements associated with such operating plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below (in thousands):</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.871%;"></td>
    <td style="width:1.24%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.725000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.24%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.725000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.24%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.956999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(115,946</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(50,678</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(89,102</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash (used in) provided by  investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(12,964</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(118,553</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,949</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,098</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,760</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135,801</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(45,812</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(60,471</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,648</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Used in Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, cash used in operating activities was $115.9 million, which consisted of net loss of $119.7 million, adjusted by non-cash charges of $28.3 million and net changes in our operating assets and liabilities of $24.5 million. The non-cash charges consisted primarily of depreciation and amortization expense of $6.6 million, stock-based compensation of $12.6 million, non-cash operating lease expense of $9.1 million and amortization of debt discount and issuance costs of $0.4 million, partially offset by amortization premiums on marketable securities of $0.4 million. The change in our operating assets and liabilities was primarily driven by decreases of $15.2 million in deferred revenue, $8.9 million in lease liability, $0.4 million in accrued research and development expenses and an increase of $7.4 million in deposits and other long term assets, partially offset by increases of $1.3 million in accrued compensation, $1.9 million in accounts payable, $3.5 million in accrued and other non-current liabilities and a decrease of $0.7 million in prepaid expenses and other current assets.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, cash used in operating activities was $50.7 million, which consisted of a net loss of $75.1 million, adjusted by non-cash charges of $25.8 million and cash used due to changes in our operating assets and liabilities of $1.4 million. The non-cash charges consisted primarily of depreciation expense of $6.3 million, stock-based compensation of $10.6 million, and non-cash operating lease expense of $8.1 million. The change in our operating assets and liabilities was primarily due to decreases of $7.9 million in lease liability, $0.9 million in accrued and other non-current liabilities, $3.4 million in prepaid expenses and other assets, $0.6 million in deposits and long-term assets and $0.4 million in accounts payable, offset by increases of $8.6 million in deferred revenue, $2.6 million in accrued research and development expenses, and $0.6 million in accrued compensation.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2020, cash used in operating activities was $89.1 million, which consisted of a net loss of $105.3 million, adjusted by non-cash charges of $21.1 million and cash used due to changes in our operating assets and liabilities of $4.9 million. The non-cash charges consisted primarily of depreciation and amortization expense of $6.6 million, stock-based compensation of $7.1 million, and non-cash operating lease expense of $7.5 million. The change in our operating assets and liabilities was primarily due to decreases of $3.8 million in lease liability, $2.8 million in deferred revenue, $0.7 million in accrued research and development expenses, and $0.9 million in prepaid expenses and other assets, offset by increases of $0.8 million in accounts payable, $1.7 million in accrued compensation and $0.7 million in accrued and other non-current liabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash (Used in) Provided by Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, cash used in investing activities was $13.0 million which consisted of $141.9 million in purchases of marketable securities and $5.9 million of capital expenditures to purchase property and equipment, offset by $134.8 million in proceeds from the maturity of marketable securities.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, cash used in investing activities was $118.6 million, which consisted of $199.9 million of purchases of marketable securities, $5.5 million of capital expenditures to purchase property and equipment, and $0.2 million of prepayment of financing lease, offset by $82.2 million in proceeds from the maturity of marketable securities and $4.8 million in proceeds from the sale of marketable securities.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2020, cash provided by investing activities was $65.9 million, which consisted of $72.9 million in proceeds from the maturity of marketable securities and $5.4 million in proceeds from the sale of marketable securities, offset by $8.8 million of purchases of marketable securities and $3.5 million of capital expenditures to purchase property and equipment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Provided by Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, cash provided by financing activities was $83.1 million, which primarily consisted of $45.0 million in proceeds from the Third PIPE Financing, $19.1 million in proceeds from long-term debt, net of debt discount and issuance costs, $19.7 million in proceeds from the 2022 ATM Offering Program, $0.3 million in proceeds from the issuance of common stock from option and warrant exercises and $0.5 million in proceeds from issuance of common stock under the employee stock purchase plan, offset by $0.9 million in tax withholding on vesting of restricted stock units, $0.4 million in payment of financing costs, and $0.2 million in payment of financing lease.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, cash provided by financing activities was $108.8 million, which primarily consisted of proceeds from the issuance of common stock of $55.0 million from the second PIPE financing, $36.6 million from &#x201c;at the market offering&#x201d;, net of issuance costs, $21.2 million under the Gilead Stock Purchase Agreement, $3.4 million from the exercise of stock options, warrants and other, and $0.9 million from the purchase of shares under our employee stock purchase plan, offset by $8.4 million of payments of financing costs.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2020, cash provided by financing activities was $135.8 million, which primarily consisted of $125.0 million in proceeds from sale of common stock and pre-funded warrants to purchase shares of our common stock in a series of private placement transactions, $9.8 million in proceeds from the issuance of common stock related to our &#x201c;at the market offering,&#x201d; $0.9 million in proceeds from the issuance of common stock from the purchase of shares under our employee stock purchase plan, and $0.2 million in proceeds from the exercise of stock options, offset by $0.1 million of payments of financing costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not entered into any off-balance sheet arrangements, as defined under SEC rules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations and Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We lease office, laboratory and storage space in facilities at several locations in California and Massachusetts. The terms of our lease agreements have expiration dates between 2023 to 2033. </span><span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total future minimum lease payments under the agreements are $105.0 million, of which $8.6 million of the payments are due in the next year. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 6 to our consolidated financial statements.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are party to license agreements pursuant to which we have in-licensed various intellectual property rights. The license agreements obligate us to make certain milestone payments related to achievement of specified events, as well as royalties in the low-single digits based on sales of licensed products. In August 2019, following the initial patient treatment of SLATE, we recorded $3.0 million as research and development expense in connection with the milestone. In October 2020, we made a milestone payment of $2.0 million pursuant to an option and license development agreement with Genevant. During the years ended December 31, 2022 and 2021, no royalties were due from the sales of licensed products. See Note 7 to our consolidated financial statements for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, in the normal course of business, we enter into contracts in the normal course of business with CROs for clinical trials and CMOs for clinical supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes, which generally provide for termination within 30 days of notice, and therefore are cancelable contracts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Use of Estimates</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This discussion and analysis of financial condition and results of operation is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to preclinical study trial accruals, fair value of assets and liabilities, and the fair value of common stock and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our significant accounting policies are more fully described in the notes to our consolidated financial statements, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our consolidated financial statements and understanding and evaluating our reported financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We perform research and development under collaboration, license, grant, and clinical development agreements. Our revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, we analyze a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, our revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (ASC 606) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#x2013; Revenue Recognition (ASC 958-605), which applies to business entities that receive contributions within the scope of ASC 958-605.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaboration agreements, we analyze each agreement to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, we first determine which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customer guidance. For elements of collaboration arrangements that are accounted for pursuant to the revenue from contracts with customer guidance, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the collaboration and license agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration, and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in our consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in our consolidated balance sheets. If we expect to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At contract inception, we assess the goods or services promised in a contract with a customer and identify those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider the terms of the contract and our customary business practices to determine the transaction price. The transaction price is the amount of consideration to which we expect to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices. The relative selling price for each deliverable is estimated using objective evidence if it is available. If objective evidence is not available, we use our best estimate of the selling price for the deliverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when, or as, we satisfy a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service, is considered to be as the services are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">received and used. We recognize revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the good or service promised to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. We concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement and the Gates Grant Agreement (see Note 7).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We record research and development expenses to operations as incurred. Research and development expenses represent costs incurred by us for the discovery and development of our product candidates and the development of our technology and include: internal research and development expense, including employee-related expenses (such as salaries, benefits, travel and non-cash stock-based compensation expense); external research and development expenses incurred under arrangements with third parties, such as CROs, preclinical testing organizations, contract manufacturing organizations (CMOs), academic and non-profit institutions and consultants; license fees; other expenses, which include direct and allocated expenses for laboratory, facilities and other costs; and costs incurred related to our collaboration agreements. Costs to develop our technologies are recorded as research and development expense unless the criteria to be capitalized as internal-use software costs is met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing financial statements, we are required to estimate and accrue expenses. We record the estimated expenses of research and development activities conducted by third-party service providers based upon the estimated amount of services provided within research and development expense in the consolidated statements of operations and comprehensive loss. These services include the conduct of clinical and preclinical studies, contract manufacturing activities and consulting services. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are realized or consumed. If the costs have been prepaid, this expense reduces the prepaid expenses in the consolidated balance sheets, and if not yet invoiced, the costs are included in accrued liabilities in the consolidated balance sheets. These costs are a significant component of our research and development expenses. We record amortization of prepaid expenses or accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these third parties. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks. We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from external CROs, CMOs, and other third-party service providers. To date, we have not experienced material differences between our accrued expenses and actual expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We determine whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#x2019;s leases are classified as operating leases. Leases with a term greater than one year are recognized on the consolidated balance sheets as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. We derived our incremental borrowing rate by assessing rates in recent market transactions, as adjusted for security interests and our credit quality. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the right-of-use asset is impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JOBS Act</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012. As an emerging growth company, we may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have nonetheless irrevocably elected not to avail ourselves of this exemption and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earliest of (1) December 31, 2023, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to &#x201c;Note 2. Summary of Significant Accounting Policies&#x201d; to our audited consolidated financial statements for a discussion of recent accounting pronouncements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ive Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Rate Sensitivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents and marketable securities of $175.9 million as of December 31, 2022, which consisted primarily of money market funds and marketable securities, largely composed of investment grade, short-term and long-term fixed income securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and short-term duration, according to our board-approved investment charter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investments are subject to interest rate risk and could fall in value if market interest rates increase. A hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Effects of Inflation</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and our clinical trial costs. We do not believe that inflation has had a material effect on our business, results of operations, or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s and Supplementary Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Index to Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:92.324%;"></td>
    <td style="width:1.278%;"></td>
    <td style="width:6.398%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pages</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_57308bc5-4700-4db4-98c0-84cef1026897" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGIS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Gritstone bio, Inc. (&#x201c;the Company&#x201d;) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5a09762a-0d3f-4587-ae23-4fe9b88f18d8" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2016.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe28b41b-7712-4002-a316-2e2a24a557b7" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share amounts and par value)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.822%;"></td>
    <td style="width:1.554%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.437999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.554%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.632%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7fd8de6-92c0-4323-983f-6c04172ec0fa" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0720ba2-c6fb-47ab-8c5f-231facdfe2b3" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad8af453-4838-41ca-b76e-1ce20e1120ce" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e919994-3ee3-4b0a-af90-3f482a90fd13" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,346</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06da4afe-a2c8-441b-a788-3888b97b7f86" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,977</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53014a7a-3b9e-4314-a917-8028a52e31ce" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42454fa4-3a55-490d-ba8b-1c010f39aa2c" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca5fc4f9-3204-4e4e-8229-dcbc57656ce6" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,672</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87211ab2-8235-4e5e-a566-1d22ddc588b7" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">182,878</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_965af7c6-55dd-4d4e-b6cf-36f0e7d09c99" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,590</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75571cd5-78b1-4844-97a4-1c9d09424055" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ecb6739-2e0d-4a99-9475-2d9fab0760ba" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,005</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0eaeddd-9bfe-4ffb-b134-3ed3c66c638d" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,335</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ac0c309-a315-412b-aa42-206eeb0674bb" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70c606ec-d349-4dde-8ad9-51133bd2f8c6" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,481</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff6e3304-fd25-48a5-ae8a-7cbcec13cfa0" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,920</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits and other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fb21f8c-f7b2-4a07-a9f6-e03274bd4c2c" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,739</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_152b7632-0813-42e0-bdf8-121f10cfcb9e" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12855c00-403e-4389-b520-30f0b3fcd6f8" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c0957a5-7e29-4298-9def-90d7c23a2043" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e5df63c-a954-4833-8a9e-bece17b4d795" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240,754</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c70e9d75-5a5c-4893-97b4-37818e892f21" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278,106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78c6db53-6555-4a7b-8226-12aec54eac62" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1699a73-61f5-490a-8626-d3fa60524118" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3e61bae-a469-450b-bfee-a7c1e510475d" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,215</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44ed531b-3b05-4492-8030-d91c6661ca45" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33f6c688-0203-4ce9-8c8b-c2bbeb3bd90b" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_181820f7-03d1-4bf0-af6a-8a6a9e161636" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48830c2d-67d8-40f5-937a-f39b88cbca6b" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,343</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68b711f1-dd54-48e2-a0eb-68e4e2e56b4a" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a170d7e-8e3b-407b-833b-587c2727dfd0" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,294</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ecd1341-511d-46b5-8aec-b0b6cdb44de4" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,483</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec3d1b80-0d4b-47ab-82e2-a921cb60b969" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,131</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d8a77c0-e046-4206-88cd-765999cbc599" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7dc5043-f567-49da-acd7-5d723a1a01c0" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,801</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd6b47b6-c87f-4970-a049-beae606d481f" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,956</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other liabilities, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_671160dd-6395-4a40-8394-b7dd51ca5a51" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0a65e04-9c87-48fe-9e98-fdc09caf5e60" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ee0e9d0-2451-4801-82aa-ef3e43e8128b" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,673</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04f77f7c-fe6e-46a9-a90c-36bf33aedcb0" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,936</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bf4ce45-782f-44c4-aab9-8522da4e957b" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d398e734-3a65-4300-b775-233582a8f039" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,128</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt, noncurrent</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1429408e-5cb2-4b9a-be6c-0e4632f10219" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,349</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97ec8626-6c29-4242-bc91-f3e2e82d5939" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6942724-c059-4f00-8513-fdde79807bb9" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faee62ce-718e-42b9-81a0-02bc76785889" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,020</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9765a238-b117-4b57-9e57-dd79a484561f;"><span style="-sec-ix-hidden:F_e7f9cea4-e613-411c-867e-84c9f2b00028;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Notes 6, 7, and 8)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74088031-41fc-4f84-88e2-0a25138b0fe7" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d6941240-2ef6-4463-86ed-9969ad8b5aeb" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09e5f592-d9cc-4ddd-b605-15462f89a7f3" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d421273b-673f-4be0-a6f6-a877627ad639" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aa5dbd1-0487-4930-8f4e-68a2779096ab" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dcdb69dc-b9fc-4200-8648-bc95a0aefaff" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2915ae2a-dbe3-4b12-ac61-baeea45dd658" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1aae79e5-6e96-48e1-aa51-5dc8891e5a46" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares<br />&#160;&#160;&#160;issued and outstanding at December 31, 2022 and 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb6607d4-c4fd-426f-84f4-31e27f5bce49" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03e71d82-4674-4463-aafe-2ea9c935266e" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5970bdf5-ca21-45c6-853e-c139a426a1a4" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_200735e2-2990-41f1-942a-76353208caf0" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4222067b-278e-4990-b7bb-9fa6c77ca940" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_2bec39d7-d506-441f-9774-a8602010eabd" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized at <br />&#160;&#160;&#160;December 31, 2022 and 2021; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a11dba5b-3aa5-4d13-b425-1f537da6d217" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4cc1af7d-fc1a-4823-b317-ac05aa5fbdfd" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">86,894,901</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80aea6d9-2bd7-461d-b2f6-fd94d3854b51" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_b7c5288a-97a0-44fe-8b5d-b751d36c7259" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,047,878</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued<br />&#160;&#160;&#160;and outstanding at December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_235b47f6-1c0e-4889-a8fc-d4889bffbdde" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f7735a7-e8a0-4a3f-be5b-ae4504a68579" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11c02dff-0efe-4ea3-ad5d-aab2384322f2" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">691,910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99c7baee-ce5a-46c4-b21b-614363f7bb6c" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">617,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c23b204-1292-472b-9a92-85b500b58fe4" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0923dea-d9d0-43eb-b728-0de4a9c332db" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f502fb3-e071-41eb-856c-894d03dfdd3d" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">521,071</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f354689f-d210-4e69-b2f9-e1959037e1e3" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">401,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a265030-20e8-454a-ae4e-0df3dc494a38" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170,781</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc625b69-3a70-4b92-a0c7-066969b64a9d" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3898c147-ad97-45f2-a828-eae8e5f02aa4" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240,754</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_712a088e-fb87-4e14-9421-7d3f27bb4995" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278,106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.038%;"></td>
    <td style="width:1.185%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.744000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.744000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.939%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and license revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f53af206-f8e7-4089-9aa1-d2a8336085af" contextRef="C_fe489596-7a91-4f59-b920-c21979d2bb8b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f5d0d0f-c669-4fb9-b457-983aa03d9ff4" contextRef="C_879914fe-a7ae-42c4-9c44-8a86ed39c875" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa308af3-92ee-45d5-9c11-cbeed925a074" contextRef="C_b75ce6de-1369-4078-83cb-4b85b869b56b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6ad9f9f-cd43-4ae0-baab-156b86350bbf" contextRef="C_b1aaf215-5549-4cb2-84d0-1af1b91cf770" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,676</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1594aa23-3749-43b1-bbc5-ecf32bc091b8" contextRef="C_525c622a-5ea4-473e-9b25-9d823536fda9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03e9d05d-ff97-43f8-a5b8-3a2e55b3357e" contextRef="C_4883c551-3073-415a-98c5-41e1b4eb5fea" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1af3fd7-1b24-4ba6-9440-bf7f8e5d0379" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_381a3929-b4c1-466d-94cc-7775b22ec175" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19b7fd05-dd83-46cb-aeef-ed554fd1500b" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f62f4508-a97e-46e6-ad66-75f2a25f630e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,403</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd3b2467-f2e5-4561-9d8d-791959cb75d3" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffc1a7c2-72ff-4816-b8c9-f1073e925fb5" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_606f22cc-961b-4a01-9d96-993a71d41db9" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3d1e5e0-9c92-4c58-890e-67ff1be9b6a5" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88aac1de-06d1-4a03-ac27-583ebfaa8452" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43ebdd71-0c81-4f8a-b121-cd9e6b83c0bd" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">140,373</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed3ce69d-fe57-4882-9af3-09a1634fd3c9" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,423</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a70cb63f-79fc-4829-9fab-0c6bf39d66a3" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db6ddee1-29ca-4735-b96c-c8ab9d00f730" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_019bbdee-f51f-4dc6-bd58-7b04ab39267c" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,209</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fc6f6a5-f7c0-4b46-a478-afc22b256036" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f80b12cd-14e2-4e92-b398-ecfebda2f35e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,976</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3433f2c5-1b69-460d-a14e-f59194bc2d1e" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdfcec54-f0ec-4593-a3de-0b761daa5190" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">715</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9d80482-ecd8-499d-b852-67753279642d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c6e527f-10d5-4ee8-b8f1-18b61c757829" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa89e599-a3cd-429a-bc79-e1c2de5d8a3e" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2a84b98-2d2a-4492-9f83-97778c5db19b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">119,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57dabc51-1086-4869-af91-7c21822368cf" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e761c88d-8852-48e7-b5fd-99660216c989" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53b12ff5-568c-4f5a-9426-9a0ea58e5129" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7a6b95c-aaae-451b-ae0c-beb363ed5698" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c09dd465-33c9-4bd9-8299-5a289c8ede3b" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c19c6c62-608d-475c-a776-8cdbb768aedd" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">119,694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bdfe1b0-d710-42d7-a0dc-54da32062fa1" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f63b734-72ee-4978-8e9b-cb25f8a0fdc8" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62816bb2-c0e2-41ec-be73-3c33e41ec08f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_9d4c100c-c930-45c0-b482-3df5784e4ac5" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.32</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_978a553f-d408-4b3f-82c4-359f1d9e5df4" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_c414a75e-ba73-435f-b3d9-404d35d684db" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.95</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c921d5ea-6778-4d8a-ae33-3b69f23ce20d" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_976a3584-59f1-48ce-ae8e-42858815cdb4" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.79</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of shares used in computing net loss per share,<br />&#160;&#160;&#160;basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89d68ccc-6b3a-4df1-8b94-dde51aff1b5d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_7985a6a4-e946-403e-95cb-ae8c997b28a4" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">90,918,333</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40942f89-30b0-4d14-b2ae-45c79b2844e3" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_b8750ea6-5533-452e-8bf2-26cf57a3b2d1" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">78,885,186</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45a20e19-c25b-4294-b966-d50bcd1c8acb" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_38b6f8bf-858a-4920-9812-8b88e5615ec1" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,792,365</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stoc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">kholders&#x2019; Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.568%;"></td>
    <td style="width:0.795%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.572%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.795%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.737%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.795%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.737%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.795%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.571000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.808%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.507000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.808%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.507000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-In</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_767c50e1-0cfd-4c63-9dad-8b042bd58eb9" contextRef="C_bca994d1-b72b-4700-b935-07f4a67abfbc" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,332,956</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4fa574b-8f84-49ab-bf70-d82c8631b0e2" contextRef="C_bca994d1-b72b-4700-b935-07f4a67abfbc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a534a6cd-9790-4a75-a5c0-b61689a97881" contextRef="C_230e86a9-5523-4a06-934f-3dc71e6f9d7b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">355,291</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d2451a5-9f6b-4dd2-9620-727075257f7b" contextRef="C_34bb80f1-a84f-4c93-9bd0-b459e3058b14" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b18ffd4-7f63-4e4a-b3e8-ae736f61068b" contextRef="C_3f58b9b7-d6f4-4132-960e-1c1e70027d7b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">220,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9f3f362-47c6-4d21-a4ab-b7e91231b433" contextRef="C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under private<br />&#160;&#160;&#160;investment in public equity (&#x201c;PIPE&#x201d;) <br />&#160;&#160;&#160;financing, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cae8d8d7-4c5a-4845-9700-a6283800993d" contextRef="C_087f69e2-ad7d-4b73-9c6f-f855a261808a" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2e1ad12-e51a-4eba-8eac-049db90af11e" contextRef="C_087f69e2-ad7d-4b73-9c6f-f855a261808a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,586,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af8560a7-4170-4657-9134-ee074a0cca72" contextRef="C_087f69e2-ad7d-4b73-9c6f-f855a261808a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fb41d13-fc4b-4db8-bb02-c8dc30c76a14" contextRef="C_2d80b699-28c2-4bce-ae73-843d1606fcd7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e2d163d-9788-460e-a1ab-912a36cbf720" contextRef="C_6cc6d2ec-75f6-431d-8f3c-3a9350689079" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of pre-funded warrants, net of issuance<br />&#160;&#160;&#160;costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65ae61b9-6d5d-4e1a-aa58-bed1002c4e1d" contextRef="C_208e185e-fe87-4dc4-85f0-dbddc9b221e0" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dd368c5-389d-439d-b250-4c847b3feefe" contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cd30aea-668c-480c-8eb4-02fcfc804c57" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under ATM <br />&#160;&#160;&#160;equity offering program, net of <br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4407aeed-f9e3-4ad5-b478-03677b54ac39" contextRef="C_8b84dd47-84c3-4d2b-8c0c-c84ff401d5a8" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd7f8aab-d2fb-44c3-93dc-c9cd56e3e67f" contextRef="C_8b84dd47-84c3-4d2b-8c0c-c84ff401d5a8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,160,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d7e925c-a85e-41e8-b75a-e3299a55b3fa" contextRef="C_36837d8e-e9eb-4701-ab19-b3e92b394404" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a84ed60-65d8-4bdc-96f3-3ad62435d985" contextRef="C_809dbee3-02e2-412e-b2d8-47155edc68df" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e798149d-a2fb-4953-b467-e97845332841" contextRef="C_44dd4f53-eec3-40d8-8778-035eeb8ebe64" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">243,878</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b769dc4-591a-46d0-837b-9781f293209a" contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55b266c9-b5be-4b23-a15a-1a975fcbd1f2" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_831b3cef-a2d1-411e-b2f6-0f4f9d66cd93" contextRef="C_d4d4328f-52cc-4211-9428-c5e7e73152dc" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc4df354-32d0-4ecd-bf89-d9f9b6f0334a" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lapse of repurchase rights related to common<br />&#160;&#160;&#160;stock issued pursuant to early exercises</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8a3db7a-3e50-4ee1-8089-cbbba8b99c10" contextRef="C_44dd4f53-eec3-40d8-8778-035eeb8ebe64" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71b993f0-5ba8-4e31-964d-9aef5c485d9c" contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e07621db-cd83-444f-b207-2c13dcb3662b" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon exercise of<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27bc0427-4718-4571-b818-e7d74df9c0a1" contextRef="C_44dd4f53-eec3-40d8-8778-035eeb8ebe64" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">197,544</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab067804-9df4-4ca7-8417-ebb301e249f3" contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24269d55-5d22-4933-ac6f-ff998dad67e4" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f83914bf-53bf-4753-8676-26f13dec2af6" contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e07ea67-18d4-4486-820b-ddac79671891" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4468ae4-e1ed-49c2-bb11-9920b5cb3b5f" contextRef="C_49047d4a-8f63-439f-b6a6-6eae31a95a12" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad56f9f6-3069-4b2a-b9db-0abe832c9ded" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b594502f-14ea-4eba-bad5-6539d42d2240" contextRef="C_78bc7e34-ffb9-4a67-a8d3-9000a9429eaa" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">47,552,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a72ddc1-aa3e-4cf3-b233-494635c43ed8" contextRef="C_78bc7e34-ffb9-4a67-a8d3-9000a9429eaa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a05c9823-b42a-486c-9175-cf28d8cca0d0" contextRef="C_92745d9d-b5a1-43ae-ae6e-0738b7391092" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">493,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c107a2be-97b5-44fd-ba7c-5bf7b8dbae4b" contextRef="C_4eaebbf5-c3fc-4967-9782-b63169338718" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">326,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83f43933-c059-4b85-bfbf-c6b691e128d9" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">166,739</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offering costs related to the sale of<br />&#160;&#160;&#160;&#160;common stock and pre-funded warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c19ded4-62ed-4740-8787-11293faee616" contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f" name="grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1fd0fe8-fcf9-4a33-8b9f-66cb24f2d5e8" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under Sales<br />&#160;&#160;&#160;Purchase Agreement, net of issuance<br />&#160;&#160;&#160;costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96e8cf7c-5e82-40d8-9d37-b1d9caa89003" contextRef="C_2ec37033-06d8-4931-9ffc-894e1d473c78" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d72c519-8c62-40ba-8437-8b93dde59de2" contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1" name="grts:StockIssuedDuringPeriodSharesPurchaseAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,169,591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3ec7758-d02e-4936-a6d5-88695ed8b8fa" contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f" name="grts:StockIssuedDuringPeriodValuePurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef6542cd-49b8-47ed-9fdc-6b748f8bc95a" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:StockIssuedDuringPeriodValuePurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under the<br />&#160;&#160;&#160;ATM equity offering program, net of<br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1916b4d2-1e41-4ecd-b80b-7054dc93122b" contextRef="C_9313b710-4b60-4e1f-b855-6c529b013687" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4f346aa-3ccd-4b0d-9f12-ea6f17f050e8" contextRef="C_9313b710-4b60-4e1f-b855-6c529b013687" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,990,869</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b4bf936-d28f-4cfd-bb80-bc4445ec98ba" contextRef="C_41e65ead-4e0c-4591-b0c4-a8797159156c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15240202-e4b0-4e39-a2d9-910eb70ea490" contextRef="C_eca7c1be-2d00-460c-b13a-ef933d52f723" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under PIPE<br />&#160;&#160;&#160;financing, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb97890f-31cd-4023-bc63-2724abe212d7" contextRef="C_324745d5-c5ad-4d27-9aeb-d15b72a94aaa" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1205757f-b36e-41b4-a66b-2305b902782f" contextRef="C_324745d5-c5ad-4d27-9aeb-d15b72a94aaa" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a435890-9b45-4aab-a38a-ce9b83118196" contextRef="C_324745d5-c5ad-4d27-9aeb-d15b72a94aaa" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f813c68-73a0-4ba3-968a-4a0a3e0da3e0" contextRef="C_b0d9da16-7637-4109-87b5-f82244fb1e67" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,652</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9977ade-7198-4256-8b58-19c331d73314" contextRef="C_b83ef403-2580-41b1-b8e4-7f8b49fbd122" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,653</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under the ESPP</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49829b89-fb33-42ee-8d21-8ce4f382644f" contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">183,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfbce754-ba00-4edb-a19d-c687c9d470ca" contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_296271c3-9e22-4025-b718-46f24713613a" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1c89c17-301e-4648-af7e-6a9c04b2d4a2" contextRef="C_ce01baa0-2b6b-406d-8ec3-3218ac59d5b9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_475438b6-2fd1-4265-b777-e0ce198dc724" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon exercise<br />&#160;&#160;&#160;of warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2bdd9df-d5b6-4780-9b16-d88d2e6128ee" contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1" name="grts:IssuanceOfCommonStockForWarrantExercisesShare" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,459,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd794fe6-7322-4df5-a4bf-de0bcd8780aa" contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1" name="grts:IssuanceOfCommonStockForWarrantExercisesValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdaaf52b-d0eb-42fc-a49b-da405ad8c577" contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f" name="grts:IssuanceOfCommonStockForWarrantExercisesValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcbba703-d68d-4fbf-a169-48e8b7a868d5" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:IssuanceOfCommonStockForWarrantExercisesValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon exercise of<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2c6f12d-92d8-41cd-93dd-8a19440fcf4f" contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">692,038</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43388814-6dc3-4626-95e6-96d278534b51" contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_576b157a-fd75-4d89-80ba-7d8b7af57a50" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c453682-069f-4f52-9196-b4a7c7ccc13b" contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a9cd548-1a77-443e-b68d-35f80669f90d" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3ffa268-11cd-422f-af1b-fb50feeffcf2" contextRef="C_4d220ecd-5fb6-43bf-b89a-7760384559a7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e41a863b-ba40-43f8-a907-f2fd154b4797" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_895dd239-584a-4b54-8da5-2fde215d24d6" contextRef="C_a25d6e22-b4d5-4e42-baee-545cb40fb3b1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,047,878</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65ee0f5f-938d-4fd6-ba70-b4306496759f" contextRef="C_a25d6e22-b4d5-4e42-baee-545cb40fb3b1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e885c7d-c85f-437a-9e52-40c7b387fd7c" contextRef="C_fef5557b-9238-461f-9d8d-6c180e1ea4c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">617,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4288bef6-2e59-48ff-a3c5-605accbf2841" contextRef="C_7a01aa4d-8457-4bc2-9506-f28d7946c515" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_434d4713-1bef-408f-8e4d-321d1daa8998" contextRef="C_8c95d954-77a7-4eb1-ad4e-f5368fb88348" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">401,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46eafb68-9ffa-47f1-a7cf-b68cc297a2cd" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under the<br />&#160;&#160;&#160;ATM equity offering program, net of<br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b61b8558-2074-4ac3-a168-c0fe6160d6d8" contextRef="C_3e3cea99-52ab-4572-a2f7-6ce19c94f86b" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb7bec78-0b51-4ce6-bb06-0f8e7f203004" contextRef="C_3e3cea99-52ab-4572-a2f7-6ce19c94f86b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,034,948</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cec6065-9ed2-41b4-ace2-51659eaf4524" contextRef="C_3e3cea99-52ab-4572-a2f7-6ce19c94f86b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12155b6a-dc13-41b4-ae6a-002b775f38de" contextRef="C_e91e3869-cc3b-4f71-bed9-29131644937a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00657d30-3bbe-48ac-9811-30598b24704b" contextRef="C_74ebd140-1cd3-4d3c-b9b1-9fb227e15317" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,592</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under PIPE<br />&#160;&#160;&#160;financing, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38c62593-9706-4855-8325-c12e1e923ea5" contextRef="C_4f197d40-b7be-4d35-9b61-95f8f0d5b16c" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcd7293c-33f9-4105-94d2-a0c83405f42f" contextRef="C_4f197d40-b7be-4d35-9b61-95f8f0d5b16c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,637,165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27259560-e239-4218-af17-40f3128ccf17" contextRef="C_4f197d40-b7be-4d35-9b61-95f8f0d5b16c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46e89f56-e098-4b0b-8f2e-4b59a6313494" contextRef="C_1ef1f41f-a1a4-42d6-8454-db92942dad65" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd8b5be3-c84d-4e74-aa63-2b7fc33c1ea4" contextRef="C_e6bd0364-0189-46f1-9a87-5b5ae7b4a68b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of pre-funded warrants, under PIPE<br />&#160;&#160;&#160;financing, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8ee633f-9ba8-48fb-8294-49994f0e5976" contextRef="C_7e100875-202a-43a8-8544-eea71c373493" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,759</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ea46562-d214-4859-85b2-1dfb2f5586d7" contextRef="C_1ef1f41f-a1a4-42d6-8454-db92942dad65" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb205017-a4b3-49c4-9ad8-c564ed4f446d" contextRef="C_e6bd0364-0189-46f1-9a87-5b5ae7b4a68b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon exercise<br />&#160;&#160;&#160;of warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f6474b6-f37f-4186-b528-3cb6aa4f5bf2" contextRef="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7" name="grts:IssuanceOfCommonStockForWarrantExercisesShare" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,442,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f506f60d-941f-4dca-af58-67df44eafc61" contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa" name="grts:IssuanceOfCommonStockForWarrantExercisesValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d5f0881-3afb-4a88-95e0-5772a7952989" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:IssuanceOfCommonStockForWarrantExercisesValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon restricted<br />&#160;&#160;&#160;stock units vesting</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_718daf7f-1dfc-4f20-921f-180a8b9716f6" contextRef="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7" name="grts:IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">215,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax payments related to shares withheld for<br />&#160;&#160;&#160;vested restricted stock units</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cff36ba-38d6-48b2-a2dc-6dbb3e4f6b20" contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa" name="grts:TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">890</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a073753d-eae6-4db8-85ba-9e279ade7823" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">890</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under the ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0950d1a8-fcdc-4820-b072-bd9ef5895b49" contextRef="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">322,646</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5fdc7f2-127d-49c1-8405-83eca8db01a1" contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_949376ac-9c04-40ab-babc-c82fbc532efd" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_279b65e8-d2ee-4077-b5a9-1b8a847ab840" contextRef="C_c50db2bb-cff4-44de-98cc-cf159a62c91f" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_330cc765-1f4b-4348-8754-38cc04cc5e6b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon exercise of<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e14869d-6a50-4108-99df-cd0c94d6c11f" contextRef="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">194,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af19413a-c8b1-4e0e-8d25-325561b449de" contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30a7c32e-895a-4cef-9b6b-12925ff33f40" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db3dd44d-a876-45e6-9622-cecebc6f3699" contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb9cab4f-5b7e-40c2-b332-7cbda658d88f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f2d05e2-dc26-44af-b9b4-92d728abb00a" contextRef="C_c86bb390-8ee5-48f9-aaf2-89a427c83966" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">119,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af1569c6-5222-4143-8817-8c691e1c896d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">119,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71e43b56-96ca-4858-a388-1de784f4df79" contextRef="C_937c1ade-1906-4692-bcc1-f9d4da800f1d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">86,894,901</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5c90c5f-ab79-437a-840e-7330d6c6063b" contextRef="C_937c1ade-1906-4692-bcc1-f9d4da800f1d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b79308dc-1a2d-420f-ab16-83a8f88b37d0" contextRef="C_3e7ededb-1c6b-46eb-a02d-62b731c0fb78" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">691,910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24f7a41e-4287-4908-a225-bbb738862229" contextRef="C_7bebca71-1135-472b-9d92-4845eaa4225b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98c2ece9-75ac-45cf-9e33-ad43413188ab" contextRef="C_ee3362ce-e6b6-4c81-9ddd-3a4c990659b1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">521,071</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8325f11b-a3f2-4129-9088-4d8e7d1b2444" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170,781</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.714%;"></td>
    <td style="width:1.138%;"></td>
    <td style="width:1.138%;"></td>
    <td style="width:1.138%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.466000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.138%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.466000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.138%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.661%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_492e262d-9abe-4ce8-9f7c-39d87a043cd0" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">119,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94e83611-022c-493f-b062-4d0bed369555" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e57c35d0-d3f4-4932-9410-2cd5133cd2b5" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_784f088e-2fad-470a-9aca-a2dd5e41c54a" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,560</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed0e9ff4-2308-4d60-81ed-3d3fe3619489" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de8bda58-c000-499e-ac4b-8645f68246e2" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,644</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net amortization of premiums and discounts on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff6fe57b-a5c5-405a-9eb6-8047a52dcb3b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">372</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0369a228-4180-45a0-ae79-8bf63c3a6435" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">817</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a90ec1e-2170-44d8-8d66-85fc8e2ec152" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10b317d4-b61e-406c-b8e3-d1366f929a5a" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76dc26af-03ae-4359-93ef-31368f834be3" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06564564-7813-4d5a-82af-59048f16fc86" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0290601-4b87-4d98-94e6-6c224a00d105" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfe6eb74-6787-4055-9e06-7cf4e792c68d" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd9718f5-ff13-4be4-bcb2-8f9a1b77a5ef" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acc81f53-106a-4dc3-a072-d439d591e2ee" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,131</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad3fad02-0a5f-48f0-8f6a-4bd156048c6b" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,052</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cb32c6c-a0f3-4538-8e13-2125572ac3d5" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8524ac63-678a-451a-8e01-ffbb134b320a" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">658</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0b86244-4d30-4527-bd7d-96f3e3fd88a9" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf9d0bf7-08fd-4d39-b708-e35bbbb65af6" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits and other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3c977cf-fc47-4239-9b39-679754020039" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_274b36c9-b205-442c-afb4-10d978aff716" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25ba6c17-99e4-4d78-8b97-e938fb56f9da" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daeda54f-365a-45cd-b673-ec66af8f35fa" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fee06806-2039-4a8d-ad90-3792c4993f19" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5adeff90-fa6e-4123-99a6-19a7a40f9150" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_133eb36f-13ea-4b39-ab56-0aaba8cbf2ed" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddb6bc90-0596-4e20-827b-f3872e2f084e" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9a642c8-4939-4efd-8bf3-3a1aaca1c546" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other non-current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01c63474-11c4-4b80-a475-ea659d3e0f0e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,509</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbca246a-7e25-4dea-b7fd-43d77aea2b22" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">859</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd1c01b6-1e97-495b-a39d-7a418e67313a" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">662</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33ef5596-11a9-4cf8-a39b-3d545c86edf4" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b544c2a-d99b-4dee-80be-e141b2f507af" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,653</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5259020a-8771-46bb-bd19-d2ebf42c6cc6" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1680ff2f-3c57-478b-8812-5899e4c0332f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,915</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce6d18d8-996d-42cd-9502-16747f2622e1" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75998d8c-bba5-465e-a9b1-fa5c4e372999" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,801</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab81bd24-5f9e-4bc2-830f-cb9e5ed411b7" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,198</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb58706a-1d29-4703-8cbb-4b1f073ccd00" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,633</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c3ec544-429e-4a5e-a531-0a457abec5e9" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,821</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbfd4d9c-fcac-4126-9228-dfc70821a077" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">115,946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d43de26-94b1-41fb-be68-334d0723a975" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0be06a53-b714-42bb-ada1-2c8ae19cca0c" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78d39bbf-5bdf-4a1c-a08b-2bd93db76c83" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,908</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5270967-d030-4687-9d54-83a6739cd21b" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">199,905</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_008518b0-b5b5-4aa4-87c5-daa27573b128" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28f7fb40-8ffe-4f54-8362-8ec3ef58a65a" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ProceedsFromMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03b3ec86-9135-4a98-8140-7d09091c0fa5" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:ProceedsFromMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,253</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3600eaf0-af50-4943-b5e6-95a32ceeb452" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:ProceedsFromMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70624fb0-a121-48e8-a6dd-6560b5eed755" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b25b562-fec8-4b7b-b0d1-e922cb6b153a" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_934ae4e8-0df5-464e-869a-6b68d92981f7" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,401</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f24d0caf-18fc-47d0-a346-965f2a8dc30c" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09be9b96-d559-4cc5-91fc-2f2db24b799f" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,463</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_415fe187-1d12-4ea8-96e0-c75aa01bb013" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,515</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepayments on financing lease</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85c8c07c-1392-4573-ac49-ca7f22068a66" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:PrepaymentsOnFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cffb1adb-8654-47e2-8724-3382c95aa6be" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:PrepaymentsOnFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e9f50b1-4eee-443d-b096-d61f60a036ae" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:PrepaymentsOnFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cd7a904-1900-4c2f-ba52-d951662760a6" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,964</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d590420f-139e-40b2-95d3-a1069a242dc7" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">118,553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ae9751e-bad5-42b0-8aa4-87672bc0ea14" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,949</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock from public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72fb28b0-50e5-45b0-a3ed-7865ad40db97" contextRef="C_62ff936f-e544-4a9d-b314-581290027ea3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7070655-de7d-4c6f-ab2d-e1f280214fea" contextRef="C_c0619058-b76c-4371-b472-a3486c28b486" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,169</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b874ddc1-576d-4dc1-8882-27e9859c1f91" contextRef="C_a08ccbdf-1ba2-463d-8a51-346c12817d18" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock and pre-funded warrants from PIPE financing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab65fe2e-7308-44fe-acf6-989d35db9bd4" contextRef="C_34e3705c-6db6-4be4-b4fa-7c9bc996cf50" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e607ec23-79f6-4866-a371-c3ce9ea6abff" contextRef="C_b2a83568-2a86-4097-8ffb-41bc0c489eae" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock upon exercise of stock <br />&#160;&#160;&#160;options, warrants and other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b133a7a-02cf-438e-823c-687691e66af8" contextRef="C_ff2af9fa-a502-476a-95ef-6236ae054f89" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df9d2660-9077-4bd7-a5ce-6d6fa3a202ca" contextRef="C_7720965d-c288-42f6-a5f1-b3a368a46f6d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,408</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17531d67-2c32-4867-aae2-f35e71f29586" contextRef="C_94f64277-8372-4366-a998-7f9abe66b1a2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">198</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock from ATM equity offering<br />&#160;&#160;&#160;&#160;program</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e124a74-b2cf-464d-b051-4844dc881e6c" contextRef="C_74ebd140-1cd3-4d3c-b9b1-9fb227e15317" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,737</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_701047ef-cbbb-481e-b53d-ec38fbc04305" contextRef="C_eca7c1be-2d00-460c-b13a-ef933d52f723" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2fc77cc-6277-4052-8a04-7be9663efbc8" contextRef="C_809dbee3-02e2-412e-b2d8-47155edc68df" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,770</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock under the ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60913ec0-b979-47ba-8337-24f17839df25" contextRef="C_ef1d018e-1582-4a48-8fb5-58317716f6c2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7bc590b-17a8-4305-8484-bbbfa51e63b3" contextRef="C_8acc4e2f-1b3b-4b68-8d11-a8d5e82e8ae1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3a35ff0-749d-48f5-bbce-2281b4cede29" contextRef="C_2f02fe40-880c-4f03-95a7-5100852f2662" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock and pre-funded warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d61e7f8-9293-4190-b85d-9d824d1e5c08" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f619f041-587a-4907-b1b7-98595280b600" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5e94cb8-3e78-407c-9d86-a340c95d1c2f" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125,026</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from long-term debt, net of debt discount and issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f43889a-408c-43a5-aa76-3ea4f99a290c" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,130</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb4a6bde-9ae5-4af6-8e74-48ceee5f4417" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62d76ced-606f-4b51-a257-fa7081ebaac4" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments of financing costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce22fac1-5742-43e6-9fea-31ebcaf81f68" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e58db76c-065c-4f3a-a36a-5ae0e3fd5c8a" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68400369-5915-4bf2-aa0a-a6ad8a82a9fa" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments of financing lease</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5420a65c-6a51-40c9-91cc-ac440036242b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:PaymentsOfFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b13ccd0a-fda5-4f73-89d6-8007b65fa272" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:PaymentsOfFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2169801-d096-4a63-a39f-76583b339e71" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:PaymentsOfFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax payments related to shares withheld for vested restricted stock units</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97fdb49c-fbf0-456e-af35-a1f248388027" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">890</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3eb676ce-63b7-486e-8668-62cd0341f57a" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a02a6d6-7934-4bad-b828-48296700c35b" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_284aefc8-eadd-4473-b551-67fc15a2d2c5" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ceffae06-d7d8-44cb-b883-750ee4637e4c" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74145545-2342-4828-9b51-20710584b3b4" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,801</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_496c7089-a5a4-49db-a60d-f916c7e2ae0b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,812</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cabe550-0069-46c9-8963-6f89d77db2c8" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,471</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b25d81d0-c381-4850-bca8-9577a0dd867c" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,648</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4dbe53f-e314-4b25-8699-4688689af966" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,577</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_216ec477-0f63-4280-8629-9e6d9c546ba3" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91def029-ebe9-40fa-896c-d60e9a9b351c" contextRef="C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdd49604-39bd-4a87-90a8-8e7af9345fba" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32ad5fc5-6047-4eab-a903-eb9b78a9a1ba" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,577</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb082764-cc61-4f1c-953d-71bc434eebf0" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of non-cash investing and financing<br />&#160;&#160;&#160;information</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment purchases accrued but not yet paid</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3eb462e-8254-4e0d-b5a3-efd4e7deacaa" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39522a59-b8e0-4b4c-a968-05f57109c4d9" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">738</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec5bc43f-c81f-41b5-a6e1-f82380bfb4a9" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing costs included in accrued liabilities and accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff8858c8-d4c4-4edc-aa93-5d7fab37e016" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_162e351c-5ec0-447d-8ac6-d634b6255d6e" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_223bf9d7-da40-4432-a875-e31dc5d19f0e" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remeasurement of operating lease right-of-use asset for lease modification</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3da4b3dd-c9e7-428e-884b-272e2404e03c" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,406</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_272d4208-d946-44af-9008-b7cfa65898cc" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,452</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bea3c6d6-3955-43b3-b908-3b31d0b47c12" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities arising from obtaining right -of-use asset from new leases</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8353827-d881-4be8-bddd-950df3fba6d6" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5e6acdf-b1ea-4e6b-954e-1181067f050f" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10b275d7-edce-4545-b032-9880a82abc58" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for interest on debt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f7034eb-72b9-4acc-8075-6c471b00da60" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">647</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca1cd03c-5517-4d8f-bc91-544928761e1a" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4ab1680-8628-4794-a6db-0be237ed885c" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_87c8d484-7a48-47d2-88c2-e6f62aa548cd" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	Organizat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ion</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc. (&#x201c;Gritstone&#x201d; or &#x201c;the Company&#x201d;) is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. The Company was incorporated in the state of Delaware in August 2015, and is based in Emeryville, California and Cambridge, Massachusetts, with a manufacturing facility in Pleasanton, California. The Company operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ea1b066-b10e-4283-a101-4bd37a3f779d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred operating losses and has an accumulated deficit as a result of ongoing efforts to develop </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">drug</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. The Company had net losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62dc25b8-1e87-42f8-b001-ed17f8bd40d7" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">119.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39d8d62d-e75e-4cea-a86f-9cb7af074a54" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">75.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78653318-c9bc-44e8-b60f-d9dc85e1bb93" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">105.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021, and 2020, respectively. The Company used net cash of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3be681ac-8582-4ea0-880f-193327596394" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">115.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e22770ca-6a32-41c6-8ffa-8a7c542992a8" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">50.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_539a2259-2d79-4b55-b7e1-2f7497096086" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">89.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through its operating activities for the years ended December 31, 2022, 2021, and 2020, respectively. The Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b0c4f73-0d37-4e9d-98cd-314723d95227" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">521.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38128d2a-0c06-46ed-9492-42f7e6febbff" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">401.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively. To date, none of the Company&#x2019;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through private placements of its convertible preferred stock, the sale of common stock in public offerings, under an &#x201c;at the market offering&#x201d; (the &#x201c;ATM Offering Program&#x201d;), the private placement of common stock and pre-funded warrants, and through proceeds received from its collaboration arrangements. As of December 31, 2022, the Company had cash, cash equivalents and marketable securities of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be307c48-f131-4255-a487-76acc263b05b" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:CashCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the filing date of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_808b6224-f7a5-408d-881e-0d24606ec7cf" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_05202508-6759-468b-9030-791fd231f75e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities and Exchange Commission (the &#x201c;SEC&#x201d;) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for reporting. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_48d9a357-1a25-4e54-86ba-6f6e41efc46a" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and transaction price and progress toward completion of performance obligation under the contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2cc31125-cf4e-43ce-9829-30f837b53756" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></p><p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:</span></p><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.</span></div></div><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</span></div></div><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_57e5c70e-9be1-4a37-a2b5-89de8e2192fb" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within short-term restricted cash and deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#x2019;s restricted cash includes payments received under the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) Funding Agreement, dated as of August 14, 2021 (the &#x201c;CEPI Funding Agreement&#x201d;) and the Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c2f25ec2-5401-47c9-997b-29aaa4b34c1f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and short-term and long-term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.953%;"></td>
          <td style="width:1.557%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.267%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.557%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.665%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33172054-ef2c-4eb8-bb49-8737e5d8fecd" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,498</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ce4d8dc-6145-4648-b151-653b993fa215" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,287</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca8702d7-1834-4c0f-98b8-6fb207ce5114" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,977</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bcab14e-0ccb-446b-b39d-2bfe74a3f545" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,285</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77c49c3b-0ae8-4d27-b219-678014049f13" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,290</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab57d86e-765f-4691-ad4f-860e9f9e33ee" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,005</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d21157f1-bd07-4203-aac6-4f628af0d0ba" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,765</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f59ce5ef-7e7b-41a2-a5bf-30e72dbd0330" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,577</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81fc5f77-b048-49ed-a213-110c59c76337" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#x2019;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_872cc23d-5893-47fe-8dc1-93a75f740a25" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_05967e7d-b88b-451f-abbd-d8e4f4fdd9ab" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e9e0c94e-4bc8-4598-b1d6-7ed43503c8a2" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> recognition of any other-than-temporary impairment in the year ended December 31, 2022, 2021 or 2020. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2022 or 2021.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_299aab8e-e01f-4abd-b3fd-213e44b16f18" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DebtPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of the Compan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">y&#x2019;s debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_622a9267-7ec6-456b-8a64-2c14a15fed26" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2022, the Company has no off-balance sheet concentrations of credit risk.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dcc4c155-665e-46da-944c-76a26e2af7f4" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:OtherRisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. Further, the Company is subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fcf3262e-eac8-4342-bb8c-10a31d993b9c" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_846a5fc8-697a-4d17-8fb0-21f7909404ae" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.315%;"></td>
          <td style="width:1.583%;"></td>
          <td style="width:31.102%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e37aafc6-ac32-40bf-a0f6-719671a93be9" contextRef="C_f2b95b5c-aee8-40eb-8cee-80a189dab5a4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c509d6c3-a6f8-441e-a248-16b10d843026" contextRef="C_672dd93b-be85-49d8-84d9-56d83b649236" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bd55e2ef-6088-4b82-be10-9fbb7267bcb7" contextRef="C_f6117e7e-2c0b-40b3-93ef-a45d9e067e05" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d1804f5c-4b3d-43a2-9116-77b12751e10e" contextRef="C_127f64ce-6b17-4ad1-9892-5332bca5d957" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2405017d-95cf-4acb-82bd-68a0874c669b" contextRef="C_b523bac1-1813-4b7d-a176-50e0e4c5ce15" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e22624a0-76ff-48dc-976d-04c989d8ac2c" contextRef="C_e6f99192-3731-4c3e-b249-3bcfe2f628f0" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or lease term</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0635b17-62dc-4515-a0cc-df621b2eff55" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_096854c6-77d8-4d6d-8482-1cc6c18d705e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_760099af-105e-4b3d-b894-233bf40a8801" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a2ba46ba-859a-46bc-8f12-4243a6e71487" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2022, 2021, or 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fa1eb8bc-2f88-4a86-af21-6da014eb0416" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#x2019;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#x201c;ASC 606&#x201d;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#x2013; Revenue Recognition (&#x201c;ASC 958-605&#x201d;), which applies to business entities that receive contributions within the scope of ASC 958-605.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#x2019;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement and the Gates Grant Agreement (see Note 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_61a9ed31-7abb-42e3-a5ae-6a06d20762b8" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#x201c;the Black-Scholes model&#x201d;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation (based on the mid-point between the vesting date and the end of the contractual term) of the expected term for its stock options as the Company has concluded that its stock option history does not provide a reasonable basis upon which to estimate expected term. Volatility is based on an average of the historical volatilities of the common stock of entities with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">characteristics </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">similar to the Company&#x2019;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_02b9c906-0cb0-463b-996f-55a8ffc716e9" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#x2019;s technologies are recorded as research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_49585d21-15d3-41ba-8624-cc5b00c0e33c" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#x2019;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#x2019;s consolidated balance sheets at December 31, 2022 and 2021. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes lease expense on a straight-line basis over the expected lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d1a4072-34f8-4462-8bbd-9feedfbacf17" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes and measures uncertain tax positions using a two&#x2014;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92c90166-f9ea-4f50-9f31-29aa9d8c004f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#x2019;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2022, the Company had not accrued interest or penalties related to uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2020, the Families First Coronavirus Response Act (the &#x201c;FFCR Act&#x201d;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 29, 2020, Assembly Bill 85 (&#x201c;A.B. 85&#x201d;) was signed into California law. A.B. 85 provides for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_70164360-5f6d-404f-9140-927a1b129780" contextRef="C_62816055-7eef-44a2-9784-8d2135365bf0" name="grts:UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> suspension of the use of net operating losses for medium and large businesses and a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4a194620-3a7b-4fe0-bd09-cf7756d17ae4" contextRef="C_62816055-7eef-44a2-9784-8d2135365bf0" name="grts:UseOfBusinessIncentiveTaxCreditsPeriodCap" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cap on the use of business incentive tax credits to offset no more than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25f97916-54ca-4ba7-aae2-cc63e183b910" contextRef="C_4989ea59-69ce-4c78-bdac-1907a737f297" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed103bfc-af9a-486c-a12d-75ad131c4258" contextRef="C_2d5436e0-6fd6-4397-a2ff-a7a44bc2b153" name="grts:MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ff87892-7f47-42c1-baa2-b29abb7a515b" contextRef="C_4989ea59-69ce-4c78-bdac-1907a737f297" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for taxable years 2020 and 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#x2019;s consolidated financial statements as of December 31, 2022.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c08da178-526b-4e79-a425-b017256d259b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#x2019;s marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dec731f2-4a5d-4aeb-930d-d39f257cdb19" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1f9f38f4-0e29-4779-82e8-9ab332b4ccab" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the FASB issued ASU No. 2020-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Codification Improvements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;ASU 2020-10&#x201d;). The standard contains improvements to the FASB Accounting Standards Codification (the &#x201c;Codification&#x201d;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. We adopted ASU 2020-10 on January 1, 2022 and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt - Debt with Conversion and Other Options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Subtopic 470-20) and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;ASU 2020-06&#x201d;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company does not expect the adoption of ASU 2020-06 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to have a material impact on its consolidated financial statements and related disclosures.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cd832e73-9d27-48d6-90f4-06265f544099" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	Cash Equivalents and Marketable Securities</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6f8b63d4-5b4a-413a-b7dd-e68ade9eb7e3" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.0%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.459999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.151%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.459999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.151%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.151%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.804%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89058c68-7ef9-4128-8f2e-8491c80f77ce" contextRef="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a357c056-d70e-408f-9593-347603b2966a" contextRef="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05b862d8-336a-421f-8ae4-ced1394b4d68" contextRef="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe0233b4-87b8-494d-80cf-94c932b8df5b" contextRef="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0c83eb9-3678-495f-b1af-69828017840a" contextRef="C_40264f68-b348-4688-915a-7b32fbef6c41" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,191</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2e18947-68bb-455c-9de0-a3182b1a34c3" contextRef="C_40264f68-b348-4688-915a-7b32fbef6c41" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df2fdfcd-3367-4fc0-85fc-3aa325138c76" contextRef="C_40264f68-b348-4688-915a-7b32fbef6c41" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c22790b-cd27-4e81-9e55-ffd1d37e4004" contextRef="C_40264f68-b348-4688-915a-7b32fbef6c41" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,191</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c96751e1-b4ac-4342-bcdd-c50ce66456ad" contextRef="C_95d7df61-6b4c-4669-b173-7200708d3836" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36bcf167-1ed7-4719-8a20-c013dbbef20b" contextRef="C_95d7df61-6b4c-4669-b173-7200708d3836" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68656287-188e-4dbf-bb3f-7de4a339af63" contextRef="C_95d7df61-6b4c-4669-b173-7200708d3836" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d2047e1-c5ed-41d4-a3e0-dafceff38e8c" contextRef="C_95d7df61-6b4c-4669-b173-7200708d3836" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">949</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9ceaa06-89a7-4531-b594-ec53969ae83b" contextRef="C_17166196-5fed-4356-b3f5-8cfb8175ba74" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b536ee4f-ccfd-4bce-9863-6f567760071f" contextRef="C_17166196-5fed-4356-b3f5-8cfb8175ba74" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b25ad30-8eb8-47bc-928c-081435960cd9" contextRef="C_17166196-5fed-4356-b3f5-8cfb8175ba74" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64d375eb-7612-4038-9a38-590f4576b5b0" contextRef="C_17166196-5fed-4356-b3f5-8cfb8175ba74" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81a7cea3-ff2a-4bb1-ad27-d49634609e91" contextRef="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,887</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a9679ab-7646-4659-8064-f28b1b13c930" contextRef="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8b8affc-fcaa-4452-9b66-fda93fe35594" contextRef="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25c27096-83c1-4ad8-8f87-76c4124fe19a" contextRef="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,853</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f614486-fde5-4f21-8f58-f3f75e46b7e0" contextRef="C_27862347-30f4-4a51-8e69-155b8a286acb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,608</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb9e9213-3ae0-4ed4-ab7e-568d2eea85e4" contextRef="C_27862347-30f4-4a51-8e69-155b8a286acb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d89df764-15e9-4109-9a34-50150527f361" contextRef="C_27862347-30f4-4a51-8e69-155b8a286acb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db410380-63ab-45fa-9655-ce2615d4df76" contextRef="C_27862347-30f4-4a51-8e69-155b8a286acb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,540</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d64e9ea0-6103-42ed-8f40-70ea8021c16c" contextRef="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,703</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5767cb39-8900-4f59-8f00-8a44bb3a7381" contextRef="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f63ddd11-a099-40e8-819b-26923d3f369e" contextRef="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04226d88-ca24-4bdc-a317-fcedf32eb70f" contextRef="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bf9db16-ed08-46d5-a54f-f48ee18af047" contextRef="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,464</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf7b05e5-b1a1-4b1b-9e40-6a39f5c87afc" contextRef="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81031189-2de7-4409-bb96-e079f6d2902b" contextRef="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">130</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bfdf3f6-b16d-4f83-a261-d16c0100e8c9" contextRef="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79f028a5-9027-4221-a264-11ff7cc5849a" contextRef="C_a1b699c9-114f-4029-b6c6-56ba4c312c56" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">933</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_050e624f-8aec-458f-a120-6b330c226494" contextRef="C_a1b699c9-114f-4029-b6c6-56ba4c312c56" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0782d2b3-2717-4bad-a363-439c411fa6af" contextRef="C_a1b699c9-114f-4029-b6c6-56ba4c312c56" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c41656f-26f3-46a2-ad41-4cbc01b63967" contextRef="C_a1b699c9-114f-4029-b6c6-56ba4c312c56" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e8d9149-bf1b-4acd-a562-a22e1210c4d2" contextRef="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2d7a8e2-5d35-4db8-b411-6eec0a437166" contextRef="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b81cff0-d0af-40c0-9b22-79a3d3f0e606" contextRef="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b908d81-fcb6-49f7-b633-a67e7f8559da" contextRef="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_435755a1-5c71-4a40-be5b-358a83cb779f" contextRef="C_6aa0ddf0-5c08-4e9d-a445-164033395389" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a655cd74-9c57-4afe-a873-d4307add97a8" contextRef="C_6aa0ddf0-5c08-4e9d-a445-164033395389" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d800261-910e-4dfc-a67c-0634e90a5b81" contextRef="C_6aa0ddf0-5c08-4e9d-a445-164033395389" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bef9e747-ba4c-441b-ac32-987113b7c6bc" contextRef="C_6aa0ddf0-5c08-4e9d-a445-164033395389" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_807ed40f-051d-4b88-bdcb-7f17b639e618" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158,691</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12e37729-edc8-4597-82f1-b792173cf912" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa6b05b8-53ed-45c7-9521-9f5b8b12f9a7" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a090362-6963-41ce-9021-d7ba07998336" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158,611</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.0%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.459999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.151%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.459999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.151%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.151%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.804%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_facc847c-791e-470f-b38f-98301d2a754a" contextRef="C_351091de-7324-4fdd-81d4-70155fd963f8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d307a2a-c5c6-4255-bc28-d263cdc096f1" contextRef="C_351091de-7324-4fdd-81d4-70155fd963f8" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f41f722-76e6-487e-94d9-57af4ab401f4" contextRef="C_351091de-7324-4fdd-81d4-70155fd963f8" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1e6e1e2-1774-4a4b-b13e-5b2e54f85dfe" contextRef="C_351091de-7324-4fdd-81d4-70155fd963f8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b75b5caa-b355-49ed-859d-7be079ae6fcc" contextRef="C_bd77beb2-c5d1-4f28-877c-995caa385c8e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f753ce4a-8b37-4687-b961-fcbc5b009d95" contextRef="C_bd77beb2-c5d1-4f28-877c-995caa385c8e" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d143dfe0-5764-475d-a59e-c17dd2413bd0" contextRef="C_bd77beb2-c5d1-4f28-877c-995caa385c8e" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8853d85d-d9dc-4fa0-8cc1-6aca78bbc8d2" contextRef="C_bd77beb2-c5d1-4f28-877c-995caa385c8e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83bfd090-717d-439d-9294-6805eda25341" contextRef="C_5a176657-560e-4e80-8117-9b6ae2388147" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4586e875-656c-4396-8020-60b0c4956a79" contextRef="C_5a176657-560e-4e80-8117-9b6ae2388147" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_107cf4c6-ab86-4635-afff-1cf31df0aa1f" contextRef="C_5a176657-560e-4e80-8117-9b6ae2388147" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34d36338-92e9-40bf-9226-2b94333e5023" contextRef="C_5a176657-560e-4e80-8117-9b6ae2388147" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a29d6bf7-4041-4c0a-91e7-a9eb4e66f130" contextRef="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d5f31b4-5ee1-4555-a774-7edb8f3c7018" contextRef="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9d59efc-5cb0-4f1f-89c0-fe6bf27187e2" contextRef="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbcc569f-7f90-4f24-9281-093ee75f1b34" contextRef="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9507d058-fee5-4565-a83b-68e3eee6aabc" contextRef="C_2152b17d-baee-4d49-a165-456d92d2f320" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5a6059c-4c48-46ad-b23a-0efec50ba3cd" contextRef="C_2152b17d-baee-4d49-a165-456d92d2f320" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89ffa4d0-3955-41c5-a93b-a78ffbecd3c0" contextRef="C_2152b17d-baee-4d49-a165-456d92d2f320" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d02a562-63c7-47bc-898a-27b387d24a33" contextRef="C_2152b17d-baee-4d49-a165-456d92d2f320" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,594</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1aa96627-5916-4923-9e03-681eb2275a7c" contextRef="C_2b45ae22-69b8-4005-8ab9-321b6b14f107" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,990</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb1c7f76-3ec1-463f-9186-a7af48790cb6" contextRef="C_2b45ae22-69b8-4005-8ab9-321b6b14f107" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66204e5f-b788-4301-aef9-916afe4fdf16" contextRef="C_2b45ae22-69b8-4005-8ab9-321b6b14f107" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e869fb95-5a8c-4f23-883e-8758bef7f0c7" contextRef="C_2b45ae22-69b8-4005-8ab9-321b6b14f107" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fd66a37-fb0d-44d8-bbc8-83285a7460b3" contextRef="C_8437c548-599f-4c6f-9584-e7e7d46f0379" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,976</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45119bcf-9c0c-434e-be2c-f3cd4bf031b7" contextRef="C_8437c548-599f-4c6f-9584-e7e7d46f0379" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6811544-690f-4fb4-be5d-8f9fd5dc4490" contextRef="C_8437c548-599f-4c6f-9584-e7e7d46f0379" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dec1818-36c2-49af-b245-ce9056f40156" contextRef="C_8437c548-599f-4c6f-9584-e7e7d46f0379" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_883f6231-4507-49e2-900b-76ea8f3d29ab" contextRef="C_077f94f8-990f-491f-98d1-d6eb5debde18" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,277</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c8589db-1d9e-4b60-970a-52a2e861c400" contextRef="C_077f94f8-990f-491f-98d1-d6eb5debde18" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_002893d5-88aa-4239-8b5c-5b2971c60c97" contextRef="C_077f94f8-990f-491f-98d1-d6eb5debde18" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f48fdb20-d461-430b-8979-747482f1b03e" contextRef="C_077f94f8-990f-491f-98d1-d6eb5debde18" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_367a5a7e-1deb-4072-a7c7-1464db3475a1" contextRef="C_3715424f-76fd-4a70-bcb7-f905fcadf133" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4013164c-7a23-4b2f-8584-f6d0cda545bc" contextRef="C_3715424f-76fd-4a70-bcb7-f905fcadf133" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfe42852-5c2b-4d3a-be74-16275d1d2991" contextRef="C_3715424f-76fd-4a70-bcb7-f905fcadf133" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1228330d-a8e8-432c-8883-d32053f3706b" contextRef="C_3715424f-76fd-4a70-bcb7-f905fcadf133" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74f69623-6e68-4b67-af7f-edc4856511a5" contextRef="C_8b0ba039-9d60-4e77-8a56-2a70e004643a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,565</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72ba9cfd-8418-4c7b-830e-a2ad4d4178b4" contextRef="C_8b0ba039-9d60-4e77-8a56-2a70e004643a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76e83720-55b3-4a98-830b-e0b1a13da241" contextRef="C_8b0ba039-9d60-4e77-8a56-2a70e004643a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_297eea9f-67a2-4775-9eb9-6b200342b605" contextRef="C_8b0ba039-9d60-4e77-8a56-2a70e004643a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca245892-83c0-47a7-af11-51e9643885de" contextRef="C_8900ff95-7d4c-4827-aab8-7f758672ca22" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a379087f-a54e-4456-abbb-1457616e76fd" contextRef="C_8900ff95-7d4c-4827-aab8-7f758672ca22" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27c1be5d-7263-4f35-a046-ef5787e1e8c7" contextRef="C_8900ff95-7d4c-4827-aab8-7f758672ca22" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc483e95-76bd-4e55-b23d-2cf767a54cee" contextRef="C_8900ff95-7d4c-4827-aab8-7f758672ca22" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,346</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc029aae-b38d-482b-b62f-6a302a84299f" contextRef="C_40424169-d409-40ab-8018-026dc29baf15" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,637</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44909b82-d212-4405-9e7b-a87d048a5d4a" contextRef="C_40424169-d409-40ab-8018-026dc29baf15" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef14cf61-073f-4ca2-9499-7e4089228f71" contextRef="C_40424169-d409-40ab-8018-026dc29baf15" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dd4a498-28a5-4113-87cf-58046982df5c" contextRef="C_40424169-d409-40ab-8018-026dc29baf15" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1111c00-6377-44d8-afe2-3c46f8ebf73a" contextRef="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44f45e2d-a657-47c2-aaa0-3be252c75a09" contextRef="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebca4f9f-0ebb-4913-920c-65e29a3b8251" contextRef="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8602aa33-2069-45c6-a66c-8121f38e6ef1" contextRef="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_146a9a0f-2ed8-480e-abc8-1fd9cc7e2520" contextRef="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f8a2aff-8544-48d3-b8d2-b3bed4edd2d8" contextRef="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbd3d416-8f88-41e1-875b-066e72e02187" contextRef="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_080ab06a-7f65-4251-9066-ba775ce8a5cf" contextRef="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38c7ec8c-30c4-4855-9dbd-c7c160be1150" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86c40c3e-a929-4e99-aeba-58bddd107541" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30ee4a67-69f6-4bb8-9f06-8120d6f4f5ae" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2385008-527f-492b-86b4-f8d9fae5d4ae" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had a total of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bba3043a-7dc9-42b2-b8e8-57b85affdcfb" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:CashAndCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3976fcc4-54a8-4c00-a6ee-ca6021ddf256" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:CashAndCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">206.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash, cash equivalents and marketable securities, which includes $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e94f0f13-34b2-4433-a7c4-743f8578a080" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">55.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2b797e6-70fa-4666-8690-c82001517ef8" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">93.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash and cash equivalents and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08951269-c272-4d16-87cb-c0c916d1ebdc" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">120.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e57648a2-6a4e-430f-9e0b-4b2e7f73170b" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">113.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in marketable securities, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All marketable securities held as of December 31, 2022, had contractual effective maturities of less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2cd7c064-04ba-41cc-97c4-32b764a63021" contextRef="C_a6647160-7b5e-4902-9018-3678bdb60427" name="grts:MarketableSecuritiesContractualMaturitiesPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_955a1a8d-da7f-4244-817e-dfd03bd0ae1b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:MarketableSecuritiesRealizedGainLossDescription"><ix:nonNumeric id="F_3837de02-5585-426b-b2ba-8b352849a702" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:MarketableSecuritiesRealizedGainLossDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no material realized gains or losses</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on marketable securities for the periods presented. As of December 31, 2022, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2526008a-eaf1-437e-8cac-e9b464b37e13" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Security" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t hold any individual securities in an unrealized loss position </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for 12 months or greater</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b019b342-c222-4bb0-a430-76061d8d4ada" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_89e6827a-8302-466b-b031-4ef6406a8b51" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_648df21b-507d-49f7-bac7-edad7717107b" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> recognition of any other-than-temporary impairment in the year ended December 31, 2022, 2021, or 2020. The Company has not recorded an allowance for credit losses as of December 31, 2022 or 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 4 for further information regarding the fair value of the Company&#x2019;s financial instruments.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0498457a-307e-48a2-8775-16b5c6bb3042" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.	Fair Value Measurements</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0cb93ce4-a88e-4c2e-bc80-e10d7127be34" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.422%;"></td>
        <td style="width:1.174%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.165%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.165%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.165%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.777000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bce47fb-20ba-484a-9bc5-bab8913aa3b9" contextRef="C_278c4452-2cac-4960-b90f-088134dd9e53" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae2a1b50-6454-44b4-abbd-bb784a23aae7" contextRef="C_e9a3cb9b-7c28-49b3-ba96-6f4a5a29c371" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae6615f4-728c-4aa4-804a-7998e393ce6b" contextRef="C_23c937ef-9873-4e7b-8401-361c0141be20" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6277d52-5c2a-404d-a818-e6b8be553636" contextRef="C_5eeb50c4-7bbf-4897-a80f-34577a6faa71" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cb98336-cc0a-4d23-9808-d8c5587ec68f" contextRef="C_8ea4d358-ae99-4f6d-8fc9-63316759fe1d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,191</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85716238-faf8-4919-a3d1-deee32fcd9a8" contextRef="C_68ae43bc-d4ba-46ef-b787-9a1a51cd49b5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,191</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a68bbd79-2792-4c8d-8f45-3d9731842177" contextRef="C_0f1c0918-b40b-45ce-a32a-5ff2e0cdb811" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2961c447-ee02-4ac0-af84-4cdde8d9272d" contextRef="C_594d238f-4b26-4a67-892c-13ccd5be28e5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d95d328c-0b21-4309-aeae-2166762459e7" contextRef="C_76e247f4-22b6-4c8d-8bcc-5e1bb0cc9367" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">949</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_176ea312-27a1-41ac-8eb8-334b996aac40" contextRef="C_489b2495-a848-4ec1-ae47-5647173197f9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c533f23-55f7-497b-ac91-783ce3722186" contextRef="C_3a579eb0-d553-498a-9517-437c3bb7acbc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">949</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd7705c4-3d47-4042-abf4-381bd40c0673" contextRef="C_5fc9c11d-6f3f-4fe0-a8a9-6900a0dbaae3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d62ef2a5-6b31-48b2-9643-a4d6bb29fe55" contextRef="C_b1d550f9-c0a6-4ff2-941b-a0771a52258d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b096f553-8d5f-4d9c-9534-2cf00b148c58" contextRef="C_2f5dbf8f-812f-4ffe-9bac-799e8547d2d6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34088781-6018-4291-baf3-f4cf6c828c0c" contextRef="C_45aa777d-f982-4434-82ec-6619331cbe4a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08fd9413-57e8-4e86-bf1b-9a436d605af5" contextRef="C_aa58fee8-bbe5-446e-8e6a-a951cc8fb7a1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93959b33-360c-4698-bf7a-1c60ec355059" contextRef="C_6fdb3010-aa4d-4332-a56d-c9ff8991e214" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,853</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_664827da-822d-474b-9da9-6bce807696b8" contextRef="C_6674d76c-7bfb-45ae-99e4-e6beb133f3b0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef7a88ef-dfb6-4d54-8716-155d18fb44b0" contextRef="C_a899ce5d-e51a-4a72-98ff-ca5442a68952" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,853</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1220fd2-4d04-4aa5-b99c-0da42b68937d" contextRef="C_2ca307da-79aa-45f0-952e-4bd76b2798b5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d299f6a-49a2-4b98-aa6a-7211b18b6c34" contextRef="C_25953651-9e56-416b-b771-e53f99a9c2b7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,540</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca01fd4f-df55-4827-8e06-40350fd63cf9" contextRef="C_e1c1fbc0-d63c-43b7-9ffc-6ad92761fe9a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,540</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8467882e-cb49-4c0f-89ea-5832a5e6c837" contextRef="C_aadd6041-4d4d-471c-8758-30fc80ec55da" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01a2aff8-642c-4385-ab63-658088a3d679" contextRef="C_af34b684-6740-4987-8a92-febe2af8bcc5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47c4bcc3-b0c2-4096-b117-4c361f50777f" contextRef="C_5df76468-2d33-4c29-bdf7-4567b8bbe0be" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62618e8a-3a10-467f-bf28-50c41d314d2f" contextRef="C_daff6bb1-ec2f-40fb-b9ff-6c866bc3bfce" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3c1010c-7f37-4aa7-8bb4-60c7cd3be4ef" contextRef="C_c884b3b8-4d8e-4b0b-b827-70428cfbef2d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edf7cb11-1135-422c-9048-6a59487e09b6" contextRef="C_cef2dcb9-4d72-401b-9b51-ca2ec7658d4f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a92a4469-0fa2-42a2-adb7-cb83c1cb250b" contextRef="C_58b1c9d9-769e-46b9-8c0b-1522ce09ece0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,389</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1201a129-fc94-4ae5-b885-755e0b7bf3a1" contextRef="C_927c9adc-769a-4197-8a7b-ca4f1f62c776" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,540</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dae0ccbd-b2b7-4100-812d-5524ab4d951f" contextRef="C_8cc492f6-e0e9-4dad-b467-56ec30f2625c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,849</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2a11e75-fb13-47f9-bf5d-d1e060d8d382" contextRef="C_97b3c3ab-b721-45c5-a7f8-8b63dd151af6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_824c2974-05c4-4e16-a951-fc82acf68887" contextRef="C_75882f1e-2c2b-4a1f-86db-757c8eb713b1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb3f1c33-3f3f-4087-9eae-d61cf77bb3b4" contextRef="C_9f752682-fc55-4997-9e66-a13d860093aa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c44678c3-7a96-4e7b-8b21-4609b4e98867" contextRef="C_4e50f083-971a-4ba3-921b-feac5bdbdbc5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8209f693-16ad-4479-a147-71ce0a026768" contextRef="C_56b7d049-aed0-43f4-a9e5-39af8293efe5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a39fe2dd-3f53-43c1-b155-4c6ab6b40625" contextRef="C_71524de7-0086-49d7-9417-13f7efabd4d3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9b4cd14-18af-4ba6-97e9-fd8f150167ab" contextRef="C_7de13c8f-bc45-44f8-a635-d16cfe8fed70" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5094886c-9843-4827-b849-3ef8cb5cb67a" contextRef="C_dd9632a7-d460-4003-8a48-c36e620a0c77" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a236f401-6e69-4d5e-97b2-607a6f8a4d3b" contextRef="C_d50b36e8-0a1e-4794-a381-440b70d6bf56" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2387f57-e615-4bdb-9c5a-ec5f2253dfa0" contextRef="C_9faed10b-deab-4fc4-8710-bcca92fcb310" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9b1993b-0ae8-4473-9487-cee1154a1562" contextRef="C_c62e59ac-4c24-44ca-b119-f4e4f1990e9b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cd09162-6dc9-4497-a6e4-ace0e544a840" contextRef="C_a9559e13-2a2f-4a2d-bb75-e9c9777abe4f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6151cb0-d622-4981-8634-851cc57cbc02" contextRef="C_73444588-46b3-4e78-bfe2-a5e3294d5d4d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a25b30c1-9a3c-4534-aeab-656566510531" contextRef="C_3295931d-4cf6-4ed7-9b11-e42a2fb87408" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158,611</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_136e78d2-e37a-4409-8386-9ca75a7a8509" contextRef="C_3dab2c7d-c16a-4d70-98ba-da1026b8f662" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,830</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_416e415a-9637-4fed-ae1b-73e22fe8b506" contextRef="C_31827499-df5a-4144-a589-97ec604bab7f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,781</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84c7bb05-1b4d-4194-8943-cf99b7f21ac4" contextRef="C_40a76726-c327-40be-89dd-1c7d982d5836" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.422%;"></td>
        <td style="width:1.174%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.165%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.165%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.165%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.777000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f53ffc3-3a5a-45e0-aa44-7b08ff5f013c" contextRef="C_bd4c978d-db21-4656-99dc-dd258c79185d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64645c8f-d8e1-47f2-9cf5-92a012102766" contextRef="C_654ac5ed-1cde-4438-bd70-e413cdecd6a8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d34183ed-ab0d-4e8e-8623-4d7fbeefe9c5" contextRef="C_f6215bc4-d5d7-4c03-9ddb-fab6020892dc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9aae01c-0b0f-4033-ab0e-f9b998946b6b" contextRef="C_1802000b-946a-45cf-9eb1-ab878fd907d2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_871bee68-97aa-4cb0-8351-fbe4a085a149" contextRef="C_739f34c4-9e15-4e81-85c9-c9c472575986" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f21da42-5db2-4aac-985c-cf0dafc51f58" contextRef="C_bece036d-3f60-44c3-9f38-745d2aac748e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c64fd63-2058-4279-a8d7-c6469e462d2e" contextRef="C_a7439677-3eea-449d-ba9d-9af37deb00df" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7e8606f-b0e4-4c8e-9304-0e2c181470db" contextRef="C_b6ab88c2-0338-4075-8ed9-d7c8fee513c0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86517c1d-6b42-4251-8567-1ca9d3abbb7c" contextRef="C_27904f74-af74-4e0d-afa5-d30b372b7427" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c72d1688-b595-405c-98a8-0fb00757443c" contextRef="C_81ba52a0-a708-443b-b8aa-b7e87669392e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74026196-98a4-41c8-a18e-35fb0b6e18d0" contextRef="C_dd661f8c-80f3-437b-94c6-39b2d87a6b09" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb865000-d385-41e5-b91e-37a160365c35" contextRef="C_9adf420e-a107-42cb-a6a6-902bddde7540" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2fd630f-d3f5-4c98-9f21-106250f3b05b" contextRef="C_d2f985e7-3856-436a-b098-7d96d2ec9b97" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf57a29e-c715-4b4e-9963-d55175479a26" contextRef="C_dd5de76e-097b-41d2-b92d-4e0353e1ee49" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9b70ff8-5c25-4a4a-a3b2-fe0b675a9a46" contextRef="C_3daa3e39-3faa-4c82-a714-e0e8c91e437f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcecc3f9-ef57-4fbc-9bbb-91069e19c392" contextRef="C_e6370a8f-2667-466f-98d3-1e9d3a327fa7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb01ffcf-c2e8-4b7b-88c4-f490c09c23cc" contextRef="C_c944192d-7243-4e20-9dee-9ed4870b3302" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,594</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f13f66b2-f09c-446a-a06e-583c3f790df0" contextRef="C_39844211-5dca-42b7-88f9-d6efbab7fcb0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_297c2b80-390f-4d78-9094-4d4098b7f6f7" contextRef="C_816d085d-25a0-4fe5-a1f4-76e96db59467" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,594</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b8ae5e6-da3b-4e8e-8cff-78286f540d7f" contextRef="C_431f0e99-dc7d-46f0-aaf5-b5f357500cef" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f20311c-4fbe-4e4a-a35b-00a1d9404cf6" contextRef="C_99d8a4f5-b851-48db-a6e7-61d21c828ead" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a38ccd21-e7c7-439a-9d67-7f7da3a6a1f9" contextRef="C_466e6120-0e46-457a-95cb-1badad395cad" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc1300a7-3d01-4acf-9457-f28fc33a776f" contextRef="C_6f4a9e62-6ab4-4592-9bff-72669d585e09" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_593bb6f1-497f-4741-91b3-78e66cebb6b7" contextRef="C_ec0b67b2-f764-458f-92ed-317ed126cda4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1936086-8f48-4e13-9194-98c296143a0a" contextRef="C_90864408-3972-4c1c-b3b8-325c747633b8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13f32961-41e7-4f1c-a027-5e7630eb3d6c" contextRef="C_a8816b30-096f-44ce-9bfe-af5d8d5e416d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a076e0b-31a7-4410-80cd-7d138bb6e69e" contextRef="C_2fb30a1b-bb4d-41a9-b08c-0a5c0e1c4848" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07c5c567-cde9-4989-ac22-7e9545e96fd2" contextRef="C_e41fdba9-8344-40fa-b5b4-2fdf9fb77166" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da93632b-4256-42aa-a398-2d503dc1afc7" contextRef="C_8a72d7d1-fd42-40dc-a974-f728dcafb2db" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_339acbb0-1ed2-4b94-82be-5a68cf391814" contextRef="C_22a30aad-6a5c-431e-97aa-6d0174548088" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_669864f6-b045-4f98-8be3-a84a97948ea9" contextRef="C_9ec3fe0f-f635-447a-a11c-3c7d34b2f6e3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6281a0e2-bc6a-458c-8f4d-740a6937e18e" contextRef="C_3c93b994-375e-41fb-a65c-a6d06c8a74af" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa0a73b1-e4e9-4437-8327-2b089a0579fe" contextRef="C_78424e0d-5b03-41a3-be95-f77504eeecf9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_457ed1d6-f9b5-4d48-8c7a-2646e55cd67e" contextRef="C_9f6cd5c7-d0e1-4f81-b026-8285e0af17ca" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1ad7c06-7e91-4a5b-937a-5310b00d47c2" contextRef="C_d375ebef-273f-4149-8fb5-f4dc8b70ab63" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e7c5eee-89d0-40c1-913b-f7d0842e527b" contextRef="C_724282bf-8130-4b80-8ac7-1b0e9d423b87" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94e97c1b-bfb3-44d2-add1-3e1a6205284d" contextRef="C_72241514-75f9-4b94-8b9f-d70213f11d47" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_621e35c7-2900-4ec8-b965-43f2db61ccd5" contextRef="C_09a42735-0d75-4484-89b9-5f969e41a1fb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_978e487e-ce55-4b32-bb84-77172af9ea7f" contextRef="C_d942367c-37c2-422b-a6e8-33a8383c90bf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_411a0072-b13a-4dd0-8244-3b451bbd4735" contextRef="C_6ecd9d54-ec05-4e5b-96c6-c81c04c9fc84" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e808fb84-7022-4758-a8e1-9f9815a1cfd5" contextRef="C_11b39c77-1e84-4dab-b60a-449a3f0ec0fa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,346</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e65ddd73-8af9-49eb-be2e-20985a187418" contextRef="C_963260b7-59bc-48cf-9042-018d5b6ef6c2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83512dc4-d4f9-4da3-90b4-271fd05e5b92" contextRef="C_94a66d4a-e27f-41e7-af27-bdb2e8470a43" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_941a8f8d-00bd-49e4-b6ea-6b0564511e7d" contextRef="C_e6c766b4-e117-4244-b35d-682f04d91b80" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4df30577-8ab3-42d8-bc8a-41a563fa3177" contextRef="C_fed14fa7-fd7b-44c6-a3d0-52c8e4029d8b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c2866c2-2b86-471d-aca4-a999165fa8bd" contextRef="C_6565d2ae-b389-4300-902c-39d3e6e112f0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3648573b-879b-4e18-b606-37b41400932d" contextRef="C_21692f50-7040-4780-a0c1-87357f75dc1d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_664606fa-69f4-4599-8b55-3166a2a4b268" contextRef="C_5c0e8577-018d-4fd4-82ea-b6e2d68a5f23" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edc55102-6000-436a-be9c-029a2d03e36f" contextRef="C_8c5761b7-e32b-45b4-becf-3a3c1d25c6a9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f79f499-dd9b-4388-96f4-3b6286a6769f" contextRef="C_292c55aa-2381-4617-8d13-a126676fe9c7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d5ef2f5-643a-4d00-a389-158d40315338" contextRef="C_10d2b101-f4a6-4310-ae5d-b86276995667" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8112c65-d295-435c-b94c-5dc821a54a13" contextRef="C_609b6c54-99ce-41d7-80bc-f34b80b29690" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb21cb06-5e4f-4885-b105-3049419b2ad5" contextRef="C_fc2d3480-29e6-4302-a16c-d5582586d81d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc96d64f-ba62-470f-b02c-d6c9e771f532" contextRef="C_d4a6100a-40e8-402e-9f0e-748c76179dad" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ba1544b-edd0-4849-906b-79587a7ea79e" contextRef="C_9c1cf7ad-dccd-4502-b51b-e6878b32a7e9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e42f8da9-0a22-4fc5-aabb-8e5c695f2344" contextRef="C_3d082462-60fe-4bab-a12e-cc1b69abbcff" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcbfe647-b3bd-4a92-a204-a7b86ea3f766" contextRef="C_73ad74f1-0195-424d-8504-c0dca88a9b7e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51b2cefb-096f-4f88-af04-b060aa405704" contextRef="C_858abaa7-2ee9-4eed-9059-5c0651392b80" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,536</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d65df54-d14c-4049-97bb-5868743390b0" contextRef="C_eb0cc90f-3d79-4014-a59c-5f9cf3d2f660" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,739</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6911a019-88d3-4c4a-8321-d232294cdbb5" contextRef="C_e6370a8f-2667-466f-98d3-1e9d3a327fa7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures the fair value of money market funds and U.S. treasuries based on quoted prices in active markets for identical securities. Commercial paper, corporate debt securities, certificates of deposits, asset backed securities, and U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc7efaaa-77fe-4324-9567-19e5b7e4d5bd" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:FairValueMeasurementLevel1ToLevel2Transfers" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8ede1dd7-406d-47e8-ac57-98b049f414bb" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:FairValueMeasurementLevel1ToLevel2Transfers" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers between Level 1 and Level 2 during the periods presented. See Note 3 for further information regarding the amortized cost of our financial instruments.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9f9e162f-f05e-4b73-b309-2bdb3658633f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.	Property and Equipment, Net</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d558a3e5-e3c1-4a7c-b664-848d3cc75b0f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.84%;"></td>
        <td style="width:1.517%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.456%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.517%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.669%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cc4575b-95f1-47bb-ad44-0fa872a4233a" contextRef="C_87523886-5199-4d42-8415-694b2b443fbe" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,155</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7913917b-76c0-4f20-8d83-f6e8a7f7bc98" contextRef="C_4bc7731c-c74f-40d3-a426-a27f2ea43498" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_390a554a-b959-40b3-9353-181f654d338f" contextRef="C_7f02ae7b-672e-42dd-aa91-702e3930b636" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,285</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eecb3907-8567-4cdd-9b31-a55e861e398b" contextRef="C_87f6c28b-d174-40ca-a77f-7d9cc17bd37c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e283f6e2-4556-4fd0-acda-a7f0c7cfa545" contextRef="C_3dded028-e6f7-4811-bc50-0118b2cfd30f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,309</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_175aed65-ecea-4a29-a210-b4dbb37a8bf6" contextRef="C_8683aae2-0a3c-46c3-989d-7ac0248bffb6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,679</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16995721-df8d-459b-baa1-8361b648625e" contextRef="C_6a755d83-b2d7-4f74-863c-9977b0a91bdc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,024</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bed2c6ab-1d56-4ed4-9cdf-b93ce5311b3d" contextRef="C_64576a2c-bdc6-440d-a223-f398708694c1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d1f8f78-670f-4617-8473-a90a1753c819" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,773</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0c2cff2-997a-4cdd-bdd7-b2dc2c55f003" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,907</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a50070d9-3d57-4997-8472-4d95edf43236" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,782</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25e0700a-efb3-49e8-9a72-6bbf7e2e65da" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,276</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e92e234c-4bff-44de-9076-a9022035eea0" contextRef="C_6ac0503d-d066-402e-877d-8f2b3b924843" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,344</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c135acc-897f-43d9-8bf2-8274da57230b" contextRef="C_652f489f-b7e8-4293-9bdf-ece64443c159" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_692766f0-6713-45ca-b5f2-e2e4804f793e" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,335</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_999a6f7f-554d-4fb6-a649-fda2c36c58b3" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,622</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9844e9f1-15e6-4f9c-8c96-4f43bb84115d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_830c815a-ef8f-42f4-9f9c-a6d1e18204f4" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59eb040c-c026-435b-97aa-8ad719e98a9d" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021, and 2020, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_91691de0-5c62-40ef-b8f9-9b51a94cae99" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.	Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases office, laboratory and storage space in facilities at several locations:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emeryville Lease</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s principal executive offices in Emeryville, California, consisting of office and laboratory space, are leased pursuant to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_527c3af6-d073-4fe2-91e3-d70603a45878" contextRef="C_3e931d49-353d-46c5-813c-21ac6372c768" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating lease (the &#x201c;Emeryville Lease&#x201d;), which the Company entered into in January 2019, with the obligation to pay rent commencing in November 2019. In conjunction with signing the Emeryville Lease, the Company paid a cash security deposit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f286dcc7-fd6b-41d3-b505-d3957536c6d6" contextRef="C_bbc0b09b-357b-4c3b-8a22-3402ebee19be" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_c051b37f-87b6-4e38-a5e0-76bce8e06257" contextRef="C_02a77114-3193-40d3-9dbf-c33becbaa06d" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is recorded as a deposit on the Company&#x2019;s consolidated balance sheets as of December 31, 2022 and 2021. The Emeryville Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend this lease for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bf029fc-0804-427b-9fd5-c4114f22f350" contextRef="C_832bf8ab-67e6-443d-94f3-635dca9a9752" name="grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" unitRef="U_RenewalTerm" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bd6ab018-99ee-4ed3-83ef-0782c6221cd0" contextRef="C_3e931d49-353d-46c5-813c-21ac6372c768" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> periods at the then market rental rate. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c379f71f-854d-46ad-8d29-1afede69faac" contextRef="C_3e931d49-353d-46c5-813c-21ac6372c768" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to complete the laboratory and office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a99b536d-196d-4e93-8f6b-9b99278efd85" contextRef="C_bbc0b09b-357b-4c3b-8a22-3402ebee19be" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69af76fe-7e19-4edb-be9d-8dadf64b2b33" contextRef="C_bbc0b09b-357b-4c3b-8a22-3402ebee19be" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million lease liability on the consolidated balance sheet as of December 31, 2022.  The Company recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26194dbd-fd6e-4df3-a2b6-7ccec3b65959" contextRef="C_02a77114-3193-40d3-9dbf-c33becbaa06d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf4ba538-1efd-415e-ba14-5b55f16649b1" contextRef="C_02a77114-3193-40d3-9dbf-c33becbaa06d" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million lease liability on the consolidated balance sheet as of December 31, 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pleasanton Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_280511ef-db2c-4d98-bfa3-6fcfa8e3e942" contextRef="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">42,620</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office, cleanroom, and laboratory support manufacturing space in Pleasanton, California pursuant to a non-cancelable operating lease (the &#x201c;Pleasanton Lease&#x201d;), which the Company entered into in March 2017, with the obligation to pay rent commencing in December 2017. The Pleasanton Lease includes a free rent period, escalating rent payments and a term that expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8ad911d8-e6d0-49e2-8e87-e46c09aa10c8" contextRef="C_51209003-b3a4-472c-aa6b-ed22f18ab53e" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 30, 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company may extend the lease term for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f97a148f-3a62-436a-90c8-97cca7d67c38" contextRef="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at the then market rental rate. The Company obtained an irrevocable letter of credit in March 2017 in the initial amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_819c42d2-41b8-4265-9574-c72276a9e181" contextRef="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as a security deposit to the Pleasanton Lease, which may be drawn down by the landlord in the event the Company fails to fully and faithfully perform its obligations under the Pleasanton lease. The letter of credit may be reduced based on certain levels of cash and cash equivalents the Company holds. In October 2022, the letter of credit was reduced to a balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_914c6ad0-de97-4bbe-b4d9-0483450ea1c8" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a389dcbb-636a-4a21-9718-db1222885e4c" contextRef="C_8f01c328-d8a6-4cb7-a4fa-466c77f2d695" name="grts:AmountOfIrrevocableLettersOfCreditWithdrawn" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ne of the irrevocable letter of credit amount had been drawn. The Pleasanton Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Pleasanton Lease, the Company received a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a82f74b-60b4-482e-ba21-bc5e01b24a37" contextRef="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the landlord for the costs associated with the design, development and construction of tenant improvements. The unamortized tenant improvement balance is recognized as a component of operating lease ROU Assets on the consolidated balance sheets as of December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in May 2019, the Company entered into a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_64427445-d54b-4618-a66b-d81741a7dcec" contextRef="C_ec5c558f-6f66-4786-9d64-c061d097aa83" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> non-cancelable operating lease for additional office space in Pleasanton, California, with an obligation to pay rent commencing in August 2019. In January 2022, the Company amended the lease to add additional leased space and extend the lease expiration date to February 2027.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cambridge Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases laboratory, office and storage space in several facilities in Cambridge, Massachusetts, pursuant to three separate agreements:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s facility located at 40 Erie Street in Cambridge, Massachusetts is leased pursuant to a</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_01e65c59-b318-4dc4-8d8f-4a50cf03586d" contextRef="C_81630994-2393-4f11-bebf-28fe95a0862c" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 67-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> non-cancelable operating lease (the &#x201c;40 Erie Lease&#x201d;), which the Company entered into in February 2016, with an obligation to pay rent commencing in October 2016. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d1145aa-09aa-4730-a555-6461e8a3b8b6" contextRef="C_81630994-2393-4f11-bebf-28fe95a0862c" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to complete the laboratory and office renovation. In September 2021, the Company executed an amendment to the 40 Erie Lease, which extends its term through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_98aac7e3-fd81-4dea-b895-7e9bc451bae9" contextRef="C_ad6f9581-caa1-40a5-b25e-f79138f7937a" name="grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and provides for monthly base rent amounts, subject to annual increases over the term of the lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s facility located at 21 Erie Street in Cambridge, Massachusetts is leased pursuant to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d9a6ee4-72ba-4ba2-9583-d1b4077a020f" contextRef="C_56c649f8-782f-49f7-806b-b288e3c37bfd" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> non-cancelable operating lease (the &#x201c;21 Erie Lease&#x201d;), which the Company entered into in September 2018. The 21 Erie Lease has since been amended five times, as a result of which the lease term extends through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d94ee6e8-7869-44a3-831b-75deb6de6372" contextRef="C_92f316c5-6c3b-4b21-9a34-423815542a35" name="grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company entered into a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_145c168a-b1fc-48d3-b975-bba7f9f02646" contextRef="C_b01748c1-8a6a-4edc-afb0-0081bb1bd20a" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating lease (the &#x201c;Cambridge Storage Lease&#x201d;) for additional office and laboratory storage space in Cambridge, Massachusetts, which commenced on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_20846724-0d37-49d2-b716-e12511647821;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 1, 2021</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company also paid an insignificant cash security deposit. The Cambridge Storage Lease was amended in June 2022 to extend the lease term through June 30, 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In conjunction with the 40 Erie Lease, the 21 Erie Lease and the Cambridge Storage Lease, each as amended (if applicable), the Company has paid certain cash security deposits, which in each case included amounts for the applicable last month&#x2019;s rent and has been classified as part of the operating lease ROU Assets. Of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f204369a-6bf0-45bd-a688-c1e1a5e35266" contextRef="C_0066c1b6-3f4e-430f-9440-978f78dfa308" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million security deposits, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed94068b-9b75-4fed-9a06-d5a9a3e330d1" contextRef="C_87c8c355-193a-4647-ba52-79383b1ab058" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded in prepaids and other assets on the Company&#x2019;s consolidated balance sheet and the remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38d92f21-aad9-4327-9312-574cdbac4efc" contextRef="C_136628c1-6491-4245-8d0f-4e52ec0eb329" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded in deposits and other long-term assets on the Company&#x2019;s consolidated balance sheet as of December 31, 2022. Security deposits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2222a572-4370-466e-b5f9-d815d6384648" contextRef="C_c7091304-4211-4a5d-9df5-4653969e7eae" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are recorded in deposits and other long-term assets on the Company&#x2019;s consolidated balance sheet as of December 31, 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston Lease</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to occupy a newly-built facility in Boston, Massachusetts, with office and laboratory space, in 2023 pursuant to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aa8419e5-f8c6-4789-8a66-f7605a179a77" contextRef="C_0ea98966-ee3e-4c56-b696-2ba4dc84bd5a" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120-month </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating lease (the &#x201c;Boston Lease&#x201d;), which the Company entered into in September 2021. The Boston Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend the Boston Lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3beb7013-1f24-4c74-9891-52069c0937e0" contextRef="C_5c56c0fa-8f94-4d89-a702-a2744c500dc7" name="grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_025fe998-e2fe-41ce-a8b0-649dcae36697" contextRef="C_0ea98966-ee3e-4c56-b696-2ba4dc84bd5a" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> periods at the then market rental rate. The landlord provided the Company with a tenant improvement allowance of up to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de708bd9-301b-454b-880c-807a42d273dc" contextRef="C_6c569a47-3f51-4dbb-bef0-103343842833" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for costs relating to the design, permitting and construction of improvements. The Company&#x2019;s obligation to pay rent is expected to commence in the second half of 2023, subject to free rent periods of three and six months with respect to certain premises. The Company expects to be provided early access to the premises to install fixtures and equipment 60 days prior to the anticipated rent commencement date. The Boston Lease is expected to expire in 2033. The Boston Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses. In connection with the Boston Lease and as a security deposit thereunder, the Company has provided the landlord an irrevocable letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60c8249b-e04b-45c3-aa37-cad8b429406a" contextRef="C_40e18178-0370-4155-b61f-eb36fe61fe35" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is collateralized by a restricted cash deposit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_445ead99-70d9-4bda-acc1-1b7e95411b52" contextRef="C_40e18178-0370-4155-b61f-eb36fe61fe35" name="grts:RestrictedCashDepositUsedAsCollateralForLetterOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and which may be reduced in the fifth and seventh years of the Boston Lease.  As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db465a6e-6c01-4eb9-9fae-0a202c878d92" contextRef="C_40e18178-0370-4155-b61f-eb36fe61fe35" name="grts:AmountOfIrrevocableLettersOfCreditWithdrawn" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ne of the irrevocable letter of credit amount had been drawn.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized a right-of-use asset or lease liability as of December 31, 2022 or 2021 for the Boston Lease as the Company did not control the underlying assets at any time in the periods ended December 31, 2022 or 2021. Under the Boston Lease, the Company is obligated to make minimum lease payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99ece39f-8daa-4a72-aa74-2c8eb3e98d06" contextRef="C_40e18178-0370-4155-b61f-eb36fe61fe35" name="grts:MinimumLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">79.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years from 2023 to 2033, which includes rent abatement during the free rent periods.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s operating leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19dc7c5d-8134-4c11-af11-24dd626440c9" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.468%;"></td>
        <td style="width:1.348%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.029%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.348%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.029%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.348%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.429%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27b8d501-3ac6-4bbc-a859-61d49ab43f85" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0173b8ff-a921-488f-a1ba-d5548d952ccc" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58c7b445-5d9d-450d-96f7-6cc46c740431" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6828445-fd37-431e-84ca-070821b0ab70" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_441fb108-c6f1-48ea-9841-25b107fecf1e" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13eade54-78c5-44be-86f9-bd58d0009c23" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69485888-04d7-41e0-a058-4430732172d6" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35757943-0504-44a4-9808-fc5a25b79456" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4e31eb7-f2d7-4fc6-89c5-12ddc8df7d45" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,518</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a722d6ec-4c11-4029-9eef-350ae7d0bca7" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental information related to leases was as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.61%;"></td>
        <td style="width:1.327%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.473%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.327%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.473%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.327%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.464%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abca80a0-1b87-4b36-803f-3200133ecb79" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,915</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b48e4e39-74c6-405d-bd72-5e2b2e7203c9" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad0a687a-99e3-415e-bf77-0e2339bc49f3" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New right-of-use assets obtained in exchange for lease obligations (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e60238e8-582c-404d-8604-6e29ba7ce7ee" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,959</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d94605b6-755c-4357-81c3-342b072c3013" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,562</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ec3ee2c-3a9e-45f1-92e7-27749b8f06f6" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f416662-fce4-4501-9e4a-4700150d65ba" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.10</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_68d616e9-5337-476e-b374-01e05a92d815" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.30</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_316c0d22-d89d-4d73-a170-a085c4ac381d" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.10</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fae12637-10a9-4bf2-a88c-c589b487feae" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5aea42ac-738e-4c6f-8337-2a9c5befd5d0" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8df64a83-7a3e-4db5-8f8f-1163a9a83b80" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_42930258-7571-4ac4-9de7-ed11e5c9ed5e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, minimum annual payments under the Company&#x2019;s lease agreements are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.882%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.038999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Financing<br />Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_231c98a1-8997-49cc-b2c0-799c450481e5" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,604</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a74ebbad-8bce-4339-8c0e-6aec22d57891" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,527</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5730fecc-59a0-4b68-9635-13e16f892ece" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89a70fda-a511-4d54-a96e-d489a853e527" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,376</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27d585f6-aaaa-4452-b5d0-3aff608cb24f" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6bd3757-7e71-4f7e-96b1-1d097820bb71" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89f9d167-c2cc-46ec-b17a-a7f9cc4fbe75" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104,979</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c66a4b22-867f-468a-85d8-823c2539ccbe" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing lease payments under Boston lease</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fcf4a28-55bb-4921-9656-995c80f2355e" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:OperatingLeasePaymentUnderTheBostonLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44bbd510-a708-40dc-8627-20d182bd21d6" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,967</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Current portion of lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c330d70-fbbd-407a-a126-400887f03f69" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,294</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b555ae9-74d0-43b0-9be9-d79f778080fc" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,673</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Guarantees and Indemnifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, with respect to which the officer or director is or was serving at the Company&#x2019;s request in such capacity. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#x2019;s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2fb939d2-bbab-49df-a77a-02b230b59c0b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.	Collaboration and License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2seventy bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2018, the Company entered into a Research Collaboration and License Agreement with bluebird bio, Inc. (&#x201c;bluebird&#x201d;). In November 2021, bluebird assigned the Research Collaboration and License Agreement (the &#x201c;2seventy Agreement&#x201d;), to its affiliate, 2seventy bio, Inc. (&#x201c;2seventy&#x201d;), in connection with an internal restructuring and subsequent spin-out of 2seventy.  Under the terms of the 2seventy Agreement, the Company provides to 2seventy tumor-specific targets across several tumor types and, in certain cases, T cell receptors (TCR) directed to those targets. The Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3010ec3b-02bb-4d6e-bad9-16c05c63ba12" contextRef="C_15303075-6c82-43e3-95ac-810ce94f5ad4" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and 2seventy also concurrently acquired </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f4d95ac-1645-404a-ba67-ed26c8cf0f62" contextRef="C_c28c4bd4-e62b-479b-85c0-f06e18613cb3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">768,115</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s Series C convertible preferred stock for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ab2eb3a-e243-4520-9f67-9e9f51f448a7" contextRef="C_ddb48a50-1ece-46f1-83ca-c31f25910907" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d477cde-47bd-4a59-aed9-d3457ca09971" contextRef="C_c28c4bd4-e62b-479b-85c0-f06e18613cb3" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.04</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">share. Per the 2seventy Agreement, 2seventy was also provided an option to acquire shares of the Company&#x2019;s common stock at the same price</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all other investors in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;). In October 2018, 2seventy purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8d446cd-1849-492b-aaec-3282f7b40282" contextRef="C_d761c15a-dc3b-4830-bc90-d5f6864753cb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">666,667</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock at the price to the public of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcb5fc5f-676e-425b-b701-f844a10cfb50" contextRef="C_2a86422f-3ae7-47a7-bad8-cd08d7056b6c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">15.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8aa5a1f3-3e6b-4625-bd01-9ba6acb8fe11" contextRef="C_d761c15a-dc3b-4830-bc90-d5f6864753cb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Under the terms of the 2seventy Agreement, the Company is eligible to earn development, regulatory, and sales-based milestones in an amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35a268c1-7c07-4bdd-bf3b-bd47466fadff" contextRef="C_990fb369-8f8b-4b5a-aae9-a7fc6e20db39" name="grts:MaximumPotentialMilestoneReceivable" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion, and single-digit royalties on sales of products that utilize the technology subject to the 2seventy Agreement. None of these events had occurred as of December 31, 2022, and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2019, the Company entered into a First Amendment to the 2seventy Agreement, which extended the timeline for the Company and 2seventy to execute a Patient Selection Services Agreement from within one year to within two years after the Effective Date of the 2seventy Agreement. In August 2020, the Company entered into a Second Amendment, which extended the timeline of the Patient Selection Services Agreement to within three years and also extended the Tissue Analysis Period from February 28, 2021 to June 30, 2021. In April 2021, the Company entered into a Third Amendment, which removed the Patient Selection Services Agreement in its entirety and extended the Tissue Analysis Period from June 30, 2021 to December 31, 2021. The amendments were entered into for administrative purposes, and the Company determined the amendments were not a modification of contract under the contract with customers guidance.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2seventy may terminate the 2seventy Agreement by giving a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b53ed89e-e87a-4764-b86f-4fae9efdb839" contextRef="C_b942a7f0-83f7-4782-aba4-13c3f1ec3206" name="grts:CollaborationAgreementEarlyTerminationNoticePeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the last payment owed by the Company on a licensed product. The 2seventy Agreement may be terminated for cause by either party based on an uncured material breach by the other party or bankruptcy of the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to 2seventy under the licensed intellectual property will remain in effect in accordance with their respective terms. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a27f1836-3fd9-4471-903a-1a8ccb8dfb3c" contextRef="C_b942a7f0-83f7-4782-aba4-13c3f1ec3206" name="grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, all of 2seventy&#x2019;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.</span></ix:nonNumeric></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that 2seventy is a customer, and the contract is not subject to guidance on collaborative arrangements. This is because the Company granted 2seventy a license to the Company&#x2019;s intellectual property and provided research and development services, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identified the following three material promises under the 2seventy Agreement: (i) transfer of a license to intellectual property and related technology know-how (&#x201c;License and Know-How&#x201d;); (ii) the obligation to perform target selection and TCR generation services (&#x201c;Research and Development Services&#x201d;); and (iii) participation on the Joint Steering Committee (the &#x201c;JSC&#x201d;). The Company provided to 2seventy standard indemnification and protection of licensed intellectual property, which is part of assurance that the license meets the contract&#x2019;s specifications and is not an obligation to provide goods or services.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considered that the License and Know-How has standalone functionality, was considered to be functional intellectual property, and is capable of being distinct. However, the Company determined that the License and Know-How is not distinct from the Research and Development Services or participation on the JSC within the context of the 2seventy Agreement, because 2seventy is dependent on the Company to execute the Research and Development Services and participate on the JSC in order for 2seventy to benefit from the License and Know-How. As such, the License and Know-How is combined with the Research and Development Services and participation on the JSC into a single performance obligation, and the transaction price under this arrangement will be allocated to this single performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has also determined that all other goods or services that are contingent upon 2seventy reaching various milestones are not considered performance obligations at the inception of the arrangement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price at the inception of the 2seventy Agreement consisted of the upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83ea3444-17a5-40cb-9227-cbafa28ff2f0" contextRef="C_a63c1a07-67c9-44ee-9005-5e3efd76ad19" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f99587ec-11ca-4f41-a7bf-de090e143045" contextRef="C_3030c951-2716-4654-8056-6101e373ddea" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million received from 2seventy for the purchase of the Company&#x2019;s Series C convertible preferred stock. The sale of the Series C convertible preferred stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3f31213-5c35-4605-8f67-f6d1bff7d408" contextRef="C_e9a61784-ec1b-4689-88b4-604b0656e5e0" name="grts:IssuanceOfConvertiblePreferredStockTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the transaction price was allocated to the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02bee6bf-3a99-4e69-969e-6cd0a58f66ee" contextRef="C_0ebc7f82-ba9a-4b25-83ff-fc9b906d1b18" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">768,115</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series C convertible preferred stock at fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_119defe2-234b-41ca-ad40-117da321fc95" contextRef="C_0ebc7f82-ba9a-4b25-83ff-fc9b906d1b18" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.04</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and recorded in stockholders&#x2019; equity.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The variable consideration related to the remaining development, regulatory, and sales-based milestones payments has not been included in the initial transaction price and continues to be fully constrained as of December 31, 2021. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon initiation of clinical trials for early-stage targets and 2seventy&#x2019;s development efforts. Any variable consideration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the License and Know-How granted to 2seventy. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> For revenue recognition purposes, the Company determined that the duration of the 2seventy Agreement began on the effective date in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f90189bf-e54e-44aa-87cd-bceb20bdcb40" contextRef="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92" name="grts:RevenueRecognitionContractStartMonthYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ends upon completion of the Research and Development Services, which is also when the participation on the JSC is no longer an obligation. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. The Company also analyzed the impact of 2seventy terminating the agreement prior to August 2023 and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to 2seventy for doing so.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when, or as, the Company satisfies its performance obligation by transferring the promised services to 2seventy. Revenue is being recognized over time using a cost-based input method, based on internal labor cost effort to perform the research services, since the internal labor cost incurred over time is thought to best reflect the transfer of services to 2seventy. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022, 2021, and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c077e7e7-aebf-4ae8-8588-bdc8083234df" contextRef="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94b3408b-99c9-45e7-a341-51f1e32c1ac4" contextRef="C_8ed7ca7f-61f0-4950-bc7b-887b37ebb035" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_620ee022-460d-49e8-bda4-82c4140d5615" contextRef="C_39d2c6fe-95e1-4040-9805-ff9f54fdd2c2" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in collaboration revenue under the 2seventy Agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amount of collaboration revenue recognized during the year ended December 31, 2022 included cumulative catch-up adjustments increasing collaboration revenue by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9ab6c9a-916b-45b1-9635-127e3a84d333" contextRef="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million due to revisions to estimated costs to complete the remaining performance obligation. The adjustments resulted in a decrease in the Company&#x2019;s loss from operations of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9824c88-ce8e-4091-b601-eeeb3c482b1e" contextRef="C_3a8b90fa-09bc-4b1c-8721-e05897f1cb0f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">6.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a decrease in loss per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b82adc5a-a249-4b19-ad98-9e63f02c171b" contextRef="C_3a8b90fa-09bc-4b1c-8721-e05897f1cb0f" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.07</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2022. Deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8869f1e2-e5ee-492c-9cff-e6c1a68ea457" contextRef="C_5b56ae1b-3299-420b-a990-12c09f3a38a3" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the consolidated balance sheet in current liabilities as of December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8f45c22-a28c-49d2-9085-a4eeb27a34ff" contextRef="C_3b607420-6945-419e-9f68-f1999ec6386b" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the consolidated balance sheets in both current and long-term liabilities as of December 31, 2021, respectively. Deferred revenue relates to the performance obligations identified under the 2seventy Agreement and will be recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3d5ab0df-98d5-49f9-a78e-c826bd182fba" contextRef="C_3a8b90fa-09bc-4b1c-8721-e05897f1cb0f" name="grts:RevenueRecognitionContractEndMonthYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_63ef284c-33d5-461e-8de2-dbe0641cd8e4" contextRef="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the deferred revenue balance during the year ended December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.929%;"></td>
        <td style="width:1.757%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.558%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.757%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42249320-42dd-4f55-9bd9-3c1cee1b2dd3" contextRef="C_aadfb6b4-e055-4e7e-82da-133de3937dc4" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,725</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f516ce0-18af-4012-bc54-8ad0a839fefd" contextRef="C_0ee0de6e-7969-4192-9194-1f65fcc5fe25" name="grts:ContractWithCustomerLiabilityAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98cc09b6-d8a5-43c4-ad7d-47aaad34d5c7" contextRef="C_0ee0de6e-7969-4192-9194-1f65fcc5fe25" name="grts:ContractWithCustomerLiabilityDeductions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5da10bc1-0630-421a-ac43-737a5021db31" contextRef="C_accde2f9-2b45-4db3-a169-1f19cc7d3a10" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01b99b5f-ddae-47cc-a220-7c1598c57d37" contextRef="C_3b607420-6945-419e-9f68-f1999ec6386b" name="grts:ReceivablesGross" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c3b65ecb-e8bc-4c25-bebc-7910591ec08e" contextRef="C_5b56ae1b-3299-420b-a990-12c09f3a38a3" name="grts:ReceivablesGross" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receivables or net contract assets recorded as of December 31, 2022 or 2021 associated with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2seventy Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gilead Sciences, Inc.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, the Company entered into a Collaboration, Option and License Agreement (the &#x201c;Gilead Collaboration Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;) to research and develop a vaccine-based immunotherapy as part of Gilead&#x2019;s efforts to find a curative treatment for HIV infection. Under the terms of the Gilead Collaboration Agreement, the Company granted to Gilead an exclusive, worldwide license to develop and commercialize a HIV-specific therapeutic vaccine utilizing the Company&#x2019;s technology. Gilead is responsible for conducting all development and commercialization activities beginning with a Phase 1 study, and the Company is responsible for contributing to preclinical research studies and participation in a joint steering committee (collectively, &#x201c;research and development activities&#x201d;). Concurrently with the execution of the Gilead Collaboration Agreement, the Company and Gilead entered into a Supply Agreement (the &#x201c;Gilead Supply Agreement&#x201d;) under which the Company will supply research product and GMP product (&#x201c;Product Supply&#x201d;) that may be required under the Gilead Collaboration Agreement until Gilead completes its first GMP product batch, and the Company will participate in a joint manufacturing team (collectively, &#x201c;product supply activities&#x201d;). In addition, the Company also concurrently entered into a Stock Purchase Agreement (the &#x201c;Gilead Stock Purchase Agreement&#x201d;) under which Gilead acquired, in a private placement transaction, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dffbee3a-0b99-4e76-8b67-ff92316a6352" contextRef="C_0f8f5e42-0701-4a64-ab34-634cae0498b7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,169,591</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the Company&#x2019;s common stock. The common shares were issued to Gilead with</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">certain </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">registration rights and certain standstill and market stand-off provisions. The Company determined that these concurrent contracts represent a combined arrangement (the &#x201c;Gilead Arrangement&#x201d;).</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Gilead Collaboration Agreement, the Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f9d5e66-9a5a-4012-af4d-e9244266b9e1" contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Under the Gilead Collaboration Agreement and the Gilead Supply Agreement, the Company will receive additional reimbursement payments for expenses incurred in the research and development activities and product supply activities. Under the Gilead Stock Purchase Agreement, the common shares were sold at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61b6d32a-96a0-470d-8bd5-b9f78e714dc1" contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">25.65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0392d04-0ff6-49b2-82d8-6bbb4430aacf" contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s common stock at fair value on closing was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b6069b7-444f-4419-887f-2ddec7a87cf1" contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6" name="grts:CommonStockFairValueClosingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">18.10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If Gilead decides to move forward with development beyond the initial Phase 1 study (the &#x201c;Option&#x201d;), the Company will receive a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53f4f64b-c2f3-4efd-8d3f-19233f7f06e1" contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6" name="grts:NonRefundableOptionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million non-refundable option fee and will be eligible to receive up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10147c39-042e-4414-9979-21a18f874fc0" contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6" name="grts:MaximumAggregateContingentMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">685.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million if certain clinical, regulatory and commercial milestones are achieved, as well as tiered royalties ranging from the mid-single digits to low double-digits on net sales of a therapeutic product utilizing its technology. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None of these events had occurred as of December 31, 2022 and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gilead </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may terminate the Gilead Collaboration Agreement for convenience by giving a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c29a6e50-c3f0-48e6-9723-41c43bd4ff4c" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="grts:CollaborationAgreementEarlyTerminationNoticePeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the expiration of the royalty term, or, if the Option is not exercised, by the end of the Option term. The Gilead Collaboration Agreement may be terminated for cause by either party based on an uncured material breach by the other party, insolvency of the other party, or patent challenge. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to Gilead under the licensed intellectual property will remain in effect in accordance with their respective terms. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5544d541-dcd7-4589-810b-539e61935999" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#x2019;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#x2019;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Furthermore, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc4f73d3-1096-4e55-a44c-e2bbcdb13ebe" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="grts:CollaborationAgreementTerminationTerm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and may terminate any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.</span></ix:nonNumeric></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services and Product Supply, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration. The Option, if exercised by Gilead, will be considered a modification that increases the scope of the arrangement beyond the Option term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identified the following performance obligations under the Gilead Collaboration Agreement: (i) licenses including an exclusive (in the HIV field), royalty-free, worldwide collaboration license and transfer of know-how and an exclusive (in the HIV field) worldwide, royalty-bearing development and commercialization license subject to restrictions on its use during the Option term and an exclusive option to release such restrictions; (ii) preclinical research and development activities, manufacturing-related activities, and participation on a Joint Steering Committee; and (iii) product supply, including research and GMP product, until Gilead completes its first GMP batch, and participation on a Joint Manufacturing Team.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considered that the licenses and know-how have standalone functionality, are considered to be functional intellectual property and are capable of being distinct. The Company also determined that the research and development activities and product supply by Gritstone could be provided by resources otherwise available to Gilead and thus are capable of being distinct.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has also determined that the pricing for optional goods and services and release of license restrictions upon exercise of the Option do not constitute material rights and are not a potential performance obligation. The Company evaluated whether there is an interdependence between the promises and determined that the licenses are a combined solution and the predominant performance obligation, while the other promises are separately identifiable in the context of the contract; however, the research and development activities are dependent on the research product supply, which is accounted for as a combined performance obligation. As a result, the Company identified three performance obligations in the Gilead Arrangement: (i) exclusive licenses and know-how, (ii) research and development activities and product supply, and (iii) GMP product supply.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price at the inception of the Gilead Collaboration Agreement consisted of the upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_888c6319-4d30-4c31-aa67-1a54a4305b8a" contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1bb41b4-70c9-471a-b9c0-25e2003f80c8" contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million received for the sale of the Company&#x2019;s common stock. The sale of the common stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e8f960d-76a6-424d-813b-17fb52095d6e" contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30" name="grts:TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the transaction price was allocated to the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea028b62-9ccd-48e7-bcdc-161ef4999d08" contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,169,591</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares of the Company&#x2019;s common stock at fair value on closing of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_901299e0-080e-4bc2-954e-4a3331563433" contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6" name="grts:CommonStockFairValueClosingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">18.10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and recorded in stockholders&#x2019; equity. The remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b6f293a-554a-46d0-b722-7c5c662dc12f" contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30" name="grts:CommonStockPurchasePriceInExcessOfFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the common stock purchase price in excess of the fair value of the shares received is added to the transaction price for the Gilead Collaboration Agreement. In addition, the initial transaction price includes estimated variable consideration for budgeted reimbursement of research and development costs and product supply. The variable consideration related to reimbursable costs and product supply has been constrained as of December 31, 2022 based on the current research and development plan forecast. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the variable consideration for the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b31ff98c-9037-4005-823a-cc35a878acf2" contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6" name="grts:NonRefundableOptionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee and for the development, regulatory, and sales-based milestones payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&#x2019;s control. As a result, these payments were fully constrained and were not included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the exclusive licenses and know-how granted to Gilead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is allocated to the performance obligation based upon relative standalone selling prices, which were determined for the exclusive licenses and know-how using an adjusted market approach and for the research and development activities and product supply using a cost plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_95dae77a-80dc-4a5e-9a4b-d0b7ddb9c11a" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="grts:RevenueRecognitionContractStartMonthYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ends upon (i) the completion of the Option term, which is expected to end </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9eba06f0-bedf-4ded-9f71-17671e82aef7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c078262-064d-4055-afb9-e22d6f677eeb" contextRef="C_201d8d2c-c046-4388-b915-a88be0e7cc5c" name="grts:RevenueRecognitionContractEndPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after the effective date, if the Option is not exercised or (ii) the expiration of the royalty-term on a product-by-product and country-by-country basis. The Company also analyzed the impact of Gilead terminating the agreement prior to the end of the Option term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Gilead for doing so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue for the exclusive licenses and know-how was recognized on the effective date of the Gilead Collaboration Agreement at the point in time that the licenses are effective. The research and development activities and product combined performance obligation and the GMP product supply performance obligation are recognized over time when, or as, the Company transfers the promised goods and services to Gilead. Research and development service and product supply revenues will be recognized over time using a cost-based input method, based on internal and external labor cost effort to perform the services, costs to acquire research materials, and costs of product supply, since the costs incurred over time are thought to best reflect the transfer of goods and services to Gilead. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to estimated total costs to fulfill each performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation and associated variable consideration will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, the Company did not record any license revenue. For the year ended December 31, 2022, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b95c187f-7f20-4b73-86a0-646e79a43fac" contextRef="C_6d8263f0-f625-4009-a8d1-d1d4686fc533" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as collaboration revenue as a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. For the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83963372-3b78-4bf7-8f06-73530e8493be" contextRef="C_89e4b4f1-1e78-4fc1-8102-81aecb3af80a" name="grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">38.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as license revenue, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fb8512d-038f-4636-a8ea-3fa2609443bc" contextRef="C_760e896a-f89d-4fe2-ac56-70d954e97475" name="grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as collaboration revenue as a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. There was no contract asset recorded on the consolidated balance sheet as of December 31, 2022. A contract asset of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a707074d-379b-4ec6-ae43-31e9220fcd79" contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 for supply costs that were incurred during the year ended December 31, 2021, but not billable until future periods when the asset is released. The contract asset relates to the performance obligations yet to be satisfied under the Gilead Collaboration Agreement. There was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_079e4a26-229d-4187-8a4b-5d9ca7ecad18" contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million recorded as deferred revenue as of December 31, 2022 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ca2caf4-2629-43ce-9329-db7adbdb1759" contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> deferred revenue as of December 31, 2021 associated with the Gilead Collaboration Agreement.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96cb8832-6afd-4d2a-aa5d-b23bb63535aa" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the contract asset and short-term deferred revenue, balance during the year ended December 31, 2022 for the Gilead Collaboration Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.079%;"></td>
        <td style="width:1.496%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.963999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.496%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.963999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract Asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edac25f7-f5a0-44a6-b7b3-8f895e7fc835" contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_671f64c9-df8e-4e75-8110-0d2a1ab5b21a" contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_771c4dfe-1011-4bcc-84c4-253dbe4519a2" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="grts:ContractWithCustomerAssetAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57144ae1-8585-432c-afbc-d79b51afecc0" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="grts:ContractWithCustomerLiabilityAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c920113f-25a4-4ed3-9521-c9cebdacf507" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="grts:ContractWithCustomerAssetDeduction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,508</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f23a2b3f-ce7d-46ff-a313-ff357bbb564a" contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e" name="grts:ContractWithCustomerLiabilityDeductions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8eda3e37-1c24-4241-bc72-e361bb1bb4b1" contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23c95bd9-61f1-41a8-8726-4c0854ec5998" contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">107</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5183a1c-f616-4892-84d5-cfab2e8c0b09" contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79" name="grts:ReceivablesGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4456f105-f8df-451a-b7a7-63ae380d32b3" contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d" name="grts:ReceivablesGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of receivables recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company deferred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_426982f5-cdde-412d-aff3-6a41dd5db0e9" contextRef="C_04956885-3d5b-41a6-b35d-28c61c1b73fc" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in incremental costs to acquire the Gilead Collaboration Agreement in the first quarter of 2021 allocated to performance obligations recognized over time, which will be recognized over time in each period proportionate to revenue recognition. As of December 31, 2022, deferred contract acquisition costs were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8e06698-8e7e-478f-9418-a9ffee35705b" contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Deferred contract acquisition costs amortized during the year ended December 31, 2022 and 2021 were negligible.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Arbutus Biopharma Corporation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2017, the Company entered into an Exclusive License Agreement with Arbutus and its wholly-owned subsidiary, Protiva Biotherapeutics Inc. Certain terms of the agreement were modified by amendment in July 2018. Under the license agreement, the Company has an exclusive license to utilize certain Arbutus intellectual property, including patents and know-how relating to immunotherapy. During the years ended December 31, 2022, 2021 and 2020, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1870759-58e1-4328-a32f-960ebe7dd0f8" contextRef="C_91453aed-a1da-44b5-bdcd-23b2fbed997d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8974ee16-01d0-404e-8cb9-a4570959837b" contextRef="C_eea11142-e7ca-4a35-9c72-576024096190" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_aaf07a05-0392-4835-a5e0-3e25d8b61dda" contextRef="C_f98f071e-224d-4373-a5ef-1f968dd60d8e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> research and development expense under the agreement. The Company is obligated to pay Arbutus certain milestone payments up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53ead0af-8fbf-43cc-98fc-dbace69909c0" contextRef="C_b32eb355-55f1-4a0d-a16e-f7a33883834a" name="grts:MaximumMilestoneConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">123.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on achievement of specified events, and royalties on sales of its licensed products. Following the acceptance of our investigational new drug application for GRANITE by the FDA, the Company made a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a4ffe5e-c5ee-4d9d-969d-e3d063c01449" contextRef="C_3dbebb0a-177e-4cad-98af-5c26d1198e0a" name="grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million development milestone payment to Arbutus in September 2018 that was recorded as research and development expense. In August 2019, a milestone was met following the initial patient treatment of SLATE in the Company&#x2019;s GO-005 clinical trial. In 2019, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47c9db4c-6fd7-4f50-8e83-aefa35eb2e0a" contextRef="C_e515ffd5-9be4-4d3e-800d-0e4d6f432f77" name="grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as research and development expense in connection with the milestone. None of the other events had occurred as of December 31, 2022, and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Profit Hospital Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2016, the Company entered into an Exclusive License Agreement with a non-profit hospital cancer center. Under the license agreement, the Company has an exclusive license to utilize certain patents and know-how relating to immunotherapy for an insignificant upfront payment, cash milestone payments on achievement of specified events, and a low single digit royalty on sales of licensed products. The achievement of the milestones and payment of royalties is dependent upon obtaining regulatory approval. Upon achievement of a milestone related to the Company&#x2019;s Phase 1 clinical trial for GRANITE, GO-004, in December 2018 the Company recorded an insignificant amount to research and development expense for amounts owed to the Hospital Cancer Center, which was paid to the hospital in February 2019. None of the other milestone events had occurred as of December 31, 2022, and no royalties were due from the sales of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Genevant Sciences GmbH</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company entered into an Option and License and Development Agreement (the &#x201c;2020 Genevant License Agreement&#x201d;) with Genevant Sciences GmbH (&#x201c;Genevant&#x201d;), pursuant to which Genevant granted the Company exclusive license rights under certain intellectual property related to Genevant&#x2019;s LNP technology for a single therapeutic indication, and the Company agreed to pay Genevant an initial payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93a71fcb-9300-4f74-9206-1f0b7ae3cdbb" contextRef="C_ce9087bc-c51a-4a95-a2a5-acee855847b5" name="grts:AgreedUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b025125-d7c8-4cb1-a9d3-17617a9b730c" contextRef="C_9e8470b2-dcb6-48e3-b5e1-9aa9a258b518" name="grts:AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">71.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7489051a-62cd-439e-a77b-232d7e7d3402" contextRef="C_f2705b27-ed81-4a40-b53a-b869c0db0739" name="grts:AgreedUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was included in research and development expense for the year ended December 31, 2020. Genevant is a spin-off of Arbutus, and the 2020 Genevant License Agreement expands Gritstone&#x2019;s intellectual property rights to such LNP technology originally obtained pursuant to the Company&#x2019;s license agreement with Arbutus. Prior to the 2020 Genevant License Agreement, the Company licensed Arbutus&#x2019; LNP technology for indications in the oncology space. The remainder of Arbutus&#x2019; IP portfolio was transferred to Genevant in the spin-off. In</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, a milestone in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_371578ec-4521-4ffc-97c9-2b9a153c7f4f" contextRef="C_3c9e7f0e-5e08-4bcf-99d9-2caf8d424011" name="grts:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was met, which was included in research and development expense for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the 2020 Genevant License Agreement, Genevant also granted the Company certain options to license the LNP technology for additional therapeutic indications of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28045c12-f5a4-40e3-b2f5-0021d1455de3" contextRef="C_95be0954-d2b5-4a76-b208-0a3189bace59" name="grts:PaymentsForOptionsToLicenseForEachIndication" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each indication and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eefc425-ed92-4824-9bbe-c7eecd82e6a8" contextRef="C_ce9087bc-c51a-4a95-a2a5-acee855847b5" name="grts:AmountToExtendOptionTerm" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to extend the option term. The 2020 Genevant License Agreement continues in effect until the last to expire royalty term or early termination. It is terminable by the Company for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either party may terminate the agreement for material breach, subject to a cure period, and Genevant may terminate the agreement if the Company challenges a licensed patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, the Company entered into a Non-Exclusive License and Development Agreement (the &#x201c;2021 Genevant License Agreement&#x201d;) with Genevant. Pursuant to the 2021 Genevant License Agreement, the Company obtained a nonexclusive license to Genevant&#x2019;s LNP technology to develop and commercialize self-amplifying RNA (&#x201c;samRNA&#x201d;) vaccines against SARS-CoV-2, the virus that causes COVID-19. Under the 2021 Genevant License Agreement, the Company made a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e98d347c-8cc8-49ee-b92e-442c93c00906" contextRef="C_72010145-f061-45d3-99d8-7968eba114aa" name="grts:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront payment to Genevant, and Genevant is eligible to receive from the Company up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8196ce71-e075-450e-992c-e4cb7eb40d9c" contextRef="C_d48b34dc-8de5-4f5a-8b9a-cf67c0c1b3bb" name="grts:MaximumAggregateContingentMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">141.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in contingent milestone payments per product, plus certain tiered royalties, upon achievement of development and commercial milestones. In certain scenarios, in lieu of milestones and royalties, Genevant will be entitled to a percentage of amounts that the Company receives from sublicenses under the 2021 Genevant License Agreement, subject to certain conditions. In March 2021, a milestone in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a26a4bc9-dc3b-46ab-a4e9-4dffbc580f4c" contextRef="C_c7666188-96ff-45eb-8de2-48af6a561ae7" name="grts:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was met following the initial patient treatment in the Phase 1 clinical trial conducted through the NIAID-supported Infectious Diseases Clinical Research Consortium (&#x201c;IDCRC&#x201d;). Both the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1316dfe9-6be7-44f2-b9b5-026d5501c267" contextRef="C_e8e7ad16-a257-4feb-83b3-d36674cafe9d" name="grts:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd7caa86-538e-4454-a791-8899608691d4" contextRef="C_e8e7ad16-a257-4feb-83b3-d36674cafe9d" name="grts:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million milestone payments were recorded as research and development expense for the year ended December 31, 2021. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a30b0c2-d422-4aa4-8697-5ee720f97761" contextRef="C_a50f3891-bc8d-430f-8444-964f174a3e3b" name="grts:MilestonePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ne of the other milestone events had occurred as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coalition for Epidemic Preparedness Innovations</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 14, 2021, the Company entered into the CEPI Funding Agreement with CEPI, under which CEPI agreed to provide funding of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3689da56-9edb-4c7b-83a0-95384623260d" contextRef="C_55acf221-1e8f-4997-82b2-c1790c656f7f" name="grts:TotalGrantAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Company to advance the Company&#x2019;s CORAL program, a second-generation COVID-19 vaccine program, with an initial clinical trial in South Africa. Under the terms of the agreement, CEPI is funding a multi-arm Phase 1 study evaluating the CORAL program&#x2019;s samRNA vaccine in na&#xef;ve, convalescent, and HIV+ patients. The study is evaluating three different samRNA vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses. The funding is also supporting pre-clinical studies, scale-up and formulation development to enable manufacturing of large quantities of stable vaccine product.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the CEPI Funding Agreement, among other things, the Company and CEPI agreed on the importance of global equitable access to the vaccine produced pursuant to the CEPI Funding Agreement. The vaccine, if approved, is expected to be made available to the COVAX Facility for procurement and allocation. The COVAX Facility aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope and continuation of the CEPI Funding Agreement may be amended depending on ongoing developments of the COVID-19 outbreak and the success of the Company&#x2019;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement relative to other third-party COVID-19 vaccine candidates or treatments. If the World Health Organization (&#x201c;WHO&#x201d;), CEPI or a regulatory authority having jurisdiction over a clinical trial performed under the CEPI Funding Agreement determines that a third-party product candidate has substantially greater potential than the Company&#x2019;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement and should be prioritized instead for a particular trial, the Company must consider in good faith any written request of CEPI not to proceed with a clinical trial of such COVID-19 vaccine candidate; however the determination of whether or not to proceed with such trial shall be made by the Company in its sole discretion. In addition, CEPI has the right to unilaterally terminate the CEPI Funding Agreement upon prior written notice if CEPI determines that (i) there are material safety, regulatory, scientific misconduct or ethical issues with the project undertaken by the Company under the CEPI Funding Agreement, (ii) the project undertaken by the Company under the CEPI Funding Agreement should be terminated, (iii) the Company becomes unable to discharge its obligations under the CEPI Funding Agreement, (iv) the Company fails to meet certain criteria set forth in the CEPI Funding Agreement, or (v) the Company commits fraud or a financial irregularity, as such terms are defined in the CEPI Funding Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the Company and CEPI entered into an amendment to the CEPI Funding Agreement, under which CEPI agreed to provide additional funding up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23865b23-7932-43ae-bd7b-52af6c0afaf1" contextRef="C_f06b8a24-0a03-4e60-8fd7-ff440ef473d0" name="grts:AdditionalFunding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, for a total of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b2ccbb6-0948-485b-804f-9dda66111ed7" contextRef="C_f06b8a24-0a03-4e60-8fd7-ff440ef473d0" name="grts:AmendedTotalGrantAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, to the Company to conduct a Phase I clinical trial of the Company&#x2019;s Omicron vaccine candidate in South Africa.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CEPI advances grant funds upon request by the Company consistent with the agreed upon amounts and schedules as provided in the CEPI Funding Agreement. The first tranche of funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5218107-6c5d-4c63-bfe4-cad1eaf8d3b9" contextRef="C_ff4ba982-5223-4146-948e-578e4a49e800" name="grts:FirstTrancheOfFundingsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received in September 2021, and the second tranche of funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e22e674-6aa1-4e54-bf93-3c78c45780a8" contextRef="C_beafcda9-72de-465a-8212-61152dcebbdd" name="grts:SecondTrancheOfFundingReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received in April 2022.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the agreement are incurred. During the year ended December 31, 2022, the Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d77c79a-4a46-44be-8c74-74e42475a64c" contextRef="C_8e40ec53-a7a5-40bf-91a9-94f9b7f15952" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under the CEPI Funding Agreement. During the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d1a066a-47ec-4fa3-a2eb-e611793cbd24" contextRef="C_f06b8a24-0a03-4e60-8fd7-ff440ef473d0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in grant revenue under the CEPI Funding Agreement. As of December 31, 2022 and 2021, short term deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da1813df-d73a-4e3a-bcf0-0981c8991703" contextRef="C_80849ef4-0531-4940-958b-b3800e6ec694" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2899f340-e36b-4f88-81f1-53e59a000aa3" contextRef="C_e95014f8-6dc9-41f7-ad01-70179a6bc0a8" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, recorded on the consolidated balance sheets. Deferred revenue will be recognized over the period in which the CEPI Funding Agreement activities related to the first and second tranches of funding are expected to take place, which is currently estimated to be through the year ended 2023. As of December 31, 2022 and 2021, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e57b319-8948-4a7a-bcc1-8e431b96540d" contextRef="C_7252815e-38c6-46dc-8937-24c805d8b308" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_912ede7f-5149-4037-b55e-5a9dece157a6" contextRef="C_082d0a7a-97c2-4602-9ad8-c0587fc21667" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, was recorded as short-term restricted cash on the consolidated balance sheet.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_73edb1ee-802d-4872-8e88-11fb176e1e44" contextRef="C_969fab0c-3062-4255-b015-879022cee5f9" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the CEPI Funding Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"></td>
        <td style="width:1.794%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.881%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0107d35-a45d-42fe-a6b5-4830283c56b6" contextRef="C_b9cf46df-3e9b-42ee-b59e-eb74338bcf32" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac05c509-c012-4b64-a11e-ddd8664e35bd" contextRef="C_0a69806e-b629-40b1-a18d-6ca603eb73b8" name="grts:ContractWithCustomerLiabilityAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42d88bef-d317-47a3-9849-51746241283f" contextRef="C_0a69806e-b629-40b1-a18d-6ca603eb73b8" name="grts:ContractWithCustomerLiabilityDeductions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bff04b26-3804-4db8-8db8-a63cdf6c929c" contextRef="C_0eca9dc8-8c2d-4467-b653-fbcf9a107933" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,952</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gates</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company entered into a Grant Agreement with the Gates Foundation (the &#x201c;Gates Grant Agreement&#x201d;), which provides funding for the Company&#x2019;s development of an optimal immunogen in the context of a therapeutic human papillomavirus (&#x201c;HPV&#x201d;) vaccine. In consideration for the work to be performed, the Gates Foundation provided the Company with an upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e0a3dbf-379a-4d48-a667-71e91cf86d6e" contextRef="C_f1213544-8876-4d28-b445-ffd3948fc5c0" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in December 2021, and future funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb166cb5-6b1d-4707-aa53-68f0ef0f2f52" contextRef="C_6d7f03df-630d-4cad-87f7-614b2528d487" name="grts:FutureFundingExpected" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is expected to be received by the Company in the first quarter of 2023, for a total grant amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef1eeeba-b215-4c93-8756-9ec2efeddae3" contextRef="C_6d7f03df-630d-4cad-87f7-614b2528d487" name="grts:TotalGrantAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the Gates Grant Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. During the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3457ede-6224-48f2-aafb-3f2f272c0da5" contextRef="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in revenue under the Gates Grant Agreement. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e783fb4d-849d-4093-9761-54894950fe2f" contextRef="C_de1f942a-daf6-4e81-ae8e-4d009e1427bc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize any grant revenue under the Gates Grant Agreement in 2021. As of December 31, 2022, short-term restricted cash and short-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b5992b8-d709-4c1b-b57a-28e83bcde398" contextRef="C_7bec73ca-4c8e-4211-838e-e975e53259b0" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_d66e4474-4a27-4a7e-98cc-0b1098729aba" contextRef="C_7bec73ca-4c8e-4211-838e-e975e53259b0" name="us-gaap:RestrictedCashEquivalentsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million  were recorded on the consolidated balance sheet. As of December 31, 2021, short-term restricted cash and short-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f092927-eede-458a-88bc-fe7710e25fdc" contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_51c573f6-f841-4a34-895d-939a8c6ceb03" contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960" name="us-gaap:RestrictedCashEquivalentsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and long-term restricted cash and long-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e197d46-b2e4-4ad1-8c70-638ac5c93d2e" contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_587716e3-f3e7-498e-a84e-d1374e46d215" contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the tranches of funding are expected to take place, which is currently estimated to be through the year ended 2023.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_724a77c1-dc56-4223-9f91-8b55a70f9f72" contextRef="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the Grant Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.308%;"></td>
        <td style="width:1.877%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.815%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3307af0-39c2-4e6e-a12c-5c2390118de1" contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89f2d28a-aa75-4abc-9d62-62d1577d556d" contextRef="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e" name="grts:ContractWithCustomerLiabilityAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_272db786-3822-4d0b-bfdd-e6399d171c10" contextRef="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e" name="grts:ContractWithCustomerLiabilityDeductions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,200</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7ea71df-d065-44da-a06a-0a654df7d2f8" contextRef="C_7bec73ca-4c8e-4211-838e-e975e53259b0" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3ea95586-38ae-4e60-ac5a-cedd565efb3c" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.	Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, the Company entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;) and Silicon Valley Bank (&#x201c;SVB&#x201d;), which provides the Company a 60-month term loan facility for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_295b620c-97f9-4171-b80d-ae192d979267" contextRef="C_dfc996c2-5a4e-4564-8277-b7d2ffbeec1d" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">80.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">borrowing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">capacity across five potential tranches. At the closing of the Loan Agreement, the Company drew </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc583796-97d7-412e-af7d-21174d33aed6" contextRef="C_8db1bd52-7abc-4eeb-9079-f65d7f8c2c1b" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the first tranche and can draw up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c31cf2ee-2923-438e-befc-fe740321e268" contextRef="C_c139338b-65f8-4c46-9f25-0a151c3415a7" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through March 2023. The remaining tranches provide up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89af693b-7659-4290-a553-47330af479aa" contextRef="C_604e35dd-089f-428e-8455-fd00d7905514" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million borrowing capacity and become available upon the Company meeting certain milestones set forth in the Loan Agreement. As of December 31, 2022, one milestone had been achieved, which provides the Company the ability to draw up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_501e10f9-a5f5-484f-9606-71528639ea2e" contextRef="C_6d3577c4-db17-46ad-8f60-2c0eb8ff2efa" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through December 15, 2023. The term loan is secured by substantially all of the Company&#x2019;s assets, other than intellectual property. There are no warrants associated with the Loan Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b844cace-84d7-403d-a9d9-25ebcf4c2826" contextRef="C_dc0d2494-fb2c-4556-8cfb-8f4cbf34588f" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings under the Loan Agreement bear interest (i) at an annual cash rate equal to the greater of (x) the lesser of (1) the prime rate (as customarily defined) and (2) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e28be20-ce4a-47ed-b00c-4e974f3d4395" contextRef="C_bbe3a914-b528-49c7-8179-6932dd627a2a" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, in either case, plus </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2ce3566-51a6-45f3-824f-b985ecf2abfe" contextRef="C_9d996bec-14d2-4de2-a3e4-8cb7d6f0f835" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, and (y) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71a05964-5e64-4d86-b8c2-0a1fbb3f2e41" contextRef="C_7c20b544-b6be-4cb6-a697-7fed0ddcd9cf" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and (ii) at an annual payment-in-kind rate which may equal </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e561a787-75be-4109-99e4-08621928ae49" contextRef="C_dd3679ef-3afd-4878-b600-1c49abe1ccaf" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company is required to make monthly interest-only payments prior to the amortization date of January 1, 2025, subject to a potential six-month and one-year extension upon satisfaction of certain conditions. The interest-only payment date has been extended an additional six months based on our achievement of one of the milestones as set forth in the Loan Agreement. In addition, the Company paid a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31f9561b-ed03-4ea8-a468-d18954bca681" contextRef="C_dfc996c2-5a4e-4564-8277-b7d2ffbeec1d" name="us-gaap:DebtInstrumentFeeAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">150,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> facility charge upon closing, and must pay a facility charge equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce2ed149-3203-4939-80a1-4031d9d04758" contextRef="C_79e7ae2f-f2dc-435d-9836-71d230ab5b96" name="grts:FacilityChargePercentageOfBorrowing" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount of any borrowings made pursuant to the amounts under the last four tranches.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All unpaid principal and accrued and unpaid interest with respect to each term loan is due and payable in full on July 19, 2027. At the Company&#x2019;s option, the Company may prepay all or any portion of the outstanding borrowings, plus accrued and unpaid interest thereon and fees and expenses, subject to a prepayment premium ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56092c0a-f329-4e94-81c2-da5e4e8e6118" contextRef="C_892682c3-ba06-4a39-8d64-2a527d6f399c" name="grts:PrepaymentPremiumRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d982002-0b62-44d3-a144-23b00d9734c3" contextRef="C_380477b0-d459-4fc3-9c66-ba4500d99c6f" name="grts:PrepaymentPremiumRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, during the first three years after closing, depending on the year of such prepayment. Upon repayment of the term loan, the Company is required to make a final payment fee to the lenders equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0010cde3-093b-4ecd-89a4-61477a0af126" contextRef="C_79e7ae2f-f2dc-435d-9836-71d230ab5b96" name="grts:FinalPaymentFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the aggregate original principal amount of the loan. Debt issuance costs have been treated as debt discounts on the Company&#x2019;s consolidated balance sheet and together with the final payment are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning on April 1, 2023, so long as the Company&#x2019;s market capitalization is equal to or less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fd7c445-deb0-41f3-a18d-d2d6576af21e" contextRef="C_ae54a29d-2a04-4259-9f48-ef7214c95a0b" name="us-gaap:CapitalizationLongtermDebtAndEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">400.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e20296fd-621e-45d3-b6ac-5eea256d6ce8" contextRef="C_b402c931-cfd8-4ccd-855e-c61c5c4d4509" name="grts:MinimumLiquidityRequirementCapitalDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company is subject to a minimum liquidity requirement equal to the then outstanding balance under the Loan Agreement multiplied by 0.55 or 0.45, which multiplier depends on whether the Company achieves certain performance milestones.</span></ix:nonNumeric></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s obligations under the Loan Agreement are subject to acceleration upon the occurrence of customary events of default, including payment default, insolvency and the occurrence of certain events having a material adverse effect on the Company, including (but not limited to) material adverse effects upon the business, operations, properties, assets or financial condition of the Company and its subsidiaries, taken as a whole. As of December 31, 2022, the Company is in compliance with all covenants in the Loan Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there were unamortized issuance costs and debt discounts of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1f2464a-d708-4f7d-9f16-ca771d811324" contextRef="C_8766ca2a-9ff6-4066-8356-6a67a4e463d3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which were recorded as a direct deduction from the term loan on the consolidated balance sheet. Interest expense related to the Loan Agreement was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d98510eb-eef7-496c-80a7-bcbf85614f3d" contextRef="C_dc0d2494-fb2c-4556-8cfb-8f4cbf34588f" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022. The effective interest rate on the term loan, including the amortization of the debt discount and issuance costs, and accretion of the final payment, was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e8a96a8-5bd0-4c3e-b83b-9bbb9cb61b30" contextRef="C_8766ca2a-9ff6-4066-8356-6a67a4e463d3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">13</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The components of the long-term debt balance are as follows:</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_da80c44b-0614-4e08-bee0-3ae89a874604" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfDebtTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.299%;"></td>
        <td style="width:1.874%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.828%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal loan balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2498f130-9c5d-4842-be0b-e919cf1a6e53" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Final fee</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_238ff31b-1a81-4051-87e0-bf6e94f7eb5f" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:FinalFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,150</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount and issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_000ec22d-ceb3-4d99-9056-da29b83f535c" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long term debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86bf574e-d0eb-4377-9ca1-a81760eba28b" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the estimated future principal payments due (excluding the final payment fee) were as follows:</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09299369-c9ec-462e-9a2c-c5604f3edcb8" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.991%;"></td>
        <td style="width:2.083%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.926%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e943fba-9be5-4764-8d12-13db8c71af5c" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_527a1b30-3f8a-4a27-904f-0beb8244cef2" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4b8dbf3-97fe-4189-b53b-fbfc11f29607" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,407</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22fc9dab-38a0-412a-9c73-cd86652c5cae" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c9ea9ea-639f-45e9-8966-acda9f1bc475" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,197</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total principal payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14c59d21-30fb-44cd-85bc-7e4ac9fb9d29" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf912ab4-8303-4457-9442-14c72957f74f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.	Balance Sheet Components</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prepaid Expenses and Other Assets</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4eb3ffe-850c-41a4-ae84-1230e40283ad" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.953%;"></td>
        <td style="width:1.557%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.267%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.557%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.665%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60b7a977-057d-4ac8-9806-9de6e91b1b5c" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:PrepaidExpenseForResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,241</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a35b509-bcb8-4a14-9b1b-684f1e876c25" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:PrepaidExpenseForResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,672</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net contract asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a44b04e0-ba18-4d15-ba47-7b7a5645d847" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:NetContractAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_feb4c653-67d8-4bf6-a700-a1c697764578" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:NetContractAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd7a1aa4-e6c5-4bd3-8827-e4790d3538de" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fc2751b-3dc6-4665-9537-f879fe707d70" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2947732-ea28-4d8f-add2-942430d04bb7" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,158</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a3fb59d-3e03-44b1-8523-a5b29cf56e2c" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d2dedf9-bf44-4a73-9e2f-2216c3804032" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:InterestAndOtherReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">529</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4443a1b-9c7c-4954-8f5a-cb93d2754da4" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:InterestAndOtherReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities-related deposits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17c5bcc8-58f3-457c-a017-64364700a5ac" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:FacilitiesRelatedDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_965f62e2-4ad3-42f1-a51e-14654eed089c" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:FacilitiesRelatedDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b586e64-aa61-47e9-9082-c573d33180b2" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">567</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53697a39-420e-4fa8-aad8-6229625ec6c7" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">866</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb1cef28-9b91-4788-97de-6b0674f7bd18" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc4b5e71-fddb-40ab-9b7d-b69b1edb7346" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,672</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deposits and Other Long-Term Assets</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_75b0d8f1-9d86-436c-b33b-7819536fc850" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits and other long-term assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.953%;"></td>
        <td style="width:1.557%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.267%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.557%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.665%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease security deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_097f53db-e50c-40aa-ac96-54544c2c347d" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97b9864c-5b0a-450d-8695-25859efee2e4" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90bd4c6b-1879-47e9-91cb-877cc7fc7a96" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">643</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6be8ade3-2ead-4535-b175-5dd57b718e91" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65a59eed-c211-44d0-b85b-f0b837c16f5c" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,162</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5be45534-5e1b-45c9-af05-b478122d1b70" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deposits and other long-term assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cb829ff-449e-46dc-9c71-0b51c6833b13" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,739</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_317ab707-752b-41f0-80eb-58f8d6c0f331" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,352</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52fd81e4-5d51-4f55-b819-46253985c5b4" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.	Stockholders&#x2019; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s amended and restated certificate of incorporation provides for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1ae84be-62bb-48c0-a917-056fb97a6895" contextRef="C_78bd9843-080b-4da9-aa64-2a6e6bff9c0d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57544abf-b6d9-4ae9-a34b-bd402bf43a35" contextRef="C_78bd9843-080b-4da9-aa64-2a6e6bff9c0d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock authorized for issuance, each with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ef8cb8b-51f5-4e2f-b38e-6a5489bb856a" contextRef="C_78bd9843-080b-4da9-aa64-2a6e6bff9c0d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0eb266e-f3df-4c5b-8dba-bde9981070e6" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5872654d-e346-4995-adc1-6ec2f8576670" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_42419c27-1445-4ae0-96c1-4860f7828005" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_17081bb4-dffb-4387-b67c-353141bee3d3" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock were issued and outstanding.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dd1e1fd-2007-40e5-9d9e-7a98eeb46c2d" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e3ce5aa2-8955-4b79-af2b-cfa1b9e0431f" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">86,894,901</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b635fb25-39b5-4ead-9258-4348097cf261" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_70aaecfd-39a3-47ed-93fe-2db5f5320065" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,047,878</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued and outstanding, respectively. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ebbe034a-caee-4957-a6fc-2e9028d5952e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the Company&#x2019;s common stock are entitled to one vote per share.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sale of Common Stock and Pre-Funded Warrants</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, the Company filed a Registration Statement on Form S-3 (the &#x201c;2019 Shelf Registration Statement&#x201d;) with the SEC, covering the offering of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c709ba2-df9a-4d88-987d-38ff8f3b1bec" contextRef="C_7855eba8-76bc-4a8c-9ce4-0799ef712f67" name="grts:MaximumSecuritiesCoveredUnderRegistrationAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of common stock, preferred stock, debt securities, warrants and units. The 2019 Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dea14a3-adb0-4a1e-9561-a66bb2f0a8e6" contextRef="C_323e95b8-22cf-4c13-a39e-cc623d224a74" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">75.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the Company&#x2019;s common stock, from time to time, through the ATM Offering Program under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The SEC declared the 2019 Shelf Registration Statement effective on November 8, 2019.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the 2019 ATM Offering Program, in October 2019, the Company entered into a sales agreement (the &#x201c;2019 Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), pursuant to which Cowen acts as the Company&#x2019;s sales agent and, from time to time, offers and sells shares of the Company&#x2019;s common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7836bcc0-e711-48ab-a9ae-f2c3d336fee4" contextRef="C_323e95b8-22cf-4c13-a39e-cc623d224a74" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">75.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Cowen is entitled to compensation for its services equal to up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80749b2f-94e0-46f3-803b-af3bee14c19b" contextRef="C_7f8d1e5e-8021-40a9-af4e-637188703294" name="grts:PercentageOfProceedsPayableAsCompensationToUnderwriter" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross proceeds of any shares of common stock sold under the 2019 Sales Agreement. In addition, the Company agreed to reimburse a portion of Cowen&#x2019;s expenses in connection with the 2019 ATM Offering Program up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce1bd321-d745-48dd-8ae5-9e44c58931f1" contextRef="C_7f8d1e5e-8021-40a9-af4e-637188703294" name="grts:MaximumOfferingExpensesAgreedToBeReimbursed" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the year ended December 31, 2021, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_988dbaa0-26b6-4ee8-a93e-9e3b09b0795e" contextRef="C_f9220959-3f8c-49ee-b09b-88b706eaf9b1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,990,869</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  shares of its common stock through its 2019 ATM Offering Program and received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dddb8cf-c766-411c-afac-23aeae64dc01" contextRef="C_f9220959-3f8c-49ee-b09b-88b706eaf9b1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net of commissions and other offering costs. During the year ended December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_912d5eab-f8db-4969-a496-89ab97bcc56b" contextRef="C_17553f60-9678-4458-869e-6553a03fa156" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sales </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of shares of the Company&#x2019;s common stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">its 2019 ATM Offering Program. As of December 31, 2022, there are no further amounts available for issuance under the 2019 ATM Offering Program.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, the Company entered into two private placement financing transactions (collectively, the &#x201c;First PIPE Financing&#x201d;), as follows: (i) to sell </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdfc1753-ddaf-4ca3-8b35-4bd99ee57ca6" contextRef="C_e79a84f8-b402-4c06-a64d-be36155f0669" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,543,351</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6242d449-4550-4dec-a05a-92ea72f31662" contextRef="C_11b7e846-cd77-420b-8752-6e1a1f336a59" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants (the &#x201c;Warrants&#x201d;) to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c6dfc68-9d43-4f46-aa78-8317958e5e05" contextRef="C_e79a84f8-b402-4c06-a64d-be36155f0669" name="grts:WarrantsToPurchaseSharesOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,480,719</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0049d3bb-21b8-4006-a43b-e3a9822e7bca" contextRef="C_11b7e846-cd77-420b-8752-6e1a1f336a59" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9352950b-4e7f-46fe-b901-d77e9a27f5cd" contextRef="C_11b7e846-cd77-420b-8752-6e1a1f336a59" name="grts:SaleOfStockPricePerSharePrepaidByPurchaser" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share was prepaid by each purchaser), and (ii) to sell an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_405708e4-f036-43b5-b9d9-c3eaea349b87" contextRef="C_80415412-bf63-429e-9fb1-589b8f52c64b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,043,127</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3d5fdb2-26e3-4a9c-a921-0ce95bd9664b" contextRef="C_5cfdaae9-b4b4-47da-bcee-8fd709202da6" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.71</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In connection with the First PIPE Financing, the Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9c80625-31ee-43b5-89cf-0353fb59d678" contextRef="C_e79a84f8-b402-4c06-a64d-be36155f0669" name="grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">119.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Warrants are exercisable upon issuance at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13cfc2cc-232d-4d80-ba97-3573f42950c1" contextRef="C_11b7e846-cd77-420b-8752-6e1a1f336a59" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outstanding Warrants generally may not be exercised if the holder&#x2019;s aggregate beneficial ownership would be more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f264047d-a0af-436e-a8cd-4b2c681d9821" contextRef="C_e79a84f8-b402-4c06-a64d-be36155f0669" name="grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total issued and outstanding shares of the Company&#x2019;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#x201c;Warrant Shares&#x201d;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#x201c;cashless&#x201d; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b53580d9-8de1-4b93-88d1-ba50d792b959" contextRef="C_b5151ebd-45f6-4030-99a1-58711cd6e0af" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">87.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company completed a PIPE financing transaction, in which it sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b684c9c8-0fdd-4910-840e-14fb8386c04b" contextRef="C_65adaa59-8507-450d-85bf-fc379014d32a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bece0053-593b-4802-bd74-7a9fa9c32e0a" contextRef="C_e6cfa898-87ba-405c-ab6e-c9fdcb066f80" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share pursuant to a securities purchase agreement entered into on September 16, 2021 (the &#x201c;Second PIPE Financing&#x201d;). The Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fd31364-a657-4e41-9d14-7f54197f45e4" contextRef="C_65adaa59-8507-450d-85bf-fc379014d32a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">52.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Second PIPE Financing.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, the Company filed a Registration Statement on Form S-3 with the SEC (the &#x201c;2022 Shelf Registration Statement&#x201d;), covering the offering of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ea20dba-59c0-49d1-bcfa-460b526ae492" contextRef="C_56766ff0-b624-4f79-bafa-518ca3d728d7" name="grts:MaximumSecuritiesCoveredUnderRegistrationAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of common stock, preferred stock, debt securities, warrants and units. The 2022 Shelf Registration Statement included a prospectus supplement covering the issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_468727b4-f402-48f6-8e76-e266bbfff801" contextRef="C_2e24acd0-67f6-4df3-a3dd-efc69b71ea26" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the Company&#x2019;s common stock, from time to time, through an &#x201c;at-the-market&#x201d; offering program (the &#x201c;2022 ATM Offering Program&#x201d;) under the Securities Act. The SEC declared the 2022 Shelf Registration Statement effective as of May 6, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the 2022 ATM Offering Program, in March 2022, the Company also entered into a sales agreement (the &#x201c;2022 Sales Agreement&#x201d;) with Cowen, pursuant to which Cowen will act as the Company&#x2019;s sales agent and, from time to time, offer and sell shares of the Company&#x2019;s common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e1b03d7-ae23-4784-a52f-57c98264b1ac" contextRef="C_11b309d8-462b-4ef1-aa32-6924156d9e05" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Cowen is entitled to compensation for its services equal to up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fcdf5e8-05a7-4e03-bb8f-598d10f5e33a" contextRef="C_210e3734-9390-4047-8e9e-6e3dac75eb53" name="grts:PercentageOfProceedsPayableAsCompensationToUnderwriter" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross proceeds of any shares of common stock sold under the 2022 Sales Agreement. In addition, the Company agreed to reimburse a portion of Cowen&#x2019;s expenses in connection with the 2022 ATM Offering Program up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae359860-d459-402e-b49f-7a90b9011e96" contextRef="C_210e3734-9390-4047-8e9e-6e3dac75eb53" name="grts:MaximumOfferingExpensesAgreedToBeReimbursed" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, the Company has received aggregate proceeds from its 2022 ATM Offering Program of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8954f06c-1da8-4b68-8fa8-27663d6f978a" contextRef="C_4aff01cb-2e26-424b-83a9-fc5583bbca7a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net of commissions and offering costs, pursuant to the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c9b21ce-41d7-42c1-a0e3-baedf87e292e" contextRef="C_6411ac81-f0a4-466a-b658-bc20a1796628" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,034,948</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, the Company completed a PIPE financing transaction, in which it sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd616883-464c-4ec5-9d8e-366ae60ed338" contextRef="C_2d75caf7-1680-40a2-922d-317eeb129d2b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,637,165</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c83f36cf-55af-4065-a0e7-7d65acb9c79b" contextRef="C_2d75caf7-1680-40a2-922d-317eeb129d2b" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share pursuant to a securities purchase agreement entered into on October 24, 2022 and pre-funded warrants (the &#x201c;Warrants&#x201d;) to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5805592c-7511-4007-9fb2-f004d5f5ba49" contextRef="C_84b52d54-d609-4bec-bfa0-0f69992f3096" name="grts:WarrantsToPurchaseSharesOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,274,923</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96fd20cc-d8da-4d08-aa05-be58d605b49e" contextRef="C_0d2325a8-cbfa-43c0-bd17-5934a79b43c0" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">2.26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cec4279-f30c-4214-af19-d4d7e988b42e" contextRef="C_0d2325a8-cbfa-43c0-bd17-5934a79b43c0" name="grts:SaleOfStockPricePerSharePrepaidByPurchaser" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">2.2599</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share was prepaid by each purchaser) (the &#x201c;Third PIPE Financing&#x201d;). The Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b139a56-12ef-4a04-add3-af2375901818" contextRef="C_217b0356-637c-4019-9519-2b40884dd4ea" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">42.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Third PIPE Financing. The Warrants are exercisable upon issuance at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2fb07ac-a14f-494a-b506-d953666815d0" contextRef="C_0d2325a8-cbfa-43c0-bd17-5934a79b43c0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outstanding Warrants generally may not be exercised if the holder&#x2019;s aggregate beneficial ownership would be more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58560173-b718-48ed-925b-dbd594d8ee09" contextRef="C_dcee5e27-efd7-4563-b1c8-df33f67e907f" name="grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total issued and outstanding shares of the Company&#x2019;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#x201c;Warrant Shares&#x201d;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#x201c;cashless&#x201d; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26039596-5f96-4d60-b065-c5adcc0b2705" contextRef="C_e6bd0364-0189-46f1-9a87-5b5ae7b4a68b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ef89f9fe-421e-4696-a2ff-19df1593aec2" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the following warrants to purchase shares of the Company&#x2019;s common stock were issued and outstanding:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.773%;"></td>
        <td style="width:1.467%;"></td>
        <td style="width:27.95%;"></td>
        <td style="width:1.467%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.704%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.639%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issue Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Warrants Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4d6c8b81-74dd-42d9-80aa-e5ad926f0781" contextRef="C_a246cd21-ac7d-4072-88f9-4cb7c5a9e332" name="grts:ClassOfWarrantOrRightIssueDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 28, 2020</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_70ee5587-d467-48ab-b8c6-07be5fe2bbc9" contextRef="C_a246cd21-ac7d-4072-88f9-4cb7c5a9e332" name="grts:ClassOfWarrantOrRightsExpiration"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b8be817-5fda-4c1f-9f2d-0a10f3eadc7d" contextRef="C_323b919c-2755-47b8-9d63-cde4b993e0b3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6d74abf-2f02-41b5-bf20-c8af1b957165" contextRef="C_323b919c-2755-47b8-9d63-cde4b993e0b3" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,573,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_55034149-4d80-4356-b419-804d729992c7" contextRef="C_59a0f9dc-319b-473d-b36c-f9544e589028" name="grts:ClassOfWarrantOrRightIssueDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 24, 2022</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8b5fcecb-65ee-439d-acd5-0aeb7637fc9b" contextRef="C_59a0f9dc-319b-473d-b36c-f9544e589028" name="grts:ClassOfWarrantOrRightsExpiration"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ba5355d-5603-499a-a6cc-ec9d5b732e71" contextRef="C_dcd7275c-0ad0-4b30-ad3b-b1c3164715c9" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b416fe3-0674-4c95-acbe-11a0ee23813a" contextRef="C_dcd7275c-0ad0-4b30-ad3b-b1c3164715c9" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,274,923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_065bd0d5-cab6-4a9a-85b4-8cb071ebe7c1" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,848,627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.4%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9371091f-e2fd-4c84-a920-2df50e11b1c0" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ClassOfWarrantOrRightWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,442,567</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants exercised, resulting in the Company issuing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_290cf8cb-412d-4011-b690-c9f9b07187de" contextRef="C_d0c4fb4f-d485-41f4-b896-f24d5158e36f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,442,567</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. During the year ended December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d27b32b-e092-418d-b3d0-d993dbd52c6b" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:ClassOfWarrantOrRightWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,459,576</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants exercised and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9001cef-7c6b-4d2b-bb8c-aeacd7244ece" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:WarrantsCancelled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,872</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants cancelled due to net exercise of the warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_388f861c-6039-4b6a-95a3-319823503957" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.	Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Award Incentive Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2015, the Company&#x2019;s board of directors approved the 2015 Equity Incentive Plan (&#x201c;2015 Plan&#x201d;). In connection with the Company&#x2019;s IPO and the effectiveness of the 2018 Award Incentive Plan (&#x201c;2018 Plan&#x201d;), discussed below, the 2015 Plan terminated. The </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd5d3fc6-6eb6-4d0a-9635-7bf6bf57be36" contextRef="C_207cd814-4d37-40e6-b825-ea029fb0acad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">92,815</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock that were then unissued and available for future issuance under the 2015 Plan became available under the 2018 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, the Company&#x2019;s board of directors approved the 2018 Plan. Under the 2018 Plan, a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19dc5287-8824-4353-a9aa-8258b850e415" contextRef="C_5c8523e8-eb7f-4abd-894a-724f7b5cac4d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,690,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the 2018 Plan, plus the number of shares remaining available for future awards under the 2015 Plan, as of the effective date of the 2018 Plan. The number of shares of common stock reserved for issuance under the 2018 Plan automatically increases on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_478ad7cf-465a-4d28-b93e-c2560bdd873b" contextRef="C_55f74884-e084-4ff0-ad23-d54d1b1004e6" name="grts:IncreaseInSharesAvailableForIssuancePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of the Company&#x2019;s outstanding stock on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company&#x2019;s board of directors. The 2018 Plan provides, among other things, for the grant of options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance bonus awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maximum number of shares that may be issued upon the exercise of stock options under the 2018 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ac93768-5353-4692-b92e-e6bee22036b7" contextRef="C_55f74884-e084-4ff0-ad23-d54d1b1004e6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s board of directors has the authority to determine to whom options will be granted, the number of shares, the term, and the exercise price. </span><span><ix:nonNumeric id="F_2a5127d7-72ac-464b-b2cb-37f9c15e4c82" contextRef="C_3b708b32-49af-4567-b476-e287d5f1de04" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" continuedAt="F_2a5127d7-72ac-464b-b2cb-37f9c15e4c82_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an individual owns stock representing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8940c488-d023-4527-b9ba-875d6c22fc20" contextRef="C_3b708b32-49af-4567-b476-e287d5f1de04" name="grts:MinimumPercentageOfOutstandingSharesHeldByIndividual" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or more of the outstanding shares, the price of each share </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_2a5127d7-72ac-464b-b2cb-37f9c15e4c82_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65b35697-2c23-47f6-b4b9-5eccb24c89cf" contextRef="C_3b708b32-49af-4567-b476-e287d5f1de04" name="grts:MinimumPercentageFairMarketValueOfSharePrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value, as determined by the board of directors. Options granted have a term of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_246f7dae-ba55-4365-8ff1-a22def767e2c" contextRef="C_33a09371-b9ca-4410-82c3-2bb6c53a0442" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82bbbf09-3fa2-41a6-9ebb-6df41b1a97eb" contextRef="C_3b708b32-49af-4567-b476-e287d5f1de04" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-year period with a straight-line vesting.</span></p></ix:continuation></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Material Features of the 2021 Employment Inducement Incentive Award Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, the Company&#x2019;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#x201c;2021 Plan&#x201d;), pursuant to Nasdaq Listing Rule 5635(c)(4). The principal purpose of the 2021 Plan is to promote the success and enhance the value of the Company by inducing new employees to commence employment with us, and by aligning the individual interests of new employees with the interests of our stockholders. Awards granted under the 2021 Plan are intended to constitute &#x201c;employment inducement awards&#x201d; under Nasdaq Listing Rule 5635(c)(4), and, therefore, the 2021 Plan is intended to be exempt from the Nasdaq Listing Rules regarding shareholder approval of stock option and stock purchase plans. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f386a295-7ed6-407f-97fd-6548b50af3d6" contextRef="C_802790aa-7b46-443c-b5ab-a61e4c953239" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">790,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock were initially reserved for issuance under the 2021 Plan. The 2021 Plan provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, stock appreciation rights, and other stock-based and cash-based awards. The 2021 Plan does not provide for the grant of incentive stock options. Awards under the 2021 Plan may be granted to eligible employees who are either new employees or who are commencing employment with us or one of our subsidiaries following a bona fide period of non-employment with us, and for whom such awards are granted as a material inducement to commencing employment with us or one of our subsidiaries. Awards under the 2021 Plan may not be granted to our consultants or non-employee directors.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Plan is administered by our board of directors and, to the extent our board of directors delegates its authority to it, our compensation committee. In the event of a change in control in which the successor corporation refuses to assume or substitute any outstanding award under the 2021 Plan, the vesting of such award will accelerate in full. Our board of directors may terminate, amend, or modify the 2021 Plan at any time, provided that no termination or amendment may materially impair any rights under any outstanding award under the 2021 Plan without the consent of the holder.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 21, 2022, the Company&#x2019;s board of directors increased the number of shares available under the 2021 Plan by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fd9a59f-bea3-4456-b037-8258a44be3b8" contextRef="C_ae943dac-f283-4812-963a-4a9313be83f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">700,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2018 Employee Stock Purchase Plan</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, the Company&#x2019;s Board of Directors approved the 2018 Employee Stock Purchase Plan (&#x201c;2018 ESPP&#x201d;). The 2018 ESPP also became effective in September 2018. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99f0e198-c075-4a00-94f1-02f19b715587" contextRef="C_5e2d29f3-6231-4c61-9133-137f73dc9a4c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">282,334</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were initially reserved for issuance under the 2018 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2018 ESPP will increase automatically each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by the lesser of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a970b7b9-865c-4f1a-bcdc-d3286e352a4c" contextRef="C_ceb9099d-6f61-44fa-836a-3e42ead5e190" name="grts:IncreaseInSharesAvailableForIssuancePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of common stock outstanding on December 31 of the preceding calendar year or (2) such lesser number of shares determined by the Company&#x2019;s Board of Directors. The maximum number of shares that may be issued under the 2018 ESPP is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_476ff9cc-8eaf-4f82-b28e-62bfa2f3d9be" contextRef="C_ceb9099d-6f61-44fa-836a-3e42ead5e190" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The offering periods are scheduled to start on the first trading day on or after June 1 or December 1 of each year. Contributions under the 2018 ESPP are limited to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d751c74b-de36-4b07-ba81-657504de4e8b" contextRef="C_ceb9099d-6f61-44fa-836a-3e42ead5e190" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of an employee&#x2019;s eligible compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b547e90e-3ca6-480e-82e0-8bbdb12a662b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.996%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.738%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.993%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.728%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.993%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.547%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b6af81c-d400-452b-bbb2-5a54fe2e993d" contextRef="C_70694a1e-9f63-4f26-821a-bb4205582c79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e47ffd84-fe76-4dcd-9cd0-7585942cd83b" contextRef="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47c16f42-4ed9-4eb8-95cd-78501d4cdd6b" contextRef="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b04c1aea-6030-4676-94c2-924b72b6d576" contextRef="C_70694a1e-9f63-4f26-821a-bb4205582c79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_22c69ea4-c728-4c90-b51c-7ccf7bf221b3" contextRef="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.57</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e60a3cee-6d73-4635-81e0-c1bf06ba4d28" contextRef="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.48</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0c713e5-f59f-478e-8e33-78f7f3ce5c16" contextRef="C_70694a1e-9f63-4f26-821a-bb4205582c79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b11abe3-1bc8-4c2c-bdcc-1567e52d72df" contextRef="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12019de1-bb00-4529-b14f-1848d469c59b" contextRef="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce585cb5-2e65-4958-8bbb-d89c58d6641b" contextRef="C_70694a1e-9f63-4f26-821a-bb4205582c79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">94.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a5d4991-d01d-44fa-b4ac-0c2a7634885e" contextRef="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">88.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92593807-816e-4348-a465-dff460345415" contextRef="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation of Stock Options</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ac6310e3-704e-4522-a2b8-b2752d592ec5" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.791%;"></td>
        <td style="width:1.064%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.392%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.064%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.392%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.064%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.232%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fff5455-4885-4cca-9dc8-442d0719ec42" contextRef="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b569a826-43c8-4fe1-8a1a-5ea3b287fbb2" contextRef="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67faf630-0be1-44b5-8872-0e444de269da" contextRef="C_2fc7bad5-4623-4bd4-9074-af6d60072963" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eb20c483-2727-4a32-bfe6-2477df9f9d03" contextRef="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.98</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_77a89366-222d-4189-b370-b3373bd686ee" contextRef="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_467913d1-f257-4f0f-a0ec-2d5f89151f0b" contextRef="C_2fc7bad5-4623-4bd4-9074-af6d60072963" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8aefae0e-c33c-4bca-b51d-9573e0f1bdf8" contextRef="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b507d54a-8c4a-4065-960c-bfa157503df1" contextRef="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd8d0a70-251e-4e3d-b897-d7615de483ba" contextRef="C_2fc7bad5-4623-4bd4-9074-af6d60072963" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c0de875-5777-4090-9e49-b5483347fd2f" contextRef="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7899399-460f-44c5-9ce2-5b63aa747b14" contextRef="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">79.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a22e347-402f-40f8-af34-b8ea9b5adaf3" contextRef="C_2fc7bad5-4623-4bd4-9074-af6d60072963" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">73.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s calculations are based on a grant date valuation approach. Using the Black-Scholes model, the weighted-average grant-date fair value of employee stock options granted was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf11c778-888e-48ee-a872-f389c539be3e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7691897c-25c3-4d0d-af2b-741753d9c964" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.03</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20465571-c441-4e75-aa53-2ac43d4c9eb1" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.39</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share during the years ended December 31, 2022, 2021, and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f82cb5a3-78e2-434d-913e-8f816cf0dca0" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the 2018 Plan and 2021 Plan activity is as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.38%;"></td>
        <td style="width:0.108%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.776%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.065%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.991%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.065%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.683%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.119%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.302%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.514%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Shares<br />Available<br />for<br />Issuance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number<br />of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate    <br />Intrinsic<br />Value<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10952826-e114-4a1e-b45d-1123f04b0322" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,459,187</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7ba33cd-4152-4854-bfdf-d9371d959807" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,107,335</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80129e08-91c6-4c2f-943b-e1d673b3e3f9" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c08078e-bdbe-4243-b9f9-7e7af66e9566" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.13</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69ad258f-b8df-4279-8828-6886abd9b1bc" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd6723ee-abd5-4cdf-9075-d8345a4762a9" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,461,915</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_692e31d3-b51d-4fab-9519-6a73b783fab5" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,518,734</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11f13a40-f372-4b96-8a4c-ab9bcb0d3236" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,168,561</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c72527d-a07d-4c63-9b08-94ec47ff1514" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_127001a8-606c-4985-a94d-3b6ca61c70fb" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">194,347</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e673f91-b887-406e-9d90-7c8cd7c3f950" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc9883eb-9272-452c-9457-b8fdff416730" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,412,026</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f335c09d-732c-4eb4-a333-28e680d108bd" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,129,929</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8eb43e2c-2eea-4efb-8ab8-e3386f54f9ff" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de6fc15a-cb88-49b0-94d8-7d1b24ab3c06" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,814,394</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99c9dd59-5395-4e10-b874-78c7486a0781" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,951,620</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07e2c8f5-374b-445f-8039-c58a39787873" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_332c65d4-cff8-44aa-bea4-adb9868dce7a" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80bf9b07-4669-45c6-b179-110db8da644e" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable &#x2013; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d620024-9820-4838-a00c-baea8698c0ec" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,122,952</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6fb9069-f23f-4d98-a3e7-6a80275d0608" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ae41481b-4945-43f1-a171-8a3b47a97c06" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.16</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcdd8abd-1562-4ef2-9a42-a377fbe6277f" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest &#x2013; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd2bc87e-822f-4e07-8416-d70a8a6efb50" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,421,425</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3abc270f-5b65-4f05-a10f-9962adbfaa6e" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6b28b575-4c75-423a-a2ab-bc6191abaeaf" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.00</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85aad888-d2f7-4a3e-a2a8-aa1c89cf8664" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022, 2021, and 2020, the total intrinsic value of stock option awards exercised was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76067861-c368-4936-9848-a72c2312c509" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d025cdb5-bcf0-458e-bf12-cec32d2fcaa0" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34f4d5f0-c19e-4c3e-aead-9fde82e429c5" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, determined at the date of option exercise, and the total cash received upon exercise of stock options was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_053e03d3-1c60-4310-a0e6-5e389096a29d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08ee256e-1c6e-453a-91bd-cdecb141f4df" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2021 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9435235-355a-4a62-abbe-ba7d809f3a3e" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t significant for 2020. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying stock option awards and the estimated fair value of the common stock on the date of exercise.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adac4810-8f23-4208-9d4c-687ad70cd065" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of total cost related to non-vested employee and consultant options is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4db71796-1117-44ee-a001-2d68f22d687f" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The total fair value of shares vested during the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9b874c9-cce6-4e79-9f57-ee062735a6be" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense and awards granted to non-employees was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd3cbcfa-0919-4488-9e70-a76b2b07e30d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56b6b0b7-4f82-4f84-88de-4c718ab32a93" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021, and immaterial for the year ended December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_443e1cb7-a16b-450e-ad19-25b3bb79e18f" contextRef="C_fd45c0a3-040d-42de-93c8-a06fd1b04f7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cde99731-e66d-41f7-ab10-9ed41f24e3fc" contextRef="C_a26fbccd-5d77-411c-acc6-ba0395a747d7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9f56e434-2071-40f2-81bc-0ed22f38f4e5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3a424e93-868b-4caa-9a18-ab3635c1a5d6" contextRef="C_a26fbccd-5d77-411c-acc6-ba0395a747d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_80b2edf9-3b74-4482-ac43-ba7123d94a47" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true" continuedAt="F_80b2edf9-3b74-4482-ac43-ba7123d94a47_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our restricted stock unit activity during the year ended December 31, 2022:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_80b2edf9-3b74-4482-ac43-ba7123d94a47_1"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.001%;"></td>
        <td style="width:1.104%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.636%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.555%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.703000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, unvested as December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c27b8aa8-d184-48f7-bd4f-0096df18d8ef" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">708,800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60b52b1b-25a5-4083-85b6-81ebbcc49dd4" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9347f20-ed77-468a-8485-5282e9c96ad3" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">350,173</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29338451-c7a4-4d64-93e0-9e95614de748" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58557186-a0fa-4378-829d-da6ff1daedd8" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">353,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05eb715b-aecd-4346-a3e5-04ca28b69d9d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canceled/Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc371c74-9172-46f3-b3d4-addf857ad6bb" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">144,147</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b3031ed-f28d-4145-a616-4bc1b3e4330b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, unvested as December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f39f7de9-4ddc-4e2c-9a20-261fc4ec148d" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">561,526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63c7887a-61f6-4792-a4ed-ed236b3313ed" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.38</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c90913a5-7f0d-4863-9e86-0b42e767daf9" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation for all awards granted to employees, consultants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018 ESPP, before taxes, is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.361%;"></td>
        <td style="width:1.468%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.610999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.468%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.610999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.468%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.011%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b1a7267-a277-4efb-a563-52dd8d21a720" contextRef="C_96bf1cf8-19d9-4d23-983b-756892fd1ff2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,730</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a1812c2-a0f4-4d14-a3c3-db5da827e374" contextRef="C_cba7109a-fc2f-4241-85c7-7086ee1b9b30" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4b20271-f946-43e4-874b-6ba775e01da9" contextRef="C_59f476dd-dd0f-4391-85f3-c22402209e5b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf26f17e-180a-461f-b96f-424675c19be5" contextRef="C_f75e133a-4af4-4545-85f4-a47ee76a38e9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,827</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_920ba5d8-3aa9-46a5-bf31-75e04e861918" contextRef="C_153cf958-71d1-4706-b096-247c7c793c25" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,926</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb9e78d9-ce10-49c9-8d24-d5a9ab0bb988" contextRef="C_8a3ecee8-3b5e-4aae-bb83-c0cec0cf42ec" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bce77c59-5e06-4149-b3f0-bc9cead8b53a" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6d465c6-10f1-4b1f-93fb-ae3583d52ecb" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,552</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68a0bbc5-623b-43d6-b82a-24d7c9dde158" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,110</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_12aa3d0d-70d0-446e-9a1b-21166d37b646" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.	Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective tax rate for the years ended December 31, 2022, 2021, and 2020 is different from the federal statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54ad75ce-7850-4132-828d-6f08ac0ee504" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_54ad75ce-7850-4132-828d-6f08ac0ee504_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective tax rate of the Company&#x2019;s provision for income taxes differs from the federal statutory rate as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_54ad75ce-7850-4132-828d-6f08ac0ee504_1"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.715%;"></td>
        <td style="width:0.999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.098%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.098%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.089%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e570cf60-9dbc-4ff7-b936-fdb00efcadb7" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bd34dca-130a-4432-bccd-9caf17901a3b" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39273ab9-a0c4-456e-a45f-e07c00de727a" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e7ac11c-2bf2-4945-8b90-632939a5c269" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02e49296-6221-4560-90a3-83b7e739c04b" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ad21dcf-57af-438f-8e8f-81e59da98f93" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aabedf4a-5a97-430c-a817-0092085da3f1" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9969314-7819-4269-b0dc-23de2474f9fa" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df5e5229-afb4-4777-9a6c-ae9a2f52428e" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11922b73-a58b-4a42-8d35-99eb9cdfe5fb" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d022999-a184-47f5-80fb-91cd3f1450f3" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_082848b5-0b93-4414-b320-05657bcaa0c0" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5748408-5bd7-4403-bf15-99e858f1e278" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee78190a-8832-41fa-88cd-6de345b4c018" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b88d8e9-6223-4133-95b1-62229ba1b5ed" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in state tax apportionment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fca21f5-cae9-438d-ae85-6e145bf2f88b" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d45721ad-c60d-4cb1-8847-6fd90933b4ce" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb1a472e-a041-4114-baba-cc9298f0d960" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-taxable stock premium</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61e69d52-6d24-4231-8066-d3da93d4c2b7" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:NonTaxableStockPremium" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c73fc160-5564-4072-8404-be7bd1f45732" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:NonTaxableStockPremium" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_406909c5-2d2c-4107-ae53-908a967df98b" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="grts:NonTaxableStockPremium" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_589325eb-f522-4fb7-8ddb-b70efbc43332" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">28.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb39c313-1cba-4233-a793-d66356e16ac5" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">33.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c9bc34d-dd29-4192-99f4-6e5c6644d8ea" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">40.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_208e6ce1-24ba-444c-9a62-2edc5c1a4281" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_897f7f06-5238-46b2-a61f-0900ff9bacac" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac784648-8513-46de-9b31-1784a1ce7250" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#x2019;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are fully offset by a valuation allowance at December 31, 2022 and 2021. The deferred tax assets were primarily comprised of federal and state tax net operating losses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tax credit carryforwards. The increase in valuation allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf66b594-b7d0-4180-ad7b-4ec934260598" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">33.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_957211ec-72f6-4e34-b79d-f2a4912df669" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during 2022 and 2021, respectively, was primarily attributable to the Company&#x2019;s current year taxable loss and increase in the effective state tax rate due to changes in the Company&#x2019;s state apportionment factors.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1689e284-5b99-481e-b90e-c982fa5b2192" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the net deferred tax assets/liabilities are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.822%;"></td>
        <td style="width:1.554%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.437999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.554%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.632%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d82d0d9-04a6-40aa-80ef-e2914f2f69a5" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60998d88-1913-4553-9f55-e36f9fbaca22" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,575</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fecb5cb4-93aa-476c-ad96-cb311dc2d99a" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adc4bc95-9acc-4c59-8e1d-7fe86b0a4108" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db17336c-1bb0-4b23-a0e6-430297d04f10" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37fb9c6e-d408-4c34-8181-2022fbc204d4" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,684</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb7720a5-e48a-40da-bf8f-a0ed1d1b90dc" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,786</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0d5bd56-9c69-4b9c-b3d9-6ceb5e6804e0" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5aaeba2c-0afe-4403-a2ba-c99bbbed651a" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DeferredTaxAssetsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_104e3019-2942-49eb-a27e-7bbe40049da1" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:DeferredTaxAssetsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69af3aef-4276-44fd-97cb-fbfa4b6c1b55" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99fb1d1f-3c3f-4f0b-b531-349c437d5cab" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,537</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efef91f6-453e-446b-85b2-d431d4e93812" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DeferredTaxAssetsOtherDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">449</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29aa0764-e43b-4aca-8161-6e7185bd63d0" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:DeferredTaxAssetsOtherDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 Capitalized Expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86c4ce53-2b7b-47e3-ad67-e874f3435ecd" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DeferredTaxAssetsCapitalizedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85067068-905d-4577-923e-30818b4a3f10" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:DeferredTaxAssetsCapitalizedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff5b396a-443a-4a4b-8528-6e4db9899329" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,905</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01f6d2a7-9e86-4a0a-b0bc-01458cb211b2" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,884</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a207db4-3de1-424e-839f-b6e655175ecb" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8231d9c5-b6e7-4dc4-a8cc-4926a7ede901" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3f6655f-e17f-4081-a32a-170c2899962c" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63284068-60fb-4566-b515-060351191501" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34ab4c62-7638-4ac2-b723-c52beeef4ea8" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DeferredTaxLiabilitiesOtherDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82d79d1f-260d-439d-9a4e-a0f8d52b45ed" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:DeferredTaxLiabilitiesOtherDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">212</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f77b03ab-98c0-41eb-93c9-ea7bfaaa881b" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0133b96f-b2d9-4412-8b0e-c17a3df97d5e" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net of allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6142bf8f-f86d-4d96-9361-ce9e8483340d" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84d6eaab-2010-49b4-9e90-59843f565d61" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning January 1, 2022, the Tax Cuts and Jobs Act (the &#x201c;Tax Act&#x201d;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Section 174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the Tax Act, deferred tax assets related to capitalized research expenses increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c946c233-424b-4548-b98f-1183645f73d6" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="grts:DeferredTaxAssetsCapitalizedExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company&#x2019;s federal and state income tax net operating loss carryforwards were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42bf2e28-a8a5-46ca-b824-88ab97056a46" contextRef="C_0147e0c5-b128-4b28-ab85-a4f52bbc6baa" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">369.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23392848-7917-4a1f-924d-377cec176277" contextRef="C_97f8a7f4-7c61-4b23-aa03-20ff4c118788" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">465.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, which may be subject to limitations as described below. If not utilized, the federal tax loss carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7149b817-456b-4faa-97dd-4871811939ac" contextRef="C_49045c9c-a554-4324-9d92-9288a8abef99" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the state tax loss carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d60186d-ff9e-4ec2-96f3-d7693ae73f38" contextRef="C_450aa048-1aac-4500-be64-715518ae710b" name="grts:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the Tax Act, federal net operating losses generated after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. The federal net operating losses generated after December 31, 2017 of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77d83950-61cc-4af3-b7ac-b87d875e5dd8" contextRef="C_e244d887-8d8a-4495-81bd-72528b63162d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">319.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are carried forward indefinitely. In addition, the Company has certain federal, California and Massachusetts research and development income tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa7fff9e-3716-450e-9930-21a711455446" contextRef="C_881d2648-16d5-4b0f-8455-333f723dd233" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f641cdae-1781-4535-b328-e3b6092daf73" contextRef="C_c6e2641f-a8ab-46ff-80f9-1485fe4c2082" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8911aae7-6d5b-495d-97ae-ad14bf340bc1" contextRef="C_e56f5102-fdf2-4a2e-919e-b83d8075a4bd" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. If not utilized, the federal research and development income tax credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b7a3315d-afa9-4665-a2d5-9110c3a9edc4" contextRef="C_1b36e023-4632-4679-a7c3-29a735d1414a" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The California research and development income tax credit carryforwards do not expire and can be carried forward indefinitely. The Massachusetts research and development income tax credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_79279abd-1a7e-4d8e-843f-3d1b40f3f2d8" contextRef="C_3f4d3587-5707-477a-b168-bf3fd63a1a9e" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c9c4087-5be4-4dea-887f-2573c051c89a" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss and tax credit carryforwards as of December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.464%;"></td>
        <td style="width:1.461%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.627%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.461%;"></td>
        <td style="width:20.987%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses, federal (post December 31, 2017)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82b8a70a-930b-4c37-ae76-4d1285df4a17" contextRef="C_afcbe2f3-7dd3-4f15-8cd0-c1d773ae4308" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">319,266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d2bd7673-eb40-4028-bdd4-3e76df590fc9" contextRef="C_5f1453e1-ff34-4769-91d5-33383d153a3f" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Do not expire</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses, federal (pre January 1, 2018)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_772e11bf-4bd1-4e68-a7b0-2285f2406c02" contextRef="C_5fb39eda-b901-4cdd-9a32-7c015ae8998c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6bc5705f-b2d3-4b05-acbe-b9c433a0cfbe" contextRef="C_a51fab37-6bd0-4cae-b9b3-b2a75e0d44b3" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2037</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_156e59b7-7fb7-4aef-9277-01a215defbb0" contextRef="C_97f8a7f4-7c61-4b23-aa03-20ff4c118788" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">465,623</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cdbc1ceb-1c92-4b38-abea-8c7e57d20863" contextRef="C_450aa048-1aac-4500-be64-715518ae710b" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2042</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits, federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2119c5a9-b6cb-49f7-8fd7-bd7d9683f5f0" contextRef="C_0147e0c5-b128-4b28-ab85-a4f52bbc6baa" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,669</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_611b48bf-093e-40c4-8450-3529aa31bf26" contextRef="C_49045c9c-a554-4324-9d92-9288a8abef99" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2042</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d7667e2-719a-4d87-b23c-50dddf25969a" contextRef="C_97f8a7f4-7c61-4b23-aa03-20ff4c118788" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,160</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7e3f779d-346a-40ef-96d3-0feac4ec9d3c" contextRef="C_450aa048-1aac-4500-be64-715518ae710b" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA: credits do not expire<br />MA: 2035 - 2042</span></ix:nonNumeric></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0afe739-cb7d-4da1-8c9f-3bf59aeaee23" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:OwnershipInterestChangeOverPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8612a836-b33a-4c99-b156-b32b68552757" contextRef="C_12768f52-aae1-4e43-bb4c-1b4a1aca508a" name="grts:CumulativeChangesInOwnershipInterestOfShareholders" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as defined under IRC Sections 382 and 383. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. Subsequent ownership</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may further affect the limitation in future years. In connection with the Company&#x2019;s IPO, which closed in October 2018, the Company did experience an ownership change pursuant to Section 382. There was no reduction in federal or California net operating loss carryforwards or research and development income tax credits as a result of this ownership change. The Company is in the process of completing an analysis through December 31, 2022 under IRC Sections 382 and 383 to determine if the Company&#x2019;s net operating loss carryforwards and research and development credits are limited due to a change in ownership and may have an ownership change pursuant to Section 382.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3e35706c-ce20-4108-a2ce-5ac8bf471cd2" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.281%;"></td>
        <td style="width:1.162%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.593%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.162%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.593%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.162%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.048%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning of year&#x2014;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71de2410-b3d4-43ae-baa7-494e5f563e11" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d7ee503-7fa0-4667-83f5-00cd71e19554" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c69e6461-accf-4245-95a6-52d542aaa2da" contextRef="C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,610</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decrease for tax positions taken during prior periods</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_928208fb-22d3-4258-9688-a0ff13100579" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd5811c3-73e2-4356-81c8-919e50d72d80" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7c3a669-024f-4743-97f0-d4cf5c5594d8" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases for tax positions taken during current period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d853925-af11-456a-a4a1-b19d9ae68be9" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,234</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dfc9109-f0b9-411b-8c59-6c914f6d1a7e" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,456</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffcb630e-adfd-44ff-b625-d67d82a76e5f" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">End of year&#x2014;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d684fde7-60fc-4076-b541-019b627afdbd" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65cc7201-a28c-4259-a8df-ed5070f5ebdf" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc32b27d-2e36-4671-830d-1a0417065f46" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If recognized, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90cc3c3e-07ec-48c4-bde6-841c485ca7d7" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7b050b2b-af49-4173-86d6-417640e33471" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3b57eeae-ea96-4b07-bbd4-30a02a6fd3c3" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the unrecognized tax benefits as of December 31, 2022, 2021, and 2020 would impact the annual effective tax rate, primarily due to corresponding adjustments to the valuation allowance. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next twelve (12) months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022, 2021, and 2020, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_834dca26-42ca-4d50-bd29-8029872c1e6b" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8817c33c-6280-4c6e-9b0e-659447fc2910" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_53b18b1e-ad1a-4278-b947-0495cde5ed87" contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize accrued interest and penalties related to unrecognized tax benefits.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is not currently under audit by the Internal Revenue Service or other similar state or local authorities. Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States and various state tax jurisdictions in which the Company files tax returns.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_efc2d671-bb01-40df-a1d3-a88e723ea8b5" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.	Net Loss Per Common Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f386e674-65c5-4f5b-9634-01011b40f7aa" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.807%;"></td>
        <td style="width:1.175%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.058000000000002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.175%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.707%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.175%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.902%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2275d11d-ed8b-42e1-93b2-145551d548fd" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">119,687</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0504b98-360e-4cbf-a68a-6a8bb283cae7" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b550bfbb-af43-49b4-a26e-f04c90acd5a9" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a9d7d74-9475-44a6-9781-add0bc811c0e" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_11c1ad05-d831-4185-9614-ee02d2be190c" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">90,918,333</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0b75f4c-6297-46f5-b715-893212507cdc" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_864ccaed-121e-4ce6-a7a9-6cdf4729e966" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">78,885,186</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_459e50fa-10c0-498a-a074-154105f9a081" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c76f1037-d2d3-4d13-9574-fe970d11f8a2" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">37,792,365</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fc5f50d-e66c-4ec0-aff7-1e7492135401" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_97993990-38f9-44ec-af3a-2e3d7d3a0d7d" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.32</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_417d4cdf-82a9-4768-a16d-f4f8755cb1aa" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_03a21803-2258-420c-b73b-06e51ca2ed80" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.95</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a140d1dd-9bba-4c2b-9a35-8ccf2a9f1b93" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_96e8163e-b4a3-4e9c-b800-b9c3dc0ca57d" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.79</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, the Company issued and sold Warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50c91912-0831-4cb4-b1c7-b74b8e42b7e5" contextRef="C_1929cfb6-f656-448a-9d1f-c017d3968257" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,480,719</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a nominal exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fbcba6f-2792-4cb6-8e1c-86bef9c97eb6" contextRef="C_c3371e94-abb3-4b37-894a-d4cc941cf1f3" name="grts:ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and in October 2022 the Company issued and sold Warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfcbd0ea-b069-4573-a2f9-903684382759" contextRef="C_687162ff-aef8-4232-aaec-424cb6facc45" name="grts:WarrantsToPurchaseSharesOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,274,923</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a nominal exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_659c463b-eac3-4c8c-9aec-eea324d2d3e5" contextRef="C_217b0356-637c-4019-9519-2b40884dd4ea" name="grts:WarrantExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (see Note 10). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95800beb-39dc-4e21-a8c8-e0bfa085e657" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="grts:ClassOfWarrantOrRightWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,442,567</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants were exercised, resulting in the Company issuing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a0fa90d-95b2-4994-856a-36fe93fb3fe9" contextRef="C_d0c4fb4f-d485-41f4-b896-f24d5158e36f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,442,567</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46ea8518-98d4-4143-98de-2b0bd14c20ae" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:ClassOfWarrantOrRightWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,459,576</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants exercised and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8aefddb-c227-4cb4-9a2f-75fa41ebcdab" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="grts:WarrantsCancelled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,872</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants cancelled due to net exercise of the warrants. As of December 31, 2022 and 2021, there are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_893addcb-8b1b-4cd3-a9f4-15d0dbb6ceab" contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,848,627</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7460a9d5-c84c-48af-96f0-ad02b63c1659" contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,016,271</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants outstanding, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares of common stock into which the Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and they are immediately exercisable upon their issuance date.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During a period of net loss, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential common shares outstanding would have been anti-dilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fb372bdc-83ed-4c9b-8db7-df60d1910254" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_fb372bdc-83ed-4c9b-8db7-df60d1910254_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_fb372bdc-83ed-4c9b-8db7-df60d1910254_1"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.932%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.433%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.433%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.141%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding and ESPP shares issuable and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82b4c190-faf1-41ea-a08b-4ea80991c880" contextRef="C_fc627979-580d-42ff-87f9-72f185ff83f5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,145,817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53aac293-6ef6-49ea-9ed3-9fd8da144a71" contextRef="C_822e2920-cab6-4373-82cb-898c8cc385e6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,170,331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a77408e-e104-427b-a47b-698f9898dd60" contextRef="C_bcae57c0-074c-498e-8541-1149ef409ac8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,213,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a826c2af-85fc-439a-a841-1563a1d47ff7" contextRef="C_ba0f5eb4-07a4-4e13-a684-5ff64c100781" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">561,526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0f01fe9-1373-4e50-b8aa-9fc4db886d82" contextRef="C_024d46a7-8550-44bd-aba2-8e45d258d9a6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">708,800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cbeddd4-40a8-4692-a051-6ea780dc13da" contextRef="C_138bc03a-533d-4ac5-8b52-13e19b3633e1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00b0fc30-4de9-4b99-943e-e1e34182f8f5" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,707,343</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09c7c4e7-b1c3-4d8b-99ef-18f6ab85f351" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,879,131</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a67dcc3-a788-4d9c-a4e2-fc63a4a431a3" contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,213,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d015722b-3181-4779-92c4-5d3de600d8ac" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.	Defined Contribution Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company began sponsoring a 401(k) Plan in 2017, which provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_159c7cd8-107a-43e9-bc24-014da532899c" contextRef="C_a6647160-7b5e-4902-9018-3678bdb60427" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the first </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4efd3955-067e-475f-9ecd-b6e92b51edb0" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of each employee&#x2019;s contribution. During the years ended December 31, 2022 and 2021, expenses recognized for the 401(k) Plan was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e57818de-4271-4bb3-ac8a-028341188396" contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21092090-749a-4b39-a427-f9497eb798c9" contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, while the amount was immaterial for the year ended December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements With Acco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">untants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, management, with the participation of our principal executive, financial and accounting officers, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including the principal executive, financial and accounting officers, to allow timely decisions regarding required disclosures.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2022, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the year ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:6.107%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision of and with the participation of our Principal Executive Officer and our Principal Financial Officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#x201c;Internal Control-Integrated Framework&#x201d; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>
  <p style="text-indent:6.107%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9c_disclosure_related_to_foreign_ju"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Dis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">closure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers, employees and consultants. The Code of Business Conduct and Ethics is available on the Corporate Governance page of our website at www.gritstonebio.com. If we ever were to amend or waive any provision of our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer, controller or any person performing similar functions, we intend to satisfy our disclosure obligations with respect to any such waiver or amendment by posting such information on our internet website set forth above rather than filing a Form 8-K.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A in connection with our 2023 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;), which is expected to be filed not later than 120 days after December 31, 2022, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits and Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-2.432%;padding-left:2.267%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) The following documents are filed as part of this report:</span></p>
  <p style="margin-left:4.533%;text-indent:-2.432%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	Financial Statements</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="margin-left:4.533%;text-indent:-2.432%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Financial Statement Schedules</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></p>
  <p style="margin-left:4.533%;text-indent:-2.432%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	Exhibits</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The documents listed in the Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:52.241%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:8.12%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:9.278%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:6.981%;"></td>
    <td style="width:3.398%;"></td>
    <td style="width:7.241%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;display:none;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;display:none;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.1pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;display:none;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;display:none;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.1pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.1pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.1pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.1pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1(a)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290860/d623029dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/02/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001656634/000119312521152379/d403517dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate of Amendment to Amendment and Restated Certificate of Incorporation.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">05/06/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290860/d623029dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/02/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference is made to exhibits </span><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290860/d623029dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(46,116,181,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;through </span><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290860/d623029dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(46,116,181,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Common Stock Certificate.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017022003366/grts-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Common Stock.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/10/22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312520326728/d51703dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Pre-Funded Warrant issued in First PIPE Financing.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/28/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312522268408/d341720dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Pre-Funded Warrant issued in Third PIPE Financing.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/25/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1(a)&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518255669/d565416dex101a.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement, dated as of October 16, 2017, by and among Gritstone Oncology, Inc., Arbutus Biopharma Corporation and its subsidiary Protiva Biotherapeutics Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/23/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1(b)&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518255669/d565416dex101b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment Number One to License Agreement, dated as of July 20, 2018, by and among Gritstone Oncology, Inc., Arbutus Biopharma Corporation and its subsidiary Protiva Biotherapeutics Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/23/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017022003366/grts-ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration, Option and License Agreement by and between Gilead Sciences, Inc. and Gritstone Oncology, Inc., dated as of January 29, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/10/22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3(a)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290941/d612395dex992a.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/02/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(A)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3(b)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex107b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3(c)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex107c.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Award Grant Notice under the 2018 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3(d)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex107d.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Unit Award Grant Notice under the 2018 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4(a)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312521153495/d303641dex991.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Employment Inducement Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">05/06/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4(b)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312521153495/d303641dex992.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Agreement under the 2021 Employment Inducement Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">05/06/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4(c)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312521153495/d303641dex993.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Unit Award Agreement under the 2021 Employment Inducement Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">05/06/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4(d)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312521153495/d303641dex994.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Award Agreement under the 2021 Employment Inducement Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">05/06/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:52.241%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:8.12%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:9.278%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:6.981%;"></td>
    <td style="width:3.398%;"></td>
    <td style="width:7.241%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement by and between Gritstone Oncology, Inc. and Andrew Allen, M.D., Ph.D., effective as of September 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement by and between Gritstone Oncology, Inc. and Matthew Hawryluk, Ph.D., effective as of September 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement by and between Gritstone Oncology, Inc. and Karin Jooss, Ph.D., effective as of September 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement by and between Gritstone Oncology, Inc. and Erin Jones, effective as of September 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017022003366/grts-ex10_10.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement by and between Gritstone bio, Inc., and Vassiliki Economides, effective as of June 23, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/10/22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017022003366/grts-ex10_11.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Program.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/10/22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290941/d612395dex993.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018 Employee Stock Purchase Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/02/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518255669/d565416dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease, dated as of February 11, 2016, by and between Gritstone Oncology, Inc. and BMR-Sidney Research Campus LLC.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/23/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518255669/d565416dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office Building Net Lease, dated as of March 24, 2017, by and between Gritstone Oncology, Inc. and Hacienda Portfolio Venture, LLC.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/23/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312519028323/d702385dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office/Laboratory Lease, by and between Gritstone Oncology, Inc. and Emery Station West, LLC, effective as of January 28, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02/05/19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001656634/000156459019042681/grts-ex102_207.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office/Laboratory Lease, by and between Gritstone Oncology, Inc. and MIL 21E, LLC, effective as of September 6, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/20/19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001656634/000156459019042681/grts-ex103_206.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Office/Laboratory Lease, by and between Gritstone Oncology, Inc. and MIL 21E, LLC, effective as of July 11, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/20/19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000156459020036449/grts-ex101_78.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Office/Laboratory Lease, by and between Gritstone Oncology, Inc. and MIL 21E, LLC, effective as of May 20, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/05/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017021001926/grts-20210921ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office/Laboratory Lease, by and between Gritstone bio, Inc. and RREF II Kenmore Lessor III LLC and RREF II Kenmore Lessor IV LLC, effective as of September 23, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/29/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017021001926/grts-20210921ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Lease, by and between Gritstone bio, Inc. and MIL 21E, LLC, effective as of September 21, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/29/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017021001926/grts-20210921ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Office/Laboratory Lease, by and between Gritstone bio, Inc. and MIL 21E, LLC, effective as of September 21, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/29/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017022014827/grts-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Amendment to License Agreement between Gritstone bio, Inc. and MIL 21E LLC, effective as of June 6, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/04/22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex10_22.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment to License Agreement between Gritstone bio, Inc. and MIL 21E LLC effective, effective as of June 13, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312520326728/d51703dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Purchase Agreement, dated December 22, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/28/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.25</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312520329870/d101143dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Purchase Agreement, dated December 28, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/30/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017022021895/grts-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement between the Company, Hercules Capital, Inc. and Silicon Valley Bank and certain other parties thereto, dated as of July 19, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/03/22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:52.241%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:8.12%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:9.278%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:6.981%;"></td>
    <td style="width:3.398%;"></td>
    <td style="width:7.241%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification by the Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 36 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cover page from the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 20221 has been formatted in Inline XBRL.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134;	Confidential treatment has been granted for certain information contained in this exhibit. Such information has been omitted and filed separately with the SEC.</span></p>
  <p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">#	Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*	The certification attached as Exhibit 32 that accompanies this Annual Report on Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Gritstone bio, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.88%;"></td>
    <td style="width:1.62%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GRITSTONE BIO, INC.</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;/s/ Andrew Allen</span></p></td>
   </tr>
   <tr style="height:7.9pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Andrew Allen, M.D., Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Andrew Allen and Vassiliki Economides his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitutes or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.991%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:45.0%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:17.843%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Andrew Allen</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;President, Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Andrew Allen, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vassiliki &#x201c;Celia&#x201d; Economides</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vassiliki &#x201c;Celia&#x201d; Economides</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ James Cho</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Accounting Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James Cho</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Elaine Jones</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Chairperson of our Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elaine Jones, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Clare Fisher</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clare Fisher</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Steve Krognes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Steve Krognes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Naiyer A. Rizvi</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Naiyer A. Rizvi, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lawrence Corey</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lawrence Corey, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Shefali Agarwal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shefali Agarwal, M.D., M.P.H.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>grts-ex10_22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	&#160;</font></p>
  <p style="margin-left:27.52%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.22</font></p>
  <p style="margin-left:27.52%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.667%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment to License Agreement</font></p>
  <p style="margin-left:1.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.653%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Fifth Amendment to License Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is dated June 13, 2022 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and entered into by and between Gritstone bio, Inc., formerly known as Gritstone Oncology, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and MIL 21E, LLC (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.653%;text-indent:6.853%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Licensor and Licensee are parties to a certain License Agreement dated September 6, 2018, as amended by that certain First Amendment to License Agreement dated July 11, 2019, as amended by that certain Second Amendment to License Agreement dated May 20, 2020, as amended by that certain Third Amendment to License Agreement dated September 21, 2021 as amended by that certain Fourth Amendment to License Agreement dated June 6, 2022 (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;);</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.653%;text-indent:6.854%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Licensee warrants and represents that, to the best of its knowledge, Licensor has fulfilled its obligations under the License Agreement and is not in default of any covenants or obligations contained in the License Agreement;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.653%;text-indent:6.855%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.093%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Licensor and Licensee desire to amend the License Agreement in certain respects as set forth herein; and,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.653%;text-indent:6.856%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, all capitalized terms contained herein shall, unless otherwise defined in this Fifth Amendment, have the same meaning as set forth in the License Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.653%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree that the License Agreement agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">1.</font><div style="display:inline;" id="x__parking__the_license_agreement_is_her"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parking</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The License Agreement is hereby amended by adding the following language to the end of Section 6:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="subject_to_ongoing_availability__license"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to ongoing availability, Licensee shall have a non-exclusive, revocable license to use one</font></p>
  <p style="margin-left:8.32%;text-indent:-0.015%;padding-left:0.013%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) additional unreserved parking space (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Parking Space</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Licensee shall be responsible for the Additional Parking Space Fee (defined below) for such space regardless of whether its Occupants use the Additional Parking Space. Licensee shall pay, in addition to the License Fee and Parking Fees, a monthly parking fees equal to the prevailing rate for the Additional Parking Space (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Parking Space Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and shall pay such Additional Parking Space Fees to SmartLabs at the time each License Fee payment is due.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">2.</font><div style="display:inline;" id="x__ratification__except_as_amended_herei"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ratification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Except as amended herein, all terms and conditions of the License Agreement shall remain unchanged and in full force and effect.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">3.</font><div style="display:inline;" id="x__counterparts__this_fifth_amendment_to"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Fifth Amendment to License Agreement may be executed in any number of counterparts, each of which shall be an original and all of which together shall constitute one and the same document.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">[signatures on following page]</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	&#160;</font></p>
  <p style="margin-left:1.653%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Licensor and Licensee have duly executed this Fifth Amendment as of the Effective Date.</font></p>
  <p style="margin-left:1.653%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.657%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.995%;"></td>
    <td style="width:50.005%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.95pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LICENSOR</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.95pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LICENSEE</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.95pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Brian Taylor</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.95pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Erin Jones</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.95pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: Brian Taylor<br>Title: Head of Field Operations</font></p><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.95pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:8.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: Erin Jones<br>Title: Chief Operating Officer</font></p></td>
   </tr>
  </table>
  <p style="margin-left:1.653%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>grts-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statements (Form S-3 Nos. 333-234211, 333-252564, 333-260292, 333-263455, and 333-268524) and related Prospectuses of Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc.),</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statements (Form S-8 Nos. 333-230581, 333-237095, 333-254177, 333-255847, 333-263451 and 333-264804) pertaining to the 2018 Incentive Award Plan, the 2018 Employee Stock Purchase Plan, and the 2021 Employment Inducement Incentive Plan, in each case, of Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc.), and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-227665) pertaining to the 2015 Equity Incentive Plan, the 2018 Incentive Award Plan and the 2018 Employee Stock Purchase Plan, in each case, of Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc.)</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated March 9, 2023, with respect to the consolidated financial statements of Gritstone bio, Inc. included in this Annual Report (Form 10-K) of Gritstone bio, Inc. for the year ended December 31, 2022.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>grts-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER PURSUANT TO <br>EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A), <br>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Andrew Allen, M.D., Ph.D., certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Gritstone bio, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:45.926%;"></td>
    <td style="width:1.028%;"></td>
    <td style="width:3.056%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:3.056%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:44.898%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March  9, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid rgba(0,0,0,1);margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Andrew Allen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Andrew Allen, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>grts-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO <br>EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A), <br>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Vassiliki Economides, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Gritstone bio, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.546%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:3.444%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:3.157%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:44.519%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid rgba(0,0,0,1);margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vassiliki Economides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vassiliki Economides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>grts-ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Gritstone bio, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of Andrew Allen, M.D., Ph.D., President and Chief Executive Officer (Principal Executive Officer) of the Company, and Vassiliki Economides, Chief Financial Officer (Principal Financial Officer) of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.467%;text-indent:-3.591%;padding-left:3.467%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:3.467%;text-indent:-3.591%;padding-left:3.467%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.467%;text-indent:-3.591%;padding-left:3.467%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.861%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.259%;"></td>
    <td style="width:48.88%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.25pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Andrew Allen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Andrew Allen, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.25pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vassiliki Economides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vassiliki Economides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img97084416_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img97084416_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ($!& # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRWE1X 5!EG8]%'O6I7+^/M,TO6/#3V&J:I;Z<'<-!//(J*)!G'4C/&>*:WU
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M;Q\R&U=F*#U(*CCZ9IWB!SO_  D.M_\ 08U#_P "7_QH_P"$AUO_ *#&H?\
M@2_^-;&@?#[6_$FAS:KI_P!G,4<IB6*1F5Y&&/N\8Q\W4D=#Z5/XC^&NN^&-
M)_M.\:TEMU8*_D2,Q3/ )RHXS@<9ZT7C>P&!_P )#K?_ $&-0_\  E_\:/\
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M#HKR#X374\'BO6]'L[^6]T2!"T4K'Y=P<!2/3(W=.N*X_P *>)9O"GC:YOI
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M>#4IVDA6)F+*"[-\P*@#AAT)JMH?@*XM=9\5S:I);2V.M/)L2%VWJK.QYRH
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MQ7K]W8VFH0&&]M8+F(]4FC#K^1J.QTO3],1DL+"UM%;[PMX5C!^N!5J>E@/
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MPTXRFQL;:U,QW2&")4WGU.!R>31S[V \(^'1OT^*5C::EN%S9PRVQ#=5"(P
M_#H/;%7+&'Q'XU^(&K^(/#=Y:VS6DGE137(R A!10HVL,E02>._O7M!T?3#?
MM?G3;,WC@AK@P+YA&,8+8STX^E.L=+T_2XWCT^QMK1'.YEMX5C#'U( &:'4Z
MB/%9HO$'@?XCZ7K7B.[MKAM08I-/;#"LG"MD;5&0"IZ=J]UJI?:7I^J(B:A8
M6MVB'*K<0K(%/J,@XJTJJBA5 "@8  X J92N,6BBBI **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HK+L/$6EZBKF&Z161BK)*=C#'L:;=^)]%L
M@?.U&#(_A1MY_(9J_93ORV=S/VU.W-S*QK45R?\ PL30_-V#[45_OB(8_GG]
M*Z2ROK;4;5+FTF66%NC+_(^AISHU(*\E85.O3J.T))EBBBBLS4**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\M7X&
MZ(J@#5-0X&/X/_B:]2HIJ36P'EW_  H[1/\ H*:A_P".?_$T?\*.T3_H*:A_
MXY_\37J-%/GEW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGE
MW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_
MT%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:
M/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_
M\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGE
MW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_
MT%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:
M/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_
M\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGE
MW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_
MT%-0_P#'/_B:/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:
M/^%':)_T%-0_\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:/^%':)_T%-0_
M\<_^)KU&BCGEW \N_P"%':)_T%-0_P#'/_B:\@\2Z7%HGB34-,AD>2*VF,:L
M^,D>^*^L*^8O&]O-=_$;5K>WB>6:2[*)&@R6)Q@ 5I3DV]1,YNWMYKNXCM[>
M)Y9I&")&@R6)Z "OH3X>?#R'PM;K?WZI+K$J\GJ+<'^%??U/X#CJ?#SX>0^%
MK=;^_5)=8D7D]1;@_P *^_J?P'&2>]I5*E]$ 4445D,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DT
MT=O!)/,X2*-2[L>B@#)-9GAWQ!:^)M*&I64-Q';-(R(9U"E]IP6 !/&<CGGC
MI7.?%O4);#P#<K$2INI4@)']TY)_,+C\:R?%-WJ?A7X4:.FC%XCLACGGB&6C
M4H2Q'IEN_;/O5J-T!Z?17BV@:^)=>TU]$\9WDBNP6ZLM?F;+\CA&"E<GG R#
MG'6NH\:2SC7X%U'Q;'HFB+%GRK2Y*7<K>N IXSQWZ>]#AK8#T&BO(O 7B74+
MUO$]@=7N=0L[6WDDL[F<GS<#(!R>>1@\]#6!H*>,->\%:GK"^*[Z"WTSS'5#
M*Y>5E0.P+[L@8QC.1GL.:?LP/?*Q?$_B:R\)Z4-1OXKB2$RB+; H+9()[D<<
M5Y*MWXQU[P'+XG;Q+-;1Z>-B0090S;2 6=E(YY[@YQVK0\9:I<ZS\$](O[Q@
M]Q+<)YC8QN(\Q<_CBCDUU$;2_&[PR6 -GJJ@]S#'Q_X_76_\)?I+^$Y/$EO)
M)<6$:%V$:_.,'!7!(P0?6O,-1^)NH#P_'H=SX4:W:YM1!%)>3$*X*A0V&0 C
MH>N/>M6W\-WGACX)ZS:W^T7,X:X9%8,(\[ !D<=%S^--Q0'>>&/%.G>+=,:^
MT[S55',;QS !T/N 3U'3FH_#?BZP\4R7Z6,-S&;&01R>>JC).>F&/'RGTKQO
MP;?77@34-'U6X<G1M:B*S'LA#%<GW4\_1C78?!T@W7B@@Y!NUP1]7HE!*[ Z
M;Q5\1-&\(W\-E?Q7<TTL?FXMT5MJY(&<L.N#726%]!J6G6]_;$O!<1++&>^"
M,C\:\2MI='\8^,O$^H:MJ=E;6Y@>VL3<SK'R?E1EW'G 7/U:NM^#6MF\\-SZ
M3*X:;3I2%PV<QMDC'KSN_2E*%D!V'ASQ-8^)K2>>S6:)K>4PS0SJ%>-AZ@$C
M]:V:\OT*1M)^..N:?&?]'OX?.*C^_M5\G\2_YUZA4R5F,****D HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%U'PG
MHVJ7!GN+0"9N6>-BI;ZXZU W@O1ELIH+:U6*21=HF;]XR^XW5T-%:JO42MS.
MQC+#T97;BM3@3;G3YI/#OAVSW794"[OIEX4$?_7_ ,,FI_!L']E>(=3TB*Y^
MT0I&DA<=-^!G^9_*NA\1L\6AW,R7'V<(NYV Y8?W1[DXKG?ATMLMO=2-.C7U
MP=[1@\J@X&?Q/\JZ54<J,G;3\V>>J:I8F%-:+IT5M=$OS?4[BBBBN$]8****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIQ4H[,****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI^HH Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***IZG:W-W:;+2\:UG5@ZR*
M,@X[$=Q32N[,4FTKI7+E%<[]E\62_(^HZ? O]^*$LWY-Q7.SIK-E(QU/6[W[
M9(Q%K9VK O)Z,P' %;PH*3MS+\3EJ8IPM>#_  _S_P"'/1**PO"^I7M[9SV^
MI*!?6DGERD8^;C(/'&?\*W:QG!PDXLZ*<U.*D@HHHJ2PHHHH **** "BBB@
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MV"<QB7(SG+*2 3G)].3Q2Z/X GTOQ%=ZS)KDMY/>6K07'G0#+%L?,"&X VC
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M9&^\P!.,^_.*@UOQ-XP.BV>@ZQI^F6%E?PK%%=2*Q4K@8)8,P!Z=LCVKMO\
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MB[,]",E)7B] HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDDFOZ_KJ4? VQ;._CM6D>PCN2MNTG4C S_GWKJZY3PM.=)AM]%O'B%VP++!
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M17W=/S]#SZM"=%KV<GJ[+7K_ %OO^IW%%%%<1ZH4444 %%%% !1110 4444
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M85I\\W+O_7F=-"G[.FH=OG^B_(FHHHK,U"BBB@ HHHH **** "BBB@ HHHH
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M/2MZBBLYSYG=FD(*"LO/\=0HHHJ2PHHHH *H:/-)/92/*Y=A=7" GT69U _
M "I-2U"'2M/EO;A9##$,OY:[B!GKBL#PAXDL=5$]G:B8R+-/.Q9,*%>9F7GU
MPPK:-.3I.26B?^9A.K"-:,&]6GI]Q>\6V<]]H$D5O$TK*Z.T2]74') _SVK:
MC(,2$*5! ^4C!'M3J*AS;BH]C102FY]_T"BBBH+"BBB@ HHHH H:A-)%>Z4B
M.566Z9' _B'DRMC\U!_"K]<AXC\6:;IFMV%M="=9+6X\Z3$>05,,B@@]^7'Z
MUU5M.MU:Q7"*RK*@=0XP0",\BMJE.481DUHT84JL)SG%.[3_ $1C:7:3VWBC
M699H'VW'EO%-CY2H&-N?4>E;U%%9SGS.[-(04%9>?XZA1114EA1110 50FFD
M7Q!9P!R(GM9W9>Q(>( _AN/YU?KB[_QGI=KXKACE6Y$EO%-;NHBR=[/$1CGD
M'8?TK:C3E4DU%7T?Y&&(JPIQ3D[:K\SM*P=(M)[7Q)K3S0/BX9'CGQ\K+@C;
MGU'I6Z#D X(]C2U$9N*:[FDH*33[!1114%A1110 4444 %%%% !1110 4444
M %%%% !1110 5'#-'.A>)PZAF0D>JDJ1^!!%25F:%_R#Y?\ K]NO_2B2J2]U
MLER]Y1]?T-.BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .&\<13SZK91O!XCFL1"Q9='XP^1@L<\\9X[?C6WX0AC@T()'#JT2^8QV
MZJ?WW\SQZ5D>-H8I+ZS;5;34[O11$VZ.PW'$V1@R!2#C&<>A^M:_@]+J/0$6
MY2[C3S7^SQWAS,D.[Y _OCUZ#% &]1110 4444 %%%% 'R!I?_"'_P#"P_!_
M_"*?VY_R%8/M/]J^3_SUCV[/+_X%G/M7U_7SAXET[QS8?$/P!_PFFLV.I;]5
M3[)]D0+Y>)8=^<1IURGKT/3O]'T %%%% !1110 4444 %%%% !1110 4444
M%%?+NDZ)IK:-8F;3+0RFWC+EX%W%MHSG(ZYKUKX?Z7J-QX,M5T_5CI^GK-<J
MD$=NI8$3R!OF[#<&(] 1794PCIQ4I26OJ<%+'*K)QC%NWH>D56N-1L;//VF\
MMX<?\]) O\S6-_PB$$W-]J>IW?JLEP0OY"K-OX4T&UQY>F0$CO(/,_\ 0LUA
MRTENV_D='-6>T4O5_P# _4BF\9Z%$VQ+WSY.R0QLY/Y#%1_\)/<S_P#'CX?U
M.;T:5!$I_$UO0P0VZ[88HXU]$4 ?I4E'-36T?O?^5@Y*KWE;T7^=SG?M7BRY
M_P!5IVGV0/\ S\3F0C_OFC^R?$5S_P ?/B!85[I;6RC_ ,>/-=%11[9K9)?+
M_.X>P3^*3?SM^5CG?^$/M9O^/[4-2O?437)V_D,5;MO"VA6N/*TNW)'0R+O/
M_CV:UZ*'6J/2XUAZ2UY4,BABA39%&D:^B* *?1161L%%%% !1110 4444 %%
M%% !1110!Q_BWGQ=X/'?[9*?_(==A7'^*^?&7@X=_M4Y_P#(==A0 45@W_C#
M2=/\16>@O(\M_=,%\N'#>5D9&_GC(^IJ/Q!XST_P]>1V4EM?7MV\9F,%E#YC
MI&/XVY&!P: .BHKGY_&FBP>&(O$'G/)9S$+$L:9D=SD; O\ >R#^5/\ #WBN
MP\1O=0P0W5K=VK 36MY%Y<J ]#C)X/\ GJ* -VBBB@ HHHH **** "BBB@ H
MHHH **** "F2Q1SPO#*H>.12K*>A!X(IVY=^S<-V,XSSBH;N\@L;<SW$@1 <
M9)ZGTHO;43M;4R/"WAF+PU:7$2N)))I2Q?OL!^4?E^I-;U4--U>WU3S/)#J8
MP#\V"&4]&!4D$<'OVJY%-%.I:*1)%!P2C C-5*HZK<V[D4H0IP4(;(?1114F
M@4444 %%(S*BEF8*HZDG I: .>\0>%+;7M2TV[EP#;2?O01_K(^NW\_T)KH:
MR)_$>GP71@WM(58*[1E2$^;;DC.<9XR 16H\T4<B1O*BN_W5+ %OH.]5[5U$
MH7O8RA"G&4I1W>X^BBBI-0HHHH ***0,I8J&!8=1GD4 -EBCGA>&50\<BE64
M]"#P16)X6\,Q>&K2XB5Q))-*6+]]@/RC\OU)K5OK^VTZ#SKF147.!D@9.,]_
MI46G:K;ZE'*T0=#$0&5\=",@@@D$$'.0::K.*=-/<RE"FZBD]UM\R]13(IHI
MTWPR)(G3<C C]*?2-0HHHH **** "BD9@JEF(  R2>U*"" 0<@]Z .>\0>%+
M;7M2TV[EP#;2?O01_K(^NW\_T)KH:R;SQ%86=PT+,TCI_K!&5)0=R1G) SS@
M'%:3SQ1LBO*BLYPH9@"WT]:KVKJ)0O>QE"%.,I2CN]R2BBBI-0HHHH ***1F
M5%W,P4>I.* %KGKSPI;7?BZTUQMO[I/G3'WW'W&_#_V45T-9/_"1V!O5MD9I
M,N$,B%2JDG R,Y )XSC'O3C6=+5.US*K"G-)3Z._W&M13#-$LHB,J"1AD(6&
M2/I3Z5C4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,T+_ )!\
MO_7[=?\ I1)6G69H7_(/E_Z_;K_THDJU\#]5^IF_XB]'^AIT445!H%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >;^++71M#4+<SZY(8X9
M+@F&]91RP"J3W)8X'H,UT_@SRQH/EK%>0R1S.DT5W/YSQN#R-_<=/SK#^(&H
M:397MI)?:/%?7-O$9[=GE*'?N"H@ Y?+<D<@ 9K=\&RJ^A%!:0VTL-Q+',D,
MGF*9 QW,&/)R3_3M0!T%%%% !17G?Q7U;Q78Z%<Q>'+=88%LY;B\U)I"IA11
M]V/'\9['M[=:QM<\3:Q9?!WPH;2_FCU'6#:6CWS-ND3>N6?)YW<=>O.>M"U5
MUW2^_0;T?WO[CUVLVUU_2[W6[W1K:[674+)4>YA53^[#?=R<8S[9S7F-M>>*
M/"OBG7O".EZC>Z_<OI*WVFG4IU:2.7=L8%VP".2V#@?*!ZYR_A[/>^%O'FJ)
MKFC1Z1#]@A?4;R\U2)]KEW(E=Q@,9';&.W'M0M6NW_#_ .0I:)_+]/\ ,Q/$
MNG>.;#XA^ /^$TUFQU+?JJ?9/LB!?+Q+#OSB-.N4]>AZ=_H^O#_B9KNCZW\0
M_AM_9.JV-_Y.JCS/LEPDNS,L&,[2<9P>OH:]PH **** "BBB@ HHHH ****
M"BBB@ KG-<OI]0O1X?TURLT@S=SK_P L(_3_ 'C5O7M7?3X8[:S42ZE='9;Q
M>_=C["I=#TA=(LBC2&:ZE;S+B=NLCGJ?IZ5M!*"YW\O\SGJ-U)>SCMU_R]7^
M1R+?"73RQ(\0:XH)Z VV!_Y!KK?#NA6_AK0X=*M9IYXHGD?S)RI=B[L[$[0!
MU8] *U**B52<_B;9I"E3A\$4@HHHJ#0**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH X_P 4\^-_!H[_ &BX/_D.NPKCO$_/CSP8/^FMT?\
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MKE]>\$6>N>*])UJ7:/LF?.0C_6@<I^39SZBNKH **** "BBB@ HHHH ****
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M5/X7M3;V,UY=Z?'97&?++;2"T:C@\_4UE^/YKB.* M,+>R169Y-FXLQXQGL
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M6%EI?A^RLM/+FUAC"H74JQ]R"!@_A6I116DFY-MFJ5E8****0PHHHH ****
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MUP_^ J4>WG_S[?\ Y+_\D'LH?SK\?\C7HK(_LW5>^MO_ . RT?V9J??6Y?\
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M*** "J;:7:/N$D9D0G(C=BRJ>O / JY133:V%**DK-#8XTAB2*-%2- %55&
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M,5YDL'!8JI/4JI.U?P Q705,FGL,****D HHHH **** "BBB@ HHHH ****
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M;#Q?93W6GPW,4<,GEL+A54DX!XP3ZUKWEW#86-Q>7#;8+>-I9&QG"J,D_D*
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M%K&B?$/PI_:VE7UAYVJVWE_:[=XM^)4SC<!G&1T]17V?7R!I>C_V5\0_!_\
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MCNQ&FF0[2%XP3R0,\Y]:Y%0DU>Z^\]V>9TH-IQEII\+.QKC_ !7XN;39&L+
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MHH **** *=ZUO9))J+PAI$3:6 ^8C/2HX9[7599$>#)MG5AO /)&013=?_Y
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M>W0UVX3X96W/FL]_C474^"^OX'H=O]EMU:VM_+C$0&Y%XV_6G3?9YP;>;RY
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M3VJ6]\37]S$5:41H>N#7J&H:#I6JMNO;"&9^F\KAO^^AS56U\(>'[.021:7
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M^9/J:"9TW6DKOW5V)(8A#"D09F"*%!8Y)^M/HHH.M*V@4444 %%%% !1110
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M\'1>(/$&FW>H37I72I88P%@EWQ?,^(ER-QC/1NAX]>[_ .$>^.?_ $.>A_\
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M^AST/_ORO_R/1_PCWQS_ .AST/\ [\K_ /(]>P44 >/_ /"/?'/_ *'/0_\
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M=:]XCUG5?$EE$GB"\\]$NBMN(R&D;:&9_G_UGH.GO79Z=JNG:Q;&YTR_M;V
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M<E;;<2B+M 9SG[OKWKO00P!!!!Y!'>@#R#_A'OCG_P!#GH?_ 'Y7_P"1Z/\
MA'OCG_T.>A_]^5_^1Z]@HH \?_X1[XY_]#GH?_?E?_D>C_A'OCG_ -#GH?\
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M9-GH@M+F";S]WE;^-F,[OQK6H.;"TY4X6E_6B"BBB@Z0HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH CN/\ CVE_W#_*O#?AA_R0/Q7]+W_T2*]T=0Z,AZ,"
M#BN5T'X>Z3X>\(:AX:M+B]>ROO-\UY70R#S%VG:0H'0<9!J6M)>:M^)2=G%]
MG<\'EMVNOAS\+[=9Y;=I=3G030MM>/,^-RGL1U!KI;WP7I>F_'&P\-:=)?6F
MDZE8F6^@BO)<W!'F$AFW;L$J,\^N,9KT1/A/H2:5X>TX7>H^3H5RUS;-YB;G
M9GWD/\G(SZ8XK8NO!>G7?CJS\72370U"TMS;I&KKY14[N2-N<_.>_I6C:YK^
M;_+3\2->6WE^M_R/$Y+Z[^']Q\2M*\/3S06=I' ;6,R,WV<R,JEE))(.'//7
M@9Z51@TO7=$LO#^OZ5X=&CWTCQ2/JUQXEA*ZD&&XJT;L!\W7 /KP>H]S3X?:
M)_;NO:K<">Y;7(EAN[>9E,6T #Y0 "#P.<GVK+TKX1>'M+U&SNC=ZM>PV+F2
MRLKR[\RWMFSG*)@8Y]2:F&EN;?3\/Z_S'/6]MM?T_K\BS\6KJ:T^%>O2P@AV
MMQ&<=0'=5;]":\^\>PI!^S5H*1C"^59M^)7)_4FO8O$NC)XA\-:EI$A %W;O
M$&/\)(X/X'!K@O#GA-_&/PBL?#/BBVU'3I;&7R7"KY;MY9.TJ74@J01R!@XX
M-2U=27^%_<V4G:S]?Q2//?'FD?$ZV^'3W'B'Q%IEWHFV'-M!&HDP679R(5Z'
M'\7YUI^)],AUKQO\,M.N'E2"XTN-9?*<HS+LY7(Y (R#CL37L/B3PC8>*/"K
M>'KV:YCM&$8+P,HD^0@CDJ1V]*IS?#_2I]=\/ZNUQ>BXT. 06RAUV.H&,N-N
M2?H15Z<UWMS7^5F9V?+YVM\[H\^\?_#S4+2;1(M"T-]6\*:?&XFT2.^>(LY9
MF+DYW-]X8()/'3!K3^%EUX>^T:OH=C#KVEW31"2;0]5;<ENO0F+(W8.X9W')
MXXKK_$_@#2/%&H6^I2SW^GZI;KLCO]-G\F8+_=+8.1R>W<UEKX/L? FAZ[K.
MF)JNL:Y/:LOVBY=KFYF;&%7@#C..@S@>U0W[LK]G_7_#_(NUVK>1C_L_7$LO
MP^N('SY=MJ$L<6?[N%;^;&O5JX[X7^&I?"O@#3K"Y0I>.IN+A3U61^<'W P/
MPKL:UGO8B.NO>X4445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&",C-7;FT70-0NUL]$O[J.+0TM](B6V>10?WAE5GP=K-^[SN()P,9/%>C44
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MNKV_9%:5"K>3$JQ*!G^$E"P]=V?2NDHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img97084416_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img97084416_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" @1$3$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **XCQ;\3M&\-"2V@87VH@<0Q-\J'_ &V[?3K5[P#J6J:WX=_M
MC56 DO)6>&)5PL<8.  /J"<GDYJN5VN!U-%%%2 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT_&B7;KF&PC,Q]-Y^5?YD_A7T345GK8$%%%%8C"BBB@ HHHH **** "BBB@
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MC/!&N-XA\(6%_(VZ<IY<Q_VU."?QQG\:Z&O&_@AK.V;4M%D8?.!=1#W&%?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ33QQD#<!(X4E%SS@]@I_2G>VR%<XV;PSXQ0W,MOXP=GE@1$#A@,@!C_ +O
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MDG^ H X;0--_MCQ!I^G%BJW-PD;,!G"D\G\LU]70PQV\$<$*!(HU"(HZ* ,
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M]1].?(=>_P"1BU/_ *^Y?_0S2$>W_!C_ )$B3_K]D_\ 04K>^(7_ "(.L_\
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M?$3Q)K]N]M=7PCMG7:\-N@16'N>I^F<5S=M;3WES';6T+S3R-M2.-<LQ] *
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG4;HI)V>.$>@!.,^IKL***YF[NXPHHHI %%%% !1110 4444 %%%% !1110
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M(-_:(T>V1HWB<C<A'3./48-8OQ2\/MKG@^62%6:YL6^T1A1DL ,,OY'/U44
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MC_T6U?*M?57BW_D3-=_[!]Q_Z+:OE6F,^G?A[_R(.C?]</ZFL;XP_P#(AO\
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M_P#L'I_Z,DKWFO!OC9_R.=G_ -@]/_1DE %'X0_\C]!_UPE_E7T/7SQ\(?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG?%/C71_"=L6O9M]R5S':QD%W]/H/<U;U?3]7U!#%9:RFGQ-PS1VN^7'LQ;
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MB$MM.NUT/Y@^Q! (/M67HO@KP]X>OFO-*L#;W#(8RPGD;*D@D89B.H'Y5OT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[XX"C@<=!7T7I&DV>AZ7!IUA$(K:%<*O4GU)/<D\TW:"Y5N!=HHHK$84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445YS\1OB-'X>A?2]
M+D5]4<8=QR(!_P#%?RII-NR /B-\1H_#T+Z7I<BOJCC#N.1 /_BOY5X!++)/
M,\TSL\CDLS,<DGUHEEDGF>:9V>1R69F.23ZTRNN$%%""BBBJ$%%%% !1110
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MZIJ&GK KMM1]Q+,.#GC'!&>.:A/CJ]T9KFW\3:-<Q_9PL1NK=<K-(V,GG Y
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MG[1)]V+J.?\ "K,!<[@S;L8!/OWJ'?<:9-1112&%%%% !1110 4444 %%%%
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M^%\>%_\ GPUC_OS%_P#'*/\ A?'A?_GPUC_OS%_\<HY6!ZC17EW_  OCPO\
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M?\+X\+_\^&L?]^8O_CE'_"^/"_\ SX:Q_P!^8O\ XY1RL#U&BO+O^%\>%_\
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M_CE'_"^/"_\ SX:Q_P!^8O\ XY1RL#U&BO+O^%\>%_\ GPUC_OS%_P#'*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "D=0ZE3T-+10!7:U+RH[3R%5ZIG@U8HHH"P4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?.7B3X8>,[_ ,5ZO?6FD%X+B]FEB<74*[E9R0<%\C@]ZS?^%3^//^@,
MW_@9#_\ %U]/T5I[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\
M\77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[
M1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I
M_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F
M_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_X
MNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS
M_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!
MD/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T
M_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,
M'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_
M $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P#
MR'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A
M4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-
M_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\
M\77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[
M1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I
M_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F
M_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_X
MNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS
M_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!
MD/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T
M_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,
M'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_
M $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P#
MR'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A
M4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-
M_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\
M\77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[
M1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I
M_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F
M_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_X
MNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS
M_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!
MD/\ \77T_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T
M_11[1@?,'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,
M'_"I_'G_ $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?,'_"I_'G_
M $!F_P# R'_XNC_A4_CS_H#-_P"!D/\ \77T_11[1@?+Y^$WCLC!T9B/>\A_
M^+KV3X2^'=5\,^%;JRUBU^S7#WKRJGF*^5*( <J2.JG\J[RBDYMJP!1114 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.@LWA'XS7^DDLEEJF6C7/RY;YT/X'<@^OXUZ]0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN+,*(UB=0IVMN&05)Z^] &[?_P#(/N?^N3?R->6?!>!;KP]KENY(26148KU
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MXL:38::QN+:R*K-+&?E(5MSD'TQQGN>G7GJ+OX.>%KFX,L9OK92<^5#,-O\
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MI\=(9&@T.<*3&C3HS>A(0@?^.G\J[?PUX"T+PK,UQ8PR27++M\^=@S =\8
MS["MC6-&L->TZ2PU*W6>W?!P>"I'0@CD&@"2TU.RO;."Z@N8FAGQY;!Q\Q(R
M!]<=JMUP.F_"+P[IFH6]['<:C)+!(LJ"290 RG(^ZH/7WKOJ "BBB@ HHHH
M**** "BBB@ K#OI_#6NW4VB7TEC=7$+ /:RD;U) / //<<CZ5N5Q>N?"[PWK
MM]+>RI=6UQ*Y>5[>7&]CU)#!@/P H \_^SP^"_B[I]AX>O6DMKB6**XAW[@F
M]MK(V#S@?,,],CTJ]XTDCUSXM66AZU=M!H\07 \S:I)3=U[%FPN:[OPY\.]
M\,7GVRSBFFN@,)-<.&9."#C  &03VJUXG\%Z/XM2+^T8I%FBX2>%@K@>F2""
M._(_K0!@^+=$\&^'_"%_&VGZ;;3M:NEL6C#2F380F&.6SD#G/UJ+X,$'P1*
M0<7L@/M\J5>T;X5>&-'N!.8)KZ13E?MCAPO_  $  _B#6GX<\%:7X5O+N?2Y
M+I$N0 T#R[HUP21@8SD9QDD\4 <)\(?^1G\3?[P_]#:KOQO_ .1=TW_K[/\
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M [C_ -\Y'U(KS[PEH'Q$L-$CGT"6WMK2\Q. ZQ%FR!@G<I.,=.W.>]>F^*?
MVG>+KBVEU&[OD6W4A(H)%5.3R2"IY/ _"NE1%C1410J* %51@ >@H ^??&ND
M^-K7[+KWB&6&22!UBBFB$>Y#DLN=JCC(/7N?>O=-#U6'7-#LM3@(*7,0? /W
M6_B7Z@Y'X4W7M$M/$6C3Z7?;Q!-C+1D!E(((()!YR*A\->'+7PMI/]FV<]S-
M )&D4W#*67.,@;0.,\_B: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YOQ1XKB\
M,*LMR!Y! YVDG))]/I7+_P#"X]']3_WZ>FHM[ >F45YG_P +CT?U/_?IZ/\
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M%QZ/ZG_OT]')+L!Z917F?_"X]']3_P!^GH_X7'H_J?\ OT]')+L!Z917F?\
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MG_PN/1_4_P#?IZ/^%QZ/ZG_OT]')+L!Z917F?_"X]']3_P!^GH_X7'H_J?\
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M7'H_J?\ OT]')+L!Z917F?\ PN/1_4_]^GH_X7'H_J?^_3T<DNP'IE%>9_\
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M_3T<DNP'IE%>9_\ "X]']3_WZ>C_ (7'H_J?^_3T<DNP'IE%>9_\+CT?U/\
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MS_X7'H_J?^_3T?\ "X]']3_WZ>CDEV ],HKS/_A<>C^I_P"_3T?\+CT?U/\
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M/1_4_P#?IZ.278#TRBO,_P#A<>C^I_[]/70W'BY[7PROB&6&,:<R(X<9)PQ
M''7J12Y6N@'5T5YG_P +CT?U/_?IZ/\ A<>C^I_[]/3Y)=@/3**\S_X7'H_J
M?^_3T?\ "X]']3_WZ>CDEV ],HKS/_A<>C^I_P"_3T?\+CT?U/\ WZ>CDEV
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M<@=_J*HZC\5-.TK4;BPNP%N+=S'(!&Q (]Z7*]@/0J*\S_X7'H_J?^_3T?\
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M&9"&5E&T$ \GZBH-7^)UCHFJ3Z=?*$N8" ZJC,!D CD>Q%+E=[6 [^BO,_\
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MG_PN/1_4_P#?IZ/^%QZ/ZG_OT]')+L!Z917F?_"X]']3_P!^GH_X7'H_J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'H?P8_Y'EO^O.3^:UE?$_\ Y*-J_P#O1_\ HM*U?@Q_R/+?]><G\UK*
M^)__ "4;5_\ >C_]%I6:^,9R-%%%:""BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW'X:?\ ))M7
M_P!ZY_\ 10KPZO<?AI_R2;5_]ZY_]%"HJ;#1X=1115B"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#W&W_P"3>C_UZO\ ^CC7AU>XV_\
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M HHHH ]0^!__ ",^H_\ 7D?_ $-:Y#QW_P CWK?_ %]O_.NO^!__ ",^H_\
M7D?_ $-:Y#QW_P CWK?_ %]O_.LU\;&<]1116@@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /1/@O\ \CQ)_P!>4G_H2UD?$W_DHNK_
M ._'_P"BUK7^"_\ R/$G_7E)_P"A+61\3?\ DHNK_P"_'_Z+6LU\8SDJ***T
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/B?4=,QA8)B(_P#</*_^.D5DUHM1!1110 4444 %%%% !1110 4444 %%%%
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M2FHC/FFBBBK$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>X_"/\ Y)SK'_7U-_Z)2O#J]Q^$?_).=8_Z^IO_ $2E14^$:/#J***L0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !17O?PN\/Z+J'@6UN+W1]
M/N9VDD!DFMD=B QQR1FMZYM?A[97#V]U!X8@G0X>.5+=64^X/(K-U+.UAV/F
M:BOI\>$_!FLV9:#2=)F@<8\RT1%[9X9,=CV->)_$3P1_PA^J1-;.\FG763"S
M]4(ZH3WZC!]/I3C44G8+'&45[W\+O#^BZAX%M;B]T?3[F=I) 9)K9'8@,<<D
M9KR/QM;P6GC75[>VACAACN&"1QJ%51Z #@4U.[L!@44450@HHHH **** "BB
MB@ HHHH **** "BBMWPAX9G\6>(8=,B?RX\&2>7&?+C'4X]<D >Y%#=M0,*B
MOIB+P=X*\.:>K75AIJ0J=IGU#8V2?5GXS4>H_#[PAXCL5DM[&UA#)^ZN=/P@
MYZ'Y?E;MU!K+VJ'8^:Z*T_$.BS>'=?O-)G<.]L^W>!C<I *G';((.*S*U$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZA\#_\ D9]1_P"O(_\
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M6LCXF_\ )1=7_P!^/_T6M9KXQG)4445H(**** "BBB@ HHHH **** "BBB@
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M+:?#S57A;:SJD1/^RSJK#\02/QKYJCD>*1)(W9)$(964X*D="#ZT13GJV!]
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M5UD/FN^0 ,?>8UB_#OP"WB^ZDNKN1HM+MV"R%?O2OUV*>W&"3[CUR.U^.?\
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M0 4444 %%%% !1110 4444 >XV__ ";T?^O5_P#T<:\.KW&W_P"3>C_UZO\
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M]4_LFUMM$ENL[55+10'/HK[<,?H37#?$KX;VF@67]LZ*LBV88+/ S;A%G #
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MM!\2:)>W&K6'VB6*YV(WG2)A=H./E8>M=#\;_P#D4[#_ *_E_P#1;U'\#O\
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M=BGIB, \?+]XCKGD9Q5KX1_\D]L_^NLO_H9KQKXB3//\0-9=SDB?9^"J%'Z
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M*** "BBB@ HHHH **** "BBB@ HHHH *['X5_P#)2=)_[;?^B7KCJ['X5_\
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MGFFT^PL](EF"D,D=KY+$="5;:I/U4\5YO\1?AT/"P74M->2739'VLK\M QZ
MGNO8$UPEG=W%A>0W=I*T5Q"X>.1>JD5]/>,H8KWP)K(FC5E^PR2@,,X94+ _
M4$"AW@UJ!Y)\)O"NB^)O[8_MBR^T_9_)\K]ZZ;=V_/W2,_='7TKK+CP%X*\+
MZG=:OK,D45@2!:6<KLRC"+N.#EG;=N..0 >G3&9\"/\ F/\ _;O_ .U:R/C;
M<RR>+;.V9R88K-61.P+.V3^.T?E0[N=K@>E6WA[P+XKTHRV.FZ9/;,0#):Q"
M)U/!P2N&4].#7A'C+PVWA7Q+<Z9YADA&)()&QED/3..XY';IFO1O@3(YCUZ,
MNQC4P,%SP"?,R<>IP/R%9/Q9MA>_$K3;0G GMX8R1VW2,/ZT1O&30&M\/?A?
M83Z5;ZWK\1F:=1+#;,V$5#@JS8/.1S@\8/(KIK9OAIJU\VE6UOH<EQP L=NJ
M;R>RO@!C_NDUU6L:9_:F@7FEQS?9Q<6[0"0+NV C'3(SQ[UYE:_!"2SNX;F+
MQ+B2&19$/V'H0<C_ ):5',I:M@<W\2OAZGA<IJ>F%CIDKB,QL2S0N0<<]U.#
MR?IZ5=^%WP_L=?MI-9U=3+;)(8X;<-@.1@EFP<X[8KT_X@V<=[X"UB.5-P2W
M,J^S)\P/Z5Q?P=\5V/\ 9)\.W4J0W<<C20;N!*AY(!SRP.>..,=<&JYI. &U
M=ZA\+]-OVTRYM]%2X1O+9?L(<*V<$,X0@$'KD\=ZI^+OAKHFMZ$VH^'8((+I
M8O-A^S8$5PN"<8'&3G@_3MTUM=^%OAG7;F6Z:&>TN97,DDEM)C>3URK KSUX
M KBO$GPR\3V.FNNEZ[<ZC8Q*5%F\K(RQYX55R5; Z].G [4HM=&!Y)11170(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T3X+_ /(\2?\ 7E)_
MZ$M9'Q-_Y*+J_P#OQ_\ HM:U_@O_ ,CQ)_UY2?\ H2UD?$W_ )*+J_\ OQ_^
MBUK-?&,Y*BBBM!!1110 4444 %%%% !1110 4444 %%%% !7LWP-TM/L^J:L
MZH7+K;1G'*@#<W/OE?RKQFO=O@>ZGPOJ$88;UO22/0%%Q_(U%7X1HYSXVZQ<
MRZY::.' M(81.5 ZR,6&3] ./J:\LKO_ (QQ/'X]=F&!);1LON.1_,&N IP^
M% >FZ/\ &2_TK0K73WTR.YFMX_+^T23GY@.F1CL,#KVKSNXEEU+4I9E@42W,
MQ80PJ<!F.=JCD]\ <TAL+P62WIM)Q:,<"<QG83G'WL8ZUT/PXLH;_P"(.CPS
MKN02M+C_ &D1G7]5%%E&[0'J/A+X4Z1I%BE]KZ1W=YLWNDI_<P\'/'1N.I/'
M''K5^QD^&>NWC:796NC27&2H1;01EB/[K;1NZ=B?6JWQGOKBT\&10P2-&MU=
MK%+C^)-K-M_,#\J\"BED@F26*1HY$8,CH<%2.00>QK.,7-7; ]'^(_PVC\.0
M?VOI!=M.W!987)8PD\ @]U)XYY!(ZYXT?@7_ ,A#6?\ KE%_-J]2NXDUGP?*
METBLMU8Y<,,\LF<_@>:\M^!?_(0UG_KE%_-J7,W!W A^.7_(=TO_ *]F_P#0
MJ]0\"_\ (BZ)_P!>D?\ *O+_ (Y?\AW2_P#KV;_T*O4/ O\ R(NB?]>D?\J4
MO@0'SM:Z-<>(/&3:5:LJRW%U(H9LX4 DDG'H 37N'_")^!/!6DK/J5K:&,':
M9[Y/.:1L=E(/.!T4=J\'>TN[_P 3RVMA&\EW+=,L2Q\'=N/?MZY[5ZI9?"36
M-3M8AXD\27#JOS+;([2A">OS,< X]!^/K<^EV!U%CI'P^\86,@TZPTR:,8W_
M &>'R)$Y.,X"LO0_7Z5XCXU\,'PEXDETU9_.A*"6%R,-L.<!NV1@CCK[=![Y
MX4\(:)X1DN8-,FEDN954S>=,&?:,XRH  ZGG%>5?&T >-+3 ZZ>F?^_DE33?
MO66P,]<\"_\ (BZ)_P!>D?\ *N:_LOX>^$)_LNL/83ZA</O=KN(2MECGI@A%
M^N..I[UTO@7_ )$71/\ KTC_ )5\S:M?OJNL7M_(S%KF9Y3NZ\DG%*,>9L#W
M?Q+\-- \2:1]JT.&UL[MT#V\UOQ#(.H!5>,'/W@,].H&*\$%A='41IX@<WAF
M\CR<?-YF=NWZYXKWOX,WDMSX%,,F-MK=R0QX_ND*_/XN:Y[3M*MIOV@+\% J
MV^;H*  "YC7D_BY/UJHR<;I] -WPY\+] \/:9]LUY8+RY1"\\DY_<Q#&3@'@
M@>I_3I5NP7X;>)YIM/L+/2)9@I#)':^2Q'0E6VJ3]5/%9?QMOIX/#=C:1N5B
MN;@^:!_$%&0#^.#^%>(6=W<6%Y#=VDK17$+AXY%ZJ11&+DKM@=W\1?AT/"P7
M4M->2739'VLK\M QZ GNO8$UJ_"KP=H/B31+VXU:P^T2Q7.Q&\Z1,+M!Q\K#
MUKT[QE#%>^!-9$T:LOV&24!AG#*A8'Z@@5QWP._Y%O4O^OO_ -D6ESMP WM)
M^&/AK3+^[NFTZ"X$K_N(IP9$A3:!C#DY)()R?7 ]_/O'OAW2]1^(.G>'?#UI
M;6EW(G^DF)2J*2-PRHX&$&[@?Q"F_&G6KJ;Q'#I"S.MI! KM&&(#.Q)R1T.
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MV_ZY+_*L*VZ&BS1116(PHHHH **** /+/C1_R!X_]Z/^;5X;7N7QH_Y \?\
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M_P )SG#?3'O7+?\ "]_^I;_\GO\ [77FOBKQ#+XH\0W.JRQ&$2[0D)DWB-0
M, X'N>G4FL:I5.-M0N?4?@OQ9%XQT1M0CM_LTB2M%)#YF_:0 1S@9R".U>!?
M$#1O[#\;:E;*N(9)//B]-K_-@?0DC\*M>!?'DO@I[T?8OMD-R%S'YWE[67//
MW3V/\J;XY\:6_C.>TN1I'V*Y@4QM(+CS/,3.0"-HQ@Y_,THQ<9:; >]^,_\
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MCQOXMA\8ZE;WZZ9]BFCB\I_W_F;P#D?PC!&3Z]O2N7K:*LE<04444P"BBB@
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M;!XZ\8_*MC5_C;JEY9M#IFG16$K'_7-+YQ QV!4#/N<_2H491;L!Z=\049_
M.M!1D_9R?P!!->4_!'_D=+S_ +![_P#HR.IV^,0NO#G]D:AH377F6OV>>8WN
M#(=NTOCRS@GK[5R?@CQ;_P (;K4VH_8OMGF6[0>7YOEXRRMG.#_=Z>]$8-1:
M [KX[?\ 'QH7^[/_ #2O*]*O/[.UBROL,?LUQ'-A>ORL#Q^5=)X[\<_\)K)8
MM_9WV/[*'&//\S=NV_[(Q]W]:Y.*)YIDBC&7=@JC/4GI6D%:-F!]1^(=.A\7
M^"[FUM9$=;VW$EO(3\I;AD)([9 KP;2_AOXFU#6TTZ?3;BS0-^]N9HSY:+W(
M;HQ] #S^9'7>&KKX@^![1K2?P]+>Z;&&80AE)CYRVUDSUR>"#[=\P:K\:]5O
M[7[-I.EQV4\AVB4R><P_W1M STZY^E9Q4EI$#V'5HUB\.WT:_=2TD4?0(:\D
M^!^K1PW^IZ3(^'N%2:$8ZE<AOT(_*O4=5?[#X*O'G+GR-.<ON.6.(SGZFOEJ
MUNI[&ZBNK69X9XF#)(AP5([TJ<;Q:!GKGQ;\%ZI?ZO%K>F6LMVDD:Q310J7=
M6&<-M'.,8''3'O61H/P;U35=(6\OKO\ LV=V^2VE@W-MP.6^8;3UX(S5S3_C
MC?P6RIJ&CPW4H&#)%,8L_4;6JIKGQHUC4+5K?3+.+3=X(:7?YL@_W20 .XZ'
MKQBJ7M$K <%K>EG1=:NM-:Y@N6MWV&6 DJ3W'/<=#[@U]0Z:/M'A.T$)#^98
MIL(/#9C&.:^4&9G=G=BS,<DDY)->B^%?BW?>'M'BTVYT]+^*$;86\[RF5>P/
MRG(%.I%M*P(R?"_A/58O&^AV^I6-Q9B2[++YT6"_E8=L ]1C STY[XKL_CGJ
M1QI.EJZX.^XD7//]U3CT^_\ Y%49?C0TVK6UZ_A]"ENDBHGVKG<VWG=L[ $8
MQWKBO&7BF3Q?KQU)[5;91$L21!]^ ,GEL#)R3V':A*3DFP.R^">BBZUR]U>6
M/,=I&(XBR9'F/U(/J%!'_ _S[KQQ\2(?!NH6UDNG_;9I8C*X\_R_+7.%_A.<
MX;Z8]Z\U\&_$V'P?H7]G1Z%]H=I6EEF^U[-[' '&PXP !U[9[URWBKQ#+XH\
M0W.JRQ&$2[0D)DWB-0 , X'N>G4FDX.4KO8#TK_A>_\ U+?_ )/?_:Z] \%^
M+(O&.B-J$=O]FD25HI(?,W[2 ".<#.01VKY<KL/ OCR7P4]Z/L7VR&Y"YC\[
MR]K+GG[I['^5$J:MH%RK\0-&_L/QMJ5LJXADD\^+TVO\V!]"2/PKZ6U&QBU/
M3+JPF_U5S"\3_1@0?YU\X^.?&EOXSGM+D:1]BN8%,;2"X\SS$SD C:,8.?S-
M>_\ BNXEM/"6KW-O(T<T5I))&Z]58*2"/QJ9WLK@?/I^''BE=;72SI4VYGVB
MY"DP8_O%\8 P,^OMGBO>[V:W\'>!W;?NCTZR"1[WVF1E7"C/J3@?C7F&G_'&
M_AM!'?Z/#=3@8\V.8Q _5=K?IBN2\8>/=4\82)'<!+>QC;?':Q\@-@C<6ZDX
M)'I[=:IQE)Z@;'P9_P"1Z/\ UZ2?S6O3OB=X6NO$_AI$L%#WEK+YR(>#(,$,
MH/8\@_A7F/P9_P"1Z/\ UZ2?S6O1/B?XGU+PJFD7VFNF]I9$DCD7<DBX'!'!
MZ^A!J9WY] .%^&?@76#XIM]3U&PN+*ULFWXN(VC:1L':%!&3S@D].,5U/QLU
M=+?P]::4K#SKN;S&7/(1/\6(Z^A_#'E^.MR;9EAT")+C'RN]R64'UVA02/QK
MS'6=:O\ 7]3DU#4IS-<28&<8"@=  .@JE&3E>0'OOPC_ .2>V?\ UUE_]#->
M+>/O^1]UK_KY:NC\(_%7_A%?#T.E?V-]J\MW;S?M6S.XYZ;#_.N+U_5?[<UZ
M]U3R?(^TRF3R]^[;GMG S^5.,6I-@=9\(M<CTGQB+:XEV07\1@!) 7S,@IG\
MBH]VKT'XK>"[_P 2VMG?:6BRW5IN1X. TB,1T)XR"#Q[GTP? *]%T#XQ:YI-
MLEM?01:E#&FU6D8I+[9;G/XC)]:)1=^:($OP]^'>L3^(K34M4L9;*SM)!-BX
M0H\C*<J IYZ@'GC%=?\ &;7X+3PVFB*X:ZO75V0'E8E.=Q^K  >N#Z5S]]\<
M[Z6W*V&BP6\I_CFG,H'X +_.O,=3U2^UF_DO=1N7N+F3&YW_ $ '0#V%)1DY
M7D!]-^"A&/ NB_9]N/L4?TW;1NZ?[6:\5N/!/CCQ#XFDMM4BNI)%E(>\N"3"
MH/)*'H1[+[# JMX-^)&I^$8'M/*6]L&)98)'*F-N^UN< ]QC\LG/1:I\;]0N
M;-XM.TJ*RF88$SS><5]P-H&?KFDHRBW8#U+Q;#Y?@/68DR0FG2@9ZX"'_"O%
M_A!K2:7XR%K/)LAOXC ,D >9G*9SZX*CW85JVOQF9=#33=0T/[>3!Y,\LEWC
MSLC!)'EGK7EV_9-OA+)ALI\W*^G(QS[TX0=FF![O\7/"%_KUG::CID)GFLPR
MR0(N7=#@Y7UP1TZ\US7P[^&)U#[5=^)],GCM]OEP03%XG+9R6P,'  QSUR:K
M:'\:-8T^U6WU.SBU+8 %EW^5(?\ >(!![#H.G.:MZA\<;^>V9-/T>&UE(P))
M9C+CZ#:M*TTN5 8'Q-\/Z%X;UJULM'\Y9#%ON(WDWA<GY<9&0>"3R>W3O[CX
M8_Y$31O^P9!_Z*%?+EU=3WUU+=74SS3RL6>1SDL3WKT[3/C-_9N@V>F?V!YG
MV:V2W\S[9C=M4+G&SCITS3G!M) >5U]4^&/^1$T;_L&0?^BA7RM7JFF?&;^S
M=!L],_L#S/LULEOYGVS&[:H7.-G'3IFG4BWL"/*Z***T$%%%% !1110 4444
M %%%% !1110 4444 %>X_#3_ ))-J_\ O7/_ **%>'5[C\-/^23:O_O7/_HH
M5%38:/#J***L04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'T9\(_P#DGMG_ -=9?_0S7COQ(_Y*%K'_
M %U7_P! 6MSPC\5?^$5\/0Z5_8WVKRW=O-^U;,[CGIL/\ZX[Q)K/_"0^(;S5
M?L_V?[2X;RM^_;@ =<#/3TK.,6I-C/I3QG_R)&N?]>,W_H!KY6KU36OC-_:^
MB7VF_P!@>5]J@>'S/MF[;N!&<;!GKZUY713BXK4&?5/C/_D2-<_Z\9O_ $ U
MY+\$]6AM/$%[ILK[7O8E,63PS)DX^N&)_ U+K7QF_M?1+[3?[ \K[5 \/F?;
M-VW<",XV#/7UKRZ*62"9)8I&CD1@R.AP5(Y!![&E&#Y6F![9\7?!NH:Q-::Q
MI5J]S)%&89XHQE]H)*D+WZL#CGIU[5_A%X+U33-1GUO4[:6T4PF&&&9-KL2P
MRQ!Y4#;CD<YS]<W2OC??VMBD.HZ5'>SH,&=)_*+>Y&TC/TQ4$_QIU6;5[6X%
MA''8PL6>UCE(:7Y2 &?'09!QCM2M.W*!O_'/_D$Z1_UW?_T$5O\ PC_Y)[9_
M]=9?_0S7E7CKXA?\)I:6<']E_8_L\C/N^T>9NR,8^Z,5?\(_%7_A%?#T.E?V
M-]J\MW;S?M6S.XYZ;#_.AP?)8""]U9=#^-DVH2$".+4")"3C",-K'\ QKUCX
MB>')O%7A%[>QV/=1.MQ "<!R 00#TY!.,\9QTZCYZU_5?[<UZ]U3R?(^TRF3
MR]^[;GMG S^5=3X6^*FL^&[-+&6.._LHQB-)6*O&/0,.WL0<<8P*<H/1K<"7
MP1\.=3U+Q*BZWI%Q!IL&3<?:%>+S."%53P3S@Y!Q@=>1G3^)_@_PSX6TFVDT
M^*:.^N)MJ1F<L-@!+'!R3U4=1U'XV[CXZSM"PMM CCE(.UI+HNH/8D!1D?B*
M\RUO6[_Q#JDNHZE.99WX'947LJCL!_\ 7ZFFE)N[ ^GM(1%\)V*:6R!19(+9
MF.0/D&TDC.>V:\+M/ OC#Q)XE6/6K:^4+(!<75TW"IDD[&.0W? 7(!(Z4GA#
MXH:IX6M!8RP+?V*_ZN-Y"C1^RM@\=>,?E6QJ_P ;=4O+-H=,TZ*PE8_ZYI?.
M(&.P*@9]SGZ5*C*+=@/3OB"C/X!UH*,G[.3^ ()KQKX0LJ_$&V#, 6AE"@GJ
M=N>/P!K6;XQ"Z\.?V1J&A-=>9:_9YYC>X,AV[2^/+.">OM7G.F:E=:/J=OJ%
ME)LN('WHQ&1GW'I3C!J+3 ]U^,.DZCJWAVR73K*>[>*ZW.D"%V *D9P.:X;X
M1VTUE\1;BUN$,<\-O-'(AZJP901^8K83X[2B$"3P\C2XY9;LA3^&P_SKD-'\
M>/IGCB]\32:>LSW0<&!9=@7<1_%@YQCTHC&7*XM =[\<_P#D$Z1_UW?_ -!%
M;?PDUR/5/!D-DTNZZT]C"ZDC.PDE#CTP<?\  37EWCKXA?\ ":6EG!_9?V/[
M/(S[OM'F;LC&/NC%<QHNMZAX?U*/4--N&AN$!&1R&4]58="/\]10H-PLP.P\
M:?#C7;+Q%<S:?82WME=3EXFMTW;-Q)VL!R,=,].G(S@>D_"[P==>%M'N)M05
M4OKUE9XP<^6JYV@GIGDDX]JY"S^.EY' JWNAP3S#J\-P8@?3@JW\ZQ/$OQ:U
MO7;:2TM8X]-M9 0PB8M(P.007../H!2:FU9@9_Q+U^#Q#XSN)[1Q):VZ+;12
M Y#A<DD>VXMCU&#7O7C/_D2-<_Z\9O\ T U\K5ZIK7QF_M?1+[3?[ \K[5 \
M/F?;-VW<",XV#/7UIR@]+ >5U]4^,_\ D2-<_P"O&;_T U\K5ZIK7QF_M?1+
M[3?[ \K[5 \/F?;-VW<",XV#/7UIU(MM6 \KHHHK004444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'N-O
M_P F]'_KU?\ ]'&O#J]QM_\ DWH_]>K_ /HXUX=6=/KZC"BBBM!!1110 444
M4 %%%% !1110 4444 %%%% !7O?P1_Y$N\_["#_^BXZ\$KOO!'Q*_P"$-T6;
M3O[)^V>9<-/YGVGR\955QC:?[O7WJ*B;C9#12^*G_)2=6_[8_P#HE*XZMGQ5
MKW_"3>)+O6/LWV;[1L_=;]^W:BKUP,_=ST[UC5459(05]&?"/_DGMG_UUE_]
M#-?.=>C>$?BK_P (KX>ATK^QOM7EN[>;]JV9W'/38?YU-2+:LAHYSQ]_R/NM
M?]?+5U/P5UB&R\2W6FR_*;^(>4WJZ9.WIW4L<^WO7"Z_JO\ ;FO7NJ>3Y'VF
M4R>7OW;<]LX&?RJA%+)!,DL4C1R(P9'0X*D<@@]C3Y;QL(]I^+W@W4=5N;76
M],MI;IDC$$\,0+.!N)5E4#)^\0<>W'4US7AWX/ZMK.FO=7\[:6^[$<,T&YF&
M.I&X%>>,$9JYI7QNU.UM$BU+3(;Z5>/.27R2PQW&TC/TP/:FZO\ &W5;NV:+
M3-.AL'88\UI/.9?IP!GZ@U"4TK#.&UW2IO"GB22R6]AGN+1PPE@SA6ZC.1]X
M<9 R >,\5]'2_9_&O@=_LTJK%J5H0K$;O+8CN >JMP1GJ*^7)99)YGEED:21
MV+.[G)8GDDGN:Z;PGX^UGPB3%:LD]DS;GM9AE<\9*D<J<?AZ@TYP;2[@2V'P
MW\27'B*/2[C3+F&,2 2W)0^4$[D/C!XZ8KT'QQ\/O!^A^%;[48K>:VFC7$&R
MX9MTAX48;.1GK[ \CK5 _'9_+('AU=_8F\X_+9_6N \5>,M5\77:2W[JD,6?
M*MXLA$]_<^]*TV]= /0O@1_S'_\ MW_]JUA?&K_D=X/^O&/_ -#>LKP'X\_X
M0G^T/^);]M^U^7_RW\O9LW?[)SG=^E4?&OBK_A,-;34OL7V39 L/E^;YF<%C
MG.!_>].U-1?/<#Z&\,?\B)HW_8,@_P#10KP?X5_\E)TG_MM_Z)>NCTSXS?V;
MH-GIG]@>9]FMDM_,^V8W;5"YQLXZ=,UPGA77O^$9\26FL?9OM/V??^ZW[-VY
M&7K@X^]GIVI1BTF!Z_\ &_\ Y%.P_P"OY?\ T6]><?"O_DI.D_\ ;;_T2]6_
M''Q(_P"$RTF"Q_LG['Y4XFW_ &CS,_*1C&T>M<YX5U[_ (1GQ)::Q]F^T_9]
M_P"ZW[-VY&7K@X^]GIVIQBU"P'K_ ,;_ /D4[#_K^7_T6]1_ [_D6]2_Z^__
M &1:X?QQ\2/^$RTF"Q_LG['Y4XFW_:/,S\I&,;1ZTWP/\1O^$,TVYL_[*^V>
M?-YN_P"T>7MX QC:?2IY'R6 M_$Z]?3OBFE]&,O;"WF49QDK@C^5>O\ B'3X
MO&7@FYMK.6-EO8%DMY&/R[N&7)'N!_\ 7Z5\\^,/$G_"5^()-5^R?9=\:IY7
MF;\8&,YP/Y5H^$OB+K'A.+[+%Y=U8$EOL\V?D)Z[2.5^G(Z\9.:;@VE;= 2:
M!\.M?O/$]M8W^D7,%JDH:YEE4K'Y8(W .."2.!@_R)'9?$+P)X2\.>%[C4+:
MWF@NBRQVZ"X8AG)'][.0 &/X=>]1-\=G*87PZH;U-YD?ELKSGQ+XIU3Q7J N
M]2E4[!MBAC!$<8[[1D]>Y.3^0II3;N] /H'X;K;+\/M(%KC9Y1+<Y^<L2W_C
MV:\EU_PCXX\0>+KBWN[:ZG'G,8YY&/V=(RV 5;H!C!P.<#I69X.^(.J>#R\,
M2+=6+G<UM(Q&#ZJ?X3Z\$']:ZJ_^.5[-:O'8:-%:SL,++)/YH7WV[1FIY91D
MV@/5GTX:?X/;3(27%O8&W0L>6VQ[1G\J^>_AO_R4+1_^NK?^@-74Z1\:;JRT
MB.TU'2CJ-P-_F7#W03S-S$_=V$  $#\*X70M<BT+Q3!K$%F7B@E9TMC+SM((
M"[\=@>N.U.$6DTP/;?C'_P B$_\ U\Q_UKYYKT/QC\4?^$MT$Z7_ &/]ES*L
MGF?:?,Z9XQL'KZUYY54TTK,&%%%%6(**** "BBB@ HHHH **** "BBB@ HHH
MH *]QUW_ )-^M_\ KUMO_1B5X=7N.N_\F_6__7K;?^C$K.>Z]1GAU%%%:""B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /2O@C_ ,CI>?\
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MPC^-\!AW_;.F5QG'EUG4BW:PT>3T445H(**** "BBB@ HHHH **** "BBB@
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M-C/>OA'_ ,D]L_\ KK+_ .AFN"LA"?V@&\_&S[;+C/\ >\MMOZXJMX1^*O\
MPBOAZ'2O[&^U>6[MYOVK9G<<]-A_G7&ZUK4FJ^)+K68D:UDFF\Y DF3&>V&P
M.1Z\4E!W8'T%\2;?7[GPFZ^'WF$ZR!IEMR1*\8!R%QSUP<#D@$>QY#X3^#=9
MT[69]<U:"2V5H6CCCFXD=F()8@\@<=^<FL[2_C??VUE'#J&DQWLZ#!F2?RB_
MN1M(SZXP/854N?C-K$^M6ETMJD-A Q9[..3F;@CYG*YXST _^M*C-+E U?CL
MI\[0F[%9Q_Z+H\-?"71-<\.V>IMJMV[7$ <K"4"H^.5Z'HV17,^-_B'!XTTV
MWMWT3[+/;R;XY_M(D(!&&7&P<'COV%9?A+QSJWA"9Q9LLUI*P:6UESL)X^88
M^ZV!C/TR#@52C+EL@.FM?^%J>']16PA74;D!\@NOVB%Q_OMG:#CID'GL37M!
MN9;?PW]IU?RHIDM-]WM^XK!,OCVSFO+%^.S[,-X=4OCJ+W S]-E<=XM^(VL>
M+8!:2K':6(;=Y$.?G(Z;R>N/3@>V0*3A*3U5@-SX*ZQ#9>);K39?E-_$/*;U
M=,G;T[J6.?;WKH/B]X-U'5;FUUO3+:6Z9(Q!/#$"S@;B595 R?O$''MQU->+
M12R03)+%(T<B,&1T."I'((/8UZAI7QNU.UM$BU+3(;Z5>/.27R2PQW&TC/TP
M/:JE%J7-$"GX=^#^K:SIKW5_.VEONQ'#-!N9ACJ1N!7GC!&:XWQ'HC>'=<N-
M+>[@NG@.&>'.!GG!R.N,9 SCIGBN\U?XVZK=VS1:9IT-@[#'FM)YS+]. ,_4
M&O,999)YGEED:21V+.[G)8GDDGN:<>;[0#*Z7P+X6?Q9XDBLV)6TB'FW+CL@
M(X'N2<?F>U<U7:^!?'T?@J"]4:2;R6Z9"S_:?+P%!P,;3_>//O52O;01[U>V
M5Y9:!]B\-Q6=O-&@C@$Q*QQCUX4Y/MW]:\@NO@WXLOKJ6ZNM3TR:>5BSR/-(
M2Q/?_5UI_P#"]_\ J6__ ">_^UT?\+W_ .I;_P#)[_[76,8SCLAGFWBCPQ>^
M$]433[^6WDF:(2AH&8K@DCN!SP:Q:Z/QKXJ_X3#6TU+[%]DV0+#Y?F^9G!8Y
MS@?WO3M7.5LKVU$%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]0
M^!__ ",^H_\ 7D?_ $-:Y#QW_P CWK?_ %]O_.NO^!__ ",^H_\ 7D?_ $-:
MY#QW_P CWK?_ %]O_.LU\;&<]1116@@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *['X5_\ )2=)_P"VW_HEZXZMGPKKW_",^)+36/LWVG[/O_=;]F[<
MC+UP<?>ST[4I*Z8'KGQP8_\ ",Z<N>#>9_\ '&_QKJ_A_J?]J^!=)N"272$0
MN6.3E#LR?KMS^->,^./B-_PF>FVUG_97V/R)O-W_ &CS-W!&,;1ZU)X)^)C^
M#]&ETYM+^VHTYF5C<^7MR ",;3QQG\363@^2PSIOCGJ6(])TM60Y+W$BY^88
M^53CT.7_ "KT?3)EN/!-G.@(633D< ]<&,&OG;QIXJ?QAKBZDUK]E"PK"L7F
M;\ $GK@=V/:NPT_XR?8?#MKI/]@[_(M$MO-^V8W;4"[L;..F<9H<'RI(#E_A
MO_R4+1_^NK?^@-7KGQC_ .1"?_KYC_K7AWAO6?\ A'O$-GJOV?[1]F<MY6_9
MNR".N#CKZ5UWC'XH_P#"6Z"=+_L?[+F59/,^T^9TSQC8/7UJI1;DF!V/P._Y
M%O4O^OO_ -D6N0^)UX=.^*<=Z$WFW%O,%SC.W!QG\*J>!_B-_P (9IMS9_V5
M]L\^;S=_VCR]O &,;3Z5A^,/$G_"5^()-5^R?9=\:IY7F;\8&,YP/Y4*+YVP
M/H7Q%IT7C3P//;V4PV7L"36TARH)X=,\9 .!GC/6O"]%^&WB/5-:%C<Z?<V$
M*L1-<S0G8@&>5R0'Z?PGOZ<T[P?\1M6\)1?9$1+S3RQ;[/*2"A/78W\.3R1@
MCKQDYKKI/CM*8B(O#R+)CAFNRP_+8/YU*C..B YCQI\.)?!^GQ7LFKVUPDDG
MEK&8V21CC/ Y!'7))&./6MKP+\,]'\4^'H=3N-3N1(79)88-@\L@G R0>HVG
MIWKAO$GBC5/%5^+O4Y@Q0$11(-L<0/91_4Y)P.>*7PUXJU7PI?M=:9,!O&)8
M9 3'*!TW#(Z9X(P1SZFKM+EWU [.YTWXC>$-3DL=(?5)['S-MLT:_:$V#[N0
M00G!&> ./05[)X>FU6;0+6;78HH-1929DC^ZO)QW/.W&>>N:\NC^.T@7]YX=
M5F]5O,#\MAKF_%/Q5UGQ)8R6$4,5A9RC$BQ,6=QW4MZ'T 'Y<5FXREN@,BWG
MAN/B9%<0LI@DU@.C#H5,V0?RKWCXC:?=ZGX"U2TL8'GN&6-EB099@LBL<#N<
M \=37S%7J^F?'"]MK"*'4-(2\N$7:TZW'E;_ '*[3S]/TJYQ=TT!S/A"XNO!
M7CO39=7AELDE&V595VD1N" S ] #@GO\M>P_$KPK<>*_#21V!0WEM)YT2M_R
MT&""H/8G(([<?B/#?&/BF3Q?K:ZE):K;%85A$:ONX!)SG _O5L^%_BGK?ARU
MAL9$BOK&(82.8D.B]@KCH/J#QP,42BW:2W ;X;^&>OZIK4<%_IT]E9Q2?Z1+
M.I4$ \A?[V>@(X]Z]:^)^O6^B>"[JW+@7-^C6T$8/)!&'/T"G\R!WKBKGXZW
M+6Y6UT&&*?'#RW)=1_P$*I_6O-]=\0ZGXDU WFIW)EDY"+C"QKG.%'84N64G
M>0'I_P "/^8__P!N_P#[5K"^-7_([P?]>,?_ *&]97@/QY_PA/\ :'_$M^V_
M:_+_ .6_E[-F[_9.<[OTJCXU\5?\)AK::E]B^R;(%A\OS?,S@L<YP/[WIVIJ
M+Y[@>@? C_F/_P#;O_[5K%^,LKP^/+66,X=+.-E..A#OBL?P'X\_X0G^T/\
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M94AU"VSL+YVR*?X3Z<XYY[^M>6V/P@\5W-\(;FVAM(,_-</.C#&>P4DDXYY
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M/#P7X0,-]-$DN6NKJ3=\B' SR>P51STX-<);_'6=85%SH$<DH W-'=%%)[D
MJ<#\37*>*OB7K?BB!K1O+L[%N&@@SEQQ]YCR?PP/:DU.6C 3^V4\0?%ZSU2,
M$13ZK;^7GKL5U5<_@!7KWQ8_Y)SJ/^]#_P"C%KY[TB__ +*UJQU'R_-^R7$<
M_E[MN[:P;&><9QUKO/%GQ7_X2CPY<Z1_8OV;SBA\W[5OQM8-TV#T]:J47=6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5[CKO_)OUO\ ]>MM_P"C$KPZO<==
M_P"3?K?_ *];;_T8E9SW7J,\.HHHK004444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5[C\(_P#DG.L?]?4W_HE*\.KW'X1_\DYUC_KZF_\ 1*5%3X1H
M\.HHHJQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!ZA\#_\ D9]1_P"O(_\ H:UR
M'CO_ )'O6_\ K[?^==?\#_\ D9]1_P"O(_\ H:UR'CO_ )'O6_\ K[?^=9KX
MV,YZBBBM!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?\@>/_>C_FU>&U]'>/?#,_BPQZ;;W$<#[5DWR D8!;T^M<-_PHW5?^@O9_\
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MRJBO5?\ A1NJ_P#07L_^^&H_X4;JO_07L_\ OAJ/:1[A8\JHKU7_ (4;JO\
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M'N%CRJBO5?\ A1NJ_P#07L_^^&H_X4;JO_07L_\ OAJ/:1[A8S?@Q_R/+?\
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M/_OAJ/\ A1NJ_P#07L_^^&H]I'N%CRJBO5?^%&ZK_P!!>S_[X:C_ (4;JO\
MT%[/_OAJ/:1[A8\JHKU7_A1NJ_\ 07L_^^&H_P"%&ZK_ -!>S_[X:CVD>X6/
M*J*]5_X4;JO_ $%[/_OAJ/\ A1NJ_P#07L_^^&H]I'N%CRJBO5?^%&ZK_P!!
M>S_[X:C_ (4;JO\ T%[/_OAJ/:1[A8\JHKU7_A1NJ_\ 07L_^^&H_P"%&ZK_
M -!>S_[X:CVD>X6/*J*]5_X4;JO_ $%[/_OAJ/\ A1NJ_P#07L_^^&H]I'N%
MCRJBO5?^%&ZK_P!!>S_[X:C_ (4;JO\ T%[/_OAJ/:1[A8\JHKU7_A1NJ_\
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MJ_\ 07L_^^&H_P"%&ZK_ -!>S_[X:CVD>X6/*J*]5_X4;JO_ $%[/_OAJ/\
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MRJBO5?\ A1NJ_P#07L_^^&H_X4;JO_07L_\ OAJ/:1[A8\JHKU7_ (4;JO\
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M'M(]PL>545ZK_P *-U7_ *"]G_WPU'_"C=5_Z"]G_P!\-1[2/<+'E5%>J_\
M"C=5_P"@O9_]\-1_PHW5?^@O9_\ ?#4>TCW"QY517JO_  HW5?\ H+V?_?#4
M?\*-U7_H+V?_ 'PU'M(]PL>545ZK_P *-U7_ *"]G_WPU'_"C=5_Z"]G_P!\
M-1[2/<+'E5%>J_\ "C=5_P"@O9_]\-1_PHW5?^@O9_\ ?#4>TCW"QY517JO_
M  HW5?\ H+V?_?#4?\*-U7_H+V?_ 'PU'M(]PL>545ZK_P *-U7_ *"]G_WP
MU'_"C=5_Z"]G_P!\-1[2/<+'E5%>J_\ "C=5_P"@O9_]\-1_PHW5?^@O9_\
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M'M(]PL>545ZK_P *-U7_ *"]G_WPU'_"C=5_Z"]G_P!\-1[2/<+'E5%>J_\
M"C=5_P"@O9_]\-1_PHW5?^@O9_\ ?#4>TCW"QY517JO_  HW5?\ H+V?_?#4
M?\*-U7_H+V?_ 'PU'M(]PL>545ZK_P *-U7_ *"]G_WPU'_"C=5_Z"]G_P!\
M-1[2/<+'E5%>J_\ "C=5_P"@O9_]\-1_PHW5?^@O9_\ ?#4>TCW"QY517JO_
M  HW5?\ H+V?_?#4?\*-U7_H+V?_ 'PU'M(]PL>545ZK_P *-U7_ *"]G_WP
MU'_"C=5_Z"]G_P!\-1[2/<+'E5%>J_\ "C=5_P"@O9_]\-1_PHW5?^@O9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH K:C_ ,@VY_ZY-_*C3O\ D&VW_7)?
MY4:C_P @VY_ZY-_*C3O^0;;?]<E_E0!9HHHH **** "BBB@#-?\ Y&.+_KW/
M\S6E6:__ ",<7_7N?YFM*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P")K#HKT?J]+^5?<CP/KV*_Y^2^]FY_PE^N_P#/]_Y!3_XFC_A+]=_Y_O\
MR"G_ ,36'11]7I?RK[D'U[%?\_)?>S<_X2_7?^?[_P @I_\ $T?\)?KO_/\
M?^04_P#B:PZ*/J]+^5?<@^O8K_GY+[V;G_"7Z[_S_?\ D%/_ (FC_A+]=_Y_
MO_(*?_$UAT4?5Z7\J^Y!]>Q7_/R7WLW/^$OUW_G^_P#(*?\ Q-'_  E^N_\
M/]_Y!3_XFL.BCZO2_E7W(/KV*_Y^2^]FY_PE^N_\_P!_Y!3_ .)H_P"$OUW_
M )_O_(*?_$UAT4?5Z7\J^Y!]>Q7_ #\E][-S_A+]=_Y_O_(*?_$T?\)?KO\
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M3_XFL.BCZO2_E7W(/KV*_P"?DOO9N?\ "7Z[_P _W_D%/_B:/^$OUW_G^_\
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MW_D%/_B:/^$OUW_G^_\ (*?_ !-8=%'U>E_*ON0?7L5_S\E][-S_ (2_7?\
MG^_\@I_\31_PE^N_\_W_ )!3_P")K#HH^KTOY5]R#Z]BO^?DOO9N?\)?KO\
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M?KO_ #_?^04_^)H_X2_7?^?[_P @I_\ $UAT4?5Z7\J^Y!]>Q7_/R7WLW/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M] 45C>$]5GUOPKIVHW(43SP@R;1@%@<$X]\5LT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 5M1_Y!MS_ -<F_E1IW_(-
MMO\ KDO\J-1_Y!MS_P!<F_E1IW_(-MO^N2_RH LT444 %%%% !1110!FO_R,
M<7_7N?YFM*LU_P#D8XO^O<_S-:5 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7?\ @#XCSZ_J!T36;<0ZDH<K(HVB0KU4KV8#)_ ]*YWXY?\ (0T;_KE+_-:
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M$>LQC.%A &?9ZZ;XE^.KK03!HVC@G5+I0Q=5W&-2< *,<LQ!^GIR*YOX,_\
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M]B$PH^@S6/\ #6&YM_BOJ4%Y,)KJ,7"32C^-PX#-^)R: -+XZ_\ , _[>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[S;95!Q[C=G\,=Z /J"O,/'?BW7-&^(&D:987ODV=Q'"TL?E(VXM*RGD@D<
M=#71> /&$7BS0E:5U&I6X"72<#)[.!Z']#D5P?Q._P"2JZ!_URM__1[T >TT
M57OKZVTVRFO+R9(;>%=TDCG@#_/:O,9/BAX@UJYD3PGX;:YMXVP9IT9\\=PI
M 4^V30!ZM17E5I\5]2TO4TLO%VA-8AQGS8D92HYYVMG<,]P>.>M>HB>%K<7
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M?+Y,CC88\!I&5E(YYSS[U<^-_P#R+NF_]?9_] ->HT4 8_A+_D3-"_[!]O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+%K]7_\ 0C6&)I5:$.;VC?W_ .9VY=B<-C*KI^PBM+[)]O(/^$3\/@X-FO\
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M117D'U04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH K:C_ ,@VY_ZY-_*C3O\ D&VW_7)?Y4:C_P @VY_Z
MY-_*C3O^0;;?]<E_E0!9HHHH **** "BBB@#-?\ Y&.+_KW/\S6E6:__ ",<
M7_7N?YFM*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\I^./\ R"-)_P"N[_\
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M&I!6GFD,43 $<]7P/0#:!U[^E>KT >+?!G_D9];_ .N7_L],^*,LNM_$32=
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MBA2%8*<$,3U8=JZF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC?( -H]L$\USNI13YF[L]>.$Q\XJC&'+%[]/O>[+?B'Q"+)6M+1@;DC#,/\
MEG_]>N(9BS%F)))R2>]#,68LQ)).23WI*X*M5U'=GU&"P5/"4^2&_5]S6\,_
M\C#:_P# _P#T UZ)7G?AG_D8;7_@?_H!KT2N[!_PWZGS7$/^]1_PK\V%%%%=
M9X04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@>Q'6O6M)DTF*+['I<\+*N7\M)=Y'/)Y)/>N(\;:?]DUG[2O^KNAN^C# /\
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M%"DJ--4T[V[A1114&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\*7]U>6,]Y))<KM<3NI &<\845NZCIMEJ]C)97]NEQ;2?>C<<?\ UC[U:HH
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MR5KA55_M#JP &<8PH]:Z>BB@ KEO#W@'2O#6N7.K6=Q>27%PC(ZS.I4!F#'
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MO \$7B+PW?7<0AD"R OEH\\ @@#Y>Q!]??% 'M4TT5O#)--(D<4:EW=V 55
MR22>@%5K35],OX99K/4;2YBB_P!8\,ZNJ<9Y(/%<P-='B3X2W^ID*)9-,N%E
M53G:ZHP/TZ9^A%>6?#OPW=^+!=:=+=R0:+$Z372Q'#2O@A%_0GV^N* /=[36
M])U"<P66J65S,O)CAN$=A^ .:NNZQHSNP5%!+,QP /4US'AKP#H_A34[F^TY
MK@O-$(MLKA@@SDXXSR0.OI7GQ?4/BWXKNK47DEKH%D=VU!U&2%)'0N>>O09Q
M[@'J\7B30IYO)AUK3I)>FQ+I"WY UIUYQ=_!?P[+9M':W%[!<?PS,X<9]UP,
MCZ8^M9GPPUW4M/\ $%[X.U1WE%MO$!;G84."H/\ =(Y'_P!>@#UJLMO$N@I,
M(6UO31*3@(;M-Q/3IFO+/%^L:KXX\;'PAI4Y@L8I#',0<!ROWV;!Y QP/4>O
M3H8?@QX;2S6*:>_DFV_-,) ISW(&" /8Y_&@#T,RQK"93(HB"[BY/&.N<^E>
M-:UXJ%Q\7;%5UQ'T2*:)AMN1]G!V\DD';USR:[[PKX(M_#&E7VG_ &Z>[CNV
M(R_R[$(("@9(SR<D8SGIQ7DFI>$M+M?BO!X=C$W]GR21*07^;#(">?K0![K9
M:]H^HS^18ZM8W4V"WEP7".V/7 .:N3SPVL+37$L<42<L\C!5'U)KFO#_ ,/]
M"\,ZD;_3TG$YC,>9)=P .,\?A4'C#P##XQU&QGN=1N(+>W1E>&,Y#9((*@\*
M>N3@Y^7TH W8O$FA3S>3#K6G22]-B72%OR!K3KS#6O@WHIT><Z5)=1WL:%HR
M[[Q(0#A2,=SCD4OP:\03ZCH]YI=U*\CV3*T3.23Y;9XS[$'\Z .?^.'_ "'-
M+_Z]F_\ 0J]NKQ'XX?\ (<TO_KV;_P!"KVZ@ HHK,\1:S%X?\/WNJRJ66WCR
M%'\3$@*/Q)% %VZO+:RB\V[N(;>/.-\KA!GTR:K66MZ3J4ACL-4LKJ0<E8+A
M'(_ &O'?#'A6_P#B7>3Z_P"(K^86@<QQI&1EN^U,Y"*,CMSSWYKJ+[X,:'(J
MMIU[>V4ZL"'+"0=?3@Y]"#0!Z369+XDT*";R9M:TZ.7IL>Z0-^1-5M>\.#5_
M"<NAPW<UOF)8XYM[,WRX^]SE@0,'/7/K7+6OP8\-Q6VR>:^GE/63S OY #^>
M: /08)X;J%9K>6.6)^5>-@RGZ$4VZN[:QMGN;RXBMX$QNEF<(JY.!DG@<D"O
M%?"_VKP#\4SX?>YDEL;IA'[/O7*-CID' )^M>@?%/_DF^K?]L?\ T<E '3/J
M=A'91WKWULMK)C9.95"-GIALX-,L=8TO4V9;#4K.[91EA;SK(0/?!KR/P-X(
M;QAX>M;O7=3NGT^V+16=I$X 4!B6)./4D>N .< "J'C[P?'X#NM.UC0;NXB#
M2%0&?+1N!D$''((SD']0<  ]XJ&ZO+:RB\V[N(;>/.-\KA!GTR:QKSQ/%9>!
MAXDDC.QK2.X$?^TX&U?S8"O+?#'A6_\ B7>3Z_XBOYA:!S'&D9&6[[4SD(HR
M.W//?F@#V*RUO2=2D,=AJEE=2#DK!<(Y'X U?KS:^^#&AR*K:=>WME.K ARP
MD'7TX.?0@UT'B_7E\%>#O/MP9)4"6UMYI+Y;'!8DY. I/OB@#?O=3L-,17O[
MZVM$;A6GE6,'Z9-)9:II^I FPO[6Z ZF"97Q^1KROPQ\-O\ A*;)/$'BB_NY
M[B] D1%?!V?PEB1W'0#@#'X5_&7PYC\)V'_"1>'+V[ADLV5GC+9*@D#<K#!X
MSR#G@GH!B@#V2::*WADFFD2.*-2[N[ *J@9))/0"JUIJ^F7\,LUGJ-I<Q1?Z
MQX9U=4XSR0>*Y&U\0OXF^$6I:C,H6X_L^YCFP, NL; D?7@_C7F?P[\-W?BP
M76G2W<D&BQ.DUTL1PTKX(1?T)]OKB@#W>TUO2=0G,%EJEE<S+R8X;A'8?@#F
MK]<MX:\ Z/X4U.YOM.:X+S1"+;*X8(,Y..,\D#KZ5U- !7E/BB__ .$L^)NF
M>%E+2:;:2"2[C7H[J"Q#>P&%_P"!'O7JDCK%&TCG"J"Q/H!7AWPD8ZI\0M2U
M*;.\P2S<G)W/(O?'N: /<Z\!F\0RVWQPDOVDPBZA]D?G $8_='\AS]17O-S<
M1VEK-<RG$<*-(Y] !DU\Q6NAS:OX:UO7\DR6<\3,JKPP<MO_ ")4_3- 'U%7
M@GB'Q%N^-<5XLC-!9W<5L,_PJI"R <^I?\Z]0TSQ6LWPU3Q$[*\L5FS2 YP9
M4!!'KRP_6O!I-$F?P:_B24[C+J'V<9SD_(S%O3!/'X4 ?1OBC5)=%\+ZEJ,
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M_P"M7*^"_A7;ZII\.L^(I9Y7NOWRVX<KE3SEVZDGKQCKUK+^*;'4OB58Z?(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT$1R,\+AV _-J].\?.D?@/63)C!MB.?4X _4B@#;@O[.YMFN8+N"6!<[I8Y
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MQO:VEG-=3W.IMY\WF[22\DA'R[5'?/&#0![GHFF66CZ+:V&G#_1(D_=G=NW
M\EL]\DD_C5R66.&-I)9%CC7DLYP!^-5[NZM-%TF6YG80VEI%N/\ LJHZ#U]
M*\6MX-<^+^N332SFRT:U883)*IZ #HSXSD]O88% 'KZ>)M DD\M-<TUI.FU;
MN,G\LUIHZR(KHP9& *LIR"/45XMXT^&.A^&?"L^IP7U\UQ&455E9"KDG&,!0
M1Z]>U=C\(K1[;P#!(Y;_ $B>250QZ#.WCT'RY_&@#C/&1&O?&G3=.#%HX'@B
M< ] #YC8QWP37MM>*^! =>^,.J:LPW) 9Y48'@9/EJ/?Y2?RKVJ@ KF/B'??
MV?X"U>4, 9(/)&>^\A#^C&NGKS3XUWP@\*VEF/OW-T#_ ,!53G]2M &)\,O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %;4?\ D&W/_7)OY4:=_P @VV_ZY+_*C4?^0;<_]<F_E1IW
M_(-MO^N2_P J +-%%% !1110 4444 9K_P#(QQ?]>Y_F:TJS7_Y&.+_KW/\
M,UI4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8GEMY%5L< DY"G\"* .9_P"$?7PQ\6M'TM+J2Y6.X@8.XP<$YQCVKU+XI_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY?& "A^\,9['D_2N2O-7^)OBJR?2#HLMK',I25_LS0;U/4%G. ,<<8R#CG-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *VH_\ (-N?^N3?RHT[_D&VW_7)?Y4:C_R#;G_KDW\J
M-._Y!MM_UR7^5 %FBBB@ HHHH **** ,U_\ D8XO^O<_S-:59K_\C'%_U[G^
M9K2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N*\;^';JXOM/\3:1%YNJ:8P)AR?W\0))4#U&3@<9R?:NUHH K
MV%[#J.GV][;DF&>-9$W#!P1GD=C[58HHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** &331V\$D\SA(HU+NQZ* ,DUP/@[1+C5/%
M.H>-=1B>,71*Z='(-KK#C:'([94 #ZD]P3W\D:31/%*BO&ZE61AD,#U!'<4Z
M@ HHHH **** "BBB@ HHHH **** "@T4&@"MJ$#W6FW5LA4/+"\:EN@)!'-<
M%_P@>J?\_%G_ -]M_P#$UZ*:::Z*.)J44U X<7EU#%R4JM]#SL^!=4'_ "WL
M_P#OMO\ XFD_X0;4_P#GO:?]]M_\37H9IA%;?VA6.3^P<'V?WGGW_"$:E_SW
MM/\ OMO_ (FD_P"$)U+_ )[VG_?;?_$UZ 132M']H5@_L'!]G]YP'_"%:E_S
MVM?^^V_^)H_X0O4O^>UK_P!]M_\ $UWVVC;1_:%8/[!P?9_><#_PA>I?\]K7
M_OMO_B:/^$+U+_GM:_\ ?;?_ !-=[MHVT?VA6#^P<'V?WG!?\(7J7_/:U_[[
M;_XFC_A"]2_Y[6O_ 'VW_P 37>[:-M']H5@_L'!]G]YP7_"%ZE_SVM?^^V_^
M)H_X0O4O^>UK_P!]M_\ $UWNVC;1_:%8/[!P?9_><%_PA>I?\]K7_OMO_B:/
M^$+U+_GM:_\ ?;?_ !-=[MHVT?VA6#^P<'V?WG!?\(7J7_/:U_[[;_XFC_A"
M]2_Y[6O_ 'VW_P 37>[:-M']H5@_L'!]G]YP7_"%ZE_SVM?^^V_^)H_X0O4O
M^>UK_P!]M_\ $UWNVC;1_:%8/[!P?9_><%_PA>I?\]K7_OMO_B:/^$+U+_GM
M:_\ ?;?_ !-=[MHVT?VA6#^P<'V?WG!?\(7J7_/:U_[[;_XFC_A"]2_Y[6O_
M 'VW_P 37>[:-M']H5@_L'!]G]YP7_"%ZE_SVM?^^V_^)H_X0O4O^>UK_P!]
MM_\ $UWNVC;1_:%8/[!P?9_><%_PA>I?\]K7_OMO_B:/^$+U+_GM:_\ ?;?_
M !-=[MHVT?VA6#^P<'V?WG!?\(7J7_/:U_[[;_XFC_A"]2_Y[6O_ 'VW_P 3
M7>[:-M']H5@_L'!]G]YP7_"%ZE_SVM?^^V_^)H_X0O4O^>UK_P!]M_\ $UWN
MVC;1_:%8/[!P?9_><%_PA>I?\]K7_OMO_B:/^$+U+_GM:_\ ?;?_ !-=[MHV
MT?VA6#^P<'V?WG!?\(7J7_/:U_[[;_XFC_A"]2_Y[6O_ 'VW_P 37>[:-M']
MH5@_L'!]G]YP7_"%ZE_SVM?^^V_^)H_X0O4O^>UK_P!]M_\ $UWNVC;1_:%8
M/[!P?9_><%_PA>I?\]K7_OMO_B:/^$+U+_GM:_\ ?;?_ !-=[MHVT?VA6#^P
M<'V?WG!?\(7J7_/:U_[[;_XFC_A"]2_Y[6O_ 'VW_P 37>[:-M']H5@_L'!]
MG]YP7_"%ZE_SVM?^^V_^)H_X0O4O^>UK_P!]M_\ $UWNVC;1_:%8/[!P?9_>
M<%_PA>I?\]K7_OMO_B:/^$+U+_GM:_\ ?;?_ !-=[MHVT?VA6#^P<'V?WG!?
M\(7J7_/:U_[[;_XFC_A"]2_Y[6O_ 'VW_P 37>[:-M']H5@_L'!]G]YP7_"%
MZE_SVM?^^V_^)H_X0O4O^>UK_P!]M_\ $UWNVC;1_:%8/[!P?9_><%_PA>I?
M\]K7_OMO_B:/^$+U+_GM:_\ ?;?_ !-=[MHVT?VA6#^P<'V?WG!?\(7J7_/:
MU_[[;_XFC_A"]2_Y[6O_ 'VW_P 37>[:-M']H5@_L'!]G]YP7_"%ZE_SVM?^
M^V_^)H_X0O4O^>UK_P!]M_\ $UWNVC;1_:%8/[!P?9_><%_PA>I?\]K7_OMO
M_B:/^$+U+_GM:_\ ?;?_ !-=[MHVT?VA6#^P<'V?WG!?\(7J7_/:U_[[;_XF
MC_A"]2_Y[6O_ 'VW_P 37>[:-M']H5@_L'!]G]YP7_"%ZE_SVM?^^V_^)H_X
M0O4O^>UK_P!]M_\ $UWNVC;1_:%8/[!P?9_><%_PA>I?\]K7_OMO_B:/^$+U
M+_GM:_\ ?;?_ !-=[MHVT?VA6#^P<'V?WG!?\(7J7_/:U_[[;_XFC_A"]2_Y
M[6O_ 'VW_P 37>[:-M']H5@_L'!]G]YP7_"%ZE_SVM?^^V_^)H_X0O4O^>UK
M_P!]M_\ $UWNVC;1_:%8/[!P?9_><%_PA>I?\]K7_OMO_B:/^$+U+_GM:_\
M?;?_ !-=[MHVT?VA6#^P<'V?WG!?\(7J7_/:U_[[;_XFC_A"]2_Y[6O_ 'VW
M_P 37>[:-M']H5@_L'!]G]YP7_"%ZE_SVM?^^V_^)H_X0O4O^>UK_P!]M_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#110
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M* ,W^S+C_H)W/YT?V9<?]!.Y_.M*B@#-_LRX_P"@G<_G1_9EQ_T$[G\ZTJ*
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M]!.Y_.M*B@#-_LRX_P"@G<_G1_9EQ_T$[G\ZTJ* ,W^S+C_H)W/YT?V9<?\
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M=2/;/\JI0DX\UM!<RORWU+5%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "I()Y+:998G*NIR"*CHH3:=
MT#2:LST#1M9CU.':V%N%'S)Z^XK4KR^">2VF6:%RKJ<@BN\T;68]3AP<+<*/
MF3U]Q7T^7Y@JR]G4^+\_^"?/8[ ND^>'P_D:E%%%>L>8%%%% !1110 4444
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M;O5H/!^D,V^;:+G9G+L^-L?TP03Z[AZ&@#M+WXB^$M/N#!/K<!<=?)1Y1^:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$=CI[+_:=VI(8\F%.F_'J3D#Z'TII-NR WM<\<>'?#K-'?ZC&)Q_RPB!D?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5)!/);3+-"Y5U.014=%";3N@:35F>
M@:-K,>IPX.%N%'S)Z^XK4KR^">6VF6:%RKJ<@BN\T;68M4AP<+<*/F3U]Q7T
M^7Y@JR]G4^+\_P#@GSV.P+I/GA\/Y&I1117K'F!1110 4444 %%%% !1110
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M:I)XP\0J96DD,ENDBC$C?W\>@Z 8]^U '3_#'PB_AG0FN+R/;J%]M>13G,:
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M3?5O^V/_ *.2K>E_\DQLO^P,G_HD4 8\?Q&NM3M5N?#WA>_U.%5S+(7$2HV
M2H.#N(SV_#-;6@^,;/Q#X=NM5M8G1[4.)K:0X9649P?8CO\ X&LGX1@#X?VI
M  S-*3[_ #&L#P&3Y'CT9.!-(<?A)0!WGA'Q%_PE/A^+5?LOV7S'9?*\S?C:
M<=<#^54;?QA-=^(-?TBWTHR3Z7#YD>)^;AL9"XV_+DG&<FJ'PC(/P_M0"#B:
M4'V^8U2\*$'XN>+2"#\B#C_@- '.^"_$GB2#5?$$T/A^XU:>6Y F!O0# 5+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"UIUDVH7\5LIQO/S'T ZFNY/]
MFZ%:J2$A7H#C+,?YFN1\.W26NLQ&0@+(#'GT)Z?KBNHU_2'U6WC,3@2Q9*AN
MC XR/TKW<MCRX>=6DKS/'Q\N:O&G4=H#X]6TG4@86EB?/5)EQG\ZX2Z:-[J5
MH4"1%R44=AGBBXM9[20QW$3QMZ,,9^GK45>?B\9.NE&I%)H[<+A84;N$KIGH
MNH?\@&X_Z]S_ .@UYU7HNH?\@&X_Z]S_ .@UYU79G/QP]#ERKX)>H4445XQZ
MIL>&[(7>K([*3' /,/'&>P_/G\*T?%]EAH;U%X/R2$?I_6M#PS9_9-)\Z0 -
M.=Y/HO;^I_&K#^5KVA-L&!*IVYZJP/'ZBOHJ.#3P?LG\4ES?U^'WGA5<4UB_
M:+X8Z?U_70\^KL]-\0:;;Z;;PRSE71 K#8QY_*N-(()!!!'4&DKQL+BIX:3E
M"VO<]7$8:&(BHSZ'H]EJMGJ#LEM*791D@J1Q^-%[JMGI\BI<RE&89'RD\?A7
M.>#O^/VY_P"N8_G1XQ_X_;;_ *YG^=>]]>J?4_;V5_PW/&^IT_K?L;NW_ -*
M^\0Z9/I]S%'.2[Q,JC8W)((':HO!_P#QX7'_ %U_H*XZNQ\'_P#'A<?]=?Z"
MN/!XN>)Q<7.VB>QU8K#0P^&DH=6C2N==T^TN'@FG*R)U&QCVSZ5%_P )+I7_
M #\'_OVW^%8NLZ'J-WJT\\%OOC<C:V]1G@#N:RKK1=0LH#-<6^R,$ G>I_D:
MUKX[&4YRM#W4WK9[&='!X2<8WGJ[:76X_7;R&^U1YH&+1[5 )&,\5FT45X56
MHZDW.6[/9IP5."@MD%%%%04%203RVTRS0N5=3D$5'10FT[H&DU9GH&C:S%JD
M.#A9U'S)Z^XK4KR^">6VG6:%RKJ<@BN\T?6(M4@P<+.H^=/ZBOI\OS!5E[.I
M\7Y_\$^>QV!=)\\/A_(U****]8\P**** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_7#^HKPGX;_\E"T?_KJ?_0&I4_@8'TY7COQW_P"8!_V\?^TJ]BKQWX[_ /,
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MMV*;GAE1MZ'N.!R?IFO.(9)OB9\4HKRWBDCTZU9#N=<[8D.0#V!8YX[9[X-
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M/'UQG&/K6AX8\"P^%]=U#4;>^DFCNT"B*1264C!+%R3N).2>!UKK:* .(O\
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M;XW@?\(]IAP,BZ(S_P  -=SX2_Y$S0O^P?;_ /HM:X;XW_\ (NZ;_P!?9_\
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M]T>]M$^]/;R1CG'+*1_6O%_A5XIL/#-QJ>F:U*+/S&#*[J>'7(93CIV_(^U
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M?$7C&T;PR#+=R!4DFA4J)),_+CN2/7Z>E 'T'12+D*-Q!;') P,TM !1110
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M:Y8YVK+$>JL.4/\ 0UP^K:>=-U![?)9/O(Q[J?\ ./PKI_#6E7>GM-)<@()
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MT#0?/*W=VO[L<HA_B]S[5UPP!@#BO=RW+FVJU7Y+]3Q\?CK7I4_FQU%)2U]
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M>W8QAC_=- '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!6U'_ )!MS_UR;^5&G?\
M(-MO^N2_RHU'_D&W/_7)OY4:=_R#;;_KDO\ *@"S1110 4444 %%%% &:_\
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M)"1K@9/4_6K5% %34=+L=7M#::A:Q7,!.[9(N0#ZCT/O6'9?#OPEI\RS0:)
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M\OAA(=Y/=GS&,QDL1+M%;(****]$XPHHHH [KX<_\Q+_ +9?^SUW5<+\.?\
MF)?]LO\ V>NZKX?./]]G\OR1]3EW^[1^?YL****\P[0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLNYK5:JTZ(\?'X^UZ5)Z]63 @  <"G9J$&G U]">&2YI<TP&G"@!:6D%+WH
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M/@_2"VZ8(+@1_>=FZ)[#&"?KZ5L:'\'M L[)1JZ/J%TPRY\QXT4^BA2#CW-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7=44?VQC?Y_P7^0?V=AOY?Q?^9PO_"N?^HK_ .2__P!E1_PKG_J*_P#DO_\
M95W5%']L8W^?\%_D']G8;^7\7_F87ASPY_PC_P!I_P!+\_S]O_+/;MVY]SZU
MNT45P5JTZTW4J.[9U4Z<:45""LD%%%%9EA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;VC:,92MS<K
M^[ZHA_B]S[4:+HIF*W-RN(^J(?XO?Z5U 7  '2O<R[+N:U6JM.B/'Q^/M>E2
M>O5B#@8'2G"C%+BOH3PQ13A2 4X"@!PIXIH%.% #J*** %HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%&M:6FGV32V4$9\R43(NTLWS<,P/ 4'I7ID:+%&L:#"J H'H!0!XO\9YFO\
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M?).YE4 G)Z]* /&-$F23X]W#WA4$7EPD>\]PK*OZ 8_#O7N3,$4LQ 4#))/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6U
M'_D&W/\ UR;^5&G?\@VV_P"N2_RHU'_D&W/_ %R;^5&G?\@VV_ZY+_*@"S11
M10 4444 %%%% &:__(QQ?]>Y_F:TJS7_ .1CB_Z]S_,UI4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !24M% $-Q"MQ;RPN2%D0H2.N",5B'PE8
M?\]KG_OI?\*Z"DQ6-7#4JKO4C<VIUZE)6@['/'PG8_\ /6Y_[Z7_  I#X4L?
M^>MS_P!]+_A70D4F*Q^H8;^1&GUW$?SLY[_A%;+_ )ZW'_?2_P"%)_PBME_S
MUN/^^E_PKH=M)MH^H8;^1!]=Q'\[.?\ ^$6LO^>MQ_WTO^%'_"*V7_/6X_[Z
M7_"N@VT;:/J&&_D0?7<1_.SG_P#A%;+_ )ZW'_?2_P"%'_"*V7_/6X_[Z7_"
MN@VT;:/J&&_D0?7<1_.SG_\ A%;+_GK<?]]+_A1_PBME_P ];C_OI?\ "N@V
MT;:/J&&_D0?7<1_.SG_^$5LO^>MQ_P!]+_A1_P (K9?\];C_ +Z7_"N@VT;:
M/J&&_D0?7<1_.SG_ /A%;+_GK<?]]+_A1_PBME_SUN/^^E_PKH-M&VCZAAOY
M$'UW$?SLY_\ X16R_P">MQ_WTO\ A1_PBME_SUN/^^E_PKH-M&VCZAAOY$'U
MW$?SLY__ (16R_YZW'_?2_X4?\(K9?\ /6X_[Z7_  KH-M&VCZAAOY$'UW$?
MSLY__A%;+_GK<?\ ?2_X4?\ "*V7_/6X_P"^E_PKH-M&VCZAAOY$'UW$?SLY
M_P#X16R_YZW'_?2_X4?\(K9?\];C_OI?\*Z#;1MH^H8;^1!]=Q'\[.?_ .$5
MLO\ GK<?]]+_ (4?\(K9?\];C_OI?\*Z#;1MH^H8;^1!]=Q'\[.?_P"$5LO^
M>MQ_WTO^%'_"*V7_ #UN/^^E_P *Z#;1MH^H8;^1!]=Q'\[.?_X16R_YZW'_
M 'TO^%'_  BME_SUN/\ OI?\*Z#;1MH^H8;^1!]=Q'\[.?\ ^$5LO^>MQ_WT
MO^%'_"*V7_/6X_[Z7_"N@VT;:/J&&_D0?7<1_.SG_P#A%;+_ )ZW'_?2_P"%
M'_"*V7_/6X_[Z7_"N@VT;:/J&&_D0?7<1_.SG_\ A%;+_GK<?]]+_A1_PBME
M_P ];C_OI?\ "N@VT;:/J&&_D0?7<1_.SG_^$5LO^>MQ_P!]+_A1_P (K9?\
M];C_ +Z7_"N@VT;:/J&&_D0?7<1_.SG_ /A%;+_GK<?]]+_A1_PBME_SUN/^
M^E_PKH-M&VCZAAOY$'UW$?SLY_\ X16R_P">MQ_WTO\ A1_PBME_SUN/^^E_
MPKH-M&VCZAAOY$'UW$?SLY__ (16R_YZW'_?2_X4?\(K9?\ /6X_[Z7_  KH
M-M&VCZAAOY$'UW$?SLY__A%;+_GK<?\ ?2_X4?\ "*V7_/6X_P"^E_PKH-M&
MVCZAAOY$'UW$?SLY_P#X16R_YZW'_?2_X4?\(K9?\];C_OI?\*Z#;1MH^H8;
M^1!]=Q'\[.?_ .$5LO\ GK<?]]+_ (4?\(K9?\];C_OI?\*Z#;1MH^H8;^1!
M]=Q'\[.?_P"$5LO^>MQ_WTO^%'_"*V7_ #UN/^^E_P *Z#;1MH^H8;^1!]=Q
M'\[.?_X16R_YZW'_ 'TO^%'_  BME_SUN/\ OI?\*Z#;1MH^H8;^1!]=Q'\[
M.?\ ^$5LO^>MQ_WTO^%'_"*V7_/6X_[Z7_"N@VT;:/J&&_D0?7<1_.SG_P#A
M%;+_ )ZW'_?2_P"%'_"*V7_/6X_[Z7_"N@VT;:/J&&_D0?7<1_.SG_\ A%;+
M_GK<?]]+_A1_PBME_P ];C_OI?\ "N@VT;:/J&&_D0?7<1_.SG_^$5LO^>MQ
M_P!]+_A1_P (K9?\];C_ +Z7_"N@VT;:/J&&_D0?7<1_.SG_ /A%;+_GK<?]
M]+_A1_PBME_SUN/^^E_PKH-M&VCZAAOY$'UW$?SLY_\ X16R_P">MQ_WTO\
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M.SG_ /A%;+_GK<?]]+_A1_PBME_SUN/^^E_PKH-M&VCZAAOY$'UW$?SLY_\
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MZ7_"N@VT;:/J&&_D0?7<1_.SG_\ A%;+_GK<?]]+_A1_PBME_P ];C_OI?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
MMJ/_ "#;G_KDW\J-._Y!MM_UR7^5&H_\@VY_ZY-_*C3O^0;;?]<E_E0!9HHH
MH **** "BBB@#-?_ )&.+_KW/\S6E6:__(QQ?]>Y_F:TJ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH 2C%+10 F*3%.HH ;BBG44 -Q1BG
M44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -
MQ1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG
M44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -
MQ1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG
M44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -
MQ1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG
M44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -
MQ1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG
M44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -HQ3J* $Q1BEQ10 E
M%+10 4444 &**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*VH_\@VY_P"N3?RHT[_D&VW_ %R7^5&H_P#(-N?^N3?RHT[_ )!MM_UR7^5
M%FBBB@ HHHH **** ,U_^1CB_P"O<_S-:59K_P#(QQ?]>Y_F:TJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK+_WV:/[#L_67_OLUI44 9O]AV?K+_WV:/[#L_67_OLUI44 9O\ 8=GZR_\
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MK+_WV:/[#L_67_OLUI44 9O]AV?K+_WV:/[#L_67_OLUI44 9O\ 8=GZR_\
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MK+_WV:/[#L_67_OLUI44 9O]AV?K+_WV:/[#L_67_OLUI44 9O\ 8=GZR_\
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MK+_WV:/[#L_67_OLUI44 9O]AV?K+_WV:/[#L_67_OLUI44 9O\ 8=GZR_\
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MK+_WV:/[#L_67_OLUI44 9O]AV?K+_WV:/[#L_67_OLUI44 9O\ 8=GZR_\
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MK+_WV:/[#L_67_OLUI44 9O]AV?K+_WV:/[#L_67_OLUI44 9O\ 8=GZR_\
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MK+_WV:/[#L_67_OLUI44 9O]AV?K+_WV:/[#L_67_OLUI44 9O\ 8=GZR_\
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MH3P,K:,ZBBHK>XCN8A)&<@]O2I:[DTU='&TT[,****8@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** *VH_\ (-N?^N3?RHT[_D&V
MW_7)?Y4:C_R#;G_KDW\J-._Y!MM_UR7^5 %FBBB@ HHHH **** ,U_\ D8XO
M^O<_S-:59K_\C'%_U[G^9K2H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *VH_P#(-N?^N3?RHT[_ )!M
MM_UR7^5&H_\ (-N?^N3?RHT[_D&VW_7)?Y4 6:*** "BBB@ HHHH S7_ .1C
MB_Z]S_,UI5FO_P C'%_U[G^9K2H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MN0\;^/K/P=%%%Y)NK^9=T< ?: N<;F/.!UQQS@T =?17C+?%#QPD(O&\-1+9
M-RLAM)MI';Y]V#7I'@[Q#+XH\-P:K-9BU,C,H4/N#;3@L.!QD'CVH WJ*\QT
MOQ;KES\7[G0I;W=IJ22JL'E(, (2/FQNZ^]>G4 %%%% !1110 4444 %%%%
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MY+>*8PEV0KN8*IR ><?,.N* -6BBO.9_'>NQ_$^/PX-,C%BTH3/EN9&0C_6
MYQ@<GI@#/I0!Z-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M444 %%8FN>+='\.S0V]_<D7,^/*@1"S/DX^@Y]2.E;= !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:*** "BBO,OB-XMUK2?%.D:1H]\;8W"*TN(D?.]]J_>!]#0!Z;1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %;4
M?^0;<_\ 7)OY4:=_R#;;_KDO\J-1_P"0;<_]<F_E1IW_ "#;;_KDO\J +-%%
M% !1110 4444 9K_ /(QQ?\ 7N?YFM*LU_\ D8XO^O<_S-:5 !1110 4444
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MG%>I6$-C%;;M/2!;>4^8#!C8Q/<8X[4 6J*** "BBB@ HHHH **** "BBB@
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MLO3[C4KN6%99(8R5$.<95FP>1GL,5'H?QCTC4+L6NIV<NF.QP)&D$D8Z_>.
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MB+3]-FU&9(Q)<>7)MCBR,D;L'..<\8_7'8>&M9D\0>'[359+,VGVA2RPE]Y
MR0#G ZXS]"*J^"M$M-"\*V,%M&JO)"DLS@<R2,H))/\ +T&*WU4(H50 H&
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M6DT>9V8JC#A?7WKNP56:ER+5?D<6+IP<>?9FQ1117K'F!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH2<8)Q7-ZE\;].@N&33M)GNXP<>9)*(@?<##'\\5B?$B,:_\5=,TA>0%@MY
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M/ZUY/X*UF[\$^(M/NKQ3'I^HQCS<]#$6(#\9^Z1GUQD=Z[;XXWNS3M(L ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% %;4?^0;<_P#7)OY4:=_R#;;_ *Y+_*C4?^0;
M<_\ 7)OY4:=_R#;;_KDO\J +-%%% !1110 4444 9K_\C'%_U[G^9K2K-?\
MY&.+_KW/\S6E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %;4?\ D&W/_7)OY4:=_P @VV_ZY+_*C4?^0;<_]<F_E1IW_(-M
MO^N2_P J +-%%% !1110 4444 9K_P#(QQ?]>Y_F:TJS7_Y&.+_KW/\ ,UI4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5?\ O$GESTP3C'H>*]#HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O/\ CRN/^N;?RKDZ
MZR\_X\I_^N;?RKDZ\O,/BB>E@?A84C*KJ590RL,$$9!%+17GG<<EJ?P[T+4'
M:2*.2SD;G]P<+G_=/ _#'2L-OA,I8[=:('H;7/\ [/7I-%=,,;7@K*7Z_F82
MPU*3NXG#Z=\,-)MI1)>7$]W@Y"<(I^H')_.NSMK:"S@6"VACAB7[J1J% _ 5
M+16=6O4J_&[EPI0A\*"BBBLC00D*"20 .237EGC?QN;PR:7I<A%N/EEF4_?]
MA[5W^OZ3<:U8_8XM0:SC;_6%(]Q<>F<C KCO^%3P?]!>3_OP/_BJ[L$\/!\]
M5Z]K,Y<0JLERP6AYA17I;?"49.W6B!V!M<_^ST?\*E_ZC?\ Y*?_ &=>O_:&
M&_F_!_Y'!]4K=OR/-**]+_X5+_U&_P#R4_\ LZ/^%2_]1O\ \E/_ +.G_:&&
M_F_!_P"0?5*W;\CS2BO2_P#A4O\ U&__ "4_^SH_X5+_ -1O_P E/_LZ/[0P
MW\WX/_(/JE;M^1VWAO\ Y%?2?^O.+_T 5J55TVS_ +/TNTLO,\S[/"D6_&-V
MT 9QVZ5:KYN;3DVCUXJT4F%%%%24%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"MJ/_(-N?\ KDW\J-._Y!MM_P!<E_E1J/\ R#;G_KDW\J-._P"0;;?]
M<E_E0!9HHHH **** "BBB@#-?_D8XO\ KW/\S6E6:_\ R,<7_7N?YFM*@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC_EX_P#'/_KTG]B_]/'_ (Y_]>N/ZG6_E_(ZOK5'O^9DT5J_V-_TW_\ '/\
MZ])_8Q_Y[_\ CG_UZ/J=;^7\@^M4>_YF716I_8__ $W_ /'/_KT?V,?^>_\
MXY_]>CZG6_E_(/K5'O\ F9=%:G]C'_GO_P".?_7H_L8_\]__ !S_ .O1]3K?
MR_D'UJCW_,RZ*U/[&/\ SW_\<_\ KT?V,?\ GO\ ^.?_ %Z/J=;^7\@^M4>_
MYF716I_8Q_Y[_P#CG_UZ/[&/_/?_ ,<_^O1]3K?R_D'UJCW_ #,NBM3^QC_S
MW_\ '/\ Z]']C'_GO_XY_P#7H^IUOY?R#ZU1[_F9=%:G]C'_ )[_ /CG_P!>
MC^QC_P ]_P#QS_Z]'U.M_+^0?6J/?\S+HK4_L8_\]_\ QS_Z]']C'_GO_P".
M?_7H^IUOY?R#ZU1[_F9=%:G]C'_GO_XY_P#7H_L8_P#/?_QS_P"O1]3K?R_D
M'UJCW_,RZ*U/[&/_ #W_ /'/_KT?V,?^>_\ XY_]>CZG6_E_(/K5'O\ F9=%
M:G]C'_GO_P".?_7H_L8_\]__ !S_ .O1]3K?R_D'UJCW_,RZ*U/[&/\ SW_\
M<_\ KT?V,?\ GO\ ^.?_ %Z/J=;^7\@^M4>_YF716I_8Q_Y[_P#CG_UZ/[&/
M_/?_ ,<_^O1]3K?R_D'UJCW_ #,NBM3^QC_SW_\ '/\ Z]']C'_GO_XY_P#7
MH^IUOY?R#ZU1[_F9=%:G]C'_ )[_ /CG_P!>C^QC_P ]_P#QS_Z]'U.M_+^0
M?6J/?\S+HK4_L8_\]_\ QS_Z]']C'_GO_P".?_7H^IUOY?R#ZU1[_F9=%:G]
MC'_GO_XY_P#7H_L8_P#/?_QS_P"O1]3K?R_D'UJCW_,RZ*U/[&/_ #W_ /'/
M_KT?V,?^>_\ XY_]>CZG6_E_(/K5'O\ F9=%:G]C'_GO_P".?_7H_L8_\]__
M !S_ .O1]3K?R_D'UJCW_,RZ*U/[&/\ SW_\<_\ KT?V,?\ GO\ ^.?_ %Z/
MJ=;^7\@^M4>_YF716I_8Q_Y[_P#CG_UZ/[&/_/?_ ,<_^O1]3K?R_D'UJCW_
M #,NBM3^QC_SW_\ '/\ Z]']C?\ 3?\ \<_^O1]3K?R_D'UJCW_,RZ*U/['_
M .F__CG_ ->I(=)6.0,[[P.VW%-8.LWJA/%TDM&5[*QWXEE'R]AZUJ 5(%I=
MM>K1HQI1LCS*M6525V, I<4_;2[:U,QH%. IP6E H  *<* *4"@!:6DI: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH K:C_P @VY_ZY-_*C3O^0;;?
M]<E_E1J/_(-N?^N3?RHT[_D&VW_7)?Y4 6:*** "BBB@ HHHH S7_P"1CB_Z
M]S_,UI5FO_R,<7_7N?YFM*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *2EHH 2DI:,4 ,(I,5)BDQ0!'MHVU)BC% $>VC;4F*,4 1[:-M28HQ0
M!'MHVU)BC% $>VC;4F*,4 1[:-M28HQ0!'MHVU)BC% $>VC;4F*,4 1[:-M2
M8HQ0!'MHVU)BC% $>VC;4F*,4 1[:-M28HQ0!'MHVU)BC% $>VC;4F*,4 1[
M:-M28HQ0!'MHVU)BC% $>VC;4F*,4 1[:-M28HQ0!'MHVU)BC% $>VC;4F*,
M4 1[:-M28HQ0!'MHVU)BC% $>VC;4F*,4 ,VT;:?BEQ0 S;2@4[%% #<4N*6
MB@ Q12T4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\
MY\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_O
MU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S
M_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\
M7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_
M]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2H
MH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^
MV8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?
M[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^
M?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_
M .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_
M[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.
M\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_
M %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]
M?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZT
MJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H
M_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,
MW^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/
M_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8
M_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO
M/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#G
MSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7
M_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^
M_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>
MM*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_U
MZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@
M#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9
MC_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_M
MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\
M[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\
MY\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_O
MU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S
M_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\
M7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_
M]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2H
MH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^
MV8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?
M[9C_ .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^
M?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_
M .?.\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_
M[]?_ %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.
M\_[]?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_
M %ZTJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]
M?_7H_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZT
MJ* ,W^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H
M_MF/_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,
MW^V8_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/
M_GSO/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8
M_P#GSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO
M/^_7_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#G
MSO/^_7_UZ/[9C_Y\[S_OU_\ 7K2HH S?[9C_ .?.\_[]?_7H_MF/_GSO/^_7
M_P!>M*B@#-_MF/\ Y\[S_OU_]>C^V8_^?.\_[]?_ %ZTJ* ,W^V8_P#GSO/^
M_7_UZ3^V8_\ GSO/^_7_ ->M.B@#,_ME/^?.\_[]?_7H_ME/^?.\_P"_7_UZ
MTZ* ,S^V4_Y\[S_OU_\ 7H_ME/\ GSO/^_7_ ->M.B@#,_ME/^?.\_[]?_7H
M_ME/^?.\_P"_7_UZTZ* ,S^V4_Y\[S_OU_\ 7H_ME/\ GSO/^_7_ ->M.B@#
M,_ME/^?.\_[]?_7H_ME/^?.\_P"_7_UZTZ* ,S^V4_Y\[S_OU_\ 7H_ME/\
MGSO/^_7_ ->M.B@#,_ME/^?.\_[]?_7H_ME/^?.\_P"_7_UZTZ* ,S^V4_Y\
M[S_OU_\ 7H_ME/\ GSO/^_7_ ->M.B@#,_ME/^?.\_[]?_7H_ME/^?.\_P"_
M7_UZTZ* ,S^V4_Y\[S_OU_\ 7H_ME/\ GSO/^_7_ ->M.B@#,_ME/^?.\_[]
M?_7H_ME/^?.\_P"_7_UZTZ* ,S^V4_Y\[S_OU_\ 7H_ME/\ GSO/^_7_ ->M
M.B@#,_ME/^?.\_[]?_7H_ME/^?.\_P"_7_UZTZ* ,S^V4_Y\[S_OU_\ 7H_M
ME/\ GSO/^_7_ ->M.B@#,_ME/^?.\_[]?_7H_ME/^?.\_P"_7_UZTZ* ,S^V
M4_Y\[S_OU_\ 7H_ME/\ GSO/^_7_ ->M.B@#,_ME/^?.\_[]?_7H_ME/^?.\
M_P"_7_UZTZ* ,S^V4_Y\[S_OU_\ 7H_ME/\ GSO/^_7_ ->M.B@#,_ME/^?.
M\_[]?_7H_ME/^?.\_P"_7_UZTZ* ,S^V4_Y\[S_OU_\ 7H_ME/\ GSO/^_7_
M ->M.B@#,_ME/^?.\_[]?_7H_ME/^?.\_P"_7_UZTZ* ,S^V4_Y\[S_OU_\
M7H_ME/\ GSO/^_7_ ->M.B@#,_ME/^?.\_[]?_7H_ME/^?.\_P"_7_UZTZ*
M,S^V4_Y\[S_OU_\ 7H_ME/\ GSO/^_7_ ->M.B@#,_ME/^?.\_[]?_7H_MF/
M_GSO/^_7_P!>M.B@#,_MF/\ Y\[S_OU_]>E_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[
M9C_Y\[S_ +]?_7H_MF/_ )\[S_OU_P#7K2HH S?[9C_Y\[S_ +]?_7H_MF/_
M )\[S_OU_P#7K2HH Q[O55GLYHEM+L%T*@F/CI]:OZ>"-.MP001&O!^E6:*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHK
MBY@M+=[BYFCAAC&7DD8*JCU)/2LK_A+_  U_T,.E?^!D?^-.P&U16+_PE_AK
M_H8=*_\  R/_ !H_X2_PU_T,.E?^!D?^-%F!M45B_P#"7^&O^AATK_P,C_QH
M_P"$O\-?]##I7_@9'_C19@;5%8O_  E_AK_H8=*_\#(_\:/^$O\ #7_0PZ5_
MX&1_XT68&U16+_PE_AK_ *&'2O\ P,C_ ,:/^$O\-?\ 0PZ5_P"!D?\ C19@
M;5%8O_"7^&O^AATK_P #(_\ &C_A+_#7_0PZ5_X&1_XT68&U16+_ ,)?X:_Z
M&'2O_ R/_&C_ (2_PU_T,.E?^!D?^-%F!M45B_\ "7^&O^AATK_P,C_QH_X2
M_P -?]##I7_@9'_C19@;5%8O_"7^&O\ H8=*_P# R/\ QH_X2_PU_P!##I7_
M (&1_P"-%F!M45B_\)?X:_Z&'2O_  ,C_P :/^$O\-?]##I7_@9'_C19@;5%
M8O\ PE_AK_H8=*_\#(_\:/\ A+_#7_0PZ5_X&1_XT68&U16+_P )?X:_Z&'2
MO_ R/_&C_A+_  U_T,.E?^!D?^-%F!M45B_\)?X:_P"AATK_ ,#(_P#&C_A+
M_#7_ $,.E?\ @9'_ (T68&U16+_PE_AK_H8=*_\  R/_ !H_X2_PU_T,.E?^
M!D?^-%F!M45B_P#"7^&O^AATK_P,C_QH_P"$O\-?]##I7_@9'_C19@;5%8O_
M  E_AK_H8=*_\#(_\:/^$O\ #7_0PZ5_X&1_XT68&U16+_PE_AK_ *&'2O\
MP,C_ ,:/^$O\-?\ 0PZ5_P"!D?\ C19@;5%8O_"7^&O^AATK_P #(_\ &C_A
M+_#7_0PZ5_X&1_XT68&U16+_ ,)?X:_Z&'2O_ R/_&C_ (2_PU_T,.E?^!D?
M^-%F!M45B_\ "7^&O^AATK_P,C_QH_X2_P -?]##I7_@9'_C19@;5%8O_"7^
M&O\ H8=*_P# R/\ QH_X2_PU_P!##I7_ (&1_P"-%F!M45B_\)?X:_Z&'2O_
M  ,C_P :/^$O\-?]##I7_@9'_C19@;5%8O\ PE_AK_H8=*_\#(_\:/\ A+_#
M7_0PZ5_X&1_XT68&U16+_P )?X:_Z&'2O_ R/_&C_A+_  U_T,.E?^!D?^-%
MF!M45B_\)?X:_P"AATK_ ,#(_P#&C_A+_#7_ $,.E?\ @9'_ (T68&U16+_P
ME_AK_H8=*_\  R/_ !H_X2_PU_T,.E?^!D?^-%F!M45B_P#"7^&O^AATK_P,
MC_QH_P"$O\-?]##I7_@9'_C19@;5%5+35-/O[5[JSOK:XMT)#RPRJZ*0,G)!
MP.#FJ'_"7^&O^AATK_P,C_QHLP-JBL7_ (2_PU_T,.E?^!D?^-'_  E_AK_H
M8=*_\#(_\:+,#:HK%_X2_P -?]##I7_@9'_C1_PE_AK_ *&'2O\ P,C_ ,:+
M,#:HK%_X2_PU_P!##I7_ (&1_P"-'_"7^&O^AATK_P #(_\ &BS VJ*Q?^$O
M\-?]##I7_@9'_C1_PE_AK_H8=*_\#(_\:+,#:HK%_P"$O\-?]##I7_@9'_C1
M_P )?X:_Z&'2O_ R/_&BS VJ*Q?^$O\ #7_0PZ5_X&1_XT?\)?X:_P"AATK_
M ,#(_P#&BS VJ*Q?^$O\-?\ 0PZ5_P"!D?\ C1_PE_AK_H8=*_\  R/_ !HL
MP-JBL7_A+_#7_0PZ5_X&1_XT?\)?X:_Z&'2O_ R/_&BS VJ*Q?\ A+_#7_0P
MZ5_X&1_XT?\ "7^&O^AATK_P,C_QHLP-JBL7_A+_  U_T,.E?^!D?^-'_"7^
M&O\ H8=*_P# R/\ QHLP-JBL7_A+_#7_ $,.E?\ @9'_ (T?\)?X:_Z&'2O_
M  ,C_P :+,#:HK%_X2_PU_T,.E?^!D?^-'_"7^&O^AATK_P,C_QHLP-JBL7_
M (2_PU_T,.E?^!D?^-'_  E_AK_H8=*_\#(_\:+,#:HK%_X2_P -?]##I7_@
M9'_C1_PE_AK_ *&'2O\ P,C_ ,:+,#:HK%_X2_PU_P!##I7_ (&1_P"-'_"7
M^&O^AATK_P #(_\ &BS VJ*Q?^$O\-?]##I7_@9'_C1_PE_AK_H8=*_\#(_\
M:+,#:HK%_P"$O\-?]##I7_@9'_C1_P )?X:_Z&'2O_ R/_&BS VJ*Q?^$O\
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M&1_XT?\ "7^&O^AATK_P,C_QHLP-JBL7_A+_  U_T,.E?^!D?^-'_"7^&O\
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M&1_XT?\ "7^&O^AATK_P,C_QHLP-JBL7_A+_  U_T,.E?^!D?^-'_"7^&O\
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MPZ5_X&1_XT?\)?X:_P"AATK_ ,#(_P#&BS VJ*Q?^$O\-?\ 0PZ5_P"!D?\
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M  U_T,.E?^!D?^-'_"7^&O\ H8=*_P# R/\ QHLP-JBL7_A+_#7_ $,.E?\
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MO^AATK_P,C_QHLP-JBL7_A+_  U_T,.E?^!D?^-'_"7^&O\ H8=*_P# R/\
MQHLP-JBL7_A+_#7_ $,.E?\ @9'_ (T?\)?X:_Z&'2O_  ,C_P :+,#:HK%_
MX2_PU_T,.E?^!D?^-'_"7^&O^AATK_P,C_QHLP-JBL7_ (2_PU_T,.E?^!D?
M^-'_  E_AK_H8=*_\#(_\:+,#:HK%_X2_P -?]##I7_@9'_C1_PE_AK_ *&'
M2O\ P,C_ ,:+,#:HK%_X2_PU_P!##I7_ (&1_P"-'_"7^&O^AATK_P #(_\
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M  U_T,.E?^!D?^-'_"7^&O\ H8=*_P# R/\ QHLP-JBL7_A+_#7_ $,.E?\
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M_0PZ5_X&1_XT?\)?X:_Z&'2O_ R/_&BS VJ*Q?\ A+_#7_0PZ5_X&1_XT?\
M"7^&O^AATK_P,C_QHLP-JBL7_A+_  U_T,.E?^!D?^-'_"7^&O\ H8=*_P#
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MO^AATK_P,C_QHLP-JBL7_A+_  U_T,.E?^!D?^-'_"7^&O\ H8=*_P# R/\
MQHLP-JBL7_A+_#7_ $,.E?\ @9'_ (T?\)?X:_Z&'2O_  ,C_P :+,#:HK%_
MX2_PU_T,.E?^!D?^-'_"7^&O^AATK_P,C_QHLP-JBL7_ (2_PU_T,.E?^!D?
M^-'_  E_AK_H8=*_\#(_\:+,#:HK%_X2_P -?]##I7_@9'_C1_PE_AK_ *&'
M2O\ P,C_ ,:+,#:HK%_X2_PU_P!##I7_ (&1_P"-'_"7^&O^AATK_P #(_\
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M\:/^$O\ #7_0PZ5_X&1_XT68&U16+_PE_AK_ *&'2O\ P,C_ ,:/^$O\-?\
M0PZ5_P"!D?\ C19@;5%8O_"7^&O^AATK_P #(_\ &C_A+_#7_0PZ5_X&1_XT
M68&U16+_ ,)?X:_Z&'2O_ R/_&C_ (2_PU_T,.E?^!D?^-%F!M45B_\ "7^&
MO^AATK_P,C_QH_X2_P -?]##I7_@9'_C19@;5%8O_"7^&O\ H8=*_P# R/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110![C<_\ )O2_]>J?^CA7AU>XW/\ R;TO_7JG_HX5X=44^OJ,****L044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110![C;_\ )O1_Z]7_ /1Q
MKPZO<;?_ )-Z/_7J_P#Z.->'5G3Z^HPHHHK004444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7N.N_P#)OUO_ ->MM_Z,2O#J]QUW_DWZW_Z];;_T8E9SW7J,
M\.HHHK004444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[C\(O\ DG.L
M?]?4W_HE*\.KW'X1?\DYUC_KZF_]$I45/A&CPZBBBK$%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'J'P/_Y&?4?^O(_^AK7(>._^1[UO_K[?^==?\#_^1GU'_KR/
M_H:UR'CO_D>];_Z^W_G6:^-C.>HHHK004444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'HGP7_ .1YD_Z\I/\ T):R/B;_ ,E%U?\ WX__
M $6M:_P7_P"1YD_Z\I/_ $):R/B;_P E%U?_ 'X__1:UFOC&<E1116@@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQG-6Y65Q'E%%=;\1_P"R?^$PF_L3[%]B\J/;]BV>7G'.-O&:Y*J3NK@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>I_!SPO::K-J.IZ
ME90W5O$H@B2>-70N?F8X(/( 7G_:->IW7@OPU=V<\"Z'ID?FQM'YD=I&&3((
MR"!D$5G*HD[#L?+-%3WEK+8WUQ9SC$T$C1./1E.#^HJ"M!!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >X_"O\ Y)?K'_7:?_T4E>'5[C\*_P#D
ME^L?]=I__125X=40^)C"BBBK$%%%% !1110 4444 %%%% !1110 4444 %%=
ME\,_[&_X2P_V[]@^Q_9G_P"/[9Y>[(Q]_C/6O8U7X;NZHB^%&9C@ "W))J)3
MY7:PSYJHKZIF\,>%;:"2>?0]&BAC4L\CVD2JH'4DD<"LK_BVO_4I_P#DM4^U
M\@L?-=%:&N_9_P#A(=3^R>5]F^UR^5Y6-FS><;<<8QC&*SZU$%%%% !1110
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MC"BBBK$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF>9Y8SNSSNSG.><UX!1&5P"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH
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M<6.DV%K-]HC'F06R(V#GC(&:\*J8RYE< HHHJ@"BBB@ HHHH **** "BBB@
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M1?B5_P (;_PB+?V'_8/VSSTQ]B\GS-O.?N<XJG*SL!XW17JWP7TC3=5_MO\
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M?AGP9IXN)([=I8@6DO[S;N'N">%&../UJ>V\?>$;^Y-C%K%JS[O+VR*R(Q]
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MB1@ !V %95- %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*UTMU+# B/AL*6'WL^@.3FKIR;35P/<IO#G@'P3I4;ZE:68C)"^;>1^?)(V
M,@8)]R%  ZX%2V_A[P%XPTUWT^QTZ2+H7M(Q"\9/(S@ @_45S-I\(-1U&. ^
M)?$EQ/Y8;;#$S2!,G^%WZ9P,_+7;^$_#&B^%$NK'2IY))FVO<"6<._5MI*C
M7^(< 9QWQ6;:6SU ^=_%>@/X8\2W>DM(95A(*2%<;U8!@?UP?<&O9?#'PW\/
M^'M"%_KT-O=77E>9<27/,4(QD@ \<?WCSUZ9Q7 _&4 >.\@ $VD9/ORU>Q:)
MK>C^.?#I($<T<J;+FU?JIXR"/3T-7.3Y4P,/3KSX8Z_=+965KH[SN0%0V(A+
M'T!91GZ"N"^*'P_M_#FS6-*!6PFD\N2 Y/DN02"#_=.#UZ'Z\=K??!O0WF%S
MI-[?:9<HP:(QR;UC8'((S\V0<?Q=J\W\=^#_ !)H(BNM4OY-3L]VU+DRL^PG
ML0W*DX]QP.:(-7T8"?#SP(WB^^DGNG>+3+8XE9"-TC=D'IQR3_C7JM[;_#?P
MQ)%IM]::1#*V $F@$SC/0LQ!('N33OA);1P?#RRD10&N))9'([D.5R?P4?E6
M)KGP=DUS7;[4Y?$11KJ9I AL]VP$\+G>,X&!G':DY7E9L \9?##2M6THZKX8
MCAAN=GFK'"W[FX3'\/93CH1P>_7(\-KZL\*Z$_AOP[;:2]X;SR-V)2FS(+$@
M8R>F<=:^:O%-FNG^+-7M(XQ%'%>2B-%QA4W';C'MBJIRO= S(HHKH? VB_V]
MXRTVR9-T/FB68%-R[$^8@^QQMY]16K=E<1[[X.TJ#PIX&M8YU6!HX#<W;-@8
M<C<Q8CC@<9]%%<]\*?%<NOG6X;IF\[[4;N-6;=M20_=!]%(_45T?CRVU:_\
M"%Y8Z+;-/=W6(B Z+M0GYB2Y P0"..?F_$><_#WP9XO\,^+[>]NM*\NS=&AN
M&^T1'"$9S@-GA@I_"N96<6WN,R_C)HJZ=XLCU") L6H1;S@8S(O#?IM/U)KB
M_#MI!?\ B?2;.Y3?!/>0Q2)DC<K. 1D<C@]J]Z^*^A'6?!DL\0'G:>WVD>Z
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MDOUC_KM/_P"BDKPZO<?A7_R2_6/^NT__ **2O#JB'Q,844458@HHHH ****
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M]QN?^3>E_P"O5/\ T<*\.J*?7U&%%%%6(**** "BBB@ HHHH **** "BBB@
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M?9Y,*_\ >0@,I/OM(S[UDUWGQ?\ ^2@3_P#7"+_T&N#K:+NDQ!1113 ****
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ME66M^-].T[48?.M)O,WQ[F7.(V8<J0>H%?0GAC_D1-&_[!D'_HH5X/\ "O\
MY*3I/_;;_P!$O2BW:0'INK_"KPI'<VMX5&G:;;*[W>;AOWG*[06=CM'WLXP>
M:T=$M_AUKHDL]*LM'N7B!#)]F DP,9(+#<1R/F&1[UF_&NYEA\&V\4;E4GO$
M60#^(!68#\P#^%>:_"F1T^(^F*KLJN)E< XW#RG.#ZC(!_ 4DFXW; T/BCX&
MM/"]S:WVEJR6%R2AB9RWE.!V).2",GO@@\\@5J?"KP=H/B31+VXU:P^T2Q7.
MQ&\Z1,+M!Q\K#UKH?C?_ ,BG8?\ 7\O_ *+>H_@=_P BWJ7_ %]_^R+3YG[.
MX'G'Q'T73] \836&F6_D6RQ1L$WLW)'/+$FO0_ WPOTVSTJ'5_$40FN9$\W[
M/.,1P(1_&IZMCDYX'IQFN?\ '=O'=_&G3[:9%>*::TC=6&006 (([BO1OB?=
M36GP\U1X'VLZI$3C/RLZJP_$$C\:)2=DNX%.Q;X::[>OI5E:Z-+<@E=B6@C+
M8SG:VT;NA.5)]:\]^)?P\A\,K'JNDB3^SI'V21,2WD,>F#UVGIST/<Y%>?65
M[<:=?07MI*8KB!Q)&X .UATX/!^AK6U;QGXBURU:UU'59YK=B"T0PBMCD9"@
M9Y //>J4&GHP.O\ AC\/+3Q)!+JVL([6*.8X858IYK <DD<[1D8P>H/ISWMY
M<_#/2=2.EW5MHD=TO#*UDK!3Z,^T@'CH37E'@;PMXF\0.\NCWLMA:1R8DN1.
MR -P2 %Y+8P?3@9(XKT.U^"^DHQNM9UB\O)B_F2N"(U<YR=Q.X\]SD&IG:^K
M ?XX^&VAWGA^YU31;>*TNH(6G7[.,QS(%W;=HXR1T(KS'X;_ /)0M'_ZZM_Z
M U?17EVJ^'/*M&66T%IMB8/Y@:/9P=W.[(QSWKYU^&__ "4+1_\ KJW_ * U
M$&W%W ]<^,?_ "(3_P#7S'_6OGFOH;XQ_P#(A/\ ]?,?]:^>:JE\(,****T$
M%%%% !1110 4444 %%%% !1110 4444 %>XZ[_R;];_]>MM_Z,2O#J]QUW_D
MWZW_ .O6V_\ 1B5G/=>HSPZBBBM!!1110 4444 %%%% !1110 4444 %%%%
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MO-A^S8$5PN"<8'&3G@_3MTUM=^%OAG7;F6Z:&>TN97,DDEM)C>3URK KSUX
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M-:OPJ\':#XDT2]N-6L/M$L5SL1O.D3"[0<?*P]:].\90Q7O@361-&K+]ADE
M89PRH6!^H(%<=\#O^1;U+_K[_P#9%I<[< -[2?ACX:TR_N[IM.@N!*_[B*<&
M1(4V@8PY.22"<GUP/?S[Q[X=TO4?B#IWAWP]:6UI=R)_I)B4JBDC<,J.!A!N
MX'\0IOQIUJZF\1PZ0LSK:00*[1AB SL2<D=#@!<>G/K7G5C;7NI:E;VUDDLU
MY(RI$JGYLCI@]L8Z]@*J$7\38'T%_P (GX$\%:2L^I6MH8P=IGOD\YI&QV4@
M\X'11VJ2QTCX?>,+&0:=8:9-&,;_ +/#Y$B<G&<!67H?K]*Y>R^$FL:G:Q#Q
M)XDN'5?F6V1VE"$]?F8X!QZ#\?7MO"GA#1/",ES!IDTLES*JF;SI@S[1G&5
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MU5+W1(9YP.9(K@QJ?^ E6_G7$^+?&VJ^+[E6O66*UB8F&VB^ZF>Y[L<=S[X
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M67_T,U\YUZ-X1^*O_"*^'H=*_L;[5Y;NWF_:MF=QSTV'^=34BVK(:.<\??\
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M116@@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TKX(_\
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M"<=.<<XKYIKO?"GQ5U?PW8I83P1ZA9QC$2R.5>,=@&Y^4<\$?0@#%7*#T:Z
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MD/'?_(]ZW_U]O_.LU\;&<]1116@@HHHH **** "BBB@ HHHH **** "BBB@
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M^('_ "(.M?\ 7L?YBOEZOJ'X@?\ (@ZU_P!>Q_F*^7JZ*.PF%%%%:B"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#W'X5_P#)+]8_Z[3_ /HI*\.KW'X5_P#)+]8_Z[3_ /HI*\.J(?$Q
MA1115B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5[CKO_)OUO\ ]>MM_P"C$KPZ
MO<==_P"3?K?_ *];;_T8E9SW7J,\.HHHK004444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5[C\(O^2<ZQ_U]3?^B4KPZO<?A%_R3G6/^OJ;_P!$I45/
MA&CPZBBBK$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'J'P/_P"1GU'_ *\C_P"A
MK7(>._\ D>];_P"OM_YUU_P/_P"1GU'_ *\C_P"AK7(>._\ D>];_P"OM_YU
MFOC8SGJ***T$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!Z)\%_^1YD_P"O*3_T):R/B;_R475_]^/_ -%K6O\ !?\ Y'F3_KRD_P#0
MEK(^)O\ R475_P#?C_\ 1:UFOC&<E1116@@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .X^$?\ R4.S_P"N4O\ Z :^C:^<OA'_ ,E#
ML_\ KE+_ .@&OHVN>K\0T%%%%9#"BBB@ HHHH YOX@?\B#K7_7L?YBOEZOJ'
MX@?\B#K7_7L?YBOEZNBCL)A1116H@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]Q^%?_ "2_6/\ KM/_
M .BDKPZO<?A7_P DOUC_ *[3_P#HI*\.J(?$QA1115B"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ]QN?\ DWI?^O5/_1PKPZO<;G_DWI?^O5/_ $<*\.J*?7U&%%%%6(**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]QM_\ DWH_]>K_ /HX
MUX=7N-O_ ,F]'_KU?_T<:\.K.GU]1A1116@@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O<==_Y-^M_P#KUMO_ $8E>'5[CKO_ ";];_\ 7K;?^C$K.>Z]
M1GAU%%%:""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O<?A%_R3G6
M/^OJ;_T2E>'5[C\(O^2<ZQ_U]3?^B4J*GPC1X=1115B"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#U#X'_\ (SZC_P!>1_\ 0UKD/'?_ "/>M_\ 7V_\ZZ_X'_\
M(SZC_P!>1_\ 0UKD/'?_ "/>M_\ 7V_\ZS7QL9SU%%%:""BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ]$^"_P#R/,G_ %Y2?^A+61\3
M?^2BZO\ [\?_ *+6M?X+_P#(\R?]>4G_ *$M9'Q-_P"2BZO_ +\?_HM:S7QC
M.2HHHK004444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI_PHF7_H8$_\!#_\77LU%)2: \9_X43+_P!# G_@(?\ XNC_ (43+_T,"?\
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M@>,_\*)E_P"A@3_P$/\ \71_PHF7_H8$_P# 0_\ Q=>S44<\NX'C/_"B9?\
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MB9?^A@3_ ,!#_P#%U[-11SR[@>,_\*)E_P"A@3_P$/\ \71_PHF7_H8$_P#
M0_\ Q=>S44<\NX'C/_"B9?\ H8$_\!#_ /%T?\*)E_Z&!/\ P$/_ ,77LU%'
M/+N!XS_PHF7_ *&!/_ 0_P#Q='_"B9?^A@3_ ,!#_P#%U[-11SR[@>,_\*)E
M_P"A@3_P$/\ \71_PHF7_H8$_P# 0_\ Q=>S44<\NX'C/_"B9?\ H8$_\!#_
M /%T?\*)E_Z&!/\ P$/_ ,77LU%'/+N!XS_PHF7_ *&!/_ 0_P#Q='_"B9?^
MA@3_ ,!#_P#%U[-11SR[@>,_\*)E_P"A@3_P$/\ \71_PHF7_H8$_P# 0_\
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M *&!/_ 0_P#Q='_"B9?^A@3_ ,!#_P#%U[-11SR[@>,_\*)E_P"A@3_P$/\
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ME_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\
MP$/_ ,71_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71
M_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71_P *)E_Z
M&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/
M_P 77LU%'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 77LU%
M'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_
M ,*)E_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&
M!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\ P$/_
M ,71_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71_P *
M)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71_P *)E_Z&!/_
M  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 7
M7LU%'/+N!XS_ ,*)E_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 77LU%'/+N
M!XS_ ,*)E_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)
ME_Z&!/\ P$/_ ,71_P *)E_Z&!/_  $/_P 77LU%'/+N!XS_ ,*)E_Z&!/\
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MA@3_ ,!#_P#%U[-11SR[@>,_\*)E_P"A@3_P$/\ \71_PHF7_H8$_P# 0_\
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M *&!/_ 0_P#Q='_"B9?^A@3_ ,!#_P#%U[-11SR[@>,_\*)E_P"A@3_P$/\
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MPHF7_H8$_P# 0_\ Q=>S44<\NX'C/_"B9?\ H8$_\!#_ /%T?\*)E_Z&!/\
MP$/_ ,77LU%'/+N!XS_PHF7_ *&!/_ 0_P#Q='_"B9?^A@3_ ,!#_P#%U[-1
M1SR[@>,_\*)E_P"A@3_P$/\ \71_PHF7_H8$_P# 0_\ Q=>S44<\NX'C/_"B
M9?\ H8$_\!#_ /%T?\*)E_Z&!/\ P$/_ ,77LU%'/+N!XS_PHF7_ *&!/_ 0
M_P#Q==7X<\$ZUX8T6YTJRUBPD@N)&D=IK%RP+*%.,2@=%':N[HI.3>X'C/\
MPHF7_H8$_P# 0_\ Q='_  HF7_H8$_\  0__ !=>S44^>7<#QG_A1,O_ $,"
M?^ A_P#BZ/\ A1,O_0P)_P" A_\ BZ]FHHYY=P/&?^%$R_\ 0P)_X"'_ .+H
M_P"%$R_]# G_ ("'_P"+KV:BCGEW \9_X43+_P!# G_@(?\ XNC_ (43+_T,
M"?\ @(?_ (NO9J*.>7<#QG_A1,O_ $,"?^ A_P#BZ/\ A1,O_0P)_P" A_\
MBZ]FHHYY=P/&?^%$R_\ 0P)_X"'_ .+H_P"%$R_]# G_ ("'_P"+KV:BCGEW
M \9_X43+_P!# G_@(?\ XNC_ (43+_T,"?\ @(?_ (NO9J*.>7<#QG_A1,O_
M $,"?^ A_P#BZ/\ A1,O_0P)_P" A_\ BZ]FHHYY=P/&?^%$R_\ 0P)_X"'_
M .+H_P"%$R_]# G_ ("'_P"+KV:BCGEW \9_X43+_P!# G_@(?\ XNC_ (43
M+_T,"?\ @(?_ (NO9J*.>7<#QG_A1,O_ $,"?^ A_P#BZ/\ A1,O_0P)_P"
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MQG_A1,O_ $,"?^ A_P#BZ/\ A1,O_0P)_P" A_\ BZ]FHHYY=P/&?^%$R_\
M0P)_X"'_ .+H_P"%$R_]# G_ ("'_P"+KV:BCGEW \9_X43+_P!# G_@(?\
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M(?\ XNC_ (43+_T,"?\ @(?_ (NO9J*.>7<#QG_A1,O_ $,"?^ A_P#BZ/\
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M'_XNC_A1,O\ T,"?^ A_^+KV:BCGEW \9_X43+_T,"?^ A_^+H_X43+_ -#
MG_@(?_BZ]FHHYY=P/&?^%$R_]# G_@(?_BZ/^%$R_P#0P)_X"'_XNO9J*.>7
M<#QG_A1,O_0P)_X"'_XNC_A1,O\ T,"?^ A_^+KV:BCGEW \S\,?"_4O"FJG
M4;'6[628Q&+;/9,5P2#VD'/%5M=^$=[X@UJYU6[UVW2>X(+K%9L%&% XRY/;
MUKU6BES.]P/&?^%$R_\ 0P)_X"'_ .+H_P"%$R_]# G_ ("'_P"+KV:BGSR[
M@>,_\*)E_P"A@3_P$/\ \71_PHF7_H8$_P# 0_\ Q=>S44<\NX'C/_"B9?\
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MB9?^A@3_ ,!#_P#%U[-11SR[@>,_\*)E_P"A@3_P$/\ \71_PHF7_H8$_P#
M0_\ Q=>S44<\NX'C/_"B9?\ H8$_\!#_ /%T?\*)E_Z&!/\ P$/_ ,77LU%'
M/+N!XS_PHF7_ *&!/_ 0_P#Q='_"B9?^A@3_ ,!#_P#%U[-11SR[@>,_\*)E
M_P"A@3_P$/\ \71_PHF7_H8$_P# 0_\ Q=>S44<\NX'C/_"B9?\ H8$_\!#_
M /%T?\*)E_Z&!/\ P$/_ ,77LU%'/+N!XS_PHF7_ *&!/_ 0_P#Q='_"B9?^
MA@3_ ,!#_P#%U[-11SR[@>,_\*)E_P"A@3_P$/\ \71_PHF7_H8$_P# 0_\
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M *&!/_ 0_P#Q='_"B9?^A@3_ ,!#_P#%U[-11SR[@>,_\*)E_P"A@3_P$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M J:I=/9:1>W<04R00/(H;H2JDC/MQ7F?_"SM:_Y];#_OV_\ \77HWB#_ )%O
M5/\ KSE_] ->"T'CYG7J4IQ4'8[3_A9VM?\ /K8?]^W_ /BZ/^%G:U_SZV'_
M '[?_P"+KBZ*1YGUW$?SL[3_ (6=K7_/K8?]^W_^+H_X6=K7_/K8?]^W_P#B
MZXNB@/KN(_G9VG_"SM:_Y];#_OV__P 71_PL[6O^?6P_[]O_ /%UQ=% ?7<1
M_.SM/^%G:U_SZV'_ '[?_P"+H_X6=K7_ #ZV'_?M_P#XNN+HH#Z[B/YV=I_P
ML[6O^?6P_P"_;_\ Q='_  L[6O\ GUL/^_;_ /Q=<7GG'>B@/KN(_G9VG_"S
MM:_Y];#_ +]O_P#%T?\ "SM:_P"?6P_[]O\ _%UQ=% ?7<1_.SM/^%G:U_SZ
MV'_?M_\ XNC_ (6=K7_/K8?]^W_^+KBZ* ^NXC^=G:?\+.UK_GUL/^_;_P#Q
M='_"SM:_Y];#_OV__P 77%T4!]=Q'\[.T_X6=K7_ #ZV'_?M_P#XNC_A9VM?
M\^MA_P!^W_\ BZXNB@/KN(_G9VG_  L[6O\ GUL/^_;_ /Q='_"SM:_Y];#_
M +]O_P#%UQ=% ?7<1_.SM/\ A9VM?\^MA_W[?_XNC_A9VM?\^MA_W[?_ .+K
MBZ* ^NXC^=G:?\+.UK_GUL/^_;__ !='_"SM:_Y];#_OV_\ \77%T4!]=Q'\
M[.T_X6=K7_/K8?\ ?M__ (NC_A9VM?\ /K8?]^W_ /BZXNB@/KN(_G9VG_"S
MM:_Y];#_ +]O_P#%T?\ "SM:_P"?6P_[]O\ _%UQ=% ?7<1_.SM/^%G:U_SZ
MV'_?M_\ XNC_ (6=K7_/K8?]^W_^+KBZ* ^NXC^=G:?\+.UK_GUL/^_;_P#Q
M='_"SM:_Y];#_OV__P 77%T4!]=Q'\[.T_X6=K7_ #ZV'_?M_P#XNC_A9VM?
M\^MA_P!^W_\ BZXNB@/KN(_G9VG_  L[6O\ GUL/^_;_ /Q='_"SM:_Y];#_
M +]O_P#%UQ=% ?7<1_.SM/\ A9VM?\^MA_W[?_XNC_A9VM?\^MA_W[?_ .+K
MBZ* ^NXC^=G:?\+.UK_GUL/^_;__ !='_"SM:_Y];#_OV_\ \77%T4!]=Q'\
M[.T_X6=K7_/K8?\ ?M__ (NC_A9VM?\ /K8?]^W_ /BZXNB@/KN(_G9VG_"S
MM:_Y];#_ +]O_P#%T?\ "SM:_P"?6P_[]O\ _%UQ=% ?7<1_.SM/^%G:U_SZ
MV'_?M_\ XNC_ (6=K7_/K8?]^W_^+KBZ* ^NXC^=G:?\+.UK_GUL/^_;_P#Q
M='_"SM:_Y];#_OV__P 77%T4!]=Q'\[.T_X6=K7_ #ZV'_?M_P#XNC_A9VM?
M\^MA_P!^W_\ BZXNB@/KN(_G9VG_  L[6O\ GUL/^_;_ /Q='_"SM:_Y];#_
M +]O_P#%UQ=% ?7<1_.SM/\ A9VM?\^MA_W[?_XNC_A9VM?\^MA_W[?_ .+K
MBZ* ^NXC^=G:?\+.UK_GUL/^_;__ !='_"SM:_Y];#_OV_\ \77%T4!]=Q'\
M[.T_X6=K7_/K8?\ ?M__ (NC_A9VM?\ /K8?]^W_ /BZXNB@/KN(_G9VG_"S
MM:_Y];#_ +]O_P#%T?\ "SM:_P"?6P_[]O\ _%UQ=% ?7<1_.SM/^%G:U_SZ
MV'_?M_\ XNC_ (6=K7_/K8?]^W_^+KBZ* ^NXC^=G:?\+.UK_GUL/^_;_P#Q
M='_"SM:_Y];#_OV__P 77%T4!]=Q'\[.T_X6=K7_ #ZV'_?M_P#XNC_A9VM?
M\^MA_P!^W_\ BZXNB@/KN(_G9VG_  L[6O\ GUL/^_;_ /Q='_"SM:_Y];#_
M +]O_P#%UQ=% ?7<1_.SM/\ A9VM?\^MA_W[?_XNC_A9VM?\^MA_W[?_ .+K
MBZ* ^NXC^=G:?\+.UK_GUL/^_;__ !='_"SM:_Y];#_OV_\ \77%T4!]=Q'\
M[.T_X6=K7_/K8?\ ?M__ (NC_A9VM?\ /K8?]^W_ /BZXNB@/KN(_G9VG_"S
MM:_Y];#_ +]O_P#%T?\ "SM:_P"?6P_[]O\ _%UQ=% ?7<1_.SM/^%G:U_SZ
MV'_?M_\ XNC_ (6=K7_/K8?]^W_^+KBZ* ^NXC^=G:?\+.UK_GUL/^_;_P#Q
M='_"SM:_Y];#_OV__P 77%T4!]=Q'\[.T_X6=K7_ #ZV'_?M_P#XNC_A9VM?
M\^MA_P!^W_\ BZXNB@/KN(_G9VG_  L[6O\ GUL/^_;_ /Q='_"SM:_Y];#_
M +]O_P#%UQ=% ?7<1_.SM/\ A9VM?\^MA_W[?_XNC_A9VM?\^MA_W[?_ .+K
MBZ* ^NXC^=G:?\+.UK_GUL/^_;__ !='_"SM:_Y];#_OV_\ \77%T4!]=Q'\
M[.T_X6=K7_/K8?\ ?M__ (NC_A9VM?\ /K8?]^W_ /BZXNB@/KN(_G9VG_"S
MM:_Y];#_ +]O_P#%T?\ "SM:_P"?6P_[]O\ _%UQ=% ?7<1_.SM/^%G:U_SZ
MV'_?M_\ XNC_ (6=K7_/K8?]^W_^+KBZ* ^NXC^=G:?\+.UK_GUL/^_;_P#Q
M='_"SM:_Y];#_OV__P 77%T4!]=Q'\[.T_X6=K7_ #ZV'_?M_P#XNC_A9VM?
M\^MA_P!^W_\ BZXNB@/KN(_G9Z_X4\:1ZZ3;7:QP7HY"KD*X]LGK[5UE?.\4
MKPRK+$Y1U.593@@UZSX/\8)K,2V=XP2^0<'H)1ZCWIGJX#'^T_=U-^_<Z^BB
MB@]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^0%J'_7M)_Z":-&_P"0%I__ %[1_P#H(HUK_D!:A_U[2?\ H)HT;_D!:?\
M]>T?_H(H O4444 %%%% !1110!AR?\CU;?\ 8,E_]&QUN5AR?\CU;?\ 8,E_
M]&QUN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G>(/\
MD6]4_P"O.7_T UX+7O7B#_D6]4_Z\Y?_ $ UX+0>#F_QQ] HHHI'D!1110 4
M444 (S*BEF(51U)K$OM?5<QV@W'_ )Z'I^%1^(@P,9^T$@_\LO3WK$C0R2*B
M_>8@"MZ=--79[."P-.4%5GJ=3HJR-:-<3,6DF;.3Z#@?UK2ID,0AA2)>B* *
M?6,G=W/*K3]I4<@HHHI&84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %/BE>&598G*.IRK*<$&F44 >N^#_&$>LQ+9WC!+Y!P>@E'J/>N
MNKYWBEDAE66)RDB'*LIP0:]:\'^,(]9B6SO&"7R#@]!*/4>],]_ 8_VG[NIO
MT?<ZZBBB@]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^S?=_P#'0I_$U:^)$P@^'NL.W0Q*GXLZC^M;6@JB>'M,2( 1K:1!0.F-@Q7
M_&K5TM_#UII2LOG7<WF,N>0B?_7(Z^A_  L_!>$Q^"9G/26]D<?]\H/Z5Z+7
M,_#[2WTCP-I=M*C)*T9F=6X(+DM@CM@$#'M7(_$_QG-Y@\*:'ODO;@A+DQ [
MESC$:XZDYY]N.YP 8'BS49?B7XYL]%T@[K&U++YP(P>1YDGT   ]<>^*]LLK
M2*PL+>S@!$-O$L2 ]=J@ ?H*YKP%X,A\(Z-MDVOJ-P US*IR.^%7V&?Q.3Z
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MDL7@BW3._6M:D^MX1_*KT/A:PAP3/J$A_P!N^E/_ +-6W6+XI\0P^&]&DO'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKV:UMHK*S@M8%VPP1K&B^BJ, ?D* )JXGXC^,-0\(6-C/I\-K*T\K(PN%9@
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MQ_WQCK[UVOA/QGIGB^UDDL?,CGAQYT$HPR9Z'C@C@\_GB@#6U35++1M/DO\
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MG ()[<>WU /0:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5U'@SPW9^(I[M+N2=!"JE?)8#.2>N0?2N7
MKT#X6_\ 'WJ7_7-/YF@ZL%",Z\8R5U_P#GO%^AVV@:PEG:/,\;0K(3*03DDC
ML!Z5@5V7Q+_Y&>+_ *]4_P#0FKC:",5%0K2C':YZ-;> =*F\-PZBUQ>"9[03
ME0Z[=Q3=C[O3-<)I=JE[J]E:2EA'/.D;%>H#, <>_->RV/\ R(UM_P!@U?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7(^+_^0_X7_P"OT_\ LM==
M7(^+_P#D/^%_^OT_^RU,]CKP/\9>C_)G75XE\3=7:_\ $[6:L?)LU" ?[1Y8
M_P A^%>VU\Y>)&D;Q/JAESO^U2=?]XXK.L]+'HY#34J\IOHOS,NNC\%>'3XB
MUZ.*13]EA_>3GV]/Q_QKG*]X\ Z$-%\-Q,Z8N;H":4GJ,_='X#]2:RIQYF>W
MFF+^K4&X_$]%_F=0JJB*B*%51@ = *6BF33);P232-MCC4LQ] !DUUGQ.K9X
MG\2[_P"U^,)(5;*VT:Q?CU/\Z]CTG_D#6/\ U[Q_^@BOG74KU]1U6YO'^]/*
MS_3)KZ*TG_D#6/\ U[Q_^@BL:3O)L]_-Z7LL-1I]O\D7****V/GS(\2^(+7P
MUHLVHW/S;?ECC'61ST%>"R3:_P#$'Q"$!:>=LE4!Q'"O]!73_&75'FUNSTQ6
M/E00^:P_VF/^ 'YUUWPHT:+3_":7Y0?:+YB[-WV D*/T)_&@#-TKX-:=%$K:
MK?33RXY6#"*/Q()/Z5JR_";PO(FU8[J,_P!Y9N?U!KN:* .$\-_#2U\-^)%U
M.*]>>)(V5(Y$&Y6/&<CKQGM7=TFY?[P_.EH \C^-G71_I+_[+6[\'_\ D39/
M^OM__05K"^-G71_I+_[+6[\'_P#D39/^OM__ $%: ._KYCT[_D=+7_K_ %_]
M&"OIROF/3O\ D=+7_K_7_P!&"@#Z<HHHH *\$^+?_([M_P!>\?\ 6O>Z\$^+
M?_([M_U[Q_UH Z?PU\,-!U;PW8:A<27HFGA#N$D4#/M\M:O_  I_PU_SUU#_
M +^K_P#$UF^&?B7X?TKPUI]A<FY\Z"$(^V+(S^=:W_"V_#/K=_\ ?G_Z] '0
M^&_"]AX6M)K;3VG:.5_,;SF#'.,=@/2MJLW0];M/$&F)J%CO\AV*C>N#D'!K
M2H ;+(D,3RR,%1%+,Q[ =:^:M0>\\9>++V>V0O).SR(I/1%4D#_OD5[)\3]:
M_LGP?-$C8GO3Y">N#RQ_+C\:Y;X-:+DWVLRI_P!.\1(_%C_Z#^M &7\(=:^Q
M>(9M+E?$5XGR G_EHO(_,9_2O<*^<_$MG+X0\?2M; H(9Q<0?[I.0/YC\*^@
M]/O8M2TZVO8#F*>-9%^A&: +-<OJ_@#0-<U.74+Z"5KB7&XK*0.!@<?A745R
MFL_$/0M"U273KU[@7$6-P2+(Y (Y_&@"K_PJGPK_ ,^T_P#W^-5;SX0^'9XR
M+>2[MG[$2!A^((_K7<VMS'>6<-U%GRYD61<C!P1D5-0!\[^*O ^J^#I4NEE,
MUJ7_ '=U%E2K=L_W37HWPU\<2:_"VEZD^Z_A7<DA_P"6J>_N*[75]/AU72+N
MQG4-'/$5(]#C@_@<&OG+PM>OH_B_3YP2#'<!'^A.T_H30!]-4444 %%%% !1
M110 4444 %%%% !1110 4444 4=:_P"0%J'_ %[2?^@FC1O^0%I__7M'_P"@
MBC6O^0%J'_7M)_Z":-&_Y 6G_P#7M'_Z"* +U%%% !1110 4444 8<G_ "/5
MM_V#)?\ T;'6Y6')_P CU;?]@R7_ -&QUN4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO$\6^/;#1]*;[0T(%N2AX\PL2V#TX&,GV/I75?&E%B\$6,:#"K?QJ!Z 1R4
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M]C7KE8OA'1?^$?\ "NGZ:RJ)8H@9L'/[QOF;GOR36U0 4444 %%%% !1110
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M)_UR/\Q616OX=_Y"$G_7(_S%:S5H,]+%Q4<-*,=K'34445QGRX4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7H'PM_X^]2_ZYI_,UY_7H'PM_X^]2_ZYI_,T'9E_P#O,?ZZ
M'9ZHWAU;H#5AIOVC8,?:0A;;DX^]SCK5+S/!7IH7_?,5<7\2_P#D9XO^O5/_
M $)JXVF=N(Q_LZLH\B=CWRZ,!T&8VWE_9_LK>5Y>-NW;QC'&,5XIX?\ ^1DT
MO_K\B_\ 0Q7K]C_R(UM_V#5_]%"O(/#_ /R,FE_]?D7_ *&*!Y@[SI/^NAZE
M\0?^10N/^ND?_H0KRK1]1?2-7M;]!DPODCU7H1^1->J_$'_D4+C_ *Z1_P#H
M0KQRD8YI)QQ"DMTE^;/:O&%BNK^$[DQ?.T:BXB(&<XYX^JY'XUG_  YTK[%H
M37KJ1+>-N&000BY"_P!3^(JSX#U0:GX9CAD ,EK^X8'G*@?*?RX_"I_$EY'X
M=\)2+:D1E8UM[==W(SP,9ZD#)_"F>DE3DUBWTC_7ZH\O\5:J=8\175P&!B1O
M*AVG(V*< Y]^3^-8M%%(^;G-SDY/=A11102%%%% !3X9)89DDA9EE4@J5Z@T
MP D@ 9)[5Z9X+\&"V$>IZG'F8_-%"P^Y[GWH-\-AYUY\L?O['5^'I]1N=%@E
MU2(1W)'('4CL2.Q]JU***9]9"/+%*]PHHHH*"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***1F"*68@*!DDG@"@!:*Y*7XF^#H
MCAM:0_[D$C?R6KVE>-O#>M3+#8:O;R3.<+&^8V8^@# $_A0!OT45R_A_QYI?
MB37+O2K*WO%FME9GDE10A"L%X(8GJ>X'>@#J**** "BBB@ HHHH **** "BB
MB@ HHHH ***I:KJ]AHEBUYJ-RL$ 8+N()))Z  9)/L!0!=HHHH ***P[3Q?H
M5]KLFB6U]YFHQ,Z/"(GX*_>^;;MXQZT ;E%%% !11574=0MM*TZXO[Q]EO A
M=VQG 'M0!:HKG/"OC;2?%XN!I_GQR08+Q7"A6P<X(P2"./7T]:Z.@ HHHH *
M*Y+3_B-H&I>)6T*!YQ<;VC25T CD8 Y .<]B.0,]NU=;0 4444 %%%% !111
M0 4444 %%%% !17,S^.-,@\8Q^%_L]Y)?N5&Z-%*+E=W)W9X')XKIJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN1\7_P#(?\+_ /7Z?_9:ZZN/\<M]FNO#]^1^[@OU#GL W?\ 2IGL=>!_CI>3
M_)G85X=\2-(?3O%,MR%/D7@\U&[9Z,/SY_&O<:RO$&@6?B+3&L[L8_BCD YC
M;U'^%*<>9&F78M86MSRV>C/#_"&D?VUXGL[5AF(-YDO^ZO)_/I^-?0H  P.!
M7G/PST(6&H:Q.SK*8)3:)(HX.#EB/_':]#>6./.^15QZG%325HG1G.(]MB.6
M.T5^>H^N%^)OB!=.T7^S(7'VF\&& ZK'W_/I^=7_ !#X^TG1876"9+R\QA8H
MFR ?]HCI_.O%=4U.ZUC4);Z\DWS2')] .P'H!2J325D:Y5ELYU%6J*T5MYE0
M=17TII/_ "!K'_KWC_\ 017S6H)8 <G-?2^G1M#IEI$_WDA13]0!4T>IU\0/
MW*:]?T+-%%%=!\P>#_%ZV>'QDLQ!V36R,I^F0?Y5Z7\-;V.\\"Z>$(W0!HG'
MH0Q_H15+XG>%I-?T1+NT3?>666"@<NA^\![\9_.O,? OC27PE?R1S(TMA.1Y
MT8ZJ1_$/?V[T ?1%%9.E^)M&UF$26.HP29'*%P&'U4\BM![NVC4M)<1*H[LX
M H ^;]5NK@>-+Q1/)M^WN,;C_?-?2HZ"OF/4G27QE=21LKHU\Q5E.01O/(KZ
M<'04 >2?&SKH_P!)?_9:W?@__P B;)_U]O\ ^@K6%\;.NC_27_V6MWX/_P#(
MFR?]?;_^@K0!W]?,>G?\CI:_]?Z_^C!7TY7S%8,J>,K=F8*HOU)). !OH ^G
M:*I?VOIO_00M?^_R_P"-']KZ;_T$+7_O\O\ C0!=KP3XM_\ ([M_U[Q_UKWB
M*6.:-9(G5T;HRG(/XUX/\6_^1W;_ *]X_P"M &]X>^%6EZQX>L=1FOKM)+B(
M.RKMP"?3BM/_ (4QH_\ T$;W_P =_P *Z'P5J%E%X+TE)+N!6%NH*M( 16]_
M:EA_S^VW_?U?\: *GAS08/#6CQZ;;RR2QHS,&DQGDY[5K5##=V]R2()XI2O7
M8X./RJ'5M1BTG2+O4)ON6\3.1ZX' _$\4 >)_%G6O[1\4BQC;,-BFS';>>6_
MH/PIF@?$V\\/:-!IMKIEJT<0/S,6RQ)R2:S/"6G/XK\<PBZ'F+)*UQ<9[J#N
M.?J<#\:]X_X1?0/^@-8_]^%_PH \!\6>+)O%MS;W%Q9PP2PH4W1D_,,Y .?3
MG\Z]/^$.M?;?#TNF2/F6R?Y03_ W(_7/Z5O:[X+T>_T.\MK;3+2&X>(^5)'"
M%*N.1R/>O'OA[J[:#XSMUF)2*<FVF!XQD\?DV* /HBOGGXG?\C_?_2/_ - 6
MOH:OGGXG?\C_ '_TC_\ 0%H ]T\/_P#(MZ9_UZ1?^@BM*LKP_-%_PCFF#S$X
MM8OXA_=%37VMZ7IL1DO-0MH%']^0 _EWH GOKJ.QT^XNY6"QPQM(Q/8 9KYK
M\.6KZMXOL(1UFNE9OIG)_0&NO\?_ !&36[=M)TC>MD3^]F(P9<=@.R_SK6^$
MWA*6 MX@O8RA=2EJK#G!ZO\ T'XT >KT444 %%%% !1110 4444 %%%% !11
M10 4444 4=:_Y 6H?]>TG_H)HT;_ ) 6G_\ 7M'_ .@BC6O^0%J'_7M)_P"@
MFC1O^0%I_P#U[1_^@B@"]1110 4444 %%%% &')_R/5M_P!@R7_T;'6Y6')_
MR/5M_P!@R7_T;'6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$>!_AY_P (
M9?75S_:GVSSXQ'M^S^7MP<YSN.:[>B@ KB/%GP\_X2CQ+9ZQ_:GV;[-&D?E?
M9]^[:[-G.X8^]CIVKMZ* ,SQ#I']O:!>:7Y_D?:8]GF;-VWG.<9&?SK.\$^$
M_P#A#M&FT_[;]K\RX:?S/*\O&55<8R?[O7WKI** "N1UOP':ZWXQT[Q!)<!/
MLFWS(/*SYQ4DJ2V1CJ.QR!BNNHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.\0?\BWJG
M_7G+_P"@&O!:]Y\0?\BWJG_7G+_Z :\&H/!S?XX^@4C,J*68@*.230S*BEF(
M"CDDUR^JZJUVQBB)$(_\>JH0<F<.&PTJ\K+;JQVIZQ)<2>7;NR1*>H."U9_V
MNY_Y^)?^^S4-%=:BDK'TE.A3IQ48H<\CR'+NS'U8YIM%%,V2ML%:_AW_ )"$
MG_7(_P Q616OX=_Y"$G_ %R/\Q45/A9S8W_=Y^ATU%%%<9\J%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP)XFT"23RTUS36DZ;5NXR?RS6K7C?B?X3Z'H?AB[U%-5NDGMT+KY[)LD/.$
M"@Y)P!S6[\*M8N%\ 7=UJ<DAMK*60I*YR?+5 Q ]AS_+M0!Z)++'#&TDLBQQ
MKR6<X _&J5IKVCW]S]FL]6L;BXY/E0W".W'7@'->+1_V_P#%WQ%+^^-GI-N1
ME-Q*1*>G'\3GGG^0P*W-:^#UEINC2W^EZK=I>VD9FW3%=K%1G@J 5Z<')_K0
M!!X3SK7QPU:_WAUM3.ROU! Q$N#]#^0KV2O'_@C:F:XUO4Y?FD/EQAL\G)9F
M_DM>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVMNO<O+N/Z U[M10!Y_X>^$^D:5*EQJ$C:A.O(5EVQ@_[O?\?RKOP JA5
MP .U+10 4444 %%%% !1110 4444 %%%% !1110 4444 4=:_P"0%J'_ %[2
M?^@FC1O^0%I__7M'_P"@BC6O^0%J'_7M)_Z":-&_Y 6G_P#7M'_Z"* +U%%%
M !1110 4444 8<G_ "/5M_V#)?\ T;'6Y6')_P CU;?]@R7_ -&QUN4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * "2 !DF@ D@ 9)KT
M3PCX1^SA-1U&/,IYBB8?=]S[T&^'P\Z\^6(OA#PB+<)J.HQYEZQ1,/N^Y]Z[
MG-- IP%,^HH4(48<D!0:<#30*<!0;#P:>*8!3Q0 X4M(*44 ***!10 4444
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M9UE8]<T?[#8I"Q9_LSQ%WX SO)]^F*D^+4&H7GA*.RTZPNKN2:Y7>MO$SE5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!113)IHK>%YIY4BB099W8*JCW)H ?17/67C;0=2UV/1]/O1=W+*[%H1F-0OJ
MW0Y[8S70TVK %%9'BC7%\-^&[W5FB\W[.@*IG&YBP4#/IDBN$\"_%.]\2>(D
MTG4;*VB,ZN89(-PY4;L$$GL&YXIJ+:N!ZE1114@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'C?_  A/B+_H'?\ D:/_ .*H_P"$)\1?] [_ ,C1_P#Q5>R;:-M ?V30[O\
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M_P"@=_Y&C_\ BJ]DVT;: _LFAW?X?Y'C?_"$^(O^@=_Y&C_^*H_X0GQ%_P!
M[_R-'_\ %5[)MHVT!_9-#N_P_P CQO\ X0GQ%_T#O_(T?_Q5'_"$^(O^@=_Y
M&C_^*KV3;1MH#^R:'=_A_D>-_P#"$^(O^@=_Y&C_ /BJ/^$)\1?] [_R-'_\
M57LFVC;0']DT.[_#_(\;_P"$)\1?] [_ ,C1_P#Q5'_"$^(O^@=_Y&C_ /BJ
M]DVT;: _LFAW?X?Y'C?_  A/B+_H'?\ D:/_ .*H_P"$)\1?] [_ ,C1_P#Q
M5>R;:-M ?V30[O\ #_(\;_X0GQ%_T#O_ "-'_P#%4?\ "$^(O^@=_P"1H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGMI_UUE_]#->>_&[_D=+/_L'I_Z,DKT+X1?\D]M/^NLO_H9KSWXW?\CI9_\
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M3CL*^?M/L->^(GB9E,YGNG!>6:9L)$F?T&3@ #O40A?5[#/<O^%H>#?-,?\
M;2;@2,^1+C\]N*Z/3]4L-6MA<:?>0747'S0N&Q[''0^QKR<_ HBV;&OYN,94
M?9<+GT/S9_']*W?AM\/KOPI?7][J4JM.W[F 0N=C1\$L?7)P ".,'UIM0MHQ
M'HU%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** $HQ2T4 -Q28IU% #<48%.HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=:_Y 6H?]>TG
M_H)HT;_D!:?_ ->T?_H(HUK_ ) 6H?\ 7M)_Z":-&_Y 6G_]>T?_ *"* +U%
M%% !1110 4444 8<G_(]6W_8,E_]&QUN5AR?\CU;?]@R7_T;'6Y0 5X)\;O^
M1TL_^P>G_HR2O>Z\$^-W_(Z6?_8/3_T9)6E+XA,]"^$7_)/;3_KK+_Z&:\]^
M-W_(Z6?_ &#T_P#1DE>A?"+_ ))[:?\ 767_ -#->>_&[_D=+/\ [!Z?^C)*
MJ/\ $8'H7PB_Y)[:?]=9?_0S7<UXSX ^(V@>'?"4&FW[7(N(Y'8[(MPP6R.<
MU2\:?%PZSI\VF:);S6T$P*2W$I =E[@ 'C/(SD\>E)P;D!P?B;4$UCQ5J=]
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MK_H)S?E6E10!F_V;=?\ 03F_*C^S;K_H)S?E6E10!F_V;=?]!.;\J/[-NO\
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M5% &;_9MU_T$YORH_LVZ_P"@G-^5:5% &;_9MU_T$YORH_LVZ_Z"<WY5I44
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M% &;_9MU_P!!.;\J/[-NO^@G-^5:5% &;_9MU_T$YORH_LVZ_P"@G-^5:5%
M&;_9MU_T$YORH_LVZ_Z"<WY5I44 9O\ 9MU_T$YORH_LVZ_Z"<WY5I44 9O]
MFW7_ $$YORH_LVZ_Z"<WY5I44 9O]FW7_03F_*C^S;K_ *"<WY5I44 9O]FW
M7_03F_*C^S;K_H)S?E6E10!F_P!FW7_03F_*C^S;K_H)S?E6E10!F_V;=?\
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M;_9MU_T$YORH_LVZ_P"@G-^5:5% &;_9MU_T$YORH_LVZ_Z"<WY5I44 9O\
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M/^O:3_T$T:-_R M/_P"O:/\ ]!% %ZBBB@ HHHH **** ,.3_D>K;_L&2_\
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M_P"OEOZ5]0U\O>/_ /D?=:_Z^6_I5TFW)MB9W\?P3M+ZRMKFUUN: 30HY26
M28)4$\@KWK8T;X+Z'8RI+J-U<:@ZD'80(XS]0,D_G7>Z-_R ]/\ ^O:/_P!!
M%7:ASEW&-CCCAB2*)%2-%"JBC 4#H .PJIJFDV&MV+V6I6L=S;OR4<=#Z@]0
M>>HYJ[14 >47WP-T^69VL=8N+="<JDL(EV^V05SWIEI\"[)'!O-<N)ESR(8%
MC./J2U>M45?M)=PL9^BZ)I_A_34T_38/)MT);:6+$D]223FIM2TVSU?3YK"_
M@6>UF&V2-B1GG(Y'(Y .15JBHOU \EOO@9927!:QUN>WA/1)H!*1^(9?Y5I:
M?\&="L[>7S[B>[NFC94DE "1L00&V#K@G/)["O2**OVDNX'F/AOX0_\ "/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CK7_("U#_KVD_]
M!-&C?\@+3_\ KVC_ /011K7_ " M0_Z]I/\ T$T:-_R M/\ ^O:/_P!!% %Z
MBBB@ HHHH **** ,.3_D>K;_ +!DO_HV.MRL.3_D>K;_ +!DO_HV.MR@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KG_CUF_W&_E7.5T=
MS_QZS?[C?RKG*#S\9\2"BBBD<84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :UA?[\12G
MYOX6/>M*N7K6L+_?B*4_-_"Q[TSOP^(O[DS2HHHH.T**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKF?&?B2\\,V=O=
M6]M!/'+)Y1$C$$'!(Z=N*BU#5/%VGZ?)>?V9IDZQKN:.&9RV.^,@=*5S14I-
M)]SJZ*Q?#'B2V\3:4MW"-DJ_++$3RC?X>E;5,B47%V844@96Z$'Z&E) &3TH
M$%%(&#="#]*6@ HI-R@X+#/IFEH **** "B@D 9)P** "BBN;NM>>R\>6FDR
MLQM[NTS&JJ.)=S')/7&%Q05&+EL=)11102%%8.K^(8M-U[2M-\R(-=.WFACR
MJ;3@_BPQ6]0-Q:2;ZA12%E7JP'U-)YB?WU_.@0ZB@'(S2!E)P&!/L: %HHI"
M0HR2 />@!:*0$$9!R/:H9KRW@N(+>69$EN"1$A/+D#)Q^% $]%%% !12!@20
M""1U%!(49) 'O0 M%)O7&=PQZYI Z,<!E)]C0 ZBBB@ HJ);F%[E[99%,R*&
M9.X!Z']#4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M'6O^0%J'_7M)_P"@FC1O^0%I_P#U[1_^@BC6O^0%J'_7M)_Z":-&_P"0%I__
M %[1_P#H(H O4444 %%%% !1110!AR?\CU;?]@R7_P!&QUN5AR?\CU;?]@R7
M_P!&QUN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !117$:-\0_[6\<7?AK^R_*
M^SR31_:/M&[=Y9(SMVC&<>O% ';T45Q_COQW_P (5]@_XEOVS[7YG_+?R]FS
M;_LG.=WZ4 =A16;<ZL+;PS-K)A)$5FUT8@W7";MN<?AG%>8GXZC)QX<)'8F]
MQ_[3H ]@HKS+2_C5HMU+''J%C<V.[[T@(E1?K@!OR%=SJ.KF#PY/J^FQ)J"I
M!Y\:)+M$JCDX8 \XSCCD\4 :E%<CX&\=1>-(KS%G]CFMF7,?G>9N5LX.=H[@
MC_\ 7774 %%</XN^(G_",Z]:Z/:Z4=2NIT5MJ3["&9B%7&TY)Q^HKMD+%%+@
M*^!N"G(!]C@9_*@!U%%>8:_\8/[#UZ]TS^PO/^S2&/S/M>W=[XV''YT >GT5
MX]_PO7_J7/\ R>_^UUT'@WXG?\);KO\ 9G]D?9/W32^9]I\SICC&P>OK0!Z#
M1110 4444 %%%% !117GOC'QWJGA[QKIFC6D%F]M=)$SM*C%P6D93@A@.@':
M@#T*BJVHWJZ=I=W?/&TBVT+S%$^\P52<#WXKE? GCU?&C7T;6'V.2VVL )?,
M#JQ;_9&,8'US0!V=%%% !1110 4444 %%4=1UK3-("&_OH+<N0$5W&YR3CY5
MZG\!5Z@ HK#\6^(T\*^'Y=4:U>YV,J"-6VY)..3@X'X&HO!GB<>+?#ZZE]F^
MS.)&B>,/N (QR#@>HH Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHKB/ _P 0_P#A,[ZZMO[+^Q^1&)-WVCS-V3C&-HQ0
M!V]%%<1XL^(?_"+^);/1_P"R_M/VF-)/-^T;-NYV7&-IS]W/7O0!V]%87B_Q
M*OA307U-K4W.V14$8?9DGWP?Y5YX/CJ,C/AP@=R+W/\ [3H ]@HK@-!^+N@:
MO<);7:S:=,Y 4S8:,DD #<.GU( ]ZWO&/B2?PIHO]J1:<+V)) DJ^<8R@/ /
MW3QG [=10!T-%8?A+Q)#XK\/PZI%#Y#,S))#OW>6P/3.!GC!Z=ZW* "BN%'Q
M&:X\>MX8LM(-P$G\I[H7&-H ^<E0A^Z<CKSCMFNZH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN?^/6
M;_<;^5<Y71W/_'K-_N-_*N<H//QGQ(***\O\0^,=2\0:F="\,!RK$JT\;8:3
M'4AOX5]^_P#-QBY'-3IN;T.VU;Q9HFB.T=[?()@,^4F7?\AT_&N??XKZ IP+
M?4']Q$G]6J+2/AAI=G'YVLSM>3'!8!BD8.?S/X_E5YO^%?V[&!AHN3P>$;&/
M]KM^=5:'J:J-+979<TSQ[X>U2988[WR96^ZMPNS/MGIGVS6U?ZG9Z;ISW]U.
MJ6ZKNWYSN],>N:Y2]\ ^&M<M1/I3QV[_ ,,UJXDC)]UR0?PQ7)?%&^,FN06$
M-RK6UO",P)]V-\G.0.^-OTIJ,9.R"-.$Y)1/2?#&OCQ)I<E\L7E()WC5<Y.!
MC&??!K:KQ'P+9^(-1NS!INH7-G8(^Z>1&^4'V'0L<5[9&NR-4W,VT ;F.2?<
MU,XJ+T(K4U"5DQU%%%09!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!KV%_OQ%*?F_A8]ZT:Y>M>PO]^(I3\W
M9O6F=^'Q%_<F:-%%%!VA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 45S7C;Q?'X-TB&]:U%V\TXB
M6'S?+.,$ELX/ P.W<5H>&]8;7_#UGJKVPMC<J7\H2;]HR0.<#/ ST[T :M%5
MM0O%T_3;J]< I;PO*P)QPH)Z_A7+^!?'3^-3?'^S/L:6NSYO/\S>6W?[(Z;?
MUH [&BBB@ HHHH ***X'Q9XWU31_&VE>'],@LY/M@C\QYU9BI=RO\+#& ,]#
MUH [ZBN>\:^(9_#'ABXU2VMEN)4944/G:I8XW-CM^74<U1^'OC"X\8:/<7%W
M;1PW%O+Y;&('8P(!!&22#UX^GK0!U]%%% !1110 445Q/Q'\:7G@^RL7L([:
M2>YD8;;A68;5 R1AAW(H [:BJ6CW%S>:)8W5XL:7,UNDDJQC"JS*"0.3TSZU
M=H **** "BBB@ HHHH **** "BBN3^(7BNY\(Z!%>V<<$EQ+<+"JS E<;6).
M 0>WZT =916;X?O+O4?#VGWU\D27-S DSK$"%&X9  //0BM*@ HHHH ****
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M;I]Q>HHHJCG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZU_R
MM0_Z]I/_ $$T:-_R M/_ .O:/_T$4:U_R M0_P"O:3_T$T:-_P @+3_^O:/_
M -!% %ZBBB@ HHHH **** ,.3_D>K;_L&2_^C8ZW*PY/^1ZMO^P9+_Z-CK<H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O$?!O_)<=6_Z^;S_T-J]NKYS73-6U
M?XI:S::+??8KTWMTPF\YX\ .V1N4$T ?1E>/?'7_ )@'_;Q_[2H_X0#XD?\
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M_&'_ )$-_P#KYC_K7*>#/BEH_ASPC::5=V=])<6_F?-$J%&W.S#DL"/O8Z4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^#=.889XS* ?O2-]T-CHH!#?CGL*['0/AKX<T:QCCFT^&^N< R372"3<V.<
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MI?!>B7/ASPE8Z5>/$\\'F;FA)*G=(S#!(!Z$=J /+?A2Z:'X]U31[QA%,R/
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MPM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'2A!(C^7&4<(?NMDD@^AYS^-;FLZ/9Z]I4^FW\9>WF&#@X*GJ"#V(/->4_\
M"I?%&DW3G0?$<<43#!?S9;=R/0A <_GVH W_ (N>)[;3_#DFBQ2JU]>[0R#D
MI'G))],XP/J?2M#X>:<GA;P+:'476VENY?.<2MC#2$*B\]#@)QZUE>&_A+#9
MZB-2\07O]IW*MN$9!*;AT+$\M]#Q]:Z#QYX1G\8:5!:0:C]D\F3S-K)N20XP
M,\Y&.?7KTH I>+OAMH&N03WBA--O%4N;F/"H< \NO3'J>#[URGP1U"^DFU*P
M:25[&*-9%4\K&Y)Z>F>3COBHH?A/XOFACL+WQ'"NG@C,27$LBJ ,<(0!T]Q7
MI/A/PE8>$=,-I9EY))"&GGD^](P'IV'7 _GUH \6T'1-+U3XDZGI'B!I$\V6
M>.-E<(?.\SCGIR-V!SDD5Z''\&O"T$AFEGU"2,9)22=0H'U"@_K2^-?A=#XB
MU'^U-,NDLKYO]:K+\DA'1N.0WKUSQWSG"C^%_C.[B%IJ?BO%E@+Y:W,TPQTQ
ML;:.E 'J.CZ/IFBV*VVE6D-O;GYOW?._W+=6/N2:\8\!7 @^,-ZMX<3S2W,8
MR#_K-Q)Z_0U[E:P"UM(;=3E8HU0'Z#%><^-?A5_;VIOJVD7<=K>2G,L<V=CM
M_>!&2I_ _AW /0[Z^MM-LIKR\F2&WA7=)(YX _SVKQ?X=3MXB^*]_K6SRTV3
M7 4GE0Q"J/KAOTK3MOA5XAOY(QXC\0?:[:#+1VXN)9 QQP,L!L'J0"<?IO?#
M?P'?>#Y=0GU&:UEEN%1(S;NQVJ,ELY Z_+^5 '?T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !117%_$#5;J.WM-#TYY([[4GV*ZX V=",]1
MR1TH;L7"#G+E1>?Q1=7NJ2V>AZ;]OCA&);EI?+B#9Z*V"&(J633O%#2,T>OV
MJ*3E5-B#CVSNYK4TG3;;2-+@LK6(111KC:#GGN<]^:NTAN:3]U'!ZGXPU_PS
M!$NK:(EQN8JMS#-A7YXR-IVD^F:[J-_,B1\8W*#CTJ&^LX=0LY+:=0R.,<C.
M/>IU4*@4= ,4"E*+2LK,6BL7Q3=O:Z%+'%_KKMEM8SG&UI/E!S[9S67\/=2>
MYT273[AY'N]/F:&9V.0WS'&#U/ [T7UL-4VX<YU?G1^<8?,7S0NXIGG'3./2
MGUAZGX5L-7U87]XTS$0"$)'*T8'S$YRI![UQ?CS0[/0["TET]KJ)Y)@C'[5(
MV1D>IH;L.$(S:C?4]0IJ2)(@=&#*>A!R#7,VW@G19;2)VCNBS1@D_;)>I'^]
M6C8Z:VD^%AI[2M(8;=UW]">M!+C'HS7HKS#X?:1;:SIMZ]^]S*RRE ?M+C _
M UW^E:-9Z-')'9K*JR-N;S)6DY_X$3BA.XZD%!N-]30JE%K&F37K645_;/=*
M2#"LH+@CKQUK%\67"?;=&L+FX,-C>3NEQABI;"Y4;AR/FQTJSK7AFSO]%GM;
M:WBBN?+_ ',P^5E<#Y26')YZ^M **LN;J;U%0VD;PV<$4K;I$C56/J0.:FIF
M857COK26[DM([F)[F(9DB5P64>X[5A>*;V9KG3M%MDF,E_+^^,8Z0 @2<]1P
M1R*OCP_:#7HM67<)8K?R HXSSU)ZD]N:1?*DKOJ:U%(""2 1D4I( R>E,@**
M** "BC(]>M% !4*W=L]T]JL\9N$ +1!AN ]2*?+*D,;22.%15+,2>@'4US'@
MQ?MRZAKTDHEEOIV4': %2,E5Q[$8-(I1O%MG5444 @C(Z4R0HJ&*[MY[F>WB
ME5IK<J)4'5,C(S]15;6HM0GTJ:/2[A+:\;:$E<9"_,,\?3- TM;%^BH[>.2*
MWCCEE,TBJ TA !8^N!3\C.,C/I0(6BB@D#J: "BBB@ HHHH **** "BBB@ H
MHHH HZU_R M0_P"O:3_T$T:-_P @+3_^O:/_ -!%&M?\@+4/^O:3_P!!-&C?
M\@+3_P#KVC_]!% %ZBBB@ HHHH **** ,.3_ )'JV_[!DO\ Z-CK<K#D_P"1
MZMO^P9+_ .C8ZW* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *2EHH 2FFG4F* &$4A6I,4F* (MM&VI<4;: (=M+MJ7%&*
M(MM&VI<48H BVT;:EQ1B@"+;1MJ7%&* (MM&VI<48H BVT;:EQ1B@"+;1MJ7
M%&* (MM&VI<48H BVT;:EQ1B@"+;1MJ7%&* (MM&VI<48H BVT;:EQ1B@"+;
M1MJ7%&* (MM)MJ;%&V@"';2[:EVT8H CVT;:DQ2XH CVTH6GXHQ0 W%+BG8H
MH 3%+12T )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\
MT&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_
M[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['
M_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"M
MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\
M"C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@#
M#_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A
M,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3
M+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?
M_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_
M -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L
M?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!N
MQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_P
MK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_
M  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH
M P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_
MX3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^
M$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+P
MW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-
M_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&
M['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0
M;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O
M\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^
M_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W*
M* ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P *
M/^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/
M_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R
M\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O
M#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]
M!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\
MT&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_
M[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['
M_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"M
MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\
M"C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@#
M#_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A
M,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3
M+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?
M_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_
M -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L
M?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!N
MQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_P
MK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_
M  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH
M P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_
MX3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^
M$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+P
MW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-
M_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&
M['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0
M;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O
M\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^
M_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W*
M* ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P *
M/^$R\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/
M_A,O#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R
M\-_]!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O
M#?\ T&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]
M!NQ_[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\
MT&['_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_
M[_"MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['
M_O\ "C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"M
MRB@##_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\
M"C_A,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@#
M#_X3+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A
M,O#?_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3
M+PW_ -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?
M_0;L?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3+PW_
M -!NQ_[_  H_X3+PW_T&['_O\*W** ,/_A,O#?\ T&['_O\ "C_A,O#?_0;L
M?^_PK<HH P_^$R\-_P#0;L?^_P */^$R\-_]!NQ_[_"MRB@##_X3'PW_ -!N
MQ_[_  H_X3+PW_T&['_O\*W** ,/_A,?#?\ T&['_O\ "D_X3'PU_P!!NQ_[
M_"MVB@#"_P"$Q\-?]!NQ_P"_PH_X3'PU_P!!NQ_[_"MVB@##_P"$Q\-_]!NQ
M_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ_P"_PH_X3'PW_P!!NQ_[
M_"MRB@##_P"$Q\-_]!NQ_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ
M_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ_P"_PH_X3'PW_P!!NQ_[
M_"MRB@##_P"$Q\-_]!NQ_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ
M_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ_P"_PH_X3'PW_P!!NQ_[
M_"MRB@##_P"$Q\-_]!NQ_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ
M_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ_P"_PH_X3'PW_P!!NQ_[
M_"MRB@##_P"$Q\-_]!NQ_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ
M_P"_PH_X3'PW_P!!NQ_[_"MRB@##_P"$Q\-_]!NQ_P"_PI/^$Q\-_P#0;L?^
M_P *W:* ,+_A,?#7_0;L?^_PH_X3'PU_T&['_O\ "MVB@##_ .$Q\-_]!NQ_
M[_"C_A,?#?\ T&['_O\ "MRB@##_ .$Q\-_]!RQ_[_"C_A,?#?\ T&['_O\
M"MRB@##_ .$Q\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_
M[_"C_A,O#?\ T&['_O\ "MRB@##_ .$R\-_]!NQ_[_"C_A,O#?\ T&['_O\
M"MRB@#E]6\7>'9=&OHX]9LF=[>1542C))4X%;6BD'0=.(.0;:/G_ ("*O44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM_=O_P#OP/\ XJC_ (7-X6_NW_\ WX'_ ,51ROL!Z'17GG_"YO"W]V__ ._
M_P#BJ/\ A<WA;^[?_P#?@?\ Q5'*^P'H=%>>?\+F\+?W;_\ [\#_ .*H_P"%
MS>%O[M__ -^!_P#%4<K[ >AT5YY_PN;PM_=O_P#OP/\ XJC_ (7-X6_NW_\
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MW_\ WX'_ ,51ROL!Z'17GG_"YO"W]V__ ._ _P#BJ/\ A<WA;^[?_P#?@?\
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M;_\ [\#_ .*HLP/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\
MBJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0
MZ*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%
MS>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__
M -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%
M4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"
MW]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_
M _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5
M]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\
M_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O
M[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!
M_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\
M"YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V_
M_P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\
MBJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0
MZ*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%
MS>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__
M -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%
M4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"
MW]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_
M _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5
M]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\
M_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O
M[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!
M_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\
M"YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V_
M_P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\
MBJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0
MZ*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%
MS>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__
M -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%
M4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"
MW]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_
M _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5
M]@/0Z*\\_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\
M_P"%S>%O[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O
M[M__ -^!_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*\\_P"%S>%O[M__ -^!
M_P#%4?\ "YO"W]V__P"_ _\ BJ.5]@/0Z*Y-?']@VB_VR-,U4Z=M+?:/)7;@
M'&?O>M9'_"YO"W]V_P#^_ _^*HLP/0Z*\\_X7-X6_NW_ /WX'_Q5'_"YO"W]
MV_\ ^_ _^*HY7V ]#HKSS_A<WA;^[?\ _?@?_%4?\+F\+?W;_P#[\#_XJCE?
M8#T.BO//^%S>%O[M_P#]^!_\51_PN;PM_=O_ /OP/_BJ.5]@/0Z*\\_X7-X6
M_NW_ /WX'_Q5'_"YO"W]V_\ ^_ _^*HY7V ]#HKSS_A<WA;^[?\ _?@?_%4?
M\+F\+?W;_P#[\#_XJCE?8#T.BO//^%S>%O[M_P#]^!_\51_PN;PM_=O_ /OP
M/_BJ.5]@/0Z*\\_X7-X6_NW_ /WX'_Q5'_"YO"W]V_\ ^_ _^*HY7V ]#HKS
MS_A<WA;^[?\ _?@?_%4?\+F\+?W;_P#[\#_XJCE?8#T.BO//^%S>%O[M_P#]
M^!_\51_PN;PM_=O_ /OP/_BJ.5]@/0Z*\\_X7-X6_NW_ /WX'_Q5'_"YO"W]
MV_\ ^_ _^*HY7V ]#HKSS_A<WA;^[?\ _?@?_%4?\+F\+?W;_P#[\#_XJCE?
M8#T.BO//^%S>%O[M_P#]^!_\51_PN;PM_=O_ /OP/_BJ.5]@/0Z*\\_X7-X6
M_NW_ /WX'_Q5'_"YO"W]V_\ ^_ _^*HY7V ]#HKSS_A<WA;^[?\ _?@?_%4?
M\+F\+?W;_P#[\#_XJCE?8#T.BO//^%S>%O[M_P#]^!_\51_PN;PM_=O_ /OP
M/_BJ.5]@/0Z*\\_X7-X6_NW_ /WX'_Q5'_"YO"W]V_\ ^_ _^*HY7V ]#HKS
MS_A<WA;^[?\ _?@?_%4?\+F\+?W;_P#[\#_XJCE?8#T.BO//^%S>%O[M_P#]
M^!_\51_PN;PM_=O_ /OP/_BJ.5]@/0Z*\\_X7-X6_NW_ /WX'_Q5'_"YO"W]
MV_\ ^_ _^*HY7V ]#HKSS_A<WA;^[?\ _?@?_%4?\+F\+?W;_P#[\#_XJCE?
M8#T.BO//^%S>%O[M_P#]^!_\51_PN;PM_=O_ /OP/_BJ.5]@/0Z*\\_X7-X6
M_NW_ /WX'_Q5'_"YO"W]V_\ ^_ _^*HY7V ]#HKSS_A<WA;^[?\ _?@?_%4?
M\+F\+?W;_P#[\#_XJCE?8#T.BO//^%S>%O[M_P#]^!_\51_PN;PM_=O_ /OP
M/_BJ.5]@/0Z*\\_X7-X6_NW_ /WX'_Q5'_"YO"W]V_\ ^_ _^*HY7V ]#HKS
MS_A<WA;^[?\ _?@?_%4?\+F\+?W;_P#[\#_XJCE?8#T.BO//^%S>%O[M_P#]
M^!_\51_PN;PM_=O_ /OP/_BJ.5]@/0Z*\\_X7-X6_NW_ /WX'_Q5'_"YO"W]
MV_\ ^_ _^*HY7V ]#HKSS_A<WA;^[?\ _?@?_%4?\+F\+?W;_P#[\#_XJCE?
M8#T.BO//^%S>%O[M_P#]^!_\51_PN;PM_=O_ /OP/_BJ.5]@/0Z*\\_X7-X6
M_NW_ /WX'_Q5:\WC^P@T9=8ETS55T]E5A.85VD,0 ?O=R119@=917GG_  N;
MPM_=O_\ OP/_ (JC_A<WA;^[?_\ ?@?_ !5'*^P'H=%>>?\ "YO"W]V__P"_
M _\ BJ/^%S>%O[M__P!^!_\ %4<K[ >AT5YY_P +F\+?W;__ +\#_P"*H_X7
M-X6_NW__ 'X'_P 51ROL!Z'17GG_  N;PM_=O_\ OP/_ (JC_A<WA;^[?_\
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M?_\ ?@?_ !5'*^P'H=%>>?\ "YO"W]V__P"_ _\ BJ/^%S>%O[M__P!^!_\
M%4<K[ >AT5YY_P +F\+?W;__ +\#_P"*H_X7-X6_NW__ 'X'_P 51ROL!Z'1
M7GG_  N;PM_=O_\ OP/_ (JC_A<WA;^[?_\ ?@?_ !5'*^P'H=%>>?\ "YO"
MW]V__P"_ _\ BJ/^%S>%O[M__P!^!_\ %4<K[ >AT5YY_P +F\+?W;__ +\#
M_P"*H_X7-X6_NW__ 'X'_P 51ROL!Z'17GG_  N;PM_=O_\ OP/_ (JC_A<W
MA;^[?_\ ?@?_ !5'*^P'H=%>>?\ "YO"W]V__P"_ _\ BJ/^%S>%O[M__P!^
M!_\ %4<K[ >AT5YY_P +F\+?W;__ +\#_P"*H_X7-X6_NW__ 'X'_P 51ROL
M!Z'17GG_  N;PM_=O_\ OP/_ (JC_A<WA;^[?_\ ?@?_ !5'*^P'H=%>>?\
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MX6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\
MWX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51
M_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?
MW;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#
M_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V
M ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_
M (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_N
MW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_
M ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +
MF\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__
M +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*
MHY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#H
MKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-
MX6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\
MWX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51
M_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?
MW;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#
M_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V
M ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_
M (7-X6_NW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_N
MW_\ WX'_ ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_
M ,51_P +F\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +
MF\+?W;__ +\#_P"*HY7V ]#HKSS_ (7-X6_NW_\ WX'_ ,51_P +F\+?W;__
M +\#_P"*HY7V ]#HKC-)^)>D:[</!IECJ=S*B[V5(5R%SC/+>]5KSXM^'K"\
MEM+J#48IX6*2(T"Y4CM]ZBS [RBO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=
MO_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_
M (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#
MT.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\
MA<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?
M_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\
MQ5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;
MPM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\
MOP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JC
ME?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO
M//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA
M;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?
M@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_
M  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=
MO_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_
M (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#
MT.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\
MA<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?
M_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\
MQ5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;
MPM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\
MOP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JC
ME?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO
M//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA
M;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?
M@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_
M  N;PM_=O_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=
MO_\ OP/_ (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_
M (JCE?8#T.BO//\ A<WA;^[?_P#?@?\ Q5'_  N;PM_=O_\ OP/_ (JCE?8#
MT.BN*TKXGZ-K=V;73;/4[F<*7*)"N=HZG[WN*BO_ (KZ!I=]+97MMJ4%S$0'
MC:!<KD9_O>A%%F!W5%>>?\+F\+?W;_\ [\#_ .*H_P"%S>%O[M__ -^!_P#%
M4<K[ >AT5YY_PN;PM_=O_P#OP/\ XJC_ (7-X6_NW_\ WX'_ ,51ROL!Z'17
MGG_"YO"W]V__ ._ _P#BJ/\ A<WA;^[?_P#?@?\ Q5'*^P'H=%>>?\+F\+?W
M;_\ [\#_ .*H_P"%S>%O[M__ -^!_P#%4<K[ >AT5YY_PN;PM_=O_P#OP/\
MXJC_ (7-X6_NW_\ WX'_ ,51ROL!Z'17GG_"YO"W]V__ ._ _P#BJ/\ A<WA
M;^[?_P#?@?\ Q5'*^P'H=%>>?\+F\+?W;_\ [\#_ .*H_P"%S>%O[M__ -^!
M_P#%4<K[ >AT5YY_PN;PM_=O_P#OP/\ XJC_ (7-X6_NW_\ WX'_ ,51ROL!
MZ'17GG_"YO"W]V__ ._ _P#BJ/\ A<WA;^[?_P#?@?\ Q5'*^P'H=%>>?\+F
M\+?W;_\ [\#_ .*H_P"%S>%O[M__ -^!_P#%4<K[ >AT5YY_PN;PM_=O_P#O
MP/\ XJC_ (7-X6_NW_\ WX'_ ,51ROL!Z'17GG_"YO"W]V__ ._ _P#BJ/\
MA<WA;^[?_P#?@?\ Q5'*^P'H=%>>?\+F\+?W;_\ [\#_ .*H_P"%S>%O[M__
M -^!_P#%4<K[ >AT5YY_PN;PM_=O_P#OP/\ XJC_ (7-X6_NW_\ WX'_ ,51
MROL!Z'17GG_"YO"W]V__ ._ _P#BJ/\ A<WA;^[?_P#?@?\ Q5'*^P'H=%>>
M?\+F\+?W;_\ [\#_ .*H_P"%S>%O[M__ -^!_P#%4<K[ >AT5YY_PN;PM_=O
M_P#OP/\ XJC_ (7-X6_NW_\ WX'_ ,51ROL!Z'17GG_"YO"W]V__ ._ _P#B
MJ/\ A<WA;^[?_P#?@?\ Q5'*^P'H=%>>?\+F\+?W;_\ [\#_ .*H_P"%S>%O
M[M__ -^!_P#%4<K[ >AT5YY_PN;PM_=O_P#OP/\ XJC_ (7-X6_NW_\ WX'_
M ,51ROL!Z'17GG_"YO"W]V__ ._ _P#BJ/\ A<WA;^[?_P#?@?\ Q5'*^P'H
M=%>>?\+F\+?W;_\ [\#_ .*H_P"%S>%O[M__ -^!_P#%4<K[ >AT5YY_PN;P
MM_=O_P#OP/\ XJC_ (7-X6_NW_\ WX'_ ,51ROL!Z'17GG_"YO"W]V__ ._
M_P#BJ/\ A<WA;^[?_P#?@?\ Q5'*^P'H=%>>?\+F\+?W;_\ [\#_ .*H_P"%
MS>%O[M__ -^!_P#%4<K[ >AT5YY_PN;PM_=O_P#OP/\ XJC_ (7-X6_NW_\
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MW_\ WX'_ ,51ROL!Z'17GG_"YO"W]V__ ._ _P#BJ/\ A<WA;^[?_P#?@?\
MQ5'*^P'H=%>>?\+F\+?W-0_[\C_XJN^MITNK6&XC!"2HKJ&ZX(R,T--;@2T4
M44@"BBB@ HHHH \5^.G_ "$='_ZY2?S%>25ZW\=/^0CH_P#URD_F*\DKII?"
M)A1116@@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ]Q^*?\ R2[2/^NUO_Z*:O#J]Q^*?_)+M(_Z[6__
M **:O#JSI[#84445H(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W&Z_P"3>E_Z]4_]'"O#
MJ]QNO^3>E_Z]4_\ 1PKPZLZ?7U&%%%%:""BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /<;?_DWH_\ 7J__ *.->'5[C;_\F]'_ *]7_P#1QKPZ
MLZ?7U&%%%%:""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]QUW_DWZW_Z]
M;;_T8E>'5[CKO_)OUO\ ]>MM_P"C$K.>Z]1GAU%%%:""BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O<?A'_R3G6/^OJ;_ -$I7AU>X_"/_DG.L?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4_\ DEVD?]=K?_T4U>'5[C\4_P#DEVD?]=K?_P!%-7AU9T]AL****T$%%%%
M!1110 4444 %%%% !1110 4444 %%>B?"CPQH_B6\U./5[/[2L$<;1CS73:2
M3G[I'I7J'_"J_!?_ $!O_)J;_P"+J)5%%V8['S717TI_PJOP7_T!O_)J;_XN
MF2_"SP8L+L-&P0I(_P!*F_\ BZGVT0L?-U%%%:B"BBB@ HHHH **** "BBB@
M HHHH ***].\"_"DZ[:6^KZO<".PE >*"$_/(,G[Q_A'';)Y[4I245=@>8T5
M=UB".UUN_MX5VQ17,B(N2<*&( YKI/AGX<LO$WBS[+J,1EM8;=YGCWE=V"%'
M((/5@>#VH;LK@<=177_$K2]'T7Q<VG:-;^1%! GG)O=OWARW5B?X2O3C]:R/
M"NC?\)!XIT[2S]R>8>9SCY!\SX]]H-">EP,>BOI3_A5?@O\ Z W_ )-3?_%U
MXS\1O#$/A?Q4]M9QLEE/&LT"DD[0>"N223@@_@14QJ*3LAV.1HHHJQ!1110
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M3>C_ ->K_P#HXUX=6=/KZC"BBBM!!1110 4444 %%%% !1110 4444 %%%%
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M_P#(SZC_ ->1_P#0UKD/'?\ R/>M_P#7V_\ .LU\;&<]1116@@HHHH ****
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M11KDG"JY &3UX%9M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+=#\1^$;'5KRZU!)Y_,W+#(@4;9&48!0GHH[T[XZD?:=#&>=DW'XI7;?"O\
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M:JB_O+&;:Y_Z9O@?^A!?S->;:WIWBS5?%-WK2:#K*R27!EB)L7!0 _(.%QP
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MK:O-I'@:<V\K12W4J6ZNI((!RS8(]54C\:<Y/F20%6R^&_@"X5[*"..[N8%
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M@@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ['X5_\E)TG_MM_P"B7KTKXW?\B79_]A!/_1<E>:_"O_DI.D_]
MMO\ T2]>E?&[_D2[/_L()_Z+DK&7\1#.,^'/P_TGQ?I-W=ZA<7L4D,_EJ+=T
M4$;0><J>>:Z*V^$F@Z7>W5_KNHE-*CDVP1SS+'D8 S(_'4YP!CMSVJU\#O\
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MYX%8?@3P)<>,KR5FF-M86Y'FS;<EB?X5[9QW[<>H%>D_&_\ Y%.P_P"OY?\
MT6]=%\-K&.P\ :4J#F:,SN?4L2?Y8'X4^=J%P,F;X>_#O37AM+Z.".XEXC%Q
M?LCR=N!O&>?05SOC3X0VUKI\^I>'GF#0J7>S<E]R@?P'KG@G!SG/;I7F7B6_
MFU/Q-J=Y<',DMPY^@!P!]  !^%=-:_%OQ-9Z9;6,!LPMO$L2R-$6=@. 22Q!
M/X4^6:U3 YOPUX>NO$^N0:9:$*SG,DAZ1H/O-COCT[U[2GPP\#Z'8*^KL''
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M5MXEGATO3&\RPMG\QIL$>;)@C@>@!//?)[=?1?A'_P D]L_^NLO_ *&:-8P
MH:%\'=!M(IFU:.6]D>1O+1IF58TW';]S:2Q7&>V>@[GSCQ/X2M7^(1\/>&$D
MDSM5U=RZQ.>6^;&=J@C.<D<_2M7XF>-M:'BZZT[3]2N;.TL]L8%O*8RS8RQ)
M7GJ<8SVK1^"L)U#7M<U>Y8RW2HH,C<DF1F9C]24_G37,ES-@=!8?"CPEHNF^
M;KLOVEPO[V:>X,,:GVP1@?4FH=9^$?A[5=*^T^')?LTQ0O ZSF6&7/3)))Q[
M@]^AJU\1_ ^O>,-0LS87EE%96\7^KGD=29"3DX"D8QM_6K7PW\'ZUX/COX-1
MNK26WG*/&EN[-M89#$Y4=1M_*IYG:]]0/GV^L;G3;Z:RO(6AN86*21MU!_SW
M[UZ3X ^%B:Y8PZQK4CI9RY,-LGRM(.FXMV'H!UZYQUB^*NCQ-\2K)$5D&I1P
M^8_8L7,9Q^"K7K7BZZ?1? ^IS60\MH+4I%C^#C:"/IG]*N4W96Z@<^GP^^'=
MS>/I\$-LU[&#OACU!S*N.N5WDCKZ5YO\0/AN_A*-+^QGEN=-=@A\Q?GA..-Q
M P0?7 [#Z\5IU_/I>I6U_;-MGMY%D0G.,@YYQVKJ]=^*'B'Q!IL^GW2V26TX
MPZ1P=L@\;B<<CKUIJ,D]P.O^!'_,?_[=_P#VK6%\:O\ D=X/^O&/_P!#>MWX
M$?\ ,?\ ^W?_ -JUA?&K_D=X/^O&/_T-Z2_B,.AT>C_"'P_J'AJPU*6\U-9K
MBSCG=4EC"AF0,0/DSC)]:\U\%:);>(_%UCI-X\J03^9N:$@,-L;,,$@CJH[5
M]%>&/^1$T;_L&0?^BA7@_P *_P#DI.D_]MO_ $2]*,FU(#N;_P""=A_:-DMC
MJ%W'98=KN2=E=@ 5VJF% !.6Y.<8Z=CN6/PX\ 7UNZ6<,5VT9*/+%?.[*PZ@
M[6P#[8J/XRZA/9^"D@@;:MW=+%*1U*;6;'YJ*\S^$UQ+#\1=/CC?:LZ2QR#'
MWE\MFQ^:J?PI+F<;W 3XA^!#X.O8)+666?3KD$1O(/F1AC*L0 /<=._'&:T_
MAS\/])\7Z3=W>H7%[%)#/Y:BW=%!&T'G*GGFNO\ C>!_PBE@<<_;AS_P!Z9\
M#O\ D6]2_P"OO_V1:?,^2X'F'CSP]:>%_%$NF64D\D*QHX:=@6R1D] !^E=K
MX#^$\&IZ=;ZOKSOY,Z^9#:1MMW(1PS,.>>H ]N>U4?B#9Q:A\8K.RF7=%<26
ML3C)&58@'D?6O3_B/J$VE^ -4FML+(46$'IM#L%)&.^"<4.3LDNH&1%\/?AW
MJ$LUG9QP/<Q9618+]GDC(X.5WG!SZBO,?B!\/Y/!TT-Q;S/<:;<,41W'SQMU
MVMC@Y'((QG!X&.>6TC5;G1-7M=3LRHN+:0.NX9!]0?8C(/L:Z+Q%\2=?\2Z8
M^G7AM8[9V!=88<$X((Y))'([8_*J49)[@6_A[\/3XP,]W>3R6^FP/Y9:+&^1
M\9*@G.,94Y(/7'T]+D\ _#FSNTL;F*U2[8 K#+J#K(P]0N\'L>U>7>"9_'-R
M?L7ABXN5MXVW,25\F/)&<[@1[X')YX/-==%\&=3U2\>^U[7H_M,TADF\B(N6
MR><,=H'Y8'I2EOJP%\<?";3[+1KG5=":2%K5&EEMY9-RE%&25)Y! ]2<UPWP
MW_Y*%H__ %U;_P! :OHN2S2V\.O8EVE2*T,.Y\ L F,G&.3[5\Z?#?\ Y*%H
M_P#UU;_T!J4)-Q=P/7/C'_R(3_\ 7S'_ %KYYKZ&^,?_ "(3_P#7S'_6OGFJ
MI?"#"BBBM!!1110 4444 %%%% !1110 4444 %%%% !7N.N_\F_6_P#UZVW_
M *,2O#J]QUW_ )-^M_\ KUMO_1B5G/=>HSPZBBBM!!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'I7P1_Y'2\_[![_ /HR.MGX[_\ , _[
M>/\ VE6-\$?^1TO/^P>__HR.O8M>\*Z+XF^S_P!L67VG[/N\K]ZZ;=V,_=(S
M]T=?2L).T[C/F70]9U+0]3BNM+GDCG#CY%)Q+S]U@/O ^E?46N11W/AS48KA
M?W<EI(KKUX*'-9FF^"/"V@SI=VFEP0RQG<LLCLY4^H+DXKD?B9\0].@T>YT3
M2KB.ZN[I3%/)$VY(D/##(X+'I@=.<^A4GSM6 Y;X(_\ (Z7G_8/?_P!&1UZ7
MXR\%V?BJ^T^YU*\-O8622&0*P4L6*X^8\ ?*<UYI\$?^1TO/^P>__HR.M_XY
MW\\=II%@C%8)FDED /WBNT+_ .A&G)-U- -RW^&_@#6+%_[-CCE _=FYM+YI
M"K8_WBN>0<$?A7CWC;PE-X0UTV1D::VD7S+>8KC<OH>VX=\>QXSBNK^!]Q*O
MBK4+8/B&2R,C+CJRN@!_ ,WYU?\ CJ!]IT,XYV3<_BE5%M3Y;@5_ /PJM]9T
MR+5]<DE6&;YH+:)@N]>S,W7!YX&#QG/:NPC\ _#FXNWL(8;5[Q!\T*:@YD7I
MU7?D=1V[UP/@Y/B/J^F+#H]_-#IBJ8DFNB/+"],*2"Q Z?*.,=JZ30/@N=/U
M*UO[[6=[V\JRK%!#C)4@CYF/MZ4I/75@<Y\1?AK'X9M1JVE2N^G[MLL4S M$
M2>,'C*]!ZCWSQB^ ? \GC+4)?-E:"PM@/.D4?,2<X5<\9X_"O9/BJH/PWU4G
ML82/^_J5QGP2UNR@^WZ-,Z1W4[K-#N/,H PRCW&,XSSD^AH4GR7 Z*Y\!?#?
M2-D.I"UAE(R/M6HM&S#UQO'\JH^(O@]H]WIC3>'BUO=JI:-6E+QR^Q)SCIP<
M]^?;4\6_"O3?$^I3ZFE]<6E],%#M@21G  SM.#G  X(''2N6O?"_Q%\)Z.;3
M1-5%UID&YE2V55E .68X(R><\!B>>!4I]F!Y&895G,#1.)@VPQE3N#9QC'7.
M>U>S>$_@_8II\=]XE:1YG4.;57*)$.N'(YSZX( YZ]:X#P':'5/B/ID5]ODD
M-RTTOF$EF= S_-GJ<KSFO=?'FAZKXC\--IFDW$$$DLJ^<T[LH:,9)&5!YSM_
M#-74D[I C";X9>!-:M9ETO:K(VQIK.\,IC8=B"S#/L?TKQGQ5X5O_"6KM8W@
MWHWS03J/EE3U'H?4=OI@GT_P3\,_$?A?Q1;:E+?:>;90R3I#(Y9U(Z<H!UVG
MKVJS\;[".7PWI]_Y9,T%UY6X9X1U).?Q1?\ )I1E:5KW \+HHHK81])N/"/P
MQTII D4$CJ<#.^XN,<X'<C/T ]JZ'5)!-X;O90,![-V /;*&OE"YNKB]N'N+
MJ>6>=SEY)7+,Q]R>37U5>?\ (I7'_7BW_HNN><>6PSY0HHHKH$%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>X_"/_DG.L?\ 7U-_Z)2O
M#J]Q^$?_ "3G6/\ KZF_]$I45/A&CPZBBBK$%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!]&?"/_DGMG_UUE_\ 0S7COQ(_Y*%K'_75?_0%KV+X
M1_\ )/;/_KK+_P"AFM+4OA[X6U?49K^^TOS;J8[I'^T2KDXQT# =JYU)1FVQ
MGF'P:UG4_P#A)I-,^T2RV+V[.T3ME8RN & /3TX]1Z"NG^."(?"VGR$?.MZ%
M!QV*-G^0KL[/3O#?@^SE:WCLM-@PHED=PI..FYF.3U[GO7B7Q-\;0^*]2@M]
M/9CIMH#L8@KYKGJV#V   R,]?6FO>G= >H?"/_DGMG_UUE_]#-4=0^'_ (8C
MUR_UKQ3J$(%Y<,T4,MR((U!Z#.02V >A Z\'&:O?"/\ Y)[9_P#767_T,UX]
M\2KR:]\?ZJ978B*00HI;(55 &!Z#.3]2:$FYNP'JFK_"#PUJ.G[M'#V4Q3=%
M(DS21OQQG<3QTZ&O"&L;E=0-@T+"[$ODF(]0^<;?KGBOH?X3S22_#RP\QRVQ
MY47/8!S@5XKXV=[3XA:O+;,T,D=XTB/&=I5LYW CH<\Y]:JFW=I@>H:!\']#
ML=-2X\0N]S<% \JF7RXHN.1E3DX]<\^@J_#\.?A]K-M)_9B12 94S6=^TA0X
M]V89&1U%<K:^&OB/XNT;[+JVH?9M.EPY2\ $C8Z<!=W7L2/7TKKO!'PTC\(:
MD^HOJ;W5P\1BVK$$0 D$]R3R/:H;:^UJ!X_XY\'3>#M9%OYOG6<X+VTI(W%0
M>0P]1QST/7V'5?#WX7P:]IR:QK+RK:R$^1;QG:7 R"S'L,],5H?'=1NT!NY%
MP/\ T777?##6K+5O!5G:P.BW%E'Y,\(/S*<G#=N&'.?7(SD&J<GR)@41X'^&
MC7GV!5LOMF=ODC4G\S(Y^[OSG'M7(_$'X70Z)I\FL:&9#:Q8,]NY+%%X&Y3U
M([G/3KTZ;6J? _3YI"^EZK/:J23Y4\8E'L 000![Y-<[XSM_B1IFF/'JU^]S
MIK*$DDLRNS&#PV%5@,#DD8.>M$7KHP."T;1[S7=5@TZPBWSS-@=<*.[-Z =2
M:]ML/A1X2T73?-UV7[2X7][-/<&&-3[8(P/J37-_ VQCEU75KYES)!#'$A]
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M*/#EUX5UV;3+ITD*@/'(G21#T..Q]O;OUKWSP-X"A\%+=LNH27<MR%#DQA%
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M1NPJ_:'N_*9L<[512!GZL:X?QO\ $R]\66YT^WMA9Z;N!9"VYY2#D%CT Z'
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MAXMU4WE\VU%RL$"GY(E]!ZD]SW^@ $QB^:]K ?0'P]U*#5? 6EM#)DP0"VD
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M .BFKPZO<?BG_P DNTC_ *[6_P#Z*:O#JSI[#84445H(**** "BBB@ HHHH
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MC/OS7I_@KXI:'X<\(V.DWEKJ#SP>9N:&-"IW2,PP2X/1AVIU$W%) ><>)_\
MD;-9_P"OZ?\ ]&&LJKNL7D>H:W?WL098[BYDE0.,$!F)&??FJ5:+804444 %
M%%% !1110 4444 %%%% !1110 4444 >XW7_ ";TO_7JG_HX5X=7N-U_R;TO
M_7JG_HX5X=6=/KZC"BBBM!!1110 4444 %%%% !1110 4444 %%%% !1110
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M&DW=IJ%O>RR33^8IMT1@!M YRPYXIN#4+ 4_B_\ \E G_P"N$7_H-=Q\#O\
MD6]2_P"OO_V1:\P\>>(;3Q1XHEU.RCGCA:-$"SJ V0,'H2/UKH_AS\0-)\(:
M3=VFH6][+)-/YBFW1& &T#G+#GBG)/DL!3^+_P#R4"?_ *X1?^@UP==+X\\0
MVGBCQ1+J=E'/'"T:(%G4!L@8/0D?K7-5<=$A!1113 **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /<;?_ )-Z
M/_7J_P#Z.->'5[C;_P#)O1_Z]7_]'&O#JSI]?484445H(**** "BBB@ HHHH
M **** "BBB@ HHHH *][^"/_ ")=Y_V$'_\ 1<=>"5Z;\.OB+I'A'P_<6%_;
M7TDLETTP-NB%=I1!W8<_*:BHFXZ#1A_%3_DI.K?]L?\ T2E<=6_XUUNV\1^+
MK[5K-)4@G\O:LP 8;8U4Y )'53WK JH[(05]&?"/_DGMG_UUE_\ 0S7SG7K'
M@7XG:+X8\+0:7>VNH23QN[%H8T*X+$CJX/Z5-1-K0:.*\??\C[K7_7RU=A\$
M-3@M]<U'3I'VR7<*O$"0 Q0G('/)PQ/T!K@O$^J0:UXFU#4K99$AN9C(BR !
M@#ZX)'ZU1L+^ZTR^AO;*=X+F%MT<B'D'^H]N]-QO&P'LGQ>'B/3KFUU?2]2U
M&#3S&(9UMIW18WW'#$*?XLXSCL.>17->'=%^(GB;37O[37K^&$-M3[3?3(9.
M,Y7KD>]=+I7QPL3:(-8TRY2Y'#-:;65N.N&((Y[<_6F:O\<+06S+HVESM.1A
M7O"%5??:I.?ID5FN9*U@/-]?;Q!HWB2./6[R2YU"R=70S7/G[1G<O<X!X.#@
MX(XKZ&UB!?%?@BYCLF5AJ%GN@+$J,LN5SW'.*^7[V\N-1O9KR[E:6XG<O([=
M6)ZUVO@GXFWOA2W73[BW%YIH8E4#;7BR<G:>A'4X/<]153BVDUN!S-AX<U.^
M\11Z&+26.],@1XV3F,=V(] .:](\5_";1-"\.WNJ0ZM>(;>/<JSA'#MT"\!>
MI(&?T/2ML_&_P]Y9(T_5-_8&./'Y[_Z5YOXW^(-]XPD6 1FTTZ,Y6W#YWG^\
MQ[GVZ"E>;?8#LO@1_P Q_P#[=_\ VK6%\:O^1W@_Z\8__0WJO\-?&^F^#?[4
M_M&"[E^U^5L^SHK8V[\YW,/[PK-^(7B>R\6>(H]0L(KB.%;98BLZJ&R&8]B>
M.132?/<#WWPQ_P B)HW_ &#(/_10KP?X5_\ )2=)_P"VW_HEZ[C1_B]X?T_P
MU8:;+9ZFTUO9QP.R11E2RH%)'SYQD>E>:^"M;MO#GBZQU:\25X(/,W+" 6.Z
M-E& 2!U8=ZF,6E(#UGXW_P#(IV'_ %_+_P"BWKSCX5_\E)TG_MM_Z)>MKXC?
M$/2?%^B6UEI]O>Q217(E8W"(HQM8<88\\BN3\%:W;>'/%UCJUXDKP0>9N6$
ML=T;*, D#JP[U44U"P'K/QO_ .13L/\ K^7_ -%O4?P._P"1;U+_ *^__9%K
MEOB-\0])\7Z);66GV][%)%<B5C<(BC&UAQACSR*9\.?B!I/A#2;NTU"WO99)
MI_,4VZ(P V@<Y8<\5/*^2P!\2;[^S/BS!?[2WV4VTV!WVD'^E>M>,]+?Q-X(
MOK2RQ+)/$LL&&QO((=1D^N,<^O;K7@7CSQ#:>*/%$NIV4<\<+1H@6=0&R!@]
M"1^M;_@OXJWGANS33=0MS?6$?$1#8DB'H,\,/0'&,]<8%-P=DUT Y70/#=]K
M/B>VT<VMPDAE N%V[6ACR-S'/3 /?O@=Z[SQI\+M&\->';K58=4O,Q;1'%*J
M-O8D #(V^Y^G;BNC;XW^'@F5T_5"WH8XP/SWUY?XS\<ZAXRNT,R_9K*+F*U1
M]P![LQXW-[XX'3OEIS;[ >W_  TLK:R\ :7]G S.AFE;;@L[$YSZXX7Z**\G
M\0ZWXZUGQ9<Z2DFHPRK,RQVEL3& F[ )*XRO3YB2.<YYH\!_$R;PI;_V=?6[
MW6F[BR",@/"3R<9X()[$CU]J[&_^.&DK:O\ V=IE[)<X^07 5$S[[6)_SVJ>
M62D]+@=TMC)I?@A=/#EY;73O)W*,%BL>W('X5\_?#?\ Y*%H_P#UU;_T!J]!
MTKXT:8VC)%KEI>R7K;Q,;6)!&06. N7!^[@5YEX9U>QT#QE::FRW$EC;S,P
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MCD5R=;J]M1!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** /4/@?\
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M ,E%U?\ WX__ $6M9KXQG)4445H(**** "BBB@ HHHH **** "BBB@ HHHH
M*]/^#/B.+3]:N-&N&"I?@-"Q_P">JY^7\03^*CUKS"E5F1U=&*LIR"#@@TI*
MZL![]\4? MUXFAM]1TM%>^ME*/&6 ,D?) !]0<\$]S7DECX!\4WU\+1-$O(F
MS@R3Q&.-1G!.X\'\,^V:[#PU\9[RQMEMM=M6O@@PMQ$0LA] PZ'Z\>^>M=*_
MQO\ #H7Y+#5&;T:.,#_T,UDN>.EAG3:=X7T;0_!T.F:E%:W%I:Q%YY;B,%2>
M69N>@SD^U>%>%]:L=-^)-KJD<8MK WC[5;@112;E&>>BAOTJYXQ^)>J>++<V
M2PI9:><%X$;>9"""-S$#@$= ![YXQQ-5"#L[]0/I/XF^'+KQ)X2:&R0R75M*
M+B.,'E\ @@>^&/Y5X'I'AG5];U8:;:64OV@,%D\Q"JPYYRYQ\HP#]>V379^$
MOB]?:+9Q6&JVQO[:,!8Y5?$J+Z'/##ICI]3763_'#0EMV:WTW4I)L?*D@1%)
M]"P8D#\*E<\=+ =;XHU&#PQX(NY?,"^3;>1!N&=SE=J#'?G%>;_ O_D(:S_U
MRB_FU<7XP\;ZEXQND:Y"P6D1S#;1G*J?4G^(^_Y8YK2^&WC/3O!UUJ$NH0W4
MJW"(J?9U5B""<YRP]:.1J#[@;GQR_P"0[I?_ %[-_P"A5ZAX%_Y$71/^O2/^
M5>'_ !'\7Z?XPU*RN=/AN8D@A,;"X55)).>,,:[+PW\7- T?PWIVG7%IJ336
MT"QNT<<94D#MEP<?A2E%\B0&)\+K6"X^)]\\RJS01SRQ9&<-O5<_DQKM?BSK
MGB'0]*LY-&9X+9W875RB@LAXVKD_=!YY]0!D=_%+'7[O1_$AUG37\N59F=0X
MR&4DY5AZ$''\O6O7K;XX:(ULINM,U".?'S+$$=<^Q+ X_"G*+YD[7 D^$EEK
M[+J&K:W+>.LZI' ;MV9V SD_,<@=/K^%<=\:\_\ ";6^<X^P1XS_ +[UNP_&
MV-]?WSV$L6CK$0$C57F9^,$DL !UX'Z]N2^(_BO1?%][97VFP7L5Q%&89?M"
M* R9RN,,>A+=N_M1%/GNT![=X%_Y$71/^O2/^5?/OC'PS>^'O$US:26K+!-,
MS6C(AVR(3D!?< @$=C7H?A[XMZ%I'ABPTV:TU)KBVMUB9DBC*[@.HR_3\*?H
MOQNM!8HFMZ?<FZ7AI+4*5?CK@D8.>U**E%MV ZGX7Z!<^'_!L<5XC1W%U*UR
M\3C!CR% !!Z'"C(]37GFF>)H$^.<]]O"VMS<-9EV'48"*1Z LJ\^G6I_%WQB
M;4]->QT&WGM!,"LEQ-@.%]% )P3ZYX[<\CRFJC!N[?4#Z'^+/AR]U_PS%)I\
M)FN+*7S3$OWF3:0VT=ST./8XYX/BWAOPGJ?B/6H["&UF5%DVW$C*5$(!^;)(
MX(].N:[/PM\9+O3+2&RUJU>^BC&T7*/B7;VR#PQZ#.1[Y/7I+GXX:(MN6M=,
MU"6?'"2[$4_\"#,?TI+GBK6 Z7XBZK;Z-X$U'S& :YA-K"G=F<;>/H,G\*YG
MX'?\BWJ7_7W_ .R+7E?BSQ?J/B_4$N+[8D4.X001_=C!//U)P,GVKJ/AS\0-
M)\(:3=VFH6][+)-/YBFW1& &T#G+#GBCD:A8"G\7_P#DH$__ %PB_P#0:F^#
M5K!<>.6>959H+1Y8LC.&W*N?R8UA>//$-IXH\42ZG91SQPM&B!9U ;(&#T)'
MZUE:)K5[X?U:#4M/D"7$)XW#*L#U4CN"/\YJ[/DL![C\6=<\0Z'I5G)HS/!;
M.["ZN44%D/&U<G[H///J ,CO6^$EEK[+J&K:W+>.LZI' ;MV9V SD_,<@=/K
M^%1VWQPT1K93=:9J$<^/F6((ZY]B6!Q^%9\/QMC?7]\]A+%HZQ$!(U5YF?C!
M)+  =>!^O;+EERVL!A?&O/\ PFUOG./L$>,_[[UZ3\)_^2<Z=_O3?^C&KR;X
MC^*]%\7WME?:;!>Q7$49AE^T(H#)G*XPQZ$MV[^U7?A[\2D\)V<VFZC;37%D
MSF6)H2"\;'&1AB!M.,]N<]<\6XMP2 YGQA:W">,M?9X)5"W\S,2A& SDJ3[$
M$$>N:^A_#%_%XE\#V4Q<-]HM?)FVC&' VN,=N0:\Q\<_%'1_$OABXTJRLKU9
M)60B2=44+M8'LQ]*Y#P=XYU+P=<R&W"W%G*<RVLC$*3_ 'E/\+=L]^X.!@<7
M*(&=J_AG5]$U8Z;=V4OV@L5C\M"RS8YRAQ\PP1].^#7O?PS\.W/AKPB(KY?+
MN;B5KB1"?]7D  'WPH)^M8=O\<-":%3<Z;J4<I W+&$=0>X!+#(_ 5R/B_XM
MWFO64VG:9:_8K.92DKNVZ213U''"CJ#USZTGSRT: H76K0ZY\9[;4+=MT$FJ
MVZQL.C*C(@(]B%S^->K_ !8_Y)SJ/^]#_P"C%KY^T.^BTSQ!IM_,KM%:W44S
MA "Q57!.,]^*]+\;_%#1/$OA.[TJSM=0CGF9"K31H%&UPQR0Y/0>E.47=6 \
MEHHHK404444 %%%% !1110 4444 %%%% !1110 4444 %?6^C?\ ("T__KVC
M_P#017R17UOHW_("T_\ Z]H__016%;H-%ZBBBL1A1110 4444 >*_'3_ )".
MC_\ 7*3^8KR2O6_CI_R$='_ZY2?S%>25TTOA$PHHHK004444 %%%% !1110
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M4N%W<844450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ]QNO^3>E_Z]4_\ 1PKPZO<;
MK_DWI?\ KU3_ -'"O#JSI]?484445H(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *]Q^$?_ "3G6/\ KZF_]$I7AU>X_"/_ ))SK'_7
MU-_Z)2HJ?"-'AU%%%6(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /4/@?_R,^H_]
M>1_]#6N0\=_\CWK?_7V_\ZZ_X'_\C/J/_7D?_0UKD/'?_(]ZW_U]O_.LU\;&
M<]1116@@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /1
M/@O_ ,CQ)_UY2?\ H2UD?$W_ )*+J_\ OQ_^BUK7^"__ "/$G_7E)_Z$M9'Q
M-_Y*+J_^_'_Z+6LU\8SDJ***T$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5];Z-_R M/_ .O:/_T$5\D5];Z-_P @+3_^O:/_ -!%
M85N@T7J***Q&%%%% !1110!XK\=/^0CH_P#URD_F*\DKUOXZ?\A'1_\ KE)_
M,5Y)732^$3"BBBM!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110![C\4_^27:1_P!=K?\ ]%-7AU>X_%/_
M ))=I'_7:W_]%-7AU9T]AL****T$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![C=?\F]+_
M ->J?^CA7AU>XW7_ ";TO_7JG_HX5X=6=/KZC"BBBM!!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'N-O_ ,F]'_KU?_T<:\.KW&W_ .3>C_UZ
MO_Z.->'5G3Z^HPHHHK004444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7N.N_
M\F_6_P#UZVW_ *,2O#J]QUW_ )-^M_\ KUMO_1B5G/=>HSPZBBBM!!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7N/PC_ .2<ZQ_U]3?^B4KPZO<?
MA'_R3G6/^OJ;_P!$I45/A&CPZBBBK$%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MJ'P/_P"1GU'_ *\C_P"AK7(>._\ D>];_P"OM_YUU_P/_P"1GU'_ *\C_P"A
MK7(>._\ D>];_P"OM_YUFOC8SGJ***T$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!Z)\%_^1XD_P"O*3_T):R/B;_R475_]^/_ -%K
M6O\ !?\ Y'B3_KRD_P#0EK(^)O\ R475_P#?C_\ 1:UFOC&<E1116@@HHHH
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M_C7M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)=PL>*?\
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M[EW<.&SC/M7&?\*5G_Y_)?R3_&O:Z*2G); >*?\ "E9_^?R7\D_QH_X4K/\
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M !KVNBCVDNX6/%/^%*S_ //Y+^2?XT?\*5G_ .?R7\D_QKVNBCVDNX6/%/\
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M%*S_ //Y+^2?XT?\*5G_ .?R7\D_QKVNBCVDNX6/%/\ A2L__/Y+^2?XT?\
M"E9_^?R7\D_QKVNBCVDNX6/%/^%*S_\ /Y+^2?XT?\*5G_Y_)?R3_&O:Z*/:
M2[A8\4_X4K/_ ,_DOY)_C1_PI6?_ )_)?R3_ !KVNBCVDNX6/%/^%*S_ //Y
M+^2?XT?\*5G_ .?R7\D_QKVNBCVDNX6/%/\ A2L__/Y+^2?XT?\ "E9_^?R7
M\D_QKVNBCVDNX6/%/^%*S_\ /Y+^2?XT?\*5G_Y_)?R3_&O:Z*/:2[A8\4_X
M4K/_ ,_DOY)_C1_PI6?_ )_)?R3_ !KVNBCVDNX6/%/^%*S_ //Y+^2?XT?\
M*5G_ .?R7\D_QKVNBCVDNX6/%/\ A2L__/Y+^2?XT?\ "E9_^?R7\D_QKVNB
MCVDNX6/%/^%*S_\ /Y+^2?XT?\*5G_Y_)?R3_&O:Z*/:2[A8\4_X4K/_ ,_D
MOY)_C1_PI6?_ )_)?R3_ !KVNBCVDNX6/%/^%*S_ //Y+^2?XT?\*5G_ .?R
M7\D_QKVNBCVDNX6/%/\ A2L__/Y+^2?XT?\ "E9_^?R7\D_QKVNBCVDNX6/%
M/^%*S_\ /Y+^2?XT?\*5G_Y_)?R3_&O:Z*/:2[A8\4_X4K/_ ,_DOY)_C1_P
MI6?_ )_)?R3_ !KVNBCVDNX6.'C\+WZ> SX5\O,7EF/S]R[N7W9QFN,_X4K/
M_P _DOY)_C7M=%)3DM@/%/\ A2L__/Y+^2?XT?\ "E9_^?R7\D_QKVNBG[27
M<+'BG_"E9_\ G\E_)/\ &C_A2L__ #^2_DG^->UT4>TEW"QXI_PI6?\ Y_)?
MR3_&C_A2L_\ S^2_DG^->UT4>TEW"QXI_P *5G_Y_)?R3_&C_A2L_P#S^2_D
MG^->UT4>TEW"QXI_PI6?_G\E_)/\:/\ A2L__/Y+^2?XU[711[27<+'BG_"E
M9_\ G\E_)/\ &C_A2L__ #^2_DG^->UT4>TEW"QXI_PI6?\ Y_)?R3_&C_A2
ML_\ S^2_DG^->UT4>TEW"QXI_P *5G_Y_)?R3_&C_A2L_P#S^2_DG^->UT4>
MTEW"QXI_PI6?_G\E_)/\:/\ A2L__/Y+^2?XU[711[27<+'BG_"E9_\ G\E_
M)/\ &C_A2L__ #^2_DG^->UT4>TEW"QXI_PI6?\ Y_)?R3_&C_A2L_\ S^2_
MDG^->UT4>TEW"QXI_P *5G_Y_)?R3_&C_A2L_P#S^2_DG^->UT4>TEW"QXI_
MPI6?_G\E_)/\:/\ A2L__/Y+^2?XU[711[27<+'BG_"E9_\ G\E_)/\ &C_A
M2L__ #^2_DG^->UT4>TEW"QXI_PI6?\ Y_)?R3_&C_A2L_\ S^2_DG^->UT4
M>TEW"QXI_P *5G_Y_)?R3_&C_A2L_P#S^2_DG^->UT4>TEW"QXI_PI6?_G\E
M_)/\:/\ A2L__/Y+^2?XU[711[27<+'BG_"E9_\ G\E_)/\ &C_A2L__ #^2
M_DG^->UT4>TEW"QXI_PI6?\ Y_)?R3_&C_A2L_\ S^2_DG^->UT4>TEW"QXI
M_P *5G_Y_)?R3_&C_A2L_P#S^2_DG^->UT4>TEW"QXI_PI6?_G\E_)/\:/\
MA2L__/Y+^2?XU[711[27<+'BG_"E9_\ G\E_)/\ &C_A2L__ #^2_DG^->UT
M4>TEW"QXI_PI6?\ Y_)?R3_&C_A2L_\ S^2_DG^->UT4>TEW"QXI_P *5G_Y
M_)?R3_&C_A2L_P#S^2_DG^->UT4>TEW"QXI_PI6?_G\E_)/\:/\ A2L__/Y+
M^2?XU[711[27<+'BG_"E9_\ G\E_)/\ &C_A2L__ #^2_DG^->UT4>TEW"QX
MI_PI6?\ Y_)?R3_&C_A2L_\ S^2_DG^->UT4>TEW"QXI_P *5G_Y_)?R3_&C
M_A2L_P#S^2_DG^->UT4>TEW"QXI_PI6?_G\E_)/\:/\ A2L__/Y+^2?XU[71
M1[27<+'BG_"E9_\ G\E_)/\ &C_A2L__ #^2_DG^->UT4>TEW"QXI_PI6?\
MY_)?R3_&NSO?"]_>^!8_"S1[8DCCC\\,NX[&!SC/?%=Q12<Y/<#Q3_A2L_\
MS^2_DG^-'_"E9_\ G\E_)/\ &O:Z*?M)=PL>*?\ "E9_^?R7\D_QH_X4K/\
M\_DOY)_C7M=%'M)=PL>*?\*5G_Y_)?R3_&C_ (4K/_S^2_DG^->UT4>TEW"Q
MXI_PI6?_ )_)?R3_ !H_X4K/_P _DOY)_C7M=%'M)=PL>*?\*5G_ .?R7\D_
MQH_X4K/_ ,_DOY)_C7M=%'M)=PL>*?\ "E9_^?R7\D_QH_X4K/\ \_DOY)_C
M7M=%'M)=PL>*?\*5G_Y_)?R3_&C_ (4K/_S^2_DG^->UT4>TEW"QXI_PI6?_
M )_)?R3_ !H_X4K/_P _DOY)_C7M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_
M ,_DOY)_C7M=%'M)=PL>*?\ "E9_^?R7\D_QH_X4K/\ \_DOY)_C7M=%'M)=
MPL>*?\*5G_Y_)?R3_&C_ (4K/_S^2_DG^->UT4>TEW"QXI_PI6?_ )_)?R3_
M !H_X4K/_P _DOY)_C7M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_
MC7M=%'M)=PL>*?\ "E9_^?R7\D_QH_X4K/\ \_DOY)_C7M=%'M)=PL>*?\*5
MG_Y_)?R3_&C_ (4K/_S^2_DG^->UT4>TEW"QXI_PI6?_ )_)?R3_ !H_X4K/
M_P _DOY)_C7M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)
M=PL>*?\ "E9_^?R7\D_QH_X4K/\ \_DOY)_C7M=%'M)=PL>*?\*5G_Y_)?R3
M_&C_ (4K/_S^2_DG^->UT4>TEW"QXI_PI6?_ )_)?R3_ !H_X4K/_P _DOY)
M_C7M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)=PL>*?\
M"E9_^?R7\D_QH_X4K/\ \_DOY)_C7M=%'M)=PL>*?\*5G_Y_)?R3_&C_ (4K
M/_S^2_DG^->UT4>TEW"QXI_PI6?_ )_)?R3_ !H_X4K/_P _DOY)_C7M=%'M
M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)=PL>*?\ "E9_^?R7
M\D_QH_X4K/\ \_DOY)_C7M=%'M)=PL>*?\*5G_Y_)?R3_&C_ (4K/_S^2_DG
M^->UT4>TEW"QXI_PI6?_ )_)?R3_ !H_X4K/_P _DOY)_C7M=%'M)=PL>*?\
M*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)=PL>*?\ "E9_^?R7\D_QH_X4
MK/\ \_DOY)_C7M=%'M)=PL>*?\*5G_Y_)?R3_&C_ (4K/_S^2_DG^->UT4>T
MEW"QXI_PI6?_ )_)?R3_ !KL_"OA>_\ "WA^[TF*/[0EQ(\AD9E4KN15QC/^
MS7<44G.3W \4_P"%*S_\_DOY)_C1_P *5G_Y_)?R3_&O:Z*?M)=PL>*?\*5G
M_P"?R7\D_P :/^%*S_\ /Y+^2?XU[711[27<+'BG_"E9_P#G\E_)/\:/^%*S
M_P#/Y+^2?XU[711[27<+'BG_  I6?_G\E_)/\:/^%*S_ //Y+^2?XU[711[2
M7<+'BG_"E9_^?R7\D_QH_P"%*S_\_DOY)_C7M=%'M)=PL>*?\*5G_P"?R7\D
M_P :/^%*S_\ /Y+^2?XU[711[27<+'BG_"E9_P#G\E_)/\:/^%*S_P#/Y+^2
M?XU[711[27<+'BG_  I6?_G\E_)/\:/^%*S_ //Y+^2?XU[711[27<+'BG_"
ME9_^?R7\D_QH_P"%*S_\_DOY)_C7M=%'M)=PL>*?\*5G_P"?R7\D_P :/^%*
MS_\ /Y+^2?XU[711[27<+'BG_"E9_P#G\E_)/\:/^%*S_P#/Y+^2?XU[711[
M27<+'BG_  I6?_G\E_)/\:/^%*S_ //Y+^2?XU[711[27<+'BG_"E9_^?R7\
MD_QH_P"%*S_\_DOY)_C7M=%'M)=PL>*?\*5G_P"?R7\D_P :/^%*S_\ /Y+^
M2?XU[711[27<+'BG_"E9_P#G\E_)/\:/^%*S_P#/Y+^2?XU[711[27<+'BG_
M  I6?_G\E_)/\:/^%*S_ //Y+^2?XU[711[27<+'BG_"E9_^?R7\D_QH_P"%
M*S_\_DOY)_C7M=%'M)=PL>*?\*5G_P"?R7\D_P :/^%*S_\ /Y+^2?XU[711
M[27<+'BG_"E9_P#G\E_)/\:/^%*S_P#/Y+^2?XU[711[27<+'BG_  I6?_G\
ME_)/\:/^%*S_ //Y+^2?XU[711[27<+'BG_"E9_^?R7\D_QH_P"%*S_\_DOY
M)_C7M=%'M)=PL>*?\*5G_P"?R7\D_P :/^%*S_\ /Y+^2?XU[711[27<+'BG
M_"E9_P#G\E_)/\:/^%*S_P#/Y+^2?XU[711[27<+'BG_  I6?_G\E_)/\:/^
M%*S_ //Y+^2?XU[711[27<+'BG_"E9_^?R7\D_QH_P"%*S_\_DOY)_C7M=%'
MM)=PL>*?\*5G_P"?R7\D_P :/^%*S_\ /Y+^2?XU[711[27<+'BG_"E9_P#G
M\E_)/\:/^%*S_P#/Y+^2?XU[711[27<+'BG_  I6?_G\E_)/\:/^%*S_ //Y
M+^2?XU[711[27<+'BG_"E9_^?R7\D_QH_P"%*S_\_DOY)_C7M=%'M)=PL><>
M#/ E[X.U*>\AW7+30^45<JH'(.>#[5E:W\*+G6M;O-3>>2)KF4R%%VD+GMG-
M>N44N>5[@>*?\*5G_P"?R7\D_P :/^%*S_\ /Y+^2?XU[713]I+N%CQ3_A2L
M_P#S^2_DG^-'_"E9_P#G\E_)/\:]KHH]I+N%CQ3_ (4K/_S^2_DG^-'_  I6
M?_G\E_)/\:]KHH]I+N%CQ3_A2L__ #^2_DG^-'_"E9_^?R7\D_QKVNBCVDNX
M6/%/^%*S_P#/Y+^2?XT?\*5G_P"?R7\D_P :]KHH]I+N%CQ3_A2L_P#S^2_D
MG^-'_"E9_P#G\E_)/\:]KHH]I+N%CQ3_ (4K/_S^2_DG^-'_  I6?_G\E_)/
M\:]KHH]I+N%CQ3_A2L__ #^2_DG^-'_"E9_^?R7\D_QKVNBCVDNX6/%/^%*S
M_P#/Y+^2?XT?\*5G_P"?R7\D_P :]KHH]I+N%CQ3_A2L_P#S^2_DG^-'_"E9
M_P#G\E_)/\:]KHH]I+N%CQ3_ (4K/_S^2_DG^-'_  I6?_G\E_)/\:]KHH]I
M+N%CQ3_A2L__ #^2_DG^-'_"E9_^?R7\D_QKVNBCVDNX6/%/^%*S_P#/Y+^2
M?XT?\*5G_P"?R7\D_P :]KHH]I+N%CQ3_A2L_P#S^2_DG^-'_"E9_P#G\E_)
M/\:]KHH]I+N%CQ3_ (4K/_S^2_DG^-'_  I6?_G\E_)/\:]KHH]I+N%CQ3_A
M2L__ #^2_DG^-'_"E9_^?R7\D_QKVNBCVDNX6/%/^%*S_P#/Y+^2?XT?\*5G
M_P"?R7\D_P :]KHH]I+N%CQ3_A2L_P#S^2_DG^-'_"E9_P#G\E_)/\:]KHH]
MI+N%CQ3_ (4K/_S^2_DG^-'_  I6?_G\E_)/\:]KHH]I+N%CQ3_A2L__ #^2
M_DG^-'_"E9_^?R7\D_QKVNBCVDNX6/%/^%*S_P#/Y+^2?XT?\*5G_P"?R7\D
M_P :]KHH]I+N%CQ3_A2L_P#S^2_DG^-'_"E9_P#G\E_)/\:]KHH]I+N%CQ3_
M (4K/_S^2_DG^-'_  I6?_G\E_)/\:]KHH]I+N%CQ3_A2L__ #^2_DG^-'_"
ME9_^?R7\D_QKVNBCVDNX6/%/^%*S_P#/Y+^2?XT?\*5G_P"?R7\D_P :]KHH
M]I+N%CQ3_A2L_P#S^2_DG^-'_"E9_P#G\E_)/\:]KHH]I+N%CQ3_ (4K/_S^
M2_DG^-'_  I6?_G\E_)/\:]KHH]I+N%CQ3_A2L__ #^2_DG^-'_"E9_^?R7\
MD_QKVNBCVDNX6/%/^%*S_P#/Y+^2?XT?\*5G_P"?R7\D_P :]KHH]I+N%CQ3
M_A2L_P#S^2_DG^-'_"E9_P#G\E_)/\:]KHH]I+N%CQ3_ (4K/_S^2_DG^-'_
M  I6?_G\E_)/\:]KHH]I+N%CQ3_A2L__ #^2_DG^-'_"E9_^?R7\D_QKVNBC
MVDNX6/%/^%*S_P#/Y+^2?XT?\*5G_P"?R7\D_P :]KHH]I+N%CS+PA\/;SPC
MK3:E"S7#&%HMCE5')!SD'VJKXC^%]UXBU^[U:25X7N"I,:[2%PH7KGVKU>BE
MSRO<#Q3_ (4K/_S^2_DG^-'_  I6?_G\E_)/\:]KHI^TEW"QXI_PI6?_ )_)
M?R3_ !H_X4K/_P _DOY)_C7M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_D
MOY)_C7M=%'M)=PL>*?\ "E9_^?R7\D_QH_X4K/\ \_DOY)_C7M=%'M)=PL>*
M?\*5G_Y_)?R3_&C_ (4K/_S^2_DG^->UT4>TEW"QXI_PI6?_ )_)?R3_ !H_
MX4K/_P _DOY)_C7M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=
M%'M)=PL>*?\ "E9_^?R7\D_QH_X4K/\ \_DOY)_C7M=%'M)=PL>*?\*5G_Y_
M)?R3_&C_ (4K/_S^2_DG^->UT4>TEW"QXI_PI6?_ )_)?R3_ !H_X4K/_P _
MDOY)_C7M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)=PL>
M*?\ "E9_^?R7\D_QH_X4K/\ \_DOY)_C7M=%'M)=PL>*?\*5G_Y_)?R3_&C_
M (4K/_S^2_DG^->UT4>TEW"QXI_PI6?_ )_)?R3_ !H_X4K/_P _DOY)_C7M
M=%'M)=PL>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)=PL>*?\ "E9_
M^?R7\D_QH_X4K/\ \_DOY)_C7M=%'M)=PL>*?\*5G_Y_)?R3_&C_ (4K/_S^
M2_DG^->UT4>TEW"QXI_PI6?_ )_)?R3_ !H_X4K/_P _DOY)_C7M=%'M)=PL
M>*?\*5G_ .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)=PL>*?\ "E9_^?R7\D_Q
MH_X4K/\ \_DOY)_C7M=%'M)=PL>*?\*5G_Y_)?R3_&C_ (4K/_S^2_DG^->U
MT4>TEW"QXI_PI6?_ )_)?R3_ !H_X4K/_P _DOY)_C7M=%'M)=PL>*?\*5G_
M .?R7\D_QH_X4K/_ ,_DOY)_C7M=%'M)=PL>*?\ "E9_^?R7\D_QH_X4K/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %;4?
M^0;<_P#7)OY4:=_R#;;_ *Y+_*C4?^0;<_\ 7)OY4:=_R#;;_KDO\J +-%%%
M !1110 4444 9K_\C'%_U[G^9K2K-?\ Y&.+_KW/\S6E0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_PDND?\_?\ Y#?_  KSZBCV,0N>@_\ "2Z1_P _?_D-_P#"C_A)=(_Y^_\
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M_P#(;_X4?\)+I'_/W_Y#?_"O/J*/8Q"YZ#_PDND?\_?_ )#?_"C_ (272/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>TO5)M+N1)&<H?OI
MV851HH:OHP/3[*]AO[99X&RIZCN#Z&K%>;:7JDVEW(DC.4/WT/1A7H-E>PW]
MLL\#94]1W!]#7+.'*46****S **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFO%'CS0?"4.=0NMUP4#I;1<R.,XR.WYFFDV[(3:6K.EHKPB]_:!NUO918Z+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#^)6C>%O#*Z;?6U_),)G?=!&A7!QZL#^E>QZ5J4.L:3:ZC;K(L-S&)$60 ,
M?7!(_6@"Y17(:_\ $KPYX>O'LYYY;BYC)$D5LF\H?0DD#/MGCOBH-'^*WA?5
M[E;<SSV4C':GVQ JM_P($@?B10!VU%%<#:_&#PQ<6UQ,_P!LM_) PDL:[I"<
M\*%8YZ<YP!QS0!WU%>>VWQE\+3W'E2+?VZ?\]98 5_\ '6)_2N\M;JWOK6.Y
MM9DF@E7<DB-E6'L: )J*S-<\0Z5X<LQ<ZK>);HW"*<EG/HJCD]1].]<:OQH\
M,&8H8-250<>885VGW^_G]* /1:*H:3K6G:[9+>:9=QW,!XW+D$'T(/(_$5E^
M)/'&A^%F2+4+AFN'P1!"NY\>I'  X[F@#HZ*X/3OB]X6OYUB=KRT+':IN(>"
M?^ %J[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\VU_XQZ1I=V]KI]G+J+QG#2"01Q_@<$GOV[=ZZOQK+<0^"=9DM=PE%H_*
M]0,?,?P&:X#X(VFF/::A=E$;58Y0NYL$I$5&-O<9.[)]A0!H:#\8[;5]5MM/
MFT6>"2XD6*,Q3"7YB<#.0N.:]-JE+H^FSWD-Y+86SW,#%XYC&-ZD]2#U[_UJ
M[0!5U/4(=*TNZO[A@L-O$TC9.,@#./J>E4?"^OQ>)_#UMJL48B\[<&BW[C&P
M)!!.!Z9Z=Q7%?&/5Y5TRQ\/VHWS:C*"RCJ55AM'XMC_OFL_X0ZA<Z7K&K^%+
MXA9(7:1%R.'4[7 ]<_*?^ D]S0!Z[7ENL?&:/2M6O=/70WF:UN)("YNMH;:Q
M7/W#Z=*]2KQ#P>H;XX:L& (^TWAY'<.: -2V^.=LTJBZT&6*/(RT5R'('?@J
MO\Z]'T#Q#IWB735OM-FWQYVLK##HWHP[&I-6T/3=<M'MM1LXIT=2N64;E_W3
MU!^E>/?!R:2V\::G8P/YEJUNS,0W!V. K>_WC_WU0!ZCXJ\8Z7X1M$EOV=Y9
M<^5!$ 7?'4\\ #U/ZUP/_"](_-(_X1YO+R<-]LYQVXV?UK'\;""\^,\%OK#'
M^SQ);Q_,V%\L@$@GLNXMGIWKVYK"S>T6T:T@:V48$)C!0#_=QB@#/\,>(K?Q
M1HD>IVT$T,;L4*2@9R.N,'D9[UL57L;&UTVSCM+*WCM[>/.R.,85<DDX'U)-
M6* "JFIZG9:/82WVH7"6]M$,L[?R ')/L*MUX7XXOKOQK\18/#5L[I;03>0%
MP<;A_K)".^!GGT% &[??'&QBN&2QT:>YB!P))9Q$6]\!6_SZ5H>'/B]8ZYJM
MMITVE7%M/<2".,I()5R?4X4@?@:['0_#6D^'+58--LXXB%VM+@&23W9NIZ?2
MK;Z5827T-\UE ;N$L8YO+ =2P(//7D$T 6Z*1F"*68@*!DDG@"N$U+XN^%M/
MN&ACDNKTJ<%K6(%?S8C/X4 =Y7&>.?'4_@N:TSHXO+>Y5L2BY\O:XZJ1L/8@
M@YYY]*M>'?B#X>\2S+;VETT-VWW;>Y78[?3J"?8$G@U7^)VA-KG@JY$,>^YM
M"+F,=SMSN _X"6X[D"@#I]-OHM3TRUOX#F*XB65?HPS5AW6-&=V"HH)9F. !
MZFO//@[K8O\ PFVG22 SV$A4*6R?+;Y@?S+#\!6K\3=;71O!-X%D"W-X/LT0
MR,G=]X_@N>?4B@"OX-^(4OC'5[FT@T8P6MNA=[DW!8=<*,;!R>3C/8^E=Q7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4HFC@0_+$XP7/N.P_G7H0 50J@  8 ':N1T[6;^'QA-INHSL\9W)%E0.^5/
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MYBF3^ZP]/YU7T2>1K:6UG.9[20PN?7'0_E212-2BBBF,**** "BBB@ HHHH
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MFT?AD]J[.V\.:%9W"7%KHNG03H<I)%:HK*?8@9%:= 'CWA_XQV&G^&[6SO\
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M&BHBA44 *JC  ]!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#WA..6ZO+AVO0)OLK\)!D=-I&=WK7H%%.5:4H\K%&E&,KH****R-#S_XT?\
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M>+E\3^'D2XE!U*T41W .<N.BO^..??/3BO-3:Z?IOQGO;?Q!;Q-975S(W^D
M%,299&R> ,D<]N: .WB\7?"^&U%JGV 0 8V'37(/US'S^-<)I^H:5I'Q7T^7
MPG=;]-O)HH60!U $C!60[P"><,.O;TKV#_A!O"W_ $ ;#_OT*=;>$?#%O=I+
M;:/8I<0.KJR1C<C#D'VZ9H WJ*** //]1^+_ (?TS4[NPFL]3:6UF>%RD494
MLK$'&7Z<5PG@GQ_I7AO5=?NKRWO9(]1G62(0HI*@-(?FRPQ]\=,]Z]T:RM78
MLUM"6)R28QDFO,/A5:V[Z_XO1X(F5+I JE 0HWR]/2@#M/"GC/3O&$=U)I\-
MU$+8J'^T*JYW9QC#'TKHJCB@A@SY44<>>NQ0,U)0 5S_ (Y_Y$76O^O1_P"5
M=!7/^.?^1%UK_KT?^5 ''?!#_D7=2_Z^Q_Z *]1KR[X(?\B[J7_7V/\ T 5Z
MC0 5R/Q/:1/AUJYC)#;8P<>AE0'],UUU9GB/2?[<\.:AIF55KB%D1FZ!^JD^
MP(% '%_!6.-?!ERZX+M?/N/?A$P/\^M>CUX?\*/$T7A[5+WP_J[&U$\OR>:=
MHCF7Y65@>A/ SZKCO7N% !7AOQ"UJUUGXB0Z/JE\UMHEBZK*R!CSMW,< '+<
M[0<<?F:]E@UC3[G5+G3(+N*2]ME5YH5/S(#T_P#K^F1GJ*\2U^UL]*^-!?6X
M(WTZYF$A\X91D==NX^P;/TV]Z .SMO%?PNM+06L)L1#MVE6T^1MP]R4R>O>N
M OM3T72?B)I^I>#KD&UD=/,B5)$"L6PZX8#Y2,'CIGM@5[*O@CPHZAET*P*D
M9!$0P13HO!OA:*X!CT73Q-'M< 1#*\\''U!_*@#SWXZ_\P#_ +>/_:5>J:-_
MR ]/_P"O:/\ ]!%>6?'524T%\?*#< GW/E_X&O4=$=9- TYT8,K6L1# Y!&T
M4 >0:K_R<)'_ -?,'_HE*]NKQ'6,1?M!0M(0JM<V^TD]<Q(!^O%>W4 %<#\8
M?^1#?_KYC_K7?5P/QA_Y$-_^OF/^M '">%O!_C;5/#=I>Z1XC^R6$F_RH/ML
MT>W#L#\JJ0,D$\>M=YX)\+^+=$UF:YU[7?M]JUNT:1?:Y9<.64AL. .@89Z\
MU=^%G_)-])_[;?\ HYZ["@#C_BG_ ,DWU;_MC_Z.2L3X3>'M(D\(QZC-I]O-
M=S2.&EE0.0 2 !GI^'6MOXI_\DWU;_MC_P"CDJO\)/\ DGUI_P!=9?\ T,T
M9'Q0\$Z6?#5QK&GV,%M>6S"20PJ$$B$X;('&><YZ\'UK8^&>I'Q!X#A2^VW#
M6\C6S^8N[<%P5SGKP5_*G?%35H-.\#7D$C+Y]YB&)"1D\@L<>@'ZD>M5?@[9
M2VG@42R*0+JZDF3)ZKA4S^:&@#E/":+'\<M21%"HLER%51@ >@KNOB;;02>
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M_-!',Q15+_/&V,D _P 2D>OXYS7M6B:@VJZ#I^H.@1[JVCF9!G"EE!(&>W-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB7&T_>PO&?[P!Z5I D=*I:M;&]TNY@_B=#MXSSVH CU\M%X;E2,D JD>03D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !145Q<P6EN]Q<S1PPH,O)(P55'
MN3P*EH **** "BH+V\M].L9[R[D$5O ADD<@G:H&3P.3]!531-?TSQ'9/>:5
M<_:($D,3/Y;)A@ 2,, >A% &E1110 45C:/XLT37[NXM=+OA<36XS(HB==HS
MCJP //I2ZUXJT/P]-!#JNH1VTD_^K4JS$C.,G:#@>YP.OI0!L44U'61%=&#(
MP!5E.01ZBG4 %%%9VLZ]IGAZS%WJMVEM"6"@D%BQ]  "3^ H T:HWNBZ5J3A
M[[3+*Z8=&G@5S^HJ73]0M-5L(KZQG6>VE!*2+T.#@_J"*LT 5K/3K'3D9+&R
MM[56QE8(E0''3H*LT44 %%%% !1110 4444 %%5-3U*TT?3IK^_F\FUA ,C[
M2V 2!T )ZD5%HVMZ=X@L?MNF7!GMMY3?Y;)R.O# 'O0!H4444 %%9UWX@T6P
ME,5YJ]A;R#^":Y1#^1-26>LZ7J+;;+4K.Y;KB"=7/Z&@"[1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7GWQI_Y)I>_P#7:'_T,5Z#7GWQI_Y)I>_]=H?_ $,5I2^->I%3X&>5
M_ N,/\0'9D#!;.0@D9P<K7TK7S3\#9DB^(!#R*@>TD50QQN;*X ]37TM6F*^
M,BA\ 4445SFP4444 %%%% 'G_P :/^29WW_76'_T,5Y3\"_^2A'_ *\I?YK7
MJWQH_P"29WW_ %UA_P#0Q7E/P+_Y*$?^O*7^:UV4OX$CFJ?Q4>W^+?$,NDQI
M;6P*W$J[O,P,*,]O?BN;TOQ9JQU.W6:X\Z-W"%&4 <G'85V'B/P^NN01[&2.
M>,\2%<Y'I7/Z+X)N([M+B_D"+&^0B');'0Y^M>/4C5=338^IP=7 1PC51+FU
MO??Y'=T445V'SX4444 ?&5Y_R-,__7XW_H=?8PN[8 ?Z1#T_OBOC754:37[R
M-1EFN7 ^NXUV'_"F_''_ $#X_P#P)C_QKT*T(R2N[''3FXWLKGT3JWBK0M"C
MC?4]3M[=9#A-S9S^6:^=?B9\19/&=ZEK:*\6E6[9C1@,R-R-Y_ G H/P:\;G
MKIT1_P"WF/\ QKT/PE\#K72]1BOM;NTOA& RVZIA-W^UG.0*SBJ5+WKW9<G4
MJ:6LB?X'^%I=)T2XUFZ2:*>^PJ1N!@Q#E6'?DD_E7K% &!@45RSFYRYF;QCR
MJP5XU^T)_P @C1/^N\G_ *"*]EKQK]H3_D$:)_UWD_\ 016E#^(B:WP,@_9Z
M_P"/77O]^'^3U[97B?[/7_'KKW^_#_)Z]LHQ'\1BH_ @HHHK$U"BBB@ K \;
M?\B;J?\ US'_ *$*WZP/&W_(FZG_ -<Q_P"A"@#P6O2/A+_Q]:I_N1_S:O-Z
M](^$O_'UJG^Y'_-J;$5_'6I3Z3X\M[VV;$D42''8CG(/L:[34;6T\;^$E>$C
M=(OF0L>J..Q_D:\_^)__ "-0_P"N"?UJ7X<^)/[.U$Z9<OBVN3\A)X1__K]/
MRH C^'<$EMXU,$R%)(XW5E/4$5L_%K[FE_63_P!EKJY/#XC\90:U;J KQ,DX
M'][C#5RGQ:^YI?UD_P#9:!FI\+O^1;F_Z[G^0KS_ ,;_ /(YZA_UT'\A7?\
MPN_Y%N;_ *[G^0K@/&__ ".>H?\ 70?R% CV;2O+_P"$=M/-V^5]F7?NZ8V\
MYK(W^"?31O\ OE*O1?\ (EC_ *\/_9*\!;[Q^M SW'?X)]-&_P"^4K?L3:&R
MB^P>5]EQ^[\K&W'MBOFZO>O!/_(GZ=_US_J: /#;_P#Y"%Q_UT;^=5ZL7_\
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MRFU! [$@[L\Y45Z#10!Y]\0/ NJ>*]9TZ\L9[...V3:XG=@2=V>,*:]!HHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^9K2K-?_ )&.+_KW/\S6E0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%)0!5U3_D$7O\ UP?_ -!->9UZ7JG_ "";S_K@_P#Z":\TKHH[,3"B
MBBMA!1110 4444 %%%% !1110 4444 2HXV;>!GJ2Q%1'K110%@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK0TK2Y-1F[K"I^9OZ"DVDKL
M!=*TJ349N<K"I^9OZ"NV@ACMH5BB4*BC  ID$$=O"L42A44< 5**Y9S<F4/!
MIP-,%.%0!(#3@:8*>* '4M(*44 +10** "BBB@ HHHH **** "BBB@ HHHH
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M1L),HLH4G:RL,C/7UZF@#W#Q+J@T7PSJ6H^8L;P6[-&6Z>9C"#\6('XUY_\
M!#3_ "]&U/42HS-.L*GOA%S^7S_I[5RWB?Q!XH\?:?)-!I,UKHEJC3OMR5.U
M<DLY #8YP .,_C7<_!B[CF\&2VZG]Y!=.&'L0"#_ #_*@#F[T?V[\?88E)V6
MDR?>[>4F\_\ CP->TUX%K4^K^!/B;?:V]D9HI99)(V<$(Z29P-PZ$=/P]Z]V
MLYVNK&WN'C\MI8U<IG.TD9QG _E0!/7(?$Z]^Q?#_4C_ !3!85YQ]Y@#^F:Z
M^O+_ (W7WE>'M.L@^#/<F0@=PBD?EEQ^E %WX-6:V_@I[CG=<W3L3[ !1_(U
MVNLZM:Z'I-SJ-Y(J0P(6Y."Q[*/<G@5XOX<^*TNA^';/1;/0!-+"I59/M!^=
MBQ8G8%SW/>I)M)\;_$V\1]0A.G:;$QV"5#&B_13\SG'&>G!Y% #/AC:7'B+X
MA7?B&>/]W"TD[D\@229  _ L?PJ7X7(OB'XB:EK=V-\B*\Z!N<.[8!_ $C\J
M];\.^'['PSH\>FV"$1J=SNWWI'.,L?<X'Y"O$;=]<^%/BRYF.GO-8N6B#.I5
M)X]V5(89 ;IZXS@T >[ZM?QZ5I%Y?RLJI;PM(2W3@9 _'I7EOP2M&GFUK5IO
MFD=DB#=.3EG[?[M8WB#Q1XH^(>GO;Z=H\MMI,:&:;82ROLY^:0@ XQPH[^O&
M.F^"%VC^'=2LA_K(KL2MSV= !_Z : ,WXQ3OJ7B'0] MV!D;YMHY.Z1@JY_[
MY/YUZ_;P);6T5O'G9$@1<]< 8%>*?%2TU72O'%GXBA@9X$$3PR[2R*\9SM;T
MZ9QW&?>NH\(?$V\\5:Y:Z>-%%O$58S7 E+@$*2,?*-N3ZDT 8GQQU"3=I.FJ
M2(L/<.,\,>%7\OF_.O5-%TR+1M%L].A4!+>)4X[G')_$Y/XUYW\8?#%_JT-C
MJ>GV\EP;96CECC7<P4\AL=^_0=ZQK3XP:[)8+IL6ABXU<*(UE!9B6&!DQ 9)
M_'K^5 #OBE-_;OQ!T7P_&ZLL>R-P/X'E<9R<9^Z$/XU[0JA%"J % P !P!7S
M?IR:IHOQ&TB\\11RQW-Q<1SR&;[VUV*[CZ=^/:OI&@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#Q+X,T/Q9#LU2S5Y0
MNQ)TP)$&<X#=JWZ*:;3NA-)Z,\/OOV??,O9GL=<6&U+$QQRP%V4>A((S^50?
M\,]7?_0Q0_\ @*?_ (JO=Z*U^L5.YG[&'8\Q\._!+P_I?V>?4F?4+J(DL&P(
M7^J$'^=>D6MK!8VL5K:PI#!$H2.-!A5 Z "IJ*SE.4OB9<8J.P4445)1SOC?
MPR_B[PO<:/'=+;-*Z-YK)N VL#TR/2O*O^&>KO\ Z&*'_P !3_\ %5[O16D*
MLX*T61*G&3NSPC_AGJ[_ .ABA_\  4__ !5'_#/5W_T,4/\ X"G_ .*KW>BK
M^L5.Y/L8=CQKP]\#[G0_$6GZHVNQ2K:3I,8Q;D%L'.,[J]EHHK.=24]9%Q@H
M[!1114%'B4WP&NI=5DO1K\(#3&7;]F/&6SC[U>V@8 %%%7.I*?Q$Q@H[!111
M4%!1110 5Q/Q&\!R^.K.Q@BOTM/LLC.2T9?=D >H]*[:BJC)Q=T*24E9G#?#
MCX?R^!(M0274$O/M90C;$4V[<^Y]:[FBBB4G)W81BHJR"BBBI&%%%% !6!XV
M_P"1-U/_ *YC_P!"%;]9^N:>=5T2\L00&FC*J3Z]1^M 'SM14]Y9W%A=R6UU
M$T4T9PRL,5!5""BBB@ HHHH **** "BBB@ HHHH T=#TF;6M7M[&$',C?,W]
MU>YKTWQWJ\/ACPM%I-B0DTZ>4@7JL8X)_'I^=,^'FBQZ/HDNM7N(WF0L"W\$
M0YS^/7\J\Q\4ZY)X@UZXO6)\LG;$I_A0=*Z,-2YYW>R,,14Y(V6[,< LP !)
M)X KW[P/X>'A_P /QI(N+J?]Y,>X)Z#\!7 ?#OP=<7VI1:M?0,EE"=\8<8\U
MNV!Z#KFO9:TQE6_N(SPU.WOL****X3L"BBB@ HHHH **** "BBB@"MJ/_(-N
M?^N3?RHT[_D&VW_7)?Y4:C_R#;G_ *Y-_*C3O^0;;?\ 7)?Y4 6:*** "BBB
M@ HHHH S7_Y&.+_KW/\ ,UI5FO\ \C'%_P!>Y_F:TJ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ I*6DH J:I_R";W_ *X/_P"@FO-*]4=%D1D=
M0RL,%2,@BJITO3_^?&V_[]+_ (5K"?*(\UHKT@Z78?\ /C;?]^E_PIITNQ_Y
M\K;_ +]+_A5^V78+'G-%>BG3+'_GRM_^_2_X4G]F6/\ SY6__?I?\*/;+L%C
MSNBO1/[,L?\ GRM_^_2_X4?V78_\^5O_ -^E_P */;+L%CSNBO1/[+L?^?*W
M_P"_2_X4?V78_P#/E;_]^E_PH]LNP6/.Z*]$_LNQ_P"?*W_[]+_A1_9=C_SY
M6_\ WZ7_  H]LNP6/.Z*]$_LNQ_Y\K?_ +]+_A1_9=C_ ,^5O_WZ7_"CVR[!
M8\[HKT3^R['_ )\K?_OTO^%']EV/_/E;_P#?I?\ "CVR[!8\[HKT3^R['_GR
MM_\ OTO^%']EV/\ SY6__?I?\*/;+L%CSNBO1/[+L?\ GRM_^_2_X4?V78_\
M^5O_ -^E_P */;+L%CSNBO1/[+L?^?*W_P"_2_X4?V78_P#/E;_]^E_PH]LN
MP6/.Z*]$_LNQ_P"?*W_[]+_A1_9=C_SY6_\ WZ7_  H]LNP6/.Z*]$_LNQ_Y
M\K?_ +]+_A1_9=C_ ,^5O_WZ7_"CVR[!8\[HKT3^R['_ )\K?_OTO^%']EV/
M_/E;_P#?I?\ "CVR[!8\[HKT3^R['_GRM_\ OTO^%']EV/\ SY6__?I?\*/;
M+L%CSNBO1/[+L?\ GRM_^_2_X4?V78_\^5O_ -^E_P */;+L%CSNBO1/[+L?
M^?*W_P"_2_X4?V78_P#/E;_]^E_PH]LNP6/.Z*]$_LNQ_P"?*W_[]+_A1_9=
MC_SY6_\ WZ7_  H]LNP6/.Z*]$_LNQ_Y\K?_ +]+_A1_9=C_ ,^5O_WZ7_"C
MVR[!8\[HKT3^R['_ )\K?_OTO^%']EV/_/E;_P#?I?\ "CVR[!8\[HKT3^R[
M'_GRM_\ OTO^%']EV/\ SY6__?I?\*/;+L%CSNBO1/[+L?\ GRM_^_2_X4?V
M78_\^5O_ -^E_P */;+L%CSNBO1/[+L?^?*W_P"_2_X4?V78_P#/E;_]^E_P
MH]LNP6/.Z*]$_LNQ_P"?*W_[]+_A1_9=C_SY6_\ WZ7_  H]LNP6/.Z*]$_L
MNQ_Y\K?_ +]+_A1_9=C_ ,^5O_WZ7_"CVR[!8\[HKT3^R['_ )\K?_OTO^%'
M]EV/_/E;_P#?I?\ "CVR[!8\[HKT3^R['_GRM_\ OTO^%']EV/\ SY6__?I?
M\*/;+L%CSNBO1/[+L?\ GRM_^_2_X4?V78_\^5O_ -^E_P */;+L%CSNBO1/
M[+L?^?*W_P"_2_X4?V78_P#/E;_]^E_PH]LNP6/.Z*]$_LNQ_P"?*W_[]+_A
M1_9=C_SY6_\ WZ7_  H]LNP6/.Z*]$_LNQ_Y\K?_ +]+_A1_9=C_ ,^5O_WZ
M7_"CVR[!8\[HKT3^R['_ )\K?_OTO^%']EV/_/E;_P#?I?\ "CVR[!8\[HKT
M3^R['_GRM_\ OTO^%']EV/\ SY6__?I?\*/;+L%CSNBO1/[+L?\ GRM_^_2_
MX4?V78_\^5O_ -^E_P */;+L%CSNBO1/[+L?^?*W_P"_2_X4?V78_P#/E;_]
M^E_PH]LNP6/.Z*]$_LNQ_P"?*W_[]+_A1_9=C_SY6_\ WZ7_  H]LNP6/.Z*
M]$_LNQ_Y\K?_ +]+_A1_9=C_ ,^5O_WZ7_"CVR[!8\[HKT3^R['_ )\K?_OT
MO^%']EV/_/E;_P#?I?\ "CVR[!8\[HKT3^R['_GRM_\ OTO^%']EV/\ SY6_
M_?I?\*/;+L%CSNBO1/[+L?\ GRM_^_2_X4?V78_\^5O_ -^E_P */;+L%CSN
MBO1/[+L?^?*W_P"_2_X4?V78_P#/E;_]^E_PH]LNP6/.Z*]$_LNQ_P"?*W_[
M]+_A1_9=C_SY6_\ WZ7_  H]LNP6/.Z*]$_LNQ_Y\K?_ +]+_A1_9=C_ ,^5
MO_WZ7_"CVR[!8\[HKT3^R['_ )\K?_OTO^%']EV/_/E;_P#?I?\ "CVR[!8\
M[HKT3^R['_GRM_\ OTO^%']EV/\ SY6__?I?\*/;+L%CSNBO1/[+L?\ GRM_
M^_2_X4?V78_\^5O_ -^E_P */;+L%CSNBO1/[+L?^?*W_P"_2_X4?V78_P#/
ME;_]^E_PH]LNP6/.Z*]$_LNQ_P"?*W_[]+_A1_9=C_SY6_\ WZ7_  H]LNP6
M/.Z*]$_LNQ_Y\K?_ +]+_A1_9=C_ ,^5O_WZ7_"CVR[!8\[HKT3^S+'_ )\K
M?_OTO^%']EV/_/E;_P#?I?\ "CVR[!8XS2M*DU&;NL*GYG_H*[2"WCMX5BB4
M*BC@5-'!'"@2*-44=%48%/VUE.;D,C"TH6I-M+MJ &!:<!3MM.Q0 T"G"EQ2
MXH !2T44 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\44 -Q1BG4M #<4H%+10 F**6B@!*6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K
M:C_R#;G_ *Y-_*C3O^0;;?\ 7)?Y4:C_ ,@VY_ZY-_*C3O\ D&VW_7)?Y4 6
M:*** "BBB@ HHHH S7_Y&.+_ *]S_,UI5FO_ ,C'%_U[G^9K2H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P ]K7\C_A1Y>L?\]K7\C_A6E10!F^7K'_/:U_(_X4>7K'_/:U_(_P"%:5%
M&;Y>L?\ /:U_(_X4>7K'_/:U_(_X5I44 9OEZQ_SVM?R/^%'EZQ_SVM?R/\
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M_A1Y>L?\]K7\C_A6E10!F^7K'_/:U_(_X4>7K'_/:U_(_P"%:5% &;Y>L?\
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M_P ]K7\C_A1Y>L?\]K7\C_A6E10!F^7K'_/:U_(_X4>7K'_/:U_(_P"%:5%
M&;Y>L?\ /:U_(_X4>7K'_/:U_(_X5I44 9OEZQ_SVM?R/^%'EZQ_SVM?R/\
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M_A1Y>L?\]K7\C_A6E10!F^7K'_/:U_(_X4>7K'_/:U_(_P"%:5% &;Y>L?\
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M_P ]K7\C_A1Y>L?\]K7\C_A6E10!F^7K'_/:U_(_X4>7K'_/:U_(_P"%:5%
M&;Y>L?\ /:U_(_X4>7K'_/:U_(_X5I44 9OEZQ_SVM?R/^%'EZQ_SVM?R/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI@?)]O:GT G<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH D@G>WD#H<'T]:Z"UNDNH]R\'N/2N;J2"=[>0.AP?3UJ9
M1N!T]%06MTEU'N7@]QZ5/60PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<*TCW#1AR "!M 8$?7CTIQ3;L@/2J*XGX9>++[Q7H-Q+J(4W5M-Y9D1-H=2
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M% %FBL'PKXML/%]E/=:?#<Q1PR>6PN%523@'C!/K6]0 4444 %%%% !1110
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MH+6Z2ZCW+P>X]*YNI()WMY Z'!]/6IE&X'3T5!:W274>Y>#W'I4]9#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9HJGI.I1:QI-KJ,,4T45S&)$690K!3TR 3]:N4 %%%% !1110 4444 %%%%
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MQ]&/M7T97R+IQ,6LVAA)<K<(4(^7.&&/I7UU6E9:W$@JEK/_ " ]0_Z]I/\
MT$U=JEK/_(#U#_KVD_\ 036*&?,7@R..;QKHL<J*Z->1AE89!&X=17TK<^&=
M!O(REQHUA(",?-;ID?0XR.O:OF7PM>V^F^*]*O;N3R[>"Z221]I.U0<DX')K
MW>Z^+G@^WB+Q7\URP!.R*V<$^WS!1^M;U4V]!(\?^)'AFU\+>*VM+'(M)H5N
M(D+%B@)8%<GW4XZ\8YKV+X3WLMY\/[,2G)@>2%23R5#9'Y X_"O#_&/B:;Q?
MXB?43 8DVB&"+.XJ@S@?4DD_C7T%X!T6;0/!6G6-RNVXV&65>ZLY+;3[@$ _
M2BI\"ON",+4?C#X?TS4[NPFL]3:6UF>%RD494LK$'&7Z9%7-;^*?AC1+M[5Y
MY[N>,[76U0-M.<$9) S^->#^+O\ D=-=_P"PC<?^C&KTOPI\&[.ZT>&\UZXN
M5N)T#K! P41J>0&)!RWY8]Z'""5V!W/A;Q]H_B^YEM]/CNXYHD\QEGB P,@=
M02._3-;NIZK8:-9->:C=16UNIQOD.,GT'J?85C^#_!ECX-MKN&SEDF-S+O,D
MH&[:!A5..#CDYP/O&O"/''BFZ\8>)',;NUE')Y5G!V Z9QZL>?R':H4%*6FP
M'J]S\:/"T$S)''J-PH) DBA4 ^_S,#^E;&@_$?PWXAN4MK:[:"Y? 2&Y786)
M[ \@GV!KE=%^">FC3$.LWETUZXRXMW55CXZ#(.2/7I[5P'CWP-+X*O[=H;AY
M[*X!,4I&&5EQE3COR"#W_"J48/1 ?2M<%K'Q:T'1-7NM-N;34GFMG*.T<<94
MGVRX/Z5+\+?%-QXD\,LE[(TM[9/Y4DC=74C*L??&1[XS7BOC_P#Y'[6O^OEO
MZ4H0O)I@>RZC\7_"VGNB*]U=LRAF^S1JP3(S@DL 3]":L:1\5?"NK3"'[7)9
MRL0%6[CV D_[0)4?B17,:-\%=*N=(@N+[5+UIYHED'D!4521G&""3C/J*XWQ
MY\.I_!T<%W#=F[L9FV;S'M:-NH!Y((('7V/'JU&#T0'T:K*ZAE(*D9!!X(KQ
M#XY_\AS2O^O9O_0JW/@OXCEOM,N]%NIB[6>U[?=DGRSP1GT!Q_WU6'\<_P#D
M.:5_U[-_Z%2@N6=@+W@+QQH?A3P)!'J-P[7#W$A$$*[GVY^\1P ..YK>M?C1
MX6N)Q'*FH6JG_EI- I4?]\,Q_2N \!?#+_A*[#^T[R^-O9>88Q'$N9'QC/)X
M7K[_ $J_XW^$L>A:/)JFCW<T\, W3Q7!4L%_O @ ''ICI5-0<K,#VNPU"SU2
MS2[L;F*YMW^[)$P8'V^OM7'Z]\4]%\.ZS<:7?6.I^? 1DQQQE6! (()<<8-<
M!\%M:GMO$DVD%\VMW$T@0]I%YR/^ Y'Y>E;7QOT(R6]AKT>,Q_Z+,.^#ED/X
M'<#]14\B4K,#U33=0M]6TRUU"U8F"YB65,XR 1G!QW'0^]27=S%96<]W.VV&
M"-I';T51DG\A7F7P4UU;G1;K1)7)FM7,T0)/^K;J!]&R?^!5K?%W6?[,\$RV
MR-B:_D$ Q_=^\Q_(8_X%4N/O<HPTCXMZ'K6K6NFVECJGGW,@C0O'&%&>Y^?H
M!S^%4OC?_P B79_]A%/_ $7)7*_!30FN==N=:D3]S:1F*-CC_6-U_)<_]]5U
M7QO_ .1+L_\ L(I_Z+DJK)320C&^ _\ S,'_ &[_ /M6O4M;US3O#VG-?ZG<
M>3;A@N=I8ECT  Y)KRWX#_\ ,P?]N_\ [5KTSQ-H$'B?0;C2KA_+64J1(%R4
M(8'(]^,?C2G;GU X^;XU^&(Y-J6^IRC^\D* ?JX-;&A_$SPSKMVMK#=O;SM]
MQ+I-F[V!Y&?;/>N8G^%?@C3(BFI:Y-#)W>:[BBQGIP5KS/QEX?TW0-4C32=7
MM]2LID+QO'*KLF#C#%>/QXSZ<52C"6B ^HJ\]OOC#H>FWTUE=Z9K$5Q"Y1T:
M&,$'_OY6M\-]:EUSP193W#L]Q#N@E8XY*G@_]\[:YOXM^"?[4L3X@T^+-[;)
M_I"*!^\B'\7U7]1]!412YK2&>D6%];ZE807MI()()T#HP[@UA>*_'.D>#S;K
MJ'GRS3Y*Q6ZJS!1_$<D8&>/?GT->0_#SXCCPI8WFGZA')/:%6FME4\K+_=]E
M;U['MR:Q+&SU?XC>,F+L6FN'WS2X^6&,?3H , >IQZU:IV>NPKGO7A3QG9^,
M$GET^POXH(3M::X1%0M_=&&))P<]./Q%<-K7Q.\">(K9(-6T34KF-"2FZ) 5
M)ZX82 C\Z]/T?2+/0M*@TVPC\NWA7 SU8]R3W)/)KP/XF>#],\(W6G1::UPR
MW".S^<X8Y!&,8 ]:4%%R ]A\ :EH.I>'6;P[82V5C#.T1CE4!BX5222&;/##
MDG/%:>O>)M(\-6GVC5+Q(0?N1CYG<^RCD_7IZUQ?P0_Y$N\_["+_ /HN.O,_
MBA=75U\0=26YW#R2D42$\*@4$8]CDM_P(T*%YM >G'XV>&1)M%KJA']X0IC_
M -#S75^'O&.A^*-RZ7>>9*B[GA="KJ/7!^HY%<'X7^%_A/6_"]G>_:KJ>:>$
M&62.8#RY".5Q@@%3Q@YKKO!?@>U\&+?""=KAKF12)'4!E0#A3CW+'\J4E#H!
MU=%%%9C"BBB@ HHHH **** ,?Q;_ ,B9KO\ V#[C_P!%M7 _ [_D$:M_UW3_
M -!-=]XM_P"1,UW_ +!]Q_Z+:N!^!W_((U;_ *[I_P"@F@#U:O#O^;@O^WO_
M -I5[C7AW_-P7_;W_P"TJ /9[W4[#31&;Z^MK42':AGE5-Q]!D\TE[JFGZ:
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MS:0/-^\D#+(JC+ \=< XQZT 3_!#_D7=2_Z^Q_Z *]1KR[X(?\B[J7_7V/\
MT 5ZC0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44U,XYZ4ZD4@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"2"=[>0.AP?3UKH+6Z2ZCW+P>X]*YNI()WMY Z'!]/6IE
M&X'3T5!:W*746Y>HZCTJ>LAA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Y'\<KX"UTBP5SEGDF=,\< !2?S;]:]%\+60
MT_PII-J%*F.TC# _WMH+?J37D?Q,!USXI:?I*C "P6QY[NV2>G'##UZ5[G0!
MSOCR]_L_P+K,XZFV:(<XP7^3/_CU<A\$;'RO#^HWQ"_O[D1CU(1<_P#LYJY\
M9K[[-X,BM5?#75TBE<D9506/UY"UK?#.T33_ (>Z:6PIE5YY&)P/F8D'GI\N
M/RH Z>WO[.[EEBMKN":2+'F)'(&*9SC('3.#^1JHWB/0TN3;/K.G+.#@Q&Z0
M-GZ9S7@G@;0M3\3WNIZ?IU\+&PE53>-CYC'N.% '7\P,?D>E\8?"?3M#\,W.
MJ:??7;S6R!G2?:5<9 ., 8X)/>@#VFD9@BEF("@9))X K@?@]J%Q?>!_+G<N
M+2Y>",DY(3:K ?AN(^E<5K&LZW\4/%#:-H\A@TN(M_$0I0'!D?'7/&!VS]30
M![%'XAT2:[6TBUC3WN6;:L*W*%R?0+G.:\MU7.M_'ZSMPX=+-H\'J%\M/-(_
M[ZR/K5^;X(:;_9Q6#5;O[<!Q)(J^43_N@9'YFL#X1VLUWX\O;N\D,TMK;,#(
M6W$N2JYSWXW<T >I^*7\-:A83:-KVI65N)0K[);E(Y%P<AADY'3^=)X-\/Z)
MH&CE="N/M5O.Y<W/G+)YA''WEXXP1Q7G?QGT*QMFAUOS[EKZ[E6+RV*^4L:H
M<XP,YSCJ3U/M7HW@>Q_L_P #Z/;E-A^S+(RGJ"_SG/OEC0!LW=[:V$!GO+F&
MVA!P9)I BY^IJ*QU;3=3#&PU"UNPOWOL\RR8^N#7A&CPCXH>-+A]<U5K90NZ
M&)2 2N[B-,\#@Y[GOSS7<V'PALM)\3Z?J5G?S26D#EY89\%S\IQA@ ",XR".
MF>: /2JHWNM:5IKA+[4[*U8]%GG5#^IKA?BAXUN]&%OHFC.ZZE= ,[QKED0Y
M "\?>8_B,>X-9.B?!A;JV6[\0ZE<"ZF_>/';D97//S,P.6YYX]>O6@#U:TO[
M/4(O-LKN"YC_ +\,@<?F*\?^,]PU_P"(]&T>%\N(RVWL&D8*,X_W?UKO/!W@
M6U\&W&H/;7<EPEWL"B5 &C"[N,CKG=Z#I7 W /B#X^1H1NBLYEQ@_=\I-W_H
M8_6@#V:W@2VMHK>/.R) BYZX P*2XN8+2(RW,\<,8ZO(X4#\35?6-4MM$TBZ
MU*[8+#;QEVYQD]@/<G 'N:\9TO2=:^+6K7&IZC=M::3"^Q4C.X*1SL4>N#DL
M?7\  >PVWB+0[R58K76=/GD8@!(KI&))Z# -:5>*^,?A-9Z'H4^K:3?W3-:J
M'>*XVL6&>2&4#&.O0]*Z7P'XLN;GX:WU]<MYUSI,<HR^29%1-ZY.>?3\* .[
MO=3L-,17O[ZVM$;A6GE6,'Z9-+9ZA9:C%YMC>6]U'TWP2JX_,&O"?!WAZ#XC
MZOJ%]KVLRBZ# F*,J)) 0>1G("C & /RKOO#7POM_#/BP:I!?//:+"P2*4#>
MKDC&2!AAC/8<XH ]!K.N_$&BV$IBO-7L+>0?P37*(?R)KSCXA^,=3O->C\(^
M''<7#L([B2(X9F;!"JW\( ^\?J.,'+M-^"&G+;)_:FIW3SX^<6NU5!]MRDF@
M#U"UO+:]B\VTN(;B/.-\3AQGTR*FKPKP7#+X>^+9T;3+UKVRW/',R-\K 1Y)
M/;*MQ]1CO6]\3/&6I?VLGA+0O,6ZEV+-)&V'+-@K&I[<$$GWQQSD ]&N_$&B
MV$IBO-7L+>0?P37*(?R)KS3XVWXDL-%LH91(LTCS[4.<X "GCUW-C\:?I?P3
MM&L=^L:G<F]<9(MBH1#[E@2W;TKBY?#$^F_$?3?#-Q=?:[>*ZC*'. (V(9N.
MQQGCU^M 'T'IEF-.TFSL@01;P)#D=#M4#^E6J** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>.QEC?&,'#.< _3GTKHOAQ\/)_#DTFK:NR-J4BE(XE(81*3R=W]XX[=B>N>
M#/\ CC_R"-)_Z[O_ .@BO0_#O_(L:3_UYP_^@"N'^,>EZAJFEZ8FGV-U=LDS
MEEMX6D*C:.N <5W>@QO#X=TR*5&21+2)61A@J0@R".QH \F^+7_(_:%_URC_
M /1IK6^."2'0M+< ^6+E@Q[9*G'\C5;XGZ/JFH>-M%N++3;RYACC0/)# SJI
M\PGD@8'%>A>*_#D'BGP_/IDQ5&;#PRE<^7(.C?S'T)H ;X,>)_!.AF(@K]AA
M!P/X@@#?KFN2^-G_ ")EG_V$$_\ 1<E<SH\_Q"\ [M-CT22_LMQ952%IE'J5
M9.1GT/Y=:;XRE\>>*]&B:[\/26]E'<+MMX86>5GVM\Q'+;0,C. .1U[ 'J/@
M;_D1=%_Z]$_E7FWA;_DNVJ?]=;FO3?!L$UKX-TB"XBDAFCM45XY%*LIQT(/(
MKS_PWH^J0?&?4K^;3;R.S>2X*W#P,(V!Z88C!S0!Z/X@\.Z=XFTMK#4HBT9.
M4=#AXV_O*>QKR;5_"GB?X;Q2:IH.KRSZ:L@:6, C:,\%TY5AT!8<_2N[\=R^
M,838R^%X \<+%[@ J6?L%VGJN,YQSR.F,UQFK>(OB!XHTE]'7PM-:_: (Y9/
ML[IN!Z@%^%!]ST[T 6/$WB-O&/P=EU/R1%-!=I'<HN=JL".GL0Z_GBNH^$\L
M4GP\L%CQNCDE63&/O>8QY_ BG>$/ T>D^"9M%U4),]ZS/<K&3@9  4-[ #GU
MS7$6^A^./AQJ4YT6W.J:;)R55"ZO[E =RL/4<?6@#VNN/^*?_)-]6_[8_P#H
MY*Y.X\4?$K7D^QZ?X=DTTOPTS0LC =\-)@#\L^E=_JVD7?B#P9-I=\\4-[<6
MP61D)9%D&#GMQN% '/?![_D0T_Z^9/Z5QWCL_8_C/I-S*"(_,M)<_P"R'P?_
M $$UH>!4\9>$-9C\/W>D22Z9/<9:<1LZ19ZLKKP 0!P?T.:ZKXB>!O\ A+M/
MCFM76/4K8'RBYPLBGJA]/8_X\ ':UXE\;G677])MD ,PMV)]<,V!^JFM"T\7
M?$;2+=-/O/"\U]-&-BW'DNY;MEF0E3]>,]>^:/#'@?7=?\4)XG\6*$4/YBVT
M@^9B/NC;_"H]#R<>^: /0-=\*Z?XGT:&PU969XP"L\;8D1L#)5B#U[Y'/Y5Y
M9JNA>+/AA&+_ $K56NM)63YUP=JD\?/&21SP-P/7'3BNX\=7/C6TO[*Z\-6P
MFL[="TZ##&5B<;2G4@ #[O/S'TKC]:UGQ_XRTPZ,/#$MG%,5\YVA>/< 00-S
MX &1D]_UR 3^.]?_ .$K^$VGZK''Y3?;E$\8)PK!74C/<9(/X^M5O"GPLT?Q
M'X:LM4;4KM))E.]$V$*P)!'3VKNM \#PV?P_/AO42LC7"LUPR= Y.01_NX7G
M_9KA;+3?'OPYN98--L_[5TZ0[@L:&12<==H.Y3T]CCOB@#9_X4AH_P#T%;_\
MD_PK0U#PE%X4^%VOZ=83SW"R(]PS28W#Y5#=.V%_G6+)XC^)?B!TMK#06TM2
M0&EDB:,CG.=S]OH,]:]3\@W6G?9[^.)S+%LN(UR4;(PP&>HZ]>U 'G?P1>(^
M%+] 1YHOB6XYVE$Q_)J[3Q;_ ,B9KO\ V#[C_P!%M7D[>&?&/P[UV>\\/6[7
M]C+QA(_-WIGA70?-D9ZC\^HK3U#Q!\0O$>BWEE'X9-E$]O)Y\CPN&9-I!55;
MDL>@ !/(^M %SX(?\B[J7_7V/_0!7J-><?![3+_3-!U"/4+&YM)'NMRK<1-&
M2-HY (%>CT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 4M7O#I^B7]Z#@V]O)+G&<;5)Z?A7F/P0L=UCK-]+&
M'$TB0AV&<X!+#_QY<_A79?$5;J7P-J-O96EQ=7$X2-8X(R[<L,G !XP#5;X7
MZ1<:/X(MXKN&6"XFEDE>*5"C)\VT @^R@_C0!Y;=WT_P_O/%GAQ#)Y=Y$%MV
MQP Q'//_ $S=AGU4?AW_ (;\,^1\'+BR=2L]_:RW+=_F9<IQ] GO3/'_ (*D
M\0>+M NX8&>&1_(O64?=C4[LD]!QO&3WP.:]'50BA5 "@8  X H \S^"=_Y_
MAF^L206MKG>!D<*ZC''U5O\ (K"^!I']I:P,C)AC./Q-:'PRTO5/#_C+6;*?
M2[V"PE#".9XF$9*/A?F(P<@G!R?QK.N?#WBKP%XPNM4\/Z<;^SN-X5$C,GR$
MAMK*N""#C!'I]10!ZQXB_P"18U;_ *\YO_0#7GGP._Y!&K?]=T_]!-1:A<>/
M_&FDW%O+I?\ 8^GB)VE!C;S9\ _(%)R<D 8P/J>E:'P<TO4-+TO4TU"QNK1G
MF0JMQ"T98;3TR!F@#G-*_P"3A)/^OF?_ -$O7MU>0^-O"?B+3?&J^+/#L37)
M9E<QQC<\;A=I!7JRL/3U(XX)](\,ZC?ZKX>M;W4[)K*\DW>9;LC*4PQ X;D9
M !_&@#RSX8_\E5U__KE<?^CTKVFO&/$'ASQ+X3\?3>)-!L9+^"XE>7;&AD(+
MYWJRKSU)((]JZ_PCXH\4:WK3PZOX=DTZQ$)*R-!(I\S(P,MCC&>W7O0!QWQR
M_P"0AHW_ %RE_FM>Q7EO]KL;BVW;/.C:/=C.,C&<5Y5\9-'U35+[26T_3;R[
M5(I YMX&D"DD8S@'%>N4 >/?\**_ZF/_ ,D?_ME>B1Z9_8O@=M,\[SOLMB\7
MF;=N["'G&3C\ZW:IZJC2:/?(BEG:WD"JHR2=IX% 'E7P*_YC_P#V[_\ M6O8
M:\J^#&DZEI?]M_VAI]W:>9Y&S[1"T>['F9QD#.,C\Z]5H ^;O WA*S\4Z[>Z
M;J-W-!+#&74QD98AL,/F'O7H'_"D-'_Z"M_^2?X5'XO\!ZS9^)&\4^$W N2_
MFR6Z'#;^=Q&>&![KWR>N:B'CKXB-%]G'A"3[20 )C:2[<^OI^N* -[P[\+--
M\-Z];:M;W]W++;[MJ2!=IW*5YP/]JK?C'X=:7XM<732/9Z@%VBXC4$..V]?X
ML#@<@_EBK7@@>*/[,GD\4>4)Y93)$H(+HI_A(' '3 !SR<UR^MZS\1-$\37M
MU;Z0;_2I7VP01IYH51@!AL^92>ISQR?3@ YTZYXM^&&L6]EJLYU#3' \L,Y9
M60<81CRI&1QTZ=L&NE^,TT=QX%T^:)MT<E]&ZG&,@Q2$5SFJZ;XV^).I6BWV
MDG2[*#(!EC:,)G&YB&^9CP, >GU-=#\8[>.T\!:;;1#$<-[%&@] (I * .N\
M#?\ (BZ+_P!>B?RKG/C+<11>"4A=P))KI B]S@$D_3_$5S6@^*O'6C>';*"'
MPW_:%GY*_99HH7<[,<9V$_R%,?PUXS^(FL6]SX@A?3M-C) 1ALV+U(6,G.X\
M#)_IB@#O?AA&T7PZTA6')61OP,KD?H:X3X,_\C/K?_7+_P!GKV2UMH;*TAM;
M=!'!!&L<: YVJHP!^0KRCX3:/JFF^(]8EOM-O+6.2/"// R!CO[$CF@"+XZ_
M\P#_ +>/_:5>J:-_R ]/_P"O:/\ ]!%>;_&?2=2U3^Q/[/T^[N_+\_?]GA:3
M;GR\9P#C.#^5>DZ4C1Z/8HZE76WC#*PP0=HX- ',?$?QA-X2T2)K(1F^NG*1
M>8,A0!\S8[D9'MD\UQ^F_##6?$]JFI^)M<N5EG'F+ ?WC+GIG)PO'\('&>V,
M5UGQ,\'7'BS1H&L"#?6;,T<;$ 2*P&Y<GH>!CG''/J.:T[Q?\1+:TBT[_A$Y
M)KB)!&)Y;>15;' ).0I_ B@#F?\ A'U\,?%K1]+2ZDN5CN(&#N,'!.<8]J]B
M\<_\B+K7_7H_\J\LU/PQXUL=?TWQ5?6CZG=^:LTT-N-YA*G(3"]MHZCC/Z^R
MW,$>MZ%-;RI+#'?6Q1E==KH'7!!'8C/3UH X3X)_\B9>?]A!_P#T7'73^/8F
MF\!ZTJ#)%LS?@.3^@KRW1(O&WPYO[RTM]!EU&WF():*%Y$;&<,K+TR#T/->G
M>$M3U?7]'NF\0Z2;&1I61(3&R!HBHQG<<YSN!Z=N* .9^",RMX4OX1]]+XN?
MH40#_P!!-=_K,R6^AZA-+CRX[:1VSTP%)->4/X9\5_#O7KB^\,6YU'3)_O0X
M+G')"LH(8D<X8?UQ3=7U+X@>-[9=(70)=,MI6_?.\;QA@.<,S=%]AU_2@!WP
M,BD\W6YLXBVPJ1GJWSGI^?YU5^$__)2M9_Z]I_\ T<E>F>"_"L7A+0([$,DE
MRY\RXF5<;W/8=\#H/S[UP/PRT;5;#X@ZM<WFF7EM;O;S!)9H&16)E0@ D8/
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MM)FBLABT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %;4?\ D&W/_7)O
MY4:=_P @VV_ZY+_*C4?^0;<_]<F_E1IW_(-MO^N2_P J +-%%% !1110 444
M4 9K_P#(QQ?]>Y_F:TJS7_Y&.+_KW/\ ,UI4 %<%K'PET'6]7NM2N;O4DFN7
M+NL<D84'VRA/ZUWM%--K8""RM(["PM[.(L8X(EB4L>2%  S[\5Q.L?"70=;U
M>ZU*YN]22:Y<NZQR1A0?;*$_K7>T4*36P'F\?P3\,I(&:ZU1P.JM,F#^2 UT
MVA^!?#GAYTEL=-C^T)R)Y?WD@/J">GX8KHJ*;E)]0"BBBI *BN;=+JTFMY"P
M25&1BO4 C'%2T4 <!I7PBT#2-5M=1M[S4VFMI5E19)8RI(.1G"#BN_HHIMM[
M@%%%%(#S[4?@]X?U/4[N_FO-366ZF>9PDL84,S$G&4Z9->@T44VV]P"J6J:3
M8:W8O9:E:QW-N_)1QT/J#U!YZCFKM%(#SF?X*^%Y92Z3ZE"I_@CF0@?]](3^
MM;>@_#GPUX>G2YMK(S72-N2>Y;>RGM@=!CUQGWKJZ*ISD^H!7R[X_P#^1^UK
M_KY;^E?45?./CCPUKUWXVU>XMM$U*:&2X)22.TD96'J"!@U=+<3/0X/A!X8U
M'3[2Y!OK9I8(W98)AC)49^^&ZGFMG1OA?X6T:5)ELGNYD(*R7;[\$=]HPOZ5
MTVDH\>C6,<BLKK;QAE88((4<&KE0YR[C"N5\5^ -*\87=O<:A<7L3P(446[J
MH()SSE37544DVM@,?PUX<L_"VD#3;&2>2$.S[IV!;)Z] !^E7-6TV'6-)NM-
MN&D6&YC,;M&0& /ID$?I5RBB^MP.)\._"_1/#.M1:I976H23Q!@JS2(5^8$'
M.$![^M=M17"?%>'5YO"UJNBQWTER+U"PLE<OLV/G.WG&<?I3UD]0,'XXW-BV
MDZ;;^:IU!;@L(PP)6,J=Q([9.W'XU'\#]$,=KJ&MRH092+:%BN,J.7(/<$[1
M]5/X<KH7PI\2ZY=B74T;3[<G+S7)W2-]%SG/UQ_2O>M(TJTT/2;;3+%"EO;I
MM0$Y)[DGW)))^M:2:C'E0B[5'6-'LM>TN;3M0B\RWF'S '!!'((/8@U>HK$9
MQ6@?"WPYX?U%+^$75S<1G=&US("$;L0% Y^N:Z36="TSQ!9BTU6S2YA#;@&)
M!4^H(((_ UHT4W)MW \X/P4\,&?S!<:F%SGRQ,FWZ?<S^M;[_#WPTWA]]%33
MECMG82%T8^9O&<-O.3D9/7C!(Z5U%%/FD^H'*>&?A_I'A-KJ739KPW%Q'Y9G
ME=69%_V1M"]0#R#TK#/P6\./.9IK[5Y79MS^9.AWG.3D[,\UZ/11SR[@,AAC
MMX(X(4"11J$11T4 8 K!\5>#-*\7V\,>HB5'A;,<T#!7 /49((P>.W:NAHI)
MM:@<CX7^'FF^$=0>[TV_U%C(FR2*9XV1QVR @/'L:F\6> ]+\8S6TNH3WD36
MZLJ?9W5002,YRI]*ZBBCF=[@8?A;PM8^$=,EL+"6XDBDF,Q-PRLVXJH[ <84
M54U_X?\ ASQ),;B]L=ETW6>!O+=OKCAC[D&NGHHYG>X'G$?P3\,1ON:YU.0?
MW6F3'Z(*[71O#^E>'K9K?2K&*UC8Y;;DLWIECDG\36E13<F]P"BBBI ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J6WMWN)-J].Y]*(86G?:O3N?2M>*-84"(./YU,I6 EAC2",(@X_G4H
M:H0:<#60R4&G U&#3@: 'T4@I: %HH%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %;4?^0;<_\ 7)OY4:=_R#;;_KDO
M\J-1_P"0;<_]<F_E1IW_ "#;;_KDO\J +-%%% !1110 4444 9K_ /(QQ?\
M7N?YFM*LU_\ D8XO^O<_S-:5 !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M15K%&*+@5?LT/_/)/^^11]FA_P">2?\ ?(JUBC%%P*OV:'_GDG_?(H^S0_\
M/)/^^15K%&*+@5?LT/\ SR3_ +Y%'V:'_GDG_?(JUBC%%P*OV:'_ )Y)_P!\
MBC[-#_SRC_[Y%6MM&VBX$"Q*@PJA1[#%.VU+BEVT 1;:7;4FVC% #-M*!3\4
M8H 3%+BEQ10 444M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF:/[(L/^?9?S- %C[3;_ //>+_OL4?:;?_GO%_WV*K_V18?\^R_F:/[(L/\
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M_GV7\S0!8^TV_P#SWB_[[%'VFW_Y[Q?]]BJ_]D6'_/LOYFC^R+#_ )]E_,T
M6/M-O_SWB_[[%'VFW_Y[Q?\ ?8JO_9%A_P ^R_F:/[(L/^?9?S- %C[3;_\
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MF:/[(L/^?9?S- %C[3;_ //>+_OL4?:;?_GO%_WV*K_V18?\^R_F:/[(L/\
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M_GV7\S0!8^TV_P#SWB_[[%'VFW_Y[Q?]]BJ_]D6'_/LOYFC^R+#_ )]E_,T
M6/M-O_SWB_[[%'VFW_Y[Q?\ ?8JO_9%A_P ^R_F:/[(L/^?9?S- %C[3;_\
M/>+_ +[%'VFW_P">\7_?8JO_ &18?\^R_F:/[(L/^?9?S- %C[3;_P#/>+_O
ML4?:;?\ Y[Q?]]BJ_P#9%A_S[+^9H_LBP_Y]E_,T 6/M-O\ \]XO^^Q1]IM_
M^>\7_?8JO_9%A_S[+^9H_LBP_P"?9?S- %C[3;_\]XO^^Q1]IM_^>\7_ 'V*
MK_V18?\ /LOYFC^R+#_GV7\S0!8^TV__ #WB_P"^Q1]IM_\ GO%_WV*K_P!D
M6'_/LOYFC^R+#_GV7\S0!8^TV_\ SWB_[[%'VFW_ .>\7_?8JO\ V18?\^R_
MF:/[(L/^?9?S- %C[3;_ //>+_OL4?:;?_GO%_WV*K_V18?\^R_F:/[(L/\
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M>\7_ 'V*/M-O_P ]XO\ OL5!_9%A_P ^R_F:/[(L/^?9?S- $_VFW_Y[Q?\
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MV7\S0!/]IM_^>\7_ 'V*/M-O_P ]XO\ OL5!_9%A_P ^R_F:/[(L/^?9?S-
M$_VFW_Y[Q?\ ?8H^TV__ #WB_P"^Q4']D6'_ #[+^9H_LBP_Y]E_,T 3_:;?
M_GO%_P!]BC[3;_\ />+_ +[%0?V18?\ /LOYFC^R+#_GV7\S0!/]IM_^>\7_
M 'V*/M-O_P ]XO\ OL5!_9%A_P ^R_F:/[(L/^?9?S- $_VFW_Y[Q?\ ?8H^
MTV__ #WB_P"^Q4']D6'_ #[+^9H_LBP_Y]E_,T 3_:;?_GO%_P!]BC[3;_\
M/>+_ +[%0?V18?\ /LOYFC^R+#_GV7\S0!/]H@_Y[Q?]]BC[1!_SWB_[[%0?
MV18?\^R_F:/[(L/^?9?S- $_VFW_ .>\7_?8H^TV_P#SWB_[[%0?V18?\^R_
MF:/[(L/^?9?S- $_VFW_ .>\7_?8H^TV_P#SWB_[[%0?V18?\^R_F:/[(L/^
M?9?S- $_VFW_ .>\7_?8I?M,'_/>+_OL57_LBP_Y]E_,T?V18?\ /LOYF@"Q
M]IM_^>\7_?8H^TV__/>+_OL57_LBP_Y]E_,T?V18?\^R_F: +'VFW_Y[Q?\
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M1_9%A_S[+^9H L?:;?\ Y[Q?]]BC[3;_ //>+_OL57_LBP_Y]E_,T?V18?\
M/LOYF@"Q]IM_^>\7_?8H^TV__/>+_OL57_LBP_Y]E_,T?V18?\^R_F: +'VF
MW_Y[Q?\ ?8H^TV__ #WB_P"^Q5?^R+#_ )]E_,T?V18?\^R_F: +'VFW_P">
M\7_?8H^TV_\ SWB_[[%5_P"R+#_GV7\S1_9%A_S[+^9H L?:;?\ Y[Q?]]BC
M[3;_ //>+_OL57_LBP_Y]E_,T?V18?\ /LOYF@"Q]IM_^>\7_?8H^TV__/>+
M_OL57_LBP_Y]E_,T?V18?\^R_F: +'VFW_Y[Q?\ ?8H^TV__ #WB_P"^Q5?^
MR+#_ )]E_,T?V18?\^R_F: +'VFW_P">\7_?8H^TV_\ SWB_[[%5_P"R+#_G
MV7\S1_9%A_S[+^9H L?:;?\ Y[Q?]]BC[3;_ //>+_OL57_LBP_Y]E_,T?V1
M8?\ /LOYF@"Q]IM_^>\7_?8H^TV__/>+_OL57_LBP_Y]E_,T?V18?\^R_F:
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M'VFW_P">\7_?8H^TV_\ SWB_[[%5_P"R+#_GV7\S1_9%A_S[+^9H L?:;?\
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MTV__ #WB_P"^Q5?^R+#_ )]E_,T?V18?\^R_F: +'VFW_P">\7_?8H^TV_\
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M]IM_^>\7_?8H^TV__/>+_OL57_LBP_Y]E_,T?V18?\^R_F: +'VFW_Y[Q?\
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M1_9%A_S[+^9H L?:;?\ Y[Q?]]BC[3;_ //>+_OL57_LBP_Y]E_,T?V18?\
M/LOYF@"Q]IM_^>\7_?8H^TV__/>+_OL57_LBP_Y]E_,T?V18?\^R_F: +'VF
MW_Y[Q?\ ?8H^TV__ #WB_P"^Q5?^R+#_ )]E_,T?V18?\^R_F: +'VFW_P">
M\7_?8H^TV_\ SWB_[[%5_P"R+#_GV7\S1_9%A_S[+^9H L?:;?\ Y[Q?]]BC
M[3;_ //>+_OL57_LBP_Y]E_,T?V18?\ /LOYF@"Q]IM_^>\7_?8H^TV__/>+
M_OL57_LBP_Y]E_,T?V18?\^R_F: +'VFW_Y[Q?\ ?8H^TV__ #WB_P"^Q5?^
MR+#_ )]E_,T?V18?\^R_F: +'VFW_P">\7_?8H^TV_\ SWB_[[%5_P"R+#_G
MV7\S1_9%A_S[+^9H L?:;?\ Y[Q?]]BC[3;_ //>+_OL57_LBP_Y]E_,T?V1
M8?\ /LOYF@"Q]IM_^>\7_?8H^TV__/>+_OL57_LBP_Y]E_,T?V18?\^R_F:
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M'VFW_P">\7_?8H^TV_\ SWB_[[%5_P"R+#_GV7\S1_9%A_S[+^9H L?:;?\
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MTV__ #WB_P"^Q5?^R+#_ )]E_,T?V18?\^R_F: +'VFW_P">\7_?8H^TV_\
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M]IM_^>\7_?8H^TV__/>+_OL57_LBP_Y]E_,T?V18?\^R_F: +'VFW_Y[Q?\
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M1_9%A_S[+^9H L?:;?\ Y[Q?]]BC[3;_ //>+_OL57_LBP_Y]E_,T?V18?\
M/LOYF@"Q]IM_^>\7_?8H^TV__/>+_OL57_LBP_Y]E_,T?V18?\^R_F: +'VF
MW_Y[Q?\ ?8H^TV__ #WB_P"^Q5?^R+#_ )]E_,T?V18?\^R_F: $O[B!M/N
M)HR3&V &'I4NG?\ (-MO^N2_RJI>Z791V,[I;J&6-B#D\'%6]._Y!MM_UR7^
M5 %FBBB@ HHHH **** ,U_\ D8XO^O<_S-:59K_\C'%_U[G^9K2H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *V
MH_\ (-N?^N3?RHT[_D&VW_7)?Y4:C_R#;G_KDW\J-._Y!MM_UR7^5 %FBBB@
M HHHH **** ,U_\ D8XO^O<_S-:59K_\C'%_U[G^9K2H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@".=BEO*ZG#*A(/X5A_P!I7?\ SV_\
M='^%;=U_QZ3?]<V_E7,UI! 6_P"TKO\ Y[?^.C_"C^TKO_GM_P".C_"JE%59
M"+?]I7?_ #V_\='^%']I7?\ SV_\='^%5**+("W_ &E=_P#/;_QT?X4?VE=_
M\]O_ !T?X54HHL@+?]I7?_/;_P ='^%']I7?_/;_ ,='^%5**+("W_:5W_SV
M_P#'1_A1_:5W_P ]O_'1_A52BBR M_VE=_\ /;_QT?X4?VE=_P#/;_QT?X54
MHZ460%O^TKO_ )[?^.C_  H_M*[_ .>W_CH_PJIUHHL@+?\ :5W_ ,]O_'1_
MA1_:5W_SV_\ '1_A52BBR M_VE=_\]O_ !T?X4?VE=_\]O\ QT?X54HHL@+?
M]I7?_/;_ ,='^%']I7?_ #V_\='^%5**+("W_:5W_P ]O_'1_A1_:5W_ ,]O
M_'1_A52BBR M_P!I7?\ SV_\='^%']I7?_/;_P ='^%5**+("W_:5W_SV_\
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M./MD0PT8]77T]QZT6!,Z;(SBBH8Y%F198R&C<!E8<Y![BIJ0)A1110,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#3T_4-F
M(9C\O\+'M6Q7*5IZ?J&S$,Q^7^%CVJ)1ZH#8HHHK,84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6U
M'_D&W/\ UR;^5&G?\@VV_P"N2_RHU'_D&W/_ %R;^5&G?\@VV_ZY+_*@"S11
M10 4444 %%%% &:__(QQ?]>Y_F:TJS7_ .1CB_Z]S_,UI4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7QA?^#[*PGL8+:4SRLCB=6/ &>,$5C7?Q)UO5KAE\'^'Y;VV11NN;B%]I;N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $5U_P >DW_7-OY5S-=-=?\
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M\4,D TR\S\\%_&JG&>&R#W%=(7 -0S5/0=1112&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 :>GZALQ#,?E_A8]JV
M*Y2M/3]0V8AF/R_PL>U1*/5 ;%%%%9C"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#A/BGXHO_#.B6;:7<>1>7%QC?Y:O
M\@4[AA@>Y7M70>$+F_O/".F7>IS&:\N(1,\A55R&^9>%P/ND?_KKR[XV74MQ
MK^DZ8F6VP&15'=G;;_[)7LMC:K8V%M:(24@B6)2>X4 ?TH K:[?'3/#^HWRM
MM:WMI)5/'4*2.O'6N)^%/B/7?$D6J3ZQ??:(X6C2$>4B8)W%ONJ/]FM/XJ7H
ML_A_?KD[[AHX5QZE@3^@-4O@[9&V\#+.4 -U<R2!NY PG\U- 'H%%>26'QG;
M&HG4M.C$D6U;2"W9MTCY((+'MTYQZ]<BJ=]\5O&%@ZSW7AN*ULW/R?:+>92P
M]G) /7TH ]GHK%\*^([?Q5H$.J01F$L2DD1;<8W'49[]CGT-8WC/XBZ=X286
MHC-YJ++N\A&P(QV+GMGTZ_3B@#LZ\G\:ZSJ,_P 5-&T6QU*\MK?,*W"6\S)D
MLY+9P<'Y,=15(?%7Q?"BZA<>&4&EYR7\B5 1[2$E?QQ57PIJ \7?&@ZS'$PA
M6-I0C#[BB(1C/7G)'XT >E^.UUMO"5V- :07V5_U/$A3/S;/?'X]<<UF_#)O
M$C>'YAXB6Z#B;]P;O/FE<<YSSC/3//)[8K(\>>/_ !'X7UEX;+2H6TY0BBZN
M;>7:TA&XJ'#!3QV'H:[/PEJE[K?A:PU+4(HH[FX0NRP@A0-QVX!)/W<'K0!M
M45YEXE^*TEMJ[Z1X;TX:E<HVPRD,ZE^A547EN<<Y_/K47A_XD^([GQ%:Z+K'
MAT17%TV$VI) 4&,[BK[B0 "3TXH ]2HK-UW7M.\-Z8^H:E-Y4(.U0!EG;!(5
M1W)P?Z\5Y?)\6_$6JW+KX>\.":)6P-T4D[$=LA,8/?'- 'L5>7?&37[W2K;2
MK73[VYM9I7>1WMY6C.U0  2",\M^E;O@+Q;JWB9]0@U;3$LI[+8&PKH26W<;
M6Y&-OK7#^/U.O_%S2]('SQQ>1$ZX!P"V]B0>ORG/X4 >O:+!/;:%80W4DDMP
MEO&LKRDEF?:-Q)))SG-7J*\X\5?%6'2]2;2M$LQJ-ZK;&;)*!N<J .6(XZ4
M>CT5XQ)\6/%FDW$7]M^'8H(G(^5H)8&8=\%B?Y5ZGHFO66O:%#JUM(%MW4LV
M\@&,C[P;TQ0!J45Y/JGQ;O[O5)+'PIHWV\(Q E:-Y#(!W"+@@<'J?P%:7@WX
M@ZUKFO\ ]B:KH0M[I4:21UWQ^6H_O(P)[@=>N/6@#T:BL/Q/XKTSPG8"YU"0
M[WSY,"#+RD8SCZ9&2:\W7XJ>+]4;S-&\,+) <XQ!+.?^^EP/TH ]DHKSOP3\
M3'\0ZO\ V-JE@+2_?<8S'D*V!DJ0>0< G\*ZKQ-XHT[PIIGVS4')+';%"F"\
MK>@'MW/;\J -JO//B]KEUI'ANTCL;R>UN;BY'SPN4;8JDGD'/4K7/?\ "UO%
MFIF2;1?#226J9RWD2S[1[LI '2N<\6>+9/']UH=DMFUM<)(87B#$YD=E&0?3
MCIC(YZT >X^&$G3PMI0N9YI[AK6-Y9)G+,S%03DGGJ>]:U(JA%"J % P !P!
M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5M1_Y!MS_ -<F
M_E1IW_(-MO\ KDO\J-1_Y!MS_P!<F_E1IW_(-MO^N2_RH LT444 %%%% !11
M10!FO_R,<7_7N?YFM*LU_P#D8XO^O<_S-:5 !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!C^+?\ D3-=_P"P?<?^BVK@?@=_R"-6_P"NZ?\ H)KTS4[,:CI-Y9$@
M"X@>')Z#<I']:\/^&WBB'P7K6HZ3KBO;QS.$9B,^3*I(Y [')R?84 >]5X=_
MS<%_V]_^TJ].O?'GA>QL6NFUJSF 7(C@F621CC. H.<_7'O7EW@&.Y\6?%*Y
M\0M RVT3R7#9)PNX%43..3R/3A3]* -[XX_\@C2?^N[_ /H(KT#PM!%;^$](
MBAC6-!9Q':HP,E02?J22?QKS_P"./_((TG_KN_\ Z"*]#\._\BQI/_7G#_Z
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M<[0H(&?3)-;/Q>B23P!.SH&:.>)D)_A.<9'X$C\:R?@A_P B[J7_ %]C_P!
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MMY$+S=$)$I8D'T 8<^QH ]\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDP:<+$VT5N6,3V[D.I;&<DYW9P/O9Z5UM% %;3[,:=I]O9K--.L*!!).VYV
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"MJ/_(-N?\ KDW\
MJ-._Y!MM_P!<E_E1J/\ R#;G_KDW\J-._P"0;;?]<E_E0!9HHHH **** "BB
MB@#-?_D8XO\ KW/\S6E6:_\ R,<7_7N?YFM*@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH7O_ $"Y/^_@_P */[0O?^@7)_W\'^% &E16;_:%[_T"Y/\ OX/\*/[0O?\
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M] N3_OX/\*/[0O?^@7)_W\'^% &E16;_ &A>_P#0+D_[^#_"C^T+W_H%R?\
M?P?X4 :5%9O]H7O_ $"Y/^_@_P */[0O?^@7)_W\'^% &E16;_:%[_T"Y/\
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M^#_"C^T+W_H%R?\ ?P?X4 :5%9O]H7O_ $"Y/^_@_P */[0O?^@7)_W\'^%
M&E16;_:%[_T"Y/\ OX/\*/[0O?\ H%R?]_!_A0!I45F_VA>_] N3_OX/\*/[
M0O?^@7)_W\'^% &E16;_ &A>_P#0+D_[^#_"C^T+W_H%R?\ ?P?X4 :5%9O]
MH7O_ $"Y/^_@_P */[0O?^@7)_W\'^% &E16;_:%[_T"Y/\ OX/\*/[0O?\
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M] N3_OX/\*/[0O?^@7)_W\'^% &E16;_ &A>_P#0+D_[^#_"C^T+W_H%R?\
M?P?X4 :5%9O]H7O_ $"Y/^_@_P */[0O?^@7)_W\'^% &E16;_:%[_T"Y/\
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M^%']H7O_ $"Y/^_@_P * -'%&*SO[0O?^@7)_P!_!_A1_:%[_P! N3_OX/\
M"@#1Q1BL[^T+W_H%R?\ ?P?X4?VA>_\ 0+D_[^#_  H T<48K._M"]_Z!<G_
M '\'^%']H7O_ $"Y/^_@_P * -'%&*SO[0O?^@7)_P!_!_A1_:%[_P! N3_O
MX/\ "@#1Q1BL[^T+W_H%R?\ ?P?X4?VA>_\ 0+D_[^#_  H T<48K._M"]_Z
M!<G_ '\'^%']H7O_ $"Y/^_@_P * -'%&*SO[0O?^@7)_P!_!_A1_:%[_P!
MN3_OX/\ "@#1Q1BL[^T+W_H%R?\ ?P?X4?VA>_\ 0+D_[^#_  H T<48K._M
M"]_Z!<G_ '\'^%']H7O_ $"Y/^_@_P * -'%&*SO[0O?^@7)_P!_!_A1_:%[
M_P! N3_OX/\ "@#1Q1BL[^T+W_H%R?\ ?P?X4?VA>_\ 0+D_[^#_  H T<48
MK._M"]_Z!<G_ '\'^%']H7O_ $"Y/^_@_P * -'%&*SO[0O?^@7)_P!_!_A1
M_:%[_P! N3_OX/\ "@#1Q1BL[^T+W_H%R?\ ?P?X4?VA>_\ 0+D_[^#_  H
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M!<G_ '\'^%']H7O_ $"Y/^_@_P * -*BLW^T+W_H%R?]_!_A1_:%[_T"Y/\
MOX/\* -*BLW^T+W_ *!<G_?P?X4?VA>_] N3_OX/\* -*BLW^T+W_H%R?]_!
M_A1_:%[_ - N3_OX/\* -*BLW^T+W_H%R?\ ?P?X4?VA>_\ 0+D_[^#_  H
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MW\'^%']H7O\ T"Y/^_@_PH TJ*S?[0O?^@7)_P!_!_A1_:%[_P! N3_OX/\
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MG_?P?X4?VA>_] N3_OX/\* -*BLW^T+W_H%R?]_!_A1_:%[_ - N3_OX/\*
M-*BLW^T+W_H%R?\ ?P?X4?VA>_\ 0+D_[^#_  H TJ*S?[0O?^@7)_W\'^%'
M]H7O_0+D_P"_@_PH TJ*S?[0O?\ H%R?]_!_A1_:%[_T"Y/^_@_PH TJ*S?[
M0O?^@7)_W\'^%']H7O\ T"Y/^_@_PH TJ*S?[0O?^@7)_P!_!_A1_:%[_P!
MN3_OX/\ "@#2HK-_M"]_Z!<G_?P?X4?VA>_] N3_ +^#_"@#2HK-_M"]_P"@
M7)_W\'^%']H7O_0+D_[^#_"@#2HK-_M"]_Z!<G_?P?X4?VA>_P#0+D_[^#_"
M@#2HK-_M"]_Z!<G_ '\'^%']H7O_ $"Y/^_@_P * -*BLW^T+W_H%R?]_!_A
M1_:%[_T"Y/\ OX/\* -*BLW^T+W_ *!<G_?P?X4?VA>_] N3_OX/\* -*BLW
M^T+W_H%R?]_!_A1_:%[_ - N3_OX/\* -*BLW^T+W_H%R?\ ?P?X4?VA>_\
M0+D_[^#_  H TJ*S?[0O?^@7)_W\'^%']H7O_0+D_P"_@_PH TJ*S?[0O?\
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MS?[0O?\ H%R?]_!_A1_:%[_T"Y/^_@_PH TJ*S?[0O?^@7)_W\'^%']H7O\
MT"Y/^_@_PH LZC_R#;G_ *Y-_*C3O^0;;?\ 7)?Y51N;N]GM98O[,D7>I7.\
M'&?PJ_8HT=A;HZE66-00>W% %BBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img97084416_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img97084416_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <"#E4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HH) !). *R;KQ-H]HQ62^C9AVCR_\ +BJC"4](JYG4K4Z2O4DEZNQK
M45R[^/-)5L"*[<>H1?ZM2Q^.])<X:.Z3W9!_0FMOJM;^5G+_ &GA+V]HCIZ*
MS+7Q%I-X0(;Z+<>BN=A_7%:=8RA*+M)6.NG5A45X-->04445)84444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'RM_ST _J*\;%X+V:YZ>Q]9E><>W:HUOBZ/O_P $ZBBBBO./H HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)[K1A1117,>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4BS1)*ARKJ&!]C7A8^BJ=3F6S/M,CQCK473F]8_ET'T445P'MA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/5
MKG['I%W<#.4B8KCUQQ^M>.UZKXL<IX8O2/11^; 5Y57M99']W)^9\CQ%-NO"
M'97^]_\  "BBBO2/G@K3TS7;W2()XK,HAF()<KDC'IGCOZ5F45,HQDK25T73
MJ3I2YH.S.I\)WES?>*5FNIGED,3\L<X^GI6YX]_Y 4'_ %\K_P"@M7.>"?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,KQ)$9O#E\J]1$6_+G^E>35[7-$L\,D3C*.I5A[$8KQJZMWM+N:VD^_$Y0_4
M'%>QED_=E$^4XBI/GA4\K?U]Y#1117J'S84444 =%X)_Y&-/^N3UT?CW_D!0
M?]?*_P#H+5SG@G_D8T_ZY/71^/?^0%!_U\K_ .@M7E5_]\B?2X/_ )%-3Y_H
M>=4445ZI\T%%%% !7M%G$8;*WB/5(U7\A7E&@V1O];M(-I*[PSX'\(Y/\J]=
MKR,SGK&)]3PY2:C.H^MD%%%%>4?3!1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNSID420Q)%&H6-%"JH[ =!3Z^;KU75FYL_0,'AHX:BJ4>GYA11161U!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5YGXQTK[!JYGC7$-SEQCLW\0_K^->F51U;2[?5[%K:<8[HXZHW8B
MNG"U_8U+O;J>?F>#^MT'!?$M4>/T59O[&?3;V2UN%VNA_ CL1[56KZ)--71\
M#*+BW&2LT%=JGQ V1JO]F9V@#/VC_P"QKBJ*RJT*=6W.KV.C#8ROAK^QE:_D
MOU.W_P"%A?\ 4+_\F/\ [&C_ (6%_P!0O_R8_P#L:XBBLOJ.'_E_%_YG7_;.
M._G_  7^1O\ B#Q+_;L$,7V3R/+8MGS-V>/H*P***Z*=.-./+%:'!7KU*\W4
MJ.["BBNE\)^'AJEP;JZ1OLD1X':1O3Z>M*K4C3BY2*P^'GB*BIT]V=)X,TDV
M&F&YF0K/<G.".50=!^/7\172T45\W5J.I-S?4_0<-0CAZ4:4=D%%%%9FX444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B?3
M&U719(XUW3QD21 =R.H_$9_2MBBJA-PDI+H9UJ4:U-TY;/0\1(()!&"**[#Q
MCX>,$K:E9QGRG.9E7^$_WOH:X^OI:-6-6"E$_/<7A9X:JZ<_^'"M71M?N]$=
M_LXC=)""Z..N,]^W6LJBKG",URR5T94JLZ4U.F[-';1_$(X ETT'U*S?TQ4=
MQ\0)V5A;V"1GLSR%OT %<;17-]2H7OR_F=[SC&M6Y_P7^1:O]2N]3F\V[G:5
MAT!Z+]!T%5:**ZDE%61YTIRF^:3NPHHJQ964^H726UM&7D<\#T]S[4-I*[%&
M+DU&*NV:_A'23J.L)+(N;>W_ 'CY'!;^$?GS] :]/JAI.E0:18I;PJ,XS(_=
MV]:OU\[BZ_MJEULMC[W+,%]4H<K^)ZL****YCT0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU-3@   # %%>1B,3.L]=NQ]7@<NI8./NZRZL****YCT HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /(^ZU_U\M_2O3/!_P -/#.K^$M-U"\M9GN)XM[L)V )R>P-:M0BDVA',_\
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MI1=D![)\2/'EUX.6PAT^&WENK@LS"=69508'9AR2?T-=9H&I_P!L^'M.U([
M]S;I(X3.%8@;@,^AR*^>OB5JS:YXXU"2/+P6>+9",D!4."?IO+?F*]@^$]Z;
MSX?62$DM;O)"23Z,2/T8#\*F4;13 [:BBBLAA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<G\0O%5WX0T"#4+."&:22Z6$K-G !5VSP1S\
MHKK*\U^-W_(EV?\ V$$_]%R54%>2 X]OC=XC+'98:4%[ QR$_P#H=30?''6E
M(^T:7I\@[^7O3^9-87PQ\.:;XG\2W-EJD3R0)9M*H5RIW!T'4>S&O3+WX,>&
M;B-A;27MK)@[2LH< XXR&!R/;(^M;2Y$[-"%\/\ Q@T/5YX[:^AETV>1MJF1
M@\63T^<8Q^( ]Z]$KY2\3^'+SPMK<NFWF&90'CD7I(AZ,/R(^H->Y?"76YM7
M\%I%<.7FL93;[FZE, KS[ X_X#43@DKH#NZ**CGGAM86FN)8X8DY9Y&"J/J3
M60R2HKFXCM+2:YE.(H4:1SZ #)JA%XDT*XF\F'6]-DEZ;$ND+?D#6C+$D\+Q
M2*&C=2K*>X/!% 'BR?'"_.L@OIEJNF&0#;\WG!/7=G!/?&/;WKVJ-UEC61#E
M6 8'U!KRY/@?I:ZJ)FU2Y>Q# _9C& Q&>A<'IVZ UZDJJBA5 "@8  X JY\O
MV0%HHJI>ZKIVF@&_O[6U!Z&>94S^9J +=%4K+5],U(D6&HVET0,D03J^!TSP
M:M2RQP1M)+(L<:\EG. /QH ?164GB?0))/+CUS3&DZ;5NXR?RS6K0 4444 %
M%9UWX@T6PF,5YJ]A;RC^":Y1#^1-6;6_L[]6:SNX+A5ZF&0.!^7T-%@+%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>% 5BW *H QN;.!G_:/)SUKLOCG&HU72) HWM!(I/J PQ_,_G6A\"@/LFMG
MR7A&?P>AR]WF \]U[P!XB\.67VR_LQ]E& TL3APF3@;L=.2*Z7X3^,KNPUR#
M0;N=I-/NLI"KL3Y,G4;?8GC'3)!]<^R>*(8Y_">KQRHKH;.7((_V"17S3X0)
M7QIH1!(/]H0#C_KHM*+YXNX'U6S*BEF("@9))X KY]\=?$V_UV[ELM*GDM=*
M0[<H<//@_>)'('H!^/MZG\4-2DTWP#J)B.'N MOGV<X;_P =S7SYH%QIUIKU
ME<ZM%++8Q2!Y8X5!9L<@8) P3C//3-32BMP9N:3\,_%.L627<%@(H' :-IY
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MG:=1E(KF,;6]MPZ?D?ZUH^12U Q_A7X'N]0U:U\07D1CTZW8R0EAS-(O3 ]
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MVEP&#5-5=%:<.L$;$<H,9;'UROY4HVC'F XVY^%?B^VL_M#:8'QRT44R.X_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#+F\,Z#<-NFT3396]7M(V/ZBK-II6G6&/L=A:VV/^>,*I[=A5NBG=@%%%%(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M']K7_P#S]2?G7N__  IKPO\ W+C_ +^FC_A37A?^Y<?]_31[2(6/"/[6O_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML4H_$536)]NW+X#5HHHKD.X**** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ)X74[E;8OYXH",3A_F?L0<9J ,'QGK=SX9\-W.I6D8EF4A0O) SW-87PO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%9UOX@T6[O!9VVKV$UT20(([E&<D9)&T'/&#^5:- !1110
M 4444 %%%% !1110 4444 %%%% !16-K?BS0_#DD<>K7Z6SR*712C,2!_N@U
MD)\4_!;L%&M#)];:4#\RE/E;Z =A163I?B;0];(73=5M;ASTC60;_P#OD\_I
M6M2L 45S^L>-O#F@7C6FIZFD%PJAC'Y;L<'I]T&LX?%3P6S #6AD\<VTP_\
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ML2R;LD>U7O%N@-XD\/7&E+,("<,DO;([&L7X:>!I_"BW=Q<WL5Q)/\H$)^4
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MEM+?XNQ1QP3^4MS,D*LWS(<, 6XYP,T1V8(^B*9)((P,@DL<  <FDFD,:C:
M69@HSTS67K)N(88+CS<F.7HHP/\ /%9I7&W9&K'*LH)&00<$$8(-/K,O;];&
MY@DV,5G&''IZ'ZUIT- F%%%%(84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SK\/_\
MDL-M_P!?%U_Z+DKZ*KYU^'__ "6&V_Z^+K_T7)7T56M7="0445RWCCQI:^#M
M)$K*LU]-E;: GJ?[S?[(_7I[C-*[LAG4T5X1IZ?$SQO$VHV^I7%K:L<QLLQM
MD;DC"A>2!TR?S)J-_$OC[X>ZC$NMO+=VTHX2YE\U) ./E?D@CT^F0:OV?2XK
MGO=%9.EZG9^*O#<=Y9S2I!>0E2T;E9(B1AAD=&!SR.XR*\G^'?B/6+#XASZ%
MKFI7=SO\RV N;AG"2H<@C<2.=I'OD5*C>_D,]NHIKND<;22,JHH)9F.  .YK
MR?P%X_N=:^(.J6=S-)):WY9K)68XB$><  ],IDGU(]S0HMIL#UJBD9E12S$!
M0,DD\ 5X?X4UW6?%_P 5&>/5;Y-,29[DVZ7$BQB)3A!MSC!.P$=#D_2B,;W8
M'N-%%%2!X=\<_P#D.:5_U[-_Z%6WH/PB\.:EX;TV]GFU 3W5I',Y250 S(&.
M!MZ<\5B?'/\ Y#FE?]>S?^A5ZQX1_P"1+T+_ +!UO_Z+6MFVH*PCQ?QM\-;O
MPA$NKZ3=S3V4;#<Q^66 D\$D=1T&1CGM7HOPK\5W7B7P[+%?N9+RQ<1M*>LB
M$?*2?[W!!^@/>K'Q4U*WL/ -]'-@R7>V")">K$@Y_  G\*Y?X$VDB6&M7A'[
MJ66*)3CN@8G_ -#%#?-"[ Y'XP_\E G_ .O>+^5>A?\ "D_#'E[?M.J9_O\
MG)G_ - Q^E>>_&'_ )*!/_U[Q?RKZ*HE)J*L!\^>+/AYJW@41ZSI.H336R,
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MFGP0_P"1+O/^PB__ *+CKTNE/XF,****@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ%7/4^%G2>W4445RC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /G7X?\ _)8;;_KXNO\ T7)7T57SK\/_ /DL
M-M_U\77_ *+DKZ*K6KNA(*^?/BK<2ZM\2QII9@L*PVR<9QO 8D#_ ('^E?0=
M?/GQ3B?2_B<-09&"RK!<*0?O;0%X]_DI4OB!GOEG:06%E!:6R!((4$:*!C
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M3$C<,S>G&<>_/:N<^"/AYT^V^()T 5U^S6Y/4\Y<_HHS]:(Z0;8';>.O&O\
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M%% 'S#\0?^1XU/\ ZZ#^0KOO@9_Q[:I_OBN!^(/_ "/&I_\ 70?R%=]\#/\
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M:G_UQ/\ *OF"#K'^%=%'83/K30O^0%9?]<5K0K/T+_D!67_7%:T*YV,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D9@JEF(
M '4FEK"\7V]U=>'IX[3)?JP7J5P>/Y54(\TE%NQ%23A!R2O8TK;4[*\W_9[F
M.39PV#TKR_XI:M$LL$T"M,J@H64' ;T-1>#]*NKO78Q);N;93F8$8&/?\<5Z
MQ+86D]H;66WC> C:4(XQ794BL+4]UW9Q4I/&4_WBLOS/DFZNYKR7?,V?0=A4
M%>V>*O@[!<;[K09! _)-N_W3Z!?3\:\@U+2;_1[IK:_M9()5ZJP_K4JISZW.
MV,5%62T*5=#X?O=RFT<\KRGTKGJD@F:WG25#RIS6U*I[.:D8XFBJU-P.ZHJ.
MWF6X@25#E6&:DKV$[JZ/EFFG9A7/>(;S)6U0\#E_Z5MW5PMK;/*Q VCCZUQ4
MLK32M*_WF.37)BZG+'E74]/+:'//VCV7YC***O:9H^H:S=+;:?:R3RMT"C^M
M>:>Z4:]5^"S?8]5U"6XS'%-$L<;,#AF!R1GZ5M>%?@];6NRZUV07$O46Z_='
MLWK7IJZ?:):"T6WC6 # 0# Q6,JD7H#3MH6-PQG(QZTM>7>-;F\TK4$L+6YF
M2TV!U7/ )["NH\":A>7^C,;MF?RVPCMU(YX_"KGA7&DJM]#EIXQ3K.C;5'4T
M445RG8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X/XBTU/
M!?Q,M]9U'4&F@FN&NU6$%IMN>C X&.HZ]!TKUFVO+>XL8+JTGB@LKE \(@3,
ML@/\JR_B+X8L=9T&XU"2Q>YO[.!C (V()[X('4=\5S'PS\5WE]%+I6I36=F8
M42.R9D6-R.044'&[@5J_>C<EH] 7]PZL$,#,>%_UD\G^ KR?QQX=O-#\3MXO
MEO%>U-W&_EI(?.1^NSI@  =<].U>KC:D;.A>&$G#SOS-,?1>XJ"\TZUU*T.G
MWUG'+;R $6A/"#.=[MU!I1=F),7P?XLMO&&D-?0020-'(8I(W.<-@'@]Q@UT
M->&:[X.U[2=?DU/PZ&AT: &YB>&;:(E1<MD$Y)X/KFNK\-?%W3M6FNUU2!--
MCA3>DK2;PPSC'3.>>@SWH<.L2KGI%<[XL7[5#8::<!;VZ6-W/91R0/<XK7T_
M5+'5;*.\L;J*>WDX21#P3Z?7VJ:>V@NE19XED".'7<,X8="*5.7))-D58<\'
M'N/C18HUC10J* J@=@*=37=(T9W8*BC)9C@ 5S7B#Q]H/AZTM[F>X-RMP2(Q
M:;9-V,9.<XXR.]2DV:'17-S!9VTES<RI%!$I9Y'. H'<FO$_'OBO5/$VJ?V;
MX?8W^CNB*4@@+^8Y.<-D9!R..G3-,UKQ7X@\9:Z^C6<4C:)?NL<2K!@F/</G
MW'N",GG P17;^#_!T'@Y;E;:]-W/>8Q(Z;8W5<_(,$X//6M$E'5[B;-#1/#^
MG:!9?8]/LA'(0)+A!(WF[\=58_> R1Z5I8^T*?E6\"=58;)X_P#/X4F%:'[D
MDD,9Y7/[ZW/L>X_SS5/6=<T_P_IZZIJT@E@5@()X1^\D;KMQQV!]JG<C<XGX
MM:[<6%A::*+7SK2[3SFEN@2RD'A5(Q@C\>M=MX T6RTCPK:O:6<EL]VBSS+*
MV7W$=_;TKR[PI:W5SXC?QA>ZI$-$BN',T]S)DG/ 0IS@\K_2O4_^%A>$O^@Y
M;?\ CW^%5).W*BT=-17,_P#"PO"7_0<MO_'O\*TM)\1Z/KK2KI>H0W31 %PA
M.5!Z=:SLQFI161I>JS7VM:Q92(BQV,L:1E<Y8,@8Y_$UG6?BN1O%E_I%[;K%
M;+.(+2Y7H\FQ7*-Z-ALCUP?2BS ZBBO/XO'%[/%I!EN](TT7EF]P\MX&V;ED
M"A5^<=CGJ>E=)X8UJ?6K.YDG6%O(N&A6XM\^5.  =Z9[<XZGD'FFXM ;E%%%
M2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^?;-#&H?SXUY YX9@:SAX:^+,ZB"2YU!8V&TLVIIC'OAR:]XHK15':P6/&M
M^"L\ES]I\27ZE=VXP6S%FD_WG(X_ $\]17L%M;06=M%;6T2101*$2-!@*!V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?E5_^S+#_GQMO^_2_P"%2BXA+A0XR3@>A/IFG--&CA&<!CT!-9ZC(/[,L/\
MGQMO^_2_X5+#:V]N28((HBW78@7/Y5+12 Y]O#UY%JU]?V&L/;?;61Y(S;HX
M!50HP3["GOX7M)X-4BN9'D&H2K,S#Y3$ZHJAE(Z$%00:W:*=V!SFD>$+72I+
M!O.:X^QV;VBB1!\P9P^X^_&*Z)5"J%4  = *6BANX!1112 **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\JM7MJP)/['MO^@G#^7_ ->C^Q[;_H)P_E_]>H_^$?U;_GQF_*C_ (1_5O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "$!@01D'@@URD?A;1!XLDD&G0?+
ML@38-H?<?FQZUU4KB*)Y#T52:\M3QY>'Q ;H0QB%P(]F.0N<]?7FNG#T9U%+
MD.7$XB%)QY^YZH    , 44R*59H4E7[K@$4^N8Z@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 C*&4J1D$8-<G_PK_3/[1^TAW$>[=Y7O]<U
MUM%:0JSIWY7:YG4HTZEN=7L( %4!0 !T I:**S- HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JN(IHP5BD0)S@,I)'ZU8HH SK6VO\ SV:[N%>,-N55'4]O
MI6C113;N)*P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A;% "T5"TS#IBF^
M>WH* +%%0"=O04]9,]<4 2449HH **** "BBB@ HHHH **** "BBB@ HHHH
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M0.XHWK_>'YT +13=Z_WA^=+N7^\/SH 6BC.:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&=U_Q_6A/&5D ^O!_D*/BO:>9I-G=@?ZJ7:3[$5B^ KK[/XHC0])HV3\>O\
M0UW'CNS^V>#[Y0,M&HD7ZBO/J>YBE+O_ ,,>_@W[7 2CVO\ YGA5*KF)UD7A
MD(8?4<T@Y&:*]4\H^C=*N%NM)M9U.0\8.:N5RWP^O/M?A&U!/S1 QG\./Z5U
M-?.58\LW$^LHSYZ<9=T%%%%0:!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%,9]M*[;159FR: '-)FF$YI,4UI%3K0(=3@<5!]IC]:>KJ_2@"=9<5,K;JJ8
MQ2AB*!ERBHXY,CFI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<DU-6#;S,C 9XK<C;=&#0(>IP:M*V152IH3DT#)Z*** "BBB@ HHHH ****
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M\/67AC2ETZP,I@#L^96W-D]><"M6LW:^@PHHHI %%%% !1110 4444 %%%%
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,CNRJ>DHEJBBBO-/7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWD4M4TEQUJ=9@U $M% YHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#C?)M9L9(4<*">I%95KXY\-7FFRZC%JT(M(G\MI)5:/YL9P P!/7M6?\5/\
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MPUJ?Q0URZUC6KJ1;-&V221X!)QD1Q@Y  !!_'N3FE&'5C/4H?B?X-FDV)K2
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M"#AQ^JG'UKUC5M1BTC2+S49L>7;0M*03C.!G'U/3\:B4;.PS*_X3CPY_;O\
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M^8T :/TJ2.0KUJNDR-QGFI,4 78Y ]2511RIJXAW+F@!U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XMXKM?LGB6[3
MH&;>/I_D5[37F'Q&M?+UB"X"\2I@GW_R*[<#*U2W<\G.8<U!2[,XRNI\ 77D
M>)1&3Q-$5_$<_P"-<M6AH-R;37[&8'&)E!/L>#_.O3JQYH-'SN&G[.M&79H]
M+^(%G]K\'WF!EHL2#\#7AM?1VHP"\TJY@(R)(F&/PKYR9#$[1MU1BI_ XKER
M^5X.)[F:0M.,NZ$KW/P%>?;/"-F2>8U\L_AQ7AE>J_"B[WZ;>6A;F.3<!['_
M .N36F.C>E?L99;/EKV[H]$HHI-R[MN1GTS7BGT(M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[:MQL,C^9M!!QC;C/'K1&2NVP/4J***R&%%%% #(YHIC((I4<QML<*P.UL
MX/H<$<>]>/\ Q=\':/I^E1ZW80Q6<YG6*2*,!4ER#R%Z!AC/'7G-5;_X=^.M
M)UNZU'1=1$\ES(TDDMO/Y#.22<,K''7MDU!+X ^('BJ[B_X2"Y\J*/@-<3JX
M0=RJ(2,_E6T4D[W$=[\)]2NM1\"6_P!J9G:WE>!'8DED&".3Z9Q] *\R^'1
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M3"9KKSL+CG!R<5VE%-S;5@.(^('Q!B\'Q1VMM"MQJDZ;T23.Q$R1N;'7D$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\^?#G_DK8_P"NES_Z
M"U?0=%5&5DT 4445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]!WN]D[NXCN:***Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAD,#D$4ZO+/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D(!ZTM,>0** (I(SGBH\8IS7!Z5$9": %*ANM,-M$>HJ1>:=M% B$6T
M0Z 5(J@<"GB/-2"+ S0!"RD#-1DYJ223/RU%0,*A>Y1#@FF75QY2_+UK*DD+
M29<?A0!IM>IGK3TO(VXS6/N7^[2[LL-JX- &\K!QQ2_=.16;:W1'RGK6BIW+
MF@"U%-\N#UILW(J =:>SY7% #!52_P#NU;'6JE\#MXH SQ2T@Z<TM !1110
M^%MK9K3A8LM9D"[WQ6I$FQ: 'U-$Y!Q4-2Q+SF@"X.E% Z44 %%%% !1110
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M5] -NBN-^&OB74/%6@WFH:D8O-%ZT:)$FU44(AP._4D\DGFNRIM6=@"BBBD
M4444 %%%% '/3^./#EOKHT274=NHF581#Y$A^=L8&[;CN.]=#7SYK7_)=8O^
MPM;?^A)7T'5RBE8 HHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MK*\0^(;#PQI1U'43((1(L8$:[F)8]A[#)^@/TK31TDC62-E9& *LIR"#W%%@
M'4444 %%%<CXZ\<?\(5#92?V=]L^U,ZX\_R]NW'^R<]::3;L@.NHK,\/:O\
MV]X?LM4\CR/M,>_RM^[;SC&<#/Y5IT@"BBB@ HHHH **** "BBB@ HHHH **
M** "BBHKFXAL[6:YN)!'#"C22.>BJ!DG\J ):*Y'PK\1-(\6ZC/86<5S#/&I
MD43* )$! R,$\\CC_P"OCKJ;36X!1112 **** "BBB@ HHHH **** "BBB@
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MG15BYLIK5]KH<=F'0U7KT$TU='CRBXNS"E4%F  R2<4@!)P!6UI.FL&%Q,N
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MP850Z4HD8'K0!H45#'*,<U,#D9H **** "BBB@ HHHH **** "BBB@ HHHH
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M)QBK,=HO!H CM;=E;<>E7Z -JX%%  :MP@!,U4IXE*KB@"T9E%)YZU3/-&*
M+PE4]*?6>&*U*DYSB@"W135<$=:=0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!F^(KN>P\,:M>6S[)X+.:6-\ [6
M5"0<'@\CO7DFA_%_4H] N8+N)M1UQI@+3]T K*1W" 9P0>!R=P]":]4\7?\
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MF_L]4NGET6&22,0I"FY/ERN" ">>.3WJ;X%WDLFGZS9,Q,4,D4B#/0N&!_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD+ 4
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MW_L'W'_HMJ\N^!?_ "$=9_ZY1?S:O5/%$,MQX2UF&&-Y)9+&=$1%)9F,;
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MJS%GXP)#D'GMAQSZ5]"UYG\3_ %SKTB:UHZ W\*;9H@=IE4="O'+CW/(  Z
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M \?'0;J4&VEN4@N(QDJ=V-LB^AP0?IVZ5H0_&3Q'8PFTU#2;>2\' 9T:-O\
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M'I_Z,DKW.P_Y!UM_UR3^0KS7XN>#+_6Q;:QID#7$UO'Y,L$:Y=DR2"H[X)/
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M,D>CR1,A!C\J.,CE2N>6.1M/7K[5W?B71D\0^'+_ $IF"&XBPC'HK@Y4GV#
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M^'S#FOH2JJ=!(\*^.'_(SZ=_UY#_ -#:O4+_ $*/Q)X CTJ1PAGM(MDA&=C
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MIU3/$-JRT+I8*,7>3N%-=PBEF/%.JN4:>3+<1CI[USI=SLD[;$L,CL"W*@\
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MJK_%4G)&*85*]:!D5Q]SBLN3[W-:[+N&*R[D;9,4 14444 % .'%%.1"[#%
M&M%_J13J;%Q&!3J )8H@X-1LI5B,58MNAI9]N/>@"FZ!UQ55M.5CFK9;%()0
M: *?]FKZU+%9K$:LY-&: "D)Q3E4MTH*XZT , SS3J*8\@0<T /R!U-)N7UK
M.GG+?=-0"63U- &SD'I16?;W&WAC5]6##(H L0S8.T]*+GDC!J <'BD9^<&@
M!>U5KF7Y"M61R*RKICYI% $(ZFEHHH *!PX-%% &I!-O4"IC6?8MEZT30!/
MV!BK-9ZDAJN1N&&* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?B1JC1Q6^F
M)N'F?O)#V('0?GG\J\[KVK7_  [9Z_;".?*2IRDJCE?_ *U<+-\.=568)'/
M\9."Y)! ^E>KA:]*-/E;LSYO,L'B)UG-*Z?8N_#W2E03ZU<?*B I$6Z8_B;^
MGYUR_B/5FUG6Y[G)\H'9$#V45W'BRY3P]X6ATNTRIE C# ]!WKS+I6F'7/)U
M7UV]#GQK]C3CA8]-7ZL*TM TMM8UFWM /D+;I#CHHZUFUZC\/]&^Q:6;^9")
MKKE<CHG;\^OY5IB*OLZ;?4PP.'^L5E'INSKXXUBC6-!A5  %.HHKPC[,****
M "BBB@ HHHH *Q_$/ANQ\161ANDQ(O\ JY5^\A_R:V**J,G%WCN3.$9KEDKH
M\<@^%^M/>F*62W2W4_ZW?RP]A@_K7I^A:#9^'[ 6MHA]7=N6<^IK4HK:KB:E
M56EL84,)2HN\5J%%%%<YTA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1136; H 1WVBJ[.6-#
ML2:;T&:!!1Q4$MTBCKS5&2].>#0!JX'K1Q6,+U\\FKD%XK8!/- %VI8WP:A#
M!AQ2]* '7!W&H13G!:F]*!E.Z8@XJB?O5ISQ[E)K,/WR* "BBB@ H'WQ12JI
M9AB@#7A_U0IU-AXB IU #HX]YQ1(AC.*DMOOU/(JD9/6@"B5##D52FL?,;(J
M^W!IOF <4 9W]GR#^(T#3W)!9B:T@V>E+F@""" 1CD5-1G-+L/6@!I-( 0<T
M['K10 ?6CCUIKR*HYJC-<M_": -'CUI.*R?M,GK4\%R3]XT 7ZFBE"<&H%8,
M,BEQ0!<F.8\@U2&>]/,AQ@]*:"#0 A8(*R[IRTG!XJ[>,53BLW.[DT %%%%
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MH **** "BBB@"CK,6H3Z-=PZ7)%'?21E87F8A5)XSD G@9(]\5Y]\/OAG?\
MA?7Y-3U2>SF*PE(1;NY*L2,DY4=LC\:]/HJE)I6 *JZE81:IIEU83C,5S$T3
M?1ABK5%2!Y7X#^'GB3PCXC6]EN]-DLY(VBN(XY9"Q7J" 4 R"!^&?6MWQ[\/
M+?Q>D=U;RK;:G$ @D8$I(G]UL>F>#_D=O15<[O<#PG3_  K\4M$06NG--';@
M\!+R(H/H&;^E6;_X4^,-<"WVI:O:37[G#+/*^$7L 0I'X# ^N:]MHJO:,5C'
M\*Z5/H?AC3],N7C>:WBV.T1)4G)Z9 /Z5Q?C?X5)KEY+JVBSK;:A(V^6*0D1
MR-_>!'*M^8/MR:],HJ5)IW0SQ&'0_BY:QBSBN;DPKP'-Y$W'U)W8KH?!/@+Q
M'IOB/_A(-<UDFY92CQ*YE:53QAW/0 A2 ,]!TQ7IM%-S; Q_%6E3ZYX8U#3+
M9XTFN(MB-*2%!R.N 3^E<[\-O!>H^#K?48]0FM93<M&4^SNS8VALYRH]:[JB
MIYG:P!7EO@KX;:QX;\7_ -K7ES8/;[9!MAD<M\W3@J!^M>I44*36@&#XL\*6
M'B[2?L5X6C=#NAG0 M&WX]CW'?\ 6O*H/!/Q(\,220:)=-);;LCR+I0C9[[)
M",'IGC\Z]SHIQFUH!XI:?"[Q1XDU5+WQ9?\ EQG'F?O1)+CT7&57_/!KV.PL
M;?3;""RM(Q'! @1% Z 58HHE)R *\VTOX>-9?%.[UDVRKI2@W%L=X_US8R H
M.0 2QZ8Z5Z3123:V *IZM:27^C7UG$5$D]O)$I8\ LI S[<U<HI ><_#CP!J
MO@_4KVXU"XLY4GA"*+=V8@@YYRHK8^(OA:^\7>'[>PL);>.6.Z68FX9@NT(X
M[ \_,*ZZBJYG>X'-^!?#]WX8\+0:7>R0R3QN[%H6)7!8D=0#^E=)112;N[@>
M9_$7X9S^)-0&KZ3)$EX4"312' EQP&!['''/& /QP;7P]\6)TCL)-0FM;9<)
MYK7:<+ZY0EZ]JHJE-I6 \4U3X):@1;#3-0M9&\O-S)=.ZEY,G[H"G"XQU.>M
M>D:]X>O-7\$'0H+N*WF:&.)Y2I92%QD#IUQU].U='12<V]P/"[7PC\4- C-M
MI<\C0$?=AO$V+] Y&#]!6AX;^%.K7FN#5?%EP&"R;VB\WS))F'3<W0+^.>,<
M=:]DHJO:,+!11168!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YE\1?AUJ_B[Q!;W]A<
MV,<4=JL)%P[AMP=SV4\?,*](MHVAM88F(+(BJ<=,@5+13<FU8#SSXD^!-4\8
MW6GRZ?/9Q+;HZO\ :'9222,8PI]*[30[&73/#^FV$S(TMK:Q0N4)*EE0 XSV
MXJ_10Y-JP'$?$CP=J'C"PL8-/FM8FMY6=C<,R@@C'&%-;_A72I]#\,:?IER\
M;S6\6QVB)*DY/3(!_2MBBCF=K >56GPSUJ#XC-XB:ZL#9G4)+K8)'\S:S$@8
MV8SSZUZK110Y-[@<C\0/!:^,-'2.!HHM1@?=!+)D#!^\K$ G!Z].H'O4?P]\
M.Z_X7TR73-5N+.>U5M]L8)&)CR<LN"HX)YZ]<^M=E13YG:P'ENG_  VUBT^)
M+^(Y+FP-FU]-<!%D?S-KEB!C;C/S#O7J5%%)R;W AO+2WO[.:TNHEEMYD*2(
MW1E(P17$?#SP=>>#]5\00S#?93/#]DG++F11O)R <@C< <@9/2N]HH3:5@/(
MI?A=K^J^-AK>L76FR6\ETLTT<<LA)0$8097T '6O7:**;DWN 5Y%J?PMUU/&
MTVNZ'=Z=#']J%U"LTD@(;(8@@*1C=GC/2O7:*(R<=@$7<5&X -CD Y&:6BBI
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@DT 3+)Y8XIK.6IM*!F@!K+D4Q8@#3RP!Q2CF@!R@=*G6%&%5NE.1V5LYXH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *UW:K<)D<..AK'>-HW*N""*W);F*'[[@'T[U1N+VWE&TQ%_0]*W
MIN2TMH<E>,'K>S,^D*AAA@"/0TKGGY <>A-,#/GE/_'JZ$<3[ L4:'*QH#["
MGU)%#YIQO53_ +1J\FECJ\F1_LBHE-+<TA2E+X49M13PN[A6^51R?4UT,5K#
M",J@SZFL:5S),['N:(5+O0=6CRQ7,1JH10JC %!(4$DX ZFEK(UNZ*1K A^]
MRWT]*UA%SE8YZM14X.3&7>MD,4M@,#^,BJ/]K7F<^:?R'^%4J*[XTH)6L>-/
M$59.]S5AUR93^]57'TP:U[6^@NU_=MANZGJ*Y.G1R/$X=&(8=Q43H1EMH:TL
M94@_>U1V=%4].O!>6^3_ *Q>&%7*X91<79GK0DIQ4D/\X^1Y3=,Y7VIE-<97
MCJ.:<.E*Q5V]QDHW1./537''J:[2N6U*V-M=L,?*QRI]JZL++5H\['P;2D4Z
M***[#S HHI54LP &2>U '2:,#_9ZYZ9.*T*@LH/L]G'&>H&3]:GKS)N\FSZ"
ME%QII/L6+%=UTH(R"#FDNK9K>3'\!Z&K&F1YD:0C@# J_*(I$*28(KFE4Y9G
M="CST_,P:JWEA#>#YQAQT8=:TY[0QDF,[U_6JQX.#UK:$^L6<M2EIRS1S\FA
MSJ?D96'UQ2+H=P3R54>I-=#16_UB9R?4J5S+MM%BB8-*WF,.W:M3H,"BE5&<
MX523Z"LI3<M9,Z*=*,%:"$IT4NQ]ZC)'0FEFA,>%<X8]0.U, P,"IT:--4QS
MNTC;G8L?>FT4A(49)P*!-]Q:4$J<@D'U%1"XA+;1,A/INJ2FT)-/8N0:A)'@
M2?.OZUJ12I,FY&R*Y^I(9G@?<A^H]:QG23V.FG7<=):HWZ*B@G6>,.OXCTJ6
MN9JQW)IJZ"BBB@84444 %%%% !1110!#/TJ 59E7<*K'@T",^^BW9.*RB/EQ
MWS71R('0BL:XM6C8L*!E.BGA=V<G!H*!1G(H %QM([UL6<>$!K/MK9I6S6U&
MNR,"@!Z\L*MC@5!&O&ZDDF!X% $S!6&":IR@*V!2%VSUI.O6@ R!0&!J-U)Z
M4B(5/- $N: ">E/6(O5F*+8.: *>T]Z*GF=3P*@%  2 #FJ$EVRL0*ENY-G>
ML\G)S0!,;IB<THO'W 5!10!KQN'0'/-/K+M93&_S'BM-7$@R* )8Y"@Q3"<M
MFDIH;)Q0 VX_U)K( PQK:==RXK,N8_+:@"&B@=** "D(R1BEJ6V3S'QB@#0M
M?]2*E/2D1=BXI: (D7#5*:ECAS0\)7F@"I);*X)/6J$D+*V *U<TFQ3U% &7
M%"S-@BKZ6RIS4NU1T%+0 =!BFDTC-0B$G- $\4A45)YQJ/%+B@1*)34BN#56
M@$YH&7:*@27'6I@<C- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP:M& XJ%AM.* ,^>T"<BJI1@>AK9(#=:;Y2>E %""V\SK5R. 1U(%"]*4F@
M)II/I36;/2G1H<Y- %B*4JM/\\U%BEQ0!*)B:D5\U5Z49(H NYHJNDF.M3*P
M;I0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8=)_\#8__BJ/^$N\-?\ 0PZ3_P"!L?\ \519@;-%8W_"7>&O^AATG_P-C_\
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MW))K4@N1,,"@"VDI6K*/O6J1J1'VB@!DG^L-)VH;ELT'I0!3NWRN*H"KERI
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M:;D]S0 4NTT XJ17!.* (]II1&WI5I8Q3F(1>E %(C'!I ,4Z0[FR*:QPI-
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M1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\
MQ-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'M
MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q
M\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5
M]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\
M(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:
M_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A
M>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_
M , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H
M_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#X
MFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A
M$?#7_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7
M_0O:3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:
M3_X!1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!
M1_\ Q-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\
MQ-'MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'M
MEV"Q\HT5]7?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-'MEV"Q
M\HT5]7?\(CX:_P"A>TG_ , H_P#XFJFJ>%/#D>D7KIH&E*ZP.59;.,$':>1Q
M1[9=@L?+E%2V]M/=W"6]M#)--(<)'&I9F/H .37IGAGX,:E?[+C7I_L%N>?(
MC(:9A[G[J_J?4"M')+<1YOI_V[^T(?[-^T?;=W[G[-N\S=_L[><_2OH_P)_P
MF7]GG_A*?L^W;^YS_P ?'_ ]ORXQ_P "]:V-!\+Z-X:M_*TJQCA)&'E^](_U
M8\GZ=/05KUSSJ<W084445F,**** "BBB@ HHHH **** "BBB@ H)Q2$X&:@>
M3- $Q<#O4;29J DYHH >3FD&*;10(E4+WJ557M57FI(WP:!DSL%%4GY?-37#
MYJ 4 (YPA-8T\KREN>!6E<R;5(K(8_>^M #6<MUIM%% #E;!J6&8QR$CN:@I
MZXV&@#=@;?'DT^JEG)^[ JW0 E+3D7><42)L- %6[0LGRUF8*G!K;X/6J=Q:
M;SN% %&BE*E3C%( 2<8H ,U8MHFWAL<416ID(-:$:"--N* '=A0:* >: +5N
M<)4C%&&":JK)@8J,DYSF@"60*#Q476BE!Q0 ;31M-/5P3BIUC!YH K"-CVI"
MI'6KQPBYQ525@QXH BV\YI20!S0*HW=SL.Q>2: 'SW2J/E/-4S?/GK5<L"#N
MSNS4?% &G!>9/S&KR2*PR*P%*@'.<U;M;AE8*U &MBFK(=V*4$%:B/#4 6B?
MD)K'O9"216HAS&:Q[L'>:!%9SG%-I6[4E P'%/7."P/2F4]?N-0!MV;YA%6:
MIV2GR@:N4")(C^\%6:K1#]X*LT#"BBB@ HHHH **** "BBB@ HHKG?%6OW6A
M_9/LT<+^=OW>:"<8VXQ@CUJZ=.522A'<QQ%>&'INK/9?\,=%17G7_">ZK_S[
MV?\ WPW_ ,51_P )[JO_ #[V?_?#?_%5U_V?6/,_MW!]W]QZ+17G7_">ZK_S
M[V?_ 'PW_P 51_PGNJ_\^]G_ -\-_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O
M9_\ ?#?_ !5'_">ZK_S[V?\ WPW_ ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G
M_P!\-_\ %4?\)[JO_/O9_P#?#?\ Q5']GU@_MW!]W]QZ+17G7_">ZK_S[V?_
M 'PW_P 51_PGNJ_\^]G_ -\-_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O9_\
M?#?_ !5'_">ZK_S[V?\ WPW_ ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G_P!\
M-_\ %4?\)[JO_/O9_P#?#?\ Q5']GU@_MW!]W]QZ+17G7_">ZK_S[V?_ 'PW
M_P 51_PGNJ_\^]G_ -\-_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O9_\ ?#?_
M !5'_">ZK_S[V?\ WPW_ ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G_P!\-_\
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M -\-_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O9_\ ?#?_ !5'_">ZK_S[V?\
MWPW_ ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G_P!\-_\ %4?\)[JO_/O9_P#?
M#?\ Q5']GU@_MW!]W]QZ+17G7_">ZK_S[V?_ 'PW_P 51_PGNJ_\^]G_ -\-
M_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O9_\ ?#?_ !5'_">ZK_S[V?\ WPW_
M ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G_P!\-_\ %4?\)[JO_/O9_P#?#?\
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M 'PW_P 51_PGNJ_\^]G_ -\-_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O9_\
M?#?_ !5'_">ZK_S[V?\ WPW_ ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G_P!\
M-_\ %4?\)[JO_/O9_P#?#?\ Q5']GU@_MW!]W]QZ+17G7_">ZK_S[V?_ 'PW
M_P 51_PGNJ_\^]G_ -\-_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O9_\ ?#?_
M !5'_">ZK_S[V?\ WPW_ ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G_P!\-_\
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M -\-_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O9_\ ?#?_ !5'_">ZK_S[V?\
MWPW_ ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G_P!\-_\ %4?\)[JO_/O9_P#?
M#?\ Q5']GU@_MW!]W]QZ+17G7_">ZK_S[V?_ 'PW_P 51_PGNJ_\^]G_ -\-
M_P#%4?V?6#^W<'W?W'HM%>=?\)[JO_/O9_\ ?#?_ !5'_">ZK_S[V?\ WPW_
M ,51_9]8/[=P?=_<>BT5YU_PGNJ_\^]G_P!\-_\ %4?\)[JO_/O9_P#?#?\
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MHQAL%(2%!)( '<TM8U]=F638AP@_6H-2Y)J4*'"@O[]J:FJ1$X9&'TYK(HH
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MFFLH<8-695#]*B*8H K_ &5/2E%NB]*D/!HYH .V**55+&G,F!0!$<TX#(H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#/Q9_]]M_\31_P@6J_\_%G_P!]M_\ $UZ+11_:%8/["P?9_>>=?\(%JO\
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M_P!]M_\ $UZ+11_:%8/["P?9_>>=?\(%JO\ S\6?_?;?_$T?\(%JO_/Q9_\
M?;?_ !->BT4?VA6#^PL'V?WGG7_"!:K_ ,_%G_WVW_Q-'_"!:K_S\6?_ 'VW
M_P 37HM%']H5@_L+!]G]YYU_P@6J_P#/Q9_]]M_\31_P@6J_\_%G_P!]M_\
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M_P#/Q9_]]M_\31_P@6J_\_%G_P!]M_\ $UZ+11_:%8/["P?9_>>=?\(%JO\
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M_P!]M_\ $UZ+11_:%8/["P?9_>>=?\(%JO\ S\6?_?;?_$T?\(%JO_/Q9_\
M?;?_ !->BT4?VA6#^PL'V?WGG7_"!:K_ ,_%G_WVW_Q-'_"!:K_S\6?_ 'VW
M_P 37HM%']H5@_L+!]G]YYU_P@6J_P#/Q9_]]M_\31_P@6J_\_%G_P!]M_\
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M,VY5![4V@""\D,=K(PZXP*P#UK;U+_CT/UK$H **** "IK:8P3*P/&>?I4-
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M@!V\TFXFCY?6CCUH <F-W-60L;#BJ?TIR.5- %T1J.@JI.</BK DRM5I>6H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"(3[XXK9M+5;:/U<]30!8HHH'6@"S ,(3ZT]@K##8Q4!F( 5. .]1DD]230
M]XP#\K TS!%)10 44]9"O4 CZ580HXR /RH J@$] :?Y1 RW JUC%5YWR=H[
M4 0]Z**:[K&A9C@"@!U-+HO5U'U-9-SJ,DA*QG8OMU-4B[$Y+'/K0!T@96^Z
MP/T.:6N;61U.58@^H-:EC?&0B*4_-V/K0!H58ADS\IZ]JKTH)!R* +M%(C;E
M!I: "BBB@ HHHH **** "BBB@!KC*D56<8-6Z@E7)S0!"0"IS6)>0,KEATK;
MJ*:$3+B@1S^TD9I-IJ]+8F,\57^SMGO0,C4%#R,YK2L8/E#$4RWLB6!:M.-
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M^H1(.2TEQ<-,XSZ#G)_'M7K/A/PAIO@_3WMK .\DI#3SR8W2$=.G0#)P/?\
M&E=1328'#_'3_D#Z1_U\/_Z"*Z;X5?\ )-=)_P"VW_HYZYGXZ?\ ('TC_KX?
M_P!!%=-\*O\ DFND_P#;;_T<]#_AH.IV5?./Q'3^Q?BA=75L-A$D5TFTD?-A
M23GKRP)_&OHZOG'XEO\ VK\3[JVB8'YX;92!GG:H/Y$FBEN#/HQW2.-I)&54
M4$LS'  '<U\_?#^=O$7Q<&J3H"7>>Z*D9"Y4A?RW#'T%>V^*96A\(ZU*APR6
M$[#ZB-J\7^"2*_C:Y9ADI8.R^QWQC^1-$/A; ]^KYU^('_)8;G_KXM?_ $7'
M7T57SK\0/^2PW/\ U\6O_HN.BEN#/HJBBBLAA7A_QPM?L_B#2=0CW))+ R;U
MXY1L@Y]?G_E7N%>0?'=%-MH;X^8/, ?8A/\  5=/X@9Z9X<U3^V_#FG:D1AK
MB!7<>C8^;]<UIUP_PD=G^'=BK'(2255]AO)_F36+XY^(VO\ AOQ-+ING6%G/
M;I&C;Y89&;)&3RK ?I1RWDT@/4J@O+?[78W%MNV>=$T>[&<9&,XKRWP9\2_$
M7B#Q99:7?Z?916T_F;WCAD5AM1F&"6(Z@=J]9I.+B]0.,TSP-H_A'PW?_9(O
M.O&M)!)=R@%V^4Y _NCV'MG.,UYM\$/^1TO/^P<__HR.O;]9_P"0'J'_ %[2
M?^@FO$/@A_R.EY_V#G_]&1U<6W%W$>^4445D,*\+^,%[/IOQ%TJ^MF"SV]G%
M+&2,C<LLA&?:O=*\#^-__(Z6?_8.3_T9)6E+XA,U'\&>,OB#"-5UG4X[&"4;
M[:S;<0JGD?(.!VY.6]:Y2\3Q5\+M<B@2^V!@)$$;EX)EZ<J?Q'(R.QZ&OHNP
M_P"0=;?]<D_D*\<^.O\ R$=&_P"N4O\ -:J$KNW0 A\+>,/B3;'5M4U465C/
M\UM;<E-N3C" X ]SR>*YV\B\3_"G7K<+=EK>3]X@5F,%P!]Y2OJ,_49!'6O=
M/"/_ ")>A?\ 8.M__1:UY_\ '50=*T=\?,)Y #[%1_@*(RO+EZ >FZ3J,6KZ
M19ZC!CR[F%90 <XR,X^HZ?A4>NZK#H>A7NISLH2VB+X)^\W\*_4G _&LGX>?
M\D_T7_KW_J:XOXW:]Y-A9:#$1NN#]HFYY"+PHQ[G)_X#4*-Y6&<]\./#3^+A
MXDU"_/F27$#PK*YP#-(=Q?CN" ?^!5:^"NJM8^(-0T.X^0W";U4]1)&<$?D2
M?^ UZ+\-M&_L3P-81.FV:X7[3+D8.7Y&?<+M'X5Y-XYAF\'?%4:I;J0DDJ7T
M?/WLGYQQZL''T-:7YFXB/H6OFSQ&-0/Q<NQI1 U Z@/LY.WA\C'WN.OK7T?;
MSQ75O%<0N'BE0.C#NI&0:^?[G_DNZ_\ 863^8J:6[!FS=_![Q+JL?VO4?$$,
M]\PR1,SN!QTWG\NE9&G>*?%7PW\0#3-:::XM!\SV\DF\,A)^>)CT[\=,Y! /
M3Z"KR_XWZ?#+X9LK_8//@NA&'[[&5LC\U7]:(SYG9@>DV-Y!J-C!>VSAX)XQ
M)&P[@C(J>N%^$5S+<?#^U65RWDRR1IGLN<@?J:[JLVK.PPHHHI %%%% !111
M0 4444 %%%% !1110 4R09Q3Z* *;<-2, 5(J61.<U%0(Q;NV*L6JIMR.M=%
M)$)5P:SYK  _**!F9M]Z=M*X/6K!M&STJQ!8C()% #;. L^YAUK55<#%-CB$
M8XIYZ9H$/4A.M#S9&!4)8FDH&*68]:8X)'%.) ZTWS$]10!%L>GKD=:D# ]*
M0B@"18RXR*=]G:FQR%3BKB,&% %=EVICO4'>I9G^;%14 (3M&35.XN.P-6+E
MP(^#S646+'F@!3(Y/6@22>M)10!:M[C:?F-7U8.,BL7H:T;:4;0,T 6NG2I-
M_P N*CI* %[U7O\ _4U.*;+&)%P: ,%ONK3:LSP>5)TXJN1D\"@!**7!]*-I
MZXH !D$5IZ<I')JG#'YDBX4X[UL1PK&HQ0!(>M)MW4&IH0#UH C*%13< ]:N
M,$*XS5*;Y3\M $4UNCKP*I-8L3TK05CWI^]: *4-H%/S"K:QHO04[.:,$T %
M-SDX%.*D=J54 YH 5 5%.ZT$X%5)[H(.#S0(N8H_&L8W\K'"TGVR<<_UH VL
M4E9L%\7(#&M!7##@T 2(Q!JRK;A53I4T+4 3T444#"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME% '102>; C^HYJ2JFG'-H!Z&K= $]NW5:GJK"<2BK5 !1110 4444 %%%%
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MC8.3CBH: "BBB@ I\!/FCTIE.@!\T4 ; ^Z**!]T4&@  S15B! R\TR2)@W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8Z!'4M% #0@%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRU3DNP1Q4(N"#UH T\TF,'-5DNUQBK",'&10!:BFSP:F8_(35#ITJ<3?)@T
M1,<FFYV]:.]17)Q$<4 4+Y@\@[C-46^\<4^1B7YIAZT )1110 \,3@ <BM&R
MF9FVMVK,3[PJ[9MB9C[T :QZU&YQTIX.12'GK0 *>*AG@$HR:L["%S3: ,9T
M9&(QQ29K4GA#KP.:I"R>@"#- !)JQ]B>IHK4J>: "S0J<D5=/6FA0!Q2T  Z
MU=B4! :K1QES5Q1A<4 +2%<TM% #/+%&P4^B@! ,4M%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"&'4445PGLA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB"9]"Q_^Q->@5RO@.W\O1YIS]Z68C\ !_4FN@U&]33M.GNY",1(2,]SV'XG
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MK:_WZG'>.=2N+1K*&UN9H7(9G\MRN1P!T_&KW@N2XGT9Y[F>:9WF(#2.6PH
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MJLY8JG"34()^9O3RRO6IQ=:JT[+1;+_@]V<[XH3538VT&E_:"V[,DD;D-@#
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M<<=.N/I4\NJ>)]94R6RW*09X^SH5'_?0Y/YU6\(Z?%J&N*L\0DBB0R,K=#C
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MN5WHKOUN4]'UVXTRQDM;" M=W$H^?&[ Q@ +W.<T^[E\4HC7-P^I1IR68%E
M_ =!78>$=+@L]&@N1#BYN$W.YZD$\ >@QBM\@,I5@"#P0>]75QD(U'RP3\V8
M8;*JM7#QYZK6FB6R_P S@/#?BNZ2]CM+^5IH9F"K(Y^9&/ Y[BO0*\?NHEBU
MV:&W^XMRRQXYX#8%>P5&/IPBXRBK7-LCKU9PG3J._*_\_P#(****\\]T****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *9*-T3 =Q3Z* >ISE(PW*5]1BI[J(Q7#KVSD?2H:[D[ZGDM6=F<;*-LK
MCT-,K0U:T,%TS@?(_(K/KU824HIH^=J0<).+"BBBF0%=#H2D6DA/0OQ^0K"A
MB:>98T&2QQ766\"V\"1+_".?<USXF24>4[L#3;GS]$2T^(9E0>],JS81^9=*
M>R\UP2=E<]B"O)(VJBFMHIA\Z\^HZU+17&FUL>HTFK,S)-+8<QOGV-5VLKA>
ML9/TYK;HK159(PEAH/8P?LT__/%_RJ1+&X?^#'UXK:HI^V8EA8]RC!IJ(0TA
MW'T[5>  &!THHK*4G+<WC",%9!1112*"BBB@ HHHH BN#MMW/M6#703+NA<>
MHKGZZ*.S.+%;H"0 2>@YKC[F0S7,CL<DFNO8;D9?48KC9!B1AZ&O1PO4\3,&
M[10VBBBNL\P**** .HTJ8S6*YY*';FKM9FAJ19,3G!?@?@*TZ\VJK3=CWJ#;
MI1;);9MES&WO6]7/PC,R >M=!7'6W1Z>%V84445B=04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $%Q56KDJY%5&X:@"*<_N
MC62?O&M>8?NC60?O&@ HHHH *D@.'J.IK5=TF* -*,Y6G=:15VC%*.HH <8R
MHS3#R,5=5-R<U7DC*MP.* ,RYM"S;DX(JA)&ZDYK>]JB:W1^M &&JL35J&U>
M3&3Q6@+.,=JE5 G2@ C0(@&.:<:,T^-"S=.* )($W<U:' IJH$'%.H *3 ]*
M6B@!-H]*-H]*6B@!-H]*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH JS#YJ@JY*F035/O0!#<C]V:ROXC6O<<Q&LD@@F@ HHHH *%^\**=$"9!Q0
M!H6X('-6#2(,(*6@"2) W6D="I]JDMAFIW0,,4 4" PQ56:S0Y('-7I8_+-,
M_"@#&DM'SP*$M'SR*V<#THPOI0!5@M%4 D<U:[8H^E'/I0 =>!5F",CK20P]
M&-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y7Q[.$T>"'G=),#^ !S_
M #%4/A];@R7UP1R J+^.2?Y"H_B!<%KVSMNR1M)_WT<?^RUL>![<Q>'_ #"H
M'G2LP/J!A?Y@UZC]S!>O^?\ P#YR/[[.&^D5^G^;.EHHILDBQ1/(YPB*68^@
M%>6?1MVU9Y1XDG:Y\1WK'J)?+ '^S\O]*]2LH#:V-O;G&8HE0XZ<#%>3:=']
MOURV1QQ-<+OY[%N:]@KT\P]V,*?9'SN1?O)UJ[ZO_-GD6MLTOB"_R>?M+J/P
M8@5JMX;\2:8S?9&D*?WK:?;G\,@_I5+Q3:/9^(KK.[;*WFHV,9!YX^AR/PKM
MM%\46.H6D:SW"0W07#K(0NX^H/3GTKIK5:D*4)4U=6U/.PN&HU,35IUY.,KZ
M:VZN_P"AR)\.^(]0;-Q',PS]Z>8'^9S71Z)X+@L9$N+Z1;B=3E44?(I_'K^E
M;-WKNEV41DFO8?948,Q^@'-7+6X2[M(;F,,$E19%#=0",\UPU<77E"UK+R/:
MPV68.%6]^>2UU=_Z^9+7E.O.^H>*;I5&7:?R5 ![84<?A7JU>.Z?<+;:S;7,
MX(6.=7?CD8;)K3+EK.2W2_K\CGS^2Y:5-[-_E_PYZ_#$L$$<*?<C4*OT Q3Z
MIKJVG-$)!?VVP\@F51_6K%O/%=0)/"X>-QE6'<5Y[C):M'NPG!^[%H\R\8NS
M>)[H$\($ ^FT'^M2Q>&]>MH8KJQ9BLD8D#03;2 1G!SCGZ5+XYLWAUL7/)2>
M,$'' (X(_0'\:W/#/B:SDTZ&SO)UAGB4(#(<*X'3GITXYKV74G'#PE35]-3Y
M*&'HU,?5IXB3B[MIWMU_R.=;0O$U_P#+.ERX&,^?/Q^IK:TCP,D3K-J<JR$<
MB&/[OXGO]/UKI9]8TVVB,DM];A1Z2 D_0#DU+I]]#J5DEW!N\IRVW<,'@D?T
MKCJ8NNX:+E7DCUJ&5X.-767/+>S=_P /\RP %4*H  X ':O)]=E-]XENRI#%
MIO+4CH<?*/Y5ZM+(L,3R-]U%+'Z"O*="B-]XEM P#%IO,8'H<?,?Y5>7^[SU
M'T1CGOO^RH+[3_X'ZGJT,2PPQQ)G:BA1GT'%/HHKS3Z!*RLCS;QQ,TGB#RR
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M>IF$_982;7:WWZ&-X#@$FM2S'_EE"<?4D#^6:]%KC_A_ 5LKRXP<22*@_P"
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M_IFN4\"M FL3-+(BN8ML88XR21T]ZPPJY<-4FNNG]?>=N9253,*%)[+7\?\
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MW,97JI=D>1P_3Y<,YOJPHHHKSSW0HHHH **** "BBB@ HHHH **** "BBB@
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M' ^ZIK2KEJSOHCNP]*WO,****Q.L**** "BBB@ HHHH **** "BBB@ HHHH
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MX SZ@>M=%113J5)5).4MR</0AAZ:I4]D%%%%0;!1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!CH&'3FJY@;-6Z* *7D,*0QL*O4TH#0!3\IC2^0U7 H%+0!
M6BA(/S"K  '2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q+[PII%\Q=K?
MR7)R6A.W/X=/TJDO@/2@P)FNR/0NO_Q-=116\<36BK*3..>7X6<N:5-7]#/T
M_0]-TP[K6U19/^>C?,WYGI^%:%%%92E*3O)W.FG3A3CRP5EY!1114EA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@ZGX
M3L=5OGNYYKD2. ,(R@# QQE36U!"EO;Q01_<C0(N?0#%245<JDY)1;T1C3P]
M*G-SA&S>X4445!L%<[:^#-.M;Z*[6:Z>2-Q( [*02#GGY:Z*BKA4G!-1=KF-
M7#TJS3J1O;8****@V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#F_$6N3:7J=C%$^V(_/,-H.Y<XQTXZ'I71@A@"""#R"*\Z\63>?X@F
M4'<(E5!@YQQD_J378>&KS[;H<#$Y>,>4WU'3],4P%\0ZA)INCR30MMF+!$;
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M:9'-:N$D:8(25!XPQ[_05ST.J>*KJ(30>:T;=&6!<']*U_&__(%A_P"OA?\
MT%JO^&?^1=L_]UO_ $(TP.;A\6:K8SB+48-PX+!X]CX]1T_E7:6MS%>6T=Q
MVZ.094UA>-(XVT5'91O64;3W&0<T[P:6.A<]!*V/IQ0!J:GJ=OI5H9[@GDX5
M1U8^E<DWB37=2F(T^ HH/2./>0/<D8_E5?6I9=:\4"T4X5)/(3VP?F/YY_*N
M\M+2&RMDM[= D:#@#^9]Z .+.M^);%E>ZA=DSC$D& 3Z9 %=O$9#"AE4+(5&
MX*<@'OBGT4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/Q3J%UINF1S6DOER
M-,%)V@\;6/<>PJWH5U->:+;7%P^^5P=S8 SR1VK+\;_\@6'_ *^%_P#06J_X
M9_Y%VS_W6_\ 0C0!K445FZWJW]C627'D>=ND";=^W'!.>A]* ,?2-<U2[\0R
M6=Q$!%EMRA,>5C..?K@<^M=-//%;0/-,X2-!EF/:L+1O%']K7_V7['Y7REMW
MF[NGM@5'XMU4VULU@+<OY\>3)NQMY],>U,#:T_4K?5(9);4LT:.4W$8R< \>
MW-6Z\]T+Q$VD63VXLC/ND+[A)MQP!CH?2NPL-5-]I#WY@,94,?++9Z>^*0#[
MK6;*TO(K.20FXD=4$:KD_,0 3VQS5^O,[W5VNM>BU(VQ0HZ-Y6[.=I'?'?'I
M73Z?XL>^OX;4Z<T8D;&\RYQ_X[3L!+XPN9[;28GMYI(G,X!:-BIQM;CBK^@R
MR3:':22NSNR<LQR3R>]9?C?_ ) L/_7PO_H+5H^'/^1?L_\ <_J:0&I15:_O
M[?3;5KBY<J@X&!DD^@KECXMU2[D/]GZ8'0=1L:0_IC% '945RFG^,0UP(-2M
M_().-ZYPOU!Y'UKJ@0P!!!!Y!% "T450UC4CI5C]I$!F.\+L#;>OX&@ M=9L
MKV_:SMI#)(B%V(7Y1@@8R>_-7Z\ST?5VTO4YKH6QE,B,NS=C&6!ZX/I79:)K
MS:Q+,C6A@\M0<E]V?T% &U16=J^LV^CVX>7YY&^Y$#RW^ KGX_$VNW*^;;:6
MKP^HB=OU!H [&BN>T7Q1%J4XM;B/R;@YVX^ZWM[&NAH ***S=;U;^QK)+CR/
M.W2!-N_;C@G/0^E &E17+7'BYI?*CTNS:XF90SC:3MXY7 Y./6JT'C&\@NQ%
MJ5FL:Y^;8K*R_@318#LJ*:CK+&LB$,C ,I'<&L+6_$\6F2_9X(Q/<?Q#/"?7
MW]J -^BN-;Q-KL,1GFTM5@Z[C$Z@>G.:W]'UNWUF%FB!25/OQMU'N#W% &G1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&2N<AAW(_P /YU/K>B0ZS;A6;RYT_P!7)C./8^HKD;1$M/&ZQ6IQ&MP4 '.
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M$?F^9\HZHW7'X$CZBO0(I8YXEEB<.C#*L#P10P'T4C,J(7=@JJ,DDX % (8
M@@@\@BD M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <UXW_P"0+#_U\+_Z"U7_
M  S_ ,B[9_[K?^A&J'C?_D"P_P#7PO\ Z"U7_#/_ "+MG_NM_P"A&@#6HHHH
M X+PM_R-$O\ NR?SKJ?$?_(OWG^Y_45RWA;_ )&B7_=D_G74^(_^1?O/]S^H
MI@9W@C_D"S?]?#?^@K72US/@AU.DSH#\PG)(]BJX_D:Z:D!PVL?\CU:_]=8?
MYBNYKA=;=8_&]N[G"K)"2?09%=U3 YKQO_R!8?\ KX7_ -!:M'PY_P B_9_[
MG]36=XW_ .0+#_U\+_Z"U:'AM@WAZS(.1L(_4T@.7\777GZY':O)MAA"@X&=
MN[DG\L5OVWB'P_9VZ00702-   (G_,\=:Y[Q/$MMXG6>>/?#)L<KG[P& 1^E
M=2F@:-+&LB643(P#*03R#^-,#GO%&I:3J=I&]M.'NHVP/W;#*]QDBNA\,SFX
M\/VK,Q9E!0Y]B0/TQ3CX>T<$ V40SP.3S^M7[>VAM(%@@C$<2YVJ.V3FD!+1
M110!PWA'_D8[O_KD_P#Z&M=S7"^$G5?$MR"<%HW ]SN!_H:[JA@<!=J=9\:F
MWER8Q+Y>,]%7.?Y$_C7?*JH@1%"JHP !@ 5P0;^S?'9>9<*T[').!AP><_\
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M_P#70[72;(:=I5M:=XT ;_>ZG]2:XNQ_Y*4W_7:7_P! :O0*\]M'6/XD,SG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 8?BG3[K4M,CAM(O,D68,1N
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M4 %%%% !1110 4444 %%%% !1110 4444 %8GBK3[K4M&^SVD7F2^:K;=P'
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ML[P376V1#M9?+8X/X"@#4HK'_P"$JT7_ )_?_(3_ .%'_"5:+_S^_P#D)_\
M"@#8HK.L]=TV_N!!;7/F2D$A=C#I]16C0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !165'X@M)=9.EK'-YX9EW%1MR 3Z
MY[>E:M !165IWB"TU.]DM(8YEDC4L2Z@# ('8GUK5H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ."C_P"1^/\ U\-_(UL>-_\ D"P_]?"_^@M6/'_R/Q_Z^&_D:V/&
M_P#R!8?^OA?_ $%J8%_PS_R+MG_NM_Z$:QO'7^JL?]Y_Z5L^&?\ D7;/_=;_
M -"-8WCK_56/^\_]*0'2Z9_R"K/_ *X)_P"@BN.\<?\ (5M_^N _]"-=CIG_
M ""K/_K@G_H(KCO''_(5M_\ K@/_ $(TT!U^K_\ (%OO^O>3_P!!-<YX%_U5
M]_O)_6NCU?\ Y M]_P!>\G_H)KG/ O\ JK[_ 'D_K0!L^)O^1=O/]U?_ $(5
M3\%_\@-_^N[?R%7/$W_(NWG^ZO\ Z$*I^"_^0&__ %W;^0H /&G_ " T_P"N
MZ_R-6O"O_(MVG_ __0VJKXT_Y :?]=U_D:M>%?\ D6[3_@?_ *&U(#G-)_Y'
MR?\ Z[S_ /LU=W7G]W(^@^,'NI(V:-I&DX_B5\YQ],G\JZ*7Q?I20%XY))'[
M1A"#^9XI@87_ #4#_MO_ .RU?\=?\>MG_OM_(5C:=--<>,(9IT,<DDNXH?X<
MC('Y5L^.O^/6S_WV_D* -O0?^0#9?]<A6-XY ^PVI[B0C]*V=!_Y -E_UR%8
MWCG_ (\+7_KJ?Y4@+ =X_ FZ/[WV7'X'@_I7.>'X]::.<Z3(J+D"3.WKSCJ/
MK78:/$EQX:MH9!E)(-C#V(P:Y2QN9_">L2PW43/"XP=O\0SPP_7\Z8&IY7C'
M_GO'^4?^%06NA:T^NP:A>A&82*TCAEZ#CH/85KGQ=HXAWB=RW_/,1G=_A^M6
M-%UN+65N&CC:/RG  ;NIZ'Z\'B@#4HHHI <-XO /B*T! (,29!_WVKN:X;Q=
M_P C':?]<D_]#:NYI@<MXX=QI]L@^XTI+?4#C^9JAI<7B;^S8/L,R+;$$H"$
MZ9]QGK72Z_IIU329($QYJD/'G^\.WXC(_&N:T#Q$NDQ-I]_%(JHQVD#E#W!'
MUS0!<\KQC_SWC_*/_"I/#&B7VEWDTMTJJCQ[1A@<G(JS<^,-*ACS"\EP^#A4
M0KS[DX_K6KIUXNH:?!=*"!(N2/0]#^N: .>UGPO-)>M?Z9)MF+;V0M@[L]5/
MZU5L?%-]I]P+75X68# +E=KJ/4^HK3B\86/VR:"X#1HCE4F W*P!ZX'(_7\*
MP?$^K6NKW%NEDK.4R"^S!;., =__ -= '5^(&5_#EVZ,&5HP00<@C(K*\#?\
M>%U_UU'\JN:C"]OX+:&3.]+9%;/8C%87A;7+/3(IH+MF0.P8.%)'3OCF@#NZ
MX'PBP7Q%((S\C1N/J,@_T%:FK>+[46LD6GL\DSC:)-I4)GOSSFE\':5):PR7
MTZ%6F4+&".=O7/X\?E0!EV*^9X^82#.+B4C\ V/Y"N]KAO$=G+I6NQ:K"A:)
MW#\] XZ@_7'ZGTK=B\6:3);B5YVC;',;(2P/IP,4 8OCD#[7:'OL;^=7?$6?
M^$/M=W7$6?\ OFL>=IO%GB >4C+;)A<_W$SR3[GFN@\8*$\/A5& )% 'YT 2
M>$/^1?C_ -]OYTGC  Z Y/:12/SI?"'_ "+\?^^W\Z/%_P#R+\G^^O\ .@ \
M(?\ (OQ_[[?SK,U7PM<PW;7VDN0V=_EAL,I[X/\ 2M+PB0OAZ,D@ .Y)/UJ&
MU\96$DLB7"O"H8['QN##/'3D&@"CIOBJZM;I;/5XR #M,A&&7ZCN/\\T_P <
MN3#8A3F-BYX[],?S-97B/48-:U* 6*-(57RP=F"YSQCOC_&NFUO1I+W08H$P
MUS;JI7'\1 P1^- &38P^*5L+?[+-&MN8P8P0GW2,CJ*FDM_%\L;1O-&58%2/
MW?(/X5!H'B:*PM5L;])%$;$+(!G:,]".O'-:EYXQTV&(_9B]Q)CY0$*C/N3B
M@!GA;1[W2GNC=!5$@7:%(.<9_P ?UKI*AL[E+RSBN8\A9%# 'M4U( HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OFKXJ_\E*U;_MC_ .B4KZ5KA_$'
MPLT/Q)KEQJUY=:BEQ<;=RPR(%&U0HP"A/11WJZ<E%W8,P=!^+OAS3?#>FV4\
M.H&>UM(X7"1*065 IP=W3CBN*^(/Q&?Q@D5C:6[VVG1/YF),;Y'Y )QP  >@
MSR>IXQZ!_P *0\-?\_VK?]_8_P#XW6SI'PN\*Z/<"X6Q:[E7[INV\P#K_#]T
M]>X[#%6I03NA'/\ P8\-7&FZ7=ZQ=Q&-KW:D"MD-Y:DY)'N>GT]#SYU\0/#-
MSX4\63211NEE/*9[.4#CKDJ.O*DXYYP >]?2]4]3TJPUFR:SU&UBN;=CG9(,
MX/J/0^XJ54]ZX6//=(^-.B2Z?'_:L-S;WBJ!((XPZL<<D$=/I7FWCOQC+XXU
MN#[-;21VL&8[6$_,[%B,D@?Q' X&>@ZUZE<_!;PM/,SQR:C;J22(XIU('M\R
MD_K6[H'P^\-^')TN;*QWW2<K/.Y=QQCCL.IZ"J4H1U0%;P!X3_L+P4-/U"$>
M?>;I+N,G^\,;20>R@#COFO#=3TW4O /C)05826DXEMI67 F0'Y6^A'4=N17U
M'6;K/A_2O$-LMOJMC%=1J<KNR&7UPPP1^!J8SL]1G$VWQJ\-R68EN(+V&?!+
M0K&'Y] V0#^.*\E\1ZUJ'C[Q8)X;1C--M@MK9#N*J,X&?Q))Z<FO6W^"GAAY
M=XN-31?[BS)C]4S^M=1X?\%Z#X9;S-,L52<J5,[L7<@]LGIT'3%4I0CJA$>A
MV5OX)\#0Q7+ )8VS37#*,Y;EGQZ\Y _"N6TGXU:%<P+_ &G;W-E/_$%7S$Z=
MB.?7M7HM[96VHV<MI>0)/;RKM>-QD,*X6]^#?A6[F:2(7MH"<[()AM'_ 'V&
M-0G%_$,\H^(_B'3/$WBC[=I43"(0+&\CKM,K#/./3&!^%>V?#6PN=.\ :7!=
M@K(5>0(5P45W+ '\#G\:JZ+\*O"^BW*7(MYKR9#E&NW#A3Z[0 /S%=M3G--6
M0CY2U5;C0O&=T9(_WUI?&0*_?#[A^!X_.O7G^-^A"P$B:??-=E1F$A0H/?Y\
M]/?'X"NK\2^!="\5,)=1MF%RJ[%N(7V.!Z>A_$&N=A^"GA>)LO/J4H]'F0#]
M$%4YQDM0.N\4ZZOAKPU>ZNT)F^SJNV,'&YF8*,GTRPS[5Y!X?^,&O-K\":GY
M$]G/(L;1QQ!2F2!E3Z_4U[5JVEVNM:5<Z;>*S6]PFQ]IP1Z$'U!P?PKS_0_@
MSI^DZW!J%QJ<MW';R++% 80@W#D;CDYYP>@Z5,'&SN!Z;11168PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M];7/"P,:"I<E6M*$HWNN:WW&+:>']>D\0V^HWPC9A*K2.&7H,#H/84_XA?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"@-
M%T\7_P!N%O\ Z3NW;][=?IG%37VGVNI0B&[B\R-6W ;B.<$=C[FK-% $-K:P
MV=LEO;ILB3[JY)QW[U#?Z79ZF$%Y#Y@CSM^8C&?H?:KE% #8HTAB2*,81%"J
M,] .E4K[1M/U*59;NW\QU7:#O8<?@:OT4 ,FB2>&2&1=T<BE6&<9!&#5:PTN
MSTP.+.'RQ)C=\Q.<?4^]7** (;JUAO+9[>X3?$_WER1GOVIEE86VG0&&UC\N
M,MNQN)Y_'Z59HH K7MA;:C (;J/S(PV[&XCG\/K3[6UALK9+>W39$F=JY)QD
MY[_6IJ* *]Y86M_&([J!95!R-W;Z&JEOX>TJUE$D5F@<="Q+8_,FM.B@"A_8
MVG_VA]O^S_Z3NW;][=>G3.*DOM,L]25%NX?,"$E?F(Q^1JW10!';P16L"00K
MMC085<DX'XU#?:;::E&L=W%YBH<J-Q&#^!JU10!';P16L"00KMC085<DX'XT
MRZL[:]C\NY@25>H##./IZ5/10!D#POHRMN%D,^\C'^M:<,$-NFR&)(DZ[44*
M/TJ2B@ HHHH HWFCV%_<I<7,&^5 %5M[# !SV/O5ZBB@ JE>:38:@VZZM4D;
M&-W1OS'-7:* ,N'PYI%NX=+%"1TWDN/R)-::J%4*H 4#  ' %+10!G76@Z7>
M2F2>S0N>K*2I/N<8R:=::)IMC()+>T17'1CEB/H3FK]% &7XC_Y%^\_W/ZBN
M?\)Z=9ZAIMPMW;I+ME&TG@CCU'-=5J-G_:&GS6OF>7YBXW8SCGTJIH>C?V+;
MRQ?:/.\QMV=FW''U-,!T'AW2;:3?'91[O]LE_P"9-:=%%(!KHDJ%)$5T/!5A
MD&LH^%]&9MQLAGVD8?UK7HH AMK.WLHO+MH4B3T48S]:;>6-OJ$'D74?F1Y#
M;=Q'/X58HH @L[*WL+<06T?EQ DA<D]?K1>65O?VY@N8_,B)!*Y(Z?2IZ* (
M+.RM["W$%M'Y<0)(7)/7ZU3N/#VDW4ADELDW$Y)0E<_D16G10!1L]'T_3WWV
MMJB/_>Y)'XFKU%% %&\T?3[]]]S:H[_WAE2?J1R:B@\/:3;.'CLH]PZ;R7_F
M36G10 @ 4    < "EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J.>WBNH'@GC62)QAE8<&I**$[:H32:LSFY_
M^D32%D^T0@_PQR# _,&K-AX3TG3Y!*L+32+T:8[L?AT_2MNBMGB*K5G)G+'
M86,N=4U?T&R1K+$\;C*.I5AZ@UC?\(AH7_/C_P"1G_\ BJVZ*B-2</A;1M4H
M4JNM2*?JDS+M_#ND6K[HK"+=C&7R_P#Z%FM2BBE*<I:R=QTZ4*:M"*7HK!65
M<^&]'NY3)-8QESR2A*9_(BM6BB,Y1=XNP5*5.JK5(IKS5S-L_#^E6$HEM[*-
M7'1F)8CZ9)K2HHHE.4G>3N.G2A35H))>6@4445)84444 %%%% &;>Z!IFH77
MVFZMO,FP!N\QAP.G -:5%%4Y2:2;V(C2A!N44DWOY^H4445)853OM)L-2Q]L
MM8Y2.C$88#TR.<>U7**<9.+NF3.$9KEDKHQH_"FB1-E;!"?]IV;^9K7CC2*,
M1QHJ(O 51@#\*=152J3G\3N13H4J7\.*7HK%>[L;6_B\JZ@CF0<@.,X^GI6:
M/"6AJVX6 S[R.?ZUM441JSBK1;0JF'HU'S3@F_-)D<%O#;1^7!#'$F<[8U"C
M\A3I(TEC,<B*Z-P589!_"G45-W>YJHI*UM#/LM#T[3KAKBTMA%*RE"0S'C(/
M0G'85:NK2WOH#!<PK+&>=K#O4U%-SDWS-ZD1HTXQY(Q27:VA3T_2K+2UD6R@
M\H2$%AN)R?Q-5KGPUH]W(9);"/<3DE"4S_WR16K1356:?,F[DO#T7%0<%9=+
M*Q0L=$TW37+VEI'&_3?RS#Z$Y(J_112E*4G>3N7"G"FN6"27D%%%%26%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M22O=[:XCN[2&YA.8ID61#Z@C(KD?B#X$7QE80-;S1P:A;9\IW'RNIZJQ'..
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M2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%5=2L(=4TRZL)QF*YB:)_HPQ
M7SYX%O+CP?\ $M-/NW*(T[6-P,D*23A3]-VTY]#5QCS)@?1M%%8_BK6/[!\+
M:CJ></!"3&< _.?E3K_M$5"U V**\'^"VB/>^)+C6I03'91E48GDROQ_Z#N_
M,5[Q52CRNP!1114@%%%% !1110 45YA=?$35)?B;!X:@A@@LTO!%))C=)(,<
MC)X /L,^]>GTW%K< HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>!?&/1I--\6Q:O K)%>QJQD7(Q*G!Y[' 4_G7OM<5\5-&_M?P+=NJ
M@S61%TA]E^]_XZ6/X"KINT@9T'AK5UU[PUI^IJ1FXA5GP>CCAA^# BO.OCAK
M(BT[3]&C8;II#<2CN%7A?P))_P"^:D^"&M"?2+[1I'_>6TGG1 _W&X('T8?^
M/5R.O*_C[XO-812$VXF^S*P.X+%&#O(]B0Y'UJXQM-^0CU/X::2N@^ ;,S8C
M>X!O)BQ  W#@^WR!>M<=KWQ9U/4=6_LOP?:>;EMBSM%O>0],JO0#W/Z5O_%_
M56TGP2EC:@1_;)5@PF %C R0!^ 'T-<O\,O$G@WPOH;2ZA?K%JUP[>:3;RNR
M(#A5!"D8XW<'OSTX25US-7 @G\4?%71(3?:C;R/:QX=_-M(]@'^T4 ('XBN]
M\"?$.T\8H]M+"+74HD#/%NRL@[LG?KV/3(Y-.;XI^"74JVL J1@@VLV"/^^*
M\DTB^L+'XP6D^@S!M/FOU2(I&5&R7"E=K $ ;B.G;CM3MS)W5@/=_$?B/3_"
M^DR:AJ$F%'$<:_>E;LJCU_E7DK?$?QQXJO98_#-AY$*<@10B1E'^TSC;G\!_
M6J?Q@U"YU/QQ#I"2 Q6T:(D>>!(^"2?<@K^ KVW0]&M= T:VTRS7$,"!<XY<
M]V/N3S2LHI-@>0/XX^)'AIA+K>FF> X7=-; +DGC#QX /;G\J].UN?Q#=>"Y
M)]'M6M=<D2-HX&:-C&2Z[@2WRGY=W7^==#14.2?09\N?\5-_PGW_ %,GVG_I
MG_K?_0/Z5ZEX?_X6M_;]E_;/_(-\T?:/^/7[O_ ?F_*N2_YKY_W$OZ5[]6DY
M;:"14U34[31M,GU"^E$5M NYW/Y #U))  ]37CD_Q,\8>*-3DMO"NG^3$G("
M1"63;TRY;Y1^7MDU?^.>JNEMI6DH2%D9KB08ZX^5?YM^E=E\-M&AT;P-IWEJ
MOFW<0NI7'5BXR,_12H_"I248\S \XE\>_$/PK<QOX@M#+ YQB>W5%;V#H ,_
MG]*];\,>)K'Q7HZ:A8DKSMEB;[T3]P?Y@]Q5C7M(@U[0[S3;A%9)XF52PSL;
M'RL/<'!KQ;X)ZG+;^*;G3MW[FZMRQ7)^^A!!_(M3TE%OL!U_Q:\5ZUX8_L?^
MQ[W[-]H\[S?W2/NV[,?>!Q]X]/6L=?B3XEU>PL=-\-69OM26V1[V[,(.USC[
MH&%'H21CT'&:/CQ_S+__ &\?^TJ[/X8Z5;Z9X$T]HD42W2?:)G'5F;IGZ# _
M"C103L!G?#ZY\<7FIW__  E+RI;P(JQI+;)'O<]U95 ( '/N1[UZ#116;=V,
M****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>,[0<9P?RKNO!EO-:^"]'@N(9(9H[5%>.12K*<="#R*3^! ;M%%%9C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'/['\[$T,7VC[3M_UBJ<[=AZ;O7M4'B'XR:1I%])9Z?9R:E)$VUY%E$<1/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ]XYD\=7%KHNAVEP]JLF\+LS)/)CCY1R  6_/)Z5Z_X*\.?\(MX6M--8JUP
M9+AEZ&1N3^ X&>^,T/W868'C?C;_ )+:_P#U]VG_ *!'7T)7SWXV_P"2VO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+Q9=K;Z'
M(A.&E^4?G6[7"^.[O=<06G]P;_SKHPL.>JD<>85?9X>3[Z?><=1117OGQX44
M44 .1BCA@<$'.:]6T"_&H:/#*3EP-KGWKR>NN\$:CY5V]G(_R2#*#_:KCQM+
MGIW6Z/2RJO[.ORO:1WM%%%>(?5!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M795QOQ!_YE;_ +&&T_\ 9Z[*J>R ****D HHHH **** "BBB@ HHHH ****
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M:_L#P?J5^K[9A$8X2&P?,;Y5(^A.?PKP7X9W_P#9_P 0=*<L DSM V2!G>I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<>#)O!FJQ6S72W4$Z;XI0FT\'!!'/(^OI]*]S^&?_).]'_ZYO_Z,:N ^.O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** .-^(/_,K?]C#:?^SUV5<;\0?^96_[&&T_]GKLJI[( HHHJ0"BBB@
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MTFH> _&L<DT)%U83G<K @.O(./9E)P?>O<? GP_?P5<WD@U<WB72*IC^S^6
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M%+9_ ,_G2(LJ3QO IQEFW8./^ LQKAO@IH7VS7[G6I#A+%-D8]9'!&?P7/\
MWT*Z(R]RXCW"RM(M/L+>R@!$-O$L2 ]=J@ ?H*GHHKG&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ****@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>*@X.:].\)ZA]MT=$8_/#\ASU->;F%*Z51'N9-7M)TGUU1NT445Y1] %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445C>'M>_
MMW^U?]&\C[!J,UC_ *S=YFS'S=!C.>G/UHL!LT444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 <;\0?^96_[&&T_]GKLJXWX@_\ ,K?]C#:?^SUV54]D 4445(!1110 4444
M %%%,E<1PNY.-JDT ]#SKQE=BYUDQC_EB-E<Y5F_N3=WLTYZNQ:JU?1TH<D%
M$^(Q%3VM64^["BBBM#(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"_IFK76E7 E@<@?Q*>C"O0M(\2V6J(%+B*?NC'&3[5Y=3E=D8,K$$<@@XKF
MKX:%75Z,[<)CZF'=EJNQ[317F^F>+[VR"QS?OXAV;K^==98>*M.O0 TGE2'^
M%A_6O*JX2K3Z71]#0S&A6ZV?9FY13$FBD^Y(C?1@:?7,=R=PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUQ)(W5F)/XFO2RZ%Y.1XF=5;0C3[ZD=%%%>J?/!1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 =/X)_P"0Q_P'^AKT2O._!/\
MR&/^ _T->B5XN/\ XWR/J,H_W;YL****XCU HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 =/X)_P"0Q_P'^AKT2O._!/\
MR&/^ _T->B5XN/\ XWR/J,H_W;YL****XCU HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 =/X)_Y#'_ ?Z&O1*\[\$_\ (8_X#_0UZ)7BX_\
MC?(^HRC_ ';YL****XCU HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KC?A]_S-/\ V,-W_P"R5V5<;\/O
M^9I_[&&[_P#9*I;,#LJ***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KSOQM=&75A #E8U'YFO0V8*I8\ #)KR+5KAKG4[B0G.7('TS
M7?E\+U'+L>1G-3EHJ'=E*BBBO8/F@HHHH *[KP-?[H);)CC;\Z_C7"UJ>'[[
M^S]7@E8G83M8>H-88FG[2DT=6!K>QKQETV/5Z* <C-%?/GV04444 <;\0?\
MF5O^QAM/_9Z[*N-^(/\ S*W_ &,-I_[/7953V0!1114@%%%% #9'\N)W_N@F
MO(=2N?MFHSW'_/1R:]+\179L]$GD4X8C:/QXKRD\UZN70T<SY_.JMY1I_,**
M**](\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#I_!/_(8_P" _P!#7HE>=^"?^0Q_P'^AKT2O%Q_\;Y'U&4?[
MM\V%%%%<1Z@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5QOP^_P"9I_[&&[_]DKLJXWX??\S3_P!C#=_^
MR52V8'94445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .G\
M$_\ (8_X#_0UZ)7G?@G_ )#'_ ?Z&O1*\7'_ ,;Y'U&4?[M\V%%%%<1Z@444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5QOP^_YFG_L8;O_ -DKLJXWX??\S3_V,-W_ .R52V8'94445(!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!. 30!Y[XWNA-JD<
M(_Y8I@_CS7+5?UFZ^V:K<3?WG_\ K50KZ*A#DIJ)\5BJGM*TI^84445J8!11
M10 4444 7]&O/L.JP3DX56&[W%>M(P=%<=& (KQ8'!KU/PS?&^T:)F8&1/E8
M?3I7FYA3T4T>YDU:SE2?J;%%%<;=_%'PM87DUI=7<\5Q"YCD0VSY5@<$=*\M
M)O8^@#X@_P#,K?\ 8PVG_L]=E7D?B_XB^&M6_L'['>2/]DUBWNYLP.-L:;MQ
MY'/4<5TG_"W/!W_00F_\!G_PJG&5EH!W%%9'A_Q-IGB>UEN=*DDEAB?RV=HF
M0;L9P,CG@C\Q6O4-6 *ANYOLUI-,?^6:%ORJ:L+Q;=FVT.0*?FD.S'L>M73C
MSS4>YE7J>SIRGV1YM<R^?<RR_P!]RWYFHJ"<G-%?2)6/B&[N["BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .G\$_\ (8_X#_0UZ)7G?@G_ )#'_ ?Z&O1*\7'_ ,;Y'U&4?[M\V%%%%<1Z
M@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5QOP^_YFG_L8;O_ -DKLJXWX??\S3_V,-W_ .R52V8'9444
M5(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M7N/LFDW,^<%4
MJ[7,^-;HP:4D2GF5\$>V,UK1ASU%$PQ53V=&4_(\\=MSEO4TVBBOHCXH****
M "BBB@ HHHH *ZWP/?>5>R69Z2C</J*Y*K6G736=_#,IQM<9^F>:RK4_:4W$
MWPM;V-:,^Q[#7A_QI\,_9=1@\06Z8BNL17&!TD ^4_B!C_@/O7ML,JSP)*OW
M74,*S_$6BP>(= O-+N,!9XR%;'W&'*M^! ->!%\LC[3=71\EU+;6\UW=16UO
M&9)IG$<:+U9B< #\:=>V<^GWT]G<H4G@D:.13V8'!KTKX,>&?M^LS:]<)FWL
M?DAR.&F(Y/\ P%3^;*>U=,I65Q'K_A?08?#7ARSTJ+!,*?O''\<AY9OSSCVP
M*UZ**XV[E!7">.KO=<P6RMPJDL/>N[/ KRCQ#="\UJXE!^7=@?0"N[ 0YJM^
MQY6;U>6AR]V9=%%%>R?,!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '3^"?^0Q_P !_H:]$KSOP3_R&/\
M@/\ 0UZ)7BX_^-\CZC*/]V^;"BBBN(]0**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XWX??\ ,T_]C#=_
M^R5V5<;\/O\ F:?^QAN__9*I;,#LJ***D HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** .G\$_\AC_@/]#7HE>=^"?^0Q_P'^AKT2O%Q_\
M&^1]1E'^[?-A1117$>H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '3^"?^0Q_P !_H:]$KSOP3_R
M&/\ @/\ 0UZ)7BX_^-\CZC*/]V^;"BBBN(]0**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '3^"?\ D,?\!_H:]$KSOP3_ ,AC_@/]#7HE>+C_ .-\CZC*/]V^;"BB
MBN(]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>:.R"BBBNDX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH Z?P3_R&/^ _T->B5YWX)_Y#'_ ?Z&O1
M*\7'_P ;Y'U&4?[M\V%%%%<1Z@4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5QOP^_YFG_ +&&[_\ 9*[*
MN-^'W_,T_P#8PW?_ +)5+9@=E1114@%%%% !1110 4444 %%%% !1110 444
M4 %9^LZDFEZ=).Q^;&$'<FKY(4$D@ =2:\S\4:R=3OS'&W[B(D*/4]S73A:/
MM9VZ(XL?BEAZ3:W>QBSS/<3O+(VYW))/K4=%%>\?(-WU84444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '3^"?
M^0Q_P'^AKT2O._!/_(8_X#_0UZ)7BX_^-\CZC*/]V^;"BBBN(]0**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!T_@G_D,?\  ?Z&O1*\[\$_\AC_ (#_ $->
MB5XN/_C?(^HRC_=OFPHHHKB/4"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***P_%/BBT\):;'?WMK=S6[2",FV
M16*$@D9RPXXZT)7 W*XWX??\S3_V,-W_ .R5C?\ "[_#7_/CJW_?J/\ ^.5@
M>%OBGH>B?VU]IM=1?[=JL][%Y<:'"/MP#EQSQSC(]ZT4)6>@CVJBO/M.^,&A
M:IJ5M86FG:L]Q<2+&@\J/&2<<_O.![UZ#4--;C"BBBD 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (#_ $->B5YWX)_Y#'_ ?Z&O1*\7'_QOD?491_NWS84445Q'J!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHHKH.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#I_!/\ R&/^ _T->B5YWX)_Y#'_
M  '^AKT2O%Q_\;Y'U&4?[M\V%%%%<1Z@4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!T_@G_D,?\  ?Z&O1*\[\$_\AC_ (#_ $->
MB5XN/_C?(^HRC_=OFPHHHKB/4"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#I_!/_ "&/^ _T->B5YWX)_P"0Q_P'^AKT2O%Q_P#&
M^1]1E'^[?-A1117$>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%07%TD"G(+-_=7K32;V$VDKLGI&94&68*/4G%<W>^(K\
M$K9Z7.2/XI%X_2N:OV\0:@6$R7!0_P  & *ZJ>$E+XFD<%?,(4](1<GZ'7:C
MXJT^P#*K^=*O\"?XUR.I>+K^]W)$WDQ$\!?O?G6=_8NHG_ETE_[YI/[%U'_G
MTE_[YKT*6'H4];W9XU?&XNMI9I>292>1Y&+.Q8GJ2<TVK_\ 8NH_\^DO_?-'
M]BZC_P ^DO\ WS75SP[HX/95/Y7]Q0HJ_P#V+J/_ #Z2_P#?-']BZC_SZ2_]
M\T<\>Z%[*I_*_N*%%7_[%U'_ )])?^^:/[%U'_GTE_[YHYX]T'LJG\K^XH45
M?_L74?\ GTE_[YH_L74?^?27_OFCGCW0>RJ?RO[BA15_^Q=1_P"?27_OFC^Q
M=1_Y])?^^:.>/=![*I_*_N*%%7_[%U'_ )])?^^:/[%U'_GTE_[YHYX]T'LJ
MG\K^XH45?_L74?\ GTE_[YJ+^SKO_GWD_P"^:.>/<'3FMXO[BK15K^SKO_GW
MD_[YH_LZ[_Y]Y/\ OFGS1[B]G/LRK15K^SKO_GWD_P"^:/[.N_\ GWD_[YHY
MH]P]G/LRK15K^SKO_GWD_P"^:/[.N_\ GWD_[YHYH]P]G/LRK15K^SKO_GWD
M_P"^:/[.N_\ GWD_[YHYH]P]G/LRK15K^SKO_GWD_P"^:/[.N_\ GWD_[YHY
MH]P]G/LRK15K^SKO_GWD_P"^:/[.N_\ GWD_[YHYH]P]G/LRK15K^SKO_GWD
M_P"^:/[.N_\ GWD_[YHYH]P]G/LRK15K^SKO_GWD_P"^:/[.N_\ GWD_[YHY
MH]P]G/LRK15K^SKO_GWD_P"^:/[.N_\ GWD_[YHYH]P]G/LRK15K^SKO_GWD
M_P"^:/[.N_\ GWD_[YHYH]P]G/LRK15K^SKO_GWD_P"^:/[.N_\ GWD_[YHY
MH]P]G/LRK15DZ?=J"3!)@?[-1?9YO^>;?E1S+N)QDMT1T5+]GF_YYM^5'V>;
M_GFWY470<K[$5%2_9YO^>;?E1]GF_P">;?E1=!ROL145+]GF_P">;?E1]GF_
MYYM^5%T'*^Q%14OV>;_GFWY4?9YO^>;?E1=!ROL145+]GF_YYM^5'V>;_GFW
MY470<K[$5%2_9YO^>;?E1]GF_P">;?E1=!ROL145+]GF_P">;?E1]GF_YYM^
M5%T'*^Q%14OV>;_GFWY4?9YO^>;?E1=!ROL145+]GF_YYM^5'V>;_GFWY470
M<K[$5%2_9YO^>;?E1]GF_P">;?E1=!ROL145+]GF_P">;?E1]GF_YYM^5%T'
M*^Q%13VAD499& ]2*;M/M^=,3T$HI=I]OSHVGV_.@0E%+M/M^=&T^WYT )12
M[3[?G1M/M^= "44NT^WYT;3[?G0 E%+M/M^=&T^WYT )12[3[?G1M/M^= "4
M4NT^WYT;3[?G0 E%+M/M^=&T^WYT )12[3[?G1M/M^= "44NT^WYT;3[?G0
ME%+M/M^=&T^WYT )12[3[?G1CZ?G0 E%+CZ?G1CZ?G0 E%+CZ?G1CZ?G0 E%
M+CZ?G1CZ?G0 E%+CZ?G1CZ?G0 E%+CZ?G1CZ?G0 E%+CZ?G1CZ?G0 E%+CZ?
MG1CZ?G0 E%+CZ?G1CZ?G0 E%+CZ?G1CZ?G0 E%+CZ?G1CZ?G0 E%+CZ?G1CZ
M?G0 E%+C_.:3% !11BC% !11BC% '3^"?^0Q_P !_H:]$KSOP3_R&/\ @/\
M0UZ)7BX_^-\CZG*/]V^;"BBBN(]0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>2?]\BBB@ \F+_GDG_?(H\F+_GDG_?(HHH /)B_YY)_WR*/)B_YY)_WR***
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img97084416_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img97084416_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &K!#@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M TE*:2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "EI*6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH #24II* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]#\/Z!I>CZEJ]U87<D\U]/YMPC2AQ&W/  Z=3UI220&_1114 %%%% !1110
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M^E7YG,<$CCJJDC/TKDO"_CO3=3T33'U34["#5+M,FW$@7G<0!@GC.!UJE?=
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MSR"62(R.=S#H<YS700Q)!#'#$NV.-0JKZ # %/HH;; ****0!1110 4M)2T
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MWK >)ZCX6U66XU-)O "OJ5P66&ZM+@BV4G_EIL+$9[]NO2O1['P'877@32]
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MG:'[3;"\FMTF>V24%DW*"1CKWH;DT!SL/PG\)0Z@+H64K*K[UMVF8Q _[O\
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M2*](O/"^A:A?"^O-(LY[H$'S7B!)QTSZ_C5XV%HU[%>&VB-S$ACCEVC<JGJ
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MQ\4/#,*V%LL2V<Y$8C 7Y0-N1WQGBN;UR(V^G>/X;5#':KJ%JTR0C&(R%,F
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MK=TMDO\ XB:7,WB>/6+N"WE)-G9HJ+&PZ2.K>N,#_&L>!A_PJ71SD8_MM/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD.YS&@7<?4XZU-10 4444 %%%% !1110 4M)2T %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%%  :2E-)0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM;Q66=(<LK=5R20#] 0*J5^74#H:***S **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M&DI324 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4M)2T
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M2Q8D;&-Q!*Y_'&?QK6>PC>HHHK$84444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1:?;-]G,2-]JO!#)/N ):,,-I SW-:>H?#Z"_@\0Q'4)8QK,D,C8C!\GR\8
M]<XJ#7OAS_;US/YVN7(LI]F^W>%)"FWM&[<Q@^@IWCU [@'(!]:6HX(4M[>.
M"/.R-0BY.> ,"I*R **** "J>KP-<Z+?0)"L[R6\B+$QP')4@ GMFKE4=9N+
MBUT2_N+1-]S%;R/$N,Y8*2/UH0'FNBO\3]#TF#3H-$L)88%VQF61=P7TX<5Z
M3HTNHS:/;2:M!'!?LN9HXSE5.>W)[8[UX+97FG,S7=SXEN&N;W2IFN978EHY
M]X(11UYQ_ABO:O!%Y>7_ (+TJZOV9KF2'+,W5AD@$_4 '\:UFNHC?J.>WAN8
MC%<0QRQGDI(H8?D:DHK(9#/:6UU"(;BWAFB'1)$#+^1J.XAL?L\5I<0P&!V$
M:1/&"I."0 .G0&K59NJ_Z_3/^OP?^@/30%E]/LI+=+=[.W:",Y2-HE*J?88P
M*<]C:27"7#VL#3I]R1HP67Z'J*GHI 1K!"L[3K$@E< -(%&Y@.@)H%O +@W
MAC\\KM,FT;B/3/7%244 1?9H/M'VCR8_/V[?,VC=CTSUQ4M%% !112$@ D]!
M0!&+B(SF$./, SBI:YP7!%Y]H_V\_A71 A@".AYJYPY3.G/FN+1114&@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* #'.:,"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF3R6_GVWS922/VX';\.*YI=)^(MMHA\-0OICZ?L, NO,7/EGC'7/0_W<UO\
MAWP9J6G>)[&\N;J.6PTRP%M;;3DR,1\YQV&2WZ5M+EL([ZBBBL1A6;JO^OTS
M_K\'_H#UI5FZK_K],_Z_!_Z ]- :5%%%( HHHH **** "JNH2>59.<\M\H_&
MK59.L29:.(=OF-7!7D14=HLS*W-,F\VT"D_,AVGZ=JPZNZ9-Y=UL/208_'M6
M]17B<U*5I&Y1117*=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%%  :2E-)0 4444 9H_Y&=_^O-?_0S6
ME6:/^1G?_KS7_P!#-:5-@%%%%( HHHH *PO$TVVUAA!^^^X_0?\ ZZW:Y+Q#
M-YFI[,\1H%_$\UM0C>9AB96IOS,FM30;G[/J2H3A91L/U[?Y]ZRZ569&#*<,
MIR#[UW2CS)H\V$N62D>A45#:3BZM(IUZ.H/XU-7EM6T/83NKHS==_P"02_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_0UT-<M6U8WZ2QK'(P60<<_Q5C5C?5&]&=M&7Z***P.D**** "BBB@ HHHH
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M_J][<3&Y/^CPRGB*)>!@>YS^&*?X#O\ ;-<6#'AQYJ#W'!_I7<*JHH50 HX
M Z5X.)C[.;@?8X&M[:A&779_(X[Q]=X@M+,'EF,C#V' _G7#5N>+;O[7XAG
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M:6W^^/\ T8:SQ&\/\2-L%M5_PO\ 0X^O9K;_ (]8?]Q?Y5XS7LUM_P >L/\
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M#%:MM*9[=)2,%AG%1*#CN7&HI;$M%%%26!I*4TE !1110!FC_D9W_P"O-?\
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M[!]SH-Z?WU_[Z%&]/[Z_]]"N?_X4EX=_Y_\ 5/\ OZG_ ,11_P *2\._\_\
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MCZQ /J;[DN1ZC\Z,CU'YU%_PI7P__P!!'5O^_P O_P 31_PI7P__ -!'5O\
MO\O_ ,31]8@'U-]R7(]1^=&1ZC\ZB_X4KX?_ .@CJW_?Y?\ XFC_ (4KX?\
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M_P#Q-'_"IM-_Z#FN?^!*_P#Q-']H4^P?V+4_F1R=%=9_PJ;3?^@YKG_@2O\
M\31_PJ;3?^@YKG_@2O\ \31_:%/L']BU/YD<G176?\*FTW_H.:Y_X$K_ /$T
M#X4:<O37=<'_ &\K_P#$T?VA3[,7]BU/YD<G177?\*JT_P#Z#VN_^!*__$T?
M\*JT_P#Z#VN_^!*__$T?VA3[,/[%J_S(Y&BNN_X55I__ $'M=_\  E?_ (FC
M_A56G_\ 0>UW_P "5_\ B:/[0I]F']BU?YD<C177?\*JT_\ Z#VN_P#@2O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 !I*4TE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %+24M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 &DI:* $HI:* $HI:* $HI:* $
MHI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $
MHI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $I:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img97084416_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img97084416_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <*"Y$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M97,4<8("Q@[0.>3R"<^_I71T %%%% !1110 4444 %%%(S!%+,0% R23P!0
MM%>;>,/BU8:1YEEHH2_O0,&8']S$?K_&?8<>_:O0K,3K8VZW3;K@1J)6XY;'
M)XXZ^E $]%<E\3+_ /L_P!J;!RKS*L"XR,[F (X_V=U?-5 'V%17Q[4L%S/:
MN'MYI(G'.Z-RI_2@#Z]HKYU\+?$_6]!N(X[V>34+ D!XYV+.J^J,3U]CD=N.
MM>_Z9J=IK&FP:A8RB6VG7<CC\B/8@@@CVH MT45\]_&"^-UX[D@[6EO'%CZC
M?_[/0!]"45\K>%-<?P[XFL=34X2*0"4<\QGAA^1./?%?5"L'4,I!4C((/!%
M"T45\V_%"_%_X_U'8Q*0;(!GL549_P#'LT ?25%>/? VP'_$WU%E.X>7 A[8
MY9O_ &6O8: "BBO(?C+XJ*)#X;M)2&;$MX1Z?P)_[,1[+[T >O45\>U[M\$[
MLR^%KVU8D^3=EA[!E7C\P?SH ],HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HKQ7XXWQ?4])T\8Q%"\Y]3N.T?^@'\ZY?X7V O_'^G;U)
M2#?.<=BJG'_CV* /I*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\*/ OV.%/$6IP_Z1(N;.-OX%/\9'J1T]C[\>K4 %%%% !1110 4444 %%%%
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M*** "BBB@ HKYP^*E]]M\?WP'W;=4@7\%!/ZDUT7P0L!)K.J:@R9\B!8E8]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK/UZ_P#[+\/ZC?APK6]M)(I./O!20.>,YQ6A7#?%O4&L? 5Q&IP;N:.#/MG<
M?T4C\: /G:O?_AQX4T:7P-87%_I-C=7-QOE:2>W20X+$ 9(SC 'ZUX!7MVD_
M%_PWINC6-C]BU4_9K>.'(CC(^50/[_M3&=Y_PB7AO_H7M)_\ H_\*\Q^+/@S
M1M'TBWU;3+9+24SK \49PC@JQR!V(V]O>MF?XW:"L>;?3M2D?/21408^H8_R
MKS;QMX[O/&5S$&A%K8P<Q6X;<=W=F.!D_P OS)0CF+626&[AE@.)DD5D_P!X
M'C]:^O:\"^&G@.[U;5K;5]0MFCTR!A*GF#'GL#\H /5<CGL>E>^T -=UC1G=
M@J*"69C@ >IKCM4^*7A72YFA-Z]U(I(86L9< @_WC@'\">E>7_$;X@3^(;^7
M3M.N&31XCM^0D?:".K-ZKGH/QZ].>\-^#]8\53.FFVX\J,@23RG;&A]SW/?
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MT<,MJS!?/MW+*&/8Y (_+%'@?Q9<^%=>AE64_89G5+J(]&3/WL>HSD'\.AH
M^E+V\M].L9[R[D$5O ADD<@G:H&3P.3]!7D7Q+^(&DZSX<CT_0M2>5Y9P;C;
M&\>8P#\IW*,@DC\J] \>V.I:GX.O;#2;<SW=QL0+O5<+N!8Y8@= 1^-?..L:
M+J&@7YL=3@$%R%#E/,5\ ].5)% ":&UJFO:>]]+Y5HEQ&TSX)P@8$] 3G'M7
MTQH?B[0_$DTT6D7IN7A4-(/)=-H/3EE%?-FA^'-6\27$MOI-H;B2)-[CS%3
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MWI.H36%_ T%U"VV2-L9!Z]N",$'(ZU[C\)/%ESKFE7&FW\K2W5CM*2L>7B/
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M@3D_0 GWP!WKYO1;_6]551YMW?74F!D[FD8^YH ]QE^-/AF-]J6^IRC^\D*
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MO?)"C_T%OSI"/)8XVED6-%+.Y"J!W)KZBM?!GAVWLX('T/3)6CC5#(UG&2Y
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M#WP"#Z\>@H ]\KG]9\;^'?#]\++4]2$%QL#[!$[X!SC.U2!TZ5T%?,_Q'O\
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M37FE:<;BW60QE_.C3Y@ 2,,P/<4QGT=H?B72/$D,TNDW?VA(6"N?+=,$\_Q
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M@'ZN#6]X?\?^'?$D_P!GL[SR[D_=@N%V.W^[V/T!SQ7D4?P>\526 N=MFLA
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M4D?J!57P3XD_X2GPQ;Z@^T7 )BN%48 D'7 R>H(/XUM7_P#R#[G_ *Y-_(T
M?+'AW46TGQ'IU^K[/(N$9C_LY^;],U]7U\>U]9:#<?:_#NF7/_/:TBD_- :
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^&-A]@\ ::"<O.&G;G^\Q(_3%=)JEZ--TB]OR,BV@>8CUVJ3_2@#YE\:7_\
M:7C35[H/O5KED1O55^5?T KT3X&V _XF^HLIW#RX$/;'+-_[+7C[L7=G8Y9C
MDGWKZ(^$=B;/P#;R'&;J:2? [<[!^B4QG<T45B^*?$EIX6T.;4+I@6 VPQ9Y
MD<] /YGT -(1XE\7=06^\=RQ(RL+2".#*^O+G/N"^/PI?A!9R7'CV&94RMM!
M)(Q] 1L_FU<3>7<U_>SW=RY>>=S)(Q[L3DU[=\&?#S6.B3ZS/&5EO6V0Y/\
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MG=BS,<EB<DFOH_XIWYL? %^%(#W!2 <^K#/_ (Z#7SC'&TLBQHI9W(50.Y-
M'O'PC\+0Z;H"ZU<1*;V]R8V(YCBZ #TSC/T(]*]%EE2&%Y9&"QHI9F/8#J:K
MZ58IIFD6=A&%"V\*1#;TX %8WC[4/[,\#:M<"0H[0&)"#@Y<A>/SI"/F:ZG^
MTWDT^W;YLC/MSG&3G%?0'P?LS;> HY<8^U7$DO7.<$)^'W*^>J^K/#%C_9GA
M;2[/^**UC#?[VT$_KF@#R_XWZ7/]JTS551F@\MK=V X1@=PS]<G\J\Y\.^(M
M0\+ZJNHZ<Z"7:499%W*ZD@E2/3('0CI7U'J&G6>JV4EG?VT=Q;R##1R+D?7V
M/N.17E.O_!16+2Z!?;<DGR+L\#V# ?7J/3GO0!8TOXWV4FQ-4TJ:$DX:2W<.
MOUP<'^==UIMYX9\2R&_L#87LP4!I/+4RJ.H!R-PZ]Z^==<\(:]X=RVI:=+%#
MNVB9</&?3YAD#/H>:H:7JE[HVH17VGW#P7$1RK*>OL1W!]#3&?6U?.7Q4U=]
M4\<W<6\M#9!;>,=@0,M_X\3^0KWS0-5&N:!8ZF$\O[3"LA3^ZW<?GFOFCQ?N
M_P"$TUS=G/V^?KZ;SC]*0CI?A/'H\7B*?4M7O;.V%I&/(%S,B9=LC(W'G !Z
M=,BO:_\ A+?#?_0PZ3_X&Q_XUX'X7^'>K>+=+?4-/NK&.))C"RSNZMN ![*1
MC##O6W_PI/Q)_P _VD_]_9/_ (W0 GQAN])U#6=/O--O;6Z=H&CF:WF60##9
M7.T\'YC_ )%/^"4C#Q=>QACL:P9B/4B1,?S/YTW_ (4GXD_Y_M)_[^R?_&Z[
M#X=?#S4_"6M75_J%Q9R"2W,*"W=V(RRDYRH_NT >DT444 -D=8HVD<X506)]
M *^3]=U1]:UV^U*3.;F9I #_  J3P/P&!^%?2_C"Z-GX-UF=3AELY ISC!*D
M _F:^6* /I'X7Z:-.\ V'RJ)+G=<.1W+'@_]\A?RKL:J:7:_8=)LK0*%\B!(
ML#MM4#^E6Z *NH:;8ZK:FUU"TAN8#SLE0, <8R,]#R>1S7.Q?#3P?#-YJ:+&
M6]'ED9?^^2Q'Z5UE17-S!9VTES<RI%!$I9Y'. H'<F@#-UG5M-\(^'WO)D2&
MUMU"101*%W'LBCI_@,GH*^=;B;5_B!XOW*HDO+M]L:9PD2 =/90!_,]35WQS
MXONO&>NA+<2?8(GV6EN!RV>-Q'=F/;MP/K[!\.O!2>%=(\^Y4-JETH,[=?+7
MJ$'I[^I^@H OZ9I^C?#SPH1),L=O -\]PX :5SWP.I/0#Z"O/-6^-]VTY71]
M*@2('A[PEF8?[JD;?S-5OC1KTESK=OH<4A\BU02RH#UE8'&?HI'_ 'T:T/A+
MX+TZ^TN76]4LX;LR2&.WCF = HX)*GC.>.?2@!WA_P"-1GO4@UZQAAA<@?:+
M8MB/W*G)(^AX]#7KRL'4,I!4C((/!%?-'Q&TVRTGQQ?VFGPK#;J(V$2=%)12
M<>G7./>O=/ -S-=^ ]'EG)+_ &<)D]2%)4?H!0!TE%%% '*?$?6?[%\#W\J-
MMFN%^S18.#E^#CW"[C^%?-(!8@ $D\ #O7N/QO8CPWIRY.TWF2,\9V-_B:\D
M\+6PN_%NCV[?=>\B#?3>,_I3&?2'A+P]#X9\.6VG1JOF ;YW ^_(0-Q/Z#Z
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MXSG\*\4^$UC]L\?VCE25MHY)CCMQM&?Q85Z?\7]W_"!2[<X^T1;L>F>_XXH
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M+I_@/6)6;!D@,(]R_P G_LU?,5>[_&J_-OX5M+-2 ;FY!89ZJH)_F5KQ?0[
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M_P *3\2?\_VD_P#?V3_XW1_PI/Q)_P _VD_]_9/_ (W2$7?@=(XU?5H@QV-
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MH<96P@!Q[1K7RYI]E-J6I6UC ,S7$JQ(/=C@?SKZVAACMX(X8EVQQJ$49S@
M8% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG^_YB@<8^78NW],5J_"WQCIWA6^OXM3+QV]XJ?OE0ML9"V,@<X(8] >E=_\
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M+>'H-*CT+SS&69YOM>W>2Q.<;#CC Z]JU+CXYW+)BVT&*-_66Y+C\@JUF_\
M"D_$G_/]I/\ W]D_^-T]/@EX@.?,U#3%]-KR'_V04QG(^)/&&L>*ID?4K@>5
M&28X(AMC0^P[GMDY-'A3PI?^*]6CM;6)Q;AA]HN=N5B7N2?7&<#O^9KT[2/@
ME8PNLFKZG+<XY,4"^6N?0L<DCZ8KTK3-*L-&LEL].M8K:W4YV1C&3ZGU/N:0
M@TK3+;1M+MM.LU*V]N@1,]3[GW)Y/UKQOXW:B9M=T[3E8%;>W,K 'HSMC!]\
M(/S]Z]PKR3QG\,O$'B;Q5=ZI!=:='!)L6))97W*JJ!SA,<D$_C0!R_P>L/M?
MCE;G.!9V\DO7J2-F/_'S^5?0=<#\-_ E[X/?4)=1EM99K@(L;6[LVU1G(.5'
M4D?E7?4 <#\7-"75/"#7R*3<:<WFKC'W"0''Y8/_  &OGNOK^:&.X@D@F0/%
M(I1U/1@1@BO#)O@EK_GR>1?:88=Q\LO+)NVYXSA.N* #X*6'G^*+R]9"5MK7
M:#S@,[#'Z!N#_2O8/$NNP>&] NM4N.1$N$3N[GA5_/\ 3)KG_AQX+N_!UC?+
M?36TMQ<R*<VY8@*H.,D@<Y9NW_UJOQ%\'^(?%\UK!8W=E#I\ W^7-*X+R'C<
M0$(X' Y[GUH \#O+N:_O9[NY<O/.YDD8]V)R:]X^'G@'3K/PO%<:QIMI=7MW
M^^/VB%9/+0CY5&<]N3TY..PKG/#_ ,&M3M-=M+G5KG3Y;*&0/)'"[LSXY P5
M QG&>>E>ST 8_P#PB7AO_H7M)_\  */_  H_X1+PW_T+VD_^ 4?^%;%% 'RC
MXDLAIOB?5+-4")#=2(@ P-H8XP/IBO9?@K=^=X1NK8GYH+ML?[K*I'Z[JR?%
MWPHUG7/%5_J=A=:?';7#*ZK-(X8': <@(1U![UT/PW\%:MX.?41J%Q9RQ70C
M*B!W8@KNZY4?WOTH [ZBBB@#,\1:7_;7AS4--!PUQ R(?1L?+^N*^4Y8G@F>
M*5"DB,593U!'!%?7]>>>-_A=;>)+F34M.G6SU%_OAQ^ZE/J<<J?<9Z=,\T 5
M?"GQ9T,Z';6^M7$EI>01B-V,3.LF !N&T'!/7&/6N/\ B'\21XF@&EZ6DD6G
M!@TCOPTQ'(!'90>?<@'C%9\_PH\8Q2E$TV.91_''<Q@'_OI@?TK3TCX,Z]=W
M _M.:WL(!]XAO-<]>@''YD=>],9B>"$\0ZWXAM[#3]4U""+(:=XIW CC!&2<
M'Z#'KBOH;7-0&E:#?Z@21]GMWD&!GD XX^M5?#GAC3/"VGFSTV(@,=TDLAR\
MA]6/]!@5%XSTB^U[PM=Z7ITL$4]QM7?,2%"A@3R >H&.E(1\MU]+_#?3QIW@
M'2DQ\\T9G8XQG>2P_0@?A7F/_"D_$G_/]I/_ ']D_P#C=>YVENMG9P6R8V0Q
MK&N!C@#% "7UTEC87-Y)CRX(FE;)QPH)//;I7R/--)<3R3RL7DD8N['N2<DU
M]3^*M-O-8\,7^G6+PI<7,?EJTQ(0 D9R0">F>U>/?\*3\2?\_P!I/_?V3_XW
M0!Z'\*-/%CX!M'(P]U(\[#ZG:/\ QU5KS?XS6LL/C2.=SF.>U0H?3!((_3/X
MU[EI-@NEZ/96"8VVT"19'?: ,UB^-O!UMXQTE8'D\F[@):WFQD*3U!'H<#\A
M]* /&OAEXML_"NMW!U'>MI=1A&D5=WEL#D$@<XY/2N_\1?&/1[6SDCT/S+V[
M8821HRD:'U.[!/TQ^-<!/\)?%\,YC2PAG4-CS([E I'K\Q!Q^%=5X6^#3QW2
M77B.:)XUY%G Q.[_ 'FXQ]!U]>U 'D,LKSS/+*Y>1V+,QZDGDFOH'X/6Z0^
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M&=EXHE:_LY19ZF1\S[<QR_[P'.?]H?D>,>87/PE\7P2E(["&Y7)^>*Y0 _\
M?1!_2F,Z+QK\6Q?6IL/#9N(0Q!DO#\C8!SA #D>Y/N,=ZJ>!?&?C;6=?M=-B
MO1=0;MTS7$(81QYRQ+  ^PR>N!572_@WXCNYT%^]O80GEV+B1Q]%4X)_$5[#
MX8\):5X4LO(T^(F5P/-N'Y>3ZGTYZ"D(W:*** "O(_CC?[;32-.5_ON\[I]
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MX(^1%B:-0?\ :+ ''T!KRN+XD>+DOI;B+5I=TSEO**AT&3G:JL#@=ABK5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 'R:/^$CT_\ YZG_ +Y-:?DQ?\\T_P"^11Y,7_/-/^^10!F?\)'I_P#SU/\
MWR:/^$CT_P#YZG_ODUI^3%_SS3_OD4>3%_SS3_OD4 9G_"1Z?_SU/_?)H_X2
M/3_^>I_[Y-:?DQ?\\T_[Y%'DQ?\ /-/^^10!F?\ "1Z?_P ]3_WR:/\ A(]/
M_P">I_[Y-:?DQ?\ /-/^^11Y,7_/-/\ OD4 9G_"1Z?_ ,]3_P!\FC_A(]/_
M .>I_P"^36GY,7_/-/\ OD4>3%_SS3_OD4 9G_"1Z?\ \]3_ -\FC_A(]/\
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M^10!F?\ "1Z?_P ]3_WR:/\ A(]/_P">I_[Y-:?DQ?\ /-/^^11Y,7_/-/\
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MF?\ "1Z?_P ]3_WR:/\ A(]/_P">I_[Y-:?DQ?\ /-/^^11Y,7_/-/\ OD4
M9G_"1Z?_ ,]3_P!\FC_A(]/_ .>I_P"^36GY,7_/-/\ OD4>3%_SS3_OD4 9
MG_"1Z?\ \]3_ -\FC_A(]/\ ^>I_[Y-:?DQ?\\T_[Y%'DQ?\\T_[Y% &9_PD
M>G_\]3_WR:/^$CT__GJ?^^36GY,7_/-/^^11Y,7_ #S3_OD4 9G_  D>G_\
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M4 9G_"1Z?_SU/_?)H_X2/3_^>I_[Y-:?DQ?\\T_[Y%'DQ?\ /-/^^10!F?\
M"1Z?_P ]3_WR:/\ A(]/_P">I_[Y-:?DQ?\ /-/^^11Y,7_/-/\ OD4 9G_"
M1Z?_ ,]3_P!\FC_A(]/_ .>I_P"^36GY,7_/-/\ OD4>3%_SS3_OD4 9G_"1
MZ?\ \]3_ -\FC_A(]/\ ^>I_[Y-:?DQ?\\T_[Y%'DQ?\\T_[Y% &9_PD>G_\
M]3_WR:/^$CT__GJ?^^36GY,7_/-/^^11Y,7_ #S3_OD4 9G_  D>G_\ /4_]
M\FC_ (2/3_\ GJ?^^36GY,7_ #S3_OD4>3%_SS3_ +Y% &9_PD>G_P#/4_\
M?)H_X2/3_P#GJ?\ ODUI^3%_SS3_ +Y%'DQ?\\T_[Y% &9_PD>G_ //4_P#?
M)H_X2/3_ /GJ?^^36GY,7_/-/^^11Y,7_/-/^^10!F?\)'I__/4_]\FC_A(]
M/_YZG_ODUI^3%_SS3_OD4>3%_P \T_[Y% &9_P )'I__ #U/_?)H_P"$CT__
M )ZG_ODUI^3%_P \T_[Y%'DQ?\\T_P"^10!F?\)'I_\ SU/_ 'R:/^$CT_\
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M ,]3_P!\FC_A(]/_ .>I_P"^36GY,7_/-/\ OD4>3%_SS3_OD4 9G_"1Z?\
M\]3_ -\FC_A(]/\ ^>I_[Y-:?DQ?\\T_[Y%'DQ?\\T_[Y% &9_PD>G_\]3_W
MR:/^$CT__GJ?^^36GY,7_/-/^^11Y,7_ #S3_OD4 9G_  D>G_\ /4_]\FC_
M (2/3_\ GJ?^^36GY,7_ #S3_OD4>3%_SS3_ +Y% &9_PD>G_P#/4_\ ?)H_
MX2/3_P#GJ?\ ODUI^3%_SS3_ +Y%'DQ?\\T_[Y% &9_PD>G_ //4_P#?)H_X
M2/3_ /GJ?^^36GY,7_/-/^^11Y,7_/-/^^10!F?\)'I__/4_]\FC_A(]/_YZ
MG_ODUI^3%_SS3_OD4>3%_P \T_[Y% &9_P )'I__ #U/_?)H_P"$CT__ )ZG
M_ODUI^3%_P \T_[Y%'DQ?\\T_P"^10!F?\)'I_\ SU/_ 'R:/^$CT_\ YZG_
M +Y-:?DQ?\\T_P"^11Y,7_/-/^^10!F?\)'I_P#SU/\ WR:/^$CT_P#YZG_O
MDUI^3%_SS3_OD4>3%_SS3_OD4 9G_"1Z?_SU/_?)H_X2/3_^>I_[Y-:?DQ?\
M\T_[Y%'DQ?\ /-/^^10!F?\ "1Z?_P ]3_WR:/\ A(]/_P">I_[Y-:?DQ?\
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M^11Y,7_/-/\ OD4 9G_"1Z?_ ,]3_P!\FC_A(]/_ .>I_P"^36GY,7_/-/\
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M_GJ?^^36GY,7_/-/^^11Y,7_ #S3_OD4 9G_  D>G_\ /4_]\FC_ (2/3_\
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M &9_PD>G_P#/4_\ ?)H_X2/3_P#GJ?\ ODUI^3%_SS3_ +Y%'DQ?\\T_[Y%
M&9_PD>G_ //4_P#?)H_X2/3_ /GJ?^^36GY,7_/-/^^11Y,7_/-/^^10!F?\
M)'I__/4_]\FC_A(]/_YZG_ODUI^3%_SS3_OD4>3%_P \T_[Y% &9_P )'I__
M #U/_?)H_P"$CT__ )ZG_ODUI^3%_P \T_[Y%'DQ?\\T_P"^10!F?\)'I_\
MSU/_ 'R:/^$CT_\ YZG_ +Y-:?DQ?\\T_P"^11Y,7_/-/^^10!F?\)'I_P#S
MU/\ WR:/^$CT_P#YZG_ODUI^3%_SS3_OD4>3%_SS3_OD4 9G_"1Z?_SU/_?)
MH_X2/3_^>I_[Y-:?DQ?\\T_[Y%'DQ?\ /-/^^10!F?\ "1Z?_P ]3_WR:/\
MA(]/_P">I_[Y-:?DQ?\ /-/^^11Y,7_/-/\ OD4 9G_"1Z?_ ,]3_P!\FC_A
M(]/_ .>I_P"^36GY,7_/-/\ OD4>3%_SS3_OD4 9G_"1Z?\ \]3_ -\FFR>)
M],B3?)/M4=25-:ODQ?\ /-/^^16!XSCC7PQ<D(HY7H/>@#=M[B*Z@2>%P\;C
M*L.]2UE^'/\ D7[/_<_K6I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5'<?\>TO^X?Y5)4=Q_Q[2_[A_E0!QOP[_P!3J?\ UW'\C7;5Q/P[_P!3J?\
MUW'\C7;4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1/\ OH4>=%_ST3_OH5E_V!!_SU>C^P(/^>KT :GG1?\ /1/^^A1YT7_/1/\
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M_P">KT :GG1?\]$_[Z%'G1?\]$_[Z%9?]@0?\]7H_L"#_GJ] &IYT7_/1/\
MOH4>=%_ST3_OH5E_V!!_SU>C^P(/^>KT :GG1?\ /1/^^A1YT7_/1/\ OH5E
M_P!@0?\ /5Z/[ @_YZO0!J>=%_ST3_OH4>=%_P ]$_[Z%9?]@0?\]7H_L"#_
M )ZO0!J>=%_ST3_OH4>=%_ST3_OH5E_V!!_SU>C^P(/^>KT :GG1?\]$_P"^
MA1YT7_/1/^^A67_8$'_/5Z/[ @_YZO0!J>=%_P ]$_[Z%'G1?\]$_P"^A67_
M &!!_P ]7H_L"#_GJ] &IYT7_/1/^^A1YT7_ #T3_OH5E_V!!_SU>C^P(/\
MGJ] &IYT7_/1/^^A1YT7_/1/^^A67_8$'_/5Z/[ @_YZO0!J>=%_ST3_ +Z%
M'G1?\]$_[Z%9?]@0?\]7H_L"#_GJ] &IYT7_ #T3_OH4>=%_ST3_ +Z%9?\
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M_P ]7H_L"#_GJ] &IYT7_/1/^^A1YT7_ #T3_OH5E_V!!_SU>C^P(/\ GJ]
M&IYT7_/1/^^A1YT7_/1/^^A67_8$'_/5Z/[ @_YZO0!J>=%_ST3_ +Z%'G1?
M\]$_[Z%9?]@0?\]7H_L"#_GJ] &IYT7_ #T3_OH4>=%_ST3_ +Z%9?\ 8$'_
M #U>C^P(/^>KT :GG1?\]$_[Z%'G1?\ /1/^^A67_8$'_/5Z/[ @_P">KT :
MGG1?\]$_[Z%'G1?\]$_[Z%9?]@0?\]7H_L"#_GJ] &IYT7_/1/\ OH4>=%_S
MT3_OH5E_V!!_SU>C^P(/^>KT :GG1?\ /1/^^A1YT7_/1/\ OH5E_P!@0?\
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M/^>KT :GFQGI(G_?0I]<7XILSI=C%-;3R*_FJ/UKK;,EK.(DY)4<T 3T444
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M[$TGVNW_ .>R?G7)^---$6G->Q32I*IR=K8%4O"6B1ZMHZW=S=7/F,Q'#\4
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M?KT^N64BSX$T& Q'?-:.M:8EY93222.KQQL5*'':@#1^UV__ #V3\Z/M=O\
M\]D_.O,O"%DVKWTT5U=3E44D;7KL7\'6;J1]JNA])* -])4D&4<-]#3ZY?PS
MI]WIM[>6LTCNB@%&<YXS5/Q5XFGM;A=,T\AKESAB/X<T =;->VMN<33QH?1F
MQ2P75O<_ZF9)/]TYKFM-\( 0++J5S+/<,,MEL@4NI>$RMN\NF74\,ZC(56P#
M[4 =,+B$JS"1=JG:3GH?2F_:[?\ Y[)^=<KX-ADN]#N8+MF\Q;A@^3SFN7U.
MTD@\6IIR74XB<@_?H ]5CECE!*.&QZ&DEGB@7=+(J+ZL<54M+)-.LR(W8@)D
MECDGBN)TM9/&.KW,EU=2);Q-@1(V,T =_#=V]Q_J9DD_W3FG":)@Q$BD(<,<
M]#7*:IX0$=F\NFW<\,Z#( ? -9^EK>/X-O$#N;AI2I.><XH [G[7;_\ /9/S
MH^U6_P#SV3\ZY;3_  7$;.)[J]NS,R@MMDP!Q7*Z-:-?>)&L)KJX\D,PX?GB
M@#U/[5 ?^6R?G4W6N'UCPB]I MS87ER75U)5W)R,UUUF)&LXBQYV\YH M44S
M:_\ >HVO_>H ?13-K_WJ0K)@X89QQ0 Z21(D+R,%4=R:5'5T#(0RGD$=Z\Y\
M:0ZK;>7-->YC8\I&2!^5=IH8=M"LCNY\H4 :=%,VO_>HVO\ WJ 'TR.:*;=Y
M<BMM.#@]*YWQ1:ZI)8S207:Q1(,@+D-^=9_P]>66PNV>0LWF#ECF@#M:*9M?
M^]1M?^]0 ^BF;7_O4;7_ +U #Z*9M?\ O4;7_O4 /HIFU_[U&U_[U #Z:SJ@
MRS #WI-K_P!ZN9\7/+&EL%D906P=IQWK2E#VDU$#I/M,'_/5/SH^TP?\]4_.
MN6^QI_STD_.C[&G_ #TD_.HYJ?<V]C(ZD7$)Z2K^=2]:X'5XS;6JO'+(&W?W
MJ[6U#FS@.[GRU_E5R@N133W,I1Y79EFBF;7_ +U&U_6LQ#Z*Y_Q%)J=G:/=V
M<T86,996!K%T2^\2ZWIS7MO<VJ ,5V,IR<4 =U17&:-XLNI-5_LO58A'<D[5
M91@?6F>*-3UG0WB>*>%XI6( P<B@#MJ*Y.TB\4W%HEPE[9_.,A2IJF_BO5='
MO1!K5L/+)P)(UP#[T =Q15:VG6[MTGAD#1N,@BIMK_WJ 'T4S:_]ZC:_]Z@!
M],>5$^^X7ZFC:_\ >KE/$!D.OV\7F,$,?(!]Z.MAZ6;?17.I^TP_\]5_.C[3
M#_SU7\ZY;[*O_/23_OJC[*O_ #TD_P"^JW^KR/*_M:AYG5+/$QPLBD_6I*X:
M8/!J5HL<K@,3GFNUVOC[U8R7+)IGI4Y*I2C5CM+_ #L244S:_P#>HVO_ 'J1
M0^BN9\1Z[<6$\-A8@-=S' R,@5$UCXFM;<W$=Y;RR@;BA!(/TH ZNBN8\,ZC
MJ&K6]Z]T1',KA0N.%XK%U36M>T_6X=-$\!,S (V#@9]: /0:*YA[;Q9!&72[
MLI2!]W8>:I:=XQF34/L&L0_9YB<!L8 ]Z .THJ,!F (8$'D&EVO_ 'J 'T4S
M:_\ >HVO_>H ?4;3Q(<-(H/N:7:_]ZN$U)Y&UN=6E?  X!II$2E:QW/VJ#_G
MLGYT?:H/^>R?G7!;6_YZ/^=&UO\ GH_YT:#O+L=^DT<APCJQ]C3ZX?0GE_MS
M8)6*[.A-=KM?^]0T$9<P^BF;7_O4R1)6C(1P&[$TBB:BN"U[6=>\/7<1EDAE
M@<Y^4'./2NLTG4H]7L$NH'!R/F7NI]* -&BN?\22:G964M]9S1A(DRRL#S5C
M0UU*2S2XO9HW,J!E" \9H V**K74OV:UDFD<!54G)KF_"7B&769+J.9@'5OD
M'M0!UM%,VO\ WJ-K_P!Z@!]%,VO_ 'J-K_WJ .8\=_\ ()B_Z[)_.NBL?^/&
M'_=%<WXY##2HLG_EJG\ZZ&Q5_L,//\(H MT4S:_]ZC:_]Z@!]%,VO_>HVO\
MWJ 'T4S:_P#>HVO_ 'J 'T4S:_\ >HVO_>H ?13-K_WJ-K_WJ 'T4S:_]ZC:
M_P#>H ?13-K_ -ZC:_\ >H ?13-K_P!ZC:_]Z@!]%,VO_>HVO_>H ?13-K_W
MJ-K_ -Z@!]%,VO\ WJ-K_P!Z@!]%,VO_ 'J-K_WJ 'T4S:_]ZC:_]Z@!]%,V
MO_>HVO\ WJ 'T4S:_P#>HVO_ 'J 'T4S:_\ >HVO_>H ?13-K_WJ-K_WJ 'T
M4S:_]ZC:_P#>H ?13-K_ -ZC:_\ >H ?13-K_P!ZC:_]Z@!]%,VO_>HVO_>H
M ?13-K_WJ-K_ -Z@!]%,VO\ WJ-K_P!Z@!]%,VO_ 'J-K_WJ 'T4S:_]ZC:_
M]Z@!]%,VO_>HVO\ WJ 'T4S:_P#>HVO_ 'J 'T4S:_\ >HVO_>H ?13-K_WJ
M-K_WJ 'T4S:_]ZC:_P#>H ?13-K_ -ZC:_\ >H ?13-K_P!ZC:_]Z@!]%,VO
M_>HVO_>H ?13-K_WJ-K_ -Z@!]%,VO\ WJ-K_P!Z@!]%,VO_ 'J-K_WJ 'T4
MS:_]ZC:_]Z@!]%,VO_>HVO\ WJ 'T4S:_P#>HVO_ 'J 'T4S:_\ >HVO_>H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ+C#X]:Y+QA_R.VD_P# ?YUL^ ?^0$?]ZL;QA_R.VD_\!_G0!;^)7_((L_\
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MX'4?^0]<?05WU<!J) UZXR<<"FC.IO$2BF[U_O"C>O\ >%(NZ+6@_P#(P?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 <;\._]3J?_ %W'\C7;5Q/P[_U.I_\ 7<?R-=M0 44A8+U('UI/,3^^OYT
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M/&'_ '17.^._^03%_P!=D_G716/_ !XP_P"Z* +%%%% !1110 4444 %%%%
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M8D]:DHH CQ)ZT8D]:DHH CQ)ZT8D]:DHH CQ)ZT8D]:DHH CQ)ZT8D]:DHH
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M444 4-3T>TU6-5N%;<OW70X8?C5:R\-V5G<"X)DGF'1IFW8^F:V** "BBB@
MJ.X_X]I?]P_RJ2H[C_CVE_W#_*@#C?AW_J=3_P"NX_D:[:N)^'?^IU/_ *[C
M^1KMJ .:\9?\>MG_ -=OZ4R/_5)_NBG^,O\ CUL_^NW]*9'_ *I/]T5I6_@P
M^9OA]V.HHHKE.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "L_6_^0:WUK0K/UO_ )!K?6ML/_%CZD5/@9U.D?\ ('M/^N2_RJ[5
M+2/^0/:?]<E_E5VKJ?&SB04445 !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_P"-/^18N?JO\ZZ"
MN?\ &G_(L7/U7^= %SPY_P B_9_[G]:U*R_#G_(OV?\ N?UK4H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *CN/^/:7_ '#_ "J2H[C_ (]I?]P_RH X
MWX=_ZG4_^NX_D:[:N'^'F[R=3Q_SW%=I^\H Y[QE_P >MG_UV_I3(_\ 5)_N
MBCQAN^S6>[_GM1'_ *I/]T5I6_@P^9OA]V.HHHKE.D**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "L_6_^0:WUK0K/UO_ )!K?6ML
M/_%CZD5/@9U.D?\ ('M/^N2_RJ[6?I._^R+3'_/(5<_>5=3XF<2)**C_ 'E'
M[RH DHJ/]Y1^\H DHJ/]Y1^\H DHJ/\ >4?O* )**C_>4?O* )**C_>4?O*
M)**C_>4?O* )**C_ 'E'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH
M_P!Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/\ >4?O* )**C_>
M4?O* )**C_>4?O* )**C_>4?O* )**C_ 'E'[R@"2BH_WE'[R@"2BH_WE'[R
M@"2BH_WE'[R@"2BH_P!Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DH
MJ/\ >4?O* )**C_>4?O* )**C_>4?O* )**C_>4?O* )**C_ 'E'[R@"2BH_
MWE'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_P!Y1^\H DHJ/]Y1^\H DHJ/]Y1^
M\H DHJ/]Y1^\H DHJ/\ >4?O* )**C_>4?O* )**C_>4?O* )**C_>4?O* )
M**C_ 'E'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_P!Y1^\H DHJ
M/]Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/\ >4?O* )**C_>4?O* )**C_>4
M?O* )**C_>4?O* )**C_ 'E'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_WE'[R@
M"2BH_P!Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/\ >4?O* )*
M*C_>4?O* )**C_>4?O* )**C_>4?O* )**C_ 'E'[R@"2BH_WE'[R@"2BH_W
ME'[R@"2BH_WE'[R@"2BH_P!Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/]Y1^\
MH DHJ/\ >4?O* )**C_>4?O* )**C_>4?O* )**C_>4?O* )**C_ 'E'[R@"
M2BH_WE'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_P!Y1^\H DHJ/]Y1^\H DHJ/
M]Y1^\H DHJ/]Y1^\H DHJ/\ >4?O* )**C_>4?O* )**C_>4?O* )**C_>4?
MO* )**C_ 'E'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_P!Y1^\H
M DHJ/]Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/\ >4?O* )**C_>4?O* )**
MC_>4?O* )**C_>4?O* )**C_ 'E'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_WE
M'[R@"2BH_P!Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/\ >4?O
M* )**C_>4?O* )**C_>4?O* )**C_>4?O* )**C_ 'E'[R@"2BH_WE'[R@"2
MBH_WE'[R@"2BH_WE'[R@"2BH_P!Y1^\H DHJ/]Y1^\H DHJ/]Y1^\H DHJ/]
MY1^\H DHJ/\ >4?O* )**C_>4?O* )**C_>4?O* )**C_>4?O* )**C_ 'E'
M[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_WE'[R@"2BH_P!Y1^\H DHJ/]Y1^\H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ)I ZWL?ZT :M%8Y\4Z*.M\GY&F'Q;H8ZWZ?D?\ "@#;HK"/C'01_P OZ?\
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M4+TU6$_@:[.B@#C?[+\5ITOX#_P$T?8_%R]+J _\!-=E10!QNSQBG22 _P#
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MU%-WK_>'YT;T_O+^= #J*;O3^^OYT>8G]]?SH =13?,3^^OYTGFQ_P#/1/\
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M7I;K1SC]@^Y:_P"$ZT;_ )Z/_P!\&D_X3O2/[\G_ 'P:K_8+3_G@M+]AM?\
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ME'_ S33X"M.US,/^!'_&NNHH XX^ 8.U[,/^!'_&D_X0)1]W49A^)_QKLJ*
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M.Z2O2RCJ1=$TU>EI'0!D-XZTD?=:4_\  #4;>.]/_ACE/_ #6^NEV*]+>/\
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MUFX_,4O_  AMXWWM9N?TKL** ./_ .$(E/WM8NOTI?\ A HC]_5;MORKKZ*
M.1_X0"Q/W[J=OK3U\ Z4O4NWUKJZ* .;7P1HZ]8<_6ID\'Z(O6R1OK6]10!C
MKX6T5?NZ?"/PJ5?#^E)]VRC'X5IT4 45TBQ7[MN@_"I5L+=/NQ*/PJS10!$L
M*I]W _"G[3_>_2G44 ,V'^]^E&P_WJ?10 S8?[QH\L_WC3Z* &>7_M&CR_\
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M;&(?A6K10!GKHFG+]VUC'X5*NF6B_=A0?A5NB@"!;6)?NJ!^%2!,=#^E/HH
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M+N>\3RTQG:^3S7?US_C3_D6+GZK_ #H M^');JXT6":[DWRN,DYK5K+\.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Y_QI_P BQ<_5?YUT%<_XT_Y%BY^J_P Z +GAS_D7[/\ W/ZUJ5E^'/\
MD7[/_<_K6I0 4444 %%%% !1110 445SUSXY\,6EU-;7&LVT<T+F.1#G*L#@
MCIZT :VJV(U31[W3S(8Q=6\D!<#.W<I7.._6O+_^%&6__0>E_P# 8?\ Q5>F
MP:SIUUHYU:"[C>P"/(9QG;M7.X_A@_E61_PL+PG_ -!RU_7_  H XG_A1EO_
M -!Z7_P&'_Q5'_"C+?\ Z#TO_@,/_BJ[;_A87A/_ *#EK^O^%'_"PO"?_0<M
M?U_PH XG_A1EO_T'I?\ P&'_ ,56MX8^%,/AKQ%:ZNFKR7#6^_$9@"AMR,O7
M<?[V:Z#_ (6%X3_Z#EK^O^%6=/\ &/A[5;Z.RL=5@GN9,[(TSDX!)[>@- &Y
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1
MW'_'M+_N'^525'<?\>TO^X?Y4 <;\._]3J?_ %W'\C7;5P_P\4F'4^<?OQ7:
M[#_>H YSQE_QZV?_ %V_I38_]4G^Z*7Q@I%M9\Y_?4D?^J3_ '16E;^##YF^
M'W8ZBBBN4Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *S];_P"0:WUK0K/UO_D&M]:VP_\ %CZD5/@9U.D?\@>T_P"N2_RJ[5#2
M4)TBT^;_ )9"KFP_WJNI\3.%#ZQM=\*:)XCB*ZG812OVF4;9%XXPPY_ \>U:
MVP_WJXO7/ ^H^)=:N9-0\0W4.CMM$-C:G&1L4,6)XY;=V;KU[5 SB+[5[CP#
M=I;>'/%<6K6V\(--FS,5Y/RAE&!U[%<GMQ7>ZS;Z5XJ\&:9+XIF&E1RM'.5>
M<0[9=C?+EQZ%CCKQ6MHGA'0O#P4Z;IT,<RKCSV&Z0^OS'GGVXJWK&AZ;K]HE
MKJEJMS D@D5&8C# $9X([$_G0!YI_P (+\,_^AEB_P#!G#_A74^"= \+:-<7
M;^'=42]>1%$RK=)-M )P?EZ=ZG_X5KX/_P"@)%_W]D_^*K1TOPWH7A@7%SIU
MFEH&3,S!V.57GN3TYH N:OK%AH6G27^HW"P6Z<9;JQ[ #N?85PGARPO_ !GX
MLB\9:E"UKI]NNS3;9_O,.<.?S)]^.P&>,/C;1O$7B5]3\5K=26-N2+'3H8PR
M '^)^1D]/J?88KT32/BEX=U;4K73+.&]66=Q'&&A55'_ (]P* *FHRMX_P#%
M?]BPD-X>TN0/?N,@7$HSB,'T!_J?2JUDH3X]7RJ %%@  !P!L2M:7X4^%)YG
MEDM)V=V+,?M##)/)[UPUOX&T.3XLW6@-#+_9T=J)5C\TYW;5[]>I)H ]OKSO
MXHPOITNA^*84+/IMVJR@8YC8Y[^XQ_P+\O0HT6*-8T&%4!0/0"L?Q;I)USPG
MJ>G(,R2P$QCU=?F7]0* .%^*<4OB#5=,T*T8%DM)[\@'._"'8!]2K#/O4>L^
M)3/\%=.6-Q)=WZ1V( /)93ACCZ)C_@0H^$S2ZYJ6HZQ=A6\BS@T]0WS%@%&X
MD^^T'\?;G'\*Z3=3?$&'PY-$!8Z%>W%ZN.N"5V<GJ,A#Z\G\ #3^(<=KX7N_
M 2D$VNFRDML7EE1H23CU."?J:F\+/'\2O$ESJ^M2J8--<"UTGDA,]'?/#=/Q
M(YP  ;GQ-C2;Q=X&BE17C>_*LC#(8&2'(([BCQO9W'A+Q';^-]+1FC++#J<2
MXPT9( /XX SZA30 SXIQ3#5-$N[^RN+SP];NS744/7=ZG&#T]2!P1D9K/\CX
M?^(Y[$Z!J<6A:G;3*T4GE%"Q[##$*QSCN3QCO72>(/$FK6<NB^(=)$M]X<F0
M&Z@MX5:3!!PWJ.O3(P5P<9KC/%NH>&?&4"6OAG1GGUJ:13YT5L8]B\Y+$=>/
M7/UXH ]MHJMIT$MKIEI;SR"2:*%$=QT9@ "?SJ=E+8P<4 .HIFP_WJ-A_O4
M/HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIF
MP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ
M-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O
M4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /H
MIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_
MWJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A
M_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4
M/HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIF
MP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ
M-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O
M4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /H
MIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_
MWJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A
M_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4
M/HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIF
MP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ
M-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O
M4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /H
MIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_
MWJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A
M_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4
M/HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIF
MP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ
M-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O
M4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /H
MIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_
MWJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A
M_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4 /HIFP_WJ-A_O4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/^-/\
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M%6(!QVQ7,3:Y=WGAB2QN3NEBD^]_L^E>A6^L6MUH/VSS4P8B2I89Z=*X[1]
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M (](O]T5-4-I_P >D7^Z*FKUX[(_.:_\67J_S"BBBJ,@HHHH **** "BBB@
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M $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244
M1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'
ML;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>Q
MO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_
MO4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]
M1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&
MQO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&
M_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^
M]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U
M244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)
M10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E%
M $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244
M1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'
ML;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>Q
MO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_
MO4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]
M1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&
MQO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&
M_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^
M]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U
M244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)
M10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E%
M $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244
M1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'
ML;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>Q
MO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_
MO4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]
M1L;^]4E% $>QO[U&QO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&
MQO[U244 1[&_O4;&_O5)10!'L;^]1L;^]4E% $>QO[U&QO[U244 1[&_O4;&
M_O5)10!'L;^]1L;^]4E% $>QO[U87C($>%[G)SRO\ZZ&N?\ &G_(L7/U7^=
M%SPY_P B_9_[G]:U*R_#G_(OV?\ N?UK4H **** "BBB@ HHHH **** .8^(
ME[+I_@#5YX6*N8A%D#L[!#^C&O /!^BQ^(?%FGZ7,Q6*:0F3!P2JJ6(!]2%(
MKZ'\;:5)K7@S5+"%2\SP[HT'5F4AP!]2H%?-.D:I/HNKVFI6V/.MI!(H;HV.
MH/L1D?C3&?2WB*TMK#P%K%K:01P6\>G7 2.-0JJ/+;H*\E^"?_(YWG_8/?\
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.UO\
MY!X_WQ6C6=K?_(/'^^*%N5#XD6[3_CTB_P!T5-4-I_QZ1?[HJ:O7CLC\YK_Q
M9>K_ #"BBBJ,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH KWW_'G)]*U_#?_ "!(/I61??\ 'G)]*U_#?_($@^E<>(^-'T^3?[K/
M_$OR->BBBL#T@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N?\ &G_(L7/U7^==!7/^-/\ D6+GZK_.@"YX
M<_Y%^S_W/ZUJ5E^'/^1?L_\ <_K6I0 4444 %%%% !1110 4444 %>1>/_A7
M-=W<NK^'8P[RL7GL]P&6/5D)X]]OY>E>NT4 ?(=U9W5C.8+NVFMYAUCF0HP_
M U#7U[+#;W<6R:.*://W74,,CZUDW]MX8T:(W5];:5:(QQYDD4:[C^7- 'S=
MHGAG6?$5PL6F6$LP)PTN,1I]6/ Z'^E?0'@7P1;^#M.=3(MQ?SX,TX7&!V1?
M]D<_7\@-"Q\9>'-2N5MK36;229B J&3:6)Z 9QD^PK<H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.X_X]I?]P_RJ2H[
MC_CVE_W#_*@#C?AW_J=3_P"NX_D:[:N'^'@)AU/!Q^_%=IL;^]0!SWC+_CUL
M_P#KM_2F1_ZI/]T4>,%(MK/)S^^HC_U2?[HK2M_!A\S?#[L=1117*=(4444
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M10 4444 %%%% !1110 4444 %%%% !1110 5'<?\>TO^X?Y5)4=Q_P >TO\
MN'^5 '&_#O\ U.I_]=Q_(UVU<3\._P#4ZG_UW'\C7;4 <UXR_P"/6S_Z[?TI
MD?\ JD_W13_&7_'K9_\ 7;^E,C_U2?[HK2M_!A\S?#[L=1117*=(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VM_\ (/'^^*T:
MSM;_ .0>/]\4+<J'Q(MVG_'I%_NBIJAM/^/2+_=%35Z\=D?G-?\ BR]7^844
M451D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>^
M_P"/.3Z5K^&_^0)!]*R+[_CSD^E:_AO_ ) D'TKCQ'QH^GR;_=9_XE^1KT44
M5@>D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6-O)Y;SJ6'4*<X^M68+F&ZCWPR*Z_P"R<UR/@JVTZ_TAI942:Z9R92_WJCT
M&V\6WMM8G-DH!8 \*: .SFGBMTWS2*B^K'%0VNHVEX2(9E9A_#GFN.N)#XA\
M:_8)CNL;<$[?[QQFG^+;./0VM=6L5\@Q,%<)T89[T =Q15;3[L7VGP72C E0
M-BK- !4=Q_Q[2_[A_E4E1W'_ ![2_P"X?Y4 <;\._P#4ZG_UW'\C7;5Q/P[_
M -3J?_7<?R-=M0!S7C+_ (];/_KM_2F1_P"J3_=%/\9?\>MG_P!=OZ4R/_5)
M_NBM*W\&'S-\/NQU%%%<ITA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5G:W_P @\?[XK1K.UO\ Y!X_WQ0MRH?$BW:?\>D7^Z*F
MJ&T_X](O]T5-7KQV1^<U_P"++U?YA1115&04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 5[[_ (\Y/I6OX;_Y D'TK(OO^/.3Z5K^
M&_\ D"0?2N/$?&CZ?)O]UG_B7Y&O1116!Z04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/^-/^18N?JO\
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M_&F&\M1UN(Q^-(O@*S/W[NY/_;2I!X TG^*6Z/\ VTHY ]OY$1U&Q'6[B'_
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M&S;[MQ&?QH EVO\ WJ-K_P!ZD6YA;[LJG\:D# ]"#]* &;7_ +U&U_[U244
M1[7_ +U&U_[U244 1[7_ +U&U_[U244 1[7_ +U&U_[U244 1[7_ +U&U_[U
M244 1[7_ +U&U_[U244 1[7_ +U&U_[U244 1[7_ +U&U_[U244 1[7_ +U&
MU_[U244 1[7_ +U&U_[U244 1[7_ +U&U_[U244 1[7_ +U&U_[U244 1[7_
M +U&U_[U244 1[7_ +U&U_[U244 1[7_ +U&U_[U244 1[7_ +U&U_[U244
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M_P!ZI** (]K_ -ZC:_\ >J2B@"/:_P#>HVO_ 'JDHH CVO\ WJ-K_P!ZI**
M(]K_ -ZC:_\ >J2B@"/:_P#>HVO_ 'JDHH CVO\ WJ-K_P!ZI** (]K_ -ZL
M+QD"/"]SDYY7^==#7/\ C3_D6+GZK_.@"YX<_P"1?L_]S^M:E9?AS_D7[/\
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M;?[FF8_X$*:=?\3/]RQ _P"!"E=#Y9=CNZ*X(ZMXL;_E@J_E3#?^+VZ2(O\
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MBWL>B>='_P ]$_[ZI//B_P">B?\ ?5>>_P#"+1_\_4W_ 'V:/^$6B_Y^9O\
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MMXWT,#Y;AF^D9H Z*BN7;QUI8^[YC?\  #4+>/K,?=MIF_X"?\* .NHKC?\
MA/5;[FG3-^?^%)_PG%P?N:/*?^!?_6H [.BN-'C/4&^[H<GXO1_PE.LO]S1&
M'_ Z .RHKC?[?\1/]S2"/^!BC^U/%;_<TL#_ ($* .RHKBS>>,FZ6"#_ ($M
M'F^-&_Y8QK^*T =I17%[?&C?\M(U_P" K2BV\9MUO(Q]$% '9T9'K7&_V;XL
M?[VI*/\ @ H_L+Q(_P![5@/^ 4 =CD>HHW#U%<=_PB^MO]_6L?\  *0^#M3;
M[VN/^"?_ %Z .RW+ZC\Z-R_WA^=<;_PA%V?OZQ(?P/\ C1_P@C'[^IS'\3_C
M0!V)D0=74?C4;74"]94'XUR@\!0_Q7TY_P"!'_&I%\!V7\5Q,?\ @9H Z7[;
M;'_ELGYT[[7;_P#/9/SKFO\ A!-/_P">LW_?9I/^$#L>TTW_ 'V: .G^U0'_
M ):I^=*+B$_\M4_.N6_X0.S_ .?B;_OLTG_"!VO:ZF_[[/\ C0!U?G1?\]$_
M[Z%+YL?]]?SKDCX"MO\ G[F_[[/^-)_P@4'_ #^S?]]'_&@#KO,3^^OYTN]?
M[P_.N//@*+M?3_\ ?1_QI/\ A 8_^@A/_P!]'_&@#L=Z_P!X?G1N7^\/SKC?
M^$"4=-1F_P"^C_C1_P (&>VI3?F?\: .RW+_ 'A^=&Y?[P_.N-_X05^VJ3?K
M_C1_P@TW;59?U_QH [+<O]X?G1N7U'YUQO\ P@]QVU>7\C_C1_PA%UVUB7\C
M_C0!V6Y?4?G1N'J/SKC?^$)O>VLR?]\__7H_X0N_[:W)_P!\_P#UZ .RW#U%
M&X>HKC?^$,U'MKC_ /?'_P!>@>#M47D:Z^?=* .RR/6EKC?^$:UZ/[FLY_X!
M1_9'BB/[FIJ?^ "@#LJ*XPVWC)/NWL;?5!2?\5HG\4;_ (** .THKB_M/C->
MMHC_ / EIW]I^+(_OZ8#_P "% '945QO_"0^((_OZ.3_ ,#%'_"7:I']_0W/
MT>@#LJ*XS_A-[I?OZ-*O_ O_ *U+_P )ZH^_ITR_G_A0!V5%<@OCZT/WK:9?
M^ G_  J9?'>F'[PD7_@!H ZFBN;7QQHI^].Z_P# #4B^--";I>?^.&@#H" >
MHIIC0]44_A6.OBS16Z7@_(U*OB/2GZ7:4 :)@A/6)#_P$4TVMN>MO$?^ "JR
MZSI[_=NH_P ZF6_M'^[<1_\ ?0H <;&T/6U@/_;,5&VF6#=;.#_OV*G%Q >D
MT9_X$*7SHO\ GHG_ 'T* *+:'IK];2+\%%0MX9TE^MHGX"M7S(_[Z_G1O7^\
M/SH Q&\(:,W6VQ]#43>"=%;_ )8R#Z/70Y'J*6@#F3X$T7LMP/I*:8W@33?X
M);E?^VIKJ:* .1;P+!_!>7"_]M#4;>!G_@U.X'_;0UV5% '%_P#"%7R_<UB4
M?4DT?\(CK*_<UO'U!-=I10!QG_"-^(H_NZS&W_ #1_97BJ/[NH1-_P  KLZ*
M .,\GQC']VXA;_MG2>=XU7^&%OI&*[2B@#B_MWC)>MFC?111_:'C'_GP7\A7
M:44 <7_:7C'_ *!P_(4?VGXP_P"@:/R%=I10!Q?]J>,/^@7_ "H_M7Q?_P!
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ML_C"3[UU"O\ VSKLZ* .,_LKQ5)][48E_P" 4?\ ".^(Y/O:O&O_   UV=%
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M_;,56U"V\7:G9/:7*1>4^,[4 -=[10!E^'K>ZM-'@@NP!(@QQ6I110 4444
M%%%% !1110 4444 1SP175O+;S('BE0HZGNI&"*^<?&7P_U3PO=S3)!)<:7D
MM'<HN0BYZ/\ W3R!D\'MZ#Z2HH X'X/0"'P&KC&9KF1S^B_^RUYA\2O"MQH'
MB6XNEA/]GWLC2PR*N%5CR4]L<X]J^B8((;:(16\4<48R0D:A0,G)X'N2:;=6
M=M?6[07EM#<0MUCF0.I_ \4 ?(=>A_"?PM<ZKXCBU>6)EL+%MXD/1Y?X5'KC
M.3Z8'K7JZ_#GPBDHD&AP;@<X+,1^1.*Z2""&U@2"WBCAAC&U(XU"JH] !P*
M)**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^Z*FJ&T_X](O]T5-7KQV1^<U_P"++U?YA1115&04444 %%%% !1110 4444
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ME0!E?\)UHG:2<_\ ;(TT^.](_A\\_P#;(ULC1].'2TB_*GC2[$=+6/\ *@#
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MI_V'I?\ SY1?E2?V#I?_ #XQ?E0!F_\ ";Z)_P ]I/\ OV:7_A-M$_Y[R?\
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MHX_YYK4M% $.%/6)?RJ-K>!_O6Z'\!5JB@#/;3;)_O6B&H6T+3'^]8H:UJ*
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ME!X[M?XK6<?]LS3QX[T[^**<?]LS72FV@;K$A_"HSI]HW6W0_A0!A#QWH_\
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M %W'\C7;5Q/P[_U.I_\ 7<?R-=M0!S7C+_CUL_\ KM_2F1_ZI/\ =%/\9?\
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MA7G/PK)'Q'TH D ^<#[_ +IZ](^-G_(F6?\ V$$_]%R5YM\+/^2D:3_VV_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4A8 X)&:6@ HII=%."R@^A-.H ***165AE6!^AH 6BBB@ J.X_X]I?\ </\
M*I*CN/\ CVE_W#_*@#C?AW_J=3_Z[C^1KMJXGX=_ZG4_^NX_D:[:@#FO&7_'
MK9_]=OZ4R/\ U2?[HI_C+_CUL_\ KM_2F1_ZI/\ =%:5OX,/F;X?=CJ***Y3
MI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.UO_
M )!X_P!\5HUG:W_R#Q_OBA;E0^)%NT_X](O]T5-4-I_QZ1?[HJ:O7CLC\YK_
M ,67J_S"BBBJ,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH KWW_'G)]*U_#?_($@^E9%]_QYR?2M?PW_ ,@2#Z5QXCXT?3Y-_NL_
M\2_(UZ***P/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSS/8T>9[&@!]%,\SV-'F>QH ?7/^-/\ D6+GZK_.MWS/8U@^,FW>%[GCNO\
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MJ?WDDJX%:.L^'_M]S%>VLHM[R+[LF.OUJL/#ES?W\-WK%TD_D_ZN.-=H'UH
MT] @^S:%9QE<,(AN^M:)4,,, 1Z&E  & ,"B@"/R(?\ GDGY5'/!$+:7]VGW
M#V]JL5'<?\>TO^X?Y4 <;\.O]3J?_7<?R-=M7$_#O_4ZG_UW'\C7;4 <SXR_
MX];/_KM_2FQ_ZI/]T4_QE_QZV?\ UV_I3(_]4G^Z*TK?P8?,WP^['4445RG2
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6=K?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW93D_B#^%>L6US!>6T=S;2I+!*H9)$.0P/<&@"6BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC_CVE_W#_*I*CN/^/:7_ '#_ "H XOX>-B'4^/\ EN*[7S/8UQGP[_U.I_\
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MUMY-.A9X49B.2165:--1YYI]CZ?)$Y4917<W/^$LTS^])_WS1_PEFF?WI/\
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MHH 9YGL:/,]C3Z* &>9[&L'QDV[PO<\=U_G70US_ (T_Y%BY^J_SH N>'/\
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M?^ R?_&JU?$/@[4]:U5KRU\5ZGIL115^SV[L$!'?AAU^E97_  KG7/\ H?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_QI_P BQ<_5?YUT%<_XT_Y%
MBY^J_P Z +GAS_D7[/\ W/ZUJ5E^'/\ D7[/_<_K6I0 4444 %%%% !1110
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MHH **** "BBB@ HHHH *SM;_ .0>/]\5HUG:W_R#Q_OBA;E0^)%NT_X](O\
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M- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0
M^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HI
MGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@
M]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T
M>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#
MT- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0
M ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /H
MIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y
M@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0
MT>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F
M#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#
M0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /
MHIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9
MY@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/
M0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'
MF#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]
M#0 ^BF>8/0T>8/0T /HIGF#T-'F#T- #Z*9Y@]#1Y@]#0 ^BF>8/0T>8/0T
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MW:?\>D7^Z*FJ&T_X](O]T5-7KQV1^<U_XLO5_F%%%%49!1110 4444 %%%%
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MQ6?]BM?^>"?E1]BM?^>"?E1[2A_*_O#V$NYH?\);I7]^7_OBC_A+=*_OR_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKG_&G_(L7/U7^==!7/\ C3_D6+GZK_.@"YX<_P"1?L_]S^M:E9?AS_D7[/\
MW/ZUJ4 %%%% !1110 4444 %?(5S.UU=37#DEY79VSZDYKZ]KY3\3:+/X?\
M$-YITT901R$QG!PR$_*1GJ,?R- 'T?K-U$O@34;K3)P(ETV5[:6!^@$9VE2/
M3CFO!_#'B?Q!<>+-&AFUW4Y(I+Z!'1[N0JRF10003R#7,)=W,<)A2XF6(Y!1
M7(4YZ\5$CM&ZNC%64Y# X(-,9]@T5\D?VIJ'_/\ W7_?YO\ &C^U-0_Y_P"Z
M_P"_S?XTA'UO17R1_:FH?\_]U_W^;_&NN^&-_>3_ !$TJ.6[GD0^=E7D)!_=
M/VS0!]$T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4=Q_Q[2_[A_E4E1W'_ ![2_P"X?Y4 <;\._P#4ZG_UW'\C7;5Q/P[_
M -3J?_7<?R-=M0!S7C+_ (];/_KM_2F1_P"J3_=%/\9?\>MG_P!=OZ4R/_5)
M_NBM*W\&'S-\/NQU%%%<ITA1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"G_/.\_[_P#_ -:M#1?AMX?T#5X-3L4N1<P;MA>7</F4J>,>A-==10 4444
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M%_NBIJ]>.R/SFO\ Q9>K_,****HR"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN?\
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M1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT
M/HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF
M+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT
M /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIG
MF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YB
MT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HI
MGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1Y
MBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /H
MIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1
MYBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /
MHIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+
M1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT /HIGF+1YBT
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M8MC]: /H7X6?\DWTG_MM_P"CGKL*X_X6?\DWTG_MM_Z.>NPI""BBB@ HHHH
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M#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:*
M$P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EH
MH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*
M6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>
M@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&
M!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/0
M48'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3
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M_7<?R-=M7$_#O_4ZG_UW'\C7;4 <UXR_X];/_KM_2F1_ZI/]T4_QE_QZV?\
MUV_I3(_]4G^Z*TK?P8?,WP^['4445RG2%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6=K?\ R#Q_OBM&L[6_^0>/]\4+<J'Q(MVG
M_'I%_NBIJAM/^/2+_=%35Z\=D?G-?^++U?YA1115&04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 4M6_Y!TE&D_\ (,@_W:-6_P"0
M=)1I/_(,@_W:QQ7\'Y_H?4Y#_#E_78NT445YA] %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !45S_P >TGTJ6HKG_CVD^E5#XD)[
M%#0_^/,_4_SK4K+T/_CS/U/\ZU*UQ7\:7J12^!!1116!H%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "CK4'A+_C]OOK_ %J<=:@\
M)?\ '[??7^M=6'_AU/E^9SXCH=911169SA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 4M6_P"0=)1I/_(,@_W:-6_Y!TE&D_\
M(,@_W:QQ7\'Y_H?4Y#_#E_78NT445YA] %%%% !1110 4444 %%%% !1110
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M3#"GV4=6/TX]Q7N7A?P)HOA1%>TA,MYMPUU-RYSUQV4?3\<UTJJ$4*H 4#
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M%% !1110 4444 %%%% !1110!2U;_D'24:3_ ,@R#_=HU;_D'24:3_R#(/\
M=K'%?P?G^A]3D/\ #E_78NT445YA] %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !45S_ ,>TGTJ6HKG_ (]I/I50^)">Q0T/_CS/
MU/\ .M2LO0_^/,_4_P ZU*UQ7\:7J12^!!1116!H%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% "CK4'A+_C]OOK_6IQUJ#PE_Q^WW
MU_K75A_X=3Y?F<^(Z'64445F<X4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'U"W@3S=TLUJZ*N8G R2,#D@4A'O]%%% !1110 4444 %%%% !1110 4444
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MT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M
M#J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;Y
MBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M
M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;
MYBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8
MM #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*
M;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>
M8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J
M*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT
M>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #
MJ*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YB
MT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M
M#J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;Y
MBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M
M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;
MYBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8
MM #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*
M;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>
M8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J*;YBT>8M #J
M*;YBT>8M #J*;YBT>8M #J*;YBT>8M #JY_QI_R+%S]5_G6]YBU@>,F#>%[G
M'JO\Z +OAS_D7[/_ '/ZUJ5E^'/^1?L_]S^M:E !1110 4444 %%%% !115;
M4-0M-*L);Z^G6"VB +R-T&3@?J0* +-%>%>)_C#J=_,\&A+]@M1E?-8!I7]^
M>%_#)]Z\_O-8U/4'9[W4+JX9NIEF9L_F: /K6BOCVM"QUW5],*FQU.\M]N,"
M*9E&!VP#@CVH ^LJ*\7\*_&2Y2X2V\2(DD#<?:XH\,GNRC@CZ#/L:]CMKF"\
MMH[FVE26"50R2(<A@>X- $M%%% !1110 4444 %%%% !1110 4444 %%%% !
M7-^-C(/#TGE^OS?2NDJM?V<>H6,MK)]V12N?2@##\&VML/#T;)$F7SN..M<U
M) =)^(8BMAMC=2=J]#D5JZ')J'AHRZ=/8SSVX8F*2-<_A5G2](N+_P 0OKE[
M$T.!B*)AR.W- &1X/4V_B>\A?AR2<'K6S\07V^%W'<R+@5'JNDW.G>(4URPA
M:;((EB49)[<5%J4-]XJO+:(6DMK91D-(9AC<0>U &WX7@\CP]9^K1AC6I/!%
M<Q-%-&KQMP58<&B"%+>!(8QA$& *DH S?^$>TC_H'P?]\U'/H&DK;R$:?!D(
M?X?:M:H[C_CVE_W#_*@#C/ATJB#4Q@8$X'Z5VVQ?05Q7P[_U.I_]=Q_(UVU
M',^,0!:V>!_RV_I38_\ 5)_NBG^,O^/6S_Z[?TID?^J3_=%:5OX,/F;X?=CJ
M***Y3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK.UO_D'C_?%:-9VM_P#(/'^^*%N5#XD6[3_CTB_W14U0VG_'I%_NBIJ]>.R/
MSFO_ !9>K_,****HR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'YS7_BR]7^844451D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD_QH_P"$M\2?]##JW_@;)_C0![#\;/\ D3+/_L()_P"BY*\V^%G_ "4C2?\
MMM_Z)>N>OM<U?4X1#?ZI>W<2MO"3W#R*&P1G!/7D_G70_"S_ )*1I/\ VV_]
M$O3&?25%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !1110 4444 %%%% %+5O^0=)1I/_(,@_P!VC5O^0=)1I/\
MR#(/]VL<5_!^?Z'U.0_PY?UV+M%%%>8?0!1110 4444 %%%% !1110 4444
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M5]* $WKZT;U]:7:OI1M7TH 3>OK1O7UI=J^E&U?2@!-Z^M&]?6EVKZ4;5]*
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M5]* $WKZT;U]:7:OI1M7TH 3>OK1O7UI=J^E&U?2@!-Z^M&]?6EVKZ4;5]*
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M?6EVKZ4;5]* $WKZT;U]:7:OI1M7TH 3>OK6!XS8'PO<X]5_G70;5]*P/&8
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M7%?QI>I%+X$%%%%8&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK_Z#MY_WW1_PGWBO_H.WG_?=>B?\*,M_^@]+_P" P_\ BJ/^%&6__0>E_P#
M8?\ Q5 'F5_XN\0:I:-:7NKW<UN^-T;2<-]<=:G\"V4U]XXT:.%68QW4<S8&
M<*C!B3^5>F#X':=D9UFZ([@1+78>%? VC>$0[V*2274B[)+F9LN5SG Q@ 9'
M8>F<XI".EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***.G6@"O?7L.G
MV<EU.V(XQDUE>&]>.NQ2R;-JJ>/<5EZD6\274T:$C3[3)8C^-NA%1^ ,):W8
M'17./SH W=8\00Z7)';I$UQ<R?=B3K56'Q*\%_%9ZI;/;/-_JW;H?:L+1F_M
M#Q]<W3'<(P0N>@XK0^(46W1$NU \R*5=I]* .OHK-T"Z:\T.TF=LN8QN/O5R
MZNH;.W>>X<)$@RS'M0!-4=Q_Q[2_[A_E61_PEVA_\_Z?D?\ "F3>+-$>"11?
MIDJ0.#Z4 8_P[_U.I_\ 7<?R-=M7#_#IU-OJ1SP9P1^5=MO7UH YSQE_QZV?
M_7;^E,C_ -4G^Z*7QBP-M9X/_+;^E)'_ *I/]T5I6_@P^9OA]V.HHHKE.D**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[6_^0>/
M]\5HUG:W_P @\?[XH6Y4/B1;M/\ CTB_W14U0VG_ !Z1?[HJ:O7CLC\YK_Q9
M>K_,****HR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"EJW_ "#I*-)_Y!D'^[1JW_(.DHTG_D&0?[M8XK^#\_T/J<A_AR_KL7:*
M**\P^@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH
M=13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U
M]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^
MM&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44
MW>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@
M!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O
M7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WK
MZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =1
M3=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]:
M '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&
M]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>
MOK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U
M%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7U
MH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT
M;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=
MZ^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '
M44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?
M6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK
M1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-
MWKZT;U]: '44W>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK1O7UH
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M2?\ D&0?[M8XK^#\_P!#ZG(?X<OZ[%VBBBO,/H HHHH **** "BBB@ HHHH
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M2C8OI3J* &[%]*-B^E.HH ;L7THV+Z4ZB@!NQ?2C8OI3J* &[%]*-B^E.HH
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MI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0
M;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]
M11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O
M7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%
M&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?
M2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8
MOI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0
M ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U
M]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11
MO7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U
M%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q
M?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C
M8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI
M0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;
MU]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]1
M1O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7
MU%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&
MQ?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2
MC8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8O
MI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0
M;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]
M11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O
M7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%
M&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?
M2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]11O7U%&Q?2C8OI0 ;U]16#XS(/A>YP>
MZ_SK>V+Z5@^,P!X7N<>J_P Z +GAS_D7[/\ W/ZUJ5E^'/\ D7[/_<_K6I0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5'<?\>TO^X?Y5)4=Q_Q[2_[A
M_E0!QOP[_P!3J?\ UW'\C7;5Q/P[_P!3J?\ UW'\C7;4 <UXR_X];/\ Z[?T
MID?^J3_=%/\ &7_'K9_]=OZ4R/\ U2?[HK2M_!A\S?#[L=1117*=(4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VM_\@\?[XK1K
M.UO_ )!X_P!\4+<J'Q(MVG_'I%_NBIJAM/\ CTB_W14U>O'9'YS7_BR]7^84
M4451D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+
M5O\ D'24:3_R#(/]VC5O^0=)1I/_ "#(/]VL<5_!^?Z'U.0_PY?UV+M%%%>8
M?0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%<_
M\>TGTJ6HKG_CVD^E5#XD)[%#0_\ CS/U/\ZU*R]#_P"/,_4_SK4K7%?QI>I%
M+X$%%%%8&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 *.M0>$O\ C]OOK_6IQUJ#PE_Q^WWU_K75A_X=3Y?F<^(Z'64445F<X444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_P"-
M/^18N?JO\ZZ"N?\ &G_(L7/U7^= %SPY_P B_9_[G]:U*R_#G_(OV?\ N?UK
M4H **** "BBB@ HHHH **** "N'\4?%'1?#=X]BB2WUY&<2)"0%C/HS'O[ '
M'?%;?C/5Y-"\'ZGJ,)Q-%%MC;T9B%!_ L*^6R2Q))))Y)/>@#UY_CHY0B/PZ
MJMV+7F1^6P5#_P +RO/^@'!_X$'_  KC+'X>^+-1B66WT2X",,@S%8LCZ.15
MK_A5GC/_ * W_DU#_P#%TQG4_P#"\KS_ * <'_@0?\*VO"7Q6N?$OB>STB32
MHH%N-^9%F+$;49NF/]FO//\ A5GC/_H#?^34/_Q==+X!\ ^)M$\;:?J&H:9Y
M-K#YF^3SXVQF-E' 8GJ12$>VT444 %%%% !1110 4444 %%%% !1110 4444
M %,EE2")I9&"HHR2>U/JAJU@^HV@M@^V-CB3W6@#G[CQ]912L(X97B4X,FTX
MK?TG6+36;;S[5\CNIX(H30].2S%J+6,Q[=I&WK7'^"H&MO$&I1PM^X0\T ==
MJNN6FDA1,6:1^%1!DG\*J6?B:WFO$M+F-[>9QE-ZX!_.N>TYO[4^($T\AWQP
M@A%/0<5=^(,0CTN&_51YL$B[6].: .QHJAHEVU]HUK<.<N\8+?6K<\\5M$TL
MTBQQKR68X H DJ.X_P"/:7_</\JH_P#"0:1_T$;?_OL5'/K^DM;R@:A;DE#@
M;QZ4 <_\._\ 4ZG_ -=Q_(UVU<1\.F!@U,YX,X/Z5VVY?44 <WXR_P"/6S_Z
M[?TID?\ JD_W13O&)!MK/!_Y;?TIL?\ JD_W16E;^##YF^'W8ZBBBN4Z0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM;_Y!X_W
MQ6C6=K?_ "#Q_OBA;E0^)%NT_P"/2+_=%35#:?\ 'I%_NBIJ]>.R/SFO_%EZ
MO\PHHHJC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *6K?\ (.DHTG_D&0?[M&K?\@Z2C2?^09!_NUCBOX/S_0^IR'^'+^NQ=HHH
MKS#Z **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H
MKG_CVD^E2U%<_P#'M)]*J'Q(3V*&A_\ 'F?J?YUJ5EZ'_P >9^I_G6I6N*_C
M2]2*7P(****P- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 4=:@\)?\ '[??7^M3CK4'A(@7M]D]_P"M=6'_ (=3Y?F<^(Z'644F
MY?44;E]169SBT4FY?44;E]10 M%)N7U% (/0T +1110 4444 %%%% !1110
M4444 %%%% !12$@=31N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7
MU% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]12T %%%% !1110 4444 %%%%
M !1110 4444 %%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&
MY?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T
M4FY?44;E]10 M%)N7U%&Y?44 +7/^-/^18N?JO\ .M_<OJ*P/&9!\+W.#W7^
M= %SPY_R+]G_ +G]:U*R_#G_ "+]G_N?UK4H **** "BBB@ HHHH **** .=
M\=Z;)JW@?5K.$;I##YBKS\Q0A\#W.W%>"_#V.TE\>Z0EZ%,)F. PR"^T[!_W
MUMKZ3U&^BTS3+N_F5VBM87F<( 6*JI)QGOQ7S+XFOM$NM<;4?#JWMJLC^:8I
M45/*?.<H58X&>0.,=J /J.BO#=(^->IV=HD.I:;%?NBX\Y9?*9O=OE(_("M8
M?'.# SH$@/<"Z!_]EH ]<HKR3_A>=O\ ] &7_P "1_\ $UK>&/BM#XE\16ND
M)I$ENUQOQ(9PP7:C-TVC^[B@#T6BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHK-UO6(-$L&N9LD]$4?Q'TH CU[5?[.L]D/SW<ORPH.I-0^']&_LG37
M,F#<S9>1OKSBN/T_Q?:"]DO]0MY9;DG"8Z(O; ]:W].\8-K>JPVMG;/''SYK
M.,\8H R?!@*^)+U7^_N-;7Q 8+X6DS_ST7^M9]Y;-X=\7KJA4_89P0Y'\!QB
ME\278\22VVF::?M$98-*Z]%P: -[PI$T7AVTW'[R!A6G>6D5]:O;SKNC<8(H
MLK86=E#;*<B-0HJ>@#GO^$+T;_GWIDW@[1T@D86_(4D?E725'<?\>TO^X?Y4
M <7\.HU%OJ2]A,!^E=MY:^E<7\._]3J?_7<?R-=M0!S'C!0MM9X_Y[?TI(_]
M4G^Z*?XR_P"/6S_Z[?TID?\ JD_W16E;^##YF^'W8ZBBBN4Z0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM;_Y!X_WQ6C6=K?_
M "#Q_OBA;E0^)%NT_P"/2+_=%35#:?\ 'I%_NBIJ]>.R/SFO_%EZO\PHHHJC
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6K?\
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MTIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44
M-\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*
M/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G
M44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WR
MU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M
M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10
M WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7T
MH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*
M=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?
M+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CR
MU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU%
M #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?
M2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7T
MIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*P/&2A?"]SCU7^==#7/^-/\
MD6+GZK_.@"YX<_Y%^S_W/ZUJ5E^'/^1?L_\ <_K6I0 4444 %%%% !1110 4
M444 9GB.VFO/"^KVMNADGFLIHXT'5F*$ ?F:^>?^%<>+O^@)/_WTG^-?3-%
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M0 4444 %9VM_\@\?[XK1K.UO_D'C_?%"W*A\2+=I_P >D7^Z*FJ&T_X](O\
M=%35Z\=D?G-?^++U?YA1115&04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 4M6_Y!TE&D_P#(,@_W:-6_Y!TE&D_\@R#_ ':QQ7\'
MY_H?4Y#_  Y?UV+M%%%>8?0!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5%<_P#'M)]*EJ*Y_P"/:3Z54/B0GL4-#_X\S]3_ #K4
MK+T/_CS/U/\ .M2M<5_&EZD4O@04445@:!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 HZU!X2_X_;[Z_UJ<=:@\)?\?M]]?ZUU8?
M^'4^7YG/B.AUE%%%9G.%%%% !1110 4444 %5-4L1JFE7=@TTD*W,31-)'C<
MH88.,@U;HH ^=O$L6L:+J4>E0:R^M?V.WVPGR2PML$?>SGC)&1D@<>]>E> -
M"N&F_P"$GN/$TFK27D!C*J#L7D''/.1CI@8R:Z/3?".C:5<:G-;6O.I$_: [
M%@0>H&>0"221GO\ 2I?#OAG3?"]@UIID;JCN7=G<LS'W^@X_"@#RKQYHVH>'
MKFYAL_$,]U_;DQ TQH]SN6;GIP!N/! '.!@X-2^ M(U#Q.]G/>>))(/[%DC5
M=,CCVM'L.!N!P.<<G!SDY]*]/N/"^E77B2WU^6W+7\"%%8L2I'8E3QD9.",=
M?IAEGX4TFP\17>NP0,+ZZ'SMN.T>N![\$_2@#;HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Y3Q3X[L_"6J6=M?V=RUO<(6-S&N5
M4CC'H3ZX.1D<<UU=<[XX?5E\*72Z-8B\NY,+M(#;%ZE@I^\1C@>I![4 >>:!
M\1[+1+OQ'<W^IWVHQRWA&GP%V?\ =AGP1NX0$%?RZ<5VNI>/8]+\(Z=K\VE7
M92Z95EA (,'!R22,?>  SC.<UR-GX)UKP5J^AZCI5H-4FN%\K4(Y-I".?F)#
M$94<<-ZJ,_>Q7J>IO<QZ7=/96JW5R(V\J!V"B1L< D\8H \H3XBZ>/B#/JK:
MO>_V+]BW):[GP9>%VB/IGJ><>N:]#\(^*(_%FERW\=E-:HDQC59>=XP"&!Z=
M_P!*\O/@37H=$B\5^09O$'VKSGL6@4KY1X"^7CJ/0= >Q%>SV$MU-8027MNM
MO<L@,L2N'"-W (ZT 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Y_P :?\BQ<_5?YUT%<_XT_P"1
M8N?JO\Z +GAS_D7[/_<_K6I67X<_Y%^S_P!S^M:E !1110 4444 %%%% !7S
M5XG\3^(+?Q9K,,.NZG'%'?3HB)=R!542,   > *^E:\XU/X/:5J>JWFH2:E>
MI)=3O,RJ%P"S%B!Q[T 3^'M1OI_@I-?RWEQ)>BQO'%P\K&0,IDVG=G.1@8],
M5XK_ ,);XD_Z&'5O_ V3_&OHS3_"MMI_@Q_#,=Q*UNT$T/FMC?B0L2?3C<:X
MS_A2&C_]!6__ "3_  H \F_X2WQ)_P!##JW_ (&R?XT?\);XD_Z&'5O_  -D
M_P :]9_X4AH__05O_P D_P */^%(:/\ ]!6__)/\*8SR;_A+?$G_ $,.K?\
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M %%%% !1110 4444 %%%% "9 ZFC</44A0,<FD\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBEIGEK3Z "BBB@ HHHH **** "BBB@ HHHH ***",C%
M";AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
M';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC
M</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WR
MUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M: ';AZBC</44WRUH\M:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/H* ,76/$*:=/':00FXNY/NQJ<$55C\1SV>H0V>K6Q@\[[DF>,^E8NAO]O\
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M )^D_.C^W=._Y^D_.@+,T:*SO[=T[_GZ3\Z/[=T[_GZ3\Z LS1HK._MW3O\
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M0%F:-%9W]NZ=_P _2?G1_;NG?\_2?G0%F:-%9W]NZ=_S])^=']NZ=_S])^=
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MOO1_P@.F?WWKK** L<G_ ,(#IG]]Z/\ A =,_OO7644!8Y/_ (0'3/[[T?\
M" Z9_?>NLHH"QR?_  @.F?WWH_X0'3/[[UUE% 6.3_X0'3/[[T?\(#IG]]ZZ
MRB@+')_\(#IG]]Z/^$!TS^^]=910%CD_^$!TS^^]'_" Z9_?>NLHH"QR?_"
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M (1.Q_O-1_PB=C_>:MZBCG8>SCV,'_A$['^\U'_")V/]YJWJ*.=A[./8P?\
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M3L?[S5O44<[#V<>Q@_\ ")V/]YJ/^$3L?[S5O44<[#V<>Q@_\(G8_P!YJ/\
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M6]11[*'8/K^)_G,'_A%++U:C_A%++U:MZBCV4.P?7\3_ #F#_P (I9>K4?\
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M5 '&_#O_ %.I_P#7<?R-=M7$_#O_ %.I_P#7<?R-=M0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5QNJ?\C2G^X:[*N.U3_D:D_W#6]'[7HQQ^)%
MNBC%%<1WA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 9.H?\A*W_ !K6'2LK4/\ D)6_XUJCI7=A/A9\QQ%_$I^GZA11176?
M.A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E:U]
MVW_ZZ5JUE:U]VW_ZZ5E6_AL]'*?]\A\_R9IQ_P"K7Z"G4V/_ %:_04ZM#@EN
MPHHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
ME:__ ,@__@0J_:?\><'^X*H:_P#\@_\ X$*OVG_'G!_N"N?&?PH^I];D7\!D
MU%%%><>X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !534_\ CP>K=5-3_P"/!Z$..Z$TO_CPB^E7*IZ7_P >$7TJY7K4_@1^?XW_
M 'FIZO\ ,****LY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 9+_ *I_H:S]%_X]3_O5H2_ZI_H:S]%_X]3_ +U92_B+YGI4?]QJ
M^L?U-.BBBM3S0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,C1O];<?[W]:UZR-&_P!;<?[W]:UZQH? CT\X_P!\E\OR0444
M5L>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4&
MA?\ (Q7'_7/^M3U!H7_(Q7'_ %S_ *US8GX4>YD7\6?^$ZVN?\:?\BQ<_5?Y
MUT%<_P"-/^18N?JO\ZY3W2YX<_Y%^S_W/ZUJ5E^'/^1?L_\ <_K6I0 4444
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M?R%(1[G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFIZO\PHHHJSE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9E73K24;8T_B;:.6/?DGCM2_!O3Y+GQFUV!^[M+=V9O=OE _4_E2$>_T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W'_'M+_N'^
M525'<?\ 'M+_ +A_E0!QOP[_ -3J?_7<?R-=M7$_#O\ U.I_]=Q_(UVU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8_B?3]5U+
M1FAT;4/L-\KAXY3G:<=5.,\'Z'Z4 ;%%><1>/=<\-RK;>,M$E2/.T:A:#=&>
M<9(Z=QWS[=J[?2==TO7;83Z9?0W*$9(1OF7ZJ>1^(H T**X"X\=^)H;F6)/
M-_(J.5#B9L, >O\ JZ8GC_Q,74-\/]152>3YS' _[]T =CK>NZ?X>TYK_4[@
M0P [1QDNV"0H'<G!KEX_BMH7F1_:K/5;*"0X2YN;7$;?0@D_I6KXB\(IXBUK
M2+ZXNA]GT]RYM'A#I*3C.3D>@ZY_6D\?W=C:>!M5-_@QR0-%&N>6D;[F/<'!
M]L$]J .CCD2:))8G5XW4,KJ<A@>A![BLCQ+XFT_PKI?V_43(4+A$CB +NQ[
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M3LOQJ0=*C\3_ /(3LOQJ0=*Z<-LSQ<]WI>GZA11174> %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !65K7W;?_KI6K65K7W;?_KI
M65;^&ST<I_WR'S_)FG'_ *M?H*=38_\ 5K]!3JT."6["BBBF2%%%% !1110
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MMTY2>>550IDA3@9/( Z"O5O!WA*T\(:1]D@8RW$F&N)S_P M&]AV ["NBHH
M**** "BBB@ HHHH **** "BBB@ HHHH *CGFCMH'FE8*B#+$]A4E4=4L#J5L
M+<OMC+?/[CTH YNX\?0I(S0VDSP*<&3;Q70:-KEIK=MYULQR/O(W45*NE6*6
M@MA;1>4%VXVCFN,\%VY@\0:FL#?N$/- '5ZMKUMI)1'5Y9I/NQQC)JK:^)D^
MW1V=]!);2R#*%Q@&L#2F_M+X@3W#G<L0(4'H.*O?$*()I$5ZH'FPR+M;N* .
MPHK.T*[:]T6TG<Y=HP6/O5]W6-2SL%4=2: '5'<?\>TO^X?Y5']OM/\ GXC_
M #J.>^M3;R@3I]P]_:@#E?AW_J=3_P"NX_D:[:N(^'1'D:F<_P#+<?RKMLCU
MH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:
M*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,C
MUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(
M]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH
M6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3
M(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUH
MR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]:
M %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6B
MDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]
M:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/
M6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %
MHI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR
M/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,
MCUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@
M!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:S-?U^Q\-Z4^HZ@T@@5@N(UW,
M2>@%:61ZU'+#!.$$T4<FQPZ;U!VL.A&>A'K0!YU+XH\6>+E:#P[X?6TL).#>
M:HG##/4*>#^ ;O6IX(\ _P#"*WESJ-S>K/?72%9$AB$<29;<=H ]0,8  ]*[
M7(]:,CUH X&XU+XGK<RK!HFC-"'(1BYR5SP?];Z4Q-4^*6]=^@Z-MSSA^<?]
M_:]!R/6C(]: ,KQ%XBL/#&DR7]_)A1Q'&OWI6[*H]?Y5Q^B>'M5\7ZG#XA\7
M1A+:+YK'2_X4!.0SCOVX/)[X Q6CXS\"7'BW5+*\37&L5LTQ%&+?S,/NR7!W
MC!X7M_#5#_A ?$__ $4/4/\ ORW_ ,<H M?$RTUW4;&PT_2K&:[LII2U\D,B
MHS(I4A=QZ9YYP>E<GXXUG6I/!#:;<>#7TFP5HU6472NL>#P-H4>F*]5T*PN=
M+T:WLKW49-0N(]V^ZD&&?+$C(R>@('7M5/Q=X>'BGP_+I7VO[+YCJWF^7OQM
M.>F1_.@"IX$U/4=0\/VZ7VCO81P6\*P.TH?SUV?>Q@;>@X]ZZBJNG6HT_3+2
MR\SS/L\*1;\8W;5 SCMTJSD>M 'BMWJ(\(VOCW0HPR>8RRVJY.T+-A6Q[A67
M_OGKQ6F;5/A_XO\ #US*4CMI]):TNI2>&DC7<?7&2$&?_KUTOB3X?VWB'Q5I
M^N->+!]F,?FP^3N\\*^[!.X8XXS@]O2K?C?P=#XSTVWMFN_LDT$N])O+W\$8
M*XR.O!_"@#GO 5G./ &LZQ=D_:-6:XN6R,<8(_4[C]"*\]T7PYJQ\)1>++68
M7(TVZW161CW@(#EVP>.N.W09SQ7O46E0V_AY='@8)$EK]F5L9P-NW.._K5#P
MAX97PMX?&DM=B\7S'<N8M@(;MC)_G0 Z#7M&UWP:^J3NO]F36["Y4DG8",.C
M8YR,D<?45Q&G>%-=L]-CO_ GBHRZ;+NDAMKI"%QGH-P(SU'*KS74>'/!*^';
MK5(HM0\[1[\L1ISQ<1$\<-N.1M^7IR,>E9L?P\U#3#)#X?\ %U]IUBQ)%L\0
MF"9Z[26&/Y^] %OP)XKU+7+C4]+UJVAAU+375)##]U^H/<C(*]C@YX Q7:5@
M>%O"MEX5LYH[>62XN+A_,N+F8Y>5N<9]AD_F?6M[(]: %HI,CUHR/6@#EO$_
M_(3LOQJ0=*C\3'_B9V7XU(.E=.&V9XN>[TO3]0HHHKJ/ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*UK[MO\ ]=*U:RM:^[;_
M /72LJW\-GHY3_OD/G^3-./_ %:_04ZFQ_ZM?H*=6AP2W84444R0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RM?_P"0?_P(5?M/
M^/.#_<%4-?\ ^0?_ ,"%7[3_ (\X/]P5SXS^%'U/K<B_@,FHHHKSCW HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:G_P >#U;J
MIJ?_ !X/0AQW0FE_\>$7TJY5/2_^/"+Z5<KUJ?P(_/\ &_[S4]7^844459RA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R7_ %3_
M $-9^B_\>I_WJT)?]4_T-9^B_P#'J?\ >K*7\1?,]*C_ +C5]8_J:=%%%:GF
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9
M&C?ZVX_WOZUKUD:-_K;C_>_K6O6-#X$>GG'^^2^7Y(****V/,"BBB@ HHHH
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MK7Z"G5H<$MV%%%%,D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_UW'\C7;5Q/P[_U.I_]=Q_(UVU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?P(_/\;_ +S4]7^844459RA1110 4444 %%%% !1110 4444 %%%% !1110
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M+GZK_.N@KG_&G_(L7/U7^=<I[I<\.?\ (OV?^Y_6M2LOPY_R+]G_ +G]:U*
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M_>'YT;T_O#\ZJ_V>G_/1_P Z/[/3_GH_YT:A=EK>G]X?G1O3^\/SJK_9Z?\
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MG1O3^\/SJK_9Z?\ /1_SH_L]/^>C_G1J%V6MZ?WA^=&]/[P_.JO]GI_ST?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9&C?ZVX_WOZUKUD:-_K;C_>_K6O6-#X$>GG'^^2^7Y(****V/,"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J#0O^1BN/^N?]:GJ
M#0O^1BN/^N?]:YL3\*/<R+^+/_"=;7/^-/\ D6+GZK_.N@KG_&G_ "+%S]5_
MG7*>Z7/#G_(OV?\ N?UK4K+\.?\ (OV?^Y_6M2@ HHHH **** "BBB@ HHHH
M S]=TQ=:T&^TUB!]I@:-220 Q'!X]#@U\KW5K=Z1J4EO.LEO=VTF".596'0C
M^8-?7%<]XD\%:'XJ3.H6I%P!M6YA.R11Z9Z'Z$'&3B@#.^&NL:CXA\(FZU>5
M;B0SO$K% -R *.<=><UX)XBTF70/$=]IS;U^SS$1L0063.5;\1@U]*>%O#T7
MA?08M+BN'G6-G;S'4 G<Q/2LKQGX T[Q@D<KR&TOH^%N43<2O]UAD9'X\4 >
M)ZS\0?$6O:.FF7MVIMQC>8TVM+CIO(Z^N/6F?#_39M3\<Z3'$I(AN%N'(_A5
M#NY_(#\:ZQ?@AK!E ?5;$1YY8!R<?3']:]+\'^"-.\'VCK;DSWDH FNG4!F'
MH!_"N><<^Y.!3&=-1112$%%%% !1110 4444 %%%% !1110 4444 %%%% $<
M\T=O"\TK!409)/:L_1M;@UE)&@'RH<9]:Q=?N)=:GDTRT<BWA7=<2#H1Z5!\
M/@([2Z4=%8C\C0!TVIZQ9Z3&K7,F"W"J!DFJMCXDL[NZ%J^Z*=AE5<8R*YNR
M?^UOB!+)*=\, (1#T'%6_'\(AL(-21<302*%84 =E15'1[MK_2+6Y8_/)&"W
MUJZS!1EB !W)H 6H[C_CVE_W#_*D^T0?\]H_^^A4=Q<0FVE_?1_</\0]* .2
M^'?^IU/_ *[C^1KMJXGX=']SJ?\ UW'\C7;4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO^J?Z&L_1?\ CU/^]64OXB^9Z5'_ '&KZQ_4TZ***U/-"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R-&_UMQ_O?UK7K(T;
M_6W'^]_6M>L:'P(]/./]\E\OR04445L>8%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4&A?\C%<?]<_ZU/4&A?\ (Q7'_7/^M<V)
M^%'N9%_%G_A.MKG_ !I_R+%S]5_G705S_C3_ )%BY^J_SKE/=+GAS_D7[/\
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M"]JW_@%)_A75_#;P[K=CX_TRYO-'U"W@3S=TLUJZ*N8G R2,#D@4A'O]%%%
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M/P[:;C]Y 1]*T=1LAJ%C);&5X@XQO3J*=86HLK""V!R(D"YJQ0!R \!Q@?\
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MY?\ M&GT4 ,\O_:-'E_[1I]% #/+_P!HT>7_ +1I]% #/+_VC3Z** "BBB@
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M%%%%6<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M,E_U3_0UGZ+_ ,>I_P!ZM"7_ %3_ $-9^B_\>I_WJRE_$7S/2H_[C5]8_J:=
M%%%:GFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9&C?ZVX_P![^M:]9&C?ZVX_WOZUKUC0^!'IYQ_ODOE^2"BBBMCS HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KZ(N[Q%<<
MX_=_UJQ4&A?\C%<?]<_ZUS8GX4>YD7\6?^$ZKR_]HU@^,EV^%[GG/*_SKH:Y
M_P :?\BQ<_5?YURGNESPY_R+]G_N?UK4K+\.?\B_9_[G]:U* "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!S?C7P_X4UF\M9/$.JI931QE8E:[2+<N>N&Z\US'_""_#/\ Z&6+_P &</\
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MBBB@ KYD\4Z)JLOB[6I(],O7C>_G966W8A@9&P0<5]-T4 ?)O]@ZQ_T";_\
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MHHHKC.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"JFI_P#'@]6ZJ:G_ ,>#T(<=T)I?_'A%]*N53TO_ (\(OI5RO6I_ C\_QO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]O;R-.2H7+IGL..<#IZUD?"[Q9JVOC4;76[@RW4(BEB)C5"8W&>B@#T/_ J
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M >G7 X(KNJS]%T2P\/Z:EAIL'E0*<D9)+-W8GN3BM"@ HHHH **** "BBB@
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MTY.4J2NSB_*UO_GT_P#':/*UO_GT_P#':[2BCGG_ #$_5\+_ ,^HG%^5K?\
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MH **** "BBB@ KS+XK^"9-8M5US38F>]MTVS1(,F6,<Y'NO/N1]!7IM% 'R
MK203*Z,T<L;9# X92/Y&NLL/B=XMT^,1C5#.@& +B-9#]=Q&X_B:]A\3?#30
M?$D[73(]E>L<M-;X&\^K*>"??@^]>=ZA\%-=@<FQOK*[C[;RT3G\,$?K3&4G
M^,7BIA@-9)[K!_B:P-8\;^(]=C:*^U69H67:T,>(T8>X7 /XYK;_ .%0^+/^
M?>U_\"!6UIGP0U&1P=4U2V@CQG;;*9&/MR% _6@#S&RLKG4;R*SLX7FN)FVI
M&@R6-?2O@;PI%X2\/I:G:]Y-B2ZD ZOC[H/]T=!^)XS4_AKP=HWA2%ETVW/G
M.,27$IW2.,YP3T Z<  <5OTA!1110 4444 %%%% !1110 4444 %%%% !1T%
M%!&1B@#)F\2Z3!,\4EVJNAPPQTK+\1ZY:W'AJX>SF$BOF,D5>G\(Z)<W#SRV
M8:1SECN/)J#4/"]G'H5S:Z? (V8%E&<Y- &+X8\+17FA*\\\GSDE0C%<57T:
M^O-"\3/HT\K2PN#@MU''%;'@G48QI;6-PXCN8&(96..*H?9O[8^(!N85S;PJ
M [CH>,4 0>#"7\27K/\ ?R:VOB!C_A%I-W_/1?ZUF10GP_XYWRC997 .U^V<
M=ZL>-[E;^*VTFW(E>9PQV<X&>] &SX35U\.VN_N@(^E:&IV;W]A+;1RF)G&
MX[4NFVILM-M[8]8D"U:H XL>";W'_(9D_(_XTV3P7>)$['6)" I.,'_&NVJ.
MX_X]I?\ </\ *@#B?AS&1;:DN[I,!G\*[;RS_>KC?AW_ *G4_P#KN/Y&NVH
MC\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI**
M (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2
MB@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJ
MDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]
MZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS
M_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\
ML_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ
M/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]
MZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS
M_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\
ML_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (
M_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@
M"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDH
MH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI
M** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>
MJ2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_
MWJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+
M/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZC
MRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>
MH\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_
MWJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+
M/]ZCRS_>J2B@"/RS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/
MRS_>H\L_WJDHH C\L_WJ/+/]ZI** (_+/]ZCRS_>J2B@"/RS_>H\L_WJDHH
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MR(KHP9& *LIR"/44 .HJG?ZMINE^7_:&H6EIYF=GVB98]V,9QDC.,C\ZI_\
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MA\"/3SC_ 'R7R_)!1116QY@4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!B^)K7P[<Z:?^$C2S-LH.'N
M2%*],[6Z@]/N\UX];7UQ8:S]G^&U]JU[!DM);20;H%R,9^;IG'4J.W->C?\
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M14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4
M245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U
M $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^
M]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9
M_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>
M6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U
M'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^
M]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9
M_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^
M6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14
M?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 24
M5'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $
ME%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0
M!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O
M4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?
M[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'E
MG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1
MY9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O
M4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?
M[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?E
MG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'
MY9_O4>6?[U $E%1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%
M1^6?[U'EG^]0!)14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0!)
M14?EG^]1Y9_O4 245'Y9_O4>6?[U $E%1^6?[U'EG^]0 7'_ ![R?[I_E7%Z
M-_Q[-_O&NPN(S]GD^;^$_P JX_1O^/9O]XUK0_B''F?^Y2]4:5%%%=Q\D%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D:-_
MK;C_ 'OZUKUD:-_K;C_>_K6O6-#X$>GG'^^2^7Y(****V/,"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J#0O^1BN/\ KG_6IZK:
M(I;Q#<8./W?]:YL3\*/<R+^+/_"=?7/^-/\ D6+GZK_.MSRS_>K"\9*5\+W6
M3GE?YURGNEWPY_R+]G_N?UK4K+\.?\B_9_[G]:U* "BBB@ HHHH **** "LO
M1?$6D^(;;S]+O8IP!ED!PZ?[RGD5J5\QZOX7\3>";Q;F6.: (W[N]M7)0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ([C_ (]Y/]TUQ>C?\>S?[QKM+C_CWD_W37%Z-_Q[-_O&M:'\0X\S_P!R
MEZHTJ***[CY(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY],D%JN+D F4M]XFI/ YMYO#80*#EB)%;N?>LG3[-;'X@RP6'_'L5S*!VR*
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MO[QHV-_>-244 1[&_O&C8W]XU)10!'L;^\:-C?WC4E% $>QO[QHV-_>-244
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M;^\:-C?WC4E% $>QO[QHV-_>-244 1[&_O&C8W]XU)10!'L;^\:-C?WC4E%
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M2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MR-&_UMQ_O?UK7K(T;_6W'^]_6M>L:'P(]/./]\E\OR04445L>8%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;1 3XAN,''[O^M6
M:@T+_D8KC_KG_6N;$_"CW,B_BS_PG4[&_O&L+QD"/"]UDYY7^==#7/\ C3_D
M6+GZK_.N4]TN>'/^1?L_]S^M:E9?AS_D7[/_ '/ZUJ4 %%%% !1110 4444
M%<]XH\%Z1XMA07\3+<1J5BN(CAU'IZ$>Q_2NAHH \CG^!D#.3;Z_)&GI):AS
M^885I:5\%]$LYQ+?W=S?;2"(\"-#]<9)[=Q7I5% #8XTAB2*)%2-%"JBC 4#
MH .PIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(RAE*L
M0>H-+10!@R>$]/,[31&:%G.6"2$ _A5_3=(M-+1A;(V6ZLYW,?QJ_10!1U+2
M;358PERA.W[K*<$?C5>Q\.V%C.)U#RS#HTK;L?3-:U% !1110 5'<?\ 'M+_
M +A_E4E1W'_'M+_N'^5 '&_#O_4ZG_UW'\C7;5Q/P[_U.I_]=Q_(UVU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ329<:DH?"S%_P"$3L?]JC_A$['_ &JVMK_WJ-K_ -ZCE17MZG<Q?^$3L?\
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M4?\ ")V/^U6WL;^^:-C?WS1RH/;U.YB?\(G8_P"U1_PB=C_M5M[&_OFDVO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ J.X_X]I?\ </\ *I*CN/\ CVE_W#_*@#C?AW_J
M=3_Z[C^1KMJXGX=_ZG4_^NX_D:[:@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0D*"2<
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M:7_</\J .-^'?^IU/_KN/Y&NVKB?AW_J=3_Z[C^1KMJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH RO$6@VWB71I=+NYKB*WE96<P, QP<@<@C
M&0.W:N0'P<T)0 -4UH < "X3C_QRO1** .8\,>!]/\*W4]Q9W=_.\R!"+J16
M &<\845T]%% &'X?\*V/ANXU&>SEN':_F\Z43,I .2?EP!Q\QZYK<HHH S]<
MT:V\0:-<Z7>&06]P &,9 88(((R".H':HM"\/V7A_08M'MM\MM'O!,^UF?<2
M3NP #UQTZ5JT4 <_X6\':9X0ANH].:=_M+AG:=E8\9P 0!P,G\ZEM?"UC:>+
MKWQ+'+<&]NX1#(C,OEA0$' QG/R#OZUMT4 <]K'@[3M9URPUEIKFUO[(Y26V
M95+@'(#94Y'4?0D&D\1>"=&\331W%W'+#>1C"75L^R0#TSR#^(KHJ* .5T7X
M?Z/HVJ+J9EO;^^0$1S7TWF,@Z<8 'K^9KJJ** "BBB@#@[&5([R[WL!\YZ_6
MM#[5!_ST6M-_"^F22-(T;;F.3AC3?^$5TO\ YYO_ -]FM(5I0CRV.7%Y=0Q-
M9U7-J_D9WVJ#_GHM'VJ#_GHM:/\ PBNE_P#/-_\ OLT?\(KI?_/-_P#OLU?U
MF78YO[%P_P#S\?W(SOM4'_/1:/M4'_/1:T?^$5TO_GF__?9H_P"$5TO_ )YO
M_P!]FCZS+L']BX?_ )^/[D9WVJ#_ )Z+1]J@_P">BUH_\(KI?_/-_P#OLT?\
M(KI?_/-_^^S1]9EV#^Q</_S\?W(SOM4'_/1:/M4'_/1:T?\ A%=+_P">;_\
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M:H/^>BT?:H/^>BUH_P#"*Z7_ ,\W_P"^S1_PBNE_\\W_ .^S1]9EV#^Q</\
M\_']R,[[5!_ST6C[5!_ST6M'_A%=+_YYO_WV:/\ A%=+_P">;_\ ?9H^LR[!
M_8N'_P"?C^Y&=]J@_P">BT?:H/\ GHM:/_"*Z7_SS?\ [[-'_"*Z7_SS?_OL
MT?69=@_L7#_\_']R,[[5#_ST6FZ ROXAN"IR/+_K6G_PBNE_\\W_ .^S5JPT
M2RTZ9I;=&#L,$DYK.I5E-6:.O!X&CA'*4)-MJVQHUS_C3_D6+GZK_.N@KG_&
MG_(L7/U7^=0=!<\.?\B_9_[G]:U*R_#G_(OV?^Y_6M2@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*XN([6W>>9
MML:#+'TJ6HYX(KF!X9D#QN,,I[T 8O\ PF6B9Q]J_P#':V+6YBO+=)X6W1N,
MJ:R_^$2T+_H'1?K6I!!!8VRQ1*L4*#@9X% '$M_R48_[IK2\?EQX?^7^_P _
M2L9KRV_X6$9//CV8(W;ABNOURP75M&FA3#,R$QD'C- $'A, >'[?'I7+:PI?
MXD1K']_RQ_Z#6MX.U&.VTI[*^E6&X@<@B0XX]LU3T6!]9\93ZP$80Q?*K$<-
MVXH K>#,GQ'>&3[^36U\0,?\(M)N_P">B_UK,\D^'O&_GRC98W(.'[ X[U/X
MSNEU1;;2;-A.TKAF,9W!1GOB@#:\)HZ>';7?W0$?2M#4HKJ:PE2SE\J<CY6]
M#3M.M?L6G6]M_P \D"U9H XP:3XLQ_R%3^0ILFE>*A$Y;525VG(P.17:U'<?
M\>TO^X?Y4 <5\.0_V;4@3SYPS]<5VVU_[U<9\._]3J?_ %W'\C7;4 ,VO_>H
MVO\ WJ?10 S:_P#>HVO_ 'J?10 S:_\ >HVO_>I]% #-K_WJ-K_WJ?10 S:_
M]ZC:_P#>I]% #-K_ -ZC:_\ >I]% #-K_P!ZC:_]ZGT4 ,VO_>HVO_>I]% #
M-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4 ,VO_ 'J-K_WJ?10 S:_]ZC:_]ZGT
M4 ,VO_>HVO\ WJ?10 S:_P#>HVO_ 'J?10 S:_\ >HVO_>I]% #-K_WJ-K_W
MJ?10 S:_]ZC:_P#>I]% #-K_ -ZC:_\ >I]% #-K_P!ZC:_]ZGT4 ,VO_>HV
MO_>I]% #-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4 ,VO_ 'J-K_WJ?10 S:_]
MZC:_]ZGT4 ,VO_>HVO\ WJ?10 S:_P#>HVO_ 'J?10 S:_\ >HVO_>I]% #-
MK_WJ-K_WJ?10 S:_]ZC:_P#>I]% #-K_ -ZC:_\ >I]% #-K_P!ZC:_]ZGT4
M ,VO_>HVO_>I]% #-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4 ,VO_ 'J-K_WJ
M?10 S:_]ZC:_]ZGT4 ,VO_>HVO\ WJ?10 S:_P#>HVO_ 'J?10 S:_\ >HVO
M_>I]% #-K_WJ-K_WJ?10 S:_]ZC:_P#>I]% #-K_ -ZC:_\ >I]% #-K_P!Z
MC:_]ZGT4 ,VO_>HVO_>I]% #-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4 ,VO_
M 'J-K_WJ?10 S:_]ZC:_]ZGT4 ,VO_>HVO\ WJ?10 S:_P#>HVO_ 'J?10 S
M:_\ >HVO_>I]% #-K_WJ-K_WJ?10 S:_]ZC:_P#>I]% #-K_ -ZC:_\ >I]%
M #-K_P!ZC:_]ZGT4 ,VO_>HVO_>I]% #-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!Z
MGT4 ,VO_ 'J-K_WJ?10 S:_]ZC:_]ZGT4 ,VO_>HVO\ WJ?10 S:_P#>HVO_
M 'J?10 S:_\ >HVO_>I]% #-K_WJ-K_WJ?10 S:_]ZC:_P#>I]% #-K_ -ZC
M:_\ >I]% #-K_P!ZC:_]ZGT4 ,VO_>HVO_>I]% #-K_WJ-K_ -ZGT4 ,VO\
MWJ-K_P!ZGT4 ,VO_ 'J-K_WJ?10 S:_]ZC:_]ZGT4 ,VO_>HVO\ WJ?10 S:
M_P#>HVO_ 'J?10 S:_\ >HVO_>I]% #-K_WJ-K_WJ?10 S:_]ZC:_P#>I]%
M#-K_ -ZC:_\ >I]% #-K_P!ZC:_]ZGT4 ,VO_>HVO_>I]% #-K_WJ-K_ -ZG
MT4 ,VO\ WJ-K_P!ZGT4 ,VO_ 'J-K_WJ?10 S:_]ZC:_]ZGT4 ,VO_>HVO\
MWJ?10 S:_P#>HVO_ 'J?10 S:_\ >HVO_>I]% #-K_WJ-K_WJ?10 S:_]ZC:
M_P#>I]% #-K_ -ZC:_\ >I]% #-K_P!ZC:_]ZGT4 ,VO_>HVO_>I]% #-K_W
MJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4 ,VO_ 'J-K_WJ?10 S:_]ZC:_]ZGT4 ,V
MO_>HVO\ WJ?10 S:_P#>HVO_ 'J?10 S:_\ >HVO_>I]% #-K_WJ-K_WJ?10
M S:_]ZC:_P#>I]% #-K_ -ZC:_\ >I]% #-K_P!ZC:_]ZGT4 ,VO_>HVO_>I
M]% #-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4 ,VO_ 'J-K_WJ?10 S:_]ZC:_
M]ZGT4 ,VO_>HVO\ WJ?10 S:_P#>HVO_ 'J?10 S:_\ >HVO_>I]% #-K_WJ
M-K_WJ?10 S:_]ZC:_P#>I]% #-K_ -ZC:_\ >I]% #-K_P!ZC:_]ZGT4 ,VO
M_>HVO_>I]% #-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4 ,VO_ 'J-K_WJ?10
MS:_]ZC:_]ZGT4 ,VO_>HVO\ WJ?10 S:_P#>HVO_ 'J?10 S:_\ >HVO_>I]
M% #-K_WJ-K_WJ?10 S:_]ZC:_P#>I]% #-K_ -ZC:_\ >I]% #-K_P!ZC:_]
MZGT4 ,VO_>HVO_>I]% #-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4 ,VO_ 'J-
MK_WJ?10 S:_]ZC:_]ZGT4 ,VO_>HVO\ WJ?10 S:_P#>HVO_ 'J?10 S:_\
M>HVO_>I]% #-K_WJ-K_WJ?10 S:_]ZC:_P#>I]% #-K_ -ZC:_\ >I]% #-K
M_P!ZC:_]ZGT4 ,VO_>HVO_>I]% #-K_WJ-K_ -ZGT4 ,VO\ WJ-K_P!ZGT4
M,VO_ 'J-K_WJ?10 S:_]ZC:_]ZGT4 ,VO_>HVO\ WJ?10 S:_P#>HVO_ 'J?
M10 S:_\ >HVO_>I]% #-K_WJ-K_WJ?10 S:_]ZC:_P#>I]% #-K_ -ZC:_\
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M(5YW,JA<+ZDD<5Y)XOTNZO/!\OB[6!_Q,-2NHOL\621;V^UBJCIR>"?P[DT
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MH 85;/#4;7_O4^B@!FU_[U&U_P"]3Z* &;7_ +U8/C($>%[G)SRO\ZZ&N?\
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MXA;PWIL-Q%IUQJ$\\P@BMX/O,Q5F]"<84] :W** /./LWQ$\5L3/<1>&K$C
M2+YYF]\@Y'?NO;CO72>%?!>F^$UF>TDGGN;@#SYYWR7(R>G0<D^_O71T4 >>
M?V)\3_\ H:]._P# 9/\ XU4MKHWQ)2[A>Y\46$D"R*9$%NH++GD9\OTKOJ*
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M5B6U0#+%)3G  Y^ZJ#_@7;(K=\17"> O&R7D,OE6]UHSP(2-Q,L283<.Y^5
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MB?\ 01A_,T?\)1HG_01A_,U0_P"$"T#_ )]G_P"_AH_X0+0/^?9_^_AH O\
M_"4:)_T$8?S-'_"4:)_T$8?S-4/^$"T#_GV?_OX:/^$"T#_GV?\ [^&@"_\
M\)1HG_01A_,T?\)1HG_01A_,U0_X0+0/^?9_^_AH_P"$"T#_ )]G_P"_AH O
M_P#"4:)_T$8?S-'_  E&B?\ 01A_,U0_X0+0/^?9_P#OX:/^$"T#_GV?_OX:
M +__  E&B?\ 01A_,T?\)1HG_01A_,U0_P"$"T#_ )]G_P"_AH_X0+0/^?9_
M^_AH O\ _"4:)_T$8?S-'_"4:)_T$8?S-4/^$"T#_GV?_OX:/^$"T#_GV?\
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M-Z[NO- '9_\ "4:)_P!!&'\S1_PE&B?]!&'\S5#_ (0+0/\ GV?_ +^&C_A
MM _Y]G_[^&@"_P#\)1HG_01A_,T?\)1HG_01A_,U0_X0+0/^?9_^_AH_X0+0
M/^?9_P#OX: +_P#PE&B?]!&'\S1_PE&B?]!&'\S5#_A M _Y]G_[^&C_ (0+
M0/\ GV?_ +^&@"__ ,)1HG_01A_,T?\ "4:)_P!!&'\S5#_A M _Y]G_ ._A
MH_X0+0/^?9_^_AH O_\ "4:)_P!!&'\S1_PE&B?]!&'\S5#_ (0+0/\ GV?_
M +^&C_A M _Y]G_[^&@"_P#\)1HG_01A_,T?\)1HG_01A_,U0_X0+0/^?9_^
M_AH_X0+0/^?9_P#OX: +_P#PE&B?]!&'\S1_PE&B?]!&'\S5#_A M _Y]G_[
M^&C_ (0+0/\ GV?_ +^&@"__ ,)1HG_01A_,T?\ "4:)_P!!&'\S5#_A M _
MY]G_ ._AH_X0+0/^?9_^_AH O_\ "4:)_P!!&'\S1_PE&B?]!&'\S5#_ (0+
M0/\ GV?_ +^&C_A M _Y]G_[^&@"_P#\)1HG_01A_,T?\)1HG_01A_,U0_X0
M+0/^?9_^_AH_X0+0/^?9_P#OX: +_P#PE&B?]!&'\S1_PE&B?]!&'\S5#_A
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M- %__A*-$_Z",/YFC_A*-$_Z",/YFJ'_  @6@?\ /L__ '\-'_"!:!_S[/\
M]_#0!?\ ^$HT3_H(P_F:/^$HT3_H(P_F:H?\(%H'_/L__?PT?\(%H'_/L_\
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M ,)1HG_01A_,T?\ "4:)_P!!&'\S5#_A M _Y]G_ ._AH_X0+0/^?9_^_AH
MO_\ "4:)_P!!&'\S1_PE&B?]!&'\S5#_ (0+0/\ GV?_ +^&C_A M _Y]G_[
M^&@"_P#\)1HG_01A_,T?\)1HG_01A_,U0_X0+0/^?9_^_AH_X0+0/^?9_P#O
MX: +_P#PE&B?]!&'\S1_PE&B?]!&'\S5#_A M _Y]G_[^&C_ (0+0/\ GV?_
M +^&@"__ ,)1HG_01A_,T?\ "4:)_P!!&'\S5#_A M _Y]G_ ._AH_X0+0/^
M?9_^_AH O_\ "4:)_P!!&'\S1_PE&B?]!&'\S5#_ (0+0/\ GV?_ +^&C_A
MM _Y]G_[^&@"_P#\)1HG_01A_,T?\)1HG_01A_,U0_X0+0/^?9_^_AH_X0+0
M/^?9_P#OX: +_P#PE&B?]!&'\S1_PE&B?]!&'\S5#_A M _Y]G_[^&C_ (0+
M0/\ GV?_ +^&@"__ ,)1HG_01A_,T?\ "4:)_P!!&'\S6;-X$T!(786SY"DC
M]X:P_"_A?2M4CO3=0LQBG*)AB,"@#KO^$HT3_H(P_F:/^$HT3_H(P_F:H?\
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M(P_F:/\ A*-$_P"@C#^9JA_P@6@?\^S_ /?PT?\ "!:!_P ^S_\ ?PT 7_\
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M+0/^?9_^_AH_X0+0/^?9_P#OX: +_P#PE&B?]!&'\S1_PE&B?]!&'\S5#_A
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M$_Z",/YFC_A*-$_Z",/YFJ'_  @6@?\ /L__ '\-'_"!:!_S[/\ ]_#0!?\
M^$HT3_H(P_F:/^$HT3_H(P_F:H?\(%H'_/L__?PT?\(%H'_/L_\ W\- %_\
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M?]!&'\S5#_A M _Y]G_[^&C_ (0+0/\ GV?_ +^&@"__ ,)1HG_01A_,T?\
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M_P#OX: +_P#PE&B?]!&'\S1_PE&B?]!&'\S5#_A M _Y]G_[^&C_ (0+0/\
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MRIR/WAH T?#G_(OV?^Y_6M2FHBQH$0 *!@ 4Z@ HHHH **** "BBB@ HHHH
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ME1BI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445FZ[JB:1I4MTW4#:OU/2@"34-8L-, ^UW"1L1PIZFJ"^*[ X9]R1?\]#TK
M"\(Z6=6>36=3S+(SG8K<@>^*[0VENR;3!$5]-@H K6>LV.H321VLZR^6H9BI
MXJA<^,-(MIS$;E6(."1T%9=QX:N;2^O?[,4QQW*J P_A]:TH_!^DK8F!H-S,
M/F8GG- &O97]MJ, FM9ED3U6J>I^(M-TI_+N+A1)_<'6N0\)1W&G>);_ $Z)
MBT4:MCTW8XKH+'PK;,\MWJ*^=<S,6.3PH]* -+3->T_5LBUG5G')3/(K2KS7
M4=,70O&=D=/+*DK E,]37I*DE 3UQS0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 52O\ 5;+3$#7=PD6>@/4T:MJ":7ILUW)T0<?7M7'>%M/?
MQ!>3:OJ>9,/^[0_=_*@#H%\5V##<0PB_YZ'I5ZSUNPU"Y,%K<+*P7<=OI5O[
M+;[=OD1;?38*Y6\TLZ!J5WJ]G'MA\G+#L#F@#<OM>L+";R))E,__ #S'6K%A
MJ5KJ41DM95<#J!VKE_ ]JEY!<ZI.HEDG<C+C.!GM52:;^PO'0$0*VT^-T8Z9
MQ0!WU9MUKVGVLQ@:=6G'_+,=:R/%VOM80QV-JV+NY(4'^Z#5O0-!M],M5,VV
M6[<9D=SN.?:@#8MI_M,(DV,@/8U-0  , 8%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 444R6588FD<X51DF@".[O;:QA,MS,L2#NQK('BRP<YBW2
M(/XUZ5R]AYGC+Q'+)<%OL-NW,8/Y5WZ6=M&@1+>(*!C 04 4(O$>EW#(D-RC
MR,P78.H-7KR_M;"+S;J98D]6K UCPZIU.TU"QA D651(J\#;GDU+XMTVWN-'
MN[J0,9(XCM^;C\J -C3]0@U.U^T6[;HRQ /KBI+JZ@LX&FN)5CC7JS5S_@/_
M )%>+_?;^E97B.9M4\76FCLQ\I?F91WXSS0!T=OXETVXG6(3A2_W">C?2MBN
M8\7Z="?#[20Q*DL)!1E&,5;\*:DVI:'"[Y,B#:Y]30!N4444 %%%% !1110
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ML.<CZUU&D:!HD#I?6$88D?*V<T ;M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445B^)]9_L726E7_7/\L?UH LZAKNGZ8VRYN$63LG<U33Q5I^
M0928HST=NE97@_15GM_[6U!?-N922!)R%KJY+*VEC,;V\14C&-@H AL=5M-2
M:46LJR",X)%17FNZ?8SI!+<)YSMM"9YK.T30VTC4KU(T(M)SE>>G%<_XLTZW
MM-=TZ2(-N9QG<<]Z /0E8,H8=",U6O=2L].C\R[G2)?]HU-!_J(_]T5S'C;3
M;=]%NKU@QF51CYN/RH Z*QO8M0M$N8#F-^AJS6#X._Y%>T^A_G6]0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6?J&M6&F<75PB.>B'J:B\0:
MLNC:3)<G[Y^5/][M7.^$-)_M$/K&I RS.YV*_('OB@#:7Q78<-)NCB/_ "T;
MI5^QU>RU&:2.TG67R\9*^]6&M+9T*-!$5/;8*PM+T(Z3KMU);QD6LX&.>G%
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M BN+\4^']*T_3XUMK?$\T@C3GN:Z[2+1;+2K:!5P0@W?7'- %ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *KWE];6$)ENIEB3U8U)/,EO \KD!
M5&237GVE+)XQ\02W-T6^Q6[8$0/&>U '3CQ98/S'N=/[XZ59A\1:9<O''!<I
M)([;=HZ@U?2TMD0*MO$%'8(*YW5]!2#5;75;.$ I(/-5>!M[F@#9U#6++3<+
M<3*LC?=3N:-/UBSU(LL$H,B_>3N*Y3PRO]L>)M0O;O$JQDK$&&0.:;XL8:%K
M]AJENNPR-M=5X#?A0!VUU=P64#37$BQQCJQK+C\4Z8TZQO,(]_W&;HU<[KUV
M-2\46-@['R% 9E!X)P#S70>(](M[W0YT$2(T:[U95 (P* -L$,H(.0>AI:Y;
MP'J<NHZ&5F;+0-Y8)ZD5U- !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 1S31V\32S.$C7DL>U8Q\6:<TA6W8SXZE.E<QJ-[-XI\3IID3LME&V'
MVGN.N:[FUTVSLX$AAMXPJC&=HR: **^*=*90/M*B0L%\L]036I-<PVT)FFD5
M(Q_$>E87B+PY#J$44UM"JW,4BL"HQD9YJUJ6GQWFCL;E6#K"> W0XH M:?JU
MIJ@<VD@D5#@L*O5Q7P]0):W2CH)"*Z#Q!K,>BZ:\[$&1N(U_O&@"Q?:M8Z=@
M75PD;'HIZFG6-^M\KLB,JJ>">]<UX8T@7"_VMJ;"6XF.41SD(/I77*JJ,(H
M]A0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)(D,;22,%11
MDD]J=7GVNZA/K_B*+1K=V6V5]LI4]^] '2/XLTWS3'!)YY'793QXJTK82]RJ
M2 @>6>O-7;'2K.PMD@A@3"CJ5!)K-\1>'8-4L\Q0JMRC HRC'?O0!K7-_:V=
MM]HN)ECB_O-5*T\1Z==SB%9@KM]S=_%]*Y*Y>75_%=II5QD);#+)G@XYYK8\
M:V,2Z,MS!&L<T+@JR#&!0!U+NL:%W8*JC))[5C/XJTX,VR3S$4X9UZ"L2_U&
MXU'P&)X2V\+ME([\<UH>%[K2[C0$*+$/+7]Z& SGN30!O6=[;7\ FM95DC/=
M:L5Q7@:-Q=ZE)'N%HS_NP>F<\XKM: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N,^(V_P#L1,9V;QGZUV=9FO:4FL:5+:M][[R?[PZ4 4O!LJ2>
M'X=G\/!^M;%[%<30%;:X\B3^]MS7"^%=2D\.W$NDZHAB!;*R$<9^M=U]OLRF
M_P"U0[?7S!0!PNDZUKVHZVU@UXJ+&Q#-Y8Z"NSU74(],TYYI6RV-J@=2QKS_
M $*^@LO$5[>S-B!6)W=C]*O0>)-+U+4OMNISE8XC^YAQD?4T ;OA329;:*74
M+L?Z5='>0?X1Z5T4DB0QM)(P5%&23VKG4\9:?=W26U@3*YY;(P%7N:R-8\4V
M&H:C_9[7)CLHS^]=>=_^S]* +FG6S:_XE;5Y$(MK<[(<_P 1!ZUU]<F?&>AV
M5FL-FQ9E&V.,+UKI[>1IK:.1UVEU#8],T 2T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '*?$#?_ ,(Y)C[F1FG^!)$?P^JKU0X;ZUM:OIT>JZ9-
M:2='''U[5Q'AJ]F\*ZA-IVIH4BD;(D R >U '?W4<TL!6";R9#T?;G%>7ZMK
MVM2M?:=-<AXH\JY" ;A7IRW]FZ;Q=0E?7>*\U@M1JOBC4(8QNCERH<=.OK0!
MU7P_ 'A2+'_/1JQ/&2EO$MB(_O[AG]*T/!=TNG1W.DW3"%H'+#><9!/;-5E1
MM=\<^?$"UG;]7QP3CM0!0N[8Z[\09+1I"BH-P./0"KGB?0#H]JNI:=/*LJ,,
M@L2#[TNK1/H7C:/5F4^1<?*6'0=N:V?%FH6[:"Z0NDSS':BHV3S0!>\-:HVK
M:-%</_K!\K'U/K6O6)X4TU],T*&*08=_G(],UMT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !65XDW_ /"/7FS[VSC\ZU:CFA2>%XI!E6&"* .$^&SK
MF_3H^5S[UWKAF1@K;6(X/I7FUO#<^#/$)DFC9K&5CEU&:] M]4LKF(21W41!
M]7 (H XC5M9U[3=<ATX7ROYS!5?RQQDUTNMQSQ>$KQ;F;S91"<MC%<GXCE2Z
M\;Z<;<^:$D7<4Y YKK_%,\4?AZ]1Y$5FB. 3R: *?@/_ )%:+_?;^E8"%F^*
M:&3[V#_*MOP#/$WAJ)!(F\.WRYY_*L_Q':OI7BFUUM5)C8[7('3C% '3>(=O
M]B7.[IMK"^':NNC3ENADROTJQXMU6%M",-M(LL\Y 14.?Y5H^&=.;3=#MX9!
MB4KEQZ&@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (Y]WD/L^
M]@XKS3PA(J>+[I9/OO(0/KFO3Z\XUS2+GP_XACUBTB,EOOWL!USWH ]'/2N(
M\5:IK.AW$)AO0\<Y. 8Q\M=+I^N6&HVRRQW"*2.5=@"#]*Y/Q]<13S6"0R+*
MX;D(=V.?:@"AX/EFG\<3RW+;IVB8L?4UUWC#;_PCT^[TXKF([=] \16>I.I$
M-TNUFQ]TGUK6\:WR7.GQ6%FZS3SN!A#G _"@#!TK4=^BV^B-*(O,?=,Y[1FM
M;Q5<Z>GAM;2TE1MF  O?WJ_;^"]/EM(#=1YF$8#'WQ6-XK\,Z=I>DFXMT*N#
MW- '3^&;N"71[>*.16=5Y7TK;KF_">C6EII\5W$N)9%RQS724 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !37SY;;>N.*=10!Y=H<@B\>7/G?>:0KSZ
MYKU&O//$^B7.F:W'K=E$7C#^9(!UW5UVEZ_8ZG:I(LZ))CYD<A2#^- &%XMU
M'6-$\J>WO T<K%=AC'RUL^')+^?3EN;^Y$K2#(4*!MKG_B#<0S65K%%*DC[S
M\J,":BN/%$-EI5MIL,NV9EQ(_P#<% %_6 WB/6XM/@.;6W;=._;<.0*ZV.-8
MHUC0851@"N1T_P 3>&](LO*BN&) RS;.6-:D7B:V&FC4+L&&WD?;$V,[AZT
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MITF_1FBN@-O4/\IK,MT_MWQ0NH(A%K:H8PQ&-Q/.: .LHHHH **** "BBB@
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M>T^A_G6[7/>"YHG\-6BK(I8 Y4'D<UT- !1110 4444 %%%% !1110 4444
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M99I:VXQ&N<"K5 !1110 4444 %%%% !1110 4444 %%%% !1110 5S_C/?\
M\(U/Y?7(KH*KWMHE[9RV\@R'4CZ&@#D_AQ(ATFY4<,)>??BNPG222!UBD\MR
M,*^,X->=:.]QX.UM[>^1OLDI^60#(^M>@1:C9S1ATNH2I_VQ0!PLNLZ_'XEC
MT?[<I:1L"3RQ7<O,+"P,MW,&V+\SD8R:\^NKF$_$:WN@X,$9^:0<J/QJW=^)
M]-UC5#%=SE-/@/"@9\T^] &IX=L9+_5I]?N4*&3B%3V'0UUE<L_C;2E$<%B3
M+,S!53;@8KHYY_L]I)/)@;$+'\!0!RU__P 3;QK;VRG,5HHE;TW UU]<KX/A
M-P][JDGWIYCL_P!VNJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#'\4[_ /A'+OR_O;?ZUS?PVD0V]\G1PXS[UV]Q ES;O#(,JXP17G-BESX,
M\0-]IC9K*4GYU&: /29%9HV5&VL1@-C.#7F^OZWKFG:@VFM>+(L@P&\L#BO0
M(-3LKB(21W414^KBO/M>\O4/'=BD1\V+<%=DY YH T_AX/W5T6Y?<<_G2?$G
M'V;3\]?-./TH\/9T+Q/?6-V1'%*2T+'H<GUIOB;_ (J#Q!9:;;?O$A;>[KRH
M_&@"OK^C7\(L=6M5+N@!D ZCI5Z_\8E]$E863AW0HP8XVY&*Z\RPV\2K+(B
M#'S,!7%Z[++XHODTO3TS:HV9I,8'X&@";X<6S1:1/(X(WR_+[BNTJMI]E%IU
ME%:PCY8UQGUJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %17.[[-)
ML^]M.*EHH \Q\$2JGB:[1_ONY ^N:]./0XX->;ZMI5SX:\1IJUK"9+7=N('J
M>N:[BPUNPU"W66*XC&1RK, 1^% '+>*-5UK0[R%8KU7CGZ QCY:W[3[8WAV6
M6]N!-))$6X7&WCI7,^/)XKB^L$@=96!Y"'=CGVKJWD2'PY^]=4_<'[QQVH P
M? '^HO/^NK51\>LUYJEE8;MH# Y^M6? %Q#Y=TGFH&:4D#=R:D\=:?/_ */J
M=NA8PMF0#TH =J/A",Z3YL$\HND0,'#'!Q[5)X%UJ?4;.:WN6W/ VU6]16LF
MMV,NA_:A.FTQXVY&<XQC%8O@'39;>VN;R:,IY[Y0'TH [*BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 9+N\IMOWL<5YEX9D6/QO="7[S2$#/KFO
M4*\Z\1:-<Z+K\>M6<1>'?O<#KN[T >BUQ7BS4]8T.2&2"]#1S$C:8Q\M=%IN
MO6&I6R2I.BL1\R.0I!_&N7^(%Q#/'9QPR+(X?[J$$]O2@#+\*S3W/CPS73;I
MVC8L<=>*[7Q7M_X1^XW?W:Y 6TFAZW8:LR,(IUVN<?=SQS6YXSU".;2DL[1U
MFGG<!0ASQ^% $/@]HK?P?,]]C[/N);/]W%<E<Z7>"&;4[&%UT]W/RANHSZ5U
M6L:5=6W@6*VA!WH TH'TYK9T#4+"YT&!3)$@5 CHS 8('.10 WPGJ]IJ6EJE
MO&(GB&'C';WK?KA_"-KL\0:C+: K9DCG'#'VKN* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTE\V"SC5QT/I6E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"11_W5%5+CP_I=S<&>2TC,K?>;UK3HH AM;2WLH?*MHECCZ[5J:BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LZ[T'2[Z0R7%G$[G^(CFM&
MB@#&7PMI 8%[1),=-W:M-;6!;<P+$HB(P5'3%344 9)\,Z*7WG3H-WK@UHI;
M0I!Y"Q@18QM[5+10!C#PIH@F,GV"+).<8K6BBC@B6.) B*, #M3Z* "BBB@
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M&1SU9A5NSL+6PB,=I"L2$Y(6K%% !5233+*6^2]DMHVN4^[*1R*MT4 %%%%
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ME=R*NYDM[A)"!ZD ]*O5X7\$?^1GU#_KR/\ Z&M>XS31V\$DTK;8XU+L<9P
M,F@!]%>(>+/C#=WHDM/#R/:0'@W3@>:PQSM'1?KU^E>C_#J62?P#I4LLC22,
MCEG<Y)/F-U- '3.ZQHSNP5%!+,QP /4UD_\ "6^&_P#H8=)_\#8_\:MZS_R
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M@:[<K:R&6PN78*BW&-KD]@PXSGUQ7&6WP/OY+ 27.L00W1&?)6$NH]B^1[]
M:\]U_0+_ ,-:M)IVHQA9E&Y64Y613T93W'!_(T ?5U4=9U6#1-(N=3N4D>&W
M3>ZQ@%B/;) _6O/_ (0>*YM5TZ71+R0R3V2!H68Y+19Q@G/.TD#Z$5U/Q"_Y
M$'6?^N']10!SL?QI\.22*@LM5RQ &8H^_P#P.NA\4^.]%\)[8[V1Y;MUW+;0
M#<^/4YP /J?H#7S+&YCD5QC*D$9]J[CPWX%USQ]-/J]W>>3!*YW7<PWM(V>=
MJ@CI^ [#V .J/QTB\X@>'W,?9C=@'\MG]:[7PMX_T3Q61!:R/!>XR;6<88X'
M)4CAAU]^,D"O'O&/PSU#PG8_V@MTE[9!@CNL91DST++R ,\9SU(]:X^POKC3
M;^WOK20QW$$@DC;T(.?Q^E,9]:W,ZVMK-<."4B1G8+U( SQ7S_\ $GQMIOC'
M^S/[/@NXOLOF[_M"*N=VS&,,?[IKW5G_ +8\/%X,+]LM<IN/ WIQG\Z^<?%G
M@G4O!WV/^T)[27[5OV?9W9L;=N<Y4?WA2$5/">KV^@^*;#4[I)7@MW+.L0!8
MC:1QD@=_6O>?#/Q(T?Q5JW]G6-M?1S>6TFZ>- N!CT8GOZ5\^:+I%QKVL6VF
M6KQ)/<,51I20H.">< GMZ5[%X ^&^L>%?$AU&^N;&2'R'CVP2.6R2/50.WK3
M&>CZCJ5EI%C)>W]PEO;1_>D<\?\ US[5YO?_ !NTJ&0K8:7=7*@?>D<1 GV^
M\<=*Y+XOZ[/?^+'TH2$6E@J@(&X9V4,6/O\ -C\#69X+^']YXR2>>.\AM;6%
MPCNREV+$9X7CMZD4A':1?'2)GQ-X?=$]4NPQ_(H/YUVOACQ_H?BJ3[/:2R0W
MFW=]GG 5CZ[<$AOP[5YUJGP2OK6R>;3]6CO)D&?)> Q%O8'<W->8Q2W%C=I+
M$\D%S"^59259&!_0B@#Z\HK$\(:[_P )'X7L=3( ED3;, , 2+PV/;(R/K6W
M0 5A>*?%=CX1L(;R_@NI8I9?*'V=%8AL$\Y(]#6[7.>/-'_MSP9J5HJ[IEC\
MZ+'7>GS ?C@C\: ,;2?BUX?UC5K73H;?4(I;F01H\T:!=QZ D.3R>.G>N\KY
M"MIWM;J&XCQYD3JZY]0<BOK/3;Z+4],M;^ YBN(EE7Z,,T <_P"*O'^D^$+R
M"UOX+R62:/S%^SHC #..<L*J>'OBAH?B36H=*M+>_BN)@Q0S1H%.U2Q&0Q[
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MC=2K(PR&!Z@CN*^5]$\4ZWX>?.EZA+ I.3'PR'ZJ<BN[TWXW:I#A=2TNUN5
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M'I_B'39+#48!+$XX;^)#_>4]C6C12$?*^I^%]3L=?O=)AL[FZEMI2G[F%F+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDIH+X^4&X!/N?+_P-(1PWPX_Y*#H_P#UU/\ Z U?3-?,WPX_Y*#H_P#UU/\
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MGA</%(H=&'1@1D&GT ?'Q!4D$$$<$'M7JWPA\8W$>HCPY?3-);S*3:%CGRW
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MI0!] 45XY\,?%_BG7?$:V-W>?:K"*)I)C)$NY1C PP .2Q'7/ ->QT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP% [ 51\0Z1_;V@7FE^?Y'VF/9YFS=MYSG&1G\Z0CY0KZUT;_D!Z?_U[1_\
MH(KRO_A17_4Q_P#DC_\ ;*]:L[?[)8V]MNW^3&L>[&,X&,XH QO'/_(BZU_U
MZ/\ RKY=KZRUW3/[:T*]TSSO)^U1-%YFW=MSWQD9_.O+O^%%?]3'_P"2/_VR
M@#TGPE_R)FA?]@^W_P#1:UY_\<H9&TS1YPI\M)I$9L< E01_Z"?RKTS2;#^R
M]&L=/\SS?LMO'!YFW;NVJ%SCG&<=*K^(= LO$NCRZ;?*?+?YE=3AD8=&'N*
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M[W_CI8_@*^<:^OY8DFA>*10T;J593W!ZBO(G^!2EV*>(B%SP#99('UWT 0?
M_3=UYJNJ%A\D:VZC'7<=Q_\ 05_/VK>^-&EF[\*V^H(JEK*<;B1R$?Y3S_O;
M*ZCP9X67PAH9TU;H7):9I6E\O9DD =,GL!WJ_K^CQ:_H-[I4S;%N8R@?;NV-
MU5L=\$ _A0!\GU[G\%=&^RZ!=ZM(F'O)?+C)7^!.X/NQ(_X#6;_PHK_J8_\
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M%>F6UM!9VT=M;1)%!$H5(T& H'8"D(SO$NAQ>(_#UYI4K;//3Y'Q]QP<J?S
M_#(KY<U"PN=+U">QO(C%<0.4D0]B/YCW[U]<USOB?P7H_BN "^A*7"_<N8L+
M(OX]Q[&@#Q7PO\3]:\-VJV1$=[9H,1Q3'!CYZ!ASCV.:Z:X^.<[1$6V@1QR=
MFDNBX_(*/YU%?? Z_5V-AK%M(N3M$\;(<>Y&ZJ:?!+Q"3\]_I:CU620_^R"F
M,X?7O$&H^)-2:_U*?S)2-JJ!A47T4=A79_"3PM+JGB%=9N(F%C8G<C$</-V
M^F=WX#UKI]%^"=C;R)+K.H276#DP0+Y:'GH6ZD8],'WKTZSLK;3[.*TLX$@M
MXEVI&@P%%(1/1110 4444 >;?%#P#)K\0UG2H@VH0IMEB4<SH.F/5A^HX[ 5
MX2#+;3@@O%-&V01E61@?T(-?7]<QXB\ Z!XF<RWEJ8KD];BW(1SUZ\$'KW%
M'D&F_%[Q3I]N(9'M+W  5[J(E@![J5S]3DUC^(O'>O\ B>$6]_=*+8$'R(5V
M(3ZGN?Q->A3_  ,@9R;?7Y(T])+4.?S#"K%C\#]-BD5K[5[FY4')6*,1!O;D
MM_GTIC/(-&T:^U_5(M/T^$RSR'\%'=F/8"OISPSH%OX:T&VTRW)81C,CD_?<
M_>/YU)H?A[2O#EF;;2K-+=&Y=ADLY]68\GJ?IVK3I"/-OC9_R)EG_P!A!/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img97084416_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img97084416_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #W M # 2(  A$! Q$!_\0
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M * </_?\_P"%'_"]+S_H!P_]_P _X4?5ZG8/K=+N>U45XK_PO2\_Z </_?\
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MG8V:*QO[<?\ YX+_ -]4?VX__/!?^^J.=!]6J=C9HK&_MQ_^>"_]]4?VX_\
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MCG0?5JG8V:*QO[<?_G@O_?5']N/_ ,\%_P"^J.=!]6J=C9HK&_MQ_P#G@O\
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M37HE%'M9]P]A3_E/._\ A2WA;_GIJ/\ X$#_ .)H_P"%+>%O^>FH_P#@0/\
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ME7H/^6G^^:B>KU-J3<(^[H5/[&M?63_OJC^QK7UD_P"^JT**GE1I[:IW,_\
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MUZ>AKT5A6FJ7EQ?VZR!$MV# L(VP[84@#/3&2/PI;K6+R&:XB2U5O(<*S\X
M8_*?RZT>PE>P_KE/EYM;?\"YN45CV5_>227?VA5!2)9(XU4_W<G![C-1+JVH
M++;K);1D21"5MH8<$$D#W'I2]C*]A_6Z=D]=?+SL;M%<]#K=U<1@-$(<[QO*
M-\V,8 ]#S^E-76-2ABBB:V5Y-J9E8, <J#@^^:KZO,CZ]2WUMZ'1T5C6%[=7
M6LR)*"D:Q,/* .%8/CDGJ2.>*V:RG!Q=F=%*JJJYHA1114FAF:;_ ,A;6?\
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M>I52IB4_=BK>O]=3:^TP88F5!M +98?*/?TID]];P6[3M*I1?[IR?\\UF_\
M".0AY'$QWEQ(K% 2#G.#ZCVI9M $SL6NF"MN;:$ PQ !/Z#BDHTK_$#J8FVD
M-?4U#<P*"3/& #M.6'!]*EK'AT!([XW,EPTI,@<JZCDC=C/_ 'U^E;%1-17P
MNYO2E4DFZBL%%%%0:A7,ZKXRMM,U"2S^RR2M'@,P8 9QG%=-7D_B;_D9;_\
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MC-SCY]G3_P#77F8W#1HN\7H^A]'E&8U,5%QJ+5=>C_X)!IO_ "%M9_Z[Q_\
MHI*O0?\ +3_?-4=-_P"0MK/_ %WC_P#125>@_P"6G^^:XI;GM0^%DM%%%( K
M"3PQ;I,DGVF<E6R!P!USCI_^K\:W:* .2N_"2:CK<UVFKZG:F*:-C'#<':P
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M/_U]7/\ Z.>GT(^T5KO1[J74I[N&=4+GY,_PG9MW?457ETG4XK4M'<2/((Y
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M4;%_,NKUBCI^\48<8/W15Z@ HHHH 1E5U*L RD8((R#52XLOD\RSV0W"*0A
M^4\<!AZ5<HIIV$XI[F'I\,]U"BZHJ6^KH"6DMSMW#)P0>X]0:9;ZS>VVN3:;
MJ-G(MJB*T6I$8CE8_P )[ _X5L74#3!'C8+-&=R,1Q[@^QJ(W84%+R Q*< L
M?F0Y]_\ &FU=W04Y\BY9ZKN7 00"#D'O15'^SV@ ^Q3O %Z1GYH_I@]/P(K-
MD\3I8ZW'I>IVLEMNB\S[:?\ CWSG &X]"?0U)JJ;E\.IT%%&<C(HH,PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*
MX_U0_P!]?_0A4M17'^J'^^O_ *$*EH'T"LS0/^08_P#U]7/_ *.>M.LS0/\
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M%HG,T5O_ /"/Q?\ /=_R%'_"/Q?\]W_(5U_6:?<\_P"IUNQ@45O_ /"/Q?\
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MB@##/A:S602Q2RI(&#;N#CZ<?A_]>M:TM4L[6.WC)*(, G&3W[5-10 4444
M%%%% $5Q_JA_OK_Z$*EJ*X_U0_WU_P#0A4M ^@5F:!_R#'_Z^KG_ -'/6G69
MH'_(,?\ Z^KG_P!'/3Z$?:-.BBBD4%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*+>"WCCA6& A%7@$C)J;1.I8BO=<SNET?]>IH>&/$EV;S4-*\1ZCIIU*V97
MMR54(P[D\9_QK#TKQ!I>H?&6Z>VNU=&L/LZM@@-(K98#\*]%6RM5E:5;:$2.
M &<1C) Z9-<"+-5^-,QM[: A-,#LF H)+8)Z=:0Y2A-MVM^1WDNHV4,\,$MU
M"DLQ(C0N,MCTI)]2L;:6&.:[A1YFVQJSCYCZ"N;N6UB7Q=;1-X6LY-/B&Y+T
MS#<A(YQQZ\8Q3O$C:O%+I\FG^&+/4&6;+,\H!A]QP/>JO'S,_8UKV3CKMKT\
M_,Z*ZU&RLH?.N;J**/(7<S#&3TJT"",@Y!JK<Z=97L'E75I#(A(8HR C(JT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *X;P__P E5\5?]<;?^5=S7#>'_P#DJOBK_KC;_P J .YKAK?_
M )+3>?\ 8)3_ -#KN:X:W_Y+3>?]@E/_ $.@#N:*** "BBB@"*X_U0_WU_\
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MBC=W2-5:0Y<@8+'WI] %3[)/_P _\_\ WRG_ ,31]DG_ .?^?_OE/_B:MT4
M5/LD_P#S_P __?*?_$U7@2XEN[F+^T)\1%0!Y:C&1GKMYK3J..&*)Y'CC56D
M.YR!@L>F30!!]DG_ .?^?_OE/_B:/LD__/\ S_\ ?*?_ !-6Z* *GV2?_G_G
M_P"^4_\ B:/LD_\ S_S_ /?*?_$U;HH RH!+-?74 U21O)VY543*Y'<[:M?9
M)_\ G_G_ .^4_P#B:G2WACFDF2)%DDQO8#!;'3-24 5/LD__ #_S_P#?*?\
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M #_]\I_\37%:#!*WQ0\4*+N56$-OEPJY/'TQ7H%<-X?_ .2J^*O^N-O_ "H
MZ)))'U VXU&XQRN#$H^88)YV],$5RT$$O_"X[M/M<N[^RD._:N?O].F*[E+.
MVCN#<)!&LS9S(%&3GKS^ KC;?_DM-Y_V"4_]#H Z[[)/_P _\_\ WRG_ ,31
M]DG_ .?^?_OE/_B:MT4 5/LD_P#S_P __?*?_$U7M[Q$U(VCWK2LV5$<B ,&
M4 D\ <8(K3JN+&U6X^T"WB$V2WF!1NR1@G/TH ?<?ZH?[Z_^A"I:BN/]4/\
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,S3?\
MD+:S_P!=X_\ T4E7H/\ EI_OFJ.F_P#(6UG_ *[Q_P#HI*O0?\M/]\TY;A#X
M62T444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "O-KB?7?#_P 0-;U&U\,7NIVUY'"J/"ZJ
M!M7GKUKTFB@#A?\ A-_$G_1/]4_[_I5?PW_;.I_$6ZUN_P! NM+@:P$ $[*V
M6#9ZBO0J* "BBB@ HHHH BN/]4/]]?\ T(5+45Q_JA_OK_Z$*EH'T"LS0/\
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-9R.FX]*EHHI@W<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img97084416_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img97084416_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )6!4H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JWVH6VG0B2X? )PH
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M#VZV'IKF3A:*6C\[&H=5N#XE&G@((0,YQR>,UM5R_P#S//\ P'_V6I6N)O\
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M.,C%-V+_ '1^534P4VY\D[*6ZM<JGC(I1YX7<=G<K:5_R";3_KDO\JH>*O\
MD"-_OK6T!@8%(0",$ CWKJJ4>>BZ5^ECFA5Y:JJ6ZW,_1H8_[(M&\M=WE+SC
MFK-^I;3[A5&28VP!]*L 8&!151IJ-/D\K$RJ-U.?SN<?I#ROX:OH+<-YZG.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 44UG5!EF ^M5WOHU^Z"WZ5,IQCNRE%RV
M1:HK.:]E;IA:A:61OO.Q_&L7B(K8U5"74U2Z+]Y@/J:8;F$?\M!6514/$OHB
ME075FI]KA_O_ *4GVN'^_P#I6912^L2*]A$U!=0G^,4X3Q'I(OYUDT4?6)=A
M>PCW-D$$9!!I:Q@Q'0D5(ES*G1R?KS5K$+JB'0?1FK15%+\_QIGZ58CN8I.
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M/CU6KT-];S<+( ?1N*VC5A+9F$J,X[HL4445H9!1110 4444 %%%% !1110
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MEB94VK=;DE%-21)4#QNKJ>A4Y!IU:)W,]@HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHKM6QQL****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 57O(]\)/=>:L4$9&*4H\RL.+L[F+
M14DT?E2LO;M4=>:U9V9WIW5PHHHI#"BBB@"Y938/E,>#TJ]6*#@Y'6M.VG$R
M8/WQU]ZZZ%2_NLYJT/M(GHHHKI.<**** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*=%(T,JR1G:RG(--HIK03UT9J:E9IKE@+NW
M%W$,,O\ >'I_A7(D$'!&"*Z*RO'LK@2+R.C+ZBE\0:6DD8U.S&8WYD51T]ZY
M<=A_:Q]M#=;_ .?^8L/4]C+V4OA>W^7^1SE%%%>,>D%=)H&I1SQ'2[TY1N(F
M/;V_PKFZ 2""#@CH16^'KRH5%./S\T8UZ,:T.5_\,=#>6;V=P8G''53ZBH,#
MTK5TZ[37=/-M.0+R(95O[WO_ (UF21O%(T;C#*<$5[KY9152'PO^K'!3G*[A
M/XE_5QN!Z48'I114FH8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%%
M!@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>
ME%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 *K,C;D)4CN.*T
M5UR\50,H<#&2.M9M%7&<H_"R)TX3^)7.ZJM??ZC\:LU6OO\ 4?C7JU/@9X%/
MXD9U%%%><=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %3Q&.:)K6X :)QC!J"I;>$S/Z*.IJX7O9$RM:[..
MU739-,O#$V3&>4?U%4:W?$FK+>SBVAP88C][^\?\*PJ^;Q4:<:THTGH>_AI5
M)4DZBU"BBBN<W+FF:C+IMXLT?*]'7^\*ZRZCBN8%OK4[HW&6QVKBHHGGE6*)
M2SN< #O7:P0KHNEK:AM\[\MZ GK7LY7*;C*,OA7X,\O'J*E&4?B?XHHT445V
MF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCV<.R#VM3^9_>4_[)L?^?9/UH_LFQ_Y]D_6KE%'LX=D'M:G\S^\I_P!DV/\
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M_O*?]DV/_/LGZT?V38_\^R?K5RBCV<.R#VM3^9_>4_[)L?\ GV3]:/[)L?\
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MCLRK_9ME_P ^D/\ WP*/[-LO^?2'_O@5:HJ?90_E7W#]I/NRK_9ME_SZ0_\
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M_P"?*/\ ,_XT?\(_I7_/E'^9_P :TJ*S^K4/Y%]R+^L5OYW][,W_ (1_2O\
MGRC_ #/^-.BT33895DCM(U=3D'G@UH44UAJ*U4%]R$Z]5Z.3^]A1116QD%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGCZ4 =91110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-=)I,TEQH]E-*V^1X$9F/<D#)H N4444 %%%% !1110 4444 %%%% !1110
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MTK4+VYU!#)'8*UMIH49)ASNX]^WX50\.WNI'Q'=:IJOAW51>7;B&)O*'EV\
MZ#.?Q->B44 8'C+2+G6O#DMK:;3<+(DR(QP'*,&VGZXJH=:UO4],O(;/0[O3
M[Q;=C')<[0GF=@.>?K7544 >7:9I>H_\)'I&I'2]9*Q+(ET]]-O+.R]ESPN>
M_2K>CV>HPZE<1VFAZA;Z*UO)]IT^[=61Y#T$63P#S[5VT.N:5<:@]A#J-M)=
MI]Z%906'X5H4 >5IX?UK5=*U+3K2UO[+2Q'&]O:W\GS>:K9**<Y"$<5L>'M)
MM[C5[>>;0=8MI;4%UFOKLNB/C&%!8YSZBN\HH X?PW#J5KINH^'KG2[B)RUP
MR71QY+AR2N#Z\UE-I6K:OX)L]'?2;NWNM*>)V5VV+<["<A&!ZXY!KTVB@#B_
M#&E6LNK?;VT75K2:W0K'+J%R7Y;J%!8_G7:54O\ 5+#2XTDO[R&V1VVJ97"Y
M/H,U:!#*"#D'D&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "B@D 9/ K.M-?TB_N);>TU*UGFA!,B1RABH'7(H T:XRZBU/PWX
MJO\ 5;339]2L=11/,CMR/,BD48S@]0176VMW;WULES:S)- XRDD;95OH:>TT
M:2I$TBB1P2BD\MCKC\Q0!YGKMCJ)\,^)]>U*W^S37XA2*UW M'&C#;N/]XUL
MQ?VCXCU_1+AM)N=/M=++2O)<X!D8IM"J >1SG-7]3\2>#M1M9M/U#6-.DB8[
M9(VN .0<^OJ*NMXL\.06L$S:S8I!*"(G,PPV.#CUQ0!@:%'J5EHFI>'[C2;I
M75+EDN0 8I=Q)4*?4YZ>U&D:5?PZAX4>6TE1;73Y(YR1_JV(& :ZS3=8TW6(
MWDTV^@NTC;:[0N&"GT.*NT <%=:1J#^%?%ELMI*9KJ^ED@3',BEEP1^5:-Q%
M>67BA=32QGGBATC8!&N2TF_.P>]=910!YUH1U"\COHM2T74X=4U972:\DB C
MA7:0J@YR%'\S570O#FQ;+2=2T'5VE@*B2;[8QM3M.0X&[&.!QBO3Z* /.O*U
MC1=/\0:*NAW5Y]M:>2WNH"I5A(IX8D\$5VNCPS6_A^RA9=DZ6R*5<=&"]ZOD
M@$ D#/2C(SC(SZ4 >32Z5KMV]I/>:=K$VHVU]'-<RO,/(**__+) <'CVSUKJ
M+33+U=/\8(UK(&NYIF@4C_6 QX&/QKLJ* //K"VU7PYJMOJ7]D7-]#=:=!;N
MD&#) Z#H03T-;O@FVN[?1[DWMI):RRWL\OE2=0&;(KI** .+U_PO>7WBNWGM
MGVZ=>A!J2?WO*.Y/SR!^%4/$^GZS?ZW?6TUKJ5Q9R0A+ 6<PCA1BN"93D=_7
MC%>AT4 >>Z7INJ6-WX3O9-.G=;:S:RN4 &Z)C@;B.Z\=11J'A_5+FSUAX;9C
M+'K:WT,3\"X10. ??G\J]"HH X"6;7-8\3P:A:Z+=V+0Z=<11O=@ >:<;1P?
M6LS3=,U1M?T+49M.UHR6T["]ENYMP+,A7*(#PN3U Z5ZE10!P:V.I._B+0)-
M.N434YYI8;]0#$JNO&X]0<\8JCH?AZ.26QT_4=!U=9+8J9)I+QFMPR<AE!;!
MY' Q7H=S>6UF(C<SQQ"6011[VQN<]%'OP:GH \V>#6=(T+6_#XT.[O&N7G>"
MZ@P4</S\V3D$>E=YI$3P:-912J5D2!%93U! '%7:J6VJ6%[=3VUK>0S3VYQ-
M'&X)3Z^E %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L'Q1J]YIL-C;:<D1O;^Y6WB:7[B9!)8CO@#I6]67KNAP:[9QQ22R030R"
M:">(_-$XZ$?X4 49VU?2=(OI]1UJR^55,5R]OL$?KN7)S[5SVE^,=3NIM7L+
M5QJ=S!8FZM7-JUN7.<;2IZ\D8(ZUN2^$[N^TJXM-3UVXNY'9'BE,2J(F0Y!"
MC@\]<]:9!X0NX]1DU*37[J2^EM&M7F\I5PI((*@=""/?- &5;>)-9F\+ZA>V
M=Y#J-_"L?^C"T,<L!)^?<F<G Y'KBFW'C2XLO#T4\6I0:A<W=TMO#(EJRF'C
M)WQ@DY&#Q]*UK;P?=0/>W;Z]<OJERB1_;%B52BJ<@;>A]Z9'X#@-M=-=:C<3
M:E/.MS]N50C1R*,*54<#C\Z ,FW\0:OJ"ZGIQN))838O+'?-I[P%&'52K'!R
M.AS4$UOJ:?!YY'U175K.-T46X!1,<KG=SGCGVKLM.T:\@M[F+4]7GU'STV?-
M&L848(X [\]:H6?@]X=!N]$N]6GNK"6+R84:-5:%>V".OX^E %#6-=U'PWI.
MFVDEXMS>WLFU)Q:'$484$_NU)+$?UJQX5\0ZAJ.K75A=>9<VZ1"2*\:S:WR<
MX*E6[^XJ<^$9Y],A@O-:N)[RUD$EI>K$J/"0,8P.",=<]:UM'T^]L(I/MVJR
MZA*Y!W/&J!0.P44 97BS6)-+:V6/5X;$N&^3[*;B60^R@]/4UR>K:M?>*? V
MG737$<!.HI;SH(,K(0X ;!(P.^VNUU?PY+?ZM!J=EJ<MA=I$87=(U??&3G'/
M0Y[U2B\$1PZ/_9HU&5HQ?B]5W0%L@ABI]<GO[T 4+_3]3C\:Z);VVJ108LIL
M;;,;<@IN^7=CG/X>]0:IXRO9->U&RL[AK2*Q(C!6P>Y,KXR<E>%';UKI=<\/
MRZK>V=]::E+87EJ'5940.&1L;@0?H*JW'A.X%_)>Z9K5QI\UR%^U[(E=9F Q
MNP?NM[B@#%A\3>(=6OM#L[80Z?+>VLLEQY\)8HR-C*@D=?0^M=PD5T-/$3W*
MFZ\O!F$?&['7;GU[9K.;0 VOZ?JSW<CR6=L]OM903)NQ\Q/KQZ5LT >?6.M:
MJFAZ/'9FRBN;W4IK:63R-J8&_P"?:#U^4&GWFKZTFF^)M/NKBUEN--C25)C;
M K-&RD[60G Z8ZUMVWA*.VATV,7CM]AO9+P'8/G+[OEZ\8W=?:GW?A9+J?7)
M3=LO]JP)"P" ^7M!&1SSUH YV2+4KOQ=X?>TU".T$FE%U06P94X7< ,CK^E:
M:WMS!XRUB&:>S"Q:>LT=P\ 4Q@GHS9Y48S5N_P#"DEPVF3V6J365Y80^0LRQ
MAPZ8 (*GZ4Z\\)P:A>7\]U=2.M[8K9R*% (P<[L^OM0!@:+XPN+GQ'!I4FH)
MJ,-U!(PE6S: (RC/RD\.I'>MOX??\B/IW_;3_P!&-45IX/N8M3TZ_N]<GNYK
M$,D:M"JIY;+M*X'?&.?:M70-$_L"UEM([N2:U\QG@C=0/)!))4'N,D]: ,'5
M=?U2U\7FPEO(=-LB(_LTDUN72X)^\I?.%/H*CT:#46^(6ONNI*(8VA+Q&#.]
M2IPH.>,>O>M/7/"UQKMRRS:S<)ITA0R60B4@[3GANHJ:3PW*OB5M8LM3EMA-
ML%U;B,,LP7IR>5XXXH QW\3ZD/ -_K :+[7!/(B'9\N!)M''TJ234];UO4M3
MM-.N;:SMM/B59'DA\QI9&3=@#(P,=Z2[\ //;7MC#KEU#IUS*9OLHC4A7)R?
MFZD9[5<NO"$IU.:]TW6+C3VND5+I$C5UEVC ;G[IQWH YW0+F>VTOP2I\AX)
MO-5T>$,RL QW*W;IBH3X]U:[BN+^T<@)*PALAI\D@E13CF4< G'T%=99^$8[
M2VT&$7CN-)9V4E!^]W CGGCK4<'A*XL+IAINN75II[RF5K-45@"3DA6/(!]*
M ,Y?$FJ/XJ%I=W,6EVS^4UM%/;$BX5AEAYF<!@>,5W-<SJOA2?6+\FZUFX;3
MC*DILO+7&5Y&'Z@9%=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<]XGUB]L)-.L--6(7NH3^4DDHRD8 R6([\=JZ&L?Q!X?C
MUV&W(N);6[M9/-M[F+!:-OH>H]J .,NM5O\ POKOB&_OIHKZYBL;<1,D?EAB
MS$ $ GOZ5:TOQ7JS:K:022O>Q7",)?\ B720?9VVY!W-PRYX]:UH_!*S/J#:
MMJ<VH&^@2&0M&(]NTY!7'3FKNF:#J-FSB[U^YO8?+,<<;Q*H /&21RQH Y:+
MQ!XJDT72-56\L"+^Y%MY#6YPF20&W9Y/'2KMUXHU;0%UNWOW@OI[2.%[:1(_
M+#&0[0&&3T/>M:'PC'#HFE:9]L<KI]RMP)-@R^"3@C/'6I;[PK::E>ZE-=2N
M\5_;QPM&!C9L)(8'UR: ,[^T]>T?5=-M]4NK6[AU%70&*'RS#*%W =3N7WK-
MM_$7B./0M.\07-S:26L]RL4EJD)!V,^W<&SU]L5N67A*6.^AN]2UBXU&2V1D
MM1)&J"+(P3@?>;'>G'PC&?"UIH?VQ]MO*DHEV#+;7W8QG\* ,VWU_57\83Z=
M>WL%@BW&VWMI;8XN(L?>63."WM3/#,6J6]WXCN9-326**\FW1?9P-S!00V=W
M ]JT[SPG-J.K1W%[K-Q-917 N8K,QJ CCH-_7 ]*DC\,36^L7UW;ZM-':7K,
M\UF8PRERNTD-U';B@#*T35/$%[X477K_ %73[9)+<LBM!A$.<!F;/Z"JVB>*
M[S4M9NM)_M!;I'LVFANOL;0E6'!^4GYAZ&MW_A$+9_!<7AN6YD:.- JSJ &R
M#D''3KVIEAX3GM]9M]5O-8FO;F.%K=M\2JK1GL .G/UH Y[0=4OO#GPV.KW%
MVMVBH1! 8=NURY'+9)//M4NF>+]475+1+B22]MIE8W &G20?9R%SD,W##C%;
M%IX+2"PO-+N-2FN=(G5A':L@!ARV[(<<G!Z5<TO0+ZRD*WNNW-_;",QI!)&J
MC:>/F(Y8X^E '&ZK?:[K?A&VUJXN;:.QN;N%H[-8LLL?F#!+YZ^V*[WQ'_R+
M.I_]>LG_ *":YW_A )5M5T^+7KI=+CF66&T,2MLPV[;NZD9[5UFHV8U#3;FS
M+E!/$T98#.,C&: /++"W;7=+\/1:9H5Q:36826;49(1$NP+R W5LU=T'4-;T
M;PGINHI<6SZ>UWY)M/*^;8TA&=^>N3TQ7H6G:<-.T:WTX2EQ#"(@Y&"<#&<5
MCKX1C7PO;:)]L?;!,LPEV#)P^_&,_A0!@^*?&%YHEY=O;ZO;2FW8'[$EHSX7
MC(>0'"MUJUJ'B34X_$\5M)=PZ;82QQ/;R36Q=)V;[RE\@*>PJS>> Q=/J<*:
MO<PZ?J+M+/:HBG+GOO/.,XXJ;4/"%WJ<26MQKT_V QQI-;+ N'VXY!ZKG% &
M+J/C2^FUK4K6SN#:16+^4FVP>X\Y\9.2O"C]:['0-0FU;0;2]NK=K>>6/,D3
M C:>AX-9EQX2E349KO1]8N-,^TX-S&D:NLA P&&?NG'>NCCC:.!8_,9V50-[
M<DGU- '"ZQIMA+XDT70]'M(89;6?[=<R1* 84'8GKEB>E=GJ4[VNEW=Q'C?%
M"[KGU"DBN6LO!>K6&I7E]!XHD$MY,)9R;-"6QT7)/ QQ73:LCR:)?1HI=VMI
M%"@<L=IH XY->\0Z=8:'J]_=VEU::A)%%-#' 4:(R="IR<_C4EAK^M2P:QJM
MU=6ZZ?IES,GDI#EYE3L3GY>WK3M \(W,UAHTNKZG<W$-I''+%8O&J".0#C<1
MRV/>M[3/#D%A8:C9RR&YBOIY99 RXP'ZK0!SXUOQ%IUGI.L:A/:2VE_-''):
MQQ;3")/NE6S\Q'&<BFMKWB#4-,U37=.N+2*RLI9%AM9(<M,L9PQ9L_*3@XP#
M6A:^"C'-:1W>L7-WIUDXDMK.1% 0C[NYARV.U%UX(\Y[J"WU>YM=+O',EQ9(
MBD,6^]M;JH/>@#&=;C7/'VBWAN8Q;S:<;F.&6W#A 2,KR>I_O=J]% P,"L=/
M#T$.NV>I0R%$M;0VJ0!>-N0<Y_"MB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH I:O9/J.CWEE')Y3SPM&K_P!TD8S7':'+%HYA
MT+5-%@LM3%HZ6]U"JE+A5'.&'(/<@UW-S$T]K+"LKQ,ZE1(G52>XKG+'PA,E
M^E[JNM7.I3PQM';F2-4$6X8)P.I]Z '_  __ .1&TO\ ZYG_ -"-<KXDU=9/
M$\VL+?1QQ>'YHXA"9 #+N_UO'? (_*MS3?!NM:5;PVMKXMG6VA/R1?8T(QG.
M,YJS9^ -%ATB2SN[>*\N)=YDO)8AYC,V><]L9H HZ_8Z<_BSPFT5I;&*>6=F
MQ$N''E@C/'-5_$UM)!XVT6'3-)L[MA:3D6TI$<>,C)Z$9_#O6Y;>%/)&@>9J
M#RMHX<*QC ,H9=HSSQ@4[7O#5UJNK6FI66KR:=<6T;Q!DA$FX-C/4^U &GH\
M#PZ>AFT^VL;A^98;<@J#]0!FL(ZCK6MZ[J5GI-U;V5KI[")I)8?,:24C.,9&
M%'K6SHNGZAI\,J:AJTFI.[95WA6/8,=..M9^H>%YY-4FU'2M7GTR:Y %P$C6
M19,< X/1L=Z *'B76[W2#;Q'6[:WN/(W-$EFT[R2#OM!^5/>LV?QCJL^C:%J
M".EC:7<;?:[P6QF6)QP 1G@'U-;ESX0F?4DO[76KJWG>W6WNGV*[3JO?)^Z?
M<5%'X.O+31X-,L/$%Q;01;U/[A7WHQS@Y[C/6@"CK'B+5;34;"(ZC;6NGS6J
MN-1^S&6&67/0G.$'O46J^,;QM?N].M+HVL5HBYE2Q>Y\UR,_P\*M:ESX+E;3
M(-+L]:N;;3DMQ;R6_EJ_F+W.3T)J2;P<8+H7.BZK/IDC1)%,%02+*JC"D@]&
MQWH YZXO]8UX^%+HS?V=<27,L;*UN2-ZJPW[20<$#H?6M"]M=5?XC6$<>K+&
MXTTDL;8$'#C=QN[^O:MS5?#CZE86,::E/#>V3B2&\VAFW8P21T.0:KWWA>[N
MI;"\AUN:WU.UA,+W0A5O-0\D%3P.: ,#4?&=_+K6IVEI<FUBL7\E,:>]QYT@
M&3N*\*/UKL?#^HSZMH5I>W-NUO/(F9(V!&&Z'@]JS+GPI.NI3WNE:S<:<UT0
MUTB1JZRL!C< ?NFNCAC,4*1M(TA50"[=6]S0!Y^?$/B0:#=Z_P#:K/[-:731
MFU\@YDC63:?FSP?PK2_M77=;U/58](N;:SM].Q&/.A\QII-NX@\C:O;-7CX2
MC/A:]T/[8^VZE>0R[!E=S[L8S^%1WGA&5[V>YTW6+C3OM2A;I(XU82X&-PS]
MTX[T 9=IXWN!]AU"^6./3[NQD;:!RMQ&?F4'N".E)I_C'4=0ATNP,20:S-=F
M.ZB*Y\N)1N+8]U*X^M;=UX-TNYT?3=,V,MO83)+'W+%?4^_>KB>'[&/Q,^O*
MF+M[<0'CC /7ZXP/PH J^--6N]#\+75_8[/M,90)O&1RP'/YUB:UX@UK0+6P
MAN;N&:\U&7"R16C,MN@7+84$ESZ=*Z7Q%HJ^(=$FTUYV@64J?,5=Q&U@>GX5
M'K7AZ+6+>UQ<2VUW9MOMKF+&Z-L8/!X((ZB@#G=-\4:C-!JL<]Y&D=O$LL.H
MW-F\"#)P0R'J1VQZU!I'CF;^T-1M[BY%_;V]BUXDPM6MV.WJNT]1Z&MZ?PM/
M?Z%<Z=J>L7%W),RNLQC5/+*G(PHXZCOUJ&W\&-_:/V[4=6FOI7M7M)@\2JKQ
MMV 'W<?C0!@:D^O7=KX:U'5+JV,-SJ<$@M8H<&+(8K\^>>,YXK1G\5:E;:1J
M5LRQG68+Y;.$;/E<.PV-CTVD_E4\/@:XC%A!)X@NIK*PN$FM[>2)3@+G"ENI
MZ]:8NF'5OB,NJI:W$5I9P[)'E0HLTP)"E0>N 3S[T =-J*W)T2X6*X$-R(3B
M79NP0.3C-<%H%U?:+X+T=+-[:6_U:98H'> *(\Y+%R#E^A/XUZ//%Y]O)$3C
M>A7/ID8K _X1&W/AFRT@W4HDLBKP72 !T=<X;'X]* ,RXU[6=&N]4TV^N(+J
M:/3)+ZUN$BV<J#E67)[^];/AA]8NM/AO]5NX)!<PI(L,,6T1DC/WL\U4B\'%
MH]0DU#4YKV_O+5K3[2\87RXR#PJCCOFM_3[06&G6UF'+B")8PQ&,X&,T 6:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/34)FUF:T,$8M8
MX0YN!,,A\\J5ZCCG-:%>>:U%%%XF\4F.-$+Z'N<J "QR>3[T =^EQ!)(8TFC
M9QU56!(_"LOQ%KT6A:3<7@$<TL0!$)D"DY(']:X_^S;/3)_!%U8P)#<SX221
M/O2[H<G<?XN?6L*Y_L.7P#?37K0-XB:X)N#,?WRR"7H,\@8QP.* /5(=0GEU
M?[*+9/L_D"0S"4$AR?N[>O3G-7%N;=Y3$D\;2#JH<$C\*\]U=)H?%&LOIR;;
MQO#P93&,,S;B,^YP/TK0\--X0@T[3IK+[(^H+ 6&#FX9MGSANY/7K0!V27,$
MDACCGC=QU57!(_"J-CKUCJ&H7ME#(/.M)!&P+#YCC/R\\UY='?(VK^'-2M5T
M>R2;4$4PVI)N%1R01*W?W!Z&NBTU=.L_$GBB.*&RBU;SMUFK(JN28_X._)ST
MH [T7,!F\D31^;_<WC=^50ZCJ$.GV<TSO'OCC9U1G"EL#.*\FT?2VU/2[%/[
M6T>VU)IU9G:-A>B7=R&;.<]L8Q6J_P#8\\WBIO$;6YU56=(EN3C;"$^0Q@^O
MJ.] 'H&BZB=6T2SU$Q^5]HB60IG.W/;--L-1DN3=&XAC@CCF,<+B97$J]CQT
M^E4_!F#X*T?N#:I_*N"N;>#^Q-4MEC5(3XD1-B?* -R\#'2@#U/[;:;-_P!J
MAVYQN\P8S3WGAC4,\J*",@LP&17 1^'M'?Q_K-H=.M_LPTV.00[!L#$D%@O0
M' ZUG:7;PZA;>!(;Q1<1E;@%9#N# 9P#ZCB@#T[[9:_+_I,/S_=^<?-]*D#H
M7*!E+@9*YY%>7'0-)70_&;K91!K6XD^SMWAP@8;/[O)SQ6MIFIVNG>,KB;4;
ME(!<:3;,DDS8$A&=V">IYH [@W, 7<9HPO/.\8XZTY)HI(_,25&C_O*P(_.O
M)]#M[35'\.QSHLUM)J-\^QNC#)(R._TI^JP+8G7=/MPT.D)JMJ;F*(D+'$RY
M?&.@) SB@#U2*>&<$PRI(!U*,#C\JR=8\0Q:9<:=#&(YWN[Q+5@) #'N[XKB
MM2>"VUJ\?P8(LC293<"S *!A_JS@<;NOO5;R_#2VW@YM,:U:^.H0&5@V9BQ^
M]O/7KZT >IM<P)*(FFC60]$+ $_A1)<P0_ZV:-/]Y@*\IE&D-X8UZ753'_PD
M?VF7!<_OPX;]V(^X&,8QUK9M]+@U7Q!>#6+9+B=-$MBZS#.USOW''KGO0!WR
MW$#2^4LT9DQG:&&<?2J5GJ,L][?1S0QQ6\#JL4PF5O,R.<C^'!XYKS>QL+2U
M\->#-1@B"7KZA&CW /SNI9@06ZD8 X-)K,445GXY2)%C4WMMD(-O)QD\=SDT
M >K1W$,I81S1N5^]M8''UI([F"9BL4\;L.H5P2*X6_MK'P]XXMWLK-8X6TF=
MIH81CSMF,9]3[]:Y[3;I4\3^&;NW_L>V2XD*&"P),BHR_=E;HQ^O.: /6_M5
MOYBQ^?%O;HN\9-++<008\Z:.//3>P&?SKRFZTRR/@+6-3\E?MT6HRM'<?QH1
M+P%/8=>!6PAT:;Q?K+>)S;EQ'$+,7A&SR2GS% >,[LY(YH [Z2XAB0/)-&B'
MHS, #3U974,K!E/0@Y!KR[5PLWC"%//TJ/2TL$_L_P#M",O PZ-MY +=.O.*
MZ[P1ISZ;H;)]O@O()9GDA:#/EHI/W5SV!!H Z2BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH CEN(("!+-'&6Z!V S6-XB\1#
M1$M8H(4N;V[D\N"%I1&"<9RS'H*Y:1='E\4^)#XI,&]0JV@NB !!MZIGOGN.
M:IV-DMU9>"FU*U261[B1 ;F,,[1 ,4#9Y/&#S0!Z9:O-):Q/<1K%,R@NBMN"
MGT![TJW,#RF)9XVD'5 X)_*L_P 2&\C\,:B=-!^UK;MY(0<YQVKF?#B^&$T:
MQ;339MK'V9MA)!G,NWYMW<G/K0!VPN8#-Y(FC,O]S<,_E2/=6\;;7GB4YQAG
M Y]*\DB_LC_A"]-E@*GQ.;M"Q4_Z3YQD^<-WVXS[8K:CT;3M4U/QPU[:QS.C
M@(S<E/W6<KZ'(ZB@#T.6>*%-\LJ1KZLP H-Q"L7FF:,1_P!\L,?G7F&F36EW
MK6BR>)7C>R.C1-:?:3^Z:7^/.>"V,=:E\2"S;4O#\.GS:='H6V4HUPI>V,V>
M V#CUQGB@#TG[1!Y0E\Z/RST?<,?G3'OK9;:6X$T;QQ*6<HP. !FO*]0TV&T
M\+7DLE_87-E<:I;EH[,%88L-\P SQGVK5:#2I?&4T.@1V[VLFES"^CM@#$6_
M@R!QNZT =OHVLVFNZ9#?6CYCE7<%)&Y1[@=*==7LT.I6=K#;I*DI;S7\T*8@
M!P=O4Y-<W\-VTL>%+*.T%JMZL(%TL:J)-P)'SXYS]:LZS%$/'OAR81H)62X4
MOM&XC9TSZ4 =&+NV+J@N(B[=%#C)J1W$<;.W102:\DM=+L5^'2ZFL"+?)J6]
M;@??!\_& >H&#TZ5Z)XLO_[,\)ZG=C[R6[!?J>!_.@#/C\;6;^"IO$A3$46X
M-'N_B#8QFGZIXHN8;VSL-(TW[?>W%O\ :2K2B-4C]<GO7&+X=D:ZMO"7E,-/
MNHDU%SVW*F&7\7(-7K-]%O\ PWHUSJ&M#2]8M8'CAN5E",-C%2"#PPR.E '1
MZAXHOK5]/L+?1S+K%Y$93:M,%6-5ZY?_  K=TRXNKJPBFO;,VEPP^>'>'VGZ
MCK7"Q76FZ]H.E7WB'41INK)YAM;Q)/)9U!QO /&T\'!J_H6I>)]9\*0W%E/9
M&[6>2,SW43!9HU.%<!?6@#7UOQ(^GW\&EZ=8O?ZG.AD6%7"*B#^)V/053U/Q
M1JFD>'!?WNBK'>-<I;I;?: 58L< [@.GX51>]C\/_$.6ZUB1(8=1L8HX[@\1
MK(A.Y23TSG(J#QYJMCK/AB/^SKU) FI6\9EB.0K%NQZ&@#;TOQ1<R:I+IFMZ
M;_9MTL!N%(E$D;QCJ0P]*KVGBK5M5=+G2O#SSZ4[[5N9)UC9US@NJGJO\ZP5
MTVYAUS7],U&ZFNM5O+%ETZ[F('F18Y10, $'KBM;PQXNT2T\+64%W>16ES;1
MK!+:R<2(XX(V]3SZ4 =J3@9/2HHKF"9BL4T<A'4(X.*K:Q=QVFAWEU)"T\4<
M#.T:]7&.E>7Z/<!/&/ARX@_L>WCN5=##IQ.54KD+(W1C^N: /6?M5N75//BW
MMT7>,FH[V]ALK:2622,,J,RJS@;L#.*\J&FV2_#V;5!"@OH]3+)<?QKB;& >
MH&.W2M.8Z-/KOBD^(6@-XB[;1;HC A\O@Q@^^>1S0!W6A:F=9T.SU(Q>4;B,
M/LW9V_C6C7/>!<?\(-H^.GV<8KH: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JO?7D.GV$]Y.2(8(S(Y'H!FK%-DC26-HY$5T8
M896&01Z$4 <[I?BZVU2_L+..-5ENK/[8?W@(5,\8]3_*MY+NVD<(EQ$SG^%7
M!-5I]/LH+:22&SMXWC@:-&2)057'W00.![5Y7:IHB^ ]*:R^SCQ$)T\CR2/.
M,GF<AL<[<9SGB@#TG2=?&I7VL6\D2P)IUSY&\OP_&<^U;!D0%074%_N@GK]*
M\KO\MIGQ M,9N3.LWE#[Q3Y<L!Z<&M/5-4L=3UOPC%I]]#)*!,=T;;MF8< G
M\: .\:^M$D\MKF$/N"[2XSD]L5,S*BEF8*HZDG %>/>'(K;4;W0;:VL$6_L;
MII+N_9UQ.!D'!SE\G'TKT7QC?PZ=X7NY[BT%W$0J&)CA3D@?,>P]: -B.Y@F
M5FCFC=5ZE6! H2YMY)/+2>)GQG:'!./I7E&GN8/$.J1++I0CGT25F33 5BW#
M. >Q8 ]NU7;+2[*R\.>#-3M8$BO6NH4:9?O.'5MP8]QQWH [O7=9BT72+R\)
MCDE@B,@A,@4OCM6A#+YMO'*1MWH&QZ9%>17']C3^$?$TNLM =?,LV\7!_>K@
M_($SR!C'2O54_P"0,O\ U[_^RT 3)=VTCA$N(F<\A5<$UG:7K?\ :.IZO:-"
M(ET^98]^[._*YS[5YH$T1? FCMIOV?\ X2 31&+R#^^,F_YLXYQC.0>*WDU&
M#2[OQNUU")W!24VN<&1"@&?]W)ZT =^EU;R*S1SQ,J_>*N"!]:<TL:HK-(H5
ML $G@YKRG15C?QM8V[-HXMKZPEBE@TW(0J0,!^S-[]:NZ*UQJ6L:?X7O(V8:
M%,\L[,.'53B#]#G\* -RX\:74$]V@T=W6WU)+$,)1\ZM_&..HSTKKR0 23@#
MJ347V2V!4_9XLJY<?(.&/4_7WJCXCOHM.\.W]W-;-<Q1PMNA7^,'C'TYH OQ
M7,$^?*FCDQUV,#BD2[MI'")<1,YZ*'!->6Z'*(?&NFM&^CQI<V4JM%IN0H&
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MI)&9([B4*%( SR,Y&>V15.Q\<VM[I,NK-IUY;Z;$C,US*%P2#C: #DDGIVH
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MZBI-K-,J[7P-V, Y!QSR*QO$OC![KPYJCZ39WQ@B/E#4(\*@8, 2.=Q';(%
M';K:6R+,JV\2B9BTH" ;R>I;U/UJ*#2]/M89(;>QMH8I/OI'"JJWU '-82ZQ
M#;>(KMKV2\@2UTY96WNI@=,GYP <[L@CFKFE>(9=5>)ET:_@M9E+QW$H4*1V
MR,Y&>V10!I0Z986WE^18VT7E$F/RXE79GKC XS0NF6"2S2I8VRR3@B5Q$H,@
M/4,<<_C6-#XM7^T;.TO-+O;+[8Y2"2<+AF S@@$E?Q%5?#_B#5;_ %K6;:?3
MIFAM[EHXW#1@1@+D*><DGU]Z .DGTZQN;9+:>SMY8$QMBDB5E7'3 (P*>;2V
M*PJ;>(B$YB&P?NSTROI^%<GIGBBTLM#^TL-1N)KF^D@BMI2KRF3/*K@XVC'K
M5QO&EK!9ZG+>6-W;7&G(LDULX4N58X#*0<$?C0!T2V\*3O.L4:S2 !Y H#,!
MT!/?%25S<'C"%KU;:[TZ\LS+;M<PO,JXE11DXP20<=C5G0?$7]OQ+/%IUU!:
MR)YD4\I4JXS[$D'V- &W1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 (.@I:** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@".XA6XMI8&)"R(4)'N,5P'_"/^(9/#,7A%[.%;1"L
M;:D)EP8PV[B/KNQQZ5Z'10!A6.F7-OXOU*^:,"UFM8(HGW DE=V>.O<4OBG3
MKK4K&TBM(P[QWL$S L!A5<$GGVK<HH XWQ#X7O-<UR^*[8[:?2C;),6'$OF!
M@".N.*:-.U[6KW1H]2T^*QM],F6=Y5G63SF48 4#H#UYKM** .%G\.:I)\.K
MG25MU-Z]P[K'YBX(,Q8<YQTKISX?TTZT=9^S_P"G[=OF;STQCIG'2M.B@#SJ
MR\#W=OX:DDBMX[;7HKZ2\@D# [CN.%)'8KQCMFM1O#DVM>(+RZU?3T2UN]*B
M@92ZL4E#,6 QZ9ZUV-% 'GTF@>)-6LM+T34=T-M9SL\E_'(A:14_U6%]3QG(
M[5=L]!UK0?$EU>VDLFJ1WMJ1(]S(B%94^YG &01QP.*[2B@#C+#3-8U+Q?::
MY?Z7#I2VL+Q,J3K(]P6Z9*]A[U=\9:9J.IVMFEG$US;QS[KJT2?R3,F.!N^O
M..]=-10!Y</!NKQZ/X@M;?2XX!?2P36\*W 8*%(W*23U[^E=??:3=W'C6QU!
M(Q]DCLIH7DW#AF(P,=:Z*B@#B-&TK6[3PE>^'KC3D CMY4@N5G4K,6)QQU7K
MWK)U/2]:L9M$_LQEM]1CTT6]R5GBW%1CY=KD @'^(&O3:S]2T+2M7*-J.GV]
MRR<*9$!(_&@#SRST&VUC2=)U+2=.-ZFGF:VGLKJ8*TC%OF8.#C.[GT-;,OAF
M:3P[*EGH4&GW<MW"[0I<!R41P<LV<9QG@5VEK:V]E;I;VL,<,*#"I&H 'X5-
M0!RVJ:5?R>+&U*&RBN;<:9) $DD $CE@0I]B.^*@\'Z-J>FZE?2R69TW39$4
M16!N1,$?^)E(R%!]*["B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"\C::QN(D&7>-E4>I
M(J>B@#@+CP1=:C\.+'3),6VKVMOL1@P//="1U4UH:M%KSZ:-(BT"UO;:2T6+
MS9+E5$;[<'<IZX]JZ^B@#A(_#6MZ ^DZAI9BO[JVLA9W<#OL\]1R"K'H0?6G
M>([/Q-K_ (;97TF"*Y2]@FAM5N5+%$;+;F/RY^E=S10!R5W#K7BC3+W2=3T4
MZ9#-$0EQ]J27#YR.%YI^EW7B^/[)8W>D6@6(JLU[]I!611P2J#Y@3[UU5% '
M.^.\CP1JN.OE#'_?0K+33]=U[4M)N;NQCTZWTU&DC8S"1I9&3:, = ,YYKL;
MFU@O+9[>YB66%QAD89!%2*H50JC  P!0!Y9%X/UGS]-N9-'!OK2\6:YO)+X.
MUR,G)4$X [X.*ZC3;'5](\6ZK(M@EQI^I3I-]I695,.%P05/)Z=JZRB@#SB;
MP7J,^DDR6L,EQ;ZO->1VLDN%GC?C!8=#CI5H^&99O#NL);>&X--O;BW\F)1<
MAV<=2"<X S[UWM% ',7>CWTNN>&KE(08K&-UN&WCY24 'UY]*HZ'IVMZ/8ZE
MI,NCPW=NTDTT4S3J$FWG(0J>1U/.,5VM% ''^#M'U+3+^_DEM#IVFRJOD6!N
M?.$;C[S C( /I78444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &'XML=2U'09+?2Y"LQ=2Z!]ADC!^9 W\
M)([UQ]OX(O)[G4(QI:Z79W]@;? N?-:.0-D%N><^V:],HH YG3)O$3VZ:??:
M-%!'' 8VN5N58.0N!M4<\^^*S[3PM?R_#1-#G"07ZC<NY@RAP^X9(ZCBNVHH
M XY;'7M9UO3+S4=.BL8=,#N%\]9#/(R[>,=%^O-4M,T35[?6+J[BT.*PM'MY
M%EL?M8>*ZD)X(4<+WSP.M=]10!Q_@[1]1TW4+Z66Q.FZ=*BB*Q-R)@CC[S+C
MA0?2E\9:7>:HT:6NAK=R+&?)O$NA#);OV/J1W_I77T4 <3!I7B'0M6;4X+:/
M5IKNTBAN1YRQ,LB#&[+<$'/UJLGA36+*+1+U$AN;RUOIKNY@5PH/F]0I/'R_
MK7?T4 <5K/A?4-4N?$1C"1?:A;/:NS AGC )!'4#(Q2K;^(=4\2:)>7VCI9P
MV7F>:PN4?)9< @#M7:44 8?B[2KG6?#=S9V>S[02CQAS@,58-C/;.*RK^'Q!
M>-H^K)HZ)=V$L@DLFN4)=&4#(?IV[UV-% 'G4OAW7[T:]//81Q2WUU:RQ1K.
MK?*C MSZ@#_"NE73+L>.SJ9C'V,V AW[AG?OSC'7I7044 >=Z=X9US3-,T2[
MBM8I+[3IK@O:M*!YB2$]&Z ]#S3M4\.:[J^FZ[>2VD<5[J!@2*T$JG8D;9RS
M=,GDUZ%10 V)2L2*>H4 URFLZ)J%WJ>O300AH[O21;0G>!NDRW'MU'-=;10!
MRSZ+?/%X50PC_06_TGYQ\@\EEX]>3VK DT/Q-:>$KSPO#I<-S$2WDW@N50,I
M?=RIYS7I%% '(:QX8NM8U"_1L16]SI*6JR[@<2!RV,=<=*LZ;/XF:W73[G2H
M;79 8_MBW*LI8+A651SU]:Z:B@#RZR\(:PEYI-W-I(%[9W2R7=W)?>8UR.06
M49P!SG!P:ZC2K+5M)\3ZF/L*S:?J%Q]H^U+,H,7RXP5/)Y';UKJ:* //X?#&
ML6UG9WD,$;7UAJ4]REN\H ECDR,;N@.#WI=4T'7M<M-<OKBSCM[JZM$M;6S$
MRL0JMN)9NF22:[^B@#FM0TJ^EU?0+J*W21+*"=9@S@ %D4*/?)!JAX8T;4K+
MQ#-=?V8-(T]X2LEJMT)4DEW AU X7C/IUKM** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 16W*#T]J6D7&./4TM !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% #(QMC /7O3\T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
M&:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T
M44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &
M:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T4
M4 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:
M,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
M &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,
MT44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
M&:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T
M44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &
':,T44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>grts-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-09T14:12:16.2279+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborativeAndLicenseAgreementsAbstract" xlink:label="grts_CollaborativeAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OptionAndLicenseAndDevelopmentAgreementMember" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SaleOfStockPricePerSharePrepaidByPurchaser" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain" xlink:label="us-gaap_SubsegmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementEarlyTerminationNoticePeriod" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PreJanuary12018Member" xlink:label="grts_PreJanuary12018Member"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RemainingTrancheMember" xlink:label="grts_RemainingTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractResearchOrganizationMember" xlink:label="grts_ContractResearchOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FundingDevelopmentCosts" xlink:label="grts_FundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightIssueDate" xlink:label="grts_ClassOfWarrantOrRightIssueDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockPurchasePriceInExcessOfFairValue1" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentInKindRateMember" xlink:label="grts_PaymentInKindRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TrancheOneMember" xlink:label="grts_TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsAmortization" xlink:label="grts_DeferredTaxAssetsAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalOfficeSpaceMember" xlink:label="grts_AdditionalOfficeSpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightsExpiration" xlink:label="grts_ClassOfWarrantOrRightsExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NonExclusiveLicenseAndDevelopmentAgreementMember" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PostDecember312017Member" xlink:label="grts_PostDecember312017Member"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WeightedAverageDiscountRateAbstract" xlink:label="grts_WeightedAverageDiscountRateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GenevantSciencesGmbHMember" xlink:label="grts_GenevantSciencesGmbHMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationRevenueMember" xlink:label="grts_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommitmentsAndContingenciesDisclosureTable" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:label="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember" xlink:label="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumLeasePayments" xlink:label="grts_MinimumLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumAggregateContingentMilestonePaymentToBeMade" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandEighteenStockIncentivePlanMember" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTaxStatusExtensibleList" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsCapitalizedExpense" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtmEquityOfferingProgramMember" xlink:label="grts_AtmEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FacilitiesRelatedDeposits" xlink:label="grts_FacilitiesRelatedDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerAssetDeduction" xlink:label="grts_ContractWithCustomerAssetDeduction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MilestonePayments" xlink:label="grts_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FinalFee" xlink:label="grts_FinalFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TotalGrantAmount" xlink:label="grts_TotalGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredContractAcquisitionCosts" xlink:label="grts_DeferredContractAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromSaleOfMarketableSecurities" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DebtInstrumentInterestPaymentExtensionPeriod" xlink:label="grts_DebtInstrumentInterestPaymentExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PublicOfferingMember" xlink:label="grts_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" xlink:label="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerAssetAddition" xlink:label="grts_ContractWithCustomerAssetAddition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis" xlink:label="us-gaap_SubsegmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndWarrantsMember" xlink:label="grts_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" xlink:label="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumLiquidityRequirementCapitalDescription" xlink:label="grts_MinimumLiquidityRequirementCapitalDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PlacementAgentCommissionsAndLegalFees" xlink:label="grts_PlacementAgentCommissionsAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="us-gaap_ShortTermContractWithCustomerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLossCarryforwardsExpirationYear" xlink:label="grts_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrimeRatePlusMember" xlink:label="grts_PrimeRatePlusMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockWarrantsOneMember" xlink:label="grts_CommonStockWarrantsOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeriesABAndCConvertiblePreferredStockMember" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncomeTaxesTable" xlink:label="grts_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedStockSubjectToFutureVestingMember" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LessorOperatingLeaseNoticePeriodToTerminate" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NoncashOperatingLeaseExpense" xlink:label="grts_NoncashOperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LeaseExpirationTerm" xlink:label="grts_LeaseExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumPercentageFairMarketValueOfSharePrice" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperationsExpectedCommencedDate" xlink:label="grts_OperationsExpectedCommencedDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ResearchCollaborationAndLicenseAgreementMember" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CepInnovationsMember" xlink:label="grts_CepInnovationsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NetContractAsset" xlink:label="grts_NetContractAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UpFrontPayment" xlink:label="grts_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SummaryOfSignificantAccountingPoliciesTable" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalSharesMember" xlink:label="grts_AdditionalSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EmeryvilleCaliforniaMember" xlink:label="grts_EmeryvilleCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantExercisePrice" xlink:label="grts_WarrantExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractEndMonthYear" xlink:label="grts_RevenueRecognitionContractEndMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesValue" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AgreedUpfrontPayment" xlink:label="grts_AgreedUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeventyMember" xlink:label="grts_SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BostonLeaseMember" xlink:label="grts_BostonLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FutureFundingExpected" xlink:label="grts_FutureFundingExpected"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationReceivable" xlink:label="grts_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_InterestAndOtherReceivablesCurrent" xlink:label="grts_InterestAndOtherReceivablesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AnnualBaseRent" xlink:label="grts_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CambridgeMassachusettsMember" xlink:label="grts_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NonTaxableStockPremium" xlink:label="grts_NonTaxableStockPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseInSharesAvailableForIssuancePercentage" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumMilestoneConsiderationPayable" xlink:label="grts_MaximumMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsToPurchaseSharesOfCommonStock" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsUnrealizedGains" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredContractAcquisitionCostsAmortized" xlink:label="grts_DeferredContractAcquisitionCostsAmortized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EsppEmployeeStockPurchasePlanMember" xlink:label="grts_EsppEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PipeFinancingMember" xlink:label="grts_PipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WeightedAverageRemainingLeaseTermYearsAbstract" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityDeductions" xlink:label="grts_ContractWithCustomerLiabilityDeductions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FairValueMeasurementLevel1ToLevel2Transfers" xlink:label="grts_FairValueMeasurementLevel1ToLevel2Transfers"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentOfLeaseBaseRent" xlink:label="grts_PaymentOfLeaseBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanOriginationCommitmentsMember" xlink:label="us-gaap_LoanOriginationCommitmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MarketableSecuritiesRealizedGainLossDescription" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalFunding" xlink:label="grts_AdditionalFunding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractStartMonthYear" xlink:label="grts_RevenueRecognitionContractStartMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CumulativeChangesInOwnershipInterestOfShareholders" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FourtyErieLeaseMember" xlink:label="grts_FourtyErieLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxLiabilitiesOtherDepreciation" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContributionMember" xlink:label="grts_ContributionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractEndPeriod" xlink:label="grts_RevenueRecognitionContractEndPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaymentsOnFinancingLease" xlink:label="grts_PrepaymentsOnFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TrancheOneAdditionalMember" xlink:label="grts_TrancheOneAdditionalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmendedTotalGrantAmount" xlink:label="grts_AmendedTotalGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumMilestonePaymentObligation" xlink:label="grts_MaximumMilestonePaymentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLeasePeriodForAdditionalTemporarySpace" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OwnershipInterestChangeOverPeriod" xlink:label="grts_OwnershipInterestChangeOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedCashDeposit" xlink:label="grts_RestrictedCashDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumAggregateContingentMilestonePayment" xlink:label="grts_MaximumAggregateContingentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumPotentialMilestoneReceivable" xlink:label="grts_MaximumPotentialMilestoneReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsOutstanding" xlink:label="grts_WarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FacilityChargePercentageOfBorrowing" xlink:label="grts_FacilityChargePercentageOfBorrowing"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AgreementTotalFunding" xlink:label="grts_AgreementTotalFunding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockFairValueClosingPricePerShare" xlink:label="grts_CommonStockFairValueClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockWarrantsTwoMember" xlink:label="grts_CommonStockWarrantsTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmountToExtendOptionTerm" xlink:label="grts_AmountToExtendOptionTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityAddition" xlink:label="grts_ContractWithCustomerLiabilityAddition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LoanAgreementMember" xlink:label="grts_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ReceivablesGross" xlink:label="grts_ReceivablesGross"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsUnrealizedLosses" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmountOfIrrevocableLettersOfCreditWithdrawn" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromNonRefundableUpfrontPayment" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfConvertiblePreferredStockTransactionPrice" xlink:label="grts_IssuanceOfConvertiblePreferredStockTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsOtherDepreciation" xlink:label="grts_DeferredTaxAssetsOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsOfFinancingLease" xlink:label="grts_PaymentsOfFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaymentPremiumRate" xlink:label="grts_PrepaymentPremiumRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaidExpenseForResearchAndDevelopment" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SecondTrancheOfFundingReceived" xlink:label="grts_SecondTrancheOfFundingReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwentyOneErieLeaseMember" xlink:label="grts_TwentyOneErieLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PleasantonMember" xlink:label="grts_PleasantonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MarketableSecuritiesContractualMaturitiesPeriod" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UpfrontPayments" xlink:label="grts_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumOfferingExpensesAgreedToBeReimbursed" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EmployeeOrDirectorMember" xlink:label="grts_EmployeeOrDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLeasePaymentUnderTheBostonLease" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember" xlink:label="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FinalPaymentFeePercentage" xlink:label="grts_FinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInLeaseLiability" xlink:label="grts_IncreaseDecreaseInLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockOptionsWarrantsAndOtherMember" xlink:label="grts_StockOptionsWarrantsAndOtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementTerminationTerm" xlink:label="grts_CollaborationAgreementTerminationTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncomeTaxesLineItems" xlink:label="grts_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromMaturityOfMarketableSecurities" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FirstTrancheOfFundingsReceived" xlink:label="grts_FirstTrancheOfFundingsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" xlink:label="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_InitialFundingDevelopmentCosts" xlink:label="grts_InitialFundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NonRefundableOptionFee" xlink:label="grts_NonRefundableOptionFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WarehouseMember" xlink:label="srt_WarehouseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsLeaseLiability" xlink:label="grts_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operations Commenced Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Storage space commenced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Next Rolling 12 Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New right-of-use assets obtained in exchange for lease obligations (in thousands):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New right-of-use assets obtained in exchange for lease obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred incremental costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arbutus Biopharma Corporation And Protiva Biotherapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborativeAndLicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative And License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborativeAndLicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative and license agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computer Equipment and Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial amount of borrowing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Line of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option and license and development agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option And License And Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option and License and Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases accrued but not yet paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BluebirdBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bluebird Bio Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BluebirdBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bluebird Bio Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BluebirdBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bluebird Bio Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of Stock, Price Per Share, Prepaid by Purchaser</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share, Prepaid by Purchaser</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share, prepaid by purchaser</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Amounts representing interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Noncurrent portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsegmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsegments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating cash flows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Amounts representing lease payments under Boston lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under the ESPP, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gates Foundation Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gates Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, unvested beginning balance | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, unvested ending balance | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement early termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Early Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement early termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PreJanuary12018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre January 1, 2018</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PreJanuary12018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre January 1, 2018 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PreJanuary12018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre January 1, 2018.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RemainingTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RemainingTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractResearchOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Research Organization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractResearchOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Research Organization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractResearchOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract Research Organization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Issuance Costs and Debt Discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Funding development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issue Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Issue Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, issue date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Need for Additional Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Need For Additional Capital Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of need for additional capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Price In Excess Of Fair Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Purchase Price In Excess Of Fair Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock purchase price in excess of fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock-based compensation expense and awards granted to non-employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based compensation expense and awards granted to non-employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense and awards granted to non-employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentInKindRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment-in-kind rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentInKindRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment-in-kind rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Taxable years two thousand and twenty two thousand and twenty one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxable Years Two Thousand and Twenty Two Thousand and Twenty One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxable Years 2020 and 2021 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Pre-funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock And Or Pre Funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock and/or pre-funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Office Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Office Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Office Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CEPIFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C E P I Funding Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CEPIFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CEPI funding agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CEPIFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">C E P I Funding Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contribution of employee's eligible compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Noncurrent Assets Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or rights expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Exclusive License and Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Exclusive License And Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-Exclusive license and development agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from equity investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PostDecember312017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post December 31, 2017</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PostDecember312017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post December 31, 2017 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PostDecember312017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post December 31, 2017.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants cancelled.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases number of renewal terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Additional Number Of Renewal Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee leasing arrangements operating leases additional number of renewal terms.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Sales Purchase Agreement, net of issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net rentable area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GenevantSciencesGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Genevant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GenevantSciencesGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genevant Sciences GmbH [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GenevantSciencesGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genevant Sciences Gmb H [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GenevantSciencesGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genevant Sciences GmbH.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Deferred Revenue Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Short-Term Debt [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class of warrant nominal exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant nominal exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Nominal Exercise Price Of Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right nominal exercise price of warrants or rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, preferred stock, debt securities, warrants and units covered in Registration Statement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Securities Covered Under Registration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum securities covered under registration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Long term debt balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement of operating lease right-of-use asset for lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remeasurement of operating lease right-of-use assets for lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposit Assets And Other Assets Noncurrent Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deposit assets and other assets noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Information Related To Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-Backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Operating Loss and Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Net Operating Loss And Tax Credit Carryforwards Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of net operating loss and tax credit carryforwards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value granted employee stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Adopted Accounting Pronouncements Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently Adopted Accounting Pronouncements [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leasing renewal option to extend lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ATM Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Nineteen At The Market Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen at-the-market equity offering program member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum Lease Payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and available for sale debt securities accumulated gross unrealized loss before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate contingent milestone payment to be made.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Contingent Milestone Payment To Be Made</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate contingent milestone payments to be made by company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue, non- current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits, Expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Limitations on Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Award Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Tax Status [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Tax Status [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Asset, after Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A, B, and C convertible preferred stock into common stock upon initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity offering program member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Excluding Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets, capitalized research expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 Capitalized Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Capitalized Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Potentially Anti-Dilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Sales Purchase Agreement, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtmEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2022 ATM Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtmEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2022 ATM Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FacilitiesRelatedDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Faclities-related deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FacilitiesRelatedDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facilities-related deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FacilitiesRelatedDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Facilities-related deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate, Type of Property [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset deduction.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Deduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetDeduction_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificates of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for issuance cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for warrant exercises, Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for warrant exercises, Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for warrant exercises, Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital offering costs related to sale of common stock and pre funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs related to the sale of common stock and pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated Certificate of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Certificate Of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended And Restated Certificate Of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent income tax rate differential.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock called by warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FinalFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FinalFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Final Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FinalFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of the fee that accompanies borrowing money under the debt instrument.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TotalGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total grant amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TotalGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Grant Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TotalGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total Grant Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred contract acquisition costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Contract Acquisition Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred contract acquisition costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Sale of marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DebtInstrumentInterestPaymentExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, Interest payment, Extension period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DebtInstrumentInterestPaymentExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Payment, Extension Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DebtInstrumentInterestPaymentExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument, Interest Payment, Extension Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deposits and other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deposit And Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in deposit and other assets noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon restricted stock units vesting, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon restricted stock units vesting, net of shares withheld, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon restricted stock units vesting, net of shares withheld, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset addition.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Addition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenues [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowing capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsegments [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock And Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock and warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrivateInvestmentInPublicEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Investment in Public Equity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrivateInvestmentInPublicEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Investment In Public Equity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrivateInvestmentInPublicEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private investment in public equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short term deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of New Accounting Pronouncements Not Yet Adopted 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumLiquidityRequirementCapitalDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum Liquidity Requirement Capital Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumLiquidityRequirementCapitalDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Liquidity Requirement Capital Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumLiquidityRequirementCapitalDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum Liquidity Requirement Capital Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and available for sale debt securities accumulated gross unrealized gain before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PlacementAgentCommissionsAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent commissions and legal fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PlacementAgentCommissionsAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Commissions And Legal Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PlacementAgentCommissionsAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement agent commissions and legal fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lapse of repurchase rights related to common stock issued pursuant to early exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lapse of repurchase rights related to common stock issued pursuant to early exercises.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short Term Contract With Customer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Contract with Customer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses, Expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrimeRatePlusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate Plus [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrimeRatePlusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prime Rate Plus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockWarrantsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockWarrantsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Warrants One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A B And C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A B And C Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A, B, and C convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Equivalents, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used for Estimating the Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Stock Subject to Future Vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Subject to Future Vesting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary space lease termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Notice Period To Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents operating lease notice period to terminate for the additional temporary space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from lines of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Lines of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Lines of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash operating lease expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LeaseExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease expiration term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LeaseExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GileadSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gilead [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GileadSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gilead Sciences Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GileadSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gilead Sciences, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage fair market value of share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Fair Market Value Of Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage fair market value of share price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperationsExpectedCommencedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operations expected commenced date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperationsExpectedCommencedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operations commenced date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperationsExpectedCommencedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operations expected commenced date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration and License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration and License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CepInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CepInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CepInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cep Innovations [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CepInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CEPI [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NetContractAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net contract asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NetContractAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Contract Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NetContractAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net contract asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock, net of issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up Front Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development-related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense For Research And Development Non Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period exceeding one year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmeryvilleCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emeryville California [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmeryvilleCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emeryville California [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmeryvilleCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emeryville California.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability revenue recognized including new contracts in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized Including New Contracts In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition contract end month year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Contract End Month Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition contract end year-month.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Decrease in loss from operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime rate percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early termination reduction of future milestone and royalty payments, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Termination Reduction Of Future Milestone And Royalty Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early termination reduction of future milestone and royalty payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and available for sale debt securities amortized cost basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen employee stock purchase plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for warrant exercises, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for warrant exercises, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreed Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreed upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2 Seventy [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2 Seventy [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BostonLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Boston Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BostonLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Boston Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BostonLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Boston Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureFundingExpected_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future funding expected</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureFundingExpected_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of funding expected in future.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureFundingExpected_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Funding Expected</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InterestAndOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and other receivables current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InterestAndOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Receivables Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InterestAndOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain/(Loss) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Canceled/Forfeited | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canceled/Forfeited | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2022 and 2021; 86,894,901 and 69,047,878 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for issuance granted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized issuance costs and debt discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonTaxableStockPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-taxable stock premium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonTaxableStockPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Taxable Stock Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonTaxableStockPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-taxable stock premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities recognition of other-than-temporary impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other than Temporary Impairment Losses, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other than Temporary Impairment Losses, Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Shares Available For Issuance Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in shares available for issuance percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone consideration payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Consideration Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum consideration to be paid in the future based on milestones per the License Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense, debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Number of Shares, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents, unrealized gains.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Pre Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceed from issuance of stock and pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Uset Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease right of uset assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issued | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price allocated to shares of common stock at fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price Allocated To Shares Of Common Stock At Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to shares of common stock at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCostsAmortized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred contract acquisition costs amortized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCostsAmortized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Contract Acquisition Costs Amortized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCostsAmortized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred contract acquisition costs, amortized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EsppEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ESPP Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EsppEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EsppEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of individual securities in an unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PIPE Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private investment in public equity financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PIPE Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term (years):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term Years [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining lease term (years).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability deductions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FairValueMeasurementLevel1ToLevel2Transfers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement Level 1 to Level 2 Transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FairValueMeasurementLevel1ToLevel2Transfers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Level 1 to Level 2 Transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FairValueMeasurementLevel1ToLevel2Transfers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement level 1 to level 2 transfers.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentOfLeaseBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent paid for the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentOfLeaseBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Lease Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentOfLeaseBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the first twelve months of prepaid operating lease base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoanOriginationCommitmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Origination Commitments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash deposit used as collateral for letter of credit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Deposit Used as Collateral for Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash deposit used as collateral for letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax payments related to shares withheld for vested restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax payments related to shares withheld for vested restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities realized gain loss.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Realized Gain Loss Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses on marketable securities, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of estimated future principal payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional funding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Funding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional funding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractStartMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition contract start month year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractStartMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Contract Start Month Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractStartMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition contract start year-month.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease termination date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Term Of Contract Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee leasing arrangements operating leases term of contract month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative changes in ownership interest of shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Changes In Ownership Interest Of Shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative changes in ownership interest of shareholders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and expected to vest (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option granted expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FourtyErieLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">40 Erie Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FourtyErieLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">fourty Erie Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FourtyErieLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">fourty Erie Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, other depreciation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized grant revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and Rights outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contribution [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contribution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution revenues [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and exercisable (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest on debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition contract end period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Contract End Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition contract end period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements expense materials and personnel costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements Expense Materials And Personnel Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements expense materials and personnel costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Class Of Warrant Or Right Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to right-of-use assets and lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment To Right Of Use Assets And Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment to Right-Of-Use Assets and Lease Liability .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerDurationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Duration [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Payments of financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of deferred financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentsOnFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments on financing lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentsOnFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments on Financing Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentsOnFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments on financing lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentsOnFinancingLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepayments on financing lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TrancheOneAdditionalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One Additional [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TrancheOneAdditionalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche One Additional [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents And Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities (in thousands):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedTotalGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended total grant amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedTotalGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Total Grant Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedTotalGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended Total Grant Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum amount of taxable income where use of net operating losses is suspended.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Amount Of Taxable Income Where Use Of Net Operating Losses Suspended</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum amount of taxable income where use of net operating losses is suspended</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cost related to non-vested employee and consultant options unrecognized weighted average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Remaining Contractual Term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Payment Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum amount to be paid upon achievement of certain milestones as defined under the research and development agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime rate percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of realization of tax benefit upon ultimate settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of realization of tax benefit upon ultimate settlement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Unit Awards under 2018 Equity Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Minimum Annual Payments Under Lease Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of business incentive tax credits period cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Business Incentive Tax Credits Period Cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Use of business incentive tax credits period cap.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premiums and discounts on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long-term debt, net of debt discount and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-Term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased compensation arrangement by sharebased payment award options cash received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Cash Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">cash received upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease period or additional temporary space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Period For Additional Temporary Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents operating lease term for the additional temporary space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases for tax positions taken during current period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Notes 6, 7 and 8)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OwnershipInterestChangeOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in ownership over period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OwnershipInterestChangeOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Interest Change Over Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OwnershipInterestChangeOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership interest change over period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasuries [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation by shared based payment award, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted cash deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of individual securities in an unrealized loss position for 12 months or greater</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate contingent milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Contingent Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate contingent milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for consulting services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in state tax apportionment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPotentialMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum development, regulatory, and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPotentialMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Potential Milestone Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPotentialMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration relating to future milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canceled/Forfeited | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate payment in specified development regulatory and commercial milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Payment In Specified Development Regulatory And Commercial Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate payment in specified development regulatory and commercial milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cost related to non-vested employee and consultant options expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment included in research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Included In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment included in research and development expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding and ESPP Shares Issuable and Outstanding [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued And Outstanding And E S P P Shares Issuable And Outstanding [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued and outstanding and ESPP shares issuable and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of stock option awards exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FacilityChargePercentageOfBorrowing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility Charge Percentage of Borrowing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FacilityChargePercentageOfBorrowing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facility Charge Percentage of Borrowing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FacilityChargePercentageOfBorrowing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Facility Charge Percentage of Borrowing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BlueBirdBioTo2SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Blue Bird Bio to 2seventy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BlueBirdBioTo2SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Blue Bird Bio to 2seventy [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BlueBirdBioTo2SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Bluebird bio to 2seventy [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease for tax positions taken during prior periods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of net operating losses suspension period for medium and large business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Net Operating Losses Suspension Period For Medium And Large Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Use of net operating losses suspension period for medium and large business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leasing term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and available for sale securities debt securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities arising from obtaining right -of-use asset from new leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Common Stock Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares common stock warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreementTotalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement total funding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreementTotalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Total Funding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreementTotalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement total funding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, facility charge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fee Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockFairValueClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock fair value closing price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockFairValueClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Fair Value Closing Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockFairValueClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock fair value closing price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Employee Related Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses And Other Current Assets Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution, percent of employees' gross pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease security deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cash security deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockWarrantsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockWarrantsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Warrants Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountToExtendOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount to extend the option term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountToExtendOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount To Extend Option Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountToExtendOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount to extend option term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Addition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability addition.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of other risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan Agreement [Member] for loan and security agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReceivablesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReceivablesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReceivablesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Receivables Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents unrealized losses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Withdrawal from irrevocable letters of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Irrevocable Letters Of Credit Withdrawn</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of irrevocable letters of credit withdrawn.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerDurationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Duration [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for options to license for each indication</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Options To License For Each Indication</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for options to license for each indication.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business incentive tax credits to offset against taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deposits and other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits and other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits And Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncurrent Deposits And Other Assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Number of Shares, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of credit outstanding, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses, Expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for options to license for each indication</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Options To License Payments For Options To License For Each Indication</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for options to license for each indication.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from non refundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Non Refundable Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from non refundable upfront payment included in transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfConvertiblePreferredStockTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, Transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfConvertiblePreferredStockTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of convertible preferred stock, Transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfConvertiblePreferredStockTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible preferred stock, Transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Lives of Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Depreciation Calculated Using Straight Line Method Over Estimated Useful Lives Of Assets Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation calculated using straight Line method over estimated useful Lives of assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license revenues [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory federal income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning of year&#8212;unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">End of year&#8212;unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Other Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Quarterly Financial Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsOfFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of financing lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsOfFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsOfFinancingLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of financing lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of gross proceeds as underwriter compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Proceeds Payable As Compensation To Underwriter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of proceeds payable as compensation to underwriter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market capitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalization, Long-Term Debt and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Capitalization, Long-Term Debt and Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, unvested ending balance | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, unvested Beginning balance | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for grants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties related to unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future Milestone And Royalty Payments, Reduction Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestone And Royalty Payments, Reduction Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Milestone And Royalty Payments, Reduction Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration, Option and License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Option And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration, option and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentPremiumRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment premium rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentPremiumRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Premium Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentPremiumRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment premium rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development-related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense For Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total principal payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal loan balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SecondTrancheOfFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second tranche of fundings received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SecondTrancheOfFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second tranche of funding received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SecondTrancheOfFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second tranche of funding received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares increase under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Taxable Year Two Zero Two One And Two Zero Two Zero [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxable Year Two Zero Two One And Two Zero Two Zero [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxable Year 2021 and 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of outstanding shares held by individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Outstanding Shares Held By Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of outstanding shares held by individual.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwentyOneErieLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">21 Erie Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwentyOneErieLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty one Erie Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwentyOneErieLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty one Erie Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Net Deferred Tax Assets/Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PleasantonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pleasanton [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PleasantonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pleasanton [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PleasantonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pleasanton [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities contractual maturities period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Contractual Maturities Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities contractual maturities period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum offering expense agreed to be reimbursed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Offering Expenses Agreed To Be Reimbursed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum offering expenses agreed to be reimbursed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coalition for Epidemic Preparedness Innovation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coalition for Epidemic Preparedness Innovation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coalition For Epidemic Preparedness Innovation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CEPI [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmployeeOrDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee or Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmployeeOrDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Or Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmployeeOrDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee or Director.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expenses incurred but not yet paid for research and development activities due within one year or the normal operating cycle, if longer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease payment under the boston lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease payment under the boston lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Amounts representing lease payments under the Boston Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer's matching contribution percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 ATM Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty Two At The Market Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand and Twenty Two At The Market Equity Offering Program Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash, cash equivalents and restricted cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of common stock ownership to exercise warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Common Stock Ownership To Exercise Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of common stock ownership to exercise warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Common Stock Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value common stock warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercised Common Stock Subject To Future Vesting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercised Common Stock Subject To Future Vesting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercised common stock subject to future vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument , interest percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for consulting services, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final payment fee percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Final Payment Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Final payment fee percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deposits and Other Long-Term Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockOptionsWarrantsAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options, Warrants and Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockOptionsWarrantsAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options, Warrants and Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockOptionsWarrantsAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Warrants and Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementTerminationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement termination term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementTerminationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Termination Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementTerminationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement termination term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturity Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from maturity of marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FirstTrancheOfFundingsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Tranche of Fundings Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FirstTrancheOfFundingsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Tranche of Fundings Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FirstTrancheOfFundingsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First tranche of funding received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing costs included in accrued liabilities and accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax payments related to shares withheld for vested restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax payments related to shares withheld for vested restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax payments related to shares withheld for vested restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reclassified common stock and additional paid in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A, B, and C convertible preferred stock into common stock upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InitialFundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial funding development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InitialFundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial funding development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonRefundableOptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable option fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonRefundableOptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Option Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonRefundableOptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable option fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WarehouseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warehouse Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WarehouseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warehouse [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one employment inducement incentive award plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, and equipment, estimated useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities that were not included in the diluted per share calculations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperationsCommencedDate1" xlink:to="us-gaap_OperationsCommencedDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ClassOfWarrantOrRightWarrantsExercised" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" xlink:to="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborativeAndLicenseAgreementsAbstract" xlink:to="grts_CollaborativeAndLicenseAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ComputerEquipmentAndSoftwareMember" xlink:to="grts_ComputerEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OptionAndLicenseAndDevelopmentAgreementMember" xlink:to="grts_OptionAndLicenseAndDevelopmentAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_BluebirdBioIncMember" xlink:to="grts_BluebirdBioIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SaleOfStockPricePerSharePrepaidByPurchaser" xlink:to="grts_SaleOfStockPricePerSharePrepaidByPurchaser_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FundingAgreementMember" xlink:to="grts_FundingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="us-gaap_SubsegmentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:to="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_GatesFoundationMember" xlink:to="grts_GatesFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationAgreementEarlyTerminationNoticePeriod" xlink:to="grts_CollaborationAgreementEarlyTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PreJanuary12018Member" xlink:to="grts_PreJanuary12018Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RemainingTrancheMember" xlink:to="grts_RemainingTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractResearchOrganizationMember" xlink:to="grts_ContractResearchOrganizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FundingDevelopmentCosts" xlink:to="grts_FundingDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ClassOfWarrantOrRightIssueDate" xlink:to="grts_ClassOfWarrantOrRightIssueDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" xlink:to="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockPurchasePriceInExcessOfFairValue1" xlink:to="grts_CommonStockPurchasePriceInExcessOfFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" xlink:to="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PaymentInKindRateMember" xlink:to="grts_PaymentInKindRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TrancheOneMember" xlink:to="grts_TrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxAssetsAmortization" xlink:to="grts_DeferredTaxAssetsAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" xlink:to="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockAndOrPreFundedWarrantsMember" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AdditionalOfficeSpaceMember" xlink:to="grts_AdditionalOfficeSpaceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CEPIFundingAgreementMember" xlink:to="grts_CEPIFundingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ClassOfWarrantOrRightsExpiration" xlink:to="grts_ClassOfWarrantOrRightsExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NonExclusiveLicenseAndDevelopmentAgreementMember" xlink:to="grts_NonExclusiveLicenseAndDevelopmentAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PostDecember312017Member" xlink:to="grts_PostDecember312017Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WarrantsCancelled" xlink:to="grts_WarrantsCancelled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WeightedAverageDiscountRateAbstract" xlink:to="grts_WeightedAverageDiscountRateAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:to="grts_StockIssuedDuringPeriodSharesPurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_GenevantSciencesGmbHMember" xlink:to="grts_GenevantSciencesGmbHMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" xlink:to="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" xlink:to="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" xlink:to="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationRevenueMember" xlink:to="grts_CollaborationRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="grts_CommitmentsAndContingenciesDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:to="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember" xlink:to="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MinimumLeasePayments" xlink:to="grts_MinimumLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumAggregateContingentMilestonePaymentToBeMade" xlink:to="grts_MaximumAggregateContingentMilestonePaymentToBeMade_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwoThousandEighteenStockIncentivePlanMember" xlink:to="grts_TwoThousandEighteenStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTaxStatusExtensibleList" xlink:to="us-gaap_DefinedContributionPlanTaxStatusExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SeriesCConvertiblePreferredStockMember" xlink:to="grts_SeriesCConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AtTheMarketEquityOfferingProgramMember" xlink:to="grts_AtTheMarketEquityOfferingProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxAssetsCapitalizedExpense" xlink:to="grts_DeferredTaxAssetsCapitalizedExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:to="grts_StockIssuedDuringPeriodValuePurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AtmEquityOfferingProgramMember" xlink:to="grts_AtmEquityOfferingProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FacilitiesRelatedDeposits" xlink:to="grts_FacilitiesRelatedDeposits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerAssetDeduction" xlink:to="grts_ContractWithCustomerAssetDeduction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MilestonePayments" xlink:to="grts_MilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" xlink:to="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AmendedAndRestatedCertificateOfIncorporationMember" xlink:to="grts_AmendedAndRestatedCertificateOfIncorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" xlink:to="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FinalFee" xlink:to="grts_FinalFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TotalGrantAmount" xlink:to="grts_TotalGrantAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LaboratoryEquipmentMember" xlink:to="grts_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredContractAcquisitionCosts" xlink:to="grts_DeferredContractAcquisitionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromSaleOfMarketableSecurities" xlink:to="grts_ProceedsFromSaleOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DebtInstrumentInterestPaymentExtensionPeriod" xlink:to="grts_DebtInstrumentInterestPaymentExtensionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PublicOfferingMember" xlink:to="grts_PublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:to="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" xlink:to="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerAssetAddition" xlink:to="grts_ContractWithCustomerAssetAddition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockAndWarrantsMember" xlink:to="grts_CommonStockAndWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrivateInvestmentInPublicEquityMember" xlink:to="grts_PrivateInvestmentInPublicEquityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" xlink:to="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MinimumLiquidityRequirementCapitalDescription" xlink:to="grts_MinimumLiquidityRequirementCapitalDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PlacementAgentCommissionsAndLegalFees" xlink:to="grts_PlacementAgentCommissionsAndLegalFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashAndCashEquivalentsAndMarketableSecurities" xlink:to="grts_CashAndCashEquivalentsAndMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermContractWithCustomerMember" xlink:to="us-gaap_ShortTermContractWithCustomerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperatingLossCarryforwardsExpirationYear" xlink:to="grts_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrimeRatePlusMember" xlink:to="grts_PrimeRatePlusMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockWarrantsOneMember" xlink:to="grts_CommonStockWarrantsOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SeriesABAndCConvertiblePreferredStockMember" xlink:to="grts_SeriesABAndCConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncomeTaxesTable" xlink:to="grts_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RestrictedStockSubjectToFutureVestingMember" xlink:to="grts_RestrictedStockSubjectToFutureVestingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LessorOperatingLeaseNoticePeriodToTerminate" xlink:to="grts_LessorOperatingLeaseNoticePeriodToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NoncashOperatingLeaseExpense" xlink:to="grts_NoncashOperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LeaseExpirationTerm" xlink:to="grts_LeaseExpirationTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_GileadSciencesIncMember" xlink:to="grts_GileadSciencesIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MinimumPercentageFairMarketValueOfSharePrice" xlink:to="grts_MinimumPercentageFairMarketValueOfSharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperationsExpectedCommencedDate" xlink:to="grts_OperationsExpectedCommencedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ResearchCollaborationAndLicenseAgreementMember" xlink:to="grts_ResearchCollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CepInnovationsMember" xlink:to="grts_CepInnovationsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NetContractAsset" xlink:to="grts_NetContractAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_UpFrontPayment" xlink:to="grts_UpFrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" xlink:to="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="grts_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AdditionalSharesMember" xlink:to="grts_AdditionalSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EmeryvilleCaliforniaMember" xlink:to="grts_EmeryvilleCaliforniaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ShortTermMarketableSecuritiesMember" xlink:to="grts_ShortTermMarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WarrantExercisePrice" xlink:to="grts_WarrantExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" xlink:to="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RevenueRecognitionContractEndMonthYear" xlink:to="grts_RevenueRecognitionContractEndMonthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" xlink:to="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IssuanceOfCommonStockForWarrantExercisesValue" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AgreedUpfrontPayment" xlink:to="grts_AgreedUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SeventyMember" xlink:to="grts_SeventyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_BostonLeaseMember" xlink:to="grts_BostonLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FutureFundingExpected" xlink:to="grts_FutureFundingExpected_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationReceivable" xlink:to="grts_CollaborationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_InterestAndOtherReceivablesCurrent" xlink:to="grts_InterestAndOtherReceivablesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AnnualBaseRent" xlink:to="grts_AnnualBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CambridgeMassachusettsMember" xlink:to="grts_CambridgeMassachusettsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NonTaxableStockPremium" xlink:to="grts_NonTaxableStockPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseInSharesAvailableForIssuancePercentage" xlink:to="grts_IncreaseInSharesAvailableForIssuancePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumMilestoneConsiderationPayable" xlink:to="grts_MaximumMilestoneConsiderationPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WarrantsToPurchaseSharesOfCommonStock" xlink:to="grts_WarrantsToPurchaseSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashAndCashEquivalentsUnrealizedGains" xlink:to="grts_CashAndCashEquivalentsUnrealizedGains_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" xlink:to="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" xlink:to="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredContractAcquisitionCostsAmortized" xlink:to="grts_DeferredContractAcquisitionCostsAmortized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EsppEmployeeStockPurchasePlanMember" xlink:to="grts_EsppEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PipeFinancingMember" xlink:to="grts_PipeFinancingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WeightedAverageRemainingLeaseTermYearsAbstract" xlink:to="grts_WeightedAverageRemainingLeaseTermYearsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerLiabilityDeductions" xlink:to="grts_ContractWithCustomerLiabilityDeductions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FairValueMeasurementLevel1ToLevel2Transfers" xlink:to="grts_FairValueMeasurementLevel1ToLevel2Transfers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PaymentOfLeaseBaseRent" xlink:to="grts_PaymentOfLeaseBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanOriginationCommitmentsMember" xlink:to="us-gaap_LoanOriginationCommitmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" xlink:to="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MarketableSecuritiesRealizedGainLossDescription" xlink:to="grts_MarketableSecuritiesRealizedGainLossDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AdditionalFunding" xlink:to="grts_AdditionalFunding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LongTermMarketableSecuritiesMember" xlink:to="grts_LongTermMarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RevenueRecognitionContractStartMonthYear" xlink:to="grts_RevenueRecognitionContractStartMonthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CumulativeChangesInOwnershipInterestOfShareholders" xlink:to="grts_CumulativeChangesInOwnershipInterestOfShareholders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashCashEquivalentsAndMarketableSecurities" xlink:to="grts_CashCashEquivalentsAndMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FourtyErieLeaseMember" xlink:to="grts_FourtyErieLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxLiabilitiesOtherDepreciation" xlink:to="grts_DeferredTaxLiabilitiesOtherDepreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContributionMember" xlink:to="grts_ContributionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RevenueRecognitionContractEndPeriod" xlink:to="grts_RevenueRecognitionContractEndPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" xlink:to="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" xlink:to="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrepaymentsOnFinancingLease" xlink:to="grts_PrepaymentsOnFinancingLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TrancheOneAdditionalMember" xlink:to="grts_TrancheOneAdditionalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AmendedTotalGrantAmount" xlink:to="grts_AmendedTotalGrantAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" xlink:to="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumMilestonePaymentObligation" xlink:to="grts_MaximumMilestonePaymentObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" xlink:to="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" xlink:to="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" xlink:to="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperatingLeasePeriodForAdditionalTemporarySpace" xlink:to="grts_OperatingLeasePeriodForAdditionalTemporarySpace_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationAgreementMember" xlink:to="grts_CollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OwnershipInterestChangeOverPeriod" xlink:to="grts_OwnershipInterestChangeOverPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RestrictedCashDeposit" xlink:to="grts_RestrictedCashDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumAggregateContingentMilestonePayment" xlink:to="grts_MaximumAggregateContingentMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_GrantAgreementMember" xlink:to="grts_GrantAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FollowOnPublicOfferingMember" xlink:to="grts_FollowOnPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumPotentialMilestoneReceivable" xlink:to="grts_MaximumPotentialMilestoneReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WarrantsOutstanding" xlink:to="grts_WarrantsOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" xlink:to="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" xlink:to="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" xlink:to="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FacilityChargePercentageOfBorrowing" xlink:to="grts_FacilityChargePercentageOfBorrowing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_BlueBirdBioTo2SeventyMember" xlink:to="grts_BlueBirdBioTo2SeventyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" xlink:to="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:to="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:to="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AgreementTotalFunding" xlink:to="grts_AgreementTotalFunding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockFairValueClosingPricePerShare" xlink:to="grts_CommonStockFairValueClosingPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockWarrantsTwoMember" xlink:to="grts_CommonStockWarrantsTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AmountToExtendOptionTerm" xlink:to="grts_AmountToExtendOptionTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerLiabilityAddition" xlink:to="grts_ContractWithCustomerLiabilityAddition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="grts_OtherRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LoanAgreementMember" xlink:to="grts_LoanAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ReceivablesGross" xlink:to="grts_ReceivablesGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashAndCashEquivalentsUnrealizedLosses" xlink:to="grts_CashAndCashEquivalentsUnrealizedLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AmountOfIrrevocableLettersOfCreditWithdrawn" xlink:to="grts_AmountOfIrrevocableLettersOfCreditWithdrawn_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_ContractWithCustomerDurationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PaymentsForOptionsToLicenseForEachIndication" xlink:to="grts_PaymentsForOptionsToLicenseForEachIndication_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DepositsAndOtherAssetsNoncurrent" xlink:to="grts_DepositsAndOtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" xlink:to="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromNonRefundableUpfrontPayment" xlink:to="grts_ProceedsFromNonRefundableUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IssuanceOfConvertiblePreferredStockTransactionPrice" xlink:to="grts_IssuanceOfConvertiblePreferredStockTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxAssetsOtherDepreciation" xlink:to="grts_DeferredTaxAssetsOtherDepreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PaymentsOfFinancingLease" xlink:to="grts_PaymentsOfFinancingLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:to="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationLongtermDebtAndEquity" xlink:to="us-gaap_CapitalizationLongtermDebtAndEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" xlink:to="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationOptionAndLicenseAgreementMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrepaymentPremiumRate" xlink:to="grts_PrepaymentPremiumRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrepaidExpenseForResearchAndDevelopment" xlink:to="grts_PrepaidExpenseForResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SecondTrancheOfFundingReceived" xlink:to="grts_SecondTrancheOfFundingReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" xlink:to="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:to="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwentyOneErieLeaseMember" xlink:to="grts_TwentyOneErieLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PleasantonMember" xlink:to="grts_PleasantonMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MarketableSecuritiesContractualMaturitiesPeriod" xlink:to="grts_MarketableSecuritiesContractualMaturitiesPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_UpfrontPayments" xlink:to="grts_UpfrontPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumOfferingExpensesAgreedToBeReimbursed" xlink:to="grts_MaximumOfferingExpensesAgreedToBeReimbursed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EmployeeOrDirectorMember" xlink:to="grts_EmployeeOrDirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="grts_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperatingLeasePaymentUnderTheBostonLease" xlink:to="grts_OperatingLeasePaymentUnderTheBostonLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember" xlink:to="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" xlink:to="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:to="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:to="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FinalPaymentFeePercentage" xlink:to="grts_FinalPaymentFeePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInLeaseLiability" xlink:to="grts_IncreaseDecreaseInLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockOptionsWarrantsAndOtherMember" xlink:to="grts_StockOptionsWarrantsAndOtherMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationAgreementTerminationTerm" xlink:to="grts_CollaborationAgreementTerminationTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromMaturityOfMarketableSecurities" xlink:to="grts_ProceedsFromMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FirstTrancheOfFundingsReceived" xlink:to="grts_FirstTrancheOfFundingsReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" xlink:to="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_InitialFundingDevelopmentCosts" xlink:to="grts_InitialFundingDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NonRefundableOptionFee" xlink:to="grts_NonRefundableOptionFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WarehouseMember" xlink:to="srt_WarehouseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" xlink:to="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxAssetsLeaseLiability" xlink:to="grts_DeferredTaxAssetsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>grts-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-09T14:12:13.0949+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="grts-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3" xlink:href="grts-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="grts-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4" xlink:href="grts-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grts-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:href="grts-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails" xlink:href="grts-20221231.xsd#DisclosureDebtScheduleOfLongTermDebtBalanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails" xlink:href="grts-20221231.xsd#DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="grts_AccruedResearchAndDevelopmentExpenseCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="grts_DepositsAndOtherAssetsNoncurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="grts_OperatingLeasePaymentUnderTheBostonLease" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLeasePaymentUnderTheBostonLease" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="grts_ProceedsFromMaturityOfMarketableSecurities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="grts_ProceedsFromSaleOfMarketableSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="grts_PaymentsOfFinancingLease" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="grts_PrepaymentsOnFinancingLease" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_NoncashOperatingLeaseExpense" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" order="15" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInLeaseLiability" order="16" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="17" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromMaturityOfMarketableSecurities" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromSaleOfMarketableSecurities" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsOfFinancingLease" xlink:label="grts_PaymentsOfFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaymentsOnFinancingLease" xlink:label="grts_PrepaymentsOnFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NoncashOperatingLeaseExpense" xlink:label="grts_NoncashOperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInLeaseLiability" xlink:label="grts_IncreaseDecreaseInLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="grts_CashAndCashEquivalentsUnrealizedGains" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="grts_CashAndCashEquivalentsUnrealizedLosses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsUnrealizedGains" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsUnrealizedLosses" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="grts_OperatingLeasePaymentUnderTheBostonLease" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLeasePaymentUnderTheBostonLease" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="grts_FinalFee" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FinalFee" xlink:label="grts_FinalFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_PrepaidExpenseForResearchAndDevelopment" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_NetContractAsset" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_CollaborationReceivable" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_InterestAndOtherReceivablesCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_FacilitiesRelatedDeposits" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaidExpenseForResearchAndDevelopment" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NetContractAsset" xlink:label="grts_NetContractAsset"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationReceivable" xlink:label="grts_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_InterestAndOtherReceivablesCurrent" xlink:label="grts_InterestAndOtherReceivablesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FacilitiesRelatedDeposits" xlink:label="grts_FacilitiesRelatedDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_DepositsAndOtherAssetsNoncurrent" xlink:to="us-gaap_SecurityDeposit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_DepositsAndOtherAssetsNoncurrent" xlink:to="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_DepositsAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidRent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="grts_DeferredTaxLiabilitiesOtherDepreciation" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="grts_DeferredTaxAssetsLeaseLiability" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="grts_DeferredTaxAssetsAmortization" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="grts_DeferredTaxAssetsOtherDepreciation" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="grts_DeferredTaxAssetsCapitalizedExpense" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxLiabilitiesOtherDepreciation" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsLeaseLiability" xlink:label="grts_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsAmortization" xlink:label="grts_DeferredTaxAssetsAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsOtherDepreciation" xlink:label="grts_DeferredTaxAssetsOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsCapitalizedExpense" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>grts-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-09T14:12:16.4291+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="grts-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="grts-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="grts-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grts-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="grts-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:href="grts-20221231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:href="grts-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="grts-20221231.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" xlink:href="grts-20221231.xsd#DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="grts-20221231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:href="grts-20221231.xsd#Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContributionMember" xlink:label="grts_ContributionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grts_ContributionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeriesABAndCConvertiblePreferredStockMember" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesValue" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" xlink:label="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" xlink:label="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesCConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesABAndCConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodSharesPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodValuePurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesCConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PublicOfferingMember" xlink:label="grts_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PipeFinancingMember" xlink:label="grts_PipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromMaturityOfMarketableSecurities" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockOptionsWarrantsAndOtherMember" xlink:label="grts_StockOptionsWarrantsAndOtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromSaleOfMarketableSecurities" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsOfFinancingLease" xlink:label="grts_PaymentsOfFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EsppEmployeeStockPurchasePlanMember" xlink:label="grts_EsppEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaymentsOnFinancingLease" xlink:label="grts_PrepaymentsOnFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NoncashOperatingLeaseExpense" xlink:label="grts_NoncashOperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInLeaseLiability" xlink:label="grts_IncreaseDecreaseInLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PipeFinancingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_ProceedsFromMaturityOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_StockOptionsWarrantsAndOtherMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_ProceedsFromSaleOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grts_PaymentsOfFinancingLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_EsppEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_PrepaymentsOnFinancingLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="grts_NoncashOperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CepInnovationsMember" xlink:label="grts_CepInnovationsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CepInnovationsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_FundingAgreementMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SummaryOfSignificantAccountingPoliciesTable" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsUnrealizedGains" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsUnrealizedLosses" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsUnrealizedGains" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsUnrealizedLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MarketableSecuritiesContractualMaturitiesPeriod" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MarketableSecuritiesRealizedGainLossDescription" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsAndMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_MarketableSecuritiesContractualMaturitiesPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_MarketableSecuritiesRealizedGainLossDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommitmentsAndContingenciesDisclosureTable" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain" xlink:label="us-gaap_SubsegmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwentyOneErieLeaseMember" xlink:label="grts_TwentyOneErieLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WarehouseMember" xlink:label="srt_WarehouseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractResearchOrganizationMember" xlink:label="grts_ContractResearchOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EmeryvilleCaliforniaMember" xlink:label="grts_EmeryvilleCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis" xlink:label="us-gaap_SubsegmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain" xlink:label="us-gaap_SubsegmentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalOfficeSpaceMember" xlink:label="grts_AdditionalOfficeSpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FourtyErieLeaseMember" xlink:label="grts_FourtyErieLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CambridgeMassachusettsMember" xlink:label="grts_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PleasantonMember" xlink:label="grts_PleasantonMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLeasePeriodForAdditionalTemporarySpace" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LessorOperatingLeaseNoticePeriodToTerminate" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BostonLeaseMember" xlink:label="grts_BostonLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmountOfIrrevocableLettersOfCreditWithdrawn" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentOfLeaseBaseRent" xlink:label="grts_PaymentOfLeaseBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperationsExpectedCommencedDate" xlink:label="grts_OperationsExpectedCommencedDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedCashDeposit" xlink:label="grts_RestrictedCashDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AnnualBaseRent" xlink:label="grts_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LeaseExpirationTerm" xlink:label="grts_LeaseExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumMilestonePaymentObligation" xlink:label="grts_MaximumMilestonePaymentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumLeasePayments" xlink:label="grts_MinimumLeasePayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="grts_TwentyOneErieLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_WarehouseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_ContractResearchOrganizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_EmeryvilleCaliforniaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grts_AdditionalOfficeSpaceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="grts_FourtyErieLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsegmentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_CambridgeMassachusettsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_PleasantonMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_OperatingLeasePeriodForAdditionalTemporarySpace" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LessorOperatingLeaseNoticePeriodToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_BostonLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperationsCommencedDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AmountOfIrrevocableLettersOfCreditWithdrawn" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_PaymentOfLeaseBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_OperationsExpectedCommencedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_RestrictedCashDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AnnualBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LeaseExpirationTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_MaximumMilestonePaymentObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_MinimumLeasePayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromNonRefundableUpfrontPayment" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="us-gaap_ShortTermContractWithCustomerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationRevenueMember" xlink:label="grts_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OptionAndLicenseAndDevelopmentAgreementMember" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NonExclusiveLicenseAndDevelopmentAgreementMember" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GenevantSciencesGmbHMember" xlink:label="grts_GenevantSciencesGmbHMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeventyMember" xlink:label="grts_SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumPotentialMilestoneReceivable" xlink:label="grts_MaximumPotentialMilestoneReceivable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementEarlyTerminationNoticePeriod" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractStartMonthYear" xlink:label="grts_RevenueRecognitionContractStartMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractEndMonthYear" xlink:label="grts_RevenueRecognitionContractEndMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ReceivablesGross" xlink:label="grts_ReceivablesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockFairValueClosingPricePerShare" xlink:label="grts_CommonStockFairValueClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NonRefundableOptionFee" xlink:label="grts_NonRefundableOptionFee"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumAggregateContingentMilestonePayment" xlink:label="grts_MaximumAggregateContingentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementTerminationTerm" xlink:label="grts_CollaborationAgreementTerminationTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockPurchasePriceInExcessOfFairValue1" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractEndPeriod" xlink:label="grts_RevenueRecognitionContractEndPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UpFrontPayment" xlink:label="grts_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FutureFundingExpected" xlink:label="grts_FutureFundingExpected"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumMilestoneConsiderationPayable" xlink:label="grts_MaximumMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AgreedUpfrontPayment" xlink:label="grts_AgreedUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmountToExtendOptionTerm" xlink:label="grts_AmountToExtendOptionTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumAggregateContingentMilestonePaymentToBeMade" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MilestonePayments" xlink:label="grts_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_InitialFundingDevelopmentCosts" xlink:label="grts_InitialFundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FundingDevelopmentCosts" xlink:label="grts_FundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredContractAcquisitionCosts" xlink:label="grts_DeferredContractAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredContractAcquisitionCostsAmortized" xlink:label="grts_DeferredContractAcquisitionCostsAmortized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FirstTrancheOfFundingsReceived" xlink:label="grts_FirstTrancheOfFundingsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalFunding" xlink:label="grts_AdditionalFunding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AgreementTotalFunding" xlink:label="grts_AgreementTotalFunding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfConvertiblePreferredStockTransactionPrice" xlink:label="grts_IssuanceOfConvertiblePreferredStockTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UpfrontPayments" xlink:label="grts_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TotalGrantAmount" xlink:label="grts_TotalGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmendedTotalGrantAmount" xlink:label="grts_AmendedTotalGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SecondTrancheOfFundingReceived" xlink:label="grts_SecondTrancheOfFundingReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ProceedsFromNonRefundableUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_ShortTermContractWithCustomerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grts_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_OptionAndLicenseAndDevelopmentAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_NonExclusiveLicenseAndDevelopmentAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_GenevantSciencesGmbHMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContractWithCustomerDurationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_SeventyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumPotentialMilestoneReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CollaborationAgreementEarlyTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractStartMonthYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractEndMonthYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ReceivablesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CommonStockFairValueClosingPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_NonRefundableOptionFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumAggregateContingentMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CollaborationAgreementTerminationTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CommonStockPurchasePriceInExcessOfFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractEndPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_UpFrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FutureFundingExpected" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumMilestoneConsiderationPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AgreedUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AmountToExtendOptionTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumAggregateContingentMilestonePaymentToBeMade" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_InitialFundingDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FundingDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_DeferredContractAcquisitionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_DeferredContractAcquisitionCostsAmortized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FirstTrancheOfFundingsReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AdditionalFunding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AgreementTotalFunding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="50" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="51" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_IssuanceOfConvertiblePreferredStockTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="52" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="53" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="54" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="55" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_PaymentsForOptionsToLicenseForEachIndication" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="56" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_UpfrontPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="57" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_TotalGrantAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="58" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AmendedTotalGrantAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="59" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_SecondTrancheOfFundingReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="60" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="61" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="62" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="63" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ResearchCollaborationAndLicenseAgreementMember" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerAssetAddition" xlink:label="grts_ContractWithCustomerAssetAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityAddition" xlink:label="grts_ContractWithCustomerLiabilityAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerAssetDeduction" xlink:label="grts_ContractWithCustomerAssetDeduction"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityDeductions" xlink:label="grts_ContractWithCustomerLiabilityDeductions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_ResearchCollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="grts_ContractWithCustomerAssetAddition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="grts_ContractWithCustomerLiabilityAddition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="grts_ContractWithCustomerAssetDeduction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="grts_ContractWithCustomerLiabilityDeductions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_FundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LoanAgreementMember" xlink:label="grts_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanOriginationCommitmentsMember" xlink:label="us-gaap_LoanOriginationCommitmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrimeRatePlusMember" xlink:label="grts_PrimeRatePlusMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TrancheOneMember" xlink:label="grts_TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentInKindRateMember" xlink:label="grts_PaymentInKindRateMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TrancheOneAdditionalMember" xlink:label="grts_TrancheOneAdditionalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RemainingTrancheMember" xlink:label="grts_RemainingTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DebtInstrumentInterestPaymentExtensionPeriod" xlink:label="grts_DebtInstrumentInterestPaymentExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FacilityChargePercentageOfBorrowing" xlink:label="grts_FacilityChargePercentageOfBorrowing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaymentPremiumRate" xlink:label="grts_PrepaymentPremiumRate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumLiquidityRequirementCapitalDescription" xlink:label="grts_MinimumLiquidityRequirementCapitalDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FinalPaymentFeePercentage" xlink:label="grts_FinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_LoanAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_LoanOriginationCommitmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="grts_PrimeRatePlusMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grts_TrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="grts_PaymentInKindRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grts_TrancheOneAdditionalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grts_RemainingTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_DebtInstrumentInterestPaymentExtensionPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_FacilityChargePercentageOfBorrowing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CapitalizationLongtermDebtAndEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_PrepaymentPremiumRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_MinimumLiquidityRequirementCapitalDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_FinalPaymentFeePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalSharesMember" xlink:label="grts_AdditionalSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndWarrantsMember" xlink:label="grts_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtmEquityOfferingProgramMember" xlink:label="grts_AtmEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember" xlink:label="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember" xlink:label="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumOfferingExpensesAgreedToBeReimbursed" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SaleOfStockPricePerSharePrepaidByPurchaser" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsToPurchaseSharesOfCommonStock" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PlacementAgentCommissionsAndLegalFees" xlink:label="grts_PlacementAgentCommissionsAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsOutstanding" xlink:label="grts_WarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AmendedAndRestatedCertificateOfIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_AdditionalSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockAndWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtmEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumOfferingExpensesAgreedToBeReimbursed" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_SaleOfStockPricePerSharePrepaidByPurchaser" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsToPurchaseSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_PlacementAgentCommissionsAndLegalFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsCancelled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightIssueDate" xlink:label="grts_ClassOfWarrantOrRightIssueDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockWarrantsOneMember" xlink:label="grts_CommonStockWarrantsOneMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightsExpiration" xlink:label="grts_ClassOfWarrantOrRightsExpiration"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockWarrantsTwoMember" xlink:label="grts_CommonStockWarrantsTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ClassOfWarrantOrRightIssueDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockWarrantsOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ClassOfWarrantOrRightsExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockWarrantsTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandEighteenStockIncentivePlanMember" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseInSharesAvailableForIssuancePercentage" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumPercentageFairMarketValueOfSharePrice" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_IncreaseInSharesAvailableForIssuancePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_MinimumPercentageFairMarketValueOfSharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EmployeeOrDirectorMember" xlink:label="grts_EmployeeOrDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="grts_EmployeeOrDirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncomeTaxesLineItems" xlink:label="grts_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncomeTaxesTable" xlink:label="grts_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLossCarryforwardsExpirationYear" xlink:label="grts_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OwnershipInterestChangeOverPeriod" xlink:label="grts_OwnershipInterestChangeOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CumulativeChangesInOwnershipInterestOfShareholders" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsCapitalizedExpense" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_IncomeTaxesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_OwnershipInterestChangeOverPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_CumulativeChangesInOwnershipInterestOfShareholders" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_DeferredTaxAssetsCapitalizedExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PostDecember312017Member" xlink:label="grts_PostDecember312017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PreJanuary12018Member" xlink:label="grts_PreJanuary12018Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="grts_PostDecember312017Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="grts_PreJanuary12018Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndWarrantsMember" xlink:label="grts_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantExercisePrice" xlink:label="grts_WarrantExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsToPurchaseSharesOfCommonStock" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockAndWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_WarrantExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_WarrantsToPurchaseSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_WarrantsCancelled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedStockSubjectToFutureVestingMember" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_RestrictedStockSubjectToFutureVestingMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTaxStatusExtensibleList" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTaxStatusExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>grts-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-09T14:12:13.1314+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="grts-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="grts-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="grts-20221231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="grts-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="grts-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="grts-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grts-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganization1" xlink:href="grts-20221231.xsd#DisclosureOrganization1" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities" xlink:href="grts-20221231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="grts-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="grts-20221231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:href="grts-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebt" xlink:href="grts-20221231.xsd#DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="grts-20221231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="grts-20221231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare" xlink:href="grts-20221231.xsd#Role_DisclosureNetLossPerCommonShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:href="grts-20221231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvent" xlink:href="grts-20221231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:href="grts-20221231.xsd#Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:href="grts-20221231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="grts-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="grts-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="grts-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:href="grts-20221231.xsd#DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="grts-20221231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="grts-20221231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" xlink:href="grts-20221231.xsd#Role_DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:href="grts-20221231.xsd#Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail" xlink:href="grts-20221231.xsd#DisclosureOrganizationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:href="grts-20221231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:href="grts-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:href="grts-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="grts-20221231.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails" xlink:href="grts-20221231.xsd#DisclosureDebtScheduleOfLongTermDebtBalanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails" xlink:href="grts-20221231.xsd#DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" xlink:href="grts-20221231.xsd#DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="grts-20221231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:href="grts-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail" xlink:href="grts-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="grts-20221231.xsd#Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:href="grts-20221231.xsd#Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:href="grts-20221231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="grts_AccruedResearchAndDevelopmentExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="grts_DepositsAndOtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContributionMember" xlink:label="grts_ContributionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grts_ContributionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeriesABAndCConvertiblePreferredStockMember" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesValue" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" xlink:label="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" xlink:label="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_28"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_29"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesCConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesABAndCConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_FollowOnPublicOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodSharesPurchaseAgreement" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodValuePurchaseAgreement" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_29" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesCConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PublicOfferingMember" xlink:label="grts_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PipeFinancingMember" xlink:label="grts_PipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromMaturityOfMarketableSecurities" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockOptionsWarrantsAndOtherMember" xlink:label="grts_StockOptionsWarrantsAndOtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromSaleOfMarketableSecurities" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsOfFinancingLease" xlink:label="grts_PaymentsOfFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EsppEmployeeStockPurchasePlanMember" xlink:label="grts_EsppEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaymentsOnFinancingLease" xlink:label="grts_PrepaymentsOnFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NoncashOperatingLeaseExpense" xlink:label="grts_NoncashOperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseDecreaseInLeaseLiability" xlink:label="grts_IncreaseDecreaseInLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PipeFinancingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_ProceedsFromMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_StockOptionsWarrantsAndOtherMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_ProceedsFromSaleOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grts_PaymentsOfFinancingLease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_EsppEmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_PrepaymentsOnFinancingLease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="grts_NoncashOperatingLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_InterestPaidNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganization1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" xlink:label="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_OtherRisksAndUncertaintiesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborativeAndLicenseAgreementsAbstract" xlink:label="grts_CollaborativeAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CepInnovationsMember" xlink:label="grts_CepInnovationsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CollaborativeAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CepInnovationsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_FundingAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="grts_CashCashEquivalentsAndMarketableSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SummaryOfSignificantAccountingPoliciesTable" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="grts_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsUnrealizedGains" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsUnrealizedLosses" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_ShortTermMarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_LongTermMarketableSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsUnrealizedLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MarketableSecuritiesContractualMaturitiesPeriod" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MarketableSecuritiesRealizedGainLossDescription" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsAndMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_MarketableSecuritiesContractualMaturitiesPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_MarketableSecuritiesRealizedGainLossDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_ShortTermMarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_LongTermMarketableSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FairValueMeasurementLevel1ToLevel2Transfers" xlink:label="grts_FairValueMeasurementLevel1ToLevel2Transfers"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="grts_FairValueMeasurementLevel1ToLevel2Transfers" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain" xlink:label="us-gaap_SubsegmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwentyOneErieLeaseMember" xlink:label="grts_TwentyOneErieLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommitmentsAndContingenciesDisclosureTable" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WarehouseMember" xlink:label="srt_WarehouseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractResearchOrganizationMember" xlink:label="grts_ContractResearchOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EmeryvilleCaliforniaMember" xlink:label="grts_EmeryvilleCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis" xlink:label="us-gaap_SubsegmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalOfficeSpaceMember" xlink:label="grts_AdditionalOfficeSpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FourtyErieLeaseMember" xlink:label="grts_FourtyErieLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CambridgeMassachusettsMember" xlink:label="grts_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PleasantonMember" xlink:label="grts_PleasantonMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLeasePeriodForAdditionalTemporarySpace" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CambridgeMassachusettsMember" xlink:label="grts_CambridgeMassachusettsMember_3"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LessorOperatingLeaseNoticePeriodToTerminate" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BostonLeaseMember" xlink:label="grts_BostonLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmountOfIrrevocableLettersOfCreditWithdrawn" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentOfLeaseBaseRent" xlink:label="grts_PaymentOfLeaseBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperationsExpectedCommencedDate" xlink:label="grts_OperationsExpectedCommencedDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedCashDeposit" xlink:label="grts_RestrictedCashDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AnnualBaseRent" xlink:label="grts_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LeaseExpirationTerm" xlink:label="grts_LeaseExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumMilestonePaymentObligation" xlink:label="grts_MaximumMilestonePaymentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumLeasePayments" xlink:label="grts_MinimumLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="grts_TwentyOneErieLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_WarehouseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_ContractResearchOrganizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_EmeryvilleCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grts_AdditionalOfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="grts_FourtyErieLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsegmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_CambridgeMassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_PleasantonMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_OperatingLeasePeriodForAdditionalTemporarySpace" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_CambridgeMassachusettsMember_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LessorOperatingLeaseNoticePeriodToTerminate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_BostonLeaseMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_TenantImprovements" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="grts_CommitmentsAndContingenciesDisclosureLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperationsCommencedDate1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AmountOfIrrevocableLettersOfCreditWithdrawn" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_PaymentOfLeaseBaseRent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_OperationsExpectedCommencedDate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_RestrictedCashDeposit" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AnnualBaseRent" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LeaseExpirationTerm" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_MaximumMilestonePaymentObligation" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SecurityDeposit" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_MinimumLeasePayments" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WeightedAverageDiscountRateAbstract" xlink:label="grts_WeightedAverageDiscountRateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WeightedAverageRemainingLeaseTermYearsAbstract" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_WeightedAverageRemainingLeaseTermYearsAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_WeightedAverageRemainingLeaseTermYearsAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_WeightedAverageDiscountRateAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLeasePaymentUnderTheBostonLease" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="grts_OperatingLeasePaymentUnderTheBostonLease" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromNonRefundableUpfrontPayment" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="us-gaap_ShortTermContractWithCustomerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationRevenueMember" xlink:label="grts_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OptionAndLicenseAndDevelopmentAgreementMember" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NonExclusiveLicenseAndDevelopmentAgreementMember" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GenevantSciencesGmbHMember" xlink:label="grts_GenevantSciencesGmbHMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SeventyMember" xlink:label="grts_SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumPotentialMilestoneReceivable" xlink:label="grts_MaximumPotentialMilestoneReceivable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementEarlyTerminationNoticePeriod" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractStartMonthYear" xlink:label="grts_RevenueRecognitionContractStartMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractEndMonthYear" xlink:label="grts_RevenueRecognitionContractEndMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ReceivablesGross" xlink:label="grts_ReceivablesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockFairValueClosingPricePerShare" xlink:label="grts_CommonStockFairValueClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NonRefundableOptionFee" xlink:label="grts_NonRefundableOptionFee"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumAggregateContingentMilestonePayment" xlink:label="grts_MaximumAggregateContingentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationAgreementTerminationTerm" xlink:label="grts_CollaborationAgreementTerminationTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockPurchasePriceInExcessOfFairValue1" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RevenueRecognitionContractEndPeriod" xlink:label="grts_RevenueRecognitionContractEndPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UpFrontPayment" xlink:label="grts_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FutureFundingExpected" xlink:label="grts_FutureFundingExpected"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumMilestoneConsiderationPayable" xlink:label="grts_MaximumMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AgreedUpfrontPayment" xlink:label="grts_AgreedUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmountToExtendOptionTerm" xlink:label="grts_AmountToExtendOptionTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumAggregateContingentMilestonePaymentToBeMade" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MilestonePayments" xlink:label="grts_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_InitialFundingDevelopmentCosts" xlink:label="grts_InitialFundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FundingDevelopmentCosts" xlink:label="grts_FundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredContractAcquisitionCosts" xlink:label="grts_DeferredContractAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredContractAcquisitionCostsAmortized" xlink:label="grts_DeferredContractAcquisitionCostsAmortized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FirstTrancheOfFundingsReceived" xlink:label="grts_FirstTrancheOfFundingsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalFunding" xlink:label="grts_AdditionalFunding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AgreementTotalFunding" xlink:label="grts_AgreementTotalFunding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfConvertiblePreferredStockTransactionPrice" xlink:label="grts_IssuanceOfConvertiblePreferredStockTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_UpfrontPayments" xlink:label="grts_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TotalGrantAmount" xlink:label="grts_TotalGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmendedTotalGrantAmount" xlink:label="grts_AmendedTotalGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SecondTrancheOfFundingReceived" xlink:label="grts_SecondTrancheOfFundingReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ProceedsFromNonRefundableUpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_ShortTermContractWithCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grts_CollaborationRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_OptionAndLicenseAndDevelopmentAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_NonExclusiveLicenseAndDevelopmentAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_GenevantSciencesGmbHMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContractWithCustomerDurationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_SeventyMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumPotentialMilestoneReceivable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CollaborationAgreementEarlyTerminationNoticePeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractStartMonthYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractEndMonthYear" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ReceivablesGross" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CommonStockFairValueClosingPricePerShare" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_NonRefundableOptionFee" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumAggregateContingentMilestonePayment" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CollaborationAgreementTerminationTerm" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CommonStockPurchasePriceInExcessOfFairValue1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractEndPeriod" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_UpFrontPayment" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FutureFundingExpected" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumMilestoneConsiderationPayable" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AgreedUpfrontPayment" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AmountToExtendOptionTerm" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumAggregateContingentMilestonePaymentToBeMade" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MilestonePayments" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_InitialFundingDevelopmentCosts" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FundingDevelopmentCosts" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_DeferredContractAcquisitionCosts" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_DeferredContractAcquisitionCostsAmortized" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FirstTrancheOfFundingsReceived" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AdditionalFunding" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AgreementTotalFunding" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="50" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_IssuanceOfConvertiblePreferredStockTransactionPrice" order="51" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="52" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="53" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="54" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_PaymentsForOptionsToLicenseForEachIndication" order="55" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_UpfrontPayments" order="56" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_TotalGrantAmount" order="57" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AmendedTotalGrantAmount" order="58" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_SecondTrancheOfFundingReceived" order="59" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="60" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="61" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="62" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="63" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ResearchCollaborationAndLicenseAgreementMember" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerAssetAddition" xlink:label="grts_ContractWithCustomerAssetAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityAddition" xlink:label="grts_ContractWithCustomerLiabilityAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerAssetDeduction" xlink:label="grts_ContractWithCustomerAssetDeduction"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ContractWithCustomerLiabilityDeductions" xlink:label="grts_ContractWithCustomerLiabilityDeductions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_3"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_ResearchCollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="grts_ContractWithCustomerAssetAddition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="grts_ContractWithCustomerLiabilityAddition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="grts_ContractWithCustomerAssetDeduction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="grts_ContractWithCustomerLiabilityDeductions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_FundingAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_LoanAgreementMember" xlink:label="grts_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanOriginationCommitmentsMember" xlink:label="us-gaap_LoanOriginationCommitmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrimeRatePlusMember" xlink:label="grts_PrimeRatePlusMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TrancheOneMember" xlink:label="grts_TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PaymentInKindRateMember" xlink:label="grts_PaymentInKindRateMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TrancheOneAdditionalMember" xlink:label="grts_TrancheOneAdditionalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RemainingTrancheMember" xlink:label="grts_RemainingTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DebtInstrumentInterestPaymentExtensionPeriod" xlink:label="grts_DebtInstrumentInterestPaymentExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FacilityChargePercentageOfBorrowing" xlink:label="grts_FacilityChargePercentageOfBorrowing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaymentPremiumRate" xlink:label="grts_PrepaymentPremiumRate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumLiquidityRequirementCapitalDescription" xlink:label="grts_MinimumLiquidityRequirementCapitalDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FinalPaymentFeePercentage" xlink:label="grts_FinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_LoanAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_LoanOriginationCommitmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="grts_PrimeRatePlusMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grts_TrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="grts_PaymentInKindRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grts_TrancheOneAdditionalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grts_RemainingTrancheMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_VariableRateAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_DebtInstrumentInterestPaymentExtensionPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_FacilityChargePercentageOfBorrowing" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CapitalizationLongtermDebtAndEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_PrepaymentPremiumRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_MinimumLiquidityRequirementCapitalDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="grts_FinalPaymentFeePercentage" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FinalFee" xlink:label="grts_FinalFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="grts_FinalFee" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaidExpenseForResearchAndDevelopment" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NetContractAsset" xlink:label="grts_NetContractAsset"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CollaborationReceivable" xlink:label="grts_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_InterestAndOtherReceivablesCurrent" xlink:label="grts_InterestAndOtherReceivablesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_FacilitiesRelatedDeposits" xlink:label="grts_FacilitiesRelatedDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_PrepaidExpenseForResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_NetContractAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_CollaborationReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_InterestAndOtherReceivablesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_FacilitiesRelatedDeposits" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:label="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_SecurityDeposit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_PrepaidRent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="grts_DepositsAndOtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AdditionalSharesMember" xlink:label="grts_AdditionalSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndWarrantsMember" xlink:label="grts_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_AtmEquityOfferingProgramMember" xlink:label="grts_AtmEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember" xlink:label="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember" xlink:label="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumOfferingExpensesAgreedToBeReimbursed" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SaleOfStockPricePerSharePrepaidByPurchaser" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsToPurchaseSharesOfCommonStock" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PlacementAgentCommissionsAndLegalFees" xlink:label="grts_PlacementAgentCommissionsAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsOutstanding" xlink:label="grts_WarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AmendedAndRestatedCertificateOfIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_AdditionalSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockAndWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtmEquityOfferingProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumOfferingExpensesAgreedToBeReimbursed" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_SaleOfStockPricePerSharePrepaidByPurchaser" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsToPurchaseSharesOfCommonStock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_PlacementAgentCommissionsAndLegalFees" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsCancelled" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsOutstanding" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightIssueDate" xlink:label="grts_ClassOfWarrantOrRightIssueDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockWarrantsOneMember" xlink:label="grts_CommonStockWarrantsOneMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightsExpiration" xlink:label="grts_ClassOfWarrantOrRightsExpiration"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockWarrantsTwoMember" xlink:label="grts_CommonStockWarrantsTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ClassOfWarrantOrRightIssueDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockWarrantsOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ClassOfWarrantOrRightsExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockWarrantsTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandEighteenStockIncentivePlanMember" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncreaseInSharesAvailableForIssuancePercentage" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_MinimumPercentageFairMarketValueOfSharePrice" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_IncreaseInSharesAvailableForIssuancePercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_MinimumPercentageFairMarketValueOfSharePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EmployeeOrDirectorMember" xlink:label="grts_EmployeeOrDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="grts_EmployeeOrDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_NonTaxableStockPremium" xlink:label="grts_NonTaxableStockPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grts_NonTaxableStockPremium" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncomeTaxesTable" xlink:label="grts_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IncomeTaxesLineItems" xlink:label="grts_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OperatingLossCarryforwardsExpirationYear" xlink:label="grts_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OwnershipInterestChangeOverPeriod" xlink:label="grts_OwnershipInterestChangeOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CumulativeChangesInOwnershipInterestOfShareholders" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsCapitalizedExpense" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grts_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="grts_IncomeTaxesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_OwnershipInterestChangeOverPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_CumulativeChangesInOwnershipInterestOfShareholders" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_DeferredTaxAssetsCapitalizedExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxLiabilitiesOtherDepreciation" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsLeaseLiability" xlink:label="grts_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsAmortization" xlink:label="grts_DeferredTaxAssetsAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsOtherDepreciation" xlink:label="grts_DeferredTaxAssetsOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_DeferredTaxAssetsCapitalizedExpense" xlink:label="grts_DeferredTaxAssetsCapitalizedExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="grts_DeferredTaxLiabilitiesOtherDepreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="grts_DeferredTaxAssetsLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="grts_DeferredTaxAssetsAmortization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="grts_DeferredTaxAssetsOtherDepreciation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="grts_DeferredTaxAssetsCapitalizedExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PostDecember312017Member" xlink:label="grts_PostDecember312017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PreJanuary12018Member" xlink:label="grts_PreJanuary12018Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="grts_PostDecember312017Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="grts_PreJanuary12018Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_CommonStockAndWarrantsMember" xlink:label="grts_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantExercisePrice" xlink:label="grts_WarrantExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsToPurchaseSharesOfCommonStock" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockAndWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_WarrantExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_WarrantsToPurchaseSharesOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_WarrantsCancelled" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20221231.xsd#grts_RestrictedStockSubjectToFutureVestingMember" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_RestrictedStockSubjectToFutureVestingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTaxStatusExtensibleList" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTaxStatusExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>grts-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-09T14:12:14.0551+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://gritstonebio.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:grts="http://gritstonebio.com/20221231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grts-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grts-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grts-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grts-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3" id="DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3">
        <link:definition>100030 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4" id="DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4">
        <link:definition>100050 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail) 4</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganization1" id="DisclosureOrganization1">
        <link:definition>100090 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities" id="Role_DisclosureCashEquivalentsAndMarketableSecurities">
        <link:definition>100110 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100130 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100150 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>100160 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100170 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100180 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100190 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100200 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare" id="Role_DisclosureNetLossPerCommonShare">
        <link:definition>100210 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100220 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100230 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" id="Role_DisclosureSelectedQuarterlyFinancialDataUnaudited">
        <link:definition>100240 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" id="Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>100270 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100280 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100290 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100300 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" id="Role_DisclosureCollaborationAndLicenseAgreementsTables">
        <link:definition>100310 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>100320 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100330 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100340 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100350 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" id="Role_DisclosureNetLossPerCommonShareTables">
        <link:definition>100370 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" id="Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>100380 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail" id="DisclosureOrganizationAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail">
        <link:definition>100420 - Disclosure - Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" id="Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail">
        <link:definition>100430 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail">
        <link:definition>100450 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail">
        <link:definition>100470 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100480 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail">
        <link:definition>100500 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail">
        <link:definition>100510 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail">
        <link:definition>100520 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100530 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail">
        <link:definition>100540 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="DisclosureDebtAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Debt (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails" id="DisclosureDebtScheduleOfLongTermDebtBalanceDetails">
        <link:definition>100560 - Disclosure - Debt - Schedule of Long term debt balance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails" id="DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails">
        <link:definition>100570 - Disclosure - Debt - Schedule of estimated future principal payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100580 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail">
        <link:definition>100590 - Disclosure - Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100600 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" id="DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail">
        <link:definition>100610 - Disclosure - Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100620 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" id="Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail">
        <link:definition>100630 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" id="Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail">
        <link:definition>100640 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail" id="Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail">
        <link:definition>100650 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>100660 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
        <link:definition>100670 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail">
        <link:definition>100680 - Disclosure - Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100690 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" id="Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail">
        <link:definition>100700 - Disclosure - Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" id="Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail">
        <link:definition>100710 - Disclosure - Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail">
        <link:definition>100720 - Disclosure - Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail" id="Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>100730 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" id="Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail">
        <link:definition>100740 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" id="Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail">
        <link:definition>100750 - Disclosure - Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetail">
        <link:definition>100760 - Disclosure - Defined Contribution Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="grts_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CollaborativeAndLicenseAgreementsAbstract" name="CollaborativeAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" name="DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" name="NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_WeightedAverageRemainingLeaseTermYearsAbstract" name="WeightedAverageRemainingLeaseTermYearsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AdditionalFunding" name="AdditionalFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" name="AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" name="AdjustmentToRightOfUseAssetsAndLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" name="AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AgreedUpfrontPayment" name="AgreedUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AgreementTotalFunding" name="AgreementTotalFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_AmendedTotalGrantAmount" name="AmendedTotalGrantAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_AmountOfIrrevocableLettersOfCreditWithdrawn" name="AmountOfIrrevocableLettersOfCreditWithdrawn" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_AmountToExtendOptionTerm" name="AmountToExtendOptionTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AnnualBaseRent" name="AnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashAndCashEquivalentsAndMarketableSecurities" name="CashAndCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashAndCashEquivalentsUnrealizedGains" name="CashAndCashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_CashAndCashEquivalentsUnrealizedLosses" name="CashAndCashEquivalentsUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashCashEquivalentsAndMarketableSecurities" name="CashCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" name="CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" name="CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" name="CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ClassOfWarrantOrRightIssueDate" name="ClassOfWarrantOrRightIssueDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_ClassOfWarrantOrRightsExpiration" name="ClassOfWarrantOrRightsExpiration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ClassOfWarrantOrRightWarrantsExercised" name="ClassOfWarrantOrRightWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CollaborationAgreementEarlyTerminationNoticePeriod" name="CollaborationAgreementEarlyTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CollaborationAgreementTerminationTerm" name="CollaborationAgreementTerminationTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CollaborationReceivable" name="CollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CommonStockFairValueClosingPricePerShare" name="CommonStockFairValueClosingPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_CommonStockPurchasePriceInExcessOfFairValue1" name="CommonStockPurchasePriceInExcessOfFairValue1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_ContractWithCustomerAssetAddition" name="ContractWithCustomerAssetAddition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ContractWithCustomerAssetDeduction" name="ContractWithCustomerAssetDeduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_ContractWithCustomerLiabilityAddition" name="ContractWithCustomerLiabilityAddition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_ContractWithCustomerLiabilityDeductions" name="ContractWithCustomerLiabilityDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" name="ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_CumulativeChangesInOwnershipInterestOfShareholders" name="CumulativeChangesInOwnershipInterestOfShareholders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_DebtInstrumentInterestPaymentExtensionPeriod" name="DebtInstrumentInterestPaymentExtensionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_DeferredContractAcquisitionCosts" name="DeferredContractAcquisitionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_DeferredContractAcquisitionCostsAmortized" name="DeferredContractAcquisitionCostsAmortized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_DeferredTaxAssetsAmortization" name="DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_DeferredTaxAssetsCapitalizedExpense" name="DeferredTaxAssetsCapitalizedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_DeferredTaxAssetsOtherDepreciation" name="DeferredTaxAssetsOtherDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_DeferredTaxLiabilitiesOtherDepreciation" name="DeferredTaxLiabilitiesOtherDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" name="EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" name="EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_FacilitiesRelatedDeposits" name="FacilitiesRelatedDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_FacilityChargePercentageOfBorrowing" name="FacilityChargePercentageOfBorrowing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_FairValueMeasurementLevel1ToLevel2Transfers" name="FairValueMeasurementLevel1ToLevel2Transfers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_FinalFee" name="FinalFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_FinalPaymentFeePercentage" name="FinalPaymentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_FirstTrancheOfFundingsReceived" name="FirstTrancheOfFundingsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_FundingDevelopmentCosts" name="FundingDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_FutureFundingExpected" name="FutureFundingExpected" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" name="FutureMilestoneAndRoyaltyPaymentsReductionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" name="IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" name="IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_IncreaseDecreaseInLeaseLiability" name="IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_IncreaseInSharesAvailableForIssuancePercentage" name="IncreaseInSharesAvailableForIssuancePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_InitialFundingDevelopmentCosts" name="InitialFundingDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_InterestAndOtherReceivablesCurrent" name="InterestAndOtherReceivablesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_IssuanceOfCommonStockForWarrantExercisesShare" name="IssuanceOfCommonStockForWarrantExercisesShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_IssuanceOfCommonStockForWarrantExercisesValue" name="IssuanceOfCommonStockForWarrantExercisesValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" name="IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_IssuanceOfConvertiblePreferredStockTransactionPrice" name="IssuanceOfConvertiblePreferredStockTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" name="LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" name="LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LeaseExpirationTerm" name="LeaseExpirationTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" name="LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" name="LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LessorOperatingLeaseNoticePeriodToTerminate" name="LessorOperatingLeaseNoticePeriodToTerminate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MarketableSecuritiesContractualMaturitiesPeriod" name="MarketableSecuritiesContractualMaturitiesPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MarketableSecuritiesRealizedGainLossDescription" name="MarketableSecuritiesRealizedGainLossDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MaximumAggregateContingentMilestonePayment" name="MaximumAggregateContingentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MaximumAggregateContingentMilestonePaymentToBeMade" name="MaximumAggregateContingentMilestonePaymentToBeMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MaximumMilestoneConsiderationPayable" name="MaximumMilestoneConsiderationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MaximumMilestonePaymentObligation" name="MaximumMilestonePaymentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MaximumOfferingExpensesAgreedToBeReimbursed" name="MaximumOfferingExpensesAgreedToBeReimbursed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" name="MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MaximumPotentialMilestoneReceivable" name="MaximumPotentialMilestoneReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" name="MaximumSecuritiesCoveredUnderRegistrationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" name="MilestonePaymentIncludedInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" name="MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MinimumLeasePayments" name="MinimumLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MinimumLiquidityRequirementCapitalDescription" name="MinimumLiquidityRequirementCapitalDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MinimumPercentageFairMarketValueOfSharePrice" name="MinimumPercentageFairMarketValueOfSharePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" name="MinimumPercentageOfOutstandingSharesHeldByIndividual" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_NetContractAsset" name="NetContractAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_NonRefundableOptionFee" name="NonRefundableOptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_NonTaxableStockPremium" name="NonTaxableStockPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_OperatingLeasePaymentUnderTheBostonLease" name="OperatingLeasePaymentUnderTheBostonLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_OperatingLeasePeriodForAdditionalTemporarySpace" name="OperatingLeasePeriodForAdditionalTemporarySpace" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_OperationsExpectedCommencedDate" name="OperationsExpectedCommencedDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_OwnershipInterestChangeOverPeriod" name="OwnershipInterestChangeOverPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_PaymentOfLeaseBaseRent" name="PaymentOfLeaseBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_PaymentsForOptionsToLicenseForEachIndication" name="PaymentsForOptionsToLicenseForEachIndication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" name="PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_PaymentsOfFinancingLease" name="PaymentsOfFinancingLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" name="PercentageOfProceedsPayableAsCompensationToUnderwriter" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" name="PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_PlacementAgentCommissionsAndLegalFees" name="PlacementAgentCommissionsAndLegalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_PrepaidExpenseForResearchAndDevelopment" name="PrepaidExpenseForResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" name="PrepaidExpenseForResearchAndDevelopmentNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_PrepaymentPremiumRate" name="PrepaymentPremiumRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_PrepaymentsOnFinancingLease" name="PrepaymentsOnFinancingLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ProceedsFromMaturityOfMarketableSecurities" name="ProceedsFromMaturityOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ProceedsFromNonRefundableUpfrontPayment" name="ProceedsFromNonRefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ProceedsFromSaleOfMarketableSecurities" name="ProceedsFromSaleOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ReceivablesGross" name="ReceivablesGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" name="ReimbursementsExpenseMaterialsAndPersonnelCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" name="RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_RestrictedCashDeposit" name="RestrictedCashDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" name="RestrictedCashDepositUsedAsCollateralForLetterOfCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_RevenueRecognitionContractEndMonthYear" name="RevenueRecognitionContractEndMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_RevenueRecognitionContractEndPeriod" name="RevenueRecognitionContractEndPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_RevenueRecognitionContractStartMonthYear" name="RevenueRecognitionContractStartMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_SaleOfStockPricePerSharePrepaidByPurchaser" name="SaleOfStockPricePerSharePrepaidByPurchaser" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_SecondTrancheOfFundingReceived" name="SecondTrancheOfFundingReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" name="StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" name="StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_StockIssuedDuringPeriodSharesPurchaseAgreement" name="StockIssuedDuringPeriodSharesPurchaseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" name="StockIssuedDuringPeriodValueCommonStockWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_StockIssuedDuringPeriodValuePurchaseAgreement" name="StockIssuedDuringPeriodValuePurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" name="TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_TotalGrantAmount" name="TotalGrantAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" name="TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_UpFrontPayment" name="UpFrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_UpfrontPayments" name="UpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" name="UseOfBusinessIncentiveTaxCreditsPeriodCap" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" name="UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_WarrantExercisePrice" name="WarrantExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_WarrantsCancelled" name="WarrantsCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_WarrantsOutstanding" name="WarrantsOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_WarrantsToPurchaseSharesOfCommonStock" name="WarrantsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CashEquivalentsAndMarketableSecuritiesLineItems" name="CashEquivalentsAndMarketableSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AdditionalOfficeSpaceMember" name="AdditionalOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AdditionalSharesMember" name="AdditionalSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AmendedAndRestatedCertificateOfIncorporationMember" name="AmendedAndRestatedCertificateOfIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" name="ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AtmEquityOfferingProgramMember" name="AtmEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AtTheMarketEquityOfferingProgramMember" name="AtTheMarketEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_BluebirdBioIncMember" name="BluebirdBioIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_BlueBirdBioTo2SeventyMember" name="BlueBirdBioTo2SeventyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_BostonLeaseMember" name="BostonLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CambridgeMassachusettsMember" name="CambridgeMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CEPIFundingAgreementMember" name="CEPIFundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CepInnovationsMember" name="CepInnovationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CoalitionForEpidemicPreparednessInnovationMember" name="CoalitionForEpidemicPreparednessInnovationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CollaborationAgreementMember" name="CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CollaborationOptionAndLicenseAgreementMember" name="CollaborationOptionAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommonStockAndOrPreFundedWarrantsMember" name="CommonStockAndOrPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommonStockAndWarrantsMember" name="CommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommonStockWarrantsOneMember" name="CommonStockWarrantsOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommonStockWarrantsTwoMember" name="CommonStockWarrantsTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ContractResearchOrganizationMember" name="ContractResearchOrganizationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ContributionMember" name="ContributionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" name="EarlyExercisedCommonStockSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_EmeryvilleCaliforniaMember" name="EmeryvilleCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_EmployeeOrDirectorMember" name="EmployeeOrDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_EsppEmployeeStockPurchasePlanMember" name="EsppEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_FourtyErieLeaseMember" name="FourtyErieLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_FundingAgreementMember" name="FundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_GatesFoundationMember" name="GatesFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_GenevantSciencesGmbHMember" name="GenevantSciencesGmbHMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_GileadSciencesIncMember" name="GileadSciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_GrantAgreementMember" name="GrantAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_LoanAgreementMember" name="LoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_LongTermMarketableSecuritiesMember" name="LongTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_NonExclusiveLicenseAndDevelopmentAgreementMember" name="NonExclusiveLicenseAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_OptionAndLicenseAndDevelopmentAgreementMember" name="OptionAndLicenseAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" name="OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PaymentInKindRateMember" name="PaymentInKindRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PipeFinancingMember" name="PipeFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PleasantonMember" name="PleasantonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PostDecember312017Member" name="PostDecember312017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PreJanuary12018Member" name="PreJanuary12018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PrimeRatePlusMember" name="PrimeRatePlusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PrivateInvestmentInPublicEquityMember" name="PrivateInvestmentInPublicEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_RemainingTrancheMember" name="RemainingTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ResearchCollaborationAndLicenseAgreementMember" name="ResearchCollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_RestrictedStockSubjectToFutureVestingMember" name="RestrictedStockSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SeriesABAndCConvertiblePreferredStockMember" name="SeriesABAndCConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SeventyMember" name="SeventyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ShortTermMarketableSecuritiesMember" name="ShortTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_StockOptionsWarrantsAndOtherMember" name="StockOptionsWarrantsAndOtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" name="TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" name="TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TrancheOneAdditionalMember" name="TrancheOneAdditionalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TrancheOneMember" name="TrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwentyOneErieLeaseMember" name="TwentyOneErieLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember" name="TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember" name="TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" name="TwoThousandEighteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwoThousandEighteenStockIncentivePlanMember" name="TwoThousandEighteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" name="TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_OtherRisksAndUncertaintiesPolicyTextBlock" name="OtherRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CashEquivalentsAndMarketableSecuritiesTable" name="CashEquivalentsAndMarketableSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" name="DescriptionOfNewAccountingPronouncementsNotYetAdopted1" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" name="DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" name="ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" name="ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998144496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 07, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gritstone bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001656634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRTS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,661,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4859534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5959 Horton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-6100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, scheduled to be held on June 16, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the fiscal year to which this report relates.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999656160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,498<span></span>
</td>
<td class="nump">$ 93,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">116,389<span></span>
</td>
<td class="nump">108,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">3,977<span></span>
</td>
<td class="nump">11,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,014<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">182,878<span></span>
</td>
<td class="nump">220,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">5,290<span></span>
</td>
<td class="nump">6,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,335<span></span>
</td>
<td class="nump">21,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease right-of-use assets</a></td>
<td class="nump">17,481<span></span>
</td>
<td class="nump">22,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other long-term assets</a></td>
<td class="nump">9,739<span></span>
</td>
<td class="nump">2,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">4,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">240,754<span></span>
</td>
<td class="nump">278,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,694<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">8,215<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,124<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">5,294<span></span>
</td>
<td class="nump">7,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">5,131<span></span>
</td>
<td class="nump">17,201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">34,801<span></span>
</td>
<td class="nump">39,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, noncurrent</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">15,673<span></span>
</td>
<td class="nump">18,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, noncurrent</a></td>
<td class="nump">19,349<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">69,973<span></span>
</td>
<td class="nump">62,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 6, 7 and 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2022 and 2021; 86,894,901 and 69,047,878 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">691,910<span></span>
</td>
<td class="nump">617,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(521,071)<span></span>
</td>
<td class="num">(401,384)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">170,781<span></span>
</td>
<td class="nump">216,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 240,754<span></span>
</td>
<td class="nump">$ 278,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid for research and development activities due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent Deposits And Other Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998113840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">86,894,901<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">86,894,901<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993863152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized grant revenue</a></td>
<td class="nump">$ 19,945<span></span>
</td>
<td class="nump">$ 48,214<span></span>
</td>
<td class="nump">$ 4,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">111,403<span></span>
</td>
<td class="nump">97,490<span></span>
</td>
<td class="nump">88,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">28,970<span></span>
</td>
<td class="nump">25,933<span></span>
</td>
<td class="nump">21,411<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">140,373<span></span>
</td>
<td class="nump">123,423<span></span>
</td>
<td class="nump">110,054<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(120,428)<span></span>
</td>
<td class="num">(75,209)<span></span>
</td>
<td class="num">(106,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,235)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,687)<span></span>
</td>
<td class="num">(75,082)<span></span>
</td>
<td class="num">(105,314)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (119,694)<span></span>
</td>
<td class="num">$ (75,155)<span></span>
</td>
<td class="num">$ (105,338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per share, basic</a></td>
<td class="nump">90,918,333<span></span>
</td>
<td class="nump">78,885,186<span></span>
</td>
<td class="nump">37,792,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per share, diluted</a></td>
<td class="nump">90,918,333<span></span>
</td>
<td class="nump">78,885,186<span></span>
</td>
<td class="nump">37,792,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Collaboration and license revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized grant revenue</a></td>
<td class="nump">$ 9,269<span></span>
</td>
<td class="nump">$ 46,717<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized grant revenue</a></td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433992831008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM Equity Offering Program [Member]</div></th>
<th class="th"><div>Private Investment in Public Equity [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>ATM Equity Offering Program [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Private Investment in Public Equity [Member]</div>
</th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>ATM Equity Offering Program [Member]</div>
</th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>Private Investment in Public Equity [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain/(Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 134,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">$ (220,988)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,332,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,670<span></span>
</td>
<td class="nump">$ 32,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,670<span></span>
</td>
<td class="nump">$ 32,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,160,963<span></span>
</td>
<td class="nump">9,586,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="nump">87,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the ESPP</a></td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(105,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,314)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">166,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326,302)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,595<span></span>
</td>
<td class="nump">52,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,595<span></span>
</td>
<td class="nump">52,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,990,869<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants', window );">Offering costs related to the sale of common stock and pre-funded warrants</a></td>
<td class="num">(451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the ESPP</a></td>
<td class="nump">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_StockIssuedDuringPeriodSharesPurchaseAgreement', window );">Issuance of common stock under Sales Purchase Agreement, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_StockIssuedDuringPeriodValuePurchaseAgreement', window );">Issuance of common stock under Sales Purchase Agreement, net of issuance costs</a></td>
<td class="nump">20,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IssuanceOfCommonStockForWarrantExercisesValue', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IssuanceOfCommonStockForWarrantExercisesShare', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,459,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,082)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">216,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(401,384)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,592<span></span>
</td>
<td class="nump">14,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,591<span></span>
</td>
<td class="nump">14,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,034,948<span></span>
</td>
<td class="nump">6,637,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the ESPP</a></td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">194,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IssuanceOfCommonStockForWarrantExercisesValue', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IssuanceOfCommonStockForWarrantExercisesShare', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares', window );">Issuance of common stock upon restricted stock units vesting, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits', window );">Tax payments related to shares withheld for vested restricted stock units</a></td>
<td class="num">(890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,687)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 170,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="num">$ (521,071)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,894,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital offering costs related to sale of common stock and pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IssuanceOfCommonStockForWarrantExercisesShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for warrant exercises, Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IssuanceOfCommonStockForWarrantExercisesShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IssuanceOfCommonStockForWarrantExercisesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for warrant exercises, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IssuanceOfCommonStockForWarrantExercisesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon restricted stock units vesting, net of shares withheld, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lapse of repurchase rights related to common stock issued pursuant to early exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_StockIssuedDuringPeriodSharesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_StockIssuedDuringPeriodSharesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_StockIssuedDuringPeriodValuePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_StockIssuedDuringPeriodValuePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax payments related to shares withheld for vested restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998111136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Follow-on Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for issuance cost</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Investment in Public Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for issuance cost</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">$ 2,348<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for issuance cost</a></td>
<td class="nump">$ 1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998219824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (119,687)<span></span>
</td>
<td class="num">$ (75,082)<span></span>
</td>
<td class="num">$ (105,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,560<span></span>
</td>
<td class="nump">6,347<span></span>
</td>
<td class="nump">6,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on marketable securities</a></td>
<td class="num">(372)<span></span>
</td>
<td class="nump">817<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,557<span></span>
</td>
<td class="nump">10,552<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">9,131<span></span>
</td>
<td class="nump">8,052<span></span>
</td>
<td class="nump">7,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">658<span></span>
</td>
<td class="num">(3,426)<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent', window );">Deposits and other long-term assets</a></td>
<td class="num">(7,387)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,879<span></span>
</td>
<td class="num">(419)<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Accrued and other non-current liabilities</a></td>
<td class="nump">3,509<span></span>
</td>
<td class="num">(859)<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="num">(363)<span></span>
</td>
<td class="nump">2,653<span></span>
</td>
<td class="num">(725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(8,915)<span></span>
</td>
<td class="num">(7,925)<span></span>
</td>
<td class="num">(3,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(15,198)<span></span>
</td>
<td class="nump">8,633<span></span>
</td>
<td class="num">(2,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(115,946)<span></span>
</td>
<td class="num">(50,678)<span></span>
</td>
<td class="num">(89,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(141,908)<span></span>
</td>
<td class="num">(199,905)<span></span>
</td>
<td class="num">(8,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ProceedsFromMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">134,816<span></span>
</td>
<td class="nump">82,253<span></span>
</td>
<td class="nump">72,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ProceedsFromSaleOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">5,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5,872)<span></span>
</td>
<td class="num">(5,463)<span></span>
</td>
<td class="num">(3,515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PrepaymentsOnFinancingLease', window );">Prepayments on financing lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(12,964)<span></span>
</td>
<td class="num">(118,553)<span></span>
</td>
<td class="nump">65,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of common stock and pre-funded warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of debt discount and issuance costs</a></td>
<td class="nump">19,130<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(8,394)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PaymentsOfFinancingLease', window );">Payments of financing lease</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax payments related to shares withheld for vested restricted stock units</a></td>
<td class="num">(890)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">83,098<span></span>
</td>
<td class="nump">108,760<span></span>
</td>
<td class="nump">135,801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(45,812)<span></span>
</td>
<td class="num">(60,471)<span></span>
</td>
<td class="nump">112,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">110,577<span></span>
</td>
<td class="nump">171,048<span></span>
</td>
<td class="nump">58,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">64,765<span></span>
</td>
<td class="nump">110,577<span></span>
</td>
<td class="nump">171,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases accrued but not yet paid</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Financing costs included in accrued liabilities and accounts payable</a></td>
<td class="nump">2,433<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification', window );">Remeasurement of operating lease right-of-use asset for lease modification</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">6,452<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Lease liabilities arising from obtaining right -of-use asset from new leases</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest on debt</a></td>
<td class="nump">647<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,169<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PipeFinancingMember', window );">PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_StockOptionsWarrantsAndOtherMember', window );">Stock Options, Warrants and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">3,408<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember', window );">ATM Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">19,737<span></span>
</td>
<td class="nump">36,719<span></span>
</td>
<td class="nump">9,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_EsppEmployeeStockPurchasePlanMember', window );">ESPP Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deposit and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PaymentsOfFinancingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of financing lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PaymentsOfFinancingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PrepaymentsOnFinancingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments on financing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PrepaymentsOnFinancingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturity of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of operating lease right-of-use assets for lease modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_StockOptionsWarrantsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_StockOptionsWarrantsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_EsppEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_EsppEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140434000097024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text"><p id="notes_to_financial_statements" style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	Organizat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ion</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gritstone bio, Inc. (&#8220;Gritstone&#8221; or &#8220;the Company&#8221;) is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. The Company was incorporated in the state of Delaware in August 2015, and is based in Emeryville, California and Cambridge, Massachusetts, with a manufacturing facility in Pleasanton, California. The Company operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred operating losses and has an accumulated deficit as a result of ongoing efforts to develop </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">drug</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. The Company had net losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021, and 2020, respectively. The Company used net cash of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through its operating activities for the years ended December 31, 2022, 2021, and 2020, respectively. The Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">521.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">401.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively. To date, none of the Company&#8217;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through private placements of its convertible preferred stock, the sale of common stock in public offerings, under an &#8220;at the market offering&#8221; (the &#8220;ATM Offering Program&#8221;), the private placement of common stock and pre-funded warrants, and through proceeds received from its collaboration arrangements. As of December 31, 2022, the Company had cash, cash equivalents and marketable securities of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the filing date of this Annual Report on Form 10-K.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995439952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities and Exchange Commission (the &#8220;SEC&#8221;) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for reporting. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and transaction price and progress toward completion of performance obligation under the contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></p><p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:</span></p><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.</span></div></div><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</span></div></div><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within short-term restricted cash and deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#8217;s restricted cash includes payments received under the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) Funding Agreement, dated as of August 14, 2021 (the &#8220;CEPI Funding Agreement&#8221;) and the Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and short-term and long-term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.953%;"/>
          <td style="width:1.557%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.267%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.557%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.665%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,498</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93,287</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,977</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,285</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,290</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,005</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,765</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,577</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#8217;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> recognition of any other-than-temporary impairment in the year ended December 31, 2022, 2021 or 2020. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2022 or 2021.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of the Compan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">y&#8217;s debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2022, the Company has no off-balance sheet concentrations of credit risk.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. Further, the Company is subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.315%;"/>
          <td style="width:1.583%;"/>
          <td style="width:31.102%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2022, 2021, or 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#8217;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#8220;ASC 606&#8221;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#8211; Revenue Recognition (&#8220;ASC 958-605&#8221;), which applies to business entities that receive contributions within the scope of ASC 958-605.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#8217;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement and the Gates Grant Agreement (see Note 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#8220;the Black-Scholes model&#8221;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation (based on the mid-point between the vesting date and the end of the contractual term) of the expected term for its stock options as the Company has concluded that its stock option history does not provide a reasonable basis upon which to estimate expected term. Volatility is based on an average of the historical volatilities of the common stock of entities with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">characteristics </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">similar to the Company&#8217;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#8217;s technologies are recorded as research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#8217;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#8217;s consolidated balance sheets at December 31, 2022 and 2021. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes lease expense on a straight-line basis over the expected lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes and measures uncertain tax positions using a two&#8212;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#8217;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2022, the Company had not accrued interest or penalties related to uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2020, the Families First Coronavirus Response Act (the &#8220;FFCR Act&#8221;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 29, 2020, Assembly Bill 85 (&#8220;A.B. 85&#8221;) was signed into California law. A.B. 85 provides for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> suspension of the use of net operating losses for medium and large businesses and a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cap on the use of business incentive tax credits to offset no more than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for taxable years 2020 and 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#8217;s consolidated financial statements as of December 31, 2022.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#8217;s marketable securities.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the FASB issued ASU No. 2020-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Codification Improvements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASU 2020-10&#8221;). The standard contains improvements to the FASB Accounting Standards Codification (the &#8220;Codification&#8221;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. We adopted ASU 2020-10 on January 1, 2022 and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt - Debt with Conversion and Other Options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Subtopic 470-20) and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASU 2020-06&#8221;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company does not expect the adoption of ASU 2020-06 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to have a material impact on its consolidated financial statements and related disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140434000071840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	Cash Equivalents and Marketable Securities</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.0%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.682%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.804%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">948</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,318</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,853</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,608</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,540</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,703</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,464</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,389</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">933</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,103</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,099</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,611</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.0%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.682%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.804%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,990</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,976</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,277</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,269</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,565</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,557</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,346</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,986</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,348</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,275</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had a total of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">206.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash, cash equivalents and marketable securities, which includes $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash and cash equivalents and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in marketable securities, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All marketable securities held as of December 31, 2022, had contractual effective maturities of less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no material realized gains or losses</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on marketable securities for the periods presented. As of December 31, 2022, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t hold any individual securities in an unrealized loss position </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for 12 months or greater</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> recognition of any other-than-temporary impairment in the year ended December 31, 2022, 2021, or 2020. The Company has not recorded an allowance for credit losses as of December 31, 2022 or 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 4 for further information regarding the fair value of the Company&#8217;s financial instruments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995336000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.	Fair Value Measurements</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.422%;"/>
        <td style="width:1.174%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.777000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,853</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,853</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,540</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,540</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,389</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,540</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,849</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,099</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,099</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,099</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,611</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,830</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,781</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.422%;"/>
        <td style="width:1.174%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.777000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,269</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,269</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,557</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,557</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,346</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,986</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,986</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,986</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,275</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,536</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,739</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures the fair value of money market funds and U.S. treasuries based on quoted prices in active markets for identical securities. Commercial paper, corporate debt securities, certificates of deposits, asset backed securities, and U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers between Level 1 and Level 2 during the periods presented. See Note 3 for further information regarding the amortized cost of our financial instruments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995562528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.	Property and Equipment, Net</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.84%;"/>
        <td style="width:1.517%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.456%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.517%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.669%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,155</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,285</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,113</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,309</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,128</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,773</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,907</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,782</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,276</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,344</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,991</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,335</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,622</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021, and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995322480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.	Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases office, laboratory and storage space in facilities at several locations:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emeryville Lease</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s principal executive offices in Emeryville, California, consisting of office and laboratory space, are leased pursuant to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating lease (the &#8220;Emeryville Lease&#8221;), which the Company entered into in January 2019, with the obligation to pay rent commencing in November 2019. In conjunction with signing the Emeryville Lease, the Company paid a cash security deposit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is recorded as a deposit on the Company&#8217;s consolidated balance sheets as of December 31, 2022 and 2021. The Emeryville Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend this lease for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> periods at the then market rental rate. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to complete the laboratory and office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million lease liability on the consolidated balance sheet as of December 31, 2022.  The Company recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million lease liability on the consolidated balance sheet as of December 31, 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pleasanton Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,620</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office, cleanroom, and laboratory support manufacturing space in Pleasanton, California pursuant to a non-cancelable operating lease (the &#8220;Pleasanton Lease&#8221;), which the Company entered into in March 2017, with the obligation to pay rent commencing in December 2017. The Pleasanton Lease includes a free rent period, escalating rent payments and a term that expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 30, 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company may extend the lease term for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at the then market rental rate. The Company obtained an irrevocable letter of credit in March 2017 in the initial amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as a security deposit to the Pleasanton Lease, which may be drawn down by the landlord in the event the Company fails to fully and faithfully perform its obligations under the Pleasanton lease. The letter of credit may be reduced based on certain levels of cash and cash equivalents the Company holds. In October 2022, the letter of credit was reduced to a balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ne of the irrevocable letter of credit amount had been drawn. The Pleasanton Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Pleasanton Lease, the Company received a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the landlord for the costs associated with the design, development and construction of tenant improvements. The unamortized tenant improvement balance is recognized as a component of operating lease ROU Assets on the consolidated balance sheets as of December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in May 2019, the Company entered into a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> non-cancelable operating lease for additional office space in Pleasanton, California, with an obligation to pay rent commencing in August 2019. In January 2022, the Company amended the lease to add additional leased space and extend the lease expiration date to February 2027.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cambridge Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases laboratory, office and storage space in several facilities in Cambridge, Massachusetts, pursuant to three separate agreements:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s facility located at 40 Erie Street in Cambridge, Massachusetts is leased pursuant to a</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 67-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> non-cancelable operating lease (the &#8220;40 Erie Lease&#8221;), which the Company entered into in February 2016, with an obligation to pay rent commencing in October 2016. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to complete the laboratory and office renovation. In September 2021, the Company executed an amendment to the 40 Erie Lease, which extends its term through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and provides for monthly base rent amounts, subject to annual increases over the term of the lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s facility located at 21 Erie Street in Cambridge, Massachusetts is leased pursuant to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> non-cancelable operating lease (the &#8220;21 Erie Lease&#8221;), which the Company entered into in September 2018. The 21 Erie Lease has since been amended five times, as a result of which the lease term extends through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company entered into a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating lease (the &#8220;Cambridge Storage Lease&#8221;) for additional office and laboratory storage space in Cambridge, Massachusetts, which commenced on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_20846724-0d37-49d2-b716-e12511647821;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 1, 2021</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company also paid an insignificant cash security deposit. The Cambridge Storage Lease was amended in June 2022 to extend the lease term through June 30, 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In conjunction with the 40 Erie Lease, the 21 Erie Lease and the Cambridge Storage Lease, each as amended (if applicable), the Company has paid certain cash security deposits, which in each case included amounts for the applicable last month&#8217;s rent and has been classified as part of the operating lease ROU Assets. Of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million security deposits, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded in prepaids and other assets on the Company&#8217;s consolidated balance sheet and the remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded in deposits and other long-term assets on the Company&#8217;s consolidated balance sheet as of December 31, 2022. Security deposits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are recorded in deposits and other long-term assets on the Company&#8217;s consolidated balance sheet as of December 31, 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston Lease</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to occupy a newly-built facility in Boston, Massachusetts, with office and laboratory space, in 2023 pursuant to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120-month </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating lease (the &#8220;Boston Lease&#8221;), which the Company entered into in September 2021. The Boston Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend the Boston Lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> periods at the then market rental rate. The landlord provided the Company with a tenant improvement allowance of up to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for costs relating to the design, permitting and construction of improvements. The Company&#8217;s obligation to pay rent is expected to commence in the second half of 2023, subject to free rent periods of three and six months with respect to certain premises. The Company expects to be provided early access to the premises to install fixtures and equipment 60 days prior to the anticipated rent commencement date. The Boston Lease is expected to expire in 2033. The Boston Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses. In connection with the Boston Lease and as a security deposit thereunder, the Company has provided the landlord an irrevocable letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is collateralized by a restricted cash deposit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and which may be reduced in the fifth and seventh years of the Boston Lease.  As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ne of the irrevocable letter of credit amount had been drawn.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized a right-of-use asset or lease liability as of December 31, 2022 or 2021 for the Boston Lease as the Company did not control the underlying assets at any time in the periods ended December 31, 2022 or 2021. Under the Boston Lease, the Company is obligated to make minimum lease payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years from 2023 to 2033, which includes rent abatement during the free rent periods.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s operating leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.468%;"/>
        <td style="width:1.348%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.029%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.348%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.029%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.348%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.429%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,973</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,973</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,518</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental information related to leases was as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.61%;"/>
        <td style="width:1.327%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.327%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.327%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.464%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,915</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,389</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New right-of-use assets obtained in exchange for lease obligations (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,959</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,562</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,174</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.10</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.30</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.10</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, minimum annual payments under the Company&#8217;s lease agreements are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.882%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.038999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Financing<br/>Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,604</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,527</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104,979</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing lease payments under Boston lease</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,113</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,967</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Current portion of lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,294</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Guarantees and Indemnifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, with respect to which the officer or director is or was serving at the Company&#8217;s request in such capacity. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#8217;s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995336000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.	Collaboration and License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2seventy bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2018, the Company entered into a Research Collaboration and License Agreement with bluebird bio, Inc. (&#8220;bluebird&#8221;). In November 2021, bluebird assigned the Research Collaboration and License Agreement (the &#8220;2seventy Agreement&#8221;), to its affiliate, 2seventy bio, Inc. (&#8220;2seventy&#8221;), in connection with an internal restructuring and subsequent spin-out of 2seventy.  Under the terms of the 2seventy Agreement, the Company provides to 2seventy tumor-specific targets across several tumor types and, in certain cases, T cell receptors (TCR) directed to those targets. The Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and 2seventy also concurrently acquired </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">768,115</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s Series C convertible preferred stock for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">share. Per the 2seventy Agreement, 2seventy was also provided an option to acquire shares of the Company&#8217;s common stock at the same price</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all other investors in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;). In October 2018, 2seventy purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">666,667</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock at the price to the public of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Under the terms of the 2seventy Agreement, the Company is eligible to earn development, regulatory, and sales-based milestones in an amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion, and single-digit royalties on sales of products that utilize the technology subject to the 2seventy Agreement. None of these events had occurred as of December 31, 2022, and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2019, the Company entered into a First Amendment to the 2seventy Agreement, which extended the timeline for the Company and 2seventy to execute a Patient Selection Services Agreement from within one year to within two years after the Effective Date of the 2seventy Agreement. In August 2020, the Company entered into a Second Amendment, which extended the timeline of the Patient Selection Services Agreement to within three years and also extended the Tissue Analysis Period from February 28, 2021 to June 30, 2021. In April 2021, the Company entered into a Third Amendment, which removed the Patient Selection Services Agreement in its entirety and extended the Tissue Analysis Period from June 30, 2021 to December 31, 2021. The amendments were entered into for administrative purposes, and the Company determined the amendments were not a modification of contract under the contract with customers guidance.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2seventy may terminate the 2seventy Agreement by giving a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the last payment owed by the Company on a licensed product. The 2seventy Agreement may be terminated for cause by either party based on an uncured material breach by the other party or bankruptcy of the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to 2seventy under the licensed intellectual property will remain in effect in accordance with their respective terms. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, all of 2seventy&#8217;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.</span></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that 2seventy is a customer, and the contract is not subject to guidance on collaborative arrangements. This is because the Company granted 2seventy a license to the Company&#8217;s intellectual property and provided research and development services, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identified the following three material promises under the 2seventy Agreement: (i) transfer of a license to intellectual property and related technology know-how (&#8220;License and Know-How&#8221;); (ii) the obligation to perform target selection and TCR generation services (&#8220;Research and Development Services&#8221;); and (iii) participation on the Joint Steering Committee (the &#8220;JSC&#8221;). The Company provided to 2seventy standard indemnification and protection of licensed intellectual property, which is part of assurance that the license meets the contract&#8217;s specifications and is not an obligation to provide goods or services.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considered that the License and Know-How has standalone functionality, was considered to be functional intellectual property, and is capable of being distinct. However, the Company determined that the License and Know-How is not distinct from the Research and Development Services or participation on the JSC within the context of the 2seventy Agreement, because 2seventy is dependent on the Company to execute the Research and Development Services and participate on the JSC in order for 2seventy to benefit from the License and Know-How. As such, the License and Know-How is combined with the Research and Development Services and participation on the JSC into a single performance obligation, and the transaction price under this arrangement will be allocated to this single performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has also determined that all other goods or services that are contingent upon 2seventy reaching various milestones are not considered performance obligations at the inception of the arrangement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price at the inception of the 2seventy Agreement consisted of the upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million received from 2seventy for the purchase of the Company&#8217;s Series C convertible preferred stock. The sale of the Series C convertible preferred stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the transaction price was allocated to the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">768,115</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series C convertible preferred stock at fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and recorded in stockholders&#8217; equity.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The variable consideration related to the remaining development, regulatory, and sales-based milestones payments has not been included in the initial transaction price and continues to be fully constrained as of December 31, 2021. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon initiation of clinical trials for early-stage targets and 2seventy&#8217;s development efforts. Any variable consideration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the License and Know-How granted to 2seventy. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> For revenue recognition purposes, the Company determined that the duration of the 2seventy Agreement began on the effective date in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ends upon completion of the Research and Development Services, which is also when the participation on the JSC is no longer an obligation. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. The Company also analyzed the impact of 2seventy terminating the agreement prior to August 2023 and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to 2seventy for doing so.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when, or as, the Company satisfies its performance obligation by transferring the promised services to 2seventy. Revenue is being recognized over time using a cost-based input method, based on internal labor cost effort to perform the research services, since the internal labor cost incurred over time is thought to best reflect the transfer of services to 2seventy. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022, 2021, and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in collaboration revenue under the 2seventy Agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amount of collaboration revenue recognized during the year ended December 31, 2022 included cumulative catch-up adjustments increasing collaboration revenue by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million due to revisions to estimated costs to complete the remaining performance obligation. The adjustments resulted in a decrease in the Company&#8217;s loss from operations of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a decrease in loss per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.07</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2022. Deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the consolidated balance sheet in current liabilities as of December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the consolidated balance sheets in both current and long-term liabilities as of December 31, 2021, respectively. Deferred revenue relates to the performance obligations identified under the 2seventy Agreement and will be recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the deferred revenue balance during the year ended December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.929%;"/>
        <td style="width:1.757%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.558%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.757%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receivables or net contract assets recorded as of December 31, 2022 or 2021 associated with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2seventy Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gilead Sciences, Inc.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, the Company entered into a Collaboration, Option and License Agreement (the &#8220;Gilead Collaboration Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;) to research and develop a vaccine-based immunotherapy as part of Gilead&#8217;s efforts to find a curative treatment for HIV infection. Under the terms of the Gilead Collaboration Agreement, the Company granted to Gilead an exclusive, worldwide license to develop and commercialize a HIV-specific therapeutic vaccine utilizing the Company&#8217;s technology. Gilead is responsible for conducting all development and commercialization activities beginning with a Phase 1 study, and the Company is responsible for contributing to preclinical research studies and participation in a joint steering committee (collectively, &#8220;research and development activities&#8221;). Concurrently with the execution of the Gilead Collaboration Agreement, the Company and Gilead entered into a Supply Agreement (the &#8220;Gilead Supply Agreement&#8221;) under which the Company will supply research product and GMP product (&#8220;Product Supply&#8221;) that may be required under the Gilead Collaboration Agreement until Gilead completes its first GMP product batch, and the Company will participate in a joint manufacturing team (collectively, &#8220;product supply activities&#8221;). In addition, the Company also concurrently entered into a Stock Purchase Agreement (the &#8220;Gilead Stock Purchase Agreement&#8221;) under which Gilead acquired, in a private placement transaction, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,169,591</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the Company&#8217;s common stock. The common shares were issued to Gilead with</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">certain </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">registration rights and certain standstill and market stand-off provisions. The Company determined that these concurrent contracts represent a combined arrangement (the &#8220;Gilead Arrangement&#8221;).</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Gilead Collaboration Agreement, the Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Under the Gilead Collaboration Agreement and the Gilead Supply Agreement, the Company will receive additional reimbursement payments for expenses incurred in the research and development activities and product supply activities. Under the Gilead Stock Purchase Agreement, the common shares were sold at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.65</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s common stock at fair value on closing was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If Gilead decides to move forward with development beyond the initial Phase 1 study (the &#8220;Option&#8221;), the Company will receive a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million non-refundable option fee and will be eligible to receive up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">685.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million if certain clinical, regulatory and commercial milestones are achieved, as well as tiered royalties ranging from the mid-single digits to low double-digits on net sales of a therapeutic product utilizing its technology. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None of these events had occurred as of December 31, 2022 and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gilead </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may terminate the Gilead Collaboration Agreement for convenience by giving a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the expiration of the royalty term, or, if the Option is not exercised, by the end of the Option term. The Gilead Collaboration Agreement may be terminated for cause by either party based on an uncured material breach by the other party, insolvency of the other party, or patent challenge. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to Gilead under the licensed intellectual property will remain in effect in accordance with their respective terms. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#8217;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#8217;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Furthermore, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and may terminate any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.</span></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services and Product Supply, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration. The Option, if exercised by Gilead, will be considered a modification that increases the scope of the arrangement beyond the Option term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identified the following performance obligations under the Gilead Collaboration Agreement: (i) licenses including an exclusive (in the HIV field), royalty-free, worldwide collaboration license and transfer of know-how and an exclusive (in the HIV field) worldwide, royalty-bearing development and commercialization license subject to restrictions on its use during the Option term and an exclusive option to release such restrictions; (ii) preclinical research and development activities, manufacturing-related activities, and participation on a Joint Steering Committee; and (iii) product supply, including research and GMP product, until Gilead completes its first GMP batch, and participation on a Joint Manufacturing Team.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considered that the licenses and know-how have standalone functionality, are considered to be functional intellectual property and are capable of being distinct. The Company also determined that the research and development activities and product supply by Gritstone could be provided by resources otherwise available to Gilead and thus are capable of being distinct.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has also determined that the pricing for optional goods and services and release of license restrictions upon exercise of the Option do not constitute material rights and are not a potential performance obligation. The Company evaluated whether there is an interdependence between the promises and determined that the licenses are a combined solution and the predominant performance obligation, while the other promises are separately identifiable in the context of the contract; however, the research and development activities are dependent on the research product supply, which is accounted for as a combined performance obligation. As a result, the Company identified three performance obligations in the Gilead Arrangement: (i) exclusive licenses and know-how, (ii) research and development activities and product supply, and (iii) GMP product supply.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price at the inception of the Gilead Collaboration Agreement consisted of the upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million received for the sale of the Company&#8217;s common stock. The sale of the common stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the transaction price was allocated to the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,169,591</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares of the Company&#8217;s common stock at fair value on closing of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and recorded in stockholders&#8217; equity. The remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the common stock purchase price in excess of the fair value of the shares received is added to the transaction price for the Gilead Collaboration Agreement. In addition, the initial transaction price includes estimated variable consideration for budgeted reimbursement of research and development costs and product supply. The variable consideration related to reimbursable costs and product supply has been constrained as of December 31, 2022 based on the current research and development plan forecast. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the variable consideration for the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee and for the development, regulatory, and sales-based milestones payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&#8217;s control. As a result, these payments were fully constrained and were not included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the exclusive licenses and know-how granted to Gilead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is allocated to the performance obligation based upon relative standalone selling prices, which were determined for the exclusive licenses and know-how using an adjusted market approach and for the research and development activities and product supply using a cost plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ends upon (i) the completion of the Option term, which is expected to end </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9eba06f0-bedf-4ded-9f71-17671e82aef7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after the effective date, if the Option is not exercised or (ii) the expiration of the royalty-term on a product-by-product and country-by-country basis. The Company also analyzed the impact of Gilead terminating the agreement prior to the end of the Option term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Gilead for doing so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue for the exclusive licenses and know-how was recognized on the effective date of the Gilead Collaboration Agreement at the point in time that the licenses are effective. The research and development activities and product combined performance obligation and the GMP product supply performance obligation are recognized over time when, or as, the Company transfers the promised goods and services to Gilead. Research and development service and product supply revenues will be recognized over time using a cost-based input method, based on internal and external labor cost effort to perform the services, costs to acquire research materials, and costs of product supply, since the costs incurred over time are thought to best reflect the transfer of goods and services to Gilead. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to estimated total costs to fulfill each performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation and associated variable consideration will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, the Company did not record any license revenue. For the year ended December 31, 2022, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as collaboration revenue as a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. For the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as license revenue, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as collaboration revenue as a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. There was no contract asset recorded on the consolidated balance sheet as of December 31, 2022. A contract asset of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 for supply costs that were incurred during the year ended December 31, 2021, but not billable until future periods when the asset is released. The contract asset relates to the performance obligations yet to be satisfied under the Gilead Collaboration Agreement. There was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million recorded as deferred revenue as of December 31, 2022 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> deferred revenue as of December 31, 2021 associated with the Gilead Collaboration Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the contract asset and short-term deferred revenue, balance during the year ended December 31, 2022 for the Gilead Collaboration Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.079%;"/>
        <td style="width:1.496%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.963999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.496%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.963999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract Asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,385</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,508</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of receivables recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company deferred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in incremental costs to acquire the Gilead Collaboration Agreement in the first quarter of 2021 allocated to performance obligations recognized over time, which will be recognized over time in each period proportionate to revenue recognition. As of December 31, 2022, deferred contract acquisition costs were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Deferred contract acquisition costs amortized during the year ended December 31, 2022 and 2021 were negligible.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Arbutus Biopharma Corporation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2017, the Company entered into an Exclusive License Agreement with Arbutus and its wholly-owned subsidiary, Protiva Biotherapeutics Inc. Certain terms of the agreement were modified by amendment in July 2018. Under the license agreement, the Company has an exclusive license to utilize certain Arbutus intellectual property, including patents and know-how relating to immunotherapy. During the years ended December 31, 2022, 2021 and 2020, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> research and development expense under the agreement. The Company is obligated to pay Arbutus certain milestone payments up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on achievement of specified events, and royalties on sales of its licensed products. Following the acceptance of our investigational new drug application for GRANITE by the FDA, the Company made a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million development milestone payment to Arbutus in September 2018 that was recorded as research and development expense. In August 2019, a milestone was met following the initial patient treatment of SLATE in the Company&#8217;s GO-005 clinical trial. In 2019, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as research and development expense in connection with the milestone. None of the other events had occurred as of December 31, 2022, and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Profit Hospital Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2016, the Company entered into an Exclusive License Agreement with a non-profit hospital cancer center. Under the license agreement, the Company has an exclusive license to utilize certain patents and know-how relating to immunotherapy for an insignificant upfront payment, cash milestone payments on achievement of specified events, and a low single digit royalty on sales of licensed products. The achievement of the milestones and payment of royalties is dependent upon obtaining regulatory approval. Upon achievement of a milestone related to the Company&#8217;s Phase 1 clinical trial for GRANITE, GO-004, in December 2018 the Company recorded an insignificant amount to research and development expense for amounts owed to the Hospital Cancer Center, which was paid to the hospital in February 2019. None of the other milestone events had occurred as of December 31, 2022, and no royalties were due from the sales of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Genevant Sciences GmbH</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company entered into an Option and License and Development Agreement (the &#8220;2020 Genevant License Agreement&#8221;) with Genevant Sciences GmbH (&#8220;Genevant&#8221;), pursuant to which Genevant granted the Company exclusive license rights under certain intellectual property related to Genevant&#8217;s LNP technology for a single therapeutic indication, and the Company agreed to pay Genevant an initial payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was included in research and development expense for the year ended December 31, 2020. Genevant is a spin-off of Arbutus, and the 2020 Genevant License Agreement expands Gritstone&#8217;s intellectual property rights to such LNP technology originally obtained pursuant to the Company&#8217;s license agreement with Arbutus. Prior to the 2020 Genevant License Agreement, the Company licensed Arbutus&#8217; LNP technology for indications in the oncology space. The remainder of Arbutus&#8217; IP portfolio was transferred to Genevant in the spin-off. In</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, a milestone in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was met, which was included in research and development expense for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the 2020 Genevant License Agreement, Genevant also granted the Company certain options to license the LNP technology for additional therapeutic indications of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each indication and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to extend the option term. The 2020 Genevant License Agreement continues in effect until the last to expire royalty term or early termination. It is terminable by the Company for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either party may terminate the agreement for material breach, subject to a cure period, and Genevant may terminate the agreement if the Company challenges a licensed patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, the Company entered into a Non-Exclusive License and Development Agreement (the &#8220;2021 Genevant License Agreement&#8221;) with Genevant. Pursuant to the 2021 Genevant License Agreement, the Company obtained a nonexclusive license to Genevant&#8217;s LNP technology to develop and commercialize self-amplifying RNA (&#8220;samRNA&#8221;) vaccines against SARS-CoV-2, the virus that causes COVID-19. Under the 2021 Genevant License Agreement, the Company made a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront payment to Genevant, and Genevant is eligible to receive from the Company up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in contingent milestone payments per product, plus certain tiered royalties, upon achievement of development and commercial milestones. In certain scenarios, in lieu of milestones and royalties, Genevant will be entitled to a percentage of amounts that the Company receives from sublicenses under the 2021 Genevant License Agreement, subject to certain conditions. In March 2021, a milestone in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was met following the initial patient treatment in the Phase 1 clinical trial conducted through the NIAID-supported Infectious Diseases Clinical Research Consortium (&#8220;IDCRC&#8221;). Both the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million milestone payments were recorded as research and development expense for the year ended December 31, 2021. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ne of the other milestone events had occurred as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coalition for Epidemic Preparedness Innovations</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 14, 2021, the Company entered into the CEPI Funding Agreement with CEPI, under which CEPI agreed to provide funding of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Company to advance the Company&#8217;s CORAL program, a second-generation COVID-19 vaccine program, with an initial clinical trial in South Africa. Under the terms of the agreement, CEPI is funding a multi-arm Phase 1 study evaluating the CORAL program&#8217;s samRNA vaccine in na&#239;ve, convalescent, and HIV+ patients. The study is evaluating three different samRNA vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses. The funding is also supporting pre-clinical studies, scale-up and formulation development to enable manufacturing of large quantities of stable vaccine product.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the CEPI Funding Agreement, among other things, the Company and CEPI agreed on the importance of global equitable access to the vaccine produced pursuant to the CEPI Funding Agreement. The vaccine, if approved, is expected to be made available to the COVAX Facility for procurement and allocation. The COVAX Facility aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope and continuation of the CEPI Funding Agreement may be amended depending on ongoing developments of the COVID-19 outbreak and the success of the Company&#8217;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement relative to other third-party COVID-19 vaccine candidates or treatments. If the World Health Organization (&#8220;WHO&#8221;), CEPI or a regulatory authority having jurisdiction over a clinical trial performed under the CEPI Funding Agreement determines that a third-party product candidate has substantially greater potential than the Company&#8217;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement and should be prioritized instead for a particular trial, the Company must consider in good faith any written request of CEPI not to proceed with a clinical trial of such COVID-19 vaccine candidate; however the determination of whether or not to proceed with such trial shall be made by the Company in its sole discretion. In addition, CEPI has the right to unilaterally terminate the CEPI Funding Agreement upon prior written notice if CEPI determines that (i) there are material safety, regulatory, scientific misconduct or ethical issues with the project undertaken by the Company under the CEPI Funding Agreement, (ii) the project undertaken by the Company under the CEPI Funding Agreement should be terminated, (iii) the Company becomes unable to discharge its obligations under the CEPI Funding Agreement, (iv) the Company fails to meet certain criteria set forth in the CEPI Funding Agreement, or (v) the Company commits fraud or a financial irregularity, as such terms are defined in the CEPI Funding Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the Company and CEPI entered into an amendment to the CEPI Funding Agreement, under which CEPI agreed to provide additional funding up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, for a total of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, to the Company to conduct a Phase I clinical trial of the Company&#8217;s Omicron vaccine candidate in South Africa.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CEPI advances grant funds upon request by the Company consistent with the agreed upon amounts and schedules as provided in the CEPI Funding Agreement. The first tranche of funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received in September 2021, and the second tranche of funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received in April 2022.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the agreement are incurred. During the year ended December 31, 2022, the Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under the CEPI Funding Agreement. During the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in grant revenue under the CEPI Funding Agreement. As of December 31, 2022 and 2021, short term deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, recorded on the consolidated balance sheets. Deferred revenue will be recognized over the period in which the CEPI Funding Agreement activities related to the first and second tranches of funding are expected to take place, which is currently estimated to be through the year ended 2023. As of December 31, 2022 and 2021, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, was recorded as short-term restricted cash on the consolidated balance sheet.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the CEPI Funding Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,698</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,952</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gates</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company entered into a Grant Agreement with the Gates Foundation (the &#8220;Gates Grant Agreement&#8221;), which provides funding for the Company&#8217;s development of an optimal immunogen in the context of a therapeutic human papillomavirus (&#8220;HPV&#8221;) vaccine. In consideration for the work to be performed, the Gates Foundation provided the Company with an upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in December 2021, and future funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is expected to be received by the Company in the first quarter of 2023, for a total grant amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the Gates Grant Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. During the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in revenue under the Gates Grant Agreement. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize any grant revenue under the Gates Grant Agreement in 2021. As of December 31, 2022, short-term restricted cash and short-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million  were recorded on the consolidated balance sheet. As of December 31, 2021, short-term restricted cash and short-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and long-term restricted cash and long-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the tranches of funding are expected to take place, which is currently estimated to be through the year ended 2023.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the Grant Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.308%;"/>
        <td style="width:1.877%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.815%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995485776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.	Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;) and Silicon Valley Bank (&#8220;SVB&#8221;), which provides the Company a 60-month term loan facility for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">borrowing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">capacity across five potential tranches. At the closing of the Loan Agreement, the Company drew </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the first tranche and can draw up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through March 2023. The remaining tranches provide up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million borrowing capacity and become available upon the Company meeting certain milestones set forth in the Loan Agreement. As of December 31, 2022, one milestone had been achieved, which provides the Company the ability to draw up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through December 15, 2023. The term loan is secured by substantially all of the Company&#8217;s assets, other than intellectual property. There are no warrants associated with the Loan Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings under the Loan Agreement bear interest (i) at an annual cash rate equal to the greater of (x) the lesser of (1) the prime rate (as customarily defined) and (2) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, in either case, plus </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, and (y) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and (ii) at an annual payment-in-kind rate which may equal </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company is required to make monthly interest-only payments prior to the amortization date of January 1, 2025, subject to a potential six-month and one-year extension upon satisfaction of certain conditions. The interest-only payment date has been extended an additional six months based on our achievement of one of the milestones as set forth in the Loan Agreement. In addition, the Company paid a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> facility charge upon closing, and must pay a facility charge equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount of any borrowings made pursuant to the amounts under the last four tranches.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All unpaid principal and accrued and unpaid interest with respect to each term loan is due and payable in full on July 19, 2027. At the Company&#8217;s option, the Company may prepay all or any portion of the outstanding borrowings, plus accrued and unpaid interest thereon and fees and expenses, subject to a prepayment premium ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, during the first three years after closing, depending on the year of such prepayment. Upon repayment of the term loan, the Company is required to make a final payment fee to the lenders equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the aggregate original principal amount of the loan. Debt issuance costs have been treated as debt discounts on the Company&#8217;s consolidated balance sheet and together with the final payment are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning on April 1, 2023, so long as the Company&#8217;s market capitalization is equal to or less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company is subject to a minimum liquidity requirement equal to the then outstanding balance under the Loan Agreement multiplied by 0.55 or 0.45, which multiplier depends on whether the Company achieves certain performance milestones.</span></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s obligations under the Loan Agreement are subject to acceleration upon the occurrence of customary events of default, including payment default, insolvency and the occurrence of certain events having a material adverse effect on the Company, including (but not limited to) material adverse effects upon the business, operations, properties, assets or financial condition of the Company and its subsidiaries, taken as a whole. As of December 31, 2022, the Company is in compliance with all covenants in the Loan Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there were unamortized issuance costs and debt discounts of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which were recorded as a direct deduction from the term loan on the consolidated balance sheet. Interest expense related to the Loan Agreement was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022. The effective interest rate on the term loan, including the amortization of the debt discount and issuance costs, and accretion of the final payment, was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The components of the long-term debt balance are as follows:</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.299%;"/>
        <td style="width:1.874%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.828%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal loan balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Final fee</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,150</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount and issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long term debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,349</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the estimated future principal payments due (excluding the final payment fee) were as follows:</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.991%;"/>
        <td style="width:2.083%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.926%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,407</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,197</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total principal payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995362272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.	Balance Sheet Components</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prepaid Expenses and Other Assets</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.953%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.267%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.665%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,241</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,672</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net contract asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,385</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,158</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,769</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">529</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">292</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities-related deposits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">567</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">866</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,672</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deposits and Other Long-Term Assets</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits and other long-term assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.953%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.267%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.665%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease security deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">643</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,162</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deposits and other long-term assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,739</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,352</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995485776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.	Stockholders&#8217; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s amended and restated certificate of incorporation provides for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock authorized for issuance, each with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock were issued and outstanding.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,894,901</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,047,878</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued and outstanding, respectively. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the Company&#8217;s common stock are entitled to one vote per share.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sale of Common Stock and Pre-Funded Warrants</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, the Company filed a Registration Statement on Form S-3 (the &#8220;2019 Shelf Registration Statement&#8221;) with the SEC, covering the offering of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of common stock, preferred stock, debt securities, warrants and units. The 2019 Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the Company&#8217;s common stock, from time to time, through the ATM Offering Program under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The SEC declared the 2019 Shelf Registration Statement effective on November 8, 2019.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the 2019 ATM Offering Program, in October 2019, the Company entered into a sales agreement (the &#8220;2019 Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), pursuant to which Cowen acts as the Company&#8217;s sales agent and, from time to time, offers and sells shares of the Company&#8217;s common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Cowen is entitled to compensation for its services equal to up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross proceeds of any shares of common stock sold under the 2019 Sales Agreement. In addition, the Company agreed to reimburse a portion of Cowen&#8217;s expenses in connection with the 2019 ATM Offering Program up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the year ended December 31, 2021, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,990,869</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  shares of its common stock through its 2019 ATM Offering Program and received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net of commissions and other offering costs. During the year ended December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sales </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of shares of the Company&#8217;s common stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">its 2019 ATM Offering Program. As of December 31, 2022, there are no further amounts available for issuance under the 2019 ATM Offering Program.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, the Company entered into two private placement financing transactions (collectively, the &#8220;First PIPE Financing&#8221;), as follows: (i) to sell </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,543,351</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants (the &#8220;Warrants&#8221;) to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,480,719</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share was prepaid by each purchaser), and (ii) to sell an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,043,127</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.71</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In connection with the First PIPE Financing, the Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Warrants are exercisable upon issuance at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outstanding Warrants generally may not be exercised if the holder&#8217;s aggregate beneficial ownership would be more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total issued and outstanding shares of the Company&#8217;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#8220;Warrant Shares&#8221;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#8220;cashless&#8221; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company completed a PIPE financing transaction, in which it sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share pursuant to a securities purchase agreement entered into on September 16, 2021 (the &#8220;Second PIPE Financing&#8221;). The Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Second PIPE Financing.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, the Company filed a Registration Statement on Form S-3 with the SEC (the &#8220;2022 Shelf Registration Statement&#8221;), covering the offering of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of common stock, preferred stock, debt securities, warrants and units. The 2022 Shelf Registration Statement included a prospectus supplement covering the issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the Company&#8217;s common stock, from time to time, through an &#8220;at-the-market&#8221; offering program (the &#8220;2022 ATM Offering Program&#8221;) under the Securities Act. The SEC declared the 2022 Shelf Registration Statement effective as of May 6, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the 2022 ATM Offering Program, in March 2022, the Company also entered into a sales agreement (the &#8220;2022 Sales Agreement&#8221;) with Cowen, pursuant to which Cowen will act as the Company&#8217;s sales agent and, from time to time, offer and sell shares of the Company&#8217;s common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Cowen is entitled to compensation for its services equal to up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross proceeds of any shares of common stock sold under the 2022 Sales Agreement. In addition, the Company agreed to reimburse a portion of Cowen&#8217;s expenses in connection with the 2022 ATM Offering Program up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, the Company has received aggregate proceeds from its 2022 ATM Offering Program of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net of commissions and offering costs, pursuant to the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,034,948</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, the Company completed a PIPE financing transaction, in which it sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,637,165</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share pursuant to a securities purchase agreement entered into on October 24, 2022 and pre-funded warrants (the &#8220;Warrants&#8221;) to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,274,923</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2599</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share was prepaid by each purchaser) (the &#8220;Third PIPE Financing&#8221;). The Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Third PIPE Financing. The Warrants are exercisable upon issuance at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outstanding Warrants generally may not be exercised if the holder&#8217;s aggregate beneficial ownership would be more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total issued and outstanding shares of the Company&#8217;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#8220;Warrant Shares&#8221;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#8220;cashless&#8221; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the following warrants to purchase shares of the Company&#8217;s common stock were issued and outstanding:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.773%;"/>
        <td style="width:1.467%;"/>
        <td style="width:27.95%;"/>
        <td style="width:1.467%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.704%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.639%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issue Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Warrants Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 28, 2020</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,573,704</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 24, 2022</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,274,923</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,848,627</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.4%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,442,567</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants exercised, resulting in the Company issuing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,442,567</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. During the year ended December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,459,576</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants exercised and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,872</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants cancelled due to net exercise of the warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995247712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.	Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Award Incentive Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2015, the Company&#8217;s board of directors approved the 2015 Equity Incentive Plan (&#8220;2015 Plan&#8221;). In connection with the Company&#8217;s IPO and the effectiveness of the 2018 Award Incentive Plan (&#8220;2018 Plan&#8221;), discussed below, the 2015 Plan terminated. The </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,815</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock that were then unissued and available for future issuance under the 2015 Plan became available under the 2018 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, the Company&#8217;s board of directors approved the 2018 Plan. Under the 2018 Plan, a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,690,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the 2018 Plan, plus the number of shares remaining available for future awards under the 2015 Plan, as of the effective date of the 2018 Plan. The number of shares of common stock reserved for issuance under the 2018 Plan automatically increases on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of the Company&#8217;s outstanding stock on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company&#8217;s board of directors. The 2018 Plan provides, among other things, for the grant of options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance bonus awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maximum number of shares that may be issued upon the exercise of stock options under the 2018 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s board of directors has the authority to determine to whom options will be granted, the number of shares, the term, and the exercise price. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an individual owns stock representing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or more of the outstanding shares, the price of each share </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value, as determined by the board of directors. Options granted have a term of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-year period with a straight-line vesting.</span></p></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Material Features of the 2021 Employment Inducement Incentive Award Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#8220;2021 Plan&#8221;), pursuant to Nasdaq Listing Rule 5635(c)(4). The principal purpose of the 2021 Plan is to promote the success and enhance the value of the Company by inducing new employees to commence employment with us, and by aligning the individual interests of new employees with the interests of our stockholders. Awards granted under the 2021 Plan are intended to constitute &#8220;employment inducement awards&#8221; under Nasdaq Listing Rule 5635(c)(4), and, therefore, the 2021 Plan is intended to be exempt from the Nasdaq Listing Rules regarding shareholder approval of stock option and stock purchase plans. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">790,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock were initially reserved for issuance under the 2021 Plan. The 2021 Plan provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, stock appreciation rights, and other stock-based and cash-based awards. The 2021 Plan does not provide for the grant of incentive stock options. Awards under the 2021 Plan may be granted to eligible employees who are either new employees or who are commencing employment with us or one of our subsidiaries following a bona fide period of non-employment with us, and for whom such awards are granted as a material inducement to commencing employment with us or one of our subsidiaries. Awards under the 2021 Plan may not be granted to our consultants or non-employee directors.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Plan is administered by our board of directors and, to the extent our board of directors delegates its authority to it, our compensation committee. In the event of a change in control in which the successor corporation refuses to assume or substitute any outstanding award under the 2021 Plan, the vesting of such award will accelerate in full. Our board of directors may terminate, amend, or modify the 2021 Plan at any time, provided that no termination or amendment may materially impair any rights under any outstanding award under the 2021 Plan without the consent of the holder.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 21, 2022, the Company&#8217;s board of directors increased the number of shares available under the 2021 Plan by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">700,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2018 Employee Stock Purchase Plan</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, the Company&#8217;s Board of Directors approved the 2018 Employee Stock Purchase Plan (&#8220;2018 ESPP&#8221;). The 2018 ESPP also became effective in September 2018. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">282,334</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were initially reserved for issuance under the 2018 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2018 ESPP will increase automatically each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by the lesser of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of common stock outstanding on December 31 of the preceding calendar year or (2) such lesser number of shares determined by the Company&#8217;s Board of Directors. The maximum number of shares that may be issued under the 2018 ESPP is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The offering periods are scheduled to start on the first trading day on or after June 1 or December 1 of each year. Contributions under the 2018 ESPP are limited to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of an employee&#8217;s eligible compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.996%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.738%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.728%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.547%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.57</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.48</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation of Stock Options</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.791%;"/>
        <td style="width:1.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.392%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.392%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.232%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.98</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#8217;s calculations are based on a grant date valuation approach. Using the Black-Scholes model, the weighted-average grant-date fair value of employee stock options granted was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.03</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.39</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share during the years ended December 31, 2022, 2021, and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the 2018 Plan and 2021 Plan activity is as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.38%;"/>
        <td style="width:0.108%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.776%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.065%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.991%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.065%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.683%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.119%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.302%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.514%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares<br/>Available<br/>for<br/>Issuance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number<br/>of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate    <br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,459,187</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,107,335</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.82</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.13</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,461,915</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,518,734</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,168,561</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.73</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,347</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.96</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,412,026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,129,929</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.73</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,814,394</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,951,620</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,089</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable &#8211; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,122,952</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.16</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">409</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest &#8211; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,421,425</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.04</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.00</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">995</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022, 2021, and 2020, the total intrinsic value of stock option awards exercised was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, determined at the date of option exercise, and the total cash received upon exercise of stock options was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2021 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t significant for 2020. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying stock option awards and the estimated fair value of the common stock on the date of exercise.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of total cost related to non-vested employee and consultant options is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The total fair value of shares vested during the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense and awards granted to non-employees was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021, and immaterial for the year ended December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9f56e434-2071-40f2-81bc-0ed22f38f4e5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our restricted stock unit activity during the year ended December 31, 2022:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.001%;"/>
        <td style="width:1.104%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.636%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.555%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.703000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, unvested as December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">708,800</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">350,173</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.46</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353,300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canceled/Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144,147</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.35</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, unvested as December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">561,526</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation for all awards granted to employees, consultants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018 ESPP, before taxes, is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.361%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.610999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.610999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.011%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,730</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,827</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,926</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,657</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,552</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,110</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995371824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.	Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective tax rate for the years ended December 31, 2022, 2021, and 2020 is different from the federal statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective tax rate of the Company&#8217;s provision for income taxes differs from the federal statutory rate as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.715%;"/>
        <td style="width:0.999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.098%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.098%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.089%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in state tax apportionment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-taxable stock premium</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#8217;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are fully offset by a valuation allowance at December 31, 2022 and 2021. The deferred tax assets were primarily comprised of federal and state tax net operating losses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tax credit carryforwards. The increase in valuation allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during 2022 and 2021, respectively, was primarily attributable to the Company&#8217;s current year taxable loss and increase in the effective state tax rate due to changes in the Company&#8217;s state apportionment factors.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the net deferred tax assets/liabilities are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.822%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.437999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.632%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,575</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,684</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,437</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,537</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">449</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 Capitalized Expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165,905</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,884</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,877</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">212</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net of allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning January 1, 2022, the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Section 174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the Tax Act, deferred tax assets related to capitalized research expenses increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company&#8217;s federal and state income tax net operating loss carryforwards were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">369.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">465.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, which may be subject to limitations as described below. If not utilized, the federal tax loss carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the state tax loss carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the Tax Act, federal net operating losses generated after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. The federal net operating losses generated after December 31, 2017 of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are carried forward indefinitely. In addition, the Company has certain federal, California and Massachusetts research and development income tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. If not utilized, the federal research and development income tax credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The California research and development income tax credit carryforwards do not expire and can be carried forward indefinitely. The Massachusetts research and development income tax credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss and tax credit carryforwards as of December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.464%;"/>
        <td style="width:1.461%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.627%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.461%;"/>
        <td style="width:20.987%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses, federal (post December 31, 2017)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319,266</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Do not expire</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses, federal (pre January 1, 2018)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,587</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2037</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">465,623</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2042</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits, federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,669</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2042</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,160</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA: credits do not expire<br/>MA: 2035 - 2042</span></span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as defined under IRC Sections 382 and 383. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. Subsequent ownership</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may further affect the limitation in future years. In connection with the Company&#8217;s IPO, which closed in October 2018, the Company did experience an ownership change pursuant to Section 382. There was no reduction in federal or California net operating loss carryforwards or research and development income tax credits as a result of this ownership change. The Company is in the process of completing an analysis through December 31, 2022 under IRC Sections 382 and 383 to determine if the Company&#8217;s net operating loss carryforwards and research and development credits are limited due to a change in ownership and may have an ownership change pursuant to Section 382.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.281%;"/>
        <td style="width:1.162%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.593%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.162%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.593%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.162%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.048%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning of year&#8212;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,610</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decrease for tax positions taken during prior periods</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases for tax positions taken during current period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,234</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">End of year&#8212;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,715</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If recognized, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">none</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the unrecognized tax benefits as of December 31, 2022, 2021, and 2020 would impact the annual effective tax rate, primarily due to corresponding adjustments to the valuation allowance. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next twelve (12) months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022, 2021, and 2020, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize accrued interest and penalties related to unrecognized tax benefits.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is not currently under audit by the Internal Revenue Service or other similar state or local authorities. Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States and various state tax jurisdictions in which the Company files tax returns.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995526128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.	Net Loss Per Common Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.807%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.058000000000002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.707%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.902%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,687</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,082</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105,314</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,918,333</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,885,186</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,792,365</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.32</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, the Company issued and sold Warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,480,719</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a nominal exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and in October 2022 the Company issued and sold Warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,274,923</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a nominal exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (see Note 10). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,442,567</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants were exercised, resulting in the Company issuing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,442,567</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,459,576</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants exercised and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,872</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants cancelled due to net exercise of the warrants. As of December 31, 2022 and 2021, there are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,848,627</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,016,271</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants outstanding, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares of common stock into which the Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and they are immediately exercisable upon their issuance date.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During a period of net loss, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential common shares outstanding would have been anti-dilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.932%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.433%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.433%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.141%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding and ESPP shares issuable and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,145,817</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,170,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,213,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">561,526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">708,800</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,707,343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,879,131</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,213,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433997219248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.	Defined Contribution Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company began sponsoring a 401(k) Plan in 2017, which provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the first </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of each employee&#8217;s contribution. During the years ended December 31, 2022 and 2021, expenses recognized for the 401(k) Plan was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, while the amount was immaterial for the year ended December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433997889360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities and Exchange Commission (the &#8220;SEC&#8221;) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for reporting. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and transaction price and progress toward completion of performance obligation under the contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></p><p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:</span></p><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.</span></div></div><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</span></div></div><div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within short-term restricted cash and deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#8217;s restricted cash includes payments received under the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) Funding Agreement, dated as of August 14, 2021 (the &#8220;CEPI Funding Agreement&#8221;) and the Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and short-term and long-term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.953%;"/>
          <td style="width:1.557%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.267%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.557%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.665%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,498</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93,287</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,977</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,285</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,290</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,005</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,765</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,577</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#8217;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> recognition of any other-than-temporary impairment in the year ended December 31, 2022, 2021 or 2020. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2022 or 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Debt Discounts</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of the Compan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">y&#8217;s debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2022, the Company has no off-balance sheet concentrations of credit risk.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_OtherRisksAndUncertaintiesPolicyTextBlock', window );">Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. Further, the Company is subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.315%;"/>
          <td style="width:1.583%;"/>
          <td style="width:31.102%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2022, 2021, or 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#8217;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#8220;ASC 606&#8221;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#8211; Revenue Recognition (&#8220;ASC 958-605&#8221;), which applies to business entities that receive contributions within the scope of ASC 958-605.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#8217;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement and the Gates Grant Agreement (see Note 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#8220;the Black-Scholes model&#8221;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation (based on the mid-point between the vesting date and the end of the contractual term) of the expected term for its stock options as the Company has concluded that its stock option history does not provide a reasonable basis upon which to estimate expected term. Volatility is based on an average of the historical volatilities of the common stock of entities with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">characteristics </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">similar to the Company&#8217;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#8217;s technologies are recorded as research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#8217;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#8217;s consolidated balance sheets at December 31, 2022 and 2021. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes lease expense on a straight-line basis over the expected lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes and measures uncertain tax positions using a two&#8212;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#8217;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2022, the Company had not accrued interest or penalties related to uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2020, the Families First Coronavirus Response Act (the &#8220;FFCR Act&#8221;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 29, 2020, Assembly Bill 85 (&#8220;A.B. 85&#8221;) was signed into California law. A.B. 85 provides for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> suspension of the use of net operating losses for medium and large businesses and a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cap on the use of business incentive tax credits to offset no more than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for taxable years 2020 and 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#8217;s consolidated financial statements as of December 31, 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#8217;s marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the FASB issued ASU No. 2020-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Codification Improvements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASU 2020-10&#8221;). The standard contains improvements to the FASB Accounting Standards Codification (the &#8220;Codification&#8221;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. We adopted ASU 2020-10 on January 1, 2022 and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt - Debt with Conversion and Other Options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Subtopic 470-20) and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASU 2020-06&#8221;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company does not expect the adoption of ASU 2020-06 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to have a material impact on its consolidated financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433992815088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and short-term and long-term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.953%;"/>
          <td style="width:1.557%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.267%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.557%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.665%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,498</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93,287</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,977</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,285</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,290</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,005</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,765</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,577</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock', window );">Estimated Useful Lives of Assets</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.315%;"/>
          <td style="width:1.583%;"/>
          <td style="width:31.102%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation calculated using straight Line method over estimated useful Lives of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995329840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.0%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.682%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.804%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">948</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,318</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,853</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,608</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,540</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,703</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,464</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,389</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">933</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,103</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,099</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,611</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.0%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.682%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.804%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,990</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,976</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,277</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,269</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,565</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,557</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,346</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,986</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,348</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,275</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998110352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.422%;"/>
        <td style="width:1.174%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.777000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,191</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,853</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,853</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,540</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,540</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,389</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,540</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,849</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,099</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,099</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,099</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,611</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,830</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,781</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.422%;"/>
        <td style="width:1.174%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.165%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.777000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,281</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,269</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,269</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,557</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,557</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,346</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,986</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,986</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,986</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,275</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,536</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,739</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995339424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.84%;"/>
        <td style="width:1.517%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.456%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.517%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.669%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,155</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,285</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,113</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,309</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,128</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,773</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,907</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,782</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,276</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,344</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,991</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,335</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,622</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433997126576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Costs</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.468%;"/>
        <td style="width:1.348%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.029%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.348%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.029%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.348%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.429%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,973</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,973</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,518</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Information Related to Leases</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental information related to leases was as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.61%;"/>
        <td style="width:1.327%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.327%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.327%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.464%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,915</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,389</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New right-of-use assets obtained in exchange for lease obligations (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,959</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,562</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,174</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.10</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.30</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.10</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum Annual Payments Under Lease Agreements</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, minimum annual payments under the Company&#8217;s lease agreements are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.882%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.038999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Financing<br/>Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,604</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,527</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104,979</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing lease payments under Boston lease</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,113</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,967</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Current portion of lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,294</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999265504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bluebird bio to 2seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue Balance</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the deferred revenue balance during the year ended December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.929%;"/>
        <td style="width:1.757%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.558%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.757%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember', window );">Grant Agreement [Member] | Gates Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue Balance</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the Grant Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.308%;"/>
        <td style="width:1.877%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.815%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember', window );">Gilead [Member] | Collaboration, Option and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue Balance</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the contract asset and short-term deferred revenue, balance during the year ended December 31, 2022 for the Gilead Collaboration Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.079%;"/>
        <td style="width:1.496%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.963999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.496%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.963999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract Asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,385</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,508</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=grts_CepInnovationsMember', window );">CEPI [Member] | Funding Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue Balance</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the CEPI Funding Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,698</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,952</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_CepInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_CepInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993604000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long term debt balance</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.299%;"/>
        <td style="width:1.874%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.828%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal loan balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Final fee</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,150</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount and issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long term debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,349</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of estimated future principal payments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.991%;"/>
        <td style="width:2.083%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.926%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,407</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,197</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total principal payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433992221360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.953%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.267%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.665%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,241</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,672</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net contract asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,385</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,158</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,769</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">529</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">292</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities-related deposits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">567</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">866</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,672</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Deposits and Other Long-Term Assets</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits and other long-term assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.953%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.267%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.665%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease security deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">643</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,162</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deposits and other long-term assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,739</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,352</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433995424544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the following warrants to purchase shares of the Company&#8217;s common stock were issued and outstanding:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.773%;"/>
        <td style="width:1.467%;"/>
        <td style="width:27.95%;"/>
        <td style="width:1.467%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.704%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.639%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issue Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Warrants Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 28, 2020</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,573,704</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 24, 2022</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,274,923</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,848,627</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433996712768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used for Estimating the Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.996%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.738%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.728%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.547%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.57</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.48</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.791%;"/>
        <td style="width:1.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.392%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.392%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.232%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.98</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the 2018 Plan and 2021 Plan activity is as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.38%;"/>
        <td style="width:0.108%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.776%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.065%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.991%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.065%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.683%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.119%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.302%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.514%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares<br/>Available<br/>for<br/>Issuance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number<br/>of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate    <br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,459,187</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,107,335</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.82</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.13</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,461,915</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,518,734</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,168,561</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.73</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,347</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.96</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,412,026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,129,929</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.73</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,814,394</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,951,620</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,089</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable &#8211; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,122,952</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.16</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">409</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest &#8211; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,421,425</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.04</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.00</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">995</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our restricted stock unit activity during the year ended December 31, 2022:</span><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.001%;"/>
        <td style="width:1.104%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.636%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.555%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.703000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, unvested as December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">708,800</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">350,173</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.46</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353,300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canceled/Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144,147</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.35</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, unvested as December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">561,526</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation for all awards granted to employees, consultants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018 ESPP, before taxes, is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.361%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.610999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.610999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.011%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,730</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,827</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,926</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,657</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,552</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,110</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998216960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Tax Rate</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective tax rate of the Company&#8217;s provision for income taxes differs from the federal statutory rate as follows:</span><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.715%;"/>
        <td style="width:0.999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.098%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.098%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.089%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in state tax apportionment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-taxable stock premium</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Net Deferred Tax Assets/Liabilities</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the net deferred tax assets/liabilities are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.822%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.437999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.632%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,575</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,684</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,437</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,537</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">449</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 Capitalized Expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165,905</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,884</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,877</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">212</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net of allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock', window );">Schedule of Net Operating Loss and Tax Credit Carryforwards</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss and tax credit carryforwards as of December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.464%;"/>
        <td style="width:1.461%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.627%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.461%;"/>
        <td style="width:20.987%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses, federal (post December 31, 2017)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319,266</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Do not expire</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses, federal (pre January 1, 2018)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,587</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2037</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">465,623</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2042</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits, federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,669</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035 - 2042</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,160</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA: credits do not expire<br/>MA: 2035 - 2042</span></span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.281%;"/>
        <td style="width:1.162%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.593%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.162%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.593%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.162%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.048%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning of year&#8212;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,610</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decrease for tax positions taken during prior periods</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases for tax positions taken during current period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,234</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">End of year&#8212;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,715</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of net operating loss and tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140434000125712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.807%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.058000000000002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.707%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.902%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,687</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,082</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105,314</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,918,333</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,885,186</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,792,365</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.32</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Potentially Anti-Dilutive Securities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.932%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.433%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.433%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.141%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding and ESPP shares issuable and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,145,817</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,170,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,213,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">561,526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">708,800</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,707,343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,879,131</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,213,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999617392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="nump">$ 119,687<span></span>
</td>
<td class="nump">$ 75,082<span></span>
</td>
<td class="nump">$ 105,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">115,946<span></span>
</td>
<td class="nump">50,678<span></span>
</td>
<td class="nump">$ 89,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">521,071<span></span>
</td>
<td class="nump">$ 401,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashCashEquivalentsAndMarketableSecurities', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 175,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993045136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Marketable securities recognition of other-than-temporary impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement', window );">Percentage of realization of tax benefit upon ultimate settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness', window );">Use of net operating losses suspension period for medium and large business</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_UseOfBusinessIncentiveTaxCreditsPeriodCap', window );">Use of business incentive tax credits period cap</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember', window );">Taxable Years 2020 and 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended', window );">Minimum amount of taxable income where use of net operating losses is suspended</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember', window );">Taxable Years 2020 and 2021 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of taxable income where use of net operating losses is suspended.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of realization of tax benefit upon ultimate settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_UseOfBusinessIncentiveTaxCreditsPeriodCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Use of business incentive tax credits period cap.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_UseOfBusinessIncentiveTaxCreditsPeriodCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Use of net operating losses suspension period for medium and large business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998046208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,498<span></span>
</td>
<td class="nump">$ 93,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3,977<span></span>
</td>
<td class="nump">11,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">5,290<span></span>
</td>
<td class="nump">6,005<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 64,765<span></span>
</td>
<td class="nump">$ 110,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999272544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, and equipment, estimated useful lives</a></td>
<td class="text">Shorter of useful life or lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993536464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">$ 55,498<span></span>
</td>
<td class="nump">$ 93,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">158,691<span></span>
</td>
<td class="nump">194,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">158,611<span></span>
</td>
<td class="nump">194,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">38,191<span></span>
</td>
<td class="nump">81,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedGains', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedLosses', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">38,191<span></span>
</td>
<td class="nump">81,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">38,191<span></span>
</td>
<td class="nump">79,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedGains', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedLosses', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">38,191<span></span>
</td>
<td class="nump">79,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedGains', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedLosses', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedGains', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedLosses', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">116,464<span></span>
</td>
<td class="nump">108,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">116,389<span></span>
</td>
<td class="nump">108,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">35,608<span></span>
</td>
<td class="nump">12,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">35,540<span></span>
</td>
<td class="nump">12,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">33,318<span></span>
</td>
<td class="nump">44,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">33,328<span></span>
</td>
<td class="nump">44,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">21,887<span></span>
</td>
<td class="nump">26,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">21,853<span></span>
</td>
<td class="nump">26,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">948<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | U.S. Government Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">24,703<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">24,719<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,036<span></span>
</td>
<td class="nump">4,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">4,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,103<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 932<span></span>
</td>
<td class="nump">$ 1,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashAndCashEquivalentsUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents, unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashAndCashEquivalentsUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashAndCashEquivalentsUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashAndCashEquivalentsUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433996668880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashAndCashEquivalentsAndMarketableSecurities', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 175,900<span></span>
</td>
<td class="nump">$ 206,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">55,498<span></span>
</td>
<td class="nump">93,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 120,400<span></span>
</td>
<td class="nump">113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of individual securities in an unrealized loss position for 12 months or greater | Security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Marketable securities recognition of other-than-temporary impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MarketableSecuritiesRealizedGainLossDescription', window );">Realized gains or losses on marketable securities, description</a></td>
<td class="text">no material realized gains or losses<span></span>
</td>
<td class="text">no material realized gains or losses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MarketableSecuritiesContractualMaturitiesPeriod', window );">Marketable securities contractual maturities period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashAndCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashAndCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MarketableSecuritiesContractualMaturitiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities contractual maturities period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MarketableSecuritiesContractualMaturitiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MarketableSecuritiesRealizedGainLossDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities realized gain loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MarketableSecuritiesRealizedGainLossDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433988118608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">$ 158,611<span></span>
</td>
<td class="nump">$ 194,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">38,191<span></span>
</td>
<td class="nump">81,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">38,191<span></span>
</td>
<td class="nump">79,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">116,389<span></span>
</td>
<td class="nump">108,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">35,540<span></span>
</td>
<td class="nump">12,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">33,328<span></span>
</td>
<td class="nump">44,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">21,853<span></span>
</td>
<td class="nump">26,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">24,719<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">4,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">76,830<span></span>
</td>
<td class="nump">94,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">38,191<span></span>
</td>
<td class="nump">79,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">38,191<span></span>
</td>
<td class="nump">79,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">35,540<span></span>
</td>
<td class="nump">12,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">35,540<span></span>
</td>
<td class="nump">12,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">81,781<span></span>
</td>
<td class="nump">99,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">80,849<span></span>
</td>
<td class="nump">96,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">33,328<span></span>
</td>
<td class="nump">44,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">21,853<span></span>
</td>
<td class="nump">26,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">24,719<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998134160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_FairValueMeasurementLevel1ToLevel2Transfers', window );">Fair Value Measurement Level 1 to Level 2 Transfers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FairValueMeasurementLevel1ToLevel2Transfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement level 1 to level 2 transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FairValueMeasurementLevel1ToLevel2Transfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993038288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 48,773<span></span>
</td>
<td class="nump">$ 41,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(28,782)<span></span>
</td>
<td class="num">(22,276)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">21,335<span></span>
</td>
<td class="nump">21,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,285<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">27,309<span></span>
</td>
<td class="nump">24,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,024<span></span>
</td>
<td class="nump">14,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="nump">$ 1,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433992864224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 6,560<span></span>
</td>
<td class="nump">$ 6,347<span></span>
</td>
<td class="nump">$ 6,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433988628928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>RenewalTerm</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th">
<div>Feb. 28, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,481<span></span>
</td>
<td class="nump">$ 22,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Storage space commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,403<span></span>
</td>
<td class="nump">97,490<span></span>
</td>
<td class="nump">$ 88,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Operating lease cash security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_EmeryvilleCaliforniaMember', window );">Emeryville California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leasing renewal option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms', window );">Operating leases number of renewal terms | RenewalTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Operating lease cash security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_PleasantonMember', window );">Pleasanton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leasing renewal option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Net rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AmountOfIrrevocableLettersOfCreditWithdrawn', window );">Withdrawal from irrevocable letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_PleasantonMember', window );">Pleasanton [Member] | Additional Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">64 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember', window );">Cambridge Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Operating lease cash security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember', window );">Cambridge Massachusetts [Member] | Warehouse Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember', window );">Cambridge Massachusetts [Member] | Prepaid Expenses And Other Current Assets Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Operating lease cash security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember', window );">Cambridge Massachusetts [Member] | Other Noncurrent Assets Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Operating lease cash security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember', window );">Cambridge Massachusetts [Member] | 21 Erie Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear', window );">Operating lease termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember', window );">Cambridge Massachusetts [Member] | 40 Erie Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">67 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear', window );">Operating lease termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_BostonLeaseMember', window );">Boston Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leasing renewal option to extend lease</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms', window );">Operating leases number of renewal terms | Segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AmountOfIrrevocableLettersOfCreditWithdrawn', window );">Withdrawal from irrevocable letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit', window );">Restricted cash deposit used as collateral for letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MinimumLeasePayments', window );">Minimum Lease Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_BostonLeaseMember', window );">Boston Lease [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AmountOfIrrevocableLettersOfCreditWithdrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of irrevocable letters of credit withdrawn.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AmountOfIrrevocableLettersOfCreditWithdrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements operating leases additional number of renewal terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements operating leases term of contract month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Lease Payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash deposit used as collateral for letter of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperationsCommencedDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the operations of the entity commenced, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperationsCommencedDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=grts_EmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=grts_EmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=grts_PleasantonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=grts_PleasantonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=grts_AdditionalOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=grts_AdditionalOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_WarehouseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_WarehouseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=grts_TwentyOneErieLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=grts_TwentyOneErieLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=grts_FourtyErieLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=grts_FourtyErieLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=grts_BostonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=grts_BostonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433996677136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Components of Lease Costs (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 8,797<span></span>
</td>
<td class="nump">$ 7,973<span></span>
</td>
<td class="nump">$ 7,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 8,797<span></span>
</td>
<td class="nump">$ 7,973<span></span>
</td>
<td class="nump">$ 7,518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998039552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 8,915<span></span>
</td>
<td class="nump">$ 7,925<span></span>
</td>
<td class="nump">$ 5,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>New right-of-use assets obtained in exchange for lease obligations (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 1,959<span></span>
</td>
<td class="nump">$ 6,562<span></span>
</td>
<td class="nump">$ 3,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WeightedAverageRemainingLeaseTermYearsAbstract', window );"><strong>Weighted average remaining lease term (years):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New right-of-use assets obtained in exchange for lease obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WeightedAverageRemainingLeaseTermYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term (years).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WeightedAverageRemainingLeaseTermYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999630016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 8,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">12,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">10,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">10,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">10,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">52,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments</a></td>
<td class="nump">104,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest expense</a></td>
<td class="num">(4,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_OperatingLeasePaymentUnderTheBostonLease', window );">Less: Amounts representing lease payments under the Boston Lease</a></td>
<td class="num">(79,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">20,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of lease liability</a></td>
<td class="num">(5,294)<span></span>
</td>
<td class="num">$ (7,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent portion of lease liability</a></td>
<td class="nump">$ 15,673<span></span>
</td>
<td class="nump">$ 18,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OperatingLeasePaymentUnderTheBostonLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease payment under the boston lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OperatingLeasePaymentUnderTheBostonLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433979798304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Aug. 14, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,131,000<span></span>
</td>
<td class="nump">$ 17,201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non- current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,894,901<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,403,000<span></span>
</td>
<td class="nump">$ 97,490,000<span></span>
</td>
<td class="nump">$ 88,643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,977,000<span></span>
</td>
<td class="nump">11,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,290,000<span></span>
</td>
<td class="nump">6,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,198,000)<span></span>
</td>
<td class="nump">8,633,000<span></span>
</td>
<td class="num">(2,821,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Decrease in loss from operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,428,000)<span></span>
</td>
<td class="num">(75,209,000)<span></span>
</td>
<td class="num">(106,017,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,945,000<span></span>
</td>
<td class="nump">48,214,000<span></span>
</td>
<td class="nump">4,037,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit Outstanding, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember', window );">Coalition for Epidemic Preparedness Innovation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Collaboration and license revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,269,000<span></span>
</td>
<td class="nump">46,717,000<span></span>
</td>
<td class="nump">3,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=grts_SeventyMember', window );">2 Seventy [Member] | Series C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bluebird Bio Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MaximumPotentialMilestoneReceivable', window );">Maximum development, regulatory, and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CollaborationAgreementEarlyTerminationNoticePeriod', window );">Collaboration agreement early termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments', window );">Early termination reduction of future milestone and royalty payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additionally, all of 2seventy&#8217;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bluebird Bio Inc [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bluebird Bio Inc [Member] | Series C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bluebird bio to 2seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ProceedsFromNonRefundableUpfrontPayment', window );">Proceeds from non refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_RevenueRecognitionContractStartMonthYear', window );">Revenue recognition contract start month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ReceivablesGross', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MaximumMilestoneConsiderationPayable', window );">Maximum milestone consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense', window );">Milestone payment included in research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | 2 Seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ProceedsFromNonRefundableUpfrontPayment', window );">Proceeds from non refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_RevenueRecognitionContractEndMonthYear', window );">Revenue recognition contract end month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Decrease in loss from operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Decrease in loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | 2 Seventy [Member] | Series C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IssuanceOfConvertiblePreferredStockTransactionPrice', window );">Issuance of convertible preferred stock, Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ProceedsFromNonRefundableUpfrontPayment', window );">Proceeds from non refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CollaborationAgreementEarlyTerminationNoticePeriod', window );">Collaboration agreement early termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments', window );">Early termination reduction of future milestone and royalty payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#8217;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#8217;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_RevenueRecognitionContractStartMonthYear', window );">Revenue recognition contract start month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ReceivablesGross', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommonStockFairValueClosingPricePerShare', window );">Common stock fair value closing price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_NonRefundableOptionFee', window );">Non-refundable option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MaximumAggregateContingentMilestonePayment', window );">Maximum aggregate contingent milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CollaborationAgreementTerminationTerm', window );">Collaboration agreement termination term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and may terminate any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue', window );">Transaction price allocated to shares of common stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CommonStockPurchasePriceInExcessOfFairValue1', window );">Common stock purchase price in excess of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Deferred incremental costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Maximum [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_RevenueRecognitionContractEndPeriod', window );">Revenue recognition contract end period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Minimum [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_RevenueRecognitionContractEndPeriod', window );">Revenue recognition contract end period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Collaboration and license revenues [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Collaboration Revenue [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember', window );">Option and License and Development Agreement [Member] | Common Stock [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember', window );">Option and License and Development Agreement [Member] | Genevant Sciences GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AgreedUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AmountToExtendOptionTerm', window );">Amount to extend the option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember', window );">Option and License and Development Agreement [Member] | Genevant Sciences GmbH [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AgreedUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember', window );">Option and License and Development Agreement [Member] | Genevant Sciences GmbH [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone', window );">Aggregate payment in specified development regulatory and commercial milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PaymentsForOptionsToLicenseForEachIndication', window );">Payments for options to license for each indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_NonExclusiveLicenseAndDevelopmentAgreementMember', window );">Non-Exclusive License and Development Agreement [Member] | Genevant Sciences GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MaximumAggregateContingentMilestonePayment', window );">Maximum aggregate contingent milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_NonExclusiveLicenseAndDevelopmentAgreementMember', window );">Non-Exclusive License and Development Agreement [Member] | Genevant Sciences GmbH [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember', window );">C E P I Funding Agreement [Member] | Coalition for Epidemic Preparedness Innovation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_FirstTrancheOfFundingsReceived', window );">First tranche of funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AdditionalFunding', window );">Additional funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_TotalGrantAmount', window );">Total grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_AmendedTotalGrantAmount', window );">Amended total grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_SecondTrancheOfFundingReceived', window );">Second tranche of fundings received</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember', window );">Grant Agreement [Member] | Gates Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ProceedsFromNonRefundableUpfrontPayment', window );">Proceeds from non refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025,000<span></span>
</td>
<td class="nump">2,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non- current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_FutureFundingExpected', window );">Future funding expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Short-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_TotalGrantAmount', window );">Total grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AdditionalFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional funding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AdditionalFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate payment in specified development regulatory and commercial milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AgreedUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AgreedUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AmendedTotalGrantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amended Total Grant Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AmendedTotalGrantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AmountToExtendOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to extend option term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AmountToExtendOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CollaborationAgreementEarlyTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement early termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CollaborationAgreementEarlyTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CollaborationAgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement termination term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CollaborationAgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CommonStockFairValueClosingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock fair value closing price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CommonStockFairValueClosingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CommonStockPurchasePriceInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Purchase Price In Excess Of Fair Value1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CommonStockPurchasePriceInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability revenue recognized including new contracts in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early termination reduction of future milestone and royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FirstTrancheOfFundingsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First Tranche of Fundings Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FirstTrancheOfFundingsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FutureFundingExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funding expected in future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FutureFundingExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IssuanceOfConvertiblePreferredStockTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible preferred stock, Transaction price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IssuanceOfConvertiblePreferredStockTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumAggregateContingentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate contingent milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumAggregateContingentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumMilestoneConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum consideration to be paid in the future based on milestones per the License Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumMilestoneConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumPotentialMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable consideration relating to future milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumPotentialMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NonRefundableOptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable option fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NonRefundableOptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PaymentsForOptionsToLicenseForEachIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for options to license for each indication.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PaymentsForOptionsToLicenseForEachIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromNonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from non refundable upfront payment included in transaction price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromNonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ReceivablesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ReceivablesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RevenueRecognitionContractEndMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition contract end year-month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RevenueRecognitionContractEndMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RevenueRecognitionContractEndPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition contract end period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RevenueRecognitionContractEndPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RevenueRecognitionContractStartMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition contract start year-month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RevenueRecognitionContractStartMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_SecondTrancheOfFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Second tranche of funding received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_SecondTrancheOfFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_TotalGrantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Grant Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_TotalGrantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction price allocated to shares of common stock at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_SeventyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_SeventyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_BluebirdBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_BluebirdBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=grts_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=grts_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_GenevantSciencesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_GenevantSciencesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_NonExclusiveLicenseAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_NonExclusiveLicenseAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433997968320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_ResearchCollaborationAndLicenseAgreementMember', window );">Research Collaboration and License Agreement [Member] | Bluebird bio to 2seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">$ 8,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(7,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2022</a></td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2022</a></td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2021</a></td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerAssetAddition', window );">Additions</a></td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerAssetDeduction', window );">Deductions</a></td>
<td class="num">(1,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember', window );">C E P I Funding Agreement [Member] | CEPI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">9,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2022</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember', window );">Funding Agreement [Member] | CEPI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">9,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="nump">2,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(9,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2022</a></td>
<td class="nump">2,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember', window );">Grant Agreement [Member] | Gates Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 1,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerAssetAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset addition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerAssetAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerAssetDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset deduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerAssetDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerLiabilityAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability addition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerLiabilityAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993726464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized issuance costs and debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,801,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Initial amount of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description Of Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Borrowings under the Loan Agreement bear interest (i) at an annual cash rate equal to the greater of (x) the lesser of (1) the prime rate (as customarily defined) and (2) 5.50%, in either case, plus 3.15%, and (y) 7.15% and (ii) at an annual payment-in-kind rate which may equal 2.00%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Prime rate percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument, facility charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_FacilityChargePercentageOfBorrowing', window );">Facility Charge Percentage of Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized issuance costs and debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_FinalPaymentFeePercentage', window );">Final payment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PrepaymentPremiumRate', window );">Prepayment premium rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PrepaymentPremiumRate', window );">Prepayment premium rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Maximum [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationLongtermDebtAndEquity', window );">Market capitalization</a></td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Loan Origination Commitments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Prime rate percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument , interest percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Loan Origination Commitments [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MinimumLiquidityRequirementCapitalDescription', window );">Minimum Liquidity Requirement Capital Description</a></td>
<td class="text">the Company is subject to a minimum liquidity requirement equal to the then outstanding balance under the Loan Agreement multiplied by 0.55 or 0.45, which multiplier depends on whether the Company achieves certain performance milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Loan Origination Commitments [Member] | Prime Rate Plus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument , interest percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Loan Origination Commitments [Member] | Payment-in-kind rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument , interest percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Initial amount of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Tranche One Additional [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Initial amount of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember', window );">Loan Agreement [Member] | Remaining Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Initial amount of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FacilityChargePercentageOfBorrowing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility Charge Percentage of Borrowing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FacilityChargePercentageOfBorrowing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final payment fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MinimumLiquidityRequirementCapitalDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Liquidity Requirement Capital Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MinimumLiquidityRequirementCapitalDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PrepaymentPremiumRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment premium rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PrepaymentPremiumRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationLongtermDebtAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the total consolidated (as applicable) capitalization of the entity which is comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationLongtermDebtAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_LoanOriginationCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_LoanOriginationCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=grts_PrimeRatePlusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=grts_PrimeRatePlusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=grts_PaymentInKindRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=grts_PaymentInKindRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=grts_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=grts_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=grts_TrancheOneAdditionalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=grts_TrancheOneAdditionalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=grts_RemainingTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=grts_RemainingTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433992718112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long term debt balance (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal loan balance</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_FinalFee', window );">Final Fee</a></td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized issuance costs and debt discounts</a></td>
<td class="num">(1,801)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt, Total</a></td>
<td class="nump">$ 19,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FinalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FinalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998044512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of estimated future principal payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths', window );">2023</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree', window );">2025</a></td>
<td class="nump">4,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour', window );">2026</a></td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive', window );">2027</a></td>
<td class="nump">6,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal payments</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999289360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PrepaidExpenseForResearchAndDevelopment', window );">Prepaid research and development-related expenses</a></td>
<td class="nump">$ 4,241<span></span>
</td>
<td class="nump">$ 2,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_NetContractAsset', window );">Net contract asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CollaborationReceivable', window );">Collaboration receivable</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_InterestAndOtherReceivablesCurrent', window );">Interest and other receivables</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_FacilitiesRelatedDeposits', window );">Facilities-related deposits</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 7,014<span></span>
</td>
<td class="nump">$ 7,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FacilitiesRelatedDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facilities-related deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FacilitiesRelatedDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_InterestAndOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and other receivables current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_InterestAndOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NetContractAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net contract asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NetContractAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PrepaidExpenseForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PrepaidExpenseForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993610944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Deposit Assets And Other Assets Noncurrent Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Lease security deposits</a></td>
<td class="nump">$ 934<span></span>
</td>
<td class="nump">$ 1,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent', window );">Prepaid research and development-related expenses</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="nump">8,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DepositsAndOtherAssetsNoncurrent', window );">Total deposits and other long-term assets</a></td>
<td class="nump">$ 9,739<span></span>
</td>
<td class="nump">$ 2,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit assets and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent Deposits And Other Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period exceeding one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433987498672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,894,901<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,894,901<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of the Company&#8217;s common stock are entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MaximumSecuritiesCoveredUnderRegistrationAgreement', window );">Common stock, preferred stock, debt securities, warrants and units covered in Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,704,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WarrantsCancelled', window );">Warrants cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442,567<span></span>
</td>
<td class="nump">10,459,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AmendedAndRestatedCertificateOfIncorporationMember', window );">Amended and Restated Certificate of Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember', window );">ATM Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,737,000<span></span>
</td>
<td class="nump">$ 36,719,000<span></span>
</td>
<td class="nump">$ 9,770,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember', window );">ATM Equity Offering Program [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtmEquityOfferingProgramMember', window );">2022 ATM Equity Offering Program [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember', window );">Private Investment in Public Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,637,165<span></span>
</td>
<td class="nump">6,637,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WarrantsToPurchaseSharesOfCommonStock', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">13,274,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember', window );">2019 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,990,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PercentageOfProceedsPayableAsCompensationToUnderwriter', window );">Percentage of gross proceeds as underwriter compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MaximumOfferingExpensesAgreedToBeReimbursed', window );">Maximum offering expense agreed to be reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember', window );">2022 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,034,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_PercentageOfProceedsPayableAsCompensationToUnderwriter', window );">Percentage of gross proceeds as underwriter compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MaximumOfferingExpensesAgreedToBeReimbursed', window );">Maximum offering expense agreed to be reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember', window );">2022 ATM Program | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IssuanceOfCommonStockForWarrantExercisesShare', window );">Issuance of common stock for warrant exercises, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442,567<span></span>
</td>
<td class="nump">10,459,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,034,948<span></span>
</td>
<td class="nump">3,990,869<span></span>
</td>
<td class="nump">1,160,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Investment in Public Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,637,165<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">9,586,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember', window );">Common Stock and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember', window );">Common Stock and Warrants [Member] | Private Investment in Public Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants', window );">Proceed from issuance of stock and pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="nump">2.26<span></span>
</td>
<td class="nump">2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_SaleOfStockPricePerSharePrepaidByPurchaser', window );">Offering price per share, prepaid by purchaser</a></td>
<td class="nump">$ 2.2599<span></span>
</td>
<td class="nump">$ 2.2599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WarrantsToPurchaseSharesOfCommonStock', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,274,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,480,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant', window );">Maximum percentage of common stock ownership to exercise warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember', window );">Common Stock and Warrants [Member] | Private Investment in Public Equity [Member] | Additional Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,043,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right warrants exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IssuanceOfCommonStockForWarrantExercisesShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for warrant exercises, Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IssuanceOfCommonStockForWarrantExercisesShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumOfferingExpensesAgreedToBeReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum offering expenses agreed to be reimbursed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumOfferingExpensesAgreedToBeReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock ownership to exercise warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumSecuritiesCoveredUnderRegistrationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum securities covered under registration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumSecuritiesCoveredUnderRegistrationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PercentageOfProceedsPayableAsCompensationToUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of proceeds payable as compensation to underwriter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PercentageOfProceedsPayableAsCompensationToUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_SaleOfStockPricePerSharePrepaidByPurchaser">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Price Per Share, Prepaid by Purchaser</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_SaleOfStockPricePerSharePrepaidByPurchaser</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AmendedAndRestatedCertificateOfIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AmendedAndRestatedCertificateOfIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtmEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AtmEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=grts_AdditionalSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=grts_AdditionalSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433988561696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">26,848,627<span></span>
</td>
<td class="nump">17,016,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockWarrantsOneMember', window );">Common Stock Warrants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightIssueDate', window );">Issue Date</a></td>
<td class="text">Dec. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightsExpiration', window );">Expiration Date</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">13,573,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockWarrantsTwoMember', window );">Common Stock Warrants Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightIssueDate', window );">Issue Date</a></td>
<td class="text">Oct. 24,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightsExpiration', window );">Expiration Date</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">13,274,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightIssueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, issue date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightIssueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightsExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightsExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=grts_CommonStockWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockWarrantsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=grts_CommonStockWarrantsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433987505168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,814,394<span></span>
</td>
<td class="nump">3,459,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value granted employee stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="nump">$ 8.03<span></span>
</td>
<td class="nump">$ 5.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees', window );">Stock-based compensation expense and awards granted to non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock option awards exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived', window );">cash received upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total cost related to non-vested employee and consultant options expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total cost related to non-vested employee and consultant options unrecognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Number of Shares increase under plan</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit Awards under 2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based compensation by shared based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to 10 years and generally vest over a 1 or 2-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Restricted Stock Unit Awards under 2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option granted expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Restricted Stock Unit Awards under 2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Award Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncreaseInSharesAvailableForIssuancePercentage', window );">Increase in shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MinimumPercentageOfOutstandingSharesHeldByIndividual', window );">Minimum percentage of outstanding shares held by individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_MinimumPercentageFairMarketValueOfSharePrice', window );">Minimum percentage fair market value of share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based compensation by shared based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If an individual owns stock representing 10% or more of the outstanding shares, the price of each share shall be at least 110% of the fair market value, as determined by the board of directors. Options granted have a term of up to 10 years and generally vest over a 4-year period with a straight-line vesting.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Award Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option granted expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncreaseInSharesAvailableForIssuancePercentage', window );">Increase in shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contribution of employee's eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember', window );">2021 Employment Inducement Incentive Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseInSharesAvailableForIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in shares available for issuance percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseInSharesAvailableForIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MinimumPercentageFairMarketValueOfSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage fair market value of share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MinimumPercentageFairMarketValueOfSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MinimumPercentageOfOutstandingSharesHeldByIndividual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of outstanding shares held by individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MinimumPercentageOfOutstandingSharesHeldByIndividual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award options cash received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense and awards granted to non-employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433996968416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail) - 2018 Employee Stock Purchase Plan [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months 25 days<span></span>
</td>
<td class="text">5 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">94.90%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999296288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail) - Employee or Director [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.90%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=grts_EmployeeOrDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=grts_EmployeeOrDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433987451184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Options Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Number of Shares Available for Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of options beginning balance</a></td>
<td class="nump">3,459,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Authorized</a></td>
<td class="nump">3,461,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted', window );">Granted</a></td>
<td class="num">(3,518,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled', window );">Cancelled</a></td>
<td class="nump">1,412,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of options ending balance</a></td>
<td class="nump">4,814,394<span></span>
</td>
<td class="nump">3,459,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">5,107,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">3,168,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(194,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="num">(1,129,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">6,951,620<span></span>
</td>
<td class="nump">5,107,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options Outstanding, Number of Shares, Vested and exercisable</a></td>
<td class="nump">3,122,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Number of Shares, Vested and expected to vest</a></td>
<td class="nump">6,421,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance</a></td>
<td class="nump">$ 9.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">4.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">8.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance</a></td>
<td class="nump">7.92<span></span>
</td>
<td class="nump">$ 9.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">9.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">$ 8.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Term (in years)</a></td>
<td class="text">8 years 29 days<span></span>
</td>
<td class="text">8 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and exercisable (in years)</a></td>
<td class="text">7 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and expected to vest (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,089<span></span>
</td>
<td class="nump">$ 17,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for issuance cancelled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for issuance granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433997189232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, unvested Beginning balance | shares | shares</a></td>
<td class="nump">708,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued | shares</a></td>
<td class="nump">350,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares | shares</a></td>
<td class="num">(353,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled/Forfeited | shares | shares</a></td>
<td class="num">(144,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, unvested ending balance | shares | shares</a></td>
<td class="nump">561,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, unvested beginning balance | $ / shares | $ / shares</a></td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued | $ / shares | $ / shares</a></td>
<td class="nump">5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares | $ / shares</a></td>
<td class="nump">5.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled/Forfeited | $ / shares | $ / shares</a></td>
<td class="nump">5.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, unvested ending balance | $ / shares | $ / shares</a></td>
<td class="nump">$ 5.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433991981600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 12,557<span></span>
</td>
<td class="nump">$ 10,552<span></span>
</td>
<td class="nump">$ 7,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Based Compensation Expense</a></td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">6,626<span></span>
</td>
<td class="nump">4,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 5,827<span></span>
</td>
<td class="nump">$ 3,926<span></span>
</td>
<td class="nump">$ 2,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999304048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in state tax apportionment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_NonTaxableStockPremium', window );">Non-taxable stock premium</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(28.30%)<span></span>
</td>
<td class="num">(33.70%)<span></span>
</td>
<td class="num">(40.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent income tax rate differential.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NonTaxableStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-taxable stock premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NonTaxableStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433999667408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 33,900<span></span>
</td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_OwnershipInterestChangeOverPeriod', window );">Changes in ownership over period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DeferredTaxAssetsCapitalizedExpense', window );">Deferred tax assets, capitalized research expense</a></td>
<td class="nump">$ 21,434<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_CumulativeChangesInOwnershipInterestOfShareholders', window );">Cumulative changes in ownership interest of shareholders</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development | Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 369,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 13,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">2035 - 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 465,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035 - 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_OperatingLossCarryforwardsExpirationYear', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 9,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">CA: credits do not expireMA: 2035 - 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CumulativeChangesInOwnershipInterestOfShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative changes in ownership interest of shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CumulativeChangesInOwnershipInterestOfShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxAssetsCapitalizedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxAssetsCapitalizedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OwnershipInterestChangeOverPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership interest change over period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OwnershipInterestChangeOverPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993491600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 109,191<span></span>
</td>
<td class="nump">$ 97,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research and development tax credits</a></td>
<td class="nump">14,877<span></span>
</td>
<td class="nump">12,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DeferredTaxAssetsLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">6,031<span></span>
</td>
<td class="nump">7,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Accruals and other</a></td>
<td class="nump">3,786<span></span>
</td>
<td class="nump">3,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">9,437<span></span>
</td>
<td class="nump">10,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DeferredTaxAssetsOtherDepreciation', window );">Other depreciation</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DeferredTaxAssetsCapitalizedExpense', window );">Section 174 Capitalized Expense</a></td>
<td class="nump">21,434<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">165,905<span></span>
</td>
<td class="nump">133,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(160,877)<span></span>
</td>
<td class="num">(127,007)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">6,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DeferredTaxLiabilitiesOtherDepreciation', window );">Other depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(5,028)<span></span>
</td>
<td class="num">(6,665)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxAssetsCapitalizedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxAssetsCapitalizedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxAssetsOtherDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Other Depreciation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxAssetsOtherDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease right of uset assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxLiabilitiesOtherDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, other depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxLiabilitiesOtherDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433998103952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 369,900<span></span>
</td>
<td class="nump">$ 319,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 13,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">2035 - 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Post December 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 319,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">Do not expire<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Pre January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 50,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035 - 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 465,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 9,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035 - 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">CA: credits do not expireMA: 2035 - 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=grts_PostDecember312017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=grts_PostDecember312017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=grts_PreJanuary12018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=grts_PreJanuary12018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433996478944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of year&#8212;unrecognized tax benefits</a></td>
<td class="nump">$ 5,481<span></span>
</td>
<td class="nump">$ 4,025<span></span>
</td>
<td class="nump">$ 2,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease for tax positions taken during prior periods</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for tax positions taken during current period</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">1,456<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of year&#8212;unrecognized tax benefits</a></td>
<td class="nump">$ 6,715<span></span>
</td>
<td class="nump">$ 5,481<span></span>
</td>
<td class="nump">$ 4,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433993024160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (119,687)<span></span>
</td>
<td class="num">$ (75,082)<span></span>
</td>
<td class="num">$ (105,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per share, diluted</a></td>
<td class="nump">90,918,333<span></span>
</td>
<td class="nump">78,885,186<span></span>
</td>
<td class="nump">37,792,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per share, basic</a></td>
<td class="nump">90,918,333<span></span>
</td>
<td class="nump">78,885,186<span></span>
</td>
<td class="nump">37,792,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.79)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433979430528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442,567<span></span>
</td>
<td class="nump">10,459,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WarrantsCancelled', window );">Warrants cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,848,627<span></span>
</td>
<td class="nump">17,016,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,894,901<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember', window );">Common Stock and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_CommonStockAndOrPreFundedWarrantsMember', window );">Common Stock and Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights', window );">Class of warrant nominal exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember', window );">Private Investment in Public Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,480,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WarrantExercisePrice', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WarrantsToPurchaseSharesOfCommonStock', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">13,274,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,637,165<span></span>
</td>
<td class="nump">6,637,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember', window );">Private Investment in Public Equity [Member] | Common Stock and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_grts_WarrantsToPurchaseSharesOfCommonStock', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,274,923<span></span>
</td>
<td class="nump">27,480,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right nominal exercise price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right warrants exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_CommonStockAndOrPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_CommonStockAndOrPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433996573152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="nump">7,707,343<span></span>
</td>
<td class="nump">5,879,131<span></span>
</td>
<td class="nump">4,213,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember', window );">Options Issued and Outstanding and ESPP Shares Issuable and Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="nump">7,145,817<span></span>
</td>
<td class="nump">5,170,331<span></span>
</td>
<td class="nump">4,213,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_RestrictedStockSubjectToFutureVestingMember', window );">Restricted Stock Subject to Future Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="nump">561,526<span></span>
</td>
<td class="nump">708,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_RestrictedStockSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_RestrictedStockSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140433992157696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan cost</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer's matching contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>grts-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:grts="http://gritstonebio.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="grts-20221231.xsd" xlink:type="simple"/>
    <context id="C_c0c7b78e-f4bd-4f7d-a7d7-c851651f4d4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_217b0356-637c-4019-9519-2b40884dd4ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_e6f99192-3731-4c3e-b249-3bcfe2f628f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_91453aed-a1da-44b5-bdcd-23b2fbed997d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0f1c0918-b40b-45ce-a32a-5ff2e0cdb811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_12768f52-aae1-4e43-bb4c-1b4a1aca508a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_daff6bb1-ec2f-40fb-b9ff-6c866bc3bfce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_654ac5ed-1cde-4438-bd70-e413cdecd6a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5df76468-2d33-4c29-bdf7-4567b8bbe0be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a51fab37-6bd0-4cae-b9b3-b2a75e0d44b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PreJanuary12018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_278c4452-2cac-4960-b90f-088134dd9e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3bf29e99-103a-4385-809e-4cd89e8893aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0ee0de6e-7969-4192-9194-1f65fcc5fe25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_34bb80f1-a84f-4c93-9bd0-b459e3058b14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_aa58fee8-bbe5-446e-8e6a-a951cc8fb7a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d75caf7-1680-40a2-922d-317eeb129d2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_dd5de76e-097b-41d2-b92d-4e0353e1ee49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_879914fe-a7ae-42c4-9c44-8a86ed39c875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bbe3a914-b528-49c7-8179-6932dd627a2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_3a579eb0-d553-498a-9517-437c3bb7acbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2fb30a1b-bb4d-41a9-b08c-0a5c0e1c4848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0d2325a8-cbfa-43c0-bd17-5934a79b43c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_201d8d2c-c046-4388-b915-a88be0e7cc5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_fd45c0a3-040d-42de-93c8-a06fd1b04f7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a26fbccd-5d77-411c-acc6-ba0395a747d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_525c622a-5ea4-473e-9b25-9d823536fda9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b2a83568-2a86-4097-8ffb-41bc0c489eae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dcee5e27-efd7-4563-b1c8-df33f67e907f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6ac0503d-d066-402e-877d-8f2b3b924843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_73ad74f1-0195-424d-8504-c0dca88a9b7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b01748c1-8a6a-4edc-afb0-0081bb1bd20a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:WarehouseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_b9585647-0f77-46d7-bf67-20e6113a6250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_87523886-5199-4d42-8415-694b2b443fbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8b0ba039-9d60-4e77-8a56-2a70e004643a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fc893192-2b4b-49b4-9a11-52f5e2e37960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4eaebbf5-c3fc-4967-9782-b63169338718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e9a3cb9b-7c28-49b3-ba96-6f4a5a29c371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_97f8a7f4-7c61-4b23-aa03-20ff4c118788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8437c548-599f-4c6f-9584-e7e7d46f0379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_59a0f9dc-319b-473d-b36c-f9544e589028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7252815e-38c6-46dc-8937-24c805d8b308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a246cd21-ac7d-4072-88f9-4cb7c5a9e332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b6ab88c2-0338-4075-8ed9-d7c8fee513c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_087f69e2-ad7d-4b73-9c6f-f855a261808a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5c0e8577-018d-4fd4-82ea-b6e2d68a5f23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_11b7e846-cd77-420b-8752-6e1a1f336a59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c0619058-b76c-4371-b472-a3486c28b486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_351091de-7324-4fdd-81d4-70155fd963f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a00793ff-fd1e-4407-a28f-21d728a53d83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_d761c15a-dc3b-4830-bc90-d5f6864753cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="C_b1d550f9-c0a6-4ff2-941b-a0771a52258d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_80849ef4-0531-4940-958b-b3800e6ec694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6411ac81-f0a4-466a-b658-bc20a1796628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_816d085d-25a0-4fe5-a1f4-76e96db59467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6a755d83-b2d7-4f74-863c-9977b0a91bdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_431f0e99-dc7d-46f0-aaf5-b5f357500cef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_927c9adc-769a-4197-8a7b-ca4f1f62c776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ff2af9fa-a502-476a-95ef-6236ae054f89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_077f94f8-990f-491f-98d1-d6eb5debde18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9adf420e-a107-42cb-a6a6-902bddde7540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a63c1a07-67c9-44ee-9005-5e3efd76ad19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_6f4a9e62-6ab4-4592-9bff-72669d585e09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_eea11142-e7ca-4a35-9c72-576024096190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_33a09371-b9ca-4410-82c3-2bb6c53a0442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ce7937c5-6a07-4c19-a8ee-29f6ffedab38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_41e65ead-4e0c-4591-b0c4-a8797159156c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_127f64ce-6b17-4ad1-9892-5332bca5d957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7c20b544-b6be-4cb6-a697-7fed0ddcd9cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_13677a63-5c18-4b4a-8b7c-a6e88324254f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ce01baa0-2b6b-406d-8ec3-3218ac59d5b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0066c1b6-3f4e-430f-9440-978f78dfa308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e6370a8f-2667-466f-98d3-1e9d3a327fa7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_44dd4f53-eec3-40d8-8778-035eeb8ebe64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c944192d-7243-4e20-9dee-9ed4870b3302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0ea98966-ee3e-4c56-b696-2ba4dc84bd5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_d48b34dc-8de5-4f5a-8b9a-cf67c0c1b3bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_7855eba8-76bc-4a8c-9ce4-0799ef712f67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_09a42735-0d75-4484-89b9-5f969e41a1fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_450aa048-1aac-4500-be64-715518ae710b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e95014f8-6dc9-41f7-ad01-70179a6bc0a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_92745d9d-b5a1-43ae-ae6e-0738b7391092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e6bd0364-0189-46f1-9a87-5b5ae7b4a68b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_78424e0d-5b03-41a3-be95-f77504eeecf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8e40ec53-a7a5-40bf-91a9-94f9b7f15952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_760e896a-f89d-4fe2-ac56-70d954e97475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">grts:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fed14fa7-fd7b-44c6-a3d0-52c8e4029d8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e244d887-8d8a-4495-81bd-72528b63162d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="C_3030c951-2716-4654-8056-6101e373ddea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_f9220959-3f8c-49ee-b09b-88b706eaf9b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_822e2920-cab6-4373-82cb-898c8cc385e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8b84dd47-84c3-4d2b-8c0c-c84ff401d5a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e515ffd5-9be4-4d3e-800d-0e4d6f432f77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_f1213544-8876-4d28-b445-ffd3948fc5c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_95be0954-d2b5-4a76-b208-0a3189bace59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_489a2772-a9a5-4e8f-845d-dfb4142824b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0f8f5e42-0701-4a64-ab34-634cae0498b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_b32eb355-55f1-4a0d-a16e-f7a33883834a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_dfc996c2-5a4e-4564-8277-b7d2ffbeec1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_207cd814-4d37-40e6-b825-ea029fb0acad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="C_64576a2c-bdc6-440d-a223-f398708694c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a08ccbdf-1ba2-463d-8a51-346c12817d18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2152b17d-baee-4d49-a165-456d92d2f320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_55acf221-1e8f-4997-82b2-c1790c656f7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-14</startDate>
            <endDate>2021-08-14</endDate>
        </period>
    </context>
    <context id="C_c7666188-96ff-45eb-8de2-48af6a561ae7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_81ba52a0-a708-443b-b8aa-b7e87669392e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_31827499-df5a-4144-a589-97ec604bab7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_51209003-b3a4-472c-aa6b-ed22f18ab53e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="C_9e8470b2-dcb6-48e3-b5e1-9aa9a258b518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_6fdb3010-aa4d-4332-a56d-c9ff8991e214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6ecd9d54-ec05-4e5b-96c6-c81c04c9fc84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8683aae2-0a3c-46c3-989d-7ac0248bffb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b5151ebd-45f6-4030-99a1-58711cd6e0af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_beafcda9-72de-465a-8212-61152dcebbdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_a8816b30-096f-44ce-9bfe-af5d8d5e416d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ad6f9581-caa1-40a5-b25e-f79138f7937a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">grts:FourtyErieLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-29</endDate>
        </period>
    </context>
    <context id="C_1b36e023-4632-4679-a7c3-29a735d1414a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_466e6120-0e46-457a-95cb-1badad395cad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7e100875-202a-43a8-8544-eea71c373493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d942367c-37c2-422b-a6e8-33a8383c90bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_62816055-7eef-44a2-9784-8d2135365bf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="C_ae943dac-f283-4812-963a-4a9313be83f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2022-04-21</startDate>
            <endDate>2022-04-21</endDate>
        </period>
    </context>
    <context id="C_3e931d49-353d-46c5-813c-21ac6372c768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_d4d4328f-52cc-4211-9428-c5e7e73152dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3c93b994-375e-41fb-a65c-a6d06c8a74af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a25d6e22-b4d5-4e42-baee-545cb40fb3b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_87c8c355-193a-4647-ba52-79383b1ab058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5eeb50c4-7bbf-4897-a80f-34577a6faa71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_672dd93b-be85-49d8-84d9-56d83b649236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_323e95b8-22cf-4c13-a39e-cc623d224a74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_ee3362ce-e6b6-4c81-9ddd-3a4c990659b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_208e185e-fe87-4dc4-85f0-dbddc9b221e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_89e4b4f1-1e78-4fc1-8102-81aecb3af80a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7f02ae7b-672e-42dd-aa91-702e3930b636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_724282bf-8130-4b80-8ac7-1b0e9d423b87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_72241514-75f9-4b94-8b9f-d70213f11d47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_74ebd140-1cd3-4d3c-b9b1-9fb227e15317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_881d2648-16d5-4b0f-8455-333f723dd233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fc627979-580d-42ff-87f9-72f185ff83f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9c1cf7ad-dccd-4502-b51b-e6878b32a7e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3e3cea99-52ab-4572-a2f7-6ce19c94f86b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bc8a647e-410d-4008-9a55-68854219c87e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8a72d7d1-fd42-40dc-a974-f728dcafb2db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1ef1f41f-a1a4-42d6-8454-db92942dad65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8ed7ca7f-61f0-4950-bc7b-887b37ebb035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_96bf1cf8-19d9-4d23-983b-756892fd1ff2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7bebca71-1135-472b-9d92-4845eaa4225b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bbc0b09b-357b-4c3b-8a22-3402ebee19be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_230e86a9-5523-4a06-934f-3dc71e6f9d7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_380477b0-d459-4fc3-9c66-ba4500d99c6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_990fb369-8f8b-4b5a-aae9-a7fc6e20db39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_609b6c54-99ce-41d7-80bc-f34b80b29690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_55f74884-e084-4ff0-ad23-d54d1b1004e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2e24acd0-67f6-4df3-a3dd-efc69b71ea26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtmEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_e1c1fbc0-d63c-43b7-9ffc-6ad92761fe9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5c8523e8-eb7f-4abd-894a-724f7b5cac4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_97b3c3ab-b721-45c5-a7f8-8b63dd151af6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bca994d1-b72b-4700-b935-07f4a67abfbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_5e2d29f3-6231-4c61-9133-137f73dc9a4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_c7091304-4211-4a5d-9df5-4653969e7eae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dcd7275c-0ad0-4b30-ad3b-b1c3164715c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ca307da-79aa-45f0-952e-4bd76b2798b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b769ed8e-6840-43c9-abce-2f0b38c64a46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5b56ae1b-3299-420b-a990-12c09f3a38a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f2b95b5c-aee8-40eb-8cee-80a189dab5a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5fb39eda-b901-4cdd-9a32-7c015ae8998c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PreJanuary12018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_56c649f8-782f-49f7-806b-b288e3c37bfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">grts:TwentyOneErieLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_dd3679ef-3afd-4878-b600-1c49abe1ccaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">grts:PaymentInKindRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_323b919c-2755-47b8-9d63-cde4b993e0b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17166196-5fed-4356-b3f5-8cfb8175ba74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d996bec-14d2-4de2-a3e4-8cb7d6f0f835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">grts:PrimeRatePlusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_2f02fe40-880c-4f03-95a7-5100852f2662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2fc7bad5-4623-4bd4-9074-af6d60072963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_72010145-f061-45d3-99d8-7968eba114aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_c139338b-65f8-4c46-9f25-0a151c3415a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grts:TrancheOneAdditionalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_af34b684-6740-4987-8a92-febe2af8bcc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_39844211-5dca-42b7-88f9-d6efbab7fcb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b402c931-cfd8-4ccd-855e-c61c5c4d4509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LoanOriginationCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="C_34e3705c-6db6-4be4-b4fa-7c9bc996cf50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c3371e94-abb3-4b37-894a-d4cc941cf1f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:CommonStockAndOrPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_153cf958-71d1-4706-b096-247c7c793c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0eca9dc8-8c2d-4467-b653-fbcf9a107933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f06b8a24-0a03-4e60-8fd7-ff440ef473d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9ec3fe0f-f635-447a-a11c-3c7d34b2f6e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c884b3b8-4d8e-4b0b-b827-70428cfbef2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e56f5102-fdf2-4a2e-919e-b83d8075a4bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6674d76c-7bfb-45ae-99e4-e6beb133f3b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_71524de7-0086-49d7-9417-13f7efabd4d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2a86422f-3ae7-47a7-bad8-cd08d7056b6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="C_78bc7e34-ffb9-4a67-a8d3-9000a9429eaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b523bac1-1813-4b7d-a176-50e0e4c5ce15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2634c472-49d7-44a4-939b-8fbd8efaf28d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_11b39c77-1e84-4dab-b60a-449a3f0ec0fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3a8b90fa-09bc-4b1c-8721-e05897f1cb0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_832bf8ab-67e6-443d-94f3-635dca9a9752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_f98f071e-224d-4373-a5ef-1f968dd60d8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_80415412-bf63-429e-9fb1-589b8f52c64b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">grts:AdditionalSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_80335036-a649-47ad-8c0a-e757af17ab30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_c62e59ac-4c24-44ca-b119-f4e4f1990e9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_36837d8e-e9eb-4701-ab19-b3e92b394404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_94f64277-8372-4366-a998-7f9abe66b1a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a6647160-7b5e-4902-9018-3678bdb60427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3d082462-60fe-4bab-a12e-cc1b69abbcff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_99d8a4f5-b851-48db-a6e7-61d21c828ead">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ae54a29d-2a04-4259-9f48-ef7214c95a0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="C_d0c4fb4f-d485-41f4-b896-f24d5158e36f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_62ff936f-e544-4a9d-b314-581290027ea3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6d8263f0-f625-4009-a8d1-d1d4686fc533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">grts:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ec0b67b2-f764-458f-92ed-317ed126cda4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3c9e7f0e-5e08-4bcf-99d9-2caf8d424011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_687162ff-aef8-4232-aaec-424cb6facc45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_dd15f766-7703-4fda-b493-3f50dfa95055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="C_4d220ecd-5fb6-43bf-b89a-7760384559a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_49045c9c-a554-4324-9d92-9288a8abef99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3b607420-6945-419e-9f68-f1999ec6386b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ddb48a50-1ece-46f1-83ca-c31f25910907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_b1aaf215-5549-4cb2-84d0-1af1b91cf770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7720965d-c288-42f6-a5f1-b3a368a46f6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8cc492f6-e0e9-4dad-b467-56ec30f2625c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e41fdba9-8344-40fa-b5b4-2fdf9fb77166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b0d9da16-7637-4109-87b5-f82244fb1e67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8acc4e2f-1b3b-4b68-8d11-a8d5e82e8ae1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_87f6c28b-d174-40ca-a77f-7d9cc17bd37c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_56b7d049-aed0-43f4-a9e5-39af8293efe5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_11b309d8-462b-4ef1-aa32-6924156d9e05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_6d7f03df-630d-4cad-87f7-614b2528d487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_f2705b27-ed81-4a40-b53a-b869c0db0739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_489b2495-a848-4ec1-ae47-5647173197f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ba0f5eb4-07a4-4e13-a684-5ff64c100781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eb0cc90f-3d79-4014-a59c-5f9cf3d2f660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3f4d3587-5707-477a-b168-bf3fd63a1a9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5c56c0fa-8f94-4d89-a702-a2744c500dc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_95d7df61-6b4c-4669-b173-7200708d3836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_94a66d4a-e27f-41e7-af27-bdb2e8470a43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_79e7ae2f-f2dc-435d-9836-71d230ab5b96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_90864408-3972-4c1c-b3b8-325c747633b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e79a84f8-b402-4c06-a64d-be36155f0669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ff4ba982-5223-4146-948e-578e4a49e800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_68ae43bc-d4ba-46ef-b787-9a1a51cd49b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3daa3e39-3faa-4c82-a714-e0e8c91e437f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6c569a47-3f51-4dbb-bef0-103343842833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_e91e3869-cc3b-4f71-bed9-29131644937a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fc2d3480-29e6-4302-a16c-d5582586d81d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5a176657-560e-4e80-8117-9b6ae2388147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4aff01cb-2e26-424b-83a9-fc5583bbca7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_75882f1e-2c2b-4a1f-86db-757c8eb713b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4883c551-3073-415a-98c5-41e1b4eb5fea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d2f985e7-3856-436a-b098-7d96d2ec9b97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_809dbee3-02e2-412e-b2d8-47155edc68df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_02a77114-3193-40d3-9dbf-c33becbaa06d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_81630994-2393-4f11-bebf-28fe95a0862c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">grts:FourtyErieLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-28</instant>
        </period>
    </context>
    <context id="C_56766ff0-b624-4f79-bafa-518ca3d728d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_8db1bd52-7abc-4eeb-9079-f65d7f8c2c1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grts:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_652f489f-b7e8-4293-9bdf-ece64443c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_10d2b101-f4a6-4310-ae5d-b86276995667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d375ebef-273f-4149-8fb5-f4dc8b70ab63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dc0d2494-fb2c-4556-8cfb-8f4cbf34588f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_59f476dd-dd0f-4391-85f3-c22402209e5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_858abaa7-2ee9-4eed-9059-5c0651392b80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9f752682-fc55-4997-9e66-a13d860093aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_afcbe2f3-7dd3-4f15-8cd0-c1d773ae4308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PostDecember312017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c28c4bd4-e62b-479b-85c0-f06e18613cb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_324745d5-c5ad-4d27-9aeb-d15b72a94aaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0a69806e-b629-40b1-a18d-6ca603eb73b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8ea4d358-ae99-4f6d-8fc9-63316759fe1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_210e3734-9390-4047-8e9e-6e3dac75eb53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_84b52d54-d609-4bec-bfa0-0f69992f3096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_7a01aa4d-8457-4bc2-9506-f28d7946c515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f6117e7e-2c0b-40b3-93ef-a45d9e067e05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5cfdaae9-b4b4-47da-bcee-8fd709202da6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">grts:AdditionalSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2f5dbf8f-812f-4ffe-9bac-799e8547d2d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_65adaa59-8507-450d-85bf-fc379014d32a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_594d238f-4b26-4a67-892c-13ccd5be28e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_92f316c5-6c3b-4b21-9a34-423815542a35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">grts:TwentyOneErieLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_969fab0c-3062-4255-b015-879022cee5f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CepInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b83ef403-2580-41b1-b8e4-7f8b49fbd122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9f6cd5c7-d0e1-4f81-b026-8285e0af17ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1929cfb6-f656-448a-9d1f-c017d3968257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a7439677-3eea-449d-ba9d-9af37deb00df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3dded028-e6f7-4811-bc50-0118b2cfd30f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_49047d4a-8f63-439f-b6a6-6eae31a95a12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e6cfa898-87ba-405c-ab6e-c9fdcb066f80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_ceb9099d-6f61-44fa-836a-3e42ead5e190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bd4c978d-db21-4656-99dc-dd258c79185d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aadfb6b4-e055-4e7e-82da-133de3937dc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_40424169-d409-40ab-8018-026dc29baf15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3dbebb0a-177e-4cad-98af-5c26d1198e0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_accde2f9-2b45-4db3-a169-1f19cc7d3a10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b9cf46df-3e9b-42ee-b59e-eb74338bcf32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4f197d40-b7be-4d35-9b61-95f8f0d5b16c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4bc7731c-c74f-40d3-a426-a27f2ea43498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_892682c3-ba06-4a39-8d64-2a527d6f399c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_ef1d018e-1582-4a48-8fb5-58317716f6c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_73444588-46b3-4e78-bfe2-a5e3294d5d4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7de13c8f-bc45-44f8-a635-d16cfe8fed70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aadd6041-4d4d-471c-8758-30fc80ec55da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7bec73ca-4c8e-4211-838e-e975e53259b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3e7ededb-1c6b-46eb-a02d-62b731c0fb78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8f01c328-d8a6-4cb7-a4fa-466c77f2d695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3dab2c7d-c16a-4d70-98ba-da1026b8f662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="C_fe489596-7a91-4f59-b920-c21979d2bb8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_45aa777d-f982-4434-82ec-6619331cbe4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d4a6100a-40e8-402e-9f0e-748c76179dad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c50db2bb-cff4-44de-98cc-cf159a62c91f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8900ff95-7d4c-4827-aab8-7f758672ca22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ec5c558f-6f66-4786-9d64-c061d097aa83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">grts:AdditionalOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_e6c766b4-e117-4244-b35d-682f04d91b80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fef5557b-9238-461f-9d8d-6c180e1ea4c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8a3ecee8-3b5e-4aae-bb83-c0cec0cf42ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0ebc7f82-ba9a-4b25-83ff-fc9b906d1b18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_c86bb390-8ee5-48f9-aaf2-89a427c83966">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9faed10b-deab-4fc4-8710-bcca92fcb310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9313b710-4b60-4e1f-b855-6c529b013687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5fc9c11d-6f3f-4fe0-a8a9-6900a0dbaae3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bece036d-3f60-44c3-9f38-745d2aac748e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3715424f-76fd-4a70-bcb7-f905fcadf133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4989ea59-69ce-4c78-bdac-1907a737f297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">grts:TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="C_8c5761b7-e32b-45b4-becf-3a3c1d25c6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dd661f8c-80f3-437b-94c6-39b2d87a6b09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0147e0c5-b128-4b28-ab85-a4f52bbc6baa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d5436e0-6fd6-4397-a2ff-a7a44bc2b153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">grts:TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="C_27904f74-af74-4e0d-afa5-d30b372b7427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_604e35dd-089f-428e-8455-fd00d7905514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grts:RemainingTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_a899ce5d-e51a-4a72-98ff-ca5442a68952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f75e133a-4af4-4545-85f4-a47ee76a38e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_024d46a7-8550-44bd-aba2-8e45d258d9a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d50b36e8-0a1e-4794-a381-440b70d6bf56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_292c55aa-2381-4617-8d13-a126676fe9c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6565d2ae-b389-4300-902c-39d3e6e112f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_eca7c1be-2d00-460c-b13a-ef933d52f723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e8e7ad16-a257-4feb-83b3-d36674cafe9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3295931d-4cf6-4ed7-9b11-e42a2fb87408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17553f60-9678-4458-869e-6553a03fa156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_136628c1-6491-4245-8d0f-4e52ec0eb329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b75ce6de-1369-4078-83cb-4b85b869b56b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4e50f083-971a-4ba3-921b-feac5bdbdbc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_de1f942a-daf6-4e81-ae8e-4d009e1427bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a1b699c9-114f-4029-b6c6-56ba4c312c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_802790aa-7b46-443c-b5ab-a61e4c953239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_23c937ef-9873-4e7b-8401-361c0141be20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cef2dcb9-4d72-401b-9b51-ca2ec7658d4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_76e247f4-22b6-4c8d-8bcc-5e1bb0cc9367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1802000b-946a-45cf-9eb1-ab878fd907d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_963260b7-59bc-48cf-9042-018d5b6ef6c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_27862347-30f4-4a51-8e69-155b8a286acb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2b45ae22-69b8-4005-8ab9-321b6b14f107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6d3577c4-db17-46ad-8f60-2c0eb8ff2efa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="C_3f58b9b7-d6f4-4132-960e-1c1e70027d7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_40e18178-0370-4155-b61f-eb36fe61fe35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7f8d1e5e-8021-40a9-af4e-637188703294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_c6e2641f-a8ab-46ff-80f9-1485fe4c2082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ec37033-06d8-4931-9ffc-894e1d473c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bd77beb2-c5d1-4f28-877c-995caa385c8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_937c1ade-1906-4692-bcc1-f9d4da800f1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_21692f50-7040-4780-a0c1-87357f75dc1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_04956885-3d5b-41a6-b35d-28c61c1b73fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_bcae57c0-074c-498e-8541-1149ef409ac8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6aa0ddf0-5c08-4e9d-a445-164033395389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_40a76726-c327-40be-89dd-1c7d982d5836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6cc6d2ec-75f6-431d-8f3c-3a9350689079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5f1453e1-ff34-4769-91d5-33383d153a3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PostDecember312017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3b708b32-49af-4567-b476-e287d5f1de04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b942a7f0-83f7-4782-aba4-13c3f1ec3206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a50f3891-bc8d-430f-8444-964f174a3e3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d80b699-28c2-4bce-ae73-843d1606fcd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_dd9632a7-d460-4003-8a48-c36e620a0c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e9a61784-ec1b-4689-88b4-604b0656e5e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_f6215bc4-d5d7-4c03-9ddb-fab6020892dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cba7109a-fc2f-4241-85c7-7086ee1b9b30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ce9087bc-c51a-4a95-a2a5-acee855847b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_138bc03a-533d-4ac5-8b52-13e19b3633e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_40264f68-b348-4688-915a-7b32fbef6c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_15303075-6c82-43e3-95ac-810ce94f5ad4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_39d2c6fe-95e1-4040-9805-ff9f54fdd2c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8c95d954-77a7-4eb1-ad4e-f5368fb88348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_082d0a7a-97c2-4602-9ad8-c0587fc21667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_25953651-9e56-416b-b771-e53f99a9c2b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a9559e13-2a2f-4a2d-bb75-e9c9777abe4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_78bd9843-080b-4da9-aa64-2a6e6bff9c0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AmendedAndRestatedCertificateOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_58b1c9d9-769e-46b9-8c0b-1522ce09ece0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_22a30aad-6a5c-431e-97aa-6d0174548088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_70694a1e-9f63-4f26-821a-bb4205582c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_739f34c4-9e15-4e81-85c9-c9c472575986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8766ca2a-9ff6-4066-8356-6a67a4e463d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_RenewalTerm">
        <measure>grts:RenewalTerm</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>grts:Segment</measure>
    </unit>
    <unit id="U_Security">
        <measure>grts:Security</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_ce7937c5-6a07-4c19-a8ee-29f6ffedab38"
      id="F_9f56e434-2071-40f2-81bc-0ed22f38f4e5">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_571251c0-d226-4450-88eb-7ee8d4a698b0">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      id="F_e7f9cea4-e613-411c-867e-84c9f2b00028"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      id="F_9765a238-b117-4b57-9e57-dd79a484561f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperationsCommencedDate1
      contextRef="C_a00793ff-fd1e-4407-a28f-21d728a53d83"
      id="F_20846724-0d37-49d2-b716-e12511647821">2021-04-01</us-gaap:OperationsCommencedDate1>
    <dei:EntityCentralIndexKey
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_faa22fcc-8797-4009-a6ec-9ffd1ef5498e">0001656634</dei:EntityCentralIndexKey>
    <grts:RevenueRecognitionContractEndPeriod
      contextRef="C_489a2772-a9a5-4e8f-845d-dfb4142824b9"
      id="F_9eba06f0-bedf-4ded-9f71-17671e82aef7">P2Y</grts:RevenueRecognitionContractEndPeriod>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_a0ff64f8-6e81-4e07-8318-11c2e3fcc076">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_c3b0f8bb-78d1-40b5-a178-d0f8420ed0af">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_97423d5b-365f-4428-b992-44f03779e075">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_2c63d63e-250e-4d37-9d4a-9aba7442fdf5">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_fcb2ca52-e6b1-4c27-a09e-4c9e7d2dd0ff">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_b5a40593-c0f2-4af2-8a8f-f60f06a57e04">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_10c74e4b-4424-4a0b-9e61-007ca1c5c1c2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_411e2d1d-9f2d-48ba-b7d7-712438d51076">001-38663</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_cd38d5c3-87a6-4fdb-b3d7-e7510b0dc845">Gritstone bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_043fe9ad-d3cf-4bd2-8da3-84c1b1408c16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_f2ed7b25-dc92-4e6c-8a63-73be381b92db">47-4859534</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_b76654ae-3f96-43fe-becc-e59fe8f055bc">5959 Horton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_08d1b9e7-a387-4cc8-b95d-9a3c568953f9">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_a9d071a1-117a-483f-b920-975619185f09">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_6daf24ac-78d0-434e-9a0c-0da781898051">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_0d30c30b-9daa-48ec-8eac-2ef206ce0565">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_cc922427-ad9c-4166-bae1-a81b8024dc6b">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_c580ea45-83e7-4a7e-8e54-003a5a75949e">871-6100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_57b88ea6-6214-4c75-bfbc-45bc689d4060">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_3d9fa77d-86a7-4b0b-b979-f476233b31fb">GRTS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_3ec26380-eb8f-4840-8538-fffa91baf707">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_0d716ecc-2c8b-47c5-ab8d-81fc22798054">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_b28591f5-673c-4c1c-877f-2c40243aadfa">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_d68f66ce-2852-46d9-b433-caca7aff35d7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_c44bcb08-0be9-4122-a8ba-ab3ec6b0cd3e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_904660a9-34a3-403c-8d6e-fc7c0da3d174">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_9701aae4-6858-4e21-b170-a91f66db1e3c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_08d296ba-8a0e-4d88-94c8-83222276d777">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_2094eee5-625e-4d6a-9549-31fe975fdf48">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_3bee35ff-5c24-4e2c-bda7-7ae6439177c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_d6e0b732-35d0-4cca-944a-5400d102cb13">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_c0c7b78e-f4bd-4f7d-a7d7-c851651f4d4e"
      decimals="-5"
      id="F_1cb1826d-d1d0-48b5-b867-9237eb862a3d"
      unitRef="U_USD">171700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_dd15f766-7703-4fda-b493-3f50dfa95055"
      decimals="INF"
      id="F_30c71761-87d4-44ab-abec-c5b1d3db776f"
      unitRef="U_shares">87661978</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_8642d2ec-fbfd-47ea-accd-25f92e7283ba">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, scheduled to be held on June 16, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the fiscal year to which this report relates.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_57308bc5-4700-4db4-98c0-84cef1026897">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_5a09762a-0d3f-4587-ae23-4fe9b88f18d8">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_fe28b41b-7712-4002-a316-2e2a24a557b7">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_a7fd8de6-92c0-4323-983f-6c04172ec0fa"
      unitRef="U_USD">55498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_b0720ba2-c6fb-47ab-8c5f-231facdfe2b3"
      unitRef="U_USD">93287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_ad8af453-4838-41ca-b76e-1ce20e1120ce"
      unitRef="U_USD">116389000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_6e919994-3ee3-4b0a-af90-3f482a90fd13"
      unitRef="U_USD">108346000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_06da4afe-a2c8-441b-a788-3888b97b7f86"
      unitRef="U_USD">3977000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_53014a7a-3b9e-4314-a917-8028a52e31ce"
      unitRef="U_USD">11285000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_42454fa4-3a55-490d-ba8b-1c010f39aa2c"
      unitRef="U_USD">7014000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_ca5fc4f9-3204-4e4e-8229-dcbc57656ce6"
      unitRef="U_USD">7672000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_87211ab2-8235-4e5e-a566-1d22ddc588b7"
      unitRef="U_USD">182878000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_965af7c6-55dd-4d4e-b6cf-36f0e7d09c99"
      unitRef="U_USD">220590000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_75571cd5-78b1-4844-97a4-1c9d09424055"
      unitRef="U_USD">5290000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_3ecb6739-2e0d-4a99-9475-2d9fab0760ba"
      unitRef="U_USD">6005000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_b0eaeddd-9bfe-4ffb-b134-3ed3c66c638d"
      unitRef="U_USD">21335000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_6ac0c309-a315-412b-aa42-206eeb0674bb"
      unitRef="U_USD">21622000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_70c606ec-d349-4dde-8ad9-51133bd2f8c6"
      unitRef="U_USD">17481000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_ff6e3304-fd25-48a5-ae8a-7cbcec13cfa0"
      unitRef="U_USD">22920000</us-gaap:OperatingLeaseRightOfUseAsset>
    <grts:DepositsAndOtherAssetsNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_7fb21f8c-f7b2-4a07-a9f6-e03274bd4c2c"
      unitRef="U_USD">9739000</grts:DepositsAndOtherAssetsNoncurrent>
    <grts:DepositsAndOtherAssetsNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_152b7632-0813-42e0-bdf8-121f10cfcb9e"
      unitRef="U_USD">2352000</grts:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_12855c00-403e-4389-b520-30f0b3fcd6f8"
      unitRef="U_USD">4031000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_1c0957a5-7e29-4298-9def-90d7c23a2043"
      unitRef="U_USD">4617000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:Assets
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_6e5df63c-a954-4833-8a9e-bece17b4d795"
      unitRef="U_USD">240754000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_c70e9d75-5a5c-4893-97b4-37818e892f21"
      unitRef="U_USD">278106000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_78c6db53-6555-4a7b-8226-12aec54eac62"
      unitRef="U_USD">8694000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_b1699a73-61f5-490a-8626-d3fa60524118"
      unitRef="U_USD">4230000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_a3e61bae-a469-450b-bfee-a7c1e510475d"
      unitRef="U_USD">8215000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_44ed531b-3b05-4492-8030-d91c6661ca45"
      unitRef="U_USD">6925000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_33f6c688-0203-4ce9-8c8b-c2bbeb3bd90b"
      unitRef="U_USD">4124000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_181820f7-03d1-4bf0-af6a-8a6a9e161636"
      unitRef="U_USD">411000</us-gaap:AccruedLiabilitiesCurrent>
    <grts:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_48830c2d-67d8-40f5-937a-f39b88cbca6b"
      unitRef="U_USD">3343000</grts:AccruedResearchAndDevelopmentExpenseCurrent>
    <grts:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_68b711f1-dd54-48e2-a0eb-68e4e2e56b4a"
      unitRef="U_USD">3706000</grts:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_1a170d7e-8e3b-407b-833b-587c2727dfd0"
      unitRef="U_USD">5294000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_8ecd1341-511d-46b5-8aec-b0b6cdb44de4"
      unitRef="U_USD">7483000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_ec3d1b80-0d4b-47ab-82e2-a921cb60b969"
      unitRef="U_USD">5131000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_9d8a77c0-e046-4206-88cd-765999cbc599"
      unitRef="U_USD">17201000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_b7dc5043-f567-49da-acd7-5d723a1a01c0"
      unitRef="U_USD">34801000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_fd6b47b6-c87f-4970-a049-beae606d481f"
      unitRef="U_USD">39956000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_671160dd-6395-4a40-8394-b7dd51ca5a51"
      unitRef="U_USD">150000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_d0a65e04-9c87-48fe-9e98-fdc09caf5e60"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_0ee0e9d0-2451-4801-82aa-ef3e43e8128b"
      unitRef="U_USD">15673000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_04f77f7c-fe6e-46a9-a90c-36bf33aedcb0"
      unitRef="U_USD">18936000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_3bf4ce45-782f-44c4-aab9-8522da4e957b"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_d398e734-3a65-4300-b775-233582a8f039"
      unitRef="U_USD">3128000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_1429408e-5cb2-4b9a-be6c-0e4632f10219"
      unitRef="U_USD">19349000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_97ec8626-6c29-4242-bc91-f3e2e82d5939"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_b6942724-c059-4f00-8513-fdde79807bb9"
      unitRef="U_USD">69973000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_faee62ce-718e-42b9-81a0-02bc76785889"
      unitRef="U_USD">62020000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_74088031-41fc-4f84-88e2-0a25138b0fe7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_d6941240-2ef6-4463-86ed-9969ad8b5aeb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_09e5f592-d9cc-4ddd-b605-15462f89a7f3"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_d421273b-673f-4be0-a6f6-a877627ad639"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_2aa5dbd1-0487-4930-8f4e-68a2779096ab"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_dcdb69dc-b9fc-4200-8648-bc95a0aefaff"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_2915ae2a-dbe3-4b12-ac61-baeea45dd658"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_1aae79e5-6e96-48e1-aa51-5dc8891e5a46"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_eb6607d4-c4fd-426f-84f4-31e27f5bce49"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_03e71d82-4674-4463-aafe-2ea9c935266e"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_5970bdf5-ca21-45c6-853e-c139a426a1a4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_200735e2-2990-41f1-942a-76353208caf0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_4222067b-278e-4990-b7bb-9fa6c77ca940"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_2bec39d7-d506-441f-9774-a8602010eabd"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_a11dba5b-3aa5-4d13-b425-1f537da6d217"
      unitRef="U_shares">86894901</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_4cc1af7d-fc1a-4823-b317-ac05aa5fbdfd"
      unitRef="U_shares">86894901</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_80aea6d9-2bd7-461d-b2f6-fd94d3854b51"
      unitRef="U_shares">69047878</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_b7c5288a-97a0-44fe-8b5d-b751d36c7259"
      unitRef="U_shares">69047878</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_235b47f6-1c0e-4889-a8fc-d4889bffbdde"
      unitRef="U_USD">22000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_9f7735a7-e8a0-4a3f-be5b-ae4504a68579"
      unitRef="U_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_11c02dff-0efe-4ea3-ad5d-aab2384322f2"
      unitRef="U_USD">691910000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_99c7baee-ce5a-46c4-b21b-614363f7bb6c"
      unitRef="U_USD">617523000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_0c23b204-1292-472b-9a92-85b500b58fe4"
      unitRef="U_USD">-80000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_a0923dea-d9d0-43eb-b728-0de4a9c332db"
      unitRef="U_USD">-73000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_6f502fb3-e071-41eb-856c-894d03dfdd3d"
      unitRef="U_USD">-521071000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_f354689f-d210-4e69-b2f9-e1959037e1e3"
      unitRef="U_USD">-401384000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_4a265030-20e8-454a-ae4e-0df3dc494a38"
      unitRef="U_USD">170781000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_bc625b69-3a70-4b92-a0c7-066969b64a9d"
      unitRef="U_USD">216086000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_3898c147-ad97-45f2-a828-eae8e5f02aa4"
      unitRef="U_USD">240754000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_712a088e-fb87-4e14-9421-7d3f27bb4995"
      unitRef="U_USD">278106000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_fe489596-7a91-4f59-b920-c21979d2bb8b"
      decimals="-3"
      id="F_f53af206-f8e7-4089-9aa1-d2a8336085af"
      unitRef="U_USD">9269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_879914fe-a7ae-42c4-9c44-8a86ed39c875"
      decimals="-3"
      id="F_7f5d0d0f-c669-4fb9-b457-983aa03d9ff4"
      unitRef="U_USD">46717000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b75ce6de-1369-4078-83cb-4b85b869b56b"
      decimals="-3"
      id="F_aa308af3-92ee-45d5-9c11-cbeed925a074"
      unitRef="U_USD">3462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b1aaf215-5549-4cb2-84d0-1af1b91cf770"
      decimals="-3"
      id="F_b6ad9f9f-cd43-4ae0-baab-156b86350bbf"
      unitRef="U_USD">10676000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_525c622a-5ea4-473e-9b25-9d823536fda9"
      decimals="-3"
      id="F_1594aa23-3749-43b1-bbc5-ecf32bc091b8"
      unitRef="U_USD">1497000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4883c551-3073-415a-98c5-41e1b4eb5fea"
      decimals="-3"
      id="F_03e9d05d-ff97-43f8-a5b8-3a2e55b3357e"
      unitRef="U_USD">575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_f1af3fd7-1b24-4ba6-9440-bf7f8e5d0379"
      unitRef="U_USD">19945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_381a3929-b4c1-466d-94cc-7775b22ec175"
      unitRef="U_USD">48214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_19b7fd05-dd83-46cb-aeef-ed554fd1500b"
      unitRef="U_USD">4037000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_f62f4508-a97e-46e6-ad66-75f2a25f630e"
      unitRef="U_USD">111403000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_fd3b2467-f2e5-4561-9d8d-791959cb75d3"
      unitRef="U_USD">97490000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_ffc1a7c2-72ff-4816-b8c9-f1073e925fb5"
      unitRef="U_USD">88643000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_606f22cc-961b-4a01-9d96-993a71d41db9"
      unitRef="U_USD">28970000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_b3d1e5e0-9c92-4c58-890e-67ff1be9b6a5"
      unitRef="U_USD">25933000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_88aac1de-06d1-4a03-ac27-583ebfaa8452"
      unitRef="U_USD">21411000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_43ebdd71-0c81-4f8a-b121-cd9e6b83c0bd"
      unitRef="U_USD">140373000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_ed3ce69d-fe57-4882-9af3-09a1634fd3c9"
      unitRef="U_USD">123423000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_a70cb63f-79fc-4829-9fab-0c6bf39d66a3"
      unitRef="U_USD">110054000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_db6ddee1-29ca-4735-b96c-c8ab9d00f730"
      unitRef="U_USD">-120428000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_019bbdee-f51f-4dc6-bd58-7b04ab39267c"
      unitRef="U_USD">-75209000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_8fc6f6a5-f7c0-4b46-a478-afc22b256036"
      unitRef="U_USD">-106017000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_f80b12cd-14e2-4e92-b398-ecfebda2f35e"
      unitRef="U_USD">1976000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_3433f2c5-1b69-460d-a14e-f59194bc2d1e"
      unitRef="U_USD">164000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_fdfcec54-f0ec-4593-a3de-0b761daa5190"
      unitRef="U_USD">715000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestExpense
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_b9d80482-ecd8-499d-b852-67753279642d"
      unitRef="U_USD">1235000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_4c6e527f-10d5-4ee8-b8f1-18b61c757829"
      unitRef="U_USD">37000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_aa89e599-a3cd-429a-bc79-e1c2de5d8a3e"
      unitRef="U_USD">12000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_d2a84b98-2d2a-4492-9f83-97778c5db19b"
      unitRef="U_USD">-119687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_57dabc51-1086-4869-af91-7c21822368cf"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_e761c88d-8852-48e7-b5fd-99660216c989"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_53b12ff5-568c-4f5a-9426-9a0ea58e5129"
      unitRef="U_USD">-7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_f7a6b95c-aaae-451b-ae0c-beb363ed5698"
      unitRef="U_USD">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_c09dd465-33c9-4bd9-8299-5a289c8ede3b"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_c19c6c62-608d-475c-a776-8cdbb768aedd"
      unitRef="U_USD">-119694000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_0bdfe1b0-d710-42d7-a0dc-54da32062fa1"
      unitRef="U_USD">-75155000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_5f63b734-72ee-4978-8e9b-cb25f8a0fdc8"
      unitRef="U_USD">-105338000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_62816bb2-c0e2-41ec-be73-3c33e41ec08f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_9d4c100c-c930-45c0-b482-3df5784e4ac5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="2"
      id="F_978a553f-d408-4b3f-82c4-359f1d9e5df4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="2"
      id="F_c414a75e-ba73-435f-b3d9-404d35d684db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="2"
      id="F_c921d5ea-6778-4d8a-ae33-3b69f23ce20d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="2"
      id="F_976a3584-59f1-48ce-ae8e-42858815cdb4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_89d68ccc-6b3a-4df1-8b94-dde51aff1b5d"
      unitRef="U_shares">90918333</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_7985a6a4-e946-403e-95cb-ae8c997b28a4"
      unitRef="U_shares">90918333</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="INF"
      id="F_40942f89-30b0-4d14-b2ae-45c79b2844e3"
      unitRef="U_shares">78885186</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="INF"
      id="F_b8750ea6-5533-452e-8bf2-26cf57a3b2d1"
      unitRef="U_shares">78885186</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="INF"
      id="F_45a20e19-c25b-4294-b966-d50bcd1c8acb"
      unitRef="U_shares">37792365</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="INF"
      id="F_38b6f8bf-858a-4920-9812-8b88e5615ec1"
      unitRef="U_shares">37792365</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_bca994d1-b72b-4700-b935-07f4a67abfbc"
      decimals="INF"
      id="F_767c50e1-0cfd-4c63-9dad-8b042bd58eb9"
      unitRef="U_shares">36332956</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_bca994d1-b72b-4700-b935-07f4a67abfbc"
      decimals="-3"
      id="F_b4fa574b-8f84-49ab-bf70-d82c8631b0e2"
      unitRef="U_USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_230e86a9-5523-4a06-934f-3dc71e6f9d7b"
      decimals="-3"
      id="F_a534a6cd-9790-4a75-a5c0-b61689a97881"
      unitRef="U_USD">355291000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_34bb80f1-a84f-4c93-9bd0-b459e3058b14"
      decimals="-3"
      id="F_9d2451a5-9f6b-4dd2-9620-727075257f7b"
      unitRef="U_USD">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3f58b9b7-d6f4-4132-960e-1c1e70027d7b"
      decimals="-3"
      id="F_3b18ffd4-7f63-4e4a-b3e8-ae736f61068b"
      unitRef="U_USD">-220988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc"
      decimals="-3"
      id="F_d9f3f362-47c6-4d21-a4ab-b7e91231b433"
      unitRef="U_USD">134344000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_087f69e2-ad7d-4b73-9c6f-f855a261808a"
      decimals="-3"
      id="F_cae8d8d7-4c5a-4845-9700-a6283800993d"
      unitRef="U_USD">1394000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_087f69e2-ad7d-4b73-9c6f-f855a261808a"
      decimals="INF"
      id="F_b2e1ad12-e51a-4eba-8eac-049db90af11e"
      unitRef="U_shares">9586478</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_087f69e2-ad7d-4b73-9c6f-f855a261808a"
      decimals="-3"
      id="F_af8560a7-4170-4657-9134-ee074a0cca72"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_2d80b699-28c2-4bce-ae73-843d1606fcd7"
      decimals="-3"
      id="F_3fb41d13-fc4b-4db8-bb02-c8dc30c76a14"
      unitRef="U_USD">32121000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6cc6d2ec-75f6-431d-8f3c-3a9350689079"
      decimals="-3"
      id="F_6e2d163d-9788-460e-a1ab-912a36cbf720"
      unitRef="U_USD">32122000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_208e185e-fe87-4dc4-85f0-dbddc9b221e0"
      decimals="-3"
      id="F_65ae61b9-6d5d-4e1a-aa58-bed1002c4e1d"
      unitRef="U_USD">3806000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250"
      decimals="-3"
      id="F_6dd368c5-389d-439d-b250-4c847b3feefe"
      unitRef="U_USD">87704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_5cd30aea-668c-480c-8eb4-02fcfc804c57"
      unitRef="U_USD">87704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_8b84dd47-84c3-4d2b-8c0c-c84ff401d5a8"
      decimals="-3"
      id="F_4407aeed-f9e3-4ad5-b478-03677b54ac39"
      unitRef="U_USD">104000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8b84dd47-84c3-4d2b-8c0c-c84ff401d5a8"
      decimals="INF"
      id="F_dd7f8aab-d2fb-44c3-93dc-c9cd56e3e67f"
      unitRef="U_shares">1160963</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_36837d8e-e9eb-4701-ab19-b3e92b394404"
      decimals="-3"
      id="F_8d7e925c-a85e-41e8-b75a-e3299a55b3fa"
      unitRef="U_USD">9670000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_809dbee3-02e2-412e-b2d8-47155edc68df"
      decimals="-3"
      id="F_0a84ed60-65d8-4bdc-96f3-3ad62435d985"
      unitRef="U_USD">9670000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_44dd4f53-eec3-40d8-8778-035eeb8ebe64"
      decimals="INF"
      id="F_e798149d-a2fb-4953-b467-e97845332841"
      unitRef="U_shares">243878</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250"
      decimals="-3"
      id="F_2b769dc4-591a-46d0-837b-9781f293209a"
      unitRef="U_USD">910000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_55b266c9-b5be-4b23-a15a-1a975fcbd1f2"
      unitRef="U_USD">910000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_d4d4328f-52cc-4211-9428-c5e7e73152dc"
      decimals="-3"
      id="F_831b3cef-a2d1-411e-b2f6-0f4f9d66cd93"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_cc4df354-32d0-4ecd-bf89-d9f9b6f0334a"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares
      contextRef="C_44dd4f53-eec3-40d8-8778-035eeb8ebe64"
      decimals="INF"
      id="F_a8a3db7a-3e50-4ee1-8089-cbbba8b99c10"
      unitRef="U_shares">30874</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
      contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250"
      decimals="-3"
      id="F_71b993f0-5ba8-4e31-964d-9aef5c485d9c"
      unitRef="U_USD">11000</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_e07621db-cd83-444f-b207-2c13dcb3662b"
      unitRef="U_USD">11000</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_44dd4f53-eec3-40d8-8778-035eeb8ebe64"
      decimals="INF"
      id="F_27bc0427-4718-4571-b818-e7d74df9c0a1"
      unitRef="U_shares">197544</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250"
      decimals="-3"
      id="F_ab067804-9df4-4ca7-8417-ebb301e249f3"
      unitRef="U_USD">206000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_24269d55-5d22-4933-ac6f-ff998dad67e4"
      unitRef="U_USD">206000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b9585647-0f77-46d7-bf67-20e6113a6250"
      decimals="-3"
      id="F_f83914bf-53bf-4753-8676-26f13dec2af6"
      unitRef="U_USD">7110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_1e07ea67-18d4-4486-820b-ddac79671891"
      unitRef="U_USD">7110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_49047d4a-8f63-439f-b6a6-6eae31a95a12"
      decimals="-3"
      id="F_c4468ae4-e1ed-49c2-bb11-9920b5cb3b5f"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_ad56f9f6-3069-4b2a-b9db-0abe832c9ded"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_78bc7e34-ffb9-4a67-a8d3-9000a9429eaa"
      decimals="INF"
      id="F_b594502f-14ea-4eba-bad5-6539d42d2240"
      unitRef="U_shares">47552693</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_78bc7e34-ffb9-4a67-a8d3-9000a9429eaa"
      decimals="-3"
      id="F_6a72ddc1-aa3e-4cf3-b233-494635c43ed8"
      unitRef="U_USD">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_92745d9d-b5a1-43ae-ae6e-0738b7391092"
      decimals="-3"
      id="F_a05c9823-b42a-486c-9175-cf28d8cca0d0"
      unitRef="U_USD">493023000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4eaebbf5-c3fc-4967-9782-b63169338718"
      decimals="-3"
      id="F_c107a2be-97b5-44fd-ba7c-5bf7b8dbae4b"
      unitRef="U_USD">-326302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      decimals="-3"
      id="F_83f43933-c059-4b85-bfbf-c6b691e128d9"
      unitRef="U_USD">166739000</us-gaap:StockholdersEquity>
    <grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants
      contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f"
      decimals="-3"
      id="F_5c19ded4-62ed-4740-8787-11293faee616"
      unitRef="U_USD">-451000</grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants>
    <grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_e1fd0fe8-fcf9-4a33-8b9f-66cb24f2d5e8"
      unitRef="U_USD">-451000</grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_2ec37033-06d8-4931-9ffc-894e1d473c78"
      decimals="-3"
      id="F_96e8cf7c-5e82-40d8-9d37-b1d9caa89003"
      unitRef="U_USD">339000</us-gaap:PaymentsOfStockIssuanceCosts>
    <grts:StockIssuedDuringPeriodSharesPurchaseAgreement
      contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1"
      decimals="INF"
      id="F_1d72c519-8c62-40ba-8437-8b93dde59de2"
      unitRef="U_shares">1169591</grts:StockIssuedDuringPeriodSharesPurchaseAgreement>
    <grts:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f"
      decimals="-3"
      id="F_c3ec7758-d02e-4936-a6d5-88695ed8b8fa"
      unitRef="U_USD">20830000</grts:StockIssuedDuringPeriodValuePurchaseAgreement>
    <grts:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_ef6542cd-49b8-47ed-9fdc-6b748f8bc95a"
      unitRef="U_USD">20830000</grts:StockIssuedDuringPeriodValuePurchaseAgreement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_9313b710-4b60-4e1f-b855-6c529b013687"
      decimals="-3"
      id="F_1916b4d2-1e41-4ecd-b80b-7054dc93122b"
      unitRef="U_USD">124000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9313b710-4b60-4e1f-b855-6c529b013687"
      decimals="INF"
      id="F_f4f346aa-3ccd-4b0d-9f12-ea6f17f050e8"
      unitRef="U_shares">3990869</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_41e65ead-4e0c-4591-b0c4-a8797159156c"
      decimals="-3"
      id="F_5b4bf936-d28f-4cfd-bb80-bc4445ec98ba"
      unitRef="U_USD">36595000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_eca7c1be-2d00-460c-b13a-ef933d52f723"
      decimals="-3"
      id="F_15240202-e4b0-4e39-a2d9-910eb70ea490"
      unitRef="U_USD">36595000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_324745d5-c5ad-4d27-9aeb-d15b72a94aaa"
      decimals="-3"
      id="F_eb97890f-31cd-4023-bc63-2724abe212d7"
      unitRef="U_USD">2348000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_324745d5-c5ad-4d27-9aeb-d15b72a94aaa"
      decimals="INF"
      id="F_1205757f-b36e-41b4-a66b-2305b902782f"
      unitRef="U_shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_324745d5-c5ad-4d27-9aeb-d15b72a94aaa"
      decimals="-3"
      id="F_2a435890-9b45-4aab-a38a-ce9b83118196"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b0d9da16-7637-4109-87b5-f82244fb1e67"
      decimals="-3"
      id="F_9f813c68-73a0-4ba3-968a-4a0a3e0da3e0"
      unitRef="U_USD">52652000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b83ef403-2580-41b1-b8e4-7f8b49fbd122"
      decimals="-3"
      id="F_f9977ade-7198-4256-8b58-19c331d73314"
      unitRef="U_USD">52653000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1"
      decimals="INF"
      id="F_49829b89-fb33-42ee-8d21-8ce4f382644f"
      unitRef="U_shares">183111</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f"
      decimals="-3"
      id="F_bfbce754-ba00-4edb-a19d-c687c9d470ca"
      unitRef="U_USD">914000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_296271c3-9e22-4025-b718-46f24713613a"
      unitRef="U_USD">914000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_ce01baa0-2b6b-406d-8ec3-3218ac59d5b9"
      decimals="-3"
      id="F_c1c89c17-301e-4648-af7e-6a9c04b2d4a2"
      unitRef="U_USD">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_475438b6-2fd1-4265-b777-e0ce198dc724"
      unitRef="U_USD">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <grts:IssuanceOfCommonStockForWarrantExercisesShare
      contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1"
      decimals="INF"
      id="F_b2bdd9df-d5b6-4780-9b16-d88d2e6128ee"
      unitRef="U_shares">10459576</grts:IssuanceOfCommonStockForWarrantExercisesShare>
    <grts:IssuanceOfCommonStockForWarrantExercisesValue
      contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1"
      decimals="-3"
      id="F_cd794fe6-7322-4df5-a4bf-de0bcd8780aa"
      unitRef="U_USD">1000</grts:IssuanceOfCommonStockForWarrantExercisesValue>
    <grts:IssuanceOfCommonStockForWarrantExercisesValue
      contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f"
      decimals="-3"
      id="F_bdaaf52b-d0eb-42fc-a49b-da405ad8c577"
      unitRef="U_USD">48000</grts:IssuanceOfCommonStockForWarrantExercisesValue>
    <grts:IssuanceOfCommonStockForWarrantExercisesValue
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_bcbba703-d68d-4fbf-a169-48e8b7a868d5"
      unitRef="U_USD">49000</grts:IssuanceOfCommonStockForWarrantExercisesValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_804f10c5-d6a7-4fbb-b4df-086426e19bb1"
      decimals="INF"
      id="F_d2c6f12d-92d8-41cd-93dd-8a19440fcf4f"
      unitRef="U_shares">692038</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f"
      decimals="-3"
      id="F_43388814-6dc3-4626-95e6-96d278534b51"
      unitRef="U_USD">3360000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_576b157a-fd75-4d89-80ba-7d8b7af57a50"
      unitRef="U_USD">3360000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_13677a63-5c18-4b4a-8b7c-a6e88324254f"
      decimals="-3"
      id="F_5c453682-069f-4f52-9196-b4a7c7ccc13b"
      unitRef="U_USD">10552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_1a9cd548-1a77-443e-b68d-35f80669f90d"
      unitRef="U_USD">10552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_4d220ecd-5fb6-43bf-b89a-7760384559a7"
      decimals="-3"
      id="F_f3ffa268-11cd-422f-af1b-fb50feeffcf2"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_e41a863b-ba40-43f8-a907-f2fd154b4797"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_a25d6e22-b4d5-4e42-baee-545cb40fb3b1"
      decimals="INF"
      id="F_895dd239-584a-4b54-8da5-2fde215d24d6"
      unitRef="U_shares">69047878</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a25d6e22-b4d5-4e42-baee-545cb40fb3b1"
      decimals="-3"
      id="F_65ee0f5f-938d-4fd6-ba70-b4306496759f"
      unitRef="U_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fef5557b-9238-461f-9d8d-6c180e1ea4c8"
      decimals="-3"
      id="F_6e885c7d-c85f-437a-9e52-40c7b387fd7c"
      unitRef="U_USD">617523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7a01aa4d-8457-4bc2-9506-f28d7946c515"
      decimals="-3"
      id="F_4288bef6-2e59-48ff-a3c5-605accbf2841"
      unitRef="U_USD">-73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8c95d954-77a7-4eb1-ad4e-f5368fb88348"
      decimals="-3"
      id="F_434d4713-1bef-408f-8e4d-321d1daa8998"
      unitRef="U_USD">-401384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_46eafb68-9ffa-47f1-a7cf-b68cc297a2cd"
      unitRef="U_USD">216086000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_3e3cea99-52ab-4572-a2f7-6ce19c94f86b"
      decimals="-3"
      id="F_b61b8558-2074-4ac3-a168-c0fe6160d6d8"
      unitRef="U_USD">146000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3e3cea99-52ab-4572-a2f7-6ce19c94f86b"
      decimals="INF"
      id="F_fb7bec78-0b51-4ce6-bb06-0f8e7f203004"
      unitRef="U_shares">7034948</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3e3cea99-52ab-4572-a2f7-6ce19c94f86b"
      decimals="-3"
      id="F_6cec6065-9ed2-41b4-ace2-51659eaf4524"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e91e3869-cc3b-4f71-bed9-29131644937a"
      decimals="-3"
      id="F_12155b6a-dc13-41b4-ae6a-002b775f38de"
      unitRef="U_USD">19591000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_74ebd140-1cd3-4d3c-b9b1-9fb227e15317"
      decimals="-3"
      id="F_00657d30-3bbe-48ac-9811-30598b24704b"
      unitRef="U_USD">19592000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_4f197d40-b7be-4d35-9b61-95f8f0d5b16c"
      decimals="-3"
      id="F_38c62593-9706-4855-8325-c12e1e923ea5"
      unitRef="U_USD">880000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4f197d40-b7be-4d35-9b61-95f8f0d5b16c"
      decimals="INF"
      id="F_dcd7293c-33f9-4105-94d2-a0c83405f42f"
      unitRef="U_shares">6637165</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4f197d40-b7be-4d35-9b61-95f8f0d5b16c"
      decimals="-3"
      id="F_27259560-e239-4218-af17-40f3128ccf17"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1ef1f41f-a1a4-42d6-8454-db92942dad65"
      decimals="-3"
      id="F_46e89f56-e098-4b0b-8f2e-4b59a6313494"
      unitRef="U_USD">14120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e6bd0364-0189-46f1-9a87-5b5ae7b4a68b"
      decimals="-3"
      id="F_cd8b5be3-c84d-4e74-aa63-2b7fc33c1ea4"
      unitRef="U_USD">14121000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_7e100875-202a-43a8-8544-eea71c373493"
      decimals="-3"
      id="F_c8ee633f-9ba8-48fb-8294-49994f0e5976"
      unitRef="U_USD">1759000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_1ef1f41f-a1a4-42d6-8454-db92942dad65"
      decimals="-3"
      id="F_4ea46562-d214-4859-85b2-1dfb2f5586d7"
      unitRef="U_USD">28240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_e6bd0364-0189-46f1-9a87-5b5ae7b4a68b"
      decimals="-3"
      id="F_bb205017-a4b3-49c4-9ad8-c564ed4f446d"
      unitRef="U_USD">28240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <grts:IssuanceOfCommonStockForWarrantExercisesShare
      contextRef="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7"
      decimals="INF"
      id="F_2f6474b6-f37f-4186-b528-3cb6aa4f5bf2"
      unitRef="U_shares">3442567</grts:IssuanceOfCommonStockForWarrantExercisesShare>
    <grts:IssuanceOfCommonStockForWarrantExercisesValue
      contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa"
      decimals="-3"
      id="F_f506f60d-941f-4dca-af58-67df44eafc61"
      unitRef="U_USD">34000</grts:IssuanceOfCommonStockForWarrantExercisesValue>
    <grts:IssuanceOfCommonStockForWarrantExercisesValue
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_0d5f0881-3afb-4a88-95e0-5772a7952989"
      unitRef="U_USD">34000</grts:IssuanceOfCommonStockForWarrantExercisesValue>
    <grts:IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares
      contextRef="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7"
      decimals="INF"
      id="F_718daf7f-1dfc-4f20-921f-180a8b9716f6"
      unitRef="U_shares">215350</grts:IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares>
    <grts:TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits
      contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa"
      decimals="-3"
      id="F_3cff36ba-38d6-48b2-a2dc-6dbb3e4f6b20"
      unitRef="U_USD">890000</grts:TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits>
    <grts:TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_a073753d-eae6-4db8-85ba-9e279ade7823"
      unitRef="U_USD">890000</grts:TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7"
      decimals="INF"
      id="F_0950d1a8-fcdc-4820-b072-bd9ef5895b49"
      unitRef="U_shares">322646</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa"
      decimals="-3"
      id="F_c5fdc7f2-127d-49c1-8405-83eca8db01a1"
      unitRef="U_USD">549000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_949376ac-9c04-40ab-babc-c82fbc532efd"
      unitRef="U_USD">549000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_c50db2bb-cff4-44de-98cc-cf159a62c91f"
      decimals="-3"
      id="F_279b65e8-d2ee-4077-b5a9-1b8a847ab840"
      unitRef="U_USD">-7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_330cc765-1f4b-4348-8754-38cc04cc5e6b"
      unitRef="U_USD">-7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_93a34a25-0de8-42bb-b7d5-be0e16232bc7"
      decimals="INF"
      id="F_8e14869d-6a50-4108-99df-cd0c94d6c11f"
      unitRef="U_shares">194347</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa"
      decimals="-3"
      id="F_af19413a-c8b1-4e0e-8d25-325561b449de"
      unitRef="U_USD">186000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_30a7c32e-895a-4cef-9b6b-12925ff33f40"
      unitRef="U_USD">186000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3bf29e99-103a-4385-809e-4cd89e8893aa"
      decimals="-3"
      id="F_db3dd44d-a876-45e6-9622-cecebc6f3699"
      unitRef="U_USD">12557000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_eb9cab4f-5b7e-40c2-b332-7cbda658d88f"
      unitRef="U_USD">12557000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_c86bb390-8ee5-48f9-aaf2-89a427c83966"
      decimals="-3"
      id="F_2f2d05e2-dc26-44af-b9b4-92d728abb00a"
      unitRef="U_USD">-119687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_af1569c6-5222-4143-8817-8c691e1c896d"
      unitRef="U_USD">-119687000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_937c1ade-1906-4692-bcc1-f9d4da800f1d"
      decimals="INF"
      id="F_71e43b56-96ca-4858-a388-1de784f4df79"
      unitRef="U_shares">86894901</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_937c1ade-1906-4692-bcc1-f9d4da800f1d"
      decimals="-3"
      id="F_f5c90c5f-ab79-437a-840e-7330d6c6063b"
      unitRef="U_USD">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3e7ededb-1c6b-46eb-a02d-62b731c0fb78"
      decimals="-3"
      id="F_b79308dc-1a2d-420f-ab16-83a8f88b37d0"
      unitRef="U_USD">691910000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7bebca71-1135-472b-9d92-4845eaa4225b"
      decimals="-3"
      id="F_24f7a41e-4287-4908-a225-bbb738862229"
      unitRef="U_USD">-80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ee3362ce-e6b6-4c81-9ddd-3a4c990659b1"
      decimals="-3"
      id="F_98c2ece9-75ac-45cf-9e33-ad43413188ab"
      unitRef="U_USD">-521071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_8325f11b-a3f2-4129-9088-4d8e7d1b2444"
      unitRef="U_USD">170781000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_492e262d-9abe-4ce8-9f7c-39d87a043cd0"
      unitRef="U_USD">-119687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_94e83611-022c-493f-b062-4d0bed369555"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_e57c35d0-d3f4-4932-9410-2cd5133cd2b5"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_784f088e-2fad-470a-9aca-a2dd5e41c54a"
      unitRef="U_USD">6560000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_ed0e9ff4-2308-4d60-81ed-3d3fe3619489"
      unitRef="U_USD">6347000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_de8bda58-c000-499e-ac4b-8645f68246e2"
      unitRef="U_USD">6644000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_ff6fe57b-a5c5-405a-9eb6-8047a52dcb3b"
      unitRef="U_USD">372000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_0369a228-4180-45a0-ae79-8bf63c3a6435"
      unitRef="U_USD">-817000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_2a90ec1e-2170-44d8-8d66-85fc8e2ec152"
      unitRef="U_USD">122000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_10b317d4-b61e-406c-b8e3-d1366f929a5a"
      unitRef="U_USD">392000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_76dc26af-03ae-4359-93ef-31368f834be3"
      unitRef="U_USD">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_06564564-7813-4d5a-82af-59048f16fc86"
      unitRef="U_USD">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_e0290601-4b87-4d98-94e6-6c224a00d105"
      unitRef="U_USD">12557000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_dfe6eb74-6787-4055-9e06-7cf4e792c68d"
      unitRef="U_USD">10552000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_fd9718f5-ff13-4be4-bcb2-8f9a1b77a5ef"
      unitRef="U_USD">7110000</us-gaap:ShareBasedCompensation>
    <grts:NoncashOperatingLeaseExpense
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_acc81f53-106a-4dc3-a072-d439d591e2ee"
      unitRef="U_USD">9131000</grts:NoncashOperatingLeaseExpense>
    <grts:NoncashOperatingLeaseExpense
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_ad3fad02-0a5f-48f0-8f6a-4bd156048c6b"
      unitRef="U_USD">8052000</grts:NoncashOperatingLeaseExpense>
    <grts:NoncashOperatingLeaseExpense
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_2cb32c6c-a0f3-4538-8e13-2125572ac3d5"
      unitRef="U_USD">7511000</grts:NoncashOperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_8524ac63-678a-451a-8e01-ffbb134b320a"
      unitRef="U_USD">-658000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_a0b86244-4d30-4527-bd7d-96f3e3fd88a9"
      unitRef="U_USD">3426000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_cf9d0bf7-08fd-4d39-b708-e35bbbb65af6"
      unitRef="U_USD">852000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_f3c977cf-fc47-4239-9b39-679754020039"
      unitRef="U_USD">7387000</grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent>
    <grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_274b36c9-b205-442c-afb4-10d978aff716"
      unitRef="U_USD">614000</grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent>
    <grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_25ba6c17-99e4-4d78-8b97-e938fb56f9da"
      unitRef="U_USD">-49000</grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_daeda54f-365a-45cd-b673-ec66af8f35fa"
      unitRef="U_USD">1879000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_fee06806-2039-4a8d-ad90-3792c4993f19"
      unitRef="U_USD">-419000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_5adeff90-fa6e-4123-99a6-19a7a40f9150"
      unitRef="U_USD">826000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_133eb36f-13ea-4b39-ab56-0aaba8cbf2ed"
      unitRef="U_USD">1290000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_ddb6bc90-0596-4e20-827b-f3872e2f084e"
      unitRef="U_USD">593000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_b9a642c8-4939-4efd-8bf3-3a1aaca1c546"
      unitRef="U_USD">1731000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_01c63474-11c4-4b80-a475-ea659d3e0f0e"
      unitRef="U_USD">3509000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_bbca246a-7e25-4dea-b7fd-43d77aea2b22"
      unitRef="U_USD">-859000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_bd1c01b6-1e97-495b-a39d-7a418e67313a"
      unitRef="U_USD">662000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_33ef5596-11a9-4cf8-a39b-3d545c86edf4"
      unitRef="U_USD">-363000</grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_3b544c2a-d99b-4dee-80be-e141b2f507af"
      unitRef="U_USD">2653000</grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_5259020a-8771-46bb-bd19-d2ebf42c6cc6"
      unitRef="U_USD">-725000</grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <grts:IncreaseDecreaseInLeaseLiability
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_1680ff2f-3c57-478b-8812-5899e4c0332f"
      unitRef="U_USD">-8915000</grts:IncreaseDecreaseInLeaseLiability>
    <grts:IncreaseDecreaseInLeaseLiability
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_ce6d18d8-996d-42cd-9502-16747f2622e1"
      unitRef="U_USD">-7925000</grts:IncreaseDecreaseInLeaseLiability>
    <grts:IncreaseDecreaseInLeaseLiability
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_75998d8c-bba5-465e-a9b1-fa5c4e372999"
      unitRef="U_USD">-3801000</grts:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_ab81bd24-5f9e-4bc2-830f-cb9e5ed411b7"
      unitRef="U_USD">-15198000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_fb58706a-1d29-4703-8cbb-4b1f073ccd00"
      unitRef="U_USD">8633000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_8c3ec544-429e-4a5e-a531-0a457abec5e9"
      unitRef="U_USD">-2821000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_fbfd4d9c-fcac-4126-9228-dfc70821a077"
      unitRef="U_USD">-115946000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_3d43de26-94b1-41fb-be68-334d0723a975"
      unitRef="U_USD">-50678000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_0be06a53-b714-42bb-ada1-2c8ae19cca0c"
      unitRef="U_USD">-89102000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_78d39bbf-5bdf-4a1c-a08b-2bd93db76c83"
      unitRef="U_USD">141908000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_c5270967-d030-4687-9d54-83a6739cd21b"
      unitRef="U_USD">199905000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_008518b0-b5b5-4aa4-87c5-daa27573b128"
      unitRef="U_USD">8809000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <grts:ProceedsFromMaturityOfMarketableSecurities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_28f7fb40-8ffe-4f54-8362-8ec3ef58a65a"
      unitRef="U_USD">134816000</grts:ProceedsFromMaturityOfMarketableSecurities>
    <grts:ProceedsFromMaturityOfMarketableSecurities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_03b3ec86-9135-4a98-8140-7d09091c0fa5"
      unitRef="U_USD">82253000</grts:ProceedsFromMaturityOfMarketableSecurities>
    <grts:ProceedsFromMaturityOfMarketableSecurities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_3600eaf0-af50-4943-b5e6-95a32ceeb452"
      unitRef="U_USD">72872000</grts:ProceedsFromMaturityOfMarketableSecurities>
    <grts:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_70624fb0-a121-48e8-a6dd-6560b5eed755"
      unitRef="U_USD">0</grts:ProceedsFromSaleOfMarketableSecurities>
    <grts:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_3b25b562-fec8-4b7b-b0d1-e922cb6b153a"
      unitRef="U_USD">4800000</grts:ProceedsFromSaleOfMarketableSecurities>
    <grts:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_934ae4e8-0df5-464e-869a-6b68d92981f7"
      unitRef="U_USD">5401000</grts:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_f24d0caf-18fc-47d0-a346-965f2a8dc30c"
      unitRef="U_USD">5872000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_09be9b96-d559-4cc5-91fc-2f2db24b799f"
      unitRef="U_USD">5463000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_415fe187-1d12-4ea8-96e0-c75aa01bb013"
      unitRef="U_USD">3515000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <grts:PrepaymentsOnFinancingLease
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_85c8c07c-1392-4573-ac49-ca7f22068a66"
      unitRef="U_USD">0</grts:PrepaymentsOnFinancingLease>
    <grts:PrepaymentsOnFinancingLease
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_cffb1adb-8654-47e2-8724-3382c95aa6be"
      unitRef="U_USD">238000</grts:PrepaymentsOnFinancingLease>
    <grts:PrepaymentsOnFinancingLease
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_3e9f50b1-4eee-443d-b096-d61f60a036ae"
      unitRef="U_USD">0</grts:PrepaymentsOnFinancingLease>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_7cd7a904-1900-4c2f-ba52-d951662760a6"
      unitRef="U_USD">-12964000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_d590420f-139e-40b2-95d3-a1069a242dc7"
      unitRef="U_USD">-118553000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_9ae9751e-bad5-42b0-8aa4-87672bc0ea14"
      unitRef="U_USD">65949000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_62ff936f-e544-4a9d-b314-581290027ea3"
      decimals="-3"
      id="F_72fb28b0-50e5-45b0-a3ed-7865ad40db97"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c0619058-b76c-4371-b472-a3486c28b486"
      decimals="-3"
      id="F_e7070655-de7d-4c6f-ab2d-e1f280214fea"
      unitRef="U_USD">21169000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a08ccbdf-1ba2-463d-8a51-346c12817d18"
      decimals="-3"
      id="F_b874ddc1-576d-4dc1-8882-27e9859c1f91"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_34e3705c-6db6-4be4-b4fa-7c9bc996cf50"
      decimals="-3"
      id="F_ab65fe2e-7308-44fe-acf6-989d35db9bd4"
      unitRef="U_USD">45000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b2a83568-2a86-4097-8ffb-41bc0c489eae"
      decimals="-3"
      id="F_e607ec23-79f6-4866-a371-c3ce9ea6abff"
      unitRef="U_USD">55000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ff2af9fa-a502-476a-95ef-6236ae054f89"
      decimals="-3"
      id="F_6b133a7a-02cf-438e-823c-687691e66af8"
      unitRef="U_USD">220000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7720965d-c288-42f6-a5f1-b3a368a46f6d"
      decimals="-3"
      id="F_df9d2660-9077-4bd7-a5ce-6d6fa3a202ca"
      unitRef="U_USD">3408000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_94f64277-8372-4366-a998-7f9abe66b1a2"
      decimals="-3"
      id="F_17531d67-2c32-4867-aae2-f35e71f29586"
      unitRef="U_USD">198000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_74ebd140-1cd3-4d3c-b9b1-9fb227e15317"
      decimals="-3"
      id="F_4e124a74-b2cf-464d-b051-4844dc881e6c"
      unitRef="U_USD">19737000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_eca7c1be-2d00-460c-b13a-ef933d52f723"
      decimals="-3"
      id="F_701047ef-cbbb-481e-b53d-ec38fbc04305"
      unitRef="U_USD">36719000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_809dbee3-02e2-412e-b2d8-47155edc68df"
      decimals="-3"
      id="F_a2fc77cc-6277-4052-8a04-7be9663efbc8"
      unitRef="U_USD">9770000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ef1d018e-1582-4a48-8fb5-58317716f6c2"
      decimals="-3"
      id="F_60913ec0-b979-47ba-8337-24f17839df25"
      unitRef="U_USD">549000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8acc4e2f-1b3b-4b68-8d11-a8d5e82e8ae1"
      decimals="-3"
      id="F_b7bc590b-17a8-4305-8484-bbbfa51e63b3"
      unitRef="U_USD">914000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2f02fe40-880c-4f03-95a7-5100852f2662"
      decimals="-3"
      id="F_b3a35ff0-749d-48f5-bbce-2281b4cede29"
      unitRef="U_USD">911000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_9d61e7f8-9293-4190-b85d-9d824d1e5c08"
      unitRef="U_USD">0</grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_f619f041-587a-4907-b1b7-98595280b600"
      unitRef="U_USD">0</grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_d5e94cb8-3e78-407c-9d86-a340c95d1c2f"
      unitRef="U_USD">125026000</grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_8f43889a-408c-43a5-aa76-3ea4f99a290c"
      unitRef="U_USD">19130000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_bb4a6bde-9ae5-4af6-8e74-48ceee5f4417"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_62d76ced-606f-4b51-a257-fa7081ebaac4"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_ce22fac1-5742-43e6-9fea-31ebcaf81f68"
      unitRef="U_USD">420000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_e58db76c-065c-4f3a-a36a-5ae0e3fd5c8a"
      unitRef="U_USD">8394000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_68400369-5915-4bf2-aa0a-a6ad8a82a9fa"
      unitRef="U_USD">104000</us-gaap:PaymentsOfFinancingCosts>
    <grts:PaymentsOfFinancingLease
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_5420a65c-6a51-40c9-91cc-ac440036242b"
      unitRef="U_USD">228000</grts:PaymentsOfFinancingLease>
    <grts:PaymentsOfFinancingLease
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_b13ccd0a-fda5-4f73-89d6-8007b65fa272"
      unitRef="U_USD">56000</grts:PaymentsOfFinancingLease>
    <grts:PaymentsOfFinancingLease
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_a2169801-d096-4a63-a39f-76583b339e71"
      unitRef="U_USD">0</grts:PaymentsOfFinancingLease>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_97fdb49c-fbf0-456e-af35-a1f248388027"
      unitRef="U_USD">890000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_3eb676ce-63b7-486e-8668-62cd0341f57a"
      unitRef="U_USD">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_2a02a6d6-7934-4bad-b828-48296700c35b"
      unitRef="U_USD">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_284aefc8-eadd-4473-b551-67fc15a2d2c5"
      unitRef="U_USD">83098000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_ceffae06-d7d8-44cb-b883-750ee4637e4c"
      unitRef="U_USD">108760000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_74145545-2342-4828-9b51-20710584b3b4"
      unitRef="U_USD">135801000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_496c7089-a5a4-49db-a60d-f916c7e2ae0b"
      unitRef="U_USD">-45812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_1cabe550-0069-46c9-8963-6f89d77db2c8"
      unitRef="U_USD">-60471000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_b25d81d0-c381-4850-bca8-9577a0dd867c"
      unitRef="U_USD">112648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_e4dbe53f-e314-4b25-8699-4688689af966"
      unitRef="U_USD">110577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      decimals="-3"
      id="F_216ec477-0f63-4280-8629-9e6d9c546ba3"
      unitRef="U_USD">171048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc"
      decimals="-3"
      id="F_91def029-ebe9-40fa-896c-d60e9a9b351c"
      unitRef="U_USD">58400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_fdd49604-39bd-4a87-90a8-8e7af9345fba"
      unitRef="U_USD">64765000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_32ad5fc5-6047-4eab-a903-eb9b78a9a1ba"
      unitRef="U_USD">110577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      decimals="-3"
      id="F_fb082764-cc61-4f1c-953d-71bc434eebf0"
      unitRef="U_USD">171048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_a3eb462e-8254-4e0d-b5a3-efd4e7deacaa"
      unitRef="U_USD">1146000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_39522a59-b8e0-4b4c-a968-05f57109c4d9"
      unitRef="U_USD">738000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_ec5bc43f-c81f-41b5-a6e1-f82380bfb4a9"
      unitRef="U_USD">316000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_ff8858c8-d4c4-4edc-aa93-5d7fab37e016"
      unitRef="U_USD">2433000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_162e351c-5ec0-447d-8ac6-d634b6255d6e"
      unitRef="U_USD">69000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_223bf9d7-da40-4432-a875-e31dc5d19f0e"
      unitRef="U_USD">5200000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_3da4b3dd-c9e7-428e-884b-272e2404e03c"
      unitRef="U_USD">1406000</grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification>
    <grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_272d4208-d946-44af-9008-b7cfa65898cc"
      unitRef="U_USD">6452000</grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification>
    <grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_bea3c6d6-3955-43b3-b908-3b31d0b47c12"
      unitRef="U_USD">3174000</grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_b8353827-d881-4be8-bddd-950df3fba6d6"
      unitRef="U_USD">553000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_a5e6acdf-b1ea-4e6b-954e-1181067f050f"
      unitRef="U_USD">109000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_10b275d7-edce-4545-b032-9880a82abc58"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_0f7034eb-72b9-4acc-8075-6c471b00da60"
      unitRef="U_USD">647000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_ca1cd03c-5517-4d8f-bc91-544928761e1a"
      unitRef="U_USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_c4ab1680-8628-4794-a6db-0be237ed885c"
      unitRef="U_USD">0</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_87c8d484-7a48-47d2-88c2-e6f62aa548cd">&lt;p id="notes_to_financial_statements" style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.	Organizat&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ion&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gritstone bio, Inc. (&#x201c;Gritstone&#x201d; or &#x201c;the Company&#x201d;) is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. The Company was incorporated in the state of Delaware in August 2015, and is based in Emeryville, California and Cambridge, Massachusetts, with a manufacturing facility in Pleasanton, California. The Company operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; segment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has incurred operating losses and has an accumulated deficit as a result of ongoing efforts to develop &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;drug&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. The Company had net losses of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022, 2021, and 2020, respectively. The Company used net cash of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;115.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million through its operating activities for the years ended December 31, 2022, 2021, and 2020, respectively. The Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;521.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;401.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021, respectively. To date, none of the Company&#x2019;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through private placements of its convertible preferred stock, the sale of common stock in public offerings, under an &#x201c;at the market offering&#x201d; (the &#x201c;ATM Offering Program&#x201d;), the private placement of common stock and pre-funded warrants, and through proceeds received from its collaboration arrangements. As of December 31, 2022, the Company had cash, cash equivalents and marketable securities of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the filing date of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_1ea1b066-b10e-4283-a101-4bd37a3f779d"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NetIncomeLoss
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_62dc25b8-1e87-42f8-b001-ed17f8bd40d7"
      unitRef="U_USD">-119700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-5"
      id="F_39d8d62d-e75e-4cea-a86f-9cb7af074a54"
      unitRef="U_USD">-75100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-5"
      id="F_78653318-c9bc-44e8-b60f-d9dc85e1bb93"
      unitRef="U_USD">-105300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_3be681ac-8582-4ea0-880f-193327596394"
      unitRef="U_USD">-115900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-5"
      id="F_e22770ca-6a32-41c6-8ffa-8a7c542992a8"
      unitRef="U_USD">-50700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-5"
      id="F_539a2259-2d79-4b55-b7e1-2f7497096086"
      unitRef="U_USD">-89100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-5"
      id="F_2b0c4f73-0d37-4e9d-98cd-314723d95227"
      unitRef="U_USD">-521100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-5"
      id="F_38128d2a-0c06-46ed-9492-42f7e6febbff"
      unitRef="U_USD">-401400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <grts:CashCashEquivalentsAndMarketableSecurities
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-5"
      id="F_be307c48-f131-4255-a487-76acc263b05b"
      unitRef="U_USD">175900000</grts:CashCashEquivalentsAndMarketableSecurities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_808b6224-f7a5-408d-881e-0d24606ec7cf">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.	Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Securities and Exchange Commission (the &#x201c;SEC&#x201d;) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for reporting. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and transaction price and progress toward completion of performance obligation under the contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within short-term restricted cash and deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#x2019;s restricted cash includes payments received under the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) Funding Agreement, dated as of August 14, 2021 (the &#x201c;CEPI Funding Agreement&#x201d;) and the Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents and short-term and long-term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.953%;"/&gt;
          &lt;td style="width:1.557%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.267%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.557%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.665%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#x2019;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; recognition of any other-than-temporary impairment in the year ended December 31, 2022, 2021 or 2020. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt Issuance Costs and Debt Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of the Compan&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;y&#x2019;s debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2022, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. Further, the Company is subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.315%;"/&gt;
          &lt;td style="width:1.583%;"/&gt;
          &lt;td style="width:31.102%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2022, 2021, or 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#x2019;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#x201c;ASC 606&#x201d;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#x2013; Revenue Recognition (&#x201c;ASC 958-605&#x201d;), which applies to business entities that receive contributions within the scope of ASC 958-605.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#x2019;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement and the Gates Grant Agreement (see Note 7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#x201c;the Black-Scholes model&#x201d;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation (based on the mid-point between the vesting date and the end of the contractual term) of the expected term for its stock options as the Company has concluded that its stock option history does not provide a reasonable basis upon which to estimate expected term. Volatility is based on an average of the historical volatilities of the common stock of entities with&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;characteristics &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;similar to the Company&#x2019;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#x2019;s technologies are recorded as research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#x2019;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#x2019;s consolidated balance sheets at December 31, 2022 and 2021. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes lease expense on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes and measures uncertain tax positions using a two&#x2014;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#x2019;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2022, the Company had not accrued interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 18, 2020, the Families First Coronavirus Response Act (the &#x201c;FFCR Act&#x201d;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 29, 2020, Assembly Bill 85 (&#x201c;A.B. 85&#x201d;) was signed into California law. A.B. 85 provides for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; suspension of the use of net operating losses for medium and large businesses and a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; cap on the use of business incentive tax credits to offset no more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for taxable years 2020 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#x2019;s consolidated financial statements as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the FASB issued ASU No. 2020-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Codification Improvements &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASU 2020-10&#x201d;). The standard contains improvements to the FASB Accounting Standards Codification (the &#x201c;Codification&#x201d;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. We adopted ASU 2020-10 on January 1, 2022 and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt - Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASU 2020-06&#x201d;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company does not expect the adoption of ASU 2020-06 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_05202508-6759-468b-9030-791fd231f75e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Securities and Exchange Commission (the &#x201c;SEC&#x201d;) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for reporting. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_48d9a357-1a25-4e54-86ba-6f6e41efc46a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and transaction price and progress toward completion of performance obligation under the contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_2cc31125-cf4e-43ce-9829-30f837b53756">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:2.269%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_57e5c70e-9be1-4a37-a2b5-89de8e2192fb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within short-term restricted cash and deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#x2019;s restricted cash includes payments received under the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) Funding Agreement, dated as of August 14, 2021 (the &#x201c;CEPI Funding Agreement&#x201d;) and the Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents and short-term and long-term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.953%;"/&gt;
          &lt;td style="width:1.557%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.267%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.557%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.665%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_c2f25ec2-5401-47c9-997b-29aaa4b34c1f">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents and short-term and long-term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.953%;"/&gt;
          &lt;td style="width:1.557%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.267%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.557%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.665%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_33172054-ef2c-4eb8-bb49-8737e5d8fecd"
      unitRef="U_USD">55498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_6ce4d8dc-6145-4648-b151-653b993fa215"
      unitRef="U_USD">93287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_ca8702d7-1834-4c0f-98b8-6fb207ce5114"
      unitRef="U_USD">3977000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_6bcab14e-0ccb-446b-b39d-2bfe74a3f545"
      unitRef="U_USD">11285000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_77c49c3b-0ae8-4d27-b219-678014049f13"
      unitRef="U_USD">5290000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_ab57d86e-765f-4691-ad4f-860e9f9e33ee"
      unitRef="U_USD">6005000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_d21157f1-bd07-4203-aac6-4f628af0d0ba"
      unitRef="U_USD">64765000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_f59ce5ef-7e7b-41a2-a5bf-30e72dbd0330"
      unitRef="U_USD">110577000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_81fc5f77-b048-49ed-a213-110c59c76337">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#x2019;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; recognition of any other-than-temporary impairment in the year ended December 31, 2022, 2021 or 2020. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_872cc23d-5893-47fe-8dc1-93a75f740a25"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_05967e7d-b88b-451f-abbd-d8e4f4fdd9ab"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_e9e0c94e-4bc8-4598-b1d6-7ed43503c8a2"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:DebtPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_299aab8e-e01f-4abd-b3fd-213e44b16f18">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt Issuance Costs and Debt Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of the Compan&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;y&#x2019;s debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_622a9267-7ec6-456b-8a64-2c14a15fed26">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2022, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <grts:OtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_dcc4c155-665e-46da-944c-76a26e2af7f4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. Further, the Company is subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.&lt;/span&gt;&lt;/p&gt;</grts:OtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_fcf3262e-eac8-4342-bb8c-10a31d993b9c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.315%;"/&gt;
          &lt;td style="width:1.583%;"/&gt;
          &lt;td style="width:31.102%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_846a5fc8-697a-4d17-8fb0-21f7909404ae">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.315%;"/&gt;
          &lt;td style="width:1.583%;"/&gt;
          &lt;td style="width:31.102%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f2b95b5c-aee8-40eb-8cee-80a189dab5a4"
      id="F_e37aafc6-ac32-40bf-a0f6-719671a93be9">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_672dd93b-be85-49d8-84d9-56d83b649236"
      id="F_c509d6c3-a6f8-441e-a248-16b10d843026">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f6117e7e-2c0b-40b3-93ef-a45d9e067e05"
      id="F_bd55e2ef-6088-4b82-be10-9fbb7267bcb7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_127f64ce-6b17-4ad1-9892-5332bca5d957"
      id="F_d1804f5c-4b3d-43a2-9116-77b12751e10e">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_b523bac1-1813-4b7d-a176-50e0e4c5ce15"
      id="F_2405017d-95cf-4acb-82bd-68a0874c669b">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_e6f99192-3731-4c3e-b249-3bcfe2f628f0"
      id="F_e22624a0-76ff-48dc-976d-04c989d8ac2c">Shorter of useful life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_d0635b17-62dc-4515-a0cc-df621b2eff55">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2022, 2021, or 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_096854c6-77d8-4d6d-8482-1cc6c18d705e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_760099af-105e-4b3d-b894-233bf40a8801"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_a2ba46ba-859a-46bc-8f12-4243a6e71487"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_fa1eb8bc-2f88-4a86-af21-6da014eb0416">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#x2019;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#x201c;ASC 606&#x201d;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#x2013; Revenue Recognition (&#x201c;ASC 958-605&#x201d;), which applies to business entities that receive contributions within the scope of ASC 958-605.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#x2019;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement and the Gates Grant Agreement (see Note 7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_61a9ed31-7abb-42e3-a5ae-6a06d20762b8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#x201c;the Black-Scholes model&#x201d;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation (based on the mid-point between the vesting date and the end of the contractual term) of the expected term for its stock options as the Company has concluded that its stock option history does not provide a reasonable basis upon which to estimate expected term. Volatility is based on an average of the historical volatilities of the common stock of entities with&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;characteristics &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;similar to the Company&#x2019;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_02b9c906-0cb0-463b-996f-55a8ffc716e9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#x2019;s technologies are recorded as research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_49585d21-15d3-41ba-8624-cc5b00c0e33c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#x2019;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#x2019;s consolidated balance sheets at December 31, 2022 and 2021. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes lease expense on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_9d1a4072-34f8-4462-8bbd-9feedfbacf17">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes and measures uncertain tax positions using a two&#x2014;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#x2019;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2022, the Company had not accrued interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 18, 2020, the Families First Coronavirus Response Act (the &#x201c;FFCR Act&#x201d;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 29, 2020, Assembly Bill 85 (&#x201c;A.B. 85&#x201d;) was signed into California law. A.B. 85 provides for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; suspension of the use of net operating losses for medium and large businesses and a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; cap on the use of business incentive tax credits to offset no more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for taxable years 2020 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#x2019;s consolidated financial statements as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <grts:PercentageOfRealizationOfTaxBenefitUponUltimateSettlement
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_92c90166-f9ea-4f50-9f31-29aa9d8c004f"
      unitRef="U_pure">0.50</grts:PercentageOfRealizationOfTaxBenefitUponUltimateSettlement>
    <grts:UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness
      contextRef="C_62816055-7eef-44a2-9784-8d2135365bf0"
      id="F_70164360-5f6d-404f-9140-927a1b129780">P3Y</grts:UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness>
    <grts:UseOfBusinessIncentiveTaxCreditsPeriodCap
      contextRef="C_62816055-7eef-44a2-9784-8d2135365bf0"
      id="F_4a194620-3a7b-4fe0-bd09-cf7756d17ae4">P3Y</grts:UseOfBusinessIncentiveTaxCreditsPeriodCap>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_4989ea59-69ce-4c78-bdac-1907a737f297"
      decimals="-5"
      id="F_25f97916-54ca-4ba7-aae2-cc63e183b910"
      unitRef="U_USD">5000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <grts:MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended
      contextRef="C_2d5436e0-6fd6-4397-a2ff-a7a44bc2b153"
      decimals="-5"
      id="F_ed103bfc-af9a-486c-a12d-75ad131c4258"
      unitRef="U_USD">1000000.0</grts:MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_4989ea59-69ce-4c78-bdac-1907a737f297"
      decimals="-5"
      id="F_1ff87892-7f47-42c1-baa2-b29abb7a515b"
      unitRef="U_USD">5000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_c08da178-526b-4e79-a425-b017256d259b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_dec731f2-4a5d-4aeb-930d-d39f257cdb19">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_1f9f38f4-0e29-4779-82e8-9ab332b4ccab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the FASB issued ASU No. 2020-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Codification Improvements &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASU 2020-10&#x201d;). The standard contains improvements to the FASB Accounting Standards Codification (the &#x201c;Codification&#x201d;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. We adopted ASU 2020-10 on January 1, 2022 and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt - Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASU 2020-06&#x201d;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company does not expect the adoption of ASU 2020-06 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_cd832e73-9d27-48d6-90f4-06265f544099">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.	Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.0%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.682%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.804%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.0%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.682%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.804%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, the Company had a total of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;206.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash, cash equivalents and marketable securities, which includes $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash and cash equivalents and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in marketable securities, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All marketable securities held as of December 31, 2022, had contractual effective maturities of less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. There have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no material realized gains or losses&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on marketable securities for the periods presented. As of December 31, 2022, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t hold any individual securities in an unrealized loss position &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for 12 months or greater&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; recognition of any other-than-temporary impairment in the year ended December 31, 2022, 2021, or 2020. The Company has not recorded an allowance for credit losses as of December 31, 2022 or 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 4 for further information regarding the fair value of the Company&#x2019;s financial instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_6f8b63d4-5b4a-413a-b7dd-e68ade9eb7e3">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.0%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.682%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.804%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.0%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.682%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.804%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924"
      decimals="-3"
      id="F_89058c68-7ef9-4128-8f2e-8491c80f77ce"
      unitRef="U_USD">38191000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924"
      decimals="-3"
      id="F_a357c056-d70e-408f-9593-347603b2966a"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924"
      decimals="-3"
      id="F_05b862d8-336a-421f-8ae4-ced1394b4d68"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b55015bc-b9b1-460e-bbd8-59c7d6a4f924"
      decimals="-3"
      id="F_fe0233b4-87b8-494d-80cf-94c932b8df5b"
      unitRef="U_USD">38191000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_40264f68-b348-4688-915a-7b32fbef6c41"
      decimals="-3"
      id="F_a0c83eb9-3678-495f-b1af-69828017840a"
      unitRef="U_USD">38191000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_40264f68-b348-4688-915a-7b32fbef6c41"
      decimals="-3"
      id="F_b2e18947-68bb-455c-9de0-a3182b1a34c3"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_40264f68-b348-4688-915a-7b32fbef6c41"
      decimals="-3"
      id="F_df2fdfcd-3367-4fc0-85fc-3aa325138c76"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_40264f68-b348-4688-915a-7b32fbef6c41"
      decimals="-3"
      id="F_5c22790b-cd27-4e81-9e55-ffd1d37e4004"
      unitRef="U_USD">38191000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_95d7df61-6b4c-4669-b173-7200708d3836"
      decimals="-3"
      id="F_c96751e1-b4ac-4342-bcdd-c50ce66456ad"
      unitRef="U_USD">948000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_95d7df61-6b4c-4669-b173-7200708d3836"
      decimals="-3"
      id="F_36bcf167-1ed7-4719-8a20-c013dbbef20b"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_95d7df61-6b4c-4669-b173-7200708d3836"
      decimals="-3"
      id="F_68656287-188e-4dbf-bb3f-7de4a339af63"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_95d7df61-6b4c-4669-b173-7200708d3836"
      decimals="-3"
      id="F_1d2047e1-c5ed-41d4-a3e0-dafceff38e8c"
      unitRef="U_USD">949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_17166196-5fed-4356-b3f5-8cfb8175ba74"
      decimals="-3"
      id="F_e9ceaa06-89a7-4531-b594-ec53969ae83b"
      unitRef="U_USD">33318000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_17166196-5fed-4356-b3f5-8cfb8175ba74"
      decimals="-3"
      id="F_b536ee4f-ccfd-4bce-9863-6f567760071f"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_17166196-5fed-4356-b3f5-8cfb8175ba74"
      decimals="-3"
      id="F_6b25ad30-8eb8-47bc-928c-081435960cd9"
      unitRef="U_USD">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_17166196-5fed-4356-b3f5-8cfb8175ba74"
      decimals="-3"
      id="F_64d375eb-7612-4038-9a38-590f4576b5b0"
      unitRef="U_USD">33328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3"
      decimals="-3"
      id="F_81a7cea3-ff2a-4bb1-ad27-d49634609e91"
      unitRef="U_USD">21887000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3"
      decimals="-3"
      id="F_5a9679ab-7646-4659-8064-f28b1b13c930"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3"
      decimals="-3"
      id="F_a8b8affc-fcaa-4452-9b66-fda93fe35594"
      unitRef="U_USD">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_940b37ed-eaf5-411f-8f22-9b3c6c7134c3"
      decimals="-3"
      id="F_25c27096-83c1-4ad8-8f87-76c4124fe19a"
      unitRef="U_USD">21853000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_27862347-30f4-4a51-8e69-155b8a286acb"
      decimals="-3"
      id="F_3f614486-fde5-4f21-8f58-f3f75e46b7e0"
      unitRef="U_USD">35608000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_27862347-30f4-4a51-8e69-155b8a286acb"
      decimals="-3"
      id="F_fb9e9213-3ae0-4ed4-ab7e-568d2eea85e4"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_27862347-30f4-4a51-8e69-155b8a286acb"
      decimals="-3"
      id="F_d89df764-15e9-4109-9a34-50150527f361"
      unitRef="U_USD">71000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_27862347-30f4-4a51-8e69-155b8a286acb"
      decimals="-3"
      id="F_db410380-63ab-45fa-9655-ce2615d4df76"
      unitRef="U_USD">35540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79"
      decimals="-3"
      id="F_d64e9ea0-6103-42ed-8f40-70ea8021c16c"
      unitRef="U_USD">24703000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79"
      decimals="-3"
      id="F_5767cb39-8900-4f59-8f00-8a44bb3a7381"
      unitRef="U_USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79"
      decimals="-3"
      id="F_f63ddd11-a099-40e8-819b-26923d3f369e"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d7c9f0cc-456d-4048-b0f7-bc57993eda79"
      decimals="-3"
      id="F_04226d88-ca24-4bdc-a317-fcedf32eb70f"
      unitRef="U_USD">24719000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c"
      decimals="-3"
      id="F_4bf9db16-ed08-46d5-a54f-f48ee18af047"
      unitRef="U_USD">116464000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c"
      decimals="-3"
      id="F_cf7b05e5-b1a1-4b1b-9e40-6a39f5c87afc"
      unitRef="U_USD">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c"
      decimals="-3"
      id="F_81031189-2de7-4409-bb96-e079f6d2902b"
      unitRef="U_USD">130000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4bef51ed-006f-4702-b7f2-c675f0d5cc6c"
      decimals="-3"
      id="F_5bfdf3f6-b16d-4f83-a261-d16c0100e8c9"
      unitRef="U_USD">116389000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a1b699c9-114f-4029-b6c6-56ba4c312c56"
      decimals="-3"
      id="F_79f028a5-9027-4221-a264-11ff7cc5849a"
      unitRef="U_USD">933000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a1b699c9-114f-4029-b6c6-56ba4c312c56"
      decimals="-3"
      id="F_050e624f-8aec-458f-a120-6b330c226494"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a1b699c9-114f-4029-b6c6-56ba4c312c56"
      decimals="-3"
      id="F_0782d2b3-2717-4bad-a363-439c411fa6af"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a1b699c9-114f-4029-b6c6-56ba4c312c56"
      decimals="-3"
      id="F_5c41656f-26f3-46a2-ad41-4cbc01b63967"
      unitRef="U_USD">932000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0"
      decimals="-3"
      id="F_0e8d9149-bf1b-4acd-a562-a22e1210c4d2"
      unitRef="U_USD">3103000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0"
      decimals="-3"
      id="F_c2d7a8e2-5d35-4db8-b411-6eec0a437166"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0"
      decimals="-3"
      id="F_1b81cff0-d0af-40c0-9b22-79a3d3f0e606"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5da4384c-ccbc-4c20-bdca-b61da1f1bbd0"
      decimals="-3"
      id="F_9b908d81-fcb6-49f7-b633-a67e7f8559da"
      unitRef="U_USD">3099000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6aa0ddf0-5c08-4e9d-a445-164033395389"
      decimals="-3"
      id="F_435755a1-5c71-4a40-be5b-358a83cb779f"
      unitRef="U_USD">4036000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6aa0ddf0-5c08-4e9d-a445-164033395389"
      decimals="-3"
      id="F_a655cd74-9c57-4afe-a873-d4307add97a8"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6aa0ddf0-5c08-4e9d-a445-164033395389"
      decimals="-3"
      id="F_9d800261-910e-4dfc-a67c-0634e90a5b81"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6aa0ddf0-5c08-4e9d-a445-164033395389"
      decimals="-3"
      id="F_bef9e747-ba4c-441b-ac32-987113b7c6bc"
      unitRef="U_USD">4031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_807ed40f-051d-4b88-bdcb-7f17b639e618"
      unitRef="U_USD">158691000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_12e37729-edc8-4597-82f1-b792173cf912"
      unitRef="U_USD">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_aa6b05b8-53ed-45c7-9521-9f5b8b12f9a7"
      unitRef="U_USD">135000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_0a090362-6963-41ce-9021-d7ba07998336"
      unitRef="U_USD">158611000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_351091de-7324-4fdd-81d4-70155fd963f8"
      decimals="-3"
      id="F_facc847c-791e-470f-b38f-98301d2a754a"
      unitRef="U_USD">79281000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_351091de-7324-4fdd-81d4-70155fd963f8"
      decimals="-3"
      id="F_6d307a2a-c5c6-4255-bc28-d263cdc096f1"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_351091de-7324-4fdd-81d4-70155fd963f8"
      decimals="-3"
      id="F_8f41f722-76e6-487e-94d9-57af4ab401f4"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_351091de-7324-4fdd-81d4-70155fd963f8"
      decimals="-3"
      id="F_e1e6e1e2-1774-4a4b-b13e-5b2e54f85dfe"
      unitRef="U_USD">79281000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_bd77beb2-c5d1-4f28-877c-995caa385c8e"
      decimals="-3"
      id="F_b75b5caa-b355-49ed-859d-7be079ae6fcc"
      unitRef="U_USD">1000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_bd77beb2-c5d1-4f28-877c-995caa385c8e"
      decimals="-3"
      id="F_f753ce4a-8b37-4687-b961-fcbc5b009d95"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_bd77beb2-c5d1-4f28-877c-995caa385c8e"
      decimals="-3"
      id="F_d143dfe0-5764-475d-a59e-c17dd2413bd0"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_bd77beb2-c5d1-4f28-877c-995caa385c8e"
      decimals="-3"
      id="F_8853d85d-d9dc-4fa0-8cc1-6aca78bbc8d2"
      unitRef="U_USD">1000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5a176657-560e-4e80-8117-9b6ae2388147"
      decimals="-3"
      id="F_83bfd090-717d-439d-9294-6805eda25341"
      unitRef="U_USD">1031000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_5a176657-560e-4e80-8117-9b6ae2388147"
      decimals="-3"
      id="F_4586e875-656c-4396-8020-60b0c4956a79"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_5a176657-560e-4e80-8117-9b6ae2388147"
      decimals="-3"
      id="F_107cf4c6-ab86-4635-afff-1cf31df0aa1f"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5a176657-560e-4e80-8117-9b6ae2388147"
      decimals="-3"
      id="F_34d36338-92e9-40bf-9226-2b94333e5023"
      unitRef="U_USD">1031000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4"
      decimals="-3"
      id="F_a29d6bf7-4041-4c0a-91e7-a9eb4e66f130"
      unitRef="U_USD">81312000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4"
      decimals="-3"
      id="F_0d5f31b4-5ee1-4555-a774-7edb8f3c7018"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4"
      decimals="-3"
      id="F_f9d59efc-5cb0-4f1f-89c0-fe6bf27187e2"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_244a9cec-d83b-4a36-8aa1-3b6aed4e6cd4"
      decimals="-3"
      id="F_dbcc569f-7f90-4f24-9281-093ee75f1b34"
      unitRef="U_USD">81312000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2152b17d-baee-4d49-a165-456d92d2f320"
      decimals="-3"
      id="F_9507d058-fee5-4565-a83b-68e3eee6aabc"
      unitRef="U_USD">5600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2152b17d-baee-4d49-a165-456d92d2f320"
      decimals="-3"
      id="F_e5a6059c-4c48-46ad-b23a-0efec50ba3cd"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2152b17d-baee-4d49-a165-456d92d2f320"
      decimals="-3"
      id="F_89ffa4d0-3955-41c5-a93b-a78ffbecd3c0"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2152b17d-baee-4d49-a165-456d92d2f320"
      decimals="-3"
      id="F_1d02a562-63c7-47bc-898a-27b387d24a33"
      unitRef="U_USD">5594000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2b45ae22-69b8-4005-8ab9-321b6b14f107"
      decimals="-3"
      id="F_1aa96627-5916-4923-9e03-681eb2275a7c"
      unitRef="U_USD">44990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2b45ae22-69b8-4005-8ab9-321b6b14f107"
      decimals="-3"
      id="F_eb1c7f76-3ec1-463f-9186-a7af48790cb6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2b45ae22-69b8-4005-8ab9-321b6b14f107"
      decimals="-3"
      id="F_66204e5f-b788-4301-aef9-916afe4fdf16"
      unitRef="U_USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2b45ae22-69b8-4005-8ab9-321b6b14f107"
      decimals="-3"
      id="F_e869fb95-5a8c-4f23-883e-8758bef7f0c7"
      unitRef="U_USD">44974000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8437c548-599f-4c6f-9584-e7e7d46f0379"
      decimals="-3"
      id="F_7fd66a37-fb0d-44d8-bbc8-83285a7460b3"
      unitRef="U_USD">26976000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8437c548-599f-4c6f-9584-e7e7d46f0379"
      decimals="-3"
      id="F_45119bcf-9c0c-434e-be2c-f3cd4bf031b7"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8437c548-599f-4c6f-9584-e7e7d46f0379"
      decimals="-3"
      id="F_f6811544-690f-4fb4-be5d-8f9fd5dc4490"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8437c548-599f-4c6f-9584-e7e7d46f0379"
      decimals="-3"
      id="F_3dec1818-36c2-49af-b245-ce9056f40156"
      unitRef="U_USD">26953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_077f94f8-990f-491f-98d1-d6eb5debde18"
      decimals="-3"
      id="F_883f6231-4507-49e2-900b-76ea8f3d29ab"
      unitRef="U_USD">12277000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_077f94f8-990f-491f-98d1-d6eb5debde18"
      decimals="-3"
      id="F_9c8589db-1d9e-4b60-970a-52a2e861c400"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_077f94f8-990f-491f-98d1-d6eb5debde18"
      decimals="-3"
      id="F_002893d5-88aa-4239-8b5c-5b2971c60c97"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_077f94f8-990f-491f-98d1-d6eb5debde18"
      decimals="-3"
      id="F_f48fdb20-d461-430b-8979-747482f1b03e"
      unitRef="U_USD">12269000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3715424f-76fd-4a70-bcb7-f905fcadf133"
      decimals="-3"
      id="F_367a5a7e-1deb-4072-a7c7-1464db3475a1"
      unitRef="U_USD">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3715424f-76fd-4a70-bcb7-f905fcadf133"
      decimals="-3"
      id="F_4013164c-7a23-4b2f-8584-f6d0cda545bc"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3715424f-76fd-4a70-bcb7-f905fcadf133"
      decimals="-3"
      id="F_dfe42852-5c2b-4d3a-be74-16275d1d2991"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3715424f-76fd-4a70-bcb7-f905fcadf133"
      decimals="-3"
      id="F_1228330d-a8e8-432c-8883-d32053f3706b"
      unitRef="U_USD">1999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8b0ba039-9d60-4e77-8a56-2a70e004643a"
      decimals="-3"
      id="F_74f69623-6e68-4b67-af7f-edc4856511a5"
      unitRef="U_USD">16565000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8b0ba039-9d60-4e77-8a56-2a70e004643a"
      decimals="-3"
      id="F_72ba9cfd-8418-4c7b-830e-a2ad4d4178b4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8b0ba039-9d60-4e77-8a56-2a70e004643a"
      decimals="-3"
      id="F_76e83720-55b3-4a98-830b-e0b1a13da241"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8b0ba039-9d60-4e77-8a56-2a70e004643a"
      decimals="-3"
      id="F_297eea9f-67a2-4775-9eb9-6b200342b605"
      unitRef="U_USD">16557000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8900ff95-7d4c-4827-aab8-7f758672ca22"
      decimals="-3"
      id="F_ca245892-83c0-47a7-af11-51e9643885de"
      unitRef="U_USD">108408000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8900ff95-7d4c-4827-aab8-7f758672ca22"
      decimals="-3"
      id="F_a379087f-a54e-4456-abbb-1457616e76fd"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8900ff95-7d4c-4827-aab8-7f758672ca22"
      decimals="-3"
      id="F_27c1be5d-7263-4f35-a046-ef5787e1e8c7"
      unitRef="U_USD">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8900ff95-7d4c-4827-aab8-7f758672ca22"
      decimals="-3"
      id="F_cc483e95-76bd-4e55-b23d-2cf767a54cee"
      unitRef="U_USD">108346000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_40424169-d409-40ab-8018-026dc29baf15"
      decimals="-3"
      id="F_fc029aae-b38d-482b-b62f-6a302a84299f"
      unitRef="U_USD">1637000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_40424169-d409-40ab-8018-026dc29baf15"
      decimals="-3"
      id="F_44909b82-d212-4405-9e7b-a87d048a5d4a"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_40424169-d409-40ab-8018-026dc29baf15"
      decimals="-3"
      id="F_ef14cf61-073f-4ca2-9499-7e4089228f71"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_40424169-d409-40ab-8018-026dc29baf15"
      decimals="-3"
      id="F_2dd4a498-28a5-4113-87cf-58046982df5c"
      unitRef="U_USD">1631000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8"
      decimals="-3"
      id="F_f1111c00-6377-44d8-afe2-3c46f8ebf73a"
      unitRef="U_USD">2991000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8"
      decimals="-3"
      id="F_44f45e2d-a657-47c2-aaa0-3be252c75a09"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8"
      decimals="-3"
      id="F_ebca4f9f-0ebb-4913-920c-65e29a3b8251"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_eec32a77-0a39-4cbe-bfd1-1ef9a2191fb8"
      decimals="-3"
      id="F_8602aa33-2069-45c6-a66c-8121f38e6ef1"
      unitRef="U_USD">2986000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93"
      decimals="-3"
      id="F_146a9a0f-2ed8-480e-abc8-1fd9cc7e2520"
      unitRef="U_USD">4628000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93"
      decimals="-3"
      id="F_2f8a2aff-8544-48d3-b8d2-b3bed4edd2d8"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93"
      decimals="-3"
      id="F_fbd3d416-8f88-41e1-875b-066e72e02187"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c1c3197c-1ff0-43eb-86a7-81ffb7a32b93"
      decimals="-3"
      id="F_080ab06a-7f65-4251-9066-ba775ce8a5cf"
      unitRef="U_USD">4617000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_38c7ec8c-30c4-4855-9dbd-c7c160be1150"
      unitRef="U_USD">194348000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_86c40c3e-a929-4e99-aeba-58bddd107541"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_30ee4a67-69f6-4bb8-9f06-8120d6f4f5ae"
      unitRef="U_USD">73000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_b2385008-527f-492b-86b4-f8d9fae5d4ae"
      unitRef="U_USD">194275000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <grts:CashAndCashEquivalentsAndMarketableSecurities
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-5"
      id="F_bba3043a-7dc9-42b2-b8e8-57b85affdcfb"
      unitRef="U_USD">175900000</grts:CashAndCashEquivalentsAndMarketableSecurities>
    <grts:CashAndCashEquivalentsAndMarketableSecurities
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-5"
      id="F_3976fcc4-54a8-4c00-a6ee-ca6021ddf256"
      unitRef="U_USD">206300000</grts:CashAndCashEquivalentsAndMarketableSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-5"
      id="F_e94f0f13-34b2-4433-a7c4-743f8578a080"
      unitRef="U_USD">55500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-5"
      id="F_c2b797e6-70fa-4666-8690-c82001517ef8"
      unitRef="U_USD">93300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-5"
      id="F_08951269-c272-4d16-87cb-c0c916d1ebdc"
      unitRef="U_USD">120400000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-5"
      id="F_e57648a2-6a4e-430f-9e0b-4b2e7f73170b"
      unitRef="U_USD">113000000.0</us-gaap:MarketableSecurities>
    <grts:MarketableSecuritiesContractualMaturitiesPeriod
      contextRef="C_a6647160-7b5e-4902-9018-3678bdb60427"
      id="F_2cd7c064-04ba-41cc-97c4-32b764a63021">P2Y</grts:MarketableSecuritiesContractualMaturitiesPeriod>
    <grts:MarketableSecuritiesRealizedGainLossDescription
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_955a1a8d-da7f-4244-817e-dfd03bd0ae1b">no material realized gains or losses</grts:MarketableSecuritiesRealizedGainLossDescription>
    <grts:MarketableSecuritiesRealizedGainLossDescription
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      id="F_3837de02-5585-426b-b2ba-8b352849a702">no material realized gains or losses</grts:MarketableSecuritiesRealizedGainLossDescription>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="0"
      id="F_2526008a-eaf1-437e-8cac-e9b464b37e13"
      unitRef="U_Security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_b019b342-c222-4bb0-a430-76061d8d4ada"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_89e6827a-8302-466b-b031-4ef6406a8b51"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_648df21b-507d-49f7-bac7-edad7717107b"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_0498457a-307e-48a2-8775-16b5c6bb3042">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.	Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.422%;"/&gt;
        &lt;td style="width:1.174%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.777000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.422%;"/&gt;
        &lt;td style="width:1.174%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.777000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures the fair value of money market funds and U.S. treasuries based on quoted prices in active markets for identical securities. Commercial paper, corporate debt securities, certificates of deposits, asset backed securities, and U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transfers between Level 1 and Level 2 during the periods presented. See Note 3 for further information regarding the amortized cost of our financial instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_0cb93ce4-a88e-4c2e-bc80-e10d7127be34">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.422%;"/&gt;
        &lt;td style="width:1.174%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.777000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.422%;"/&gt;
        &lt;td style="width:1.174%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.777000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_278c4452-2cac-4960-b90f-088134dd9e53"
      decimals="-3"
      id="F_6bce47fb-20ba-484a-9bc5-bab8913aa3b9"
      unitRef="U_USD">38191000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e9a3cb9b-7c28-49b3-ba96-6f4a5a29c371"
      decimals="-3"
      id="F_ae2a1b50-6454-44b4-abbd-bb784a23aae7"
      unitRef="U_USD">38191000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_23c937ef-9873-4e7b-8401-361c0141be20"
      decimals="-3"
      id="F_ae6615f4-728c-4aa4-804a-7998e393ce6b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5eeb50c4-7bbf-4897-a80f-34577a6faa71"
      decimals="-3"
      id="F_c6277d52-5c2a-404d-a818-e6b8be553636"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8ea4d358-ae99-4f6d-8fc9-63316759fe1d"
      decimals="-3"
      id="F_6cb98336-cc0a-4d23-9808-d8c5587ec68f"
      unitRef="U_USD">38191000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_68ae43bc-d4ba-46ef-b787-9a1a51cd49b5"
      decimals="-3"
      id="F_85716238-faf8-4919-a3d1-deee32fcd9a8"
      unitRef="U_USD">38191000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0f1c0918-b40b-45ce-a32a-5ff2e0cdb811"
      decimals="-3"
      id="F_a68bbd79-2792-4c8d-8f45-3d9731842177"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_594d238f-4b26-4a67-892c-13ccd5be28e5"
      decimals="-3"
      id="F_2961c447-ee02-4ac0-af84-4cdde8d9272d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_76e247f4-22b6-4c8d-8bcc-5e1bb0cc9367"
      decimals="-3"
      id="F_d95d328c-0b21-4309-aeae-2166762459e7"
      unitRef="U_USD">949000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_489b2495-a848-4ec1-ae47-5647173197f9"
      decimals="-3"
      id="F_176ea312-27a1-41ac-8eb8-334b996aac40"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3a579eb0-d553-498a-9517-437c3bb7acbc"
      decimals="-3"
      id="F_0c533f23-55f7-497b-ac91-783ce3722186"
      unitRef="U_USD">949000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5fc9c11d-6f3f-4fe0-a8a9-6900a0dbaae3"
      decimals="-3"
      id="F_dd7705c4-3d47-4042-abf4-381bd40c0673"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b1d550f9-c0a6-4ff2-941b-a0771a52258d"
      decimals="-3"
      id="F_d62ef2a5-6b31-48b2-9643-a4d6bb29fe55"
      unitRef="U_USD">33328000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2f5dbf8f-812f-4ffe-9bac-799e8547d2d6"
      decimals="-3"
      id="F_b096f553-8d5f-4d9c-9534-2cf00b148c58"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_45aa777d-f982-4434-82ec-6619331cbe4a"
      decimals="-3"
      id="F_34088781-6018-4291-baf3-f4cf6c828c0c"
      unitRef="U_USD">33328000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aa58fee8-bbe5-446e-8e6a-a951cc8fb7a1"
      decimals="-3"
      id="F_08fd9413-57e8-4e86-bf1b-9a436d605af5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6fdb3010-aa4d-4332-a56d-c9ff8991e214"
      decimals="-3"
      id="F_93959b33-360c-4698-bf7a-1c60ec355059"
      unitRef="U_USD">21853000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6674d76c-7bfb-45ae-99e4-e6beb133f3b0"
      decimals="-3"
      id="F_664827da-822d-474b-9da9-6bce807696b8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a899ce5d-e51a-4a72-98ff-ca5442a68952"
      decimals="-3"
      id="F_ef7a88ef-dfb6-4d54-8716-155d18fb44b0"
      unitRef="U_USD">21853000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2ca307da-79aa-45f0-952e-4bd76b2798b5"
      decimals="-3"
      id="F_b1220fd2-4d04-4aa5-b99c-0da42b68937d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_25953651-9e56-416b-b771-e53f99a9c2b7"
      decimals="-3"
      id="F_4d299f6a-49a2-4b98-aa6a-7211b18b6c34"
      unitRef="U_USD">35540000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e1c1fbc0-d63c-43b7-9ffc-6ad92761fe9a"
      decimals="-3"
      id="F_ca01fd4f-df55-4827-8e06-40350fd63cf9"
      unitRef="U_USD">35540000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aadd6041-4d4d-471c-8758-30fc80ec55da"
      decimals="-3"
      id="F_8467882e-cb49-4c0f-89ea-5832a5e6c837"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_af34b684-6740-4987-8a92-febe2af8bcc5"
      decimals="-3"
      id="F_01a2aff8-642c-4385-ab63-658088a3d679"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5df76468-2d33-4c29-bdf7-4567b8bbe0be"
      decimals="-3"
      id="F_47c4bcc3-b0c2-4096-b117-4c361f50777f"
      unitRef="U_USD">24719000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_daff6bb1-ec2f-40fb-b9ff-6c866bc3bfce"
      decimals="-3"
      id="F_62618e8a-3a10-467f-bf28-50c41d314d2f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c884b3b8-4d8e-4b0b-b827-70428cfbef2d"
      decimals="-3"
      id="F_d3c1010c-7f37-4aa7-8bb4-60c7cd3be4ef"
      unitRef="U_USD">24719000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cef2dcb9-4d72-401b-9b51-ca2ec7658d4f"
      decimals="-3"
      id="F_edf7cb11-1135-422c-9048-6a59487e09b6"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_58b1c9d9-769e-46b9-8c0b-1522ce09ece0"
      decimals="-3"
      id="F_a92a4469-0fa2-42a2-adb7-cb83c1cb250b"
      unitRef="U_USD">116389000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_927c9adc-769a-4197-8a7b-ca4f1f62c776"
      decimals="-3"
      id="F_1201a129-fc94-4ae5-b885-755e0b7bf3a1"
      unitRef="U_USD">35540000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8cc492f6-e0e9-4dad-b467-56ec30f2625c"
      decimals="-3"
      id="F_dae0ccbd-b2b7-4100-812d-5524ab4d951f"
      unitRef="U_USD">80849000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_97b3c3ab-b721-45c5-a7f8-8b63dd151af6"
      decimals="-3"
      id="F_e2a11e75-fb13-47f9-bf5d-d1e060d8d382"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_75882f1e-2c2b-4a1f-86db-757c8eb713b1"
      decimals="-3"
      id="F_824c2974-05c4-4e16-a951-fc82acf68887"
      unitRef="U_USD">932000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9f752682-fc55-4997-9e66-a13d860093aa"
      decimals="-3"
      id="F_cb3f1c33-3f3f-4087-9eae-d61cf77bb3b4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4e50f083-971a-4ba3-921b-feac5bdbdbc5"
      decimals="-3"
      id="F_c44678c3-7a96-4e7b-8b21-4609b4e98867"
      unitRef="U_USD">932000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_56b7d049-aed0-43f4-a9e5-39af8293efe5"
      decimals="-3"
      id="F_8209f693-16ad-4479-a147-71ce0a026768"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_71524de7-0086-49d7-9417-13f7efabd4d3"
      decimals="-3"
      id="F_a39fe2dd-3f53-43c1-b155-4c6ab6b40625"
      unitRef="U_USD">3099000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7de13c8f-bc45-44f8-a635-d16cfe8fed70"
      decimals="-3"
      id="F_e9b4cd14-18af-4ba6-97e9-fd8f150167ab"
      unitRef="U_USD">3099000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dd9632a7-d460-4003-8a48-c36e620a0c77"
      decimals="-3"
      id="F_5094886c-9843-4827-b849-3ef8cb5cb67a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d50b36e8-0a1e-4794-a381-440b70d6bf56"
      decimals="-3"
      id="F_a236f401-6e69-4d5e-97b2-607a6f8a4d3b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9faed10b-deab-4fc4-8710-bcca92fcb310"
      decimals="-3"
      id="F_e2387f57-e615-4bdb-9c5a-ec5f2253dfa0"
      unitRef="U_USD">4031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c62e59ac-4c24-44ca-b119-f4e4f1990e9b"
      decimals="-3"
      id="F_a9b1993b-0ae8-4473-9487-cee1154a1562"
      unitRef="U_USD">3099000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a9559e13-2a2f-4a2d-bb75-e9c9777abe4f"
      decimals="-3"
      id="F_9cd09162-6dc9-4497-a6e4-ace0e544a840"
      unitRef="U_USD">932000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_73444588-46b3-4e78-bfe2-a5e3294d5d4d"
      decimals="-3"
      id="F_c6151cb0-d622-4981-8634-851cc57cbc02"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3295931d-4cf6-4ed7-9b11-e42a2fb87408"
      decimals="-3"
      id="F_a25b30c1-9a3c-4534-aeab-656566510531"
      unitRef="U_USD">158611000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3dab2c7d-c16a-4d70-98ba-da1026b8f662"
      decimals="-3"
      id="F_136e78d2-e37a-4409-8386-9ca75a7a8509"
      unitRef="U_USD">76830000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_31827499-df5a-4144-a589-97ec604bab7f"
      decimals="-3"
      id="F_416e415a-9637-4fed-ae1b-73e22fe8b506"
      unitRef="U_USD">81781000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_40a76726-c327-40be-89dd-1c7d982d5836"
      decimals="-3"
      id="F_84c7bb05-1b4d-4194-8943-cf99b7f21ac4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bd4c978d-db21-4656-99dc-dd258c79185d"
      decimals="-3"
      id="F_9f53ffc3-3a5a-45e0-aa44-7b08ff5f013c"
      unitRef="U_USD">79281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_654ac5ed-1cde-4438-bd70-e413cdecd6a8"
      decimals="-3"
      id="F_64645c8f-d8e1-47f2-9cf5-92a012102766"
      unitRef="U_USD">79281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f6215bc4-d5d7-4c03-9ddb-fab6020892dc"
      decimals="-3"
      id="F_d34183ed-ab0d-4e8e-8623-4d7fbeefe9c5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1802000b-946a-45cf-9eb1-ab878fd907d2"
      decimals="-3"
      id="F_c9aae01c-0b0f-4033-ab0e-f9b998946b6b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_739f34c4-9e15-4e81-85c9-c9c472575986"
      decimals="-3"
      id="F_871bee68-97aa-4cb0-8351-fbe4a085a149"
      unitRef="U_USD">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bece036d-3f60-44c3-9f38-745d2aac748e"
      decimals="-3"
      id="F_1f21da42-5db2-4aac-985c-cf0dafc51f58"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a7439677-3eea-449d-ba9d-9af37deb00df"
      decimals="-3"
      id="F_3c64fd63-2058-4279-a8d7-c6469e462d2e"
      unitRef="U_USD">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b6ab88c2-0338-4075-8ed9-d7c8fee513c0"
      decimals="-3"
      id="F_d7e8606f-b0e4-4c8e-9304-0e2c181470db"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_27904f74-af74-4e0d-afa5-d30b372b7427"
      decimals="-3"
      id="F_86517c1d-6b42-4251-8567-1ca9d3abbb7c"
      unitRef="U_USD">1031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_81ba52a0-a708-443b-b8aa-b7e87669392e"
      decimals="-3"
      id="F_c72d1688-b595-405c-98a8-0fb00757443c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dd661f8c-80f3-437b-94c6-39b2d87a6b09"
      decimals="-3"
      id="F_74026196-98a4-41c8-a18e-35fb0b6e18d0"
      unitRef="U_USD">1031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9adf420e-a107-42cb-a6a6-902bddde7540"
      decimals="-3"
      id="F_cb865000-d385-41e5-b91e-37a160365c35"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d2f985e7-3856-436a-b098-7d96d2ec9b97"
      decimals="-3"
      id="F_a2fd630f-d3f5-4c98-9f21-106250f3b05b"
      unitRef="U_USD">81312000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dd5de76e-097b-41d2-b92d-4e0353e1ee49"
      decimals="-3"
      id="F_cf57a29e-c715-4b4e-9963-d55175479a26"
      unitRef="U_USD">79281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3daa3e39-3faa-4c82-a714-e0e8c91e437f"
      decimals="-3"
      id="F_f9b70ff8-5c25-4a4a-a3b2-fe0b675a9a46"
      unitRef="U_USD">2031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e6370a8f-2667-466f-98d3-1e9d3a327fa7"
      decimals="-3"
      id="F_dcecc3f9-ef57-4fbc-9bbb-91069e19c392"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c944192d-7243-4e20-9dee-9ed4870b3302"
      decimals="-3"
      id="F_eb01ffcf-c2e8-4b7b-88c4-f490c09c23cc"
      unitRef="U_USD">5594000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_39844211-5dca-42b7-88f9-d6efbab7fcb0"
      decimals="-3"
      id="F_f13f66b2-f09c-446a-a06e-583c3f790df0"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_816d085d-25a0-4fe5-a1f4-76e96db59467"
      decimals="-3"
      id="F_297c2b80-390f-4d78-9094-4d4098b7f6f7"
      unitRef="U_USD">5594000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_431f0e99-dc7d-46f0-aaf5-b5f357500cef"
      decimals="-3"
      id="F_8b8ae5e6-da3b-4e8e-8cff-78286f540d7f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_99d8a4f5-b851-48db-a6e7-61d21c828ead"
      decimals="-3"
      id="F_2f20311c-4fbe-4e4a-a35b-00a1d9404cf6"
      unitRef="U_USD">44974000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_466e6120-0e46-457a-95cb-1badad395cad"
      decimals="-3"
      id="F_a38ccd21-e7c7-439a-9d67-7f7da3a6a1f9"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6f4a9e62-6ab4-4592-9bff-72669d585e09"
      decimals="-3"
      id="F_bc1300a7-3d01-4acf-9457-f28fc33a776f"
      unitRef="U_USD">44974000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ec0b67b2-f764-458f-92ed-317ed126cda4"
      decimals="-3"
      id="F_593bb6f1-497f-4741-91b3-78e66cebb6b7"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_90864408-3972-4c1c-b3b8-325c747633b8"
      decimals="-3"
      id="F_e1936086-8f48-4e13-9194-98c296143a0a"
      unitRef="U_USD">26953000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a8816b30-096f-44ce-9bfe-af5d8d5e416d"
      decimals="-3"
      id="F_13f32961-41e7-4f1c-a027-5e7630eb3d6c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2fb30a1b-bb4d-41a9-b08c-0a5c0e1c4848"
      decimals="-3"
      id="F_7a076e0b-31a7-4410-80cd-7d138bb6e69e"
      unitRef="U_USD">26953000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e41fdba9-8344-40fa-b5b4-2fdf9fb77166"
      decimals="-3"
      id="F_07c5c567-cde9-4989-ac22-7e9545e96fd2"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8a72d7d1-fd42-40dc-a974-f728dcafb2db"
      decimals="-3"
      id="F_da93632b-4256-42aa-a398-2d503dc1afc7"
      unitRef="U_USD">12269000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_22a30aad-6a5c-431e-97aa-6d0174548088"
      decimals="-3"
      id="F_339acbb0-1ed2-4b94-82be-5a68cf391814"
      unitRef="U_USD">12269000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9ec3fe0f-f635-447a-a11c-3c7d34b2f6e3"
      decimals="-3"
      id="F_669864f6-b045-4f98-8be3-a84a97948ea9"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3c93b994-375e-41fb-a65c-a6d06c8a74af"
      decimals="-3"
      id="F_6281a0e2-bc6a-458c-8f4d-740a6937e18e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_78424e0d-5b03-41a3-be95-f77504eeecf9"
      decimals="-3"
      id="F_fa0a73b1-e4e9-4437-8327-2b089a0579fe"
      unitRef="U_USD">1999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9f6cd5c7-d0e1-4f81-b026-8285e0af17ca"
      decimals="-3"
      id="F_457ed1d6-f9b5-4d48-8c7a-2646e55cd67e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d375ebef-273f-4149-8fb5-f4dc8b70ab63"
      decimals="-3"
      id="F_f1ad7c06-7e91-4a5b-937a-5310b00d47c2"
      unitRef="U_USD">1999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_724282bf-8130-4b80-8ac7-1b0e9d423b87"
      decimals="-3"
      id="F_1e7c5eee-89d0-40c1-913b-f7d0842e527b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_72241514-75f9-4b94-8b9f-d70213f11d47"
      decimals="-3"
      id="F_94e97c1b-bfb3-44d2-add1-3e1a6205284d"
      unitRef="U_USD">16557000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_09a42735-0d75-4484-89b9-5f969e41a1fb"
      decimals="-3"
      id="F_621e35c7-2900-4ec8-b965-43f2db61ccd5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d942367c-37c2-422b-a6e8-33a8383c90bf"
      decimals="-3"
      id="F_978e487e-ce55-4b32-bb84-77172af9ea7f"
      unitRef="U_USD">16557000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6ecd9d54-ec05-4e5b-96c6-c81c04c9fc84"
      decimals="-3"
      id="F_411a0072-b13a-4dd0-8244-3b451bbd4735"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_11b39c77-1e84-4dab-b60a-449a3f0ec0fa"
      decimals="-3"
      id="F_e808fb84-7022-4758-a8e1-9f9815a1cfd5"
      unitRef="U_USD">108346000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_963260b7-59bc-48cf-9042-018d5b6ef6c2"
      decimals="-3"
      id="F_e65ddd73-8af9-49eb-be2e-20985a187418"
      unitRef="U_USD">12269000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_94a66d4a-e27f-41e7-af27-bdb2e8470a43"
      decimals="-3"
      id="F_83512dc4-d4f9-4da3-90b4-271fd05e5b92"
      unitRef="U_USD">96077000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e6c766b4-e117-4244-b35d-682f04d91b80"
      decimals="-3"
      id="F_941a8f8d-00bd-49e4-b6ea-6b0564511e7d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fed14fa7-fd7b-44c6-a3d0-52c8e4029d8b"
      decimals="-3"
      id="F_4df30577-8ab3-42d8-bc8a-41a563fa3177"
      unitRef="U_USD">1631000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6565d2ae-b389-4300-902c-39d3e6e112f0"
      decimals="-3"
      id="F_4c2866c2-2b86-471d-aca4-a999165fa8bd"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_21692f50-7040-4780-a0c1-87357f75dc1d"
      decimals="-3"
      id="F_3648573b-879b-4e18-b606-37b41400932d"
      unitRef="U_USD">1631000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5c0e8577-018d-4fd4-82ea-b6e2d68a5f23"
      decimals="-3"
      id="F_664606fa-69f4-4599-8b55-3166a2a4b268"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8c5761b7-e32b-45b4-becf-3a3c1d25c6a9"
      decimals="-3"
      id="F_edc55102-6000-436a-be9c-029a2d03e36f"
      unitRef="U_USD">2986000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_292c55aa-2381-4617-8d13-a126676fe9c7"
      decimals="-3"
      id="F_0f79f499-dd9b-4388-96f4-3b6286a6769f"
      unitRef="U_USD">2986000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_10d2b101-f4a6-4310-ae5d-b86276995667"
      decimals="-3"
      id="F_4d5ef2f5-643a-4d00-a389-158d40315338"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_609b6c54-99ce-41d7-80bc-f34b80b29690"
      decimals="-3"
      id="F_e8112c65-d295-435c-b94c-5dc821a54a13"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fc2d3480-29e6-4302-a16c-d5582586d81d"
      decimals="-3"
      id="F_eb21cb06-5e4f-4885-b105-3049419b2ad5"
      unitRef="U_USD">4617000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d4a6100a-40e8-402e-9f0e-748c76179dad"
      decimals="-3"
      id="F_dc96d64f-ba62-470f-b02c-d6c9e771f532"
      unitRef="U_USD">2986000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9c1cf7ad-dccd-4502-b51b-e6878b32a7e9"
      decimals="-3"
      id="F_3ba1544b-edd0-4849-906b-79587a7ea79e"
      unitRef="U_USD">1631000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3d082462-60fe-4bab-a12e-cc1b69abbcff"
      decimals="-3"
      id="F_e42f8da9-0a22-4fc5-aabb-8e5c695f2344"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_73ad74f1-0195-424d-8504-c0dca88a9b7e"
      decimals="-3"
      id="F_bcbfe647-b3bd-4a92-a204-a7b86ea3f766"
      unitRef="U_USD">194275000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_858abaa7-2ee9-4eed-9059-5c0651392b80"
      decimals="-3"
      id="F_51b2cefb-096f-4f88-af04-b060aa405704"
      unitRef="U_USD">94536000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_eb0cc90f-3d79-4014-a59c-5f9cf3d2f660"
      decimals="-3"
      id="F_6d65df54-d14c-4049-97bb-5868743390b0"
      unitRef="U_USD">99739000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e6370a8f-2667-466f-98d3-1e9d3a327fa7"
      decimals="-3"
      id="F_6911a019-88d3-4c4a-8321-d232294cdbb5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <grts:FairValueMeasurementLevel1ToLevel2Transfers
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_fc7efaaa-77fe-4324-9567-19e5b7e4d5bd"
      unitRef="U_USD">0</grts:FairValueMeasurementLevel1ToLevel2Transfers>
    <grts:FairValueMeasurementLevel1ToLevel2Transfers
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_8ede1dd7-406d-47e8-ac57-98b049f414bb"
      unitRef="U_USD">0</grts:FairValueMeasurementLevel1ToLevel2Transfers>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_9f9e162f-f05e-4b73-b309-2bdb3658633f">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.	Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.84%;"/&gt;
        &lt;td style="width:1.517%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.456%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.517%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.669%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_d558a3e5-e3c1-4a7c-b664-848d3cc75b0f">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.84%;"/&gt;
        &lt;td style="width:1.517%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.456%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.517%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.669%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_87523886-5199-4d42-8415-694b2b443fbe"
      decimals="-3"
      id="F_9cc4575b-95f1-47bb-ad44-0fa872a4233a"
      unitRef="U_USD">1155000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4bc7731c-c74f-40d3-a426-a27f2ea43498"
      decimals="-3"
      id="F_7913917b-76c0-4f20-8d83-f6e8a7f7bc98"
      unitRef="U_USD">987000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7f02ae7b-672e-42dd-aa91-702e3930b636"
      decimals="-3"
      id="F_390a554a-b959-40b3-9353-181f654d338f"
      unitRef="U_USD">2285000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_87f6c28b-d174-40ca-a77f-7d9cc17bd37c"
      decimals="-3"
      id="F_eecb3907-8567-4cdd-9b31-a55e861e398b"
      unitRef="U_USD">2113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3dded028-e6f7-4811-bc50-0118b2cfd30f"
      decimals="-3"
      id="F_e283f6e2-4556-4fd0-acda-a7f0c7cfa545"
      unitRef="U_USD">27309000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8683aae2-0a3c-46c3-989d-7ac0248bffb6"
      decimals="-3"
      id="F_175aed65-ecea-4a29-a210-b4dbb37a8bf6"
      unitRef="U_USD">24679000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6a755d83-b2d7-4f74-863c-9977b0a91bdc"
      decimals="-3"
      id="F_16995721-df8d-459b-baa1-8361b648625e"
      unitRef="U_USD">18024000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_64576a2c-bdc6-440d-a223-f398708694c1"
      decimals="-3"
      id="F_bed2c6ab-1d56-4ed4-9cdf-b93ce5311b3d"
      unitRef="U_USD">14128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_7d1f8f78-670f-4617-8473-a90a1753c819"
      unitRef="U_USD">48773000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_e0c2cff2-997a-4cdd-bdd7-b2dc2c55f003"
      unitRef="U_USD">41907000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_a50070d9-3d57-4997-8472-4d95edf43236"
      unitRef="U_USD">28782000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_25e0700a-efb3-49e8-9a72-6bbf7e2e65da"
      unitRef="U_USD">22276000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6ac0503d-d066-402e-877d-8f2b3b924843"
      decimals="-3"
      id="F_e92e234c-4bff-44de-9076-a9022035eea0"
      unitRef="U_USD">1344000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_652f489f-b7e8-4293-9bdf-ece64443c159"
      decimals="-3"
      id="F_4c135acc-897f-43d9-8bf2-8274da57230b"
      unitRef="U_USD">1991000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_692766f0-6713-45ca-b5f2-e2e4804f793e"
      unitRef="U_USD">21335000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_999a6f7f-554d-4fb6-a649-fda2c36c58b3"
      unitRef="U_USD">21622000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_9844e9f1-15e6-4f9c-8c96-4f43bb84115d"
      unitRef="U_USD">6600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-5"
      id="F_830c815a-ef8f-42f4-9f9c-a6d1e18204f4"
      unitRef="U_USD">6300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-5"
      id="F_59eb040c-c026-435b-97aa-8ad719e98a9d"
      unitRef="U_USD">6600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_91691de0-5c62-40ef-b8f9-9b51a94cae99">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.	Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company leases office, laboratory and storage space in facilities at several locations:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Emeryville Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s principal executive offices in Emeryville, California, consisting of office and laboratory space, are leased pursuant to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating lease (the &#x201c;Emeryville Lease&#x201d;), which the Company entered into in January 2019, with the obligation to pay rent commencing in November 2019. In conjunction with signing the Emeryville Lease, the Company paid a cash security deposit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which is recorded as a deposit on the Company&#x2019;s consolidated balance sheets as of December 31, 2022 and 2021. The Emeryville Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend this lease for an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; periods at the then market rental rate. The lessor provided the Company a tenant improvement allowance for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to complete the laboratory and office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ROU Asset and a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million lease liability on the consolidated balance sheet as of December 31, 2022.  The Company recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ROU Asset and a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million lease liability on the consolidated balance sheet as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pleasanton Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company leases &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,620&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of office, cleanroom, and laboratory support manufacturing space in Pleasanton, California pursuant to a non-cancelable operating lease (the &#x201c;Pleasanton Lease&#x201d;), which the Company entered into in March 2017, with the obligation to pay rent commencing in December 2017. The Pleasanton Lease includes a free rent period, escalating rent payments and a term that expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company may extend the lease term for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; at the then market rental rate. The Company obtained an irrevocable letter of credit in March 2017 in the initial amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as a security deposit to the Pleasanton Lease, which may be drawn down by the landlord in the event the Company fails to fully and faithfully perform its obligations under the Pleasanton lease. The letter of credit may be reduced based on certain levels of cash and cash equivalents the Company holds. In October 2022, the letter of credit was reduced to a balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ne of the irrevocable letter of credit amount had been drawn. The Pleasanton Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the Pleasanton Lease, the Company received a tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from the landlord for the costs associated with the design, development and construction of tenant improvements. The unamortized tenant improvement balance is recognized as a component of operating lease ROU Assets on the consolidated balance sheets as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, in May 2019, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; non-cancelable operating lease for additional office space in Pleasanton, California, with an obligation to pay rent commencing in August 2019. In January 2022, the Company amended the lease to add additional leased space and extend the lease expiration date to February 2027.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cambridge Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company leases laboratory, office and storage space in several facilities in Cambridge, Massachusetts, pursuant to three separate agreements:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s facility located at 40 Erie Street in Cambridge, Massachusetts is leased pursuant to a&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; 67-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; non-cancelable operating lease (the &#x201c;40 Erie Lease&#x201d;), which the Company entered into in February 2016, with an obligation to pay rent commencing in October 2016. The lessor provided the Company a tenant improvement allowance for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to complete the laboratory and office renovation. In September 2021, the Company executed an amendment to the 40 Erie Lease, which extends its term through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and provides for monthly base rent amounts, subject to annual increases over the term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s facility located at 21 Erie Street in Cambridge, Massachusetts is leased pursuant to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; non-cancelable operating lease (the &#x201c;21 Erie Lease&#x201d;), which the Company entered into in September 2018. The 21 Erie Lease has since been amended five times, as a result of which the lease term extends through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2021, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating lease (the &#x201c;Cambridge Storage Lease&#x201d;) for additional office and laboratory storage space in Cambridge, Massachusetts, which commenced on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_20846724-0d37-49d2-b716-e12511647821;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company also paid an insignificant cash security deposit. The Cambridge Storage Lease was amended in June 2022 to extend the lease term through June 30, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In conjunction with the 40 Erie Lease, the 21 Erie Lease and the Cambridge Storage Lease, each as amended (if applicable), the Company has paid certain cash security deposits, which in each case included amounts for the applicable last month&#x2019;s rent and has been classified as part of the operating lease ROU Assets. Of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million security deposits, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded in prepaids and other assets on the Company&#x2019;s consolidated balance sheet and the remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded in deposits and other long-term assets on the Company&#x2019;s consolidated balance sheet as of December 31, 2022. Security deposits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million are recorded in deposits and other long-term assets on the Company&#x2019;s consolidated balance sheet as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Boston Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company plans to occupy a newly-built facility in Boston, Massachusetts, with office and laboratory space, in 2023 pursuant to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120-month &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating lease (the &#x201c;Boston Lease&#x201d;), which the Company entered into in September 2021. The Boston Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend the Boston Lease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; periods at the then market rental rate. The landlord provided the Company with a tenant improvement allowance of up to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for costs relating to the design, permitting and construction of improvements. The Company&#x2019;s obligation to pay rent is expected to commence in the second half of 2023, subject to free rent periods of three and six months with respect to certain premises. The Company expects to be provided early access to the premises to install fixtures and equipment 60 days prior to the anticipated rent commencement date. The Boston Lease is expected to expire in 2033. The Boston Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses. In connection with the Boston Lease and as a security deposit thereunder, the Company has provided the landlord an irrevocable letter of credit in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which is collateralized by a restricted cash deposit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and which may be reduced in the fifth and seventh years of the Boston Lease.  As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ne of the irrevocable letter of credit amount had been drawn.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not recognized a right-of-use asset or lease liability as of December 31, 2022 or 2021 for the Boston Lease as the Company did not control the underlying assets at any time in the periods ended December 31, 2022 or 2021. Under the Boston Lease, the Company is obligated to make minimum lease payments of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years from 2023 to 2033, which includes rent abatement during the free rent periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s operating leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.468%;"/&gt;
        &lt;td style="width:1.348%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.029%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.348%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.029%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.348%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.429%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.61%;"/&gt;
        &lt;td style="width:1.327%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.327%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.327%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;New right-of-use assets obtained in exchange for lease obligations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, minimum annual payments under the Company&#x2019;s lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.882%;"/&gt;
        &lt;td style="width:2.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.038999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease Financing&lt;br/&gt;Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Amounts representing interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Amounts representing lease payments under Boston lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Current portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, with respect to which the officer or director is or was serving at the Company&#x2019;s request in such capacity. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#x2019;s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_3e931d49-353d-46c5-813c-21ac6372c768"
      id="F_527c3af6-d073-4fe2-91e3-d70603a45878">P120M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SecurityDeposit
      contextRef="C_bbc0b09b-357b-4c3b-8a22-3402ebee19be"
      decimals="-5"
      id="F_f286dcc7-fd6b-41d3-b505-d3957536c6d6"
      unitRef="U_USD">600000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_02a77114-3193-40d3-9dbf-c33becbaa06d"
      decimals="-5"
      id="F_c051b37f-87b6-4e38-a5e0-76bce8e06257"
      unitRef="U_USD">600000</us-gaap:SecurityDeposit>
    <grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms
      contextRef="C_832bf8ab-67e6-443d-94f3-635dca9a9752"
      decimals="0"
      id="F_1bf029fc-0804-427b-9fd5-c4114f22f350"
      unitRef="U_RenewalTerm">2</grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_3e931d49-353d-46c5-813c-21ac6372c768"
      id="F_bd6ab018-99ee-4ed3-83ef-0782c6221cd0">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:TenantImprovements
      contextRef="C_3e931d49-353d-46c5-813c-21ac6372c768"
      decimals="-5"
      id="F_c379f71f-854d-46ad-8d29-1afede69faac"
      unitRef="U_USD">4000000.0</us-gaap:TenantImprovements>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_bbc0b09b-357b-4c3b-8a22-3402ebee19be"
      decimals="-5"
      id="F_a99b536d-196d-4e93-8f6b-9b99278efd85"
      unitRef="U_USD">8100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_bbc0b09b-357b-4c3b-8a22-3402ebee19be"
      decimals="-5"
      id="F_69af76fe-7e19-4edb-be9d-8dadf64b2b33"
      unitRef="U_USD">12800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_02a77114-3193-40d3-9dbf-c33becbaa06d"
      decimals="-5"
      id="F_26194dbd-fd6e-4df3-a2b6-7ccec3b65959"
      unitRef="U_USD">8700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_02a77114-3193-40d3-9dbf-c33becbaa06d"
      decimals="-5"
      id="F_bf4ba538-1efd-415e-ba14-5b55f16649b1"
      unitRef="U_USD">13900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AreaOfLand
      contextRef="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c"
      decimals="0"
      id="F_280511ef-db2c-4d98-bfa3-6fcfa8e3e942"
      unitRef="U_sqft">42620</us-gaap:AreaOfLand>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_51209003-b3a4-472c-aa6b-ed22f18ab53e"
      id="F_8ad911d8-e6d0-49e2-8e87-e46c09aa10c8">2024-11-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c"
      id="F_f97a148f-3a62-436a-90c8-97cca7d67c38">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c"
      decimals="-5"
      id="F_819c42d2-41b8-4265-9574-c72276a9e181"
      unitRef="U_USD">1000000.0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-5"
      id="F_914c6ad0-de97-4bbe-b4d9-0483450ea1c8"
      unitRef="U_USD">600000</us-gaap:LettersOfCreditOutstandingAmount>
    <grts:AmountOfIrrevocableLettersOfCreditWithdrawn
      contextRef="C_8f01c328-d8a6-4cb7-a4fa-466c77f2d695"
      decimals="-3"
      id="F_a389dcbb-636a-4a21-9718-db1222885e4c"
      unitRef="U_USD">0</grts:AmountOfIrrevocableLettersOfCreditWithdrawn>
    <us-gaap:TenantImprovements
      contextRef="C_18a1f963-f56e-4dd0-b135-cf05e7b0737c"
      decimals="-5"
      id="F_4a82f74b-60b4-482e-ba21-bc5e01b24a37"
      unitRef="U_USD">1200000</us-gaap:TenantImprovements>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_ec5c558f-6f66-4786-9d64-c061d097aa83"
      id="F_64427445-d54b-4618-a66b-d81741a7dcec">P64M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_81630994-2393-4f11-bebf-28fe95a0862c"
      id="F_01e65c59-b318-4dc4-8d8f-4a50cf03586d">P67M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:TenantImprovements
      contextRef="C_81630994-2393-4f11-bebf-28fe95a0862c"
      decimals="-5"
      id="F_9d1145aa-09aa-4730-a555-6461e8a3b8b6"
      unitRef="U_USD">2100000</us-gaap:TenantImprovements>
    <grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear
      contextRef="C_ad6f9581-caa1-40a5-b25e-f79138f7937a"
      id="F_98aac7e3-fd81-4dea-b895-7e9bc451bae9">2025-04</grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_56c649f8-782f-49f7-806b-b288e3c37bfd"
      id="F_6d9a6ee4-72ba-4ba2-9583-d1b4077a020f">P24M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear
      contextRef="C_92f316c5-6c3b-4b21-9a34-423815542a35"
      id="F_d94ee6e8-7869-44a3-831b-75deb6de6372">2023-06</grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_b01748c1-8a6a-4edc-afb0-0081bb1bd20a"
      id="F_145c168a-b1fc-48d3-b975-bba7f9f02646">P17M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SecurityDeposit
      contextRef="C_0066c1b6-3f4e-430f-9440-978f78dfa308"
      decimals="-5"
      id="F_f204369a-6bf0-45bd-a688-c1e1a5e35266"
      unitRef="U_USD">700000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_87c8c355-193a-4647-ba52-79383b1ab058"
      decimals="-5"
      id="F_ed94068b-9b75-4fed-9a06-d5a9a3e330d1"
      unitRef="U_USD">400000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_136628c1-6491-4245-8d0f-4e52ec0eb329"
      decimals="-5"
      id="F_38d92f21-aad9-4327-9312-574cdbac4efc"
      unitRef="U_USD">300000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_c7091304-4211-4a5d-9df5-4653969e7eae"
      decimals="-5"
      id="F_2222a572-4370-466e-b5f9-d815d6384648"
      unitRef="U_USD">700000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0ea98966-ee3e-4c56-b696-2ba4dc84bd5a"
      id="F_aa8419e5-f8c6-4789-8a66-f7605a179a77">P120M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms
      contextRef="C_5c56c0fa-8f94-4d89-a702-a2744c500dc7"
      decimals="0"
      id="F_3beb7013-1f24-4c74-9891-52069c0937e0"
      unitRef="U_Segment">2</grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0ea98966-ee3e-4c56-b696-2ba4dc84bd5a"
      id="F_025fe998-e2fe-41ce-a8b0-649dcae36697">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:TenantImprovements
      contextRef="C_6c569a47-3f51-4dbb-bef0-103343842833"
      decimals="-5"
      id="F_de708bd9-301b-454b-880c-807a42d273dc"
      unitRef="U_USD">19100000</us-gaap:TenantImprovements>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_40e18178-0370-4155-b61f-eb36fe61fe35"
      decimals="-5"
      id="F_60c8249b-e04b-45c3-aa37-cad8b429406a"
      unitRef="U_USD">4600000</us-gaap:LettersOfCreditOutstandingAmount>
    <grts:RestrictedCashDepositUsedAsCollateralForLetterOfCredit
      contextRef="C_40e18178-0370-4155-b61f-eb36fe61fe35"
      decimals="-5"
      id="F_445ead99-70d9-4bda-acc1-1b7e95411b52"
      unitRef="U_USD">4700000</grts:RestrictedCashDepositUsedAsCollateralForLetterOfCredit>
    <grts:AmountOfIrrevocableLettersOfCreditWithdrawn
      contextRef="C_40e18178-0370-4155-b61f-eb36fe61fe35"
      decimals="-3"
      id="F_db465a6e-6c01-4eb9-9fae-0a202c878d92"
      unitRef="U_USD">0</grts:AmountOfIrrevocableLettersOfCreditWithdrawn>
    <grts:MinimumLeasePayments
      contextRef="C_40e18178-0370-4155-b61f-eb36fe61fe35"
      decimals="-5"
      id="F_99ece39f-8daa-4a72-aa74-2c8eb3e98d06"
      unitRef="U_USD">79100000</grts:MinimumLeasePayments>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_19dc7c5d-8134-4c11-af11-24dd626440c9">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.468%;"/&gt;
        &lt;td style="width:1.348%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.029%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.348%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.029%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.348%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.429%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_27b8d501-3ac6-4bbc-a859-61d49ab43f85"
      unitRef="U_USD">8797000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_0173b8ff-a921-488f-a1ba-d5548d952ccc"
      unitRef="U_USD">7973000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_58c7b445-5d9d-450d-96f7-6cc46c740431"
      unitRef="U_USD">7511000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_c6828445-fd37-431e-84ca-070821b0ab70"
      unitRef="U_USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_441fb108-c6f1-48ea-9841-25b107fecf1e"
      unitRef="U_USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_13eade54-78c5-44be-86f9-bd58d0009c23"
      unitRef="U_USD">7000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_69485888-04d7-41e0-a058-4430732172d6"
      unitRef="U_USD">8797000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_35757943-0504-44a4-9808-fc5a25b79456"
      unitRef="U_USD">7973000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_a4e31eb7-f2d7-4fc6-89c5-12ddc8df7d45"
      unitRef="U_USD">7518000</us-gaap:LeaseCost>
    <grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_a722d6ec-4c11-4029-9eef-350ae7d0bca7">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.61%;"/&gt;
        &lt;td style="width:1.327%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.327%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.327%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;New right-of-use assets obtained in exchange for lease obligations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_abca80a0-1b87-4b36-803f-3200133ecb79"
      unitRef="U_USD">8915000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_b48e4e39-74c6-405d-bd72-5e2b2e7203c9"
      unitRef="U_USD">7925000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_ad0a687a-99e3-415e-bf77-0e2339bc49f3"
      unitRef="U_USD">5389000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_e60238e8-582c-404d-8604-6e29ba7ce7ee"
      unitRef="U_USD">1959000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_d94605b6-755c-4357-81c3-342b072c3013"
      unitRef="U_USD">6562000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_7ec3ee2c-3a9e-45f1-92e7-27749b8f06f6"
      unitRef="U_USD">3174000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      id="F_2f416662-fce4-4501-9e4a-4700150d65ba">P5Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      id="F_68d616e9-5337-476e-b374-01e05a92d815">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      id="F_316c0d22-d89d-4d73-a170-a085c4ac381d">P6Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="3"
      id="F_fae12637-10a9-4bf2-a88c-c589b487feae"
      unitRef="U_pure">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="3"
      id="F_5aea42ac-738e-4c6f-8337-2a9c5befd5d0"
      unitRef="U_pure">0.074</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      decimals="3"
      id="F_8df64a83-7a3e-4db5-8f8f-1163a9a83b80"
      unitRef="U_pure">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_42930258-7571-4ac4-9de7-ed11e5c9ed5e">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, minimum annual payments under the Company&#x2019;s lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.882%;"/&gt;
        &lt;td style="width:2.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.038999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease Financing&lt;br/&gt;Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Amounts representing interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Amounts representing lease payments under Boston lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Current portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_231c98a1-8997-49cc-b2c0-799c450481e5"
      unitRef="U_USD">8604000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_a74ebbad-8bce-4339-8c0e-6aec22d57891"
      unitRef="U_USD">12527000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_5730fecc-59a0-4b68-9635-13e16f892ece"
      unitRef="U_USD">10658000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_89a70fda-a511-4d54-a96e-d489a853e527"
      unitRef="U_USD">10376000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_27d585f6-aaaa-4452-b5d0-3aff608cb24f"
      unitRef="U_USD">10466000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_b6bd3757-7e71-4f7e-96b1-1d097820bb71"
      unitRef="U_USD">52348000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_89f9d167-c2cc-46ec-b17a-a7f9cc4fbe75"
      unitRef="U_USD">104979000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_c66a4b22-867f-468a-85d8-823c2539ccbe"
      unitRef="U_USD">4899000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <grts:OperatingLeasePaymentUnderTheBostonLease
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_2fcf4a28-55bb-4921-9656-995c80f2355e"
      unitRef="U_USD">79113000</grts:OperatingLeasePaymentUnderTheBostonLease>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_44bbd510-a708-40dc-8627-20d182bd21d6"
      unitRef="U_USD">20967000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_4c330d70-fbbd-407a-a126-400887f03f69"
      unitRef="U_USD">5294000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_1b555ae9-74d0-43b0-9be9-d79f778080fc"
      unitRef="U_USD">15673000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_2fb939d2-bbab-49df-a77a-02b230b59c0b">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.	Collaboration and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2seventy bio, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2018, the Company entered into a Research Collaboration and License Agreement with bluebird bio, Inc. (&#x201c;bluebird&#x201d;). In November 2021, bluebird assigned the Research Collaboration and License Agreement (the &#x201c;2seventy Agreement&#x201d;), to its affiliate, 2seventy bio, Inc. (&#x201c;2seventy&#x201d;), in connection with an internal restructuring and subsequent spin-out of 2seventy.  Under the terms of the 2seventy Agreement, the Company provides to 2seventy tumor-specific targets across several tumor types and, in certain cases, T cell receptors (TCR) directed to those targets. The Company received a non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and 2seventy also concurrently acquired &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;768,115&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s Series C convertible preferred stock for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;share. Per the 2seventy Agreement, 2seventy was also provided an option to acquire shares of the Company&#x2019;s common stock at the same price&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;all other investors in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;). In October 2018, 2seventy purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;666,667&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock at the price to the public of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Under the terms of the 2seventy Agreement, the Company is eligible to earn development, regulatory, and sales-based milestones in an amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion, and single-digit royalties on sales of products that utilize the technology subject to the 2seventy Agreement. None of these events had occurred as of December 31, 2022, and no royalties were due from the sale of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2019, the Company entered into a First Amendment to the 2seventy Agreement, which extended the timeline for the Company and 2seventy to execute a Patient Selection Services Agreement from within one year to within two years after the Effective Date of the 2seventy Agreement. In August 2020, the Company entered into a Second Amendment, which extended the timeline of the Patient Selection Services Agreement to within three years and also extended the Tissue Analysis Period from February 28, 2021 to June 30, 2021. In April 2021, the Company entered into a Third Amendment, which removed the Patient Selection Services Agreement in its entirety and extended the Tissue Analysis Period from June 30, 2021 to December 31, 2021. The amendments were entered into for administrative purposes, and the Company determined the amendments were not a modification of contract under the contract with customers guidance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2seventy may terminate the 2seventy Agreement by giving a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the last payment owed by the Company on a licensed product. The 2seventy Agreement may be terminated for cause by either party based on an uncured material breach by the other party or bankruptcy of the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to 2seventy under the licensed intellectual property will remain in effect in accordance with their respective terms. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additionally, all of 2seventy&#x2019;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company concluded that 2seventy is a customer, and the contract is not subject to guidance on collaborative arrangements. This is because the Company granted 2seventy a license to the Company&#x2019;s intellectual property and provided research and development services, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company identified the following three material promises under the 2seventy Agreement: (i) transfer of a license to intellectual property and related technology know-how (&#x201c;License and Know-How&#x201d;); (ii) the obligation to perform target selection and TCR generation services (&#x201c;Research and Development Services&#x201d;); and (iii) participation on the Joint Steering Committee (the &#x201c;JSC&#x201d;). The Company provided to 2seventy standard indemnification and protection of licensed intellectual property, which is part of assurance that the license meets the contract&#x2019;s specifications and is not an obligation to provide goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considered that the License and Know-How has standalone functionality, was considered to be functional intellectual property, and is capable of being distinct. However, the Company determined that the License and Know-How is not distinct from the Research and Development Services or participation on the JSC within the context of the 2seventy Agreement, because 2seventy is dependent on the Company to execute the Research and Development Services and participate on the JSC in order for 2seventy to benefit from the License and Know-How. As such, the License and Know-How is combined with the Research and Development Services and participation on the JSC into a single performance obligation, and the transaction price under this arrangement will be allocated to this single performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has also determined that all other goods or services that are contingent upon 2seventy reaching various milestones are not considered performance obligations at the inception of the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price at the inception of the 2seventy Agreement consisted of the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million received from 2seventy for the purchase of the Company&#x2019;s Series C convertible preferred stock. The sale of the Series C convertible preferred stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the transaction price was allocated to the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;768,115&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series C convertible preferred stock at fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and recorded in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The variable consideration related to the remaining development, regulatory, and sales-based milestones payments has not been included in the initial transaction price and continues to be fully constrained as of December 31, 2021. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon initiation of clinical trials for early-stage targets and 2seventy&#x2019;s development efforts. Any variable consideration&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the License and Know-How granted to 2seventy. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; For revenue recognition purposes, the Company determined that the duration of the 2seventy Agreement began on the effective date in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and ends upon completion of the Research and Development Services, which is also when the participation on the JSC is no longer an obligation. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. The Company also analyzed the impact of 2seventy terminating the agreement prior to August 2023 and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to 2seventy for doing so.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue is recognized when, or as, the Company satisfies its performance obligation by transferring the promised services to 2seventy. Revenue is being recognized over time using a cost-based input method, based on internal labor cost effort to perform the research services, since the internal labor cost incurred over time is thought to best reflect the transfer of services to 2seventy. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022, 2021, and 2020, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in collaboration revenue under the 2seventy Agreement. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The amount of collaboration revenue recognized during the year ended December 31, 2022 included cumulative catch-up adjustments increasing collaboration revenue by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million due to revisions to estimated costs to complete the remaining performance obligation. The adjustments resulted in a decrease in the Company&#x2019;s loss from operations of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and a decrease in loss per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, 2022. Deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded on the consolidated balance sheet in current liabilities as of December 31, 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded on the consolidated balance sheets in both current and long-term liabilities as of December 31, 2021, respectively. Deferred revenue relates to the performance obligations identified under the 2seventy Agreement and will be recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in the deferred revenue balance during the year ended December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.929%;"/&gt;
        &lt;td style="width:1.757%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.558%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.757%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; receivables or net contract assets recorded as of December 31, 2022 or 2021 associated with the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2seventy Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Gilead Sciences, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2021, the Company entered into a Collaboration, Option and License Agreement (the &#x201c;Gilead Collaboration Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;) to research and develop a vaccine-based immunotherapy as part of Gilead&#x2019;s efforts to find a curative treatment for HIV infection. Under the terms of the Gilead Collaboration Agreement, the Company granted to Gilead an exclusive, worldwide license to develop and commercialize a HIV-specific therapeutic vaccine utilizing the Company&#x2019;s technology. Gilead is responsible for conducting all development and commercialization activities beginning with a Phase 1 study, and the Company is responsible for contributing to preclinical research studies and participation in a joint steering committee (collectively, &#x201c;research and development activities&#x201d;). Concurrently with the execution of the Gilead Collaboration Agreement, the Company and Gilead entered into a Supply Agreement (the &#x201c;Gilead Supply Agreement&#x201d;) under which the Company will supply research product and GMP product (&#x201c;Product Supply&#x201d;) that may be required under the Gilead Collaboration Agreement until Gilead completes its first GMP product batch, and the Company will participate in a joint manufacturing team (collectively, &#x201c;product supply activities&#x201d;). In addition, the Company also concurrently entered into a Stock Purchase Agreement (the &#x201c;Gilead Stock Purchase Agreement&#x201d;) under which Gilead acquired, in a private placement transaction, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,169,591&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of the Company&#x2019;s common stock. The common shares were issued to Gilead with&lt;/span&gt;&lt;span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;certain &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;registration rights and certain standstill and market stand-off provisions. The Company determined that these concurrent contracts represent a combined arrangement (the &#x201c;Gilead Arrangement&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Gilead Collaboration Agreement, the Company received a non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Under the Gilead Collaboration Agreement and the Gilead Supply Agreement, the Company will receive additional reimbursement payments for expenses incurred in the research and development activities and product supply activities. Under the Gilead Stock Purchase Agreement, the common shares were sold at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s common stock at fair value on closing was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If Gilead decides to move forward with development beyond the initial Phase 1 study (the &#x201c;Option&#x201d;), the Company will receive a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million non-refundable option fee and will be eligible to receive up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;685.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million if certain clinical, regulatory and commercial milestones are achieved, as well as tiered royalties ranging from the mid-single digits to low double-digits on net sales of a therapeutic product utilizing its technology. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None of these events had occurred as of December 31, 2022 and no royalties were due from the sale of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gilead &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;may terminate the Gilead Collaboration Agreement for convenience by giving a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the expiration of the royalty term, or, if the Option is not exercised, by the end of the Option term. The Gilead Collaboration Agreement may be terminated for cause by either party based on an uncured material breach by the other party, insolvency of the other party, or patent challenge. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to Gilead under the licensed intellectual property will remain in effect in accordance with their respective terms. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#x2019;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#x2019;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Furthermore, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and may terminate any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services and Product Supply, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration. The Option, if exercised by Gilead, will be considered a modification that increases the scope of the arrangement beyond the Option term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company identified the following performance obligations under the Gilead Collaboration Agreement: (i) licenses including an exclusive (in the HIV field), royalty-free, worldwide collaboration license and transfer of know-how and an exclusive (in the HIV field) worldwide, royalty-bearing development and commercialization license subject to restrictions on its use during the Option term and an exclusive option to release such restrictions; (ii) preclinical research and development activities, manufacturing-related activities, and participation on a Joint Steering Committee; and (iii) product supply, including research and GMP product, until Gilead completes its first GMP batch, and participation on a Joint Manufacturing Team.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considered that the licenses and know-how have standalone functionality, are considered to be functional intellectual property and are capable of being distinct. The Company also determined that the research and development activities and product supply by Gritstone could be provided by resources otherwise available to Gilead and thus are capable of being distinct.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has also determined that the pricing for optional goods and services and release of license restrictions upon exercise of the Option do not constitute material rights and are not a potential performance obligation. The Company evaluated whether there is an interdependence between the promises and determined that the licenses are a combined solution and the predominant performance obligation, while the other promises are separately identifiable in the context of the contract; however, the research and development activities are dependent on the research product supply, which is accounted for as a combined performance obligation. As a result, the Company identified three performance obligations in the Gilead Arrangement: (i) exclusive licenses and know-how, (ii) research and development activities and product supply, and (iii) GMP product supply.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price at the inception of the Gilead Collaboration Agreement consisted of the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million received for the sale of the Company&#x2019;s common stock. The sale of the common stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the transaction price was allocated to the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,169,591&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;shares of the Company&#x2019;s common stock at fair value on closing of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and recorded in stockholders&#x2019; equity. The remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the common stock purchase price in excess of the fair value of the shares received is added to the transaction price for the Gilead Collaboration Agreement. In addition, the initial transaction price includes estimated variable consideration for budgeted reimbursement of research and development costs and product supply. The variable consideration related to reimbursable costs and product supply has been constrained as of December 31, 2022 based on the current research and development plan forecast. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the variable consideration for the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million option exercise fee and for the development, regulatory, and sales-based milestones payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&#x2019;s control. As a result, these payments were fully constrained and were not included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the exclusive licenses and know-how granted to Gilead.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price is allocated to the performance obligation based upon relative standalone selling prices, which were determined for the exclusive licenses and know-how using an adjusted market approach and for the research and development activities and product supply using a cost plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and ends upon (i) the completion of the Option term, which is expected to end &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9eba06f0-bedf-4ded-9f71-17671e82aef7;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; after the effective date, if the Option is not exercised or (ii) the expiration of the royalty-term on a product-by-product and country-by-country basis. The Company also analyzed the impact of Gilead terminating the agreement prior to the end of the Option term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Gilead for doing so.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue for the exclusive licenses and know-how was recognized on the effective date of the Gilead Collaboration Agreement at the point in time that the licenses are effective. The research and development activities and product combined performance obligation and the GMP product supply performance obligation are recognized over time when, or as, the Company transfers the promised goods and services to Gilead. Research and development service and product supply revenues will be recognized over time using a cost-based input method, based on internal and external labor cost effort to perform the services, costs to acquire research materials, and costs of product supply, since the costs incurred over time are thought to best reflect the transfer of goods and services to Gilead. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to estimated total costs to fulfill each performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation and associated variable consideration will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2022, the Company did not record any license revenue. For the year ended December 31, 2022, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as collaboration revenue as a&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. For the year ended December 31, 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as license revenue, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as collaboration revenue as a&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. There was no contract asset recorded on the consolidated balance sheet as of December 31, 2022. A contract asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 for supply costs that were incurred during the year ended December 31, 2021, but not billable until future periods when the asset is released. The contract asset relates to the performance obligations yet to be satisfied under the Gilead Collaboration Agreement. There was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million recorded as deferred revenue as of December 31, 2022 and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; deferred revenue as of December 31, 2021 associated with the Gilead Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in the contract asset and short-term deferred revenue, balance during the year ended December 31, 2022 for the Gilead Collaboration Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.079%;"/&gt;
        &lt;td style="width:1.496%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.963999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.496%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.963999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contract Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of receivables recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company deferred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in incremental costs to acquire the Gilead Collaboration Agreement in the first quarter of 2021 allocated to performance obligations recognized over time, which will be recognized over time in each period proportionate to revenue recognition. As of December 31, 2022, deferred contract acquisition costs were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Deferred contract acquisition costs amortized during the year ended December 31, 2022 and 2021 were negligible.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Arbutus Biopharma Corporation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2017, the Company entered into an Exclusive License Agreement with Arbutus and its wholly-owned subsidiary, Protiva Biotherapeutics Inc. Certain terms of the agreement were modified by amendment in July 2018. Under the license agreement, the Company has an exclusive license to utilize certain Arbutus intellectual property, including patents and know-how relating to immunotherapy. During the years ended December 31, 2022, 2021 and 2020, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; research and development expense under the agreement. The Company is obligated to pay Arbutus certain milestone payments up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million on achievement of specified events, and royalties on sales of its licensed products. Following the acceptance of our investigational new drug application for GRANITE by the FDA, the Company made a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million development milestone payment to Arbutus in September 2018 that was recorded as research and development expense. In August 2019, a milestone was met following the initial patient treatment of SLATE in the Company&#x2019;s GO-005 clinical trial. In 2019, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as research and development expense in connection with the milestone. None of the other events had occurred as of December 31, 2022, and no royalties were due from the sale of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Non-Profit Hospital Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2016, the Company entered into an Exclusive License Agreement with a non-profit hospital cancer center. Under the license agreement, the Company has an exclusive license to utilize certain patents and know-how relating to immunotherapy for an insignificant upfront payment, cash milestone payments on achievement of specified events, and a low single digit royalty on sales of licensed products. The achievement of the milestones and payment of royalties is dependent upon obtaining regulatory approval. Upon achievement of a milestone related to the Company&#x2019;s Phase 1 clinical trial for GRANITE, GO-004, in December 2018 the Company recorded an insignificant amount to research and development expense for amounts owed to the Hospital Cancer Center, which was paid to the hospital in February 2019. None of the other milestone events had occurred as of December 31, 2022, and no royalties were due from the sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Genevant Sciences GmbH&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the Company entered into an Option and License and Development Agreement (the &#x201c;2020 Genevant License Agreement&#x201d;) with Genevant Sciences GmbH (&#x201c;Genevant&#x201d;), pursuant to which Genevant granted the Company exclusive license rights under certain intellectual property related to Genevant&#x2019;s LNP technology for a single therapeutic indication, and the Company agreed to pay Genevant an initial payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;was included in research and development expense for the year ended December 31, 2020. Genevant is a spin-off of Arbutus, and the 2020 Genevant License Agreement expands Gritstone&#x2019;s intellectual property rights to such LNP technology originally obtained pursuant to the Company&#x2019;s license agreement with Arbutus. Prior to the 2020 Genevant License Agreement, the Company licensed Arbutus&#x2019; LNP technology for indications in the oncology space. The remainder of Arbutus&#x2019; IP portfolio was transferred to Genevant in the spin-off. In&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022, a milestone in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was met, which was included in research and development expense for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the 2020 Genevant License Agreement, Genevant also granted the Company certain options to license the LNP technology for additional therapeutic indications of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for each indication and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to extend the option term. The 2020 Genevant License Agreement continues in effect until the last to expire royalty term or early termination. It is terminable by the Company for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either party may terminate the agreement for material breach, subject to a cure period, and Genevant may terminate the agreement if the Company challenges a licensed patent.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2021, the Company entered into a Non-Exclusive License and Development Agreement (the &#x201c;2021 Genevant License Agreement&#x201d;) with Genevant. Pursuant to the 2021 Genevant License Agreement, the Company obtained a nonexclusive license to Genevant&#x2019;s LNP technology to develop and commercialize self-amplifying RNA (&#x201c;samRNA&#x201d;) vaccines against SARS-CoV-2, the virus that causes COVID-19. Under the 2021 Genevant License Agreement, the Company made a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upfront payment to Genevant, and Genevant is eligible to receive from the Company up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in contingent milestone payments per product, plus certain tiered royalties, upon achievement of development and commercial milestones. In certain scenarios, in lieu of milestones and royalties, Genevant will be entitled to a percentage of amounts that the Company receives from sublicenses under the 2021 Genevant License Agreement, subject to certain conditions. In March 2021, a milestone in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was met following the initial patient treatment in the Phase 1 clinical trial conducted through the NIAID-supported Infectious Diseases Clinical Research Consortium (&#x201c;IDCRC&#x201d;). Both the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upfront and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million milestone payments were recorded as research and development expense for the year ended December 31, 2021. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ne of the other milestone events had occurred as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Coalition for Epidemic Preparedness Innovations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 14, 2021, the Company entered into the CEPI Funding Agreement with CEPI, under which CEPI agreed to provide funding of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the Company to advance the Company&#x2019;s CORAL program, a second-generation COVID-19 vaccine program, with an initial clinical trial in South Africa. Under the terms of the agreement, CEPI is funding a multi-arm Phase 1 study evaluating the CORAL program&#x2019;s samRNA vaccine in na&#xef;ve, convalescent, and HIV+ patients. The study is evaluating three different samRNA vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses. The funding is also supporting pre-clinical studies, scale-up and formulation development to enable manufacturing of large quantities of stable vaccine product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the CEPI Funding Agreement, among other things, the Company and CEPI agreed on the importance of global equitable access to the vaccine produced pursuant to the CEPI Funding Agreement. The vaccine, if approved, is expected to be made available to the COVAX Facility for procurement and allocation. The COVAX Facility aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The scope and continuation of the CEPI Funding Agreement may be amended depending on ongoing developments of the COVID-19 outbreak and the success of the Company&#x2019;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement relative to other third-party COVID-19 vaccine candidates or treatments. If the World Health Organization (&#x201c;WHO&#x201d;), CEPI or a regulatory authority having jurisdiction over a clinical trial performed under the CEPI Funding Agreement determines that a third-party product candidate has substantially greater potential than the Company&#x2019;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement and should be prioritized instead for a particular trial, the Company must consider in good faith any written request of CEPI not to proceed with a clinical trial of such COVID-19 vaccine candidate; however the determination of whether or not to proceed with such trial shall be made by the Company in its sole discretion. In addition, CEPI has the right to unilaterally terminate the CEPI Funding Agreement upon prior written notice if CEPI determines that (i) there are material safety, regulatory, scientific misconduct or ethical issues with the project undertaken by the Company under the CEPI Funding Agreement, (ii) the project undertaken by the Company under the CEPI Funding Agreement should be terminated, (iii) the Company becomes unable to discharge its obligations under the CEPI Funding Agreement, (iv) the Company fails to meet certain criteria set forth in the CEPI Funding Agreement, or (v) the Company commits fraud or a financial irregularity, as such terms are defined in the CEPI Funding Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2021, the Company and CEPI entered into an amendment to the CEPI Funding Agreement, under which CEPI agreed to provide additional funding up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, for a total of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, to the Company to conduct a Phase I clinical trial of the Company&#x2019;s Omicron vaccine candidate in South Africa.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;CEPI advances grant funds upon request by the Company consistent with the agreed upon amounts and schedules as provided in the CEPI Funding Agreement. The first tranche of funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was received in September 2021, and the second tranche of funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was received in April 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the agreement are incurred. During the year ended December 31, 2022, the Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million under the CEPI Funding Agreement. During the year ended December 31, 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in grant revenue under the CEPI Funding Agreement. As of December 31, 2022 and 2021, short term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, recorded on the consolidated balance sheets. Deferred revenue will be recognized over the period in which the CEPI Funding Agreement activities related to the first and second tranches of funding are expected to take place, which is currently estimated to be through the year ended 2023. As of December 31, 2022 and 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, was recorded as short-term restricted cash on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the CEPI Funding Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Gates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the Company entered into a Grant Agreement with the Gates Foundation (the &#x201c;Gates Grant Agreement&#x201d;), which provides funding for the Company&#x2019;s development of an optimal immunogen in the context of a therapeutic human papillomavirus (&#x201c;HPV&#x201d;) vaccine. In consideration for the work to be performed, the Gates Foundation provided the Company with an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in December 2021, and future funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million is expected to be received by the Company in the first quarter of 2023, for a total grant amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the Gates Grant Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. During the year ended December 31, 2022, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in revenue under the Gates Grant Agreement. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize any grant revenue under the Gates Grant Agreement in 2021. As of December 31, 2022, short-term restricted cash and short-term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million  were recorded on the consolidated balance sheet. As of December 31, 2021, short-term restricted cash and short-term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and long-term restricted cash and long-term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million were recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the tranches of funding are expected to take place, which is currently estimated to be through the year ended 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the Grant Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.308%;"/&gt;
        &lt;td style="width:1.877%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.815%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_15303075-6c82-43e3-95ac-810ce94f5ad4"
      decimals="-5"
      id="F_3010ec3b-02bb-4d6e-bad9-16c05c63ba12"
      unitRef="U_USD">20000000.0</grts:ProceedsFromNonRefundableUpfrontPayment>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c28c4bd4-e62b-479b-85c0-f06e18613cb3"
      decimals="INF"
      id="F_4f4d95ac-1645-404a-ba67-ed26c8cf0f62"
      unitRef="U_shares">768115</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_ddb48a50-1ece-46f1-83ca-c31f25910907"
      decimals="-5"
      id="F_9ab2eb3a-e243-4520-9f67-9e9f51f448a7"
      unitRef="U_USD">10000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_c28c4bd4-e62b-479b-85c0-f06e18613cb3"
      decimals="2"
      id="F_8d477cde-47bd-4a59-aed9-d3457ca09971"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.04</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d761c15a-dc3b-4830-bc90-d5f6864753cb"
      decimals="INF"
      id="F_f8d446cd-1849-492b-aaec-3282f7b40282"
      unitRef="U_shares">666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_2a86422f-3ae7-47a7-bad8-cd08d7056b6c"
      decimals="2"
      id="F_dcb5fc5f-676e-425b-b701-f844a10cfb50"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_d761c15a-dc3b-4830-bc90-d5f6864753cb"
      decimals="-5"
      id="F_8aa5a1f3-3e6b-4625-bd01-9ba6acb8fe11"
      unitRef="U_USD">10000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:MaximumPotentialMilestoneReceivable
      contextRef="C_990fb369-8f8b-4b5a-aae9-a7fc6e20db39"
      decimals="-8"
      id="F_35a268c1-7c07-4bdd-bf3b-bd47466fadff"
      unitRef="U_USD">1200000000</grts:MaximumPotentialMilestoneReceivable>
    <grts:CollaborationAgreementEarlyTerminationNoticePeriod
      contextRef="C_b942a7f0-83f7-4782-aba4-13c3f1ec3206"
      id="F_b53ed89e-e87a-4764-b86f-4fae9efdb839">P120D</grts:CollaborationAgreementEarlyTerminationNoticePeriod>
    <grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments
      contextRef="C_b942a7f0-83f7-4782-aba4-13c3f1ec3206"
      id="F_a27f1836-3fd9-4471-903a-1a8ccb8dfb3c">Additionally, all of 2seventy&#x2019;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.</grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_a63c1a07-67c9-44ee-9005-5e3efd76ad19"
      decimals="-5"
      id="F_83ea3444-17a5-40cb-9227-cbafa28ff2f0"
      unitRef="U_USD">20000000.0</grts:ProceedsFromNonRefundableUpfrontPayment>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_3030c951-2716-4654-8056-6101e373ddea"
      decimals="-5"
      id="F_f99587ec-11ca-4f41-a7bf-de090e143045"
      unitRef="U_USD">10000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <grts:IssuanceOfConvertiblePreferredStockTransactionPrice
      contextRef="C_e9a61784-ec1b-4689-88b4-604b0656e5e0"
      decimals="-5"
      id="F_b3f31213-5c35-4605-8f67-f6d1bff7d408"
      unitRef="U_USD">10000000.0</grts:IssuanceOfConvertiblePreferredStockTransactionPrice>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0ebc7f82-ba9a-4b25-83ff-fc9b906d1b18"
      decimals="INF"
      id="F_02bee6bf-3a99-4e69-969e-6cd0a58f66ee"
      unitRef="U_shares">768115</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0ebc7f82-ba9a-4b25-83ff-fc9b906d1b18"
      decimals="2"
      id="F_119defe2-234b-41ca-ad40-117da321fc95"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.04</us-gaap:SaleOfStockPricePerShare>
    <grts:RevenueRecognitionContractStartMonthYear
      contextRef="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92"
      id="F_f90189bf-e54e-44aa-87cd-bceb20bdcb40">2018-08</grts:RevenueRecognitionContractStartMonthYear>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92"
      decimals="-5"
      id="F_c077e7e7-aebf-4ae8-8588-bdc8083234df"
      unitRef="U_USD">7700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_8ed7ca7f-61f0-4950-bc7b-887b37ebb035"
      decimals="-5"
      id="F_94b3408b-99c9-45e7-a341-51f1e32c1ac4"
      unitRef="U_USD">3000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_39d2c6fe-95e1-4040-9805-ff9f54fdd2c2"
      decimals="-5"
      id="F_620ee022-460d-49e8-bda4-82c4140d5615"
      unitRef="U_USD">2800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92"
      decimals="-5"
      id="F_b9ab6c9a-916b-45b1-9635-127e3a84d333"
      unitRef="U_USD">6400000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3a8b90fa-09bc-4b1c-8721-e05897f1cb0f"
      decimals="-5"
      id="F_c9824c88-ce8e-4091-b601-eeeb3c482b1e"
      unitRef="U_USD">-6400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_3a8b90fa-09bc-4b1c-8721-e05897f1cb0f"
      decimals="2"
      id="F_b82adc5a-a249-4b19-ad98-9e63f02c171b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_5b56ae1b-3299-420b-a990-12c09f3a38a3"
      decimals="-5"
      id="F_8869f1e2-e5ee-492c-9cff-e6c1a68ea457"
      unitRef="U_USD">1000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_3b607420-6945-419e-9f68-f1999ec6386b"
      decimals="-5"
      id="F_f8f45c22-a28c-49d2-9085-a4eeb27a34ff"
      unitRef="U_USD">8700000</us-gaap:ContractWithCustomerLiability>
    <grts:RevenueRecognitionContractEndMonthYear
      contextRef="C_3a8b90fa-09bc-4b1c-8721-e05897f1cb0f"
      id="F_3d5ab0df-98d5-49f9-a78e-c826bd182fba">2023-08</grts:RevenueRecognitionContractEndMonthYear>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_5b788e7f-503c-41d5-8242-fb6f0cb19d92"
      id="F_63ef284c-33d5-461e-8de2-dbe0641cd8e4">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in the deferred revenue balance during the year ended December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.929%;"/&gt;
        &lt;td style="width:1.757%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.558%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.757%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_aadfb6b4-e055-4e7e-82da-133de3937dc4"
      decimals="-3"
      id="F_42249320-42dd-4f55-9bd9-3c1cee1b2dd3"
      unitRef="U_USD">8725000</us-gaap:ContractWithCustomerLiability>
    <grts:ContractWithCustomerLiabilityAddition
      contextRef="C_0ee0de6e-7969-4192-9194-1f65fcc5fe25"
      decimals="-3"
      id="F_0f516ce0-18af-4012-bc54-8ad0a839fefd"
      unitRef="U_USD">0</grts:ContractWithCustomerLiabilityAddition>
    <grts:ContractWithCustomerLiabilityDeductions
      contextRef="C_0ee0de6e-7969-4192-9194-1f65fcc5fe25"
      decimals="-3"
      id="F_98cc09b6-d8a5-43c4-ad7d-47aaad34d5c7"
      unitRef="U_USD">-7678000</grts:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_accde2f9-2b45-4db3-a169-1f19cc7d3a10"
      decimals="-3"
      id="F_5da10bc1-0630-421a-ac43-737a5021db31"
      unitRef="U_USD">1047000</us-gaap:ContractWithCustomerLiability>
    <grts:ReceivablesGross
      contextRef="C_3b607420-6945-419e-9f68-f1999ec6386b"
      decimals="INF"
      id="F_01b99b5f-ddae-47cc-a220-7c1598c57d37"
      unitRef="U_USD">0</grts:ReceivablesGross>
    <grts:ReceivablesGross
      contextRef="C_5b56ae1b-3299-420b-a990-12c09f3a38a3"
      decimals="INF"
      id="F_c3b65ecb-e8bc-4c25-bebc-7910591ec08e"
      unitRef="U_USD">0</grts:ReceivablesGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0f8f5e42-0701-4a64-ab34-634cae0498b7"
      decimals="INF"
      id="F_dffbee3a-0b99-4e76-8b67-ff92316a6352"
      unitRef="U_shares">1169591</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30"
      decimals="-5"
      id="F_1f9d5e66-9a5a-4012-af4d-e9244266b9e1"
      unitRef="U_USD">30000000.0</grts:ProceedsFromNonRefundableUpfrontPayment>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6"
      decimals="2"
      id="F_61b6d32a-96a0-470d-8bd5-b9f78e714dc1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.65</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30"
      decimals="-5"
      id="F_c0392d04-0ff6-49b2-82d8-6bbb4430aacf"
      unitRef="U_USD">30000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <grts:CommonStockFairValueClosingPricePerShare
      contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6"
      decimals="2"
      id="F_9b6069b7-444f-4419-887f-2ddec7a87cf1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.10</grts:CommonStockFairValueClosingPricePerShare>
    <grts:NonRefundableOptionFee
      contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6"
      decimals="-5"
      id="F_53f4f64b-c2f3-4efd-8d3f-19233f7f06e1"
      unitRef="U_USD">40000000.0</grts:NonRefundableOptionFee>
    <grts:MaximumAggregateContingentMilestonePayment
      contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6"
      decimals="-5"
      id="F_10147c39-042e-4414-9979-21a18f874fc0"
      unitRef="U_USD">685000000.0</grts:MaximumAggregateContingentMilestonePayment>
    <grts:CollaborationAgreementEarlyTerminationNoticePeriod
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      id="F_c29a6e50-c3f0-48e6-9723-41c43bd4ff4c">P90D</grts:CollaborationAgreementEarlyTerminationNoticePeriod>
    <grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      id="F_5544d541-dcd7-4589-810b-539e61935999">Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#x2019;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#x2019;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.</grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments>
    <grts:CollaborationAgreementTerminationTerm
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      id="F_dc4f73d3-1096-4e55-a44c-e2bbcdb13ebe">Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and may terminate any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.</grts:CollaborationAgreementTerminationTerm>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30"
      decimals="-5"
      id="F_888c6319-4d30-4c31-aa67-1a54a4305b8a"
      unitRef="U_USD">30000000.0</grts:ProceedsFromNonRefundableUpfrontPayment>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30"
      decimals="-5"
      id="F_f1bb41b4-70c9-471a-b9c0-25e2003f80c8"
      unitRef="U_USD">30000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:TransactionPriceAllocatedToSharesOfCommonStockAtFairValue
      contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30"
      decimals="-5"
      id="F_8e8f960d-76a6-424d-813b-17fb52095d6e"
      unitRef="U_USD">21200000</grts:TransactionPriceAllocatedToSharesOfCommonStockAtFairValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6"
      decimals="INF"
      id="F_ea028b62-9ccd-48e7-bcdc-161ef4999d08"
      unitRef="U_shares">1169591</us-gaap:CommonStockSharesIssued>
    <grts:CommonStockFairValueClosingPricePerShare
      contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6"
      decimals="2"
      id="F_901299e0-080e-4bc2-954e-4a3331563433"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.10</grts:CommonStockFairValueClosingPricePerShare>
    <grts:CommonStockPurchasePriceInExcessOfFairValue1
      contextRef="C_80335036-a649-47ad-8c0a-e757af17ab30"
      decimals="-5"
      id="F_2b6f293a-554a-46d0-b722-7c5c662dc12f"
      unitRef="U_USD">8800000</grts:CommonStockPurchasePriceInExcessOfFairValue1>
    <grts:NonRefundableOptionFee
      contextRef="C_13f202dd-5eaf-4d93-8f04-21e8dde01fb6"
      decimals="-5"
      id="F_b31ff98c-9037-4005-823a-cc35a878acf2"
      unitRef="U_USD">40000000.0</grts:NonRefundableOptionFee>
    <grts:RevenueRecognitionContractStartMonthYear
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      id="F_95dae77a-80dc-4a5e-9a4b-d0b7ddb9c11a">2021-01</grts:RevenueRecognitionContractStartMonthYear>
    <grts:RevenueRecognitionContractEndPeriod
      contextRef="C_201d8d2c-c046-4388-b915-a88be0e7cc5c"
      id="F_3c078262-064d-4055-afb9-e22d6f677eeb">P4Y</grts:RevenueRecognitionContractEndPeriod>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_6d8263f0-f625-4009-a8d1-d1d4686fc533"
      decimals="-5"
      id="F_b95c187f-7f20-4b73-86a0-646e79a43fac"
      unitRef="U_USD">1600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod
      contextRef="C_89e4b4f1-1e78-4fc1-8102-81aecb3af80a"
      decimals="-5"
      id="F_83963372-3b78-4bf7-8f06-73530e8493be"
      unitRef="U_USD">38600000</grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod>
    <grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod
      contextRef="C_760e896a-f89d-4fe2-ac56-70d954e97475"
      decimals="-5"
      id="F_8fb8512d-038f-4636-a8ea-3fa2609443bc"
      unitRef="U_USD">5100000</grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d"
      decimals="-5"
      id="F_a707074d-379b-4ec6-ae43-31e9220fcd79"
      unitRef="U_USD">1400000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79"
      decimals="-5"
      id="F_079e4a26-229d-4187-8a4b-5d9ca7ecad18"
      unitRef="U_USD">100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d"
      decimals="-3"
      id="F_0ca2caf4-2629-43ce-9329-db7adbdb1759"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      id="F_96cb8832-6afd-4d2a-aa5d-b23bb63535aa">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in the contract asset and short-term deferred revenue, balance during the year ended December 31, 2022 for the Gilead Collaboration Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.079%;"/&gt;
        &lt;td style="width:1.496%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.963999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.496%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.963999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contract Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d"
      decimals="-3"
      id="F_edac25f7-f5a0-44a6-b7b3-8f895e7fc835"
      unitRef="U_USD">1385000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d"
      decimals="-3"
      id="F_671f64c9-df8e-4e75-8110-0d2a1ab5b21a"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <grts:ContractWithCustomerAssetAddition
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      decimals="-3"
      id="F_771c4dfe-1011-4bcc-84c4-253dbe4519a2"
      unitRef="U_USD">123000</grts:ContractWithCustomerAssetAddition>
    <grts:ContractWithCustomerLiabilityAddition
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      decimals="-3"
      id="F_57144ae1-8585-432c-afbc-d79b51afecc0"
      unitRef="U_USD">122000</grts:ContractWithCustomerLiabilityAddition>
    <grts:ContractWithCustomerAssetDeduction
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      decimals="-3"
      id="F_c920113f-25a4-4ed3-9521-c9cebdacf507"
      unitRef="U_USD">1508000</grts:ContractWithCustomerAssetDeduction>
    <grts:ContractWithCustomerLiabilityDeductions
      contextRef="C_bc8a647e-410d-4008-9a55-68854219c87e"
      decimals="-3"
      id="F_f23a2b3f-ce7d-46ff-a313-ff357bbb564a"
      unitRef="U_USD">-15000</grts:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79"
      decimals="-3"
      id="F_8eda3e37-1c24-4241-bc72-e361bb1bb4b1"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79"
      decimals="-3"
      id="F_23c95bd9-61f1-41a8-8726-4c0854ec5998"
      unitRef="U_USD">107000</us-gaap:ContractWithCustomerLiability>
    <grts:ReceivablesGross
      contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79"
      decimals="-5"
      id="F_d5183a1c-f616-4892-84d5-cfab2e8c0b09"
      unitRef="U_USD">100000</grts:ReceivablesGross>
    <grts:ReceivablesGross
      contextRef="C_2634c472-49d7-44a4-939b-8fbd8efaf28d"
      decimals="-5"
      id="F_4456f105-f8df-451a-b7a7-63ae380d32b3"
      unitRef="U_USD">700000</grts:ReceivablesGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_04956885-3d5b-41a6-b35d-28c61c1b73fc"
      decimals="-5"
      id="F_426982f5-cdde-412d-aff3-6a41dd5db0e9"
      unitRef="U_USD">100000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_8b9b0098-3da3-4b92-a7bd-36dc7b785d79"
      decimals="-3"
      id="F_e8e06698-8e7e-478f-9418-a9ffee35705b"
      unitRef="U_USD">0</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_91453aed-a1da-44b5-bdcd-23b2fbed997d"
      decimals="-3"
      id="F_c1870759-58e1-4328-a32f-960ebe7dd0f8"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_eea11142-e7ca-4a35-9c72-576024096190"
      decimals="-3"
      id="F_8974ee16-01d0-404e-8cb9-a4570959837b"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f98f071e-224d-4373-a5ef-1f968dd60d8e"
      decimals="-3"
      id="F_aaf07a05-0392-4835-a5e0-3e25d8b61dda"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <grts:MaximumMilestoneConsiderationPayable
      contextRef="C_b32eb355-55f1-4a0d-a16e-f7a33883834a"
      decimals="-5"
      id="F_53ead0af-8fbf-43cc-98fc-dbace69909c0"
      unitRef="U_USD">123500000</grts:MaximumMilestoneConsiderationPayable>
    <grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense
      contextRef="C_3dbebb0a-177e-4cad-98af-5c26d1198e0a"
      decimals="-5"
      id="F_0a4ffe5e-c5ee-4d9d-969d-e3d063c01449"
      unitRef="U_USD">2500000</grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense>
    <grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense
      contextRef="C_e515ffd5-9be4-4d3e-800d-0e4d6f432f77"
      decimals="-5"
      id="F_47c9db4c-6fd7-4f50-8e83-aefa35eb2e0a"
      unitRef="U_USD">3000000.0</grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense>
    <grts:AgreedUpfrontPayment
      contextRef="C_ce9087bc-c51a-4a95-a2a5-acee855847b5"
      decimals="-5"
      id="F_93a71fcb-9300-4f74-9206-1f0b7ae3cdbb"
      unitRef="U_USD">2000000.0</grts:AgreedUpfrontPayment>
    <grts:AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone
      contextRef="C_9e8470b2-dcb6-48e3-b5e1-9aa9a258b518"
      decimals="-5"
      id="F_6b025125-d7c8-4cb1-a9d3-17617a9b730c"
      unitRef="U_USD">71000000.0</grts:AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone>
    <grts:AgreedUpfrontPayment
      contextRef="C_f2705b27-ed81-4a40-b53a-b869c0db0739"
      decimals="-5"
      id="F_7489051a-62cd-439e-a77b-232d7e7d3402"
      unitRef="U_USD">2000000.0</grts:AgreedUpfrontPayment>
    <grts:MilestonePayments
      contextRef="C_3c9e7f0e-5e08-4bcf-99d9-2caf8d424011"
      decimals="-5"
      id="F_371578ec-4521-4ffc-97c9-2b9a153c7f4f"
      unitRef="U_USD">1000000.0</grts:MilestonePayments>
    <grts:PaymentsForOptionsToLicenseForEachIndication
      contextRef="C_95be0954-d2b5-4a76-b208-0a3189bace59"
      decimals="-5"
      id="F_28045c12-f5a4-40e3-b2f5-0021d1455de3"
      unitRef="U_USD">1500000</grts:PaymentsForOptionsToLicenseForEachIndication>
    <grts:AmountToExtendOptionTerm
      contextRef="C_ce9087bc-c51a-4a95-a2a5-acee855847b5"
      decimals="-5"
      id="F_7eefc425-ed92-4824-9bbe-c7eecd82e6a8"
      unitRef="U_USD">1000000.0</grts:AmountToExtendOptionTerm>
    <grts:UpfrontPayments
      contextRef="C_72010145-f061-45d3-99d8-7968eba114aa"
      decimals="-5"
      id="F_e98d347c-8cc8-49ee-b92e-442c93c00906"
      unitRef="U_USD">1500000</grts:UpfrontPayments>
    <grts:MaximumAggregateContingentMilestonePayment
      contextRef="C_d48b34dc-8de5-4f5a-8b9a-cf67c0c1b3bb"
      decimals="-5"
      id="F_8196ce71-e075-450e-992c-e4cb7eb40d9c"
      unitRef="U_USD">141000000.0</grts:MaximumAggregateContingentMilestonePayment>
    <grts:MilestonePayments
      contextRef="C_c7666188-96ff-45eb-8de2-48af6a561ae7"
      decimals="-5"
      id="F_a26a4bc9-dc3b-46ab-a4e9-4dffbc580f4c"
      unitRef="U_USD">1000000.0</grts:MilestonePayments>
    <grts:UpfrontPayments
      contextRef="C_e8e7ad16-a257-4feb-83b3-d36674cafe9d"
      decimals="-5"
      id="F_1316dfe9-6be7-44f2-b9b5-026d5501c267"
      unitRef="U_USD">1500000</grts:UpfrontPayments>
    <grts:MilestonePayments
      contextRef="C_e8e7ad16-a257-4feb-83b3-d36674cafe9d"
      decimals="-5"
      id="F_dd7caa86-538e-4454-a791-8899608691d4"
      unitRef="U_USD">1000000.0</grts:MilestonePayments>
    <grts:MilestonePayments
      contextRef="C_a50f3891-bc8d-430f-8444-964f174a3e3b"
      decimals="-3"
      id="F_9a30b0c2-d422-4aa4-8697-5ee720f97761"
      unitRef="U_USD">0</grts:MilestonePayments>
    <grts:TotalGrantAmount
      contextRef="C_55acf221-1e8f-4997-82b2-c1790c656f7f"
      decimals="-5"
      id="F_3689da56-9edb-4c7b-83a0-95384623260d"
      unitRef="U_USD">20600000</grts:TotalGrantAmount>
    <grts:AdditionalFunding
      contextRef="C_f06b8a24-0a03-4e60-8fd7-ff440ef473d0"
      decimals="-5"
      id="F_23865b23-7932-43ae-bd7b-52af6c0afaf1"
      unitRef="U_USD">5000000.0</grts:AdditionalFunding>
    <grts:AmendedTotalGrantAmount
      contextRef="C_f06b8a24-0a03-4e60-8fd7-ff440ef473d0"
      decimals="-5"
      id="F_6b2ccbb6-0948-485b-804f-9dda66111ed7"
      unitRef="U_USD">25600000</grts:AmendedTotalGrantAmount>
    <grts:FirstTrancheOfFundingsReceived
      contextRef="C_ff4ba982-5223-4146-948e-578e4a49e800"
      decimals="-5"
      id="F_c5218107-6c5d-4c63-bfe4-cad1eaf8d3b9"
      unitRef="U_USD">11300000</grts:FirstTrancheOfFundingsReceived>
    <grts:SecondTrancheOfFundingReceived
      contextRef="C_beafcda9-72de-465a-8212-61152dcebbdd"
      decimals="-5"
      id="F_0e22e674-6aa1-4e54-bf93-3c78c45780a8"
      unitRef="U_USD">2700000</grts:SecondTrancheOfFundingReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8e40ec53-a7a5-40bf-91a9-94f9b7f15952"
      decimals="-5"
      id="F_6d77c79a-4a46-44be-8c74-74e42475a64c"
      unitRef="U_USD">9500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f06b8a24-0a03-4e60-8fd7-ff440ef473d0"
      decimals="-5"
      id="F_3d1a066a-47ec-4fa3-a2eb-e611793cbd24"
      unitRef="U_USD">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_80849ef4-0531-4940-958b-b3800e6ec694"
      decimals="-5"
      id="F_da1813df-d73a-4e3a-bcf0-0981c8991703"
      unitRef="U_USD">3000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_e95014f8-6dc9-41f7-ad01-70179a6bc0a8"
      decimals="-5"
      id="F_2899f340-e36b-4f88-81f1-53e59a000aa3"
      unitRef="U_USD">9400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_7252815e-38c6-46dc-8937-24c805d8b308"
      decimals="-5"
      id="F_9e57b319-8948-4a7a-bcc1-8e431b96540d"
      unitRef="U_USD">3000000.0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_082d0a7a-97c2-4602-9ad8-c0587fc21667"
      decimals="-5"
      id="F_912ede7f-5149-4037-b55e-5a9dece157a6"
      unitRef="U_USD">9400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_969fab0c-3062-4255-b015-879022cee5f9"
      id="F_73edb1ee-802d-4872-8e88-11fb176e1e44">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the CEPI Funding Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_b9cf46df-3e9b-42ee-b59e-eb74338bcf32"
      decimals="-3"
      id="F_c0107d35-a45d-42fe-a6b5-4830283c56b6"
      unitRef="U_USD">9379000</us-gaap:ContractWithCustomerLiability>
    <grts:ContractWithCustomerLiabilityAddition
      contextRef="C_0a69806e-b629-40b1-a18d-6ca603eb73b8"
      decimals="-3"
      id="F_ac05c509-c012-4b64-a11e-ddd8664e35bd"
      unitRef="U_USD">2698000</grts:ContractWithCustomerLiabilityAddition>
    <grts:ContractWithCustomerLiabilityDeductions
      contextRef="C_0a69806e-b629-40b1-a18d-6ca603eb73b8"
      decimals="-3"
      id="F_42d88bef-d317-47a3-9849-51746241283f"
      unitRef="U_USD">-9125000</grts:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0eca9dc8-8c2d-4467-b653-fbcf9a107933"
      decimals="-3"
      id="F_bff04b26-3804-4db8-8db8-a63cdf6c929c"
      unitRef="U_USD">2952000</us-gaap:ContractWithCustomerLiability>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_f1213544-8876-4d28-b445-ffd3948fc5c0"
      decimals="-5"
      id="F_4e0a3dbf-379a-4d48-a667-71e91cf86d6e"
      unitRef="U_USD">2200000</grts:ProceedsFromNonRefundableUpfrontPayment>
    <grts:FutureFundingExpected
      contextRef="C_6d7f03df-630d-4cad-87f7-614b2528d487"
      decimals="-5"
      id="F_cb166cb5-6b1d-4707-aa53-68f0ef0f2f52"
      unitRef="U_USD">1000000.0</grts:FutureFundingExpected>
    <grts:TotalGrantAmount
      contextRef="C_6d7f03df-630d-4cad-87f7-614b2528d487"
      decimals="-5"
      id="F_ef1eeeba-b215-4c93-8756-9ec2efeddae3"
      unitRef="U_USD">3200000</grts:TotalGrantAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e"
      decimals="-5"
      id="F_d3457ede-6224-48f2-aafb-3f2f272c0da5"
      unitRef="U_USD">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_de1f942a-daf6-4e81-ae8e-4d009e1427bc"
      decimals="-3"
      id="F_e783fb4d-849d-4093-9761-54894950fe2f"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_7bec73ca-4c8e-4211-838e-e975e53259b0"
      decimals="-5"
      id="F_8b5992b8-d709-4c1b-b57a-28e83bcde398"
      unitRef="U_USD">1000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="C_7bec73ca-4c8e-4211-838e-e975e53259b0"
      decimals="-5"
      id="F_d66e4474-4a27-4a7e-98cc-0b1098729aba"
      unitRef="U_USD">1000000.0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960"
      decimals="-5"
      id="F_8f092927-eede-458a-88bc-fe7710e25fdc"
      unitRef="U_USD">1900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960"
      decimals="-5"
      id="F_51c573f6-f841-4a34-895d-939a8c6ceb03"
      unitRef="U_USD">1900000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960"
      decimals="-5"
      id="F_2e197d46-b2e4-4ad1-8c70-638ac5c93d2e"
      unitRef="U_USD">300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960"
      decimals="-5"
      id="F_587716e3-f3e7-498e-a84e-d1374e46d215"
      unitRef="U_USD">300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e"
      id="F_724a77c1-dc56-4223-9f91-8b55a70f9f72">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in the short-term deferred revenue, balance during the year ended December 31, 2022 for the Grant Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.308%;"/&gt;
        &lt;td style="width:1.877%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.815%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_fc893192-2b4b-49b4-9a11-52f5e2e37960"
      decimals="-3"
      id="F_a3307af0-39c2-4e6e-a12c-5c2390118de1"
      unitRef="U_USD">2225000</us-gaap:ContractWithCustomerLiability>
    <grts:ContractWithCustomerLiabilityAddition
      contextRef="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e"
      decimals="-3"
      id="F_89f2d28a-aa75-4abc-9d62-62d1577d556d"
      unitRef="U_USD">0</grts:ContractWithCustomerLiabilityAddition>
    <grts:ContractWithCustomerLiabilityDeductions
      contextRef="C_48b2e67e-c8fe-449e-a98f-d6b48eadfc5e"
      decimals="-3"
      id="F_272db786-3822-4d0b-bfdd-e6399d171c10"
      unitRef="U_USD">-1200000</grts:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_7bec73ca-4c8e-4211-838e-e975e53259b0"
      decimals="-3"
      id="F_f7ea71df-d065-44da-a06a-0a654df7d2f8"
      unitRef="U_USD">1025000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_3ea95586-38ae-4e60-ac5a-cedd565efb3c">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.	Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2022, the Company entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;) and Silicon Valley Bank (&#x201c;SVB&#x201d;), which provides the Company a 60-month term loan facility for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;borrowing &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;capacity across five potential tranches. At the closing of the Loan Agreement, the Company drew &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from the first tranche and can draw up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million through March 2023. The remaining tranches provide up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million borrowing capacity and become available upon the Company meeting certain milestones set forth in the Loan Agreement. As of December 31, 2022, one milestone had been achieved, which provides the Company the ability to draw up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million through December 15, 2023. The term loan is secured by substantially all of the Company&#x2019;s assets, other than intellectual property. There are no warrants associated with the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Borrowings under the Loan Agreement bear interest (i) at an annual cash rate equal to the greater of (x) the lesser of (1) the prime rate (as customarily defined) and (2) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, in either case, plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, and (y) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and (ii) at an annual payment-in-kind rate which may equal &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company is required to make monthly interest-only payments prior to the amortization date of January 1, 2025, subject to a potential six-month and one-year extension upon satisfaction of certain conditions. The interest-only payment date has been extended an additional six months based on our achievement of one of the milestones as set forth in the Loan Agreement. In addition, the Company paid a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; facility charge upon closing, and must pay a facility charge equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the principal amount of any borrowings made pursuant to the amounts under the last four tranches.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All unpaid principal and accrued and unpaid interest with respect to each term loan is due and payable in full on July 19, 2027. At the Company&#x2019;s option, the Company may prepay all or any portion of the outstanding borrowings, plus accrued and unpaid interest thereon and fees and expenses, subject to a prepayment premium ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, during the first three years after closing, depending on the year of such prepayment. Upon repayment of the term loan, the Company is required to make a final payment fee to the lenders equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the aggregate original principal amount of the loan. Debt issuance costs have been treated as debt discounts on the Company&#x2019;s consolidated balance sheet and together with the final payment are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning on April 1, 2023, so long as the Company&#x2019;s market capitalization is equal to or less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Company is subject to a minimum liquidity requirement equal to the then outstanding balance under the Loan Agreement multiplied by 0.55 or 0.45, which multiplier depends on whether the Company achieves certain performance milestones.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s obligations under the Loan Agreement are subject to acceleration upon the occurrence of customary events of default, including payment default, insolvency and the occurrence of certain events having a material adverse effect on the Company, including (but not limited to) material adverse effects upon the business, operations, properties, assets or financial condition of the Company and its subsidiaries, taken as a whole. As of December 31, 2022, the Company is in compliance with all covenants in the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there were unamortized issuance costs and debt discounts of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which were recorded as a direct deduction from the term loan on the consolidated balance sheet. Interest expense related to the Loan Agreement was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2022. The effective interest rate on the term loan, including the amortization of the debt discount and issuance costs, and accretion of the final payment, was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. The components of the long-term debt balance are as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.299%;"/&gt;
        &lt;td style="width:1.874%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.828%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal loan balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Final fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the estimated future principal payments due (excluding the final payment fee) were as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.991%;"/&gt;
        &lt;td style="width:2.083%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.926%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total principal payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_dfc996c2-5a4e-4564-8277-b7d2ffbeec1d"
      decimals="-5"
      id="F_295b620c-97f9-4171-b80d-ae192d979267"
      unitRef="U_USD">80000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="C_8db1bd52-7abc-4eeb-9079-f65d7f8c2c1b"
      decimals="-5"
      id="F_fc583796-97d7-412e-af7d-21174d33aed6"
      unitRef="U_USD">20000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_c139338b-65f8-4c46-9f25-0a151c3415a7"
      decimals="-5"
      id="F_c31cf2ee-2923-438e-befc-fe740321e268"
      unitRef="U_USD">10000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_604e35dd-089f-428e-8455-fd00d7905514"
      decimals="-5"
      id="F_89af693b-7659-4290-a553-47330af479aa"
      unitRef="U_USD">50000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_6d3577c4-db17-46ad-8f60-2c0eb8ff2efa"
      decimals="-6"
      id="F_501e10f9-a5f5-484f-9606-71528639ea2e"
      unitRef="U_USD">10000000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_dc0d2494-fb2c-4556-8cfb-8f4cbf34588f"
      id="F_b844cace-84d7-403d-a9d9-25ebcf4c2826">Borrowings under the Loan Agreement bear interest (i) at an annual cash rate equal to the greater of (x) the lesser of (1) the prime rate (as customarily defined) and (2) 5.50%, in either case, plus 3.15%, and (y) 7.15% and (ii) at an annual payment-in-kind rate which may equal 2.00%.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_bbe3a914-b528-49c7-8179-6932dd627a2a"
      decimals="4"
      id="F_0e28be20-ce4a-47ed-b00c-4e974f3d4395"
      unitRef="U_pure">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_9d996bec-14d2-4de2-a3e4-8cb7d6f0f835"
      decimals="4"
      id="F_b2ce3566-51a6-45f3-824f-b985ecf2abfe"
      unitRef="U_pure">0.0315</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_7c20b544-b6be-4cb6-a697-7fed0ddcd9cf"
      decimals="4"
      id="F_71a05964-5e64-4d86-b8c2-0a1fbb3f2e41"
      unitRef="U_pure">0.0715</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_dd3679ef-3afd-4878-b600-1c49abe1ccaf"
      decimals="4"
      id="F_e561a787-75be-4109-99e4-08621928ae49"
      unitRef="U_pure">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_dfc996c2-5a4e-4564-8277-b7d2ffbeec1d"
      decimals="0"
      id="F_31f9561b-ed03-4ea8-a468-d18954bca681"
      unitRef="U_USD">150000</us-gaap:DebtInstrumentFeeAmount>
    <grts:FacilityChargePercentageOfBorrowing
      contextRef="C_79e7ae2f-f2dc-435d-9836-71d230ab5b96"
      decimals="4"
      id="F_ce2ed149-3203-4939-80a1-4031d9d04758"
      unitRef="U_pure">0.0050</grts:FacilityChargePercentageOfBorrowing>
    <grts:PrepaymentPremiumRate
      contextRef="C_892682c3-ba06-4a39-8d64-2a527d6f399c"
      decimals="2"
      id="F_56092c0a-f329-4e94-81c2-da5e4e8e6118"
      unitRef="U_pure">0</grts:PrepaymentPremiumRate>
    <grts:PrepaymentPremiumRate
      contextRef="C_380477b0-d459-4fc3-9c66-ba4500d99c6f"
      decimals="3"
      id="F_1d982002-0b62-44d3-a144-23b00d9734c3"
      unitRef="U_pure">0.025</grts:PrepaymentPremiumRate>
    <grts:FinalPaymentFeePercentage
      contextRef="C_79e7ae2f-f2dc-435d-9836-71d230ab5b96"
      decimals="4"
      id="F_0010cde3-093b-4ecd-89a4-61477a0af126"
      unitRef="U_pure">0.0575</grts:FinalPaymentFeePercentage>
    <us-gaap:CapitalizationLongtermDebtAndEquity
      contextRef="C_ae54a29d-2a04-4259-9f48-ef7214c95a0b"
      decimals="-5"
      id="F_5fd7c445-deb0-41f3-a18d-d2d6576af21e"
      unitRef="U_USD">400000000.0</us-gaap:CapitalizationLongtermDebtAndEquity>
    <grts:MinimumLiquidityRequirementCapitalDescription
      contextRef="C_b402c931-cfd8-4ccd-855e-c61c5c4d4509"
      id="F_e20296fd-621e-45d3-b6ac-5eea256d6ce8">the Company is subject to a minimum liquidity requirement equal to the then outstanding balance under the Loan Agreement multiplied by 0.55 or 0.45, which multiplier depends on whether the Company achieves certain performance milestones.</grts:MinimumLiquidityRequirementCapitalDescription>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_8766ca2a-9ff6-4066-8356-6a67a4e463d3"
      decimals="-5"
      id="F_f1f2464a-d708-4f7d-9f16-ca771d811324"
      unitRef="U_USD">1800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:InterestExpenseDebt
      contextRef="C_dc0d2494-fb2c-4556-8cfb-8f4cbf34588f"
      decimals="-5"
      id="F_d98510eb-eef7-496c-80a7-bcbf85614f3d"
      unitRef="U_USD">1200000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_8766ca2a-9ff6-4066-8356-6a67a4e463d3"
      decimals="2"
      id="F_0e8a96a8-5bd0-4c3e-b83b-9bbb9cb61b30"
      unitRef="U_pure">0.13</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_da80c44b-0614-4e08-bee0-3ae89a874604">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.299%;"/&gt;
        &lt;td style="width:1.874%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.828%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal loan balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Final fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_2498f130-9c5d-4842-be0b-e919cf1a6e53"
      unitRef="U_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <grts:FinalFee
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_238ff31b-1a81-4051-87e0-bf6e94f7eb5f"
      unitRef="U_USD">1150000</grts:FinalFee>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_000ec22d-ceb3-4d99-9056-da29b83f535c"
      unitRef="U_USD">-1801000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_86bf574e-d0eb-4377-9ca1-a81760eba28b"
      unitRef="U_USD">19349000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_09299369-c9ec-462e-9a2c-c5604f3edcb8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.991%;"/&gt;
        &lt;td style="width:2.083%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.926%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total principal payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_4e943fba-9be5-4764-8d12-13db8c71af5c"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_527a1b30-3f8a-4a27-904f-0beb8244cef2"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_a4b8dbf3-97fe-4189-b53b-fbfc11f29607"
      unitRef="U_USD">4407000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_22fc9dab-38a0-412a-9c73-cd86652c5cae"
      unitRef="U_USD">9396000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_7c9ea9ea-639f-45e9-8966-acda9f1bc475"
      unitRef="U_USD">6197000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_14c59d21-30fb-44cd-85bc-7e4ac9fb9d29"
      unitRef="U_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_cf912ab4-8303-4457-9442-14c72957f74f">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.	Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Prepaid Expenses and Other Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.953%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.267%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid research and development-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net contract asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest and other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Facilities-related deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deposits and Other Long-Term Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deposits and other long-term assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.953%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.267%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease security deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid research and development-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid rent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deposits and other long-term assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_e4eb3ffe-850c-41a4-ae84-1230e40283ad">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.953%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.267%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid research and development-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net contract asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest and other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Facilities-related deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <grts:PrepaidExpenseForResearchAndDevelopment
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_60b7a977-057d-4ac8-9806-9de6e91b1b5c"
      unitRef="U_USD">4241000</grts:PrepaidExpenseForResearchAndDevelopment>
    <grts:PrepaidExpenseForResearchAndDevelopment
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_8a35b509-bcb8-4a14-9b1b-684f1e876c25"
      unitRef="U_USD">2672000</grts:PrepaidExpenseForResearchAndDevelopment>
    <grts:NetContractAsset
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_a44b04e0-ba18-4d15-ba47-7b7a5645d847"
      unitRef="U_USD">0</grts:NetContractAsset>
    <grts:NetContractAsset
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_feb4c653-67d8-4bf6-a700-a1c697764578"
      unitRef="U_USD">1385000</grts:NetContractAsset>
    <grts:CollaborationReceivable
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_dd7a1aa4-e6c5-4bd3-8827-e4790d3538de"
      unitRef="U_USD">135000</grts:CollaborationReceivable>
    <grts:CollaborationReceivable
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_0fc2751b-3dc6-4665-9537-f879fe707d70"
      unitRef="U_USD">688000</grts:CollaborationReceivable>
    <us-gaap:PrepaidInsurance
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_e2947732-ea28-4d8f-add2-942430d04bb7"
      unitRef="U_USD">1158000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_4a3fb59d-3e03-44b1-8523-a5b29cf56e2c"
      unitRef="U_USD">1769000</us-gaap:PrepaidInsurance>
    <grts:InterestAndOtherReceivablesCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_6d2dedf9-bf44-4a73-9e2f-2216c3804032"
      unitRef="U_USD">529000</grts:InterestAndOtherReceivablesCurrent>
    <grts:InterestAndOtherReceivablesCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_d4443a1b-9c7c-4954-8f5a-cb93d2754da4"
      unitRef="U_USD">292000</grts:InterestAndOtherReceivablesCurrent>
    <grts:FacilitiesRelatedDeposits
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_17c5bcc8-58f3-457c-a017-64364700a5ac"
      unitRef="U_USD">384000</grts:FacilitiesRelatedDeposits>
    <grts:FacilitiesRelatedDeposits
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_965f62e2-4ad3-42f1-a51e-14654eed089c"
      unitRef="U_USD">0</grts:FacilitiesRelatedDeposits>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_1b586e64-aa61-47e9-9082-c573d33180b2"
      unitRef="U_USD">567000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_53697a39-420e-4fa8-aad8-6229625ec6c7"
      unitRef="U_USD">866000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_eb1cef28-9b91-4788-97de-6b0674f7bd18"
      unitRef="U_USD">7014000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_cc4b5e71-fddb-40ab-9b7d-b69b1edb7346"
      unitRef="U_USD">7672000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_75b0d8f1-9d86-436c-b33b-7819536fc850">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deposits and other long-term assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.953%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.267%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease security deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid research and development-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid rent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deposits and other long-term assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:SecurityDeposit
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_097f53db-e50c-40aa-ac96-54544c2c347d"
      unitRef="U_USD">934000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_97b9864c-5b0a-450d-8695-25859efee2e4"
      unitRef="U_USD">1305000</us-gaap:SecurityDeposit>
    <grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_90bd4c6b-1879-47e9-91cb-877cc7fc7a96"
      unitRef="U_USD">643000</grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent>
    <grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_6be8ade3-2ead-4535-b175-5dd57b718e91"
      unitRef="U_USD">1047000</grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent>
    <us-gaap:PrepaidRent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_65a59eed-c211-44d0-b85b-f0b837c16f5c"
      unitRef="U_USD">8162000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_5be45534-5e1b-45c9-af05-b478122d1b70"
      unitRef="U_USD">0</us-gaap:PrepaidRent>
    <grts:DepositsAndOtherAssetsNoncurrent
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_6cb829ff-449e-46dc-9c71-0b51c6833b13"
      unitRef="U_USD">9739000</grts:DepositsAndOtherAssetsNoncurrent>
    <grts:DepositsAndOtherAssetsNoncurrent
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_317ab707-752b-41f0-80eb-58f8d6c0f331"
      unitRef="U_USD">2352000</grts:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_52fd81e4-5d51-4f55-b819-46253985c5b4">&lt;p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.	Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s amended and restated certificate of incorporation provides for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock authorized for issuance, each with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock were issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,894,901&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,047,878&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock issued and outstanding, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Holders of the Company&#x2019;s common stock are entitled to one vote per share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sale of Common Stock and Pre-Funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2019, the Company filed a Registration Statement on Form S-3 (the &#x201c;2019 Shelf Registration Statement&#x201d;) with the SEC, covering the offering of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of common stock, preferred stock, debt securities, warrants and units. The 2019 Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock, from time to time, through the ATM Offering Program under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The SEC declared the 2019 Shelf Registration Statement effective on November 8, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the 2019 ATM Offering Program, in October 2019, the Company entered into a sales agreement (the &#x201c;2019 Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), pursuant to which Cowen acts as the Company&#x2019;s sales agent and, from time to time, offers and sells shares of the Company&#x2019;s common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Cowen is entitled to compensation for its services equal to up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the gross proceeds of any shares of common stock sold under the 2019 Sales Agreement. In addition, the Company agreed to reimburse a portion of Cowen&#x2019;s expenses in connection with the 2019 ATM Offering Program up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the year ended December 31, 2021, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,990,869&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  shares of its common stock through its 2019 ATM Offering Program and received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, net of commissions and other offering costs. During the year ended December 31, 2022, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; sales &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of shares of the Company&#x2019;s common stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;its 2019 ATM Offering Program. As of December 31, 2022, there are no further amounts available for issuance under the 2019 ATM Offering Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2020, the Company entered into two private placement financing transactions (collectively, the &#x201c;First PIPE Financing&#x201d;), as follows: (i) to sell &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,543,351&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and pre-funded warrants (the &#x201c;Warrants&#x201d;) to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,480,719&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share (of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share was prepaid by each purchaser), and (ii) to sell an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,043,127&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock at a price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.71&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In connection with the First PIPE Financing, the Company received aggregate net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Warrants are exercisable upon issuance at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The outstanding Warrants generally may not be exercised if the holder&#x2019;s aggregate beneficial ownership would be more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total issued and outstanding shares of the Company&#x2019;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#x201c;Warrant Shares&#x201d;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#x201c;cashless&#x201d; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2021, the Company completed a PIPE financing transaction, in which it sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share pursuant to a securities purchase agreement entered into on September 16, 2021 (the &#x201c;Second PIPE Financing&#x201d;). The Company received aggregate net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Second PIPE Financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2022, the Company filed a Registration Statement on Form S-3 with the SEC (the &#x201c;2022 Shelf Registration Statement&#x201d;), covering the offering of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of common stock, preferred stock, debt securities, warrants and units. The 2022 Shelf Registration Statement included a prospectus supplement covering the issuance and sale of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock, from time to time, through an &#x201c;at-the-market&#x201d; offering program (the &#x201c;2022 ATM Offering Program&#x201d;) under the Securities Act. The SEC declared the 2022 Shelf Registration Statement effective as of May 6, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the 2022 ATM Offering Program, in March 2022, the Company also entered into a sales agreement (the &#x201c;2022 Sales Agreement&#x201d;) with Cowen, pursuant to which Cowen will act as the Company&#x2019;s sales agent and, from time to time, offer and sell shares of the Company&#x2019;s common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Cowen is entitled to compensation for its services equal to up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the gross proceeds of any shares of common stock sold under the 2022 Sales Agreement. In addition, the Company agreed to reimburse a portion of Cowen&#x2019;s expenses in connection with the 2022 ATM Offering Program up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, the Company has received aggregate proceeds from its 2022 ATM Offering Program of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, net of commissions and offering costs, pursuant to the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,034,948&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2022, the Company completed a PIPE financing transaction, in which it sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,637,165&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share pursuant to a securities purchase agreement entered into on October 24, 2022 and pre-funded warrants (the &#x201c;Warrants&#x201d;) to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,274,923&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share (of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2599&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share was prepaid by each purchaser) (the &#x201c;Third PIPE Financing&#x201d;). The Company received aggregate net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Third PIPE Financing. The Warrants are exercisable upon issuance at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The outstanding Warrants generally may not be exercised if the holder&#x2019;s aggregate beneficial ownership would be more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total issued and outstanding shares of the Company&#x2019;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#x201c;Warrant Shares&#x201d;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#x201c;cashless&#x201d; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the following warrants to purchase shares of the Company&#x2019;s common stock were issued and outstanding:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.773%;"/&gt;
        &lt;td style="width:1.467%;"/&gt;
        &lt;td style="width:27.95%;"/&gt;
        &lt;td style="width:1.467%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.704%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.639%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issue Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 28, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,573,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;October 24, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,274,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,848,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.4%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;	&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,442,567&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants exercised, resulting in the Company issuing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,442,567&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. During the year ended December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,459,576&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants exercised and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,872&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants cancelled due to net exercise of the warrants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_78bd9843-080b-4da9-aa64-2a6e6bff9c0d"
      decimals="INF"
      id="F_a1ae84be-62bb-48c0-a917-056fb97a6895"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_78bd9843-080b-4da9-aa64-2a6e6bff9c0d"
      decimals="INF"
      id="F_57544abf-b6d9-4ae9-a34b-bd402bf43a35"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_78bd9843-080b-4da9-aa64-2a6e6bff9c0d"
      decimals="INF"
      id="F_6ef8cb8b-51f5-4e2f-b38e-6a5489bb856a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_e0eb266e-f3df-4c5b-8dba-bde9981070e6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_5872654d-e346-4995-adc1-6ec2f8576670"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_42419c27-1445-4ae0-96c1-4860f7828005"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_17081bb4-dffb-4387-b67c-353141bee3d3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_4dd1e1fd-2007-40e5-9d9e-7a98eeb46c2d"
      unitRef="U_shares">86894901</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_e3ce5aa2-8955-4b79-af2b-cfa1b9e0431f"
      unitRef="U_shares">86894901</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_b635fb25-39b5-4ead-9258-4348097cf261"
      unitRef="U_shares">69047878</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_70aaecfd-39a3-47ed-93fe-2db5f5320065"
      unitRef="U_shares">69047878</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_ebbe034a-caee-4957-a6fc-2e9028d5952e">Holders of the Company&#x2019;s common stock are entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <grts:MaximumSecuritiesCoveredUnderRegistrationAgreement
      contextRef="C_7855eba8-76bc-4a8c-9ce4-0799ef712f67"
      decimals="-5"
      id="F_9c709ba2-df9a-4d88-987d-38ff8f3b1bec"
      unitRef="U_USD">250000000.0</grts:MaximumSecuritiesCoveredUnderRegistrationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_323e95b8-22cf-4c13-a39e-cc623d224a74"
      decimals="-5"
      id="F_6dea14a3-adb0-4a1e-9561-a66bb2f0a8e6"
      unitRef="U_USD">75000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_323e95b8-22cf-4c13-a39e-cc623d224a74"
      decimals="-5"
      id="F_7836bcc0-e711-48ab-a9ae-f2c3d336fee4"
      unitRef="U_USD">75000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:PercentageOfProceedsPayableAsCompensationToUnderwriter
      contextRef="C_7f8d1e5e-8021-40a9-af4e-637188703294"
      decimals="3"
      id="F_80749b2f-94e0-46f3-803b-af3bee14c19b"
      unitRef="U_pure">0.030</grts:PercentageOfProceedsPayableAsCompensationToUnderwriter>
    <grts:MaximumOfferingExpensesAgreedToBeReimbursed
      contextRef="C_7f8d1e5e-8021-40a9-af4e-637188703294"
      decimals="0"
      id="F_ce1bd321-d745-48dd-8ae5-9e44c58931f1"
      unitRef="U_USD">50000</grts:MaximumOfferingExpensesAgreedToBeReimbursed>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f9220959-3f8c-49ee-b09b-88b706eaf9b1"
      decimals="INF"
      id="F_988dbaa0-26b6-4ee8-a93e-9e3b09b0795e"
      unitRef="U_shares">3990869</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f9220959-3f8c-49ee-b09b-88b706eaf9b1"
      decimals="-5"
      id="F_9dddb8cf-c766-411c-afac-23aeae64dc01"
      unitRef="U_USD">36600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_17553f60-9678-4458-869e-6553a03fa156"
      decimals="0"
      id="F_912d5eab-f8db-4969-a496-89ab97bcc56b"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_e79a84f8-b402-4c06-a64d-be36155f0669"
      decimals="INF"
      id="F_cdfc1753-ddaf-4ca3-8b35-4bd99ee57ca6"
      unitRef="U_shares">5543351</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_11b7e846-cd77-420b-8752-6e1a1f336a59"
      decimals="2"
      id="F_6242d449-4550-4dec-a05a-92ea72f31662"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.34</us-gaap:SharesIssuedPricePerShare>
    <grts:WarrantsToPurchaseSharesOfCommonStock
      contextRef="C_e79a84f8-b402-4c06-a64d-be36155f0669"
      decimals="INF"
      id="F_7c6dfc68-9d43-4f46-aa78-8317958e5e05"
      unitRef="U_shares">27480719</grts:WarrantsToPurchaseSharesOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_11b7e846-cd77-420b-8752-6e1a1f336a59"
      decimals="2"
      id="F_0049d3bb-21b8-4006-a43b-e3a9822e7bca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.34</us-gaap:SaleOfStockPricePerShare>
    <grts:SaleOfStockPricePerSharePrepaidByPurchaser
      contextRef="C_11b7e846-cd77-420b-8752-6e1a1f336a59"
      decimals="2"
      id="F_9352950b-4e7f-46fe-b901-d77e9a27f5cd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.33</grts:SaleOfStockPricePerSharePrepaidByPurchaser>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_80415412-bf63-429e-9fb1-589b8f52c64b"
      decimals="INF"
      id="F_405708e4-f036-43b5-b9d9-c3eaea349b87"
      unitRef="U_shares">4043127</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_5cfdaae9-b4b4-47da-bcee-8fd709202da6"
      decimals="2"
      id="F_a3d5fdb2-26e3-4a9c-a921-0ce95bd9664b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.71</us-gaap:SharesIssuedPricePerShare>
    <grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
      contextRef="C_e79a84f8-b402-4c06-a64d-be36155f0669"
      decimals="-5"
      id="F_c9c80625-31ee-43b5-89cf-0353fb59d678"
      unitRef="U_USD">119800000</grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_11b7e846-cd77-420b-8752-6e1a1f336a59"
      decimals="2"
      id="F_13cfc2cc-232d-4d80-ba97-3573f42950c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant
      contextRef="C_e79a84f8-b402-4c06-a64d-be36155f0669"
      decimals="4"
      id="F_f264047d-a0af-436e-a8cd-4b2c681d9821"
      unitRef="U_pure">0.0999</grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_b5151ebd-45f6-4030-99a1-58711cd6e0af"
      decimals="-5"
      id="F_b53580d9-8de1-4b93-88d1-ba50d792b959"
      unitRef="U_USD">87700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_65adaa59-8507-450d-85bf-fc379014d32a"
      decimals="INF"
      id="F_b684c9c8-0fdd-4910-840e-14fb8386c04b"
      unitRef="U_shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_e6cfa898-87ba-405c-ab6e-c9fdcb066f80"
      decimals="2"
      id="F_bece0053-593b-4802-bd74-7a9fa9c32e0a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_65adaa59-8507-450d-85bf-fc379014d32a"
      decimals="-5"
      id="F_6fd31364-a657-4e41-9d14-7f54197f45e4"
      unitRef="U_USD">52700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:MaximumSecuritiesCoveredUnderRegistrationAgreement
      contextRef="C_56766ff0-b624-4f79-bafa-518ca3d728d7"
      decimals="-5"
      id="F_8ea20dba-59c0-49d1-bcfa-460b526ae492"
      unitRef="U_USD">250000000.0</grts:MaximumSecuritiesCoveredUnderRegistrationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2e24acd0-67f6-4df3-a3dd-efc69b71ea26"
      decimals="-5"
      id="F_468727b4-f402-48f6-8e76-e266bbfff801"
      unitRef="U_USD">100000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_11b309d8-462b-4ef1-aa32-6924156d9e05"
      decimals="-5"
      id="F_8e1b03d7-ae23-4784-a52f-57c98264b1ac"
      unitRef="U_USD">100000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:PercentageOfProceedsPayableAsCompensationToUnderwriter
      contextRef="C_210e3734-9390-4047-8e9e-6e3dac75eb53"
      decimals="3"
      id="F_6fcdf5e8-05a7-4e03-bb8f-598d10f5e33a"
      unitRef="U_pure">0.030</grts:PercentageOfProceedsPayableAsCompensationToUnderwriter>
    <grts:MaximumOfferingExpensesAgreedToBeReimbursed
      contextRef="C_210e3734-9390-4047-8e9e-6e3dac75eb53"
      decimals="0"
      id="F_ae359860-d459-402e-b49f-7a90b9011e96"
      unitRef="U_USD">50000</grts:MaximumOfferingExpensesAgreedToBeReimbursed>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_4aff01cb-2e26-424b-83a9-fc5583bbca7a"
      decimals="-5"
      id="F_8954f06c-1da8-4b68-8fa8-27663d6f978a"
      unitRef="U_USD">19600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6411ac81-f0a4-466a-b658-bc20a1796628"
      decimals="INF"
      id="F_1c9b21ce-41d7-42c1-a0e3-baedf87e292e"
      unitRef="U_shares">7034948</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2d75caf7-1680-40a2-922d-317eeb129d2b"
      decimals="INF"
      id="F_dd616883-464c-4ec5-9d8e-366ae60ed338"
      unitRef="U_shares">6637165</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_2d75caf7-1680-40a2-922d-317eeb129d2b"
      decimals="2"
      id="F_c83f36cf-55af-4065-a0e7-7d65acb9c79b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.26</us-gaap:SharesIssuedPricePerShare>
    <grts:WarrantsToPurchaseSharesOfCommonStock
      contextRef="C_84b52d54-d609-4bec-bfa0-0f69992f3096"
      decimals="INF"
      id="F_5805592c-7511-4007-9fb2-f004d5f5ba49"
      unitRef="U_shares">13274923</grts:WarrantsToPurchaseSharesOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0d2325a8-cbfa-43c0-bd17-5934a79b43c0"
      decimals="INF"
      id="F_96fd20cc-d8da-4d08-aa05-be58d605b49e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.26</us-gaap:SaleOfStockPricePerShare>
    <grts:SaleOfStockPricePerSharePrepaidByPurchaser
      contextRef="C_0d2325a8-cbfa-43c0-bd17-5934a79b43c0"
      decimals="INF"
      id="F_3cec4279-f30c-4214-af19-d4d7e988b42e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.2599</grts:SaleOfStockPricePerSharePrepaidByPurchaser>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_217b0356-637c-4019-9519-2b40884dd4ea"
      decimals="-5"
      id="F_8b139a56-12ef-4a04-add3-af2375901818"
      unitRef="U_USD">42400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0d2325a8-cbfa-43c0-bd17-5934a79b43c0"
      decimals="INF"
      id="F_d2fb07ac-a14f-494a-b506-d953666815d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant
      contextRef="C_dcee5e27-efd7-4563-b1c8-df33f67e907f"
      decimals="4"
      id="F_58560173-b718-48ed-925b-dbd594d8ee09"
      unitRef="U_pure">0.0999</grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_e6bd0364-0189-46f1-9a87-5b5ae7b4a68b"
      decimals="-5"
      id="F_26039596-5f96-4d60-b065-c5adcc0b2705"
      unitRef="U_USD">28200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_ef89f9fe-421e-4696-a2ff-19df1593aec2">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the following warrants to purchase shares of the Company&#x2019;s common stock were issued and outstanding:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.773%;"/&gt;
        &lt;td style="width:1.467%;"/&gt;
        &lt;td style="width:27.95%;"/&gt;
        &lt;td style="width:1.467%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.704%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.639%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issue Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 28, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,573,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;October 24, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,274,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,848,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <grts:ClassOfWarrantOrRightIssueDate
      contextRef="C_a246cd21-ac7d-4072-88f9-4cb7c5a9e332"
      id="F_4d6c8b81-74dd-42d9-80aa-e5ad926f0781">2020-12-28</grts:ClassOfWarrantOrRightIssueDate>
    <grts:ClassOfWarrantOrRightsExpiration
      contextRef="C_a246cd21-ac7d-4072-88f9-4cb7c5a9e332"
      id="F_70ee5587-d467-48ab-b8c6-07be5fe2bbc9">None</grts:ClassOfWarrantOrRightsExpiration>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_323b919c-2755-47b8-9d63-cde4b993e0b3"
      decimals="2"
      id="F_8b8be817-5fda-4c1f-9f2d-0a10f3eadc7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_323b919c-2755-47b8-9d63-cde4b993e0b3"
      decimals="INF"
      id="F_b6d74abf-2f02-41b5-bf20-c8af1b957165"
      unitRef="U_shares">13573704</us-gaap:ClassOfWarrantOrRightOutstanding>
    <grts:ClassOfWarrantOrRightIssueDate
      contextRef="C_59a0f9dc-319b-473d-b36c-f9544e589028"
      id="F_55034149-4d80-4356-b419-804d729992c7">2022-10-24</grts:ClassOfWarrantOrRightIssueDate>
    <grts:ClassOfWarrantOrRightsExpiration
      contextRef="C_59a0f9dc-319b-473d-b36c-f9544e589028"
      id="F_8b5fcecb-65ee-439d-acd5-0aeb7637fc9b">None</grts:ClassOfWarrantOrRightsExpiration>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_dcd7275c-0ad0-4b30-ad3b-b1c3164715c9"
      decimals="4"
      id="F_9ba5355d-5603-499a-a6cc-ec9d5b732e71"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_dcd7275c-0ad0-4b30-ad3b-b1c3164715c9"
      decimals="INF"
      id="F_2b416fe3-0674-4c95-acbe-11a0ee23813a"
      unitRef="U_shares">13274923</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_065bd0d5-cab6-4a9a-85b4-8cb071ebe7c1"
      unitRef="U_shares">26848627</us-gaap:ClassOfWarrantOrRightOutstanding>
    <grts:ClassOfWarrantOrRightWarrantsExercised
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_9371091f-e2fd-4c84-a920-2df50e11b1c0"
      unitRef="U_shares">3442567</grts:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d0c4fb4f-d485-41f4-b896-f24d5158e36f"
      decimals="INF"
      id="F_290cf8cb-412d-4011-b690-c9f9b07187de"
      unitRef="U_shares">3442567</us-gaap:CommonStockSharesIssued>
    <grts:ClassOfWarrantOrRightWarrantsExercised
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="INF"
      id="F_3d27b32b-e092-418d-b3d0-d993dbd52c6b"
      unitRef="U_shares">10459576</grts:ClassOfWarrantOrRightWarrantsExercised>
    <grts:WarrantsCancelled
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="INF"
      id="F_d9001cef-7c6b-4d2b-bb8c-aeacd7244ece"
      unitRef="U_shares">4872</grts:WarrantsCancelled>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_388f861c-6039-4b6a-95a3-319823503957">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.	Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Award Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2015, the Company&#x2019;s board of directors approved the 2015 Equity Incentive Plan (&#x201c;2015 Plan&#x201d;). In connection with the Company&#x2019;s IPO and the effectiveness of the 2018 Award Incentive Plan (&#x201c;2018 Plan&#x201d;), discussed below, the 2015 Plan terminated. The &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92,815&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock that were then unissued and available for future issuance under the 2015 Plan became available under the 2018 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2018, the Company&#x2019;s board of directors approved the 2018 Plan. Under the 2018 Plan, a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,690,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under the 2018 Plan, plus the number of shares remaining available for future awards under the 2015 Plan, as of the effective date of the 2018 Plan. The number of shares of common stock reserved for issuance under the 2018 Plan automatically increases on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of the Company&#x2019;s outstanding stock on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company&#x2019;s board of directors. The 2018 Plan provides, among other things, for the grant of options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance bonus awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The maximum number of shares that may be issued upon the exercise of stock options under the 2018 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s board of directors has the authority to determine to whom options will be granted, the number of shares, the term, and the exercise price. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an individual owns stock representing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;or more of the outstanding shares, the price of each share &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;shall &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;be at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the fair market value, as determined by the board of directors. Options granted have a term of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-year period with a straight-line vesting.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Material Features of the 2021 Employment Inducement Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2021, the Company&#x2019;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#x201c;2021 Plan&#x201d;), pursuant to Nasdaq Listing Rule 5635(c)(4). The principal purpose of the 2021 Plan is to promote the success and enhance the value of the Company by inducing new employees to commence employment with us, and by aligning the individual interests of new employees with the interests of our stockholders. Awards granted under the 2021 Plan are intended to constitute &#x201c;employment inducement awards&#x201d; under Nasdaq Listing Rule 5635(c)(4), and, therefore, the 2021 Plan is intended to be exempt from the Nasdaq Listing Rules regarding shareholder approval of stock option and stock purchase plans. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;790,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock were initially reserved for issuance under the 2021 Plan. The 2021 Plan provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, stock appreciation rights, and other stock-based and cash-based awards. The 2021 Plan does not provide for the grant of incentive stock options. Awards under the 2021 Plan may be granted to eligible employees who are either new employees or who are commencing employment with us or one of our subsidiaries following a bona fide period of non-employment with us, and for whom such awards are granted as a material inducement to commencing employment with us or one of our subsidiaries. Awards under the 2021 Plan may not be granted to our consultants or non-employee directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2021 Plan is administered by our board of directors and, to the extent our board of directors delegates its authority to it, our compensation committee. In the event of a change in control in which the successor corporation refuses to assume or substitute any outstanding award under the 2021 Plan, the vesting of such award will accelerate in full. Our board of directors may terminate, amend, or modify the 2021 Plan at any time, provided that no termination or amendment may materially impair any rights under any outstanding award under the 2021 Plan without the consent of the holder.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On April 21, 2022, the Company&#x2019;s board of directors increased the number of shares available under the 2021 Plan by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;700,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2018, the Company&#x2019;s Board of Directors approved the 2018 Employee Stock Purchase Plan (&#x201c;2018 ESPP&#x201d;). The 2018 ESPP also became effective in September 2018. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;282,334&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were initially reserved for issuance under the 2018 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2018 ESPP will increase automatically each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the shares of common stock outstanding on December 31 of the preceding calendar year or (2) such lesser number of shares determined by the Company&#x2019;s Board of Directors. The maximum number of shares that may be issued under the 2018 ESPP is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The offering periods are scheduled to start on the first trading day on or after June 1 or December 1 of each year. Contributions under the 2018 ESPP are limited to a maximum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of an employee&#x2019;s eligible compensation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.996%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.738%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.728%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.547%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.57&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.48&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Valuation of Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.791%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.392%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.392%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.232%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.98&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management&#x2019;s calculations are based on a grant date valuation approach. Using the Black-Scholes model, the weighted-average grant-date fair value of employee stock options granted was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.03&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.39&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share during the years ended December 31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the 2018 Plan and 2021 Plan activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.38%;"/&gt;
        &lt;td style="width:0.108%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.776%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.065%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.065%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.119%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.302%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.514%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Available&lt;br/&gt;for&lt;br/&gt;Issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate    &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,459,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,107,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,461,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,518,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,168,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,412,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,129,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,814,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,951,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and exercisable &#x2013; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,122,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest &#x2013; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,421,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022, 2021, and 2020, the total intrinsic value of stock option awards exercised was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, determined at the date of option exercise, and the total cash received upon exercise of stock options was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in 2022, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in 2021 and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t significant for 2020. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying stock option awards and the estimated fair value of the common stock on the date of exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of total cost related to non-vested employee and consultant options is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. The total fair value of shares vested during the year ended December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense and awards granted to non-employees was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2022, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021, and immaterial for the year ended December 31, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9f56e434-2071-40f2-81bc-0ed22f38f4e5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes our restricted stock unit activity during the year ended December 31, 2022:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.001%;"/&gt;
        &lt;td style="width:1.104%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.636%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.555%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.703000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, unvested as December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;708,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;350,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Canceled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, unvested as December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;561,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation for all awards granted to employees, consultants&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and our&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2018 ESPP, before taxes, is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.361%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.610999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.610999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.011%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_207cd814-4d37-40e6-b825-ea029fb0acad"
      decimals="INF"
      id="F_dd5d3fc6-6eb6-4d0a-9635-7bf6bf57be36"
      unitRef="U_shares">92815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5c8523e8-eb7f-4abd-894a-724f7b5cac4d"
      decimals="INF"
      id="F_19dc5287-8824-4353-a9aa-8258b850e415"
      unitRef="U_shares">2690000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <grts:IncreaseInSharesAvailableForIssuancePercentage
      contextRef="C_55f74884-e084-4ff0-ad23-d54d1b1004e6"
      decimals="2"
      id="F_478ad7cf-465a-4d28-b93e-c2560bdd873b"
      unitRef="U_pure">0.04</grts:IncreaseInSharesAvailableForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_55f74884-e084-4ff0-ad23-d54d1b1004e6"
      decimals="INF"
      id="F_1ac93768-5353-4692-b92e-e6bee22036b7"
      unitRef="U_shares">45000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_3b708b32-49af-4567-b476-e287d5f1de04"
      id="F_2a5127d7-72ac-464b-b2cb-37f9c15e4c82">If an individual owns stock representing 10% or more of the outstanding shares, the price of each share shall be at least 110% of the fair market value, as determined by the board of directors. Options granted have a term of up to 10 years and generally vest over a 4-year period with a straight-line vesting.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <grts:MinimumPercentageOfOutstandingSharesHeldByIndividual
      contextRef="C_3b708b32-49af-4567-b476-e287d5f1de04"
      decimals="2"
      id="F_8940c488-d023-4527-b9ba-875d6c22fc20"
      unitRef="U_pure">0.10</grts:MinimumPercentageOfOutstandingSharesHeldByIndividual>
    <grts:MinimumPercentageFairMarketValueOfSharePrice
      contextRef="C_3b708b32-49af-4567-b476-e287d5f1de04"
      decimals="2"
      id="F_65b35697-2c23-47f6-b4b9-5eccb24c89cf"
      unitRef="U_pure">1.10</grts:MinimumPercentageFairMarketValueOfSharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_33a09371-b9ca-4410-82c3-2bb6c53a0442"
      id="F_246f7dae-ba55-4365-8ff1-a22def767e2c">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_3b708b32-49af-4567-b476-e287d5f1de04"
      id="F_82bbbf09-3fa2-41a6-9ebb-6df41b1a97eb">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_802790aa-7b46-443c-b5ab-a61e4c953239"
      decimals="INF"
      id="F_f386a295-7ed6-407f-97fd-6548b50af3d6"
      unitRef="U_shares">790400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="C_ae943dac-f283-4812-963a-4a9313be83f7"
      decimals="INF"
      id="F_5fd9a59f-bea3-4456-b037-8258a44be3b8"
      unitRef="U_shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5e2d29f3-6231-4c61-9133-137f73dc9a4c"
      decimals="INF"
      id="F_99f0e198-c075-4a00-94f1-02f19b715587"
      unitRef="U_shares">282334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <grts:IncreaseInSharesAvailableForIssuancePercentage
      contextRef="C_ceb9099d-6f61-44fa-836a-3e42ead5e190"
      decimals="2"
      id="F_a970b7b9-865c-4f1a-bcdc-d3286e352a4c"
      unitRef="U_pure">0.01</grts:IncreaseInSharesAvailableForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_ceb9099d-6f61-44fa-836a-3e42ead5e190"
      decimals="INF"
      id="F_476ff9cc-8eaf-4f82-b28e-62bfa2f3d9be"
      unitRef="U_shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_ceb9099d-6f61-44fa-836a-3e42ead5e190"
      decimals="2"
      id="F_d751c74b-de36-4b07-ba81-657504de4e8b"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_b547e90e-3ca6-480e-82e0-8bbdb12a662b">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.996%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.738%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.728%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.547%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.57&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.48&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_70694a1e-9f63-4f26-821a-bb4205582c79"
      decimals="2"
      id="F_1b6af81c-d400-452b-bbb2-5a54fe2e993d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7"
      decimals="2"
      id="F_e47ffd84-fe76-4dcd-9cd0-7585942cd83b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4"
      decimals="2"
      id="F_47c16f42-4ed9-4eb8-95cd-78501d4cdd6b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_70694a1e-9f63-4f26-821a-bb4205582c79"
      id="F_b04c1aea-6030-4676-94c2-924b72b6d576">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7"
      id="F_22c69ea4-c728-4c90-b51c-7ccf7bf221b3">P0Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4"
      id="F_e60a3cee-6d73-4635-81e0-c1bf06ba4d28">P0Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_70694a1e-9f63-4f26-821a-bb4205582c79"
      decimals="3"
      id="F_d0c713e5-f59f-478e-8e33-78f7f3ce5c16"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7"
      decimals="3"
      id="F_6b11abe3-1bc8-4c2c-bdcc-1567e52d72df"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4"
      decimals="3"
      id="F_12019de1-bb00-4529-b14f-1848d469c59b"
      unitRef="U_pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_70694a1e-9f63-4f26-821a-bb4205582c79"
      decimals="3"
      id="F_ce585cb5-2e65-4958-8bbb-d89c58d6641b"
      unitRef="U_pure">0.949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_bb8fb8ca-060b-4084-a021-40c2ee8a01b7"
      decimals="3"
      id="F_5a5d4991-d01d-44fa-b4ac-0c2a7634885e"
      unitRef="U_pure">0.880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_b7314d04-c0e5-4232-b3ae-1996a0502fb4"
      decimals="3"
      id="F_92593807-816e-4348-a465-dff460345415"
      unitRef="U_pure">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_ac6310e3-704e-4522-a2b8-b2752d592ec5">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.791%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.392%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.392%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.232%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.98&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e"
      decimals="2"
      id="F_4fff5455-4885-4cca-9dc8-442d0719ec42"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf"
      decimals="2"
      id="F_b569a826-43c8-4fe1-8a1a-5ea3b287fbb2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2fc7bad5-4623-4bd4-9074-af6d60072963"
      decimals="2"
      id="F_67faf630-0be1-44b5-8872-0e444de269da"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e"
      id="F_eb20c483-2727-4a32-bfe6-2477df9f9d03">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf"
      id="F_77a89366-222d-4189-b370-b3373bd686ee">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2fc7bad5-4623-4bd4-9074-af6d60072963"
      id="F_467913d1-f257-4f0f-a0ec-2d5f89151f0b">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e"
      decimals="3"
      id="F_8aefae0e-c33c-4bca-b51d-9573e0f1bdf8"
      unitRef="U_pure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf"
      decimals="3"
      id="F_b507d54a-8c4a-4065-960c-bfa157503df1"
      unitRef="U_pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_2fc7bad5-4623-4bd4-9074-af6d60072963"
      decimals="3"
      id="F_cd8d0a70-251e-4e3d-b897-d7615de483ba"
      unitRef="U_pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e"
      decimals="3"
      id="F_1c0de875-5777-4090-9e49-b5483347fd2f"
      unitRef="U_pure">0.779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_81d9a073-d270-4fa5-aedc-1e98f759bbaf"
      decimals="3"
      id="F_f7899399-460f-44c5-9ce2-5b63aa747b14"
      unitRef="U_pure">0.790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_2fc7bad5-4623-4bd4-9074-af6d60072963"
      decimals="3"
      id="F_4a22e347-402f-40f8-af34-b8ea9b5adaf3"
      unitRef="U_pure">0.730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_cf11c778-888e-48ee-a872-f389c539be3e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="2"
      id="F_7691897c-25c3-4d0d-af2b-741753d9c964"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="2"
      id="F_20465571-c441-4e75-aa53-2ac43d4c9eb1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_f82cb5a3-78e2-434d-913e-8f816cf0dca0">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the 2018 Plan and 2021 Plan activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.38%;"/&gt;
        &lt;td style="width:0.108%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.776%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.065%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.065%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.119%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.302%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.514%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Available&lt;br/&gt;for&lt;br/&gt;Issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate    &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,459,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,107,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,461,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,518,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,168,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,412,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,129,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,814,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,951,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and exercisable &#x2013; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,122,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest &#x2013; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,421,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_10952826-e114-4a1e-b45d-1123f04b0322"
      unitRef="U_shares">3459187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_f7ba33cd-4152-4854-bfdf-d9371d959807"
      unitRef="U_shares">5107335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="2"
      id="F_80129e08-91c6-4c2f-943b-e1d673b3e3f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      id="F_1c08078e-bdbe-4243-b9f9-7e7af66e9566">P8Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_69ad258f-b8df-4279-8828-6886abd9b1bc"
      unitRef="U_USD">17153000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_cd6723ee-abd5-4cdf-9075-d8345a4762a9"
      unitRef="U_shares">3461915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_692e31d3-b51d-4fab-9519-6a73b783fab5"
      unitRef="U_shares">3518734</grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_11f13a40-f372-4b96-8a4c-ab9bcb0d3236"
      unitRef="U_shares">3168561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_8c72527d-a07d-4c63-9b08-94ec47ff1514"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_127001a8-606c-4985-a94d-3b6ca61c70fb"
      unitRef="U_shares">194347</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_2e673f91-b887-406e-9d90-7c8cd7c3f950"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_bc9883eb-9272-452c-9457-b8fdff416730"
      unitRef="U_shares">1412026</grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_f335c09d-732c-4eb4-a333-28e680d108bd"
      unitRef="U_shares">1129929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_8eb43e2c-2eea-4efb-8ab8-e3386f54f9ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_de6fc15a-cb88-49b0-94d8-7d1b24ab3c06"
      unitRef="U_shares">4814394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_99c9dd59-5395-4e10-b874-78c7486a0781"
      unitRef="U_shares">6951620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="2"
      id="F_07e2c8f5-374b-445f-8039-c58a39787873"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_332c65d4-cff8-44aa-bea4-adb9868dce7a">P8Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_80bf9b07-4669-45c6-b179-110db8da644e"
      unitRef="U_USD">1089000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_0d620024-9820-4838-a00c-baea8698c0ec"
      unitRef="U_shares">3122952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="2"
      id="F_e6fb9069-f23f-4d98-a3e7-6a80275d0608"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_ae41481b-4945-43f1-a171-8a3b47a97c06">P7Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_dcdd8abd-1562-4ef2-9a42-a377fbe6277f"
      unitRef="U_USD">409000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_cd2bc87e-822f-4e07-8416-d70a8a6efb50"
      unitRef="U_shares">6421425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="2"
      id="F_3abc270f-5b65-4f05-a10f-9962adbfaa6e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_6b28b575-4c75-423a-a2ab-bc6191abaeaf">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_85aad888-d2f7-4a3e-a2a8-aa1c89cf8664"
      unitRef="U_USD">995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_76067861-c368-4936-9848-a72c2312c509"
      unitRef="U_USD">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-5"
      id="F_d025cdb5-bcf0-458e-bf12-cec32d2fcaa0"
      unitRef="U_USD">5800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-5"
      id="F_34f4d5f0-c19e-4c3e-aead-9fde82e429c5"
      unitRef="U_USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_053e03d3-1c60-4310-a0e6-5e389096a29d"
      unitRef="U_USD">200000</grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived>
    <grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-5"
      id="F_08ee256e-1c6e-453a-91bd-cdecb141f4df"
      unitRef="U_USD">3400000</grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived>
    <grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-6"
      id="F_d9435235-355a-4a62-abbe-ba7d809f3a3e"
      unitRef="U_USD">0</grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-5"
      id="F_adac4810-8f23-4208-9d4c-687ad70cd065"
      unitRef="U_USD">14500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_4db71796-1117-44ee-a001-2d68f22d687f">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_d9b874c9-cce6-4e79-9f57-ee062735a6be"
      unitRef="U_USD">9900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_bd3cbcfa-0919-4488-9e70-a76b2b07e30d"
      unitRef="U_USD">600000</grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees>
    <grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-5"
      id="F_56b6b0b7-4f82-4f84-88de-4c718ab32a93"
      unitRef="U_USD">700000</grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_fd45c0a3-040d-42de-93c8-a06fd1b04f7c"
      id="F_443e1cb7-a16b-450e-ad19-25b3bb79e18f">We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to 10 years and generally vest over a 1 or 2-year period</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_a26fbccd-5d77-411c-acc6-ba0395a747d7"
      id="F_cde99731-e66d-41f7-ab10-9ed41f24e3fc">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a26fbccd-5d77-411c-acc6-ba0395a747d7"
      id="F_3a424e93-868b-4caa-9a18-ab3635c1a5d6">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_80b2edf9-3b74-4482-ac43-ba7123d94a47">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes our restricted stock unit activity during the year ended December 31, 2022:&lt;/span&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.001%;"/&gt;
        &lt;td style="width:1.104%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.636%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.555%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.703000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, unvested as December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;708,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;350,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Canceled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, unvested as December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;561,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_c27b8aa8-d184-48f7-bd4f-0096df18d8ef"
      unitRef="U_shares">708800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="2"
      id="F_60b52b1b-25a5-4083-85b6-81ebbcc49dd4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_f9347f20-ed77-468a-8485-5282e9c96ad3"
      unitRef="U_shares">350173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_29338451-c7a4-4d64-93e0-9e95614de748"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_58557186-a0fa-4378-829d-da6ff1daedd8"
      unitRef="U_shares">353300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_05eb715b-aecd-4346-a3e5-04ca28b69d9d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_cc371c74-9172-46f3-b3d4-addf857ad6bb"
      unitRef="U_shares">144147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_3b3031ed-f28d-4145-a616-4bc1b3e4330b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_f39f7de9-4ddc-4e2c-9a20-261fc4ec148d"
      unitRef="U_shares">561526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="2"
      id="F_63c7887a-61f6-4792-a4ed-ed236b3313ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_c90913a5-7f0d-4863-9e86-0b42e767daf9">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation for all awards granted to employees, consultants&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and our&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2018 ESPP, before taxes, is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.361%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.610999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.610999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.011%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_96bf1cf8-19d9-4d23-983b-756892fd1ff2"
      decimals="-3"
      id="F_1b1a7267-a277-4efb-a563-52dd8d21a720"
      unitRef="U_USD">6730000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cba7109a-fc2f-4241-85c7-7086ee1b9b30"
      decimals="-3"
      id="F_9a1812c2-a0f4-4d14-a3c3-db5da827e374"
      unitRef="U_USD">6626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_59f476dd-dd0f-4391-85f3-c22402209e5b"
      decimals="-3"
      id="F_a4b20271-f946-43e4-874b-6ba775e01da9"
      unitRef="U_USD">4453000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f75e133a-4af4-4545-85f4-a47ee76a38e9"
      decimals="-3"
      id="F_cf26f17e-180a-461f-b96f-424675c19be5"
      unitRef="U_USD">5827000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_153cf958-71d1-4706-b096-247c7c793c25"
      decimals="-3"
      id="F_920ba5d8-3aa9-46a5-bf31-75e04e861918"
      unitRef="U_USD">3926000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8a3ecee8-3b5e-4aae-bb83-c0cec0cf42ec"
      decimals="-3"
      id="F_cb9e78d9-ce10-49c9-8d24-d5a9ab0bb988"
      unitRef="U_USD">2657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_bce77c59-5e06-4149-b3f0-bc9cead8b53a"
      unitRef="U_USD">12557000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_e6d465c6-10f1-4b1f-93fb-ae3583d52ecb"
      unitRef="U_USD">10552000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_68a0bbc5-623b-43d6-b82a-24d7c9dde158"
      unitRef="U_USD">7110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_12aa3d0d-70d0-446e-9a1b-21166d37b646">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.	Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The effective tax rate for the years ended December 31, 2022, 2021, and 2020 is different from the federal statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The effective tax rate of the Company&#x2019;s provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.715%;"/&gt;
        &lt;td style="width:0.999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.098%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.098%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.089%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in state tax apportionment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-taxable stock premium&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#x2019;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are fully offset by a valuation allowance at December 31, 2022 and 2021. The deferred tax assets were primarily comprised of federal and state tax net operating losses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;tax credit carryforwards. The increase in valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during 2022 and 2021, respectively, was primarily attributable to the Company&#x2019;s current year taxable loss and increase in the effective state tax rate due to changes in the Company&#x2019;s state apportionment factors.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the net deferred tax assets/liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.822%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.437999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.632%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accruals and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 174 Capitalized Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning January 1, 2022, the Tax Cuts and Jobs Act (the &#x201c;Tax Act&#x201d;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Section 174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the Tax Act, deferred tax assets related to capitalized research expenses increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, the Company&#x2019;s federal and state income tax net operating loss carryforwards were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;369.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;465.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, which may be subject to limitations as described below. If not utilized, the federal tax loss carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and the state tax loss carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Under the Tax Act, federal net operating losses generated after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. The federal net operating losses generated after December 31, 2017 of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million are carried forward indefinitely. In addition, the Company has certain federal, California and Massachusetts research and development income tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. If not utilized, the federal research and development income tax credit carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The California research and development income tax credit carryforwards do not expire and can be carried forward indefinitely. The Massachusetts research and development income tax credit carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss and tax credit carryforwards as of December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.464%;"/&gt;
        &lt;td style="width:1.461%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.627%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.461%;"/&gt;
        &lt;td style="width:20.987%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expiration Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating losses, federal (post December 31, 2017)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Do not expire&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating losses, federal (pre January 1, 2018)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035 - 2037&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss, state&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;465,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035 - 2042&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits, federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035 - 2042&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits, state&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;CA: credits do not expire&lt;br/&gt;MA: 2035 - 2042&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period in excess of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as defined under IRC Sections 382 and 383. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. Subsequent ownership&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;changes &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;may further affect the limitation in future years. In connection with the Company&#x2019;s IPO, which closed in October 2018, the Company did experience an ownership change pursuant to Section 382. There was no reduction in federal or California net operating loss carryforwards or research and development income tax credits as a result of this ownership change. The Company is in the process of completing an analysis through December 31, 2022 under IRC Sections 382 and 383 to determine if the Company&#x2019;s net operating loss carryforwards and research and development credits are limited due to a change in ownership and may have an ownership change pursuant to Section 382.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.281%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.593%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.593%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.048%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning of year&#x2014;unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Decrease for tax positions taken during prior periods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases for tax positions taken during current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;End of year&#x2014;unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If recognized, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the unrecognized tax benefits as of December 31, 2022, 2021, and 2020 would impact the annual effective tax rate, primarily due to corresponding adjustments to the valuation allowance. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next twelve (12) months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022, 2021, and 2020, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize accrued interest and penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is not currently under audit by the Internal Revenue Service or other similar state or local authorities. Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States and various state tax jurisdictions in which the Company files tax returns.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_54ad75ce-7850-4132-828d-6f08ac0ee504">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The effective tax rate of the Company&#x2019;s provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.715%;"/&gt;
        &lt;td style="width:0.999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.098%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.098%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.089%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in state tax apportionment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-taxable stock premium&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="3"
      id="F_e570cf60-9dbc-4ff7-b936-fdb00efcadb7"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="3"
      id="F_5bd34dca-130a-4432-bccd-9caf17901a3b"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="3"
      id="F_39273ab9-a0c4-456e-a45f-e07c00de727a"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="3"
      id="F_1e7ac11c-2bf2-4945-8b90-632939a5c269"
      unitRef="U_pure">0.076</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="3"
      id="F_02e49296-6221-4560-90a3-83b7e739c04b"
      unitRef="U_pure">0.102</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="3"
      id="F_9ad21dcf-57af-438f-8e8f-81e59da98f93"
      unitRef="U_pure">0.079</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="3"
      id="F_aabedf4a-5a97-430c-a817-0092085da3f1"
      unitRef="U_pure">-0.004</grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential>
    <grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="3"
      id="F_b9969314-7819-4269-b0dc-23de2474f9fa"
      unitRef="U_pure">-0.001</grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential>
    <grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="3"
      id="F_df5e5229-afb4-4777-9a6c-ae9a2f52428e"
      unitRef="U_pure">-0.006</grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="3"
      id="F_11922b73-a58b-4a42-8d35-99eb9cdfe5fb"
      unitRef="U_pure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="3"
      id="F_3d022999-a184-47f5-80fb-91cd3f1450f3"
      unitRef="U_pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="3"
      id="F_082848b5-0b93-4414-b320-05657bcaa0c0"
      unitRef="U_pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="3"
      id="F_f5748408-5bd7-4403-bf15-99e858f1e278"
      unitRef="U_pure">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="3"
      id="F_ee78190a-8832-41fa-88cd-6de345b4c018"
      unitRef="U_pure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="3"
      id="F_2b88d8e9-6223-4133-95b1-62229ba1b5ed"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_4fca21f5-cae9-438d-ae85-6e145bf2f88b"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="2"
      id="F_d45721ad-c60d-4cb1-8847-6fd90933b4ce"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="3"
      id="F_fb1a472e-a041-4114-baba-cc9298f0d960"
      unitRef="U_pure">0.094</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <grts:NonTaxableStockPremium
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_61e69d52-6d24-4231-8066-d3da93d4c2b7"
      unitRef="U_pure">0</grts:NonTaxableStockPremium>
    <grts:NonTaxableStockPremium
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="3"
      id="F_c73fc160-5564-4072-8404-be7bd1f45732"
      unitRef="U_pure">0.025</grts:NonTaxableStockPremium>
    <grts:NonTaxableStockPremium
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="2"
      id="F_406909c5-2d2c-4107-ae53-908a967df98b"
      unitRef="U_pure">0</grts:NonTaxableStockPremium>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="3"
      id="F_589325eb-f522-4fb7-8ddb-b70efbc43332"
      unitRef="U_pure">-0.283</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="3"
      id="F_cb39c313-1cba-4233-a793-d66356e16ac5"
      unitRef="U_pure">-0.337</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="3"
      id="F_3c9bc34d-dd29-4192-99f4-6e5c6644d8ea"
      unitRef="U_pure">-0.403</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_208e6ce1-24ba-444c-9a62-2edc5c1a4281"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="2"
      id="F_897f7f06-5238-46b2-a61f-0900ff9bacac"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="2"
      id="F_ac784648-8513-46de-9b31-1784a1ce7250"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_bf66b594-b7d0-4180-ad7b-4ec934260598"
      unitRef="U_USD">33900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-5"
      id="F_957211ec-72f6-4e34-b79d-f2a4912df669"
      unitRef="U_USD">25200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_1689e284-5b99-481e-b90e-c982fa5b2192">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the net deferred tax assets/liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.822%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.437999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.632%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accruals and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 174 Capitalized Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_3d82d0d9-04a6-40aa-80ef-e2914f2f69a5"
      unitRef="U_USD">109191000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_60998d88-1913-4553-9f55-e36f9fbaca22"
      unitRef="U_USD">97575000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_fecb5cb4-93aa-476c-ad96-cb311dc2d99a"
      unitRef="U_USD">14877000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_adc4bc95-9acc-4c59-8e1d-7fe86b0a4108"
      unitRef="U_USD">12271000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <grts:DeferredTaxAssetsLeaseLiability
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_db17336c-1bb0-4b23-a0e6-430297d04f10"
      unitRef="U_USD">6031000</grts:DeferredTaxAssetsLeaseLiability>
    <grts:DeferredTaxAssetsLeaseLiability
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_37fb9c6e-d408-4c34-8181-2022fbc204d4"
      unitRef="U_USD">7684000</grts:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_bb7720a5-e48a-40da-bf8f-a0ed1d1b90dc"
      unitRef="U_USD">3786000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_b0d5bd56-9c69-4b9c-b3d9-6ceb5e6804e0"
      unitRef="U_USD">3184000</us-gaap:DeferredTaxAssetsOther>
    <grts:DeferredTaxAssetsAmortization
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_5aaeba2c-0afe-4403-a2ba-c99bbbed651a"
      unitRef="U_USD">9437000</grts:DeferredTaxAssetsAmortization>
    <grts:DeferredTaxAssetsAmortization
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_104e3019-2942-49eb-a27e-7bbe40049da1"
      unitRef="U_USD">10633000</grts:DeferredTaxAssetsAmortization>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_69af3aef-4276-44fd-97cb-fbfa4b6c1b55"
      unitRef="U_USD">700000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_99fb1d1f-3c3f-4f0b-b531-349c437d5cab"
      unitRef="U_USD">2537000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <grts:DeferredTaxAssetsOtherDepreciation
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_efef91f6-453e-446b-85b2-d431d4e93812"
      unitRef="U_USD">449000</grts:DeferredTaxAssetsOtherDepreciation>
    <grts:DeferredTaxAssetsOtherDepreciation
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_29aa0764-e43b-4aca-8161-6e7185bd63d0"
      unitRef="U_USD">0</grts:DeferredTaxAssetsOtherDepreciation>
    <grts:DeferredTaxAssetsCapitalizedExpense
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_86c4ce53-2b7b-47e3-ad67-e874f3435ecd"
      unitRef="U_USD">21434000</grts:DeferredTaxAssetsCapitalizedExpense>
    <grts:DeferredTaxAssetsCapitalizedExpense
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_85067068-905d-4577-923e-30818b4a3f10"
      unitRef="U_USD">0</grts:DeferredTaxAssetsCapitalizedExpense>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_ff5b396a-443a-4a4b-8528-6e4db9899329"
      unitRef="U_USD">165905000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_01f6d2a7-9e86-4a0a-b0bc-01458cb211b2"
      unitRef="U_USD">133884000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_1a207db4-3de1-424e-839f-b6e655175ecb"
      unitRef="U_USD">160877000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_8231d9c5-b6e7-4dc4-a8cc-4926a7ede901"
      unitRef="U_USD">127007000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_e3f6655f-e17f-4081-a32a-170c2899962c"
      unitRef="U_USD">5028000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_63284068-60fb-4566-b515-060351191501"
      unitRef="U_USD">6877000</us-gaap:DeferredTaxAssetsNet>
    <grts:DeferredTaxLiabilitiesOtherDepreciation
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_34ab4c62-7638-4ac2-b723-c52beeef4ea8"
      unitRef="U_USD">0</grts:DeferredTaxLiabilitiesOtherDepreciation>
    <grts:DeferredTaxLiabilitiesOtherDepreciation
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_82d79d1f-260d-439d-9a4e-a0f8d52b45ed"
      unitRef="U_USD">212000</grts:DeferredTaxLiabilitiesOtherDepreciation>
    <grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_f77b03ab-98c0-41eb-93c9-ea7bfaaa881b"
      unitRef="U_USD">5028000</grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets>
    <grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_0133b96f-b2d9-4412-8b0e-c17a3df97d5e"
      unitRef="U_USD">6665000</grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_6142bf8f-f86d-4d96-9361-ce9e8483340d"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_84d6eaab-2010-49b4-9e90-59843f565d61"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <grts:DeferredTaxAssetsCapitalizedExpense
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-5"
      id="F_c946c233-424b-4548-b98f-1183645f73d6"
      unitRef="U_USD">21400000</grts:DeferredTaxAssetsCapitalizedExpense>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0147e0c5-b128-4b28-ab85-a4f52bbc6baa"
      decimals="-5"
      id="F_42bf2e28-a8a5-46ca-b824-88ab97056a46"
      unitRef="U_USD">369900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_97f8a7f4-7c61-4b23-aa03-20ff4c118788"
      decimals="-5"
      id="F_23392848-7917-4a1f-924d-377cec176277"
      unitRef="U_USD">465600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_49045c9c-a554-4324-9d92-9288a8abef99"
      id="F_7149b817-456b-4faa-97dd-4871811939ac">2035</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <grts:OperatingLossCarryforwardsExpirationYear
      contextRef="C_450aa048-1aac-4500-be64-715518ae710b"
      id="F_5d60186d-ff9e-4ec2-96f3-d7693ae73f38">2035</grts:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e244d887-8d8a-4495-81bd-72528b63162d"
      decimals="-5"
      id="F_77d83950-61cc-4af3-b7ac-b87d875e5dd8"
      unitRef="U_USD">319300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_881d2648-16d5-4b0f-8455-333f723dd233"
      decimals="-5"
      id="F_aa7fff9e-3716-450e-9930-21a711455446"
      unitRef="U_USD">13700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c6e2641f-a8ab-46ff-80f9-1485fe4c2082"
      decimals="-5"
      id="F_f641cdae-1781-4535-b328-e3b6092daf73"
      unitRef="U_USD">7700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e56f5102-fdf2-4a2e-919e-b83d8075a4bd"
      decimals="-5"
      id="F_8911aae7-6d5b-495d-97ae-ad14bf340bc1"
      unitRef="U_USD">1500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_1b36e023-4632-4679-a7c3-29a735d1414a"
      id="F_b7a3315d-afa9-4665-a2d5-9110c3a9edc4">2035</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_3f4d3587-5707-477a-b168-bf3fd63a1a9e"
      id="F_79279abd-1a7e-4d8e-843f-3d1b40f3f2d8">2035</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <grts:ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_1c9c4087-5be4-4dea-887f-2573c051c89a">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss and tax credit carryforwards as of December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.464%;"/&gt;
        &lt;td style="width:1.461%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.627%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.461%;"/&gt;
        &lt;td style="width:20.987%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expiration Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating losses, federal (post December 31, 2017)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Do not expire&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating losses, federal (pre January 1, 2018)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035 - 2037&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss, state&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;465,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035 - 2042&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits, federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035 - 2042&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits, state&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;CA: credits do not expire&lt;br/&gt;MA: 2035 - 2042&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</grts:ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_afcbe2f3-7dd3-4f15-8cd0-c1d773ae4308"
      decimals="-3"
      id="F_82b8a70a-930b-4c37-ae76-4d1285df4a17"
      unitRef="U_USD">319266000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_5f1453e1-ff34-4769-91d5-33383d153a3f"
      id="F_d2bd7673-eb40-4028-bdd4-3e76df590fc9">Do not expire</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5fb39eda-b901-4cdd-9a32-7c015ae8998c"
      decimals="-3"
      id="F_772e11bf-4bd1-4e68-a7b0-2285f2406c02"
      unitRef="U_USD">50587000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_a51fab37-6bd0-4cae-b9b3-b2a75e0d44b3"
      id="F_6bc5705f-b2d3-4b05-acbe-b9c433a0cfbe">2035 - 2037</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_97f8a7f4-7c61-4b23-aa03-20ff4c118788"
      decimals="-3"
      id="F_156e59b7-7fb7-4aef-9277-01a215defbb0"
      unitRef="U_USD">465623000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_450aa048-1aac-4500-be64-715518ae710b"
      id="F_cdbc1ceb-1c92-4b38-abea-8c7e57d20863">2035 - 2042</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0147e0c5-b128-4b28-ab85-a4f52bbc6baa"
      decimals="-3"
      id="F_2119c5a9-b6cb-49f7-8fd7-bd7d9683f5f0"
      unitRef="U_USD">13669000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_49045c9c-a554-4324-9d92-9288a8abef99"
      id="F_611b48bf-093e-40c4-8450-3529aa31bf26">2035 - 2042</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_97f8a7f4-7c61-4b23-aa03-20ff4c118788"
      decimals="-3"
      id="F_2d7667e2-719a-4d87-b23c-50dddf25969a"
      unitRef="U_USD">9160000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_450aa048-1aac-4500-be64-715518ae710b"
      id="F_7e3f779d-346a-40ef-96d3-0feac4ec9d3c">CA: credits do not expireMA: 2035 - 2042</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <grts:OwnershipInterestChangeOverPeriod
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_b0afe739-cb7d-4da1-8c9f-3bf59aeaee23">P3Y</grts:OwnershipInterestChangeOverPeriod>
    <grts:CumulativeChangesInOwnershipInterestOfShareholders
      contextRef="C_12768f52-aae1-4e43-bb4c-1b4a1aca508a"
      decimals="2"
      id="F_8612a836-b33a-4c99-b156-b32b68552757"
      unitRef="U_pure">0.50</grts:CumulativeChangesInOwnershipInterestOfShareholders>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_3e35706c-ce20-4108-a2ce-5ac8bf471cd2">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.281%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.593%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.593%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.048%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning of year&#x2014;unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Decrease for tax positions taken during prior periods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases for tax positions taken during current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;End of year&#x2014;unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_71de2410-b3d4-43ae-baa7-494e5f563e11"
      unitRef="U_USD">5481000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      decimals="-3"
      id="F_1d7ee503-7fa0-4667-83f5-00cd71e19554"
      unitRef="U_USD">4025000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc"
      decimals="-3"
      id="F_c69e6461-accf-4245-95a6-52d542aaa2da"
      unitRef="U_USD">2610000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_928208fb-22d3-4258-9688-a0ff13100579"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_cd5811c3-73e2-4356-81c8-919e50d72d80"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_d7c3a669-024f-4743-97f0-d4cf5c5594d8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_3d853925-af11-456a-a4a1-b19d9ae68be9"
      unitRef="U_USD">1234000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_9dfc9109-f0b9-411b-8c59-6c914f6d1a7e"
      unitRef="U_USD">1456000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_ffcb630e-adfd-44ff-b625-d67d82a76e5f"
      unitRef="U_USD">1415000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_d684fde7-60fc-4076-b541-019b627afdbd"
      unitRef="U_USD">6715000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_65cc7201-a28c-4259-a8df-ed5070f5ebdf"
      unitRef="U_USD">5481000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      decimals="-3"
      id="F_dc32b27d-2e36-4671-830d-1a0417065f46"
      unitRef="U_USD">4025000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_90cc3c3e-07ec-48c4-bde6-841c485ca7d7"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_7b050b2b-af49-4173-86d6-417640e33471"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      decimals="-3"
      id="F_3b57eeae-ea96-4b07-bbd4-30a02a6fd3c3"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="-3"
      id="F_834dca26-42ca-4d50-bd29-8029872c1e6b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="-3"
      id="F_8817c33c-6280-4c6e-9b0e-659447fc2910"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0a04396c-b70e-4ab9-9a25-4a17ac0b643b"
      decimals="-3"
      id="F_53b18b1e-ad1a-4278-b947-0495cde5ed87"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_efc2d671-bb01-40df-a1d3-a88e723ea8b5">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.	Net Loss Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.807%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.058000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.902%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,918,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78,885,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,792,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2020, the Company issued and sold Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,480,719&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at a nominal exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, and in October 2022 the Company issued and sold Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,274,923&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at a nominal exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share (see Note 10). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,442,567&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants were exercised, resulting in the Company issuing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,442,567&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2021, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,459,576&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants exercised and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,872&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants cancelled due to net exercise of the warrants. As of December 31, 2022 and 2021, there are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,848,627&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,016,271&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants outstanding, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The shares of common stock into which the Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and they are immediately exercisable upon their issuance date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During a period of net loss, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential common shares outstanding would have been anti-dilutive. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.932%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.433%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.433%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options issued and outstanding and ESPP shares issuable and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,145,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,170,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,213,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;561,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;708,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,707,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,879,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,213,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_f386e674-65c5-4f5b-9634-01011b40f7aa">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.807%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.058000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.902%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,918,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78,885,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,792,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-3"
      id="F_2275d11d-ed8b-42e1-93b2-145551d548fd"
      unitRef="U_USD">-119687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-3"
      id="F_e0504b98-360e-4cbf-a68a-6a8bb283cae7"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="-3"
      id="F_b550bfbb-af43-49b4-a26e-f04c90acd5a9"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="0"
      id="F_7a9d7d74-9475-44a6-9781-add0bc811c0e"
      unitRef="U_shares">90918333</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="0"
      id="F_11c1ad05-d831-4185-9614-ee02d2be190c"
      unitRef="U_shares">90918333</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="0"
      id="F_d0b75f4c-6297-46f5-b715-893212507cdc"
      unitRef="U_shares">78885186</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="0"
      id="F_864ccaed-121e-4ce6-a7a9-6cdf4729e966"
      unitRef="U_shares">78885186</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="0"
      id="F_459e50fa-10c0-498a-a074-154105f9a081"
      unitRef="U_shares">37792365</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="0"
      id="F_c76f1037-d2d3-4d13-9574-fe970d11f8a2"
      unitRef="U_shares">37792365</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_3fc5f50d-e66c-4ec0-aff7-1e7492135401"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_97993990-38f9-44ec-af3a-2e3d7d3a0d7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="2"
      id="F_417d4cdf-82a9-4768-a16d-f4f8755cb1aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="2"
      id="F_03a21803-2258-420c-b73b-06e51ca2ed80"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="2"
      id="F_a140d1dd-9bba-4c2b-9a35-8ccf2a9f1b93"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="2"
      id="F_96e8163e-b4a3-4e9c-b800-b9c3dc0ca57d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_1929cfb6-f656-448a-9d1f-c017d3968257"
      decimals="INF"
      id="F_50c91912-0831-4cb4-b1c7-b74b8e42b7e5"
      unitRef="U_shares">27480719</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <grts:ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights
      contextRef="C_c3371e94-abb3-4b37-894a-d4cc941cf1f3"
      decimals="2"
      id="F_7fbcba6f-2792-4cb6-8e1c-86bef9c97eb6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</grts:ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights>
    <grts:WarrantsToPurchaseSharesOfCommonStock
      contextRef="C_687162ff-aef8-4232-aaec-424cb6facc45"
      decimals="INF"
      id="F_bfcbd0ea-b069-4573-a2f9-903684382759"
      unitRef="U_shares">13274923</grts:WarrantsToPurchaseSharesOfCommonStock>
    <grts:WarrantExercisePrice
      contextRef="C_217b0356-637c-4019-9519-2b40884dd4ea"
      decimals="4"
      id="F_659c463b-eac3-4c8c-9aec-eea324d2d3e5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</grts:WarrantExercisePrice>
    <grts:ClassOfWarrantOrRightWarrantsExercised
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_95800beb-39dc-4e21-a8c8-e0bfa085e657"
      unitRef="U_shares">3442567</grts:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d0c4fb4f-d485-41f4-b896-f24d5158e36f"
      decimals="INF"
      id="F_9a0fa90d-95b2-4994-856a-36fe93fb3fe9"
      unitRef="U_shares">3442567</us-gaap:CommonStockSharesIssued>
    <grts:ClassOfWarrantOrRightWarrantsExercised
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="INF"
      id="F_46ea8518-98d4-4143-98de-2b0bd14c20ae"
      unitRef="U_shares">10459576</grts:ClassOfWarrantOrRightWarrantsExercised>
    <grts:WarrantsCancelled
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="INF"
      id="F_d8aefddb-c227-4cb4-9a2f-75fa41ebcdab"
      unitRef="U_shares">4872</grts:WarrantsCancelled>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b769ed8e-6840-43c9-abce-2f0b38c64a46"
      decimals="INF"
      id="F_893addcb-8b1b-4cd3-a9f4-15d0dbb6ceab"
      unitRef="U_shares">26848627</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1"
      decimals="INF"
      id="F_7460a9d5-c84c-48af-96f0-ad02b63c1659"
      unitRef="U_shares">17016271</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_fb372bdc-83ed-4c9b-8db7-df60d1910254">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.932%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.433%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.433%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options issued and outstanding and ESPP shares issuable and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,145,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,170,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,213,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;561,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;708,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,707,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,879,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,213,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fc627979-580d-42ff-87f9-72f185ff83f5"
      decimals="INF"
      id="F_82b4c190-faf1-41ea-a08b-4ea80991c880"
      unitRef="U_shares">7145817</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_822e2920-cab6-4373-82cb-898c8cc385e6"
      decimals="INF"
      id="F_53aac293-6ef6-49ea-9ed3-9fd8da144a71"
      unitRef="U_shares">5170331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bcae57c0-074c-498e-8541-1149ef409ac8"
      decimals="INF"
      id="F_4a77408e-e104-427b-a47b-698f9898dd60"
      unitRef="U_shares">4213738</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ba0f5eb4-07a4-4e13-a684-5ff64c100781"
      decimals="INF"
      id="F_a826c2af-85fc-439a-a841-1563a1d47ff7"
      unitRef="U_shares">561526</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_024d46a7-8550-44bd-aba2-8e45d258d9a6"
      decimals="INF"
      id="F_a0f01fe9-1373-4e50-b8aa-9fc4db886d82"
      unitRef="U_shares">708800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_138bc03a-533d-4ac5-8b52-13e19b3633e1"
      decimals="0"
      id="F_7cbeddd4-40a8-4692-a051-6ea780dc13da"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="INF"
      id="F_00b0fc30-4de9-4b99-943e-e1e34182f8f5"
      unitRef="U_shares">7707343</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="INF"
      id="F_09c7c4e7-b1c3-4d8b-99ef-18f6ab85f351"
      unitRef="U_shares">5879131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_42ef2bb8-3a4d-4cdc-99bb-9b6304455660"
      decimals="INF"
      id="F_5a67dcc3-a788-4d9c-a4e2-fc63a4a431a3"
      unitRef="U_shares">4213738</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      id="F_d015722b-3181-4779-92c4-5d3de600d8ac">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.	Defined Contribution Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company began sponsoring a 401(k) Plan in 2017, which provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the first &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of each employee&#x2019;s contribution. During the years ended December 31, 2022 and 2021, expenses recognized for the 401(k) Plan was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, while the amount was immaterial for the year ended December 31, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_a6647160-7b5e-4902-9018-3678bdb60427"
      decimals="2"
      id="F_159c7cd8-107a-43e9-bc24-014da532899c"
      unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="2"
      id="F_4efd3955-067e-475f-9ecd-b6e92b51edb0"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_9cbbe066-7e05-4445-a3b6-4ad618f88f00"
      decimals="-5"
      id="F_e57818de-4271-4bb3-ac8a-028341188396"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_1fb2663d-9e70-4c23-9eca-34e81d76ce26"
      decimals="-5"
      id="F_21092090-749a-4b39-a427-f9497eb798c9"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanCostRecognized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M\UB89'_1-E]W,.P@+TT$BXIBV(.(QOE__%Z ."@86PT%3E'@_%!@]QL*W*+
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M7C:7&T8U>".@WZ^YYOC]C?D(U7UT7/X/4$L#!!0    ( '*!:5:H@SH,X (
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M&^$>QMB\C^V^H;-A#=1!C3JX#+6L1$0V.A62_H&D#;G4'.ZQ>+C\/8/N$-C
M'M;8PQ=A4Z4V[<C# Y+GK*<B&I!!#1F\"-)\^)4F/*%\W48:G"4]%=$@'=6D
MHY.D,Y%E9GEVJ=91MVH]&];@#&O.\ +.3J4:'LQ5'[?7:I?(!O6XIAY?3GV\
M4L<''&$0C@?C@SD^# S&># *1V$[KX?_[5_X<N(S95M)=N!NB3P"[N[MP?8
M](7(->4*,5B95-P;&0U9GBG*CA9YL2TOA3:;?-%,S3D,I TPSU="Z*>.W>GK
MDUWT%U!+ P04    " !R@6E6%/,%LUH%   ]%P  &    'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;*U876_;-A3]*X17#!O0Q"+UG3D&&GOK"BQ;T+3KP[ '
M1J)MH9+HB;2=[=>/I&3)IJ[4M/"+K8]SCW@N+\E#S@Z\^BPVC$GT7.2EN)UL
MI-S>3*<BV;""BFN^9:5ZL^)50:6ZK=93L:T834U0D4^)XP33@F;E9#XSSQZJ
M^8SO9)Z5[*%"8E<4M/KWCN7\<#O!D^.#]]EZ(_6#Z7RVI6OVR.3'[4.E[J8M
M2YH5K!09+U'%5K>3-_AF28@.,(@_,W80)]=(2WGB_+.^>9?>3AS=(I:S1&H*
MJO[V;,'R7#.I=OS3D$[:;^K T^LC^R]&O!+S1 5;\/Q3ELK-[22:H)2MZ"Z7
M[_GA5]8(\C5?PG-A?M&AP3H3E.R$Y$43K%I09&7]3Y^;1)P$X& @@#0!Q [P
M!@+<)L!]:8#7!'@F,[44DX<EE70^J_@!51JMV/2%2::)5O*S4O?[HZS4VTS%
MR?F"EX+G64HE2]&C5'^J4Z5 ?(7^V+**ZLX1B)8I6O!"5=9&=_F>H=^X$.@*
M?7Q<HA]>_8A>H:Q$'S9\)Q14S*92-4U_8)HTS;BKFT$&FH$)NN>EW CT<YFR
M])Q@JC2UPLA1V!T995RRY!JY^#4B#B% @Q8O#\= ^/+EX<Z(&K?M)M?P>0-\
M[]F>E3NF1EK"UV7VG^JL=45+J1Z8%U#&:\;0,.KAOY_C./;\V71_FH8^RHL(
M]LY12P#EN&$+.M/DM9H\$^4.:&KJJUPC]JRF,<'$#23#&TN,GA9OQ)8F[':B
MJE.P:L\F\^^_PX'S$]3IER1;7HCL+'E^FSS_"P4A&*V2C1F:J2J"G&_UR(4R
M6#/YIX6 L>H_JQ+ZL#CT8L>JA#XJB@+/A4LA:-4$HVK>LE+50F[$T%1-<YF0
MNC;V8&$'O2:0* ZMABX E!^[EN@E@,(>QK"<L)43CLKYP*42PWOU#8D)^YVC
MAY;=.0",N!ZQY0 P[#B^!^N)6CW1J!XSV:\J7APUJ34!TA+UOGZ%B>.1R!(#
MX$*?.+$E!J)S @</S#MQJR8>5?.NE$P-2*F6K(078(7%_33&86"I $"!/6_V
M,2'VX>9CIUNRG9<):.H*7&X=J"]<>_:'8"?S>BT"YAI0<6(\\*B*WY6IS55A
M@:W'P!=Q'$2AW7X &/I.1&P)$*'CNWA@9&#2R2#CJYC<L HE9^9(RP+7LH;K
M0HO91=F6EV([SV-G</"XP_E8JFU+;IR-3A]2>P*U$?G,)'W*&1(LV569S. Y
MM*$^KP*[4B",/7U"(#)4(IW/P:-.8+[H%0<HPNMY+%/SL6<K 8"ACWW?%@,1
MJIIWHP%!G?? X^;C.'216@V0V-"*O=:;KRP!==5<\5DSKEUBJP)@SG7<$P7
MR'48#TCJ# @>=R"0I#3+=]+>C#2B@I>) F"0*  V(JJS(7C<AWPRNUZ67M&]
M6K;7#)6[XDGI4YL[(U&@G5#C36W=]/RU,UZE_*J^[?N-V(EQY-H^:P$@PRB*
M?!P%=C+Z2#<,8^(&0PMG9V/PN(^Y5#[&"J-O6H8RTD<.9:2/_$)&.BN$Q[W0
M@N<Y?>*UIS/V.\\2[2F.&TN!_KIG.DE_@VI'V;]Z/;LDV_)2;.>G#YU)(^,F
M[5MV[ WEZ8P=D\"RQ0L Y04AMET; '.]8,"VD<ZVD7';]O94Q'AUC#-];75<
ME&UY*;;S+':ND8RZJ6^K#M(_T'&"WK8$@GEQKSKZ*#^TIY/IR;EBP:JU.9\5
M:G+<E;(^B6N?MF? ;\S)I_7\#M\LZY/<CJ8^6+ZGU3HK!<K92E$ZUZ&:Y:KZ
MK+:^D7QK3B^?N)2\,)<;1E-6:8!ZO^)<'F_T!]H3\_G_4$L#!!0    ( '*!
M:5;=-A%']0T  ,^N   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULO9U;
M<]LV'L6_"D?;V6UGHHH$>.W:GFDMWIFMITEW'W;V@9%HBQ-)5$G*3OKIEY1E
MT0 HF+1/FH=8%^+W!P$< B(/@(N'HOQ<K;*L5KYLUMOJ<K*JZ]U/LUFU6&6;
MM/JQV&7;YIO;HMRD=?.VO)M5NS)+EX=$F_6,J*HYVZ3Y=G)U<?CLIKRZ*/;U
M.M]F-Z52[3>;M/SZ2[8N'BXGVN3I@]_RNU7=?C"[NMBE=]F'K/Y]=U,V[V8G
MRC+?9-LJ+[9*F=U>3G[6?DITITUP..+?>?90/7NMM*?RJ2@^MV_"Y>5$;7.4
MK;-%W2+2YL]]=IVMURVIR<<?1^CD%+--^/SU$]T[G'QS,I_2*KLNUO_)E_7J
M<F)/E&5VF^[7]6_%0Y =3\AH>8MB71W^5QZ.QZH39;&OZF)S3-SD8)-O'_^F
M7XX%\2R!1L\D(,<$A$M K3,)Z#$!Y1+HQID$^C&!SB4@Y$P"XYC X!(8SID$
MYC&!R24PSYV#=4Q@\2=MGDE@'Q/87 +K7+$ZQP0.E^!\Q:E/-:?RIWTNAG:J
M;+ZVR;F2TIZJ6SO4]^RQ81U:Y3RMTZN+LGA0RO;XAM>^.#3M0_JF,>;;5H4?
MZK+Y-F_2U5?7Q;8JUODRK;.E\J%N_C02JRNEN&W>%8O/JV*]S,KJ'XK[QSZO
MORI3Y?</<^7[[WY0OE/RK?)Q5>RK=+NL+F9UDYN6.5L<(__R&)F<B?RQJ--U
M3[)K>;*?/[Y_RLNOM[=9F6_OE)NRN"O3C?+?]]GF4U;^KX<ZEU-OROR^.7<E
MW-YG5=T607MV-_M/ZWSQ%$Y"=^7TZV*S::XXAP*58;Q78)17%HC_FEAO+*;@
MA:I=+O/VTIRNE9LT7T[#K7*=[O*FF<B@X9NAKRW"Z.V1WUB@\0LY6"SVF_WZ
MH.U?ZU56*DVU-IWUJNU%[S/%;WKIV?=)454_R*(DPZ/,L]M\D==G:+/FXG2Z
M0I'3%8H<\/H9_"_I.MTN,B6M&_KB1X5J[Q2B:D[?%>>19!U([?CC_DJC.M7U
MB]G]\RN,-& [[OFIVJ6+['+2E%65E??9Y.KO?]-,]9]]%Q8DS.TY 8O-O(>,
MYR-A@9AY:AC$T=@3")$Q(R0L%D^ <$TG$0^9$J(ZMGTZCFGD]-3(Z9!&_DZI
M5FF3T4&-74H<>>K72-@<"7,?8<;S5F522AS#Y(2!C.HC80$2%B)A$1(6(V$)
M",:H43^I49>J,:RJ_:'/:4;!53L">J=LFQ_$S;O\Z9M%4=6]@UXI>:PJ=>%J
MXYB6RK;[N7@0)1HA[%$N,E\>$N:+^>=ZC  9+AQ2IE%_F7+YBI'Y2D PIL$;
MIP9O0!K\4__4U_"E$<8V?"1LCH2Y2)AG"'V;UASJF)1M:+YXG&/8IF[9G%"0
MF0N1L @)BY&P! 1C=&>>=&<.UEV#G][NM\OF5]1#6I;IMI7;X&['%%J(;5DJ
M_\-'FINQLD+"7"3,0\)\)"P85$TA,F2$A,5(6 *",<JS3LJS!BMO\7BOZ]#Q
M*:T"2Z5>98K[X>:F3VJ6>#'6N/'#M33X6*$A82X2YB%A/A(6#*BD$!DP0L)B
M)"P!P1B9V2>9V0B9R<:5T@!CQY5(V!P)<VVAP1*=VOP(ST/&])&P  D+D; (
M"8N1L 0$8Z3IG*3I2*7Y^[;,TG7^9S/>7!=5I332W*3EYZQ./ZTSI<H6^S*O
M\WY-.D)CG?)W2J^ET<=*#0ESD3 /"?.1L  )"Y&P" F+![3%!!20T9FF=H_8
M5:G2DG17'7K ,MOMR\4J;=Z5K3ND:CYY?&Y6%VSWV/[@:SYN#F_[S[K]/DO+
M]5<E^Y*5B[SJE^4Q'^S]!$Z6\KR.U264YD)I'I3F0VG!@)H*H1$C*"V&TA(4
MC=7G,PN,]M?K4S:DE>=G[)@62IM#:>Z1QCR]4VV+NSY[T* ^E!9 :2&4%D%I
M,926H&BLJ#O7B":WC9S_Y;EK7C[)]/3 0REVK5>G7ZY$_&VFFGR_"C650&DN
ME.9!:3Z4%@RIJA :,H+28B@M0=%8#7:F%DWN:GFE!J5=)]3U J7-H317$XTO
MFF,9O)G-@T;UH;0 2@NAM A*BZ&T!$5C==O97S2Y_^7@^IVVDQN6K6YWV;9*
M6V7V"E(7FJFE"<]#Y %'"PU)<Z$T#TKSH;1@4%V%T)@1E!9#:0F*QLJL,]UH
M<M?-O[+Z<.NU5U:BY6.JJ0;5^-NL\ABCE07URD!I'I3F0VD!E!9":1&4%D-I
MR8!FSHJK<]9H<FM-_[0!HO:*3;1E:*9I48?7&M0_ Z6Y1QICH^0?'D(C^E!:
MT%,'ND-50OG>"6J.@=)B*"WI*9$I)693)F>TT7E?-+GY13[;X(Q&D)Z$:RAM
M#J6YFN@=T2W#(*9#>3U!_2]06@"EA5!:!*7%4%J"HK'2[/PRVG##S-BI!W+T
M:(F*CA1J&H[!S3[H.:R1BL%)Q87FS8/2_"---@,!&C <5K31F:+E9G;$T+PE
M*!K;_CM3BB9WI2!F(LA#C-8!U,@"I;E0FJ>)5@KJ.*IM<N-@O^= 0SW\XV4#
M]:! :1&4%D-I"8K&3KCN#"M$;E@Y38(_2.WY0_#6L%FE:_&.?KI=]LU@Z),G
M$;T/4]W@?2KR+(Z5'93F0FD>E.9#:<&@N@JA,2,H+8;2$A2-%6;G5"%RI\H;
M9BT0T8GA"#<3Y>%'BPYJ)8'2/"C-A]*"(5450D-&4%H,I24H&JNYSDA"7FLD
M&3R%01YA[( 42IM#:2X1_1>:337>V^A!H_I06@"EA5!:!*7%4%J"HK$Z[<PF
M1&XV><M\!B)Z+:86Y3M'J%D$2G.A- ]*\Z&T $H+H;0(2HN'-,H$%9(57><4
M(7*G"-!E241S J4F;R21YV>T"*%&$BC-@])\*"T85%<A-&8$I<506H*BL2KL
MC"1D^/(M()^E/.+H(2O4I *EN42T()@.42G_\!P:U8?2 B@MA-(B*"V&TA(4
MC=5MYU$APY=_Z?EI^2%=9Y5R\S0EZ>>[,CNLSON*1R+RC(R6,]0' Z6YI,?+
MHYF.P2]#Z4'#^E!: *6%4%H$I<506H*BL7KN?#7D38O*C-1SKXY%;PI1;2J,
MDJ'V&BC-A=(\*,V'TH)AE15"@T906@RE)2@:*\_.6T->NQ@-/TR6/KX471DZ
M;Q259V2T_J +S9 7W2X>-* /I05]Q6_SBH(N'P.EQ5!:@J*QBNK<.F2X6V>8
MHJ2#5*AO!TJ;0VDN$0TTFJH;CF'QBUI#X_I06@"EA5!:!*7%4%J"HK$KS7?N
M'BIW]XR9W4=[UBE1#=Z">"V/.%9K4)H+I7E0F@^E!<,J*X0&C:"T&$I+4#16
M:)U;A\K=.K+Y?53T>$PM0[4%94$=.5":"Z5Y4)H/I0506@BE15!:#*4E+[=R
M5EJ=*8>^9E.@=H'^'JGUK G29-CF5W"1AQPM-:BOAO9L3</=1_"@$7TH+>BI
M U.S#&%V'S1J!*7%/><@/H_O.TA7-6J?F=!*G^T0])8M@LXT?>P>0=A-@K"[
M!(EF"=-1=4M<01<:UX?2 B@MA-(B*"V&TA(4C95FYX*APUTP8R?MR=&C):J+
M-_<<P^%&E7,J^C<T7=C?QH7FS>O+&S>QZ.5# FB>PC/EQ06-SI07UP/'T+PE
M*!K;J#M3"?WV>P+)0XQNW% 7"93F0FD>%3TIEDIUA[_3[?<<:)K4TDR#EPW4
M(0*E15!:#*4E*!HKPLXA0O^J#8+D@49+$>H H>+:)<0FNLIW1]!-@J T'TH+
MH+002HN&558,#9J@:*P,.V,'_6:[!5'1!& (SXOEX4?+">K7@-(\*,V'TH(A
M515"0T906@RE)2@:J[G.K4&_^=9!\@BC^SRHJ0-*<VG/BB*$F+JP1S+4V0&E
M!5!:"*5%4%H,I24H&JO3S@-"O]T^0K1G\Q:+[QNA/@XHS872/"C-A]("*"V$
MTB(H+1[0)A-41'9W\L[!H<L=',!9=\=([+*1_),Q>7;&2A!*<Z$T#TKSH;1
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M15$_O9DU_(>B_'R(<?5_4$L#!!0    ( '*!:5:A=U<S80,  +$-   8
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M_06J@GJ:+V:9,+]H7<4Z%HH+(5E>@=4,<D++)WZLA-@"N/T# *\">+N X #
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M-,:Z)#,W)"$E"7WGG6!&&A#8Q\^>D&QS8 =Z J?G;@,7GM#)!A(QXV/%;LL
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MVPVIO^,@43L>9#.A,.R2^$,;;$'T-"TC]AG26R5BJN14DM*&<,):$TV$?Y>
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M2@/%1=>''!-6EE3FJ L80E"P7@LV-^IL(D[N5EJ\0\-QVI?K"]H41Z*:L&,
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MZA*K!^8]3PD%-/4^+^4P5DBZ<TT+\T7QP,IX]U<YB7GPCDU)G.0N45[H0<2
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MY2,9(DS=:1>BF$F+N6SB5EV&FL&0#=?D&V1EKR]-:]1$MSS@WRB'^%J7=#L
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MBRE1S2S:"$96;O[#A,5ITBUS/#10=@/^OI$8>2M8 _T_!"[^ U!+ P04
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M:0HVUKE:/14;LZ-G0MW2+89 'A]D-T(TSQ-L*QS0YU66')9DTJ[Y'$U[U"P
MBW#;DFCR'8F2Z^UPG8 J9YKSRW88\H6 <*B4."F3=FOOI<HU3M3JZ=92VP8Y
M\(T[5$H[B^$$C"LR1[_ P0BCY?O#)JI?XM/SN%:.[@T/>KDRW!;;)R>+R*A6
MPV/71"]:UWP+96_X,C,5H5!"N/%;?UO?EWX9K@DWR\-EZ^^DO8&!@&EK;!T-
M%Y?G(>VG#]YL^=+PTG@4H?QVHR30BA;@][6!A\4/Q*"^1?[B/U!+ P04
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MF<W.$KU. >L6;08$)-CLXJE.WHM:PK?7N B<OI$(!8C[4M2X"&CW[&,"EA7
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M.MUC$Q9BE3HCWLG:R*B*R)DUEW]!M5B(</6]WD/@3),I=I0?]RA0'R3@MJX
M7Y&CS(1S8:X[*7EH2ROPM#C3!@[#N]-FK">B2)EB_HH+T7!.D(%,$.?7V&K
M<A/8[)ASZ#PIIAA_,\&BA"^RJ/SG\SFD%,)XGQ-M )'/%I^:,-A2=>(D$%]?
M  LEOX*]:&1C@G=X&CXH[-].$5EN !XD(<(B98,O4HJCG&Y 7!M,ZX)?:RH
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M)=N]X"N:'>+\QD<S24\^G6;[A$MP/8D++@/U1:X$D=?1JX$%&WR17!Q?^,Z
M+Y+3;J, A";'E_XCG_1%UUM&R4QB)C[#KI2<+>[8<P^O$ "9MTY#49UPY-#>
M=PWX#YS];#UMJR3-?P$=SQXO/(@TYSAC:'-0CE\DY\=/7%"!A5ER?A[ O]X]
MWR4K(5R W+9HF.XI6"&"TC)=+YXKL..$0D%,#YF8EL*/$'+BL6@M>L_')O0&
M!% 7+I#<A>1C^,A$/Q99'/$$$1@&6DXZE<O[F.XS3,FG!>&"6S*1B;CY)"G
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M'NW_I:=(]ICP?EIBS/+* =4_U@U/*""'U?5B!T&'AAB"!*@.)RJZY[(\NN\
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M5>-Z84D9LZN*^\S4D%-*";_A:Z =BKR<(1:T#!J'2&?^)FJ5!).F.YX'[PH
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MT;^9BXOAQ>2*+B\%/'UW29=7XG(X?7=U]+OQ6PM ZTR3.K'O0]*X]UFO4%B
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MJ(:T]ILL$_E5_$VSU.)#A: _' V&9_/SL_C<HAO,9W.]@2JP<Y.7:D<3WBE
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MO< (>J53PC6\$;@V.6]N! Q2K:U2>^""-IB^H.-GSYV.Q/>1KW\K;JUKKC
M0 WP<6*\\$W=>#&F4$0J3TV=9UX:9LUO## $(:V$UDZ%G:T0XDW&"LJ@?MTT
MW7/_1H:Q#W'S4'RLEPZPC[76*J31%.E_55N&UM)OHOD=L*[:NW6/BT)JRC*
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M5)4I^'*M)*Q' _!^94S5W- "[?=&K_X'4$L#!!0    ( '*!:5:\&2F0D04
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MZ9,(E=U \K6DVN@6UL#PD77U+U!+ P04    " !R@6E6GBK66 $#  "W!@
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M3*,A[+NEX8Z85*@++YEN&%2EU97>VZOR32M&+^&MI-\S77!I0."24J/AQ5D
MNI7)UK"J]M*4*DM"YX\E?5E0NP!ZOE3*=H8KT'^K9G\!4$L#!!0    ( '*!
M:5:!LT3[\"D  ,.+   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;+U=
MZW/;1I+_[K\"Y=V[LJLH69(C/^+$5;)L[WHK#Y<59^OJZCZ Y%!$# (,'I*Y
M?_WUK[MGI@<$*#O9NR^)10(S/3W]?O&[V[KYU*Z=Z[+/F[)JO[^_[KKMMX\>
MM8NUV^3M<;UU%7VSJIM-WM&?S?6C=MNX?,DO;<I'9R<G3QYM\J*Z__([_NQ]
M\_*[NN_*HG+OFZSM-YN\V;UR97W[_?W3^_Z##\7UNL,'CUY^M\VOW97K/F[?
M-_37H[#*LMBXJBWJ*FO<ZOO[%Z??OCKC%_B)7PMWVYI_9SC*O*X_X8]WR^_O
MGP B5[I%AR5R^M^-NW1EB94(CM]UT?MA3[QH_^U7?\N'I\/,\]9=UN4_BV6W
M_O[^L_O9TJWRONP^U+=_=WJ@<ZRWJ,N6_YO=RK/G]/"B;[MZHR\3!)NBDO_G
MGQ41YH5G)Q,OG.D+9PRW;,10OLZ[_.5W37V;-7B:5L,_^*C\-@%75+B5JZZA
M;PMZKWMY);>1U:OLJKBNBE6QR*LNNU@LZK[JBNHZ>U^7Q:)P;?; _^OA=X\Z
MVAH+/%KH-J]DF[.);4[/LA_KJENWV9MJZ9;I H\(Y@#XF0?\U=G!%5^[Q7'V
M^'26G9V<G1U8[W% Q&->[_'$>F,G_N^+>=LU1#C_,W9B6>^;\?7 3=^VVWSA
MOK]/[-*ZYL;=?_F??SE]<O+B +3?!&B_.;3ZRU=Y6[2XM/=8N^IRD/@8D']@
MF>R7M2-N6=2;;5[M@)!%7;6$DV7>N66V*JJ\6A1YF;7TO",.[=ILG=^X;.Y<
ME=%AMWE#SQ45+](LZ6E'5-VMLX]5@16N\%Z;7;O*-7E9[O"<V^*;/%["MBEH
MEVT)POO/OSP[.SMY\?'XZCC[V\7%>_[[],7#+*^664?0-CV>PU^-N^Y+/@:?
M"U]>N47?%%VA3[SYO%CGU;7++NO-IFA9O#S <[K+U9O+L#Y)/5IQ6S< Z9@1
M<S<NZ/09D-<4+3VB0,37L)]^>"DH9K *>O-V71,ZCNK;BEYL^WE;+ MBSN/L
MHBP)GYUK]%)($)5 JYR(2+1J\X4<.MZ$*PL2& PGW44"@!S%;[_.VZRJL[Y*
MSA;V!^((#T5UX]I.CRCW! S0-SVQ=,,'<K_W1;?+-JY;U\OC W1^'NC\_""!
M?FP=D/6F[8H-B&:,Q+]N!3ZY$&FXB]%K%)Q![^%(0K^> (DHZ*3$,R2**U)>
M>"/K:OKK$R$A;(7+^:U?7LN"W3KOLGRU(GTD1,N$!:K? )E,KWG;NDY>+(M\
M7I21;I=%NRCKML>N]"3!!J+$QLF3@>QQB_[?XW3JF6<$CL;=N*K7G=UGL@%:
M^F-)?$2L&5]B1G5-09>=7?6+M3D[<6_9+]TLF_<=LT15 ](-2X"NGI'J)'HF
M O4KKO*BR6[RLG?3B)B-/-E [Q[5JZ.>;MJ^YDA9IR^3-EU\.H(27S*'TJF$
M!O2$LR$[00J1\,*GVZ:^)M33-=:W>2/OE\Y3$"&!+22(NGI>%M>R;N0,7!<T
M22N4))K=->UQ]F.D($#6LB2(>*15U@4]3(#0]0%08LA*@:(O;XA!ZYZ>HUT:
M(L#FD^N.VJU;0)6K2"S=#90Z(:??;$5,,#$:XIV3M* [Q_'HW_1.WM95/B^=
M/4/1+/H-41 D#PFE1=<32(04LH!:.F%?@DJ)P)MLU=0;>J=N#3L<D@=/@CQX
M<I";W^+J?_57_S:0];N*%'7/=#TF(O[THH;UZ3R$EX),+J(S2XOK@M19LUCO
M6"@6YN4-8;.'3B2<FQ?X#HBMP4:]+#AWW2UDM[TJH5>Z:KE<,':>/:CGL"GX
MAHIJVW=MU(8JUZ'%3I^^(-*X31=\T%?[;Q]G/P\_8[;5?RJ],  D.CLRD&@/
MD#-?.WBO$';Q_,RL",7A67 W?I)ZWI'S %4"FFGKOEFP^%@ZXLDE:#/5EL=D
M1NR!OP<JV?:E%[1#?%A<Y'-R5?BI?^=!<1. :$DL59('M8Q'QQMSHB%:17PJ
M]DUN\J+4XXRQVMM(-$5K*' )><^*UQLU++!F@,9]+CK_)TEK,? "S"SJY;!R
M,&;ZA2,7">(Y([^II&/$PVWS@K]@Z0@6S\UY8>N1'&Q(4I Y9P6H)^@1C)($
M 0?-V08%R\#\*&@) +G_?')MM*%A).4O9C;(\ 1#W;IQ[H@40#/.K.,,R'J&
MK+'ZEK[[5FS#)R^R'W"AV:FENM_[&BJ-,=V*U0M'4T_@U7[#)C7ICP*WG O)
M139P(C- [BSG58\9HBI !RD89R/$+VJ ]JSV &-]O&3]0U#ZDP3P#$\!EG'*
MGF6NX!V69/TL.KIL%G7^KR&$CRV$(U+G;EX=RJ[(K_;3K^?7!+<$=Y3Z4R88
MK/J2OB2]*A8UK47DA!MKG!5NV(/H!CQ>,A9(?O%QY;1$[*WQM,%2J4UCJ)GL
M]%KYNW.>7_$WGA3145@%42]=J<9Z1"\@+V&Y&/2SU9Y<AR%(L;*\?1:MY AB
M-']K6MR;N,<<-FB6A.ARYQ<AHXG5JG^(CD)N#+M&\UWB!1$,UB9<)3*/EH$-
MT>WIU@5]?$W6T;_D4I3N"!1C],;G UW)S2@O#"X@R@:+W+%K%;"__&HC(.I,
MYDW#'K8WO945XHZ)2Z9>7\;A'I69>;MF6N5_X%IH)Y&#[.04QGQGBY&YEQSB
MQHE(=2PRQ9]KB8-VH ?^I.F'9C*K-?TBX8TM6<>?V<I3KHAGAM?@%!7T6;LF
MM^$(MYP191&9'[(*GP:K\.E! ^Z2SC[+\-_LC<4 X/U %T;,#_3A@3'K\.#B
MXX&<\1W'-I3_)!=SNR[(56)MU[**)K8K2H[!K<F9H7^5!3V_3%QN=AN(SJ^)
MJDMBU,['--@Z I,]>/R0^)&#;)!MX/C;-2(R9%&M0<4S%@7L 0Y,4:;&Z#ZI
MKDCV+R!>*K?SLG9%?H$*&'D,3["5_$O# FQG'"'!S,*1> 9O= (V67AU6W0>
M(0>!2X(5!8E^D*#KB)#$&R;KFLP=\56P#YF4Z@'FD$#& X\!D@7I=]JNR4N6
M'B2.F(D4+.$O&!._P\U1B\E;=J3O8.X$=6KHNHD$$+@SK!EYL*RK:WG!*Z2[
M.3X11ORNVL9\\))%"9^:Y-^2$$*H1X!M-JI:AW#JK;,0$'P%@S#Z@)=U7O*Z
MC)TW6S)9-N1GOM>H7P6J>U=5]8W>NX_=7;YY_RZ$U=[2>@#UPE_-+)/C2O3B
MHK\F]S@[_8:#NZ=)= [K[+^_%Q#\&]/86[HRC;C]K>&PMG\A>] 2Q_Q$!E+V
M]&%*8+<%6;Y]5X HY,C8$@OO+2H\ (($]9-0;:.P!7H@+-CXTO! @LE(E[)_
ML#:SCE4RB=2;8LE.)HB--!F)7*^+%RQ_AC*?H324R#9,(+/A?8>XC]&"AXB/
MN8=L+J_7NKK+2T^ ;;YQ08L1"&2VC2UIPD]ZBFQ%IR8ZX:?KOB68VX??WGM-
MI+>9$ZH>G\[N(<3/I'#O<DK=97_-SL]GWSQ_1O]X_GAV]NSIO0^#\SZ>/7_Z
M-#L]I2_/[_TPB9;SV=GSD^S)[.3D_-XO?,0#R!Z^_-?LR3>SIT_.Z1^GIR>S
M<]KP@'Y[%O3;LX/Z[4<6N4P5,9@]ILG^P#()[8LDUQ#49[@K7C0874"V6+YT
MTW2V*CZS+4:F ST5-M((X5"G1)A:$Z=O7/ &(1:">\Q<E9<:J8N12ZLO9J(K
M^XKTD$CV:](&:M'7;6N=H1SL!1N'5)M$&LB^Z3=((;A@+"&6[];(1-XX?ZX'
M6.DAHG=C\#, J8X6 U9=LSV%K?&R&+7U2IO#IZS+^44",]NYO(DO3'.LK#7P
M6_+67!QKWM)-7,+P$(79GJYA[G8UAR#_/$2@'59G(@E)C)"A\"^V/MM.+(5Y
M9T$C0SM?_D9*0C,0^D80CW1?FZ+?M,%B#8%:1-%%2'&XG@^W\Q9(82B#29Y@
M$LN&[WQ,0:<"K29!;PV>A') ,<=D'DX1I=@)"W M(UM<!OA-$I*9.^O=TZY$
M_'E#P!?LB,PR&T@Z(K0<@5.&;'7@@+.L<MXQ4<2;E^G,2V#(^VA09BW450@V
M2_B"#3Q@6[- B8"19 %"'&3E.O%B'=NI$E4PQ[<N!#SHKIV@TSE*"]2]0/I?
M$<<QC1%\ 2 $T:(+K99X*P>^@4&8P>8KD ^]D4@[_4UGTP]6^:*K&]A'USF[
MNZ("\:J/_BW[)DGU&6F$ZP;5WW*(K1T/49I (FY)O,DUKB#ZZ181NPQYTQ(1
M:7+)26B#.&$W$$QDB2]@G!PP"MD&92KT5U%T;&IOB7W;$!"48^J&-3]4:!"@
M+#XYQ/Z :Z1ZZ"NVI.8A6F#CBKO)NP3X!G"Y^(%$X) AHJ)R#493>,]%8U\^
M+L0AL!G;LX3)&!CPN0NVRH5W<9GD&R_I\6*S+2&AE A9P %T729)NQ(R:F0^
MA%99QSE[LIEW482P=D&JQ9" N#4-/2IDN^W)?UH@/6ZBPS%FK('JG4TIAJ38
M!)',(EVRJ>@IUJ<,A?V"\)E-IA10%M&Y:TN@C 8(8U"IYXD1&#BF!>&9$J D
MH;OH6+$]0M\5#2.'M&%S+?FP:5'0.%'<1&B,PR.0XU%@_42^*&VHB_E3G81N
M5IRJ0WS%!N+%=\R1V*^P!P*?"PEZ2%R.2!?G8.\2\-LE66X6M:+?&\=,%+=$
MW>N"?2>]"26%8%W'(ZY=R:YJS\G0OAUN6]6,0MK7BQ\ ,HH-@UT%AQ4YLB[+
MS!K@7&.CSACAA/Y_<DB6 !:C)21&(.*$'9]IV49K3=SLP'5'F%U3X#VRGRQ3
MV<66M"M$H=?N&1=QB$#Y?\:98NOT4)#K>7 "GA^TWE]#6KPCNF![ZK)N56[Q
MYZ^]63/F%?P[UI4_"__8@A_STK8D/5AF*^=B*)$CN/)!B'A(EB"^BR"DKTVI
MM$J/C4Z)>-/E[Q?+9%$&L?A468[J'(8PVG<AYZ4;A@06XKBX+RC$L5.)'9:L
M);F\9<^.7C1TT^AME*+S;B07&'482PZUO#1>D($Z]Z(Z7ISQBF)L,6I8X(LS
MHLO<77%S>A(K D\.1U/K"OJMB554EZ*Z/A3MI]'2OS^QGDF\V*@^L_NV9KW"
MMF+;SW\;Y(B Q\7>VJIF&ZSM0ZR' R:C N<XN_S*-]2Z9LW/6<>ZOUZ3J5)]
MLE&_-"E1='W(9^)D28&<.LPA= A=/V?EK*XY<C)NJ35TM!R7&'")39M:W:C.
M[=C=^(KC,"?ZZA+$I8\$M4?>@I$PS):,8K%KQX\V5FK6F3H64?1Z:\$]I_M&
M1-BG)9@E:R?O:JF*&I^T4MT*4PTUKB4%\=V(T3AFEP 5!(H)<6Q1 KI39"8Q
M"Q"=QI>[W=:U R])0].:VN)X^#5XNY(P)QNSUW3NPHO&A P8YW&W(XFT^'.P
M=2K((+-\X6((5XB_LMZZ^)^&.Q@F@EAV9?LBO9L4F19Y2IVH"9,8B:][]N><
MH&IO"19=^]4,:,!D'$^8!4EZ--B.=X?2N?B EATQ<_:M4ICV1VDDXZ#@.2B'
M367VZ4&Y^3,+# A)0<;'2@EO*OKW9]8;4D*0M\166=4SBKC8#F^WQ!8E63V,
M_5H*+#561IO"NS\BB_F:;+6"1/AB7=5E3;Z"%*\RY8OE -KP93X+CJ]\<CNV
MJF^*)4F9]@5?1N6$)+6:!NMLD$-FN7=3,$U@]WSKB/ 6]!9G+3O-4T!=QTB>
M K!A"V]E4D\E_(N&,3/GQ)(5;B^")^2!D;*EC/CS]YZC6L$<CC8)GH.\4;.
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MQ3-O) W,U="@'U:\Q'9+XLL@=M@)!8^LBRT6F4EB!RGDV20,7J9)']Y$6UZ
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M5HU#P;R7&FM?V9+3.CPVV=(H<L0N^FX>W/(4;T>F .J?KL/-0:W"L@W"NE9
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M,:1W4TBGMSV-*6_C\+IL*ZCRC;N(M/3<DQ/:,E6:Q*",8$,_WMN3=5R=1E=
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MC\7,_0\S%N*(NDT;4B\<'^4N(S.NA.4NCYY&>RCWY"49LI%)122@;MV@J"
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MO T\])ET5%3BXP2#GB,C)!K+X7C*""S*6SMMBS&?FC",!"3NG%0D!H?_?8X
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M08V>GOMQ6W[</6F.&&N7&N^O6NH,LRKP,[OY4@E$YMB020XQD?W3R3?*-?Y
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M_N?:Y<0F>("^7]6DVO4/;( B*0;OY?\"4$L#!!0    ( '*!:594A,N8RP,
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M@0RK0_M=]5WGQ;SOW9^%W4CM*&!%KNG)E(IK^W[83[QI0P]:&T\=+0QK^H5
MRP:T7QGC]Q,.,/R4+/\#4$L#!!0    ( '*!:5:,4(C=700   P,   9
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M=9#& =<W0NC]Q&PP_ .P^!=02P,$%     @ <H%I5MH/\<-9!   3@P  !D
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M5TQJON4IU5!T*->&54)QC9(@Z=$&\@0VLF#2[EQ%*U,5'_M>W-N.53"7E9
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MQ@!^WPJA.\4$Z/]"K/X%4$L#!!0    ( '*!:59:5J:/#0,  )\&   9
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MJ@V:%N#_A5)V\T(.VLO[Y#]02P,$%     @ <H%I5H][)Z\)!   CA$  !D
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MB*(.OD&;X,#Q#;H2O&$ZXU+7"LB/JU0;A1_#ST/9-ESQ82Y;(!>ZHAG,/:P
M#>H%O.3D*!P%EQU*XU9IW,6>/&#!Y34'(@OR58H5,:!*_,)0?THY%1D<4MS)
M>5@Q6@QE"LK:W+,V]Y:*B8Q5E!,NJ=@=1X[Q$OI!$/1NF<"] H"$_7 8])X$
M+:4R[#?DC< <#9:U,(2*G#"M:X?/I#::G")H$H3DK/<^JSX1V'2.23CM#^(I
MZ7!PV#HX_&\'01N&18L"B]K8BZ_:'"OZAFW%Z$-V=AYPV$YT<(!IG!Q-HC"Z
MM(;&^Y,AB?MQ,+;#$<%4IR,[')-1/YR.>X_26$7_:&N]/^B+OU?P):B5:VN:
MN"MH:K]=;3OG5=,P_H8W;?>.JA43FG H$!J<C]$!U;2R9F)DY=I'*@TV(S=<
M8_<'90-POY#2[";V@/9_DOP!4$L#!!0    ( '*!:5;Y942=A0,  (8(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;*U6;6_;-A#^[E]!J$'1 FXD
M42^64]M G#18@78-ZFS[,.P#+9TMHA2ID52<[M?O2-F*"[A&,.R+*+[</<_=
M/=1IME/ZFZD!+'EJA#3SH+:VO0I#4];0,'.I6I"XLU&Z81:G>AN:5@.KO%$C
M0AI%>=@P+H/%S*_=Z\5,=59P"?>:F*YIF/Z^!*%V\R .#@M?^;:V;B%<S%JV
MA178W]I[C;-P\%+Q!J3A2A(-FWEP'5\M,W?>'_B=P\X<O1,7R5JI;V[RL9H'
MD2,$ DKK/# <'N$&A'".D,;?>Y_! .D,C]\/WN]\[!C+FAFX4>(/7MEZ'A0!
MJ6##.F&_JMTOL(_'$RR5,/Y)=ONS44#*SEC5[(V10<-E/[*G?1Y>8D#W!M3S
M[H$\RUMFV6*FU8YH=QJ]N1<?JK=&<ERZHJRLQEV.=G:Q9(+)$LC**^!&-:V2
M(*TA;Q[86H!Y.PLMPKC#8;EWN>Q=TI^XC"GYK*2M#?D@*ZA^=! BOX$D/9!<
MTK,>;Z&\)$D\)C2B](R_9 @Z\?Z2G_C[HK=,\G^8T\48@Y9&"5ZQ7B:R(O<:
M#":A7U ;<L<E)HDS05:X"(U/T)_7:V,UJNJO4RGJ":2G";B;=F5:5L(\:!V6
M?H1@\?I5G$?OSX27#N&EY[PO5GASJTZ HXZAM(Q7Y,,37F,#QL?WQ=:@R4VG
M-49"KHT!:TX%<1;F=! '/#C&4QZOW.,QCT=*3#LWUI'$;;)1 C\07&[)&RYQ
M174&3<W;JQ%6'YHU.D %C)P"G SBT0')03-=UAZI@D?\SK2N0N\T""S6$94+
MDHYI&N-(Q_F$CGY%Q2,+7\2>%7G]JJ Q?4_B<5)D([SJ@JV5[H6@D0=_=+>"
MQ$E&\J(8.'!I.NWO43R.LP*?DWPZ^B@M(#M[E(-G'X9D=$KHE([N6,D%MQS,
M0+F"5AF.24J*],!IU%<MRR>DR//1@[*HQ_;%Z;X@DW$4IW[$X,D9G66#SK(7
MZ^SVP/A97Y^4W+Y[ -V<4=A9@-,*^P&I#U4X).N0_B=M?0+\T!,#F$-NOS^7
MXX),$Y="E$>4_0<%YFF"ME$Z.;+%$A7C.*=#G?O*5B\($^F,)\G4"SK)3M<T
M/.H-#>BM[X N0YVT?9L85H<F>]WWEN?C?8?^S/06E4X$;- TNIQ@]73?]?J)
M5:WO-&MEL6_YUQI_%$"[ [B_4<H>)@Y@^/58_ M02P,$%     @ <H%I5A8M
MNG+) @  &08  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULC551;]HP
M$'[G5YS2J=TD1!*3 J,0"=I.ZT-;5+;U8=J#20YB-;%3VRGMOY_MA)1)%.V%
M^.R[[[[O[#LF6R&?5(:HX;7(N9IZF=;EV/=5DF%!54^4R,W)6LB":F/*C:]*
MB31U047NDR 8^ 5EW(LG;F\AXXFH=,XX+B2HJBBH?)MC+K93+_1V&P]LDVF[
MX<>3DFYPB?IGN9#&\EN4E!7(%1,<)*ZGWBP<SR/K[QQ^,=RJO358)2LAGJQQ
MDTZ]P!+"'!-M$:CYO. EYKD%,C2>&TRO36D#]]<[]&].N]&RH@HO1?[(4IU-
MO9$'*:YIE>L'L?V.C9YSBY>(7+E?V#:^@0=)I;0HFF##H&"\_M+7I@[_$T":
M .)XUXD<RRNJ:3R18@O2>ALTNW!27;0AQ[B]E*66YI29.!TOM4B>,I&G*-49
M7#]73+_!YQ]TE:/Z,O&U26$=_:2!F]=PY .XD,"MX#I3<,U33/\%\ VWEB#9
M$9R3HXA7F/2@'W:!!(0<P>NW@OL.K_\!7B/Q]VREM#1OXL\AD35$=!C"]LE8
ME33!J6<:0:%\02\^/0D'P<41@E%+,#J&'B]-WZ55CB#6<*-4A2E0GL)]I94V
M"\8W\$BEI%PKT (6E4PR\RQAF5%#QD;I#.%2%"7E;V?*K@KS_-U%'])ZE,UA
MK3.7QMP,%BN4[>UT7>:UR$VG6YK;/9KECJ8Z1//T9$3"X86"I":K+%G8HD1@
M[R40[R48=UQIP+QYA.O7DDGJFKRQ42;,Y%I(EB#<58ZER=C6;:^8G58&&3D9
M =P)CO )@EX00MCOG@_[W6$0=>X3+9Q?5,O=\PMJ3S*,NE])OT,&W5$TZ@[(
M$ X]"'^O70N4&S>4K/:*Z[ISV]UV[LWJ=G]WKX?F+94;QA7DN#:A06]X[H&L
M!U%M:%&ZYE\);4:)6V9F=J.T#N9\+83>&39!^V\0_P502P,$%     @ <H%I
M5C/>-F9&!@  8A   !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULO5C=
M;]LV$'_W7T&XW=  BBU2WVEBP$G3K@]=C:1I,0Q[H"7:%B*)'DG9R?[Z'4E)
M=E)%R%[V8IWLNQ_OXW='TN=[+N[EAC&%'LJBDA?CC5+;L^E4IAM64CGA6U;!
M+RLN2JK@5:RG<BL8S8Q164R)ZX;3DN;5>'9NOEN(V3FO59%7;"&0K,N2BL=+
M5O#]Q1B/VR]N\O5&Z2^FL_,M7;-;INZV"P%OTPXERTM6R9Q72+#5Q7B.SRYC
MK6\4ON=L+X]DI"-9<GZO7SYG%V-7.\0*EBJ-0.&Q8U>L*#00N/%W@SGNEM2&
MQW*+_M'$#K$LJ617O/B19VIS,8['*&,K6A?JAN]_8TT\@<9+>2'-)]HWNNX8
MI;54O&R,P8,RK^R3/C1Y>(T!:0R(\=LN9+S\0!6=G0N^1T)K YH63*C&&IS+
M*UV46R7@UQSLU.Q6\?3^]!+BRM 5+Z'6DIITO?M&EP63)^=3!<MHY6G:0%Y:
M2/(")";H"Z_41J+K*F/94X I^-<Y25HG+\D@X@>63I"''41<0@;PO"YHS^!Y
M+P6]H8(U02_H(W!,H;D0M%HS(_\Y7THE@#!_]45OL?U^;-U$9W)+4W8QABZ1
M3.S8>/;K&QRZ[P<\]SO/_2'TV:WM'<17:"ZAD;:Z5A+=Z4B@0]&U5#E0-:_6
M2&T8^DAS@;[3HF;:PM0:+6J1;B!T9!I0HD\0MP+S.RB6@ SC&%V7VX(_,O;<
M8E'0JB\C@S[W9^0;>,>LL]IU[>>N]5.:5;?MJL+ZN6[\K(V?.CKKZ^UB@?9,
M,)32(JT+@U?+-@.7!05^WZ8;#F1&W.3K="OR5"N4/&/%D?**%S"D]!L])/=L
M] >C C'-901,9.42U@<VCC0;-26Q_G!'UP];&#6@E.6[/ -]])BS(D._OHD)
M)N_1+WW2P4HQ42)W$KCH$=:36HPZT8^M.+K)Y?WI2D!M<L@&I%,A 2$C//$
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M#\?:+,L:<V.Y ?7<H</>/6[,-#/&9B7600QI/7T.)2PRS>)AQ%QGZ&%G8ET
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MD#0 _R^$T.L7,M!=S6?_ U!+ P04    " !R@6E6A@T*:-X#  "B"   &0
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MCWSS,[03FFB^E.?2_))-VS?P2%I+Q8L6C",H6-G\TX?6$3L G.@P(&H!T5/
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MW0&_+SE7VQ=MH+NRG_\'4$L#!!0    ( '*!:5:F<T>(NP(  &4'   9
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;*U576_:,!3]*U9639U$FR\2H(-(
M+6S:I$U"I=T>ICT8YT*L.C:U'>C^_6PG32E?Z\->$CLYY^2<:^=ZN!'R014
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M(6O5[F%5^Q]?J14F,/+,CZI KL'+WK\+T^#CH<C_2>Q5 >*V /$I]9<"$#N
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M.A^9KQ+93-'-A1:5FUR70ILYV"T+)!E*N\$\SX70NPN;H/TO8_H?4$L#!!0
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M^6;W1J>;O*KRU>[C@TIO55$;Z+_?Y7GUY4O]DJC#2\$N_@]02P,$%     @
M<H%I5KM([\3] P  U!   !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
MO5C;;N,V$/T50ET4N\ FNOB>V@;B:(L&:(H@Z;8/BS[0TM@B(I%:DK*38C]^
MAY(LWQ2M8ZA]B46*<V;.&6K(R7@MY).* #1Y3F*N)E:D=7IEVRJ((*'J4J3
M\<U"R(1J',JEK5()-,R-DMCV'*=O)Y1Q:SK.Y^[E="PR'3,.]Y*H+$FH?)E!
M+-83R[4V$P]L&6DS84_'*5W"(^C/Z;W$D5VAA"P!KIC@1,)B8EV[5[[K&8-\
MQ5\,UFKGF1@J<R&>S. VG%B.B0AB"+2!H/BS@AN(8X.$<7PM0:W*IS'<?=Z@
M_YJ31S)SJN!&Q'^S4$<3:VB1$!8TB_6#6/\&):&>P0M$K/*_9%VN=2P29$J+
MI#3&"!+&BU_Z7 JQ8] 9O&+@E0;>J0:=TJ!S8.!YKQAT2X-NKDQ!)=?!IYI.
MQU*LB32K$<T\Y&+FUDB?<9/W1RWQ+4,[/;VA*B*?OF9L16/@6A'*0W)'Y1-H
M.H^!/$*02:89*')!KL.0F6S1F-SR8L^9W+WW<3&+/Y!WA''R9R0RA2AJ;&L,
MT+BQ@S*861&,]THPKD?N!->1(I]X".$^@(W,*GK>AM[,:T3T(;@D'?<C\1S/
M(Y\???+^W8<-J9>:"&].QW,W>#4P_NDP3CW,'MU.E<U.CMMIRB8<9#/99E-M
ML_GE=[0EMQH2]4]=I@I'W7I'IAI=J90&,+&PW"B0*["F/__D]IU?ZD1M$\QO
M"6Q/X&XE<+<)O1#8B!J<K'2=N(630>[$5.;5U!WT1HXSME>[LATO\YQ^YW"9
MWQCRF8+T*D%ZYPE21[N ZNWPZ?6ZH^$!Z^-5HXXW'!R0;@SK3-+]BG2_D?3=
MJ7GN'^?9<[I'>>X?,79=3/-AGAN#.I/RH*(\:*3\1Y;,01*QP!(?LA4+,SP$
M=LH)%G[*2<;Q[A&S?R$DL5"*I$+E!P;!PX)@=4^*ZHZ#)2[4"/BMJ1C/!D?"
M'$K7&/5;*TM+8'L"#RN!AV_?4WBS"L22%QJB]D)'("]T1/D%%NY42+RJ$9:D
ME$F\B^DZ"8='6_!0PA^N\)M6[)$=561'C60?-KMDB3?3?#^8[8)\D69M$?V(
M=SD52)8:)>IH-OOC F%QNS'<M/(5WW7GUG^"ZC>BGKG-7&=[X7-^L-&>69(E
MY,L=F$^Z]O!OAGCKZ=\JFM\6VKY\._=E]_^Z8I6>VE*Y332_+;1]E;VMRMX9
MU3# XT-BIVC.'OSR-M,I?H(BK%6XV8M'7H#*VB^_V?+-:K:$5JAI[[1["<AE
MWC8;=3*NB]:HFJU:\^N\(3V8GYF6/6\CMS!%OX_Z+TT=BV&!D,[E ,]@6;30
MQ4"+-&\JYT)CBYH_1D!#D&8!OE\(H3<#XZ#Z1\;T.U!+ P04    " !R@6E6
MX+.O@1,/   DNP  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6S%76UO
MW#82_BO"7G%H@206]:Z<;:!U+FB ! CBI/>AZ ?9IFU==E>N)-LM<#_^I/5Z
M.:2D$2D/P2^)7ZC1<#BS?C0/Q>?XL:J_-[><M]Y?F_6V.5G=MNW=VZ.CYO*6
M;XKF377'M]UOKJMZ4[3=M_7-47-7\^)J=]%F?13X?G*T*<KMZO1X][//]>EQ
M==^NRRW_7'O-_693U'__PM?5X\F*K9Y_\*6\N6W['QR='M\5-_R<M]_N/M?=
M=T<'*U?EAF^;LMIZ-;\^6?W,WIZQS.^OV WYK>2/#?C:Z^=R457?^V\^7)VL
M_-XEON:7;6^CZ/Y[X&=\O>Y-=8[\N;>Z.MRTOQ!^_6S]_6[VW6PNBH:?5>O_
ME%?M[<DJ6WE7_+JX7[=?JL=?^7Y&<6_OLEHWNW^]Q_U8?^5=WC=MM=E?W'FP
M*;=/_Q=_[2,!+F#1Q 7!_H) ]X)P?T&XF^B39[MIO2O:XO2XKAZ]NA_=6>N_
MV,5F=W4WFW+;K^-Y6W>_+;OKVM/W15E[OQ7K>^Y]XD5S7_-ND=K&>^V]+[?%
M]K(LUM[/3<.['Q7;*^]C65R4Z[(M>>.=WU_\MUL,[VOE35GIU\G[PB_OZ[K<
MWGB_%$W9>#^^XVU1KG_J[W&X[I5TX2MPT>^?^.:"UW]TP[^=O_-^_.$G[P>O
MW'I?;ZO[IO.I.3YJNT#TTSFZW$_ZEZ=)!Q.3?L<OWW@A>^4%?A",7'ZF?SF3
M+S_JPG]8@^"P!L'.7CB[!J^F8KT/SE4?436>OW_L['D?6KYI_AB+Q=/-H_&;
M]Y\3;YN[XI*?K+H/@H;7#WQU^L]_L,3_UUADB(Q)<0H/<0HQZZ?[V%SWX7KH
MPS4VVR<3Z<Y$_R'V<,KB+&'=.CW >8P,RZ,@C0_#) ^C@X<1ZN%9T=QZ__[S
MONS<VQ7 <_*.>8J:,ET7(F/2K./#K&.7^1M3QHG(F!2GY!"GY.7Y^V0B!HD9
M9BQ7TW<X*F,A"\:S-SWXER[+7N]_WJ=JR__V/A7U]PY;O+_O/G;1W$9O9+IF
M1,:DF&2'F&0N<SNCC!.1,2E.^2%.^<MS.]?*[>&H- \R-I[;S!= QU^<W6?5
M9L/K'=CY7-SQ&LUM_#ZFBT9E38X*@'_,97[O[TX5*R)K<JP$3&,HNM'+<=R&
M\8R#03$PW_<G:D$ *88C*;P6ZKNJ+EKNO>,7K7?>K_A3(J!%@=[0>-I$UN3P
M"!3'(J=%08K\J*S)L1+8CZ&02;,H2#'<WII<%.'4'PB!SA@.S\YOJ[I]_977
MFSW.*2[67#O_4=O&,R2R)D="X$"6.LU_4G1(94V.E<"'#(55FOF?#3.6)6&6
M*]!G;)R?A5$RD=L"G3$<GFGG=O<'X-N;\S?>UWJWP+-IC][6>"F)K,E=&($0
M ]]I'X84-U)9DV,E<&. 8BV]M-_;D !_'$>^DO4CPU@0)/EXT@>@K8;C-9.D
M-WH"P.]KO)(V>FJ!P()!Z#3K28$AE34Y5@(8!GA_3R_KHV'6AV&0J5D_'!9%
M>1I-9+T 9 $.R,RR?@G6QQTP7E(;+;E H+X@<9K^I+B0RIH<*X$+ [Q!J)?^
MZ2"O Y;%H9K^(\.2' R3?11X+,#QF%'Z\[HMK\O+K@ :K[KNBN"N:LH63W[2
MEAV5-3E8 A8&N=/D)T6'5-9D[DF@PQ#O'^JQ3_X@J_-(1?DC@^(XG_C@#P4D
M"W%(9HSQ;ZH'7F][PM6[ZC_^F\/0T:F1MO*HK,FQ$M P=$JYAJ0 D<J:'"O
MNE+0KN'PXSQ*V2#UA\-8GD\@_5#@LA#'92:IOYM.MXZ7W[NUU40\^.V-U]-&
MQRX4 #%T2M>&I.B0RIH<*X$.0P+*%K=A/.,AM\N2.$XG:D2 MQ ';Q^K[<WK
M=EEW$S=M/$,;';M0(,30*:4;D@)$*FMRK 1 # EHW7#(V$:P'[^?R<BHA$VD
M=21@683#,MVT-FQLXG<UWIUCHUD7"608.25Y(U)D2&5-CI5 AA$!R1L-:=G0
MSU6P,S(JR+.)7GXD\%B$XS&#C%_6W\'O;[R>-EIV$=B1YY3+C6AW\=E AI%
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M@U36Y%@),)@34-7YD(,>?'H/AP239S3F G_E2UEJO5PWWSJ..V2\NC;:@KD
MA[E37CHGQ7Q4UN18@0.M*4ZTGN>ET2'*6=;P,.NES+1V(1@>>DU\ZK658Z]]
M<.ZU[_;@:Y_VY&LJ<TJ\ A OBL.O<2/FLS8Z_MH'YU_[2ZEK@_)9=$XV[IAY
MA*R<E.V#H[)]IX3U\^W)XF4#BC(?')?M4YR7C1LQG[71B=D^.#+;7TIS!XNX
MO/%@T)ZM365."1HX7=MW>[RV3WN^-I4Y)5[@A&V?XHAM?TA59WXV.'QO;%R>
M^.G$033,!V=L^TN)[67%8'H6-^Z>^;K;Z",R*-C"G)+:C%C(Q9*2"Y1R(2"V
MGXU@CRSX&,4_ "%G]%,LU(?9,PRQ-@N5.26@ ,4RIY0V(Q9UL:/J F5=<"T4
MW0(9X;5'SN\>&X<<X,V@I,J,IHJ50EGTM$(LW$)E3HDLP*O,*=?-B&5@[.C
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M=\JB?2*!-S:3!=O((^6 OGR$: F\]?DP(E_Z?'0$5FN"5S3!N^(VX779AH[
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MRQUS65 -YY+_9(4I)]XGCQ2PI TWUW+S%;I\3BQ?+KEV7[+I? ./Y(TVLNK
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MVE@"QO&O<I0=K6:E:8.-N:2;1FKBN]V9JIG9>3':%PZ<)-8 9FV3M%(__-I
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MEO:NOI5O?7$<HC6U1ML_-(^"$.V>H9J!:B:J6:AFHYJ#:N[I@\@[_1 ?W:<
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MJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQI76#O*T+WIVJ"YXX\>[-9+1
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MAQW]\"#]/9=$?8^]C&WH:(\QCD?O$(XZPM%!PF?)*J4M_X,%<&,:WU"Y,M8
MM5#;9P453C72]C;4Z(VHL_@RBOM5C3M5XX.J7*.?/;E&=YUS"D_*,M''/GY3
MA/AJ,+SZCSW<FT+WH'UE>L6E 8%+BHO.+TB^;A^)UK"J]H.Y4);&W&]+>E=1
M.P>Z7RIE=X:;]>ZESOX"4$L#!!0    ( '*!:58O"UQ5:0(  %4&   9
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MP^82])'*6]P7A,,:9<%IBN'+]E[1#K1H[-&\$AH/>OM8XET,I#' [VLA],/
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M--ABW;# GR H&X#[2RG-;F+[;/M;3?\!4$L#!!0    ( '*!:5:ORG$&31$
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ML*I9KBX$+72_N:)"=J]ZF "6#:::()^O*15/%VJ!YE\6X0]02P,$%     @
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MP$0<Y?90S<VA?C"UQ,LU'Q/3>$?,J6D.%4@?[K!P3*R7PYW]PXV!<'?_\.E
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MDHLT-JFT1.-'R30^"";?^E).3!\$=9\OYS(0'EC04*X.CM/X7H('N62\.""
MKD Z#/S8)J\XF"6Q]\4;.+LA OO!N1S]^' #SKZ<@R]  WR#&>' C\!CY M^
M(1_*ZY\;&G,<>7RB">EY8E]S<R_GF9=HCY<0@>\T$AL.OD8>\>H*- FYP(W>
M<<^14N,-<8? @!< Z0AU.+3XN#A4N&,4TV"D^HP]^OZ.PR5A::2SV,UV,JYX
M*:,O4Q7<<A[CR"5=D<L4F]V*DRIPQ;?8)=<#F>:<L!T93'__#8[T/[I0?Y*R
M6@S,(@:F2GLE!C1?9TNR]J/(C]8R4X-]^#.E5JHT*5J[J6%:#AS;$VU7A:8T
MWA.:54"SE-!FL=A0YO_;7+H9 JL#P0@ZT&H@4-KHB6!4(!@I$?S)<"2ZW1^U
MW+\T+!E_PVSXK[30TW^[\-]6^K](ED\0=".P6PB@"65FCQH E"9Z A@7 ,9'
M9@>)O .I,6[A,L?0-)SFQ+3'-5.HYK)3N.P<5=2Z7'0^LWI]DK(:6*B7G517
MSM"/6'"!LTG!HE*\9 "VA/FT<^WE2JO!MZ!N&T8S^]76^Z*K\ 38MP#DDK7U
M T=C:P2;$)0F^D) )02DA/#UE3#7YWM H'89@XYIF,T^HC;2%T1)%*"R!ZL+
M62Y;!P&1XR"GB>(4G1Z6K1ZJ>WTC5V0I.Y E[2X_<BPX0GH35WM@,YWJ+I<M
M'*I[^#OYK;A^ 9HE[@(\$2[3!,@!@&3K+6%QG9@Z^CY$R+%0$],I&C\L.S]4
MM_X^P+=RER9O! 4[^;@3?9LVC$P$3=2J>Z>@#;#D#=!6-K%?Z4:0>)>S'6%R
M8PO>JPBX8WYWVX6?Q!-R_*=@';"D'5#-.^9%&YOO)QJY#J<RF<YPW%K'2DM]
MD91L!"K[O[*#99(05:G2T#:: $Y!,%!),)":8"C[5RY;@Z /G2:%59OH"Z%D
M$4C-(I3=*Y>M01BW9T%MHB^$DD6@ RPBZUJ*;,@5U'#80Z>9#OFPO4E3]Z\D
M"$A-$ X4K&,Z5&ZI!L09HN;V0>U0WPDIN012<XGC !_N3+DYI[8*=<.I_C4C
M<(J/"ZBD)J@'-6F%Y9XDGW63M;N@D6#8%3$.P$_"0G#F1^"-8,;/.P.BMC[.
M1 %R@(??NG9YBP]J@"!,OO(!:'=HJL>F9"^H!WLY(C;[\N50S-1>V0W$:+P_
M=J?@/ZCD/TC]X>23XU=/OT-!5+N6+YO.H)V"-*&2-"$U:>H,VFR]9F2-!0&W
M,D1^Q'T7/.$@[BZ]F0&[^DU*'[?J3L<H&UK&GAY24B6DIDK'^7]42W':WZ3T
M%JQ3\"RCY%G&@0\Y_P?]X?Z26Z].FN,T=SUJ%X\-@58Y( H)6Z?G9ARX-(Y$
M=F92/"W.YF;IB53C^1Q>+;(3ME)-=N#W'3.Y4> @("NI4A_:<HI9=H:6W0BZ
M38^AEE0(&J:7&X(]PI(!\OV*4O%^DQ@H3C*G_P%02P,$%     @ <H%I5@XN
M9\Z. P  6 L  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULM5;;;MM&
M$/V5 1L4+6";-U$75Q(@V4GJA\2&A3@/11]6Y$@D3.XJNTLI!O+QG24IBHDH
MPC+0%Y)[F9ESSNX,9[P3\EG%B!J^9RE7$RO6>G-MVRJ,,6/J2FR0T\I*R(QI
M&LJUK38265089:GM.4[?SEC"K>FXF'N0T['(=9IP?)"@\BQC\F6.J=A-+-?:
M3SPFZUB;"7LZWK U+E!_V3Q(&MFUERC)D*M$<)"XFE@S]WKN]HQ!L>,IP9UJ
M?(.ALA3BV0SNHHGE&$288JB-"T:O+=Y@FAI/A.-;Y=2J8QK#YO?>^X>"/)%9
M,H4W(OV:1#J>6$,+(ERQ/-6/8O<W5H0"XR\4J2J>L*OV.A:$N=(BJXP)09;P
M\LV^5T(T#'SOA(%7&7@%[C)0@?*6:38=2[$#:7:3-_-14"VL"5S"S:DLM*35
MA.ST=*%%^'PY)UX1W(B,#ENQ0JY+6)0'!6(%CZBT3$)-FPH#^,(3#3.C:*)?
MX(];U"Q)U9]C6Q,FX]D.J_CS,KYW(K[KP2?!=:S@/8\P^MF!361J1MZ>T=SK
M]'B+X17X[@5XCN?!.[!!Q4RBJEX=$?Q:,[^(X)_2S#AJTVPF)>-KI$NK8?D"
MS7T/[*68GNV8C"[@_;?<"'?'2=?<+"BXUS%*T#'C<+\Q[M0%?!9\2](C67S.
MLR6MTV$L2CK_/(HT!;J:QN._;<J7+'KM+$RZ7ZL-"W%B43XKE%NTIK__YO:=
MOSHTZM4:];J\3^]SK33C4<+7%Y!7+&".ZX1SFJ-,2AD/$7[L3^='Z_F41,I0
M01'*E)GM=. ,AXXSMK<M$(,:8M )\4ZIG#!U!0Z. ON!XP[\]L#].G"_,_!3
M*<:KJ/>/$%SZ@>^?XCZH(0PZ(=P8\5.,;+H_*TQ>#6=P#,?M]=S>H!W.L(8S
M?,-MP6+BO*LR/ (8]-W Z[?C&]7X1IT9_[4H[@1IMD5)/ROX2(FN@2HNP@>6
M2'AB:8YM>$;_0PZZSJ&X.V_0==F2A8TZV1RT%O0RYJBI\94W:E?8;?R(W->E
MXSE0JI^;]Q.6WHG3=KT#%N]U&7H.%J\-RTE=#C\;M[-.MZ?J.;C\-EQ^< +7
MH<"[;ZGP1SE[#M)>R\7RA[\ M1O-3H9R7;1T"D*1<UWV/?5LW3;.RF;IL+WL
M.3\Q29F@(,45F3I7 ZH;LFSCRH$6FZ)U6@I-C5CQ&5/KB])LH/65$'H_, 'J
M9GKZ'U!+ P04    " !R@6E6E_;OZV<#  !C#@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6S-5VUOTS 0_BM60 @D6-Z:=!MMI749+Q(3T\K@ ^*#
MEUP;:TX<;+<=_'K.3I:U75:&E ]\:6SWGB?WW/D<WV@MY(W* 32Y+7BIQDZN
M=77LNBK-H:#J0%10XC]S(0NJ<2H7KJHDT,R""NX&GA>[!66E,QG9M0LY&8FE
MYJR$"TG4LBBH_#4%+M9CQW?N%B[9(M=FP9V,*KJ &>BKZD+BS&U9,E9 J9@H
MB83YV#GQCQ/?,P!K\97!6FV,B9%R+<2-F7S,QHYG/ (.J384%!\K. 7.#1/Z
M\;,A==IW&N#F^([]G16/8JZI@E/!O[%,YV/GT"$9S.F2ZTNQ_@"-H,CPI8(K
M^TO6C:WGD'2IM"@:,'I0L+)^TMLF$!L /WX$$#2 8!<P> 00-H#PJ8!! QC8
MR-12;!P2JNED),6:2&.-;&9@@VG1*)^5)N\S+?%?AC@]F6F1WKR98N0R<BH*
MW$Z*VH2\(3/<8]F2 Q%S8LU(A]G9K1D#>9F IHR_0MS5+"$OG[\BSPDKR9=<
M+!4M,S5R-;IK7NJFC6O3VK7@$=?\@)R+4N>*G)499-L$+NILQ09W8J?!7L8$
MT@,2^J])X 5!AT.G3X?['?#DZ7!OCYJP35UH^<)'^,Z*BHM? &0&<L52?.94
M0E>23C@7:3W\/">7D(I%R7ZCU05()HRQTHI\_X0O(!\U%.I'5[9J;P;=WICS
MZ5A5-(6Q@P>00I? F;QXYL?>VZY(]TF6]$2VE85!FX7!/O;)WRJC*Y(UX] R
MFH-YA7L]BH8C=[49H@XK+XJ";:ODH=70][W6:$M3U&J*]FJZQ"A1F>8$"Y<D
ML,*O0X5GO6ZK_?LY%-<@.[?)7NI_W29]DB4]D6V%-&Y#&O]7Q1KWF84^R9*>
MR+:R,&RS,.R]6&O&:*/ XF'H[=1JAU$<Q#NE^M!H,(C"[E(];!4=[E7T'DJ0
ME-M*/<GP@L"4EM3<I9Y4K'O)_W6;]$F6]$2V%=2C-JA'_U6Q'O69A3[)DI[(
MMK+@>_=W4Z_W<FTH-S^(T6&P^VWML J/'A1LAU40;WRG:UGNQNV[ +FP78PB
MJ5B6NKZ;MJMMIW1B^X.=]:GIH.RM_IZF;K_.J5RP4A$.<Z3T#H9XB,BZHZDG
M6E3VCG\M-'8,=IAC%PC2&.#_<R'TW<2\H.TK)W\ 4$L#!!0    ( '*!:58S
MR3ZUZ@,  ! .   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;*U7RY+B
M-A3]%95323I5,_@!S:,#5'7C3&46DW31DV21RD+8UZ!J6W(D =U_GRO9F$>$
MS6(V8,GW'.N<J\?5="_DJ]H :/)6Y%S-O(W6Y8/OJV0#!54]40+'-YF0!=78
ME&M?E1)H:D%%[D=!,/0+RK@WG]J^9SF?BJW.&8=G2=2V**A\?X)<[&=>Z!TZ
MEFR]T:;#GT]+NH87T'^4SQ);?L.2L@*X8H(3"=G,>PP?XC R !OQ)X.].GDF
M1LI*B%?3^)S.O,","')(M*&@^+>#!>2Y8<)Q_%N3>LTW#?#T^<#^R8I',2NJ
M8"'ROUBJ-S-O[)$4,KK-]5+L?X5:T+WA2T2N["_9U[&!1Y*MTJ*HP3B"@O'J
MG[[51IP PN$50%0#HDO X J@7P/ZMP(&-6!@G:FD6!]BJNE\*L6>2!.-;.;!
MFFG1*)]QD_<7+?$M0YR>?^:)*(!\I6^@R$?R@O,JW>9 1$:6D B>L)Q1FR'L
MT1L@+YKJK1;RG7R"%"3-R9&"+*D&HH4-7(BBI/S]1T5^R3*PZ3W&W,6@*<M_
MFOH:19BA^$D]X*=JP-&5 8<1^2*XWB M3R$])_!1?6-!=+#@*6IEC"'ID7[X
M@41!%#D&M+@='CK@\>WPH$5-OTEHW_+U.Q-*8J:27*BM!/+WXTIIB8OL'Y?C
M%>/ S6AVG@=5T@1F'FXM"N0.O/D/WX7#X&>76]^2+/Y&9&=.#AHG!VWL\^-,
MS^J9SBIO-7HK<1:[K*PHP\!RFDUW-P]Z9E[L3CVZ*2KNBCI3==^HNN]4925\
M(!R/%5S5!W4KX) Q[5)548;AV4B"T?!"EC,L#*(+75?8)FYAPT;8L%78,^ Q
MP(%KDC+<<"3P!)1+3#O-7= ;!-^[-J9%)S!T ^-.X/!_P#,+1HT%HU:F):X!
M*I,-H3S%PV^'IWI9&$?,C$TDI$P['1DY$Q)>Y&UQ)6QRD5YW6#1VIW?<:!NW
M:OL=SQ3I&GP[["Z\EI5%)W!\)9T=0%RC[>F<-)(GK4R+#>5KP%V'J,.B);0L
MA33GL<FKRXZ)8].XR&-W2#QQYG R<.<P#([51M JZ3?!/Z(,NL(2 VN;Y)7@
MQEVP;>$L!()N+8>8R]EV?R&HG>M<S4GM%-Z8H!W-MU691',LI2GN/4Y%[7QW
MT;C7OS);NZ#]?F]T9;YV00>!XZOGED1'2Z)6LJ]"XU%22K%C]FJ -Y.38].]
M(=>4[7GNCHG;8RI!_DFI7(!<VRN'(HG8<EV5C$UO<ZUYM,7\1?^3N>[8$OQ(
M4]V5OE"Y9ER1'#*D#'HC/.]D=?VH&EJ4MB!?"8WEO7W<X)4-I G ]YD0^M P
M'V@N@?/_ %!+ P04    " !R@6E64W!?K=D&  #X-@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6R]FUUOVS84AO\*X15#"[2Q1?DCR1(#B:5B&9:A
M:-KMHM@%(QU;0B71HZ@X&?;C1TJ*9-HR'16GO4DLF><1>5[JB*\E76RX^)I'
M )(\IDF67PXB*=?GPV$>1)"R_(2O(5/?++E(F52;8C7,UP)86 :ER9".1M-A
MRN)L,+\H]WT0\PM>R"3.X(,@>9&F3#Q=0\(WEP-G\+SC8[R*I-XQG%^LV0KN
M0'Y>?Q!J:]A0PCB%+(]Y1@0L+P=7SKGO3G1 V>+/&#;YUF>BAW+/^5>]<1->
M#D:Z1Y! (#6"J7\/L( DT235CW]JZ* YI@[<_OQ,?U\.7@WFGN6PX,E?<2BC
MR\'I@(2P9$4B/_+-KU /J.Q@P).\_$LV5=L9'9"@R"5/ZV#5@S3.JO_LL4[$
M5L#8.1! ZP"Z$^",#P2X=8#[TH!Q'3!^:<"D#BB'/JS&7B;.8Y+-+P3?$*%;
M*YK^4&:_C%;YBC,]4>ZD4-_&*D[.;[* IT ^L4?(R3MR%8:Q%I EY":KIJ&6
M\[4'DL7)&]7B\YU'7K]Z0UZ1.".?(E[D+ OSBZ%4G='(85 ?^+HZ,#UP8(>2
M6Y[)*"=^%D)H H9J%,U0Z/-0KJF5Z$%P0ESG+:$C2CLZM'AYN-,1[KT\?-01
M[MO#?V/9"1F5X<ZI)1ENHZM;\MR7Z/KE=_4MN9&0YG]W*56AQMTH7:K.\S4+
MX'*@:E$.X@$&\Y]_<J:C7[JRC GS,&$^$LS08]SH,;;1M1ZJCN>@SYH'EA35
M><425:A9%D"7*A5P5@)UO7^8N^[92,VMA^UT[[>B$[K;RK-VKF\>D6!&'B=-
M'B?6/"XBEJW4E%9IY)L,1![%:\(?0) UB)B'78FT$UWR!$QT5;"%-;#O5,:$
M^4@P0X)I(\'4FK#/F8" K[+X7PB)9(_D'C)8QC(G,F)2+0R*)"1QJHXO"2R7
M4"X%RH:"R<Z9/MV;P[NSO&HQ.=S".\KPK:/ZQIS-FIS-K#F["@)1J'3%F01%
MET1=--6,5==9&:O9+"!1J5'9Y*0XE-VNQ,V.I65QM(4W.YHXZ]"^,7&G3>).
MK8GS8 E"U*E@>0XR?TL"MHXE2\H4Z4,R$40$'E4^\\[Y=;I?(YVQ.]Y)U7ZK
MW519N]KW%$:"&5D]:[)Z9LWJ;9S%:9&2+[>0WH/H7!18"7T7!9@P#Q/F(\$,
M&9Q1N_H>X2W3:A:2)*@T#Y7F8]%,5;8\D6-?9!1IH0JROFP%7>N-IHKS)<DC
M)B#B20B=:XCK^E!Z1&U=.9GLU!Y[AWJ+@4GSL6BF&+05@UK%^/A<X/4ETX,'
M2/@ZA4R2_\A"70.42<UBUIEY*[?WZ8))\U!I/A;-5*BUF@ZBUW10S28JS4.E
M^5@T4Y76<#IVQWE=Y&I/KDM7H$Z7YS6XLJ%AN5;GJGHMU7J*L!6+,U7,I-:O
M4[)]CSF;[1E1>W=Z2X'J6+%HIA2M9W7L%M-2PF[5FI8%4:&$Z%[BV]&]SQ=4
M2XM*\[%HIDBMJW6FB%4,R4S6JF#2/%2:CT4S56E]LV,WSHA5;-_H.I/]*H9D
M=FLI,&D^%LV4HG7BCMV*?VKS_I;XC^M85#]BZI_/.A-NQ]&1.^D\&3!=MH=*
M\[%HI@*M:W?LMOT]*)?!DLYDH]IU5)J'2O.Q:.8]IM:Q4T3'3E$=.RK-0Z7Y
M6#13E=:Q4[MC_T-= ?@:=$7*5B3AZH(1,"&>E#O<,-%]?[)&&C=8IF?[=UCL
MA^Z==E1OWC4&Y\S=&H.9T-9U4[OKWD\HO*SJ'^$>JOKVL-Y)1K776#13BM9>
M4ZM11%P"U0<RED#N='JV.^%1334JS<>BF5JTIIK:377?-= 1G#X;R#M"1^/N
M!Q90+34JS<>BF4*TEIK:+76]%%(.^I"Y[I0#U4RCTCQ4FH]%,^5IS31%--,4
MU4RCTCQ4FH]%,U5IS33]46::=IAI=_\W07M_>FN!ZJ:Q:*86K9NFN&[Z".[@
MN@K53:/2?"R:J4#KIJG=3=_) X^CV.-ZUR-4+XU*\[%HYB.*K9=V$;VTB^JE
M46D>*LW'HIFJM%[:Q??2[KX/'4\G4^KN7!#LA^Z==E0OC44ST]XZ;O<[.>XC
MW",>PQ[=6Q%4XXU%,Q79>H3:;KR_71$[]]"UVA[66PK<9Z>_A^]V6]_M_JB;
MV>[^S>PSU<W=.H7JO%%I/A;-E*)UWJ[=>?==N![!+:[.&QE#3C(N]9.<L8!;
M]<6QVH5JP%%I/A:M4FFX]89/"F)5OEJEKLN\R&3UADRSMWE]ZZI\:6EG_[5S
MOJA>PFHQU3MAMTRLU*E#$E@JY.ADI@8@JM>LJ@W)U^5[1/=<2IZ6'R-@(0C=
M0'V_Y%P^;^@#-"^[S?\'4$L#!!0    ( '*!:58;Q0HL'00  +8.   9
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MHJTJJK;0=B-1:2K:OJBB+^52U^OV>_N9;9VY*;-*?%&[^FJ>V7;<\L#VZP[
MJ=VZ*>M*AE&[8+K57-?5FXG=[NA=>PH!1BL%1OLGS-^6-%41B5,H-%I)-&K7
M:(WR=_ B?SM!-V#^?@*?0G^Q2G\QJZII\?.IF&B;\ #=W*-K=Z<IW4IDL6-%
MUAOKU0'< Q\8=NNFK"O]Q>PZZ=B/J0-PTXOS<H-$VQ+L&E\<BD2KBLS=NE%,
M0<[SBU9,3K'*].9RL>PM+W,O\BM,MQJ^N0F^YG*.&YPD,$-3[ZR'!ZO<7*YN
M&EHL\_O)>Z&U2//'!7 4>&8 OI\)H9\;9H+RBGO\/U!+ P04    " !R@6E6
M\9M OB<#  !Z"0  &0   'AL+W=O<FMS:&5E=',O<VAE970V."YX;6RM5EU/
MVS 4_2M60 BDC7PT31&TD5JR:3P@(0K;P[0'-[EM+1([LQT*^_6[=D+6CU"0
MQDMB.^<<WW-S_3%<"?F@E@":/!4Y5R-GJ75Y[KHJ74)!U:DH@>.7N9 %U=B5
M"U>5$FAF247N!IX7N05EW(F'=NQ&QD-1Z9QQN)%$545!Y?,$<K$:.;[S,G#+
M%DMM!MQX6-(%3$'?ES<2>VZKDK$"N&*"$PGSD3/VSY.!P5O =P8KM=8FQLE,
MB ?3N<I&CF<"@AQ2;10HOA[A$O+<"&$8OQM-IYW2$-?;+^I?K7?T,J,*+D7^
M@V5Z.7+.')+!G%:YOA6K;]#XZ1N]5.3*/LFJP7H.22NE1=&0,8*"\?I-GYH\
MK!'\Z!5"T!"";4+X"J'7$'KO)80-(;29J:W8/"14TW@HQ8I(@T8UT[#)M&RT
MS[CY[5,M\2M#GHZO>"H*('?T"13Y3*985EF5 Q%S,C:_A.EG<@LYU9"1>RXA
M%0O._F '&60"'.9,*W*<@*8L/T&%^VE"C@]/R"%AG-PM1:4HS]30U1BLF=)-
MF\ F=6#!*X'Y ;D67"\5^<(SR#8%7'396@U>K$Z"O8H)I*>DYW\B@1<$'0%=
MOI_N=]"3]].]/6YZ[8_K6;W>FS^.)$REN5"5!/)S/%-:XF+ZU97Q6C'L5C0;
MS+DJ:0HC!W<0!?(1G/CHP(^\BZYL?:18\D%B&YD,VTR&^]3C"2P8YXPO3-$_
M Y5'!V>!'UQ4Z^6N,<^SIMR[4EM/,;!3F*WV,>Z'9U@FC^LIVP6%7M#?!"6[
MH"#RO1:T8;'?6NSOM8C%AV>" H+GA+52"L7,OJNP]P"<9)4T"2@E0T )^.I>
ML_4T_;7@O"V/;R*2?8@-=U'K+MKK#I>"=:?>LI=64@+7C<$N?]%.;'[0"[<L
M=H#"?K3EL@OD][N-#EJC@[U&<2?\GQH=[%16-/"WRN]R%[1;R,DN:*.0:W/N
MVJE4@%S8TUV15%1<U[MV.]I>(,;VW-P:G^#%HKX'_).I;R775.+:522'.4IZ
MIP/,MZQ/^KJC16G/OIG0>)+:YA(O1R - +_/A= O'3-!>]V*_P)02P,$%
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M)4O*5 'Y^ZHHQ,N)JJ#9WCG[#U!+ P04    " !R@6E6E!C8#Y\#   W#P
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MF&/F6*X)5XC"RD &K8%I.5G,!L5&B\P]KTNAS6/MEJD9IT!: W._$D+O-C9
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ <H%I5L D7CJ\"   ^C4  !@              ("!# @  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( '*!:59*-8JWGP8  ( <   8
M              " @?X0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !R@6E6J(,Z#. "  #E"0  &               @('3%P  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ <H%I5A3S!;-:!0
M/1<  !@              ("!Z1H  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( '*!:5;=-A%']0T  ,^N   8              " @7D@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !R@6E6H7=7
M,V$#  "Q#0  &               @(&D+@  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ <H%I5J8^$;?-"@  G3P  !@
M ("!.S(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( '*!
M:58^_]!RM04  .T,   8              " @3X]  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !R@6E60*>.K<(H  !2@@  &
M        @($I0P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ <H%I5F1EBRU:!@  01$  !D              ("!(6P  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !R@6E65<SM-?\%   <$
M&0              @(&R<@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( '*!:5;N(:MN.@,  #('   9              " @>AX  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ <H%I5N\IFJ>@
M#@  42X  !D              ("!67P  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !R@6E6/,?6(/@B  #6A@  &0
M@($PBP  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( '*!
M:5;+<M2WW @  $$6   9              " @5^N  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ <H%I5I+1. UG P  "0@  !D
M         ("!<K<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !R@6E6[E=WQW$+  #,+@  &0              @($0NP  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( '*!:5;Y<]IFM0T  ' H
M   9              " @;C&  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ <H%I5CNF8DB7#   >R0  !D              ("!I-0
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !R@6E6O!DI
MD)$%  !P#0  &0              @(%RX0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( '*!:5:>*M98 0,  +<&   9
M  " @3KG  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M<H%I5H&S1/OP*0  PXL  !D              ("!<NH  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !R@6E65(3+F,L#  "@"   &0
M            @(&9% $ >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( '*!:5:,4(C=700   P,   9              " @9L8 0!X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ <H%I5MH/\<-9!
M3@P  !D              ("!+QT! 'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !R@6E66E:FCPT#  "?!@  &0              @(&_
M(0$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( '*!:59>
MD=[MR@0  ,@+   9              " @0,E 0!X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ <H%I5H][)Z\)!   CA$  !D
M     ("!!"H! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '*!:5:Q]G']$08  *8/   9              "
M@7,^ 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ <H%I
M5H8-"FC> P  H@@  !D              ("!NT0! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !R@6E6:VQ:FF@#  #^"@  &0
M        @('02 $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( '*!:580-OSYCP0  +X7   9              " @6], 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ <H%I5J9S1XB[ @  90<
M !D              ("!-5$! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !R@6E6#9#]<YT#  #7$   &0              @($G5 $
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( '*!:5:_G5N,
M< D  "!,   9              " @?M7 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ <H%I5KM([\3] P  U!   !D
M ("!HF$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !R
M@6E6X+.O@1,/   DNP  &0              @('690$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( '*!:58-ZO,%9P(  -P%   9
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M970T-BYX;6Q02P$"% ,4    " !R@6E6X.$]/<$#  #O#0  &0
M    @($_D0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M '*!:5:0V?CHGP,   H.   9              " @3>5 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ <H%I5M/O1@F4*@  \?@" !D
M             ("!#9D! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !R@6E6M8G=]X $  !?%@  &0              @('8PP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( '*!:58? Q!O#PD
M .Q.   9              " @8_( 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ <H%I5L928C5X @  M04  !D              ("!
MU=$! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !R@6E6
M+PM<56D"  !5!@  &0              @(&$U $ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( '*!:5:)\;?22 ,  .D)   9
M      " @237 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ <H%I5OV%6;K7 @  8@<  !D              ("!H]H! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !R@6E6K\IQ!DT1  !-\@
M&0              @(&QW0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( '*!:58#DOM^P@,  +X0   9              " @37O 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ <H%I5DA\#+P[
M"P  ,G$  !D              ("!+O,! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " !R@6E6SWW>13,#  #A"0  &0
M@(&@_@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( '*!
M:5;$!Z=)7@,   8*   9              " @0H" @!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ <H%I5H[ -L64!0  U1P  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( '*!:58;Q0HL'00  +8.   9
M  " @?X= @!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
M<H%I5NZ*&)9/!   [A8  !D              ("!4B(" 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " !R@6E6\9M OB<#  !Z"0  &0
M            @('8)@( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( '*!:5;#EPHJ6 ,  *H+   9              " @38J @!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ <H%I5A2I9>EX!0
MZBD  !D              ("!Q2T" 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " !R@6E6E!C8#Y\#   W#P  &0              @(%T
M,P( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( '*!:5:H
MWY[P[0(  *P)   9              " @4HW @!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ <H%I5GO\@H-% P  S!0   T
M     ( !;CH" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !R@6E6EXJ[',
M   3 @  "P              @ '>/0( 7W)E;',O+G)E;'-02P$"% ,4
M" !R@6E6)I=^%%0%  #G+P  #P              @ ''/@( >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ <H%I5JQM4%<\ @  KRH  !H
M ( !2$0" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M<H%I5D!K%[H  @  QBD  !,              ( !O$8" %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     %  4 #G%0  [4@"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>408</ContextCount>
  <ElementCount>444</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>99</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganization1</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Debt - Schedule of Long term debt balance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails</Role>
      <ShortName>Debt - Schedule of Long term debt balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Debt - Schedule of estimated future principal payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails</Role>
      <ShortName>Debt - Schedule of estimated future principal payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail</Role>
      <ShortName>Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Common Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail</Role>
      <ShortName>Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="grts-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Defined Contribution Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, grts:RevenueRecognitionContractEndPeriod, us-gaap:OperationsCommencedDate1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  grts-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="grts-20221231.htm">grts-20221231.htm</File>
    <File>grts-20221231.xsd</File>
    <File>grts-20221231_cal.xml</File>
    <File>grts-20221231_def.xml</File>
    <File>grts-20221231_lab.xml</File>
    <File>grts-20221231_pre.xml</File>
    <File>grts-ex10_22.htm</File>
    <File>grts-ex23_1.htm</File>
    <File>grts-ex31_1.htm</File>
    <File>grts-ex31_2.htm</File>
    <File>grts-ex32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img97084416_0.jpg</File>
    <File>img97084416_1.jpg</File>
    <File>img97084416_2.jpg</File>
    <File>img97084416_3.jpg</File>
    <File>img97084416_4.jpg</File>
    <File>img97084416_5.jpg</File>
    <File>img97084416_6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1015">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "grts-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1015,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 408,
   "dts": {
    "calculationLink": {
     "local": [
      "grts-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "grts-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "grts-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "grts-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "grts-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "grts-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 755,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://gritstonebio.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 9
   },
   "keyCustom": 119,
   "keyStandard": 325,
   "memberCustom": 60,
   "memberStandard": 39,
   "nsprefix": "grts",
   "nsuri": "http://gritstonebio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Cash Equivalents and Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Net Loss Per Common Share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Defined Contribution Plan",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_5b788e7f-503c-41d5-8242-fb6f0cb19d92",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Collaboration and License Agreements (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables",
     "shortName": "Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_5b788e7f-503c-41d5-8242-fb6f0cb19d92",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Net Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Organization - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfInvestments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_f2b95b5c-aee8-40eb-8cee-80a189dab5a4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_f2b95b5c-aee8-40eb-8cee-80a189dab5a4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "grts:CashAndCashEquivalentsAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "grts:CashAndCashEquivalentsAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_3295931d-4cf6-4ed7-9b11-e42a2fb87408",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_3295931d-4cf6-4ed7-9b11-e42a2fb87408",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "grts:FairValueMeasurementLevel1ToLevel2Transfers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "grts:FairValueMeasurementLevel1ToLevel2Transfers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_3e931d49-353d-46c5-813c-21ac6372c768",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail",
     "shortName": "Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail",
     "shortName": "Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_7252815e-38c6-46dc-8937-24c805d8b308",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_aadfb6b4-e055-4e7e-82da-133de3937dc4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
     "shortName": "Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_aadfb6b4-e055-4e7e-82da-133de3937dc4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Debt (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_6d3577c4-db17-46ad-8f60-2c0eb8ff2efa",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Debt - Schedule of Long term debt balance (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails",
     "shortName": "Debt - Schedule of Long term debt balance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "lang": null,
      "name": "grts:FinalFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Debt - Schedule of estimated future principal payments (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails",
     "shortName": "Debt - Schedule of estimated future principal payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "grts:PrepaidExpenseForResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "grts:PrepaidExpenseForResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "lang": null,
      "name": "grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
     "shortName": "Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_a246cd21-ac7d-4072-88f9-4cb7c5a9e332",
      "decimals": null,
      "lang": "en-US",
      "name": "grts:ClassOfWarrantOrRightIssueDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_70694a1e-9f63-4f26-821a-bb4205582c79",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
     "shortName": "Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_70694a1e-9f63-4f26-821a-bb4205582c79",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_2ec37033-06d8-4931-9ffc-894e1d473c78",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_2ec37033-06d8-4931-9ffc-894e1d473c78",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail",
     "shortName": "Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_6bdbd2dd-450c-4a25-b735-2e8f4b8fd25e",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Detail)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Stock Options Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail",
     "shortName": "Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_b769ed8e-6840-43c9-abce-2f0b38c64a46",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_0147e0c5-b128-4b28-ab85-a4f52bbc6baa",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail",
     "shortName": "Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_afcbe2f3-7dd3-4f15-8cd0-c1d773ae4308",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_272dd00e-a656-48f0-b0cd-e1d7138f9bb1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_e08658ca-f8cb-47e3-8939-dd5d4c08e9fc",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
     "shortName": "Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "grts:ClassOfWarrantOrRightWarrantsExercised",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
     "shortName": "Net Loss Per Common Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_c3371e94-abb3-4b37-894a-d4cc941cf1f3",
      "decimals": "2",
      "lang": null,
      "name": "grts:ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail",
     "shortName": "Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Defined Contribution Plan - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
     "shortName": "Defined Contribution Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganization1",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20221231.htm",
      "contextRef": "C_9cbbe066-7e05-4445-a3b6-4ad618f88f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 99,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "grts_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid for research and development activities due within one year or the normal operating cycle, if longer.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AdditionalFunding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding.",
        "label": "Additional Funding",
        "terseLabel": "Additional funding"
       }
      }
     },
     "localname": "AdditionalFunding",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AdditionalOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Office Space",
        "label": "Additional Office Space [Member]",
        "terseLabel": "Additional Office Space [Member]"
       }
      }
     },
     "localname": "AdditionalOfficeSpaceMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_AdditionalSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Shares [Member]",
        "label": "Additional Shares [Member]"
       }
      }
     },
     "localname": "AdditionalSharesMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_AdjustmentToRightOfUseAssetsAndLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to Right-Of-Use Assets and Lease Liability .",
        "label": "Adjustment To Right Of Use Assets And Lease Liability",
        "terseLabel": "Adjustment to right-of-use assets and lease liability"
       }
      }
     },
     "localname": "AdjustmentToRightOfUseAssetsAndLeaseLiability",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital offering costs related to sale of common stock and pre funded warrants.",
        "label": "Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants",
        "terseLabel": "Offering costs related to the sale of common stock and pre-funded warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate payment in specified development regulatory and commercial milestone.",
        "label": "Aggregate Payment In Specified Development Regulatory And Commercial Milestone",
        "verboseLabel": "Aggregate payment in specified development regulatory and commercial milestone"
       }
      }
     },
     "localname": "AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AgreedUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed upfront payment.",
        "label": "Agreed Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "AgreedUpfrontPayment",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AgreementTotalFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement total funding.",
        "label": "Agreement Total Funding",
        "terseLabel": "Agreement total funding"
       }
      }
     },
     "localname": "AgreementTotalFunding",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AmendedAndRestatedCertificateOfIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated Certificate Of Incorporation [Member]",
        "label": "Amended And Restated Certificate Of Incorporation [Member]",
        "terseLabel": "Amended and Restated Certificate of Incorporation [Member]"
       }
      }
     },
     "localname": "AmendedAndRestatedCertificateOfIncorporationMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_AmendedTotalGrantAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Total Grant Amount",
        "label": "Amended Total Grant Amount",
        "terseLabel": "Amended total grant amount"
       }
      }
     },
     "localname": "AmendedTotalGrantAmount",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AmountOfIrrevocableLettersOfCreditWithdrawn": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of irrevocable letters of credit withdrawn.",
        "label": "Amount Of Irrevocable Letters Of Credit Withdrawn",
        "terseLabel": "Withdrawal from irrevocable letters of credit"
       }
      }
     },
     "localname": "AmountOfIrrevocableLettersOfCreditWithdrawn",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AmountToExtendOptionTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to extend option term.",
        "label": "Amount To Extend Option Term",
        "terseLabel": "Amount to extend the option term"
       }
      }
     },
     "localname": "AmountToExtendOptionTerm",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AnnualBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual base rent.",
        "label": "Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "localname": "AnnualBaseRent",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc.",
        "label": "Arbutus Biopharma Corporation And Protiva Biotherapeutics Inc [Member]",
        "terseLabel": "Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc [Member]"
       }
      }
     },
     "localname": "ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_AtTheMarketEquityOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market equity offering program member.",
        "label": "At The Market Equity Offering Program [Member]",
        "terseLabel": "ATM Equity Offering Program [Member]",
        "verboseLabel": "ATM Equity Offering Program [Member]"
       }
      }
     },
     "localname": "AtTheMarketEquityOfferingProgramMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_AtmEquityOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 ATM Equity Offering Program [Member]",
        "label": "2022 ATM Equity Offering Program [Member]"
       }
      }
     },
     "localname": "AtmEquityOfferingProgramMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_BlueBirdBioTo2SeventyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Bird Bio to 2seventy.",
        "label": "Blue Bird Bio to 2seventy [Member]",
        "verboseLabel": "Bluebird bio to 2seventy [Member]"
       }
      }
     },
     "localname": "BlueBirdBioTo2SeventyMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_BluebirdBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bluebird Bio Inc.",
        "label": "Bluebird Bio Inc [Member]",
        "terseLabel": "Bluebird Bio Inc [Member]"
       }
      }
     },
     "localname": "BluebirdBioIncMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_BostonLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston Lease [Member]",
        "label": "Boston Lease [Member]",
        "terseLabel": "Boston Lease [Member]"
       }
      }
     },
     "localname": "BostonLeaseMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CEPIFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CEPI funding agreement.",
        "label": "C E P I Funding Agreement [Member]",
        "terseLabel": "C E P I Funding Agreement [Member]"
       }
      }
     },
     "localname": "CEPIFundingAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge Massachusetts [Member]",
        "label": "Cambridge Massachusetts [Member]",
        "terseLabel": "Cambridge Massachusetts [Member]",
        "verboseLabel": "Cambridge Massachusetts [Member]"
       }
      }
     },
     "localname": "CambridgeMassachusettsMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CashAndCashEquivalentsAndMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and marketable securities.",
        "label": "Cash And Cash Equivalents And Marketable Securities",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndMarketableSecurities",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashAndCashEquivalentsUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents, unrealized gains.",
        "label": "Cash And Cash Equivalents Unrealized Gains",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrealizedGains",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashAndCashEquivalentsUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents unrealized losses.",
        "label": "Cash And Cash Equivalents Unrealized Losses",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrealizedLosses",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashCashEquivalentsAndMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale debt securities accumulated gross unrealized gain before tax.",
        "label": "Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale debt securities accumulated gross unrealized loss before tax.",
        "label": "Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale debt securities amortized cost basis.",
        "label": "Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities debt securities.",
        "label": "Cash Equivalents And Available For Sale Securities Debt Securities",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities [Abstract]"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "nsuri": "http://gritstonebio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "grts_CashEquivalentsAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities [Line Items]",
        "terseLabel": "Cash equivalents and marketable securities [Line Items]"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesLineItems",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CashEquivalentsAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities [Table]",
        "terseLabel": "Cash Equivalents And Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesTable",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CepInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Cep Innovations [Member]",
        "verboseLabel": "CEPI [Member]"
       }
      }
     },
     "localname": "CepInnovationsMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ClassOfWarrantOrRightIssueDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, issue date.",
        "label": "Class Of Warrant Or Right Issue Date",
        "terseLabel": "Issue Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssueDate",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right nominal exercise price of warrants or rights.",
        "label": "Class Of Warrant Or Right Nominal Exercise Price Of Warrants Or Rights",
        "terseLabel": "Warrant nominal exercise price",
        "verboseLabel": "Class of warrant nominal exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "grts_ClassOfWarrantOrRightWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right warrants exercised",
        "label": "Class Of Warrant Or Right Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_ClassOfWarrantOrRightsExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights expiration.",
        "label": "Class Of Warrant Or Rights Expiration",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsExpiration",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CoalitionForEpidemicPreparednessInnovationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovation",
        "label": "Coalition for Epidemic Preparedness Innovation [Member]",
        "terseLabel": "Coalition For Epidemic Preparedness Innovation [Member]",
        "verboseLabel": "CEPI [Member]"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CollaborationAgreementEarlyTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement early termination notice period.",
        "label": "Collaboration Agreement Early Termination Notice Period",
        "terseLabel": "Collaboration agreement early termination notice period"
       }
      }
     },
     "localname": "CollaborationAgreementEarlyTerminationNoticePeriod",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement [Member]",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CollaborationAgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement termination term.",
        "label": "Collaboration Agreement Termination Term",
        "terseLabel": "Collaboration agreement termination term"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationTerm",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CollaborationOptionAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, option and license agreement.",
        "label": "Collaboration Option And License Agreement [Member]",
        "terseLabel": "Collaboration, Option and License Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationOptionAndLicenseAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CollaborationReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration receivable.",
        "label": "Collaboration Receivable",
        "terseLabel": "Collaboration receivable"
       }
      }
     },
     "localname": "CollaborationReceivable",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue member.",
        "label": "Collaboration Revenue [Member]"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CollaborativeAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and license agreements.",
        "label": "Collaborative And License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeAndLicenseAgreementsAbstract",
     "nsuri": "http://gritstonebio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "grts_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Line Items]",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments and Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Table]",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CommonStockAndOrPreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and/or pre-funded warrants.",
        "label": "Common Stock And Or Pre Funded Warrants [Member]",
        "terseLabel": "Common Stock and Pre-funded Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockAndOrPreFundedWarrantsMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CommonStockAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and warrants.",
        "label": "Common Stock And Warrants [Member]",
        "terseLabel": "Common Stock and Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockAndWarrantsMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CommonStockFairValueClosingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock fair value closing price per share.",
        "label": "Common Stock Fair Value Closing Price Per Share",
        "terseLabel": "Common stock fair value closing price per share"
       }
      }
     },
     "localname": "CommonStockFairValueClosingPricePerShare",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "grts_CommonStockPurchasePriceInExcessOfFairValue1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Purchase Price In Excess Of Fair Value1",
        "label": "Common Stock Purchase Price In Excess Of Fair Value1",
        "terseLabel": "Common stock purchase price in excess of fair value"
       }
      }
     },
     "localname": "CommonStockPurchasePriceInExcessOfFairValue1",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CommonStockWarrantsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants One [Member]",
        "label": "Common Stock Warrants One [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsOneMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CommonStockWarrantsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants Two [Member]",
        "label": "Common Stock Warrants Two [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsTwoMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software [Member]",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software [Member]",
        "verboseLabel": "Computer Equipment and Software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ContractResearchOrganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Research Organization.",
        "label": "Contract Research Organization [Member]",
        "terseLabel": "Contract Research Organization [Member]"
       }
      }
     },
     "localname": "ContractResearchOrganizationMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ContractWithCustomerAssetAddition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer asset addition.",
        "label": "Contract With Customer Asset Addition",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAddition",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContractWithCustomerAssetDeduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer asset deduction.",
        "label": "Contract With Customer Asset Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeduction",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContractWithCustomerLiabilityAddition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability addition.",
        "label": "Contract With Customer Liability Addition",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAddition",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContractWithCustomerLiabilityDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability deductions.",
        "label": "Contract With Customer Liability Deductions",
        "terseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductions",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability revenue recognized including new contracts in period.",
        "label": "Contract With Customer Liability Revenue Recognized Including New Contracts In Period",
        "terseLabel": "Collaboration and license revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContributionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution.",
        "label": "Contribution [Member]",
        "terseLabel": "Contribution revenues [Member]"
       }
      }
     },
     "localname": "ContributionMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CumulativeChangesInOwnershipInterestOfShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative changes in ownership interest of shareholders.",
        "label": "Cumulative Changes In Ownership Interest Of Shareholders",
        "terseLabel": "Cumulative changes in ownership interest of shareholders"
       }
      }
     },
     "localname": "CumulativeChangesInOwnershipInterestOfShareholders",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_DebtInstrumentInterestPaymentExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Payment, Extension Period",
        "label": "Debt Instrument, Interest Payment, Extension Period",
        "terseLabel": "Debt instrument, Interest payment, Extension period"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentExtensionPeriod",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_DeferredContractAcquisitionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred contract acquisition costs.",
        "label": "Deferred Contract Acquisition Costs",
        "terseLabel": "Deferred contract acquisition costs"
       }
      }
     },
     "localname": "DeferredContractAcquisitionCosts",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredContractAcquisitionCostsAmortized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred contract acquisition costs amortized.",
        "label": "Deferred Contract Acquisition Costs Amortized",
        "terseLabel": "Deferred contract acquisition costs, amortized"
       }
      }
     },
     "localname": "DeferredContractAcquisitionCostsAmortized",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxAssetsAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, amortization.",
        "label": "Deferred Tax Assets Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortization",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxAssetsCapitalizedExpense": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Capitalized Expense",
        "label": "Deferred Tax Assets, Capitalized Expense",
        "terseLabel": "Section 174 Capitalized Expense",
        "verboseLabel": "Deferred tax assets, capitalized research expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedExpense",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxAssetsOtherDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Other Depreciation",
        "label": "Deferred Tax Assets, Other Depreciation",
        "terseLabel": "Other depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherDepreciation",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating lease right of uset assets.",
        "label": "Deferred Tax Liabilities Operating Lease Right Of Uset Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxLiabilitiesOtherDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, other depreciation.",
        "label": "Deferred Tax Liabilities Other Depreciation",
        "negatedLabel": "Other depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOtherDepreciation",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit assets and other assets noncurrent.",
        "label": "Deposit Assets And Other Assets Noncurrent Disclosure [Abstract]"
       }
      }
     },
     "localname": "DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract",
     "nsuri": "http://gritstonebio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "grts_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Deposits And Other Assets.",
        "label": "Deposits And Other Assets Noncurrent",
        "terseLabel": "Deposits and other long-term assets",
        "totalLabel": "Total deposits and other long-term assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of New Accounting Pronouncements Not Yet Adopted 1",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted1",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of need for additional capital.",
        "label": "Disclosure Of Need For Additional Capital Policy [Text Block]",
        "terseLabel": "Need for Additional Capital"
       }
      }
     },
     "localname": "DisclosureOfNeedForAdditionalCapitalPolicyTextBlock",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_EarlyExercisedCommonStockSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercised common stock subject to future vesting.",
        "label": "Early Exercised Common Stock Subject To Future Vesting [Member]",
        "terseLabel": "Early Exercised Common Stock Subject To Future Vesting [Member]"
       }
      }
     },
     "localname": "EarlyExercisedCommonStockSubjectToFutureVestingMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early termination reduction of future milestone and royalty payments.",
        "label": "Early Termination Reduction Of Future Milestone And Royalty Payments",
        "terseLabel": "Early termination reduction of future milestone and royalty payments, description"
       }
      }
     },
     "localname": "EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent income tax rate differential.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_EmeryvilleCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emeryville California.",
        "label": "Emeryville California [Member]",
        "terseLabel": "Emeryville California [Member]"
       }
      }
     },
     "localname": "EmeryvilleCaliforniaMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_EmployeeOrDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee or Director.",
        "label": "Employee Or Director [Member]",
        "terseLabel": "Employee or Director [Member]"
       }
      }
     },
     "localname": "EmployeeOrDirectorMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_EsppEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "ESPP Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EsppEmployeeStockPurchasePlanMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_FacilitiesRelatedDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities-related deposits",
        "label": "Facilities-related deposits",
        "terseLabel": "Faclities-related deposits"
       }
      }
     },
     "localname": "FacilitiesRelatedDeposits",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FacilityChargePercentageOfBorrowing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Charge Percentage of Borrowing",
        "label": "Facility Charge Percentage of Borrowing",
        "terseLabel": "Facility Charge Percentage of Borrowing"
       }
      }
     },
     "localname": "FacilityChargePercentageOfBorrowing",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_FairValueMeasurementLevel1ToLevel2Transfers": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement level 1 to level 2 transfers.",
        "label": "Fair Value Measurement Level 1 to Level 2 Transfers",
        "terseLabel": "Fair Value Measurement Level 1 to Level 2 Transfers"
       }
      }
     },
     "localname": "FairValueMeasurementLevel1ToLevel2Transfers",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FinalFee": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Final Fee",
        "terseLabel": "Final Fee"
       }
      }
     },
     "localname": "FinalFee",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FinalPaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final payment fee percentage.",
        "label": "Final Payment Fee Percentage",
        "terseLabel": "Final payment fee percentage"
       }
      }
     },
     "localname": "FinalPaymentFeePercentage",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_FirstTrancheOfFundingsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Tranche of Fundings Received",
        "label": "First Tranche of Fundings Received",
        "terseLabel": "First tranche of funding received"
       }
      }
     },
     "localname": "FirstTrancheOfFundingsReceived",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-on Public Offering [Member]"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_FourtyErieLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "fourty Erie Lease [Member]",
        "label": "fourty Erie Lease [Member]",
        "terseLabel": "40 Erie Lease [Member]"
       }
      }
     },
     "localname": "FourtyErieLeaseMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_FundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Agreement.",
        "label": "Funding Agreement [Member]"
       }
      }
     },
     "localname": "FundingAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_FundingDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding development costs.",
        "label": "Funding Development Costs",
        "verboseLabel": "Funding development costs"
       }
      }
     },
     "localname": "FundingDevelopmentCosts",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FutureFundingExpected": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funding expected in future.",
        "label": "Future Funding Expected",
        "terseLabel": "Future funding expected"
       }
      }
     },
     "localname": "FutureFundingExpected",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Milestone And Royalty Payments, Reduction Percentage",
        "label": "Future Milestone And Royalty Payments, Reduction Percentage",
        "terseLabel": "Future Milestone And Royalty Payments, Reduction Percentage"
       }
      }
     },
     "localname": "FutureMilestoneAndRoyaltyPaymentsReductionPercentage",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_GatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gates Foundation Member.",
        "label": "Gates Foundation [Member]"
       }
      }
     },
     "localname": "GatesFoundationMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_GenevantSciencesGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genevant Sciences GmbH.",
        "label": "Genevant Sciences Gmb H [Member]",
        "terseLabel": "Genevant Sciences GmbH [Member]",
        "verboseLabel": "Genevant [Member]"
       }
      }
     },
     "localname": "GenevantSciencesGmbHMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_GileadSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences, Inc.",
        "label": "Gilead Sciences Inc [Member]",
        "terseLabel": "Gilead [Member]"
       }
      }
     },
     "localname": "GileadSciencesIncMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_GrantAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Agreement.",
        "label": "Grant Agreement [Member]",
        "terseLabel": "Grant Agreement [Member]"
       }
      }
     },
     "localname": "GrantAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued research and development expenses.",
        "label": "Increase Decrease In Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deposit and other assets noncurrent.",
        "label": "Increase Decrease In Deposit And Other Assets Noncurrent",
        "negatedLabel": "Deposits and other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositAndOtherAssetsNoncurrent",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in lease liability.",
        "label": "Increase Decrease In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right-of-use assets.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseInSharesAvailableForIssuancePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in shares available for issuance percentage.",
        "label": "Increase In Shares Available For Issuance Percentage",
        "terseLabel": "Increase in shares available for issuance"
       }
      }
     },
     "localname": "IncreaseInSharesAvailableForIssuancePercentage",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_InitialFundingDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial funding development costs.",
        "label": "Initial funding development costs"
       }
      }
     },
     "localname": "InitialFundingDevelopmentCosts",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_InterestAndOtherReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and other receivables current.",
        "label": "Interest And Other Receivables Current",
        "terseLabel": "Interest and other receivables"
       }
      }
     },
     "localname": "InterestAndOtherReceivablesCurrent",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IssuanceOfCommonStockForWarrantExercisesShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for warrant exercises, Share",
        "label": "Issuance of common stock for warrant exercises, Share",
        "terseLabel": "Issuance of common stock for warrant exercises, Share",
        "verboseLabel": "Issuance of common stock upon exercise of warrants, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForWarrantExercisesShare",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_IssuanceOfCommonStockForWarrantExercisesValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for warrant exercises, Value",
        "label": "Issuance of common stock for warrant exercises, Value",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForWarrantExercisesValue",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon restricted stock units vesting, net of shares withheld, Shares",
        "label": "Issuance of common stock upon restricted stock units vesting, net of shares withheld, Shares",
        "terseLabel": "Issuance of common stock upon restricted stock units vesting, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUponRestrictedStockUnitsVestingNetOfSharesWithheldShares",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_IssuanceOfConvertiblePreferredStockTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of convertible preferred stock, Transaction price",
        "label": "Issuance of convertible preferred stock, Transaction price",
        "terseLabel": "Issuance of convertible preferred stock, Transaction price"
       }
      }
     },
     "localname": "IssuanceOfConvertiblePreferredStockTransactionPrice",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]",
        "verboseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lapse of repurchase rights related to common stock issued pursuant to early exercises.",
        "label": "Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises"
       }
      }
     },
     "localname": "LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares.",
        "label": "Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises Shares",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares"
       }
      }
     },
     "localname": "LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_LeaseExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration term",
        "label": "Lease expiration term"
       }
      }
     },
     "localname": "LeaseExpirationTerm",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee leasing arrangements operating leases additional number of renewal terms.",
        "label": "Lessee Leasing Arrangements Operating Leases Additional Number Of Renewal Terms",
        "terseLabel": "Operating leases number of renewal terms"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee leasing arrangements operating leases term of contract month and year.",
        "label": "Lessee Leasing Arrangements Operating Leases Term Of Contract Month And Year",
        "terseLabel": "Operating lease termination date"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_LessorOperatingLeaseNoticePeriodToTerminate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents operating lease notice period to terminate for the additional temporary space.",
        "label": "Lessor Operating Lease Notice Period To Terminate",
        "terseLabel": "Temporary space lease termination notice period"
       }
      }
     },
     "localname": "LessorOperatingLeaseNoticePeriodToTerminate",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement [Member] for loan and security agreement",
        "label": "Loan Agreement [Member]"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities [Member]"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_MarketableSecuritiesContractualMaturitiesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities contractual maturities period.",
        "label": "Marketable Securities Contractual Maturities Period",
        "terseLabel": "Marketable securities contractual maturities period"
       }
      }
     },
     "localname": "MarketableSecuritiesContractualMaturitiesPeriod",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_MarketableSecuritiesRealizedGainLossDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities realized gain loss.",
        "label": "Marketable Securities Realized Gain Loss Description",
        "terseLabel": "Realized gains or losses on marketable securities, description"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLossDescription",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_MaximumAggregateContingentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate contingent milestone payment.",
        "label": "Maximum Aggregate Contingent Milestone Payment",
        "terseLabel": "Maximum aggregate contingent milestone payment"
       }
      }
     },
     "localname": "MaximumAggregateContingentMilestonePayment",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumAggregateContingentMilestonePaymentToBeMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate contingent milestone payment to be made.",
        "label": "Maximum Aggregate Contingent Milestone Payment To Be Made",
        "terseLabel": "Maximum aggregate contingent milestone payments to be made by company"
       }
      }
     },
     "localname": "MaximumAggregateContingentMilestonePaymentToBeMade",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumMilestoneConsiderationPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum consideration to be paid in the future based on milestones per the License Agreement.",
        "label": "Maximum Milestone Consideration Payable",
        "terseLabel": "Maximum milestone consideration payable"
       }
      }
     },
     "localname": "MaximumMilestoneConsiderationPayable",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumMilestonePaymentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum amount to be paid upon achievement of certain milestones as defined under the research and development agreement.",
        "label": "Maximum Milestone Payment Obligation",
        "terseLabel": "Maximum milestone payments"
       }
      }
     },
     "localname": "MaximumMilestonePaymentObligation",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumOfferingExpensesAgreedToBeReimbursed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum offering expenses agreed to be reimbursed.",
        "label": "Maximum Offering Expenses Agreed To Be Reimbursed",
        "terseLabel": "Maximum offering expense agreed to be reimbursed"
       }
      }
     },
     "localname": "MaximumOfferingExpensesAgreedToBeReimbursed",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of common stock ownership to exercise warrant.",
        "label": "Maximum Percentage Of Common Stock Ownership To Exercise Warrant",
        "terseLabel": "Maximum percentage of common stock ownership to exercise warrant"
       }
      }
     },
     "localname": "MaximumPercentageOfCommonStockOwnershipToExerciseWarrant",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_MaximumPotentialMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration relating to future milestones.",
        "label": "Maximum Potential Milestone Receivable",
        "terseLabel": "Maximum development, regulatory, and commercial milestones"
       }
      }
     },
     "localname": "MaximumPotentialMilestoneReceivable",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumSecuritiesCoveredUnderRegistrationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum securities covered under registration agreement.",
        "label": "Maximum Securities Covered Under Registration Agreement",
        "terseLabel": "Common stock, preferred stock, debt securities, warrants and units covered in Registration Statement"
       }
      }
     },
     "localname": "MaximumSecuritiesCoveredUnderRegistrationAgreement",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment included in research and development expense.",
        "label": "Milestone Payment Included In Research And Development Expense",
        "terseLabel": "Milestone payment included in research and development expense"
       }
      }
     },
     "localname": "MilestonePaymentIncludedInResearchAndDevelopmentExpense",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of taxable income where use of net operating losses is suspended.",
        "label": "Minimum Amount Of Taxable Income Where Use Of Net Operating Losses Suspended",
        "terseLabel": "Minimum amount of taxable income where use of net operating losses is suspended"
       }
      }
     },
     "localname": "MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MinimumLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Lease Payments.",
        "label": "Minimum Lease Payments",
        "terseLabel": "Minimum Lease Payments"
       }
      }
     },
     "localname": "MinimumLeasePayments",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MinimumLiquidityRequirementCapitalDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Liquidity Requirement Capital Description",
        "label": "Minimum Liquidity Requirement Capital Description",
        "terseLabel": "Minimum Liquidity Requirement Capital Description"
       }
      }
     },
     "localname": "MinimumLiquidityRequirementCapitalDescription",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_MinimumPercentageFairMarketValueOfSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage fair market value of share price.",
        "label": "Minimum Percentage Fair Market Value Of Share Price",
        "terseLabel": "Minimum percentage fair market value of share price"
       }
      }
     },
     "localname": "MinimumPercentageFairMarketValueOfSharePrice",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_MinimumPercentageOfOutstandingSharesHeldByIndividual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of outstanding shares held by individual.",
        "label": "Minimum Percentage Of Outstanding Shares Held By Individual",
        "terseLabel": "Minimum percentage of outstanding shares held by individual"
       }
      }
     },
     "localname": "MinimumPercentageOfOutstandingSharesHeldByIndividual",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_NetContractAsset": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net contract asset.",
        "label": "Net Contract Asset",
        "terseLabel": "Net contract asset"
       }
      }
     },
     "localname": "NetContractAsset",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New right-of-use assets obtained in exchange for lease obligations [Abstract]",
        "label": "New Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "terseLabel": "New right-of-use assets obtained in exchange for lease obligations (in thousands):"
       }
      }
     },
     "localname": "NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_NonExclusiveLicenseAndDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Exclusive license and development agreement.",
        "label": "Non Exclusive License And Development Agreement [Member]",
        "terseLabel": "Non-Exclusive License and Development Agreement [Member]"
       }
      }
     },
     "localname": "NonExclusiveLicenseAndDevelopmentAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_NonRefundableOptionFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable option fee.",
        "label": "Non Refundable Option Fee",
        "terseLabel": "Non-refundable option fee"
       }
      }
     },
     "localname": "NonRefundableOptionFee",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_NonTaxableStockPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-taxable stock premium.",
        "label": "Non-Taxable Stock Premium",
        "terseLabel": "Non-taxable stock premium"
       }
      }
     },
     "localname": "NonTaxableStockPremium",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash operating lease expense.",
        "label": "Noncash Operating Lease Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_OperatingLeasePaymentUnderTheBostonLease": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease payment under the boston lease",
        "label": "Operating lease payment under the boston lease",
        "negatedLabel": "Less: Amounts representing lease payments under the Boston Lease"
       }
      }
     },
     "localname": "OperatingLeasePaymentUnderTheBostonLease",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_OperatingLeasePeriodForAdditionalTemporarySpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents operating lease term for the additional temporary space.",
        "label": "Operating Lease Period For Additional Temporary Space",
        "terseLabel": "Operating lease period or additional temporary space"
       }
      }
     },
     "localname": "OperatingLeasePeriodForAdditionalTemporarySpace",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating losses, Expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "grts_OperationsExpectedCommencedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations commenced date.",
        "label": "Operations expected commenced date",
        "terseLabel": "Operations expected commenced date"
       }
      }
     },
     "localname": "OperationsExpectedCommencedDate",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_OptionAndLicenseAndDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option and license and development agreement.",
        "label": "Option And License And Development Agreement [Member]",
        "terseLabel": "Option and License and Development Agreement [Member]"
       }
      }
     },
     "localname": "OptionAndLicenseAndDevelopmentAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued and outstanding and ESPP shares issuable and outstanding.",
        "label": "Options Issued And Outstanding And E S P P Shares Issuable And Outstanding [Member]",
        "terseLabel": "Options Issued and Outstanding and ESPP Shares Issuable and Outstanding [Member]"
       }
      }
     },
     "localname": "OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_OtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other risks and uncertainties.",
        "label": "Other Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Other Risks and Uncertainties"
       }
      }
     },
     "localname": "OtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_OwnershipInterestChangeOverPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest change over period.",
        "label": "Ownership Interest Change Over Period",
        "terseLabel": "Changes in ownership over period"
       }
      }
     },
     "localname": "OwnershipInterestChangeOverPeriod",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_PaymentInKindRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment-in-kind rate [Member]",
        "label": "Payment-in-kind rate [Member]"
       }
      }
     },
     "localname": "PaymentInKindRateMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PaymentOfLeaseBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first twelve months of prepaid operating lease base rent.",
        "label": "Payment Of Lease Base Rent",
        "terseLabel": "Base rent paid for the year"
       }
      }
     },
     "localname": "PaymentOfLeaseBaseRent",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PaymentsForOptionsToLicenseForEachIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for options to license for each indication.",
        "label": "Payments For Options To License For Each Indication",
        "terseLabel": "Payments for options to license for each indication"
       }
      }
     },
     "localname": "PaymentsForOptionsToLicenseForEachIndication",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for options to license for each indication.",
        "label": "Payments For Options To License Payments For Options To License For Each Indication",
        "terseLabel": "Payments for options to license for each indication"
       }
      }
     },
     "localname": "PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PaymentsOfFinancingLease": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of financing lease",
        "label": "Payments of Financing Lease",
        "negatedLabel": "Payments of financing lease"
       }
      }
     },
     "localname": "PaymentsOfFinancingLease",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PercentageOfProceedsPayableAsCompensationToUnderwriter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of proceeds payable as compensation to underwriter.",
        "label": "Percentage Of Proceeds Payable As Compensation To Underwriter",
        "terseLabel": "Percentage of gross proceeds as underwriter compensation"
       }
      }
     },
     "localname": "PercentageOfProceedsPayableAsCompensationToUnderwriter",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of realization of tax benefit upon ultimate settlement.",
        "label": "Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement",
        "terseLabel": "Percentage of realization of tax benefit upon ultimate settlement"
       }
      }
     },
     "localname": "PercentageOfRealizationOfTaxBenefitUponUltimateSettlement",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_PipeFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private investment in public equity financing.",
        "label": "PIPE Financing [Member]",
        "terseLabel": "PIPE Financing [Member]"
       }
      }
     },
     "localname": "PipeFinancingMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PlacementAgentCommissionsAndLegalFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent commissions and legal fees.",
        "label": "Placement Agent Commissions And Legal Fees",
        "terseLabel": "Placement agent commissions and legal fees"
       }
      }
     },
     "localname": "PlacementAgentCommissionsAndLegalFees",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PleasantonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pleasanton [Member]",
        "label": "Pleasanton [Member]",
        "terseLabel": "Pleasanton [Member]"
       }
      }
     },
     "localname": "PleasantonMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PostDecember312017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post December 31, 2017.",
        "label": "Post December 31, 2017 [Member]",
        "terseLabel": "Post December 31, 2017"
       }
      }
     },
     "localname": "PostDecember312017Member",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PreJanuary12018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre January 1, 2018.",
        "label": "Pre January 1, 2018 [Member]",
        "terseLabel": "Pre January 1, 2018"
       }
      }
     },
     "localname": "PreJanuary12018Member",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PrepaidExpenseForResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense For Research And Development",
        "terseLabel": "Prepaid research and development-related expenses"
       }
      }
     },
     "localname": "PrepaidExpenseForResearchAndDevelopment",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail": {
       "order": 1.0,
       "parentTag": "grts_DepositsAndOtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period exceeding one year.",
        "label": "Prepaid Expense For Research And Development Non Current",
        "terseLabel": "Prepaid research and development-related expenses"
       }
      }
     },
     "localname": "PrepaidExpenseForResearchAndDevelopmentNonCurrent",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PrepaymentPremiumRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment premium rate.",
        "label": "Prepayment Premium Rate",
        "terseLabel": "Prepayment premium rate"
       }
      }
     },
     "localname": "PrepaymentPremiumRate",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_PrepaymentsOnFinancingLease": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments on financing lease.",
        "label": "Prepayments on Financing Lease",
        "negatedLabel": "Prepayments on financing lease",
        "terseLabel": "Prepayments on financing lease"
       }
      }
     },
     "localname": "PrepaymentsOnFinancingLease",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PrimeRatePlusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prime Rate Plus",
        "label": "Prime Rate Plus [Member]"
       }
      }
     },
     "localname": "PrimeRatePlusMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PrivateInvestmentInPublicEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private investment in public equity.",
        "label": "Private Investment In Public Equity [Member]",
        "terseLabel": "Private Investment in Public Equity [Member]"
       }
      }
     },
     "localname": "PrivateInvestmentInPublicEquityMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants.",
        "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants",
        "terseLabel": "Proceed from issuance of stock and pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs.",
        "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ProceedsFromMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from maturity of marketable securities.",
        "label": "Proceeds From Maturity Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfMarketableSecurities",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ProceedsFromNonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from non refundable upfront payment included in transaction price",
        "label": "Proceeds From Non Refundable Upfront Payment",
        "terseLabel": "Proceeds from non refundable upfront payment"
       }
      }
     },
     "localname": "ProceedsFromNonRefundableUpfrontPayment",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ProceedsFromSaleOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of marketable securities.",
        "label": "Proceeds From Sale Of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ReceivablesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables Gross",
        "label": "Receivables Gross",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesGross",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently Adopted Accounting Pronouncements [Policy Text Block]",
        "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_ReimbursementsExpenseMaterialsAndPersonnelCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursements expense materials and personnel costs.",
        "label": "Reimbursements Expense Materials And Personnel Costs",
        "terseLabel": "Reimbursements expense materials and personnel costs"
       }
      }
     },
     "localname": "ReimbursementsExpenseMaterialsAndPersonnelCosts",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_RemainingTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Tranche [Member]",
        "label": "Remaining Tranche [Member]"
       }
      }
     },
     "localname": "RemainingTrancheMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of operating lease right-of-use assets for lease modification",
        "label": "Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification",
        "terseLabel": "Remeasurement of operating lease right-of-use asset for lease modification"
       }
      }
     },
     "localname": "RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ResearchCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaboration and License Agreement",
        "label": "Research Collaboration and License Agreement [Member]",
        "terseLabel": "Research Collaboration and License Agreement [Member]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_RestrictedCashDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash deposit",
        "label": "Restricted cash deposit",
        "terseLabel": "Restricted cash deposit"
       }
      }
     },
     "localname": "RestrictedCashDeposit",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash deposit used as collateral for letter of credit.",
        "label": "Restricted Cash Deposit Used as Collateral for Letter of Credit",
        "terseLabel": "Restricted cash deposit used as collateral for letter of credit"
       }
      }
     },
     "localname": "RestrictedCashDepositUsedAsCollateralForLetterOfCredit",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_RestrictedStockSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Subject to Future Vesting.",
        "label": "Restricted Stock Subject to Future Vesting [Member]"
       }
      }
     },
     "localname": "RestrictedStockSubjectToFutureVestingMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_RevenueRecognitionContractEndMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition contract end year-month.",
        "label": "Revenue Recognition Contract End Month Year",
        "terseLabel": "Revenue recognition contract end month year"
       }
      }
     },
     "localname": "RevenueRecognitionContractEndMonthYear",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_RevenueRecognitionContractEndPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition contract end period.",
        "label": "Revenue Recognition Contract End Period",
        "terseLabel": "Revenue recognition contract end period"
       }
      }
     },
     "localname": "RevenueRecognitionContractEndPeriod",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_RevenueRecognitionContractStartMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition contract start year-month.",
        "label": "Revenue Recognition Contract Start Month Year",
        "terseLabel": "Revenue recognition contract start month year"
       }
      }
     },
     "localname": "RevenueRecognitionContractStartMonthYear",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_SaleOfStockPricePerSharePrepaidByPurchaser": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Price Per Share, Prepaid by Purchaser",
        "label": "Sale of Stock, Price Per Share, Prepaid by Purchaser",
        "terseLabel": "Offering price per share, prepaid by purchaser"
       }
      }
     },
     "localname": "SaleOfStockPricePerSharePrepaidByPurchaser",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and restricted cash.",
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of depreciation calculated using straight Line method over estimated useful Lives of assets.",
        "label": "Schedule Of Depreciation Calculated Using Straight Line Method Over Estimated Useful Lives Of Assets Table [Text Block]",
        "terseLabel": "Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of net operating loss and tax credit carryforwards.",
        "label": "Schedule Of Net Operating Loss And Tax Credit Carryforwards Table [Text Block]",
        "terseLabel": "Schedule of Net Operating Loss and Tax Credit Carryforwards"
       }
      }
     },
     "localname": "ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental information related to leases.",
        "label": "Schedule Of Supplemental Information Related To Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_SecondTrancheOfFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second tranche of funding received",
        "label": "Second tranche of funding received",
        "terseLabel": "Second tranche of fundings received"
       }
      }
     },
     "localname": "SecondTrancheOfFundingReceived",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_SeriesABAndCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A, B, and C convertible preferred stock.",
        "label": "Series A B And C Convertible Preferred Stock [Member]",
        "terseLabel": "Series A B And C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesABAndCConvertiblePreferredStockMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C convertible preferred stock.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_SeventyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2 Seventy [Member]",
        "label": "2 Seventy [Member]"
       }
      }
     },
     "localname": "SeventyMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grants exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants Exercised",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for issuance cancelled",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for issuance granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted",
        "negatedLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award options cash received.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Cash Received",
        "terseLabel": "cash received upon exercise of stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ShortTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term marketable securities.",
        "label": "Short Term Marketable Securities [Member]",
        "terseLabel": "Short-Term Marketable Securities [Member]"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense and awards granted to non-employees",
        "label": "Stock-based compensation expense and awards granted to non-employees",
        "terseLabel": "Stock-based compensation expense and awards granted to non-employees"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares common stock warrants exercised.",
        "label": "Stock Issued During Period Shares Common Stock Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_StockIssuedDuringPeriodSharesPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares purchase agreement.",
        "label": "Stock Issued During Period Shares Purchase Agreement",
        "terseLabel": "Issuance of common stock under Sales Purchase Agreement, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseAgreement",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value common stock warrants exercised.",
        "label": "Stock Issued During Period Value Common Stock Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_StockIssuedDuringPeriodValuePurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value purchase agreement.",
        "label": "Stock Issued During Period Value Purchase Agreement",
        "terseLabel": "Issuance of common stock under Sales Purchase Agreement, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseAgreement",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_StockOptionsWarrantsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, Warrants and Other [Member]",
        "label": "Stock Options, Warrants and Other [Member]",
        "terseLabel": "Stock Options, Warrants and Other [Member]"
       }
      }
     },
     "localname": "StockOptionsWarrantsAndOtherMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax payments related to shares withheld for vested restricted stock units",
        "label": "Tax payments related to shares withheld for vested restricted stock units",
        "negatedLabel": "Tax payments related to shares withheld for vested restricted stock units"
       }
      }
     },
     "localname": "TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxable Year Two Zero Two One And Two Zero Two Zero [Member]",
        "label": "Taxable Year Two Zero Two One And Two Zero Two Zero [Member]",
        "terseLabel": "Taxable Year 2021 and 2020"
       }
      }
     },
     "localname": "TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxable years two thousand and twenty two thousand and twenty one.",
        "label": "Taxable Years Two Thousand and Twenty Two Thousand and Twenty One [Member]",
        "terseLabel": "Taxable Years 2020 and 2021 [Member]"
       }
      }
     },
     "localname": "TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TotalGrantAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Grant Amount",
        "label": "Total Grant Amount",
        "terseLabel": "Total grant amount"
       }
      }
     },
     "localname": "TotalGrantAmount",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_TrancheOneAdditionalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche One Additional [Member]",
        "label": "Tranche One Additional [Member]"
       }
      }
     },
     "localname": "TrancheOneAdditionalMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche One [Member]",
        "label": "Tranche One [Member]"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price allocated to shares of common stock at fair value.",
        "label": "Transaction Price Allocated To Shares Of Common Stock At Fair Value",
        "terseLabel": "Transaction price allocated to shares of common stock at fair value"
       }
      }
     },
     "localname": "TransactionPriceAllocatedToSharesOfCommonStockAtFairValue",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_TwentyOneErieLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty one Erie Lease [Member]",
        "label": "Twenty one Erie Lease [Member]",
        "terseLabel": "21 Erie Lease [Member]"
       }
      }
     },
     "localname": "TwentyOneErieLeaseMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nineteen at-the-market equity offering program member.",
        "label": "Two Thousand and Nineteen At The Market Equity Offering Program [Member]",
        "terseLabel": "2019 ATM Program"
       }
      }
     },
     "localname": "TwoThousandAndNineteenAtTheMarketEquityOfferingProgramMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Twenty Two At The Market Equity Offering Program Member",
        "label": "Two Thousand and Twenty Two At The Market Equity Offering Program [Member]",
        "terseLabel": "2022 ATM Program"
       }
      }
     },
     "localname": "TwoThousandAndTwentyTwoAtTheMarketEquityOfferingProgramMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TwoThousandEighteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen employee stock purchase plan [Member]",
        "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Award Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employment inducement incentive award plan.",
        "label": "Two Thousand Twenty One Employment Inducement Incentive Award Plan [Member]",
        "terseLabel": "2021 Employment Inducement Incentive Award Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment.",
        "label": "Up Front Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_UseOfBusinessIncentiveTaxCreditsPeriodCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Use of business incentive tax credits period cap.",
        "label": "Use Of Business Incentive Tax Credits Period Cap",
        "terseLabel": "Use of business incentive tax credits period cap"
       }
      }
     },
     "localname": "UseOfBusinessIncentiveTaxCreditsPeriodCap",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Use of net operating losses suspension period for medium and large business.",
        "label": "Use Of Net Operating Losses Suspension Period For Medium And Large Business",
        "terseLabel": "Use of net operating losses suspension period for medium and large business"
       }
      }
     },
     "localname": "UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_WarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercise price",
        "label": "Warrant exercise price",
        "terseLabel": "Warrant exercise price"
       }
      }
     },
     "localname": "WarrantExercisePrice",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "grts_WarrantsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants cancelled.",
        "label": "Warrants Cancelled",
        "terseLabel": "Warrants cancelled"
       }
      }
     },
     "localname": "WarrantsCancelled",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_WarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Outstanding",
        "label": "Warrants Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "WarrantsOutstanding",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_WarrantsToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase shares of common stock.",
        "label": "Warrants To Purchase Shares Of Common Stock",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseSharesOfCommonStock",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_WeightedAverageRemainingLeaseTermYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term (years).",
        "label": "Weighted Average Remaining Lease Term Years [Abstract]",
        "terseLabel": "Weighted average remaining lease term (years):"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermYearsAbstract",
     "nsuri": "http://gritstonebio.com/20221231",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r305",
      "r335",
      "r621",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r375",
      "r569",
      "r585",
      "r615",
      "r616",
      "r638",
      "r649",
      "r658",
      "r713",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r375",
      "r569",
      "r585",
      "r615",
      "r616",
      "r638",
      "r649",
      "r658",
      "r713",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "auth_ref": [
      "r598",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "auth_ref": [
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r248",
      "r571",
      "r639",
      "r656",
      "r708",
      "r709",
      "r716",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r248",
      "r571",
      "r639",
      "r656",
      "r708",
      "r709",
      "r716",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r358",
      "r375",
      "r407",
      "r408",
      "r409",
      "r545",
      "r569",
      "r585",
      "r615",
      "r616",
      "r638",
      "r649",
      "r658",
      "r707",
      "r713",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r358",
      "r375",
      "r407",
      "r408",
      "r409",
      "r545",
      "r569",
      "r585",
      "r615",
      "r616",
      "r638",
      "r649",
      "r658",
      "r707",
      "r713",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r305",
      "r335",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r147",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r224",
      "r271",
      "r272",
      "r442",
      "r468",
      "r473",
      "r474",
      "r475",
      "r514",
      "r534",
      "r535",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r147",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r224",
      "r271",
      "r272",
      "r442",
      "r468",
      "r473",
      "r474",
      "r475",
      "r514",
      "r534",
      "r535",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "auth_ref": [
      "r147",
      "r195",
      "r196",
      "r203",
      "r210",
      "r271",
      "r272",
      "r442",
      "r468",
      "r475",
      "r514",
      "r534",
      "r535",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r376",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r210",
      "r376",
      "r671",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r249",
      "r250",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r640",
      "r657",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r249",
      "r250",
      "r598",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r640",
      "r657",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r210",
      "r376",
      "r671",
      "r672",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r697",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WarehouseMember": {
     "auth_ref": [
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warehouse [Member]",
        "terseLabel": "Warehouse Member"
       }
      }
     },
     "localname": "WarehouseMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "verboseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r195",
      "r196",
      "r197",
      "r252",
      "r253",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r416",
      "r417",
      "r418",
      "r441",
      "r442",
      "r452",
      "r453",
      "r454",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r497",
      "r498",
      "r505",
      "r506",
      "r511",
      "r512",
      "r513",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r655"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r72",
      "r155"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r161",
      "r582",
      "r593",
      "r597"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r106",
      "r535",
      "r588",
      "r589",
      "r679",
      "r680",
      "r681",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain/(Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r655"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r689",
      "r690",
      "r691",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r195",
      "r196",
      "r197",
      "r199",
      "r210",
      "r252",
      "r253",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r416",
      "r417",
      "r418",
      "r439",
      "r440",
      "r441",
      "r442",
      "r452",
      "r453",
      "r454",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r497",
      "r498",
      "r505",
      "r506",
      "r511",
      "r512",
      "r513",
      "r514",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r572",
      "r573",
      "r574",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r97",
      "r98",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r80",
      "r82",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock Based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r33",
      "r324",
      "r508",
      "r683"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities that were not included in the diluted per share calculations"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Net rentable area"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r646",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset Backed Securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r119",
      "r133",
      "r156",
      "r185",
      "r239",
      "r242",
      "r246",
      "r264",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r458",
      "r460",
      "r487",
      "r655",
      "r711",
      "r712",
      "r758"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r151",
      "r163",
      "r185",
      "r264",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r458",
      "r460",
      "r487",
      "r655",
      "r711",
      "r712",
      "r758"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r258",
      "r278"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r63",
      "r256",
      "r278",
      "r578"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r51",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganization1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases accrued but not yet paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizationLongtermDebtAndEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the total consolidated (as applicable) capitalization of the entity which is comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument.",
        "label": "Capitalization, Long-Term Debt and Equity",
        "terseLabel": "Market capitalization",
        "totalLabel": "Capitalization, Long-Term Debt and Equity, Total"
       }
      }
     },
     "localname": "CapitalizationLongtermDebtAndEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r706"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Deferred incremental costs"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r153",
      "r618"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r46",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r40",
      "r45",
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r40",
      "r114"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities (in thousands):"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r185",
      "r215",
      "r216",
      "r218",
      "r220",
      "r229",
      "r230",
      "r264",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r333",
      "r334",
      "r337",
      "r341",
      "r348",
      "r487",
      "r617",
      "r670",
      "r685",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Common stock called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of Warrants Outstanding",
        "totalLabel": "Class Of Warrant Or Right Outstanding",
        "verboseLabel": "Number of Warrants Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r123",
      "r139"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Notes 6, 7 and 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r287",
      "r288",
      "r602",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares available for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r689",
      "r690",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r655"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2022 and 2021; 86,894,901 and 69,047,878 shares issued and outstanding at December 31, 2022 and 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r167",
      "r169",
      "r175",
      "r579",
      "r583"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r131",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue Balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r351",
      "r353",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Balance at December 31, 2022",
        "periodStartLabel": "Balance at December 31, 2021",
        "terseLabel": "Contract assets",
        "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Contract Asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerDurationAxis": {
     "auth_ref": [
      "r643",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.",
        "label": "Contract with Customer, Duration [Axis]"
       }
      }
     },
     "localname": "ContractWithCustomerDurationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerDurationDomain": {
     "auth_ref": [
      "r643",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.",
        "label": "Contract with Customer, Duration [Domain]"
       }
      }
     },
     "localname": "ContractWithCustomerDurationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r351",
      "r352",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance at December 31, 2022",
        "periodStartLabel": "Balance at December 31, 2021",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r351",
      "r352",
      "r356"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion",
        "verboseLabel": "Short term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r351",
      "r352",
      "r356"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Deferred revenue, non- current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Deductions",
        "terseLabel": "Collaboration and license revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r333",
      "r334",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r646",
      "r648",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r183",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r318",
      "r325",
      "r326",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r120",
      "r121",
      "r132",
      "r189",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r509",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument , interest percent"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description Of Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r115",
      "r117",
      "r302",
      "r509",
      "r634",
      "r635"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal loan balance",
        "totalLabel": "Total principal payments"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Debt instrument, facility charge"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r17",
      "r115",
      "r331",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Prime rate percent"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r17",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Prime rate percent"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r189",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r509",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r116",
      "r314",
      "r329",
      "r634",
      "r635"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized issuance costs and debt discounts",
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Financing costs included in accrued liabilities and accounts payable"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs and Debt Discounts"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r259",
      "r278",
      "r282",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for credit losses",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of individual securities in an unrealized loss position for 12 months or greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r262",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of individual securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Revenue Recognized"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r105",
      "r748"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Gross deferred tax assets",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Net deferred tax assets",
        "totalLabel": "Deferred tax assets, net of allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r105",
      "r748"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Federal and state net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r105",
      "r748"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r103",
      "r105",
      "r748"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Research and development tax credits",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer's matching contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTaxStatusExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates tax status of defined contribution plan designed to provide retirement benefits.",
        "label": "Defined Contribution Plan, Tax Status [Extensible Enumeration]",
        "terseLabel": "Defined Contribution Plan, Tax Status [Extensible List]"
       }
      }
     },
     "localname": "DefinedContributionPlanTaxStatusExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r43",
      "r70"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r355",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r381",
      "r412",
      "r413",
      "r415",
      "r420",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r176",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r213",
      "r215",
      "r218",
      "r219",
      "r220",
      "r224",
      "r474",
      "r475",
      "r580",
      "r584",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share Basic [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r176",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r215",
      "r218",
      "r219",
      "r220",
      "r224",
      "r474",
      "r475",
      "r580",
      "r584",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Total provision for income taxes",
        "totalLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r186",
      "r424",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r745",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r447",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in state tax apportionment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r745",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r745",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r745",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total cost related to non-vested employee and consultant options expected to be recognized",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Total cost related to non-vested employee and consultant options unrecognized weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r82",
      "r146",
      "r171",
      "r172",
      "r173",
      "r190",
      "r191",
      "r192",
      "r196",
      "r206",
      "r209",
      "r228",
      "r268",
      "r350",
      "r416",
      "r417",
      "r418",
      "r441",
      "r442",
      "r473",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r535",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r480",
      "r481",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r109",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r316",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r481",
      "r542",
      "r543",
      "r544",
      "r634",
      "r635",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r483",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r316",
      "r360",
      "r365",
      "r481",
      "r542",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r316",
      "r360",
      "r365",
      "r481",
      "r543",
      "r634",
      "r635",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r316",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r481",
      "r544",
      "r634",
      "r635",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r316",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r542",
      "r543",
      "r544",
      "r634",
      "r635",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r484",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r284",
      "r327",
      "r346",
      "r462",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r630",
      "r700",
      "r701",
      "r702",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]",
        "verboseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenues [Member]"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments",
        "terseLabel": "Marketable securities recognition of other-than-temporary impairment",
        "totalLabel": "Other than Temporary Impairment Losses, Investments, Total"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r43",
      "r69",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r30",
      "r125",
      "r126",
      "r141",
      "r176",
      "r195",
      "r200",
      "r201",
      "r203",
      "r204",
      "r215",
      "r218",
      "r219",
      "r475",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Decrease in loss per share"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r425",
      "r431",
      "r437",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r422",
      "r423",
      "r431",
      "r432",
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r570",
      "r682"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Accrued and other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r116",
      "r128",
      "r174",
      "r238",
      "r507"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r35",
      "r322",
      "r332",
      "r636",
      "r637"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt",
        "totalLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r178",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest on debt"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating leases rent expense",
        "totalLabel": "Operating Leases, Rent Expense, Total"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r527",
      "r654"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Minimum Annual Payments Under Lease Agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r756"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Amounts representing interest expense"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating leasing renewal option to extend lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating leasing term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r185",
      "r264",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r459",
      "r460",
      "r461",
      "r487",
      "r628",
      "r711",
      "r758",
      "r759"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r122",
      "r137",
      "r655",
      "r687",
      "r703",
      "r752"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r152",
      "r185",
      "r264",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r459",
      "r460",
      "r461",
      "r487",
      "r655",
      "r711",
      "r758",
      "r759"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Collaboration and license revenues [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r3",
      "r121",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Initial amount of borrowing",
        "totalLabel": "Long-Term Line of Credit, Total"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoanOriginationCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments to borrowers or third party investors for the origination of a loan.",
        "label": "Loan Origination Commitments [Member]"
       }
      }
     },
     "localname": "LoanOriginationCommitmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r121",
      "r134",
      "r315",
      "r330",
      "r634",
      "r635"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long-Term Debt, Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtBalanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Next Rolling 12 Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Debt, noncurrent",
        "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Total"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities",
        "totalLabel": "Marketable Securities, Noncurrent, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r40",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r44",
      "r127",
      "r142",
      "r150",
      "r166",
      "r168",
      "r173",
      "r185",
      "r195",
      "r200",
      "r201",
      "r203",
      "r204",
      "r208",
      "r209",
      "r217",
      "r239",
      "r241",
      "r245",
      "r247",
      "r264",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r475",
      "r487",
      "r629",
      "r711"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "negatedTerseLabel": "Net losses",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r149",
      "r193",
      "r194",
      "r197",
      "r198",
      "r210",
      "r211",
      "r212",
      "r254",
      "r255",
      "r269",
      "r270",
      "r443",
      "r444",
      "r445",
      "r471",
      "r477",
      "r478",
      "r479",
      "r494",
      "r495",
      "r496",
      "r515",
      "r516",
      "r530",
      "r536",
      "r575",
      "r576",
      "r577",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing information"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r239",
      "r241",
      "r245",
      "r247",
      "r629"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (loss) from operations",
        "totalLabel": "Loss from operations",
        "verboseLabel": "Decrease in loss from operation"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r521",
      "r654"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Non-cash operating lease expense",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r753"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: Current portion of lease liability",
        "terseLabel": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion",
        "verboseLabel": "Noncurrent portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r519",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Less: Amounts representing lease payments under Boston lease",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r526",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r525",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Net operating losses, Expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperationsCommencedDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the operations of the entity commenced, in YYYY-MM-DD format.",
        "label": "Operations Commenced Date",
        "terseLabel": "Storage space commenced"
       }
      }
     },
     "localname": "OperationsCommencedDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "verboseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r162",
      "r655"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r164",
      "r165",
      "r263"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities",
        "verboseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities, noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets Member"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments of deferred financing costs",
        "negatedTerseLabel": "Payments of financing costs",
        "totalLabel": "Payments of Financing Costs, Total"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payment for issuance cost"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Tax payments related to shares withheld for vested restricted stock units",
        "terseLabel": "Tax payments related to shares withheld for vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r358",
      "r359",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r655"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses And Other Current Assets Member"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r619",
      "r631",
      "r705"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r620",
      "r632",
      "r705"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail": {
       "order": 2.0,
       "parentTag": "grts_DepositsAndOtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt, net of debt discount and issuance costs",
        "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from equity investment",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r38",
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit",
        "totalLabel": "Proceeds from Lines of Credit, Total"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r71",
      "r154"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "verboseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r73",
      "r138",
      "r581",
      "r655"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r56",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r99",
      "r143",
      "r766"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r673",
      "r684",
      "r767",
      "r769"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r45",
      "r50",
      "r118",
      "r135",
      "r153"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r673",
      "r684"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash, current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r599",
      "r601",
      "r673",
      "r684"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Short-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r600",
      "r674",
      "r684"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Unit Awards under 2018 Equity Plan"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r84",
      "r136",
      "r592",
      "r597",
      "r655"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r146",
      "r190",
      "r191",
      "r192",
      "r196",
      "r206",
      "r209",
      "r268",
      "r416",
      "r417",
      "r418",
      "r441",
      "r442",
      "r473",
      "r588",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r236",
      "r237",
      "r240",
      "r243",
      "r244",
      "r248",
      "r249",
      "r251",
      "r354",
      "r355",
      "r571"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Revenue recognized grant revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r524",
      "r654"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Lease liabilities arising from obtaining right -of-use asset from new leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r524",
      "r654"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share",
        "verboseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Computation of Potentially Anti-Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Long term debt balance"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Net Deferred Tax Assets/Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r52",
      "r55",
      "r215",
      "r216",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of estimated future principal payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of noncurrent assets.",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Deposits and Other Long-Term Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Summary of Company's Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r378",
      "r380",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r653",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail": {
       "order": 0.0,
       "parentTag": "grts_DepositsAndOtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Operating lease cash security deposit",
        "verboseLabel": "Lease security deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r675",
      "r676",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Number of Shares Available for Issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Share based compensation by shared based payment award, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Canceled/Forfeited | shares",
        "terseLabel": "Canceled/Forfeited | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled/Forfeited | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Issued | shares",
        "verboseLabel": "Issued | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, unvested ending balance | shares",
        "periodStartLabel": "Outstanding, unvested Beginning balance | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, unvested ending balance | $ / shares",
        "periodStartLabel": "Outstanding, unvested beginning balance | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested | shares",
        "terseLabel": "Vested | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum contribution of employee's eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares authorized",
        "verboseLabel": "Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Number of options ending balance",
        "periodStartLabel": "Number of options beginning balance",
        "terseLabel": "Number of shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock option awards exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "negatedLabel": "Granted",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value granted employee stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "terseLabel": "Number of Shares increase under plan",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options Outstanding, Number of Shares, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options Outstanding, Number of Shares, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r385",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Option granted expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued price per share",
        "verboseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermContractWithCustomerMember": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which duration is classified as short-term.",
        "label": "Short-Term Contract with Customer [Member]",
        "terseLabel": "Short Term Contract With Customer [Member]"
       }
      }
     },
     "localname": "ShortTermContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r522",
      "r654"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r51",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r185",
      "r215",
      "r216",
      "r218",
      "r220",
      "r229",
      "r230",
      "r264",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r333",
      "r334",
      "r337",
      "r341",
      "r348",
      "r487",
      "r617",
      "r670",
      "r685",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r82",
      "r146",
      "r171",
      "r172",
      "r173",
      "r190",
      "r191",
      "r192",
      "r196",
      "r206",
      "r209",
      "r228",
      "r268",
      "r350",
      "r416",
      "r417",
      "r418",
      "r441",
      "r442",
      "r473",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r535",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r228",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r23",
      "r82",
      "r83",
      "r84",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A, B, and C convertible preferred stock into common stock upon initial public offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r4",
      "r5",
      "r82",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the ESPP, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for consulting services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r82",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock, net of issuance costs, shares",
        "verboseLabel": "Number of common shares sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r82",
      "r84",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r24",
      "r82",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A, B, and C convertible preferred stock into common stock upon initial public offering",
        "verboseLabel": "Reclassified common stock and additional paid in capital"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r4",
      "r5",
      "r82",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under the ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for consulting services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r82",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r82",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r61",
      "r655",
      "r687",
      "r703",
      "r752"
     ],
     "calculation": {
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r184",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r350",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Business incentive tax credits to offset against taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Tax credits, Expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r260",
      "r261",
      "r327",
      "r346",
      "r462",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r700",
      "r701",
      "r702",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r195",
      "r196",
      "r197",
      "r199",
      "r210",
      "r252",
      "r253",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r416",
      "r417",
      "r418",
      "r439",
      "r440",
      "r441",
      "r442",
      "r452",
      "r453",
      "r454",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r497",
      "r498",
      "r505",
      "r506",
      "r511",
      "r512",
      "r513",
      "r514",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r572",
      "r573",
      "r574",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r626",
      "r646",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government debt securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. Government Debt Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r626",
      "r646",
      "r648",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r421",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of year\u2014unrecognized tax benefits",
        "periodStartLabel": "Beginning of year\u2014unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decrease for tax positions taken during prior periods"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases for tax positions taken during current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r231",
      "r232",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants and Rights outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r214",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r213",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gritstonebio.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://gritstonebio.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "https://asc.fasb.org/topic&trid=2126967",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r663": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r664": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r665": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r666": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r668": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0000950170-23-007022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-007022-xbrl.zip
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MKD$-/\^FKXY8=_LM9MD6QBP*SR#U\E8#: 3KAL(ZE^Q:"C2J_.X[?C52WM<
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MA.FC)@DWZK&MBFOD&E279/_HYD3_YP#-N.JU3VS#L*AE9R[<85P#P;26905
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M',"FIZQ4:]E#K*Z 2T98+5*"V*)/(9J"XW:NV*4Y&V;O<?'%^]1ZG5, %U.
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M/D[39$\J8H:#EM]O/<;5Z/CP4_>ZRC[_Z[]]:3=;H^/<*V0LYTA.7D+TU/!
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M&"R+%YZ\D=G".\<X@ BH^OVM* 1WLEJ2C]48ME5K^SSAI67,F(&7_I5W@$'
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M4\^-_9?O0P'-Z@@KA*LB0X(#+5*OS+D6'+9,PJ&$'H$R4%&XQC!!;!-\5[S
ME]]&\&IXK9? &E(,,-]$.256)2()(A%CP2-L+L6<\T(DH<C"W)MGZ4T4WM57
MMW,@#M>6<WLOB(32;HZZ4LJ>WV_W4(_N"W_4ZX[\3FLB1X/>))QTAQO2H[]<
MF5W^2)OLE&B'2+$A7O'5F$L*<%"EBF!+.(1D$$4AX?K2_82K&A4Y#)2(:P+F
M\T2>RSRG/]6UE9.))&P?#'/CA_B+""%_$N ).+\LC;T4U F+5539*;##\(UF
M"-UFU^JT?2FRL8!A_0]?8KD@',.#5L_[[>CRZ/3(&[3[V);[$!=<\3O5PWL<
MP_6V&-(DRF8,R@1',Q?X$/ P0LD/:<:B#*-"S>LE89@Z8RD[O<G$[P7M+N8C
M!/XX% -_(&2_VQFU!H/@R:W=SH-)=H+K2[.3ZG3?Q>+ZFV _7<=^7D15R2OL
M4;A@]?NXMM?)V,87OU.=L3E8Q4&0B!56:+JB[T1)$)<A][S@GRF$T0FUQ,&/
M@C3+U$Q2UK*R##%'4V00-U%:YO%"\X=U;SU:1E7:]@0S1^PO)FM12R:B3$')
M9KJJR$U?#HN 22X99$ 4R$%*L(<@=^-%'K%83; ;$LA9?RQ0[T;-7"8Y"VI$
M)X2O"!W8O-V^$HRD-#H&.^ +7%,"4DSAP\FXV3D.9);;8(<9V HW>(_,1)1%
M8-]CA9W8152<MWX++O/*E7"D]M)J'0&-Y5,9Q]I*] [6M "Z$T;K#@3*/0+U
MVY\N#R\)ABV;XT&G[7=Z8=/O!@$8R-VN\'O=9C-L-=O!N-794,XLDNZW%%]Z
M4#?=[37N.S?9+XA0UZ-IDWN*'3G%]37H8"B^9]2&4S4?5Y(WX![E.?8H]X#S
MD?I&J)\3M%C@9^N,&T$?_G>92*_3;'CM9KOM'> S,?9*&*N" ^R8<)\:.$MS
MTN]@KF#HD)M7HGL8^&R:H,F3!V#O_%&*C*"P$;M:S.=9^B4"EBSA)W]Y!OFS
M>X>LY.4[PK>&LV2!V0*).&SW0S]LH< <CGO^>-@?^*-V9R#AK[;HA,L",V@&
M@_%@*/U)=QSZW<D@],4@'/C!L-?J]UJ3;MB5JP+S(WFZWL6I*+[SRB3BT7[[
M]-OEV^\\/$)XNO\=*( !G%N<_^T[OU>3JV^2<A:FA?K^N_]J#5I' RV+]*KV
M11C! #$LI^&Q!96R<R"(TQPMGSF(77G?E;&O*W769&\A6UW%_?UW\67U*PLO
M^DO[J-M&VPI4=C *C[Q+_,^:.[]^#H9E2!%,;;L.N$> 2,%AA#9GFG$/EFD:
MHZL5!N]]C\[/69J9Y:9E02$;52]HO4+ @-2U17ZQ?2I"X=;#Y'.T:6? ;4()
M]JP&XZ]8V)%W1:CZ(@XT^'Z82MV7CCTR GX,? 9.3CF>\06PAD)$B7D'VLWW
M<L9)JFQO,HW 6)V# 7ZT:PZ:S<^SM1I.=9ZD[3AU5!* !8_Y8N;F_E^LN?NG
M?#$OZ6+:-Y8U F T<"$'Q%XZ)+"=A+Y30G= VK8&_98_'(1=,$_%V!=C&?A!
M;]P*.^%X,.A/EB5T&+9ZDP&:M(-F!R1T*/QQ=]3Q.Y->,YR(4:_9ZZWI[T2G
M1H?&[/U#=7(UD<V';\OJ\_?O[A76PT&CWV\U1H/AGDKLG>/=3V*)_:>R1%3F
M9?823'&ID_Q&-_/MA]/??CU[?W7IG;\__7#Q\</%R=796^_'__4NSMZ=79R]
M/SW;7@GT/ ZX8;_;#MO GB;C"=@& RD0VRCTV[W)J"T'[6%G_.3VJF_3H*1P
MQ'D2I* Y$6S2CPL8368R">05#/UC#%SL.T^"83''[<Y*N?,2^",F(JA.&'5O
M>B5YWZJ&&: +?P03>.%=ZN -QDH$91B VDN1S"0I0?G_54KZ% 8EKL_*=PZ3
M":8R+&.C)Y,.KXV#5I^E=X-TW<@Z"%3S,WT4F%Z1>A_!-/?.S\]-WRKUZ@N3
MSO$.-LYK-?V_8[B !N180@B6!BKO]RSK%DREJN<DY7XMM9=$D\*$#E#(17F.
M\A6?C3"\RTT;06,O3/"6? H+*2C."N<>3'GF*@.%]A(,AJ]PB6XA06U&&.Q?
M]=UN[<5F;::UFS$UM8=S<2TY+=NGZ_)&Q+=P=XZ_\WYPV[8E-/1JRM5FM_2*
MF@&!R#CEC_+MV-WM)+4=[9PT>K )T;#_<-^DI2?NJ9D>?E7-=+O7:^C_A>LP
M%R&:PIJ,6E'RA"J5612&L31C\H:J41];O3)\$>+>C.(RW' 0\,^7&#WGJ?*^
MNE/=RU-53-'L<KLW+[P\C:/0J^_CVN-?<QZO1 ZOIA]LE%H^@B;ZE8@92@YO
M _O'(L4G<8D=KD1[5JWQX\G%E7>^?3QD5PY\*^-X6RX8'N+W%<-]K9.FF>WX
M4;\D8[>/IW\T!$'_W%??MMG4&[> &[R(DWRS%'1>R)G7.MH^9K'-$D!XTPR#
M,?\&RYA]:GW2N7E_FAQZC=&HT1IUOH8B:%ZA##".$*7)&RJXC&$>ST8K&O/8
M$(O8)H+9;>FR@ZRCX\2.$SM/$CLG3NX\1>Z(3UF4?_XT$9@+NN_"YP*6ZKWC
MI3H!Y 00"J"^DT!. CU) OWH)-!3)-#X4YED,D_C&QE^R@LQF7S"*@,,/^^Y
M./K-K!N3JR83RI2JA=V=;/J69=/0R28GFYXDF]I.-#U!-+4_S;-TCK.7^RZ*
M/IJ%.MGC9(^3/4[V/%GV=)SL>8+LZ7R*Y;6(40(%4N*$]UT$_8+KQ5H3O5XG
MB9PD0DDT<)+(2:*G2**NDT1/D$3=3["Y\E,N)K)8? JC'#%1RFSO3:)?87#O
MDE;MO:U6[:22DTI_1BKU]R<1NK]#:;&KN G[F!7KCG3OCO1Y./KFSWDM0W^@
M.G.C)[@=Z<O[J0GN05V**TQQA2F[RZ]?2@-_W7)ZY]79,[[^$EZ=GO/J/,&K
MT_O$H-.?)FGVJ8))S3\QPNLG^4>Y[_X=QMY%7-A[ #7/_BBC8M& 1V*"VB*L
M1H66^RNV0\L8[>H<NP%EWL<R"Z8B9YQ._JV%B^5\1\YWA+ZCH9-]3O8]1?;U
MG>Q[@NSK[[ED^_\N)#QP(\/_WPD<)W"<P'$"Y\D"9^ $SA,$SN!3U24YIQ!Z
M27BXGW0/QT^3/1=)OYKU6\#)9A_(@CJQ^EF^,TU53],DY,;S^ P(MC+FKJX?
MYI)G[ZPJ)^1(R(V<D'-"[DE"SF$)/$G*B4]_8 /@"%O(WTC\1ZS_5FEC>R[E
M_L=:/LFK_ZFVP,XA\T[&:6FZ?R$J@9-A3H;!_%O-MA-B3H@]18@-G0Q[@@P;
M?IIHTP.Q" IELN7E?![3WR+;<QE6F5ZFX0M'N"ZM/5AX;T4AG-!R0HN$ED-Q
M<T+K24)KY(36$X36Z!-WVLH_10E:6N(ZDTIP8<.M3R((]EQHG?+ZL?TPBJJW
M]AYX_\ &92=! ,LM,,4%NY^I?U*#5/A!)?0J*\U)-R?=4+IUG%_12;>G23?G
M5WR2>!.?<$.S-,X9#B'\!JI/3]6*23Q]-*MV0LD))2>4G%#:@%!RL*5/$DKC
M3VD&]M8$CPIEPI[+HP_%5&;>>;5>)XF<)'*2R$FB#4BB4R>)GB*) @N4YU/&
M=4J?BA0KN^ 0DT__W/=*KLIGAY5<(L-#\][QZKW_+K,H#Z. 4@6]8BH*,*?D
M#?P2I%D^EX'+(732[,]+,P?KXS!@W)&Z(W6P/@[69V<4R.>6TB\!Z^-P?1RN
MS^XR;(?KX]Q!.\C87Z2?6M.Y@Y[23ZWY*8PR23TN/\DO,BBI &<2!3)#=)]L
MGNZ].T@MO^&=Z?5['R:\ Q1//\5=@/E([Z<4#AISOURZE_, D0>HVW0"S FP
M)PFPEA-@3Q%@+4ML!>EL+I/\6XBP5[+JU%JT$TM.+#FQY,32!L22:P;Z)+'4
M_I0SD.?B4WJ;@"DQC>:?P*0H1)1\&LM$[CN&C\(Q77@?]/(1A^>4=\#[$7<@
MHAH:_IXLK0KW1^'WW(FBZ@2=$W1.T#E!MP%!YSJ//DG0=8Q4HV0R3(\"7I]7
MJ67[#H&@1=J%O?R:_+K*!-AGG#K64"6G['3TSF%Z8+W!&3J?HI-I3J8YF;81
MF>9ZF#Y)IG4_S;,H":*YB!$.0=7^?YI(F7]"K.QHWQ$2/NKEV] '[V#YC.U#
M6^#*2YW ^I,"RZ5!NYQ9=Z3N2%T:M$N#WAD=<0_2H'_?OJN]*R>^C8K7-\:O
M71:T<_CL(%]_$8>/:V_Z)(=/[Y/\,HW&49&O0W3^E ?3/7?XG*GE-[PUB,[>
M93"581D[CX_S^"B/3\M)+">QGB2Q^DY@/4%@]1&O!<MW/G_*RQF,L=AS ?4.
M7NRUFO[?O4M>KQ-%3A21*'+M!+9$%&V)W>QDR(,R)(=/1?$-X")?GO_T_N3J
MMXNS2R<NG+@@<=&]3US ?\4XEO3G75O]_;?&65]Q,RK"=]MQYW;LX#6,EO9S
M:I2TN;B6S$M],8'%OA'QK5CDQ]]Y/]R]\_VC?G_@[N7+$Z(7A7AD6?$IVH,(
MJ=[;G5['E7>^'33B+LRK<.YG):[W:;&$FGL+?_J_I.EG_'?5 _(QN]Y[F&NW
MVD_=^'^6>1%-%GL@,Z^F4>Z=)$DI8CB">9H5V)K,^,4:7I0$<4GG\M=_^])N
MMH+C'\L<K*L\YW^'Q]CQ["-P:^_<(R?L.:7SZJ>KZDO^9'2<4X.S,L_!6J-'
M3Q(1+W*81SJQ D6G:1)&A7[F0N9E7- C'^:23;TU,U!3&#0\7**(DMQ,9*+(
M*E9D5;56-<-@ISH8JIA*;R9%@D_!^RX9G]EKM\[PG_BM*D.-8+_/OG#C.^\D
M*/!KL%Z[#4_DGIAA!4[H'=A/'!YY)W%LO=M+J:E!,24JJCZ=>' P19JA6>=-
M!(PM,FD_02C205K&H3>67HB-YD+O[C4>>>?P@G0FO4#D,F]XB[2$/Q.0M? U
MT/(]O_7&"P_X#) 0$/#UPLO+8(HKU#LKHEG#[*'Y$$;%9.]"KODNS\O9FL_'
M,H[DS9HOB%YG\WCM:/AEE)1KOX'M6?TX7/>LA!L]6SN^_(((W:N?7Z<B7OTT
MPINUYJ4SL5C],!W_$XEKW9)AL<F:3S.)..)KODCQ0D?K9C1/<[I'<LVL<BD_
MK_ETNG[C"N"*<LW+;Z-XS7MO<1#S*5YBIO4\ J8E,@_V-9/$!10U(X6K!=*'
M< G2#.XV?( X69,2G4L>X:9SR8#ZI,A@QX&DTXPN9P*2A#!,^++FDH@WQZ]Y
M @CH(C(TR6VR/O*NZ.%[[@'S0MGPQB7/-DD++X;E8#U>D3;L9\4X+8LW2Q(K
MC&[6>5M;I"JLZ YAE ,5+-Y,8OG%EE^<W*EDD.;E])0/$\B*8Q)2/L9T\C=C
MN.[D#5LGTBJIT#YJ]T??[Z.,JVVKV=,HP4WQ:6OO?>^R9G#/MMN[V6NW[/_I
M?$^J(]R%=MLHCQ8UU*>U\WO^W7_A1<Q+!+R+9!(LZ"Z7</7$/"I HL'%AW\&
MJO0'.*^2M?Q,/O6R,@$+G03IK02)"?_%[T 0HJ:22!GF>%,]]'$BMT IR:J#
M:J=*3X^C&,$BBM1+QU1.:SVNIE*I\G <ZO^ZJ^JNZK=S5>G.P5I(U<2KD\GK
M$E2M-%N 7GDCXW1.^5JHD?"EPU_,LS0L02T%'3*,0A![N;M)VW.J[B:]UDUB
M:X'M4[Q)RJF!\M#HZ!Z0Y6=9>#@%NG'TA[(MJZ? >(KHXJ7S4J% W'/]T%3W
MT&L:!26JU\4T!6W6,FE_NCAY?WYU]E+^2+772[')O 3KO5:H--BH;V[0/7[A
M!3X7,36\RU].W''MRG$QJ/.'BY-?\&Y>9V*F4%E$LM"&ZNJEI?MI3,@U%QYN
M]<03<_CE#?MWT'J=R8Q<9&4NG=#='B)P0G<+A2Y<,X$&(#E)LPAO$<A#_%&:
M7*?:6D3=-H&OC!Y<9'#!\LK[O21=&][*:R?*_62$>B@Q(TI;M7>\H6$9OW2S
MDZ""*H0G01$@Y[,:14V+C&9X5_5;_)>X$5&L;5[XC)8^R=(9>VSYMXYA; _Q
M.H:Q90P#O_HIBXJ\2!/IG;W]Z0QTE%[GV,.+KY!%T<$? QGB3:6+>"." '8&
M;WB!^?.Y'31;<D.5!?P)_.$@.KS[97H@_('RA_-M+V=IYF._4)R+E\@4@RPP
M$>4_1S<\\CETJV-D.,10GM!:115^HW&\ %;!G,2$@*:P_?$"0V>(1X08<_24
M)^<17&[)/"XLV74.*DFA(F,3<M-/Z%]E[@'%2 PRT> 'D5KJ\C;AZD*X_S<8
M$I Q_%BBLJ07E+(QM#SW:#8K89!\D6.<#X= GLZ<7N9%5@::7=(JR>M_$V4B
MCA<^3Q%Y,"[=,<+MN92.$;Z6C_X.[4.I&\IN2=+$J"UY 8P-O0W+JA)[#N'F
M9Q@=)OW'\ATJD\A=NNTA '?I7DO[L!0";)N._9\:^KJPSR"\P7Y0ZQP&H'ZD
M[%@ I3Z0>3XI8Y+9LWDL"[ER+]V-VY[3=S?NM6X<QZ[HUA38=.UZ86G],Q%1
MKAC^+;]$>:&] I1>B?_ 2P?Z]BU<LQ@L;%5J1 /^  HF^@54.P)WW[;H[-U]
M>VVU,O/BZ#,0X31-0U0JK=#R!&1@<LV7DAW<J$6Z\/(N'+*[6%OAN*+@$=A<
M^)'VF%3AH>A?]%A#19NU4(/7E9A07&96SI6[;MM\].ZZO98<FV>1R2C,9#0;
MEUE>\Y"LS<.H(K;N%FW/B;I;]%JW*$+?!-Z:6BQSK.J(O%D:RM@VSJ)@*=E0
M/]I8YQ&A8*@,IJHZ96T8QLK[5?4$)F8+&Q1,O5L)@A%^#/>[=$D56T1![M:^
M6OI^D,XI*]&*],$UP;H7KIU)/9DCLD643Y5FR7X4%0_$,*GD?'T882ZS8N$1
MXD?ND<M3AT?7IS+JF\M2./TG1^Y4)<\$ X,JKJ"FYN[L]M"/N[-;81[6$Z%
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M3FRF@[Y%,M;B-/C,7B0&P^9W*]PY>ANBYXP78'=FR#!PYS2\7)0DZ8VR(?%
M(D*)4[DD;+#2NS " 9]DXKKR'/M@[>:ROI>UZC*UN2(,,ZUK@X6<%7" A&6
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M2?@A;%)*8I,I]%"'->[.]3WRB)0C!N+RK<@:)N6:Y&*>LFIJA/4\ZA#6E26
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M!\I^6FZ7C%@)4;Z21(3/ZG:]ZE'MF[RCX;%Z$9I=]9[)=^)N$^@V:5USE0]
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M_3B+5-4+_AKC>PK5)R: 'Q_4>5H>=AB)N0.9ZC9&BK7(*ECGY>U,QW@$"L$
MQC -OA1N ('C1$D:J%IW"U"+ILAK<)KS,[ E[$2W#N]9UXE2+ZJ(5$Y,[2G@
M6DT+JL_15"X4OC487XI$HYS9%O^K JU&,:GR%%!;MY"[E@"Z$&PACYC<\.>+
M(BW2+\M9!:A4-NBJ TWFL$X@;Z!;X)/4W.[*!\5QK@TUN,**-]QBAA+YT3!)
M"8&0E+J[=KYTNTC)A=.17]2DKI:ZD&^+C'<2_06-SB744PT0$BI,-,T%T7>
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MJ'MFSAIY1.]39 ?;J2>95(U D[2X[Z1)>5)-8'"F>9G!#;'W&U'H?SGQ=9V
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MTQ5)[T9L"\S)P/+7Y0B\#KVB/<*!9]WIY(B2)Y=D?QW3SBJT%9F=-9)ZZ*U
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MLPAX@ORAB.81*'513)*<L6,OY'6:B8E,HC&.IC710\S[Q$#83//LRC^TK"G
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M5*&TCO=C:,,CBPJ8NH7%^E.$C7V\RR"B]K -T%:"(^^ /SXD1RA'C+!-;=5
MQ7@J4?_A>\JQ&'2#TE@+CRZJ=_#S^>\<ECC]<''R2\/$G7Q&I*.I7)Y<7/JG
MZ>]^6\^7@_SP6]/-(),*JC^W\*'L*=E>1]7;P#@O=5P.Y[FR1T<\-8\B;Q2Z
M@7>F$Q_^/TP4&^K2,I<<P'I?V.78P) 5F]&@.OJ8>0UTA[QG=H$]<7*!_SVL
MXO,X(O8TF"YB\C?:T]^=F(3+Q7KV7"R\ [^KVQ:!E?#(.^Q8\#,(/!MWKD4Q
M"-+^*5ROP-6MTVE0!"9E-'HX8DE!X^M,4L)+[>S@Q\C<1(;Y-A2"UDQ7,8RU
M.7;(0X \@%>J3E!V6,0,D> S%23Q.BY>4HG<<IL5._?+])8Q5C"F[F01Q:(F
M'K,WE8$%RAKP?LK6"!#:6[7>,Z&6*@=AO% ;<.3]9E($8$-G)FQCMJNAMRI*
M@$EC&.LO?3A=#PXUIKU6R,RT$.Q6\Y>.];57SB<9'"1&O*;>7"SH!!@9M?Z@
M_*-D<"=\"S]5</@\3G&7CLP\<AV3BY#M4Y_ E!-#$*-:!_Q5N%]#VS]X%#BG
M*:AMJ!=761B:DJI$BKHLQX#A&)/PZK_21%<CAWINEGS<M,9R@;DB:E'<Y1#[
M*L1YBJW<KVD/B(H#B6\NY_@OA+<V>-?>7P;MGK73$9^P6AEUB,=)Y2I>"5^#
MD4!KTEH.-C.\1ICK-%M.,L-1)>4/<P*?SJEKH#A'U&_\[RP*?>HQ*?T0IDQ]
M'./TU@O3<EQ]%G'27KH HYU:NB%H)YB^ FNI*(=O);=M55M!J%^CKE7I'RYY
M^?D%)BMSQBJ\Y"RGGRIM\_3#[^=O_=;(B-6/KH/9,XE,O!9\'OIB8(I/A9P+
M-X-07Z.D2G# YJIPO:Z1C1(FO_*= E=G3-KK-4>I]6K.X"K24"P:7ZO04[O6
M69KI- *6Q$JMKX#X*4N9DR\PEYEO>:788Y;A'7H]=C#(34:8F7O5&6'5-L'F
ME/4$D)QRC&] 0#<\Y0M1J7B\]@08=X:<B<00R-QQ2ITI;T4"3W!C6]I3^!HH
M(B2IYAV0F*>$*.\DJ5*]K31BRGIDV:9MGC$\%*YDJ'#[6K)134:P3@*'>8-V
M08D5K"-PI>GJLO?*!')<XVL5;9- N]1HAG$=<E)TB<(4,P!>PDU-,=/5RMM2
M+:*LQ"!]XY6+P-S;@A29 #2 -;=_W:5:5%>R83<#"19%2BU$*"=XJ8N'=D1<
MSJ//TKKYJ+URXJ_.%T/<;\7VJ,<)7G72,_(J3XT3\E$'P^8>46AV@;HOQ>;'
MUNJK)'Q4V]?Y*BAY=H73XE?.J'R&Y';FC&3X3!'<E<M)ENC=.R IZO_XX</E
M58-%JG]Z]O&\\JSY[\]_YDS?C'5S<X4"N@M@F&!O3^K7;G*SR3!#GHR\5QEH
MU.F8\P+S6B\QIDSO'Q%P]ZO%'*3)CV HT@P^4#\@$DN1P(;"I!"KN1/V>I6X
M3&)7RQ>0@Z:*!\AT3DULD.RKGC0R!IL'RVM"I'DE#U,R/],9F0M5T0@U!$+)
MG A0 .7DF'$-S 52%]7 ]NZ5E'&I=%NQ'3O(A%IMETKGVGIN!RVR0J;KK#1?
M5R[*2E8L]7Q36>)QW%"53Y;LL6682/);4K?@\S]*#$"CL(%!1$;"9JU&1.WA
MU(L:ID.)KN2TI9;J+HKV#U:!LNFG7&-WFGC[%>YQ^M^?KT !XD'MB#TF=R$^
MU!5ZK)GEUGY<DO(C=QQ$(E7-!RW/1;IB=[ 1CJ5XH!G")?IQX2&N@_)AF^(4
MFIJV3'))16_&@%=N_4ICXY>H0550P'B!KT[/JN8\5N!7Z6=Y.B-O [<QPNL[
MA6, ]:^RD'271'X_FGE8?'Y@BI5A3$ZT,X,?DKVH]]DR^^S-G0D56 >"@@,"
M=59P"+NVV;2JH#"&W*2D3F6UYV%,"0HQEF).HUA:A9^J,UM]@_#%A'@E]>BJ
M;:[EO3D ]A?PV1OS4^GC&L@KXO+)N3S4CAG=?5(W_*4X5(J9JC*;>3,PDKGH
MVN*J-7*@F2G+LJH7C0E6"5U?NNZ[FC7K_76/'Q;:E_-YFA4<\<$U_!C!O/X*
M?!;Q&&&84'@_T2&\P\NKHF?XX&F*A3BX'^BQ.YM'M+/8>(,*^L%PSX'Q)^F-
MZB.,-M&A8='O==>L<SBJJ"BY^]])',OLFK=C-8D%]OK]^<GYV\?U$7;Y0H_F
M='!FAF(N5+#3"92-;_./'*E3Q<4&YX/OI+X8&*JZ,QN(F"4.&"4E:2ZHQRR(
M;3)?,3 ><W:F1>SV-BW#[_#IHH,C+:^G'AON*"GF%DW<IMEG-L]%5B0RRZ?1
MW'B\X"?4;E87H^MXINX2CJU&L=Q1Q%51N.:VM#=?Z#%.59J+.? ?V%*=HO3Q
M]T,6<>MXU3)CJ@<_==A>.QI7YP4[$9<R^9?P#N"/PUJD5V _P%J';)36P(0I
MQ+DBI%;Q!6J/<S3@E?A6__6LXV=E6_CXV^I0-Y1%NDL,ZUFW]\+JG*G:97I7
MNEDF\2XG(YXYDZG#:4.F'^<\%DG.8#P<IUUJ<*J/B3-;+,\N0DY4N%-<)K,"
MNG)/ U3."R?^RKTZ:Y.@KM#5/+SE?J>ZS+"R+I9B1S80C)**NE,R:[93$4^0
M:3^Z-:B[YX]GHZ?GGNFAQQ>\ELKH;OESW/)W<IS5K_ERPJ(^$H677\].K-E0
MIURU49E2!W"FE"*NXTF4[U46&CM.F9\Z6Q&N=*; ^$7EF\!L#,R-,QAE-5BA
M**DI1ZRD:J1(3O$9'>=+C&=%;:JA!]G04,P/]LO_YC2[QV[G+SHEESIS6KSH
ME2J%5O9YUWC_EB2U/]BNVPD)E]3NDMK7);7?HE]V+%UFN\MLUYGM1MVB>2DZ
M49L1>N?OWS(>+"J'BA:BO/+])]Y;>'0VAK-E]F*BIR^2*.]$\-T8WP1K=PTW
M88WT;6.,+P&6,8Y2)W2?0^B>E->P'+@4K>$ZF6L$9YT;WB-TQW$IQU$6XI'I
M,E[]&>8%IAKJFT3BV=N?SO[Z;ZU>Y[@JDD5G"YXF['$-,5#!\%=<U$(TU-'!
MJ],+=/0K"PQ&:C45Q+65THKLH>26 7IFE0U7LQ7UG"BKXWUZ8W,0LU"1Z[P.
MAFY\_(;A2G$!DPGL"!F(-L'KW=.?'3;8#DT2%9I5DA_/2E(/&7@Y)5@R:BUA
M&B)R[Q\EOBR? Q5@\R3T+.G7<+3Z:R9-_%XOV9KPB7[@D#9K>9JX-ZO/$LD9
M)BX4*.H$0QPH[LJYOT:S@/G_I6VK%:1JU 5AR_X^6J=Y8* ("/ 2+@A<G%.<
M, $>$;(LS$%F&3GWTN#SUPCCZVM,XN$ [U]:1VTX2#,)*R;S6$&[U'50[V!%
MKIR"C<==)UP"CB<DX4HZL^ %IF!+Z)H89A&LU$.X2ZN@_30J!:F^+6^%RUEU
M.:OK<U8[+F?5Y:QN!RUJS4IQ;TIY"%+N&3)>>*IP1['\!3D#2!F26 )Q)[O'
M;"XVQT-LR3*C)DPH=O4#_GCAZV=9EI5)D2WP8_4GHD5'K*F1:4_2#BVU-+%0
M5.Q>(X*+_6AF>FQRF>L1&<<ZU"/$W,0@G;SQ#J)#=/)'2HM!6Y!F;2!9^/F<
M]"]Z4+*.B4C/T:SVA%)_,!F$BJI48BWV?]#F(TUM7F9Y*5BEP\_7Z#K',+&E
MF4TP4]BC?@$AB5U+*= ^!E1;M&_#V@C2V_1>'*BZ50Q5DL,HEBK'C]. \:'#
M8]HRF -, K3B!6A\J'H6RMUQYQ'0FY[TYJ-J-[1C)T]C1"M?]N\(HHU<PY1_
MF4M*&,6JSR*OZT]P*<J)4+IN8UF'4LTL(H5P4VE)3-O1_F4[.\/W*^O!E8VI
M:J(;VLRDOZNN2);#6!L?AKMJ8E9>R:I?"+H(<\P"P\]Z/EZURL8BKHO#8E;K
M6%:-)2C3UK9BZ'?LD#2..GA5I&JXKU:<E'I"U\B@$C6D]\\T0O.OD)(FA[<D
M*N!?;%(8/"OJOJMZJM2=;?KVLAUD?<!YRL"I*/7W_[+WKDUN&UFVZ%]AG)B^
M416'59;*#[7MB(DHEV1;<UJVCB3WW+C?0!(LH@4";("H$OO7W[WV(W,G )8D
MMS1Z(6+&7:HB@40B<^=^K+W6BL.W06Z4(1S+K&D W=NG07)0 :.KSN5,Z47K
M.$1ZOY+#Q+7>-F1X<S>J)$-[6S?EZA:Y 9>KM0',[=WV#0A.T=>$5DF:@8VB
MYA?F#H+.;)2MSWK<<2[W,LY8)RSB4KMSSQ^JFOA@PQR*S/XPCH ].7^#9H/H
M726'D 37=+-;>:*NQ=#"G'(_)_*PCPH&[ ,<>> E;(=K?B3&EXSN;8,U!]F3
M/41O])BLW;44 \-?MVWF_AY#WJY:=I@Y;"]&"\#%QKMLN\4_%*V388IW0 ?0
M6ZS+CA^5I@6L RKD(/O(93#>Z&&T"D&_YH*@BJE!\&?D$;O/[)29$MW_1J+;
MROR7:;[TLEET>]IL/Q7U;I/1.YY=U<W.I^">-K2@;C)\PA6.WI#<<G(+WH9W
MNYK]OMS7R/'>_PYBM/<?2%+\5;[L1*/J2-;[[K=XHG\^O>M]]O*UZ#3?BF-@
MA[\4;^F'_^K* Z?LK=M(/SB2K+6!#58?"%;T;XC,9JBG<5_@[&^_/:5;+3>5
MH.@ERVP<*S15)4[C3OIM*'8A\Y@#.&E(\A*G( UET:#.38:<KI><B0$TCC\H
M%4 G_?,1!^9]+CJ'X/X;'C_-:>+<W.3;HMUST(0!%7+(MX<*/9@X="LZ;$NY
M'S^.CIRSG@K7AV&72OOG9;,G$_!6<QJA$D=W3MQ4YGF"M"(ZFG/G?9[ @>!U
M6MNW$C_%MC833($VY16 B*RGRI^3'8UBR'S&PH'K7)A@=*O/CWBS,3K.QUQ;
M5#YD3]!Z5_A+J+^M61N+[A9X8U1Y]N#0*.3\U+R;62=W#!^)Z*%NA,@*W6[R
M].;&)6 8;$QQ@4.^Q1F@H/LXN$3=T(C+HL;U_?7X@=62E <G.0;3%OQW-E>Q
MP#)NVJ2'2 ?@!F4O8^S1DM3$[&55WYYMZMOSV<_DW]>WUJ$CAXI+2=VQX"S4
ML9B5$1S\-'ACVO8M21?78&KAH#=Q6O?$ C %XJ#5V$/ATBN!QO-UC28($:.3
M=3#*G:SK(LT@\H@V:J:3_E7NH>52XFQ3;\=DGI,K339YLLFOW2*[K%B%CV01
ME^8+QPX?)>D,E'397^*H=YN]S#F!' NY,3)>:YWW/QY\#2G/@'[3%+0BHNQ6
MBE/(T_R1*^[R=MQ)* S&I5BSY41Q4DW^CV][!>VQ>G$<:LST6JX__$G#;*"R
M?!VXA\*B\<?4MQE,SM"FU0,DR=E_HXU=JEGS^>V02-?\N64]NM>_4F\OLR6.
M1<9V*5^:I*L!^T(7#?W1H!F*8]F2-^ORVH,Y$A2!>XWQ@.;\0,3%?,\BL>'[
M(([<YD@$>&-N L=&QK$'>8'=)W0@L=7]_>S>O6][IG84,L&N?;BQ026@A;*:
M_<?7'O_0C@)<^?8AA\X4E\KR&"9G."U%#('P<7H)7<-)F+%5UL"SWFN3E&R@
M&E*D=.BL<>R_<0/39!#?.GU]=-^$EFE^Y_D:_<]N?_8*7SW[,.-J(&C.7,U,
M7+/C-X1S()^&9\H)S4&>C%?T=_=FJ^S0CN;+YII*B]L3<*"S90:/Q1?PVF[+
MEAOI.K;>,6=7[ =9Q) DS%8HVD'Y>PWB3^9G%(.F]FT^6V=%"1(-Y _%EO-?
MR7>"Z]NHTX-_T*S2YET>D)_=(;T^Q]^+-2/F(JZGVV]$"'Q/QTK+12EST\#]
MQINHTY2[=]"EAA!2S:]-NAY_-7C"09X4)L"^DEZLD&]D"[0W5K8@Z+G0B8\J
M<%Y=Q]N)39]RG%..\S4Y3I!>@^\SM-',?MDN?IT.AO>9P+RXAP0F_CM ]=*'
M8N^,[SYS_ )O]@IG)_;[N:8OX8)$IQP#B%_UN<>G/<#$D4_.X^]<LF78?Z%U
MMK18.A[1-WF9J;-BUXZUI;+840Q1954-6ULL ?.,0?\)(NX7X=^G>H"('^WT
MQ$5M2*;D-G?A!9UN\8$8N6MNHW=*7>/-$6#I@_MI-# ::WB,Z0 @$>.0N?(Q
MW7+\$QHX9B/PT+OC W$3CKQ(^!L9%S.[YMB+";52+(A>%IK.4=K"G,Z1/AS<
MV*TA7/9X*/$Q8QX_5>#=! $-$-!O)@CH>UR)DP_P=OQF;WVR<A3ECE<[/Z5Q
ML-5HT3KF@MVG\X;Y1;EOD>E+^N?@^>SQ6NNGW'?(08U=-:: CAT9=]V7W9I;
M8SAMT-_1Q#/6G>T>4*6=D&$XZQS'GSWNGVC/J(ZV,8XFT%*PI&;+,E^ZU:>+
MJ4E[+?%Q@+(:;4"]V^V)C<%ODGN;]N5[2=H<6^E_*F7#"=CC^9IC]WKC;,WW
M=V1K."U 6V*%VADZ9M<.7*;K,,#')>."D5K:A"&Y88,MZ=+(4(0\!XV(/A'&
M/@+,.O)LH^F.!!8&Z)@BKL7Q/7(7I))Z:8^LCP:?FH.G?,+G;;-^CZP<][^=
M'V7F^*VNSAZ%(^EM,PHG++WUIEF"L4_RF$)8>/R$',;[:4!_-XU#GY,=Y>X@
MVQ,$=0+9<RB=\.BDIG@L#S!6J;SOBE-:SSOEDHNS9R>O3KU_$RHSQ_I1O_%Y
M@UW>Q-PW)]][%<P1Q^@USM#)X71([T >S+6HGRL?7C_)T%KF89^#PN0=%2*1
MY6%XQI&*I)4BM3(9O:)CJTR*=#HG+8T)>C6,;*,AYAU7&X[XAL[9-E &H!#[
M4M4 \"X0#D,\F]E: ?X#RKL-H YK->99#,B@/.1+@HR;,5J,H(SZW0-''G2V
MUIK?>\[93"[H_W0!Y*Z7_IY\T-%[?28^Z/CF^?A\T&F;_)E([>@NP4D_AX$&
M'9849D$_TL*PSI.&*CVZ;[,&83P?!'@EVRKTG9%EI-D3NC_FV5H+Q@]R \C:
M=V2P%83(B0.N"LB_Q^QQN\D:(32W 6$WK[.;NHGMM%Q%YG,%[L22WEO-)6X^
M5BL';>?CDO8JK49:LE.X\]XE@Z&D]S,] ;M+M2FPO)4N\+33_R0!$D(;D3*,
M;KJR"JWUE40$X,6]\^\\=*QC'XA5+9>Y$\\)#8Z1JT<J?CW"6T6U#6&U?65A
MAKO5'5I.U@U=X BY'_9VV,8GR;J*\94^+WND>$3@W-";<9;1H9ZRZSEV[7U?
M625&4XH!=D.-^H=LW&[@TR]S*Q?_^OCO_SO0<HO'8,S8/$LE,S!5JID5Z'WW
MMUXKIG=3IS+)T\ FSQI':V4B:@?*0&+'G0Z09Y?JJW>)1#-?K:D76#X_>:6C
MOE+RYP60F4S,VTN/C^Z_1#&W'3E]!<I6;-'G8-C7Z[)>D+U@/BMVG@&-;4,$
M%JA$V>\=B;?&AR)[3[\\9R#;CL6\R$%EWL@(\%PHMC:[R8HR,^(&M-:2BQ"9
M/\NR7@;F3(U/+__?V<_9LA#/1H6UBFW263#V7 -Q=4<5@49H=JM@\.@W)5(5
M; .3:HX$T46[D>0+D!T%_.?)>WX_"[Y=DC^JN2*.*I/TRY'MH'P(ULRXRG>Y
M'KM5D%!P;S7PE(7U0<<BE]H#N6?;R2+2TW5PEL;^^+'JV)%A,GZHN'%:BN0C
M-ZLS<:N/WX/CR8 +%Y1YCY3T5DG V0O1:;AC)-Y#";T$__&M!P:YY* Y,<@'
M"6&%X] =NB-W'/-19;D_C7WG9-I>[]YEE5?SW^@VG/V:9R7-]N_-=58I4^[L
MY+]__=U<.\F3CB&2-]D-%L,_NJ9H5X4 DVOI[>JM!0HLT63V)ELC\$.I[Y4E
M6V/(2H'.,'0\[[-*W;UK[ \$U+%7;)/).?CN=C C%3>&'>#4$FV2?W$]H]V#
M5UB!X7Q0< <D3X4TEG2<.Z[:0MNEK^MZ!>@X^_>'D*,")$$8J608:)20#;O,
MC<YQ,-=&MW3'<Y[L-Y&(*YC5VTTNIBC>H6[XGK&51&X1R+SX%)?4F[:F@)2)
MJ4D:I@8Y[1%E\&-8,Q\G?CGRJ0K.M//K2S-D1Z;_.&5&H7/57T<HGNRCH+PE
MUR2IE\(<6U0$F=:'S&!KA@YY/UJ*2^YD;)'C#*2DJN@FJP8X_4HGY77+2-NT
MW#4^*S=_@D-^%-/Q"9Y0][^=X) 3(^;'L1;?VJK+^;Z(+6<(@:65ECOKE]"%
M[BH34\=IN6'"$VZAC;G\-SH^;OBB:#OC"G@.%64KU6H]BD5.R1VATTI;VXY=
MCLZX$[F@,+S-UDW6K<0%7-.35%RP+QHY+1LI+[3J&G#F4-)<:Z[3WGFS\]F5
MHZ0)DJ%2"^:\-4<P*5;!5;W>3!MT"@S>:JG_C#<=P[VB@M>N#F+%R1'X>*4#
MY_38WE&CNN;W"XZ2/)])Q+?\<<RO^8@GZ"WJ+0.Z^P$,H?W$'O[X^8)WN?H1
M&_LW"JYF#ZQK!K%,;00IT5 PI=,VZ>^<Y-[>Q9MXXMEA)COX?N=7N,UN8 >8
M]+*NM*XMD*95<5.L.H;W]?6_HAB7=?'QZ7A3<Q$,M2"NX7-"L*6K+06*E7+_
M*$,G)R$]BDYEI-8XV.5;127G:<*3HZ@5YD(.L)6U:8FER90>+1I8H5 !D _G
MS1G%Z?O>Z"+3\IXF6L;1O,RU&J!WT 3#:^?+Y3FU&Z/50AV >332O!1S$AG'
MM?+W@PB[0/)DU^)IL_+0&N&0)@)< J3*:U,[FRL+A]"H.LXKC%@%T@RQH;R\
MO6=89BTY6/L\\EEQWM@(9]V]SI7&@Q.TG!<U* C[5Z_\Q3BYP,18=5)3/%:C
MA&HP>9' KBZ;FM:**!"'TNA7ZD8!2ZD9YXPY8>V&]'+_V>6*^8R/:!=PZL2^
MC&G)8XC6K]=G=.6S=I.7((1E09F0Y1Z^>S?7(QRT<^.6DI74>S$@Y<O#ZRFJ
MF[H$\;!PTKZR_9(GG(%8P<:M0CNSW18KMT#!=[8EFU)DE51@T[7+@O3\XE H
M-EK 5O5MT/!+;S_;M<JC-7S3?:[Q\,KGP4=*)C <MB,S8Z0IV')G+2VL@J>9
MC<RF*//>'FV7&2?E4.VF&>&:,RYA58CR0*:ZR6!8:5_=9@UY_#L%#R E=VZO
M8F[U1*E9;)AQF2<A/,-OF*S[QP<ON*,V??G<TY259VQ"^EL[+#Q[R5G(\);U
M-2P#4G*+KJ&#;HH)W@-^/^5O6V805T*BEJ[ 6&-F4J*%?(:S8&;J43DVU*MB
MRU2!.UE*$B^"78C!#V5=79\Q^I._B<IT#1$#VAMH):?_V9$A [$_][(Q>QV3
M?&:SS6'1T)[C"C.#,\9.35K?.4I3;WGTW")+3&>!A='AT#EZ;&I*V:UH/A!%
M!I.C M05Y81?F8[%?G;UY'?MG)?]]&=OI,^Y"B)>X'T5EO1O+N;?W;LW:__9
MX9OKNNZ?WVLMIG-'1HNR>4'F9Z543P]8QA!7IR.,\_<T>;1!JR*;<S@8CH)"
M"<&++.!NE[\\>3K!5KYPRY&N-O-C%_DUG!X5#UCFQ4[9FM3F.VTRVC@L;6J.
M'>V?$M6R%ETT.=8Y%_6R+0S"-5F=)^30D$GHX-6T87W/95LKU6@BVP##Y@J4
MK7EP([J"XHOP-81B&1Z[(NW$@>1]:RRHG+V"N\&^8%,;F:CZ0^,;Z]@&I2_9
MG<3%EZF*6H8\+'/GG+M&'P8I<EU9LQ6?KE:>WUR*$3$(G+I4#,#A/J4B7R4T
M>O)+4[P(UY O>D^9:97-NZ1Q6$=([^A7; ^R!F1/FNXZV#T6;J08AHTH^3@Y
M%Q-W&>J$>6DF+LZB>]GL@?LG&O$YZ,;T]WF@/[5?_NVWI_.Q>U^9MJM<'DNH
MZ;M:NL#GTF*CB]96N*Y5'641^V[LH)*B<I&HA+S9J657"K5@#%E05>KQ9BO:
MIF"X-NGK-8JF2BJ&8_05:XW0ZKS_W=G%/3H/\I=<U=W1@RW!M9U2N7I]7/.3
M_:$+7Z[$SCWI<>3BK#^5O#>/:".8 ?;]5A* F)F X\K><@QGBRUCR@(/9>_N
M.'-Y[5D'D>+E5=S2+APXON/?#/H &N!P-XY_]P:!=R (NX^&J3*<V#EB;X'O
MPZTHTT'X!1^$+R(9(+;,W+R[04X'S[63W;7L=#%!/P1B[2]SPS2SR(X<1<),
M6K2J2LJ5(UJ6PLMMWO%85LGYEVF0K*-BOF?;$]A9_^S8?\<9)TY?Z 7A':0M
M5'.QX K(6>;J[4>C?CZ[#/4%6%)-BK4'\I51:9 #$O4P&BI-ZK]LL*-V-N^/
M707&XH!:)2OU7^8T5HAP>28AW1WO*4^MJ;5>PB.7NIV ]0OX(/SF;-Y$QJA5
MFQ:/"1L;G9WY\@!.,#97-<UKL7S),F:9U+ARA+G^57A;IJ)HM!M8N]Q2=,%$
MO39+UV[HF?*X^F0L,+Y]31N0(9<98V]#8 #P5[V5@B9Y%+1"SX*S<^0%C9T:
MR-V$#PPFU0 WZ059N ]YNN9L64([&([)7'XC\6/Z^;RZ*1KEG^1V.E.,H(6V
M"R%6XF\D%Y@,]A=LL%$''6G Z9G0M;2LGK7<<QT._;*FO0:*9[768L;_C,./
M5%RK5F3%FMO@+-%: J=#K.'6<K&<KJ_HE<QB_P]DZ1J*RUVHD(YUOZ&W<[V1
M?D7$9%Q$*&+P=([VL7XJ0A4-))VHOC:[>K3@:MI[='4+)APXWV>R^3,Q-QX/
M!LE8GM%1Z#08)?^'&4+>)/3 5WD.B+-""I,7)O\K1@;F4I'+(BZSHN.F6@UD
M,>,#3@;@"S8 P]0%1TXYI$1:P% D$HS93E7PVZ'/AO?Z'^?/S^>S1^=_T'\]
MGEU;;R\[7)"K#=X!Q(G;<K;3!#AX(QX92L0K8QEK6P^*94VQZ**:8SA=1;:#
M@_#K'%MDMX&*Z>RYV04\@%8#Z :F?#KX1MA\<0"9:"O9N1H,3(_K@Y]/=)*
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M/DMZ)>2].GT++:U+T38AH$\OJ!:&3 +*N.) %ESP ZUV TO:" 4.^7N+8J5
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M\MGSLZOZ[V<7<_<1[3M@6D+\]NKWOS]^>';_>_!TRBY0L);@*OQ+#UEOKI.
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MP:8NC3$-'"9[TVFB:S 54>19B" V7OPA=>>V>E<%HH?T&?N"I_'VS",5W\_
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MEW*G&L(LZ8L_<+W7^ON%SF^+E1%KT/TX .5'I,TGVSCA2=\(3SK8\5CXYAN
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M];,3<5.ZVE(0U:MZV>%KPJ6I;CN[S%R+9R _N<I&JJG"%EG;ULN"<SHA_O'
M]V-[-!"R4/B @ODXQ0Q*I='=U7V-$NMSU$JY-U['9)!;"S<:U2E(]3O<M3&
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M+_[[67=?@GS-(4I5^)E!?;/OOOW;-]_][?EY=@\W\;^_KWZ_?4LB=/1L15/
M1#6*PCQ_SC]R0H_3B68I$JS9S)0]NN1YPEE(<,0I%HGY+A6&-FB@6B:3730U
M;:^<(Z>!9+(\<<@G1JF2%[=8.ETS'6(\P"#*XT40NF0XB\:1?BUG.H^8OK@4
M@HCTRY['0@:(A.P3\IC9/7T3[M.7":_W98 -B  0]V&39WL,(8<W@3.945=
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M/KO,T*T%18I05/<^U5^@&BZ=PF"%J$@FZZBKIVAFGP?P^0+^F!!D<]F1O8E
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M19S3,]!%ZC(_S5X(ZE<:!DQ?CZ0[F \7S+E]B3DLX=HQF#@OD-QH> 1[U ?
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M'.6I)_UQ3&=YTA]WE3)6V= 4<6==(Y$CHY,9--V[=<RPU\O(/M!R[KR>P"\
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M*Z_<F)[O5-&35)@IQN$X;(<'FO_:6100O>&!U?)'C\V%$CJK?Q*8Z16Q M]
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MR9QF3[6:QJSG0H@7<7P?ZH9KAOQU752L\PQ[,MPTKX6MPX_1 [_[6M-AF;;
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MP3RIB$E%W"7;7DIE\#$Y]8ZJO_](4ZP3W<'MZ0Z^F^@._HIT!Y.!G SD'Q<
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M=3/O6SK]=+L.')N\Y*SW1V8O=\6*E']*?KEI*KHPGAW[X^@P-.NRT"6B/72
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M/^TJ;]>X0JZSG/.Y: ;R:DW=9"Q\R "RR.DKB9,]<F%?E(R>%3 =,M1"C"E
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MKIJNBZK6LP@OPT ,Y62T$:&AFJQ4L':.+=DG0JL6OECE3(<C[O^RKT4HG,4
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M]N0+3B;GTW/G&F>>QE(#C3/S%.&SB-.\XX)U9'X0H\<$X73^#;H9H"8\FC+
M>(/.#XP^-K+V(!M6K,=&^6?#M_PXV80O,1"/205:"K/RV9U81_XGER>,_G"#
MD;[;K0&;;DCT'"3%1;:HWGG]%6;=TO_+2LKPQDKO&;Z +8P2O0;5>3^!$:T_
MO^]OM(G=PL@[CT6$)HWR!6L4]3OCP[[/9@=#QT9XIB1T7'2H=PF/W0UM/^L
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M)W1BLD?-362@M;/G*-O8Q)0>SRX[XDV$(L,!HPM31%#!=0>HM"QV=8,USIZ
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MW9<0D/-ND*O>_ ]A=Q>SP_Z>\'+&+!2IG1P_QD0U<X*9J&S=4-E-0,=_-\U
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M4=Z!^+E"PU\QPMIQ*ITH31U).NUU&H"+LY95!MDKF3V=A V0RU45ZITQ!4]
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MV('_+#S_->F[$%JN2%>5+3/_38\7JEA'U*@^^?'%#Y_*=\D?SMBK7:#>!@[
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MV2#,!N$:%Y94ZT"& ,Z<,H$(BOEA[]UT.#N/G=+_3,C/E +3WD'(]?*M;P0
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MD(G#$IS&=N<(:-= KU/F@5HXCY.10&OM XG&-#H8",+4YF/ 6B-L+EH])DX
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M6G9Q,AV+ :S-SU(0N6NJ.Q[=A1&1COQ2FV=V1;L1UDQ65DLQ6NJ+F"H0"WY
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MKH#GZK"4XI44*]9D6#8A^\QP'F-0CF,[QQPC8:5KO3[\$=YRX\ OJS5[QM!
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M,V9O/_640;7.1V^'1+_=$%GQ?/1C+\NR]#1[PDT<MN Q=K"QN7JNW#C0HLK
M%B87\: ;&:AL\$KZK_O0MTHIF0PR%TXA5WQCL8MNEB3\2VL4DT/Q4F1\CTM/
M_7PV:0Q:4RV^H%;Q+K.40X=_W+DW+SV&VY<4$+K1^>V%$@%S]&YW6BO90:B$
M7R @JQ4=B($S[!J[]80.<_ -R(VA7IT-CV)L).V%<Q&44FHF=)71@%E_DZR"
M;6K$D-FJX,67KV<-.MVDOELZD^>V[O9+KB&!H966ZJI<[H6,^EL)*TTXDM&
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M7_V!'(+KV-\1R3V6Y':12]%&R@!K48//P@?Q^#EJS-5;J2E(5L37/5L<S>Z
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MM&=LY#53CO !\4^KL'GG]>?+UY?RRO57JC^?%3%#Y:<B*V;"ZD:;+#![WR6
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M2"<).%<:C1A+>A7[GRX,]R9Z (4PS;N!XP$%Y9NXIIE1%W$O&XM?ZM+O=$\
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MZ-2[K5W*0W8\B'E3HG?)TA@&C3:ZO?20E[-ORG;7F38P4\@$I0BS&-I!O8_
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MSO-B5;-0MYO1.C-D+054-&6*E6E5@&YQ8$!^B% R5VZ39U@T*,P!L*KM /%
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M'Z]N\M+P0#NG5THX#]]P"C'.WH]Y&,J-$WB?DZ*2^QN<2FS?D2RNF\T$NIM
M=^<RL=\!]#Y/7K-F2EU'*+DX1E#%GVC/CLO2X1OQ-!M;\,E+H?O<E(M2\$9P
M8:N6_CLACTYNIE+SP^EN=)L6;M2@$$(G2T34*]#]-L@A*ZT95DSWOQJ"SV*
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MF<F4RZ#FR7S9:5N=TRN>MM6#;*L\NKMO^&:YWIL *C+IOP>'I&O GW.[3F%
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M<BJ-%V1>*R%5X6RB'*0A$X(Z&V#FTJ"@EJ=!T[JM1<C5GJ26<[)&GZ58TMK
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MP5/\Q=41PB+6*=AO-F#XDN,,C('=+.&FHOE#P;VB-=8V$V\0:G&8H<W;N(^
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M+[AH+WQNV\9:R^=XF3,>9DH1CT$(S(9%2=S'76($MD34[1^KZ!OZ,\MT@"U
M=:^Z+)U@3,B??V\B.$+8/[3O("?8E:2E[O&DPY"):NL)G# &2X(RYQ#^F9O@
M-ETY!P@[(50Q1<1W8E(/N8A*X\91'@OJ-R:NL55"/$[%=?,>L=]2KP,%&!I/
M#,>DP' !9N/&GC3?$#0EY3"HZ7-;7^370#$LZ=SA4 );1P&U7.7@@;KUZN&
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MP;*?6H&3QVG&NM:1!# Q $?%K'I#HVV4JL.\8WR5@ARRF'!2U34;^62-$IX
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M'1!E#*8VG&*BBGJ0U#;E%*(V+FPS88YN>ALD$[P:IR6[SE*\N5S5 S#BZ(Z
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M!<W7@\BZ")/L:-N!IX5CU84U=*80E..SR>R])+2%>R$T>7+?E]RM^GLX[)^
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M[;ZCQ_>R:%;4%0S_323O^%.]+@E.]0(E4$RE>"L%B 10!YHXE ;+8_\PCQV
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MD;K&_V2M452-+OE[V/#G'LO6V"<V"MBT6L<%4QL J2U8GZO!8[??78VA[JE
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M)$*+J\=5C&GB+7S77@3 6X( U\A7^"I8-L*Z 5ZO\7>#+N'L@NRF%S0ON"Q
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M]]/.)FJ$^&/?5GDM\I=2 &B-$;/VDK$2L:Z#:,TV'>?$V'5R;[\-3K 0_Z?
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MA\_9JA7?10GW%X! A@%&;B._^.ODTXGQV^GIAY<" HM7];>V=L*3&G,E,?@
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M_U>\=FM=CHOC[9GX.)6VZXA!NNR^?G$O.B.MH06MN6R/60FR%E4? $X8EK^
MM[C')BG[RB-U0[Y\#3_=<HHC6@KE-;FP);-NL&N9O)VWZ$U*+#^XF%2&:KLN
M6B/5TBP&FV]Z8V3RE/$""Q:^!*V6T)0M93$F7/%*Z+V\A+';]5#_'6V"==%2
M?C&ENTXCKKB(=)]N@7W 7(+I%/"_3(08S-F>&GB4AB+BBTG!\/Z:"3^$K^4T
M)N=QHQ_+OONF)\8;_CV>:,'W9'K@NL(ZXT3*&PO>KLNB2Q_KTU*%-22;SW:Y
MF]WY)1A@;*JLO117)_E*&G1R:2S^A*7Z:<.9?70%HKLF+$HS\9M,^ZI'B5,[
MLN&[L#7G-RP7QWIFZSV^M1#!0T2]9T?1D&_WN1_=B<:TX#5/B,:()<HK(DIU
MC]RP&&JON]2 ]4IZJ(9W#FDQXYQ+T8U*XNG;U)SNKDSTR<VC*E7C4HR=%%L"
M4<_ARY@.4%2-R$5H1O'+3F[)@;G^PMR=3NK*7E63^GQ<4.^1NQM7R:4<%<F-
M\J:6\:&S;'@Y[#['6QA5(L\;IK S"ROF>0O<AMF_<_PZM(P("]?".+=\@YK2
MK(/?A" ?I\C+E-9Z=!UM\U9-S:3DJT36^7J)F.-=EQ?7="T;AN*6>2JSP[N)
MP#37(EN6=4^,]>?VGD\3VH6MEO-*ML85QL3+BPKFERY&<Y#&9I\B)GAE6D?R
MYE=UIV<8<YH+AN>M*D<8YT9\,&928!$  ?_N;_ALT0*C\W+>$XW:CB8U"9[L
M8K_+JO[:QW)2";VV2XV.;LXVV((]!PJD?9XPORH_PBTGQB?$+9/&$5TE3.DR
METG_" #ZEJO=O0!YJZF?.T^]X[>PNAL$W3'3W1?NHP]0(R\==W&+VRB%#D!)
MP=+O'2W[PH"3BWZ=U[([>_+3OCQH2YNO@AUZI39-I]PXN+),QJAVKP34O?TP
M.&5%40_YYVVE19M1:44Q3Q1S+?:V$0541Q.>9K](\X:S2TJXW@.4+"4UYUZD
M*P?U@_S_!Q,%=*\IU;AUG5/R?2>/T#N/67/;!6H!7\B>3E(@P!XMF?&UK"[E
M/8@4CZZXQ=E)D[XNJG%:M.><KO!D6HE&8R*5F#<>[.<H5M@ER&-Q3%YM%0\)
MOQ30%=85<Q$W[3F(%[60IM4D.[*"+E]+HN9+^<$ %_H**>B\O\#D:G']8#(O
MH72Q_*NXVHZ46C<C.G43ZZMEM%5EG .?&5P+5]B/0]S@EH5DDC78C4/]W_4.
M(2PTKJP%LQ#]B.MV,>"@D5KGT82K#K"M:U%4HYL=7U%_5(41B+;;^!K^M0@,
M5%3%ZR O^@8IW1Z*8KWI<*NAVS*D;M=!J=JY/CY9?JAZQ754-HQV:OZ [^]W
M[$&E/9>'=$+NWW,YKN T7-$?%[#*&VDSB,14VO5ZVY>H/OJJ!/S"5R:_A\FJ
MDRHB=+,3O#'IG2&:P_/4]"7]9U7C/5/YJC>@\$'\BWIUT>M&/-OLJ%2R,1Q(
M7\$,W<47CG+/L/<2)P"O'"\[-6_@I^I&XX-[J7#W2)5QWY*X/[N0B]LHH\\O
M\/$Z3(G(>!]0]];S<M9;E?AA0CGN4"UJBG%5O6,&4U_:Q #I_,I],?J-?G4B
M_>R\NZZ$!AE_ .<I]H:C.<S0YXHR7^*"N,-2/CEJZ]*,ZOJ@S@.RISDOVRV+
M1O ; J<B;0?5X]-283IQ62<N[TE<MG3BLDY<5N,PKML<'3U;-8P #XC*.F"#
MQ*"11(6A6A@ZW95-;FK)I]==72[Q-'=-B(A1BU4(.Z=%+I40.O)@[E2TRQK5
M[V*8N]+Y!S;4%[_LVGT/%&!986R-E1=Y796BM":'0K5PG:[K:Y;!BR+R)-3N
M+XWP\B8B?P^;J8P3Y$16BS#FI8^M8;!J7B]#*LUFN) ,Q "UR?-PVJL3XXWT
M](COR_J1T@6]I>&WL@?Q97!,ED,&;-=O4H;_A.N!^S\JOFC,R[M@HUP>#N$
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M6R&5)@VE<UCLJAAU:U1/P&AI>URJ_V?:Y.+(2Q"@+K7UT3ML1?_Y'&3_;K6
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MZ-EV2ET6><$L3I%K+R_K:)661%H%'_0^Z(.OUL'7*OA@5'#J1"$+')<XU/=
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M!Q#5[\HW0E#/U$W)6D36;!A-2Y_#ECZ*D5RK715VX2@(KM7NL:C=*$H"K*9
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M9Y:B#!]92_.2I6]I7>;E63-29K\(738O"/9L:P$K4C)N?(,X&+\,3H!Z(OL
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M&\@[#^0-#2X-"RWXXI:1,MJ2YU)1*<RJP%(*]LHLR8C(^]_AY*Q<#[RWCL(
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M5OG9^FDX7>W#R3_.TXWGA8A1,E3.+BW#:AZXI.X$#AP^O@[F(&X$<PCF8$\
M$8 (#CU !" ">^K?GOH2.$#D^#J8@[B1$9P:"%V?$=0I2Q9*(&-<(N58(E>B
M(B9JJLDQE;3],".H1*DB1D<RJ$PJY43>QT@^&LF4TMH89 3ADAZH 1G+NB?G
MBCZQK/O)C_]UXWKMBZ7<FUK+,+JP.-UN7FW#FW<]RS=N^,82[B] !:68#:5D
MJKX,5Q=G35%91TP::Z-6(4G_(2JXZ%3.RI)320X7.T1RJ<%)<JI6Q7C6P3W\
M$N[QO#]F$7O@J1@"ZEK<" OF 0 YV^I"B)1%C:0&C^YEX_G)IZQ-D<78.@8
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MJ[+K8[2D+T.=#('#)$/7XD868&)9 -C3E.VI+X$#1(ZO@SF(&R "$($] 40
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MO'S'#E_N[5(K#(_!'74G<&#P\74P!W$C?S^Q_#WL:<KVU)?  2+'U\$<Q(U
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M.:\*S\K*9*\,O;X(;P\0]+P>D.3R2!P 9Y1)&'F\*1B$4IB@G'PHA0'(QPD
M+68027-/+ID! &(@IQH M$!$YERTST5\" ".J<I9TI1-L*1JC!15KL2<4<(4
M[F/DOXI!WOG\DK\]&P*-%^V3;O+Y.OU+B'^'\'=<JL^7W/BE]J-%$O!$4_9$
M?0D<\'M\'<Q!W"B'3:P<!GN:LCWU)7" R/%U, =Q(X:;&@C=L+E.EF2M=I29
M*$-"SE P69-SQNN2770UW+DE_X88[K_#R5GY> AWVY2>8$LG&:(X^*+>! X
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M2-BK', 7?J@W@0-\CZ^#.8@;+7T3:^F#/4W9GOH2.$#D^#J8@[@!(@ 1V!-
M!"""0]\?B" -^+!IP!1CL$Q2-BX/Y;1*@1M/RA47;7#M7_5=&JJ/E0;T2 /V
MYX>PG1E]S1_O:VZ/WM3:?/[LS>E@S-CA/&5J-^-9DSF(&]1N:K[U>FJ713*5
MBT;31':D>&H_R9S)!>Z58C75H5I[^^ZJ3US"<6AGWAT>?'[NM"]Y7KYCD[/Q
M8LGD:(5>N*,INZ.^! X,/KX.YB!NY.@GEJ.'/4W9GOH2.$#D^#J8@[@1R$T-
MA&Y8>B*E<XXK,CE)4D88\KJT/TP6UFFIHN9W:=7]G-L4/QW'W395+Y?2,,1R
M\$B]"1PP?'P=S$'<B.40R\&> "( $1QZ@ A !/;4OSWU)7" R/%U, =Q(R$X
M-1"Z/B&HK8E<VT U6TTJ.T^.Q4 V#SV[M3VBV1A;D)$0A$?"6N)[4-WT'-'!
MW"F&9N1#^^YI6>_"8)=]C)OT99B3H6N8;>A:W(CY)Q;SPYZF;$]]"1P@<GP=
MS$'< !& ".P)( (0P:'O#T20.'[8Q'%26AHGB!E?254MR'-O**I@DTTI<1G'
MZ"1]DO_W;+=_TS[*[L?-DYQ7PV<()R_"*C];/PVGJWTX.<P''A)*3]_+)_U0
M_G6VVC71O2S;GU:IG&><?RAI\VI]>)<1U[2SI=8">R+@P7H3.&#[^#J8@[@1
M^R'V@ST!1  B./0 $8 ([*E_>^I+X "1X^M@#N)& G%J('1] I$'G[)6CGBP
MEI22A>*P.%;JZI@QOGJ6Q^@\10(1'JR+3E4LFIV:X_J^[!<GFQU6Q$Z9SHW:
MMA_;L\OV%T'IT_UBMSE9Y<6O#VY?NIJ#6CYA')^K&.08>LLQ/*1]OL^,FCI@
MJ$ QH!A0K!OC (H!Q8!B$S#4O@0.% .*=60<0#&@&%!L H;:E\"!8D"QCHP#
M* 84 XI-P%#[$CA0#"C6D7'</XH]5-O4]&#LMY=' -U?5[J_JJPU"..(#Y=)
M*B$JA<HCU:A9+:765,6'W5\J"\%*>[JNT9"2L5)T/I"UADFGM/;!?MC]]7W9
M/UNGS9ORM\UN]_FM6KMV#-M/'^W9L@WQW6@]6R M=S+UASO/O^O#L?>E,; >
ML!ZP'K >L)Z/LIZB>'!&1HI!L<9@JJ/@F:4J:N9:166]':/G':P'K.<!6,]]
M;7$>KQ%^DEK]I.N*FY-\7XK^<S@)ZU068;_XMJ3R)I;M0O+E0C#!^YCPZDN_
MDV&^& KJ6MP8:YP'Q7->YRRD)^U4(!6U(I>#IL;PBN Z"Y7-AQ0O")U-$8*B
MRII44>VG4 III5-4K$89^94+-8:1Q=WSL_UN']9YM7[U*YJW.SSZ/K][]OU?
M/LKKC%\R99?..DPAPN'T)G"@[/%UT'5\\IL^K 8P/1&8-KH45G4E+UTF5;-I
MD&M90V#)C/+&:E]'@>GALIO7+5XKV]UW_SI;[=^.LB] C':KU8P=UASP 2C=
M@Q8F=.B!TD#I^:!T<4XGV[Z%:U"MI WDBQ:D6+)1.ENS31^B="U5:VTC>2$=
M*<,;QN>&\29QQPHO027W0"AMN%UJ(0'5@.K>! ZH/KX. -5S@.KI82TZ-&YF
M'$HX%TLU)(KVI%RM%&329)@.*<4JG.(?,@X;& ]!97)*6U(Q"?*:&6I/SM8K
MDS378S*.SVK3 .N8N .^;9\I: MHR^.U&M 6T);'2%NDRLIR2;R1%U+,57*E
M,1(I>.8Y!.>]^Y"VN.1U]EJ1M:'1EA(YA:P*U>%>MQJ=DVK41,GGT!;%^%(Z
M!>XR;2\,[@+NTJ4.NK8:<!=41[X(]$T)-1I'OM9 RM8&X#;5X1J%E(2W0:0K
M-R@(*W)FK% PV@SY#4:1I4R%YT8?7/7QX7H8N%DR9X#U_55''L.E!_?@K.9Q
MZ\&SW>[L, *RJ<UYO'FS&;Y+\P#-YIL'6.Q?ES_&[>+W%\?G_3^?_/A?BW)P
M$.VUM?V2]:O%Z7;S:AO>+!?KLF__>M-+5Y>_-&UV^]WPJW^#<.]&SQ\-CTYK
M1\V^%*F0) 7>@""Q6DP39S;Y2K@GBTPE>$]:A$A*6T%!5$LF%>Z35]69^*'G
M?Q'>'B[.>5X/&'!Y,IX..AKGWALUFO_'?'T/L<.H YU]Z6 .X@;UGP< U&AC
M2=81BYJ32L50C,P0JZ[8*IAD3(T! ._<?LG?G@UX?GX'VOGP4?LFAX=V=QP]
MLDLFU=*KT2:/X(2F[(3Z$CB0]_@ZF(.X@;SS0-Z&ELDPH\F7+$CQJ*A]/D&:
M&^U+J$J+^T3>PY6CUP/OK6,PP"X\4&\"!^P>7P=S$#=@=QZPRP77.II .7%Y
M ;NE_94Q$:W55;I</H3=XGF1SGA*23;8K993+-F3\%QRHY27-AP1=OU2>V O
MW%!W @?V'E\'<Q#WO6$O+DZY4;W]7)P">P*( $1PZ $B !'8TU3LJ2^! T2.
MKX,YB!M9P*F!T/590,:,MEDRDC$64BXD\HYSDDQ[%X6R3,4KT_FJQ,P5(YZR
M))5EHN@C)U^C$+9P+?F56Z,>. O8YW4*C]P-W=?E!NB!GX#[^40/_(MG+[Z[
MJ9.]KM;ME<UG7+:\+]#;_B4^7KIDA/:2O&7#A)+6Y*30E+@HO'@A2]!7;@:L
MW-O<?/S0%CGX>$T^FN;C=76591VY20_>V^[<T9:T@N1C+K9O=,58*TC^#0"0
M4[;"-YHN9?6D.&O.7&5!@24G%=-5B2NKN6\#  _2VVZ61MHE-QICKG!"O0D<
MR'M\'<Q!W$#>>2"OL"WPTH91&2ZP4H*[X5)V2XI5R85+J?(KUY..B+P]][;#
M TW9 _4E<,#N\74P!W$#=N<!N\H4YZLV5)AWI"*+Y*HHP^61/AC)I?)71LIX
MJ;PJ7BGPH!I49S-LGU:4HQ>^_35D<_W.Z8>!7;7DN*(*;J@_@0-[CZ^#.8@;
M;8D3:TN$/4W9GOH2.$#D^#J8@[@!(@ 1V!- !"""0]\?B" +^*!9P)1=U+%(
M2DYE4L4J"L%($M'6)&4:;JZ]LN'"Q,RD4<2X\Z1,Y>2#LZ2C#L5&%8P[YF*I
M(0N("ER';@C[W=';?NAM'WY]'7K:\^+?8;L-Z_UNB1[W^_?UKA0C924?@QMN
MX8CDA%>DO/>JLJ*]-5?FF IGS%E-@HE 2K87.JT4E1(L3])*Y>7#[V]?6NVQ
MP7U.=!\S9%V+&SFCB>6,8$]3MJ>^! X0.;X.YB!N@ A !/8$$ &(X-#W!R(H
M/#QL^W$)RF@C* NNAH4+GIR.@GBN452MG<E7IGYNTW[\)/_OV6Y_R$?]N'F2
M\VKX#.'D15CE9^NGX72U#R?_.$]"GI<GQKEEU@VG&@MVX))Z$SAP^/@ZF(.X
M$<PAF(,] 40 (CCT !& ".RI?WOJ2^  D>/K8 [B1D9P:B!T?48P1L$TXY:"
MBI*43XI\R(Z2-JID594R>8Q69&0$X9(>V\KMAU'=]#S1S1NW3]N/Y>>R3:M=
MN:DAN;WHLG^YC[&;OBQY,@0/0QY=BQL$;VIN]89%C]4HJZ*A*FTEQ9VAJ(4C
MF:()054=J_B0X'D9I I"$\O%D1(Q4K194RRL<".DB.G=/2JOMOO=-Y<>_7E]
M>O#GAQ&$OVRV%XSNNPN7OCLL7+[CFF6Y5$HLM;&8-H,CZDW@0-_CZV .XD:.
M?F(Y>MC3E.VI+X$#1(ZO@SF(&R'<U$#H^A"N:F:J89G\T(:K<@H4JG9D;*Y*
ME5"3X1^&<+*%=;YX3YS)883<:7+,%U(I.U^<:R%>N%4(=U@>,DIR7BI$</!#
MO0D<X'M\'<Q!W(C@$,'!G@ B !$<>H (0 3VU+\]]25P@,CQ=3 '<2,-.#40
MNCX-R+*NS#E.,M1(*CA'7A=&VEH1K-?".W^EDR/%6)@Q9 O3I)32%&0T[=79
M<%>=JXPA#0@_]"C7!J,_]S;]N=NRVV]7:5_R31VZ%T]NKF&W^*D]>[5^U<=4
M2E\V/1E^A[F'KL4-?C<U!WL]O[/<Y5!M';8Q)5)5,/*"M[\Z%ESTEIMZ95/X
M.)VZ?V]^_8=W;OW\GP;O_=_GSOO[LG]>#ZV[NW^L]J]?EY/\\J)M]TZ=O(+K
MI=08SX*;ZD[@P.;CZV .XD8"?V()?-C3E.VI+X$#1(ZO@SF(&R "$($] 40
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MXEEX4I9)<HTW-(K!*[,RI3R0A/M8?#T2L?AH+YZ1?<YJ3YU./ 9GUYG(P0;
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M,XT0+JO5)0'-< TGE[<+;Z5:#!;B+YXL&P&OUNIH81]*%"@"YI':,K/-<#K
MSO'!\<'QP>47G0S!G:%S>D!COZ&3%33*LIR!C9,)0B,6$\;2!.P>1HL\9V'N
M[[3C_)) X=TYCC\!W/D-T,Z/@&^.U8\SB-RP/2>'YDARIX#GP(6S(+A3P.>B
M@#FG+.%2D9PI4*:L2$BF4DIH!OI2Q06EV-OZZR.!]ZV [R_.YX30:0NAF9'<
M:=\Y<.$L".ZT[[EHWR34ZE*2Q$\*0GD<$!;&*3PO];- <<8$_98XG].^3@C-
MM,;/->,\2OB.W5[#3PU&Z8IR!>>Z7%U^4U#.95O- Q0X/C@^.#ZXE)Z3(?C)
M6R4GJ/Z?=;QUUM4>ZTJH,"R8"$B<4IQ*KA*2%XJ1""PKP8HL*))OJD+LK2L+
MPMX5;SH(=KS,2!JZ 0?W@]T?<']^/P\9/#.>.? Q!RZ<!<$=^'#@8U[@0\69
MY&DBB)_$V(DM8@ D$D9BIGP5%3(6&3M*8/4^P4>VB/*C]4P]9R'JX(>#'_/1
MAJ=T<LZ"X Y^./@Q+_B19-3WHR0G<1[$A/(B)(SY@$$2)C.6A2PO=N#'5T66
M[Q-^!+X#'^<)/EQ)Z5.+22\5:]0\$J1FQN+3P:&.#XX/C@\N2>UD".[L,F>7
MS<LNBVGH,_0()RP."';S(7D@!&&":H,MI"'_]LZXNT;93PB_CF*4A6'FDGS/
MTBASR,,ACQEPX2P([I"'0Q[S0AX\B(20/B.%9( BBC0B62X3DOE^RI.X8&$:
M?GO/W_M$'O'1^@.>L_ATP,,!C_GHP5,Z.6=!\),''DYA6X7-PB#),S\@TL_1
MV$\B,/OS@J1)G$4\BD G!]_>!/BH"MO5 Y^&W)EA/? \67."PN0W]J>W[D*P
MM5JR5DFOK;SFBM5PMX]E>W6EEA+/K7>C&OP4_M[6I< ?S4!0//NN@/BTD9KC
M@^.#X\,]98!QN%K5 Z7B=>LUU;($63I1!C/CUEDPYA,'Y'-9,W]+Z 3!AW/!
MWF71Y6DA.<T%*7CA$QHGBK BB@D+BI!F49;YX4ZSQ6\I2/[5H+_?*L"$_X.X
MKUI*,/#>5/4'!(,_@)TG7U77:[5J&"[S.#5#^3P+EC\A%\8/@ZTP/]E]GGY=
MAXY.4PD[=#13QCP9=.10A445D>()AF))$O&4T Q0198D&4E"(?V(!D6<'K72
M^&%0Q8D,<#UU5/$49-[,2.Y @0,%\SH@#A2<'2@(F1^R1"8DS2-**&>P0[(P
M W@0YDGJ^R**=_+,OZ7^UX$"!PKF$9 ^5L*,:U!]#);_HEI/P(GUUG5U4THE
M/7X[J@K&0WM3MJ5R,V1/&RHZ/C@^.#[<4[Z:,YUF>T"<Z71^IE-&F2I$1A23
M8 ;1-"(\C@.2I(4(8A;*4,3'B-("-'H%R.B]!48_W/X.-M+;59^'^[+'1L>)
MRT8+/Y]GZ:ZSE^8OZ&9&<H<$'!*8UP%Q2.#LD(!01<% K1.9R@RTNN"$9UE$
MTMA7BB91JNC.=/JOB:P^,!((_&R1)O,<4^^@P/PEW<Q([J" @P+S.B ."IP=
M%$AI0.,8S/HPPEE2&$K-<5PO;)W CS/*(WZ42;T/#06B>)'Y@8,"9R'I9EC6
MZZ*HQXJB/H-#6V-I_O=>N3(_P0\ZN+HP(5;UKTUY R( "W_9:E+6BY_/(]=H
M9IOA=,"CXX/C@^/#TYCH<!8$/_E.1"<(%%S][5U&',T3D?I93EC,**&YY(0E
MOB1%'L '*F3*_Z;FRYT1AQ8<_O_U ,A^[;$8?O!R):=_&%WY'EZL I//0+P?
M+>B#WY<;S*A]_:>X8JM+]2MKU>NB4*+]?$.P@:T./]T];Q@,PB"<95KMS(2T
M*\AU\&8^VO:43LY9$-S!&P=OY@5O L&XBF.?^'Z2$YJ(G&1Y$I&DR'*9II*'
M(CM&N/J4X4WB+VAZ-'_W.0MI!V\<O)F/MCVEDW,6!#]Y>.-@03?X(8PEZ'*?
MB"@+",T ('#!,I+':<I\*;,DW<EB^YK0]5QAP5WA[R!<)/1H2?%.J,TTFNUJ
M@N<DIEY]=LC:8ZW'%9!DA<7"5>&MM9B81Y;7S#;"Z6 _QP?'!\<'EQ8\>YO)
MI04[V^INVTI1R54<%41% ;99"F.2)3DZ7[,LR7)6Y$FR;5N%:2BE[RO"DC@!
M>ZP >\P7DJA ID&4%6!G!4>UK8YD*OD+,!A=IK 3?@X=S)D/#AW,E#$.'3PU
M=! &B1(T38E?)!&A8>8#.@ASDJM$YB*F"6?1-CKPF4^C/!&$IP 1*.-P.0-8
M05F0,N'SA$9\AN@@#1;^\1RI#AT\,>$W,Y([=.#0P;P.B$,'9X<.\D"JP@<X
MH+C*"?4+ANE:@LC$5SG+>10'.W%9Y6=)G E&BDQP0E,5P7>BG$@92RK\3.6%
MF!\ZB+,%]5V_D?.0?:[(V(5E6>LI^/.W!F1=,MX\L(KC@^.#X\.##(,(+T*$
M&++:\*6:MUDU[P3P_YS'&?M\[CK+;(:89[]E5DA)\\2G),JY))1E*<E]EI%,
MI:S((QH7?&>B'D^37,E,D22C/J&1R GC0I&P\'F4B80R>MQ"FJ-89@E=I$D\
MR_S73YXL9YO-0/[-C.0.8SB,X3"&PQCSQQA1R&1<B)@ SD@)58P3EOL143SG
M:<9R%NQB#)<YYD"& QF/3G(',AS(<"##@8SY@XR"^UF8)I0(D02$%H$@>1Q)
MD@9<T(@JQ0O?): ]NN!T(,,5_\XFRLRKI;PW,?5ALUXO%4X,9TM/EHU85LVF
MAOM4A0?'ENCH<KFZ 5FAQP.OY# L^&^\]OYJM\SXWW)EY (<]WGD:LULDYP.
M7'5\<'QX6GP JN,G__5=^-W#\F3^('Y.;'*L<:QQDLQ),G=<'&O.@S5.DCE)
MYHZ+8\V,_7:N.F1. 8;W=;4&NMYJGQS6AZS1B^>M-[6X8@W<CPE1;Y3T^*;U
M5E7KW2KXE)6N-F3N^L[QP?'!\<'U^'6)$F<"!5WZ@TU_8)'B- D5R<*8$JI\
MX'S,(J(*254J%1-L)\?RZ^:]K<N6+5__N58K6;88T'R[$INZ5O*'3?M+U?X_
MU;X'*'2<3(=%0)-9YCG,3)J=A?IP:GP>?#BEC>_4N%/CYZ3&HSP.0Q;GA&?*
M)Y1305B>9,2/BS@-_%Q0F1]GKMD#JO$TFF>RXLQDV5DH#Z?$Y\&'4]KX3HD[
M)7Y.2ER)&&L."B*RH" TX&!7)RH@119&F<\+3MF.$O^Z*60/J,2CP%GBLU3B
MKGS@3,.0;[IJ ! 53=MXI9X0J"3\T$<@ER7CY;)L2V6ZU\'?X1WAXC6[97RI
MYI%2,+.]<#JHS_'!\<'QX9[ZX<Z,"^=I!3VYY#1G!74%V466Q9G(B*0"(Y)@
MT3"61R26:<%XE"H_V)D7]C41R1\5;]\VS0:PDGJ%0*FS@7[<U ">?JE66&GY
MKG[/8$.QI?W]MYJM&K/>HYA'X8)&T2S;?L],S)V%7G'Z?1Y\.*6-[_2[T^_G
MI-^#)%0XMX/$2OB@JU-),B82(I.(\B2,8YFH8X0JYZ'?D]PI=Z?<9TARI]SG
MP 6GW)UR/R?E'H81+W*9$LFPQ3N-0L*R-,;9WU+$,L@+?T>Y?TT(<Q[*/5Z$
M,YW9-3,Q=]+135=D.2>Y\ZNZ5@P;HNG:RJKPL.:2Z59H2_A >5I DZH@&_B%
M-8UJ\0C;#Z\K61; DV_HA.8RV^8!"QT?'!\<'YY&=M1YFDDNT_.IFDD1F$<\
MDO :N4H)#3-%LHQR$J:A B. *C_:F6O\)3'.R[IMGD^0TKOB78>3?D(D]"N^
M_+OB]T:]1(C4O*EJ_?>?1P#I2+68U'<9H+.TD9QR=\I]!EQPRMTI]W-2[CB"
MBH9^1F1.03U35I#<AU]Y*@J6Q%F>B1WE_B4!SADI]V1!X] I=Z?<9TARI]SG
MP 6GW)UR/R?ESA6+1"(3$N4Q6.$1CPC/0;G##X'T.4U%$'Y+@'-&RCU:!"EU
MRGV.RMW5;IYI=%.?Y&EU9ETV&-PLZNK:JWC+RA7^JJ6TMQ7FQ$M6\$ =ZVSF
MD;PSLSUQ.JC0\<'QP?'A:>1'G:>5Y-) GZR5E$5QE(4ID5D6$,I51KB4DN2Q
M+XNHX PLJ&/4<&[90N\T/%+R[>KUG^**K2X5&$>F'8;2R.HG"ZQNCY/^&;O*
MS5F:1TZK.ZT^ RXXK>ZT^CEI=1:KA E9$!XH1JA*."ATJD@09(&?I(4?^\4Q
M*C<?5ZL'OBO9=%I]CB1W6GT.7'!:W6GU<]+J@<_#-)8I45(H0F.PN[D?A23/
M,I]E(>,BSHY1LOG 6OW?JJXD:ZY0DOT9^@%]X;3Z'+6Z*]0\TU#F*SA\>KJE
M+K\L40FHIO5 [DC%VWDDWLR,RZ<#\!P?'!\<'YY&>M-Y&CPNA?.I&CQ^D?H1
M59RD(<\)94*0S$]CD@B:!MSW)4/CY=N#DV\MY,%1&K^H]C@%%S1U&9ES-&.<
MKG:Z>@9<<+K:Z>ISTM6"!4+ZD2!Q'*2$RJP@7.0!B2G-PRQ- A7LC*?^FI#C
M473U_;D<SUEDG86.<+IZ'GPXI8WO=+73U6>EJRGC09+Y)$O"C- TIX0EDA.?
MJS!*E<RR>*?OP=<$$IVN?D*ZN@L/PG]Q+J'^\1!%_G(G0<)O)<@@?^:C2V='
MCA.49A^4TO,OK^$U;K&V<E6U<)>V0EG55,M2LE9)KS!C-=D27A7^@*79S<51
M6/'-1_6\=N8]D>,$=V;@9UL4O>IS)-;L4AG%0E@!K_N<+3^RV^;%=]Y?GP;M
M>;64]T;YO]=EV[352GF\K!;>VY68]5$_.?K^THG85V,1^Z87L1]Z$7L4LB>.
M[)KL/RJAKKFJO2A8>*$?AG/>U(^OOV1Y<RSDVQM-OVRNX0_"VDQ9*C)),TI2
M1M%FDB'),A$2E11)R%A,,R&/$8O\8=.4*]4T/ZI&U.4:[9N7*_D#:\KF7?$>
MK"F@@NX<\QL\YX=E)?[XSH-+V1KW0KU1A^P0 B?+3__R8LVD!.A$T&AX'E\D
M27K/6\98)YJ*&J[];UO];X_0_G= :*=^8H.+_WA77[)5^6_6Y\R=] MM#5[X
M.HD3?+/U\E!)ED>AI?D^+O)YV<+ZQ1T"OC_?.!NC._:?I'A\D4;1?=/\GYNF
M+8O;,P#F>^"A]\PXDL2+_D/S!_G"JVJO^["]4H!YM*G9??R]5S8>PSNU2ERM
MX'4O;SUKCGI2W:AEM4:SM 7J*H1)Y?7U!H3>E8*WQA9!F%\K,&^^]M@*/EX5
M"CU8F\:398.I]!?>;\-CO8^L@6M$5:^K6L.N<N7ALK30Q%WSHUJRCZQ6^,'+
MS25P#;!"$"_,W1N/PRWUMUZ#*KN]*9=+M?!> 8]A(:N2Z<M>L6M>E_(2/OF9
M-0T35YM&M6VS\#Z6[16\+M!Z4S#1ZGE-'ORD<_WQKN^Q?1%; 07'=YV^@QGZ
MHO!%O'UBT3EEN^H.Q0*.8($'OL).\Q%A@8\]&624LJA(T_PH  -@#>#*4:^Z
M#^K2*."Q>];^<>R8??O+FXEGEC1*8-83^DD!E7SWWW"0#KIF3UR,P,>:'A??
MKA&_&5 =$,Z/'"J<%S'. "#\5/YK4TJ0M/N.T"F\@#>#[;$//,Y2OGSF@?H,
M]'=*1^J>J3K&(5<&2^G1D^-)=%738.]& $)X!;PN$V)SO5EJO"5548JR]? 3
M#VSOS=(,LEM=5OAE58 Z;+5WS**_O1#G\RD718LH7=!@#L23]>;R7+3WNJ[D
M1K2(O:7V8 *ZA<VPW* K!#$5?HH_PNK$LEQA>%?OB?Z7MBX!!.F_P<UN2OW%
M2[6"?62N9!*>7C8M[JL;@.B;-8!V,] 0('NCNCU7K9HI0+YBTENIMMN)L+W.
MA.K_Z>#^'7 _":4(8YZ10&4IP/TB(]P'N*]DD!89E]27Z5'@OFK!Z*VNU4^P
MOPYF8"23#(P8_@Z: 'ZZN_]*D%\<+G(X\=WKP0V6)5JV9_)"[CC>=1RC7&82
MSB11:0S6MU",L"PI"!RYE!5^2EE,CY&^?(_',8TO@O,_C:AKS^2EW(F\ZT2F
M61)'49 1D7,!R@X[DR9^060N11:K@/,\.D:2XGTJ2#^^.-QX],1W;W<D.XCK
MW2I6-YX"0U5Z.^%K_6]@CB_\Y"_0G%JC]QOLIMLI(MZ@TQHAL<#&% X0W_FP
M!W3[G2#)#RA[KI(L8()D<182JIA/L@Q$2Y!'49C&>1+E.\K^*[$W]E9YKPU&
M)7^X_;W!-DJ]Y_TE;G\]/.+8P#R^.-P:\<1/D0/F3BS<CUA089BF/@#XA$4@
M%@*1D*PH&,E8*F(:YGG(=OJK?:4-\"AB(?:?@KGN# 0G&8XM&>(H9V$8YR24
M:4XHCV/"4Q60L$AIGOIYXF<[4Q*^TA9Y%,F0Y>?O.@ ;!19^>>65;3,* +&>
MI,<W9-"U?R"BY*R:I^'%"+DO:)%&Q)=1"J9&#D@A$Y)$ 4W#2.8Q8(YMR<'3
M)%<R4R3)*&"*2.2$<:% VO@\RD1"&=WMQ*Y,D];7K,:I<\W+8<_]:+;<D;%$
M&#P!D>&PQ!,YIE$6A)D,&?&%#S9]HN"8TCS$N%RJDD)Q7NP,3,#I\=+W%6%)
M#-_)"I_ 89=$ >X/HJP 91\\]C&E?G!Q>#+LB6_IX9@V)AEV2U5W.CK8T=&5
MATD "V^%B<'PU9U<W_Q%LR=I !3ZC?*X4O#(-:8!*-,RMP$&Z8=AIJ^"OZCQ
M'75BR:IJ;;H H@#\:ZUNU&JCS"Q0O(-^"5%=7ZM:5U;9YS<7WL]LQ2YUE82G
M_L3W:'8S6$P1+/P%;VF!#*ZD40K+L;UBTVYJM8U/ /1L-,X9@:)J93):,,=X
M7<,^JH%//7J"O]SH3Y; =ITWBLO&K\/C=6D\/@VV0Z%TJDW35N*/A4E;1C+9
M=ZQ6YA-,"UYO^+(4\ E\!0_%PL,U88ITGXS-6GT'6,L?JNVO[-.VG^&'W;4O
M?_O9>V>O\ !*7];LNL_@-BO9>8F=99E$#T4L>3ZRNF8K3(HV;.YH40FE9 .\
M%*K4NP&9:8BQ7#)>&7IZ^MN7MA+9>[E_NRZV-HW4_N^%\8*K?VU@R4M-;UR"
MH83F;*/$IC8(UJ'*IZ&NN(K\5-",%$$4@)(">Y31+"5I K9&F$3<C_FWH$H]
MVQPM4?S_ZV'KO5S)G_N-]Z'?=Y^OL^YR6J=/PFD-*Q%7DY/.U;($7=!X'^$:
M^,UK-@5" 11+((=1 FF1 L)JM1J2%U%,HZ!G'OQ>5A(//XA)+,F [WU42U!5
M(,_:*[QLN:P^ZLH4U KE$G^4MH:DO2H;[^5JM0&5\ZO226NPS]X /;S )__?
M)./]KY/*2/A=EC=WU%_NUB%]0_VEG_$D#"DI4A83ZF>29%F@P*X*:>(G2J1B
M!Z%]3<SF Z"J$L@/TA[ &6PR5++OJR4RI'F@FLL@>U)%<X<.37CQ'Q\VU_"F
MM[A/1XSQ!LYX'6O&V_3^JX']&#1V[&<D2>,<[(6,D]R/?)+F02'#*"C26!VE
M&MC4_6[MQ%OS[Q?N1E>K^;65#)H+N ?']=>?D:O_Z8/N*C5[(J-A,FGN\\F>
M/B-S#!:\9K6I=<2;U!*K+$T%X^^ 3> 3W:BBZ7*VP:*!Z]1:6V.#- '# )ZR
M1F.LKQ+]_>+#A??WER_?#V6@UM;SZLW2%@_4ZA+->*V5K4%Y/J4  ]+3[]J-
M@4($<UTV#>+2B07VX?6K@59G@N 0:M4:'L$^N3@CYN*Y^_11PR)C/)MUB<E9
M=H</7[-5[&-8RRQL_7@%Z/.65!\1NS8;WI2R!)4.9C"@73ULJ*N@YFR)I]9L
MLA8LYL88 >.##E@97J0KAIXL8->WL:K ,)F\6_]\;2WCL", WJU]12,&K$_'
MN"#PA=#T;F^]:]5>5?+3</@!T ?-9,ZB."4!"P%)J)B2+.&,)$6B:* *09.=
M7LM?@SY^;]2[XC4HF&L4G0YEW"_*^+W1]EA/[QF43YY0J;&KC/Q2H6\P4R^[
M]XI](V/1:X,BT,"I#@Z!.@3)"(@8.T1T_NFV@M_^ *'9[6(MS/^YD:;'  A4
MUGJLP+X7!D%IE8H@[!J%KP9/#*=.FB\N[6C)#GK(LA'+JMG4G;=<PS9\\.3*
M'H,-3@YU0*]U2&[/.JR'WER$CO<5.MJEZ8,Q?$GC1NV"N? ^;,35Z-U-C:%:
M>'S3:A6*80#48/BDMEIX4H'^P\+!SC?#RMJ[8<N-.DR(Q9XK=;]C4A5D T)D
M_#5L*C+]LO9O$],9!#4OO)79 _8-%]OJ%T&Q4%WIXR60'N,#'UEMOK]4W0X"
M(FC_'B+OBL.),?<=-"FR"QU[C=E) HY3!7IM&N' E34:.0QTA+M<E7!QK6LQ
M<:&@P%=V4?#A#2AT[**B6ZU8WSC!B \Z#"P^7ZH;=!T <3;7:QOEP,TXVKR]
M)PYV,4?VLJ9::1_[Z!W*6FRN80<A4@$0(UITG)G:8'3[;Y:X2S'\8((! !J:
MT7&8!7X(A8B" *"#**A"5[ B>1;F)/*++$IY'*7Q3CK3U^"'-[!'_X%;]%W1
M-PQ\NVH /NC#9[P8#E;<+ZQ )GC_Z 3%T+AQQ C7=.JXVG50D7#N07Z4S15J
MD;',OBI5S6IQ=6MGKO:\ #N#H7Z3Z,P??4'+*E!_J&XVYH9<M1]U+'HDTHQ<
M!Y%H0Z6@ )GWK.*PX!LMR<K5>M,V@PMC)^P-AMKDCL\VJ]VO7WCOMO_FF3Y4
M^D<K6/4* &.TI2C7&#[U/FKYB$JJ-'JE4WQ:9Z%%UNFJV_VO4MEAU#9L7FUJ
MH?6L5&NE]^J6&7JQSU"?XYZ9=$L!H:W^U-#AT:#_'#M]SHL6)RB8 C^?-D[5
M__O,7M7G3_U';%3MB/OP7:I=B^I[:U$]K^W\V%.TOEV=.W0]0M>[>'0'>]:J
M6'8NIAV$.T:WC%<;<]DQH:MN" 5+LEW!0!3U8!:_P<$LP.:O.AE*YP?>L')I
MWV>/E^$S[+.,WK/0.I_]\V8PJLIF9*%)]!OJ@$\7W]2.KP6R5OU9MMVOM5J;
M-(!^ VB7H=DY9I=HYY%-"06EU*CE4A<"=3MES4K]@?:RH:N(C38/AK!7<)54
M->;=CAQQG<&W9WOJK%*&VZRT;89A=Y?2),'N7C\Y _# D:%I[4^M+-$7.*%0
M>U4K1=H2O5O[C-G]!JK)1;8Y:,\/9.K8_:=SI,*+,,G_\F)'1,+MUTMV^QP.
M]Y][Q*/=HQVO]64$5E^W+_0F)K#QKIOG>!:78$3NW?+#KADOXKS.P(2N/5'+
M%1*%:-K>^=QMR7$'V<?4C,(@2;,LIX&?ACG-_O+"CG0+PUY=CO;#=%DG3_/O
M_OLG5 9>,%99^#TEC6!I3.Z*[AYH#FP7+:EU8HQJ&IU:/TV%UP$.[4)";IJ^
MA<;]/U)(Y5B':!_SCJ?9G3YW^I[ Z0OW $83-(*CMMHYCQJS2QVM@L/9'>#^
M5(YP:%=RLPL&%YXJ]1-D"9B@!96N';[=;^Y@SF:3N(/Y> <S&A_,/1&'SS#K
MM@,7@VDW_NN7FW8357I[,?(J'4I4P%RY)7Q8%F4_M / ,BKH6HTC&_@,0,5H
M#BXU&;"4#M_7O"Y ^6:4]8X&PS3R/\+J>^6(RTL^0JI,98W"5G5&'OZ.###&
M>SF.NE52+6UFX;!M<4,L,6UBM*UUBN%DFX]@G4GQZ))#AA2=@?-#[@U6FW;Y
M-1>Z,J+&8I/E;7>32S#9\-O=1? J6&&**^:WDY1-6,,X(:68&,IP&TQ@:'<"
ME@+^?%G50'F]U^UYAJ6,,FZ&ZX?S:G:\U:U;&WNP*,?4W7=<S+H__\@,*_D<
MMXH[*5^:2<SJ6F?O=WE45F0/#)SDX]J47Z^Y4BA)S7RDYLKT7M^J>UV8C+5R
ME(NETW\TN-*-_8U?0VF_A4GF;4#0W^+YTG^I-]LY3]I19S^8B' L[_Y3I^Q8
MX3UL(4P!4W9GP=^:JZIN"9X:#TXJUEC/(<4G3E4L4E^1G*N 4!:EA(4\)EDN
M5:;"( ^+G0K1KTGQP0+1ERNY52?Z*QQ16 MP>/_G+O/G(3)_7NGR<?S7>[U5
M/CXP2'\^@\B-2S4^4ZWP:D>,FQ)H[:!NVE&+"=#F5[ B^&FI9Q]-JC-TQBB@
M#" :X(EKE+1]SP/ME?:>1=]W!<\(V!%O?;S"VK -  F$$ L-Q'3R[U9VE2X=
M&3)GK>$_>7Z)X&ZE;CL# LNR+;PSE^$5.O'KMUJC\MM1#JPY= *[8R P:<VR
MI5I73=EV!#FXN#EO2'<^3_U\[@Q) F,9T9!J =.8+/M:R;*U.="XB1EL=9-9
MSM"X&&7V#X5:N@%*BZ66VC  2T/C.;OG;>N"%0H&-*1-!*T+F]8*C9C!\3:"
M6/6@N'J@V-]S@(/+:G5IOM"9\)\&GQ,S0W_7IA+J%U]J5+LT0SI?2B (G&NL
M(UWL]T9L+]3*% U(#<'Z".&07/ZJ8DM]8TV>U^M2JFN =.]M=2L.B/7>KE;5
MC94J?8WJJ]?OWPXEEV_@CKC:EQUW%IYY8U,882>%!M3T,IS6;N*==F^P6_KZ
M=RW%WN!6-U#Z[[6NS.^^X3UK0"9C7HZ7?K\UUA3[7&S:$G>&>6U\)MYXYZ9&
MRN*N;,WTKF8 _[KS$IC/VE=K:P\FU!PVIQ.AAT7H_=LB(BS"6(F0Q!3GF:8B
M)WF><A+FC#'*(RJ";VK=H;O5?!!72FZ6ZEVQOV_-U"3Y#6W"+^R?X-3*EZJ5
M4=\99KJ"Z;ZV9I@>7(J3A'OGUAW-KD;R7_M:>^&^+63[*JZ15^DND:]U5K.Y
M[OQ$;04652?V&]A<O1L#EO!QY>V[Y:B8S+Z%5\!;@W#65U>;!M;<?/]\!C;6
MZ4[#[%*5O;_9GF>[P3&V::L77*?-Z*5CJHG_0E].ENRVVK3PE#^5?&&>&/B:
MWO8+&JVL&_6\,361?1!,%]:9>W\WK *6T:=,WY1-:4(#S[N[3"Z%:V4OZO6C
MD_@BCR.,\_SMKZV\\]+@(H[3S[S2_[SKHHLP.?(M[V.121)_PRWAUWH_NZ[,
M#C8=E@[Q:;^\#>-XT?T?3PEL'9,K_]QDS.,?]I\=W1=1L*4]A^9\[CN9AP1#
M=[;T8<OFD3:[VZ3JN%FS!QG_,-QY/&[L$].SXP50'C_7/?[<J7E8Q_%1N3U.
MXY_3^9L[G^=T(IVZ.S.&.G4W,U[TZBY\8'5G#92>>/$:+%8T/KVI#IG[Z3HU
MM;A=T/;8Y_,3^V#\..#("6R(V1UQ)V[GPPLG;I^>N WF=#Z=N'U,<\6ZD[_0
M7O'314A]X$GX;5L N/#9['L@+_T)!H!>'<KC_*9C?BP>?Z$:?B V/W:C@OOF
MQJHZ'5Y\Q9%[P-/UGW,Z17N5SV/Q4D?LMIGYK6PX0?E[8-!=%*2A'U.BBE 0
MJGA&.*<YR=(H5;',"B7D,>91[L_[?MF^LO4!NB'AP;E!T61N4'3W),IX0?/L
MX. @)]>.?!1FI$Z<<I\3-T[I$#CE[I3[^2GW1"@J,RE($M"8T(2"<@_B@"1Q
MQ/,\*E@8Q,>88OMPRCV/%F&6.N4^=^5^3QZ=8SGUG$?G&)O@UVFV[9S<M3-C
M[JE!O2_EAA.)<XPI.J0V0Z&Y'ZD)EJ5^*%,29!$E5/@%R3.>D:3@@$^$BH.
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M3YB1R]JJOAV\,<[D/QL5>][<N"<5*X/,IT4L0+M&DM"(A20/@H2D*0_"- Y
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MK-XAT#1_:!)FENE_PM-?F'DVS&Q]+DW[ )IK  PZ022CH"AM:\[<C-JIJ74
M9B[EYNW-15]IU7_;K*\?W#/\5^[LRS_1W_="UWLMM25H-7^T$K*6Z7_"TU_(
M>C9D[:-WWL1.UC$R8,T-<K8-0F4D:Q,UOW/S_YAD/5V]^T:R/FS):\&K^>.5
MT+5,_Q.>_D+7LZ%K78W"P!J*XPJH*P)95E"I%6[-1H[E$'3]*U5_3-Q[VNU.
MPL@C0Y+T"1?OPK^\6K]]RYMR3A>K*[KBS3@F))%O1XN$8.70'CR1;Z.@Y:?E
M&Z?"1,I#3!0 G=6074+@XFSRB3C:G:,1';3W.GEP;9)\UGG(MCF(I>6H@\L4
M=MJ-/(MIP=HSJ_?J6Q!TFC\Z"3G+]#_AZ2_D/!MRSLYZ9FQ02NM$FPM#BMZ"
M;\Z'X)4*NAV!G(_H6S!6V%K@2MA:V%JF_TS8>H9L^X_W\175\2D#1C:.JE40
M>>I &G*!9&(!%767$\FK4M-SJHX]&# >NB5%=2RBX_(_C8/;(ELD?T2V#"Q;
MA.[OZ1ZK#8XS!*\-H+(1$MFI>;AJZ(+/+JM#T/U!#1S3SK^1G?^A44GJ3PR@
MSIX;DUZM-U?K35?Y/;?S]H-RO^.8$47*B?%M&- 4+ZY(N4>E7-04"I.%U@P!
MYJR!IDX0%9.WZ%7BI'>\N*BR#5W%,74!AUHWB,T82-D67X)^UVAS #.'T6<Q
M!K'E"CH).0LYR_07<IX7.3M*/B2:]EG0 WJ7("J/T$S,.FM;DMW99SD .1_1
MS.&%K 6MA*R%K&7ZSX2L9TBVXN5X2G10S)%:*] *$2"Z23MX#ZU2LHVM<VFG
M(^0Q1<?^O1RH1'6<NI=#9,M<&71.^2.R9139(G1_1_?&%1-4\A!MT8!48Z?N
M&"!,79P--M:)#D'W!_5R3!O_;J\.34&E&7@YI!['W##IKR]^?+':]EA<]_3_
M)@>'F'%'T1)B>YO!H(N FQ]8/E*IO'F-&*<-&NYBK!G=Q9B+T&P+CM'GP#N'
M1"9$;RP&L*IA%WVN/X=] NU<CF2BIY*'<'!8=^:5F'(%G82<A9QE^@LYSXR<
M6TZ<C+9@B14@3Z5..R&#\[$:9HJ=H8] SD=T<,B]6$&KD8?],VP]\UA( HR7
M ./3]0SI5CP<3\F.&E-MP6/7#)P M4K3!5T$I[13SH1F_<ZMCF/*COU[.,)>
MVY<M&7:7Z^&078:Y,NB<\D=DRRBR1>C^GNYSIW@;%7A+&= U@N2=@\+&:U=Q
MT@*'H/O#UN-P9VZ_SDQ!I1EX.*0>Q]PPZ=;#\7K=1_OR;?_._*MRR$[4H0UP
MN3^:-[^.EKOJ,V9]<5Y7'T_MP2*VF.!\)E&^-#PB$0>$XT<DHD=.3%TB=J4(
M:+A";*@@**:HC"[:[_3<JZ&DIDKIBM)70(41LFH!<G$A)<N50AK")6+P+*AQ
M[;Z?2:</=6F?"0)[H@]$'X@^&#A11!\L3A^XX$/)-D%,2@&VJ=1(ZU]%0LS9
M4K!QY\3H /K@F'UCC @&P4$1#'.)A0B&@8-S,H)AAH0O5IDG';K>UEJU!E(I
M=1'#$:).&8Q/QE;;K$_\G,)G_U:9<6NLS5WW+-=:(\)IOMPLPFG@X)R,<!+!
M<2<X%!KC:XQ0R"!@K@7(Z@"M<&W6< YJIT/O/@3'80NNX%G0283%HN#NJ!5:
M[E[M,/8>_<$HSTXB/C>,_;3>TL7J^LUZLX7.+&]7_6/_C;<3M.S'YB,7SL;1
M+WOU2(JX'-KA+>)R<>(2<TLU:P]<503TU0$Y;- P,NM(36%X*"XQ<W.:*RCE
M&V!0!G)H!HH/KJGJ2IFL00/8?+3V9^AQ6$NXJ,QYX-Y@PRX"003"F(DB F%Q
M J&TD)5C!UF3!LPZ0V)4X,FFYDH,U'9\P <0"$?T^3@G@D%P4 3#7&(A@F'@
MX)R,8)@AX8O/YRGA$[6R6L<$IG( 1)4@Y^2!54C-5Y.4R<\I?/;O\]%VW-OS
M<U<^RW7ZB'2:+SN+=!HX."<CG41RW-^IRJTVVSQD/;EV6K1 QFNHVA>EE>)8
MTB$DQT&=/M,AC(U[M?J(LGAVO#MX(9_]^7H&B-$,$>I/Z\O73[AW7HYC>1TL
MUJ,IQC[RTT]__YWY[KAQ&5]XC!8J"8^$1U!-4$W21L*SS/ (J@FJ2=I(>)85
M'D$U035)&PG/S#9<'[];*973Q]R4?;7>7*TWM.4]UDR7\_MQ %8:3LQ@T&?/
M:G+>?G?>'E)3)I*#I$P -$9/Y^T(6K<62G$1$ST\;R>=?4HE]0=A U0F0?;%
M@_.9L%AMBO-#7'Y,5CKK"C2-/.S"S:-$8C&#+MR\%&Y63K$WG6(C\53&*C8@
M;13X;*TJIM-TPB-P\R'O'?XW;]:5KM],>?)WHS1^+X0M>#7PL MACQ*)Q0SZ
M[ E[AH0K]_Z>%!XAFFJR!1-T ,Q4@:RW@#85U+J1IYURF\<4'@>X]R>R0R[Q
MB6Z9*X7.*8,6,^BSURW"]_>7[CJK>^<;&-\ZRWLR0!4U8,E%=5ZWR>]40-P'
MWQ_TTEVR>VU6)I T SO'Q^X<L7.,#TA_??'CB]6VQ^*ZY[XTOE^(?I-V*P/K
M/&FW(GKP,_L_'&O2V!5=TQF02@5ROHM"8U@;K0I6\U /NDIH(Q8H731VY6@4
MY%JHBT)=2??7R54-80JQ9UKZW@OJB3R83RQ$'@P<')$'IR8/BJF!(AMPU3K
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M"(O^'!"Y/ZT_HPI<43503E? '.-D&,\0F@Y3\4?V>N>H+P>?N$8&'U$!VI*
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M8C&#/GM6D_/VN_/V5I1)1 S9QCJ=G6?(WC3P9)6AB":E]O"\'14:U#Y!194
M%66(2D=0QM=B4J:FW1B7'\^\W6N!#0&G^8/38,,N[#Q*)!8SZ,+.2V%GQ*12
MC@:JT080U53W*F2@&*K"2*XB'8&=Y>:AX)40MA#V8)%8S*#/GK!G2+AR\>\I
MX<%-8VE>@PJV 18RD# E"(PJ)F-B"SL5OH\I/ YP\4]DAUSC$]TR5PJ=4P8M
M9M!GKUN$[^\O^M>*A"F"B>0 M;800VG@HD*?HJG-E4/P_6&OW9UYJX761P:E
M@]^A$TO'^)#TUQ<_OEAM>RRN>_9_DY%#3(WCB EIN3*PTI.6*Z((/V,,T?U/
M40J\#0$0:P1J;, 6]"UR;L'N'#TQ%VNH/UR1[8JP9(;<J@;-+9'12;<<AS"&
MF+.4]JH,I?/*":+>8,,N\D#DP9B)(O)@<?( L:%C4X&\Z_(@% -$I,!F-LZ4
MX$BE(\B#^3I31#&<(! .-NRB&$0QC)DHRU$,,V1\L<8\:8W)A;"E!HIS!DS:
M0C*J@.]R*)'-T;@=:\PQE<_^K3%.=,\XAS4S\=*(<)HO-XMP&C@X)R.<1'#<
M"8[HE2&R%HSR73RXXH&\+Q"UT<U&]MP.(C@.ZLTQ9RGNU7(KNN+9T>ZH]5GN
M7NTP;A[]P2C/3B$^-XK]M-[2Q>KBZ>+9X[A4!TO=>4E+Z;8RL+24;BLB+9^6
MEAH])5(-#-<(&!4#Y1)!MYI*"=-1GGHH+8LN5J=0^H.: K2<(7H*78ZVE@-9
MDY,=PN2#9]Y(XWM!/9$'LXF%R(.!@R/RX-3D@6F1#+4&T2%V>5 MY%@-9)NY
M(M=J:CR"/)BOR4<4PPD"X6##+HI!%,.8B;(<Q3!#QA>3SY.WGW*U%;6'V&($
MU*PA!I=!><_!L#(Z[C2^/Z;RV;_)1X][4W[NPF>Y+A]13O,E9U%. P?G9)23
M*(X[Q:&BHJP\06C> 1JG(76U 9E"<(4CN;)3B'\?BN.@+A\\\WK< OQSUQ6+
M<?D\7K)''[)FCY:B/=_H\AG']SI8:LY+.A[0.VE>F E6Z_IF\G\-+1['7J;]
MPSBY]N41%OTY(')_6G_:6 *76,"J,IWU.0>IYOZI0NGHDEEKMV,%,L'4JB;3
MD'>^/Z>+T*Q*!=8U:!M;RED/8072"<\L[M4,=%S,%"TZ"/8--NRB,T1GB,X0
MG3$?G1%]055LUPS))$!."8@S@8NYUJI5<+ASF^T .F.^GB(1'B(\GG_817B(
M\!#A,0/A,4/A(-:D)S=J%#.2#^!3ZV(HYPBI*3^5 U#5-VR.^#D%U/ZM2<&*
M?CI14I 21"+ 1(") )NQ !/A<B=<LK'1*17!F=  DYG<2AFAQ9H:\=3+_"#"
MY; ]QA*>F3"7"HES%"C/[W+J7T_3Z?%A^=W)T7^?[?SW<G%3GV]4?H7[@<9E
MJ+&8(7-H[3\8SO?)^.:]R_"*7O,[. 1J_3._I(O_HE^NO_]N]<\G,/IY?5$/
M-O;_UFGQ>KN^Y%4^7Y^M_OVRO#BIJ7W0P?V/];8_:;M>O5I?WGJ,IYV3U1_/
M+^FRG-/%ZL=M_\;;_MCK;Q]S+V-^.^9_X,)O,V]65I^MC#)FV.G\W(OY#^G\
M3LG^Q\W;_BJE_[N>__S(<+D7WH>G!TR;;QVQ_WMSO3UOORR W'ZX7JW;:F=6
MKNBR3E_T?V[?< >(M_UC_K)Z0W5%'3&F8HK]:9_:$Y_A&/R#[.T_M43.9!5:
M@E!+ C390([<5\PA1T>MU=+RPR5R#CYQC0P^XG0)J#^1<F$P364;BT="?[]$
M?KW97K]\1==O?KBLTW_^YW_>G/_<U[R==OIW_OR^4.<7+)+]1XMD]_0B.;@7
MZ=$E\LQG]*J_P,44PBF-%_*9)$N?/(%+P;=2$!Q2!)R:I))GAD*^HWBMS3C_
M+1M9SY2E1OD7CY^TS7Q&O\_2\\M5Z6-Z=OOWBG\=VMO\_62MXK-5?_?E37_J
MK42Z7DEZ/-D@)V%335NPV/D+T5J@T+,EH&W1A4@J[MPD^"TD=K_/^TB&;%_1
M9O/+^>7K_T,7-[R7S'#NQ>,[O$M)C&GZR\1^:F(7DT,*["&H1H#>>X@^*2C1
M**6=#MQVRN%]S0'&\29VLJ>#^+<3_).@+[/^Z<($R6GC$Y0^EP'K5!0IE Q%
ME:1]U9QKV0><'V[U8=0+7/PLEXG\65WB@L=(!CPA]TFI&B16&;I*X=""U4'M
M+*Z_!KX/-Y&U?:$6/Y$[7#^BPC=\?<7]0__,%[^,<#3QR,[DB$>07[!3>ZCA
MF.%<_.'BXM-S</6&+^J*/KV/>W:[93N]RI2:-W2QXM;>S=?^:MO[E^A/O>#K
MZ]7V31^C0P#V>_R[V\*_+^9<:BC*(RC,7;WJ4B!-RS+;56TG9&^5V;EX1=YC
MZ!,,0G8=,I,RD)2.8'V(N6:OT(2/=BT^A7VO?AV1/[\?AO_5W]FZ?@1WT,?Y
M9;W93 :7:[Z<_S3:_M=Z]0O3YM<CO8='*XM [A>KG][PAOOL[Q,],Q]U5B?G
M2%.L4&DRE1E$B'TA!K5597-5Q'J'U%/)F:?:6H&5 T1T0#9W>J?J]53PLRGU
MV5G]OS^X+SA9WO_ UV5S?C51\B-OU48;*O<4<BY.%;Y\AFQZ*L9LG8F8*"CS
M\*WJEHWWMG:E$KJ0+L;VKPJ!18Y=@OC"QG_C6YWY[+M<3^#:']+Q]OX*PNIU
M_Z0=:3>KB_YQ^?'\6V0^KM:/**@);&^/&*]NP?=ZU=_=]70>75^L'CF;_/A(
MLIY_^H1#EACW'.N,5RH2,#7=EQ@=B&*A IPR>LS]W]KN8ZW\X"[. \/K1+CG
MES?KFP>W<O[7^OI\>K/:_+D_XLWU7S9_6E^^YDV?_SWF?VGW/_]XM7+W>W[Y
M<*&B=HF[KU7>$_?E>JFKE.WJS7I2@#T9NK(^__F\3CKO@Q0[GU;B??C>0]&$
M0*NKNY%=ROG@!"3:K-[>3J,)9U_WS]M!>"$?[U;1?&#$N+Y%0<KG%ST/;G=:
MSF\?.OFYWLV'1Q<,7>5O/U!&T_2XS?]W^?E@=MST[U_<KQ5^F<9UPV7],V]^
M>;'ZC_7JNJ^RSMMYH?Z;6\^KVY$OYYMR\_9Z2Y=E6I],OXDVYST-IS<WS='2
M _/N;6SO9-KUN_<R?;8/7[+R1*/K#6WOEN'3ARX;KN==R&ZV;\XOIV5+9XGI
M^^?7US>\>?_/ATND_,OJYGHBCYOKA[]6".0I XC2*5LT4(PQT^5.!82VK[^\
M\KK&VB4J?8N<O2>0?^]3^WPS^0W_TO[]\F>^WMYZ#[_J2L0._#]2^".QCR9T
MO=M7FM/I29>_RG:6Y.91>8K9[:P_?XO\?<:/YC'69G0&IT+MR^06H,_( %RI
MAJ"#5F%G$8*&FYDN[UK"_IQ2^W(\Y0PI]Y5XCZ'S_KA1^R1I?_X;BP#\6YSM
M2'@;TPYI$S2N)]R":9<&MOSVJN/BII/^^PC< ^2TP%_Q9>U4_PGU_,[6UV&Z
M?Z%V:>5RO;W]U9OIZ7T$.X^L_VM"\ENI_@Y[[]8PC^TZW;VX?O&I4 PYUOO8
MK/QV6^E"RO#^R+R:O.4KO)TR[68S3=L^.=^E^C2?-_R:-O7\\O7M?&U]_JY^
MGDZ0[[G[;D*^JU64ON_+Q/>N]+Z*WFYN;D'FQ4/#\(Y'^/]?K?Y'_^^!-WP4
MIHBNTXA5?75U>YX30W"@?7;%Y]S!<V<7Y6L8\H]]G&X/VO]P?EUZ"M[TM?)/
M_27_]6)=_O;=BCO$7DWS=G/#CUV8 _]"1?.[[Z^H3L/_KNBT>Q&L_<SDCG.9
MW >U[^.+_V\*PNHV"JL_,TTQV+DB\>D9MPL/WS#C2DZV, +%ODKO(H0AEZB
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M\&BFY6]T0-E;\"ZJ&,E6'W:6S-0L9A\1?$ U-2;JRVQ*!AIG[B\V=?"=MXM
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M,4AX67)"<D)X^9%];)6:3Q:TIPJ((?5E+P8(NK B97SP<:?6G\^A*NR/Y*H
M;4.@Q YLHA9-LMQ8NE0+!LE]KA.R%]QVJ=[VD>\Y/<NNU&(J.'1A?2D8,+1=
M3FH!+$[<D4V-3:U@F[-=J!4-64]'',53]AF5-V['I*"=P<H!E(H>,-4 "74
M;5O@1KEBM4>NF7BFTKAMO.1^_SS@;7S8$FD@TF#,W!%IL#AIP"ECJ1I!1VK3
MV8J'%#A!J[%II[0/M-/C(536ML0&N6 7$=@BD+<.JO:E<6Q<PY%[/(@T$'@3
M:3#W\(@T&#@X(@U.31HXE3!&7R!%M(!3$^\<,8'E%DMV)7=M\% :U)J\-12@
MHE> 2EF(A!&*]>R-(E5"F/61D B#$P2W\4%+A($(@S%S1X3!XH0!&>L;*@V=
MTZ?6!8XAA6S JT"^=;ZO=F?/H#J5NP:(H$@S8$@(9*,&1)6#JCXW-Y?2PL^/
M:2(,GJ=VQ8<C>_=JTJQ\.-!ZUZS\XNG"PN.8) =+W7DI2>ED,;"2E"85HB0_
MUZ3"QM!< /;: >::(15'P,4U8YRMC=3N+5WBJE6&RI0!6T&(02O(I5 RK62K
MCWSZA&?*ZF%]QZ(EYP%OX\.62 .1!F/FCDB#Q4D#2EFG9#,HXCA=2+*0, 8H
MS%H[).W\3O^JX@V[1 6P&.S/*019ZP0-&5M_-<4IS]R8(M+@!.%M?-@2:2#2
M8,S<$6FP.&F02E5)>P.^EM1I/@4@SPC]72IVB!1Q9]> DG.)M05#I@&2Z;,J
M!P><2@HA4.X*06J(B#"8%[B-#UHB#$08C)D[(@P6)PR*UTZ7K*!Z8P!3U!"]
M18C]N\6%DHO:V3,(%A%=C( ^VZD@683<V  YMB9A=17KK(TI(@R>'=RDZLDI
M6$[&\5P.%M!Y:< #&OG,"S,!9EW?3&:DH57@5R3A$?/M'\;)M2^/L C) 9'[
M,8>SRU85#8EL 71=0]+D-O&N_\\[K9S5#X5D5XLN65T!2YLJVTX%4[+6P#AM
M.>484,7C[C!I%\^\WJLSY;C@*')R$) ;;-A%4(B@$$$A@F(^@D);SR%6 VP#
M39>>$D0;/:1"P5&@Z%3:$125LBFA?W3M^W-J4)!B)JBDE?$Y-C\Y8(XI*((_
MBU:)GA ](>=6LPZ/2 R1&"(QEB4Q4'M&[0B2MP&P<05BG2%8-J9QS$[Y'8FA
MHPF8$M36GX@:$<C%-)6 *UYAIAR.[(J)^BQ$V;(0B2$28][A$8DA$D,DQK(D
M1L02<E8.=,;:Y4)"B DME)925PI&4]EIJHN*@@_&0[&FRQ*5N3^G5M EU!1-
M==%*X1?1%WMTV/2OIV(?CP_+[T[NQ*+/=OY[N;BISS<JOV+[0.,RU%C,D":T
M#A\,Y_MD?//>X79%K_D=' *U_IE?TL5_T2_7WW^W^N<3&/V\OJ@'&_M_VYQO
MK[?K2U[E\_79ZM\ORXN3FMH''=S_6&_[D[;KU:OUY:V_E;9<5W\\OZ3+<DX7
MJQ^W_1MO^V.OOWW,O8SY[9C_@0N_S;Q967VV,LJ88:?S<Z_<!Z#SKQ$YYJ##
M<J_^[BJ][1;5HYOM^EY@3V_R_/+U2_7][</A@GY9WVS[K_@[=[5^^^NTNAW%
MNR?T=+F@JVM^><U7M.G)?S] MRO&=Z_]W:<\WC^?7Y_G\XOS[2\O[U_C$:?W
MNU^+Z04:\[MI;!];B-R]OQ<ZX!<]3GW!H](+&\+>7JV_-^_DO3W[>PLAJ%__
MZ*]\Y<]<7XB__?;"X:Y!WN/2%RV)XQA\$8?:Z'VF\I;[C\574-2Q(]''??KI
M[[_3^-WPMQ^'3*TCJ-R]3HJ'(E>/DZF_^6[?Z'-CG&0?GD'W?5?].&@^O^2_
M+IOSJ^G$8<9I/]8<&"?)/V9T(X1^$H3^K5=_GSN;1Y\/@^6WK)U&B80@[8DA
M[9_X9[Y8R8))L%:P5K!6L/;P6&O&24_!6L%:P5K!VL5BK1TG/05KI1+@$%[R
M&3IB7]'UFQ7_Y\WYSW0QV0-?CG,E1UAW+ZPK41E%E4HD)!*G%PE!JA&C(I&0
M2$@D!*G&CXI$0B(AD1"D&C\J$HD!(G& '<M];5?+CN7^PO_AWW]>7_(OJ_[I
M_\;;5>N?Y7J<LPE)TZ-%XLE"-?//NR.FV+?4Y3JYCI'?&H090O C;6Z;LZT5
M"Y:FXIR.%1 A0L@JMN::TK8\K+:5*Y848H6:C0;TSD-*M4"MQL42DH[NT-WL
M'M8,3V=FOP4]EXQCAR7Y<6!HL&%_[H(>D@!"Y$+D2R5RCQY=B0UJY$[*H1E(
MI3E(AI0V6IG@=RIS>X=4'$]U,BL#HHV0IPX@C)WU.[E63T?N)B9$+D0^1Q@2
M;A\E)X3;%Y-4PNUWW%XMZFBG7AM954".#-$;.[7K:IFY<2KN(;<W;[3+!:&Z
M&@"+LI!JS?T]9J^,BLG4,NN2V$L&L<4PQ^PQ2(A]E)P08E],4@FQWQ%[242L
M= &550-4UDX4S]!23BDF]-GGA\2N8Z=OI3+T'T\[]J5!XJS[$V.(K285ZJ$[
M=@JQSXO8Y4+8R=DK7JW?ON7-;1GY*[KBC7B@%F"NV&L7H,&R;EA-?7(M T6=
MW7<B"SHS^P@I4%=:)2N(UFEHF9%4=*1QIY]ZL*E9+-@UF7;35HV&Z$J"D@H&
MXX)+\="=R!X<J>BSKA:'[44F*#0T"8LU0A)@GH,N-+P4&M;-Z$IHP-5L (D*
MI,ZI4)JJU(K3S<4=BR(75M97L,TK0"P6.B]'".BJZ:\0,/*L-TD$@P2#Y/1#
M<F)V@S[[G!!>ON-E6SRVZBT8Y2*@"0DHU@#]VSXQ>E,-/^1E"FB3#P$L<U]2
M8^JSA?I?B9H-E;-2M<GR6%!(4$B867)"<D*8^:O\@H&C5[Y!5HR )3(DJQ 4
MFZ*CQJ#JCJT@>\HQ%@/*]G4RJN @<DU00XF-V6E;E*R8!8.D:L-IVPHV5^NI
M,W5/X[SM3R\WF_/M.4OQAB7X"_;JO-IWM\=%0^EP]=<_58A?9-\HP/R(7\$[
M'8JNX#,:0.,F[X$/H NE:BGG''9J.9B0%+: 0--?R*KVK\A!M2K;8') $XZ^
M(6/'O0%ZL$:F F]2^V&NL1 =,'!P1 ><F@XHP53M8X3LD@-4;C),4 35LE+!
M!<3=FDY19W*&%%!0<2H%D2%'(LB!8_ ^V63F;9@0%7""X#8^:(DP$&$P9NZ(
M,%B<, BHC-?)3W*@+_9UB4 Z,EC7E4'VK&-5#X5!K=[K%@M$U2R@#=/%T^+!
MIFQJ#.2S2K)!(-)@;O V/FR)-!!I,&;NB#18G#0H.7JGE()JH^O2@!WDI+LT
M"-3GGO6NV)T24XEJ0Z.XBP@5 $W)0)ZZNE FUUHY.)RW942$P;.#V\%+5WPX
MLG>OMC_;R=TP3\-Y_^(#1'*&H/73>DL7J_*@[_$XYD@QG8SARQ/A.+2'6(3C
MXH0CF>D.D&I=.+8N'$N*D)K1H)4W3C6;E=OQ&E?34G0<H&M-#V@]05;]B:$F
M7PV7E-.132=1GUEMAK4;BW:<![X--NSSVD$2(7 ZB2)"8'%"H#07R"2&$J;*
M5QD94O(6JG,Z. R)S$X#DEI=Y> 95 H94%<#.9FIQ+FRSK)FQB,?+NV_ 8D(
M@1/$M_%Q2[2!:(,Q<T>TP>*T04LYJ-8BN&*Z-B D()L--%;9!T>)<$<;V$ID
MV2:P[;;Z9C1 02.PXEB29K3AR*5"S+Z-)R(-3A#>QH<MD08B#<;,'9$&BY,&
MM7 IMB7@Y@)@RP52SAF25CZQ3L4F\U :L+=!46Q@O._/\;Y!BM6"YNF>JS6A
MT:'/#V94JT2$P2#&DV5?<9TA(OWX9KW90J>'MZO^@?_&6\H7_$%1DY?C6"[%
M8/)$)/JX3S_]_7>=*9[+1'X_3,\4I5]ESL!QDMA(; 3-!,TD8R0V"XJ-H)F@
MF62,Q&89L1$T$S23C)'8S&13]?';?.[VQ0YSF<_].O*RZ_H;I\BK:9A;'^AM
M?^ZZK2I?K:_/M^.<,@H#CG%P-=@!QZD<LLOA^8"@^>G#<\Y*MU8:%,,1,(<,
M,1:$ADD5E8JQ9:?28TF(>C+9!X,6D(V"5)DA<<485+96F>/ZZMR92SCL\;F@
MT- D+%?I) 'F.>A"PTNAX:9M\W[RLW?.!41/0,HSN&B+;2&IVG;J*MH4$8W6
MX&HA0)-#I^Z6H'INF7)H)<^[>))@D&"0>-4E)V8WZ+//">'E.UXV*123HP*;
M5 .L(4)2"?M7J%+L'.M;V&V$X*N*KH)QI  ;.R#=$(+GY&ON*U5_Y-HTLCP6
M%)HA"@DS2TY(3@@S?[I588[$CCU4LAF0(T,LK4&()OKF4-7I<O?'S(Q6-\6I
M+Y%+J("^*2!J#K)KU@6G5.%#7PB7%?.\,.C@E[C$;S ^ KU:OWW+FW).%ZLK
MNN+-.,8A,1H<+1*"E4/[YD2OC8*6C^RD-*.LUF6ZH,]=K]T6\'$9E")=$RHL
M;:> 3THU$DX"+3H-&.O4'H(#>%V-+EWH,=7C[J0@GJ6PUZT4@:'YP]!@PSZO
M?1-)@!D,NO#P4GB8;"RETR=P* '0)H)4?8#00B5+GG1+._LFWK/71H%B]( N
M].>XDD%GJE1M__K@/#RC-DV"08)!"SC/D)R8P:#//B>$E^]X.1=M^UHX@*VJ
MKW6I-$B=::&9V(JU%(+?.<_P#2FQ-^ I8^?E9"#EZ0S$>)^JBXZ/W5E9UL<"
M0W.$(:%FR0G)":'F3U*S2S9GWSHKI]   VI(.EL(D;TOW'^6=TR 7*:Z]).A
M/_B)FF.G<\,5K Y<M?&E$LJ263#HF*4-]F<L&"!&,T27=^'_\.]7Z\W5>D-;
M[FF<MQ_4C1W'$B<. W%C#0.1X@@5F?9X*0.=K%?10VP8 5G;+M,20HK%)*_1
MDJ(=AT%_/***8%,P@$47R#;W?QI7 @9O^S^.W"+(GR5GQ10J,#3PL,]KNT02
M8 :#+CR\%![6MMF)< $U!\#6.964">"X\ZGB;*O?*2E$,6J?K0*5? /$PM-)
M!@,U5V-UC-K/VV$@&"08),<8DA.S&_39YX3P\ATO!U+!L\I@-75>1JT@JE(A
M5&UCSIY]XH>\;%HG9=(9<L;:"9T29!4+*')%L2X84=;' D,"0T+-DA.2$T+-
M7T?-*A17G ]0*B? %!-0,08")X>.^YJX[K:P1=UJ[H0<+2*@:@399033:DLM
MAZ"]ER6S8- \.M**P^ P#H._OOCQQ6K;8]&S_-M\!5*Y8!2=(-:K&0RZB+/Y
MP>>GQ5FE9+TU&= XW_^BJ7)!BF"J4[863:WLUH"D8&JH&EI%T\59+4 I(+1@
M8BW4LJGYN/LFVIP9G\0!*C T\+#/:Y-$$F &@RX\O!0>MC91R5F!YMHY-2>$
M:#*#(Q]+LTE'C3OG%X:L(JK@R15 JQE2Z 3NJ](!'485CWQ^(3PL,#1'&!)J
MEIR0G!!J_B0U>Y^BQ^8A*W2 K:^.8V8+%+$O>Q-&IIVB0HF+;:P:-&_[<S#T
M9?54']"64"UFTSS;69]?" 8)!@DO2T[,;M!GGQ/"R_>\;*(FQ09R\315(2C3
MY;@* 17Y9 /KN&/YLR79G/KBV@;'@+I-17?[XIGZFMF72 %IWDT2!(-FX"N0
MR@4CH<LCOH+7ZS[:EV_[8Z1^P0)]!F+ FL&@BUB;'YP^T@.:% 6;-3!.)E"T
M :(U 4Q6,9%R(;4=L18B&F15P65EI_L9%C(G!RT$IY"92SMR!4A]EM)>CS<$
MA>:/0H,-^[SV3"0!9C#H0L-+H6%T4X7&ZJ&E[*9&SQ%B"03&HV?G2O5AAX93
M\Z6Z$J JUH M:LC*>(AFJL%,38="L]XS$0P2#)*S#,F)V0WZ['-">/E^>:RI
MAJ+\="ER:I#@,B3;>=E9K;)2%4/9N2-9IS.,S U,L*TOCS%!;)W5&]82<U"4
M_:$]!K(\%A2:/PH),TM.2$X(,W^ZX!^'XI@98JH*4)6I/X+-T$)5$0T[$_+.
MQK5!$TUN$+7MS\E10:2^@-99<:IH;(Y!5LR"05*]X)1=!K<9OYH^"M?]N OD
M_N0XBF&O1JS<'\V;7T?+76U7U^N+\[KZ>)(/%K'%!.<SB?*EX1'9-R P?UKV
M)>04RE0;LF4+B-4 U:K!LB9OE#,1ZZ[L,ZB=1@BNI;L[G#DUJ$$9;9O6%0\M
M^QYNR/@SY\*P_M+/Y,V'OZR'7/!-A( ( 1$" R>*"('%"0%O--O)_6"24H!<
M(N3D':!MIF:O2ZGNH1!0B= $ZT#5,-W^C%T(I)R@RP*?&#7I=N@"23.Z92(J
M8![@-CYHB3 083!F[H@P6)PP2"$RQL!0V'62S]9 SIWI0]#!4$M,H>U8-A(:
MZT,!&XH!-&:Z?LH1K*5HHRU)Y4-?/Y4= L$WT0:B#40;C)([H@T6IPU0:U(J
M=$6@+0'6JB :1+ 9G<ZY8K [FP:>2TW5(7!174_P9 'UQ4.)NB@LJ96(LFD@
MPF PE\G'5J /1_;NU?9G/+D;YFDX[U]\@$C.$+1^6F_I8G7]9KW90N>1MZO^
ML?_&6\H7/.LR%W+^=&BOGDC)H7W%(B47)R4YJMAN]Y64,8#!1:#(&E)+43O2
MI>V>/VF=;2HA@.;^1*R4(7O5A2@FLDUU@=D.?6/WX3:3BF<6_; >9)&3\P"X
M\8%+Q(&(@S%S1\3!\L2!=[768"'2Y#A-W(F>#8-1*79M$ /JN%/.PUOC50[@
M4BZ L31("@TH':O+GIN?KAK/NVN(:(,3Q+?Q<4NT@6B#,7-'M,'BM$&T3IM:
M$"I.VJ"2[3P_M5 /NE7EV.6T4U(D(7E?D8!-F$J*< !J)D"NV7#$H B/7%(D
M^3,5]NI/$6UP@O@V/FZ)-A!M,&;NB#98G#9(J"FV6$&I7*=] X2^\B?P63F/
M3G?BW[G=RKX$[[N 8*T#X&1GR=95\-$TA37I'-6L_2DB#)X=W*0*RL*=)W]:
M7[Y^PG+R<AQ7YF"Q'DT>]I&??OK[[_H:4ISF0X=*PB/A$5035).TD? L,SR"
M:H)JDC82GF6%1U!-4$W21L(SLPU7:6X]TH;K;MGI5^O-U7I#6YY_6^L39;XC
M'F,-%HG%#/KL.4R.TN]+/=1FE0L!(DV%HDV-D$NDJ5VU\[:1U2$\/$IO7#4V
M"M!JR(!8/)"M"IPID5&95..AZT/N=.[R5@][F"XH)"@TNI*6G%C&H,\^)X29
M[YFYF.A],6!R](!!5Z!"")12TMXUBGG'Y.:==]400[8Q 5JE("E3P*9JV;/6
MIHG)33!(,$AX67)"<D)X^2MXV7J,+M@,,:2^^F4=I^HT'FS(J%&I9,T.+QOM
MDVE.05"H.I='!32UXHS!NM""JT5763$+"@D*"3-+3DA."#-_5:\CCYV(&X%/
M#0%=2A"S<V"U]V0(L_$[Y61<41RG_>^I?@Q@JPC1,$WWR4SUD5PSA[XR+BOF
M>6&0W/(Z.=/!7U_\^&*U[;'H62X]KI=B-9 N%0/+..E2(7+O,]4#:W%.*P->
M3:TMK>^JC5,!91*9JBQ;O]/!*A87O,X!V)K<)6+&_IS2P)(MNAI7/*7C;L28
MLQ3W6EA8^E2<(+R-#ULB#40:C)D[(@T6)PU4"ZEA2E#K=$9C8X3DV]3 RIOH
MR0>?=J2!2:;K"2(P-FI KP/$JBV0-KX_H75I$40:B#28&[R-#ULB#40:C)D[
M(@T6)PVP.FZF.?!XV]OR_['WKLUM'&F:Z.?]%Q7>\88=P63GK;(RI=Z)4-OM
M6<_IMARV^FS,IQ-Y%=$&4>@J0!+GUY\WLZIP(0"*HD"R .;LM@4"=<U\+\][
MQQCIF"Q)2NDX9J1D;"=(1+"CAF"" M<"X 2!<WP)I"4%!2BA2@ ()QTDRL#@
M!0JW\0NM# PR,!@G[V1@<'; P$M"J!4E<E25H.1+BXSB%I7.2DITR35A._46
M6!EA2XZ4LAYQXBHDL;$H,&[@ U5"G7:]108&SR[<\M#KG)3R>AAZ/;V[ ?%X
MTB9'QKJGA23S>(H1(\D\GB(CR<\@24.)-5B@TO. N)0E,@27B&&N.%&&ZMV9
MU\%2Q[C$B"H?74R8(DV$1:XL)2VE</*I*X3XA2!Y<E46;]G)=,K;DZ'!B#<G
M0X.7!@V<5<()0 5&"XIXA>%3;-#AA%6^JD@HV<Y42\>U(!AKQ+&7\!_JD0K8
MHXI+6X&.5DX_,30X>F)*A@8O4+R-7VQE:)"AP3AY)T.#LX,&S&A2<FZ0=PXC
M+KE""@N#*E7*2E=>5\KO#+RVQ(9*.^2L=8B7F")3$KB$D)4TC,)I3US.,NZ^
M(AD:G(9X&[_8RM @0X-Q\DZ&!F<'#3RG03JM$-:4(AYLB;0V!DE?6J%BBQ+.
M;T,#YK"D7,3JV. 1-]K$2A:/K"5&*#C;AG#2J2D9&#R[<,N=4%Y"TLEXLBY'
MMJ&GA0$?,96/7M(H,%V]C.E(HT:!#V#")^2W?QL/K]U_AS.0'*'DW@\DC37!
M"UXAPXQ#7"N*-,4<Z<I(X34+E1"W@63%M*MX( B3F!=-N4.RA',L=E9+J96I
M_!/[F!2_H%5Y(GG.>U@GP\F1"+F1+7L&%!E09$"1 <7I (J2&&I], @K$1 /
M4B(= !P8++#6')<5WO%,R5)JHW6%J/<*<>\=4KA4J+18E(0I:N1C%TW= A2
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MJ#+V)3,,*58R1"0)HN2.,;E3.U(%3+4',"<JZA&GSB&M%4$5IIXIAHU@XAF
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M,O1PRN(*5J"3TO&B<+?H0(SW@JMD&7;7O'03,%7!(BPQ1YR"4%+!E<AR8.E
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M*8D\#:!]B/5(2X.CT\99[9D0ZM$TUHL:?8)BZ<.9:ZM.0[3WFH"R:A*ZM_-
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MM^=ICHJ<G]M6WU3G/9+]97D-5['PMYM\^/<_PW^.!<A6\+^_Q8#^*TJ=\!9
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M&O?[ FR0WZ\TB/&?VW;IW1;%M^F'35+_^9>?[B[Y$_*"D/)LR;U;D4%C[3@
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MT*W8.Y9R=7L8F7\_YQ?FIG@_Z<KV'L4W=Z"FR93,.ZD\\K+28* +CHP4 ?$
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M]1WR6@M?=1(8,6)L\=%C]&T#X-XZJE @FD6SM7JQ$@W)\CT'#&C\I)[6^?T
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MLQ<#GACPQ( GS@M/)*E5PCA%,A88X4Q+(O,D(]Q2*;BW0JFO.(/H48E!F@^
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M(7B?BIP*<Y0HU^>(_Z.&#&,6[5P5P.7HIP><=GV#XH0R]]!I92U(JP5EXJ]
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MNB&6K3R^KS7FVPAIO7L[^3R3^!A)3;X!.5VU=5OF"4W3TL48_0;B5L-_=&E
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M>5FL_Z@5&#IZ'\*SIJ1+>6Z)M%A*I;PG1B6><)Y8E5I*%<TV<4@.FTH!DY-
M,T:XP.'DRDF2JTQZHQGC>KVC=[U@XU@1E/.'UIM%2"LRNV$, 1;XAB.M[E!
M_MV5(OY6)H9JP\\8X,549GW.B*<YN)F">CCNB26>6Y-[PZE36]6&CDN3<@=B
MY;S CEE-I%&:V)#EEEIF4BR\W>:BZ(H.7T?H> 7WM1F /([T\&\!OM?MK,TZ
M[FJBFB)*K?'MQ6@Z7N%MF1?1_'=U@Q=U&]-&B])JV')O96+L/6^O6X')TH!F
MJ]B'-"[\ J^ST5.U\JV=A+<,IO!5Q7Q<E[YH? #,>^FK*,=MSU$THQM=3:@/
MJEHA ,!N4$"U0G)SKVU=P>7MT\#JU@&P^B'K]$P-IH:\QF<K')UDFANKB+.I
M(3S3AFCN%>$N!&.%I(%O*1R;9UG&I"0*AV)SX0VJ'HPLZ)!ID3'M#[?;#WF-
M1^8U'LQ8T9S^/2V**$*@?F(H&A;DJNZX?_?V%8#?:C'%TC=X[>TDQ*9\T% _
M%977$2"W%VKY$>H*B-F\6-PLD?C;GUY_>-T!\<O1CV73U#_(X"$99"G+7 "A
MRXS/ 0V'!'"Q$80FF1,"%C;)\BW*"^ES[5A&="*0)@-E,#4I<6F6Y=QJN)P;
M</$1<?$09KYWTH_+K=8R(R*5Z-0)3G2N&)%2J8S*3#''GWR,!U/RN0=Y!R2-
M#=B/H5=Z2)Z<70ZLK ?[)'5*#;4)<3P!S*0U)R ;.1'>YPD-*L^SK1G-6M"0
M2H73G"4VO-! ).<< !@/+.<X\]E\II@\BL3SW=FRRQ^%XZ /E;8GQ%SSU1:C
MMS6P]><?PMGPNH27.\+)GZ>%\S>%';W'V55P0L&[1X+Q27E;EX8,^9SCGO!?
M.Y9!QB_N2^G$%WY^_W;T!AX1?;@-%B%\[:*)CM3U:_'=*]P$L_(6-G@4FL\/
M=3X/J]G,I'):9$1Y9PBW.8)+38D"@,JS)$TRZC8MK1#:AB1AA'D9"%=@F&5B
M$F)9KJC-1!;RL&9I/Y8@J'_!"J^Z N(X+:+T,CM72[M:\+ J,AAC=+>1;W=G
ME^'K7S^\^@5%X6JF;S#F!^"DA.>^\I.&1KE+X[4IP.6[:[:N):O'1F $V4?+
M!?8LAAG\>34-N'LPPT4MHD75R:0>W2S&\X+HV4T7?JGF"P>ZX%:/%PTO%S[8
MZG,L'Z_.8G9W#G<TT?"J#R]O_46LM, N<NO;=,Q?W_[C_[8!H*:/O/XZ3,^L
M?B/<\<@5(?@XN7#C:W! XGR&K>AU(#<65\U!B_OYR+31FVI:_![7<NZ+R<HT
MQ&5>M?E('5'6R.KDD<ZJUEYNANFA>+59:5!G_AC?]W%D_7A<$Y7Y."&QQ#!Q
M_2SMLF*'+-90-N&I.&P"#FVW?_C,,7@=I8PLZNPQBA:6BFQ2T&(%3%W- L=U
M$4"PZD$4V)N/3X##P##F7=3]^E6<*;UZFC!\=I3YC8,Q76J$/<*VVV1>8&@?
MMRP>P?DUO%BMVUX\ *L&M)D%6MS@ 6KYO*_&I8'CX_^U*.I-1KKOJFJ5TOJ6
M[VJ"WGES]=EM/GR!I4$U[9QW%U$N_\ AH+54&-\4#=SJ8JR;7&JM'_[QZO\;
MO=&V (!7UUG!); VJ4O]-"/J8IW6Q^V/Z.*FJNLIQ@4.GMOUD)NJLJIKC,<8
M) 8K-HLRI>?Q+V.4H&HC!W71$#07U75-GX23[0NL<QKDXQDF>E:VG/HF[Q<+
M_6KE=E!48MF:\?7,H$AT@C2)4=\A@_Y5B3^N;.E2\MK# 38Q=NEV= 35HCY!
M9=AGI#<LL(5/QC;)]HO@/I9YP#WW7?-8WD:1Z.1\YDA=Y+?_.RJL$NR2(9@G
MK&_S?\O9&"RFUV.P0;_.KO2D^'>]?EWJXG__^NL*QUF\K\@GMLH@"0"AG*&
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M#)=>.P#OOC_,Q&>ONU&0MCF)=XIL/>2G%1)7N-$@'(<@2R[38#B #JX ?E"
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MD8D*@7"N/.&9LT39G!%J!+.93%/#TB=7W;2DH>O,TDN^UN.T.5WDJ?H\O'I
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MIJQ%,=Q[NV/,36#.(4J<1ASGK<N90Y%9HRF-ROFM;I2/4@Q7H*CHA>?0"S_
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M\<Y%+"52$0O$.1?(,@<JQ@9)=-(ZX>UL47\:PV*=2[>$7+\TR"<[^&^&X+_
M[7X<-TD^8";;\[P;9HOX7<?DTA$JEUNK\J_\.>LRA,TZ@X>XAAH#9K>+Z5WA
M]AW<W@9LJ[_,&_MH^4C+M\A/^\XNYM/W+JOU6?.0>27Q^^9P-+:7L,#O&JOE
M?7N[IEG2]ZL3?$Y8.:_CNY4]MEJ@QOG27ON[U3/ 0ZS#QA>C>N1&8^#3=ZMK
M;!P(1X;U\C6W97JH%/L^K^V?Y^&6 \F09YZ]\SBJAD8<\'HDK\K=1]&APOQP
MEQMB?+]%N>?#268>>3GX8[:+T*>M^-'-)M]-X=WBC@HQ6/V7!1QLN#;/X%V;
M;9 _V"WV+B(8?H#]ESS9\NIJQZXY5YPW1;0C0+77).D.;MXG3%9LV_"Q[D^D
M71^T\CD+Z^IGD W7(IQ[-E@G]L+F[8 J1[ I[M Q!R7HCG!UEXE9&/N9]L$O
MW\Y'RU!+X>ZWQ-U NOQM4[7=)<(63G\V3E\&RYO,]L+H;X717Y28A39%"!<A
M?$O"\CIHO [)?+YR?G6'CXM0?C;&O\/'LO0D/LC)@M6 <@S4H <A_GUI]T*N
MUV<*;_ @O7::(,7SB%^:1[YC:U$4-A@J$U9Z:U"-I5SZ0 FR7L$Y6%&D=3*(
M>Z>\L"8R1J\EK.XL,6R<*=G:NA[%SHD[9W"[TV O+Z.=Q<GQ1Q36L02JFU@"
M7G/%-9+\RQ,D7[\W_VO7,+PJ+1ZK5%ZLPN291)/",0JA%0I<*L2U=<AI+Q%6
M+HH4J7-^*Y?^,**IOO('';_P^74ZB47>%'ES]4:3Z?%0XA$,]X*\]<_=X:"=
M4OJU*-F$S ^M)HY0]N[K#Z1=U+DM1\H-Z#Q)R"0:$+8$)Q9M -UU4[$QRIPA
MQB.JA$!<.8U,D SY$+DSAD7LV*MT]GAX"]1L*N]-3"WB[Z \TQF=4_1_=VA1
M&*![#%#4]]&H;R>#XM8E1%.>[4R<0"Y1C+RVB3@C%)%;92,'4]\;?O*G-TL6
MB@T4WM_=K\BB#LBB9_"4'SA,TC,R[7%'"8$9)]P@'O*@@=RKTW&2W>4\*)J;
MGGMUD^V%L3B9X!$CQ@';,UAH)CU*1G >A3;X:AY2\93#RM_L_7]XQU6_]_YQ
M =>.I%T<NZ-<.Y%\] Y)$2-()A.0]4$@;*-3DJGDM\>F'$8R%4=YD3<]EC?'
M!$[[ZRA_/BU1+.VNR-X]DUJ<%4R(@(3$#'%C+++2>Q2]"<(I1J/:2DX)'M"X
M$AZT7P"8[AA&-C"76ZHQ(KDB(D>-.^(HO[W3&KZ]%781@!VPS@L">+L(X+[I
MPQVC6&^(<_CL[@((N@T(J.-$IL@0EHHC[HT 2]=%1(C%,5*F";//!@@.ZGJ_
M:TYAQV7;=NI[$7+%5U_00Z'%D=*B\[[C-TV=PBG=+*#L/G3N&JD*>0IYBE3K
MMB<GCQ,&<R=,%[G/7/'E=(!5[D^@[LN\XLU9>G.P%"[@()"W37-48Y$6CB/M
M'58DNJC\5GC'*6EBT!%)S7,6EC?(.A]S+J9CVDMNN7QA;PZ5 \WU0%)U)-Z<
M'>Q3_#EW^G/@]]Q(=$=N2!A=E"ZM5PNXI_\P[\]0E6>=+/A//>G1__-B/70\
M9Z=6<9*[[>]NJSR+;3?D,J[BMFP(I@@V)*%(4T#<:XZLH1C1D 2.A#CBMP:"
M/Z03^?XTOU7NPRHE(CQ18[(!YW0@Y'Z%>>1[_ZHY^'H 8QY\5B_&\\P3RW%F
MJS$SN0=X_KCL_MM"?P;[!,@0<4)S9P="D),&(V^2R7!1JQ"W0G_8\^1X0H%K
MV/TD<>2TD2A1'@01.C*9ML#BU23%=H+:CI$L9<=O[_C=XPJ'U?W4 "EJX+Z,
MP )5CE&'(C:Y_$SGS.V 43"&Y3&CU,NM;&^2')62!62B JO)4P:_>8L8CYH$
M)7VD\N75 ,$#+LQ *-E;KMC6 \VHA[+!;]G@P6!,?$Q(P4Y&/,!6=TY[9*/-
MJ1R<@^QX\@9?[>6?\M2H\?C)>YD/M.KON*WU-O:KY:K"(D_);>9OW1Q NSIZ
MN.OU._E^-P>6;YGW_POL_\;,WU5_PP!&:TD\RO/D$'?2(B,LRZ4UFC*1A\QM
M508^9D30SZ/:CZ?U8M8.?#Z/D[HIO?D]C[>,X:<\^JS!+#]:$#2_V<MVY-S#
M!@4A.<18??_^/$]!FYRT@U7$W=.#R';SR(Z.#WI6ZYV0X3\UX!$U1*@VZ?3T
MH3Z$OJE%;L_/#WG7R+0/('-"]6F27?YY/.EO8SOIPLBT,OBXIX.//TVJ#XL3
M>!VP7H@8[![WY:9Y5X)6#*-9]//IK&Z'PEXLA\KF4ZMVQ-N-O5O]L)I*WAR3
M/UJ/;-\[D7SK_I]^^[P>"QY3RL=?Q$FLUP/*X#A=[>*=:_?7U^\_@->I_:*N
MFWG(X^G7P=7+-.?.\^3@/*QV.5.YH-W;T&X0@24OD8Q9_0<,X$$R@91+TB6A
M7&3R)GB@6/F@"8?#F4(<1XF<I@)%BZE)#EMOP]9\P34PV%1)'S)2.XD9*/QX
MN84=FIW1-NO^G%IOR(<+.QKG.,C'Z>RO&>4]$3<;.M!$]!8X[_:*M"/!&U<'
M<,XDK^#5&$"[6N%F5G=:S!>SC;GF\/9Q=H/?\E#RL[AQXK6#6NX]3BS>-455
M]/:Q<R2HSC_B^7S9CANXX_&J>\E8U;]M<]N@LF < V3-5RCJ[Q;U1TSP@FJ%
MM*8\=]5AR!IK$:@S[;3 D9.M9EK":T%9U"@ZE<!B=@%IPRU2E"?EA+>>;ZF_
M#;?^<N)ZJ\]^C_#40%109Q\;4?MI*6F?FA0RD 86'N.WIMK:J;:P=",['E_F
MH%>SOHTRVZW%5BQS/E[4S6>3]7B0Y3UF\<S")2<GNY6CS3"EWJ4:!WFZ^Q+K
MK@%PE1LG74/ +1]_V77KFZ]W[_>I\L!8V!TY&0?6833QLPC0"JXXJ?Z?G2SL
M[+(B^?+1^M,F-#( 10Y"N'G/S8-R@(28!AODY1]-%FU !?;+R6GS,5Q\O,C>
MFNLGY6D#[K+(G]OD#U?:!N5!C$AAL[-9(V=81)X*B5T(6K'MWCDB*:XU1Q'#
M#YY2KBBD# 7! W$$8QZO.YL_+8G_:;(-HE?RYK<XRP:8/;DN><X7&[T#$+U_
ME]W]7?V.7/!\OV+=5L'NXMB=&GUCO/:2E_.TQZLXY.I$>"<?FZ/RHD^"G2VY
M$QC>5F.PGN'PK;N&V%J]V2:^O"^D:&7.E<C(^&(48@UB"R0.2($<$X6+P</
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M_Z[Z\QM8_1N#U@Z[]G^=C>;U?#J)E1M-!]6GB1^^J:W]K(O[ZW0.)\VGU4^
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M2F?KS5KB3[]^O+UWQ8 +,R!:E5$;181U>-F+#N\*)7JSZ$6']T6')^4L8Z"
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M^L4 I-$?A05NLU,,9X(R@9@0%J2XI,B"A$?.JJ"Q2<RRK7RMA^"QUV(!N1U
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M(R*>[/]B U;RH_IAZ_^I2/:^.M *4QVC ^W-,56!&>N!Y-$I(ARRT0> &1P
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MUL>3<X^,T<-"93M-YQJXVC<7U$IG\Z2M)Y5++F_LR#AV,,RY15#NRI[X4=X
ME2F>@KX)K::%$CSUAI0IYT26)B>%<X:8G/K26"G$9@!IWP=@WOG2-TU7C?.F
M;?V\_>^5%7RS,H([/B#-B[&(ME;G%NVQ_C#8,/%I^8$>J<8:QJ$'OA!B(<1"
MB(40ZZES=$8H*Y@@S!H=RF8$T;D2Q&692#//,FW3QSZI]/@02XAQCA +(19"
M+(18"+&B9 Y"K'BA!4*LFR"6L,I8(1UQCBLBF>)$J5*2S*<VRZ1TA=>/?:3L
M\2&6I!C%0HCUR&?<UEF3=C?;7?9XR:; CN6]A[D1GEII_E[/]229-?5)U0:E
M"3HDJ3H-%OH(^C:>.J?(A'Y88'RGE3:7]34?\Z"P7;T(9RD1CD<@*G=G4/R
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M/0&VKK=W<[![),5.C_^@&D(UA)$4E(G!$7WP,H&F>34FFDHO*%.$*\F)5-Z
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M%^CY=15 _MQQ[+!Z Z!Z>Q;J#4N!L!3HFO;P%$N!#F CKI4"G0P=4X1*H(.
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M"_)?L?#TGO[%'KCZ/0[&(4M9I!P9H)@Q^I+REZQX[G )!0L%:]=.X%"9&D>
M[."<PN]&B9&$R!Z+(4]7NX,QS*@$!O,K2'PD/A)_('8:K4!D0#8.'(O\0'Z@
MK3A0XJ,P(#^0'XBEL"H($YIWJ HR3UL5%#U;GUOF)8+$UWWKA$)]T$:I$&<L
MY2)7+YVD(F7Y<RD5NE(5U%4.=9,%Y_7:+P,J)$(-$9F&B)XA [3$$946Q<G3
M9RQD6 "Q*[[2]"7-7O)HJB!0U%#4#E34(JHU0BF+3,J0(5AJ--C :'2!&$RB
M(?&1^$A\M ('S@[,'B,_D!]H*^(A/@H#\@/Y@5@*2XTPP7EK/)@/ B=@]R&L
M*KI/]R'^#$J*MG8?^OELHD_;IR\/BF!G19A%0%LY8%L943%0I GQ9RQED7)D
M@&*&?8;0?*%@':"OAWV&(A8S[#.$Q3^##55&!PNBB%8A\9'X2/Q#(#Y:@5C9
M@?E<Y ?R VU%/,1'84!^(#\02V'Q#R8T;V&_?.+#H%C\,PSR/TZ.:X "],F7
MOO%3ZY.J38ZU\Z&;C_]V5)EJWB8KYL8X7TUF(\;@_P6+N\9I_;RZ'OQ^Z85^
M?@2K_GJTY_WQL JXX>P/?D#[8SP,>X#F."J$&XEG<L@,P7H%Y AR!&U&;.1'
M@4".($<05V&1V^&'Y*.SZ5&8="0^$A^)?PC$1RL0*SNP;@'Y@?Q 6Q$/\5$8
MD!_(#\126.2&16ZW%KEAAZOX@HWQD7]_16X[J>_)94;52Y=FJ629\]_D<^AP
M]2L\.(R^>UL?']?3Y/.\MG\D:V/QL,T5]@E!@[ECMGXF[.6;6+@::?>79RQG
MD7)D@((&]ISEV.@*!0L%Z[!</JP!BEC,L 8(:X &&[&,#A9$$;1"XB/QD?B'
M0'RT K&R ].ZR _D!]J*>(B/PH#\0'X@EL(:($QIWAH0%H/ "5@#=*@YK@?4
M %&54I93SBD5(LM>?FWF+?'?Y!?Q#"J WOG6-M4L/.UJ(1 6_V#N%"WESH=O
MX9 [K/T9&$<&*&=4O&3T)1](:3K:+Q2L@0C68%P]E*EGB0DC80@6^L0=EHQ.
M7T41F4+B(_&1^(= ?+0"L;(#<[?(#^0'VHIXB(_"$!<_4!CB$ 8$3EC5\YQS
ME7(L!Z$',=1[J.1_>&<?3@7/<EZ\="G+J0B-?1XVV&T893VKQCX?856_AL>Y
MY)^Z:?1TGE1MNX!?JVGR:]6T\^3C^X^_P(]3/;75]"L6_3QSJ4=#BD4_6/2#
M'!FDG/&78.DY?>ZP"04+!6O'GN! !IFC3#U+3!@)0[#H)^ZH973Z"B/X2'PD
M/A(?K<"!LP/SZL@/Y ?:BGB(C\(0%S]0&.(0!@1.6/3SG'.5<IP.0@]BJ/=0
MR;^#HA_.LT+2XJ43DN6<8M7/6M7/[T=5X[#J!\4>+>E^+6F!13]8]#,PC@Q0
MS$*;G_0EI]CK!T4+10O+?E"FG@THC(0A6/83=]PR.GV%,7PD/A(?B8]6X,#9
M@9EUY ?R VU%/,1'88B+'R@,<0@# B<L^WG.R4JX&WNA?X)=(.0P-"+.\CK4
MF/O#"X!8P5/X3+UT:99*ECG_C5&FGT$)T-\J4$FM3]Y\;;P_AL]&"=#(NT2W
MH3+H@YW7QC<)RT8)IRP?)>8LT5/X\W$]_9K\M:GF[;R>^N3#-+SZU[-1\GYJ
MQZ/D36,6\T6;_%S5LR,-+Y>\K9O9\KVZ.\ WDW9AVLI5NCE+/C;UO#K1X0OS
M(P_T\0O8:FUW.ZPVBC*/@09\P ;\,WG:7&W\"?AG+&61<F2 8D:+EUR\9,5S
MQV@H6"A8.W= 4:@&S<(7^J=8Y/)^L#*2>-YCQ1)N".BIL4B'$]"+A&_/-004
M10 .B8_$1^(? O'1"L3*#JP40'X@/]!6Q$-\%(:X^('"$(<P('#",J;GG 7M
MRI@,EC%A&=/31_/W5<9DGD$9TYMC/W6A?"GY;7$<"I8^3'TRKY-;RIO^<S$Y
M2SCM:IL*K&V*(8_UC)/#:-6QM@EKFYXI1P8H9EC;A.8+!0MKF["V:4MMD\':
MIJ'5-@V#0Y$PZ+D&@*((OR'QD?A(_$,@/EJ!6-F!=0+(#^0'VHIXB(_"$!<_
M4!CB$ 8$3EC$])S3G7"W@<RRB$(38NU25+5+5*64Y91S2H7(LI=?FWE+0N'2
M%_$,"I?>UI.)-LOGC9(/L_,:HHW2I55YDO'S4^^GR5^KB=<N^6PK/[6^[:N3
MNBNN+UVZ5/RDIXM0G<15J'_B#$N1,)>+MGGGMAFGNF$MTL X,D YH^)E&.PV
M$!R,]@L%:R""!7<3*%0H5-&"PD@8@H5$<4="H]-74<3"D/A(?"3^(1 ?K4"L
M[,!</?(#^8&V(A[BHS#$Q0\4ACB$ 8$3%A(][V3E6+S0/_VO02A#+"8ZU'#[
M3AHA*:HD>^DRQH5*G?^F%'\.\]Q"(Z-0ZP._ 9F2-Z>Z<<G'B9YB=4^<>0,T
MF ,VF)_)TS8_B3_C_8RE+%*.#%#,&'U).38:0L%"P=HM7Y4:RLF1QQ&J ;+P
MQ1ML-(2-AC# .1A#AL%^)#X2'XD_$#N-5B R=P93\,B/P^<'V@H4!A0&%(:G
M)SX")ZP/PG3G17V0P?J@",.+\9$_\OJ@7&;T\J"T_#D,2OL5'AR:_WR>U_:/
M5;NAOS8Z3$ZK@=>^:R!TZ:\7#8BZY27S(Y]@F1'F:='N/N(\LY=O8N%JI-GW
M9RQGD7)D@((&B(#E6&B$@H6"M7//,4>A&C0+<:(9%AIAI'1 A@RS!DA\)#X2
M?R!V&JU 9.X,YO*1'X?/#[05* PH#"@,3T]\!$Y8:(0)SXM"(XN%1A&&%^,C
M__ *C>PS*C3ZY-MY4]DP=JRO*NIKA2Z5'&%=$:9ET<QB75&,R?9G+&>1<F2
M@H9U16C 4+"PK@CKBK;4%5FL*\*Z(@R,#L:089( B8_$1^(/Q$ZC%8C,G<'4
M/?+C\/F!M@*% 84!A>'IB8_ ">N*,.%Y45?DL*XHPO!B?.0?7EV1>\YU1?^8
M5G,L+L+<+-K:.&PM%A=A<='P.#) 0</B(C1@*%A87(3%15N*BQP6%V%Q$49'
M!V/(,%. Q$?B(_$'8J?1"D3FSF#^'OEQ^/Q 6X'"@,* _(B='XBEL-[H.>=
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M#GWSD-_7O=,L:!<&(]\=@Q$3#=G;D>S=WWE9]^0!I3!#;-9C-&@%YG_;-41
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M169NRK3:.TNU+GYX0W_1U^U%+Q;F^%YA+ JV;RQBKG"R;B(!?RL![_S3C00
MIV2M#3$T7.\<ZK>\3BMPY DH$ MB.4*LK;\Q3#ZJ0AYU0U$H#!#<0K+;G>+J
M A%E <$G^ 2_"L$G"XB" R[(X *"O  \( -D@ S@(1T/"B?<0O46*YN(*G46
M502YA3Y9?8)ZO$-LLE&KSR>GSS6F'[^-ZP?.NY!(A0@\\*%V?$""%H$(A( 0
M$ )$W$!$9A'E8#?BW]ALW.L3BBL*1-0$!)_@$_PJ!)\L( H.N""#"RC9 O"
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M/3TY?7]R8-EQS.@\B<EUR/Q+LK 3+_YTD 2_);9'%Y2X(%^/H&!*%0K%H)"
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MJAJEU=TN@LZA(&05*8V*&Z*XFP#JDIG]TC)1+)9WJ^BT[DR1C2W1>E3+$+7
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MMQUR-'0UAE3?3!@T]C142U\_CD+;YJC*]5S-.H!W@R=QR-;7!.;FN()-&SW
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MOK38=:ZGNTC0M/!)XFZ W&#G;-NG0I'I6*@LN92<Q/OU.Z0DZT92E"R+9'J
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M9( )L^C)W\E_GD$W?_P_4$L#!!0    ( '*!:580*88GS$X  (&9!0 5
M9W)T<RTR,#(R,3(S,5]D968N>&UL[7U9<^0XDN;[_ IMSLN,[>99?525=?68
MSFK-*C-DDK)J>E_**!*A8!>#C 9)2=&_?AV\@@P"(,AP$@ SS&:Z,C, $/X!
M<+@[_/C+?[VN@Y-G0F,_"G]Z\_'=AS<G)'0CSP^??GKS]?[MZ?WY]?6;__KK
MO_WE?[U]>W)Q=?WEY MY.3EU$_^97/BQ&T1Q2LG)?]Q__L^3_SF[NSFY\</?
M'YV8G%Q$;KHF87+R]F25))L?W[]_>7EYYRW],(Z"-($/QN_<:/W^Y.W;8OAS
M2ASV[R<73D).?OSTX=-W;S_ __WP\/$//W[\]./'/[W[PZ<?/O[O#Q]^_/"A
MUBW:;*G_M$I._L/]SQ/6"[X=AB0(MB=7?NB$KN\$)_?E1__/R77HOCLY#8*3
M.]8K/KDC,:'/Q'N7CQD !3\&)1FOL?]C[*[(VKF)W&QZ/[VIT?/Z2(-W$7UZ
M_^G#A^_>5[V$+=C?WI;-WK)_>OOQT]OO/KY[C;TW)[ :89Q]6^$C97/VJY=4
M'>J-__@^_[%JVAKZY;NL[<<??OCA??9KU33V>0UAT(_O_^?SS7T&R5M8S 0
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MU9;:7M?6DBP-M=C+&K#OO&UF!J0QU,3VB3"3]G%41%6G>6LQD4N(O=SQK<5
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M\* 4S6:%I-W2")A?L@6DV+/.AE'^A23WZ7KMT.UBR?L=_GQ'LH2CM=RC</R
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MOBNWWQXVH Z9R6&/@=EVN*5Y@'7&YT2"DJ@YVI)\B<++5S=(8_^9#-U-O<?
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M8]@65K)?.\=S>@\6=UE_Z.^&+@Y8D/:7"UKX*>"IQ=/-TD5H!NO/JRUT,'8
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MP7'?,9L?2L4@ZEM#3."RFDNQDTF!\LFR394Q2GHB3N#^B/!]>X]TONY1"-)
M"I9_<V46ZQ/CT-#0#5;0K@A^$ZY"[@N B^=1FXC8KZ\-&>:2R;)4@,;%*"2&
MKRSYN9?(TMG=65A,:SR,DVD5(O<#>O50/WM<!W"??_GT^9\^?6FW*_3J.QWU
M'/8SXL]LLLOW'"W,(&K<A-HDSCV)3.3"EW&9!X1R3@A,@4<[G"/,=9JQM!/^
M<X[+7<J$.L5Z&%%7U68PP@JH1_\&$\F"T-<BMO;M9<YRQ$,RE>7J$<^Y3T^W
MZ59-T =G6R[SL0BDGJE4/>F8R^4]6+V?KB*O0FAVRJR:QA/ W+@(HTVNS>W4
MM;:'M:"4^&X&G^C=S>E1G8&T$>!B@3A7WM@LSP_4,=39>/E7D:M87^?^L4'&
M!K*=+,!,NT-R!30$'&6#H=^Y9ACJR$UI[S12OMTL"- AA3E17O2?X;H5R+&Q
M\5AJ-<T*!$:-<EUK,9JGGT=4BV*M\+NFO$5]6P?[M9I%J-F?M48&W_[5WF]^
M:P]SJ.N>+^):A.M<!#XTXZYK&[NVXRIAE#SK4IID->?F0$+&ZS[L:'87-.".
M\^:0G\Y>;O3WJAR"CU2!1/#64D*K3T_G""!M3N&FEB[>8M366!PMS3!2FAW*
M]A"-EAXN[%K!7V [,_?8(BD3.K%T^G6L5E?;*3!^3^&6A+E+2 S^R@C8"VS0
M]OFL#^OV-*IH^!T1N.V=1A-WUG7)EH%FTW3MP0VLA4+?KZ]SY) NP"M=:P<3
MOZ4Y"D+P!KZ&H$F=;1\SK)AV%<9P-V-:-M; ;3/N[4'@F"*+#-;\P\(B5]Q9
M8SKRR-(L#>D86;Y.^4?"GY2; /[UY_-9_8R+WXYV%;V&W.I\!Q=[*HISZ#PH
MY3O2^.@:(.C*RLV3><1QQ2H?&7O=.IZ37EW-V5H./1_5;$TUH*6(#F@#,QEE
MW)%,(E=A)))7M880I8FQ3]<8LP'K($(UJK7&FK[!?@1&NCP>?!I[<+X?XVQ-
M?1"S05'6R2WZM@:#U:H1/II(M7HC@R"FW5*VM'*P<)PBB)_CAG6$\S1:3RP/
M:6YM8(X!*P0B+'F!HIG-EY4J,BW&HOVIN'U04":\ @V_2R]I[3(1'WXAH!^
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M["Q,UB]>NO+.DW0MDX?BX"Y-\O#5@[]BJ(VWIAN0R#&X>+@R(@8FQ<A$&9J
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M&(21VTF!]5 \#A;O(Z.<1#M,5,)$[%]-$ESN@O+_7L<"WE$Z1#FN\ %54#7
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MP&U9)<_'.*5>A/KI5R^,S^@R21&O;I":7Y D2-.F-<H%JX7*7S%>G)0H8Z=
M^!2GP^H@R2F(PJFUQ3DA3VP>&#!D+6L@\]-PS0URM_2M-*S>I4D,/_H\NA2>
MY#^A^S!9YP<80JK%LM L'VWE ZR8<JM#HIQ"_L2<I6S4HUZ!8E\4@V$*&0S7
MGW_RV1KB/:NA>A."\!7 [<;J0/.H8@&[K4Q[&!H^+]9:C$24H0J0<F6P8V0X
M^@7QNE-5PCG/I<5LO8[8N%YTYD48<//P0FEN.AA?T":,N)(L=)R<%8;"<@A2
MY7#D8'U$WD:=$'019OR,@U^  #,ESJ5$C@CHRG28Q;):!H[E"]>=-ITB#CFS
M+>%,9"'KIE)<4*HL*-HAJL4+65D)AGY8YETC9F*QH,]L03?E@C[C@@J1,??>
M[47,K58A+]0!JXF*$@@O-/9A?N7U<!/&]#JGJT$>;&4DMD"5L92[B/R,PQ$V
MGDV[N3VNHUV&9Q^:X0;7P52^]%WD<1%\]HQ2$LXLPU1F7 :6IW]%AV,MR#&(
MAX.P2& Q"N,_8G@ 2VH%:L$>E]+\5G#'B!.%.MO6'.T !S@FYBH6T][?;[PT
M63,F\EJR[!%,/VJ>N6T!M;041A%'L M?J0*8CGL-LPPU?U[ 3YGGLS!+0X^E
M,I"*W,YW)$SEU-<U(>IL+-^Q4UBWJ&/)V(JI_^;)??F+AYA3:J=QUNJ/%)U@
M%$17FL*%(^'=+S"TC8J\%,6+-60;R:%./3[6;HWM#<+_8\T^%LR'ABO,2L'<
M3H1SX:U.2,#G=K1K$E67@XAAR$X!"66,$W)QY%SG"%)[,X3U$\* ;JUAD*XS
M.E_>T[7PS7+O<%$*4(ENX?;ENTV*^5;Y(KGTTFA;5+4=!B"[YA69TV(:).4N
M=*4T8"6Y*^3&[K68#?Z=XGS*NK<?;<$B=:WF2U+.0(8;*.4G*]%0PC$@)X)_
M9U,AEQ]UK78 <2WL+VO6 "][0?UPQ\QB&E>0F4SP7?:;;"=C@@U:95FUN#$3
M0)/I;4SL0:O<-IG%]OO&%B.W:BP;"&"M?\L1TL1,\*"S H\ !85!$@N:KIKB
M,0Q4FV Q&$B?:/)UCY+%2.'NM,K=V\C<G8M*L-1TODA!V$&FB%&F(O?\B(IM
MZ!L)5F$<9CG7;B_?L12<@:HNLB0<4ZLK0Q QQK%R&4V 0?9,EP4G01$_]])T
MNTQ2K,V7P01"G@.)A1\/13<J*TRBHE\9@)0CL-J21\9A308I.64F#1\'(@6K
MM&1U"V/9DJIM\5I':$HJS&*DVF6509N7Z&J%NHD7W7EK$X]Y29 PBJ,\! 9X
MB$:?/H)7BQC6JS#SO0BWTF4<7,#S<^CL1=PQI\=+S )%@B2GS4!E"XW*A4R
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M\ 43F7(P:4[4=+J;W;E;O"$-3%Z<GA(R4#C\OT=BOYKTU!MP [['O?.K\3X
M B^5]<RN8Y@2S7(,E'C(41,I\]R&Q6YAG3A6*W=M*[;"/D>1/.E/N5(##KVA
M? P67W)"^#!*JJ(M5Y671MM%B99\+Q7%^9+#17\+(YA5$M-9'-PG6R_*MS)9
M=I!W$<>MP#2G<F0,UQ+A4BLY.*]3QH>7\9X@E@8T\]-P;>=N''U](G5IE#%)
M,2A&:@@4[V)<%L8G1I;RNRWQ;,S5J+L^#6R8\9!^9J]>&*'S!!0G1 *M5@R?
MK9(T1YW]/,ER4+P.B*E0'MN"&D%R'X9%:0MI C@JQF8!K0QJM5X^O;HJA$WA
MPZQ-'RPDKU@C#&;-<(T"7*/2FT>\8HTPNX$\X50LG)$LS?_,WC.<\@.\9UX:
M)@,B;20):U$UNZ5M%(OC*U4-*/"Q44'6_)E5G/7\LK3-(,>Z+&L#CT!E/E6+
M#IZ/^I0JD0;JI.S%]4UG#0NCJFY!\+2H_^9VC_S%BVOK;#<(<O&6+%Z230;3
MN61F-1IK:R<-#]/HK!AE.YK!/KOBP\- 1(Y$Y% ?G/7: X%+D,LEH'()J%P"
MCFNVEDNP'F$)9,8=7@M%16=X+6M!"1D+J#25VB>3%AF[FS7\6 0JP%_?1,GG
M8^2X7N!0QS2* F^U((V,%SNSI6%:Y3OJ^,CC\ELZ"0M&?TK0NL-K]@US>2I<
MO3*B)&54)\]&5.% X-MQ@J*8H:VX?,2P"$0:X]'DFYJ8M5AR3HK4$CDG/.]Z
M#@2?_Z:Z[E9K8%^%$4W/05=Y3M)#0WTY)<)($4EKLI-N*'9M>^9:;+^FP%9S
M.(V-(:W'PETW0N/(92NML->%R=C(HW5XU 6-08"X7F&B+QUL^N;42%B2(UX4
M)6\HP$R9AZ@R?962K7AW=/+F6R,:T!<BJ%D/TA\R:;'$8TQVQP,IDO(''5EV
M#I4R9?90%(Q-7RQYZ?F]M#;G\L$6Z :\&CH,^O^S]ZW/D>/(G?\*(NPXST14
M>Z?;#N_:_E1ZS>I.K=+I,1-[\\%!%5$2=U%DF0]UZ^+^^$,F'@1)D/4@09":
MC;!WU!*9B01 ()^_!.]H<7*\2%S:DB;11(F@.GTY+!K(>,(T:D,1]"G[2@,
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MA$VOM=R*&5RT#Q]![GIM]HGK[KK_XO-^9/'G%F#W7S M&(X%;M>M,4,7?F7
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M/"D)\FN($J-QJN,TRN'$J)VTHXMS8/U(SZK= \I%1JG27<9Y%$:L +S;$IY
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MN05\T?^+O[]+P1>9O]\QP):*L=IW=Q3NLS6> NXQ0(=30P%$?3T6H6\:@_A
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ME"-2,'(XII'@MCQ/H/*9[.L[+R.\HBKG/-A%?,.9?=+'2#BY28)8IU[V4D&
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MDE+4(P?&45)>"11<@4)I9JZ+D5R*S"S2*F&7'TW8VEE>6^*D7&(%F14H?A-
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MS9):T28=(XTZ%)-5)6Q#&-6X:LY0U%P+VHHZJGT'48PP>"%Y+G(2)SEYI[D
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M+14!D?)2I(T@3E)G$E4*NF3= .)374NP>I%&#S'A('M=I7=!FD<!D_^&6<@
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M? +!;4RNCT0J3A=T=/VY*;BFC#*URL6"R=BKS5,F<_!:G5.'$O"- 0ECPJ,
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M7GU#T?8=3]P?$&P<G\>^Z_MBYR.]8LDW2Q1->)4[T8P/?=FKNLY/]!"<:7G
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M& YP_& SL$B:H:Y&TZ7E1R94ODEVV,'(^">M8Y(R3T8/Q*U6'C"Y3M*#)!0
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M1#,4 P<?4G!U_)( [SZ\\T-H#4#YL(!L<,@?/_)OACL,9.*>)XY< +SD#NX
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M@PP][[Y]<[=.N '/J*@,G##31!N9B"GXV.#"PTV8'E'^6215T(3VN[8XZC"
MJ;=!5\V<&BS'.[WQ)#PJ15&D!,+-N?@3]S,PF8887[[F)4#N0[(#H%S/)2/
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M6,2T?#B!-?&:?U6BRT*&^<O/IPK1)_^S$Y0U#@6E*/2,;2#)S%66P+,L26Y
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M*-23U08QO;T[+6Q-8U8$S?[-'D".B&+B#GSP79S-;A.#\U*<9Z<W542<5O<
M%BBCP0:H'?XJ(Y@6#H.YN95@M$YBE+.L5H.=NCQ M$J?]8S&AFH3R^].5FO3
M.Y$/?C,CT&5LH\;!>^4$Z/74RQ: %,7!P@'FT_:\3]N7;+\/,!E.4%U>!3^8
MTA"F=_E@YZT:D+9+"OSH#87/0YKRO 'G(B5R:@7;O='(Q+YM ?P8I4#^%);O
M;WK'TA>DGL18&HN+V'?,"H13WWN5&+9UE?[B70[.U8)?XKRB&9)7.R(]N=^@
M)O1I68JOJA0+]>Z>HYJ6 WJ8HZ;']\79=FF2/Z19.6_GXT4_D2QM1_-ZF"DL
MV"1'M+.Y74QO6XD%:01R<Z9O^X9[!"EZMO8$XJ(4!I(^Y[+U;ITX],,-HA[3
M+=*A6<T-;+HF+:(=QVYO>KN)%J&ZUSBSMGVCW8 UR@V$'XGXKQGZ KI(/Y>M
M5M56\-/JU(\;WGWQ3;'T""9"0"!M.67XB>@35,7B$XE7((3+ERK<&'<>SO1V
M[K#0M2"1SC#:+@!0K23PSPR.?GL X=G<$#7(%MF^S.9&/,UU6L1N959[TYM2
MM C-TKF,65N_Q4  4+J/_\J<&-(5'$\>]1LG=;Z$3N;Y\.=SV7KM:=R'ZRC>
M84JESUW540QL5"Z)HETKV=GT%NZXF-6=+0N3]=M<ZNW@_(9PW)?#^7/6!E''
M_'^%KX7E.JM/"V4Z^)YP%:87YSZH^F$? ?#NHGCAP;,!;XWB\3^?\L[#&%B:
M+PFD[S9)?2@IROW06()&(Y,O8BHWX?<AY.@,>\%S($4O8[A]#;W5:[]6:Z4J
M:V9FY\VUUY &(* ]M.-.D-/!4*R9G!2CM302SAJZ *4BP3=+?O+'-3SD_13]
MB>F:8??0)G.Q/P -B4+*O\ /QBA;=KFV7$DKWWE*KX?DV$:ZNXF[H=T>2E9<
M)":&I]T^2IP@+Y'WX!^ E]>'D9MFIZ$,3/D90+,Y RB]']0NL9]6:G[B?B9<
M(-0LHDN2@^0>[WL(/^(]OE#N,I*1U>/D ^-.4*:G@0D] +@Q\O(!DAN-U\/D
M];*DF& U-_-V#)J+6^32/A2A"2I6C73W"=P_RLU(U,O 1![!MXK9&$<A_*,+
M3D_7<!F.Y%37!+?QH7FP#\1AQEJ&UJ8_P8,%?CDX+KQH#[5\%F42RE3'D?19
MWV4>+&0W,T%^C-*_@[2@\@-M)AU',NT+5,M%).M9&</M-WG0NKMW+"^9K<9S
M39>1Y<4>U<"1=%197N))#;-^?C#+:TJH0<GSIUF>PEP-**KGSO*$T(J[DN<J
MM#S]LX(^H>"Z'"/+\^1!4W>,%K#],L/6V>E*]-?+UO\5O+@$L%GC[^PI)A#.
M=H&T[YE -IL%0N\V@6I6^_E^=(+3K/6K.>T);K,M('4C0."Z;(- [[T#P?2R
M[85>]QL$PLNV'7I=K!#OKE;3(3BG8.$5<J?-H<)];O5>W"WP,E2XGIYOO^[K
MQ8!S;RE[C3? K&X Y ?7S_,X.8&;X90-7Q((Z@N$TM]L<1W SR#=1M[R &)R
M?0+;@'46(-L=7>-AZUUE^D-^^(R$6S_^FB]'VS@.RM%C7*=.OS+.>9TKEM3'
M0?<^Y1(L#HX?H&5 1=4A<5S1VVD(TYM?O2*.&D*VOR>CEL(YKYUK04&<\EPZ
M49:?+#C?^JE,=[%&WC)\1@P,C>H-#I"2VM9ZOV%ZWZL6W-&,L.UB@5&@Y[P$
MPV64Z>G\Q&8ZFUEO29X+VJ:<6B7GM54OHAP/ONI#>2ZESFM6ZP'<.]5LVI6T
M"D5FSE64WU&J^&TZC6CLA=$2"A('<0LFZU2W_K.3(BOA*+E<ZB.9EKN]:R4Q
M.=IREU-GX+1L/,NC]35P98=-/4:4_Z3+>(VJ,#".I'H9)0J1#!5 L;-1"Y]5
M*@HQ^V,4NHR?5_!/"20>+D2^5$(S7]N'#,"U@F,OUQ6J%F\^*WL+O:T!HML8
M.W18/X/=*X@9TU$=1==$DSBM3!+^K9P@_,O79[#/8G?K5#;4-;IV 3&4Z.GQ
MT=F!FVCG^&%C6FI]M2FWO_H!<+P7>&B$+HI%<:F8<YOV!#8![@^;Z/#> WZ.
M*_Q#"2G\"SRG-DYP"X^W]$AA;UJ+P4G*OT5=R-;/$ZI6J"#2X"D&[E.P8TD3
MK9\PDP$''W*_^^GV.H.*P@[$V--9<73*631=1AI)&#6E!V7[,)MI$S$UC>H4
M+-[4.MAR1ZF_-JJO@@QJCK%WY4=<J4AMIP\[L+\/P^C@L,]#=KMA5E!UQ09=
MH:L<^57T\04]YH!F"W>A6,WU(77[='^7A1XTIV1P8K?6=\"CQ]EW<(/G!>4X
MQSNUH3XZ8N1^%F-";:>-"OFUD5F7$8W^;F8?_69/GV4UA/LJF(1SA6M856%5
M-F;LPZR3V7/R\C$M$$M]HQR+!F'2MB[L8Y@AS93&TW5U'=]2MAO>P8:09QL=
M]G)Q1W?620"JV4>6LJ?(6B7,I7#.V,=Q+,_3B97H1JO%+--=[:!;UD-<&1Y
M_!J9!FL<\2_0GH= U\(S@"7S;;O(EA)G3 _/O%5[;56J&3+$Y;XE&Y3CV+,T
M\:%P>S)<B_8RT3B'IUZK>(@,D]-8C;Y;FNZ1MCTC9T_0!#)0:QH>4]D!J@5Y
M7\_L+0>B6#H2G-'8:-C7"7+Y=UJ4+D:G4(1.^NCA,\K(MP+QKL.T)(<Q+5'X
M'$>_@:*A8:F7H@],LHQD^SOZ*R=P0A>\; %(4>HN.,#9O;Y=QALG]/^5)U*
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MM8-J.X=A:%@*F;RA4D9-JP!L.6Q\LY3/5T.6E)DT1&*-0,XLM?0EPQ Z ,<
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M2#Z]_R^ H<KB5B.]ZD8N'5,^#=2&QA</N5@/3H#DJLHZ4KH9GXK0><]LKN]
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MKV"?,R3\T\[/=F@/T>U76D-M=!3^H@<?S@\>Z,=G /\0YR').1Z50XE&G]H
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M_ .EO@"WJ8FZ ODB02F4H:<%++.EU4P;;.3VD_!S"0=A:AJ"$KUTIX?#!UR
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MV5"\7M+(_6,;!7"62?[ZD5,3^UQN@EZRU\3W?"<^+N-\4I]!NHV\^_  K6$
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M)MRT6E&;FJ ;T>:L+(CE.0L[;.1^CRQLQU.+R4'"\VP'JR_S*3\F&:02PX0
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M=-J&P$G ,RIDLEQ#ZR/-B5+@*<% 4U@@Z51#PZ0/D@VNPP@2:(]2@76-+E,
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MB-*3&'[>&5+99]PC--7B1S9,A-24ZU9"PY#QOD>.DIO6CNTTR6[1<*/+C(?
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MN S1,G1@A8V@CF?D :TS00J@#,%0H$UXCUQB !(8;YF^2VO2^[>=1C:*W]R
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M<R@AV@E*.'-@6P0MWO4HN@;VR')J^(%, \L5&8:Y0FS.U ;+U"92&SB #VB
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MQ8B.M:WL.P?X&_HGOW0.[&_O_P]02P,$%     @ <X%I5L[L<:8%"0  25X
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M%+!_%-#8;PI@).8I@ SQ.@=5!? /XG!9+5SG:8Q6&@YZ>!J*/ *= -P%!%4
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M:6"Y(L,P5XC-A=I@G=I$:@,7\#444*9#T/0]AZ"![H/'QL1 ,Y %+(D7MH<
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M@ &D O:R58R&$D;G"0 )'&?OILBZUCYA+BN4;5J:VT,$^]$4[4(A$BO8=BL
M2V93!0"V?;^I8("*2^)Y.I)BQ#"33^F@>$U+%=D%2S(A)PRNCH?2I13T ;\
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MGR"W)#B'^^&*9&MI:)6"*@(X)YUWGB;W<_"X(<J+(4I[210F(JVJB'X]3IC
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M&5GD1?/8;>HO9SE]U6T67^KR'U!+ P04    " !S@6E6LO._@);0   D[
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MORP9?SHY!T]4Q8GU5]I>V/T(I/4V_^!=L5$UQVNMOB>O:6G,BK.^$0'X;>9
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MA\T>_6:#S1(U2RQR'PE--"ZWSM9?"@$D@LO!<^W7A/S:U<@%.6W>5*]6SG-
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M8LM=NE5PEHP2,!+DZ5D*0S'6-3/+'W&\U1%3AJH-A3X$(#>U9R5YV+0X?S.
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MY!$(5C;<#*I+8^'3*)[5JN?4]16TP0>UZ1=WV7M:%//]3&:49>?#M]/ZI4Q
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MV0HA6^]H,R7IPS07$[Q7+W-O!2G$;DT=.Y3CC>[J>VMQ]D\'/;?V$(Z ZN9
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MK(!,WY)RVLC'/DNV.:&[<+I$-SUQGO,&./TBV4&[_0,#@Z[_&,N???0^;K$
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M2?' @30@K0IRA9FY0(?;5^-/O[D/5R@T,E"V><P22Q\A[,%7:!GN&-V<I_"
MQXJ(&. D1HV$]PC3_XFF(.O+8JDF)53;(4DB'09P)4/'J@K96W+K(ML,M7H6
MPN<=4;M\3%L%K$CW\HE,K%5UXRL/QJS ?$D[Y=O)JKR)O5B'O7(H&U49K>B[
M5;7MI/5YJ13EEDXH9-^YAVGE X.ST3$VT+%IMA+1*!6)3#R^:V?HPU42GS9O
MC\FD\Y*3IWP41!<AG#_%39 6EX,D!T1#8ZSXEHV.R#ZET;FL'6IY5LL/L5Z6
M$-T_\_G5F\T^H7%V'<#SX6\R6.M!K@#B$1&?$.YO(1D5P$NW"/2(+O5>4YCT
M.&%12-3167NVZR9<YL(PJ1F) *S7<8+V*LWHYBGY".-S[=H7^;UN!53U]61M
MW.CH$Z$,AA%(JW\@K[=WE&DI9DH#[#ZTU*:>KJG7I"Y2W-7("E?+!G]K"N[8
MFHWFY%#58+L>83@]<'"H4WA;H2M5QK5,*Z0F\ P0ZD,7NN(+_(IJX?TEMWJR
MHH[0(FQ3\)P!'7,+Y$[M"M:;*Z,FT57V^T48\DHH3B-IPZB:233XR4_K>Z*;
M_+%Y1'MU4@L!''6'/Y(NZHSNXH.1ER4-D5BPF#-([[!TU,%?VL[1O+VEZ8UU
M=?*]97,UG5B;HQ!H[Z ^4Z0N>5/$+D#XWB],Y0-=@.#)MZS)AO)W>06+LE3$
MA!\(9H04-!_!"FZE.37NL8Y3NO+^L=!A3(=D4FV[7[>$^0;5T=$U8NB#\D8<
M?ZO6MP0$JM+ ?P3J,WPD5^7\=@<YR7*_R#/,5/2I&NG<CPP00"A$P:KT,6=T
MD3SC@/6RICGHEY&6)>F8@<"^74DB;RICE#0N>;&6&C>ZF+2YMU6WL[?CD/<;
MAQ/6/SMCADUWLNL@-;L<_,)CBWRHC7EJGITPU"7P)&.DF2FG:?3K_ZD;Y_\
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M_$9Q 5; JOEMAM-3'\KUB.O])MQ$>(B?3:D2 ZB97<NQJB(QX-N10<SO=<8
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M>(WRNRP8HH<8?L %W0D;5[,OYMY4+ %FB7TLN6Z]/C0&*#T.7A'&>PB:JMI
MF"'G\QOA])9B/:UHRD0J7=>=*1H[;2$8-FG&*=\L>N7-OI%^HF03#J5)M!H
M%X'S[20E)>T5V$PNL$53?D4=EO,6@10_VXLPH2F?:36@9A$9M.7@-J1*O0''
M-QN.B=61N#UL5N^7E0\I-PU<2I7CZ>C:?*&IJH(._=(QPPJ>*J%QP205#[95
ME;)YL[%@6:3[SVGJ_^+FA&*!U)'@D!PS4U?Q9'<_0_MX,ZK-]^S]I*3]>^%
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M7"DA?J.X]F6$?0&8574L%5JS9+Q;Y_.>U]2J\K-^<<)4<4(M",!K@O4^U9>
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M(]P=V[L4K4NPY5YIP862[S'FE[PJ5!DP#GFEH_WX'4/,U5H:^=XKE7%D]/%
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M5KTOI07U8;N%@R$"RFI3?OA@I*_A9&]$?M*1'L[!,R=+;JU,&2S$!Y_+;/P
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MK7!O0&W3ZL<6?YJ6[4;-R7=C99OB&^%UVI)B:^?=WNG7AXD/[7P=X&EI)@'
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MPHB])'8;,FRE BES#CP0^EA"/(^>V6@>&J0;^JBP$W:^*WIQW?KO!^KFP1T
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MJBBX$",4@E'5^WX3PG$0T/LD=C33K^Y@4A(N4;UC^M5&<'_->O?S (_2KEY
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M>@2K09\1O?;7DLT@^!T ]4,J5.J"3.I:$-82]!V+5.\%7(I^%NED0&4\_['
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MKZ\F%"T-X$'0* BB M(%B8V :"@&E*H0,$IBH3>EQ1"*](X4J:%W"$4.34P
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M0\>\%01?9F;95N&>#S:W[-V_(&MQO@CD9:SMFI0]\;7UNCD[?1,^D6DMR-D
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MAEUVL!#2# VP/VU  U:7\"N:\</20(.E^7-*L?E+_!GH1DUYDGW,A??B'B8
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M2(XL:0]DNB5,UZ.</3:X/$:?K0C==OA^XX[D4_E&F%QS=9M>H85%^* %(NE
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M2^$"2[NAH;:B*GEKZW$$P>M/O>M8"D7/792QO+U=;.SYQ\?Z2"AX;>._88=
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M@YU7F*]8O.EM&OAEC3'JJQ/BK#RQG/])17-=U3MK.TZ[=W["[T!C1I-)7QW
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MJ37K-%1:V>XT##\0NJ4C'QQ4/8)T:%27I2>M #?6?=;+87Y]0_<0N?WYX6B
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M!XO0\_T)\-Y7"-(=_J>;\:Q:^<52K\[O-\L*H@%YAIZK\U=H *:/!HB7V]'
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MU$C.F =WW%]EG*CGJ^.395UZG:SLL1.R]Z+U%.52W6OMT;N-0OL&M<3P&^9
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M<YK/KCK3"4F#O4APM5IOA;92&=/'^)$LI_-VE3@>>1]%*TC,[>[760\I=C%
M33,S<M\;-D>1&[6S,4*[,C@B-4,;:^&O,DQ!7@P<-#%KW!3=3>4F^#@Q"3J<
M3GI:778:COK6BSZUX +>9=-LI'_&ER_$7[)($886+AQY)5Y'7;F,!;87<QR0
M4[!4<(>QIMH6R.+JI7;.,\GDP*O2@XCSE9FW_?L5/D *;N+RK)#1%5?R5-1\
M#%F=^['$NZ>BW;,19WHU7W_.)B6Z*WK4/F-!)4;YA)#%)P)UK[69-*'-,^E#
MS],S>[?>\AO[<DVO2=F7I8?8TF6/]T%1UUQFD,?J7)JYRPO29O-UQEA@)2M=
MVNZYU15E.B_5,8M)\51Y"9;PNN27EX5W,C.,V )?8>A*8_V1FI^$$Y9J'3.$
M:F1"O'=[&'^,$*C:^TUC >M)IV _B_,R!'.G1)C)Y!2A1]Y0G0M]WSX6:%1P
M:L7(5Y==F<\+=2QREW684G=8G5%F5)YQJ5*;NQO8!*%H;[3J8+N$* Y9]I=]
MBNEI;Q.Y \FY=T)!AH;,\]9-Y'AVV_DYC^CPCE75OJ,0E1@3854[34!T[_7J
MO9L:SY <CGV#YO+/Z\9+RX]GP0+^CU37H@+$]^=MU!<D"/SI_>%)[6X_^NAR
M,QQR[?%$:A,C2*/>D5"E6>47GBQ0P3T38%L);ED&)&K7+>/O77LU0P@"+0[5
M2A<-.#V6T0W-M\7SJBJJ3+C"QQQ1P!&0N!\]<32_,SXEJ4<](+=VIZ&,!^6!
M#E\5D+JID<_:TP'%4UW>2CXB.1^Q>:=&_\HA5AS)(YH6B,<H[[TTE3//UV%"
ML"G$N3NK'+'"+*$!Q"4%G<R%U 1+OQ0U9"<7'/T&P[R+Q )"G**WCX2[6HI!
MQ*OBMX*+"FQKD@:6A8K<9+_K;1NT6?(Q'DAOW8MW]7HNV=-"*K;AGBP.);__
MKH_6TH8CZB>/HNC[0ZDU_!!3(YC_)0@-.&Q*X_4.=?6K!$*BD _R\E)LJ^1'
MAT/AA^$C?K(VV4.NPI@A]L1?'X_#C-/(LC.F67T#Z Z41F^]0H1V)WQ6%C 1
M&B]M?8.TO_GBI&*=_)'M1E_E1.O)S4;I)?;+&]K-.3:67-RW4KW9H=S1@7<(
MKIY<5\0OOJ+A!-O# W=H>HUMNV]PKIN.WB;IUN*2 D*.Z+[/^'&,>S L*? @
M>#HQ^@ZEG0,<#Z$PKXTT4G35+%*K@^E6*/5FSX,,=5Z'$F>>--DCA^S\5K-E
M%KPTKR[+&2-YQ=/%+A]\I'EGC8^&FH6^VLWKQDZZ>$'GSOYM7PT/V:,R*5A7
M@:N54=  PT94/>=NPF_7]7]$^H>@/UZ+M44SX/S'GRU;@UJ_JA(1(,P#B1*<
M]4<)"8@CHE:MLR*&_S \,5EKISB]00F9N@HY9%K::D0JX5S/2Q0HV"U,R%-0
M:-""GQ.NZD<=F)8D'%,36-ZWIQL+G-)N@[9.(8=&4R'CHTB5H1=(._B4UKC8
MQZH!5P+H($_13G)$_F.P)0M-/#F!L])>AHQ'$_*EA\1H)Q/]C$XUI?V4H__E
M4,^$H2+OEJ!&QN4BUPGA;0_URB:Q^$*1Y+: S&T=+BEI0FYR+5.[ZG*D/&S@
M.O7!LPEA"TJ_W1W.-GK\@AXNUH 3V[>&J%+19EX_Z=%M=_6J 38\V^-5QJ6'
MB1Z"]!R0JXQ#+.;BO6@A."9I&40S]V-SLL4Z2'!&1^MV BDK(/V$0D5\IUD6
MK_%J43 >^RNWH='&I*58=$P2])@"<L[(*M6W+R)_C2(TX%J(@4;G6-(VHB>T
MVIMU @KRKJ')$ $VIF(2>_U>CLG)9V]\N&J1:VBX2?/ \R,G3GNX$PZ\JWWB
MJE>L9:P+[6YR_-6C5CHFE V>/,JV269FCE-DULKG:4$L^NRSD]^O:;XQ4F1U
M2<UTGR$"Q&7S[I7Y6$)/$Z7FV4#0MBDATB#GAXVS+=/1EWFS_N![I'FWV\G!
ML\-I5&FKEZ0V$BR7QV#0MU8)RE4RK[RB)#[_Z.9TZ(DK"R3NF84^F$)"/83R
M.@9T8 Y?-^-H,-]D"BDZJ4%,IU^DV6Y2J\W'W[^>^'ZI@)5(H5)9>G.:77$(
M7M,^J<"<F#.&WNH5NFH7JZ"SR)DG5!- H#8HHQ>%O-<ABJSHI+(IK4EB(TWX
MUK.[<OF2R]QJ$')J5$^/S MV=5?_14ZI#1'KVUCQ-3-\P1'W<].3PL8"BN$;
MN!EK>7Y315.Y5/+GL ([DEWSK8>L'?M'R-?&V*$/3T2N$BLI),^(B,YD3<CA
MPVXQ6!=Y?!)*;^QDY_TUA"?I<R<&]##"C DMZL1@][: U6K[$X?^?3/+ Q$\
M/ND%4*.O;EZ0'R-?\,XMH9B\X^FUN%?:J]Z^1 R@3K<,>1FO'<G1DW&K*##H
M_J@YHF@P<7F1\X;0Z'T7^;90ORX.4A$N><20^*&QRTQQ6IR*WG8PQY=[J_8]
M+"CS)C\L@ @>E#5CZ^.VJ9PSZA$XJQ& HMWUZ@RP0&_.[\U; 2R0M3$^P<L-
M]NHL$FWW<3HV0W/N&X*2?YU_WCZQ]#.WG/N9RFHT!@KUH>^X80X_Z;@IKA&(
M>"LWVR?7"M9AN$QJ=9E#_@":@Z,RNPO>" ]3H$Z7N>D)2B"+9[MS+HFQ92NV
M4Z94"$BQ$>:+]_[86'[;RWPN(=YN'?)ZAGI#@21L8WG6+5\R8]LE/9WRE6?/
M0.QQ-/A:;.ZWKW82/O;2%&YW.HE,9I7DJN6!/K3 )NM+D@8MXGG#=<_9XOC9
MOLJ(.Y&5*[9QM:%X/ACV4#K37JI.)%^WV2P[5>,]:XMY!V<O0[^S)"H_Z*VS
MCE]HBI5(1(?RL]1'D\N*<M]G'[9Z</W2ZF%NN6Z@P "GCW9GI]F8@1XK7+L:
ME'#.SUX+=EK!;(AO_9&U$\KO$R/\YG&H^QEG[::N42N;YYU_@)5><ZI\,$N@
MHG;E#1]CM]V:(:JFRRM^ T,]4;SDD*!LPZ72:F7G( 5*U]$=T[WL6N^0UZ')
MOW^+XLN&%WWK-N\F3_*/@RAZ+FM[+$#$M:%O1H5AG#;:T&-:""=1/-YJ]GWV
MDYC\ZV>D&@O.:!!"&$L*Y60%-IO)1E<;S07FIGO61%F2> B6 QK'^Z3$=@F#
MT:+#AWN4R-(?MA\6K6O.1)L'MJ$B7(3\2GNFZ05H07AHTW?)_6[!RF_6/XHI
MYQ2XI1GFOO< I(=MTG2M:$:<]ES' E/9T &[(N3/ (0U2B>XXDIM\D][=UF
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M;)F7J^&8)//,P=EA@M>A00?^^DY:7,SIKP90#&A?:*/EZ 0+E(N[M!! 5GU
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M&\HN(V(]\^[*<2OM^<]C7V ^2'#2:(P:*WZ8!D,Y#G_S;A+O-_H+%B +6F=
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M^ITXUN$):U)' 2+QH/D*^U5$DR2'TL[26F55+-=Z2/Z"<MX/7XL"8@J*(2#
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M>@S_^MB:\#?N/_:V+/C/+<,*)SOY8[^'<<C\QV(VM\R;D-6O,OA<QH9G%M#
MH@,@)AY'H7Y;/O\R?L^ Q?RP8>!+=Z=S(#9/T4@ 6/3O!C2W#'RDX-<F*?YZ
M-%I]"IO7/HL;7K=:8Z&=D80&YN6D1'Z>/O&-^=1TIU25*^91F8Q-OQ.P6RA.
MSGE6<-DUXSH*+P252G>T)WNII;FYBU.#5.)<>;OM,"0QQ$R/)>ZCGKU&5GXM
M3;K>7&IRXM@01 ^QL&$60T7W5@G"(NNRUU*?Y5@/ZRIU73HK;]SFG:(BE-J
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M\(&=9<39N\9NNP@?@ 3.W&6!O@X3N.0E5Y'9-K*P51K\YJ;%0RFG63T\* 2
MJKU;\['0<?L]WX$?6X[3ZO=GV/@\^B'S#-)#:K7GVHX:^L]!;\:S=!O$?>@O
MQRIBY7_?A[-BP 7R9+C<']T8KR#%;[3;.O>;92%/3IBT<&U+!5UIM8<"&SPU
M:U$LHN<I9^\GMKT8?A876;I;A0:R?G)X'76<UXEZ1[>3^5\@)/8KEF%<T.B^
M/4\Q7DQ9N9YQ90<ZV[:L-;VI.%F*&!^ ("*QU+TIP=%D8U]->^YV<E[*3>2G
M_ ,>Y!L/<Q"T0CWUAET*B@2+36NA;E,6?G$_3AE/F4 U@B?D*5+#R^(RQ*!U
MW9Q?(++/G:+P!+HO\^E3Y;P]K*OQQN'+)N%N"\S#*Z-V'XZ;PRBJJ(\:<K1V
M0;U.U\5B;3FN\7GS+$MJ\S!LNIXG1G9\CMLM.QLV;4X,L2$<,R.4%#T(V\6)
M;LO3JR45UXCOLQH>78Z+'./5[:H6G:^ P$QEY0[&YY;!C[!0=+&;T(*;S2X!
M;9?G2H/%RA<)$SB3XI[V]'-ERN=@7T#/6@F?D_J;F8\_5E,)RS#LW\.+G$YU
MDB2ZK&FC'O3$KD,T0#]?RF-!1_L-CJ@'X!O;U!/*N9=5UF_Y:HZPS5S.0;@[
M:<M-GT_A@DC[]BEO\#>8E?PWGV\SVDEZ39/E7HP$G6T1 *#Q](%A=5C#,YXP
MB6?.^7T4'Y4K6!^JK@@"2 G]]SU='L8')A2C"4>:E_$Q,_:GQ'7QLKB1L-67
M,[Q3C.4]Q>QERO/$[W%@?M\1 $L:Z2K%3)-A<5M+DT1RJ[JG5 >ZVTYV'2+>
M-].7X;NU"TNDS"GZ:EB (I3#M:&JLFT*/IG'#X6/0K%38%D%+,>6K5PGE[I*
M74GJI58_SYU+VMNP=&\$(I/> #/HI1S[PR=L_3IO10"B_^B.*" RBU84.X"_
MJK!]M@ID$MS9GD5>0#M.D0&N9?HC $+_9:%WR?O<E]$]VZ5R9#!1:-WG^^KC
MIV87'2B_I_P[>QD<"P>6U4@W__GJ_6BU,F+FTQES"\-'0WDBX$B/X$Q4)XY!
MA@F'WW1+9@-19K<A6C.+.1QQJ)!H%W5:A=@YHNK2R.HN*/B>T,TY@SP15D\O
MEWS'A(RO-MY_-9B--K&[Z^^TX^B?E[P\32H[ZPX)O-=*^A4M$8C1^?PW*]JP
M%#LF4P.9;TTS \U!)SV/$Z5Q4JAAI&C=V93)2S\[)@S"6"T9F6)R%C7';+@Y
MBVQ2?;E9WLW(M<[<I8@?))84Z7"!, A^J$:>Y"042NS4-G0:'E) .C[M;,)(
M/7S%YE(M=3_<C$. .1I[+("3[UXJ8*']+NGOKP F8ZMC@H_[)RE-K6AO :4!
MFT\2S-<\" Z:_S2TRIC&7YX>[)C?F MQ< 9V@9^?O=_$LJ!T<!0FH&?9,#.?
M@CXW>^$] _Z:C9PV[$[XY(G)WH#GZ>M#[^B*7O/#T_W9C.F6H34UWO>J_A/>
M#R991KS?<A6S35_'R@$4";S[ [Y@PZ)=X3*8HJ7Z*P#ES/2B];NR>7T[^4"_
M$1:*WQE\-R6\,E7  /B+WU*\T!35,@,3&>IL4NM*?;G'/%4&:3@6]HG0%XLI
M]Y21I\L+I9!/18)<&IT&'.**1%,ULM$LCWO]<C.^,KMWN%P!Z"HQ7!)"*0]J
MH 63.N; Q% U-W ! %@,RG8^760\R*[F>/.]U?XQ3C27SQ\#:!YLZ-(<YZE,
M/>-Q84BNJ8UG2+\"2 .E)8/8Z$2-I7V$E[[1(KG#T3XU%W=AJK-R^YE[E@W:
MB%8I$10H]$?5^(.ZN!<)(0TUK+^^'BHQ?_3B*6G)7R##Q.9AY( 5ATGHUE"+
M /DG9G87!FF$<V:'/4,O\KWMQ[AM%KC$E<)Z+6GO2"PXFC@(^6<66S_JY9H"
M::!LI$S\3C['LSY,?T2WXQ>"Y>C W88J9F.Z]8<>=MNO/"6- 7Y)RW'>"<B:
M#WH_@[6T^#VJ.B8 J8X'QDN4&2$&NUM9/:R*/%POX^T_EKTIRQ3FV.KNDCI>
M!EI^9CY .?^B.3])S\G*D;5*Z>?KN<9M]'MIS<=!7JUA4A!YL!PZ)C7NMN+#
MY[Z'/G.0X75/JW(R( 0"2)TG'Q:\@]$+1DJ-VYZ(BU1R^5U/AB7>OP*X^\GL
MBI&GK1=M@QGM-ZK,1X_=;2U8KBE:\B$VA8HX5+E?WP"V+X(VC1DFBFPJ8*+F
MO/8UD:L+-.QKG7(R2_$]>Z/--1@SW'-5!EQK#&SSFPFWD9&ZCPO7^-B0P&&I
M5>R@\IV%1G$5S,!EZM?IK<PI9JOIHKC%_@M+8=N7M9V#8A\&1%LK8IAU3%[_
M[2AX_FN=2==<_H%!DO^"L/]"L,S@+-.F<R^?1F2Z2^U+K@;7[LW#NG]\OU&#
M%;@"Q*D67 $:G:\ WX/<7;RBV]3/6/&,:Q)R_NCUZZG_::NW_]"9;#CS[[$G
MCF+!*5&77@&,\'Q/6G\.&=UA@GGA+4F>>!F)AG/--RQ6V@PB,E)!1\7B[2E#
M6%:I^PWCOD-H6$6-/8?O90W I65(76D0'X,1YYJ=L$-6:.8)0ACG!UU[?Z(*
M10BCFT)]<JX IAXF[_V7CZ2FZ^V6Y!Q+K.!%'D9W5U8J;_AH(B!GE()#YZA4
M_/D%5YN)3M[92LAXY?1>&*/9>,V1_5]$SI=#L63*1=Z6N,EAGHK%71#'WDL)
M*:M98=NYFX-"I"<G<.XPO7M?V,+DHIZ;=F_BZ8$,L#2;5DK[,_,TRJVU+KA4
M,*<T6[^Q/U;N3<:C3I-WK'DDBP6$49XN>R;+- $GJORO,@W&]K(K-(F#:2U5
MB]M+^FY[O!1"Q XZGPR,- DOSDS]$(M*9-K=?&JEB/V^L&K+ E%Y?0=K/6XY
MOF=W_:/CU*^.C E1!6M?#8!5ETR,8]18D;B3?S-J""<C)G_I!KLDTOY;E==D
MHOO."@WV85*2 \SB,GKWD'__0OY+/0OM1185[!>$"K9,A3P6TT$+SS14NQ[Y
MCI>+1WG:0 9#@#VF]QK'DY]AIH6^W;\F4GF-E15QLPT*;N&%ZV)"EWL:M)9I
MJDNG3E^)S4D3MS@1$!&.QJCQ=SJ._CS;,1F'50ONS&OV'$J-/H[O6ZRW\[(B
MA"2Z2%%C\@HQ=@.<%E'B%X\Z611U"SHE"<D7VAD=(VXY!0X7M22W@LE=))7;
M?]8MQ#K>2+VAVC5#M7(D<E]+G>@H,,;1?S(V'1** R&'@BI2K04P.5'G*[9Y
M=&DE4P2<#D[J6DSRKS"S-9@=<=E?L])1H@KB^LK?MT%OI5_%8L*.N.P-FE'D
M>=Q9>6H6Z1BF1)JRG[M /'#DY22DUA-N[=VG\&9_FV)P[Y5YP/3G55",+6O$
M1A7TUYX$"0)$Z9YH-E$$3^#T,S0R$K[UA777+&8>27./4DS#_=E*<-XR5,:,
MDP3VMGD;X7%+P+=W2L(% 4ZTP>,2@XMRGU"(RNCWDL3H\_7DP7MF)4]N^ SZ
M)C[A"W<E'&VZEP7Q<_F:Q;Z[B@,$0#N;;I?!VQE,^PG>6=PBWG;=B&ZAG["/
MD-UIRYRF#_XX:6P!G][XO+#4[;K'$\VYE-$TOB%FF>V2M>UZ'I20RGW/9[/=
MW&K.4S."/EP%Y()I^[$M5AUBDZQ6EK&W4C>W=8W&]%9L&CDT&"-O*YC<;A!N
M\)%WB*QAN#LDO\2"R/=MU1U$Q??;K,A#@9JUI-T@2# >"V.&L>[G5E$\WJH/
M,\HE?SN8ZKE>GY-'F6[0'G_G3>8(EW9K_INYT!;+.LDR+D%'%J]<MZ-N1I+'
M(D[,1B[YU/$*0""XMB"&"<)KK.SL-/ TS.Q"(N*B:7C=KKM3:K/#F9Z[^J<[
M3"/ZY:@=/<-'(G,G.G6M-[^CC\9>?IWC;-F5L$8BC,I05/TS/A^KJW0TDT.+
M1ET'VM,+@2Q,_*.Y+"+,\<CZUDECZN']AV-4&N<GB1E/G=?R-]ZQYWBP(F9J
M22!1R;$M!5[?6B7:"MH<W@)' XJP.W?:FZDK&UUGE)5U$:.VYD1/0\,56E9O
M&R*BO]Y-2=4VM<(J3RZA0!'[[!6.;$5U7!4:A#'+3HK,L^%F8Z:3C>Y#N.>1
MSKB&/Z\DR;R+C//^(77D/I+D!"9.CDO]_WF483T6;JL+XOA'Y?M_W>)5?T#D
MK70%^"C\(E4-UW-A]<5A]"S3^A"5J-4IE+E_<OKS9VIDS+#R7UU?Q6)5WEIP
MV"_5%>5&L]U%RPNYH7G[Q>KW3TY:AN:'U$XBM:C,/U(=6_TU=0VZ;"Y08/XX
MPN AWT::2YO&U^JK4]%%7^:<1]_@7 0?S)31BPZ!8=T71;#)/AU-I(YN<%][
MM;Y-\^/F3QZJVUOQU;DNG,Y[!X;<S?E7 #OH9%UN_*I/CB9[<K/K''KP!NS)
MM[ME,GS*=R,9/[7&_E[*8PP F:DGH4JBK3&-2_/R6K65$\=]UG9?6&ZKDTJ7
M^]<D6KSD\T4!F>=<! ?<W99P185;<!>8N+5]/46; ,.78+'8&JJ-"(J4VFQO
MN[$]6THN997@<RW$H*)W7!M3YPC_<0OZ3_TX@XM!O66XRNBW$E?:(WUUT>2M
M%KKSP)<)(R6##$8C.<C<4-8R@RFKF@J'7[K\0799HF!WQQ@^ H2$SO#(969G
M$Q!6KE1 G?U.MI2AH8JE!IA?363U$Y[,EJ2X[F$1^R-VJKP^+8D]3G$?FH/,
MC*[,O!E/5<"*5IG-F'B3.$3W1/Z)(\8S4,W!EGM)^0URL3V9^4&T<LTH]YL(
M!:)J-E#"G5I0!+/8VT9@%QC4 /Z&T;YX%;8 M<XRE"E;3OT0$D1KLVH%+Y&(
MJI3&NL(X_9?'%Z=2!R%<F1,U("KW/BV4RXRR[W9,1^:3!<Z/ZC#G Z51>R/
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M%])LK[22I($:\O?(TS;B,T2*?^T@BOI^O<@))-5 !">M=F<A;S4/-@SI3YR
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M'02>-HKKB!IPS+[Z;V-?_L_/4^/XN]MH)ZHH\];.(C("$S>J>R$\XSO4?&J
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M2F\?\( >]$31%?>!^DQQ+D_XHSZ1FW5FDK,A?3.I=E,:*W\ILB>5?IYF-8M
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M3X7\_@_D;[Z+ZA\AH']7A'?&#@<LS<5BO)JQ,:+PL0S9IIR_E\G_!PK_<^;
MW_6B__Q]*_W8)$=:ZK^N:OFWD__),JK_PV_V[U M]&\O7IRMD)/?O )V!WS
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MK-!4$/F,*7K!T%RS>MC (\AQN\Z?_NPW+-/6_5=I"_,YXAQQCO@G1'28$N*
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M_\?CK>NJ-GO32NM^EE?>Y%J>M8- 2-C%(%WD+?1#J?=>1G8P!Z?7W^VJ975
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M)]2<3-A*,?8^OQI0]>I9]/Z.MAW_='JC^KNQ[9\N_N.M%QL._N(_^0(SK;G
M+SIXNOG69]7G&1.)E-O6?7BD2U4!6N@/;Z+PR2B!-5DK2=,[S\(]':=>"SO)
M9UW>A\!G>1YX^*H2J0!/L83:G%T-\GT^)=9"K%<?Z^08$)BPV5AP,9PO*#U[
MM'";C,S1Z'=^"H/EX@M[9@R\H!['0RS5ZG$(Q[$RBA&QUNO%_-/3?%6(*J4R
MDT);_/;94>U;M&[(_V*++7Z7AN<8ZY9!G*QQ*OZ=:@8CCJQ43!W%!35PPN?M
MD:N*A I@>7E^WG]LE"</RJMD43AG8S5JZF7[-;SS[?-?/EX.H%X(T<JS-25K
M49E5D<%"F:X(!JTO%%P.NNG*ZP#NR<DP("7X61,!AC$]XL_YHC3%HS[<C>Q1
M@!_@RI/0R^M8DF;Z[;A!)^.D?$PW9:+;5S0MR7[&-!\MD(J)<FN0WJ_S%TH_
MLNX!NHB1TL(>=[ICP[99N5#QY\N[YJ\35'C@%EI"\[L1!)-YW@$Z"1 1Q)_E
M\,<SJ>R+WZS*A55<RJG>POR>0:6]6NHR"-RJ9LY2I9T?)Q1:./.<F 7!J8-7
M\&WV&GHB#MO5I=B&' #G?$-@4)NP1""?2/*!4"GN,&'XEU)RNA%5P5%&_);X
MK>YS@G!OUH9JLEC];5*YKU/4LO(:<M);:<V8CH=HN\?@..DT>R9JD&JL<?+S
M'5QOR9E4]^[E=BC^X.?Q^47C=L=;7MY@BDM#O.@\\>J?B$ZCJ8<A(31&BGQP
M^VY@3TBZ9?K.+^,>X!(E]\ Y?<1L*A:Z&G"47]K:JSR/\PDZ$"":S ,-BIK\
MLFD1/"Y'!,4+^?6\P7,F=*""+7]N7\=S$).#J0;1^M.\4.(+LSY:3[8?YOKV
M9M0)$QM];NLX@^ =3T_93^4P>MRZ>E&S4N<=8[X2<($AQ*A<:_;9F7Q>:-!"
MS(7#UQ,%+'O#$U + N;'?LN=:V)]#[!+.Q2I8> \V9?&QL&4'V5F-!/:Z79G
MRH6S<\RN-M%01ZC<I3/&O'F,^L+SR/UZ#*OA-VA>/%LBQJQ8]X^*WY(A&?9!
MM"%Z4KTH8KYCTE")2IV9[81+BU8#E(2X!W3>X78*Q[1.3C@*1?3^?+4($!RE
M#91:(P!TKE'+]GBFRJ[B>KI8@,V$GL9BLQ#@>*RO;&V<93R=:U+(! K$X5?G
M*W"JA+H$MM*!5)LZ]9$"6:DTSKD*KM3[5OH\1TWRDH(:W(MK,4H(4!?1KK#8
M9J(K:]^%<@F1$..5;1KOOM3M-GHZ$OY R(<Y4<W)#X3\KTC=O]WX>Q09;Y?^
MD#$MXNZPF"7! 'Q"#"5Z_BBZ*T:2S [&_BOKU.[P96VTX#)K ,59?]&,_E)<
MH;Q9V31;:0Y5O!^<*KJ-\G@9#_R :%:-UJ_O 2&P35+?(<<<<XO& ^5U^HBH
MQ=/EI%W.%CPK)Y::5$]/"^&REX-/L$Q4\;VPWZ+M\/WD#'W[FNGD\TS5]L9.
M^>$W@745[=DF03[HD\',3C>^ED^Z:\F>O)"ZF\4-7W0L,><]PVI8>_33;ML*
M=UC^]_.X(=PK@$2:%?K8Q[07!=H@=[,$Y@UC?KS\;1G^W</YGM^']ASTM;[<
M#7HI]*6JF HK3I(P$D3K?!/ZL3+2Z] \H6<GP'NTV2DRZB<6(+W$ ZM;XHKI
MNO;N 9V-]TM2\^Y^??9;SN-R9A#$Q*]JH1:9]N/+RB2;:R2GYF>#IXHC!]\M
M IOV7J(O8S9%MRUAVY.#/6:.C*8.TX$U["2I.:H -?($QK6IF#T?H;9'!>";
M]F,D_I[JS-L7C2'^\A\P(55VF%)85'Z\WZ!J#@"QU<R&IIJ*\.'&NJ ET35(
M*:'E)%,Y3!1(DN@;',H8L0^2/\2 '@B^T#G]R#H(X88;W -"W>+V4/2M/_2Q
MN'MB8A*.JGF_A?&(.(]Z6Z'/_:IN9M;XUFM:I&<D+\3ZN$.(UH?/NVG^9J4G
MF+[8>K:V1K/X$579-]>SE:TQ?R.L\/,-A(Y_TXV#>?PC P/WG!8#*E+&]94W
MXLB,IS?_H\JX@D61]?4WI@[4S#9^WI/XXRO*DU8\"/\](""O7U1J-?RF_I!3
M,N:9"98E(H'1C1JP@N=-<FN!V)1X,@?MD($/+M295UI81M0H^DDN_N("C])M
M^7F@A0$N%/+"EBB8DMY'O9YJ;"S#*<)48#Q[5*QO<VUQRS-L63!OV$UVW1OD
MZJK*VX\5MFX+D48Q(64*;7A?&T3OW_S8;&OC*"]C] )+1+JG=[8^_8,L,[*>
M^-./&4Z4,ZOTK%,1^9+LC'EA+PQPZ:EBKS#%S*5GDZ##R\DD:/=LSANP"9ME
MA\, VRCBJ4/[JLTZSK?2[!5U'_V%!-=$OPE?ZVA*/G8'AG'> ^!LR.0\L)Z2
M0MZ\/&-CI(=( =L[3[3 >X OS?ENK'#W"_DMG(QR<1^=8 BC61%$>JKZ3653
M.]MB2NHH_65O?0:!,PPMN8MG >(0>Y?3P9%Y(;<%D)5P@;X<G=)I6ER4LP;Q
M#>4_ZXAD2)?$5(%T@S*'BY$@@]D3Y03GKJ&B)BZGA7L _8<[7DE:=1T_<'"7
M00M?-[B"5\K2C:1L%%'TK0)MM! ZTOQ.^5A_&#$M^GX?QJ;]90(]A4*-4 [&
M)J&/L'ZKD-X.6U5077MXN&/*^FU$=S,7D#80X/5B-5+#B*SC.B$;@&E%]SF:
M@4Y $CCV#=0O3@EF!1Y_<6L8J6?X\_A'%]TI3L*71WHA=)?D[?N@F0-(-!%8
MEJ J$K'+K[2)YN/MLK4M"T4W%L(0YT"J%PS3ZX>7\&B>MDR,"V+YR=]$1IO,
M$J-M.T!8$1MIU1:%OU]U$8"X?LALVLLRQ%Q6@ 6/%HY_02/UAX>C0DWSVC:>
M7RT.Z12SV%YY!Y1)!-HA-5>UPU=#-<;L*Z?('>T%7HX(S77Z(U=N/J03-M$M
M<8QILWZ6::F!\CS:0JOK?"-6V2N>X3F&R1S40HRT;1*SYLC&73(RE*ZHRK)4
MRPURR)1?L2P<<43JR,#MT:V]GS<UUTTNN=VH:2VPHF_XIJ'U.GE>XYQ&$O4^
MN#A?94KF4)?"M!G:6'[3&BU)R2N#P[[L;Q)G;#CG4 )PLM*Q3&CC)/,I"?YO
M!M/J-?$("9@B8/;O DLP\N<:A2AG-B,I1W'!GPTS42)*?%BT<><]H,00YH<B
M6=A-@@B/AN2FZ33<G2P$L\:+;BP4,L/(]V8J4&_*IUI>Z>Z< !ATX0%F=9\9
MTV\]SV N[W7'U8E97J-IR0)H_'P$'UQ"@#AQ@V_L_)+G&^PKXS>_R[P<UK=N
MSTI7L>FK:\.6B)\0RS\C_JK&]5A!!@"Y1%1VZ@-#74';KB S48<.:F+Y_GY!
MU'/6ZF.=#A6"&YK#/3F]+X<?(_H*+#@BJ\S]&QDMJ9T-L3K3R>; [S2;ZEJ#
M-G6W NCO4C]\DQH58@C;O54X]J;644Q7'JNZJ:YK-&%4X$+S,?6O_I">G(+O
MM1,Q@>2$&9I8"S2H#)705;P>(UT/^!)9?_88?(U2N]4^CEP4> /W>MF7YDIK
M8X6Z'+XTHPF( I;3Y-6@2,&J>YWZ5)=DVV9-K2P'S_8H.;[Z'YT2':3H/,GI
MX8N.YGT1J%&VK#IW&<+U[JHH25JX%?^6:OS@RUJ<X2FGW9S%FAZ.;/"8;;N$
M(8JDJ!6GB0^SV!IJB3=S8,LS0'^JE'T@U/XG;I9ZK_9?F.G)/0#+AA-N3[/K
MC5?WB<TB)J_LSRW%"S__;9US$PW0%*BKA77@FK.+FEFWACS&-$H57X!':.^<
MG!CMH.J#@W(MZ?%0NI,,?JLTK\;_="'S,?6_'@-Y\?3?KIU&_8SS^QUICTVW
M&;(:>+@>ZW[T7]0A[MCK:"BT>/KJ>[Z/!]=#] W\.DTU)N-,)/,6Q&@[K6NN
MXZH/N;#^G=W?OGKG[YBT&5!K,JO)(U\%>VZ B4?M\U+780<)C=%C7]E1'XV!
M!H@YY=".G0+K$=_+!BPF[>9Y?QM^D[O%_O")EO0]/VLB-6\#[W4:*$GQZ/+;
M;-^Y57^[ 6Z(HEAN;LOY%>FO6P80;JC=IG7?>BD_;$VA!!PDF'U#FO1N:)D#
M>86[@$Z]FSG>)%60FIAH;&A)\91)ZI;,W\#CLZ]E'N$N7IP9C=G%-?ZT>D32
M1CZ-UG(AB<U$1+RR"A#TJL+ ZX80;"]GRS\U*-C=U2SKO7M!J[^8%;830,PP
M$/WBF;'KKG#<GT!B+6K-#_Y*-3P#3EN'=+L]*3E9I7WYJEJ,F8^_=GZ8IILX
MB*A(J;\)$7Z(IBTMZ6KUUEM?RK=%T+9?_]/5ZS,2_::&\S]R%N475W8&5(SN
MN;^6CLZD9(AUA';_+MQ3+OTMS0^:16$]C SEF>)IZ]^B^T[0/0#]KZBZQRL/
ML 2\57.M+OAN5P)NDORW=F44^[]Z-?@_NTV.5P\VDSHA",=KET,;!)"T'@<'
M$/L<U9\_<VOMX&-EMSB;33-A&R4!N5I+!FE11&^[3'78J&<_>S@C>Z5#GR@%
M.4<<R/\@.N@C&40&=^?KU/ [&%Q]7??3&]$K[]MINP/]S,I+P(P7<F8W^9G'
M+-0UZY^W'[??.K)E"G_JK#JQSQQVLC;@EN@4&?&;G,9GACGDB*YU]M#.-N?T
MI5>C 88E#MK*Z92V%LDOA^-('2V[$8^ZW7BNX\ZW]6:7YZ>G_$U\)=0O-##?
MH<+Y23]B.FY#\5!Z)<O/3;8I_S19<$YSF)E6#VEX3;A32]#> XP<B372*'D*
MBHSRU[78.G*%"? GOIMXHBBSQ]>/M2,M<ZKX!:1RPJB_989>T7UTDCN'"3ZX
M>=,UV=MFA1ZSW4]7[A.&C;KC8]5$N;L(PX0NSYK^7@1-ZQI2![@::2DS7144
MA5MVR5T&]HWL\7P6*\8:G!4*7Q,.R_] ['C^1BT>(RZB$964NAP$>9=K?4VE
M?:EC;%@TI'CUQ2-=C36\.8:IM2Z!][N[WO=K/Q4I&6$7!E6GI#]A+?RY'FJY
MC"74X?I>M_.V9SH._-0$JD,B_N>ET=W"YU'EN?HE5<$C!,UK+$Y--,CV6];8
MK)3M'DU-SRQK,Y;);!96>.)YYB181+MB(J\1]/LVD[[ )"99D'F,TK][/CZO
ML%A&+*7E"P@@_35^RYEFQ2.L+2NVLUOKHED)O!N-5U9C6'QTM'R&<R3*M\K.
M"AS+J&EH.-G4^&W"'L73=?ZH3OC-;";E^$:,H*B%\BLYC225^?D$UR<:7HJ[
M5@LN3LK[^>1]C#%:!5G5B@.];W,VF)FGSB)YNX796^(L,6:3S:,PY$S>C&"K
M8>]H0^&L#S3K]@YVAX2BF)H:PE;<79F.W.X@T39"*"9N=?6H-.#MJ&IBMSZZ
M--QNUE$#Z] $=G=J;"9#,O[N*279AF>*X&)''G?WE()!;?H_\B"PL-70F-'C
M)"D$J4$-B-8@C)><1Y,\KE$,M^);2^4PX[=FPPPP+/_"\,)^@N1]D8XE,L*
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MZY-^K &GZ-1TCX7C=!(UE!83YZBYW+B7*NL'E\NC"ES02Q35!A/M?GW*HHK
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ME;1$9J=%0DC@^T4/AIWGF=!B([O4:D-S)[25]IRW4^\[)@M1KVJ.%W*,ET+
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M\"QB '*][&_?LKZ*H?TF0-5='L*:</P!-^#(@RL.V5Z,8&1KGKXBW^&S?_"
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M+CI> (I'D!S]8V]-W5]#@E;'-GD*DW>C>AXD[^*G,U6Q8!VGWSS2B=)'52!
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MC%7XMIPO+/6>]281!I *4A5Z;BUH>I*V.#(W7+H#:=97-C3D/ZM12!+BU\4
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MS/(=^7M6[T69=!/_8-1P=]VM!V:&*<X&@8]_$L756%_2N3E4O@0OZ/9#@MG
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M_;#H3I^JT^K(1W>'0"(B"=Z] S[LZ@2Q1_@" #9GX;4Z7L$L)FZ)AZ,ZE-%
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M]'GO5U4I:L<JF!W? :WIM)('28)G/P%#XXE'IPQ5QVHHQ=92-& //7/5AGZ
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M;%:T?/Q5F^K9_S5J/4 :MWB[D>;KRAZE9=Y<0.9\PZ?O%] O:YR/%?>YY:*
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M!N$0GHUXPODE<+5B9OMM!QKP7T9QU/D;HH'[[YK0@-E-W"W-5(5V#2-=C83
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ML</RUN5"+SI8>>X.UL=*.=ZI0Q+6^G-:"ZF%,SA\SZU49.[YHDB=^KF2/$@
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M7>NMYB_GE-ZEAB7"PZ=H @.JO@N++U\I:BAPF9_YLY;&+8CU AN8?ZS[Y"/
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M\\4MS<H$9=\0GXO=5*UU\%F>JY"9QE.B1#:25W75B?,O7Q ]T"N5 &F'[]:
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MI5VX?;SZE%][9+^^/Q*J7#J$UG4A/DNKGU1\O44^=ROFH5M,^&QD749O>8/
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MXZ3F56!]K+6P21P-N3J_PNE37AFY?>ACMO#T>]6 /-[!(R[2I<S@RI2OC-!
M##T*VN(N.B3Y*%IOBN,RFT>LY'LO=9(@1GZ']+%>CH/T#.3RMU6I] SS[*Z;
MR"X;TACF)C#_[!T65GO135UI 61K.O>/P/?)OE_4^#NV%]U2&@D6V^3L21S&
MJVV(/-F@5U&AHQI*KCT+6U/7*G[64;'@;TM7KXYG'FG:/)6<:9V^PD2^XQ21
M/5EX-]Z)__V2\\3[(Z#IY*6/FY18'R-!O:M%WX// _C23*[T+=VOKU(D);I
MW\>AU\-0$R9EKLJ]&[+T\CS 3-MS.EU(TN7CYS/^&;LWV,X\.\_N=%;?Y^7S
M9C?7)WW!J0F/5(2@Y*MD'X<U&_?N$QQYE!XY3.0*]:$I![T'YU)J#]6-RRMO
M*%Z-=Q'%=_?\V#ZOM]T:=<RNTW[F9'"&9SG80*1%Q$,X;<'_X:&3K>TR6-",
MEW3VVUIZ-,@'595W5ML^RA=PP^IFY"2Y^\[7,S%[R)5^%$\6T0SEI(4]^YW<
MEMU=>U;//,A1!W00N7>FO+_F7K%X>KNM.FV),W63JW5>ZF2T'T*T;]R/)C;Z
MIJ[D+CW,<D'9Q6L:OK&)=E"V2: &T<RIA$,^URDANEPG7T]#*_7"&3;$HJ(*
MDJ J[1]085E0&Q3]H:AF=S(5#:_5]1#.SO9\SJ]VZ_I6\P;XKGVMWMSP(<,!
MNN*?A_=3OL*'\YJCB>Q2K=OSA=;UKT6I^3<G>S64XOF=$+Y]=B?&X(:K6CPK
M@P^QR4:L&6F\Y;@WHRMIB\Z1OQ7L@%NDK\:-50,J+=-Q]1Y"Z\J>"MW*S!@3
MSU#YP8M2KFP$;>/NQ)*>%UX[0G\*&851V,PX<TK$ @^%BN6VIB[P9R&K?-!7
M=O4L!W05)+<V*36OF*B'EXY32Y+;\HI<4[Z_H%$)0QXU-W ,4%L)$^G*.7+;
MN+PN*/ NJ.,]\_KF"F\E.AKR="MZO-'>]=6,DJD9$A=UNGP 4T'=<.)J8!SB
M3OL9>SWZ*77'TZX.4!4+).)1G&+RK-M5^B<)#9S^\D.O.-9=HY7H.CHF\99+
M"%>\B#T2<I%1S4<:WL\C8LK>UU#P]['$/VW\C/<^/":F8UZH&7V_,I0T7(.'
M'I$;.R)W9-4$C0T]X D6V<Y!$6E51R09=.[ZZF=YX/=AI)2?68^ :!0J4>94
M<Z[>(XRWES;M"=*NQ:?51O'Y7BP; W\HT9PS:-&5$E&)T_LQYSHOV]-3L!BO
MC@7HCP"FK!Q2V@MU"6),=\CEIV(?W8A_-YO/2"A=<?!F)1GVUD@WGBM1@ZV;
M;OEJZAYJ('YV\"L3*;*JY<0@&*WB8%JH<Y:)7V;^7++M":\CL"@O13M:=!\)
M:_YA><<UV?XL7119V<=24[:\+3SGT 8PBN\,U*W/1J$C$S,.2:%G=(Q.$/J#
MVA3&FRU/*F/F=4=B<HS>6,L 5M(?$K! N]?J]RWG)U?[PG5,@\K3^)NXRKL4
M7SPP5Q[$US?8\CG^0G-%^?%!YWKH %*EV8-(D;""E.S!71[6IW,_=\FOR<F"
M6Z>K9[WI8'>1,LD6Z4+]Q7?IDL&2C-5]1(D3^ZS>.?6U<_7[A])XM;L,'],&
MJ%E.B]S P;1HL_CAS/?7QO70_$,'/!N%EE[DBND^W)EY-D<&9E>]WXY2[5 @
M/.FYPY-[ UE/N4P%QDOO&NI?6I22/^A3KH9Q:1@Y.;XNRF7V]R/V4OLH-H*F
MRA5"451,O?7V/L 7,[H>PBBV%,)V*?FEY_&LRF61,/0];L9I"=&G778W;1_L
MXRD33BILCU&,UR<^'6Q@=.6?)G3B9!1F/!YCJQ(A%\E?$#"<W!FOXVD1ERTM
M7K]LFDFCFUF;-*+D)]C11;%R&9S#;SF\V4#<Y=W?-P<A>S']A$6]]5&L#Y30
MI9,E791RV7*M<>6N),TLG,9L4SC-TBAT-GBK2/UVVQ&1C_=;S;[DRK2[,873
MYH., SK=.]2 SX0RO\#8 2P7S9>YJ@\>F% :N,4O0QG4PRWROOE!8>KA,]E!
M'V!9=*E.KM6Y7P]M*3P@&T$YGDJXHGG#G[)7SG-A()=;YY*S]R640<[/U:=K
MF)O!2@XWW>"FJ:]%KT7-JPV7=O:!!L-'AL,\!4=M#!Y_J>C/KL8O:2TG2VAS
MJ*B,F+K\/6Y=4YIM2LD<N:?N"K84__1H'L(I7DC:2@ZA/V[^?CBOW.!W.*!&
MU4K"&M%(8$F2RD3Z8R#48?BS% &NSW=X\I>NU<C'G8K+_61]HNAVU?WEP;B[
MPX\C,:J1WY\??!>RH4.%Z558OI![GF[IS%S^D+ X4O:!;_H]R2.8)HH1"]R<
MQG$D ^CIS6$E(>)[HSMW8V:G("_B6IG8TVD2C-4#Z7R-\>ZI!8_>ZI-<N"8Z
M:RAD 2%"@;_5\/<9YHP)E2<1"7UZ0*.& NX?0N+=--O$T@V8^/GF.+7ZO5.K
M]@Q?Y#8>0I#A:YQQY?I&5W?2PC!4)-QR.!="$.*H+2DQ)[%Y6W;FT(VW^&R!
MF3]N2]U?^_FTIP$6B/6%G-F&88'[)215835/[LM0JOWIG(E):^C"="*F7@T+
MR%U!KAU=SS@6P=4)AO,$_<TXDIAAH!I J:KQGYG; 2I%:6*!6VP*6*!RYN36
M^D"#"+0CT10+O,+'W=Q>,QG-B<,:]PD+3-B<D1^L&ER'+RB688'/?M"5:DXZ
M*-G5)0R5J\3]G=LA'G:%6EZ96B7.+&X#MVG,1(^UW$?V&XB0//[;N<-"G3>T
MLJ//8@=,S*EH?)OM!QA28^TOR3&8Q,VZH,/<$\^\L,!&F)YIFV*2\4Y_P-A[
M1&6$JD-CK\*9$GUUA:V4EJMF$Q/[0-V$E(BRATN']D;,:V/(\Z:.?4B\Y]F<
M%1E:;$YQ\]:D L[2L'^Q]'9Y^.DHS)/4$)<$]F962\@LW>NC&X,C]&8B-^=K
M48.Y$T]"=Y2$/ED7\1-RX>&[4-ZON.VSAJ9 UCX>=.R 5=0:U<*3>7LH9P5M
M_<=(WI[$I:<:UFX5>=.A,IW[BU.4 _>890_E;UB-S5L"5)A4C%/ICO2:I4I0
M<E;CJ?;P31RGTQ[6\F:.08WVV'7LR,?*;L3>N%J4>U%^Y?Y!YIT^7=^#R%R:
M.$1A1UFM<4J)73B"$);JB9>M;>DM,EB^*0L6'[ 1\/1(<@C^&<1Q?^VB%X6#
MQ M7:<N@TX$Q@8S\**%9@U\S,#ZM0@XGL,"C>@XHT24G""6:#H$%B%'N ^L*
MGT\E!UX$_ZQ;!7.61O)VRSWEI$&TMRSNZ,7.K,EJ[7?0LE]N2COU\<";/-W9
MG/2TP0TJY18,'!=Z9>H=9T@V#<N1))$Q/J"FI4J)A%M1>UEI>7B)>9 6I0L[
M@K7K+^@Y_7U+B_$#' 8=K"3<_??(VH72YL$!R;+YV5UYKMX7J^HO+[':@J>4
M>7F!%1("_)<.O9;?*M:3;"3OYTWV3F3'+LGBFN8")-OBX?PVY80Y4JNI2(FJ
MG) E@HS,.6^%_Y+*\O..D7Q?L+\D'UN8I!Q)ZA<W6]^EWOF"-D("!J<%O R=
MPZ[ZZXAMOXU7]/$)&?3P*Z-/CW?E9?EM'U(,F8) 4H7-@HK$!GJCAD&*>Y^&
M6%]C7D87DFIP3ZQOKUF.6#60OE@CNIK.NG-K>+!-^&U(V 9C<^TR_/1FR'8A
MZ",3%9(GW#$P4;FLE$^$2"J4,%UX8A(0 _PK@H8T8\R]&08=X2%A'UU#79F:
M:6),$A2>L+=T<;VME)UV/EIO%]J:ID8>QB!2Z,K/;LO:LD[QN;E4HO%Z10D
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M>M;D?=TUW;S\E$CJIO:_1,S85L=;NA9Q!VK?W."M!D$/FYN<N(46$I5B#K_
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MB=\KAQHO&X^_6HXOE=:]UN72)38/CQP2PNIU9.8QYN(6*W>'_6;TW M)YS&
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M]J(Q\>6'#W#LMZZ;EHBM-&IV43]?-[ANO?O2_E;3_D"FE,TCLG6=26"7I?;
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ME%4"R*#X:"'XW/7K)1V6NLR[<N!]2HV=% 3D9<TH+\\1$;\K<:L&O7'B%P4
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M1ZVVD[D%50);QXWZS217#'(!IALD#]6?M(M:.C]):4MGC^VU?I.^.-1^Y?4
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M .K7#$E2.UKI$J4<@MZQ$<9>;H=\5#^-EH!1V2/&EHN^3*[Q=4J+NEHIY6$
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M>82(S]8,I-^6<*+X/5QBQ-+B0A[XD+.W40^AK7K]W34SSLRB@J<O*@/A7]E
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M<L9CVI$I_LM_^0]%Q2)O! 2I)H#5 UL@R,M@9#WP)QZ_.9&7.\@S[S+X6VG
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MOW=Q_]*S1PEJ[(N^$[ULFK J4^B$L>W8Y]C/QP' AKD62L19I3IL]$E??*?
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M&3?.=@.NCY42*7U49\IYD+<L!'QP%H)G>G6TR;RV9VX23O:X*S =;L?B1A#
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M+P6F7]>;W$[B*C_Y_+VU/_KJ>S3?28-]+;2C '#XB\?2'7$CM>=[6M58YYN
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M[9@[V#@=Q0&4Z'/5P9=N@19U=>UT/,DWV8_?;6"VVMPTGF[ICW UU,7Y#+'
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MO=.W??$.VQ;9\7;;1]BVXL;JS,.+G19RHW$O"IN)\K+*DDIU;WUM!LV76O3
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MS\:]\U?&9?Z7<?]EW'\9]U_&_9=Q_V7<_R+C2O]6Q '_9MV."O__S[K!R*+
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MOU9^?"MD>D3KV]NK%RF\)_-NU$Z;:(<*TLEU<\OQ_.[,'-WKUFNFYE]5C?0
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M\C(T=;<B^R9G'))+7.2OV*LPZ^]VL=+$)X,HR;2:Z:I)LK(HR#DCT*1Z.?)
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MDV=LN3-!#AD30T ;V9!;1YL'))Q#@SW!W"9S.,8AX#[?.!'RB5_/JHS]730
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M];Y3:\(=]3LHW8_/Q?>P6/O%P<?&.]7KDJ1*PU2(19F@'4K&\B"!-V)/R)G
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MOLKHT%S:ZW7'R"C/H4BOC.&T!$SZD$L-))FQ']HX\=&14P-RZ+P")&KD(PQ
MO#J;M/^NJTH]<"M&91C,&0,2941BO>K.BOU.%R$7PE9T_Y\-XS^ !\1'$@,:
M;MM&[9)=L)7F/+?P[D+R0ELT^K/=-YPG'&]9R%QP/JGI4>]5"GL_&-^S'C-[
M//^3UBK&+K,7DS7-KV+;YS\.DJ47(KEH2WZ%]O'MC>)-W3M(Y2W(S@3PQ*Z4
MX-O6Z2GE?]YC;GEBY.I:>8N,5>[),8B/V@IX>B0Z?OH5Q"&SC>V" I VDD$/
M",!O9HY!8\@AB06N%TBGR#BVU3 !H@E9I1B5#LF($+:O_]I5QD\-$(*P,&^Z
MI"VG,)7J<$;;RI_GU>:B\Q%5J_2 T6]5+31;,R[9A*F6(HG-4OUUG1\ZXAA/
M;V4J"TX/O@\Y+0WQQH.A ($(*4OGG&FO-$N>S@\+Z ^<[J%\QU1 MEJE%A-3
M_]NGM?Y+!Y5JPX#MK\:+K:NL'99H0-G$759WQ9R9&"M<+@G[M3^KJRO_ J@9
MH0"9GB*PN(V/)S]WPEF]^B?YE)FNL]02^/Q4,$T+2P&Y5.P?'F>%<'S\>YRW
M^?,LIJE[$:F,SGFGBM#3<,6(3G=L9_OQ7X\2VB6>W##MH$9Y:&CR@+[JU?,M
M\ CGQ>@CTH?W'W_#T1+,_6U:1?^Y[6;6PI66MK*<(E7B;[]M!>^;L:@6S"D,
MC1/I7EE$] P*:NNNM& 9@$74PY^'2P5TOR A\GOLO0*IO"VV1'LX1Z!2I2SD
M]&\S\29.J$B DS$)Y /D@ZY7_BY2->YJ2KFA9F,_.KU>_%)+NPL?YP7L(.3-
M]]'BYB&;R> 'JGSIZURM*>6L987K!G/9HE\Y%T]X Y'$C;"T1"_[G(.ZI&[V
M'$BE(O_Z8U#K!V>A)5(Y17WT!")[BHL>3[CFTAY.9Q++7G?QZ[/@-W73X1L*
M7PPS5M9>[RBJKZ%=B2S9)$)^Q.D:LYM$QS(>*?N]BP9K8:"/]J@S:;4PW]GN
M7Y.X8A0 :ZLZJ26L<O;>9N.L;@[G0QO.Z,JT#/^9P+T"2E+M[YZ*,)$@22"4
MO'GTY.#AJDIPRU!TK=@07J=V^&C8Y[AA]'"\^"OIER':J7C7H(=:W_::,@[M
MM<4/$,FG+=?NLY#-SF\;]:=4T/&_N;QI@ 0T,XPBY)<]DJ7TIO;NLR0K%J[S
MO_;/P.&0V>QN<OTS1T9<D+7;8[I>S[GU"*ZQU$U)+6-L[XQ.6LB,G ]QH.Y@
M]ZY3+WI0[G<Y>B?BUTF,H O?%0Y1RM6(.LDES8?S?CV):H8M[8N$6]Y,AU(#
M:<569Y^(!W)?'5,];AO&C&,\,=5C()?DS@:_LV9W"@56W)W48#TP/#>UD3X4
MW;8\YK%Y*;G\.]/_<V@+-O$<ZXZ_+BOS7:^-\_M:P$I[*NWC*E4T-]3>@F^)
MI(@N^>8] L'.%IB[NX:1@ZOR!.^VP)X&>\&^P&_6G?DWI3D>D>W "U;QGFLO
M970%IXZVM=]GQ&H:4&I)\;_)FQN-P79:O:FG&FFL(866S5YC?0\K+HYXGKS!
MP6W51ELR;FD;Y.0VNH L;('7#TR IEVDK;*:P^O@H*6+9;.(=JMW3!C+=0[R
MM7,*UYQ="*NEG72<]SO6S&G.E:U-C=/=2^)^$D0]Z^S=6?&?"-Z'G*4'&6'"
M)IN69JVNE92/]]- 9.E#T0Z8]T6U;C5V=)V1SQB'5BG1B#866;"R4]MP5WJ!
M'B7%V+2^&?F#F?REDJ58E6!3Q)ME<FETU^>8A;FB[,)4K<]T[]I.8J2,RDE[
M^-*UG1!W1O^K89O020;=*$C@$02+B>QV!<RVHZ:,87<1J)+"/EO]["')K-T;
MU55YO:&93A=I2%;)]HSA9'"1P59-"/GR_ _IL2BO.V=,6%[OX_[#>8TY+HV#
M O0.%:"=7S0*,#Q91TB'_OT<;9=3LRB ^ [RK](#GA_,I?[C\J\DH95:,[YF
MQ4M"9?SU<?&C8Y&>N@31\"\..?09+^?C6M<+2G.!4$TX+])G\4)(! 6@,,)9
M+F:](NP2CT\B,;-3:1?J$PT[2H7\>I@EH#[]3HH,[:QQ)>GRP$G6BBO:E3$>
M5L[/PVS-U/=BW-3O,F)T0T+3)C;/(?<::<A2CAY%!NK\\KUZ,7<?N)@Y#IKF
M\ER1M86S*E=.(-[F31O+KL\,/- EL3<(SSG%HI_8;"%NQ(<.$<)E2RN;)'KK
M2+)LCU=M"!P[^$CG8EPPNS?_JO\S*.WTHE =EGPM%)AHNZK/I5:FO#L7/<0%
MR@2)F(AQL&45_&NBJ6INQ7UZVI0"H#*/?O-$Y?:Z*$-AJ>)D,T4;-#+H,J(0
M8G^6JH:ECV7V:;D_))]A090U-C+?706$L8;V6(__*X6S%,F_6R 50] >[$@2
MA"[YU2&;2KH,))#5K&T4X* ';;Z3%<:4@XJ_JS'^#;0JY\5WM,:+3ZY$PQ(H
M"(A(W=,VA@ERS@##V'J<FZKXGH^&G3S :Q-,AHHG9A5*T<176)MRP*9T(\XW
M=*RM"152J4V107F)*MTA;%">_.&5*# PSFR[Q+_\F(YL5QH(U\"N^EQ?$\3T
M]LC7;??<C&Q;5V!0_MQ+W*GM<'N47UW[-]/[@H[/69YLL.[(9?T!%2FCH3U.
M+/M*TP&G&9#858Z[>NSW6GI765>T)_84R8';:I7Y*U1>"3JT&D[UN_;-1RX_
M:EC$]12#Y>5"I7C.#A2/>5BKY:.1(VQSG0YV-+=RQT$&+I($(>40XF<%<UV4
M[<PE7P6&;]EK;G?^TV'>9K &="A B/?NEFN-NW:BO=1WR<BS8+EUIEB?:3*H
MZR&S>'B_6MA#Q>UL*0 K&5]2['<JH[_LJ=UY?9"4H&4K"V?KIUMOQG0CII?7
M02XQ=X9DJ>C<@(.QEIQEDMLAHX?X.<+TCR8^["68D9_'RE*OIG#4 <Q.E[2L
M__9I<KDH]]MUC^GH@4=G1IL/FQ5*BT]L+S L48#3/0:D'R?N_.U0],1[\_B/
MKJ/+6QS2*R^/ I2H0_B,0$8UAV/(I^+ :X?8BY CQ:U<6/#OONKZ!8M$1"11
M7'_D1M>[;Z::$.AL.<:Z"#++<$T;MY1&A )$CSU% <H"6I!A>N<M(>E'RE6V
M5Z8H0';,]\+#!^DBSP2KC[F&%0\5\SDVNQ0NB8RN80E=-6D/1GD^.%/I6340
MUR8VGT17V]=NQ&/1IN=KQ!H#M8L1]]!/%5B! AAD(:TUU3PRPDK#ZB7=(:$/
MF_R$GC<'>2R=1JM0KFS5G!;;8GMR#R/DH31T>D<[+T$;QR)<_(QJU7)J/B_3
M0B3&FL6CSU+QS%-C[>&Y+HNXZ-HOV1)XAO:"\E+/8E\J8RP50R]*&DV%??/\
M#L[ZN)?YZ7]TVKS!,>&WDZ#GG-[S)H-+/!OMK%]M=J-$!V>;%T1^X-8V -Y)
M'^M"XPYH@MO).,S1>*%6R>*4)LY5BL+>>6A)A_ILD12LK7R8EH!'X?BB///X
M=?Q\C[KX.=:;X+Y-''%I*CB)7H7KJ-\>8T'2Z&$NKI?;.[+E!7;8Q&* 4)_@
M;+5V*[$L!XPY+#:PQ^8CT3:A4=76B.?C0Y& O*2#]GJ$,E=P^:B.'W'=H-C<
MW27''O=C7C+0,LFW2B,6CU@O2@#7!B/OE>B%?8]:6S[^>2T=@X\T#6BY=_9E
M<Y*^M9!.!ENM6X38C$(KX+QMGW-4M:,TJ'W3LGN!R%W;+G1O:#UZIP9R4I+0
MD>1ZIOW1:8?&+N10KV#+QZ $)'KZ!G0Y%573%DG6U&$@G9]7N7O5'^BF1#[H
MF)HXZ#:@*B+@/HW;<M^;6B3P(7)LC!YTTN_+&.4'B[$3V,YG?%>' F"#GZYT
M4P_]8HKMJPYVG5/U<>$UN>W&?'@Y-2(>G_PH%WHO'*CV("^^OT= SD%D;[44
M$RC"Y'M2FN+)8K]L-H%?$\A<3Z%!F/J R1*SP7P-8%ZXE>Y> *HMDXHP#@(2
M5BJ!IUX=?:ZYQ[UW\:D.026_RM'< /.0:1E+4[[3E#JL_N;Z,(95.CPEQ:57
MTCSSFQN2#)[=>6X%659VF>?!Q?HAN\Y?L/E8N-1QM$F@0QQ+FG+8^J2 -08,
MY7K6"V"N(';W2!KH*_["P"N3:V1@Q9[30VY+#6%ZYQ@T*![1>EYJ,]9, M:6
M&\.Z/&FQ=#88$)RZ3?EY)<4DC+"P5,A0<?$9O,D1XE!7[:^=#-&H\NS&KB>V
M3UF9:9KME*8?1=AFRMK:2X9_Z*_H$*KT+R&@I)?!(KF8&(\=)K#A#6(@/"VR
M)(A_:(>A*CQXD3L]??Z.:I7>JZBG\2U4(OV.U;L?[XY-HCU_NI7[[*0X(H?W
MI=.RFNAY [P981,KBW!MXT\&CRT.[>^H,TFN !^S^DY[DZTC>2&D$,L<:3:K
M;$?J93YV[">BK#:+G\_ZZ%-.\G%*SC'U6X&$YH>>I8Z.3+.6]L*3T?(#[,AM
M,].(C6KYVTV2"#$XQ%92W'.XXZQ/]'G,1>=W5Z@KWN$FIV.K,-\6$FLD*]B.
M_M<[6Q?[QG2$>V/SU=)YJ!#-Q8&-,QW[1FI_1+>E&S,*4*>^UK]0?8N! <$C
MCEWQOIY32<IO=>A>ZM"=H9<>I;9JXQLQDH/-9=6CZ^GMY5MZ'=^.I?)_[:=2
M1JV63#(NT4-P+V3BHG_1*7Y/N2]W1\AI=:;B-LL?PS2F@.K#3O^)+TO>>1DE
M* "4(/PZ=^5Y@W._,%%B9-[Q4<$U.FCZ3/3],I"O>$\\"^9L'9.JO4>>;E7-
MJ+K@^=HQ78OI^&L+X:GO,@.FSH# 1:Q<X,R*XSY+0ECY3LSC.13 O:SY,;[6
M\;.*T9,F\;-=5;X81UM,!;)7=G<!*\P;2$S=%IP'DTZ%570"ZJ.G]_3=7JF2
M#'WH]>WYT<%,H,#9<_6H;F_?P#P>7"&/;#O4RLT#8-GU>Y;=%0UO-MM9M"3+
M1-?M'5K>G(</QDISTT0]@V*=\##-B+;O]$C'_4+8C>CR"NXY"$DP:UBQ][:^
MCE<17T5G N=#&Z$P<Z3\;TL ,1"AXKK2>[Z_(.V?1\:TJ]_6-WE@RUE.@K0]
MFK7?A[&UK[BH&GTYI0*2>))!C0G UCR[W N3I^LZR[*I*4"7WC=@ /V7#;(I
MSU>'W!M!D@(,9YYY- V%'Y78NM6>L'P:\@8@K#IV#YP)2:R25-*_+LX;R9U;
M$E\<"\01_"CV4Y&S W)\<I32QVR"B;3KG')+<VMTX@O:_Q!Y9A%D2K9KL,(D
M]81^[JRDS%,4#BD4ZLK];!_Z:8K8*^DB3:%B.$JW'!ZR+:F<O[@M3=DT=A+\
MIJ8^B8_6]@''UQR?N0)FS[ING%PW&U]80N<EZR<N(>:6,9Q?Z]K6,7TQ=1<^
M_5[=\BL:_6M%+IB1ASV^!Y)T!0!0NNJ7](HY=("BLY5C*%6;NP<D1&"SAMFL
MQ2^;UXQ9#S+'2)*[(+<W\FDW<+8&W(>ZBNX<2#,L*(XDQ(PJK$=2+>WCJHY9
M"8'/_=X=?DX@U@7K><2IMZUI,OUX"@FN\<R(DLZG.]234U'#G&2!>\%VE&-H
ME*;W1I=?8.F'RXRL2HG2=$,P=)#<<&!>*H_^$$'B@[I@D>LTD*O\P[!8/S=\
M^$K$KP%-(,YIL0U26;Z3^N3AM@.]!IY$GQ0?@M$.1\;7J#AWJ]S27:@DD:8Q
M6K^]+-#SK0_E!EEL7+6)9Z0LJ;;"GWYC16@/ST<!F!L4T/%^$@6X9"_J*/HW
MZW6#:1U_?35H$X&) C#MAZ( QIP&:T[>&.BH?RZ++L_C<KF_T,\>FB)!@]G(
M$^ EG]7ZY>6SY1YTJ2A_O0E!)PP#IZD,'S_L-],CI*0?"\POJ+(T)V->O,WJ
MOF"@XK@[R!<GQGC:,S:Z"B/L2):H+*\+F>"9OE7VLT"\MV.<!^9!/[&V<#>]
M1X1UUXBRMDX?/.M(K-T7R6PNX4L/ITT#2TX94K2EJKYJ]-CS,(K<$U P2^[]
M5/<AS:['@B$>)Y=X4>L6? 4JG/XVVV"[G@1T3R];B;OQNXUZ"+]B;"^C>VS2
M<0NV1?P"TZ%S1"SX*(?D(CF)&!._O */^,YV=I47-TN2/MAY5ZFRD"PSR'&)
M'(,O-LS!JVBC)0!RI.Z4?F6-SJZ-/C//Z= 'L;9Q4QK/4-KRAA=P3=W2O1]/
M:ZW9'F9V*@D#4N<>4K2FD: -^6-N<T6UAWZ5L\+3N?)CG93[SV)3\&HH);4-
M#SD[$^BI8+%SNF(1^\N:?JP NH]^H(U?JLNRGJ<0=*F8<_=V9N&"86>8H99;
M(DRAVPVXD:[W8(#;!L<#=@5U!P=V"7F] 65]=Y%^0035>WGG(G@#UXUR*:V.
MUKRJ$6Z]1/56_(.W8?'5(TWUT[!FWVH!VN,]0[F<C@YOW'IA!8HKZ;9&]%"0
MJB9(#<D8<U4>2W482'X71,?W@. WOP8=I\0V!.63;,XQ9YT._,05OJL5&B\*
M39OC3>Z'?+214,"^BV/#S^\V #[1>W%>CP*<:7ZTY1H2"Q3J!K4QL=+Y4+%.
M3XUY$XV_G6ADRC4VX+-<JS;FB]0R>:RZ+".T!KE[LEIWB"SWW*;9#65\X>-2
MT<PO)8H'I&82*6[=K"S]Z$T]<K("_/3HRL#7D2OFQ>M 2;-#/T*5G+3YPIG(
M=EO<'?'7Z3()NX,_O[P+7!H@H;5/B8T^$7)=5O472J?$E^86WY_D]/#:8W;L
MW::*>&SWU=&'T"A1NHJP(Q++*HV@L>G*:R*E.H$HC)FX@8A1DI:4+GA#.OWC
ML831I>^J.S" WIA^%FZEHVMBRAYARQX(/8K'(K[3MG2R:;5%1P/R?S:R5_G3
M/!I:H_QI-$HG;",%('&I'>YI6Q9!>-_RO/>.1[)#Y*8B/>$4'LX2YY@TNA3O
M XZT[ 0A^RW'74-,W/*[&&Y9>M./ :N+61L]DANN2[[7?\:(FUO"QBF@VS%=
M>I=>H3)1]?#7\5L%0(]RMOT&\C:0X\@0@I13UD VKZ$+_ &/TB 1N.G2C_E]
M8[$/9O6&'7Y#\4_DE[.^:JN5T;,LSRML([DG;&N*OB7P$'U>)<5Y?[RX=JOI
MWI)WF%GSN'.^1C4S^0AM&/D' 8]50,OYU-IJW"F%;R4S[,!_]T._/JM%YQ3=
M7?['/\WI[-NO234*]FAN\3E#*$-Y0R[E0IAOS6=8Y'<<KBOY^42JE?,M$C/T
M %>TPL]:\/7?%[0TEB=;I5^^@S-<WC?NGTJV<G<-%3(FG=\!9>QP,B?<U@DN
MMWN)>41 00O @1K+N"DM,^"Y:<<?/>$M%OZ)]TDSFZO1CY#1#Z(X4**5A+FZ
M?68M "4(+8"K#ZGIIRHL&.CD+/-QO<8+\RW_X=1WBK#JY>5^6]Y<6Y'RQH+9
M(L6=/X5A7'O<FR)*=LF:_-F(X#0EDHC;4EV9Q42>(M>3%Q8834J>=#TNDO09
M!7 VJWN\>ODP$&N%:0JVI9LF"@>96^4-?05[]C'\&FZ,CU *5.MC4Q7#E*3=
MF&V)?>\>/EA<./>>PL;((XAG-<;]C&I7'&,:PQB$$!_?=[;%V$K0CA&LV+/X
M-5OTP2$C=FX)+VT]SV!D<LGS LK]<-'H4#DPP>DHAX) <^8A)D9E&O^=O2VC
M_ ($T5BH7DDR!.SS$QEUCA=9+96_[U,4SXI96FR_0%45\7-%4>]IYAM_M31!
M@)/F LY1J0:\N&@@!TSM:,LIRSU>:%.2XX?Q4_C.J2;38;Z8M%D4V8=F&O@M
MJ-&/.RL-=;Y/XN(ODC3/WVJULFYBNP5U$@) 2UO0M 67VC$;RJ\289+64U:F
M_CV,8>8XOA%VGMR%<Y;TK&,E>[D6O\QEK5LZ/_JT1EQ0E69*,^GV>"SA&S(S
MN]E=_)#_>K_CPO0PU_4N]Y.C%G0J?I).L27BZA[0M:O^#!B?-3\B0R.SP>&V
MWL#-NC099 UQY<FPX=FKV:L.6._IJWR;DJ'1X+*+T<TW?A*TY(H(=4^X]D(!
M=D-UTRD\7W^=MK*SN'Q[,AF=\U W"6>ZOU_EMCPC ,?;$50G)OB%=JCS@& S
MC6%J[X.3Z)JN6:AGF5O@DYP4-JJ^OK:EV!FT0\)%T%0H,=<?<C;&UN\+E_=5
MF=*'=<1X!S$85?5ZB@;:$GO*5]:/E] OZU#LX1VE]J^1<IBE+>V)G94^@__\
M9FBY0.$W./.,LOES#R<O5@859[JWP+: BO(6:6L\,"B=4,A>JCGE@64VEEAE
MBR7]0W ?]A?,'GLCW952P#Q<'+Q&?)VOFAK2)?SXU9%+V6F/=U!:W. 6==5Z
MT%>9 IV?:T/W;M.'2=W9Q_=B7TD6%>+%V-[AMWE5Z3;&2FEFN T^)Q5>FLP
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M-J+)LJ!/JG4'B07IAR#G48"SXM>>[]$YQ@+AY6$D"O#,?1Y.A +PH0!7KBC
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MI+]5!HS7X[*-/HS)2%FATH@A-/"2XE$%(,0J&I1HOA2K[_EPXM7[?PN3>GJ
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MT/$"=^G108=?_!<<':<?$UZ!T9:J&0Z31\HK#5WAM"##(II"C6 EH<NV%2C
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MB:V0WY4^Z>4-"21FCZW!"YPUPL=_*[5#$=B=OJ(O90ON;$E:+0Z'PW39*R/
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M5"DD;B[B&)C8I\T= W1^7MQ:/M2>-:"RMZ?9(#[+)^D73(GD?/.3^!WF\RK
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MH*9JDES4-GZ+[QWVMA3V2LPC?3N-X@MI;D]U5GDP+F<B7X=/WI.7Z?PPL&A
M)-HC2R3%F =4OX(;#=ZOA:>H14ZX^#)[!UOH;XHQ2B+,2(WJ4$^@PJIL87<
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MBS_ '/@\8"\BF>-T_DYV/@&CNR6B/YSI37IS4!8\(]7%IJ3P>BDMSHXHAZQ
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M&L5U;OX&+2G(. 2Q&B+X@[-UX?Q2#ZO^8SU1W(_\-=$TEI#'7_^!8KTY;M4
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MQIL#(9"P+)R$&LKV$>(YSY:=+JJK51[GA9*JG7+1?))]D QAY,(Q7HU3)B8
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MU7Q(/PJ!W\$ 7:$XAX+4!P,H=O>]BRN5+"@B" +K$L5=T/[:D>C+(.30*XG
MC":WOSPSI$VV! ,,6F(];$LN!J"_BS\XJCD ^MVIL2Y1\#\@R_B<T8<L>[(5
MI5*YZBN:EW H3@QVL@>O&.22$:R!1NGW&\&:B(?O"P=,)2KS3K^(L CV17F1
M$;9>J<J4G9J]9:)16EXY=$A-O:9_"8&::ORVH9VOYM1^HH83R<\4?%0J4[2I
M%BOBT).GI*2'C?M57OYE+00=+-0HZX$+!]N5I\D8@'7:]FRY^5NX+%JJ&G34
MVQQ+[X+RMV[>BL$ 7$#Y;[;:7;'$^O3NZQ<>J:N6"N4&Z*?"S5O8S))?^\4_
M?<_D+_DO$1RU%UA3D-F[L(-<7((F0',L4O<)&C% "3G6P!,/'JUGEE,2<>8H
M"6C *T;DRKHR[WZWNVQUXU"3+<]U=YR.1..>8)\3F?+8P)=-B$*.I^:B$$/F
M$/058VIY#T1W$-]9QOYMBJA)S36+AZ0TD!"Q94@+&#E^7%ZJLT%#+."3D*7;
M3;CP_N2P$[!4U=T+%.QL'DE1G*X):$UHTK C8+SFNZ%'<,.'U8_\,2>.688/
M81INR'."3:X[N2&SQ#]N/LW,-_*5I+ST[4,-B?M)SAC.HA(/>1RTU\\^0 *)
MCA5O2C=W^]'8X>#![;@E2<.91C(<VR6"+_$1^/A',_??(-0>BF.WAG>?1">E
MGV],!JAF!)9FXHULEQHV5VG-6^5OBOJO6W2Z5<47*&7/O&<3D3X9/#34]S?Q
M(+WX.H!G E:=89'6+0^Z(Q/"F5'^1]8B^,>5CJ!%%A=7!SO7\Q&9<T$IVA^:
M$/8\B/;)9)F]7+Z1:J1GVA')F!OH-&)BPOJH\AOJL]QW[HM]<2_\I:D"S_MP
M4;-QV'1BQN[H;CQGJ9^A- PT)WX1(6Z&]W8YUU>"45A>2#P@9\Q.V!P,S!_S
MPDK=Y]$DKIZZ,[/(F W%!AO#ZC<BHCU]U5 2_$7+ F3#/I\/+RX%-3;8$@V?
M7$/@?EC S4 2W4QU*^'@.^H'Q7'B-93R(V>B68A>BN#]N-[")[;#>8I6U$_0
MYT9\UM"Y,%(>M,9/$+O4$-*0O!=>>-0-@M^09/:'SY<AO3+W^CUS-D5MK;QC
M1\>]@W)*PM,FS O]C\TH'FAFWF-,[5B&XB! 73L6J?!PLV%^B^O"\G-LWPUK
M)D!35FB\+4E&:#@?.S)H:4N)4HYCIU@^J!_/P0^\Q[Z$? J<=.O+O$VELAV1
M0GH*G%N53A%IWV:Z2I(Z9(\<VPMJ(@03;DB8M&B,\;Z@@_FO1.[>.62Z "_H
MYG;+ATR;V6$ XH9^"( -_]^DD04MW H1&+C<[;3Q?F_F>\?1A+#48<L BJA2
M@DVNS%-BG"X"YQW?HI;DA9+E^C6>YB"!&C51MHKWFA*^0,GMI8=Y52G70EKN
M'_"9XMG8?P1_2O5^Z^T$-%_.-(:KM]];5%PS.;.20K66/BU17,A)<=H#-D+F
M@Q*>K47NQ<BB14-ZD)^7,M.F(,;F#AB@8WS%;H#NM'AT*?4DTF:I-$=2Q"#X
M+!,YTGG,3#_DFZ0C(NM,=^7QTR7TIB_T8O-8G+=-G%N^?&11)&***IC12%22
M#F49@;2>-X'W)Q]OK7<?8PUH?OZ4>%+J2(SR]&WO'B=N8&G1QAE9"G0JN<5O
M\N4=KZ*9%'\BPE)VQ-M*OHZM<R:&=@VU/EN\!(Z:Z(<E]F$'@P!87UX8#SKN
MW$@.1I E63D+/ZM:\=^A>& 8)!TE6SK< -:OCE\PC=A9'MJ]]="AZVN%<LN>
M4L<#H5)I_VFVFC1RFR&GF@HEBKYG :'9%8K,^_=K?'N[K9*2/,;._BOJQ7 G
M(F0C!5@(I9,?;SFW2FY87W\@W/] U/M-HE+]C8=Q11MFI02-%VDVX\>J1ADM
MX^F1'T=$R#1GR/C5L6EAVI'!&<XD!-95W%2J5I9:'>0(6R_EA.]UBS.H/#P^
M:VR($Z*@8%;U)W)N[7<\T\S3TI^V>*@RI_7]@\[W]*5H<A)R]WZ5CQ+LNJ9T
M5F 9JA=45)I"2\T4/Q;XB'0M:8X1 ^S*(6Q1462K>-7C#1_0].38BZ8QQ5^@
M+,:I3 5=$[YEO=X>@&0TX/WV)]!_P"HXJU1N.X:+HT,08#)/F]'*9@KS*=U$
MF2QS9[MH_J(P!3_[:'VH5G]2VL[-)4$>OQ#./$Y.[/TB3PJT#69TPFF^!V<9
M7^J9F5\LQ #M4IO-AWC89*$Y7.="/]>(SQH/>[?XY1=I)3^6;Y[(^%J'D@NT
M;>OR>>)U60Z)W4=(MWMS?M*9[C^N5KK5,U^+HZ_,'^TG\RRO_U&%\%A8E:DY
M-DU]ZBM#W>ZI@)B%^A9MWZ[\&K@\T[/>IL%F X@9;:G3UHK>4%#@VMXU*R%>
MR(TL03G39)QHJ$Q=Q&82K]P7K;;92LUVJ5#@Y?W.QL'AA.4/N3_ML?\BAHW8
M;K[]V92K&_V.V_N+F#5V;/,_QYQXK689(>G_NT_%#'/7H)\EH:]K7GOWKQFW
M7WR P;?T(CO)R8MWWFD?902Z^FB%'-22/T6!BMT"W-?:=][P6#[^+-/8WL"I
M9@EAE(T<R5W15+:A>/ZDG\C>WC1"1U?1W)FZ@_?YRT^/OFS+>%$O-%KP0*2K
MF\/"O]=$0^J6\DH)$ ^#^(*.ID.O]TJZ/('-20]"I>$C'0:3VD,C:Y[:<U>O
M@(EO&R$/487-E$KJN3\H0][-BNR73V,3B/T!R;],*8JQ(7[/PS5TK=!^IO+/
M:+?ZPL%@Y6GFSV@W]6P9]BU<%"U5!3OJA<0"6K\MG?/;F0ZM4@S QFAPM M)
M*.;ZIV=%QB.RMI<^?%^X&:Y8SQP"] JN/JKN^O%@>"-]Q*FW-%K^BN;')\4#
MZ@OO672]N&T7.ZJO>8(:]X4NF[-IR6T'!!VUH"R"6J>5[HO=Y-V))CWOV7!"
MT=""N,Y\J\V[2\QPP82H%U4(B5*:N*D7QU!*&TX-J9MVA"+"NG;D%H?T68D2
MGYG3JC<,K>(M N\_Z,*S%G\*(5_;M.3OU+\W@KIA;2OQLTRGZ$=5FX*.J_S]
M+U7PI63L-&'747PF*P%"+L_62]KF!$4?\%?$M!B[M H6+L""F5D0 AES_2N+
M=6PWYQ;>BC Z;9+K^ZSZ/ J91[$@N$#42+\E1?1W2\GHBFA1Q9HOETBN19"S
M'QV7!'5*W"F#QR4P_:E/"7O;559UGII"YF7[_<1NN&VHF,BBGC)R_4PW+E[G
M236EO"WC&]V4%7GVY9,T(M!5,><"5S6MD:+M5^4QHA]G5IU>2\U&W&MKO-*@
MLR2$"CN[?8%EC,FM25Z;5^55,:NK+T((/I;WK.%([BH!BC(.<XR(U=3%XL>6
M>@^Z5<P6^L\3;JH'NSO6BQW3#GQ9K796TFZ7*?.85=@4M72:KT_)'23+.B<S
MPUVA7G/P-(6WZ=*.,\D,.L4:ZN4>O((H;%6P4)HS<U3R;[A8WM-G(N!:]QH]
M@)6"W8'Q?S/ 5OA)J)68O$?^U&2[(V.BDY_(LV]I]SF"^OP<3\AUWZ:1;G)F
M^(B &9$CZ*M]HO(8H!P]>?R>[N'IG/X,R=IN$I022\I0=/8 *@4#[#AO"PX@
MU]!/]"S1C2RG*OBID+8C#)#OB %N-Y_K6;@Z+NZAV)E9RX>;OZ B*VH-A'8\
MCN%@)7]Q<0N0'\L^[Z;!T3'H$$<_$^L4U,5U5$/EAGF/Z,821<T2-=0W)^A:
MS@:O:(:(F6>Y*E )[9?KRF5G5 >;3+B?X>Q"M.<_+V6]?D[9_MUH@,3VGOWA
MY(7E]99$!I040AU=64J30B#G\BRJ9.=$[6(09]Z#Z(3V[HZU=4!E8\6]EBN7
M5-/4NP?M)1G7_#T=398XUVC&XVD.= +X[W[B$C*E-82F;S_25%>_>]C')"&?
MTC_,X"A">ONCK_35>X2XR7D6#]W5/\;'G]R?GNYZ,"PWP0)VW!81P'D3<M"+
MYG?59_"GD,U3]IE79.2B.D=])]_0 P<U:&6ZIMSVXMV60V" HO<?"W-'F>>6
M0H U"7;D]'.XR['IL2=-S$7A#]CQNS==LY^Z:"&N4$M#43WS\6HRP,U0]E4C
M#BLS=V_3(PSP'0\]!SJ.=<_Y6;%*_,\5JP"[DR:),>NF.WR!%'/?)^DRP/<R
MW3Z9C46*EHV>:69 @S>;]^VB,0#T.\L9!_=T'E!$3NL:C[XF?KD2]-6KD.*N
MMT%">:GG/#8IAY7@+Y&C@FTQ@,%]#* -K($6W#' :"T&^ "[*(E$ZC<?\4*6
M3S" 94GW@BGJ@]>?FG>ME;3Y\!_R@,\M'W\=1:7>WE&]VZ2_,^TX+4R'*GQ<
M[GQA,]V>R-%5Z!K3<-5ZYHO/R]U7F4#4H^BY6EED\X+3R$+=+7A#??/0N. #
MSDMAU3\J3!D=$X$]LY+;3Y&%"^%O-GC>C4Q^VZF\/&,HS7+BR^K-KBE?NO5V
MCG&(5U"G(W;>WV;E'6ZWXV7:2[ZC$8<XWR8]%2+VNO==C3?"Z>\.2U;S\'%$
M"8G:#T;[#C2/U"::%2^8YT;??']%:]:O(-+!,A .C6BXOVA+^>[+L&FH6LRM
M'Z/C0]S4>.EVG?5D7,V=D91:YF>7SAC+E*&:\,#W0U*2>&&[(@,V+8/XCKF;
M;Q]5UH-S9[H=B6K#>NF^Q3'9N;/D+19#@UW)%S7"%VQ)2CY[64/8VTR]!I\&
MV-EOMJ!CM]TULLG*LJ8V'V[=;'>D_??^*C]?[AXLKU(TB"QL=9>GN-GP&K'+
M4W^UY?0B9"<Y-XU Y@E 0N:NC^UJS R(?PQ[FSM]E:L:14"!OR@#O!U5U24M
M[2(GT=71?88!K*KW)=L4Z7>CDN#I+]=R15H8'269CJC7JF!TGCSBW;$W8=.Y
MJ*,X0!,#,+V&*.SQV!3O%1O55B;<\E.?B6$S>>E!#R2&?(>*26>[.GS7W:Q^
M;Q/>=J?75"(D\\.HERB4OIE>[-X;SE>CL5+=G[ ^"+:W=IA&+I.19_YH/+ED
MDF<UP87I.WYX7Y34(>L^Z)J6-SNB*VCAC5PE<:!E4.O5Q_6IS%EVP%)M&EE$
MR/SA7N@<37/RZ[<-%7??YM<$^4'F+Q<V_.TA9L.T ;([R]S%UC)WLB^OP924
M-4J69=Y.?F^ZVGT39<G3(4$X;EPYPT$3^>T(C^4^ZHJE#Y+-/$<\)_VM*H-Z
MA$K]YTM9,D\?GM")?O4* ,S,0+0[E5X:T^#/,BF$O.PO,^\_XSA]W]+_>"GQ
M<"J;-S)GP(UTN8IFP!'O>H01[5S6$>O1WH7%#J ^>D3@5,R[B5[P:[>EE)L4
M[L$3/DN)E6T[0^G?AA]5%5*]YA.U,ZO>O?^%_:HR?HZ["W6GI]'8"I8 VH\S
M/:?"TKY&9*L'#B&K0'N) TCI/-T-]Z[2!<5%&CF]+)F>A=$=.W''_50DH?@/
MP'W'S:8,D2C.K=$X I5V2QQ?E"/^7)Q>5:9[T;XQW*C0(-VZR; 46$2+*S'B
MZL;4G@B,5B'7K(;SZ@9-0L3"*C1O]# AN9K[&UDD$63)BWJ"MA63U=W)147W
MUN?"1.D_: P>SCH,[50R".?*/J\U88B_&!EER78]:>W-JD+DY!KAG<85VWSO
M$,(W\BG>.XF\.))DSEPLI=WPOE8A;SLYI^6X(G7U,HP)+ :(@[=TR5%\<JAA
MT *S+=]MTN-^^^GPU/$RE!5K W+@<M.7[G,Q>5N6[Q,&=WWD;G_=Y4E)WII.
M;/NQ0S-4S&II0GOU4ZLD:+:+$P_4SGRS&O'T/7.N]:7!KFV5K#13MI)[;G1[
M.M3Z75U0I?*(X6]SHAZN!U^%NZ@=Y(59GBN]3,,ML'!/CHLTY#E.MXL['B(I
MK]X'',!?"IT7O(6;ZA&E'2_%!*UVXP:5EB^W=BV@OSX6G3=-E9)DJ(8Q6KVN
M,2X;RJT-9B3D2'JB \/109UI! 5)\+W<2BRN2GX8:V\MWN$G_$V.0S=5+8#5
M^TH]$WF[-CB(1X/T8;]PL%XQ+TX,^*U-;NYP<5.L(<>AT \3G/IW91&V=_&?
MM_@/Z$L)X-B$/'T5HA5,=$7^M@_WN]$F7J0.N,;,*&;S,+_5\J6OP8_@@05)
MIA7[%!'$*)HX<>21<$-UK49'QEK?U%)!])=C5O\4M\-"?2:D_\(>Q?>JXW@E
MTFFO:8_8B9W#3<+C2RFDFLCD](>U\X71)!Z[U@2U82ZBCC7D2$(;T2A.O-P1
MVXS1PSX=)-GKFO<F!IDD8T'.X72S?AE^6I_F<38M!R3(ME[_K+><*\_*/R'W
MXHY5*D_3*\B#=CAU(4)(1X^A5<C7F-C15>+'U9[>V9/(^=JUT1"@=!X6_!S9
MK5E;X?_TGO9TNDNMT.4@7<ZNUM[E)?'(;!?J%D_6H:[D^2'7S4O0_03YO2^>
M!:#'D'EUV"".OGFQI_'PX3FT<J3HUB@=@Z$76ILRR3/W4NJWQCL?'\6^(HKV
M(Y@/Z1@2NY'AZKZYN:;\]>5*C5=GI"C^B>9Y(3028NA#QJ^(',F9T>=IRL\!
MYP;.][ ?/$X]#L3I$L<YT\SIOJE$H4A9V+5)IZ<LC3?H/Z.9Z&E952Y!5U$?
M(XR>J.9F=(#0#!?)G=EQIR/-WH#(#OU%7I\SDL)F#QALT:(AP-8_,U+/+X#T
MW#Q!UX#0?I;?MT8$P:>7]+%$CH^E?26W9"?5R?=AB68["VXYSG*#)@F1@&9J
M_*B8=<$#-@%Z3UF);Z*F8^$6KL>GF5^KR\(C3*W[\>T>D7]'QV92M"^ B<NI
M]=;K/T&\I;M+![TN6['N'[(0M60WU"0WOV]R8X!!6;)5("P;B\\XBOOX3B*&
MSMZ4._&0V5Z;D2@N%&VXJ]S9+W0P,BFKS)UF[LF#-1-C^U=%PEPJ0JOVJ'5<
M1<M9MLZ'#E=\>ADAKL\^W4E]R@3"TS5]7Z*I!VU>U*$J/[7?OB7(4W\I1I*I
MMG J)<M9)#!@ :G.T\?4=;\"E(\!7&"-3MY,7T8.FQ]]FU./.[Z7L]"MFS3O
M);PAR3@0Z,G!,9JQ]?Q]IB]Y'V78=8FE+VCG=<G+*@4 \ IGJI9)5*LYJ(O2
MO"YL&Y'<2_."[%2M99>[- TWJ;B:K6SS3B7U]PUKZ[O[5RD$[SIX<>)6%>;W
M\+*5EX4I>K#VDQ/YCYZ_L#=[6!99L1ES4?+JP8_[I]<CL*I#5](SWH2!/ZC5
MLRHY)F091<9ZD"O':M :Z$.J8#0T;A>=378$VS\V(0J/>:K*TQXK$!;7+*U$
MLK&>DZN=#5=]SMC<6&VY>9?_O?6T)9\-[-F+N6>J?/&7&RZ_\!KR#<FUSY)E
MU:G'Y;%I(2E*)B]C(A6BB>U]KC1YR47HD>"P5/[]FHJHG8@U6M8SH4:K7M8/
ME\B[Q_.TE9B;,WNI1W5T5^]\."\2!R5K#MV.+LZN3%KUD"?A];(?1+^(EAO-
M"+D3]L?,P&7Y7:])$3:B<WE5@.6MA\)SYI?L,T530C+9T=0Y30QCGXRU4CM'
M(=K; A<2T"=EK[6D\)S*A2#HZDKC@27..%TILWY_9/+Q!^2K<?UAI?,\4R'G
M;)@6[WFH^3508UCD=W6%35N4.O7<!X'['8@!U@FIY5='K1<@^I81*P/5YI!)
MX1F''Q=#,V.=]?J2#Z;Z%_>5XN -X3"SC2/Q @1\KNB*=P]D;Q$#A+]]T&>4
M9MZWOQWNJJZO-7 D&)(B<+GKG(*R5LM!=D/KH!?%2?;:PWPGU1C>8+V^%1+2
MR!C*XZ'4C]=Q"D0?W-CH3B\%-59Z,/1:9YT/5?%OBK)T.&H2'IB=X,YH7\D7
MDV=_FY699R(Z:LPLZ^X&GRL!K0QB %@G!J#?<5J=S)AZR!_J)(P!?$+:0KM"
M= FM@I57C'M9 KFH5H\E'4YHRJ=ZORY>#V^D-0*!M4,:;[GR.#?>LV'(B'5A
M<^+R\JY<(PMG^'JO_4XK<V )Y2I.I;537]<7H38*ZR#-&7'[$9$M]<SP[&@C
MJ7@':ME\P0W[EU(TB7<?KK+P&9X,J!UE.*[@?<_+M[&>&]]\R7Y)P.H%XFQ4
M_;6 Z: S]TMF\^*J+O^[GIW"J'!3S4Q+V#Y>/09P/(,FC:I]B*FG_?<JRHW9
MFQ_,76[*]:M<'&ZWY0U):P[Y;AQK?H%-WX4_?''$U'HH^+IA^G?S#W^QN,*A
MGS&;!FLXW__^[X[_0O(%I;.H R$RH]A4*SD9B"?1C7SPF!!/O(X2J;&BT312
MY"S\1.CX[8D]MRVAF.+-P%:Z5B8W4#+@N9:&C%>VO=Z[2$Y=/+N==AK=3<1-
MSB]FZDC"%>'CX>ZX,80RAV]_O6MN6,A?2Y0FP\*. :85MC#  @4<=D$\!4;C
MR**IUE$\"^M96FR#3A71!"8FY6'4;.GX5$ *Y^!(1PICPW!"++WQQ?27'DU\
M+L@][D[/&TNDT@MC*W.QA1OEG]T8/!Y[:X8CPOM2:*\"*!Q\Z#I]OD?VQED4
M+KIM?)W,SU4=<1H"[.^8+CDW3TX**#TPXN>CF+N:3GY>H+PKWHWLAF^UG"6/
M8W-(0G!P9K1N62+MRL)R5&I3^Q?&>?M^<JG^@0Y;0#K?[)I\VL8Q?&:27]AO
MCC7%(LD&(#&&$Z DMW0Q0&#3O8?QKQ-=@JUL3.*F3[P]66U9[0,UNMEH^R$D
M1\!N V2)&AX1S,Q:G*>[JVALV,)&9[3]0'@O6A\T'TFYGLA;[EALB8#-;=[M
M:.L)69 _[U>\QQ$)MO%RW9U'^F>Z]G72>\=C (+F:>N$!,^MFN>RH:PF?ONX
MRR1)AW0[(;O-OU,HSO<-",TACX%ZY4AQ427HT:KZ>V(96A7Y+F66M"UU]#VD
M]Y8&_*CR(NN-YLALXA/UWOT)TN\2GV47/DS5B]J2F6FX$-I;9FP,*@?=8=?(
M*\J=\(W6=L)9FF-!=AOF(FW&^S$ N,YCVFS\JN%TV9@D$*,LU:U/ON4;FVM^
MUMQI0"-38*&Q<R7R^K=.^0EJB"_A9L<16X[C!-&QO*=H^H"#C<E0Q2DOL>V#
MQ@*:V:0UX7[''V8%[[#<J'(/8,219(2%H=1MYW> 63>+$_+S^I=VC\L]EM+P
M4D<:7>/?-2AF3;C&Z4$Z,L[.#A\B/2MD&08TK+^+,/EL[/@:2,/,W;WS@A,#
MPHNGTK\5=W"SJNU$V;_X"_5\FT2]'N0K+=YA_3+V;*2GC'4_<^73/(0EOQ@<
MS,S= $^)M78V?0TE.?!E^YK*<]7Y4L0[./[2ALX]5U/)JN3;U8.'$SGA_NS1
M4T^+LIQ8?5N+A62BZ9BDV7#I7AI?6S?#ZX,N!<98A39]<.=%H/,>4 V<GPZ4
MPJ$W<K2V#"A1MLS9SL3=KR.:C'P>RU DG5J -41 [V]G>[R$5P?%@>^9/7KI
M71^0Y(9": >'TG/=#) !N/):\ 95\/+^;K(K]Y0J;$\W$ZH+&^ZD];ME_*!J
M<" R%D+IJ\2]3CIQ,! "H]1I#[T5D'6?/C/OX$WK15MT=*0&:X2'9AA2MG6J
M.D+0Z'*)AF ?V/DV-PMT-,:=J-@FODD0\4X5;->UI5H[W=AK71^Y3WT$"6H0
MST6:RH8JCZ2]S)"*8]L3=7DC_N-M;\&UK[-)^8^^UD\<7 C-RP85+U1Z;!76
M[EZ]\XD[+WS"N64ZR5NPNM"3#1Z8;U4FFWOQKA!O59NIR"O"L=/EA29WX<,]
M1V=E8D46<63Y_-OL5WOV"QND.[4VK-$^T=?IV#_XN!V6/D'*+H26DKLJB]B4
M\C*52G[>+FV3BAXQIYO=TO>5$='XF/FMDUXUK,0OA+,HG!ST<X,C>_\YNJX=
M Z2'P/<"FVC*$)"0B(0\^4=2QR[Q][Z01CU]Y+^EOX3(1,LGGUPX!V$ :>H5
M$.[/'N L9_OQI\5OAZQ5K1DKJ3?9!YY@@ #B!=O3\U$,L+<)00A V@+@U:B+
M3<C)$0B9>,3%G3K]8M=Z.WWB(/GV?'>0D[7^R/.JNE&2\:]%><PR7'(B=*?N
MFIFJ,D]R[]A\"WOQ%DM=69E+I(_O\[WG-;):V$U0%I]JA'M>@9<!%Z5J&* 9
M&XYV0/WU(3TC0A?>0N@@ Y/261:%W0YE5=454Q[:?/VU6#"<LOW-G-3EW;1R
M:E&ZY>=IQSW3PPV67<PD8V+7"HL;AV"4AO-UD0$0..MQ:<E6KS>(')GEM 3;
MR<0 DA;]X>:U6;.[ZMJJJG5"353(.C 54EUFNTWI\5A#K;R(*2VMX]':?LE^
M ^6Q!P:(JJK^GSU]PCUF3;2Y^,WIGW^P4PIPA>X08@#6<$IT?>_/,LG'VHC2
M*4JT%/WM"Y</&$"*:AUR[;*M;Y3W@ %BJQ323+[O?OP- 9K<0HL[[YTLH,'Z
MDT_9D&$OO'\6K7YM\:?% KY+MJ>4SJ"S5=#A#9VCWXXDF8GU8.UZ;. Q&T'J
MYHJ(^:?1'\GXP^(&]DLH&MD6^%!>%JF[LJBIS]=<NIF)RO58=NJ4,J0YFK2?
MA'D=[D*(]@O.;@CJN#GG'P8!S\H( 7$FL$'?&30""6O/E1S_U)&E-4,!3VD?
M@Q!=)8.3!N1D+ZI7-_C>#N[H-@H+&^_N*&90'HY7/K^<I($V_.#=&K9D THV
M10E@@.A*T%8H!E"80U:>"#07I9[S,$FZM,_B*8P>TKUI_!+H=JE36KBWZ[*]
M-V^%7U^G9M7QT%V53)^\3-^6TJ=(/0QP<P9V-(,!;NA#EB"GC$?D9^N@J#1R
MV<BV,SIX7NTCD^;D8_'SXX/Z-X[ZO#/WSZ#-,MAC?C::(+^(:;C<A#@;]%$X
M!A,B39\TPCO#._L_V][M3S U63[0%](_FD\]I3S<.UN[4"(A)VF049P<DB0J
MD<2K%K1\/)8])!CJL?[5L^KT(X3BA%H; Z ?7V<Y&FI.ULS!+T&>/PWM:*(-
MU?S2$=.28A&+%AY@]V:"/$(XOWE*DE6(%R5[2;/8\P&T(UH^?:;*CKB%H0;-
M@6Y.MM<7@2/@&""876XT5!X#N!'N^(]Z7ZF'.T-6IH41+]!3XK:M$JS,-^"H
MYSTML]+GM4$U>TBHO#[>//AJ,E['M00&FGC:",,)=Z%Y2+''^@T?UF5FJ1(K
M)3Y3\8=O#KD<N_4Z,T*XDR;^FTV3%>>]G-YT]^H,GWFMZ!'\W8$OC^U0XFBI
MNIE<3&M^NGM4[$Z>HCWY\^@D.5FQ!RRQ+0/-PXT9YAG5@?(YT6PA@KR[V[@%
MOC'RXD N-[[*-ZGG#PC$KDDRF\\/A)AJC'Z0A1;'#)].]T6\N*P.$Y[XYJ8Q
MT'P[@JNTF^7TDCGH:!8#'%[#!CY=.#9BUB;'5R7F#*7O2']H=NE-E?8!D6A*
M(;JQ+S;XP@5R<4D%7V<!1+S^-N7Z"*J1=RS1X^6<9@SK#AOUI1CP[1C7=?Y.
MM[5. Z(IY%L]D/[0#9V[/\HZ6#BUW)Q,F.J8DTB(CE+)L ^K+ L#0)- 9T"I
M"'*VL/4B.==L<W.D F;NC/^1*/NI%W\--EL1P%E_Q/.=F0W>]=G#F83_%,Y>
M4LK\0KYZM86MK*>4%\F/?6 2/[U3\['[(0Q?2S[754BN\I-U+$]4W5HZ&[MW
MY:K!%<BRZ3@&V(I'#TCB=]F>TAV"SU8P0/FPZU;G,++9H!J>$NI0IBW>XJ<U
M"?_09"?"]((Y=0X4(+3TFDY,*NOI_3@?WU27PB8VI*IM#O+.FQ%M>6<=UC>)
MDO9K9$* Z"L2'_&S#Y+,T0NE9%JN1K*AX*]2+5>T[ -C$7TL\)WA!H_.NK'
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ME./Q2O-KJ9\8YR:=$S=NEO&UJZU4ZPT,"V8E.)$R(QU#.W:7I+D'\%E4(%S
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MOFV_9$EE-/3BE;=?[:STXNT I_K3(EM!,-?JE<F;7BD:4][I<B49M5[2"[
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MA1,Z/2 _RX_2IY3/M;8>Z6=,6U5RB\9M!=_6!*6G$5?\/1LWUV#TD.7$GPO
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MJ%[T=YMX?#/N_]_-JAWESZ6A.W3:/QPOFMBI'7=#SFH;MEM !RR;\\>#YPD
M;!H-G%TW@$S*H5R-\HW10+?T,JI6Z##WJ%U_E,O.5D#,:I?O)/ #1?.>#X@N
M9AM$9%M0B"0_"=V1<2:;"*V9\RPZ.RHT72P*;IS.KLQSB'_[?>FA/ $:N+3^
M#.=KATS5=H\6S M6F@4\6LS8@]R*J:2[I4E:2ZD=%49[GL3I=>K'S6WO?=?F
M_L'M[8_A[U>'7.S70 2386"+Q]'&D[8[JK1A[D_:$*JNH/6)QI"J #%]R]U%
MU<C.SYKR)NQ9U +F=%\I=.IJB-5D2==I/__"S(!M^V?D#0)_ROQWK?^71#_*
M7_?N^G^IM/M/K]"-H_V>WQZAX"WAD8D?6WGQ).A0T]VV!?>KG'.8K\ JS)L+
M_O734RKC]R/X!D<16Y9-\'$LWXJ=<E7<9+#,HF%C<#9S7N[L9>TEM?>+1]?#
M!T7$2S:<'*&> XCEGQ\H"ZJN"17 /IXWB&)#V&C#F9.S9#.F?#XOQL=W?7KO
M)P=Z%P*L'\UC@><XJ8;+C4FO[ZQ513P.T353X78*D ($'ZI8C\'F6R&EUCUY
MB% UU$B=%K&'=VD<ZI#/Z2J:VASPU/9)G^ZS^FQU,EK8\[DR0LC@S5L\#$JZ
M8T\_O,/]8!3VN/B#_"VAN-$?/;2]MH\P2QCV!D74C-[( AZG[837ME+8)URV
M^RAWEB-^"%8G?R=VMPA[4/3HYSY2J#U@74L(I=:''9U893V!^-B(%V;D^:Q2
MJ/.DR'_NL$-T-2>XA[V02Y&O:GC_I,/AC3#E *47M*](;RL[C9 IN!ET._\S
M66P*^WM;J2G<J?O8\E6]C@BJK7JBA7@D^_WQ\;DBB>/QH6N/NI^)TCDIN:Y'
M$#[9L?S;DW&E2,6O_?E@>]71@BF!A#6<<"IIZ0!Y[VN0)V/I?L+SP4;$3;"W
M,>XVV<JV'-$J:P^J7IG@#(ETT\7\^#>KZ-#(AS#/0GQUAM@*?7<EEK2X47-_
M.;PMPM.[K<JTPZD$R0OO?<S1%4+T.IA.;T[%3_3RFVE1@]=]$HPV,-]B9ES@
M'FK^_DQ<W(5;WD(ZLW,2JSA*,CE/NP-%,%K_PBS2,/;M$LV9T(UQOC&B&0=A
ME.:(FA2=HCWLHFO*[.6H,EQ#\54]6_R*X9<?;DF^.+4JV&"RPS;W4ZJ4+P4J
M7EY.B4RJBC(#3DIF)4?BIBR%-E7I?B+[Y(@G@QWG"F4U,8NQ@O,$W7PE)1'R
MCKM=$Z7BF(L2D-:1&?TMT0QM/;=O^NU1(M^=H]PB@Y WW4E4<7&7B]["P;FK
M NQB3:76K)\5'9XHX#Y=_B"?/3C:8(^0?S;!WX#-Z=JWVM"@;;K.$79FU,:!
M(5!WY3M\ Q^V5:4\@/595?(^HNDT\QDMP?=/E5+9-)0@P5@F:[HI#C%]'3OA
MRQPRAS7P_7-3,JF3D\.U!2?%G*9% !%YY5^XHS0*08B$$RI6S #X:D-_5LMV
MJ,V/^NULVUW3!,..JNJHA_W1/5=_:]40'+!2!WD*=?!SV.D[WTYF"^VJR-GG
M=TM2,&@;V,>\?3*-MGUOC/%?2M*+;MESFWD%K!.STREBI@D0MC70H0%IF&O#
MVTS<2*<HA6^)X\7XQ"+JLH 3&>2&@(2*JM(@Z?;7G<^4$<SN7%\J3SJ'CTBW
MBA^1%M1KP>1*VHBQPDE,V/S]<!?5K\;)YPN87&.T\;X1(L)J9VK /3Z&Z'LW
MYE$W.W2B+F]:6 "?<F=/5?Q.IZFK1 N%P-6+6"'RYH:_"O("(1E][X50ZT+6
M,Z#4],J]N<V1V\>;1OZ+AHP:H_PLI9/V;[\XC(CP\I4%!-,_F$7 1ZHVT@@Y
MFA":V9M3&56HVQ,#J6N0/EPWU2\,NS,UO1=$WUVSOR"T"VWT I\CRMKIK4,$
MFG5HXVN/L/WP).!&);* C)45=E"28&P)AQ8L36'8DRT"N/(_Z,%>&I-V16;#
MQ^ZCA;N:% \Y, -4L*!IQT49[-\D21!*!K#QM2SF(O,3\P1^G<$$:-2-P5F6
M"3_6?EA?)]5*#OT[<16:V%SG0(_[+2?J)+X"FW2TL$OH6Q?PT336/0&QY.E]
MA75*TST'T%V]*XU'M*SR]L2(+6F^Q6'"\Y.J^) 0^W+:B^W1R/-)87%<^.V.
M$SGXZY=C?AFA\>ZFHU<QE=YQ+BMF LPX<+I5SVQB/T?9B^/ HY2<0FKV)$)%
MHD=\N<(YA1GA46@,CK*%R,)O5#5$ TR)7ZY_P;0T'Z3 #!#9GVBX%P(<:"*T
MBVP\ _D0>>WWUEB#9X/BIRE7KC5C#Q;>]"R_+6MC3UK/2LSZX1[K3IH)7M0_
M<H9#SZ=)N;:,N%P.;,3-(_?$#LO,A\_H<>H-I&Y&[W8Z.%8XW2Z_3,E.98P5
M--"0\/,@*^XB>5PNQ H1K2X:MGAZ9JT3;/*(8&^F:I0^W @1NM  Z22O##5W
M?D$:7DI,;$7#I] 5Y9!A"F @SB<_#TN1NO1+TK(K5117J19/MY<4XO "G;Y9
M!9(G(^P7^*$B+0]G'@\+T[H5,Z#>9J7[B6\OK@<(H %<:_=76WN=MI)KXKR/
M=W1$4V.*5=TXK@_Z(KY(P6[E97K+-\))3LEL+<0G;V5'=$HQO91[I"IVV._)
M20)H?U*&K>N,U+M?-BWFA5ZW_9;RHBKYA^_I_%,VHO*5Y5$8Z>;1E3%#K"_V
M[[\__CB>[VH>L,BH$_N Q"^7UXG"280ES'U;AQ!6UDF5H^/:1,)1N;""*3Y)
M(?E9'_.XR#3=CP<IL%@ :IU2_VZU,:TXSQ3A-"+($WWF0EIR%3)H<;^OY\X"
M%SV]H$L+)!5+CW](QWR,.U^]?Z8U?J59'L!2.Q*>%M:RO#<-8=[JXZ]<N91^
M@]R644(('QJ'SA-O[7M?G(JKQ4J:H %K:7<GSP5?@:TQ56P)):6R\?*:\NGO
M]=.ZT:9Y=Z(WG"<9_)RWV+]I+T)#7$3,C D0GV1>[U9G%,)/NN[*7/.!L4]<
MF:6'P[XD_<PEEP5+#:I;0G??O!O^E$=TN?8B"I<"(.P+.3IG32.P)]TP;?>E
M;!QI><0TC-I,%=;&95.D\?_ MYN0M6!,T!2(Y*-+Y>NZWZ<P,C!,K%&R8,I
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M!&+^_4_:Z/O=QN\V?K?QNXW?;?RW:N-_:1N$^]F?1*LEUK9FK4$VV,L#YL3
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M*$(KA@0C<76;_G!J\@"T*!^7#QFT,>[^B\&A;#2Z<H8D"B",*!*/WX#?@-^
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MK[/J:WP^/*)68EQ(SOW"M. $)I61@7-%+BF\BE.LNY"6;C$XL_O$DKITS4_
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M!+]]P__<4E91X/44MALU9UTE/3>;013\O3^6X</#M!0_E*9@7,Z/;5$7T:#
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M'E%OFG#"'7A:.N<-*B-.^D2GH!'=H_J#_H,PDKT-:;ID56^\Q#+V%(=IZFX
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M9'$0][7IMU;V;IJ"08M'<WQ!];)+7M,Y9"O1Q,%MW1B=2\\<ZF\#7<_:*+_
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M,!V.:<=XNZ*!3[B7]9!=MJHT;P%H>\)CT:;W^UR9=;5!3Q_<";HM6[6"^69
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M,?JR=3IRWD#EM:71>[YL]U78T4[U9:P;OPT<<!0K7:JV#T.88T]O=5CK[;2
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MX%G]M@_-]8*I3[7M"!B8C'8%'P^S1C7LADUFL+E\J0PP(QP3\3J05U]>D\$
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M1ZM>S*$0Y^./C*K)@9)^[1U)8[Z^*;L$2DP[H@&^F9,\CP*E5<.^ [KF5-"
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M?S:0%0CFEG/JEI%U3CEY\BS3;YR-9X_W+:Y?LI=P)IY.&G$CA5U8ZP8QNML
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MY@_NUBVO&4$SGMWNZ@V%%K7]K,/838X_KQ@'YC3VO[H5?YBVVC1S7;Z[3!2
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MP)5K-3Z\+H+.3:"!LQGZO6QO030 F:JYOHY$ ^'C7S:,2:XTL_7Q+%VX1<D
M]E\,4?D;/\1/-I(^:>VOA7K+9O8MO8C/C/:[?])YSW$=U,WWZX3I4+-'<MX+
M$MQ$;NE+/98Q:LO%O?+] X^T^$<-._7L>;8M9=?1\ 7]1MG35B%^Z[&8:6./
M5XHQ8?S$5SJ;_..@FYY:/U^S3(^\EB%5_\>,Z9M_C&G&G+3K@&%,)R@8G1KA
M8,:TG!+D$I2'"HNIS-G'28G\07].L@O98L ,.2[1H\)S:&N3V+@WMPES0J(
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M<]TAN 4O\MO.T_2.&=;B@=BK(D03C?)BQSY'JX;-DKDTWW6><)^7>>-' 8X
M!T@_F0NWCY0=>7Y\"&K7VM%)7OV._5.5'N(N.F.DLKG_2W!:2SHARSZ\U=#-
M<-\*7I%"A>.Z7$_TIMVS,>RN1=X/&S%*?$O23J_QL+,=8TIHRYLL94R-7.$-
MM[B4=+U<(]M*LFW;S6OF&K]F?47B?[TYI%U.;'F/WJ<+N:$>$!W]X@K>/*UZ
MJLRR1+GA_\OU"LP;.RA?3&&J/@ 27,+4VB08W;H(C??^ =+!%-<7T#^^Z\)D
M#3UN0P/LY^\)RE!D@W*O^9'*>"@I+>/C=ILG%4=_E5!K)G^:WB[*M[Y_89@\
M8] T,7[(.J!9B-@7"IM:C1C+GS;5FDU<E[_Y[GQT6,U)49]8K4OZNYW6H/?K
M/*2V[)3$_V+O+:/BBK)UT<)"@@:7($EP=_<0+ 0([I(0/+AK 0GN'@@6W IW
M=PMN17!W*[2 HNK2_8[T?:?[C2MM[XS^\8W:/_9>>ZVYIM=<<T_^@C&O]AEB
M>PZ$M)*5[J>%=B2^I:)2$^L\%4\]UK]KB"10_/HYV0ES)9C^/ON>7Z@\K9:&
M.;V63W#_4SZ&LD>6RSY])HM'9()\5?;!B -+,-CO51_Q'F_^R@-6N2"UU$KC
ML;'^+%^QHL'P6]]<]2#J(#-/CN-;L"M6DYQ>6LU(KP572HM"7LL575M'\XP%
MC^'[\Z:3 <&26898^&H&E?2]G^M>T6]=FE^N:\M+'?C"<W_TUVI\0JYA!_"L
MU[]+:W]C+"$_L;1,U?B6E'/R1?516NO8@.W TS2)?_M-$-=UXSVV9ZA)5$"-
MC#KR AOF0ZN9ZON\^"5N!J2-?!^*;1XN'F5\\H\7MUI\E6<E;5LNZU5\9Z=+
MBPW2O^.F9+ BR50<G)4K&*=;#5S 5!HCIB>1SXA^6ZTPP9?5B5-Q+%13%=.?
M#E2T>1*=.>=72.^=-7UC*>6S<F.&-O2=6VIS+>B_!7$9;O\H8%'L7GE)_A Q
M.(AO&8J#KNP<LZW!!T0=*+--\P;?&T,4HY]>HM39[ D3DF/'!>(;?M]>BFE[
M9Q=2]4X"3V..8;&!PW\V)YPE]N2ORC_1EEH>D;:QN(XS&HD?T&Q*I5RMKH%<
M$X[#F38D1I G*>ML3!L"6A##[X:@GTE-<9V"X]D,D9DL-JJMY'X_7#U,K=[B
M\?X@*#6Q0&ZE>KE*W*IQODPTK;<"=JZU-$,C:G8EE1!  /3*,>Z/.+A]J97
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M@*,ALL_+"1)]@1W]Y&]?X9$ZMD.D8U[W&UDM2VZ\EZN$>\*SH\,+UO7GOIG
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M>J8=Y2-4<JB^8.7%6=D<2ZP%\+OT0X&4;^C<F"LU8@\.F&J+75<2P+*6$8"
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M43#%S=.0YDA%4&N#VU0T_HXQ'RU*3-+MRQB5 JG2:U]VELR;1Y_=*R,KO%6
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M_%Y^B4>@D&R@0ZPT'4JSOJM2#PUT03+T&[5341\S@(?S7.4(2]6CVVY6D",
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M)JO+7P\7O^"VYGN@A0/UNB;V%8IICU>>W^O)M5F:F&'=D"7X:<-4/60[L@D
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M83[##HD:I+F$2%8&?"SI;)I:S-86/ODHKTP3E,P7"E+:M%I\2V20>>S*,9L
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M(^^T'P,"5'5VDO+X^+A)J5@A<V';X(:NJT <^\1KM_FG"<1C4=A4E]$.IV$
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MY7,U$Z0@??+3N\0F#4P:/3 'LMDP#M=[Y!O]/DVV[LT;[+(M[H#T#1)B?[_
MLOWV)ZZ^RMK(29CKR0YGZY:\SR"31.1\AW&>KQ#T3:3)R3R=19<A]^4:VE)+
M$+XG<'EK?D-V]RE#7\OL%E*Q L6\J\#<QI)93(XECD5%+]$T90#H%>5<21MU
ME:P]L9O<SI^N076E?=V,-RE26)1+D3#HN\]E2^C3!5GA W^3E=$9D]DB ]E4
MAVTKNRI$]0'KM[3$_:TH]=N[AF5YZY= 7_\)3\OYYRS;B\C'\DZ$S[TP*<?H
M/$<TV^'N6Z6L^DW3+H;OE)F'HYCBEL:V>>/DNX&TKL?Q*HKKA*'T[,T12!+<
M=/:7<'Q'D0:IY:+GC* $VZ?QK3WN[4^N@*6R'8D/ &MSM_J$=5D3^<^4C/$'
MJ;Z <AZXBR2\(2/F2=PV(3@!NER#3S#7G<Q<EV31T T \?KN,6W'7S'-C>I)
MQ/J6>>S:< I<'"7E6:51U?,<FPT>MD!^21-7[Z(?W)ZU1]X>M^66ZEH)Q''D
M#0BG6 C%AM+X97!!H9,CHQ$P-UF!W?.-;-HG)BU1: @I_%NM\D DB<3/0NDB
MZ$6WV 0=;$DV4>5>RDU<[I+6HC'W:7;Q1RU8?_ )IQ^QY0 CBR^OZ3+7G[=!
M[1"XN7$W2YT$@4WB7-I3:LD8W&(*)U.FS]G<'[NG/\> [S7WX]_2]9!(\6"%
M2[\\]'K-B*$-L4G'KE425+US_UK^4YNIQ)8;HC.6U7 HD4/_RVL\.:X:?:&P
M\(5\LVFQK>@' @=?8"^XTN_52GX"YTH/,-+N[K,"F$^X#+KQ)ZB\Y7G^<J]W
M841BHR/C6VKDB>"^G.D0B< UG>A5H:.\'>^H'_^!DSX\;4Y-P_[%[O)SOU63
M^-@'@$_"O<U\"V^9/CRB^SHYH26@I>>1]  S$_JN.N0;:#*IQXB^$B81S9+B
M][6OWTGD?G_9 D^\3WG79B!EHSX*P0UF6J5IO5"-QL?89'$];M4)!KU/+BZ4
M&99M$,UQK(GC*7K)_!,"0&_,U=)6^2VEQH,M1FS$*!CDQ^(1]KBNW,>DWC11
MMRS)8K-R#W3O==5.8.5LF49?.?7JU<ARX@0V8J79"4LJ6O(U""=,^E6VV-M-
M040"2FD:<K9?DI5G0(=\=,^6=.9\G%R;]5,PZE:(%S@@#-L ^D>Q2[.M"D6V
M?/YGG/\25JO=%003N'HB6;C"M'9[=",:]N8-$2-%F#("6V)><_EJ*1]FT4/^
MW:>-PAG_9D[LW7]E> !(]QL*0EI [IM@7.7<!7D\YX']SCP3"K0 <310KB;<
M=</F%!ONM]F%U/=DCCO(PUSY4389*AHP]MMJQ4F'D E&"<9&&,4A/5(&*;(N
M3>%;S@VQL8<ZOE)DE\RUPQ2)$P9+"G&=[-_DB;9?BW>6.?>E/:F$107FE&X;
M=1'&.F4S.R,X1,MOZ"YVW5:?P.,WDCSX]./.[$8Y3[[+R-.Y#<B"@@6M<LNR
MQ/OD34/9XJ25ALG<:3^G^7M/07OZNT\9/"#GBTK>FD2RI%B8NBW=5&.:TC?.
M\.A2[_<*!S@<<51T&IA.@&5?!W:FN$/NR_^9FL0^6]XB^PQ4YHV-P)W^8BJ#
M/7_(734<\QZX?P@KCUPEC1^+[JES))=1)5M7'8>0C=5)J%\:ZTVFS Z_O]8#
M#OF@P=YT03]$O)\K,ZUM#GC#W)/_A"? 7Y&>K-6Y\QY8WP2+#BDIC>I9/$G?
M"6C>_F7XPYL]3GF=W4#/C:K>Z FL&2FK"+K#RD=&QK4RHJ":F$/,L&A-IQNW
M ^9SYOG57 >.D?XV;?6K]US*_[WX,#F&[#QX &0S%><E)_SX>>+&<$Y0AX(;
M>42P9WD_PPT%W]KM'>@6K5P!Y5MC7.OOG92W@2-^* XST)CW )A#8>DX_GL)
M)MY,N#;*6);D'P!U:[?"T%&D$'A@+!\\%X/ZP6(KZ88Q(MZ6%;D$WM]#2=:-
M!P"CQ*\'@!$*WMY:-Z ^,_0ZB@8IZ06^]Y9] &2$GZ5_ YUK]=^[-*+^KM>Z
M]._1M!;6?\U&R,7/P1IW_=?TG[:@\O2_)Y$T,]SA@B[X"J_0]T7.E$D? (,^
M0<@N<M MGN:IZWH:ZP,@[@;K_BL'^)*R(+<9TTN[5_F&9;'^'O7DB4&#/QVG
M-Q3\7+=W#+> LF^;^:@&Z"/G4>_?+I-=+RO/7SQ(#H[JW7Z]W-H12R*+8V"+
M'GFUK6[<_='KW@=6FEZ%L%O!(9$I1O]B5*+XG!'&A'0]%OD3Z:),>'"^O&(L
M>9*]'2A,EA-S^WBL82^CG.:,.6$MLHU9HI;/(YPFR)L;G3TJ3A7M]O):_4":
M__,2IM=<%,+"9GV%C<5C>"Z)2M_2"Y.1BND:G7%YVU<V]: 2(0\[K,LF+UBT
MC8C?J?H]_IQJ^YFDSM;TK2F_\=97I^BG!^<\Z<PE@9E7'X^;+X$W<Y7[BXGQ
MGEF=CGD&7;-L.,?L6\09M)A[@8!M^A_9&^&6A.BPZZ!-7P)1C+DKXV-*@_:%
MY>')IZ!7&XE45%M+X=>GCU!&$)$%GLL"LY^W1QJQ3EZE_)+H5FK43ZSAH<J)
M_OZX;AU]+7-4Z-[QT @M4;CE<5:-'95T52'CM(/LNM33/3]I!S&P-&H0H%SW
MP67@2U:4&]L;H4 JEK1?D_\=^+2VH,+"<>*+O3[[&_IO]UZRB,6_0RO!"QZX
M!$$G0;LS)[=EA599!^[449=IAC5/&I<N =[Q_N(CP@AN]%_PH*VG9XDA>N1:
MTW9.B0/@;S,#E[2^'X"Q<-GU:Y-5MAFR-$]%W^\*3\2NDE@+A9_YL;8Z;*G7
MP_HAP0^ T-.LZJG.FR!N&A.CV'*?M+WE=.OK 83O^KZ)7-9LR22?2E$X-@Z6
M)*;04[[-$O^U:7-OVU<G'@,DTKA-<;P#:M(^4^N6"'F61B[$B^$(O[HCG8K(
M3?'?A&L8KL!3XW=6?DP38E),%5;U9RM5KSZ_&^Q*$QXHQZV,LP]A(*&RR[;B
MS&;&->4X$Y2AAP.VIHD_I(V@BYRR;K$B$+TW>@\ &/]/%-O;!(=Q,M;.)-+\
M, 5S4[@V$<TS%OE[D?9Z'4>'UM@JS!T+>.7F5/SY]!*%\N<@ZB(?TPPZIR69
M:+5 _:7((YT4KT T(0XAC*V N0LR=N4*>HO->Y&[[O;'+E'L, SW1W=?BF/F
M!Q/ZL)F\M)0#L^"ABY@^O!R.!WU:ZZ$\QI'IJ1:3K::;6-]V8*Q!)T>E-TWO
ME7$> )Y)<#!Q[-6+EJ4-4-11C=S>>*T5R2(;,T^W6#I[,1$Z,*T[(-#WW$N3
MU:."#Y$>F7YQ0;%C\P#HF>5 /H*MEF^*^JKK!+(Q7YA>F)&\R[>.77 @ )1;
MVUHH*H)K!'+-*[8D/OUZLP5-U30D[5F4#4V#N137-MPQ?HWQE]QVD/&"8(]5
M%N[9?,9L?:JJ^U\>1 A,AG$%\'$]9>1?J0C?OVP,PGT&G:N$KJ:7PM?>GIU4
MV^=9Q[>0*%,D5WU9]K=C1V.,C2/\XCB;#Z;TL.+4VX8NVG_/9HKXSIKGZ.^D
M7*^7DSR#MGYM7X#@AW^MD'\-Q"N*)QN0S_Q"N[7O?"1;Z_( H&-QF^'S>$*O
M]Y8Q '+4P7"/H2V\">R&D6[RL/RD#:'ZR;EITO*5S@#2G2C1U4JZQ?4M;_H2
MUU9KQ5TB=62W /W'$A4H0+4_DZ6NO26%>&R_PD>+FN[;]6<89T!]Y%*D/KB8
M'>>*Z@#2,O-OYN*]$1WM,EB#ZTNCUA0R>3Z-G<53(9T ^H:1:G<<G0=L:YV[
M]!7!2KY0KPDF=B>9>N5XQ!OG^TTO3.!7"58"G*LC[>54"]BVS/JZLL1[-\Z*
M1&Y4=^+;BGH_Y[PZ4O0!,(R.7 5=)W@E1I3JP(,4HU6G<B]LMSG0&#&('*3H
M9/\6GNW?*B'AK_OF@'4RL2LC<404?8\Q027([R"Z]B^.I/_?.4?21GDHWXIL
MEXCM=T'5B"'+=VKZU9\ZJ?;H.M'%-(PIP-MI*R@0TFF_Y%9KXTZ0P$4]*)KU
MWF\0A2&E7LR>:YW@&^+M!T#Y @A%DM[E@L("-HS/PGPT4?<AV0^ (-._*7L9
M")$I,:4\76/6,(N&9.W8]RPVY:*X$ <G1\/<I\M+6NBA\  8)A=6+UUI#="Q
MZ$/*!--HS_O8QLJY&$G M;@H+-DM L;;FP@M5"Q3S.]\C4]IM4@R!,&6ZT>'
M1E[M5DD\HRQM>WUSF\Q0X3E;!:):P=98F4H;,3II2@A:H)ENK;.1Y-T+T^B/
M_E,-V2R\*]21'6D3G:P]9M"NKX,]AK>E#V!2(;JV^QO.% %>>^6EOFR?'@#/
MH/:WV^D#VF/I9#[2^1X1/6=M/[E^/:YY1/X=#RBPRVI?L.V\=C!XBZZ8*'R9
MPI;E &O!_MV=^5@*,SQI1QO# ]2=?@,T1389H "-TUAJ;BR= +Q=&GU[@!+D
M&;6^6 IEZ]'_ J+\?X^QLW\ ,*, <!ZE1W^69^RC7/._@VCQ9!L[>%!@IOTX
M&@E1N##^-\0],"8#;:=8KUWW/P!DF=57GSFOH;=O&TRW0X_ ^X]:%5J"_E-0
MU<Z KG)/B('RAYQ=?=&;HN.PM[7BWNY32&RE!>997>#!;+_<)VVY[:O$\>O0
MF%R9Z#YA"&.]*/NSY8X(<P-?$RG?4S [(#&JFF%)/?FS>='$;QWLS9^9J58I
M/ ,9I?WV!;; 9S#BX"\HI!)";@7!GVKG;BJ*P21O7B%>_$WFM4(1#3,4'(U\
M\8 BWQG:(UL9;K19S\ ]U#8>AGS?FB# ?7/PBNC'!A-L('3(E,X)6 *;0X0V
MK=U[@<Y+UOIXQ]HPP,-@),I4KTO='@ DJ%[]!66X&@%=\I<QKLLB4#URO(:2
M?G/V,"ZD_"J*?AA,H8B17B&8R)# =-T=$9&<=.\;?0_0+M1.1!"@:)NS&LJH
M4;_+P+EB3TXGI5HW8I+W>0*SY7_9"1GU#!Y82N6S WNT>)]L'?2ZI5.Y5EIL
MO.1X#DY1_?XY\F/?#].QZ5P&*A?2 @]K3BWFX29O!)SVQ[(_F+'FGM?(,+_U
M 1#-?XPN\R-2OZ=NZ1P\P\8Q[+QF3W\G;<7@R>9&?&R,YR*5!:<?\K)-._+-
M,]@"":+:UN^&K$V"92/?H=0R]!IT_[AX/)9$:%9H1O,IH"@;@#:OG?:W@&<L
M/>CV/OH!(&4]^NJB8?!_B&6@+(P+N=!I%';FCGS'A&KD3U"NYUJO\0T;^'H4
M9Q)$0WQ)YTG1;PR_F !!<]8&@7,V VTBJ)>GA:%&B04IKSL%CUD8W]?3MS'&
M_#@5$\MTC5>Y'G#Q.0&Z]$P[W><53*G\JVN4[/M9E*_>!HH6WD^'-1!U%XS*
MW088Y:[;?*V%V^09R%'F: 7/<ZEA*I-MGQM;MA.YWI4J]E#GMD70?F1ZW4M@
M)#WV.)TV1@A1 2B&U"M_HH_>L@^EIHL.*?]4,<-I=UKVW#)3T1.C@;/31$:R
M@^EBCFP$031A'N5*9Z<!?.JOWZ4,6]\9&_?)!ADK]%=5PE7S5_HL9DY/?U>P
M^GQ@A"YC8$2/ML9+S;@8JBL;'XFFZ'*:H+US@QN_= *P=1I]HWH4_\?T,V;N
MWY,)_U>W)0!QCFR;8KQGC\VL'6T3/J.'4(+T9B-J(#[O[7&_VY :&WVR-P$E
MV,XHR<P=:P5KGY8##6MRA_@6MC>?[<GG.-6HQ4AU4KY B8RNOZG]G%;K*7!)
MY)6KZ]A^W? ?>D^&%RX25^/:!,SY0/HV3$[UYD.RVH_<YFF(69Y"<QR1-*#!
MREL;DO[4"CKRAJ*58L:9[@5!%OVL:AJ-+XC*2.]DB^O4QKMB76\V.@:=_.79
MK&IU#20"'%OL:-@MB .7^!;^@40_:TN+9"%^0IH,,T##WMZG?*7/SV]OLF19
MX7E >KM]Z2<2W3!6IG,E&P6*F=3Y\#)@ AI3:GR\O+29=7)LO<1[UC\_;J)S
M7;L(/@Q<6&M$"5W(3<1Y9%+%2:N>6#=;)X8[[EKL W^X6U%65YIXQRN5U888
MZNX-,0#O"J"9+?6I ;1%^E.MR@8Z3+1!@4!GA>GAK_JC3FM=_>VU%NJ$O\M)
MK2E[!8?$\1/,9?!R D7#%VJ:*)X$=4.R9RNMSGZ/_RYKE78<I1VX/-!P\).5
MDG[QV@5/A#A6T>!;SG\[!H!7O)J7\RE6\NG=-(6C9^5F2=7ZE-<X8YI'G9PF
MA)TQ6F^IH58;8RMY)&Y4<AD'4PM GY<7@!?WLO]1.EUJ<)M9J:*WF?0@[3A&
M1>].06%\J:"8NCN1Y2-G(2-VP237=Y["V;F EV*3IX-YV]3<DN0DXIMISWNU
M=*F4R1QI7__)P'#M<55L-?R.R-%\=0FP($MQ?;XJR6]W_)M%VIS\E9,E8 _%
MS"1Q2:OD4V%Z%2.[I9_I$_QZ_0VH 8U:SU.R9KQ<=$A4'M^RH6$X*OY#Q9HT
MM 5?+^JW_"'!WI1*--]_J;!IR^RF:*#<$V%[J]GZ=RN\TT<D:'M.U:S$:C'L
MQ>0)FXZKRG)T=ZDJS+5\$<'OYF^6X$Y8K@S5G[ C,W6.)\_6Q^>G\"6DRF:6
M^S3MQ(8V@)G8.K6E[#%E1W[ZONZ7ESQU_2ZPTT?1ZIJ!U)I\_2-'3W3F;NNW
MCCECJ[/:"E9.<E.)>2&&/."8!,NB;WKO"X?7]41!< API,L[80?]H#)Z<>.3
M^A1,Z/<QDF+E1N)%\O)E,@>2$45^#*2MX39J2JP] DEQE3JQH4[BW$BA\C<U
MG@<-:7;T/@FF7+SS8F:;9F>["6UB_,O]7]@];^./C83IVXOZB_#EC'[;N=NQ
M"N&/.D@>&V5OV1,P/#T8-SZ8>R3_7,U4Q:F*K<_Q-'K'",2A)L7;S</GE,D^
MT(U!O-CHH)I_A+C]]?/KX9WF4N8QDA0651Y:VO/AG?9^>TMH>NM)6S;")K\\
M.2/-1C_TA'/;,B_R1%8]$/_OL:XMK@158:8%9.$(/,S]JGOQ^^(4LB"'/QN5
M<T']A7<)@HC1Q?"79>A3_]1&)*++HM'7UC/2[#!)LMM9M\PGC.Q V5S^\=>=
M&;(BFC_21-2Y];3)/W.;"17AT[#M6U*./\E'2^7R&2\87OZL%5R;Z&<J2;KX
MM@(]O$68;P9-^ZE=[R..3-S9V&TU]NJV#26JJPS3^0M):[.G:,^$\SV_6#.+
M6@^KAPAE8)98B$T.-%.\*-&@P-K)P,G9A4SCA&P:LUD^:NW9T?&WSA:.N7@7
MO2M@]1+ P#902+[13>!1L)^!;YFK+37&SVRN1[KK6OI6DD3R3C^Y#ILQ?)3?
MC?#*!8WS_W3U,Y^;LSVD HH;EB6!;G&UQUTT9;24 *K29,_^MP?J%A@AEFEL
MJD:":B61/)3T&9#-7]( S[;Z,XNWTQ:>E]"PFCF_]]99<@'7ZH$2/_OS@.Q+
MZYI5PWE0XT2=*IY*?0PF]^UJ,/O5(OM]3G- U,8IS@$]1<UK*[<LGC4HBWVR
MO$3IO8BWEG:X'YT5_:OIS?;VQC:(S@91@-T^A:6Y^/3%!36TH'#7O0$OA#^$
M<E--(2N8"NH/).PU(JZ ^7XG;_HZQRV+EV:2XJ;)M YQRI^MW\\4M<:T_W:I
M:$]@F7BKE/+[3*K9YKV4:6,$;0S@L+_6!%Z\<1*_>0>WY\>-F,\)X6*3;LX*
MY%$65A_CGU657G1_!+1QJ:T)6>7I?2$MS3GMSSWBY,75;<OP!D9QO5(Z<K>\
M,SKX^4VZT+.SI_3(VOF)-[8 ;=IT_!H/A(Z/S"M[Y,)UD&/%0)K1IG.D[:CP
M55E?.*G-1YQM^S8Z*^IO$5,]5<MKG(<C3SN)QV6;7F=Z+*7Z9(O-&4H_J:V@
M=?_7)3$CTW7";[?ND3[BWN*]/==_5):_0.3.M&FD=I2-[K'+]6#(!.]2.*/J
M5,V^#[2QI37V1'.424NL$CV#/_JLN#NY/N12'^JK-W5T/N382C$L^_L8'<3&
MGV-F:<F(.;5NF/4>?[>9;P+L1N-(A1@2/"^7&V\!Y7G8*Y/K&5:$<)R8QNDN
MS80=@@=*1=AI4Y;-!<-:N/,]BA4%1+Y:!#6QJ7\+:Y5"_L+WG$3@?'VOZ!'X
MEMQ#U1(=[6KM'CA7D*E4ZK\)WM"$F_F(L\3%*.!6Q*PD8MIN"0GW<0?*<$?W
M)S>O1V.U!WVQ*P75I%VSY5X045YCPSNW'*']8BYE>>'"*5KHD%JX;?:B1V6+
M+-W(38O-MX:7DZQ)C8-,IG:.%_17\Q/2+$O+!*(]:_@U8++#M47!.4'8R$Z)
M]\?81^L6,_*G4+TTMK/2_(@O+ZK:FEI",,"O2ZN+3H6VW#3VR)JE:8<)^1\
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M'G_IDN148&3F@GFF28)69\1/$K\E2:[CB]S)<H+\S."(_VVV(\\8,=R]*[[
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M^&/]YQ'@75V9;7%X_PA\#WIXV?TP]PA$G,:RGEYZNSM\^]/&)M\V6^7U]/3
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M9V*#;(5'FYDV@^Y";EWN7;'O,8M6+'M%.,P2:_,@@D2.]ZQ7)SS5BV,VUF>
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MZD1?AP+Z!9DQ=,CIZAB<#'9B!+3\X90S5*D7YU2]V+)FE.//\%\PL>X/R71
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MM! 50/F3MP7"7@3NR$Z#(ORTH'7W/IG81R)0#A)P"Q["Z&F\AJVJREDY+".
MJC("(K!&?P_42)<\%Y%[!?@-X+Y<UW8V3<>#+0M'Q.ESMZ4L!=W[?GV_HO"W
MD?5V(A85HZ)N3UJ0P,_\AY*\F"\3.;TL[Q*00%S HK7Q@WV%#G# DZZV.^VT
M AV". E0KJRHVMQK%48F*OAH+HC[)P=%@@%1,13T0EL[$2"O= )W0/ UWHM@
M@\S,@^[^)^D]TIA;MKSVX]XA,E4Z70CI<[9SKFX/4_(UG^=M3CP?<OKN:N,7
ME#KF_BU=,U$^4YVM.5I)97!YGG_-ZWUO17T&,\KN<=$Z[SB!A,E&MS_( [Q9
MUOZQM0SU-1^@@,O/13^(F-=FW(C46C7G(R\WOLV%%Z*G5^E;=1TDN7]H_L],
M'/)_F+JRJ]:H=]T OC&\LN?2( [VVG(-_PT*RN:VH=#'$5:PPB'0]A"/BGDH
M@W'I'A%3#H:-3(KV2/=>.X6&+I9\,,+]L#C_MY0M)?\C&,JY$<:$4;JK&UU!
MFM?B-E?NQ!-I^;&8GR3#CH0K!AG$)VL'/QC[*<F>3X!=1@/2(;XZW^3W1[1W
M#?--Y""\4)-$ &5FCN# L.Q*W9&=O@ZL>^NRZ=G; 'SK;#[+);3D8P.<7H#I
MT7B2!:E=HA,S&M [XSW$R&?=3B6=2AE)<*<'M-E8@[?E.6]BV%-!.+ M90F<
MPBE;ZT=NMBC<V&41='80CZ&1&VCL#761Y5-#"-KA[-J16#"+V0Q0[E!F,.V'
M-R#@VV#B7+EK=&5EA?!2>4G6@STB$(X)0OD(?7V(R$$D<IJ_7^KNAO1-6!3D
MUOVY#U+ .BQ+DY-ZGEL:B^!EQ[']3TL^],?^9[#B5_#J&W$MT>%ETT^BNFON
M(R:3E]@#SH+\GX[>>S?A+3M,&2@S5)VW4%'UYJ%7\[JO@$1L_HMP($9&<3DS
MEL[GCC+I[T7)W;45N3L;-T&V;F4HB:^9FE *I&NC]A50 =^SL\!VQ5UVYB<.
M30Z!T(]?TU2"=NIK8+^UW?Q57O(9M!!WH_H+BNR,N@3*MFQ?*S42P6*X=?EH
M\Z$D.8"ZO+J",%X!NBC*:277'I>Q\9N_.)<>M \FLC:B/;/0;KQNR:=DQBL9
MB<BY*/9._XW98YS5SB\Y&0J!E<VK4<)4CR$OOK-JG8WJ,BK3?J_\'+(9Z/G#
M:<T'L; ZV+DK_-*<^A7X3A:-8U8QMY6\I*^VYTL=<=$=$\.%*Z#(A%JG>S;1
MR#AU_9FBJZ;,^?R"M\JPB"G<"M*N&YV#=%E5;#-N;%<4>CX_JN+:45 R5.NH
M^&/"^&-'=P>G/Q9[D\= ;,/OGB)4]/HU3\'+GIVD70X0*FQ*T;-&4ASY+.>I
M<CU#?0K=.')M]PE.."Q8[TEK2),(232RRSV[RZWK,13"3RR26U=E[\UW3I2%
MI;7TCLME#N+E/,_FN)6;PE2+UDJV><F^/[S/"R]>#!,*7:9V'7QC,)PQT*X0
MN6TZAF4@IS 8O[-^UVT$C>$>[._*ZL,L6+TX;&-:>86_IR-7 !D8-+PPMV$;
M*3#Z5C5H_C94<=J"? JKA?J2G:21/JN=L,+%H?)-7R#[ WNS ;'B2\T-_S5^
MN6=VUF$=K]W#Q:4VE?'P<#&R41!E]WKYB0_O&'T<06&O:=AP@X4F#:Y%38CT
M(?A635C5(/^=U;K<O($$-?,%VK"X&87]TG6#.,4$U@4'Q/*:O+47HQMC_F&1
MC8)X--)C\F5R_J_L[!"/#-[UDQC%Y%IDV202OG+MIH1_/YLF(ZD8I).JZU+8
M$2H5>;92;3GW*>*WZR_(8&?P **]IM+VQT>4E2C'["L;-L*08%DW=L#(D;G1
M0;\CC+!\LQ@)ZW64K6?&#6)H^(BU"%:7;7#*C3?S N$($+P(@:>CN,PTJ1P.
M<]?'@DB#I<S@0IH^FDQ@L0'\6A2NC]88TZ$U>Q6Y+6[&\#0BPT;K2SX!@!]$
M#@][[U D5>"T\'.ZO*NK%U!V2DD?>M<Q22 -!>S;9P?H]M6*ZO65G?<9N%2,
MY/G9<?46V/F4V7B0BK8.Z>IX3I(CR$X\4GN[[]<OE4<6>^-!#[*#AQ  !W$7
M-;K ,:''SSQ(D"=P!)%XD O]48-&$<>YC'(46+P1%'OHC2*)-^0*43/(8N$N
M#N+2%4P#'8)PWH.X>T,X3PTYW34W-08T!W &S)$JS!#BL/0!_%UY;>T,U_Q=
M)02^XD,(4PT$%J1J2^.)"'[889!"%SF ._A?F@OV/VXZWG6C"(1.+Z +SO2]
MNX$<$*-UB* A1LF)RN+0[RMCJ^]&1NKIJ*-30H.@>#2J:HV]3[N/067M5F9$
MBD"Y%<,Q6Y7]"UDJL$'?KVZZT;9[:2#B9,HVI3B-;4I2VN!%EAU;&NXR#II>
MG4MNS6UG QDI0N@CZ+/NUETEVKBQ()8<_ -,$;2P5<.1;H! F>'@9<&BU0HG
M"2!1";//Y/G(:1C^([6HPVTIB,V^'2[MU<WYF?T+BNR>?:;0MBLL( E!DQ1.
M9F<XB1NL9@"43:/MW-+@G,]<I4@X*[=/ZSZ2VY6SI=2@2#W0F)[/AG.I?PO?
MB>V?=3R%)S+[I13+Y^RU 4K361[?1BH68UQ1A-&)[9'"S5A9/,3K\&$$T)\Q
MP,94F&CF0_OSOI"!<V)&(LZSF\X"Q4;1./3RH,>*FK8 *U(-#4D3YQC,ZE,!
M]!":6+7]7BC"2!T_VQP.]1LU2;1$ /5(SCJ%Z$K^CTZ)P-I_4=FG/_;?9[=B
M4?$N!%93<-*%7#;X%>!;BX$+L53'8X*/L1)U',-K?:*''WZ;X\>[V687&L%A
M8PM8B25Z'>_B$<-!.LUT\U(V\REP"F3"W'6Q6Q('-ONYJF;V(<V!F(ZHNV$V
MLT'ZAP1N[8$I)9S?ALP#!_FV^7;BO0EV4_?XC-&M/-%TY% +AKPD/:R5*AF_
MT#Z..+$P4Q[O8N.[ IV^KBW1VF*K:CC%!G#!A2YY9?BLNOZ,/U(7=F]>[-PM
MX-N2M084/.DU^]?&SI*P5N-/1^R!Z)?@?EM%E0F&9HJ#DO :/D::C9FF,+!X
M#Z%X-%'WO*2,NL=<=207"^X3.O-:-@E8C&R2Q,O!4'7C<3EOBN1SAJQ&SLVV
M\HEJ9JZ?A;1#_&N1-F3S+&[O#?R.BEX]TBTG#\<ZBJP:H^469-)_*V0:Z1JY
MJH[G]&7@"&V5)X7T^89&S+/]JG32LU."/X^/W3LZ .<*4].S%RV;: [:.LK=
M('':AH$*T2F<D0EJT3=8%N48\DID2+X*+\9H&27D9_L(YM?6-[YE)A0.P?N"
MSD8L.BVCXA4[.8H0+:2H(9IL(L+G_6/IQ,SW0\3S::A^9E]N220>E%=9].T$
M3F,&=?H?+8BZ^-^ M4\%ADH:)%5)W^%51Y'N:LAQF-R+4QXQO5M#M$VGI9M0
M#DI\<7>(_T-/M'%= M(1])-%+\?NWE9^5TE%'8.%OS[L"E!78OER+U><"-/H
M7C[5ZS:1Z^9?3^+8L^GJLL>W@$0TTFHG4J7.F?/=QO(\H6(M^0EW-_B(OQU3
MEW!>& 7.S<XMZGDA(CW-O?$BE>VM9>2BBH+14IRG60TEWV\6X5/:E?4^K%H\
M3+P0G*1G6@ I;JY.%-K)("[^(@-(=T+ZQJK2'IV0,.3;)U>\7!*G$SQ<M!IG
MSZ[M&_C[:2F(P?-EB'7<>Z8@CF&6"$5>> M4(PZ!K^$O(=#+M+J:D>2# **%
M80_:E-\E]')FP>/:6U'$N;&8;E%MB8.B5[1VPC0H,[W'K&G+<FN<KZ>F9S1\
M=7A;ZFF!R=M9*W93]C>LV,]O0^TFC-_R?EC!79.'%<NQ+BX5T/I(#$J1!1Z&
MQZ:3#G@[# EQ2=$<1]6,OAC"U&EBD$%_"RUQ:4<KK@ M?=E*1\F1 ?R18)&Y
M9'0UC9,M[B/II9QD@B0%<?C"P'Z-CM\1BO35VY98(E"&X2GMS_'&-L'VVCYV
M/);GBT'WQ])O<2M2>Q1XEJ)!@(T@10,[&VAR2Q#'-9<XJ%AJ6,#%+E5\U56*
M3$Q+.]Z[@$\A6.IFB(]FF'B;J!")=X'^: <(Q_0;_G [R'TH^I!@I)Y)D-BJ
MK1LC\Y?ZOB<.3ZOU_'8'$1,Y( "_^?%"Q8B4VE)7J)ZN0*3X*5<)KPI@.S+8
M))POQRR8[V)+Z8: TQ6+!O_SUO.N/,3T#5;D<P3[2'W]1QT=/)9X'X"+[?+V
M-EG@0$ON%3#C$'BN<Q?/&M%^!835MY@>\*Y*GMQCO + <N</IVFO@*PW"E?
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ML\;GO@UP&&"R;:?:Q0Q"_^FSY'^;(98(ZBJ14UTW.$'FC2ZRP@6V*-)__]L
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M/?O=#"F;==^K^A;N79IGHA;IF!EQSO@ZO!_YV8A8$O:\^ES7BGC^0O:'J=$
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M*P!:+%(UET99#O4Z?AO <?)>?O=1%N;GZAC_Q$2/!OU,W%N\D3>XE9<,)U>
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MJ&UA*26"!N.EU0;A2A+\CS#;<JPUDZ#M&7NZ:=[<*!.5JV_@39B:ASW-RD;
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M2&OH<)N@+5 BK"XG_,A&W^Q(8\$ 1?1T?)ONA62^5(?T^=IUHU(HX.&=\'I
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MNYGV?R1 @W;BG)0R<*:4JM,Z0/&JV3OR;-X.7D$_8W5CW/:9SGYE$*+B\HT
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MK>XASE"V:)6#;3AV47>O% HY WV>G=.4BEB)+2NI%I?@?IIH_?U.J:L:QH>
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M*K:D0^EC1GK]BCIG4]Q;\$2D6EB#@N->2\E367WG]!->(#32R68(K!J(_C&
MH;@@4[-UOGAPMK Q>?;[-8-&*7C;YH\WT560X4RT&UN$= UT?LW:*(*'?+%<
MLIU:@G+R*+%FP=-Y5@[;:C"%(8<Y9@+KN%RQ1_.JZ>2GL#1.Q9JS7U&Y#Q_+
MG4W7QW+W+<'P,J2*OH*\7\H>+<A(SX9&09Y]ZG:<BK?,9, 0 /HVMD4A=@,Q
MI'G/TY,GS55@(1OJYVB CNK*/C&;LMCK+<D9GJA>N9LP;_,)ODGM1"[>G4G;
MIZJ-T;0</\U8I*=*U@O#O[3.&7>PFE;60[THY9,XJ6<WDGI$[^SB9UJL35/W
M75LC=4(:1",?C4R8MN(!**_PG-#F%S:M_7K,-_RF1RWS 1#/SC3W?"T5O;^@
MWJ@\]G/!3'.TWOE+AE^LNE0"*0U]^1)1.0^)-B0_H*-9O**:I>*6R:/T[U?[
M=Z4^[:6DZ+227#WCZ81AR"7Z[?Z&)&VPS.]R&7E:S2%O7V=C,614[<!G1/Z0
MO)3# V 1Z'05<#V=X*1>RJ>BIFU)WM)42!E1H5+6F-2<B1E?W%FZL^.!34=#
MH0IQ6*MI>>_RUP]_&$M/H5N")/X:38^6T# %B?T ?%7Z* [WN,0Q"2,C#^R?
M)3GED9,=-?7CT9,)C&;7-&!^ -!WBB,3E1#32?L&QU6J[<]NSME* [D9PE[Z
MXM+>_YS)T6%;$?%[+9OF<@%+B6E'N9,O#U)O5191R3J0XB(FYEG\2QO>7G8<
M-?)T_(R_/Z]HQ9S5J_[.F^([W3$C)3WVU+L9)>ZJ;139X@> X+R'HWC-R'X.
M4=#XP9APKKO+Y&/,KFUYJHU V/D1LYE/-[?*>O7%M3O:+MLD8G^UMEZ.+NK1
M48%TD*XC<ZO$414,(="?EG$N+HZ%M?(.(SQQ-S^;WI;%#WVF943CXH"?]I8W
M=](PW<\2?G(&<7Q#Y3]BI!Z9N;4S@=1''\HW!4KC(4@<?25[);+8!F]Y>-ZN
M*3XSM.BKW!X-)#PM;.32LEBT9YH=5B@W@,)! BR*^3<QJFW?@Y1KXG8WZ[J#
MZAFSVC_/9"]?UNA,<;S3?K$J]45NU;#95]6DO\+S_GAH"/&-D1Z>)EO,&'!E
M>N^&6&GE9S.B?LT?)-8M_]&93!#WVNKX;Q$,QY6E9$+GD[F/LO[EH'F'1O(K
M\^;'9-F(0/O]6KI@Y*E\49FI155L&-JO+# KWY*5;MSTQ#YZWQ9^.N?7=%%B
M&2S0[J=Z\T_=@SYS.]#C&SH#@_JG;@)@$BS:GUQ&Y+959>E.\OE!7!TC3UBD
M^!@G+W3VS:?WM5UKPQT*Y)EQT".#@.S3>VE3SX@NIQTE>WO(AZ:>0?DK\^OK
M;-NQ8TSX77S^D'/!$Q7B5Y&;C_'(@/FHG+"34O;O<MF02R-B[6I3Z.;G&<7%
M]@E?3T@^!;-^14>,#F?75/!J<.>M\]X<H6(;J1U%VI/7%#S3Q.8F.=T8,FZ?
MB*Q/8L0_%[P2) ,J&>XQC'/"JO+R6"#J_CFF*#NZRVSUT>N=R0:3).3$+\3"
M#J^L3A&LZPRL18)L/#A7$ 773-WI9&&=15&1BL)&ZZY$\\;(M7?47+,QMO!U
M>RD[=F[T^BPYRSB3UN<@$4FAC<^QAK\"MJQOI9Z:$[_KG[LE/"O-?LK,[FOU
MJ9N8^P&X&.NY']"J/(YFE[9O)*053C4LD;]9,-EJ>ZO8/K%L9+"L[.8D.M *
MP:M^]@.(C[R3=DL,6!GP8^ATK!=*G9<2$^HY0:W?BR"=0+#1U!F043'Q,2,J
M+G:=EH4FR]DI^Y\;I.8Z4V0/.#=2H4P<ER[CQJWY4FPW9MED;M'Q1AO@ "M6
MO_@&+N==!,*R>"+?4N;T-#RZ[!J=3ZL-^/6A'\T_6O2TQ?R-/MPS<LO+#8;N
M/@"K(P)/A+2'P,T[M)>XMX-MQ)=%.QKI(N]TFA:2W3=DLS(\Q!X #N1 C\N:
MKQS%:K*:&_/A.SV=HVX,S6/4_N]T;<1!S<-F/'>+MVV%;..N1OH]&M61>DW%
M[X ?V6FB!"EG%PB+_! 8A8S ]S^;P? 4,SA.(I7&W.N]0\%6 <-C_#HX**BY
MI7R%O#R9T6IQY6P;X2TF\_>H96QP[$62Z!]G(0KRO<O)Q.T9!"5"L+NG,;!C
MLE-&/6,1.7[W5%T:%+#H]  \969[;^7 %<[(X?M%/>8N+2;T"%39TB#X,PZ=
MIHUEY'Y(SU@T0QXA35SG4R0CF\N8O0E-[OP.KAKG[:I-6W9>2$U=_]''/!J[
M -J[86VAC 0MB!OL\2;9@Q,_?*"6P/5+_0WJOI5L>&-C8W^2;(.7M8(2T[M]
M5KCD(QG&ABO";!Z36&@J=($F,=QHVA03AI22M"EG%,WP*9+( 661/1%4G=<:
M8_@XP@/3C^\<O8"Q\PIGAXYQAMQK$'1;J#G]8'#W2RD2M2M9,MBM_&'G(?K"
M#"/8&80>YRM696094RA;8%.E+^,LR_%KV7QR)N.RQ*_6,^XX])UIT!% .\.G
MZUYJ!A//'F>@IE@YF=5H?8PA0S4JKTF7NV#SL[JI#J\S2!A'4I\S;F!@"0F6
M1"\SDZF5G=H^O1I_93LX6!KG*%9:<[0<_BP6GFM!:Q?KPA;;.W)TAW6**!G6
M+7&,5PO\8GEVTG]>W#5=,E$]]K%MY<)*9"UX2CFJEM)D'M=A,$YF@Q]H[^O=
MRQYOL#ZG-E.LK:.,VHDM(%HQY-H6/*_0;DPQT!\2P0L;;:1IH*A@/UID]U@S
MX'2*94YQN1\9NF-3(IVI3AP?W1YFY0LOS&7V:M:_^1BC4\[0[5V>;U[<A8]<
MC'UW%#*?0K41-,PSJ_/)^--Z:G#3=;?$9@(8OBLO,:DCC@J&('7$\ [RX<$.
M',._73R;M1IJZZJJ9$Z#;2OH,#:^!41+#-LF3GYGJM7D&YQ/D,_2;?[Z .#L
MM[ 6OC7/^\'=C7Z!S>@A&D=(Y\L%G9S$P>?_W7>!_KI9/$4(D07.%,[X%H@<
MEMM$[JE![" V"PYA*V<F%$MZ\30YQEO4<#NG5E6'SS&/\5P_G;]JS>AC*CM#
M0S3@B%']3>*PO.">+S%'[V5^N?Z"',]S+@Y"1Q3&+XE[ZMVQ,@Q1(")/G'S@
M"Z@0[%JD<AQHGW%E_TJ%/PH.*6*V%_ 3[SVIV$=XJ#0N,&W.*[1J.!M4%-F>
M*6-I4PXG)1N@RCV1)W7%$Q-K?"0]G]:(Z?@):[U"/9>BY9Y[WOGIMZ[P?AC=
M,E.A7 VC/0(] !)?91CB"JDAR-0ZM/G5XY..QD:9)5\28<6(,'OV9:\-W;4W
M29;[AC2(]8CBN;R)A#=DJEPA1FTY]U_./-=U; Y#TDEB2>DH  FO$8F<GC5E
MZTN>-]$B%E,<)*XC]P4TT.]MFIK_F;!+KSE!CCV3@SO%M>K]LL\7V]&Z7(H2
MJ#71G4+<1E95JHZU*PH-KSQ4&7L1-[UP6LY;5?I6]B4&J1/AO.BR'D GQ;/Z
M?D%C!B\IQ4)W"K?H9CL^>X;VJWUH216Q8P(HVO +I2XVN'9/W.[/\G;A#V[#
MA2Y1*U9Z+,T_,M+R6JYAE /O:D/,D?E?/;:CX!02B1H/0'";U .0?7@;^ #<
M*GME]6O$JRG/7DN43033[\E+(Z=F%_*J[5N4\Y<6>SYA+%]9"$).,BSNZ9$E
M3$_>RK-1:B)42EJ%F'\?>%W$P'^5&$@2O',\V!NMDE@!AV26V&ZKQJB,TR=\
M'% 8X]ABS#;TR2=_ $2UC-FR]VD8FP7;I9Y^ 7#.C,A48Y3&3>NE.^WQ7WHG
M,\0;U^[*A- \*6W;NQU)SI<JY*'55DL&Z_/7[U_3N/%=A-7V$1UPO%X3NO+9
M,H/3&N.[?2$[5K1UOH->H.ZA=^]R4A'(,50=WGOM.-CGM=3%+;L24D4@ RI>
M.'$DEE9JW^V77>*)09KN$XJ;/!L$&^;E2HX1B9#@=0$6L8G[[UN?J5WN7QR+
M"O/3?=6VJQGN\'RSZ]=1ZV:O(,8CGW8!5J@XZ%$;]/Y".]ZR+35A\I-RCHQ@
M,)5[^&KC]$[9>=5:1GZR^"A_?+ *R=HOZ"/1\[J]LOZ>>5H^[@G''-9 "F87
MS1PY1=$O]>.7,?3(GQ?A\3U9BJ5?O$ [HYW4+:RD<L64>."B=M0BN[]52[]U
MBNF#ZEZZC5BBT4U7=;_IDXUUSCCG3JLJW 6/;RO<[-Q_>(UW&6:GQJO)HM@0
MHDL0*=$BT5'_,DW$TUC/2(.7PM+<'\,K.2@#'KZ?X.JX^R5=_CZQ>!VAE[;*
MVYOQ49)&#>O8G399(@K<P'M,,_Q<S!<K9,C0D:#5R"*SU41*3*>[/IDGQ17)
MV9.9^_? XYK@UW!QBH^^EF*F*E:&5Z2$THSTRA*!B 'II*72XB!WZCVZ&->!
M]_;HG5T)7)-$);*155K$S6)L8&]MI=0,S+M<S!&:MK/,.?7JI>XA13F]9H@\
M)I7+WHR$_IDU,W0+/8N,D I*H>L!:O<\619$6C-+HQ1&;#,T8E'<5EUI7P3#
MLDR>_(E!U1T,)[K8Y<EVD0%G,"OPY2$<!TJG8= LXH+&N(6V<W,>D^.,L<76
M\E3DNX]O51P78FX8"L7V7OBM@E/1^^=S-;BQK2AH.EL_[)SVV)08C#A^'1=Z
M*[R>@3;DO91Y7IX+I(V[)A*ZB<84[4I0SM=$/V.5(CL5XH1Z96R"D?IV%M$2
M'?/+-9]+<%DWB']"AU@3OUB@_8IV"1CVGH&4P1;3I/MU0P1>-2A7U$;+TFV8
M1T[!ZK\ZT+B%HP^CU@3TH17:*IR63$>6L';SGXC]X7_F^EL8\G+S\]YT3_2N
MB8/B=*AZDFQ#!(Y/GT]'ZW%&MOY<_=BM;M+ONJV=%]WJ&G]8T':::A*HS7_F
MT$@/C0A2D]9?ZB!TX-"?36 N><.K/S6O0\"/ZS'&5]OLWKF><?GPV!3-[YSX
MV2KR+/(&!S V_RW'Y'3VW;.%LO5F+&YL7&=#9.)@RIHJ?P\;'GD#9JZQU5JK
MVNY\>UV]R&KPE4U0IX#+U;'1IP@WIT(;=E('C*'VV: &ZH63]5V[C"/Q^+_I
M6Y-,AEV?3@H_-]*.^G$91Q/C)-#0&_&+XHV758'R ^ S.G=?))PRU]B97(/>
M8Z-]-MB2$OF^GKV%M6KT (1L"XA35\56Q=(,2\R)^,%,?=Z$I=M15#J6[ZI.
MHCTFA%/9*(M/>+UR^I9(YVZQR>_>E)0O&3):7BB-8)&OU@B-10_97##?6T&,
M;<KMYLOTIR9Q?<%=I 7@W+EN9RQJN_&]/HZ>O\GA,$@?R1+()/<CX7C^ZTC#
M@HU:N1GQ8L&)8--Y^S/^0U'ELCTR;NG\3K"DL)=-,L-DUE2\D\<:NUA 8\,D
M_<A;ACK"[2[OK\BR9XZOGHV]4G\MK1YS8N/ OMI<[\D<91'>36'02M2M&51K
MBKB,+M0T+MG*M!JYI*H($=5C/^^8W<50&KHO5T,]$ ]V'2ED@W_WB%%M]%RP
MB" !?;1"1PL:\GKU_ \R[*_ "-XZUB*?=U8]9_WH8<'95__KV(#K-,]^HJ^Z
M#>SDU64?%!J\H:7-H2;)MV@C9X<@D[?%B*']P=.?:)9TL^C?G'I4&JZU3G:S
MF*>U^C[6LV)ZW@B#:"]&-^[=##J$??1#&DI%I>3RWC*PN0JV4YQOG%6H >"O
M:@ 5(*(]6U+[>[+6-%WP9)&?@>Q-XY2MP)<*A]88\/W<3.U"5/724D'$%#-3
MFTSY86<6G9'#7%!)CPOM+TE/ADF/+N:(CWE-1W>=3:QQ1-\%Q'1BLP=U7JR$
M&TL0@5FO+,(30XOV;KN46K/H@XKR+2,*]TRYJG*V-BD\3D?/[%(?Q3I1V1N%
M&[L7D'9*S6;8K*Q!\<F-K:TFEV.E?Z@93<0I:QOMN/RTBPSS5Z='&3FKQ4G/
M]S44VEB^]DLK.2,3;=W-!T#]Z2DC[3)P=NN79.NH'I@O-&*NM S3,]O1@'U_
M &),&L8:IF^E$36MP3I$"Y@KDJUB$1Y\I2O=D["&%KN;],*30'BB"!==ELN(
M2C;"K:J+BJO,B3Z/I:,D$A#[RL:=EV2)DV,1YPB4,4,C<U;)&:-WA5Q7M?E*
M(,YV7WX=X5!V5]GGZZ5N"YG_= H:R#XZY^M07F/WTV^P_G,[2>LI^[&E:*>/
MZ@%0@!<OJS[^P+413B6->M:Q'7/\Z/TRV13KQU\ES2_Y+O5NCA0C%FU633,2
M-QX M'"MBM3I!)N^[HS/#B/BJ2V:\-PL&S=2Z=TA!NZ8"D;M[9!;([ZE^3E;
M)L5>)ZH<<^;1@#VC>'!3X@>\ M- ;NP*VDF&9Y13@XY'E2H_Q/P=V!2X0SBX
M(_/B3SB[.LIU!+7@Z@WU)5:5,^QKK\E>IC/HZP8G;7IZ.$#$6D=.2K^S3BW(
MC\M_K5M4<I?Q%5/=O-W[=I04DH;<&W&&(7)W>2X6*L6GAD)R"63URP>.14[Q
M/NAH"RH)=%_XALBZK$5I49C&7<4++5&PM(5P@ED/?61APGQ=76=Z$JR)$:BR
M,W0SQ0!(J@@@ *A+0RX#7%++]K&.2N6\SE?\&(S(?11*U=_&ZJ[V?#C$#W7+
MU!-B<^/W82HSMOT;C_R5I*0$,I+!M8K/6DY$%-MJST-2&YO,2%Y(JL?UC&J;
M!-E_'UGM-6@9'J<=03M#;?@%LG6V]9Z,97L6@LG5G1^;%7S/?*W-U=E=1Z^N
M+TT=WZ/ZQ#]XZU"(_?5V^?>PK)MNRO)<_@&EA5P)\#ONGEV_3M"S$=#74YZ2
M]7(!B9/RF<YEVB"96NT/.LV.>'%$&;0',9^V#2":71-!FS ,<V$];?I:WT+Z
M4@U?LK>91U\/\GW-14P:_3C>4#Y3>QXP[,<U7?.%;B3LE7VG[Y85@[@_RNW(
MGA',JR<:3KQ7_'3DX#U$0D/^_IW6JGYQ^)9"=VJ:IT_S7*/1[_([!\VQ\X4H
M[FY% VQ<HT4%<1^']FX =W&;]Z;11R-L1H"P6"8CR51/\A;KC5%HL&O#JS-K
MCG>"C0W*P]O%Z$=8.=UL/O[]$'^ZHS>'.CH4V),^E:I#*>^K2Y".Q]LETVE,
MU0\ C__1+^A!W%\1Q2M]:TO34H;L5/(CH0.V4;:>@SQ=Y%QN_4V$\P"-T H_
MQF<,&?$,^G664L,%A@IMQTSAZ-N*VP>@ER4/>CKB^A_]]AO6N*@Q3NHN<2C*
MKDM"I "KB3HT:Y<!U%GQ<<,73'F@<IVEJ.UN]9QE@2WFK1("7W_TA^LP5N\M
M=*1"FU@#:GTU_\TQ/@*')2\5Q8@@N$!?3E7J]HM496XX/-7\35P/:-J@O>Z(
M4?&6(=O%\#*5B4:S&4VY\?3L7>UER(<WATJE_$17R0J?7_/]8/[@,AO8$L=?
MPHK(2_'9&RG:TQ@SM$%6[?*FU? PCL^Z/-^>G7*O;C"NBC_;JON- .DQ/'F?
M\Y?SRY#$[;%??X'B\]![/%]/1 GKC273UQCG2$K;%_@O%GU%("L .35+7G5"
M1KU ) .&!:FZ-'W@?VJ PRXG6/ 0GPHR0A]H(J/):[S^G5\C6&60PPC(_Q8J
M%]]ZRS<8W<.8MC?K(/,HEW4+\MC0W I9W,EC'LQ]4GXH2WG-X#^.O86CP.9\
MT.VX4 ?;?4MK6^EXD@RRE2^HM7M#)0@!\^6<!=BS/OOT#X/VAP93(QT\W"A[
M1AA.TTLT6626CT]CYO;ON3SPU!"BWPC>@,BL%J&RCAQ$662WV!F_O\G7PSK\
MYUYEL!P!37XQ0L<U)0>?95@[<SI6Q[J+99<%I9L[G[>SM\M(:S%CRHL!O$C
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M!#IN*K: B:Q,P:W69 VGS@ZMJ;/)*Y;WOR=[IN!A\1'--LM+?KW;!E+'? _
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MG.M09]HU<*KOA"F^CR:G22<2'%)RY4?XY<?]W\%='HC)#!7]E T,?GZ,CP\
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MW[\U\F\$)60C0^Q ?9(N>.(=E_0/3G+_33L<V)(.$"=MH]1#F^E],=F%5@J
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MYO1TZ8TYB>X:Q/Q,\BHML-*^SI.16/=<Z%!M$B:M_-I5(:-YKTA&[NFM:\D
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M,F?71<AA%;ZBBHAX"NNFF^RT2=U.>*64FH[L@(HM-Q&>M1-"V[,>0BK^>@1
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M@]E7:T8[40*I&UKVF>_Q^]!XZ))L_1EM"'_2GUZ1C#2<C)]UHX0WANHG.(T
M\7O'^T'=/@G%.9$'$OO8^"F/V<GI301 200IOP@"N>D)4+A >4:WY EL-#^Z
MB#T^!<'HX 3!RFF!=2'?;;17L?=1V/\\I8'SK65PG(KE;)3A%RL?6SHR!0U,
M\9,R N?1R=&.!U'3,S#>./4;^PU4 DYG?^GW+K;T#3YOZT%!SPA@TA./L^2/
M8B(RU_'J#6>)5.39?POK@OP^75SRITS*N W&E;>1/K]SD+ M(]JYBTRL/CGO
M]M$9^=08@$LXOF-5X$'E4=C^F&HU["ZN27@CI>QJ^UOG,?D7]*B%NIWSPJ\+
M+A]==5;"31IN%.W7105$U!1L'AT*<)7;DS^'S-/77QT:L*[:8G6N(P!\B.F2
M(;G)68IJ)]HF372"XTK:]2K995F@BYT%!"NCY_!QS;D"KTWD*#ILYT"/.J2%
MX";@;;UG.H58EEDFMP@C <T%ZU3FM6.FQ$2:CE8()=]HVX%QQM*?2RVWKOX=
M&;NZ(??;WUHM/%$@//V5<!B][?HA&?8;W>#J*-(9$[,IJK#!" ^OE3RWX^ 6
M=K=@Z7I9OB]"@;]JYE^8=/7QC)#[@PV;,SN:#Y2FV)WUA9;A(RKLS1WHD<%9
MEQ>T6921[V\35[U*C/+H5\)*JAQ9V1P-V0MC<,0YB$$Z5]:O5X>#DHKF+9X5
M+?;-5.:N8<FC$GV<>V =<+*]94Z!/ 0A"7R\HR7G5R%#R4=IXH@+N2:9-<IW
M\K7.<OE27(E[]=J<Z >UU)%NKD$^%&Y1QUTNXTM[D_.ZG4SN^<EV6>KGM?==
M5[UG93D%Q1O\1,:<V6$L__3T"_\,L/J?&M3:>Q9 C.82F<@'[8*3*9#.:<RI
M=-M=\L69O/1;YL]B 7P[/IBU]Z8A*>MJ=5V1#++[71MW\?IS MW,&DGSL%%R
MOD)!(3=M8<=F;^Q(4)M+T:-JV(1(ET-Y#!%X:UC)"S._9(J[EW<!KU/$X5.
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M6/#C4=&RMLY*#VV#GXFR [_+'5FY%/!%]\93OOJ;'%$*.B4F_ARLOQ!47H4
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M_5+R+H%MHR>F'0MEV&Y%]ZIG</("H]"FYM2$B.!&U'; ^/(@ %IGK:#7>H(
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M&EHD_?!C0X]3<(@/>GQ'$MY2\YE>R<5$@D9$H?)3D3-(LZ&L5@S,!0%$BQ+
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M:^4YA@5N&?,?DS[UV/TPINX,.[TX08_VHOTUM$Q:QR/Q$@%\(!S_82=D*R/
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MPJU<!J<:3&>-@(H4$<V_)7K1^J[O)3E-?Y.*'O0CZ"G;Q(D4W?<EN@"*B Q
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M(/G*D7M(JN9@MUBC(_,M=:&2[,07/B L&J40_D&E]-<G;XH;[N/-]Y70E*R
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M3)V\$%17><)GI/O-FPFE@./TS>MX?Z@^@?O@/W.NH?8$]XBB'5@K5L2C;0D
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MEL=F!L:.EMZ@&V3=E+NN8_YG=S?YS6_^GV4Y\!8!Z(:,-ZW/G43]*OZ(C2
M[.<JG  @H&MWN]R)D_UO[8S#4+=*8@PZ[M?#;G;5?' 8^)CQVJ,95SRV@2-9
ML&>@4Q22D%IS_?1D[XITDXC]0".( /2V$ !' G"JTQ!;EN/?JRBG+???F\C0
M-N/,"4#\9?638]@)$FH4T3YS&ZV_P[LA\F98G41_7'BM1;U7NL[598Z^$-8>
M;H&C.[^;4?WD[(^NU09?,)#.;UA=Y?"I-M"S^I_79"%C=];:HFGZB5>,^%JW
MW] %@BL3Y49?)O:D0 48S!ENI9*6P]2(!L8K&D5_W1"XGUHBG[>)(K^82UFM
MU).XX0,..J#-YVLJB JDQ>I#HGAO&&/NY[B3SU^3__)9H#:^[9N(2_R@^2=Q
M]Q("$!D(#-=S?)HTL?UF3"/4R:7TX<&J(AM@GN>9P8*M6$!L\-A4D.1]JPVA
ME8]N[6<.AKTKD$['C%=#WV0()G8F9]JF^*_GZBDSJGR\D>Q);X0.8W$63-P<
M3G%;1KZ0TEV XQ(;P/B:)GRTW1XB%KK+/-RT/MFTS[W9>&WM,"4B>+-D ;J?
M>FUH@&&MQLH2(@MY%L"3@D7G_%2B^^-;9;YUIWD1T*JF=4;)MGM0&)L$REKS
M?8@+VB< )X>P/PYD\*Q'M,[=<!?U%[-U*&98J*^,-'/X\OZ: SW9E8.NQ[,-
MQ&TGF_F10C8>*M0W0YZWZ,B R$MTXTBZGIY=*7AG\-,ZR@ZR:TJ#;WU& #@0
M@0BB4>AB(]?9ZRR\BLF9MF9F_%Y_2382G7T\3W16"MIU"=*_ BD0WA?V'N@$
MDQB3+F*DX4R?I^A6.RD6N:7U19G)R&@R'O"8RF '<G[:8LHJ$PUFLU'RL;Q#
M-0=&KM*O SG3$A-4B>HPSQ716)<B$A$<_GD!;S1<6)VUNA-Z=1E_61XM.V;)
M[2G<4^#8'K88F+-79M@U*Y;8I4M7>S_"UOFPF'.G3I!]UQSVSA6XU"29D;2.
MO[JS@KL]2U<^HE=L!%A46ZY:.*K/BS)L1P^>3>@'HP-%SLWOJ7/3Z^C<4LI4
M,)75'?AG?WI>^!7TU\N$)P)+0P!8?>?.W"..I;S 5 1@$;YN>K!])N=, "Y
MT0.&!* LC@!P94')H_>;J G =T0Q%/EN[H0(<0O+0 !N]>GB&]X3 %F$"0:,
MBSJI.O-1/7\:XRXX&+[+/ 9=GX3N<[/M\+.B38AW'N,55 9.B2'XZ-B&W7K*
M^0A<['OX(07TC(&%"JO'>OQ;9_[F-_\;B4)-D?[PJJH)%YN/,T,G@7@H92DO
MYV4'W9VP9;1*6H9:VXXG!UH]/,NX],>>_TV0:#=N;>F_E8L12P7,.Y&M/2ST
M<<F9/LNB%TVXUZX"2DM_;7'F9CCRF+:=CPS#_D6TC:W TFR+7#K*ZX6KZ4Z)
M/]/*\=Q$_%:_RXI2%?YX!C9<2^\>(S*G*NXN0M?]\I&FXVW3>Z%(GFCFH^)W
MSZ9?6-@$WABJ%T'RYNJ3FKM5];5'MU2N,/.+GG;EE]JIDNE2U0NV)[2CR6*S
MDB*JA4[N&E$HJX>;4"3,]T^QFPVPW_O*30#F;GTYT7W\R59'7#A*WW:\V\GQ
M=5SDFF^";^)!\3M-AX;F 0=2!3\"4%69]!)9%WJ6.9V5Z+SJ92YV5'KU3NX%
M@>)"G3\JN&*OE!GL+32]YEL15,^694Y03V)KA["_X"G*3G%X=5DM?B&&\E'W
MB- //R^QWJ@:Z"=T(NS5>,7UYPW-_7"9H3*GQFF7W D5K[A9_^3OPQ;FQ"X,
M:!#XC_.<@+_[*V1^'G;?Y#5VWY0>[U4*0<W2PCS%K0&K,@T9\@31Y4A4$BW:
M@_M[VZW@M2M;W.FQ;_-L7253 C]:VFP]Z'.ZT*GGRTST1S-(6KAYEBVCQ:8(
M/$]O2OG'YX:&6OD.5PH! 'TS4#OKOP=K.K#%[5XBR/">H5XSF7MK/IQU7!XQ
MI%]:@Q/LOWOPA->,<B7%NJZ GR(]+R>D32=,['Y[]:104R/TF[7<PAS-3$"M
MA'WWTWA%EYIN#O519,!XO3Y]<3C+HS[?\1A_8?+[#'M[M&V4CW5AV3FV'0R6
M](5::FDS4V,W5K.C]F V?W;KY]_\YC?_C1X,RV#YX):AJ-7SHH ^'XVE&"]I
MB3I2,KJ/IW-BYS9@Q>:+6S^4SP;>]ZWM(9<V0NK H#4)SN0.&.5>(5?UII&'
MP4C95 ^>*6S@>_.\5UG4_EG>0QH8J>'$>/2 679.B&7&K)C6SAK37B'/BDG$
M9+Z'^[G\ ?WI:O WO_DO3T&9I1YO;GSLA4*Q+)[(.IYO?3A#3T>/&DTQO=@6
M/6'>]E+AMN]='+&J<J9*:I)Q&AO^<G89P[GY,V'7-72L?/E"A<$5MJ6OVM^_
M/I!J^64L[.,5[D'YV9Y:D']W;M'LX)=)C@FKR'L.P]*/!SZ64/M'7+6#YR)G
M48KJS\^E_^8W_[4IX:,S+FV,N$T3_GX)G.Z()$77-2"I#*#.3KCU'%(*WT)F
MGS!3ZXC$[?Q9EU$-.;^5KO-5+T,A?V<AN(58#*$SR->9E=-V5\Q9I.8(P556
MU\((2_(\=(5TW^RA/"R&,:EDI(^O[G\MPO<W\4PI^,E=UWT3\&\]K_0WO_G-
MOQVB/N\N[8;AIL_2'0^3#ANL9L>=D@S=5>M<=RD$@[\OUQJ@ V\2@-Y2 F!.
MGH\?,$YZ^/5<)MS]NQ]'$YQHHHEBRO$J-1(3NSJM,$AC\K[P)ZFQ".JYRVO1
M$U1]N((MNY5Y@IH20OU^>)EU6+KVL!#>W"8[ZH#RGSP,[HZD'Y.S<BX,;6P6
MVKYW[-9Z;<NW8%85Z?<=<CY2:"/%"NV3=W1R5B:$<^)KV78I[=;L5W@TW9=1
M 9\8OY8J"QK+1MTIZ6O]L[M-_>8W_Y=!P=4%ID+O&,]4?+-%>(ZT6UQ\2D7&
M;)Y5INCOS12^31XG$1\ /\O7"A0C -_=E D PHH #!8AVQ 1>#"&Z[4. ="H
M2BI[VI\Z;&5"K":NT\.O44==\<G?87 KCWJ-3E?G9GSD90Z-@T[*17)?5GC!
MY%JEQJR>49>+T\V>;B:+ "E8@604!@KVYZX:+/\H',#H8W#%V3K$DTR&B^E=
MD+B%<V#-YC/_Z^/W>7$J+KE;O/8>)(E6WKHFT1"RT/6N/*XKU;,W_?IH@\N\
MD6VS3 TJ4H;/3J7:.CFT=BW\"]E!2<_%"_/>=S8RARJ%:J7JA$BHA/&2BM[*
M!>;C7CM*PI3[>ZT.7"!4]=[^# YVR>.%+C[N2H]NW:+69>!B\44SL#9VJ2MC
MML.%ZR8V]L^T.:KCXN++'</>,*!=HY;\C5'@".D[P:\\' RTDJ<>?]5S6*)D
M6&VF8: 770D=U)877PM:Q1&C.3#)\;P_# ,R4"22-<^8$9(A^;^,M5WAE/,[
M[8P@1-B2[:;.RT3UVY^]XH! AV9/MLRN=5WA 4:L7YM7H76Q'=BZVKN]*.,I
M+(D]R+5(05LH!?GD\AEM9+%W6]L48^&HA[WWVP(/.8Z)PE79,C7*,N[&5/0<
MJ=W>E5<'Q9Y)C6LJ']ZZ19//6YP^_P;*R?YR *>U,0'?\E!5(_5BNRV@(@V9
M,8(/%]EF2.]4?H'$6Y=,?U27>R<D!\N<O:P^_%:J>77UCZV@NGQ^F!NMXOY]
M9"<_+XW.'W,/P_J(:/V4,-"(@TZ2?+OQ$45?>4-S.);T!?[=L1Z3EH;1=E2]
M?:ZW++VAAH^)?M-8RX5P5V+-;H"R,(MG@UA.SLS;M&-*]VW)4O4(JXS9BZ\=
MW&'N T^#%%M:%ED[JVR%'9K_5Z)/?ZN'7)JHH,OGK^67\!$"8%W64[@1='Y;
MW-]S7\7@C#-OW)-"16WU A^7^HQYL#ZLW_.0J]J\2@ D&9?69UK:DJ/VI%4$
MBS?Y!7;_<#S71/_'PB&'DL\%A.J'$8"P_LZ3:SRC+1<O4#Q"T!%?9#Q0IYB+
M>:P0UGT\^,IL'R'X(+_BB=^D,#3J[8%\Q74-$_WM_TA/#N:YM_X.G[R%>9DT
MPM=,*^BN\([IQ53W>SW [Y2NJWQ O)JO"ZYZ+&E_^V'1Y^^0> 0)=C*PBO5^
MY3<==H.IF+:A#XFX2B1TYZT^?G3GJ4[_9$KK8Z(!C],>*!L,2VZS8/.)V,^H
M+!@#DL=P-GCDZI5^SY@QKN^FEE6D#4G(=^$J\P%%5: =[$]!+2=))XV3K^5%
M%5^!^1NUV5;5H%=W3,.]", D :!RS[]WX>DFR"(X?4UF'3]DP$;:\06LJB%'
M^Z$UZD=J>RUY/?[IU&PJ<X.(U/!E7&3IE?NW:L.LJI+%L@.UT2]Z E]KO&#/
MCAJH1+K[37^SM2V:&' 5_/"R6MXEMNF.&"I(Z$[):1]4?N33KE.%/:F^[T;&
M$G73;;N9AKZ&G[?M;5$I;$-HYV;\[;=$O+1PG[+5$_=//)LZG>./HG./KKRV
MSK\X5FQ?9S]!YZ?R)C^L<2->U!(B>^<SC8:<@+YYB$B"/ITH,J'?F1@M0YG]
M%;IP=^<HY25^=AC7K'CW\/ONE37^E%$%)39]-DN+%U>_IH50NL@%>5SO_A0U
M2\*9\B3JSFA=W6=M;1![@B_ '9;_QEU5=LEAHR)&>MFS6R^K1L$\5@T0RR3G
MYA%?:6?D31J8+#N_1D( 5MY5W2D]IDFQP+,/EOHWE=L;N)N\=%(7^'7#=3$Z
M.D/^$<.AT$;S:'96>7UE4Z5*JL0;1]XY"<NPMN(7\_.QE#>C4N(NT282 !+U
MB/IMKE,_E3TOA\G#[T?6G_@S*DKE@O[L0/%O?O./V-G^B]*?5>GKWJ%R([AK
ME4=3#3$E*)2L><8"VROF%_/Q'6X$@)D +(KE09'?H*O:O=[0A<8:E,,M82FI
M#5RRI^I71>U@<+C$"5)6J<5( 8KA07'"W!;J8L"*=89U;TN+=N4%W@1_]9'J
MY^\RARNO!%ZU=?V)+4)K+#ZR==1*\_":I_S.C^->?K\CH9'PQ$%7JS+\WE+"
MQ(U7OA9!1#@"P'C01RPS4O\P[Q/\TZ,E68IE]J7T-\ WUL5YZ-.K[^]T2GX!
M=?Q3?\]?U@3@Q2(!&$K0I@3A).HQ:;Q^'I[C4^[LK67R*R\O.V?N@]C@@1(H
M M!) (Y9[A& #6;XB8#R_G8X=2Z4HCP]ZH9K';,7I_QR:F(T;5#?CE?KJ1,)
M-L3XZ>S9-^I75914F@P0[P-)=)"\])Z+B1.&KX7*6T?%L-K)(FU.Y:ZE.\CQ
M@7?7Z=B^G ]EEQ-V;PBRGCO7S6W&N7@9WD)Y?&T;LG&; )S<%T?_S7AUS7<>
MXY_4#9Q>:<*_C:W>CB$ N^+Z!&!"#+)OD:2!9Z,(\998"$"^=1\;%Y:2FZ_Z
M0!L!\H^]OMD]\*@%].M7U(J_RWQW/4-1QRNDBL?%7XUW91TDF:D4)&&(_.&&
M@;\L^)J7%C]_M((\ 2A[3@"$LP4=/4%,+7 *A*3+Q=K&G,+NZY=PGU>.OBK+
MM"QF .@R:*DE]JAY&'O_<()W8,KAOG;T<]JIYC*!W$"VC'.-[#O0,G!,97YN
MK7Z$Y)G[NQ. ..EX F!*20 RHZ[/206M-M+:>QG,A>3X=9,E&O2.SYJQ?P.N
M1R>.+@3A>(*Q%>BWJ0UJ3A03:N9?JXX=E2T8++9R"8"[KY?8>H<[! 1=-!IM
M6M^ KEZH=],5[$-)++\85CMRO79U\=L-J;JT(?HR3^(LK/7\Z$E9XB5\80&3
MNM3%R(LN6R]R+1S9=WR9H0;M&$3;C^V+QXQA#6BC*:$/^O%7)7G'W$*@%R@U
MILJ;%KBP%01 ^J0*?_4& 8@9(S<Y1>DTY$N%YYD5J]LM"G(=FOR,<Q73:RDR
M0HX%_YHCE33CBRR_RXM(:\PRKV#I7M:">,":+H(SI=:)44>A'@[FS\K'A7YX
MU9%<J4J@#S=V[FT)VI)^">%^.]\?4?S+]U/A_:Q/L_KM@]FA+C0*-56LP4$#
M@>D0QL.KW8WZ,T1+!.!*/;APE<>O<"V>R;I&@]D9,@<P)YM-5Q(CIQIDH[C9
MC],[KVO(W?Q'&0/1N3>0/1[H1)LM ?B&M#1R:@<?)S5MF)6?6PWK7XO\_OB
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MRU,^1#:OU*=R7_K\E%[!2X5B&4]DZU?F9U^[#Y TYG!*SBBKSE,,E<FNS$G
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M5>D7AT62-,#P9L#6C#>S5Y]G$V4CB_K\F1I^:W>+)_'V/<_EVVV@8KKGHE)
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MM=L""?'"9L%%9M4[TG/\994^^S]^?1IV9!WWN0KBS4W52Q+KU#I$53N%9=S
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M3+G 2DOB=$UO2:UJ"#R"'.9V\6+Y<!NY>Y$$W"O=_;)]N41&M6.PA]<OP 2
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M36[CGI]__1WT"7X+Z$@]_P-02P,$%     @ <X%I5J&['>T4D0  \JD  !$
M  !I;6<Y-S X-#0Q-E\S+FIP9]2\=5!<7]LMV 1W)S@$"(3@[A:"!PWN#DVG
M<9=@ 8);@-"X0Z!Q:-R=X-ZXNVO0F]\[\[U3UZ;F3GVWIN8YM?[:N\[9Z^QZ
MUEG/4[7/R_S+&@!/459!%H#P"@! ^'L!7A8!T@ T%!14%&0T5%14='0T#"PB
M;"Q,3"PR D)<(BIR&FHJ<DI*6@9V)EHZ5GI*RG<"S*R<7+R\O#1,0F*"W*+L
M/+S<_]P$ 1T='0L3BQ0;FY3[#>4;[O_E>.D X*,AE"()(B+0 5[A(R#B([ST
M &C^KA,9X5\!^#\#X14B$C(**AHZ!N;?"75X@%<(B(BOD!"1D9&0_H[Z_1T'
M(.$C$[SADD(A5#=#I7,BX@Z,ST&C_U#52:PQ<<; 8^X<A(Y!\IJ4C/PM(],[
MYO>\?/P"@D+"TA]E9.7D%10_:VIIZ^CJZ5M86EG;V +M7%S=W#T\O;R#OX6$
MAGT/CTA(_)&4G/(S%9*;EU]06%1<\JNZIK:N'M;0V-35W=/;US\P.#0Y-3TS
M.S>_ %_?V-S:WMG=VS\XO[B\NKZYO?MS_P\O!  BPG_$_Y 7_E]>KY"0$)%0
M_^&%\,KCGPGX2,AON% (I-11S9P(Z;@#T8@^Q.=4=:+3\VB<$9L[3V"0,/"N
MOSW_A]J_F/T_(Q;T_XK9OXG]7[S@ "Q$A+^;AX@/D #<WK_+#<#XWPA$!47@
M.T!NQ'\N"O(+LE]%O/O_)0"3&A!%P+O<B/]4, .9;?_37_/_ A!CSN>B.%K8
MV).P0[[I))H,3;R7W_YJ5@L0+RAE']N@KK+9$*%BZEFA?AY]<$$*U4SQ7%)!
MK2*C==ODD]NX5V4O6I<_+L!;XEMDU<"/B_KD*7C#EV-Q]J#;?$X54['AC^=O
MFT:RBJ3>@V>/2K]8C%HD"-6(9<\5\>(#"Y-8I:C5R>K,=Q:J27M3>S]H:T=7
M&"^O'&*6+.HOP/64J\F2MPV\MT,-LE*R#V/J=E<HSOI2-CC"Q5G]5%;'# R@
M$X4; /.MK<V*Y2>0D.3ST%U>QPL@-G[Q&=+*+E,Y!E16[%,*@2DM6J?..?=5
MEYASI0>F;V2 _6P\#?67.X6DP_#E*8"W_8IG?A;=$+>B;RUD7F!"&0^_]]">
M@UT7%,3V+Z[$XX49J*%?69?@>XY^F3SY(F7O%+#6%:B\+W)C9)9PM863OC<_
MO&F%O9:X[!\Q>@'<CKIH@W::,5&F1=^P7<H4]KO/&<24.!439=#01[?OEH/V
M1"CJP[J3YU(N<BQK]6R2#-[+?ZI!7'+C+<!1$UPE]U6F)CZG)#?4!CH'$I^D
M5Z%PJDK%W.V>$X_?-?= UT_1E:%P&:K15=;<&KPRLH!1N:H*\CH_@Q[UNU@-
M$VRC WK=MW0-L?D(!K0X0GVOG_] =687->^(_:R$)$!3UA$K,O;-OKV+6=VQ
M=]@F=.-R5?IV<8,Y<#N=!.DOB9V4949=OY+5G!*O2]56])<6T[ZSFR4CI _$
MD'D>#FRTN&@I@>5ZV[ GKQ?<;8N4PF?(AO(&*Z\EU/)> '.J4^9UDX\N&WX\
MW1?V$Z,I+,/DXG>3RL$Y]PD2!"*:%UC7>:7[>4.C.<"'TVO_-I.L=*<QT>DY
M ?=9=2^8#KX4M5.;#@;/-=\:EZ?#)PEDRSGR5?=<IC_6K,Z_&!9K<7[V^1/J
M"Q^EZ&=%/'(!/1R0KR06\ :)6[<[(YBIXD[>MCI+4&)\'?' /QYVL[]9!>IM
M\#]X>.5T&GKO%C*/CQ#W*+$2Y%?!EEU-.Y[0*MC.B*,4S#8RQ)]W>EUM1A]\
M?,:XP(%8E/9'G,(/.MEWSE-*5>-LX%H@B;(8PH61Y0K:DL*?YDM(. O6=&[$
M>\G_63)COV7._[=>X*CV&+-ER9S;!^?)@2BK#NRUMJQIBV@=1:X+SCTB[44%
M?NWQ.\+[N0]TQ)5JJI!1-"TM*E;*E3;\\E.>1<\R\G4T] =YN%G/_?8&K?Z$
MM5K>E79[-*&&/[YSX'M8UAEM5\L]?-9;GRIB*O=7G)&Q1:U>MB/1%ODZY^'@
MT'SR9Q)I;(HQZ^UV&?_&AL%/#<0H^=%7Z5>[!5[$T)C8#9H(:L;8WIC8&X>$
M299P]W>QT\XBIL\,<]R70G=F&RRZ!5ZUPV!MOFJ/+?#@ $WHU-VD9L<]@AO%
MZTQYC9OE@BA[5X(2*^I\FT"5NM:ZU@\W*9Q+M()L1($=XNDZ$8=?"299'U77
MFEE\W&/8/G#"K(Q@RN,9_6(7+MJL9OXX=\W]R1 "4@)LWD$LKL20+\P#U'E,
M1,[L =XO@)N,,/CSX,VA0^TNM2JD^?+YQ$67O"AB=^K1)]_3C<W"TR$72&[>
MPQW?G/T"")A+C&;JZEZGN1F#$S[XN[\ 1,;$'=+:3S;%N,8.(7N3/J59W[\B
M9#YXP/,G;Q4-2LPK!F]Y_^!1ESB5S.L-51FN+$K1^TTG:&E\#8!DZN4&D4#T
M" 1_6&7, U ;*W#/5C+67P!X,AMIIR0J89HQ7@@\2G6Y:C@84?=1'GO(5B-^
M/AYGF]UX=C6?>&$SU,R&B;]98&3BP1RQMW[%-^9B-VPJ72YXH?=P:7;?RH22
MU9B&70@[GPBF0C)+VJ&MI4-3@N(OU7%"8RFVV+ R<2Y/=QI<4M'H@@)YAI6(
M!P-2(='XJ&?BS]W>#F%U#R9$)G?5KL*_E&D9@>ZUB@B=ZEF&,4^ @@$8V?'4
M\J+^-X'7^!\ICS_3ARSYH7A/MLZT>*#;7_;4- S)&J*8'0E#_MSOG)QLKJ>$
M[$R3I;Z9&>IGR+H<P!&ZHN%\9*F;/06S/PMX.BZ.$:UHE89Q58(;<;QC[6VW
M$"<L9VKW[-N&&7/L4LCZ?TR]^_+$ VDT$5H"1MJ ?QFG&;'TZ.LV<K =>3"*
M?!L<Y8GKKLBA JV("GBAY*Q#^4\6WLJ_A7T(9[&W(MU3]:_PUH@.V+ ^OPTO
M%U4J!0ISA)FVD?L6D+4\%=D[X@H^L=AT/HM&]KC?'A8;8'-?JCJFX \S#34R
MV#"1;N$'&[*G%H'N8WMB20J#R^0*!VIVM#V#3\D$$>DCVLOO>)[Q54,SZ2 [
MUQ5UF#LQ2N$+CC@,J(CG#(G:T^[X*X?/;_CU97[?"U6WMX69/8@8YF(1H"@P
MQ6#;+MHYIBEIMT!65G9T26R^#[4X)?>+!HZ)SVPUC85<02G6>B AT#8.#C!4
MN:>L)V6XU&-_\'COW71ML[)%/S5*56OL[_I$N=C?GS8=,?I1J1I*MC[9E/N#
M@.U6#SHW(44+M^!+W^V%K$^[9*4H&\2P!VEETC#[4\[*Q5C#JU[/Y,AU,>K3
MGA7^&L@X7V%F.=ALR;VGA^8GUC4I0%NL=WDI"[.%PW;4>-+H@V:2\8?O'9SP
MLN64Y/NO1$^0$_H]%H-%@[W?R?_./PEU0Y2*<_);U;IS["U^_HM%8$K50I<2
M)S?7PU:6O;#W+&ZH1:+D^<S,M-.^OMNO>9%EX$W*BOV'$M.[_LK[KWQ*FG6>
M7Y$Q!\-.KS'7O1B]$TZ<[A$^1'RRD7$[)^SUEHG2+ZQ8?[<Y10$$FC<B!2SC
M"#V!)CZKUX*%V:2*Y*$%T99Z;TWSL+BY56=;1'H@W 9WXIC[HHYNA 2]=,":
M 2K=\XMC[,5]>*W;\'R+S 8N4F=Y<>U$>5FR30"7?,NH+,^\8]X\C3<EX;Q<
MM8'1HK',#GQ)1M2K[RZ=\[%7%IX1M!PIVU;_FF%SD+O\\070G#X7KX]V1?/=
M>SOKFPF_M&*"3@03>SCGIW+AR_2OEMILR8GK/K'?;KU'9KKXVQN7?D_1\"HU
M;ZOQC,KBJFS=% SPK)17@%DM"(R6NNV_K?%6(R$]*:O-M,@4[9,CW0__3ES\
MV$BM5.H5-J'BJ.Q%4@'R@Q9].REHG*K@4R^*AAOGSE]*#>*.(C!XQWF>JAOX
M6RW?$?9"7&P+^RXZD]<W#4*3WR:^E5+Y:NC,E=CO;8>&:S(A*F=3ZNF^J).@
MRS:IB74PQ8Q/^,AP/]M5:8653TQ/&]Q)O)-)/2'*)-%5*E_'! L:79/CVWS*
ML[;>I(CQ%,5AF8 2D!ZMQ2P%8_3E<N,X9SN-3>8JL 5 (MZ5_ \M-HY-ESB'
M";%RJ6R],O@IRV6+P'*YO4),<%\N]-&X[<WL=2NO'B^J4MH0-YF 5WKE*%?_
M7S?UNX4XSS-,:[I%%D[S7:(Z0>2&H"*!X1*=+?@X IIO=*!/DG1.8MD,="-E
MB!%H4J^M(2/3ZSB>SK*;Z029BNT)UQ!K(\5D4R=%FFVD42GUW(>&?*DF.\+C
MG<0/&7S&/S06R ?"D].?*6=<,[@W1G<4B N:LSY'02\H[2DP$5>+KJ$.6'O\
M).V$+9_.Y5C$$[![<_^$G<8G9IVZ\382-,3:KC3?V%-4933N_*@N=^XPM=R:
M&YGEAX36K!]FN.H9*_VJF]V>Q<F/9U".OS@V%_-7AS=%FRCY$_DJG3V%EC)4
M/17)19_T$&PZ(<P'R)$RN.=,P=0SQRUEE+>GF6[#-VJNC_5<)7!7#MIT,NLK
M4WTKYY=C%BI8&\;+KDW"'3W%[S<\KXRX.[\.?WG+LE./P)"YF^"/D0-F@+C%
M]N#BZ"\KN>3K+?(8I-+X)ZLB2SWV/Z*$ ,2"NYN&#I^IJV>^,2(WQOZ^&+9?
MO)N%-#6=R&(5-0A5H#=E@MIQ?"7.'N<T]/=U#I\3]AX\UBN)LOJOH6F@CV>J
MO2)^]-VWA HV'I87JK:3*6B=NL%CTA?!=P_C:ZCE#D:+'MCSHSRCS,Y<Z5'>
M<V-PXY2B@Q< SG4[T0'YCQ? 8JZ"A,]-$$8Z%N/2!06#Q>/[GIH1G_6QL&>:
MAN;D.:5V[)L4N<5VW(#\9PDH]=AO7"\=':.!SA^WJ'31W60#O5Z,61:O@Y]9
MX7O>5+]'BE;@/$OPVH*>+\3?1:]$$>\>9AU"[?'%,>Z*?+,Y,\V&71)>OTJA
MI88;:7GP -KRSS]4-X5J8Q7EH-*UO']0:9]N>;V6\^7,.-]]JRWQ[=R/.50F
M)*R@9;2-)I,0#VW. TA;$E5R0>%*-L&@F8M *I&%X!]N!-3XN0HB03U#G**^
M9RYJ[*K:Q@?$%8K4Q[A(QBX<]"OQI##47F;:F:,CMU-LDWU,UW5ZB$5\@J-@
MQR:#W_N4OI$7P/P]1TKT"P".:.]M ^P_5!(($C7; !NHI/1Z9V9^^5) \!V*
M%]0?(^S1QY/5!5'?;D:<@GQ43W9#%-R:%4^$KMB1MY78..4;ZG5:KYLWQCW"
M$#-U8AUF6[J5S^I2(IZ9/<NQ%0UB:PP^5;,Z*6KRG =]#: 9S6$(N\O/CB,R
MQ;HBXW6F%8-YGV VV-/3VB0P2[,0$ ?2KJU=563RL>&(B72*$\V![4_I9SBL
M=5?6/BUH"0$XLE\U^1AQ2Z#Z&D;TR_O$TH&Y%2QC%##_Q!#'J'A?9(^O[Z!6
MG!H]"/RS^R-FGED]-MV;GV)8S%Q<BHT+RIQ2%J.7#02/C5];@(I!7ZF;Y]JZ
M/=A_S8FDZ @G?(RKEWT-PO-YSB/>9V:;;=T\15\T#N'>AP/;&S$Z Y(ZU)P%
M12][<4A>R=YE%(^5VO$+VWQS<,.M'!T?.%/$_2#) -X4Y&M?>P&0&WC6L]09
M*)15L"XQW$RY&>Y2/J.T3'7KVS<6>Q;U9LVOT"G36UUZY>3B[FQG47E;9(TF
M=GM#=\.@CRXV9#&'VK#P<HK/T<-_P@1WQ=/"[W?%WJ>_EJ+>;,7\@=/<_]9E
MA(4[-]D:(Z^$Z54+QF;WO5]*-Z8#Z>(!3*F"1._KQ$V0DKP!,M>!1,$7$]%,
MWO.3L+S#6X)NTWM##]EEFF&"H<'$^Q? ^TQ5KLPA-%,TVN E#=;X&F(=C>YB
MU'ACCD(YIX)#<>ZS\L0RTMKYLMM.T<MU<+Z(K$!6\VW$,W5=>!Z#.,7TE1+4
M0K:M2MSNVPPKAT#!!%,I8ESW')!2_:CC)DV5:'[EKORR>YPU=&<4GW54ELB&
M5/W "UHIM2=507VV&WJU>F<D/"UCA6E1?X"PD\D SM^=]NV/N)+ W2,WCBVQ
MN]5^[:S*=_4,[N+-Z0&/ 7 R5/4U%!#:98@T >HR1/_W,'P!1+4HTX3PHO.]
MHO,:?B]-% OS(4!X#%5=_SRR,8:[N-@O"N]-D&,PU[1X]R=1Q%E,5HKHJ&,A
MMYJC12M[/Y?>IW2A>Y<V@7,RJCKS&ZZJ=Q5C8X$,R,&-,<\N^5;BP HHJ2?(
M%#Q^ADUB:I);4SOBHS#[+>S3-+C\L;U]6Y["83:G[EPEV*?8+VA1IR;Y\*UO
M_@\"^0/4BG69GP0'WB@I96,VXCFV-8/6SY98>J%] T)KE^-N5]#W_5-U9/FM
M,[W+R\%2($[-"Y.=</>M/XUKU"\ Q43E<^K(LD]G^_ "Z'0Q]R!10)R8T_ZI
MS$_<RO':$>[GF_O1&?/&5O M 0K3;]'T"T?AS"1=3Z4/^';J+P";PA%EV KV
M\<-4@K/79H*W>7B+R?JPQ\<4@RI9]_<(J=[!P5>[$050S]%^N7/^Q/QAONJ"
M-0^(3@JU1L@?P1> [9GXCV-:CK%U(X*#H:Y1$+*/GUBP?N'-TP*5R.7=].Z'
M*9PFOCR[=C@+S0^F)1?8%%G_OLK,G!98+#3J)MRKP70YE#GF!>"1/D<(*O.\
M..W1#_V>:(LI%N4T<#*A5!<<%>4"(5Y5$]B^\UE7N*8O5LB3M&%KN>C$]$X:
M79V$.92QN;&@E]EO7+(5&L52*V[["786P2,#@6C-7&D9P2-<KXCJA?J\^D!B
MHNK9@R4O .O""NNYYOH_=.K-'D5S\*3%5RMIA7I[][[:Y+Z8R&5Z"^0)DH.#
MAV.?]30\F;H3L"7Y?_Z<)A4;)Q DP%L,[!!U&2,MA:2$\RK3K;-=4VE,SMJ0
MH;-F4WIO5OX2KF\7RPH7%;$ ;PV"2WASY0X<2QJ(:3<@#21U')BVD+XTY)#G
M+*+9FP,28H9@4D1$+!PY@$>>TEE]>)ZNJE71_KD4<E?2SU<*<?@QNNFW8@?M
MP77-4/^/"1?'%GHD![J247B<99('WC/-IP1[$*MN@U6[^N1+9K6)P7=8F,Z"
MMWE& 5&>JM+D".,A0?[6A V+IU]L1)IVQ;P.%4KNY*1F6=G**FKWMH-F7DFB
MO\E3XP28NHSC7+.] ,)KQ=B/V1SJ0$H^H8#O6S\0@Z?$D_@+H/O>8BT>Y-%/
MK;4:E/3R:P[WWA/%Q$<M'+G[<-Y[Y<(L2NW/)7IY&OZ>:)V#HZK4UR[*4U^N
MHL59,-$^\E<&$7 J]*EX9WHGJK.WYK=!FB(.M L'?]*F*_+;,P%LYGA'1'KT
M^:$N;^NS2N!+(S2K\OE8<NV3R=G "3V!K^_&RSAZHU<J;+ G.BXR3='&/OWU
MW'PWC07 *)(']?IZ1@E>=$O,I%%NGD4&=6N4$.(/8_J3UQ2H;37M,,@$3YME
M'+&AV^#QW;2^33BOD;5-F/(,FWV!5$*\/'I_N=B[&D2-B,&&<_$08'&T^*9.
M3<11G&C*3Q2D*]3QV3J6_TXWR!4_*T@B$ZG_"V0P.$I*B9VV=_1V[K"'I8?!
M@%Y@U*X80N?^2K2JY.1U9)I(](<)F^3!QV%WUFX+2\HSKSWA>ZT_Z?U(,<*_
M$GBNRI6ZGD6FW,0(/_E]_EP9K-G\*<V)UM@##P5]4Y#*+NE6$@CZBG5V^[V<
M8%-SBB[3C93 LA1_3S$^_KK$^JPPQ"F'/9PQ#??&+JYKV3F/ODUJ%/311+_N
M01?S^PB\[RWGR9\NPNCYJS%BQ$.(II*(0K'!^T[.((U) ('TA&K.EI/B$5JY
MJ$C^\LJ\L:IUA5/1N=WV3R]_%:_]E0R'['WWIMY9*'8N]&D2*1/<DZ(>PZDB
M@C.#])7M[&ABJ<5[)O(MC(<SPS%8</=\HUS7[MZ]Q-SABX-I0QW9,JL]1KGP
MUDV>&I=<=SMZ><'->:[!GP?89D;J]4)&>P'(T%;8:K8&5#IB6^%O5_ FS0D9
M88QT5"1SACIC XRKTP0"2VC5-F9(,0H6(&U.XUSA$MJ"B]\&'<R&'F_9)N._
M8S7R9(G5_WI&Y*:*<&>A-XU]_9R(!6-U/L%D?P'<5LK:541=L<D>=JOMWR-G
M9C X<6);N>!=+ /6.&[E)12GQ-G/]J:1 V?+ODX;V*3L8IU<W3]H\NLOS_3'
M\!F1S7*!06"LJDI4)[;TK=TB(G93P0IL3R8M<?8I-R4H3K]TU50>N-)@>(>W
MW&50-//I >.H3A7!\U_+N(G'2OG7,BZ?QY&LZ^JP350FM2C4VF!U.*0Y$,GF
M^JATFW$MH*]ZCE2A=(E2J?[;'X\R/(JOVLO%@(T*!XBG+6+Y=OH?]G7<\5HC
M @CPFC]8%"ZY/KZ/R5KSQP;J:,.T]375EO1WA^+UJGGF1"_O=FHW9UT'76M*
M"IYJ=!$:EM!E.\1;W[,)_$VHRH2VC+_Y]%W6\F(+*?N:OK)D&JNT(LR8L*4=
MM'!E^VET,0MKJ,Q/,3AB/S="T%P^5T9^'%E+/2#;%:#]T9C][.C6$=X+U6VY
M#+"0257X<M4_6W8 .4G*I>,O*C: HPJJ\DL6M 6WXIPZ4EAD [WM"[R*X?JL
M.AY%;CV!/U/$O D#[S3O,U.LRO8OYNWPT(^M^NX&:2DI8^3$9&3=H*RZ,OY/
M.> ;A9\,+G_R+ @[ %<C<D6>D;(S)PRPJ3HEI9*\[4EF:3RQKS] #9@>ZT_L
M#Q^-R'<F+*>2U)&0?P)>4\A*C9%2[6>=1=O^M:?\ B\ <Y,ZW2[:^D07:UY
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M??^H@8<_'%VF^HGZRD4>Y\/NNDX(>QUJDX]0DF7B;Q_+C&02!U=HS3J8Y9E
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M*#O.A;$13X.W:8V&Z$DIW7K=_.<A)O-T5<]C]21QE9[K^-$1'5MX8BZ?ARU
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M5ICA%+KNLQ/;]Z!L]09GL5*2C'+-5N7=A:TKV 01S;YA]$4"1\.8LMFB$(]
M&<_SE;/BC,N#14O]3D3Z1/&U\>DEX#^TU'<#^WK1#J^^CA8/DV,MEN6O^;T
M>'U73;R)=-2$]QY!B(\?LKJA=*S,]OQ9;+>\?X0TG )>1>T6M1K4GZ^&EE\3
M585I1A?&/S8,RJ(=[Y7+3GX-;;QNJ:V[2W6CV@KP*Y4.IXL5!,;LO/T\4P5O
MM'43K&U]K?+\>^:H#OK.,+<[=[6CW2X$YFK4<F*XRQBCV7']9+QAH$SRO$.
M5+DX2$? $XHAO]$8B_4H-7&-+:(4]* 9]J"QP4#@&Z(V),?23.%R#-EKD?3?
M@,S@JEX)^5\A&NNQ5^2L/))73919ABIK:$:\ _^M,O79!5X9.*@O[8Y/1C0A
M3O%E$>]!D"8Z2TQ8/P\T)[^5]5@\#$$*/-7((K#MEGZ&"T>WW]CSW$2O<A2*
MN60N@^*F.(Y<.;YGT@I?]_#/O>9<;"V[17K?8O?3M,QSO2EB.S!LD'PLP7^=
MC)I)@.9@=(S#>I6'9FE560KAP%L@XDKYJ]Z;J8IDO3RC$4)Z^I#K;H#\[:\J
MS\MN'CL6<TB9M77BD(9Z$,\NA?0F4"+:!9Z<5P0RP:]]/5$0<WULVN"S /[N
M^,:RJX2^40S9N;1$JL 6CS^I=.&@26,ID#JPQ*"D,1KV--,O$BBT$X+4<84M
MTA=G?'>K-HZ9'8.D%8;?MAMGV<!$"K XORU/5)\NNTHCXW XL8#51UGEQZWA
M/K?7.9-;';>V]V8X8X8GD)U V5J^+U=.FJDX'49$;OQP\8O\V$CH1>)^'R'6
MT\?!9T[ZQBBE 24I$8C0;K6IBGN 9Z0$+D8AJ?I3\R9\9D:BM38J_HIX)V]#
MO!#.-IKSU$BPO&R(9E;[@+YH%W+>[BYN4>MZ>PU=9DMX 6PPIO!X9HJ9GV!Z
M*?"[VQ975>[3EWIO(CZ"J%%HSDI<7>)CCVM? ).AOQ3>4$U3LTQ>*;]6%6YK
M8C]AM^"6>U=OY:7#M',Q;0D0W'*'?F^1RA_)S; 6^X!8A,QJ+V F2>6RY]<T
MEV47ZV9QKJJ9K.R^*BM $N^7[)/F%F\I*6ZE;?XJ;H'!HRP<O.Z 9K(J[<&?
M5X3MS1(Y2#(W%#ZAPF"IIO)91'5=*8DK,Q(UUE?$"^S!5IY-!<WAX>95*?O\
MT(&?(-8'],7?,-O(PNGV/LJR(WN-]GVH>$$04<RSGYY/=M?H;*>T8D&JJ)\D
M[RL;H^T)^+L9B,QD@_:\.9O(EZ.UKO&,.@/I-?X@7S51*G'U1/V.H!D\4;'#
M75-=1O*_JS7_6VBW3;/Q#ENX^+D0MP!"N!47-0D<4;[6PG1NDHWEX.7F86-Q
M,B0WB#Z9$6(*O]IH)^GF6B3\"H9O[<TL42>::3K6YK(\5>XW>^^?(U*^^V]D
MU#G4H5#9#W+%#FK"-C639CJ.:Z-!SPP$!\)M>85?8H#$Y6P%3T/%Y@"&%P#>
MGM^!S#EC6K'MW%R3V!-TO3YDZ8\]!0B9P1+'1R<ND.ML+#0L%4R5,V?_V->B
M,8XNVG?QV"%B(Q'M4-=R?E=]HA2MJ@#JSC-$AUX->ZB=KQW;"-'B>=ND:PG2
MBB@S]6JWGX7N0U8:/4#6]CDZUM;P@EBS3" $-T(")JI5IF<P#!;/ &&W)%]^
M<&GW?%OM$CQ03M'] K D;P^,*=U^BGT@[H5EQ7(<DY$=]AVWLF2?.4[)]3B\
M]K?R,K%9=&@>[!OCP6XFO7URD8[00<P^!YPK_F88WYE,6*!CE/*,,:P<4VZQ
M( Y?>S+H$Z>KGKKVVIY(5$Y/9 !1!AEEQSF-\L0;05<?O<9> (:+?W28SV#/
M"GV)SYLO@#VP1E83JIZ+"W)&;8H CQP6?O080Q2QID^B9FT%WM[]6N(#AT9]
M\\7S782DXI.,BP1!C_68](.]1'5[G=F#_6ES3;K]"\!&\)<X1^)'/8XYV4B/
M[RJQ LDW_FYFFR+UYUF?GHFF[0,.CUL^9Z_8R:G4SQP5M"#%OF5$#J>2O.8;
M/ECAG3X"MQ@PJ"\2YH\AN3_\N*"Q]W 9T]]BK >*$N9E'?OC+.JC!L#%H*5I
M22GT --=]Z^WU'4N/1+GF^>OQ;[.V60-OO^AU7%][=M5WH.;P@2O87U4S;%[
M'6EC4ZHWYCCQ)U=P&TOQ?F;W!1#GXS_'L6^L7@2,7WQ$:VZ=.M:T(UC\-"8*
M?)@L_$"Q<W@KMZ^68.JMG!+!2R7[5/:ESD?H)$4H0BC07GAS[BR_Y5P[L,CN
M5=>E;G70WN:MQB<$LOTLU;Z6KAVXW$2+:+?.V18>M+>Q$D2APW.RB<&IL)OG
M=%U2Q^)$M/*N:8K]"BS;66X%EE.=H>=2C$']37R_^5!T\6M+TML]9P.;1A$,
MNT^"UGA]M=6SPE"T(:/.$]6<%2[/*IE_:AJZP(PT]O>A",JC<O8Q;X'#3V7;
MST]#V$^.-^N#E+'J\@68Z 26.X;=WGA8\*54?.&\^U/K\ ?Y=>WE\]BMDJ77
MHM/SF*'Z &K)_LJ[\3I0?>W4-4@D+620J_<=6^ <8JN<V\8ISGS;,-2NCXF
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MV@8*%'_^J/>\'DK-W9:7>I4/R:15ZR2JOZI(9>,YL. 0$IPK!['&M#Z<=L)
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MF/1/B3I-#E7&C%]RV$VZ+NMWPYCFMQ.:^2F&5PG/VC[EOLSZSCP\Y"H 1[)
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MP<L99<@B-_IAS&MN0F/U=O);I8U@_ONQ\JIV(0%TFQ#:<L>;?V2E .ZDG6H
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MNJ/>C8W><R$":55F+'YY0*K:JEE\@Z(W4;4AY/T5\@:3N'WWS7TQC5'A3I'
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MRS]J+J2O?7&D:)R>MC/OYQ[QJCR!-6]O&F,-111T[7_DM.:51,;L>XQ9YS;
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MLK$9 E^)0=\"BD??$H\O ,O(0DB!S92/\,$M$,0[8^=P=K(8K1KG@G%05@J
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M5?=;7ZV[%%5U1.]XG&7[.-S$.K#YW?>C8H.68"C&6*GJ4T[Z22/N-*]?Q@\
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M="V8:9O?OUO;?<\;^][R,!9ZILE+=O$6(*2JKA>_$M_>CLT<]Y/YT/ K\>C
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M0H<<P#9A>L/Y#<2PS@9SS-)^@<+?[2-X?TT;<Q7"YS'B&5C@)1;@!.:]Z;%
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M/8G21E<9(.:5,L]WY68#DZ_DQ8HLA0\JLK)JON'&?^124!0H69 0*/[ %&1
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M!?=!+# -!HL,(09\K8H$F#X[]Y"@!T\^NERHR9VM9S*6X;%9'RCADM"5-;'
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M02>//!P'>\Y.DV4*228?T<5G3E>R&'<(,@H]FJJ3ATLYFH1=H<X=PX@'O];
MHRL"&^0"&>6IL\J2(44$VK4%LUSHT@';N1R"J6'?+0SNP(B!'.JHBA?\C\[2
M_B.RA :[/5-;WP@LP?'/KSX 5;-]1Y3K6& "4Y;SGWM)>I1%[EUM>&Y:#CN%
M,KVY2J(=I^C';E@M%Y_AD&U9S?)Z1:FVY:Y"-UIWXS$#,]*F/BF3=IR:VBP
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MY>C6L9$&7L$=7./&!D7MUK,EU,(PKA@MPUH^KWQCPC"K>7Z^R=<FH>XZIM*
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MP1!55D'/& AKQ./P(QT\6_=$FBY;O+07]\1:%5:5WB=[$ Z2@(-<_ [%,I,
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MZ^O8I^'#7E<'8<VT.17'/981_:22]!G\F4$2>\'_A[WWCFMB:]>&!U%1$;"
M2(V*6YJ("H@@$-1-$R'T*D1%*2)BH4D;%!&D141!40P]H!0+16E!$+!00Q6D
MBX"T!!)(2#+Y9E#WWL_SG.?[[?<[[^\]YSNO?\PO:V:M63.36>N^KNM>:^Z%
M%AVIOY;EQ&RTND(]+:=#WHFM#[HXL-#2PG.\:^'68OZ&8)7-[J*7@R9?A8_8
MN \:H>E?8<!P/7=XT$B8GN"C-9<$M'ENF%B[6#"$BOF]7ZZE*S]3X.NY%W1Y
M'2SCY-BWKYG8M:[O2>W!NT)$H7VMPIG?5$DIH+CK),EAX%@+AM_-@-2*WFB>
MA2,0#/5!04&N&_UH4GV?K=C$<2VM0O3E#T,P#MRWL8U=A@GC+0DUF>5'(4"&
M.P'^_Z94/Y/V-(\:(+W@#;-4I7G"X63)#:](V*!Q"59:@/.-:#G@"W%H+Q'M
MJ_N:+8L>DN_ ]"'$UQNR R^!<@Y1[%:&"0_2C0X4!\]$J7Z!R^R@;&26[B;>
MSO_(W6+6PB/"+AL.7?0R0,_&&;!?#M>TZ9VBV2W/7F#:U]9GW>?ID(%(E%L3
MIT._+1-O;&^YL[]=M=9S4E2!*(IQ]@(:1A O&$&^^C66LA^!O>H'_&I+WP.P
M!;!&K#CQ+.6*]^L0L IF_)6[+Y0\$Z"OS?\0"8R S\O-^KQE> ;=T,\TC/N\
M7?4&W1';WDS7TSBF!GV*FCN'?E9N4J%B@_F>,3!%%"(8T@58*UL7T,**AMD"
M/[1#F<;IY)UP5ZSBD_2-[DKKQ?^0#@^;8=#P#6%+I3./UAW-N^OR73I@82%1
M[[ 7E6;*+AI^TZ5WA;K\O$I,\.W'Q4(#<#8.)BAK=U42 W1@(??)%+Y7XI!<
M1]>LZTOH"(Y^7!%.=:$R?<2LF>ES&7-MS"CX/X9Y[MK<R<5"]P)2(K0YA1B@
M5\:6SYT[S0$>PVHH,!*S \7X@H=% +\YM+D[8,+7:3(22\?DH2/K!H,N.6 ^
MI:#GZM#,0;.@.]VP42G'+E:E\)^!R=EQ2"83FW?\L3I)+#<LN*CRO(> O8T
M^Z70YHD# ITDU)M5@+-T=*'5I,]36DYBK;\8V'!L(VU7%BC@YME)0E=9" P9
M22SUX*I#=F$WCL\N>J_!C)CO>9E%["N/@%22^GE;[2&;@TN:OP?RIDG>.JA%
M2@(^.QQIA:;?NE!RK/SP,^\(E'RW\K59'&!E"2(HC([TKPRG*UZ =88H,#G_
M^*[UUD ^&?2NIP>77B.&0-4,2_-OPV7O6NZYDENZG)A)/?@GHM@IS\VUBRH'
M>R$N;8E[0G5!^+I]01^S'T*?(C&J=3GM1SB ?BW@<_>[%9"V%P)33(^IX(3T
MH)?Z3M0="(;$P-4_M,>QG6.V+^W-A'>::.A.UWAH_;)9F:4;9Z "=%^AR-LA
M0; Z8"NSY_PD3,MHV4@N!Z#;;'&:M3M.')O 8%%N];EF E4<( SP+K3>4WF(
MA#,;(:OLH _H:CI+02M<N3/27M,H63?\^[G@WJ9,&>%;";^6)7! FB7#[1-9
M)RG7:I\Y%ZR;(;F3))8Y!>8!YUIM:QS:Q#(_>^_XML!'^HIN"MG3:GDSU;5/
M&M.487]?+".' P2M Q(B/>^'IQ>,Z5*A.<@+^":KNFS51Y>MNFM&/Z(A=OUA
MXY?S?I8L:_OCN^"4GY\)DZ["I.P[Q@!:D='-&Y!0W\B%CEX!?B;A:X;TV^,8
MY_&+'=*]>7JL$DQ3R&Y3R]A45_1H:; 7OL?*"7+</)_":_F7:2CMZID1,+.Z
MRYKDK5T*R^@7>Z4_IGO:&D#Y QU_<=OA^=2)X=/K'L7<R_L7Q]^:#Q+'GJW2
M?[/RHDX@>V0V7#AIU9>>FP^X,1GO>D.,[0:D9^*Z/%-9 IK!U]-"M#33*E/:
M-=8.!9E^[',MKFVVBMAZ:VEJQTOS(;W0!%VG+/TJZM$KNWB^?&*[13,Z^_L#
MRFY<[Q'9E73T1JS*[H8@0#QIL>"F(W=BC8E!SC?7U9GJ4S9O>-[C0D.A5LV@
MY[,.L8E#?6(Z[]N\>MV=-1VDQ' LWCPWTH9_/X_FC%^4K9&PX9TK#3=.\50
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MP;^9?OC,])-&!HJ2#FUP(XXK*(YR@*[\)L17-[32:9&FAAN#E-.K]H)"4\O
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MHY:5=ZV3_7KM'T*;,"L/).80NV=F(]]Y7!!(W,^(6R]!6*]VBIXTZ^G-JW"
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MNR$]^^RIZWSJD4"]I'!KQT=>%>#1O?=U[G8'23*=!]OE9*JXB^#,AC+R0F(
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MC=\BW4^* DOO/>CT$<,RVSW 6>MM&CK#.[\OHZQPT*_$#$-+4JD?E.'.Z^$
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MEN0?-' /W-]LG#2XYF<\P=YR#"*A\8*?G<N, CO3"HPX)BE0J*V4O;*F$R'
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MNF"F,*KN;EH152([WK0D> <.ZF10/K=OSZGU G2\.<B[OF:!2#ONN,M&NR,
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M@*;@.+J82&QTLMCFF6HQ:<SB.54\<TW5PH8=_ZGM["G%^N1E&P&I^+$(WWT
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M>#!PSO34'*[(T_/<+PFF:FA'&(!!&@/H=**%N;97_66UC>G3+^X3M6NYXAG
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MSN]#);GV6N7$<;K]XR15$MG?H2"W']=W]K_I%)5Q)2Z,G\F_I8B,%%+#[V$
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M4=,A;@K)%W1+A\"8S5YX-VO'2$:/\KR3+%V.P6QV1,?1<70<'4?'_U#\W4(
MUGQ1/2]*(A)PFMB5B13^H![<MT#D"87E7)]?%4I(+#]>8'GX6N\9BF+I -AR
MJJ0 + GDSJ-Q)Z93MXXH<U1\296S_GI5+2!=.H+[R'9+![,I<9]KY^_<2QAV
MH$ "2:U(8"H7(52@-_1C$A@M_(4',\BWS;9[?^^+"7%[STI)]YZBME])&T )
M@@*3CT"#-1O3:J@%MY;/<=\CN2N R+0J@!=F:)N302<).J.BD$#URXV(,=2\
M?X^F,L*:5\X&ES[VH'N-<V"?)[.'*/3PCD"J9]8Z-EJ'H=<&66!;Q1M(0'FR
M' G@)M0L<2U0X+Y%/;#>^*_>&D"'/Q?^Y-8*H?SEG*$BO/(4)$# >YWN7M4-
M@0MCB -L.I@/7K(WJ92U2)X5/'D\H^"0'.5(AX]^"=EYX\9Q92LW;4_/F #?
M>^1X%1%QUJEI0S@JZA%U;2RC>8:1K&5I3<*8\X08LZ1SE?UXNC>JM4;U3)<0
M"9^]0);@1M(E"MLA7W>.+'_"/&+B6DA;%QSJ4UK2MS'@:,_HFY,3/CM(E?U4
M-/[9(+6WV"40/_9Y3T]K ^;[V>&7R)NX?&X8)I<..,-:3E=;^'WJ];Q$'D1+
M$S++1S"Q%@";K5IE5%)O[Z];>G#8XOQ=30Q>-E%R!=WYEM*00W-/'YH73(&S
M>B5'[VM?C5%+_7BQ".]8/Z^XS7-IX>/ZY-*O3=(PI#3QRIZY-OV.X'?[5(ZH
MUGV.UHA'YRZ8R+:)2S3,;-RO3*0BD4JDS0),\\WKL])*.]+%"/&)SYX;(?!5
M3H^:RF&;E-55]DC,\YQ]/BYHRLWIICT?ZC]AX\7<E'2.M6-J.=6Y/-^N15U5
M/^>>T0N'&=M$0@R^]+3ZD%@;B1>):T9KGLO2<O%M*TR84CF>TI\X7H]1WM5F
ML)^Z5&[(8J=O;6%-30UVT;.[[FGYM-9SS5_P720N5$E-@/Z0))6'\OOYRG>Y
M\RLO:2^D.XJKM[)$M[R.S7]UE9KD2N0QCF\26BT>2)?&S.9A,4]S. FAT0>9
M0X#\#[>#G\+,J2YW!5A<PMQ0,!AE DR+?[&]Q.)%SI'U K3TOZL.$YVW?=+$
M%\@D:+HM[]HS1"V<X?4@!<&M(Y(0YDE*-E]CRD,EWBPR]';;%P)+&_>[9DA_
MWU&2X&Z#''FCTCW],U'/]M!^D6GMJ10Z/!YO[2G\8L<QT-TFU(SQ[9;LG,(R
M4=[=.9A% Z !T #_]P _N.)BTH1]<+92'Z-,^=<=<6D0PT&OI$H*V]B]^4EF
M'UCW]8UHWG?7RJK.&SBQPHXQ;'PC0\(OLZGL]'!MP%6%*4?)"?6202,72LH2
M)\.$#H7;TH]EZAY'-O!7!ZT@)N IM5DEQ_7Y*%[5M+&O:V+/?O!^WR]$@CT1
M$J5M;YF@=JXML#9[*:'7GY:AO,/OEG9;OJ%GO$Z3M8V!2U%R>/%M3>*-\(2%
MM!=P%21 '5Z !.X<\]TZW=8V7G+:3B#AN:\4_N3%XP?NJ?EKVK M1#S",>&N
M6YP,&8U*/$NHDO*2]K#$S:=W.U&BR;B&2\2B^/*.+ZZ8\(*CPPABR ?.9LA,
M#L+'9OKW;U,SA*?8L<^P#4T5ZHA0QJ?*J0E]X*#@TU>X<I)>=4,*FR(>9@,^
M.?%H\M2T>$_%],/YF!PBD$NJ$3O4T !KI08+N^;@IMP6):]^>2.':R=?&W!7
MZYD(]H1\9A'EY+!:@'*K%GZ=8WH%KL7J%/]I!P+)MU9O%]M@CT3?02%N,@;S
M-52;=0P#LBOVN*-,>KSZ8OQKF.[4M&25URSC)QUHBG/TNR'I7=<M"7O(K.N
MA[ '&-BNKZLNWM*,@.IQT[A)MRE)2I6?=1M6C%%LO'-;\Z@Y((]H>(L$(D3
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MUL6$3\+R8 G>2MM@%_B1:)@TT<P9MCZ#<C7QFM"5ZOL@R6J.YN0G4LF U$6
M'$-,Y-I^^9'M\$WND_EF$$ *F^R'>_\$/]K4Y/B%'S]9^"^T69ISYN\L<9;/
M5J.DDX]F+ON5IKYJH#9]W3^]WI-H)Y+SS?CQTV\GGE/5]QQ,-6!O5R O4*\0
MVF^?#S'M59S7^4&G/KT2@CVV 9)]AN(Y-#KNSA!*J]]9WO] JB*!ZLR(FT%?
MCSRE8,_"*W'P$#P-K2BFOO5UT;<HU$2C*CB)L/@@BK73U-FOB$ W)64EA@ ;
M%9>T)WS?1.V0!\',^31>-KB-FS^7%GQ@NN^Q1H>_9]CC "=_KWV6?1$[QG(>
MVP5.A5<R)4UF<\MD^M;A?:)2HZ*7_1,B!DDH\M;23--""B4'??%5K3*40BB.
MR?K3LR28F64^2Z'W<Z-R>L^.\<%?T5^49E%T3MF&1IFQ#[N#V3 F6SV]JX*D
MOYO&L43=(6Q2$G:C4!0)7%^%(@%'&8@+:-[=*@#A,H,2:@#4EW54BU=#&!8\
M8(!5^7"YYEBWE:O:&V;5C?1>?_LZ'4C9Z'P)?+$5,O<1"2S(#?]<%SQX<H%V
MZUA7#@)#%$&(,8T$YO,*69  3Q9H<[$$+J<SKD%@!L*?NKRAYJ]^S'WM(=N-
M _!DQ9%97J<T;"3P1*PB8IE%KQ]VB!:FH##?79[?Z^N[7/.J#B25X\33VURG
M-Y[R(O2X_T4N*ID3<\N_^\G)<8@U)4QD]&H2D!(#:^P8 LH+1,7/:PXDA<P@
M1L3Z(A**TTP8Q"U)NZNL65,>Y*;A3@9%+]KK2RO%![HOEIV?">S1M=EZFDZ6
M%?LDD#SE..BC(\,4Y9G+"GZ=2M>966@0QX>)%! GC]6Q2#WN4'"2YT*,))LZ
M3RB18GK.4:CUAM\<P9RHU(%?]T("97RT&B7D*<X3_!3&5%[.?H+WK1Z-](P3
M&U:S?':L[DM35Q>XH[=&X$]]S5\0D/Q&TA7!\Z]T2I8^(8&YD'M]EYK"CQ#>
M6F?@7[=/Q+RZU]0=:+#5PV#E_/2#@PYRW=:>_.1C/VWSB0UCX1AH^Z[/;-&C
MZ?O_#7TO>=)Y[-=T68R^Z+(DQJ_O'*A/TA?O'*AS[Y;PXT:_VCU01P.@ =
M?PE RG==EJ)1)DVK/ZC+(DBD(M7*Q)YRQ"@M09$I&BCT;KPWX!![%,@0M%)P
M1UR<M%SB(3VY];CUOET[1AS$P4JCG+:O$+&DV+J"K5W4RIQ*DO_RP8.&41W,
M*67&X:[&] YS^XM)Z:US3*O#!^A?"F$_Q'S,FX@YQ<!8"6=<\/_,?+*[PLV?
MO\<^E6[^P^S'*]3CEZ;U.V=2-0NS?4:[;@<=N<TFXGK&:18'$/L] JG:[^WE
M7-YL[5#"V9Q_$PK1IHS28GH=82'(&'$3*)\W@+Z97W[H=U[CJ@]W!P<-MBCL
MZ=EL,BUS6KUE+J*4J ^)5CHU"9):/*N#[AXB'6 7I>9E3T\D@%^<9TL@X.06
M?>?]3!UPSXI7O,1][HP#N;^Q37M#Q:GN04N*6D\GZ<E\\?JP(<*."V=TWQX.
M.D="FT-$'(>SYI'&%$WLW_5)2$#DP>F>:S/\9 ZGG-_/KT2D")UNCYT7-"40
M9-=;R#FD:*SSF##'Z8S7'7S-H_Z.ER"#E,W@<1#VUI)T0Z0NH]$94CN2PQ#7
MKJSD[[YBO&!FR52M55@'!QP"NQ]J7%-5^,EX!C]QMA5H$:U:\G^J6N)H9/3V
MZF^?EK5-:UP3JEPFS)37OO+J5*-TNOTA)D( '4/'T#%T[-\>D\?V*J4\E5<Z
M^R_)\F4.K%;^*KWV9E?NW=&_A^$G8+SX!INV W":%DVS2 NRNT\?7-4U3+Y@
MS[9HVO0>\1P#S[60,\DJ0H98^>&9'ISZ66._5),@\&# .&-;)A)PVK"AX@Y*
M,V<,'%$Y6X6QD3WM4QSAH@>G:!G.FE?HJK *FK5\X#!-. -R? >OL\$!K)M@
M3(,!E$TF29A;@VS:2("_\KX>&'/FEH19G?J]9X]2'CDYK9XS\>D9V&)L3XS$
M"UBIPY:>'XW?<$C #N3VKG$.-.<ED30VAFR93T8<@HO2-/7 '$:O]\F\G,FA
M]'Q&(CQT#2ZN"!N\YQL]$=P-MJ9XY^I@RQ;@"S>%C^8:/5G*U#AQX81HQ0<&
MSI::!P@]>J]M#[FQ5+^W.);RZFR/WL378\NO>YJW]RJ%PO=>L&^K^"'9BE%G
M]9-E=T(D0 *IAD9L62">OT<? /^'#H!;*4^B'M$]E[:25/VK]^WO$THKA0[^
MD;UM=/C[A3UJ>ZF/]Y@\Y#_%\UVYA9%EC];+CUH=ZPJ5)8M<4R6K^+E(H,E;
M0T[A8S$3$O!K4$,";URJ$5YZP%K:CTKRZWP=%<J]WF]5E*9(70J/A*4+F(VG
M! 0XXF+3A+Q"G.P_"6DL3X$,/(P8Y@?)26LP;!MP&Y+<.&UN!,<)@.MLV_VJ
MB%B^.-D/(Z.%-6*_@:.(@Q]; Z+L"!*('DF[#%-" N>H41QR=O_&N:GPX@X.
M>XD3.(@D6\N3V?,!/3P>9 >U#ZZ,(,P;X1>0@+]?+!+H-MHZN5QE?TZ04 9_
MWU_@K](R.Q[-,ZU+2("WTJ*@HSTWS57SM#F/[[HA&&K1K=#LR!5Q^LWE=A2A
M">]O]M]U7&%5@:&O[80$F$KB+J-M'OV';!YIE#T\-+-J#X$J;@LE@)%1QM26
M?@H>G#N"I7:LPHP;.C4EM+(2UU7\W$#C9NT8@<U&4Y&]KD5:'!EJTM I= J=
M0J?0*73J6ZH=VZL3M*OV8H;*>L/S )@OJL<VW[>.<!I+FP/.M63]4_E.[;%>
MO:JB7-<,<7MK54AZ&Y17CM)A?@ /"J&DDD8;#3@6""X'FH]!\57CO"P(3#P$
M0Q&C1N$KR?G1)%M#_I"^9B4MFGM8MVE,5HB&E;$KP023E-3-TZFTV1=[U"H)
M'?DQ&.HQQL9U,(U^-/(L_;/IYO;Q2#R:'ZU)RT$'?5TNPO0KY//S]195.8KA
M0II'R1ZQK?1 BD*F"F6M+1-@*C)%Z4%74@T&=/UB232"_5EG,3![.OQ@DD.6
M;FGP._'=>IRZ3&&U9:=<[MX@,20<(QGPZP^5PL[[/2L&^^.VT)(C6G)$A[\F
M_%G)<;'!HP7F*^"/HW&SC7DH/?B$."GX1/$5*HN#>+6V'4EMO JWLMO-"L*X
M%\14>LX(5TO/\KX;L:?#'/7T);,*F>U2T5UYE70F\/@C:L[CL9K.,/ES1179
MP:RJ[\[XZ(2*DJ7):3XZ#-=OR_)UEM*U.8>(Y$BBN9S=+('?[52@%U1E:=)<
M6".<3AJ?<R?AY?&[DZ-7CCF%%;Q@-NF'LH;T?S=]#_H>M:']79/Y4M@O-6 %
M%:1Q,<KJDVNF*L6<0LW&_:KF2?!C]SG6?-AU!N6U*%I-+V,9)[YS!P?::,(H
M$NYI*^53YYY@LJ DFK_L/8@_=]=?U/SLM/_H@YK >F-61RSA.Q.A0\]\@G[_
MJ&6BW9&Q7[T\X=,'\ZMWKU2)W[<R4N>>EOF0H9<TW".O'JM2$2PK],2;K^6<
M&^+RN*#PP/%ST$X*HGHP-]#;SG,--YC&8H) 5?7#VEV)+'G0R<)3"TJ300T/
MER I%N/V*<>$C&;P0*J]K#W4!YEM<!D%A@A5S&X42/&\CU-+:';DWF#DY,_7
MK\-MUGZ8YV7(M_)H<I+LJF7X8-D-YPO568#X-_T7)=!\L YD"1'AAUIX[O5=
M:*(\0J@1?_/9%;[G&+X_J#CBS4^T=D\*\Y"\ P5:='>T.W(U_$RX@ZLNX&2%
MXVW? OEBW457!79Q_=7@FE9BM,=G[NO[-8GR]8*;3OM7 3K*$$445;X1<(%O
MZC KPV_!7&EP)9N26KIHCYC?W?G<$PX$[36RF;G7_*;B4(GSTA9>TGN(*\M4
MNH4'7=K%C7T;5OI"P<6^JL(DVHE(WGWJBFJM]B0D3$]>_7LT-VU8K-5#XP#J
MRWO#OM\K.X1[SNQDM^T&OS^5\XD7"?QD+9ASAS72OQ1J3MB[(T9'8DN+]Q5G
M&FDH ^@L=!8Z"YWU8]8>E=J<G#2HIE7=MD8.=OX?<:U#"'A%M:8 M[WPA0_*
M$Q= K6S+5J=,$[,R+TAH>4N1D&\D^UBMS"B'!"XK/WAI#N&JD%]@ARY+AZQK
M*+<;F6_)&P@AY/UU\4C&/3\)1Q)B+ <_*531'MHD>U5PY8'+F=#*[(>&U(!S
M%?]4"V]*9!HK[%*\GK+%RR2.E>>K31(+A>=O=Q?>><O/L^%@IY @A1U^;0$B
MJ/9@2K+5(/5"Q:5,,?#),QAN-5J!XU> +?V2QU:&D:(SGWUT[I'YBW2RO5DY
M:*S_N>$$S%*EB84F6*'E<\Y2+(UH.35!/28NCD7$81X%CO"W/&!3YJFKA2\P
M.3>2 %K,3WG#'90)5)1CO\N4]7N9*['/L&JY7=8V\/IX*9-RI?GVH^[**P=N
MRV.V2F'C87MD%O"2?RHG='R^[M-28\DA]BZ_MR@J_%-;3JUB$DIRLD]0WGIJ
MD#T15JBIP#F@PI2NQKXZ_9I\IB]WCI_0CO2X TVA-V*!9DE% U^5Q:6_3Q"1
M)2OS)EA@X;J^5%6SBLCA0/Q[::<G;K7'!U=:7FZ79Q5=E=-LX?%0B)H) ?KF
M7Y\'X79IPV)PE"TO-ZF5-DH4Q-QYS*MK8-#<WGZ%8+8J2E",_W3_O,<X$E@:
M+PEC,SHV/G70B^G4&=&I&94]HE\EG%N0>.,9IM-%4)Q%]ZGFW!)7R*0Y>&,6
M[)?:M;W-GDC<CM;V^0NT?3)^V[& 7+H]76?Q\TG&2Z&&E<LQ=S=D$R.QIC5N
M7F:)X_8 T%GH+'06.NOGK-<@$D<>%E-?.81YXW>G%N,'QO:ENTLHA4V]P!LK
MZ:J<Y_6L6PN;\NEM[.4ZJ^#R&GW;$I N?N_#Q<)FF(-+H!@=$BAV3(LJ%(NC
M,"U7]@E)P#/!9"!H@<@U9/.G!0T%3=ULE5'\-%"0'4RU)BR[=3@2+U4GC:8)
MP:EB'R:KU$)[,GF@1D?..4+MM5!_;7ML"6GA9<_- K6;0N]*3U"1K-4T8HL-
MHUZ:=F"*_A&;N]XB?;6P=!Y$BG$L#5NDR:I#X#[/JW&%>6:,+1PS2G;8*]NA
ME,LM45DJ5[$TZPO6>%YPD?EBDKRKXO;).E561*RF4)7=@2'LI[6YKNASJ4FX
M _R^A63Y/J'T__^VH0@A72F IZ?\18:<!0]W::SA+28Q?%>E]?[!L*K[WE0B
M9LC/-F;H$;\PM(H6Q?_3HOBN"Y^]1]@?Z:(SN,KV.]3H\/<,>S92U?9>/71D
MMOI&XN0U]I"^7RI3C/%=A6F<<DL%R3;'^G1+&6T[U9D<Y2LT,W)P74D3BG;D
M4VDM)!I2.]=KF*E?E/3!GZ[6W7<M^&Q&@'#KR!7QRPN^JA>.0^+L]04!N^$H
M.^8%YHR+2U RR1P$O:&3+(Q6!L*PIG$<IB4YGQITX2&1C\3$?0=UH15PHWS=
M'W-1]!L:-%>I!))&D$"-B5KJR@I1I1V/U)VO&C6GFAVY2G8T:,![6'N-'69_
MCTX-6H/F/^$U[.ONGP1W*R4!T->O_>-M9Y6.5NDB>T&R4\W>GA-*H8/;<536
M+L\/&&E("ZVL$#[<6=@!LKVP_%BH@NWRG>5?"@-=$5T171%=$5WQ?[FB)JS6
M>= VE'(*/F5[=T,>;^?B1O6.]_6\?6\1_ZL!K6V"UC9!A[]3^+/:)MMA$"Z]
M("PXWSO<&2UF;TU2X7X$0XO/J[KD#3;%@HK#I;:1QD)0TN3%4'%"%2TCH;N$
MH-(W:4$?+HC2^%O3K$7BJ4-\?*3<X-S)O9[J]QQ4#J%0]]C')82C,63@&A(X
M.GS!@1*6(>U^/Z>)^<#%]Y>(/*G'1^328'+AEY! )"="' 5?V4+2B@3*%@M1
M.>0@&#ZD++OPW(+R6$4Q;48S37.TDR'GJ."+=#+I5_'@3VD\2,!%:1B\@0D9
M:07#U<R*,>;QW#,ER70WGD;%6U]^L_YJ9&GXX8/+TJ5W;?Q$A+-_3Y].]EP@
ME7N<W^-H+W];V<FG4,T-[\ALO.S+5P)Z=3 C<A=6GLN\\2%1/W>%S> *=(M6
M,;/=H'!3X?ULPF,Z<3P),58])BW6F2ZAOJQJ& -6]@)6'#G3YA.>1FRUY*F@
M$!%IU@=^L-O7_"%'D[2']*W33C:/<N:\K)*U&0#5Y\UPE63Q48GSN-H9/SXA
M>:U2#>:,[ROV=.NV]1N1 I66$&!:)YGT7+>&3GL.[J.YTTPK*:8-1)GB%YHO
MF*2=>S%P%-AC+A0ERI9=BX4T"O4C-HG(-Q#^[8M.B2K^4@-&E,\Q&GXBT';<
MFIJM]5:7G#<4#/+L!0%3AU]L5%VMHB'3YP&M&VS1IZ.WKOYOMJ[<?E6+Y/SG
M%4)##12I'FH214T667"KU(&=&.#<V'C@-U%;1(1"_#OL'X\Q_;98+8-JCA"J
M54 F.H:.H6-_:2QKCT'N_I[BZ#<\#Z[-%]7C[5_?'A4PPQ;Z7IV'#M@KUY_(
M%\![D=)0*^5:NG;51/W8_.I543O;V'/CLD=>#%Q\SY(Y#5IK[]J0E"[VO-7"
M/#>JH .]8QU*=<@CV=\D'*Y06WR^N(DYJZK5CCLG.X5Z/9Y>6O:CW1B=G ^6
M-::7121>XG@:3C,?QZ2%A3MN7'REPWCN4I &_:O>8ADP%:.BG:DS)O=!Q[4#
MXZ"M($?>1QZ+DC!U"R2PC!&,! X((P$"Y;[3,"B>NYV@?NQYOW,%JD853XW?
M6<1PBL=LYD;B"?X^4:]K7W%C%\/*>T6S+ BJL*<[P&LKAZC/^(378,E2<Q0W
MMI4/U%3RUJR#3;.G+MBON' H=PM<N?IX56SK>I^2H6B95C3+0SSE_I9"S:Z^
M%!QH6$8UB$__2L/IR.,16 >*:8H4-C>]#>SX-8N) \!+31"H=I\*IZN=>GZ4
M["K).USA>?*[P17!6A7^W;HANILW[CO?G&HRUL&T+?-C5Z?(['%8Q")*L-8E
M6DGIKB^(,7E,]S:;V$*JF_Z]]W6/<$>N.=CU9:/UM7CQ@1D**C^7DC.BH$"S
M'S4_O 6+8XN>E#H$=EOK3ZAJ_&#GI=J+D"DK'#R6LQR+/IWZ/UOBDQ$$4KNZ
M'Z7?S:;EOT$"Y4F+\'H[88'DQ8YF7R9[^M9M4^%,]G2H9)@@P%FC<5,JRD:F
MZ;M01^0RQ$*D9/5 [&#AXTE96Y; 4\\\.@VY1WS5/T&[ +IDTKXT+.>8GDE+
MUAJ:RY,D[42'W-Z3'^"?FY)H6A$QAY[MD,GQN?WT,V?T1T"3MY3&(1/#XLL$
M'F0X/=*,0AB):$>RSVEQE,H[1\WK^A/"0<7/)^DPBI4WI%'YW!Z $2KCUP E
M?DN]AL=+>K<S/%G+"=+\.%\[*X5IE[4<@\HW)P1^[#4:$ V(!OQ+ !DQJVZ>
M^F*_&N=?.F)]8.73I=]P;'(U>_Q>N#Y]C#>V_-TG&.LAZV,(HFK/DO$CX*WE
MB&&-6TW\H$N0LMP%RRT,6B10O&.\P,5D:&[C@"02L*>%=;2P2V'7]L^G\J@A
M 7Y1)# 7BP1()XHI88P5-L(^9E-36PR*3-%+EN]K8X]7#)CQQ2KD-?W^GAB;
M2,QS#!J] 8L[(?:$&'B=,R5C?:#- 5G_PUI</G2-&\E.,JB1L6J6ZS[+B"=$
M$B]H=!QS3?HL)#_R=N;N3@O: O5_IX72_5F@OMUV02@I3JV3O?EZ#BN[.(U5
M3]137#8<E6A'/HN%"\I5GDG"<==>%V=M^?0_I/UP@>F-<%^]U0<2$BJ3.?7
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M(^];0;<0"?WHVR?,,+ AA:TF^,#*9J1W7-Z_X'ZMELD:],@Y$2T6ZD/2K2&
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MX]Y^>5$2Y9\9N:B?6+U4.^WYF$E[0T$XEK@@H4*HK=-^&[Z[\Y.S^P]_.)]
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M_)W'T/5TN4F1H12P0<R+N,A^3L:*1D8KD_W(+A,CHBKWCX,,66BN$LWM7VK
MA\&JT+M5>C2;5^XE4O)U$K[S4HB5W?RR'UQ?> M\V;W,L]@$[V.O:)='"JT%
M_91N&B-![2"EBVKWB.&D=%(Z*?U7ES!?;3&N#WXNW'P8\IK:'P7,TY_L_?_G
M]_XZG^H:<6O((7KS;_T')U'9V^VU/ZBBDGXXF+JY$?7+.?J83(EOF;K8=P>_
MBWPV>]N_8>W9+>M-75[NLA3H7/OM;:TF];P;DT'""H*25U\+KTKM"[FH?A!F
M= AM/!I+(3)\&^>#?9J:)6<A*W_#0N3RN"P#A>>&)G4\X Y*A;4W'PW%:&FL
M1C9;=8DS>]'*/7EH XI*XL[DQJ$# JMM\*_Z8\-&.@;EL4=T+=$,"J0"M#F=
M<6.B)/^2@%]\J+CJZ9A#O&K\%Y#MAUR08W,4D*SC*1S^SV9HJJ'J%</3K@$:
MZ/5U7W>G&[09=J\P.2Z;0;@I7C9<;>;.-G]R2&[[*4^BUVIZKPB6Q;FOA[ _
M%]=-S)9?<[%O6;RRD<*&A"Z6H)^6K6WJX&#T="#1<F/>:#LKL<)GD9V6@REK
M(X,+@^4'_9'T'Y$)12@L?\B+HR7W8Y*<_^?1VO[-@:+@.^64G 4?GOODP7UU
M19O7/'IVJ;I_%W$G@"$_I>&7@S6_&ZY;KT?8Y6G\5LC- >,FA"@B#_$A\]V\
M*&"HX(-B5N%O#CJ^I\O1E$B1]E<7][L1=%>I4< I(H\!I. T"K!2Q@4C15$
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M\ZL*[@L_*GKRSOVD!'JGVZ++V9^"G/NR<6>($ZIDQ/P59S$#XZDU"] DLK1
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MH_+A_&(LTL< 96<B5N8&:&Y4]P!_._7X+O7.*.AX6<F1Y&*L"=B=>AS4(L2
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MYLYY,,O&\IAROTW<O<_6T??9VP+"7*XRGG&FH:<?F\*^![KH)IK2FC?FY/W
MRTB7@YRK3$6Q\U#FHM1*2 8AQHJ2"LES>UE%E0\/S8T>A+<A*-JO"QIBSIWF
M\.XY"WK#7?TM-!,536GDC@S[G>I8(::$ *$G#.'LQF_DL16U6XE*3-.HU,5O
MR>8I\L:9Z>XL0Z)3R$;@1_2+9F7)H2;X\^*VO94M<^AA@MR%=U\9KE_J W%J
MEQ*Z2H&OXSD?_'T<T5[AI<O!9DCWRSM<^K^A.@PJK%^#^_$MC<]:YX%[DSV>
M!'U#S1\-$$H%A6$+'L<]X"XXW)5[W_<-E7M,0;+$=_OJ$L36OZT4S;#X'\:P
M?T.M-F78?XF\2[&S8<W[K4L2WU!'S,6I^JD[O!/<>^B_=<GX=]3US)11L<.+
M_]KK<&.MKG:;SIH9*FV(.Y:*H9_S4@D%;/3;7S._&IC!9YOWP/:')#+;^%^,
MCO,A#:&!_Y<8F/^J8#.PPX_5Q85=[)W">_NX;CFSM>R[ED2F#O@H@#GC<8T^
MHX<AZ*"3$&-7U2LOJ03*&DA9^8X[6<JY]_V<+7CNO5EB 3=,9O;87.QNH$CE
MJQN(Q.M7VQ%/W26$1M*% .&*W>RO6K'MJ>!]!9#O[MHV=CSE2#@>'V-'R\Z>
MJ!9)4Q:I,(U)0*Z(-<?;/2I%R"*6*5Q]RSV_.E,T;64[MZSL_OWP LF76XT;
MP.:&2X!E8SR'3 %)E_NSZT5>_D^M*Y'R()9V:#KG%/I7[OSCP4R7Y1#%Z?IB
M(/S8]3Q@WOK^=B&I49A^D/T3064F<XOA_1G],CIE4%LMEDUDF^Z5M7!IIE<#
MYKWG\03?K<^4EY<%,;-+!*3 E,X#(0?R)0.S.ZP94J]VQUV&7"EMVI"Z=#=?
MR0Q>$PS3RN8;$73JZ]T9U?0NQ;\_F['56J0F:IX]EABB1H'_4I]&"!=P*%&6
M9=U9/S*L[9M^Y^6WFV/WG:%1W!82E[02+8L*.\#?3L03F)DZBI=#5H?.FY7E
MT__PSR^G,CB!_V9X"U><)89.QN*V:-BW)0GNG+U>[KW)2?1DE_Z*X@>R\61/
MP;G/4P2"*BV]UB0^N5(-4G7.L5-7YQTW:BLVM>E?N)&DPV2?N$K3)RQ.XPL[
M3]WHZ%SY8"-77VMG)X^= '[\)7!X4L$#%-" EOOGE%GR@[=NL,ZX0@C5I$]U
MI-\E7L5A=2;=1C#5)7OR%9# RMAP-5HO7(RMU?C\N:1$1-IA)2+D$_P(;][(
M2;$Q2N4HT,FWI?S4L=8KW.@%%A_AU?U>6NN&]?%HN"1T4V9+.)];8&Q"@F^8
M_9+?#7%EA83HAZX)B#4V).&&+PH0U;9$ :<NHP"_1!QA(>B!'_>ZV'W^1R61
M[P8/BS0GI-Z%2R?P8,U["AU#-.8]:+OG>* M9@6:)N>,]E\UJT=-5>.&UDBU
MZ_;76DKUS_39Q9KS3TH;!&"-%MS$"N5#HYE"_&NX#6=K;]JMK1B%$#!$V5W
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M62 90@)KB2AC;%[^VDI*M%+(T=,51\E"LP]Z1CYG_1+AQ4G[R]42%4ZPHRQ
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M=<I8*Z'8$]B&D#R9._X*>9>73 ^&7PKER&=^79ECQ-FO')A[0-Z)1[5$=3Z
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MT290W%5+@PS(T/:B*K\I\P8)2))!'FJ %JX-@-90CLG>0CH"GQ,=X9N"0%
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M_.%/9=H7;50YRY)4="OL.K[>4;6F81DZV@CCF69]YZHV6>:J@B=OGS^U26$
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M]3PE<4S^2\]*#00*,0TY1^-)OV,[7D!PJ20-JG_:G(2Z/&CG?53 A]]OB9]
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MR23 S,;)Q<O+2_- 2$R06Y2#AY?[>R<(&!@86'>P2+&Q2;GO4=[C_I<?V!<
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M 0=O[$N.EYMY,&!1$@9\L_K+ MLAIMS=Y[.F7]..4CW@N,WHZ\+Q"!Q!?@F
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MY:V+*$);5ER7'=@GB#P+%N$RP<F(<7EW=REH)%%=B@R-[MU_7)M(-H=H!\V
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M0B8HVZ$D3L;[9V^URZ(0_3%$&KTU$S3&7AN[[6]*WLU(I*+(1!IULE9F66;
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MQ.U1VHV*7@ '8WUMZ+7TRT?:"*MY[7+>NVN56X)+X =1R^$Z62+) 8$=.2J
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M\ M:Z2"XWN =2[C[DE\KF BI^ MEM'>@+R@;^.[< 3WL)1APR?*9!0[9^&%
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M\7/ZG.7A[ RP^=P ;.K_ %!+ P04    " !S@6E6"M8A5C*M   0V   $0
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M>@%1T LC2:!6$S#TF//3-1/(1"S+U2,$TB_^*Y(_Y7B=X,VE\_8K/Q6@C9^
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M-IQ,Y"F%@/T7@FN$T] %%D+"MMX:E_BKY:61/$=]0B>Z#]RPB04=OXP5AK'
MI";EL-['LX-)BP8XCJWA'<E@./0,T*/_?8B,H18G7HN^LKI$GN$8/)]WG*]6
MA7>-XU\TFV"X951]Z0=W;XHF9\0KRCU4H:EYXGHQARJ$NZXR/#OD;987])8!
M,6+^=1#3]UY3,2<*V01E)4B1:I";S&5.BMX*;!:$?O2C=L1LU:W?M.._QP9-
M"<VHDR3'J K1+3+ H5\.D9#^^17]1_&'/XPX]!:*4[F2Y0I/V4Z?]&;(>8ZZ
MX5O[,S\M-+/9B&:,V HJIM5'2ZO(M$_6/I' *\XN0R>83*,S2R6K1T5MJBM2
MU:X6=!8O H2B YXGY3<%LU0Z? ]U07^Y3E! MLN&:1,VB@OR]&2V) 7RI?T\
M-?'TXSIN<YCC:)97TD?(SZ)KG:DF%6%U^WX1IV 0FDDX1LA3KW$ XK,VWI8_
M0JC_>BL$J7>A_:6Q744HM7^_!GN VV,!L/5XXF/ON=B@-H&<K.PP=FF(X7=T
MJV1L%\/E*E-ZJ=TG%PN)PWS=>QQJ3XB$E_@^0J"I4?4=S7&K4"W,^_$&43K[
MR#F2!:JO:>T9X/ T?LMMD;[8:#DI( /^SMV["0ZS_.F^%Q/7KAXX\:>P-\M"
MQN_HHXPE?2M9BP+I0:#LGQW5'?$<;I.$K[,KNCK5<)ZMOAF^X'7,*X>%:(^M
MCN+?XUS]RS@Y>R12^OK5">OK.XGDE'.7&$F^>WI-H@81L=$0*3T]47.Z+#7#
M@:)^O1+_,?AC92.1R.9LQ!9%^36FF;'FA2MW:',<]CXON-=6ORU-O"U5=@OT
MT-\F0M ?J,IZL85)LJ6Z/.+]/IT@*ULWN5!R)MXV#U_"EYDNDY#/@.ODE'E8
ML8#RIY><7,^OF[1Y>?^#Y:-YIW2BD&QNJ/M#@^P7/@)?9Y"W1=X!S-029$F>
MSO7VL*TKF_KR92)""K%#^B*Y85HG?;,J\=)]XUHRYZ N3\ :3;04-8WS[$F
M7)JQG$\G3/5]Y!@$^58_RI8560T8"?LY;_D[>= %K[]E.D;WC:L"R.$V$>Q)
M(U1FF[CSL2V&>#+SILQ+[C&5(<?;5Z4/H@!64^PX<BPZZ1[UU0YZ,^UO6IYW
M7E=*):_47\+W[TJ&7.K*KD*606#Z/M2^Q:B)LFT%NT^MYJW!560..HIW $_B
MN2FJ/P-!^:CG"7Q&!#PL%J2K16]$RX)!+QG-,?LXI'3N_5]-NPHRO1(UF08+
M%FFU-WT]W7VPR.AJ]'B^V%$K]N:VS ^C^1K?&;&R@/W\QEA//5U>S^XOJ/*W
M#QV:7(7%;!)XT@*T!0IT7R$$LO^,&)+&]/!8^E3L2'D*#[BRNBC78)01?4 [
MMK!XV=914KKWGH).?(*IW%NI2K3:=31].M\.8-^'C835H3YRN5J-J0@!;,2K
M?RJ+Z!S+HVD^(A2U4.**@SS+YCCG-D]WI9*)ZBQ(0Y10M*IV8(5+RP9'VGH4
M+E$9<ROY@?3MHH!T+6LMGKCQ/F/63?H$ MO S^]1AXC.[J9/X=?&D><PK[S(
M1 @P_DDDNF#-,CK]@T/X9&@.DE*+9J@PI4B8K,'0(X: N301]O>O3;"=A\?7
M[P,1T$61#;YR%6Z[0/0R3!J_:?9" G<&J'(J27G:HY=+8Z:84;B$^TW%_R':
M+9/?<((.]'Y]8IY,P;[N?WH_S\RMKO\,4#9O<)$A"JC<$@?;5/0]?1JM]^5D
MFWX1L*ZR/RAMR0>3*G,1WV@SL[I+PG@&>&D<;4C;T\6WZ[=1IY="1S0L:K--
M0$R4KPRC6:GY-B4+&I_/3!@]5T0BAGP2'PT6?2.ST1=A#*2*G9GL(WI(5IG_
M> \0OR.N]'-\(&%F<HC)^JU.M<F\G ^!4N77KF.6J(MO=5 @O#^#IB51=S51
M/\TB6SI#Y)C'UIU14JU5<<NQ.='.Q0FEQJW*?@;@%_VFKLG-EW3U%8MTF:[X
M1JOS/"5%T3'5)S=@38%XPY6D9_3W0DE?MYSL-LEJQ#>5E456;>Q3>2X8& =4
M[XQM2,0_>'[-'6")TWD!:"&K."'3+S Q'3,=4W.CYQW3S!2O"QSOW[!R"KNU
MQM6_KE:@=QE-HG!W^HICH(F(\_RV=5^18G?G5S&.A[C':,MQ)QW>H.>^_3VM
M8P385"W>E?"L*&])(VT&KL-Z@B2S;*HLR%,\ZABK?EN,6'L30H&<IGRQ)U7T
M\?GX;952T<9?8Q476O</\B^MW5KGAV?W%<G@)X5?IN71&!LD)?1@@@+6>E?5
MY!$*A>^"T\"5@9K%@9=OBXSJ2-RXJ4Q<_)P?,)@=.Z[AQ]P@BU>MG;1X$W#B
M^+/N,>#ZC:<<JT5G *"1J\N:ZSKU-MRO8 Z@^96"* /9M:%0,WBK;[GU1'*>
M%SR0MGSJD.NU%S@F(L3X>"NC(LDCPK<%6BR%J\&'N9"5";.WFD\];KZ[BY%[
MV_7J7HYYZ LZ1BJ 98./0J=^.4O1ZDJ/;$[GM/>A:T$\;S5N@SW:SDUTH;9W
MM;QT9?#XB"EAQ8DOQB/?DC0!?OEQ6_?D5RH;Z-O/O04FK-KG<7FG"R9]G6PT
M*L9OVYX[PFNMJH S5(XSQGMLXCM?:]NWKV> 6HR4&@X.LZU:R7>ID4\@9F^P
M["_G))@' '='$GKTHR[+QMY4S(\RGF_=X9_\Y):C(S51?,1P78N$@M=$HFZ>
M4#3>F?B>T;[?=8+6&G,&:#*"P,E>VKCE3+YJ("UG.<#!Y4'QKFZEN3^V3D#)
MCNV2E<^'ZJ)[=NS,Q85U1@IQPC]8HVP?/T@.&_ &.C6 \I?M!MUY8C[2.D\;
MB9N:=$BT$W0G%X^^/B;YY=IDCJ^ F=!3>J_@(LD97 S/ *6&&5>TT-H$_D*\
MRVX &7S[7MX4#(Z*-9<17LF+Z\H=$T>+Z]%R?R8*(COOJ-&@DD'93E+M<P*
MQSYHMV=)N^"*_MLL5NWO =R;-+I(!?@:-RY.YXM#UE&-N K;:"Y$L=L%!H,%
M5UL9)@J%'%KBIRJ0&%0S-M=4D+0@5(/]Q16ARSI.,$R-P=X"0SS]?4R%[>/S
M.>P@XB)Z_:EW==-[0?,6BN@C8G9T&Z)/Q[;?C=3 WOUK6X^%G]&6EWZJ[^1)
MH*GW+H?*+7^K(&Q_S92E*ILS-O-G<N+MBY]LYQFCU&$1SX'>]_%0'"ZD;8JF
MIN+QVRP\>A=CX"\.U7 DN"S&L4L74KBF->E61Q$.XG/[-BX+?+6[H*><D:_T
M"F%6WBMZ2-BO#3FRYSLHP@25U6 '"EY==G%=ATD9A;+8+(3\T-D%*H>@Q@K3
M:!H_8W3Y-V3NM#'-V?2EAKNQ)1%R$GV+91L 6?R;$\A2ML5X^F9DT B8D<3Q
MI\I&_E"\K."V?D]6+WYYSMX@.]G?9G[0N=8&F_1HVVP"6U)_X5M$\JE<@<E:
M7P,H2J'ZJ:O!@GFOV14S]B]#C8FA)@29_O7VS]]8C'-/=HVP6.RMN>W'?46D
M+YZA/H\<VE7D0H7TI/WPQL'M!,2'2J-"[//PXXWT,048;.Q$?6M!=@)B*>(7
M\8+!IZ!O@SPFP$5+Q[_PC4?R--FZ!LZDM)_KZI-]W6K_CNO6N:][CL:'LF/5
M>(M&DW0J[\RR2(NJ[ @M1LK(FA\56>Q7;^0>)%4AKI4,P@E#YCB)S#Y4RMKL
M]3M0GH>LK:P2M4IBAO"?,*(,?ECF?&/J^7&09XXKVA'9K1!(<?M\BH=R,\FZ
MJES/6Q>YM6[_M]A2R%PH^<$ SG>8&^COPI[Z1KY0%S/J'?3L<'?W!N@5^8 D
MQF'V;D9'Q)47GH#,=4K78WU2??H[4?0;\=WK#5*/VY@JHV:/I+<[(WUO?IT.
MD@$[V5>:0Q?VG"Z_9[NOGL\P36OAN,A8:8J=2^VQK5&((U^K;=LE3N4=M=JX
M!.N^XP;-<\N09$8!\@HR7AL,;.1\ <=DQ'5H3KW/5Y@I]&_;Z\$%VUOXCTF[
M?EU.WID %[HXK^=*Z* L_-^BS42?5SCRT@9^,ET)='(IJ**2Z(]?1A7E!M;F
M-(JI46N_SR^P2;>(YQ5G]1?$4=%D44UHX)1K!%8+W'7<,Q&"8?\W=E-"@KF:
M&HJI]9\\/+E8C!-/P<F=IN%B;5(AT/$JD2YTW\+@JK)IZI,.=@6J*(1P9/G$
MZ$ LE//\WZG_D='Q9#_,;B5'0[]06KWWI+$Q^FXFR<]F6%&(],%F1PB!:HNE
MSDD_)L].CCS%W%[@O[,) CM5CZP9IWWJ40/2[*5S=GI,MTV=()N>V%MW:O&C
MI;J@=:(QX\2LMPO[J&*>?7HSY646Y=>?\_(R*Y)<)E)?:0G_8QA(7[]W=\A\
M(;FZ*R[&]JUUB>/8R>3JUZN>M!YF.+/2ND!K8$EO0$"0<'X"%T%S%ANJ/_FR
M1DV*S?;NTCW#[_V8LNE_BIH*4^O[YROVJWKMP63?@1]7WH[*708WG9P!]D2R
MWFU[*'TULJXQ5EJ)G.7"E9:?YAK4:RW[!+<N"TDHZLA_-?,ON'SNFEB;MW6E
M0RY6"1MKEV1=.O L[O*(5\*P\*Z +:,OWEN:=[_=F]Z"O+-.18CYU6!SG?97
MI4*AE3HZED6!ONLN.D'4,I\)<F[2C[1?R,X4#&EWJ!SS1%[Z6"9\9>LCAV#!
MJ!0+>HV_COD5+%^,[BN /]H2RQ_^J$Z<>.2,)UZFFG=2#M\<RQ@ F<TW8Q4?
MF<(D5ZBWU=FULCF\@X1TY?>\?-PS?TZ,\:A%H,1P-8(%+C)2#'6BP[L4;Y#A
M<:=5+#O&8@O$Z,Q@!ZG3KGS31YQS]C7>D!+)\F+-V2NMEPYGRK+"P.8%0XD'
M$O)E;%*!N=AWCC6[,R8$7..+>#-W>61W;."$QJ/4R2$K-[)*PA99AT2 H93L
MW);S+=X/73REK[K5Q3%M>>BP9['N%EH[M5.?W-,K,W-.C!/. #'EV$H2&R:F
M)A';B?$),R*%?LE[U?D\N%VS9L]=,J/0E4<A4G=*67+P]2WQBWX!GDWJHD,N
M3D69U?0-6I@)2UTEO5!$0U]NJK?_\*,CR$B;@_;CT)V\,@PFJ:TQEB@;HR4^
M)OGT:W:QQ[.J9Q9IBV< 4K?+O%V%DW5SWI+&MWP2OL!1\K&CC6_"9B\GN'D9
M].1-Y219]RO WFG1=U]3T'!5>))ALUQ&@-[6V]O([6Y2!#[H<S->6=D^8.,%
MZNO2!WV0F A/;Q'F9)PI-+;E[0)R)X#FX^ZI,8#I_]FJ[7\E0.C"8CN+\49:
M7YJ';(CL44MZ0;T.O5:;5 ^TZ'857AJE=UA\B6<N&2F067GE\[G+_<V)#36<
M;J4UO"0ZMIND'ZUJ[<V410KJ9"3GJ_-2/2H(N!A,-:C)I5_U>L7@\97!D@;E
M@JYA<[KW7.]WU(_1S]X%+R8]!V/5C <3/8.J5VT^CON<7ZYH@1*RA0KD'@53
M)8:N-F/VU:6 .4/O\3]GE\&336\%OAXQ=QOQ10(=2E ,B^JJH0;*983V(:ES
MEWM/Q@"Z^UOHORG</V!%$X5UV<Q5!5NEH@W']*R><50$("8C+<S9FZ7@VXYX
MR:7TJ^H:JFJ^R2__D4J!Z6'(&2"6&L0QR9Y[A.,]F2Z/=MSF]M[;+^#Z;2HE
M72]C;,=ZBU<1K6K29$+]^24Y/H1 X;7O?Q<3A ;D@QK'UT9JL<8S?5R@HV;1
MH I@@4.W.;6]!=W$QX'IJ FZZ._&:FP%=$&M'SC,C-(O?*<:M;*$/-X,SY0K
M=E'P/M=B VD(=U>9#S\%]X' NR;[_"NQJU[D3,8%KBK3?!_5Y3?-P5)9&HRV
M!DI-_"&KS<4IO1V]L#YX>4^O=-J>KD&29HRGM7O#]Y].@E8+7[JRWN7>YI9'
M/(O1NF;]0"AH.?XU1$;OZ+<9_WH6YC+$+]*)O\ ^#SOG$T.2T9X:6AE0;17@
MDCVRN*][:*Q+-5Z[,C+?^&C!K'=\(O/%/28V&N"X_[?_3AU&T_U>CS;T/HF@
M@3CE-X8+W85I0<#L\JN3L,M/;JG&;4]O(XK9XEZCWB:P)2#\7DS &!DQ4Z/,
MP<<'#6> 9[TG,;EG@)YDE?TN_\UZ+>]C2XWG+5Z-N<,_S<'5,8PR3J\V4>'M
MFKX"$]U:"Q@"; +J*%'2XSS4KVUK#5M@'_0[XM8_ Z3)!F\@54HDSP 'VV]/
M#S#>_(&C%OL3Y[&$JDS$:=G)N:XSE'*(1GOK$)Y)2<QPGV"XLAN9ARV3T46/
MM=FY8R,_QW0'O2 ^Q]6=JQ/\6YNOV:?-_<&+S5.GOX! ]T%^=J.$_8F-_1OZ
M='KT"RY[R_A)P[JRP/"/;B[9>/I\9X><>4WTETJ8%I(\=M3>AY-4%H1,.^+_
M$]6,^++G[8J2S@!<2F7,VD?^M[>%S$:9) 56N9"<7X6*19HIH/U:7 _ ]'R
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MYO#0[;40IBXCLQ&61#E&KIRC^I1U%F:W<R07V>MGE[EV:L6B,FO:0\W'@2/
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M'JHF47^J-[:YD;(,"K3.<OEAT+M&.ZP*TA.9LMX^C9#5ND>HAA!KU)'>^1
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M27F_&WV5H.O>P)&OG)Y_>$S!\3Y(H?A)]KVI[\\O6W.<W:0O[U*9??<<I*7
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M=_^'I,<"#U ?1S#YEBN,E3XF^:S,#UH*7<?X?;W.:#]2O'SI3<A!ZS\A!;
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M=%I!2Y[;/[0^=S),N*$\P<I98IG@W9'N[%U 4!=1OU)OV'U?$)P0O2!C ]Z
M]>%UY<Y.S($ME,=UP?YJT4\$C*RL[U*EY)93$E0\.]3=B!MI3>9MUT-M!^J8
M?."LQMXMKTC!T?RDL$@!OI0L*7NR<3@[V477EOS (#@D.)L6=BR&FJ;5D 3B
MBW;&%W!@Z5,]+QJS=G<S*8E__;A@XZ)DIOU0:TJT;E3I?7S1$<%66Z95/W:R
MYA8XU\Q5Y*-))TO\C)REN=$AWP^L6T"RF:B'DOE97%UIG$U@Z65>D)8US_B@
MZK>I.R72G8JC;VR%#!'0*6<Y83/'\9:E\G$;HQKL#^==N^>N!R$S[CEG'L3R
M: 8I3'&<YC]X!/ Z=Y,@)3\:]1*<H!Y&7NDLG)4.TY0^-9<:N5=HK/C,%I.F
M8 -LZ>: '8P*,$GJ9@6[]E T_21L?;#>DZ1JR&M]"VB,T.;[+AJ3PQN]\D7L
M37>1/^XW@'?6AF+-?@*9[\K5F8:RT.PX(@%.>.>50[58W3#&Y[1?C8MKS;;F
MRA8/LIM@=X/I('Q>-(Q]G4#<#"=$O?_<(<W&W.G0+4":5\I\_O(;2E3H9D\[
M:=?R20=9*7/.2O$.R^<YDK5)E.-C@LL[HY!WN\MQ8]VFWOQ*(E]EZ21VN8!@
M0,,([%IYK&6U$=+N.$5-<\D3"8F5]_8XC.TEO'@8)NT#L@D 7R(STD@FGQZ0
M<-?*)3 *+E'6;@&U]U&MU?9=?"6V<8Z^.#%OZ%[L""Y4P>. CSOKZ* &72HQ
MXPJ%.I" )M8&5WL778%%+\ZYYHNO^X]O"LDX4 TB ?ZF79_I!]H&,R)51D]J
MY55*AY#0_)W27]%&+B^/R+1(^3_@!.,X953O8_9!W0QQ*V&XB0Y,\=MIO"^U
M$Y+C<TAW--AK7C(-K]8.P8)"1)'ARAM/>6&Q9C^M/3;:7 %KCH^^[Y36W\TY
MI'Q0,^+H+,E5B./$\G$#_N77F7HU?/%FH/T!RWTKOV1:;U654&/R.W;'1*-:
MOZ2%Y:%8^,Z[/#$?E94\SFQIDIRW0 T++$&/?I!95\+,LVI^J)>HJ@,B(XC"
M7E#) 7KUGEJ$+:::.SD0QUK=J$"D1(NH%S2-_;\G8&$':SAH]^8MR)X$'5JC
MXOV&@G.8B@_'2'6EJ;))B8;^?.A0^RSP)&CJ <_68UZ#9U5?;I1E&3NE 1T&
MP@>3561M!]C^2V/ZY=2+$$BUELB4V[=",-\%9?JDET 70ATM<Q=[ 39[/^ 7
MJRS/[0AH/30-NE_?O>-VH8;@:'$ML2C[*LLRVV(;3'<+"'3\ZIY8MDS1T\3N
M?((PNWI:(I8R69;%EV*3\LZ(C23,>NBK!H5@7I6)3_9$25"MQ^HI%6L;N<W3
M;,!!A RK&69,4#,E<Z34(*]:32'US3+$Y;&U[7=:K)DD( 7SSAB<%XH!JW8[
M\[YP>[?@9OY4G)7SZPZ&'U!R%I6Z'VR['J?^_;2-)6L:\3/R0]=\I#=W&SCF
MLK$L+GHWDW<8>: WU?9(&HO/BM8/>XS>B[N^]&2'2FT(>B*?!ZF $3EB,7XJ
MP4EUPAC>U7/M*3]X%K#47[KW1'MZ4M92M+.%+O>-Q'A?N:W5R6F+M9:SG.9>
M:O4P*BA$6M[("/54.INZO4& RJ5H-N$3#>D^ZH?_:=N4#;,<W3C7E-Y'SN1&
M+V[HR;7:E;Y8HIO;/6^VUBDW<V@H.W7;K!:W]^QP'TY++F3F5^BJ@@(=G*6C
M7.K4EO^5DJ2I$^9DZ9X( U]ZGHR=6_ZT@C'1STIX=VL*3:B/IS:>7(0XCH)-
MOI[.U.:0C+EK]Y'6MR8F^VK9Q\,?%[VX2A54FI_5$>JXHNWUH9T(>?MV!!8^
MKBUIO'A*[B0#?(^7S61+]J8?DN'&%_>\H*B43M/60]E#?]W2Z0;_D>F^MN[S
MF%7I4)Z')=D8Q;@2;8JU.3&4!$ES6N4C-KR!!=:&OHBI3W*Y TD_<1.NS3"3
M^F'R>[B?^(1J6R9GTE*?O-:?0G6%=QE%]J'D?SC7J^HH#[#31IQ.&AO:8B72
M4IF^=/C:TX3+"2%.>O2.E8.G.D3.,I$:ID^1]P*+O&S;GSR!,MI!OI\C/X/%
M#3D]-W6_V_QN>&Y(5MBW4,VEC=?DUGGNR"T/_+)1)#LTO:BRVC>]1+.XB^K;
M*_FU@C*6V@.JJR"AY&O7CEM 2MR:YP(@&JH!#-*MTF$7C-&$XLA-O9HJV]V4
M=M/0RIX(D52H+&%7 A)(:^(LT9"FX+$6ED.=Y/>/P2:^=N:\WV1-AHV^O*V^
M<X@)LQJ9P58:/;9YL%$%UX:()8UYR)8>UD%#7I+.)56*<NKZ9IDW*0X@CA>8
M['"H7RQ_2, Q)0JMPP_YQ %-<R\Z;>#J1LN#[>5!\ TAAL]B,HFN66RLC4W>
ME!QTG*J(+EWL6;#_5W(66![8/Y!7X I(5!IKNU'VM(U@JH.WR#$Q?H_IDU=6
M81Y_$N8S8$YC7&VWD$?:#NMI-MQ^K>ZHESN4&2K9^,PU0=;2K@!XBDENSEO\
ML\*]8IDR+T$)BSU]27X#A9 ;[9V?E#*X4886NH4)'D1&U#!>6Q;U\SY 0;$&
M3S=G$&LQ(AT$=_B2_'VT8BF?1O.2(H_=#9;>7RH^[C8GJVI__5,_N<INMDI@
MR6Q>\ZKUHQJFF[WL"0]&XQ89]$L=[8"C*.4@B3$J>6>,ZVT*B=)'!J1F4O3$
MIDHM,M;)CI*_Y5'5VC 3=:4EQ[W-4;+HE6-*QJ_R+J]B[*WZ8]JD.D1P['3X
M\L/H ]W)F)PLS0D9R8LFS3!#%=R:A6!^_GES,Y,Z8(NG4H3];1C2 1W].1U]
M2\J:EA?#A99DB)&1JHT+X^Z.Y0Q!EVAA@N38<H3PZ_V0[E$RGJJZ+ >[QQEV
M741!K=DT7W'Y\;L,9\M+^W E]/6S)[I>5L(O7(R_<BUA7"  #DN0 ^)$TXPM
MLB^G$9-Z/>3VX#;BH?N1N]%65\UV"7!+R]D7PSP]*CI#2#;JXN(8*;_1=_9#
MK*8X6B6'D3[!F&#BNH></>84LT4.3EE: A&3O6^5GH155_JSA0[K.-/TNF6S
MG;C%Z[ ?=,<2OX-+$E].07)]9KTX$ZUY^ZC,ROU6.6WX$JP-_2"V"Q@T+!V;
MGK63M80X. _;@'@2N-6F.9(OWZ)*^7( NGS+Y&O[B#^_FT)FWH18>OJLE@Q#
MU%'C0-XMP#$\>(PBM8LX5+\?I4#\B.T]6 @R\R97>4'5P8_<9]I'IZ=;032_
M,+^ 0"CZ*8,:0P72OJV1@.Y"=[-JI#=3A+/TX^J[D;L0OP<_-]W7,6X!>+>
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M=]'!(5@@$-PA^."N(;AD( 0"##[8 (,[P0,$#Q @. GN-K@$=Q\88) $=]<
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M0&PQ@K^(^$NT-.B&?\@UG<(?2 *HK3:Q,61D63G0&J>9I?!5[@:=BG:D1HT
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M>!(@LZUT^ =,I%=:Y3^ W;Y?1[X"LXFL=4+@X<G(CNS<=HBPTNFK>)3SXC_
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M-)[-4H135[":\49L=&&>3YA>YQE]"U3FTZ0SS(TE+DP9\XV-B^\PZ\6O:GO
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M2:GEP-^NC&X+@\8>Y9*.CZ\</!'''B4P+WG(O>5R.:=YL[X>[=55548TX/R
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M+FAT;5!+ 0(4 Q0    ( '*!:5;::XU)A"$  'V/ 0 1              "
M 3#D!0!G<G1S+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( '*!:5:&53A 8A(
M !H. 0 5              "  >,%!@!G<G1S+3(P,C(Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " !R@6E6$"F&)\Q.  "!F04 %0              @ %X& 8
M9W)T<RTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ <H%I5KN(?SH0 @$
M(H(+ !4              ( !=V<& &=R=',M,C R,C$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( '.!:59TE.]I.G,  #O "  5              "  ;II!P!G
M<G1S+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " !S@6E6,X5U\TH)  "I
M60  $               @ $GW0< 9W)T<RUE>#$P7S(R+FAT;5!+ 0(4 Q0
M   ( '.!:5;/O6T?. 0  'H?   /              "  9_F!P!G<G1S+65X
M,C-?,2YH=&U02P$"% ,4    " !S@6E6]L>IO2,)  ""7P  #P
M    @ $$ZP< 9W)T<RUE>#,Q7S$N:'1M4$L! A0#%     @ <X%I5L[L<:8%
M"0  25X   \              ( !5/0' &=R=',M97@S,5\R+FAT;5!+ 0(4
M Q0    ( '.!:59H>D"59@4  -M%   -              "  8;]!P!G<G1S
M+65X,S(N:'1M4$L! A0#%     @ <X%I5K+SOX"6T   ).P  !$
M     ( !%P,( &EM9SDW,#@T-#$V7S N:G!G4$L! A0#%     @ <X%I5@P@
MOB^HA@0 9DH( !$              ( !W-,( &EM9SDW,#@T-#$V7S$N:G!G
M4$L! A0#%     @ <X%I5JXRY/,1: ( :_(# !$              ( !LUH-
M &EM9SDW,#@T-#$V7S(N:G!G4$L! A0#%     @ <X%I5J&['>T4D0  \JD
M !$              ( !\\(/ &EM9SDW,#@T-#$V7S,N:G!G4$L! A0#%
M  @ <X%I5B2RJIPV0 ( 4UX$ !$              ( !-E00 &EM9SDW,#@T
M-#$V7S0N:G!G4$L! A0#%     @ <X%I5O)FHI"'-0  .$T  !$
M     ( !FY02 &EM9SDW,#@T-#$V7S4N:G!G4$L! A0#%     @ <X%I5@K6
M(58RK0  $-@  !$              ( !4<H2 &EM9SDW,#@T-#$V7S8N:G!G
64$L%!@     2 !( <P0  +)W$P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
